PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Osicka, R; Prochazkova, K; Sulc, M; Linhartova, I; Havlicek, V; Sebo, P				Osicka, R; Prochazkova, K; Sulc, M; Linhartova, I; Havlicek, V; Sebo, P			A novel "clip-and-link" activity of repeat in toxin (RTX) proteins from gram-negative pathogens - Covalent protein cross-linking by an Asp-Lys isopeptide bond upon calcium-dependent processing at an Asp-Pro bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEISSERIA-MENINGITIDIS; AUTOCATALYTIC CLEAVAGE; LOW PH; SEQUENCE; TERMINUS; FRPC	Clinical isolates of Neisseria meningitidis produce a repeat in toxin (RTX) protein, FrpC, of unknown biological activity. Here we show that physiological concentrations of calcium ions induce a novel type of autocatalytic cleavage of the peptide bond between residues Asp(414) and Pro(415) of FrpC that is insensitive to inhibitors of serine, cysteine, aspartate, and metalloproteases. Moreover, as a result of processing, the newly generated amino-terminal fragment of FrpC can be covalently linked to another protein molecule by a novel type of Asp-Lys isopeptide bond that forms between the carboxyl group of its carboxyl-terminal Asp414 residue and the epsilon-amino group of an internal lysine of another FrpC molecule. Point substitutions of negatively charged residues possibly involved in calcium binding (D499K, D510A, D521K, and E532A) dramatically reduced the self-processing activity of FrpC. The segment necessary and sufficient for FrpC processing was localized by deletion mutagenesis within residues 400-657, and sequences homologous to this segment were identified in several other RTX proteins. The same type of calcium-dependent processing and cross-linking activity was observed also for the purified ApxIVA protein of Actinobacillus pleuropneumoniae. These results define a protein cleavage and cross-linking module of a new class of RTX proteins of Gram-negative pathogens of man, animals, and plants. In the calcium-rich environments colonized by these bacteria this novel activity is likely to be of biological importance.	CAS, Inst Microbiol, CZ-14220 Prague 4, Czech Republic	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Sebo, P (corresponding author), CAS, Inst Microbiol, Videoska 1083, CZ-14220 Prague 4, Czech Republic.	sebo@biomed.cas.cz	Linhartova, Irena/R-3683-2017; SEBO, Peter/N-2043-2019; Linhartova, Irena/J-8413-2014; Sulc, Miroslav/K-1029-2014; Havlicek, Vladimir/H-2626-2014; Osicka, Radim/H-6776-2014; SEBO, Peter/F-7423-2011	SEBO, Peter/0000-0002-9755-7715; Sulc, Miroslav/0000-0002-2659-0489; Havlicek, Vladimir/0000-0002-8614-7059; Osicka, Radim/0000-0003-2626-5456; SEBO, Peter/0000-0002-9755-7715				Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Forman S, 2003, INFECT IMMUN, V71, P2253, DOI 10.1128/IAI.71.4.2253-2257.2003; Guan ZQ, 2003, J AM SOC MASS SPECTR, V14, P605, DOI 10.1016/S1044-0305(03)00201-0; Hauck CR, 2003, CURR OPIN MICROBIOL, V6, P43, DOI 10.1016/S1369-5274(03)00004-3; Lally ET, 1999, TRENDS MICROBIOL, V7, P356, DOI 10.1016/S0966-842X(99)01530-9; Lidell ME, 2003, J BIOL CHEM, V278, P13944, DOI 10.1074/jbc.M210069200; Merz AJ, 2000, ANNU REV CELL DEV BI, V16, P423, DOI 10.1146/annurev.cellbio.16.1.423; Osicka R, 2001, INFECT IMMUN, V69, P5509; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; Repka V, 2000, ACTA VIROL, V44, P249; Ryan RO, 2003, PROTEIN EXPRES PURIF, V27, P98, DOI 10.1016/S1046-5928(02)00568-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schaller A, 1999, MICROBIOL-SGM, V145, P2105, DOI 10.1099/13500872-145-8-2105; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; THOMPSON SA, 1993, MOL MICROBIOL, V9, P85, DOI 10.1111/j.1365-2958.1993.tb01671.x; THOMPSON SA, 1993, J BACTERIOL, V175, P811, DOI 10.1128/JB.175.3.811-818.1993; Thuveson M, 2000, J BIOL CHEM, V275, P30996, DOI 10.1074/jbc.M002399200; Tzeng YL, 2000, MICROBES INFECT, V2, P687, DOI 10.1016/S1286-4579(00)00356-7; Vogel U, 1999, MOL MICROBIOL, V32, P1133, DOI 10.1046/j.1365-2958.1999.01469.x; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85	21	53	56	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24944	24956		10.1074/jbc.M314013200	http://dx.doi.org/10.1074/jbc.M314013200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15044436	hybrid			2022-12-25	WOS:000221827900008
J	Araki, Y; Miyagi, N; Kato, N; Yoshida, T; Wada, S; Nishimura, M; Komano, H; Yamamoto, T; De Strooper, B; Yamamoto, K; Suzuki, T				Araki, Y; Miyagi, N; Kato, N; Yoshida, T; Wada, S; Nishimura, M; Komano, H; Yamamoto, T; De Strooper, B; Yamamoto, K; Suzuki, T			Coordinated metabolism of alcadein and amyloid beta-protein precursor regulates FE65-dependent gene transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE CLEAVAGE; INTRACELLULAR DOMAIN; INTRAMEMBRANE PROTEOLYSIS; CYTOPLASMIC DOMAIN; ALZHEIMERS-DISEASE; MEMBRANE-PROTEINS; PRESENILIN; FE65; RECEPTOR; NOTCH	The Alcadeins (Alcs)/calsyntenins and the amyloid beta-protein precursor (APP) associate with each other in the brain by binding via their cytoplasmic domains to X11L (the X11-like protein). We previously reported that the formation of this APP-X11L-Alc tripartite complex suppresses the metabolic cleavages of APP. We show here that the metabolism of the Alcs markedly resembles that of APP. The Alcs are subjected to a primary cleavage event that releases their extracellular domain. Alcs then undergo a secondary presenilin-dependent gamma-cleavage that leads to the secretion of the amyloid beta-protein-like peptide and the liberation of an intracellular domain fragment (AlcICD). However, when Alc is in the tripartite complex, it escapes from these cleavages, as does APP. We also found that AlcICD suppressed the FE65-dependent gene transactivation activity of the APP intracellular domain fragment, probably because AlcICD competes with the APP intracellular domain fragment for binding to FE65. We propose that the Alcs and APP are coordinately metabolized in neurons and that their cleaved cytoplasmic fragments are reciprocally involved in the regulation of FE65-dependent gene transactivation. Any imbalance in the metabolism of Alcs and APP may influence the FE65-dependent gene transactivation, which together with increased secretion of amyloid beta-protein may contribute to neural disorders.	Hokkaido Univ, Neurosci Lab, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Shiga Univ Med Sci, Neurol Unit, Mol Neurosci Res Ctr, Neurol Unit, Shiga 5202192, Japan; Natl Inst Longev Sci, Dept Dementia Res, Aichi 4748522, Japan; RIKEN, Lab Cell Asymmetry, Ctr Dev Biol, Chuo Ku, Kobe, Hyogo 6500047, Japan; Katholieke Univ Leuven, Natl Cell Biol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Univ Tokyo, Dept Integrat Biosci, Grad Sch Frontier Sci, Chiba 2778562, Japan	Hokkaido University; University of Tokyo; Shiga University of Medical Science; RIKEN; KU Leuven; University of Tokyo	Suzuki, T (corresponding author), Hokkaido Univ, Neurosci Lab, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tsuzuki@pharm.hokudai.ac.jp	Suzuki, Toshiharu/B-5342-2013; Yamamoto, Tohru/A-3801-2012; De Strooper, Bart/F-6507-2012; de+Strooper, Bart/Z-1638-2019	Yamamoto, Tohru/0000-0002-1652-0233; De Strooper, Bart/0000-0001-5455-5819; 				Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Araki Y, 2003, J BIOL CHEM, V278, P49448, DOI 10.1074/jbc.M306024200; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Guenette SY, 1999, J NEUROCHEM, V73, P985, DOI 10.1046/j.1471-4159.1999.0730985.x; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hintsch G, 2002, MOL CELL NEUROSCI, V21, P393, DOI 10.1006/mcne.2002.1181; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kinoshita A, 2002, J NEUROCHEM, V82, P839, DOI 10.1046/j.1471-4159.2002.01016.x; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Meyer EL, 2003, J BIOL CHEM, V278, P23786, DOI 10.1074/jbc.M301360200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sato T, 2003, J BIOL CHEM, V278, P24294, DOI 10.1074/jbc.M211161200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schulz JG, 2003, J BIOL CHEM, V278, P48651, DOI 10.1074/jbc.M308424200; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Taniguchi Y, 2003, J BIOL CHEM, V278, P30425, DOI 10.1074/jbc.C300239200; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Verdile G, 2000, J BIOL CHEM, V275, P20794, DOI 10.1074/jbc.C000208200; Vogt L, 2001, MOL CELL NEUROSCI, V17, P151, DOI 10.1006/mcne.2000.0937; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800	43	69	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24343	24354		10.1074/jbc.M401925200	http://dx.doi.org/10.1074/jbc.M401925200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15037614	hybrid			2022-12-25	WOS:000221702500060
J	Arif, SAM; Hamilton, RG; Yusof, F; Chew, NP; Loke, YH; Nimkar, S; Beintema, JJ; Yeang, HY				Arif, SAM; Hamilton, RG; Yusof, F; Chew, NP; Loke, YH; Nimkar, S; Beintema, JJ; Yeang, HY			Isolation and characterization of the early nodule-specific protein homologue (Hev b 13), an allergenic lipolytic esterase from Hevea brasiliensis latex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTOID-BODY FRACTION; MASS-SPECTROMETRY; B 7; IGE; IDENTIFICATION; ARABIDOPSIS; EXPRESSION; PATATIN; CLONING; POLLEN	Recurring reports of a highly allergenic 42-46-kDa protein in Hevea brasiliensis latex appeared to have been resolved with the discovery of a 43-kDa allergenic latex protein that was a homologue to patatin. However, the low to moderate prevalence of sensitization to the protein, designated Hev b 7, among latex-allergic patients could not adequately explain the frequent observations of the 42-46-kDa allergen. This led to the hypothesis that another, more allergenic protein of a similar molecular mass existed in Hevea latex. We report the isolation and purification of a 42.98-kDa latex glycoprotein showing homology to the early nodule-specific protein (ENSP) of the legumes Medicago sativa, Medicago truncatula, and Glycine max. The protein is allergenic, being recognized by immunoglobulin E (IgE) in sera from latex-allergic patients. The IgE epitope resides on the carbohydrate moiety of the protein, and the presence of a similar carbohydrate component on potato tuber patatin enables the latter to inhibit IgE binding to the ENSP homologue. The cDNA encoding the ENSP homologue was isolated by reverse transcription-PCR and cloned. The protein predicted from the cDNA sequence has 391 amino acids, the first 26 of which constitute a putative signal peptide. The deduced molecular mass of the mature protein is 40.40 kDa, while its iso-electric point is estimated at 5.0. The discrepancy between the predicted and observed molecular mass might be due to glycosylation, for which three N-sites on the protein are predicted. The purified protein showed lipase and esterase activities and may be involved in plant defense.	Rubber Res Inst Malaysia, Kuala Lumpur 50450, Malaysia; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Appl Biosyst Inc, Foster City, CA 94404 USA; Univ Groningen, NL-9700 AB Groningen, Netherlands	Institute Penyelidikan Getah Malaysia; Johns Hopkins University; Thermo Fisher Scientific; Applied Biosystems; University of Groningen	Arif, SAM (corresponding author), Rubber Res Inst Malaysia, Kuala Lumpur 50450, Malaysia.	sitiarija@lgm.gov.my	Moussa, Luciana/M-2257-2013					AKASAWA A, 1995, J ALLERGY CLIN IMMUN, V95, P1196, DOI 10.1016/S0091-6749(95)70076-5; ARCHER BL, 1963, CHEMISTRY PHYSICS RU, P43; Batanero E, 1999, J ALLERGY CLIN IMMUN, V103, P147, DOI 10.1016/S0091-6749(99)70538-5; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; Bernstein DI, 2003, J ALLERGY CLIN IMMUN, V111, P610, DOI 10.1067/mai.2003.164; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163; Brick DJ, 1995, FEBS LETT, V377, P475, DOI 10.1016/0014-5793(95)01405-5; DICKSTEIN R, 1993, MOL PLANT MICROBE IN, V6, P715, DOI 10.1094/MPMI-6-715; Foetisch K, 2003, J ALLERGY CLIN IMMUN, V111, P889, DOI 10.1067/mai.2003.173; Fuchs T, 1997, J ALLERGY CLIN IMMUN, V100, P356, DOI 10.1016/S0091-6749(97)70249-5; Gomez J.B., 1979, MALAYSIAN RUBBER RES, V4; HSIA RCH, 1958, T I RUBBER IND, V34, P267; Jekel PA, 2003, PHYTOCHEMISTRY, V63, P517, DOI 10.1016/S0031-9422(03)00224-3; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; Kostyal DA, 1998, CLIN EXP IMMUNOL, V112, P355; Kurup VP, 2000, CLIN EXP ALLERGY, V30, P359; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; Midoro-Horiuti T, 2001, ANN ALLERG ASTHMA IM, V87, P261, DOI 10.1016/S1081-1206(10)62238-7; MOIR GFJ, 1959, NATURE, V184, P1626, DOI 10.1038/1841626a0; MOTULSKY H, 1995, INTUITIVE BIOSTATIST, P233; Neubauer G, 1999, ANAL CHEM, V71, P235, DOI 10.1021/ac9804902; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Parker DM, 1998, MOL PLANT MICROBE IN, V11, P514, DOI 10.1094/MPMI.1998.11.6.514; Plou FJ, 1998, BIOTECHNOL TECH, V12, P183, DOI 10.1023/A:1008809105270; PRESCOTT A, 1987, PLANT MOL BIOL REP, V4, P219, DOI DOI 10.1007/BF02675414; ROBERTS MR, 1993, PLANT J, V3, P111, DOI 10.1111/j.1365-313X.1993.tb00014.x; Seppala U, 2000, ALLERGY, V55, P266, DOI 10.1034/j.1398-9995.2000.00392.x; Shevchenko A, 2001, ANAL CHEM, V73, P1917, DOI 10.1021/ac0013709; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Sowka S, 1998, EUR J BIOCHEM, V255, P213, DOI 10.1046/j.1432-1327.1998.2550213.x; Subroto T, 2001, PLANT PHYSIOL BIOCH, V39, P1047, DOI 10.1016/S0981-9428(01)01325-0; Subroto T, 1996, PHYTOCHEMISTRY, V43, P29, DOI 10.1016/0031-9422(96)00196-3; Sunderasan E., 1994, Journal of Natural Rubber Research, V9, P127; Taipalensuu J, 1997, EUR J BIOCHEM, V247, P963, DOI 10.1111/j.1432-1033.1997.00963.x; TATA SJ, 1980, J RUBBER RES I MALAY, V28, P77; TOMAZIC VJ, 1995, J ALLERGY CLIN IMMUN, V96, P635, DOI 10.1016/S0091-6749(95)70262-8; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; Wagner B, 2001, J ALLERGY CLIN IMMUN, V108, P621; Yagami T, 1996, FOOD AGR IMMUNOL, V8, P121, DOI 10.1080/09540109609354910; Yagami T, 2000, RRD ALL CLIN IMMUNOL, V1, P41; Yeang HY, 2000, J INVEST ALLERG CLIN, V10, P215; Yip L, 2000, INT ARCH ALLERGY IMM, V121, P292, DOI 10.1159/000024342; Yusof F., 1998, Journal of Rubber Research, V1, P95; YUSOF F, 1995, PROT SOC 1 EUR S DAV	46	52	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23933	23941		10.1074/jbc.M309800200	http://dx.doi.org/10.1074/jbc.M309800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15024009	hybrid			2022-12-25	WOS:000221702500014
J	Kariya, Y; Yasuda, C; Nakashima, Y; Ishida, K; Tsubota, Y; Miyazaki, K				Kariya, Y; Yasuda, C; Nakashima, Y; Ishida, K; Tsubota, Y; Miyazaki, K			Characterization of laminin 5B and NH2-terminal proteolytic fragment of its alpha 3B chain - Promotion of cellular adhesion, migration, and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED EPITHELIAL-CELLS; RECOMBINANT LAMININ-5; BASEMENT-MEMBRANES; SCATTER FACTOR; BINDING SITES; GAMMA-2 CHAIN; HUMAN TISSUES; LAMA3 GENE; SHORT ARM; EXPRESSION	Various laminin isoforms have specific biological functions depending on their structures. Laminin 5A, which consists of the three truncated chains alpha3A, beta3, and gamma2, is known to have strong activity to promote cell adhesion and migration, whereas a laminin 5 variant consisting of a full-sized alpha3 chain (alpha3B) and the beta3 and gamma2 chains, laminin 5B, has not been characterized yet. In the present study, we for the first time cloned a full-length human laminin alpha3B cDNA and isolated the human laminin 5B protein. The molecular size of the mature alpha3B chain (335 kDa) was approximately twice as large as the mature alpha3A chain in laminin 5A. Laminin 5B had significantly higher cell adhesion and cell migration activities than laminin 5A. In addition, laminin 5B potently stimulated cell proliferation when added into the culture medium directly. Furthermore, we found that the alpha3B chain undergoes proteolytic cleavage releasing a 190-kDa NH2-terminal fragment. The 190-kDa fragment had activities to promote cellular adhesion, migration, and proliferation through its interaction with integrin alpha(3)beta(1). These activities of the NH2-terminal structure of the alpha3B chain seem to contribute to the prominent biological activities and the physiological functions of laminin 5B.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Kihara Mem Yokohama Fdn Advancement Life Sci, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University; Yokohama City University	Miyazaki, K (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, 641-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.	miyazaki@yokohama-cu.ac.jp						Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Aumailley M, 1999, MATRIX BIOL, V18, P19, DOI 10.1016/S0945-053X(98)00004-3; Baker SE, 1996, EXP CELL RES, V228, P262, DOI 10.1006/excr.1996.0325; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Colognato H, 1997, J BIOL CHEM, V272, P29330, DOI 10.1074/jbc.272.46.29330; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; Doliana R, 1997, FEBS LETT, V417, P65, DOI 10.1016/S0014-5793(97)01251-9; Ekblom P, 2003, MATRIX BIOL, V22, P35, DOI 10.1016/S0945-053X(03)00015-5; Ettner N, 1998, FEBS LETT, V430, P217, DOI 10.1016/S0014-5793(98)00601-2; Ferrigno O, 1997, J BIOL CHEM, V272, P20502, DOI 10.1074/jbc.272.33.20502; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; GALLIANO MF, 1995, J BIOL CHEM, V270, P21820, DOI 10.1074/jbc.270.37.21820; Garbe JHO, 2002, BIOCHEM J, V362, P213, DOI 10.1042/0264-6021:3620213; Goldfinger LE, 1999, J CELL SCI, V112, P2615; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Hirosaki T, 2002, J BIOL CHEM, V277, P49287, DOI 10.1074/jbc.M111096200; Kariya Y, 2002, J BIOCHEM, V132, P607, DOI 10.1093/oxfordjournals.jbchem.a003263; Kariya Y, 2003, J CELL BIOCHEM, V88, P506, DOI 10.1002/jcb.10350; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; McLean WHI, 2003, HUM MOL GENET, V12, P2395, DOI 10.1093/hmg/ddg234; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Mizushima H, 1998, HORM RES, V50, P7, DOI 10.1159/000053118; Mizushima H, 1996, J BIOCHEM-TOKYO, V120, P1196; Nielsen PK, 2001, J BIOL CHEM, V276, P10906, DOI 10.1074/jbc.M008743200; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; Nievers MG, 1999, MATRIX BIOL, V18, P5, DOI 10.1016/S0945-053X(98)00003-1; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; Pulkkinen L, 1999, MATRIX BIOL, V18, P29, DOI 10.1016/S0945-053X(98)00005-5; PYKE C, 1995, CANCER RES, V55, P4132; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; Shang ML, 2001, J BIOL CHEM, V276, P33045, DOI 10.1074/jbc.M100798200; TERRANOVA VP, 1986, J CELL PHYSIOL, V127, P473, DOI 10.1002/jcp.1041270318; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tsubota Y, 2000, BIOCHEM BIOPH RES CO, V278, P614, DOI 10.1006/bbrc.2000.3851; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286	45	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24774	24784		10.1074/jbc.M400670200	http://dx.doi.org/10.1074/jbc.M400670200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044476	hybrid			2022-12-25	WOS:000221702500108
J	Mauceri, D; Cattabeni, F; Di Luca, M; Gardoni, F				Mauceri, D; Cattabeni, F; Di Luca, M; Gardoni, F			Calcium/calmodulin-dependent protein kinase II phosphorylation drives synapse-associated protein 97 into spines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA RECEPTOR TRAFFICKING; HIPPOCAMPAL-NEURONS; CAMKII; SAP97; SUBUNIT; SURFACE; DOMAIN; IDENTIFICATION; LOCALIZATION; BINDING	Synapse-associated protein 97 (SAP97) has been involved in the correct delivery and clustering of glutamate ionotropic receptors to the postsynaptic compartment. Here we demonstrate that synaptic trafficking of SAP97 itself was modulated by calcium/calmodulin-dependent protein kinase II ( CaMKII) in cultured hippocampal neurons. CaMKII activation led to increased targeting of SAP97 into dendritic spines, whereas CaMKII inhibition was responsible for SAP97 high colocalization in the cell soma with the endoplasmic reticulum protein disulfide-isomerase. No effect was detected for other members of the membrane-associated guanylate kinase protein family, such as SAP102 and PSD-95. Transfection of activated alphaCaMKII T286D dramatically increased concentration of both endogenous and transfected SAP97 at postsynaptic terminals. In vitro CaMKII phosphorylation of the SAP97 N-terminal fusion protein and metabolic labeling of transfected COS7 cells indicated SAP97-Ser-39 as a CaMKII phosphosite in the SAP97 protein sequence. Moreover, transfection in hippocampal neurons of SAP97 mutants that blocked or mimicked Ser-39 phosphorylation had effects similar to those observed upon inhibiting or constitutively activating CaMKII. Further, CaMKII-dependent SAP97-Ser-39 phosphorylation determined a redistribution of the glutamate receptor subunit (GluR1) of the AMPA receptor. In conclusion, our data show that CaMKII-dependent SAP97-Ser-39 phosphorylation regulates the association of SAP97 with the postsynaptic complex, thus providing a fine molecular mechanism responsible for the synaptic delivery of SAP97 interacting proteins, i.e. ionotropic glutamate receptor subunits.	Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy	University of Milan; University of Milan	Di Luca, M (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Via Balzaretti 9, I-20133 Milan, Italy.	Monica.Diluca@unimi.it	Mauceri, Daniela/C-4969-2014; Gardoni, Fabrizio/A-3135-2009; DiLuca, Monica/A-7632-2012	Mauceri, Daniela/0000-0003-1225-4633; Gardoni, Fabrizio/0000-0003-4598-5563; DiLuca, Monica/0000-0003-2298-615X				Bassand P, 1999, EUR J NEUROSCI, V11, P2031, DOI 10.1046/j.1460-9568.1999.00611.x; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Currie S, 2004, BIOCHEM J, V377, P357, DOI 10.1042/BJ20031043; Emptage N, 1999, NEURON, V22, P115, DOI 10.1016/S0896-6273(00)80683-2; Firestein BL, 2000, NEUROREPORT, V11, P3479, DOI 10.1097/00001756-200011090-00016; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Gardoni F, 2003, J BIOL CHEM, V278, P44745, DOI 10.1074/jbc.M303576200; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hall RA, 1997, NEUROSCIENCE, V78, P361, DOI 10.1016/S0306-4522(96)00525-8; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Karnak D, 2002, J BIOL CHEM, V277, P46730, DOI 10.1074/jbc.M208781200; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; Kouzu Y, 2000, MOL BRAIN RES, V76, P142, DOI 10.1016/S0169-328X(99)00344-7; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Rumbaugh G, 2003, J NEUROSCI, V23, P4567; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Wu HJ, 1998, J CELL SCI, V111, P2365; Yoshimura Y, 2002, BIOCHEM BIOPH RES CO, V290, P948, DOI 10.1006/bbrc.2001.6320	25	69	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23813	23821		10.1074/jbc.M402796200	http://dx.doi.org/10.1074/jbc.M402796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044483	hybrid			2022-12-25	WOS:000221570900125
J	Rock, MJ; Cain, SA; Freeman, LJ; Morgan, A; Mellody, K; Marson, A; Shuttleworth, CA; Weiss, AS; Kielty, CM				Rock, MJ; Cain, SA; Freeman, LJ; Morgan, A; Mellody, K; Marson, A; Shuttleworth, CA; Weiss, AS; Kielty, CM			Molecular basis of elastic fiber formation - Critical interactions and a tropoelastin-fibrillin-1 cross-link	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROFIBRIL-ASSOCIATED GLYCOPROTEIN-1; FIBRILLIN-CONTAINING MICROFIBRILS; TISSUE TRANSGLUTAMINASE; TERNARY COMPLEX; MARFAN-SYNDROME; DOMAIN; MATRIX; ORGANIZATION; MAGP-1; MODULE	We have investigated the molecular basis of elastic fiber formation on fibrillin microfibrils. Binding assays revealed high affinity calcium-independent binding of two overlapping fibrillin-1 fragments ( encoded by central exons 18 - 25 and 24 - 30) to tropoelastin, which, in microfibrils, map to an exposed "arms" feature adjacent to the beads. A further binding site within an adjacent fragment ( encoded by exons 9 - 17) was within an eight-cysteine motif designated TB2 ( encoded by exons 16 and 17). Binding to TB2 was ablated by the presence of N-terminal domains ( encoded by exons 1 - 8) and reduced after deleting the proline-rich region. A novel transglutaminase cross-link between tropoelastin and fibrillin-1 fragment ( encoded by exons 9 - 17) was localized by mass spectrometry to a sequence encoded by exon 17. The high affinity binding and cross-linking of tropoelastin to a central fibrillin-1 sequence confirm that this association is fundamental to elastic fiber formation. Microfibril-associated glycoprotein-1 showed calcium-dependent binding of moderate affinity to fibrillin-1 N-terminal fragment ( encoded by exons 1 - 8), which localize to the beads. Microfibril-associated glycoprotein-1 thus contributes to microfibril organization but may also form secondary interactions with adjacent microfibril-bound tropoelastin.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ Sydney, Sch Mol & Microbial Sci G08, Sydney, NSW 2006, Australia	University of Manchester; University of Sydney	Kielty, CM (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	may.kielty@man.ac.uk	Cain, Stuart A/G-2836-2017; Weiss, Anthony S/F-8103-2010; Weiss, Anthony S/GYV-0157-2022	Weiss, Anthony S/0000-0002-8106-4836; Cain, Stuart/0000-0001-8417-1058; McGovern, Amanda/0000-0001-7727-3283; Mellody, Kieran/0000-0002-8164-9148				Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; Bax DV, 2003, J BIOL CHEM, V278, P34605, DOI 10.1074/jbc.M303159200; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Kettle S, 2000, INT J BIOCHEM CELL B, V32, P201, DOI 10.1016/S1357-2725(99)00120-X; Kielty CM, 1997, MICROSC RES TECHNIQ, V38, P413, DOI 10.1002/(SICI)1097-0029(19970815)38:4<413::AID-JEMT9>3.0.CO;2-J; Kielty CM, 2002, PHILOS T R SOC B, V357, P207, DOI 10.1098/rstb.2001.1029; Kielty CM, 2002, J CELL SCI, V115, P2817; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Lack J, 2003, J MOL BIOL, V334, P281, DOI 10.1016/j.jmb.2003.09.053; Lin S, 2002, J BIOL CHEM, V277, P10795, DOI 10.1074/jbc.M110246200; MARTIN SL, 1995, GENE, V154, P159, DOI 10.1016/0378-1119(94)00848-M; MAYER U, 1994, EUR J BIOCHEM, V225, P573, DOI 10.1111/j.1432-1033.1994.00573.x; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Qian RQ, 1997, BIOCHEMISTRY-US, V36, P15841, DOI 10.1021/bi971036f; Quondamatteo F, 2002, MATRIX BIOL, V21, P637, DOI 10.1016/S0945-053X(02)00100-2; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; Reinboth B, 2002, J BIOL CHEM, V277, P3950, DOI 10.1074/jbc.M109540200; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Robinson PN, 2001, CELL MOL LIFE SCI, V58, P1698, DOI 10.1007/PL00000807; Schittny JC, 1997, AM J RESP CELL MOL, V17, P334, DOI 10.1165/ajrcmb.17.3.2737; Segade F, 2002, J BIOL CHEM, V277, P11050, DOI 10.1074/jbc.M110347200; Sherratt MJ, 1997, INT J BIOCHEM CELL B, V29, P1063, DOI 10.1016/S1357-2725(97)00028-9; Sherratt MJ, 2003, J MOL BIOL, V332, P183, DOI 10.1016/S0022-2836(03)00829-5; Toonkool P, 2001, J BIOL CHEM, V276, P44575, DOI 10.1074/jbc.M107920200; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Trask TM, 2000, J BIOL CHEM, V275, P24400, DOI 10.1074/jbc.M003665200; Yuan XM, 1997, EMBO J, V16, P6659, DOI 10.1093/emboj/16.22.6659	36	124	125	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23748	23758		10.1074/jbc.M400212200	http://dx.doi.org/10.1074/jbc.M400212200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039439	hybrid			2022-12-25	WOS:000221570900117
J	Mosbahi, K; Walker, D; Lea, E; Moore, GR; James, R; Kleanthous, C				Mosbahi, K; Walker, D; Lea, E; Moore, GR; James, R; Kleanthous, C			Destabilization of the colicin E9 endonuclease domain by interaction with negatively charged phospholipids - Implications for colicin translocation into bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL CATIONIC PROTEIN; CHANNEL-FORMING COLICINS; ESCHERICHIA-COLI; ANTIMICROBIAL PEPTIDES; ACTIVE-SITE; MEMBRANES; IMMUNITY; BINDING; MECHANISM; DNASE	We have shown previously that the 134-residue endonuclease domain of the bacterial cytotoxin colicin E9 (E9 DNase) forms channels in planar lipid bilayers (Mosbahi, K., Lemaitre, C., Keeble, A.H., Mobasheri, H., Morel, B., James, R., Moore, G.R., Lea, E.J., and Kleanthous, C. (2002) Nat. Struct. Biol. 9, 476-484). It was proposed that the E9 DNase mediates its own translocation across the cytoplasmic membrane and that the formation of ion channels is essential to this process. Here we describe changes to the structure and stability of the E9 DNase that accompany interaction of the protein with phospholipid vesicles. Formation of the protein-lipid complex at pH 7.5 resulted in a red-shift of the intrinsic protein fluorescence emission maximum (lambda(max)) from 333 to 346 nm. At pH 4.0, where the E9 DNase lacks tertiary structure but retains secondary structure, DOPG induced a blue-shift in lambda(max), from 354 to 342 nm. Changes in lambda(max) were specific for anionic phospholipid vesicles at both pHs, suggesting electrostatics play a role in this association. The effects of phospholipid were negated by Im9 binding, the high affinity, acidic, exosite inhibitor protein, but not by zinc, which binds at the active site. Fluorescence-quenching experiments further demonstrated that similar protein-phospholipid complexes are formed regardless of whether the E9 DNase is initially in its native conformation. Consistent with these observations, chemical and thermal denaturation data as well as proteolytic susceptibility experiments showed that association with negatively charged phospholipids destabilize the E9 DNase. We suggest that formation of a destabilizing protein-lipid complex pre-empts channel formation by the E9 DNase and constitutes the initial step in its translocation across the Escherichia coli inner membrane.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England; Univ Nottingham, Ctr Biomol Sci, Inst Infect Immun & Inflammat, Nottingham NG7 2RD, England	University of York - UK; University of East Anglia; University of East Anglia; University of Nottingham	Kleanthous, C (corresponding author), Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England.	ck11@york.ac.uk	James, Richard/B-2252-2009	Walker, Daniel/0000-0002-4206-2942				Butko P, 1997, BIOCHEMISTRY-US, V36, P12862, DOI 10.1021/bi9702389; Carreras E, 2003, BIOCHEMISTRY-US, V42, P6636, DOI 10.1021/bi0273011; DUCHE D, 1994, J BIOL CHEM, V269, P6332; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; GarinotSchneider C, 1996, J MOL BIOL, V260, P731, DOI 10.1006/jmbi.1996.0433; Jakes KS, 1999, Q REV BIOPHYS, V32, P189, DOI 10.1017/S0033583599003492; Kadner R. J., 1996, ESCHERICHIA COLI SAL, P58; Kleanthous C, 1999, NAT STRUCT BIOL, V6, P243, DOI 10.1038/6683; Kleanthous C, 2001, TRENDS BIOCHEM SCI, V26, P624, DOI 10.1016/S0968-0004(01)01941-7; LINDBLOM G, 1991, BIOCHEMISTRY-US, V30, P10938, DOI 10.1021/bi00109a019; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P15144, DOI 10.1021/bi9811617; Morein S, 2000, BIOPHYS J, V78, P2475, DOI 10.1016/S0006-3495(00)76792-0; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Mosbahi K, 2002, NAT STRUCT BIOL, V9, P476, DOI 10.1038/nsb797; MUGA A, 1993, J BIOL CHEM, V268, P1553; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; Pommer AJ, 1999, J BIOL CHEM, V274, P27153, DOI 10.1074/jbc.274.38.27153; Pommer AJ, 2001, J MOL BIOL, V314, P735, DOI 10.1006/jmbi.2001.5189; Pommer AJ, 1998, BIOCHEM J, V334, P387, DOI 10.1042/bj3340387; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; Scholz SR, 2003, BIOCHEMISTRY-US, V42, P9288, DOI 10.1021/bi0348765; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; Stroud RM, 1998, CURR OPIN STRUC BIOL, V8, P525, DOI 10.1016/S0959-440X(98)80132-2; van den Bremer ETJ, 2002, PROTEIN SCI, V11, P1738, DOI 10.1110/ps.0200502; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Walker D, 2003, BIOCHEMISTRY-US, V42, P4161, DOI 10.1021/bi0273720; Walker D, 2004, J BACTERIOL, V186, P866, DOI 10.1128/JB.186.3.866-869.2004; Walker DC, 2002, NUCLEIC ACIDS RES, V30, P3225, DOI 10.1093/nar/gkf420; WALLIS R, 1995, BIOCHEMISTRY-US, V34, P13743, DOI 10.1021/bi00042a004; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0; Zakharov SD, 1996, BIOPHYS J, V70, P2774, DOI 10.1016/S0006-3495(96)79847-8; Zakharov SD, 2002, BBA-BIOMEMBRANES, V1565, P333, DOI 10.1016/S0005-2736(02)00579-5; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	34	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22145	22151		10.1074/jbc.M400402200	http://dx.doi.org/10.1074/jbc.M400402200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15044477	hybrid			2022-12-25	WOS:000221417100058
J	Blaustein, M; Pelisch, F; Coso, OA; Bissell, MJ; Kornblihtt, AR; Srebrow, A				Blaustein, M; Pelisch, F; Coso, OA; Bissell, MJ; Kornblihtt, AR; Srebrow, A			Mammary epithelial-mesenchymal interaction regulates fibronectin alternative splicing via phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEINASE GENE-EXPRESSION; GROWTH-FACTOR; EDA EXON; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; GLAND DEVELOPMENT; PREMESSENGER RNA; EIIIA SEGMENT; CELL-ADHESION; IIICS REGION	The way alternative splicing is regulated within tissues is not understood. A relevant model of this process is provided by fibronectin, an important extracellular matrix protein that plays a key role in cell adhesion and migration and contains three alternatively spliced regions known as EDI, EDII, and IIICS. We used a cell culture system to simulate mammary epithelial-stromal communication, a process that is crucial for patterning and function of the mammary gland, and studied the effects of extracellular signals on the regulation of fibronectin pre-mRNA alternative splicing. We found that soluble factors from a mammary mesenchymal cell-conditioned medium, as well as the growth factors HGF/SF ( hepatocyte growth factor/scatter factor), KGF ( keratinocyte growth factor), and aFGF ( acidic fibroblast growth factor), stimulate EDI and IIICS but not EDII inclusion into fibronectin mRNA in the mammary epithelial cell line SCp2, favoring fibronectin isoforms associated with proliferation, migration, and tissue remodeling. We explored the signaling pathways involved in this regulation and found that the mammary mesenchymal cell-conditioned medium and HGF/SF act through a phosphatidylinositol 3-kinase-dependent cascade to alter fibronectin alternative splicing. This splicing regulation is independent from promoter structure and de novo protein synthesis but does require two exonic elements within EDI. These results shed light on how extracellular stimuli are converted into changes in splicing patterns.	Univ Buenos Aires, Lab Fisiol & Biol Mol,Dept Fisiol Biol Mol & Celu, Inst Fisiol Biol Mol & Neurociencias, Consejo Nacl Invest Cient & Tecn,Fac Ciencias Exa, Buenos Aires, DF, Argentina; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Srebrow, A (corresponding author), Univ Buenos Aires, Lab Fisiol & Biol Mol,Dept Fisiol Biol Mol & Celu, Inst Fisiol Biol Mol & Neurociencias, Consejo Nacl Invest Cient & Tecn,Fac Ciencias Exa, Ciudad Univ,Pabellon 2,C1428EHA, Buenos Aires, DF, Argentina.	asrebrow@fbmc.fcen.uba.ar	Blaustein, Matías/ABF-7951-2020; Pelisch, Federico/C-3815-2011; Pelisch, Federico/H-9219-2013	Blaustein, Matías/0000-0001-6309-6888; Kornblihtt, Alberto/0000-0003-4322-0831; Pelisch, Federico/0000-0003-4575-1492				Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; Bissell MJ, 1999, CANCER RES, V59, p1757S; BOS JL, 1989, CANCER RES, V49, P4682; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; Chauhan AK, 2004, GENE, V324, P55, DOI 10.1016/j.gene.2003.09.026; Colman-Lerner A, 1999, ENDOCRINOLOGY, V140, P2541, DOI 10.1210/en.140.6.2541; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Cunha G R, 1992, Epithelial Cell Biol, V1, P105; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Desprez Pierre-Yves, 1993, Molecular and Cellular Differentiation, V1, P99; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; Imagawa W, 2002, J STEROID BIOCHEM, V80, P213, DOI 10.1016/S0960-0760(01)00188-1; Inoue T, 1999, BIOCHEM BIOPH RES CO, V260, P225, DOI 10.1006/bbrc.1999.0881; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; Liao YF, 2002, J BIOL CHEM, V277, P14467, DOI 10.1074/jbc.M201100200; Lim LP, 1998, MOL CELL BIOL, V18, P3900, DOI 10.1128/MCB.18.7.3900; Manabe R, 1999, J BIOL CHEM, V274, P5919, DOI 10.1074/jbc.274.9.5919; MARDON HJ, 1992, J CELL SCI, V103, P423; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Mostafavi-Pour Z, 2001, MATRIX BIOL, V20, P63, DOI 10.1016/S0945-053X(00)00131-1; Muro AF, 1999, MOL CELL BIOL, V19, P2657; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; OYAMA F, 1993, CANCER RES, V53, P2005; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Paumelle R, 2000, MOL BIOL CELL, V11, P3751, DOI 10.1091/mbc.11.11.3751; Peters JH, 2003, J LAB CLIN MED, V141, P401, DOI 10.1016/S0022-2143(03)00042-8; Peters JH, 1996, CELL ADHES COMMUN, V4, P103, DOI 10.3109/15419069609010766; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Recio JA, 2002, ONCOGENE, V21, P1000, DOI 10.1038/sj.onc.1205150; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Saito S, 1999, J BIOL CHEM, V274, P30756, DOI 10.1074/jbc.274.43.30756; Sakai T, 2003, NATURE, V423, P876, DOI 10.1038/nature01712; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Shimao Y, 1999, INT J CANCER, V82, P449, DOI 10.1002/(SICI)1097-0215(19990730)82:3<449::AID-IJC20>3.0.CO;2-H; Simian M, 2001, DEVELOPMENT, V128, P3117; Srebrow A, 2002, FEBS LETT, V514, P285, DOI 10.1016/S0014-5793(02)02382-7; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; Werbajh SE, 1998, FEBS LETT, V440, P277, DOI 10.1016/S0014-5793(98)01473-2; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431	50	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21029	21037		10.1074/jbc.M314260200	http://dx.doi.org/10.1074/jbc.M314260200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15028734	hybrid			2022-12-25	WOS:000221273800059
J	Yuan, FH; Lu, LY; Guo, SL; Wang, CM; Li, GM				Yuan, FH; Lu, LY; Guo, SL; Wang, CM; Li, GM			Evidence for involvement of HMGB1 protein in human DNA mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; TUMOR-CELLS; IN-VITRO; MICROSATELLITE INSTABILITY; REPLICATION FIDELITY; CHROMATIN PROTEIN; COLORECTAL-CANCER; ESCHERICHIA-COLI; BINDING; IDENTIFICATION	Defects in human DNA mismatch repair predispose to cancer, but many components of the pathway have not been identified. We report here the identification and characterization of a novel component required for mismatch repair in human cells. A 30-kDa protein was purified to homogeneity by virtue of its ability to complement a depleted HeLa extract in repair of mismatched heteroduplexes. The complementing activity was identified as HMGB1 ( the high mobility group box 1 protein), a non-histone chromatin protein that facilitates protein-protein interactions and recognizes DNA damage. Evidence is also presented that HMGB1 physically interacts with MutSalpha and is required at a step prior to the excision of mispaired nucleotide in mismatch repair.	Univ Kentucky, Med Ctr, Dept Pathol & Lab Med, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Li, GM (corresponding author), Univ Kentucky, Med Ctr, Dept Pathol & Lab Med, 800 Rose St, Lexington, KY 40536 USA.	gmli@uky.edu	Yuan, Fenghua/F-8736-2011; Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578	NATIONAL CANCER INSTITUTE [R01CA085377, R29CA072956] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85377, CA 72956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; BIANCHI ME, 1991, GENE, V104, P271, DOI 10.1016/0378-1119(91)90261-9; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Dintilhac A, 2002, J BIOL CHEM, V277, P7021, DOI 10.1074/jbc.M108417200; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; Fleck O, 1998, J BIOL CHEM, V273, P30398, DOI 10.1074/jbc.273.46.30398; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Grasser KD, 1998, EUR J BIOCHEM, V253, P787, DOI 10.1046/j.1432-1327.1998.2530787.x; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Gu LY, 2002, ONCOGENE, V21, P5758, DOI 10.1038/sj.onc.1205695; Guo SL, 2004, J BIOL CHEM, V279, P16912, DOI 10.1074/jbc.M313213200; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Iams K, 2002, J BIOL CHEM, V277, P30805, DOI 10.1074/jbc.M200846200; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lee KB, 1998, GENE, V225, P97, DOI 10.1016/S0378-1119(98)00542-3; Leung WK, 2000, J BIOL CHEM, V275, P15728, DOI 10.1074/jbc.M908768199; Li GM, 1999, ONCOL RES, V11, P393; Li GM, 2003, FRONT BIOSCI-LANDMRK, V8, pD997, DOI 10.2741/1121; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Lynch HT, 1999, J MED GENET, V36, P801; McCulloch SD, 2003, J BIOL CHEM, V278, P3891, DOI 10.1074/jbc.M210687200; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Ramilo C, 2002, MOL CELL BIOL, V22, P2037, DOI 10.1128/MCB.22.7.2037-2046.2002; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schmutte C, 1998, CANCER RES, V58, P4537; Stros M, 1998, J BIOL CHEM, V273, P10355; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tran PT, 2001, P NATL ACAD SCI USA, V98, P9760, DOI 10.1073/pnas.161175998; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	60	101	111	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20935	20940		10.1074/jbc.M401931200	http://dx.doi.org/10.1074/jbc.M401931200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15014079	hybrid			2022-12-25	WOS:000221273800047
J	Lu, M; Xia, LJ; Luo, D; Waxman, S; Jing, YK				Lu, M; Xia, LJ; Luo, D; Waxman, S; Jing, YK			Dual effects of glutathione-S-transferase pi on As2O3 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis	ONCOGENE			English	Article						arsenic trioxide; prostate cancer; glutathione-S-transferase pi	ACUTE PROMYELOCYTIC LEUKEMIA; ARSENIC TRIOXIDE AS2O3; ACTIVATION; RESISTANT; EXPRESSION; PROTEIN; ERK; DIFFERENTIATION; TOXICITY; INDUCER	To determine the effects of glutathione-S-transferase pi (GSTpi) on the actions of As2O3, As2O3-induced growth inhibition and apoptosis was studied in three prostate cancer cell lines: DU-145, PC-3 and LNCaP cells. As2O3 inhibited cell proliferation of DU-145 and PC-3 cells ( both cells express GSTpi), but not of LNCaP cells ( which lack GSTpi expression) at concentrations below 1 muM. LNCaP cells stably transfected and expressed GSTpi (LNCaP/GSTpi) became sensitive to As2O3 growth inhibition. As2O3 arrested cell growth of DU-145, PC-3 and LNCaP/GSTpi cells in the G2/M phase of the cell cycle at low concentrations (<2 mu M), but did not induce apoptosis. At higher concentrations (10-20 mu M), As2O3 induced apoptosis in LNCaP cells, but not in DU-145 or PC-3 cells. The apoptosis induction due to As2O3 treatment of LNCaP cell correlated with the activation of JNK and p38 and induction of p53 protein. LNCaP/GSTp cells became insensitive to As2O3-induced apoptosis with reduced JNK activition. These data indicate that GST pi increases growth inhibition due to As2O3 treatment and prevents As2O3-induced apoptosis in prostate cancer cells. Therefore, it appears that As2O3 inhibits cell growth and induces apoptosis through different mechanisms.	CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Jing, YK (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, Box 1178, New York, NY 10029 USA.	yongkui.jing@mssm.edu			NCI NIH HHS [CA93533, CA85478] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Bode A, 2000, DRUG RESIST UPDATE, V3, P21, DOI 10.1054/drup.2000.0114; Chen GQ, 2003, CANCER RES, V63, P1853; Chen GQ, 1997, BLOOD, V89, P3345; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Cookson MS, 1997, J UROLOGY, V157, P673, DOI 10.1016/S0022-5347(01)65248-0; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Gurr JR, 1999, MOL PHARMACOL, V56, P102, DOI 10.1124/mol.56.1.102; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang MJ, 2002, LEUKEMIA LYMPHOMA, V43, P2191, DOI 10.1080/1042819021000032980; Iwama K, 2001, INT J CANCER, V92, P518, DOI 10.1002/ijc.1220; Jing YK, 1997, CANCER RES, V57, P1668; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Liu J, 2001, MOL PHARMACOL, V60, P302, DOI 10.1124/mol.60.2.302; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; LO JF, 1992, BIOCHEM J, V288, P977, DOI 10.1042/bj2880977; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Moskaluk CA, 1997, CANCER-AM CANCER SOC, V79, P1595, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1595::AID-CNCR23>3.0.CO;2-S; Park JW, 2001, BIOCHEM BIOPH RES CO, V286, P726, DOI 10.1006/bbrc.2001.5416; Polek TC, 2003, ENDOCRINOLOGY, V144, P50, DOI 10.1210/en.2001-210109; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Styblo M, 2002, ENVIRON HEALTH PERSP, V110, P767, DOI 10.1289/ehp.02110s5767; Styblo M, 2000, ARCH TOXICOL, V74, P289, DOI 10.1007/s002040000134; WANG HF, 1993, BIOCHEM BIOPH RES CO, V192, P1093, DOI 10.1006/bbrc.1993.1529; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Yang CH, 1999, BRIT J CANCER, V81, P796, DOI 10.1038/sj.bjc.6690766; Yin ZM, 2000, CANCER RES, V60, P4053	36	35	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3945	3952		10.1038/sj.onc.1207500	http://dx.doi.org/10.1038/sj.onc.1207500			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007384				2022-12-25	WOS:000221382000006
J	Bedrosian, I; Lu, KH; Verschraegen, C; Keyomarsi, K				Bedrosian, I; Lu, KH; Verschraegen, C; Keyomarsi, K			Cyclin E deregulation alters the biologic properties of ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; cyclin E; cell cycle; lovastatin	TUMOR BREAST CELLS; POTENTIAL PROGNOSTIC MARKER; E EXPRESSION; LUNG-CANCER; G1 ARREST; SURVIVAL; OVEREXPRESSION; PROLIFERATION; AMPLIFICATION; SENSITIVITY	We have previously shown that the low molecular weight (LMW) forms (trunk 1 and trunk 2) of cyclin E are biochemically hyperactive and induce G1/S progression in normal epithelial cells. Here we investigate the biologic consequences of LMW cyclin E expression in ovarian cancer cells. Using a panel of ovarian carcinoma tumors we find that cyclin E overexpression is invariably due to the presence of LMW forms and that expression of these forms appears to correlate with more advanced grade and stage of disease. Despite similar expression of p21 and p27, cyclin E overexpressing tumors have higher kinase function. Using an isogenic ovarian cancer model, we find that clones that overexpress the trunk 1 (T1) protein have a 10-fold increase in cyclin E kinase function, a 20% increase in S-phase fraction, a 10-15% decrease in doubling time and a 20% increase in colony formation compared to parental cells that express only the FL cyclin E protein. T1 clones were resistant to G1 arrest but more sensitive to cisplatin. Therefore, in ovarian tumors, the presence of LMW cyclin E forms confers altered biologic properties. Our data provides a potential mechanism for the poor prognosis of patients with LMW cyclin E expressing tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; Univ New Mexico, Canc Res & Treatment Ctr, Dept Expt Therapeut, Albuquerque, NM 87131 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of New Mexico	Keyomarsi, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Box 66, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Verschraegen, Claire/AAE-7620-2020; Keyomarsi, Khandan/H-2716-2016	Verschraegen, Claire/0000-0001-6544-3089; Keyomarsi, Khandan/0000-0002-5440-0849	NCI NIH HHS [T32-CA09599-14, R01-CA87548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009599, R01CA087548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKLI S, 2003, CANCER BIOL THER, V2, P16; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cappella P, 2001, INT J CANCER, V93, P401, DOI 10.1002/ijc.1351.abs; Chen XM, 1999, ONCOGENE, V18, P5691, DOI 10.1038/sj.onc.1202948; Del Pizzo JJ, 1999, AM J PATHOL, V155, P1129, DOI 10.1016/S0002-9440(10)65216-9; Farley J, 2003, CANCER RES, V63, P1235; Fukuse T, 2000, CANCER RES, V60, P242; GrayBablin J, 1997, CANCER RES, V57, P604; Harwell RM, 2000, CANCER RES, V60, P481; Itamochi H, 2002, ONCOLOGY-BASEL, V62, P349, DOI 10.1159/000065067; Jang SJ, 1999, EUR J SURG ONCOL, V25, P157, DOI 10.1053/ejso.1998.0619; Johnson KR, 1997, CLIN CANCER RES, V3, P1739; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Kolfschoten GM, 2000, BRIT J CANCER, V83, P921, DOI 10.1054/bjoc.2000.1373; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Mishina T, 2000, CLIN CANCER RES, V6, P11; Muller-Tidow C, 2001, CANCER RES, V61, P647; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pestell KE, 2000, MOL PHARMACOL, V57, P503, DOI 10.1124/mol.57.3.503; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith ML, 2000, ANTICANCER RES, V20, P2537; Sui L, 2001, GYNECOL ONCOL, V83, P56, DOI 10.1006/gyno.2001.6308; Wang XD, 2003, ONCOGENE, V22, P769, DOI 10.1038/sj.onc.1206166; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wingate H, 2003, CELL CYCLE, V2, P461, DOI 10.4161/cc.2.5.464	35	58	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2648	2657		10.1038/sj.onc.1207408	http://dx.doi.org/10.1038/sj.onc.1207408			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15007381				2022-12-25	WOS:000220714900006
J	Teo, H; Veprintsev, DB; Williams, RL				Teo, H; Veprintsev, DB; Williams, RL			Structural insights into endosomal sorting complex required for transport (ESCRT-I) recognition of ubiquitinated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATING ENZYME COMPLEX; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; DOWN-REGULATION; TSG101; POLYUBIQUITIN; DOMAIN; BINDING; HOMOLOG; SURFACE	The endosomal sorting complex required for transport (ESCRT-I) is a 350-kDa complex of three proteins, Vps23, Vps28, and Vps37. The N-terminal ubiquitin-conjugating enzyme E2 variant (UEV) domain of Vps23 is required for sorting ubiquitinated proteins into the internal vesicles of multivesicular bodies. UEVs are homologous to E2 ubiquitin ligases but lack the conserved cysteine residue required for catalytic activity. The crystal structure of the yeast Vps23 UEV in a complex with ubiquitin (Ub) shows the detailed interactions made with the bound Ub. Compared with the solution structure of the Tsg101 UEV ( the human homologue of Vps23) in the absence of Ub, two loops that are conserved among the ESCRT-I UEVs move toward each other to grip the Ub in a pincer-like grasp. The contacts with the UEV encompass two adjacent patches on the surface of the Ub, one containing several hydrophobic residues, including Ile-8(Ub), Ile-44(Ub), and Val-70(Ub), and the second containing a hydrophilic patch including residues Asn-60(Ub), Gln-62(Ub), Glu-64(Ub). The hydrophobic Ub patch interacting with the Vps23 UEV overlaps the surface of Ub interacting with the Vps27 ubiquitin-interacting motif, suggesting a sequential model for ubiquitinated cargo binding by these proteins. In contrast, the hydrophilic patch encompasses residues uniquely interacting with the ESCRT-I UEV. The structure provides a detailed framework for design of mutants that can specifically affect ESCRT-I-dependent sorting of ubiquitinated cargo without affecting Vps27-mediated delivery of cargo to endosomes.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; MRC Ctr, Ctr Prot Engn, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology; MRC Laboratory Molecular Biology; University of Cambridge	Williams, RL (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	rlw@mrc-lmb.cam.ac.uk	Veprintsev, Dmitry B/H-2228-2012	Veprintsev, Dmitry B/0000-0002-3583-5409; Teo, Hsiang Ling/0000-0002-3849-809X; Williams, Roger/0000-0001-7754-4207	Medical Research Council [MC_U105184308] Funding Source: Medline; MRC [MC_U105184308] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bilodeau PS, 2003, J CELL BIOL, V163, P237, DOI 10.1083/jcb.200305007; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Ciani B, 2003, J BIOL CHEM, V278, P37409, DOI 10.1074/jbc.M307416200; Clague MJ, 2003, TRENDS CELL BIOL, V13, P603, DOI 10.1016/j.tcb.2003.10.002; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Feng GH, 2000, CANCER RES, V60, P1736; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Howell PL, 2000, ACTA CRYSTALLOGR D, V56, P604, DOI 10.1107/S0907444900002936; Jiang F, 1999, BIOCHEMISTRY-US, V38, P6471, DOI 10.1021/bi9901329; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kloor M, 2002, BBA-GENE STRUCT EXPR, V1579, P219, DOI 10.1016/S0167-4781(02)00543-2; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Ponting CP, 1997, J MOL MED-JMM, V75, P467; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Smith GD, 1998, ACTA CRYSTALLOGR D, V54, P799, DOI 10.1107/S0907444997018805; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Thomson TM, 2000, GENOME RES, V10, P1743, DOI 10.1101/gr.GR-1405R; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Turner MA, 1998, NAT STRUCT BIOL, V5, P369, DOI 10.1038/nsb0598-369; Uson I, 2003, ACTA CRYSTALLOGR D, V59, P57, DOI 10.1107/S090744490201884X; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Villalobo E, 2002, MOL BIOL EVOL, V19, P39, DOI 10.1093/oxfordjournals.molbev.a003980; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271	68	95	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28689	28696		10.1074/jbc.M400023200	http://dx.doi.org/10.1074/jbc.M400023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15044434	hybrid			2022-12-25	WOS:000222265400106
J	Zabolotny, JM; Haj, FG; Kim, YB; Kim, HJ; Shulman, GI; Kim, JK; Neel, BG; Kahn, BB				Zabolotny, JM; Haj, FG; Kim, YB; Kim, HJ; Shulman, GI; Kim, JK; Neel, BG; Kahn, BB			Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKT/PROTEIN KINASE-B; FAO HEPATOMA-CELLS; RAT ADIPOSE-CELLS; SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; C-ZETA; PHOSPHOINOSITIDE 3-KINASE; RECEPTOR SUBSTRATE-1; DIABETES-MELLITUS	Previous studies implicate protein-tyrosine phosphatase 1B (PTP1B) and leukocyte antigen-related phosphatase (LAR) as negative regulators of insulin signaling. The expression and/or activity of PTP1B and LAR are increased in muscle of insulin-resistant rodents and humans. Overexpression of LAR selectively in muscle of transgenic mice causes whole body insulin resistance. To determine whether overexpression of PTP1B also causes insulin resistance, we generated transgenic mice overexpressing human PTP1B selectively in muscle at levels similar to those observed in insulin-resistant humans. Insulin-stimulated insulin receptor (IR) tyrosyl phosphorylation and phosphatidylinositol 3'-kinase activity were impaired by 35% and 40-60% in muscle of PTP1B-overexpressing mice compared with controls. Insulin stimulation of protein kinase C (PKC)lambda/zeta activity, which is required for glucose transport, was impaired in muscle of PTP1B-overexpressing mice compared with controls, showing that PTP1B overexpression impairs activation of these PKC isoforms. Furthermore, hyperinsulinemic-euglycemic clamp studies revealed that whole body glucose disposal and muscle glucose uptake were decreased by 40-50% in PTP1B-overexpressing mice. Overexpression of PTP1B or LAR alone in muscle caused similar impairments in insulin action; however, compound overexpression achieved by crossing PTP1B- and LAR-overexpressing mice was not additive. Antibodies against specific IR phosphotyrosines indicated overlapping sites of action of PTP1B and LAR. Thus, overexpression of PTP1B in vivo impairs insulin sensitivity, suggesting that overexpression of PTP1B in muscle of obese humans and rodents may contribute to their insulin resistance. Lack of additive impairment of insulin signaling by PTP1B and LAR suggests that these PTPs have overlapping actions in causing insulin resistance in vivo.	Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Yale University; Howard Hughes Medical Institute; Yale University	Kahn, BB (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrine, 330 Brookline Ave,Res N 325E, Boston, MA 02215 USA.	bkahn@bidmc.harvard.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668; Kim, Jason/0000-0002-7185-042X	NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080756, F32DK009003, R01DK060838, P30DK046200, U24DK059635, K01DK062212, R01DK060839, R01DK040936] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA049152] Funding Source: Medline; NIDDK NIH HHS [K01 DK62212, R01 DK060839, R01 DK040936, R01 DK060838, U24 DK059635, R01 DK080756, P30 DK046200, DK09003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad F, 1997, METABOLISM, V46, P1140, DOI 10.1016/S0026-0495(97)90206-7; Ahmad F, 1997, J CLIN INVEST, V100, P449, DOI 10.1172/JCI119552; AHMAD F, 1995, J CLIN INVEST, V95, P2806, DOI 10.1172/JCI117985; AHMAD F, 1995, METABOLISM, V44, P1175, DOI 10.1016/0026-0495(95)90012-8; Ahmad F, 1997, J BIOL CHEM, V272, P448; AHMAD F, 1995, AM J PHYSIOL, V268, P932; Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; Anai M, 1999, DIABETES, V48, P158, DOI 10.2337/diabetes.48.1.158; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; Beeson M, 2003, DIABETES, V52, P1926, DOI 10.2337/diabetes.52.8.1926; Bezerra RMN, 2000, J NUTR, V130, P1531, DOI 10.1093/jn/130.6.1531; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Calera MR, 2000, J BIOL CHEM, V275, P6308, DOI 10.1074/jbc.275.9.6308; Carvalho CRO, 1996, ENDOCRINOLOGY, V137, P151, DOI 10.1210/en.137.1.151; Chen H, 1999, BIOCHEMISTRY-US, V38, P384, DOI 10.1021/bi9816103; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; Cheng A, 2002, EUR J BIOCHEM, V269, P1050, DOI 10.1046/j.0014-2956.2002.02756.x; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; Cheung A, 1999, J LAB CLIN MED, V134, P115, DOI 10.1016/S0022-2143(99)90115-4; Clampit JE, 2003, BIOCHEM BIOPH RES CO, V300, P261, DOI 10.1016/S0006-291X(02)02839-5; Di Paola R, 2002, AM J HUM GENET, V70, P806, DOI 10.1086/339270; Echwald SM, 2002, DIABETES, V51, P1; Egawa K, 2001, J BIOL CHEM, V276, P10207, DOI 10.1074/jbc.M009489200; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Etgen GJ, 1999, J BIOL CHEM, V274, P22139, DOI 10.1074/jbc.274.32.22139; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; Furuhata Y, 2002, J ENDOCRINOL, V172, P127, DOI 10.1677/joe.0.1720127; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Goldstein BJ, 1998, VITAM HORM, V54, P67, DOI 10.1016/S0083-6729(08)60922-X; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; Gum RJ, 2003, DIABETES, V52, P21, DOI 10.2337/diabetes.52.1.21; Gum RJ, 2003, MOL ENDOCRINOL, V17, P1131, DOI 10.1210/me.2002-0288; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; Hori H, 2002, DIABETES, V51, P2387, DOI 10.2337/diabetes.51.8.2387; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; Kanoh Y, 2000, J BIOL CHEM, V275, P16690, DOI 10.1074/jbc.M000287200; Kanoh Y, 2003, ENDOCRINOLOGY, V144, P947, DOI 10.1210/en.2002-221017; Kanoh Y, 2001, ENDOCRINOLOGY, V142, P1595, DOI 10.1210/en.142.4.1595; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Kim YB, 2002, J BIOL CHEM, V277, P32915, DOI 10.1074/jbc.M204710200; Kim YB, 2003, DIABETES, V52, P1935, DOI 10.2337/diabetes.52.8.1935; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; KUSARI J, 1994, J CLIN INVEST, V93, P1156, DOI 10.1172/JCI117068; Li PM, 1996, CELL SIGNAL, V8, P467, DOI 10.1016/S0898-6568(96)00101-5; Minokoshi Y, 2003, J BIOL CHEM, V278, P33609, DOI 10.1074/jbc.R300019200; Mok A, 2002, J CLIN ENDOCR METAB, V87, P724, DOI 10.1210/jc.87.2.724; Mooney RA, 1997, BIOCHEM BIOPH RES CO, V235, P709, DOI 10.1006/bbrc.1997.6889; Ogihara T, 2002, HYPERTENSION, V40, P83, DOI 10.1161/01.HYP.0000022880.45113.C9; Ogihara T, 2001, DIABETES, V50, P573, DOI 10.2337/diabetes.50.3.573; Pagliassotti MJ, 2002, AM J PHYSIOL-ENDOC M, V282, pE170, DOI 10.1152/ajpendo.2002.282.1.E170; Ren JM, 1998, DIABETES, V47, P493, DOI 10.2337/diabetes.47.3.493; Rondinone CM, 2002, DIABETES, V51, P2405, DOI 10.2337/diabetes.51.8.2405; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Shimizu S, 2002, ENDOCRINOLOGY, V143, P4563, DOI 10.1210/en.2002-220517; Standaert ML, 2002, DIABETES, V51, P2936, DOI 10.2337/diabetes.51.10.2936; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Tremblay F, 2001, DIABETES, V50, P1901, DOI 10.2337/diabetes.50.8.1901; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Vollenweider P, 2002, DIABETES, V51, P1052, DOI 10.2337/diabetes.51.4.1052; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Worm D, 1996, DIABETOLOGIA, V39, P1208, DOI 10.1007/BF02658508; Wu XD, 2001, J CLIN ENDOCR METAB, V86, P5973, DOI 10.1210/jc.86.12.5973; Yeo TT, 1997, J NEUROSCI RES, V47, P348, DOI 10.1002/(SICI)1097-4547(19970201)47:3<348::AID-JNR13>3.0.CO;2-Y; Zabolotny JM, 2001, P NATL ACAD SCI USA, V98, P5187, DOI 10.1073/pnas.071050398; Zhang WR, 1996, MOL ENDOCRINOL, V10, P575, DOI 10.1210/me.10.5.575; Zinker BA, 2002, P NATL ACAD SCI USA, V99, P11357, DOI 10.1073/pnas.142298199	76	129	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24844	24851		10.1074/jbc.M310688200	http://dx.doi.org/10.1074/jbc.M310688200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15031294	hybrid			2022-12-25	WOS:000221702500115
J	Banerjee, S; Hess, D; Majumder, P; Roy, D; Das, S				Banerjee, S; Hess, D; Majumder, P; Roy, D; Das, S			The interactions of Allium sativum leaf agglutinin with a chaperonin group of unique receptor protein isolated from a bacterial endosymbiont of the mustard aphid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICE BROWN PLANTHOPPER; BACILLUS-THURINGIENSIS; DELTA-ENDOTOXIN; NILAPARVATA-LUGENS; SNOWDROP LECTIN; GROEL HOMOLOG; PLANT-LECTINS; VIRUS; INSECT; BUCHNERA	The homopteran sucking insect, Lipaphis erysimi ( mustard aphid) causes severe damage to various crops. This pest not only affects plants by sucking on the phloem, but it also transmits single-stranded RNA luteoviruses while feeding, which cause disease and damage in the crop. The mannose-binding Allium sativum ( garlic) leaf lectin has been found to be a potent control agent of L. erysimi. The lectin receptor protein isolated from brush border membrane vesicle of insect gut was purified to determine the mechanism of lectin binding to the gut. Purified receptor was identified as an endosymbiotic chaperonin, symbionin, using liquid chromatography-tandem mass spectrometry. Symbionin from endosymbionts of other aphid species have been reported to play a significant role in virus transmission by binding to the read-through domain of the viral coat protein. To understand the molecular interactions of the said lectin and this unique symbionin molecule, the model structures of both molecules were generated using the Modeller program. The interaction was confirmed through docking of the two molecules forming a complex. A surface accessibility test of these molecules demonstrated a significant reduction in the accessibility of the complex molecule compared with that of the free symbionin molecule. This reduction in surface accessibility may have an effect on other molecular interactive processes, including "symbionin virion recognition", which is essential for such symbionin-mediated virus transmission. Thus, garlic leaf lectin provides an important component of a crop management program by controlling, on one hand, aphid attack and on the other hand, symbionin-mediated luteovirus transmission.	Bose Inst, Bioinformat Ctr, Kolkata 700054, W Bengal, India; Friedrich Miescher Inst Biomed Res, Prot & Peptide Analyt Lab, CH-4002 Basel, Switzerland	Department of Science & Technology (India); Bose Institute; Friedrich Miescher Institute for Biomedical Research	Das, S (corresponding author), Bose Inst, Bioinformat Ctr, P-1-12,CIT Scheme,VII-M, Kolkata 700054, W Bengal, India.	sampa@bic.boseinst.ernet.in	Das, Sampa/C-7132-2015					Andersson JO, 2000, CURR BIOL, V10, pR866, DOI 10.1016/S0960-9822(00)00816-2; Bandyopadhyay S, 2001, PLANT SCI, V161, P1025, DOI 10.1016/S0168-9452(01)00507-6; BARTON KA, 1987, PLANT PHYSIOL, V85, P1103, DOI 10.1104/pp.85.4.1103; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Douglas AE, 1997, FEMS MICROBIOL ECOL, V24, P1, DOI 10.1111/j.1574-6941.1997.tb00418.x; Douglas AE, 1998, ANNU REV ENTOMOL, V43, P17, DOI 10.1146/annurev.ento.43.1.17; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; ESKANDARI F, 1979, PHYTOPATHOLOGY, V69, P45, DOI 10.1094/Phyto-69-45; Filichkin SA, 1997, J VIROL, V71, P569, DOI 10.1128/JVI.71.1.569-577.1997; FUJIMOTO H, 1993, BIO-TECHNOL, V11, P1151, DOI 10.1038/nbt1093-1151; GATEHOUSE A, 1992, Patent No. 9202139; HILDER VA, 1995, TRANSGENIC RES, V4, P18, DOI 10.1007/BF01976497; Hogenhout SA, 1998, J VIROL, V72, P358, DOI 10.1128/JVI.72.1.358-365.1998; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; KOZIEL MG, 1993, BIO-TECHNOL, V11, P194, DOI 10.1038/nbt0293-194; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Moller Holger J., 1996, P627, DOI 10.1007/978-1-60327-259-9_99; Morin S, 1999, VIROLOGY, V256, P75, DOI 10.1006/viro.1999.9631; Nayak P, 1997, P NATL ACAD SCI USA, V94, P2111, DOI 10.1073/pnas.94.6.2111; Peferoen M., 1990, The molecular and cellular biology of the potato., P193; POWELL KS, 1995, ENTOMOL EXP APPL, V75, P61, DOI 10.1007/BF02382780; POWELL KS, 1995, ENTOMOL EXP APPL, V75, P51, DOI 10.1007/BF02382779; Ramachandraiah G, 2002, ACTA CRYSTALLOGR D, V58, P414, DOI 10.1107/S0907444901021497; Rao KV, 1998, PLANT J, V15, P469, DOI 10.1046/j.1365-313X.1998.00226.x; Roy A, 2002, J AGR FOOD CHEM, V50, P6775, DOI 10.1021/jf025660x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Silva FJ, 2001, TRENDS GENET, V17, P615, DOI 10.1016/S0168-9525(01)02483-0; VAKSER IA, 1994, PROTEINS, V20, P320, DOI 10.1002/prot.340200405; van den Heuvel JFJM, 1999, TRENDS MICROBIOL, V7, P71, DOI 10.1016/S0966-842X(98)01434-6; VandenHeuvel JFJM, 1997, J VIROL, V71, P7258, DOI 10.1128/JVI.71.10.7258-7265.1997; Wunn J, 1996, BIO-TECHNOL, V14, P171, DOI 10.1038/nbt0296-171; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; Young MJ, 1999, TRENDS MICROBIOL, V7, P346, DOI 10.1016/S0966-842X(99)01577-2	36	45	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23782	23789		10.1074/jbc.M401405200	http://dx.doi.org/10.1074/jbc.M401405200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15028723	hybrid			2022-12-25	WOS:000221570900121
J	Dumas, JJ; Kumar, R; McDonagh, T; Sullivan, F; Stahl, ML; Somers, WS; Mosyak, L				Dumas, JJ; Kumar, R; McDonagh, T; Sullivan, F; Stahl, ML; Somers, WS; Mosyak, L			Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ib alpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IB; FACTOR A1 DOMAIN; VIII-VONWILLEBRAND-FACTOR; VWF TETHER BOND; BINDING DOMAIN; IX COMPLEX; IDENTIFICATION; DISTINCT; AGGREGATION; ADHESION	The adhesion of platelets to the subendothelium of blood vessels at sites of vascular injury under high shear conditions is mediated by a direct interaction between the platelet receptor glycoprotein Ibalpha (GpIbalpha) and the A1 domain of the von Willebrand factor (VWF). Here we report the 2.6-Angstrom crystal structure of a complex comprised of the extracellular domain of GpIbalpha and the wild-type A1 domain of VWF. A direct comparison of this structure to a GpIbalpha-A1 complex containing "gain-of-function" mutations, A1-R543Q and GpIbalpha-M239V, reveals specific structural differences between these complexes at sites near the two GpIbalpha-A1 binding interfaces. At the smaller interface, differences in interaction show that the alpha1-beta2 loop of A1 serves as a conformational switch, alternating between an open alpha1-beta2 isomer that allows faster dissociation of GpIbalpha-A1, as observed in the wild-type complex, and an extended isomer that favors tight association as seen in the complex containing A1 with a type 2B von Willebrand Disease (VWD) mutation associated with spontaneous binding to GpIbalpha. At the larger interface, differences in interaction associated with the GpIbalpha-M239V platelet-type VWD mutation are minor and localized but feature discrete gamma-turn conformers at the loop end of the beta-hairpin structure. The beta-hairpin, stabilized by a strong classic gamma-turn as seen in the mutant complex, relates to the increased affinity of A1 binding, and the beta-hairpin with a weak inverse gamma-turn observed in the wild-type complex corresponds to the lower affinity state of GpIbalpha. These findings provide important details that add to our understanding of how both type 2B and platelet-type VWD mutations affect GpIbalpha-A1 binding affinity.	Wyeth, Dept Chem & Screening Sci, Cambridge, MA 02140 USA	Pfizer	Mosyak, L (corresponding author), Wyeth, Dept Chem & Screening Sci, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	lmosyak@wyeth.com						ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERNDT MC, 1992, BIOCHEMISTRY-US, V31, P11144, DOI 10.1021/bi00160a027; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUDDE U, 2001, REV CLIN EXP HEMATOL, V4, P335; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cauwenberghs N, 2001, BLOOD, V98, P652, DOI 10.1182/blood.V98.3.652; Celikel R, 2000, NAT STRUCT BIOL, V7, P881; Celikel R, 2003, SCIENCE, V301, P218, DOI 10.1126/science.1084183; CHRISTOPHE O, 1991, BLOOD, V78, P2310; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1990, J CLIN INVEST, V86, P785, DOI 10.1172/JCI114775; Doggett TA, 2003, BLOOD, V102, P152, DOI 10.1182/blood-2003-01-0072; Doggett TA, 2002, BIOPHYS J, V83, P194, DOI 10.1016/S0006-3495(02)75161-8; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dumas JJ, 2003, SCIENCE, V301, P222, DOI 10.1126/science.1083917; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; Fukuda K, 2002, STRUCTURE, V10, P943, DOI 10.1016/S0969-2126(02)00787-6; GINSBURG D, 1993, THROMB HAEMOSTASIS, V69, P177; Guruprasad K, 2000, J BIOSCIENCES, V25, P143, DOI 10.1007/BF03404909; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Lankhof H, 1996, THROMB HAEMOSTASIS, V75, P950; LAVALLIE ER, 1993, J BIOL CHEM, V268, P23311; Li CQ, 2002, THROMB HAEMOSTASIS, V88, P673, DOI 10.1055/s-0037-1613274; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; Miller JL, 1996, THROMB HAEMOSTASIS, V75, P865; MILNERWHITE EJ, 1990, J MOL BIOL, V216, P385, DOI 10.1016/S0022-2836(05)80329-8; MILNERWHITE EJ, 1988, J MOL BIOL, V204, P777, DOI 10.1016/0022-2836(88)90368-3; Miura S, 2000, J BIOL CHEM, V275, P7539, DOI 10.1074/jbc.275.11.7539; Miyata S, 1999, J BIOL CHEM, V274, P6586, DOI 10.1074/jbc.274.10.6586; MOHRI H, 1988, J BIOL CHEM, V263, P17901; Moriki T, 1997, BLOOD, V90, P698, DOI 10.1182/blood.V90.2.698.698_698_705; MURATA M, 1993, J CLIN INVEST, V92, P1555, DOI 10.1172/JCI116735; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RANDI AM, 1991, J CLIN INVEST, V87, P1220, DOI 10.1172/JCI115122; RODEGHIERO F, 1987, BLOOD, V69, P454; RUGGERI ZM, 1980, NEW ENGL J MED, V302, P1047, DOI 10.1056/NEJM198005083021902; RUGGERI ZM, 1982, BLOOD, V60, P1453; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; Ruggeri ZM, 2003, CURR OPIN HEMATOL, V10, P142, DOI 10.1097/00062752-200303000-00008; RUGGERI ZM, 1987, BLOOD, V70, P895; RUSSELL SD, 1993, BLOOD, V81, P1787; Sadler JE, 2000, THROMB HAEMOSTASIS, V84, P160; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; SADLER JE, 1991, J BIOL CHEM, V266, P22777; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SIBANDA BL, 1993, J MOL BIOL, V229, P428, DOI 10.1006/jmbi.1993.1044; SOBEL M, 1992, J BIOL CHEM, V267, P8857; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; WEISS HJ, 1982, NEW ENGL J MED, V306, P326, DOI 10.1056/NEJM198202113060603	63	156	162	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23327	23334		10.1074/jbc.M401659200	http://dx.doi.org/10.1074/jbc.M401659200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039442	hybrid			2022-12-25	WOS:000221570900067
J	Inami, M; Yamashita, M; Tenda, Y; Hasegawa, A; Kimura, M; Hashimoto, K; Seki, N; Taniguchi, M; Nakayama, T				Inami, M; Yamashita, M; Tenda, Y; Hasegawa, A; Kimura, M; Hashimoto, K; Seki, N; Taniguchi, M; Nakayama, T			CD28 costimulation controls histone hyperacetylation of the interleukin 5 gene locus in developing Th2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR GATA-3; CUTTING EDGE; TH2-SPECIFIC EXPRESSION; COORDINATE REGULATOR; CYTOKINE EXPRESSION; ACTIVATION; IL-4; DIFFERENTIATION; IDENTIFICATION	Interleukin 5 ( IL-5) plays a unique role in allergic inflammatory responses, and the understanding of molecular mechanisms underlying the generation of IL-5-producing cells is crucial for the regulation of allergic disorders. Differentiation of naive CD4 T cells into type-2 helper (Th2) cells is accompanied by chromatin remodeling including hyperacetylation of histones H3 and H4 in the nucleosomes associated with the IL-4, IL-13, and IL-5 genes. Histone hyperacetylation of the IL-5 gene displayed a delayed kinetics compared with that of the IL-4 and IL-13 genes, suggesting a distinct remodeling mechanism for the IL-5-gene locus. Here we studied the role of CD28 costimulation in the generation of IL-5-producing cells and the histone hyperacetylation of the IL-5 gene locus. CD28-costimulation selectively enhanced histone hyperacetylation of the IL-5 gene locus that appeared to be mediated through NF-kappaB activation and subsequent up-regulation of GATA3. The CD28 costimulation-sensitive histone hyperacetylation spanned almost the entire intergenic region between the IL-5 and RAD50 accompanied with intergenic transcript. Thus, this is the first demonstration that CD28 costimulation controls a chromatin-remodeling process during Th2 cell differentiation.	Chiba Univ, Grad Sch Med, Dept Immunol, Chuo Ku, Chiba 2608670, Japan; Chiba Inst Technol, Dept Life & Environm Sci, Chiba 2750016, Japan; Chiba Inst Technol, High Technol Res Ctr, Chiba 2750016, Japan; Fujisawa Pharmaceut Co Ltd, Dept Biosci, Exploratory Res Labs, Tsukuba, Ibaraki 3002698, Japan; RIKEN Res Ctr Allergy & Immunol, Lab Immune Regulat, Yokohama, Kanagawa 2300045, Japan	Chiba University; Chiba Institute of Technology; Chiba Institute of Technology; Astellas Pharmaceuticals; RIKEN	Nakayama, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Immunol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	tnakayama@faculty.chiba-u.jp	Taniguchi, Masaru/N-7932-2015; Nakayama, Toshinori/E-1067-2017	Taniguchi, Masaru/0000-0001-7821-7179; Nakayama, Toshinori/0000-0002-1434-2007				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agarwal S, 1998, CURR OPIN IMMUNOL, V10, P345, DOI 10.1016/S0952-7915(98)80174-X; Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Asnagli H, 2002, J IMMUNOL, V168, P4268, DOI 10.4049/jimmunol.168.9.4268; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Donovan CE, 1999, J IMMUNOL, V163, P6827; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Holloway AF, 2003, J EXP MED, V197, P413, DOI 10.1084/jem.20021039; Johnson K, 2003, MOL CELL BIOL, V23, P2438, DOI 10.1128/MCB.23.7.2438-2450.2003; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kane LP, 2003, IMMUNOL REV, V192, P7, DOI 10.1034/j.1600-065X.2003.00008.x; Kimura M, 2001, IMMUNITY, V15, P275, DOI 10.1016/S1074-7613(01)00182-0; Kishikawa H, 2001, J IMMUNOL, V167, P4414, DOI 10.4049/jimmunol.167.8.4414; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kubo M, 1999, J IMMUNOL, V163, P2432; Lavenu-Bombled C, 2002, J BIOL CHEM, V277, P18313, DOI 10.1074/jbc.M110013200; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lee HJ, 1998, J IMMUNOL, V160, P2343; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Mohrs M, 2001, NAT IMMUNOL, V2, P842, DOI 10.1038/ni0901-842; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; O'Garra A, 2000, NATURE, V404, P719, DOI 10.1038/35008191; Omori M, 2003, IMMUNITY, V19, P281, DOI 10.1016/S1074-7613(03)00210-3; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Rodriguez-Palmero M, 1999, EUR J IMMUNOL, V29, P3914; Rulifson IC, 1997, J IMMUNOL, V158, P658; Schwenger GTF, 2001, J BIOL CHEM, V276, P48502, DOI 10.1074/jbc.M107836200; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WARD SG, 1995, EUR J IMMUNOL, V25, P526, DOI 10.1002/eji.1830250233; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Yamashita M, 1998, INT IMMUNOL, V10, P577, DOI 10.1093/intimm/10.5.577; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Yamashita M, 2000, J EXP MED, V191, P1869, DOI 10.1084/jem.191.11.1869; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zhou MX, 2003, ONCOGENE, V22, P8137, DOI 10.1038/sj.onc.1206911	57	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23123	23133		10.1074/jbc.M401248200	http://dx.doi.org/10.1074/jbc.M401248200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039422	hybrid			2022-12-25	WOS:000221570900042
J	Ito, T; Hozumi, Y; Sakane, F; Saino-Saito, S; Kanoh, H; Aoyagi, M; Kondo, H; Goto, K				Ito, T; Hozumi, Y; Sakane, F; Saino-Saito, S; Kanoh, H; Aoyagi, M; Kondo, H; Goto, K			Cloning and characterization of diacylglycerol kinase iota splice variants in rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P16(INK4A); KAPPA-B COMPLEX; PHOSPHATIDIC-ACID; MOLECULAR-CLONING; ANKYRIN REPEAT; NUCLEAR-LOCALIZATION; SIGNAL TRANSDUCTION; ZINC-FINGER; PROTEIN; ZETA	Diacylglycerol kinase (DGK) catalyzes phosphorylation of a second messenger diacylglycerol (DG) to phosphatidic acid in cellular signal transduction. Previous studies have revealed that DGK consists of a family of isozymes including our rat clones. In this study we isolated from rat brain cDNA library the cDNA clones for a rat homologue of DGK iota(rDGKiota-1) that contains two zinc finger-like sequences, the highly conserved DGK catalytic domain, a bipartite nuclear localization signal, and four ankyrin repeats at the carboxyl terminus. In addition, we found novel splice variants, which contain either insertion 1 (71 bp) or insertion 2 (19 bp) or both in the carboxyl-terminal portion. Each of the insertions causes a frameshift, and the resultant premature stop codons produce two truncated forms (termed rDGKiota-2 and -iota-3), the former lacking the ankyrin repeats at the carboxyl terminus and the latter lacking a part of the catalytic domain and the ankyrin repeats. Truncation of the carboxyl-terminal portion clearly exerts effects on the detergent solubility and enzymatic activity of the splice variants, although all three variants showed similar cytoplasmic localization in cDNA-transfected cultured neurons despite the continued presence of the nuclear localization signal sequence. Immunoblot analysis using anti-rDGKiota antibody raised against the common amino-terminal portion clearly shows that these rDGKiota variants are indeed expressed in the brain. These results suggest that the carboxyl-terminal truncated forms of rDGKiota-2 and -iota-3 that exhibit reduced enzymatic activities might show a dominant negative effect against the intact rDGKiota-1, and that the modulation of signal transduction by the splice variants may play some roles in the physiologic and/or pathologic conditions of neurons.	Yamagata Univ, Sch Med, Dept Anat & Cell Biol, Yamagata 9909585, Japan; Yamagata Univ, Sch Med, Dept Otorhinolaryngol, Yamagata 9909585, Japan; Sapporo Med Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 0608556, Japan; Tohoku Univ, Grad Sch Med, Dept Cell Biol, Div Histol, Sendai, Miyagi 9808575, Japan	Yamagata University; Yamagata University; Sapporo Medical University; Tohoku University	Goto, K (corresponding author), Yamagata Univ, Sch Med, Dept Anat & Cell Biol, Iida Nishi 2-2-2, Yamagata 9909585, Japan.	kgoto@med.id.yamagata-u.ac.jp	Ito, Tsukasa/R-7201-2016; Sakane, Fumio/H-2693-2017; Hozumi, Yasukazu/AAO-6439-2020	Ito, Tsukasa/0000-0002-4237-3564; Sakane, Fumio/0000-0003-0857-0377; Hozumi, Yasukazu/0000-0002-9102-5419				Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; Ding L, 1998, J BIOL CHEM, V273, P32746, DOI 10.1074/jbc.273.49.32746; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; Goto K, 1999, CHEM PHYS LIPIDS, V98, P109, DOI 10.1016/S0009-3084(99)00023-7; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hogan A, 2001, J BIOL CHEM, V276, P26526, DOI 10.1074/jbc.M104156200; Houssa B, 1999, J BIOL CHEM, V274, P6820, DOI 10.1074/jbc.274.11.6820; Hozumi Y, 2003, EUR J NEUROSCI, V18, P1448, DOI 10.1046/j.1460-9568.2003.02871.x; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1983, J BIOL CHEM, V258, P1767; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Liu ZT, 2001, J BIOL CHEM, V276, P5900, DOI 10.1074/jbc.M007311200; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sakai N, 1999, MOL PHARMACOL, V56, P917, DOI 10.1124/mol.56.5.917; SAKANE F, 1991, J BIOL CHEM, V266, P7096; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; Ueyama T, 2000, BIOCHEM BIOPH RES CO, V269, P557, DOI 10.1006/bbrc.2000.2331; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Zhang B, 2000, J MOL BIOL, V299, P1121, DOI 10.1006/jmbi.2000.3803	41	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23317	23326		10.1074/jbc.M312976200	http://dx.doi.org/10.1074/jbc.M312976200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15024004	hybrid			2022-12-25	WOS:000221570900066
J	Lin, QC; Inselman, A; Han, X; Xu, H; Zhang, WJ; Handel, MA; Skoultchi, AI				Lin, QC; Inselman, A; Han, X; Xu, H; Zhang, WJ; Handel, MA; Skoultchi, AI			Reductions in linker histone levels are tolerated in developing spermatocytes but cause changes in specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE DEVELOPMENT; MICE LACKING; CELL-CYCLE; H1; SPERMATOGENESIS; CHROMATIN; TRANSCRIPTION; PROTEINS; DEPLETION; MEIOSIS	H1 linker histones are involved in packaging chromatin into 30-nm fibers and higher order structures. Most eukaryotic cells contain nearly one H1 molecule for each nucleosome core particle. Male germ cells in mammals contain large amounts of a germ cell-specific linker histone, HIST1HT, herein denoted H1t, which is particularly abundant in pachytene spermatocytes. Despite its abundance in male germ cells and significant divergence in primary sequence from other H1 subtypes, inactivation of the H1t gene in mice showed that it is not required for spermatogenesis. Analysis of germ cell chromatin from H1t null mice showed that other H1 subtypes, especially the testis-enriched HIST1H1A, herein denoted as the H1a subtype, were able to compensate for the absence of H1t to maintain a normal total H1 to nucleosome core ratio. To disrupt the compensation, we generated H1t and H1a double null mice by two sequential gene-targeting steps in embryonic stem cells. Elimination of both H1t and H1a led to a 25% decrease in the ratio of H1 to nucleosome cores in double null germ cells. Surprisingly, the reduction in H1 did not perturb spermatogenesis or produce detectable defects in meiotic processes. Microarray analysis of gene expression showed that the reduced linker histone levels did not affect global gene expression, but it did cause changes in expression of specific genes. Our results indicate that a partial reduction in linker histone-nucleosome core particle stoichiometry is tolerated in developing male germ cells.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Univ Tennessee, Dept Biochem & Mol Biol, Knoxville, TN 37996 USA	Yeshiva University; Albert Einstein College of Medicine; University of Tennessee System; University of Tennessee Knoxville	Skoultchi, AI (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	skoultch@aecom.yu.edu		Inselman, Amy/0000-0002-3335-7482	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD033816] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA079057, R56CA079057] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA079057, CA79057] Funding Source: Medline; NICHD NIH HHS [HD33816] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHLEY T, 1995, CHROMOSOMA, V104, P19, DOI 10.1007/BF00352222; Barra JL, 2000, MOL CELL BIOL, V20, P61, DOI 10.1128/MCB.20.1.61-69.2000; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; Cobb J, 1997, MOL REPROD DEV, V46, P489, DOI 10.1002/(SICI)1098-2795(199704)46:4&lt;489::AID-MRD7&gt;3.0.CO;2-K; Cohen PE, 1996, BIOL REPROD, V55, P310, DOI 10.1095/biolreprod55.2.310; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; DOBSON MJ, 1994, J CELL SCI, V107, P2749; DONG YH, 1994, NUCLEIC ACIDS RES, V22, P1421, DOI 10.1093/nar/22.8.1421; Drabent B, 2000, HISTOCHEM CELL BIOL, V113, P433; Drabent B, 1995, DNA SEQUENCE, V6, P41, DOI 10.3109/10425179509074698; Eaker S, 2001, J CELL SCI, V114, P2953; EVANS EP, 1964, CYTOGENETICS, V3, P289, DOI 10.1159/000129818; Fan YH, 2003, MOL CELL BIOL, V23, P4559, DOI 10.1128/MCB.23.13.4559-4572.2003; Fan YH, 2001, MOL CELL BIOL, V21, P7933, DOI 10.1128/MCB.21.23.7933-7943.2001; Fantz DA, 2001, BIOL REPROD, V64, P425, DOI 10.1095/biolreprod64.2.425; Freidkin I, 2001, NUCLEIC ACIDS RES, V29, P4043, DOI 10.1093/nar/29.19.4043; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; Hellauer K, 2001, J BIOL CHEM, V276, P13587, DOI 10.1074/jbc.M011196200; Hogan B, 1994, MANIPULATING MOUSE E; Inselman A, 2003, CYTOGENET GENOME RES, V103, P277, DOI 10.1159/000076813; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; Karrer KM, 1999, J BIOL CHEM, V274, P33020, DOI 10.1074/jbc.274.46.33020; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; LENNOX RW, 1984, J BIOL CHEM, V259, P669; Lin QC, 2000, MOL CELL BIOL, V20, P2122, DOI 10.1128/MCB.20.6.2122-2128.2000; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; Moens PB, 1997, CHROMOSOMA, V106, P207, DOI 10.1007/s004120050241; Patterton HG, 1998, J BIOL CHEM, V273, P7268, DOI 10.1074/jbc.273.13.7268; Puig S, 1999, CURR MICROBIOL, V39, P168, DOI 10.1007/s002849900440; Rabini S, 2000, EXP CELL RES, V255, P114, DOI 10.1006/excr.1999.4767; Ramon A, 2000, MOL MICROBIOL, V35, P223, DOI 10.1046/j.1365-2958.2000.01702.x; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; SAUNDERS MJ, 1990, MOL CELL BIOL, V10, P5721, DOI 10.1128/MCB.10.11.5721; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; Tanaka M, 2001, DEVELOPMENT, V128, P655; Ushinsky SC, 1997, YEAST, V13, P151, DOI 10.1002/(SICI)1097-0061(199702)13:2<151::AID-YEA94>3.0.CO;2-5; van Holde KE., 1989, SPRINGER SERIES MOL; Wang ZF, 1996, GENOME RES, V6, P688, DOI 10.1101/gr.6.8.688; Wang ZF, 1997, J MOL BIOL, V271, P124, DOI 10.1006/jmbi.1997.1166; Wei Y, 2002, DIFFERENTIATION, V70, P204, DOI 10.1046/j.1432-0436.2002.700409.x; WILTSHIRE T, 1995, DEV BIOL, V169, P557, DOI 10.1006/dbio.1995.1169; Wolffe A., 1998, CHROMATIN STRUCTURE; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	47	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23525	23535		10.1074/jbc.M400925200	http://dx.doi.org/10.1074/jbc.M400925200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039436	hybrid			2022-12-25	WOS:000221570900091
J	Takaku, H; Mutoh, E; Sagehashi, Y; Fukuda, R; Horiuchi, H; Ochi, K; Takagi, M; Ohta, A				Takaku, H; Mutoh, E; Sagehashi, Y; Fukuda, R; Horiuchi, H; Ochi, K; Takagi, M; Ohta, A			A Gcn4p homolog is essential for the induction of a ribosomal protein L41 variant responsible for cycloheximide resistance in the yeast Candida maltosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR PROTEIN; AMINO-ACID STARVATION; HOST-VECTOR SYSTEM; MESSENGER-RNA TRANSLATION; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; C-FOS; MASTER REGULATOR; LEUCINE ZIPPER; DNA	Cycloheximide (CYH) resistance in the yeast Candida maltosa is based on the inducible expression of genes encoding a variant of ribosomal protein L41-Q, with glutamine at position 56 instead of the proline found in normal L41. The promoter of L41-Q2a, one of the L41-Q gene alleles encoding L41-Q, has an element similar to the Gcn4p-responsive element of Saccharomyces cerevisiae. In a previous study, this element was shown to be essential for the induction of L41-Q by CYH. In the present study, a C. maltosa GCN4 homolog, C-GCN4, was cloned. It had a long 5'-leader region with three upstream open reading frames. Enhanced expression of the C-GCN4 reporter fusion gene upon the addition of 3-aminotriazole or by mutations in start codons of all three upstream open reading frames indicates that C-GCN4 expression is under translation repression as was seen with GCN4. The C-GCN4-depleted mutant was unable to grow in a nutrient medium containing CYH and did not express L41-Q genes. Recombinant C-Gcn4p bound to the consensus DNA element for Gcn4p, 5'-(G/ A)TGACTCAT-3', located upstream of L41-Q2a. Thus, C-Gcn4p, which likely functions in the general control of amino acid biosynthesis, is essential for the expression of L41-Q genes.	Univ Tokyo, Dept Biotechnol, Biotechnol Res Ctr, Bunkyo Ku, Tokyo 1138657, Japan; Niigata Univ Pharm & Appl Life Sci, Fac Appl Life Sci, Niigata 9568603, Japan; Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan	University of Tokyo; Niigata University; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Ohta, A (corresponding author), Univ Tokyo, Dept Biotechnol, Biotechnol Res Ctr, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.	aaohta@mail.ecc.u-tokyo.ac.jp						Albrecht G, 1998, J BIOL CHEM, V273, P12696, DOI 10.1074/jbc.273.21.12696; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Grundmann O, 2001, J BIOL CHEM, V276, P25661, DOI 10.1074/jbc.M101068200; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HIKIJI T, 1989, CURR GENET, V16, P261, DOI 10.1007/BF00422112; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V2, P319; Hoffmann B, 1999, MOL MICROBIOL, V31, P807, DOI 10.1046/j.1365-2958.1999.01219.x; Hoffmann B, 2001, MOL BIOL CELL, V12, P2846, DOI 10.1091/mbc.12.9.2846; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; KAWAI S, 1991, AGR BIOL CHEM TOKYO, V55, P59, DOI 10.1080/00021369.1991.10870559; KAWAI S, 1992, J BACTERIOL, V174, P254, DOI 10.1128/jb.174.1.254-262.1992; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; Marbach I, 2001, J BIOL CHEM, V276, P16944, DOI 10.1074/jbc.M100383200; MASUDA Y, 1994, CURR GENET, V25, P412, DOI 10.1007/BF00351779; Meimoun A, 2000, MOL BIOL CELL, V11, P915, DOI 10.1091/mbc.11.3.915; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MUTOH E, 1995, J BACTERIOL, V177, P5383, DOI 10.1128/jb.177.18.5383-5386.1995; Mutoh E, 1999, BIOCHEM BIOPH RES CO, V258, P611, DOI 10.1006/bbrc.1999.0631; Mutoh E, 1998, GENE, V224, P9, DOI 10.1016/S0378-1119(98)00518-6; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; OHKUMA M, 1991, DNA CELL BIOL, V10, P271, DOI 10.1089/dna.1991.10.271; OHKUMA M, 1995, BIOSCI BIOTECH BIOCH, V59, P1328, DOI 10.1271/bbb.59.1328; OHKUMA M, 1993, CURR GENET, V23, P205, DOI 10.1007/BF00351497; Ohkuma M, 1998, J BIOL CHEM, V273, P3948, DOI 10.1074/jbc.273.7.3948; OHKUMA M, 1991, AGR BIOL CHEM TOKYO, V55, P1757, DOI 10.1080/00021369.1991.10870878; Ohtsubo Y, 2001, J BIOL CHEM, V276, P36146, DOI 10.1074/jbc.M100302200; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAO PM, 1993, J CELL PHYSIOL, V156, P560, DOI 10.1002/jcp.1041560315; Ruiz-Echevarria MJ, 2000, CELL, V101, P741, DOI 10.1016/S0092-8674(00)80886-7; SASNAUSKAS K, 1992, GENE, V116, P105, DOI 10.1016/0378-1119(92)90636-4; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHURCH A, 1974, J BACTERIOL, V117, P1131; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; TAKAGI M, 1985, J GEN APPL MICROBIOL, V31, P267, DOI 10.2323/jgam.31.267; TAKAGI M, 1986, J BACTERIOL, V167, P551, DOI 10.1128/jb.167.2.551-555.1986; Takaku H, 2002, BIOSCI BIOTECH BIOCH, V66, P1936, DOI 10.1271/bbb.66.1936; THIREOS G, 1984, P NATL ACAD SCI-BIOL, V81, P5096, DOI 10.1073/pnas.81.16.5096; Tripathi G, 2002, EMBO J, V21, P5448, DOI 10.1093/emboj/cdf507; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wang P, 1998, FUNGAL GENET BIOL, V23, P81, DOI 10.1006/fgbi.1997.1023; Wanke C, 1997, MOL MICROBIOL, V23, P23, DOI 10.1046/j.1365-2958.1997.1741549.x; WOLFNER M, 1975, J MOL BIOL, V96, P273, DOI 10.1016/0022-2836(75)90348-4	59	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23030	23037		10.1074/jbc.M400888200	http://dx.doi.org/10.1074/jbc.M400888200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039451	hybrid			2022-12-25	WOS:000221570900031
J	Umlauf, E; Csaszar, E; Moertelmaier, M; Schuetz, GJ; Parton, RG; Prohaska, R				Umlauf, E; Csaszar, E; Moertelmaier, M; Schuetz, GJ; Parton, RG; Prohaska, R			Association of stomatin with lipid bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; DIFFERENTIATION-RELATED PROTEIN; DOMINANT-NEGATIVE MUTANT; ENDOPLASMIC-RETICULUM; TARGETING DOMAIN; PERILIPIN-A; DROPLETS; CELLS; CAVEOLIN; IDENTIFICATION	The oligomeric lipid raft-associated integral protein stomatin normally localizes to the plasma membrane and the late endosomal compartment. Similar to the caveolins, it is targeted to lipid bodies (LBs) on overexpression. Endogenous stomatin also associates with LBs to a small extent. Green fluorescent protein-tagged stomatin (StomGFP) and the dominant-negative caveolin-3 mutant DGV(cav3)(HA) occupy distinct domains on LB surfaces but eventually intermix. Studies of StomGFP deletion mutants reveal that the region for membrane association but not oligomerization and raft association is essential for LB targeting. Blocking protein synthesis leads to the redistribution of StomGFP from LBs to LysoTracker-positive vesicles indicating a connection with the late endosomal/ lysosomal pathway. Live microscopy of StomGFP reveals multiple interactions between LBs and microtubule-associated vesicles possibly representing signaling events and/or the exchange of cargo. Proteomic analysis of isolated LBs identifies adipophilin and TIP47, various lipid-specific enzymes, cytoskeletal components, chaperones, Ras-related proteins, protein kinase D2, and other regulatory proteins. The association of the Rab proteins 1, 6, 7, 10, and 18 with LBs indicates various connections to other compartments. Our data suggest that LBs are not only involved in the storage of lipids but also participate actively in the cellular signaling network and the homeostasis of lipids.	Med Univ Vienna, Vienna Bioctr, Inst Biochem, MFPL, A-1030 Vienna, Austria; Med Univ Vienna, Mass Spectrometry Unit, A-1030 Vienna, Austria; Johannes Kepler Univ, Inst Biophys, A-4040 Linz, Austria; Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, Brisbane, Qld 4072, Australia	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Medical University of Vienna; Johannes Kepler University Linz; University of Queensland	Prohaska, R (corresponding author), Med Univ Vienna, Vienna Bioctr, Inst Biochem, MFPL, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.	rainer.prohaska@univie.ac.at	Parton, Robert G/C-5673-2009; Schuetz, Gerhard/B-1243-2008	Parton, Robert G/0000-0002-7494-5248; Schuetz, Gerhard/0000-0003-1542-1089; Moertelmaier, Manuel/0000-0003-4239-9809				Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; Baulande S, 2001, J BIOL CHEM, V276, P33336, DOI 10.1074/jbc.M105193200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Caldas H, 2003, HUM MOL GENET, V12, P2981, DOI 10.1093/hmg/ddg321; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Durauer A, 2000, J CHROMATOGR A, V890, P145, DOI 10.1016/S0021-9673(00)00241-7; EMAMI S, 1992, ARCH DERMATOL, V128, P1213, DOI 10.1001/archderm.128.9.1213; Fong TH, 2001, BIOCHEM BIOPH RES CO, V289, P1168, DOI 10.1006/bbrc.2001.6080; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; GOODRUM JF, 1990, J NEUROCHEM, V55, P1928, DOI 10.1111/j.1471-4159.1990.tb05778.x; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1065, P195, DOI 10.1016/0005-2736(91)90230-6; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P123, DOI 10.1016/0167-4781(91)90047-P; Imamura M, 2002, AM J PHYSIOL-ENDOC M, V283, pE775, DOI 10.1152/ajpendo.00040.2002; Kamataki A, 2002, BIOCHEM BIOPH RES CO, V293, P1007, DOI 10.1016/S0006-291X(02)00323-6; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Lefevre C, 2001, AM J HUM GENET, V69, P1002, DOI 10.1086/324121; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; Mairhofer M, 2002, BLOOD, V100, P897, DOI 10.1182/blood.V100.3.897; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Milla P, 2002, J BIOL CHEM, V277, P2406, DOI 10.1074/jbc.M104195200; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Munster PN, 2001, CANCER RES, V61, P2945; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Ohashi M, 2003, J BIOL CHEM, V278, P36819, DOI 10.1074/jbc.M301408200; Ostermeyer AG, 2004, J CELL BIOL, V164, P69, DOI 10.1083/jcb.200303037; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Prattes S, 2000, J CELL SCI, V113, P2977; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rey O, 2003, BIOCHEM BIOPH RES CO, V302, P817, DOI 10.1016/S0006-291X(03)00269-9; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; SALZER U, 1993, BIOCHIM BIOPHYS ACTA, V1151, P149, DOI 10.1016/0005-2736(93)90098-K; Schild H, 2000, NAT IMMUNOL, V1, P100, DOI 10.1038/77770; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; Snyers L, 1997, EUR J CELL BIOL, V73, P281; Snyers L, 1999, FEBS LETT, V449, P101, DOI 10.1016/S0014-5793(99)00417-2; Snyers L, 1998, J BIOL CHEM, V273, P17221, DOI 10.1074/jbc.273.27.17221; Snyers L, 1999, EUR J CELL BIOL, V78, P802, DOI 10.1016/S0171-9335(99)80031-4; STEWART GW, 1992, BIOCHEM SOC T, V20, P785, DOI 10.1042/bst0200785; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Targett-Adams P, 2003, J BIOL CHEM, V278, P15998, DOI 10.1074/jbc.M211289200; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Than NG, 2003, EUR J BIOCHEM, V270, P1176, DOI 10.1046/j.1432-1033.2003.03475.x; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29; Vance JE, 1997, BBA-LIPID LIPID MET, V1344, P286, DOI 10.1016/S0005-2760(96)00153-1; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801; Wilson SHD, 2001, GENOMICS, V76, P81, DOI 10.1006/geno.2001.6610; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; YAMADA M, 1987, HEPATOLOGY, V7, P1224, DOI 10.1002/hep.1840070609; Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	70	201	207	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23699	23709		10.1074/jbc.M310546200	http://dx.doi.org/10.1074/jbc.M310546200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15024010	hybrid			2022-12-25	WOS:000221570900112
J	Werneck, CC; Trask, BC; Broekelmann, TJ; Trask, TM; Ritty, TM; Segade, F; Mecham, RP				Werneck, CC; Trask, BC; Broekelmann, TJ; Trask, TM; Ritty, TM; Segade, F; Mecham, RP			Identification of a major microfibril-associated glycoprotein-1-binding domain in fibrillin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-ASSOCIATED MICROFIBRILS; RICH MICROFIBRILS; TERMINAL DOMAINS; MAGP-1; MATRIX; LOCALIZATION; TROPOELASTIN; PROTEINS; BINDING; TRANSGLUTAMINASE	Using yeast two-hybrid, ligand blotting, and solid phase binding assays, we have shown that microfibril-associated glycoprotein-1 (MAGP-1) interacts with the 8-cysteine motif of fibrillin-2 encoded by exon 24. Binding to this sequence was demonstrated for full-length MAGP-1 as well as for the MAGP-1 matrix-binding domain encoded by exons 7 and 8. The matrix-binding domain, but not the full-length protein, also bound to regions of fibrillin-2 defined by exons 16 and 17, exon 20, and exons 23 and 24. Interestingly, no binding was detected to sequences near the N or C terminus where MAGP-1 and MAGP-2, respectively, were shown to interact with fibrillin-1. The localization of MAGP-1 binding to the 8-Cys domain encoded by exon 24 suggests that the bead structure of microfibrils consists of exon 24 and portions of the central region of fibrillin-2. Exon 24 in fibrillin lies in the region of the molecule where mutations produce the most severe phenotypes associated with Marfan syndrome (fibrillin-1) and congenital contractural arachnodactyly (fibrillin-2). It is possible that these mutations alter the ability of fibrillin to bind MAGP-1, which may contribute to the severity of the disease.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63110 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA	Washington University (WUSTL); Washington University (WUSTL); Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Mecham, RP (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	bmecham@cellbiology.wustl.edu	Werneck, Claudio C/C-7568-2012	Werneck, Claudio C/0000-0002-9413-0572	NHLBI NIH HHS [HL62295, HL53326, HL71960] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062295, R01HL071960] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aho S, 1998, MATRIX BIOL, V17, P401, DOI 10.1016/S0945-053X(98)90100-7; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; Charbonneau NL, 2003, J BIOL CHEM, V278, P2740, DOI 10.1074/jbc.M209201200; CHEN YP, 1993, J BIOL CHEM, V268, P27381; DAVIS EC, 1994, J CELL SCI, V107, P727; Doliana R, 2001, J BIOL CHEM, V276, P12003, DOI 10.1074/jbc.M011591200; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; KIELTY CM, 1995, INT J BIOCHEM CELL B, V27, P747, DOI 10.1016/1357-2725(95)00028-N; KUMARATILAKE JS, 1989, EUR J CELL BIOL, V50, P117; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; Lin S, 2002, J BIOL CHEM, V277, P10795, DOI 10.1074/jbc.M110246200; Penner AS, 2002, J BIOL CHEM, V277, P35044, DOI 10.1074/jbc.M206363200; Qian RQ, 1997, BIOCHEMISTRY-US, V36, P15841, DOI 10.1021/bi971036f; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Ryan MP, 1998, MOL CELL BIOL, V18, P1774, DOI 10.1128/MCB.18.4.1774; Segade F, 2002, J BIOL CHEM, V277, P11050, DOI 10.1074/jbc.M110347200; Sherratt MJ, 2001, MICRON, V32, P185, DOI 10.1016/S0968-4328(99)00082-7; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Trask BC, 2001, BIOCHEMISTRY-US, V40, P4372, DOI 10.1021/bi002738z; Trask TM, 2000, J BIOL CHEM, V275, P24400, DOI 10.1074/jbc.M003665200; Trask TM, 1999, BIOCHEM J, V340, P693, DOI 10.1042/0264-6021:3400693	30	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23045	23051		10.1074/jbc.M402656200	http://dx.doi.org/10.1074/jbc.M402656200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044481	hybrid, Green Published			2022-12-25	WOS:000221570900033
J	Holmqvist, K; Cross, MJ; Rolny, C; Hagerkvist, R; Rahimi, N; Matsumoto, T; Claesson-Welsh, L; Welsh, M				Holmqvist, K; Cross, MJ; Rolny, C; Hagerkvist, R; Rahimi, N; Matsumoto, T; Claesson-Welsh, L; Welsh, M			The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; T-CELLS; ACTIVATION; KDR; DIFFERENTIATION; TUBULOGENESIS; STIMULATION; KDR/FLK-1; GAMMA; GENE	Previous studies have shown that the adaptor protein Shb is involved in receptor tyrosine kinase signaling. In this study, we demonstrate that Shb is phosphorylated in an Src-dependent manner upon vascular endothelial growth factor ( VEGF) stimulation using porcine aortic endothelial cells expressing the human VEGF receptor 2 (VEGFR-2) (KDR). In co-immunoprecipitation experiments, we could detect an interaction between Shb and the VEGFR-2 in human telomerase-immortalized microvascular endothelial cells. Furthermore, in a glutathione S-transferase pull-down assay, the Src homology 2 domain of Shb was shown to interact with phosphorylated tyrosine 1175 in the C-terminal tail of VEGFR-2. VEGF-induced Shb phosphorylation was lost in porcine aortic endothelial cells expressing a chimeric murine VEGFR-2 (Flk-1) with a mutation at the corresponding position. Shb expression was specifically decreased by 80%, in a transient manner, by using the short interfering RNA technique. Reduced Shb expression led to a loss of stimulation of phosphatidylinositol 3-kinase, phosphorylation of focal adhesion kinase at tyrosine 576, the generation of focal adhesions, and stress fiber formation in response to VEGF. Furthermore, we show that VEGF-induced migration is inhibited in Shb short interfering RNA-treated cells. Our data demonstrate that Shb is important for VEGF signaling in endothelial cells. This is achieved by Shb binding to tyrosine 1175 in the VEGFR-2, which regulates VEGF-induced formation of focal adhesions and cell migration, of which the latter occurs in a phosphatidylinositol 3-kinase-dependent manner.	Uppsala Univ, Dept Med Cell Biol, S-75123 Uppsala, Sweden; Uppsala Univ, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; Nihon Univ, Sch Med, Div Cell Regenerat & Transplantat, Tokyo 1738610, Japan	Uppsala University; Uppsala University; Boston University; Nihon University	Welsh, M (corresponding author), Uppsala Univ, Dept Med Cell Biol, Box 571,Husargatan 3, S-75123 Uppsala, Sweden.	michael.welsh@medcellbiol.uu.se	Rolny, Charlotte/AET-0493-2022; Welsh, Michael/AAF-8564-2020	Welsh, Michael/0000-0002-5467-9755; Claesson-Welsh, Lena/0000-0003-4275-2000; Rolny, Charlotte/0000-0003-4979-9266; Rahimi, Nader/0000-0002-6745-1725				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Avraham HK, 2003, J BIOL CHEM, V278, P36661, DOI 10.1074/jbc.M301253200; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chou MT, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-32; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Cross MJ, 2002, MOL BIOL CELL, V13, P2881, DOI 10.1091/mbc.E02-02-0103; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Holmqvist K, 2003, CELL SIGNAL, V15, P171, DOI 10.1016/S0898-6568(02)00076-1; Hooshmand-Rad R, 2000, EXP CELL RES, V257, P245, DOI 10.1006/excr.2000.4896; ILLC D, 1995, NATURE, V377, P539; KARLSSON T, 1995, ONCOGENE, V10, P1475; Karlsson T, 1996, ONCOGENE, V13, P955; Karlsson T, 1998, CELL GROWTH DIFFER, V9, P757; Lindholm CK, 2000, BIOCHEM BIOPH RES CO, V278, P537, DOI 10.1006/bbrc.2000.3847; Lindholm CK, 1999, J BIOL CHEM, V274, P28050, DOI 10.1074/jbc.274.39.28050; Lindholm CK, 2002, BIOCHEM BIOPH RES CO, V296, P929, DOI 10.1016/S0006-291X(02)02016-8; Lu LG, 2002, CELL GROWTH DIFFER, V13, P141; MATSUMOTO T, 2001, SCI STKE; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Qi JH, 2001, EXP CELL RES, V263, P173, DOI 10.1006/excr.2000.5102; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Venetsanakos E, 2002, EXP CELL RES, V273, P21, DOI 10.1006/excr.2001.5424; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Warner AJ, 2000, BIOCHEM J, V347, P501, DOI 10.1042/0264-6021:3470501; WELSH M, 1994, ONCOGENE, V9, P19; Welsh M, 1998, ONCOGENE, V16, P891, DOI 10.1038/sj.onc.1201607	35	191	201	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22267	22275		10.1074/jbc.M312729200	http://dx.doi.org/10.1074/jbc.M312729200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15026417	hybrid			2022-12-25	WOS:000221417100074
J	Penrose, KJ; Garcia-Alai, M; de Prat-Gay, G; McBride, AA				Penrose, KJ; Garcia-Alai, M; de Prat-Gay, G; McBride, AA			Casein kinase II phosphorylation-induced conformational switch triggers degradation of the papillomavirus E2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PAPILLOMAVIRUS; SUBSTRATE DETERMINANTS; CIRCULAR-DICHROISM; DNA; E1; TRIFLUOROETHANOL; REPLICATION; CHROMOSOMES; SEQUENCES; PLASMIDS	The major phosphorylation sites of the bovine papillomavirus E2 transactivator protein are two serine residues, 298 and 301, that are located in a flexible hinge region between the DNA binding and transactivation domains. Phosphorylation of serine residue 301 promotes ubiquitination and rapid degradation of the E2 protein by the proteasome pathway. To understand the mechanism through which phosphorylation regulates the intracellular levels of this unique papillomavirus regulatory protein, we have carried out an extensive mutational analysis of the region surrounding the phosphorylation sites of the E2 protein. Our results indicate that casein kinase II phosphorylates serine 301. However, phosphorylation of serine 301 is not a sufficient recognition motif for proteasomal degradation; other residues that directly surround the phosphorylation sites are crucial for E2 degradation. The phenotypes of E2 proteins mutated in this region indicate that phosphorylation of serine 301 induces a conformational change that leads to degradation of the E2 protein. In support of this model, circular dichroism studies of the conformational tendencies of peptides from this region indicate that phosphorylation at position 301 decreases the local thermodynamic stability of this region. Thus, this region appears to have evolved to display a marginal local thermodynamic stability that can be regulated by phosphorylation, leading to targeted degradation of the E2 protein.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Univ Buenos Aires, Fdn Inst Leloir, RA-1405 Buenos Aires, DF, Argentina	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Leloir Institute; University of Buenos Aires	McBride, AA (corresponding author), NIAID, Viral Dis Lab, NIH, 4 Ctr Dr,MSC 0455,Bldg 4,Rm 137, Bethesda, MD 20892 USA.	amcbride@nih.gov		McBride, Alison/0000-0001-5607-5157; Prat Gay, Gonzalo/0000-0001-5748-6863	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000713, ZIAAI000713] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABU HO, 1998, MOL CELL BIOL, V18, P5670; Andrew CD, 2002, BIOCHEMISTRY-US, V41, P1897, DOI 10.1021/bi0113216; Bastien N, 2000, VIROLOGY, V270, P124, DOI 10.1006/viro.2000.0265; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Ciechanover A, 1999, MOL BIOL REP, V26, P59, DOI 10.1023/A:1006964122190; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; HAWLEYNELSON P, 1988, EMBO J, V7, P525, DOI 10.1002/j.1460-2075.1988.tb02841.x; HUBBERT NL, 1988, P NATL ACAD SCI USA, V85, P5864, DOI 10.1073/pnas.85.16.5864; Ilves I, 1999, J VIROL, V73, P4404, DOI 10.1128/JVI.73.5.4404-4412.1999; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; Lai MC, 1999, J BIOL CHEM, V274, P11832, DOI 10.1074/jbc.274.17.11832; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; Lehman CW, 1997, J VIROL, V71, P3652, DOI 10.1128/JVI.71.5.3652-3665.1997; LUSKY M, 1991, P NATL ACAD SCI USA, V88, P6363, DOI 10.1073/pnas.88.14.6363; MCBRIDE AA, 1989, J VIROL, V63, P5076, DOI 10.1128/JVI.63.12.5076-5085.1989; MCBRIDE AA, 1991, J VIROL, V65, P6528, DOI 10.1128/JVI.65.12.6528-6534.1991; MCBRIDE AA, 1997, HUMAN PAPILLOMAVIRUS, P54; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Messenger MM, 2002, J BIOL CHEM, V277, P23054, DOI 10.1074/jbc.M200111200; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Penrose KJ, 2000, J VIROL, V74, P6031, DOI 10.1128/JVI.74.13.6031-6038.2000; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rohl CA, 1997, BIOCHEMISTRY-US, V36, P8435, DOI 10.1021/bi9706677; Sanz JM, 2002, BIOCHEMISTRY-US, V41, P1923, DOI 10.1021/bi0157619; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shi ZS, 2002, ADV PROTEIN CHEM, V62, P163; Skiadopoulos MH, 1998, J VIROL, V72, P2079, DOI 10.1128/JVI.72.3.2079-2088.1998; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Steger G, 2002, J GEN VIROL, V83, P503, DOI 10.1099/0022-1317-83-3-503; Szilak L, 1997, NAT STRUCT BIOL, V4, P112, DOI 10.1038/nsb0297-112; TIFFANY ML, 1972, BIOPOLYMERS, V11, P2309; Voitenleitner C, 2002, J VIROL, V76, P3440, DOI 10.1128/JVI.76.7.3440-3451.2002; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zetina CR, 2001, PROTEINS, V44, P479, DOI 10.1002/prot.1113; Zou NX, 2000, J VIROL, V74, P3761, DOI 10.1128/JVI.74.8.3761-3770.2000	40	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22430	22439		10.1074/jbc.M314340200	http://dx.doi.org/10.1074/jbc.M314340200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15014086	hybrid, Green Published			2022-12-25	WOS:000221417100092
J	Vatamaniuk, OK; Mari, S; Lang, A; Chalasani, S; Demkiv, LO; Rea, PA				Vatamaniuk, OK; Mari, S; Lang, A; Chalasani, S; Demkiv, LO; Rea, PA			Phytochelatin synthase, a dipeptidyltransferase that undergoes multisite acylation with gamma-glutamylcysteine during catalysis - Stoichiometric and site-directed mutagenic analysis of Arabidopsis thaliana PCS1-catalyzed phytochelatin synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-METAL DETOXIFICATION; BINDING PEPTIDES; THIOL PEPTIDES; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; CAENORHABDITIS-ELEGANS; PHENOTYPIC SELECTION; TRANSFERASE PEPTIDES; AMINO-ACIDS; CADMIUM	Phytochelatin ( PC) synthase has been assumed to be a gamma-glutamylcysteine dipeptidyl transpeptidase (EC 2.3.2.15) and, more recently, as exemplified by analyses of the immunopurified recombinant enzyme from Arabidopsis thaliana (AtPCS1-FLAG), has been shown to catalyze a PC synthetic reaction with kinetics that approximates a bisubstrate-substituted enzyme mechanism in which millimolar concentrations of free GSH and micromolar concentrations of heavy metal.GSH thiolates (e.g. cadmium.GS(2)) or millimolar concentrations of S-alkylglutathiones serve as cosubstrates. Here, we show, by direct analyses of the stoichiometry of AtPCS1-FLAG-catalyzed PC synthesis, the kinetics and stoichiometry of acylation of the enzyme and release of free glycine from gamma-Glu-Cys donors, and the effects of the Cys-to-Ser or -Ala and Ser-to-Ala substitution of conserved residues in the catalytic N-terminal half of the enzyme, that PC synthase is indeed a dipeptidyltransferase that undergoes gamma-Glu-Cys acylation at two sites during catalysis, one of which, in accord with a cysteine protease model, likely corresponds to or is at least tightly coupled with Cys(56). The identity of the second site of enzyme modification remains to be determined, but it is distinguishable from the first Cys(56)-dependent site, which is amenable to gamma-Glu-Cys acylation by free GSH, because its acylation not only depends on the provision of Cd2+ or GSH with a blocked, S-alkylated thiol group, but is also necessary for net PC synthesis. We conclude that des-Gly-PCs are not generated as an immediate by-product, but rather that the enzyme catalyzes a dipeptidyl transfer reaction in which some of the energy liberated upon cleavage of the Cys-Gly bonds of the gamma-Glu-Cys donors in the first phase of the catalytic cycle is conserved through the formation of a two site-substituted gamma-Glu-Cys acyl-enzyme intermediate whose hydrolysis provides the energy required for the formation of the new peptide bond required for the extension of PC chain length by one gamma-Glu-Cys repeat per catalytic cycle.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Rea, PA (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, 3800 Hamilton Walk, Philadelphia, PA 19104 USA.	parea@sas.upenn.edu						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cazale AC, 2001, FEBS LETT, V507, P215, DOI 10.1016/S0014-5793(01)02976-3; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; CHEAH E, 1993, PROTEIN ENG, V6, P575, DOI 10.1093/protein/6.6.575; Clemens S, 2001, EUR J BIOCHEM, V268, P3640, DOI 10.1046/j.1432-1327.2001.02293.x; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett C, 2002, ANNU REV PLANT BIOL, V53, P159, DOI 10.1146/annurev.arplant.53.100301.135154; Cobbett CS, 1999, TRENDS PLANT SCI, V4, P335, DOI 10.1016/S1360-1385(99)01465-X; Cobbett CS, 2000, PLANT PHYSIOL, V123, P825, DOI 10.1104/pp.123.3.825; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GRILL E, 1989, P NATL ACAD SCI USA, V86, P6838, DOI 10.1073/pnas.86.18.6838; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; HOWDEN R, 1995, PLANT PHYSIOL, V107, P1059, DOI 10.1104/pp.107.4.1059; Humm A, 1997, BIOCHEM J, V322, P771, DOI 10.1042/bj3220771; Humm A, 1997, EMBO J, V16, P3373, DOI 10.1093/emboj/16.12.3373; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KLAPHECK S, 1994, PLANT PHYSIOL, V104, P1325, DOI 10.1104/pp.104.4.1325; KONDO N, 1984, TETRAHEDRON LETT, V25, P3869, DOI 10.1016/S0040-4039(01)91190-6; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KUBOTA H, 1995, PLANT SCI, V106, P157, DOI 10.1016/0168-9452(95)04020-U; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Maier T, 2003, PLANTA, V218, P300, DOI 10.1007/s00425-003-1091-7; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Mathews C.K., 2000, BIOCHEMISTRY; MEHRA RK, 1988, ARCH BIOCHEM BIOPHYS, V265, P381, DOI 10.1016/0003-9861(88)90141-5; MEHRA RK, 1988, P NATL ACAD SCI USA, V85, P8815, DOI 10.1073/pnas.85.23.8815; MEUWLY P, 1995, PLANT J, V7, P391, DOI 10.1046/j.1365-313X.1995.7030391.x; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; ORTIZ DF, 1995, J BIOL CHEM, V270, P4721, DOI 10.1074/jbc.270.9.4721; Oven M, 2002, J BIOL CHEM, V277, P4747, DOI 10.1074/jbc.M108254200; Rauser WE, 1999, CELL BIOCHEM BIOPHYS, V31, P19, DOI 10.1007/BF02738153; RAUSER WE, 1995, PLANT PHYSIOL, V109, P195, DOI 10.1104/pp.109.1.195; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Vatamaniuk OK, 2001, J BIOL CHEM, V276, P20817, DOI 10.1074/jbc.C100152200; Vatamaniuk OK, 2000, J BIOL CHEM, V275, P31451, DOI 10.1074/jbc.M002997200; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110; Vatamaniuk OK, 2002, TRENDS BIOTECHNOL, V20, P61, DOI 10.1016/S0167-7799(01)01873-X; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2	40	98	106	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22449	22460		10.1074/jbc.M313142200	http://dx.doi.org/10.1074/jbc.M313142200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15004013	Green Published, hybrid			2022-12-25	WOS:000221417100094
J	Gustafsson, AB; Tsai, JG; Logue, SE; Crow, MT; Gottlieb, RA				Gustafsson, AB; Tsai, JG; Logue, SE; Crow, MT; Gottlieb, RA			Apoptosis repressor with caspase recruitment domain protects against cell death by interfering with Bax activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; CARDIOMYOCYTE APOPTOSIS; CYTOCHROME-C; ENDOPLASMIC-RETICULUM; CARDIAC MYOCYTES; INHIBITOR; MITOCHONDRIA; EXPRESSION; RELEASE; STRESS	Myocardial ischemia/reperfusion (I/R) is associated with an extensive loss of myocardial cells. The apoptosis repressor with caspase recruitment domain (ARC) is a protein that is highly expressed in heart and skeletal muscle and has been demonstrated to protect the heart against I/R injury (Gustafsson, A. B., Sayen, M. R., Williams, S. D., Crow, M. T., and Gottlieb, R. A. (2002) Circulation 106, 735-739). In this study, we have shown that transduction of TAT-ARCL31F, a mutant of ARC in the caspase recruitment domain, did not reduce creatine kinase release and infarct size after I/R. TAT-ARCL31F also failed to protect against hydrogen peroxide-mediated cell death in H9c2 cells, suggesting that the caspase recruitment domain is important in mediating ARC's protective effects. In addition, we report that ARC co-immunoprecipitated with the pro-apoptotic protein Bax, which causes cytochrome c release when activated. TAT-ARC, but not TAT-ARCL31F, prevented Bax activation and cytochrome c release in hydrogen peroxide-treated H9c2 cells. TAT-ARC was also effective in blocking cytochrome c release after ischemia and reperfusion, whereas TAT-ARCL31F had no effect on cytochrome c release. In addition, recombinant ARC protein abrogated Bax-induced cytochrome c release from isolated mitochondria. This suggests that ARC can protect against cell death by interfering with activation of the mitochondrial death pathway through the interaction with Bax, preventing mitochondrial dysfunction and release of pro-apoptotic factors.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA	Scripps Research Institute; Johns Hopkins University	Gottlieb, RA (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM 220,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	robbieg@scripps.edu	Logue, Susan/K-7748-2019; Logue, Susan/G-3002-2010	Logue, Susan/0000-0001-7938-3558; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060590] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 60590] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Chau BN, 2000, MOL CELL, V6, P31, DOI 10.1016/S1097-2765(00)00005-8; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; Cook SA, 1999, CIRC RES, V85, P940; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Ekhterae D, 2003, AM J PHYSIOL-CELL PH, V284, pC1405, DOI 10.1152/ajpcell.00279.2002; Ekhterae D, 1999, CIRC RES, V85, pE70; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gustafsson AB, 2002, CIRCULATION, V106, P735, DOI 10.1161/01.CIR.0000023943.50821.F7; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kajstura J, 1996, LAB INVEST, V74, P86; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Li PF, 2002, MOL CELL, V10, P247, DOI 10.1016/S1097-2765(02)00600-7; Long XL, 1998, J CLIN INVEST, V101, P1453, DOI 10.1172/JCI345; Misao J, 1996, CIRCULATION, V94, P1506, DOI 10.1161/01.CIR.94.7.1506; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Neuss M, 2001, J BIOL CHEM, V276, P33915, DOI 10.1074/jbc.M104080200; Newmeyer DD, 2000, CELL DEATH DIFFER, V7, P402, DOI 10.1038/sj.cdd.4400665; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; ROUSLIN W, 1983, J BIOL CHEM, V258, P9657; Saraste A, 1997, CIRCULATION, V95, P320; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Thomenius MJ, 2003, J CELL SCI, V116, P4493, DOI 10.1242/jcs.00829; TSUCHIDA A, 1994, CIRC RES, V75, P576, DOI 10.1161/01.RES.75.3.576; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Wang B, 2003, J BIOL CHEM, V278, P14461, DOI 10.1074/jbc.M209684200; Wang DC, 1998, MOL CELL BIOCHEM, V180, P163, DOI 10.1023/A:1006815814283; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yaglom JA, 2003, J BIOL CHEM, V278, P50483, DOI 10.1074/jbc.M306903200; Yajima H, 2003, BIOCHEM BIOPH RES CO, V309, P520, DOI 10.1016/j.bbrc.2003.08.030; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	39	140	148	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21233	21238		10.1074/jbc.M400695200	http://dx.doi.org/10.1074/jbc.M400695200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15004034	hybrid			2022-12-25	WOS:000221273800083
J	Yamashita, T; Hoashi, Y; Watanabe, K; Tomisugi, Y; Ishikawa, Y; Uno, T				Yamashita, T; Hoashi, Y; Watanabe, K; Tomisugi, Y; Ishikawa, Y; Uno, T			Roles of heme axial ligands in the regulation of CO binding to CooA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING TRANSCRIPTIONAL ACTIVATOR; RESONANCE RAMAN; RHODOSPIRILLUM-RUBRUM; NITRIC-OXIDE; GENE SYNTHESIS; OXYGEN SENSOR; HISTIDINE 77; DNA-BINDING; PROTEIN; MYOGLOBIN	CooA is a CO-dependent transcription factor of the bacterium Rhodospirillum rubrum that contains a six-coordinate heme. It has as its heme axial ligands Pro(2) and Cys(75) in the ferric state and Pro(2) and His(77) in the ferrous state. To probe the regulation of CO binding and the ligand switching mechanism in CooA, we have prepared site-directed mutants in which the residues contributing the axial ligands are substituted. The properties of these mutants were investigated by resonance Raman and CO titration methods. Wild-type CooA binds CO with a modest dissociation constant (K-d) of 11 muM, this value being typical for gas-sensing heme proteins. The K-d value was greatly decreased in the P2H mutant, indicating that Pro(2) coordination fine tunes CO sensing in CooA. The bound CO in P2H gives rise to a nu(Fe-CO) stretching Raman line at 490 cm(-1), which is similar to that in wild-type CooA. Thus, Pro(2) is the ligand that is replaced by exogenous CO. In the H77A mutant, equilibrium CO binding is biphasic, and at high CO pressures two CO molecules occupy both axial sites. The nu(Fe-CO) stretching Raman line for the first CO molecule was observed at 497 cm(-1). Some of the His(77) mutants showed an additional nu(Fe-CO) line at 525 cm(-1). The binding affinity of the second CO molecule correlates with the five-coordinate component in the ferrous His(77) mutants and also with the acidity of the side chain at position 77. Thus, we propose the Cys(75)-His(77) ligand switch is controlled by His(77) acting as a proton reservoir.	Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan	Kumamoto University	Uno, T (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Oehonmachi, Kumamoto 8620973, Japan.	unot@gpo.kumamoto-u.ac.jp	Uno, Tadayuki/E-1622-2013	Uno, Tadayuki/0000-0003-2056-5781				Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2003, ACCOUNTS CHEM RES, V36, P825, DOI 10.1021/ar020097p; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CASIMIRO DR, 1995, BIOCHEMISTRY-US, V34, P6640, DOI 10.1021/bi00020a009; Chan MK, 2000, NAT STRUCT BIOL, V7, P822, DOI 10.1038/79559; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; Coyle CM, 2003, J BIOL CHEM, V278, P35384, DOI 10.1074/jbc.M301000200; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Dhawan IK, 1999, BIOCHEMISTRY-US, V38, P12805, DOI 10.1021/bi991303c; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; Kincaid J.R., 2000, PORPHYRIN HDB, V7, P227; Kumazaki S, 2000, J BIOL CHEM, V275, P38378, DOI 10.1074/jbc.M005533200; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Nakajima H, 2001, J BIOL CHEM, V276, P7055, DOI 10.1074/jbc.M003972200; OLDFIELD E, 1991, J AM CHEM SOC, V113, P7537, DOI 10.1021/ja00020a014; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; PRODROMOU C, 1992, PROTEIN ENG, V5, P827, DOI 10.1093/protein/5.8.827; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Reynolds MF, 1998, J AM CHEM SOC, V120, P9080, DOI 10.1021/ja981146p; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; Thorsteinsson MV, 2000, J BIOL CHEM, V275, P39332, DOI 10.1074/jbc.M007691200; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Uno T, 2004, J BIOL CHEM, V279, P5886, DOI 10.1074/jbc.M311748200; UNO T, 1987, J BIOL CHEM, V262, P4549; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; YU NT, 1983, BIOCHEMISTRY-US, V22, P4534, DOI 10.1021/bi00288a028	40	27	28	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21394	21400		10.1074/jbc.M400512200	http://dx.doi.org/10.1074/jbc.M400512200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15026411	hybrid			2022-12-25	WOS:000221273800103
J	Lew, CM; Gralla, JD				Lew, CM; Gralla, JD			Mechanism of stimulation of ribosomal promoters by binding of the+1 and+2 nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; OPEN COMPLEX-FORMATION; ESCHERICHIA-COLI; SIGMA-SUBUNIT; TRANSCRIPTION INITIATION; DEPENDENT REGULATION; CONSERVED REGION-3; CHAIN INITIATION; DNA; ELEMENT	The rate of transcription of Escherichia coli ribosomal RNA promoters is central to adjusting the cellular growth rate to nutritional conditions. The +1 initiating nucleotide and ppGpp are regulatory effectors of these promoters. The data herein show that in vitro transcription is also regulated by the +2 nucleotide. Both the +1 and +2 nucleotides act by driving polymerase into an altered conformation rather than by increasing the lifetime of transcription complexes. The unique design of the ribosomal promoters may stabilize a distorted state of polymerase that is relieved by the binding of the two nucleotides required for transcription initiation.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, POB 951569, Los Angeles, CA 90095 USA.	gralla@chem.ucla.edu						BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; Barker MM, 2001, J BACTERIOL, V183, P6315, DOI 10.1128/JB.183.21.6315-6323.2001; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Cashel M, 2003, J BIOL CHEM, V278, P5539, DOI 10.1074/jbc.M211430200; DAUSSE JP, 1975, EUR J BIOCHEM, V57, P569, DOI 10.1111/j.1432-1033.1975.tb02332.x; DICKSON RR, 1989, J BACTERIOL, V171, P4862, DOI 10.1128/jb.171.9.4862-4870.1989; Dombroski AJ, 1996, P NATL ACAD SCI USA, V93, P8858, DOI 10.1073/pnas.93.17.8858; Fenton MS, 2003, J BIOL CHEM, V278, P39669, DOI 10.1074/jbc.M307412200; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; GRALLA JD, 1980, BIOCHEMISTRY-US, V19, P5864, DOI 10.1021/bi00566a031; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Holmes SF, 2003, J BIOL CHEM, V278, P35597, DOI 10.1074/jbc.M304496200; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; Jores L, 2003, J BIOL CHEM, V278, P16834, DOI 10.1074/jbc.M300196200; Lew CM, 2002, J BIOL CHEM, V277, P41517, DOI 10.1074/jbc.M206912200; MANGEL WF, 1974, J BIOL CHEM, V249, P2995; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Murray HD, 2003, MOL CELL, V12, P125, DOI 10.1016/S1097-2765(03)00266-1; NIERMAN WC, 1979, J BIOL CHEM, V254, P7921; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OHLSEN KL, 1992, J BIOL CHEM, V267, P19813; OHLSEN KL, 1992, MOL MICROBIOL, V6, P2243, DOI 10.1111/j.1365-2958.1992.tb01400.x; REINESS G, 1975, P NATL ACAD SCI USA, V72, P2881, DOI 10.1073/pnas.72.8.2881; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SEVERINOV K, 1994, J BIOL CHEM, V269, P20826; Stano NM, 2002, J BIOL CHEM, V277, P37292, DOI 10.1074/jbc.M201600200; STEFANO JE, 1982, P NATL ACAD SCI-BIOL, V79, P1069, DOI 10.1073/pnas.79.4.1069; Strainic MG, 1998, BIOCHEMISTRY-US, V37, P18074, DOI 10.1021/bi9813431	30	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19481	19485		10.1074/jbc.M401285200	http://dx.doi.org/10.1074/jbc.M401285200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15010465	hybrid			2022-12-25	WOS:000221164500014
J	Shajahan, AN; Timblin, BK; Sandoval, R; Tiruppathi, C; Malik, AB; Minshall, RD				Shajahan, AN; Timblin, BK; Sandoval, R; Tiruppathi, C; Malik, AB; Minshall, RD			Role of Src-induced dynamin-2 phosphorylation in caveolae-mediated endocytosis in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; IN-VIVO; PLASMALEMMAL VESICLES; ALBUMIN TRANSCYTOSIS; PH DOMAIN; PROTEIN; BINDING; TRANSPORT; PATHWAY	Albumin transcytosis, a determinant of transendothelial permeability, is mediated by the release of caveolae from the plasma membrane. We addressed the role of Src phosphorylation of the GTPase dynamin-2 in the mechanism of caveolae release and albumin transport. Studies were made in microvascular endothelial cells in which the uptake of cholera toxin subunit B, a marker of caveolae, and I-125-albumin was used to assess caveolae-mediated endocytosis. Albumin binding to the 60-kDa cell surface albumin-binding protein, gp60, induced Src activation (phosphorylation on Tyr(416)) within 1 min and resulted in Src-dependent tyrosine phosphorylation of dynamin-2, which increased its association with caveolin-1, the caveolae scaffold protein. Expression of kinase-defective Src mutant interfered with the association between dynamin-2, which caveolin-1 and prevented the uptake of albumin. Expression of non-Src-phosphorylatable dynamin (Y231F/Y597F) resulted in reduced association with caveolin-1, and in contrast to WT-dynamin-2, the mutant failed to translocate to the caveolin-rich membrane fraction. The Y231F/Y597F dynamin-2 mutant expression also resulted in impaired albumin and cholera toxin subunit B uptake and reduced transendothelial albumin transport. Thus, Src-mediated phosphorylation of dynamin-2 is an essential requirement for scission of caveolae and the resultant transendothelial transport of albumin.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Minshall, RD (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, M-C 868,835 S Wolcott Ave, Chicago, IL 60612 USA.	rminsh@uic.edu		Shajahan-Haq, Ayesha/0000-0001-7616-320X; Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL 60678, T32 HL 07239, HL 71626] Funding Source: Medline; NIGMS NIH HHS [GM 58531] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071626, P01HL060678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058531] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Andersson E, 1998, J BIOL CHEM, V273, P4747, DOI 10.1074/jbc.273.8.4747; ANTOHE F, 1993, EUR J CELL BIOL, V60, P268; Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; Gilbert A, 1999, J CELL SCI, V112, P1101; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Henley JR, 1999, FASEB J, V13, pS243, DOI 10.1096/fasebj.13.9002.S243; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; John TA, 2003, AM J PHYSIOL-LUNG C, V284, pL187, DOI 10.1152/ajplung.00152.2002; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kim YN, 2002, ENDOCRINOLOGY, V143, P1726, DOI 10.1210/en.143.5.1726; LEMMON M, 2000, BIOCHEM J, V273, P27725; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; Minshall RD, 2002, HISTOCHEM CELL BIOL, V117, P105, DOI 10.1007/s00418-001-0367-x; Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057; Niles WD, 1999, J MEMBRANE BIOL, V167, P85, DOI 10.1007/s002329900474; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PITCHER J, 1995, J BIOL CHEM, V1270, P11070; PREDESCU D, 1993, AM J PHYSIOL, V265, pH725, DOI 10.1152/ajpheart.1993.265.2.H725; Predescu SA, 1997, AM J PHYSIOL-HEART C, V272, pH937, DOI 10.1152/ajpheart.1997.272.2.H937; Predescu SA, 2003, MOL BIOL CELL, V14, P4997, DOI 10.1091/mbc.e03-01-0041; Predescu SA, 2001, MOL BIOL CELL, V12, P1019, DOI 10.1091/mbc.12.4.1019; Scaife RM, 1997, CELL SIGNAL, V9, P395, DOI 10.1016/S0898-6568(97)00041-7; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1992, AM J PHYSIOL, V262, pH246, DOI 10.1152/ajpheart.1992.262.1.H246; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Tiruppathi C, 1996, P NATL ACAD SCI USA, V93, P250, DOI 10.1073/pnas.93.1.250; Tiruppathi C, 1997, J BIOL CHEM, V272, P25968, DOI 10.1074/jbc.272.41.25968; Vogel SM, 2001, MICROVASC RES, V61, P87, DOI 10.1006/mvre.2000.2274; Vogel SM, 2001, AM J PHYSIOL-LUNG C, V281, pL1512, DOI 10.1152/ajplung.2001.281.6.L1512	39	167	175	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20392	20400		10.1074/jbc.M308710200	http://dx.doi.org/10.1074/jbc.M308710200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15007081	hybrid			2022-12-25	WOS:000221164500118
J	Lee, EH; Rho, SH; Kwon, SJ; Eom, SH; Allen, PD; Kim, DH				Lee, EH; Rho, SH; Kwon, SJ; Eom, SH; Allen, PD; Kim, DH			N-terminal region of FKBP12 is essential for binding to the skeletal ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; FK506-BINDING PROTEIN FKBP; SARCOPLASMIC-RETICULUM; FK-506-BINDING PROTEIN; DEFECTIVE REGULATION; SELECTIVE BINDING; CHARGE MOVEMENT; MUSCLE; CONTRACTION; COMPLEX	It is known that the two types of FK506-binding proteins FKBP12 and FKBP12.6 are tightly associated with the skeletal (RyR1) and cardiac ryanodine receptors (RyR2), respectively, and their interactions are important for channel functions of the RyR. In the case of cardiac muscle, three amino acid residues (Gln-31, Asn-32, and Phe-59) of FKBP12.6 could be essential for the selective binding to RyR2 (Xin, H. B., Rogers, K., Qi, Y., Kanematsu, T., and Fleischer, S. ( 1999) J. Biol. Chem. 274, 15315-15319). In this study to identify amino acid residues of FKBP12 that are important for the selective binding to RyR1, we mutated 9 amino acid residues of FKBP12 that differ from the counterparts of FKBP12.6 (Q3E, R18A, E31Q, D32N, M49R, R57A, W59F, H94A, and K105A), and we examined binding properties of these mutants to RyR1 by in vitro binding assay by using glutathione S-transferase-fused proteins of the mutants and Triton X-100-solubilized, FKBP12-depleted rabbit skeletal sarcoplasmic reticulum vesicles. Among the nine mutants tested, only Q3E and R18A lost their selective binding ability to RyR1. Furthermore, co-immunoprecipitation of RyR1 with 33 various mutants for the 9 positions produced by introducing different size, charge, and hydrophobicity revealed that an integration of the hydrogen bonds by the irreplaceable Gln-3 and the hydrophobic interactions by the residues Arg-18 and Met-49 could be a possible mechanism for the binding of FKBP12 to RyR1. Therefore, these results suggest that the N-terminal regions of FKBP12 (Gln-3 and Arg-18) and Met-49 are essential and unique for binding of FKBP12 to RyR1 in skeletal muscle.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA	Gwangju Institute of Science & Technology (GIST); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kim, DH (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.	dhkim@kjist.ac.kr		Rho, Seong-Hwan/0000-0002-8650-8205; Lee, Eun Hui/0000-0003-4555-1730	NIAMS NIH HHS [AR P01-44650] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHERN GP, 1994, FEBS LETT, V352, P369, DOI 10.1016/0014-5793(94)01001-3; Ahern GP, 1997, BIOPHYS J, V72, P146, DOI 10.1016/S0006-3495(97)78654-5; Avila G, 2003, J BIOL CHEM, V278, P22600, DOI 10.1074/jbc.M205866200; Barg S, 1997, AM J PHYSIOL-CELL PH, V272, pC1726, DOI 10.1152/ajpcell.1997.272.5.C1726; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Bultynck G, 2001, J BIOL CHEM, V276, P47715, DOI 10.1074/jbc.M106573200; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Deivanayagam CCS, 2000, ACTA CRYSTALLOGR D, V56, P266, DOI 10.1107/S0907444999016571; DeLano WL, 2002, PYMOL USERS MANUAL; DULHUNTY AF, 1992, PROG BIOPHYS MOL BIO, V57, P181, DOI 10.1016/0079-6107(92)90024-Z; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Fulton KF, 2003, BIOCHEMISTRY-US, V42, P2364, DOI 10.1021/bi020564a; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; KIM DH, 1984, BIOCHIM BIOPHYS ACTA, V775, P320, DOI 10.1016/0005-2736(84)90187-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Main ERG, 2001, J BIOL PHYS, V27, P99, DOI 10.1023/A:1013137924581; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Masumiya H, 2003, J BIOL CHEM, V278, P3786, DOI 10.1074/jbc.M210962200; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Ogawa Y, 2000, TRENDS CARDIOVAS MED, V10, P65, DOI 10.1016/S1050-1738(00)00050-5; Reiken S, 2003, J CELL BIOL, V160, P919, DOI 10.1083/jcb.200211012; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; Rollins CT, 2000, P NATL ACAD SCI USA, V97, P7096, DOI 10.1073/pnas.100101997; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; Sorrentino V, 1999, TRENDS CARDIOVAS MED, V9, P54, DOI 10.1016/S1050-1738(99)00003-1; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; Xin HB, 1999, J BIOL CHEM, V274, P15315, DOI 10.1074/jbc.274.22.15315; Zhang J, 2003, J BIOL CHEM, V278, P14211, DOI 10.1074/jbc.M213164200; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; Zhang XJ, 1999, BIOCHEM J, V340, P519, DOI 10.1042/0264-6021:3400519; Zissimopoulos S, 2002, BIOPHYS J, V82, p59A	52	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26481	26488		10.1074/jbc.M309574200	http://dx.doi.org/10.1074/jbc.M309574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15033987	hybrid			2022-12-25	WOS:000222003000071
J	Walker, JV; Nitiss, KC; Jensen, LH; Mayne, C; Hu, T; Jensen, PB; Sehested, M; Hsieh, T; Nitiss, JL				Walker, JV; Nitiss, KC; Jensen, LH; Mayne, C; Hu, T; Jensen, PB; Sehested, M; Hsieh, T; Nitiss, JL			A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE ANALYSIS; GYRASE-B-PROTEIN; SACCHAROMYCES-CEREVISIAE; ELECTRON-MICROSCOPY; DOUBLE HELIX; ATP BINDING; ENZYME-DNA; RESISTANCE; MECHANISM; DRUGS	Type II DNA topoisomerases are ATP-dependent enzymes that catalyze alterations in DNA topology. These enzymes are important targets of a variety of anti-bacterial and anti-cancer agents. We identified a mutation in human topoisomerase II alpha, changing aspartic acid 48 to asparagine, that has the unique property of failing to transform yeast cells deficient in recombinational repair. In repair-proficient yeast strains, the Asp-48 --> Asn mutant can be expressed and complements a temperature-sensitive top2 mutation. Purified Asp-48 --> Asn Top2alpha has relaxation and decatenation activity similar to the wild type enzyme, but the purified protein exhibits several biochemical alterations compared with the wild type enzyme. The mutant enzyme binds both covalently closed and linear DNA with greater avidity than the wild type enzyme. hTop2alpha(Asp-48 --> Asn) also exhibited elevated levels of drug-independent cleavage compared with the wild type enzyme. The enzyme did not show altered sensitivity to bisdioxopiperazines nor did it form stable closed clamps in the absence of ATP, although the enzyme did form elevated levels of closed clamps in the presence of a non-hydrolyzable ATP analog compared with the wild type enzyme. We suggest that the lethality exhibited by the mutant is likely because of its enhanced drug-independent cleavage, and we propose that alterations in the ATP binding domain of the enzyme are capable of altering the interactions of the enzyme with DNA. This mutant enzyme also serves as a new model for understanding the action of drugs targeting topoisomerase II.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Rigshosp 5444, Lab Ctr, Dept Pathol, DK-2100 Copenhagen, Denmark; Duke Univ, Dept Biochem, Durham, NC 27710 USA; Rigshosp 5074, Finsen Ctr, Lab Expt Med Oncol, DK-2100 Copenhagen, Denmark	St Jude Children's Research Hospital; Rigshospitalet; Duke University; Rigshospitalet	Nitiss, JL (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.	John.nitiss@stjude.org	Hsieh, Tao-shih/G-9305-2012; Wu, Wan-lin/G-8937-2012; Nitiss, John/E-9974-2010	Nitiss, John/0000-0002-1013-4972	NATIONAL CANCER INSTITUTE [R25CA023944, R01CA082313, P30CA021765, R01CA052814] Funding Source: NIH RePORTER; NCI NIH HHS [CA52814, CA21765, R25 CA023944, CA82313] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benedetti P, 1997, J BIOL CHEM, V272, P12132, DOI 10.1074/jbc.272.18.12132; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Chang S, 1998, J BIOL CHEM, V273, P19822, DOI 10.1074/jbc.273.31.19822; Dong JW, 2000, J BIOL CHEM, V275, P7980, DOI 10.1074/jbc.275.11.7980; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; Fass D, 1999, NAT STRUCT BIOL, V6, P322; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; Fiorani P, 2000, ANN NY ACAD SCI, V922, P65; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; Hsiung Y, 1996, CANCER RES, V56, P91; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Kingma PS, 1998, J BIOL CHEM, V273, P17999, DOI 10.1074/jbc.273.29.17999; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; Leroy D, 2001, BIOCHEMISTRY-US, V40, P1624, DOI 10.1021/bi0019141; LEVIN NA, 1993, GENETICS, V133, P799; LEWIS RJ, 1994, J MOL BIOL, V241, P128, DOI 10.1006/jmbi.1994.1480; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; Mao Y, 1999, BIOCHEMISTRY-US, V38, P10793, DOI 10.1021/bi9909804; Morris SK, 1999, J BIOL CHEM, V274, P30690, DOI 10.1074/jbc.274.43.30690; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Nitiss JL, 1998, BIOCHEMISTRY-US, V37, P3078, DOI 10.1021/bi9723257; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; NITISS JL, 1992, CANCER RES, V52, P4467; Nitiss John L, 2002, Curr Opin Investig Drugs, V3, P1512; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Reid RJD, 1999, P NATL ACAD SCI USA, V96, P11440, DOI 10.1073/pnas.96.20.11440; Renodon-Corniere A, 2002, BIOCHEMISTRY-US, V41, P13395, DOI 10.1021/bi0263614; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Schultz P, 1996, P NATL ACAD SCI USA, V93, P5936, DOI 10.1073/pnas.93.12.5936; Sehested M, 1998, CANCER RES, V58, P1460; SHMERLING ZG, 1982, FEBS LETT, V140, P260, DOI 10.1016/0014-5793(82)80909-5; Strumberg D, 1999, J BIOL CHEM, V274, P28246, DOI 10.1074/jbc.274.40.28246; Walker JV, 2002, CANCER INVEST, V20, P570, DOI 10.1081/CNV-120002156; Wang HM, 2001, J BIOL CHEM, V276, P15990, DOI 10.1074/jbc.M011143200; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WASSERMAN RA, 1993, CANCER RES, V53, P3591; Wessel I, 1999, CANCER RES, V59, P3442; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; YANG L, 1985, CANCER RES, V45, P5872	51	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25947	25954		10.1074/jbc.M312314200	http://dx.doi.org/10.1074/jbc.M312314200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15037624	hybrid			2022-12-25	WOS:000222003000004
J	Midura, RJ; Wang, AM; Lovitch, D; Law, D; Powell, K; Gorski, JP				Midura, RJ; Wang, AM; Lovitch, D; Law, D; Powell, K; Gorski, JP			Bone acidic glycoprotein-75 delineates the extracellular sites of future bone sialoprotein accumulation and apatite nucleation in osteoblastic cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX VESICLES; IN-VITRO; EPIPHYSEAL CARTILAGE; RAT BONE; NONCOLLAGENOUS PROTEINS; ALKALINE-PHOSPHATASE; INSITU HYBRIDIZATION; COLLAGEN FIBRILS; N-RAP; EXPRESSION	Addition of an organophosphate source to UMR osteoblastic cultures activates a mineralization program in which BSP localizes to extracellular matrix sites where hydroxyapatite crystals are subsequently nucleated (Wang, A., Martin, J. A., Lembke, L. A., and Midura, R. J. (2000) J. Biol. Chem. 275, 11082-11091). This study identifies for the first time novel extracellular spherical structures, termed biomineralization foci (BMF), containing bone acidic glycoprotein-75 (BAG-75), bone sialoprotein (BSP), and alkaline phosphatase that are the exclusive sites of initial nucleation of hydroxyapatite crystals in the UMR model. Importantly, in the absence of added phosphate, UMR cultures after reaching confluency contain two size populations of morphologically identifiable BMF precursors enriched in BAG-75 (15-25 and 150-250 mum in diameter). The shape and size of the smaller population are similar to structures assembled in vitro through self-association of purified BAG-75 protein (Gorski, J. P., Kremer, E. A., Chen, Y., Ryan, S., Fullenkamp, C., Delviscio, J., Jensen, K., and McKee, M. D. (1997) J. Cell. Biochem. 64, 547-564). After organophosphate addition, BSP accumulates within these BAG-75-containing BMF precursors, with hydroxyapatite crystal nucleation occurring subsequently. In summary, BAG-75 is the earliest detectable biomarker that accurately predicts the extracellular sites of de novo biomineralization in UMR cultures. We hypothesize that BAG-75 may perform a key structural role in the assembly of BMF precursors and the recruitment of other proteins such as alkaline phosphatase and BSP. Furthermore, we propose a hypothetical mechanism in which BAG-75 and BSP function actively in nucleation of apatite within BMF.	Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Orthopaed Res Ctr, Cleveland, OH 44195 USA; Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, Kansas City, MO 64108 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City	Midura, RJ (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.	midura@bme.ri.ccf.org			NIAMS NIH HHS [AR-45171] Funding Source: Medline; NIDCR NIH HHS [DE-14619, DE-11197] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE014619, R03DE011197] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; BASKEY AL, 1995, ANN NY ACAD SCI, V769, P249; BIANCO P, 1993, J HISTOCHEM CYTOCHEM, V41, P193, DOI 10.1177/41.2.8419459; Bonewald LF, 2003, CALCIFIED TISSUE INT, V72, P537, DOI 10.1007/s00223-002-1057-y; BONNUCI E, 1989, CONNECT TISSUE RES, V22, P43; BONUCCI E, 1992, BONE MINER, V17, P219, DOI 10.1016/0169-6009(92)90740-5; Bonucci E, 1995, Connect Tissue Res, V33, P157, DOI 10.3109/03008209509016996; BONUCCI E, 1978, CALC TISS RES, V25, P179, DOI 10.1007/BF02010766; BONUCCI E, 1988, CLIN ORTHOP RELAT R, P243; Bonucci E., 1992, CALCIFICATION BIOL S, P19; BOSKEY AL, 1992, CLIN ORTHOP RELAT R, P244; Chang YL, 2000, J BIOMED MATER RES, V52, P270, DOI 10.1002/1097-4636(200011)52:2<270::AID-JBM5>3.0.CO;2-1; CHEN JK, 1992, J BONE MINER RES, V7, P987; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; CHEN Y, 1992, J BIOL CHEM, V267, P24871; EANES ED, 1992, CALCIFICATION BIOL S, P1; ECAROTCHARRIER B, 1989, J BIOL CHEM, V264, P20049; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; Gorski JP, 2003, J BONE MINER RES, V18, pS196; Gorski JP, 1996, CONNECT TISSUE RES, V35, P137, DOI 10.3109/03008209609029184; Gorski JP, 2004, J BIOL CHEM, V279, P25455, DOI 10.1074/jbc.M312408200; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; Gorski JP, 1997, J CELL BIOCHEM, V64, P547; Gorski JP, 1998, CRIT REV ORAL BIOL M, V9, P201, DOI 10.1177/10454411980090020401; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; HALE JE, 1987, J BIOL CHEM, V262, P1916; HALL BK, 1987, CLIN ORTHOP RELAT R, V225, P255; Herrera AH, 2000, CELL MOTIL CYTOSKEL, V45, P211, DOI 10.1002/(SICI)1097-0169(200003)45:3<211::AID-CM4>3.3.CO;2-P; HULTENBY K, 1994, EUR J CELL BIOL, V63, P230; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; HUNTER GK, 1994, BIOCHEM J, V302, P175, DOI 10.1042/bj3020175; IKEDA T, 1992, J HISTOCHEM CYTOCHEM, V40, P1079, DOI 10.1177/40.8.1619274; INGRAM RT, 1993, J BONE MINER RES, V8, P1019; Irie K, 1998, ANAT RECORD, V252, P554; Kimura K, 2000, VITAM HORM, V58, P257, DOI 10.1016/S0083-6729(00)58027-3; Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149; MAJESKA RJ, 1975, BIOCHIM BIOPHYS ACTA, V391, P51, DOI 10.1016/0005-2744(75)90151-5; MCQUILLAN DJ, 1995, BONE, V16, P415; Midura RJ, 1996, GLYCOBIOLOGY, V6, P677, DOI 10.1093/glycob/6.7.677; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; Nefussi JR, 1997, J HISTOCHEM CYTOCHEM, V45, P493, DOI 10.1177/002215549704500402; PERESS NS, 1974, CALC TISS RES, V14, P275, DOI 10.1007/BF02060301; POCKWINSE SM, 1992, J CELL BIOCHEM, V49, P310, DOI 10.1002/jcb.240490315; Qin CL, 2001, EUR J ORAL SCI, V109, P133, DOI 10.1034/j.1600-0722.2001.00001.x; RIMINUCCI M, 1995, CALCIFIED TISSUE INT, V57, P277, DOI 10.1007/BF00298883; SATO M, 1992, FASEB J, V6, P2966, DOI 10.1096/fasebj.6.11.1644260; SATOMURA K, 1991, ACTA ANAT, V142, P97; Sela J., 1992, CALCIFICATION BIOL S, P73; Shen ZX, 1995, MATRIX BIOL, V14, P773, DOI 10.1016/S0945-053X(05)80020-4; SHEPARD N, 1981, HISTOCHEMISTRY, V70, P107, DOI 10.1007/BF00493202; Shepard N., 1992, CALCIFICATION BIOL S, P41; STANFORD CM, 1995, J ORTHOPAED RES, V13, P664, DOI 10.1002/jor.1100130505; STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420; Sugawara Y, 2002, JPN J PHARMACOL, V88, P262, DOI 10.1254/jjp.88.262; Thiry M, 1999, PROG HISTOCHEM CYTO, V34, P93; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200; WANG A, 1999, T 45 ANN M ORTH RES, P209; Wang AM, 2000, J BIOL CHEM, V275, P11082, DOI 10.1074/jbc.275.15.11082; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Winchester SK, 1999, J CELL PHYSIOL, V181, P479, DOI 10.1002/(SICI)1097-4652(199912)181:3<479::AID-JCP12>3.0.CO;2-D; WU LNY, 1991, J BIOL CHEM, V266, P1195; Wu LNY, 1997, J BIOL CHEM, V272, P4404, DOI 10.1074/jbc.272.7.4404; WURTHIER RE, 1985, CHEM BIOL MINERALIZE, P113; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1989, CONNECT TISSUE RES, V22, P653, DOI 10.3109/03008208909114117; Zhang RQ, 2001, BIOCHEMISTRY-US, V40, P14898, DOI 10.1021/bi0107445; Zhu JX, 2001, HISTOCHEM J, V33, P25, DOI 10.1023/A:1017587712914	69	63	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25464	25473		10.1074/jbc.M312409200	http://dx.doi.org/10.1074/jbc.M312409200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15004030	hybrid			2022-12-25	WOS:000221827900070
J	Balasubramanian, S; Eckert, RL				Balasubramanian, S; Eckert, RL			Green tea polyphenol and curcumin inversely regulate human involucrin promoter activity via opposing effects on CCAAT/enhancer-binding protein function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; TRANSCRIPTION FACTORS C/EBP; CORNIFIED CELL-ENVELOPE; MOUSE EPIDERMIS; KERATINOCYTE DIFFERENTIATION; GENE-EXPRESSION; C-FOS; (-)-EPIGALLOCATECHIN GALLATE; CANCER CHEMOPREVENTION; MOLECULAR-MECHANISMS	Antioxidants are important candidate agents for the prevention of disease. However, the possibility that different antioxidants may produce opposing effects in tissues has not been adequately explored. We have reported previously that (-)-epigallocatechin-3-gallate (EGCG), a green tea polyphenol antioxidant, stimulates expression of the keratinocyte differentiation marker, involucrin (hINV), via a Ras, MEKK1, MEK3, p38delta signaling cascade (Balasubramanian, S., Efimova, T., and Eckert, R. L. (2002) J. Biol. Chem. 277, 1828-1836). We now show that EGCG activation of this pathway results in increased CCAAT/enhancer-binding protein (C/EBPalpha and C/EBPbeta) factor level and increased complex formation at the hINV promoter C/EBP DNA binding site. This binding is associated with increased promoter activity. Mutation of the hINV promoter C/EBP binding site eliminates the regulation as does expression of GADD153, a dominant-negative C/EBP factor. In contrast, a second antioxidant, curcumin, inhibits the EGCG-dependent promoter activation. This is associated with inhibition of the EGCG-dependent increase in C/EBP factor level and C/EBP factor binding to the hINV promoter. Curcumin also inhibits the EGCG-dependent increase in endogenous hINV levels. The curcumin-dependent suppression of C/EBP factor level is inhibited by treatment with the proteasome inhibitor MG132, suggesting that the proteasome function is required for curcumin action. We conclude that curcumin and EGCG produce opposing effects on involucrin gene expression via regulation of C/EBP factor function. The observation that two antioxidants can produce opposite effects is an important consideration in the context of therapeutic antioxidant use.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 2109 Adelbert Rd, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA134274] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarwal C, 1999, J BIOL CHEM, V274, P6190, DOI 10.1074/jbc.274.10.6190; Aggarwal BB, 2003, ANTICANCER RES, V23, P363; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 1999, NUTR REV, V57, P78, DOI 10.1111/j.1753-4887.1999.tb06927.x; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; Barthelman M, 1998, CARCINOGENESIS, V19, P2201, DOI 10.1093/carcin/19.12.2201; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; Bonte F, 1997, PLANTA MED, V63, P265, DOI 10.1055/s-2006-957669; Bush JA, 2001, EXP CELL RES, V271, P305, DOI 10.1006/excr.2001.5381; Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO;2-E; Chung JY, 1999, CANCER RES, V59, P4610; Chung JY, 2001, FASEB J, V15, P2022, DOI 10.1096/fj.01-0031fje; Dong ZG, 2000, BIOFACTORS, V12, P17, DOI 10.1002/biof.5520120104; Duvoix A, 2003, BIOCHEM PHARMACOL, V66, P1475, DOI 10.1016/S0006-2952(03)00501-X; ECKERT RL, 1989, ENVIRON HEALTH PERSP, V80, P109, DOI 10.2307/3430736; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Green H, 1980, Harvey Lect, V74, P101; Greenwald P, 2002, CANCER METAST REV, V21, P217, DOI 10.1023/A:1021202709003; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HERMAN WH, 1995, J BIOL CHEM, V270, P11654, DOI 10.1074/jbc.270.19.11654; Huang MT, 1997, J CELL BIOCHEM, P26; HUANG MT, 1988, CANCER RES, V48, P5941; HUANG MT, 1991, CANCER RES, V51, P813; Hungness ES, 2002, BIOCHEM BIOPH RES CO, V290, P469, DOI 10.1006/bbrc.2001.6168; Jee SH, 1998, J INVEST DERMATOL, V111, P656, DOI 10.1046/j.1523-1747.1998.00352.x; KATIYAR SK, 1993, CANCER RES, V53, P5409; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Kelloff GJ, 1999, ANN NY ACAD SCI, V889, P1, DOI 10.1111/j.1749-6632.1999.tb08718.x; Khafif A, 1998, CARCINOGENESIS, V19, P419, DOI 10.1093/carcin/19.3.419; KORUTLA L, 1995, CARCINOGENESIS, V16, P1741, DOI 10.1093/carcin/16.8.1741; Kumar AP, 2003, NEOPLASIA, V5, P255, DOI 10.1016/S1476-5586(03)80057-X; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Leu Tzeng-Horng, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P357, DOI 10.2174/1568011024606370; LU YP, 1993, CARCINOGENESIS, V14, P293, DOI 10.1093/carcin/14.2.293; LU YP, 1994, CARCINOGENESIS, V15, P2363, DOI 10.1093/carcin/15.10.2363; Manson MM, 2000, TOXICOL LETT, V112, P499, DOI 10.1016/S0378-4274(99)00211-8; Maytin EV, 1999, DEV BIOL, V216, P164, DOI 10.1006/dbio.1999.9460; Maytin EV, 1998, J INVEST DERMATOL, V110, P493; Mehta K, 1997, ANTI-CANCER DRUG, V8, P470, DOI 10.1097/00001813-199706000-00010; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Mukhtar H, 1999, P SOC EXP BIOL MED, V220, P234, DOI 10.1046/j.1525-1373.1999.d01-40.x; Nakayama K, 2001, J IMMUNOL, V167, P1145, DOI 10.4049/jimmunol.167.3.1145; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; Phan TT, 2001, J TRAUMA, V51, P927, DOI 10.1097/00005373-200111000-00017; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Shim M, 2003, J BIOL CHEM, V278, P19674, DOI 10.1074/jbc.M301356200; Steinert P M, 1995, Cell Death Differ, V2, P33; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Surh YJ, 2002, FOOD CHEM TOXICOL, V40, P1091, DOI 10.1016/S0278-6915(02)00037-6; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Surh YJ, 1999, MUTAT RES-FUND MOL M, V428, P305, DOI 10.1016/S1383-5742(99)00057-5; Tedeschi E, 2002, ANN NY ACAD SCI, V973, P435, DOI 10.1111/j.1749-6632.2002.tb04678.x; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wong Y F, 1996, J Obstet Gynaecol Res, V22, P171; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; YAN MH, 1994, J BIOL CHEM, V269, P19067; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	67	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24007	24014		10.1074/jbc.M314331200	http://dx.doi.org/10.1074/jbc.M314331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044435	hybrid			2022-12-25	WOS:000221702500022
J	Bernard, J; Harb, C; Mortier, E; Quemener, A; Meloen, RH; Vermot-Desroches, C; Wijdeness, J; van Dijken, P; Grotzinger, J; Slootstra, JW; Plet, A; Jacques, Y				Bernard, J; Harb, C; Mortier, E; Quemener, A; Meloen, RH; Vermot-Desroches, C; Wijdeness, J; van Dijken, P; Grotzinger, J; Slootstra, JW; Plet, A; Jacques, Y			Identification of an interleukin-15 alpha receptor-binding site on human interleukin-15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH-FACTOR; ALPHA-CHAIN; IL-2 RECEPTOR; 3-DIMENSIONAL STRUCTURE; SEQUENCE ALIGNMENT; IL-15R-ALPHA CHAIN; NATURAL-KILLER; BETA-CHAIN; IN-VIVO; PROTEIN	To identify the epitopes in human interleukin-15 (IL-15) that are responsible for binding to the interleukin-15 receptor alpha chain, antibody and receptor mapping by peptide scanning and site-directed mutagenesis was used. By using peptide scanning, we identified four regions in IL-15. The first region ((CKECEELEEKN95)-C-85) is located in the C-D loop and is recognized by a set of non-inhibitory antibodies. The second region ((102)SFVHIVQMFIN(112)) is located in helix D and is recognized by two antibodies that are inhibitory of IL-15 bio-activity but not of IL-15 binding to IL-15Ralpha. The two remaining regions react with a recombinant soluble form of the IL-15Ralpha; the first ((44)LLELQVISL(52), peptide 1) corresponds to a sequence located in the B-helix and the second ((ENLII68)-E-64, peptide 2) to a sequence located in helix C. The latter is also contained in the epitope recognized by an antibody ( monoclonal antibody B-E29) that prevents IL-15 binding to IL-15Ralpha. By site-directed mutagenesis, we confirmed that residues present in peptide 1 (Leu-45, Glu-46, Val-49, Ser-51, and Leu-52) and peptide 2 (Leu-66 and Ile-67) are involved in the binding of IL-15 to IL-15Ralpha. Furthermore, the results presented indicate that residues in the second peptide (Glu-64, Asn-65, and Ile-68) participate in IL-2Rbeta recruitment. This finding could have implications for the dynamics of receptor assembly. These results also indicate that the modes of interaction of IL-15 and IL-2 with their respective alpha chains are not completely analogous. Finally, some of the IL-15 mutants generated in this study displayed agonist or antagonist properties and may be useful as therapeutic agents.	Inst Biol, Grp Rech Cytokines & Recepteurs, Unite 601, INSERM, F-44093 Nantes 01, France; Pepscan Syst, NL-8219 PH Lelystad, Netherlands; Diaclone, F-25020 Besancon, France; Univ Kiel, Dept Biochem, D-24098 Kiel, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Kiel	Jacques, Y (corresponding author), Inst Biol, Grp Rech Cytokines & Recepteurs, Unite 601, INSERM, 9 Quai Moncousu, F-44093 Nantes 01, France.	yjacques@nantes.inserm.fr	Mortier, Erwan/B-2189-2009; Mortier, Erwan/AAH-7925-2021; QUEMENER, Agnès/R-9489-2019	QUEMENER, Agnès/0000-0002-4026-8496; Mortier, Erwan/0000-0002-6321-6488				ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; BAMBOROUGH P, 1994, STRUCTURE, V2, P839, DOI 10.1016/S0969-2126(94)00085-9; BLACK J, 1989, SCIENCE, V139, P1550; Blanc C, 2000, J IMMUNOL METHODS, V241, P43, DOI 10.1016/S0022-1759(00)00194-0; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Bulanova E, 2001, J IMMUNOL, V167, P6292, DOI 10.4049/jimmunol.167.11.6292; Bulfone-Paus S, 1999, FASEB J, V13, P1575, DOI 10.1096/fasebj.13.12.1575; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Chang DZ, 1996, J BIOL CHEM, V271, P13349, DOI 10.1074/jbc.271.23.13349; COLLINS L, 1988, P NATL ACAD SCI USA, V85, P7709, DOI 10.1073/pnas.85.20.7709; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; Farner NL, 1997, CYTOKINE, V9, P316, DOI 10.1006/cyto.1996.0171; Fehniger TA, 2002, CYTOKINE GROWTH F R, V13, P169, DOI 10.1016/S1359-6101(01)00021-1; Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; GIRI JG, 1995, J LEUKOCYTE BIOL, V57, P763, DOI 10.1002/jlb.57.5.763; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GREENE WC, 1985, J EXP MED, V162, P363, DOI 10.1084/jem.162.1.363; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lehours P, 2000, EUR CYTOKINE NETW, V11, P207; Li XC, 2001, NAT MED, V7, P114, DOI 10.1038/83253; Lodolce JP, 2001, J EXP MED, V194, P1187, DOI 10.1084/jem.194.8.1187; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Maple JR, 1998, J COMPUT CHEM, V19, P430, DOI 10.1002/(SICI)1096-987X(199803)19:4<430::AID-JCC5>3.0.CO;2-T; Marks-Konczalik J, 2000, P NATL ACAD SCI USA, V97, P11445, DOI 10.1073/pnas.200363097; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Pereno R, 2000, ONCOGENE, V19, P5153, DOI 10.1038/sj.onc.1203873; Pettit DK, 1997, J BIOL CHEM, V272, P2312; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAUVE K, 1991, P NATL ACAD SCI USA, V88, P4636, DOI 10.1073/pnas.88.11.4636; Shanafelt AB, 2000, NAT BIOTECHNOL, V18, P1197, DOI 10.1038/81199; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Slootstra JW, 1996, MOL DIVERS, V1, P87, DOI 10.1007/BF01721323; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; Stevens AC, 1997, AM J PHYSIOL-GASTR L, V272, pG1201, DOI 10.1152/ajpgi.1997.272.5.G1201; TEJEDOR F, 1982, ANAL BIOCHEM, V127, P143, DOI 10.1016/0003-2697(82)90156-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILKINSON PC, 1995, J EXP MED, V181, P1255, DOI 10.1084/jem.181.3.1255; ZURAWSKI SM, 1993, EMBO J, V12, P5113, DOI 10.1002/j.1460-2075.1993.tb06206.x	52	53	92	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24313	24322		10.1074/jbc.M312458200	http://dx.doi.org/10.1074/jbc.M312458200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15039446	hybrid			2022-12-25	WOS:000221702500057
J	Bobe, R; Bredoux, R; Corvazier, E; Andersen, JP; Clausen, JD; Dode, L; Kovacs, T; Enouf, J				Bobe, R; Bredoux, R; Corvazier, E; Andersen, JP; Clausen, JD; Dode, L; Kovacs, T; Enouf, J			Identification, expression, function, and localization of a novel (sixth) isoform of the human sarco/endoplasmic reticulum Ca2+ ATPase 3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; CALCIUM-PUMP; MESSENGER-RNA; DEPENDENT RELAXATION; MONOCLONAL-ANTIBODY; TISSUE DISTRIBUTION; MEMBRANE-VESICLES; LYMPHOID-CELLS; HUMAN-PLATELET	Understanding of Ca2+ signaling requires the knowledge of proteins involved in this process. Among these proteins are sarco/endoplasmic reticulum Ca2+-ATPases (SERCAs) that pump Ca2+ into the endoplasmic reticulum (ER). Recently, the human SERCA3 gene was shown to give rise to five isoforms (SERCA3a-e (h3a-h3e)). Here we demonstrate the existence of an additional new member, termed SERCA3f (h3f). By reverse transcriptase-PCR using monocytic U937 cell RNA, h3f mRNA was found to exclude the antepenultimate exon 21. h3f mRNA expression appeared as a human-specific splice variant. It was not found in rats or mice. h3f mRNA gave rise to an h3f protein differing in its C terminus from h3a-h3e. Of particular interest, h3f diverged in the first amino acids after the first splice site but presented the same last 21 amino acids as h3b. Consequently, we further investigated the structure-function-location relationships of the h3b and h3f isoforms. Comparative functional study of h3b and h3f recombinant proteins in intact HEK-293 cells and in fractionated membranes showed the following distinct characteristics: (i) resting cytosolic Ca2+ concentration ([Ca2+](c)) and (ii) ER Ca2+ content ([Ca2+]er); similar characteristics were shown for the following: (i) the effects of the SERCA inhibitor, thapsigargin, on Ca2+ release ([Ca2+](Tg)) and subsequent Ca2+ entry ([Ca2+](e)) and (ii) the low apparent Ca2+ affinity and the enhanced rate of dephosphorylation of the E2P phosphoenzyme intermediate. Subcellular location of h3b and h3f by immunofluorescence and/or confocal microscopy using the h3b- and h3f-specific polyclonal and the pan-h3 monoclonal (PL/IM430) antibodies suggested overlapping but distinct ER location. The endogenous expression of h3f protein was also proved in U937 cells. Altogether these data suggest that the SERCA3 isoforms have a more widespread role in cellular Ca2+ signaling than previously appreciated.	Hop Lariboisiere, INSERM, U348, IFR6, F-75475 Paris 10, France; Univ Aarhus, Dept Physiol, DK-8000 Aarhus C, Denmark; Natl Med Ctr, Inst Haematol Immunol, H-1113 Budapest, Hungary	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Aarhus University	Enouf, J (corresponding author), Hop Lariboisiere, INSERM, U348, IFR6, 8 Rue Guy Patin, F-75475 Paris 10, France.	jocelyne.enouf@larib.inserm.fr	BOBE, Regis/F-4951-2016; Kovács, Tünde/O-6020-2017	BOBE, Regis/0000-0002-8225-9117; Kovács, Tünde/0000-0003-1064-2616; Andersen, Jens Peter/0000-0003-0654-4300				Alvarez CE, 2002, J BIOL CHEM, V277, P24728, DOI 10.1074/jbc.M202512200; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; BOBE R, 1994, J BIOL CHEM, V269, P1417; Bobe R, 1998, FEBS LETT, V423, P259, DOI 10.1016/S0014-5793(98)00106-9; Borge PD, 2003, J BIOL CHEM, V278, P11359, DOI 10.1074/jbc.M209521200; BURK SE, 1989, J BIOL CHEM, V264, P18561; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; Chandrasekera CP, 2003, J BIOL CHEM, V278, P12482, DOI 10.1074/jbc.M212745200; Chicka MC, 2003, J BIOL CHEM, V278, P18464, DOI 10.1074/jbc.M301482200; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Dode L, 2002, J BIOL CHEM, V277, P45579, DOI 10.1074/jbc.M207778200; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; Gelebart P, 2003, BIOCHEM BIOPH RES CO, V303, P676, DOI 10.1016/S0006-291X(03)00405-4; Gelebart P, 2002, J BIOL CHEM, V277, P26310, DOI 10.1074/jbc.M201747200; HACK N, 1988, BIOCHEM J, V250, P355, DOI 10.1042/bj2500355; Hadri L, 2002, J BIOL CHEM, V277, P36471, DOI 10.1074/jbc.M204731200; Kao J, 1999, AM J PHYSIOL-LUNG C, V277, pL264, DOI 10.1152/ajplung.1999.277.2.L264; KOVACS T, 1994, J BIOL CHEM, V269, P6177; Kovacs T, 2001, BIOCHEM J, V358, P559, DOI 10.1042/0264-6021:3580559; Launay S, 1999, BLOOD, V93, P4395, DOI 10.1182/blood.V93.12.4395.412k06_4395_4405; Launay S, 2003, BLOOD, V101, P3220, DOI 10.1182/blood-2002-09-2730; Liu BF, 1996, J BIOL CHEM, V271, P5536, DOI 10.1074/jbc.271.10.5536; Liu L, 1999, CURR EYE RES, V19, P389, DOI 10.1076/ceyr.19.5.389.5289; Liu LH, 2001, J BIOL CHEM, V276, P26737, DOI 10.1074/jbc.C100275200; Liu LH, 1997, J BIOL CHEM, V272, P30538, DOI 10.1074/jbc.272.48.30538; Martin V, 2002, J BIOL CHEM, V277, P24442, DOI 10.1074/jbc.M202011200; Martin V, 2000, HYPERTENSION, V35, P91, DOI 10.1161/01.HYP.35.1.91; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; Nurtdinov RN, 2003, HUM MOL GENET, V12, P1313, DOI 10.1093/hmg/ddg137; Odermatt A, 2000, HUM GENET, V106, P482, DOI 10.1007/s004390000297; Ozog A, 1998, FEBS LETT, V427, P349, DOI 10.1016/S0014-5793(98)00464-5; Pan Y, 2003, J BIOL CHEM, V278, P13367, DOI 10.1074/jbc.M213228200; PAPP B, 1991, J BIOL CHEM, V266, P14593; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Varadi A, 1999, DIABETOLOGIA, V42, P1240, DOI 10.1007/s001250051298; Ver Heyen M, 2001, CIRC RES, V89, P838, DOI 10.1161/hh2101.098466; WUYTACK F, 1994, J BIOL CHEM, V269, P1410	47	62	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24297	24306		10.1074/jbc.M314286200	http://dx.doi.org/10.1074/jbc.M314286200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15028735	hybrid			2022-12-25	WOS:000221702500055
J	Herrmann, R; Heck, M; Henklein, P; Henklein, P; Kleuss, C; Hofmann, KP; Ernst, OP				Herrmann, R; Heck, M; Henklein, P; Henklein, P; Kleuss, C; Hofmann, KP; Ernst, OP			Sequence of interactions in receptor-G protein coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-ACTIVATED RHODOPSIN; TRANSDUCIN ALPHA-SUBUNIT; CARBOXYL-TERMINAL SEQUENCES; COVALENT CROSS-LINKING; G-BETA-GAMMA; CRYSTAL-STRUCTURE; CONFORMATIONAL SWITCH; COMPLEX-FORMATION; ADENYLYL-CYCLASE; ESCHERICHIA-COLI	Guanine nucleotide exchange in heterotrimeric G proteins catalyzed by G protein-coupled receptors (GPCRs) is a key event in many physiological processes. The crystal structures of the GPCR rhodopsin and two G proteins as well as binding sites on both catalytically interacting proteins are known, but the temporal sequence of events leading to nucleotide exchange remains to be elucidated. We employed time-resolved near infrared light scattering to study the order in which the Galpha and Ggamma C-terminal binding sites on the holo-G protein interact with the active state of the GPCR rhodopsin (R*) in native membranes. We investigated these key binding sites within mass-tagged peptides and G proteins and found that their binding to R* is mutually exclusive. The interaction of the holo-G protein with R* requires at least one of the lipid modifications of the G protein (i.e. myristoylation of the Galpha N terminus and/or farnesylation of the Ggamma C terminus). A holo-G protein with a high affinity Ggamma C terminus shows a specific change of the reaction rate in the GDP release and GTP uptake steps of catalysis. We interpret the data by a sequential fit model where (i) the initial encounter between R* and the G protein occurs with the Gbetagamma subunit, and (ii) the Ggamma C-terminal tail then interacts with R* to release bound GDP, thereby decreasing the affinity of R* for the Gbetagamma subunit. The mechanism limits the time in which both C-terminal binding sites of the G protein interact simultaneously with R* to a short lived transitory state.	Charite Univ Med Berlin, Inst Med Phys & Biophys, D-10098 Berlin, Germany; Charite Univ Med Berlin, Inst Biochem, D-10098 Berlin, Germany; Charite Univ Med Berlin, Inst Pharmakol, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Ernst, OP (corresponding author), Charite Univ Med Berlin, Inst Med Phys & Biophys, Schumannstr 20-21,Campus Mitte, D-10098 Berlin, Germany.	oliver.ernst@charite.de		Henklein, Petra/0000-0001-7468-8926				ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Gautam N, 2003, STRUCTURE, V11, P359, DOI 10.1016/S0969-2126(03)00054-6; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Heck M, 2000, METHOD ENZYMOL, V315, P329; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; Jian XY, 2001, J BIOL CHEM, V276, P48518, DOI 10.1074/jbc.M107129200; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; Kisselev OG, 2003, STRUCTURE, V11, P367, DOI 10.1016/S0969-2126(03)00045-5; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Marin EP, 2001, J BIOL CHEM, V276, P27400, DOI 10.1074/jbc.C100198200; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Matsuda T, 2000, METHOD ENZYMOL, V316, P465; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Morizumi T, 2003, J BIOCHEM, V134, P259, DOI 10.1093/jb/mvg139; Natochin M, 1999, J BIOL CHEM, V274, P7865, DOI 10.1074/jbc.274.12.7865; Natochin M, 2001, J NEUROCHEM, V77, P202, DOI 10.1046/j.1471-4159.2001.00221.x; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; Shukla P, 1999, J GEN PHYSIOL, V114, P609, DOI 10.1085/jgp.114.5.609; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Szundi I, 1998, BIOCHEMISTRY-US, V37, P14237, DOI 10.1021/bi981249k; Taylor JM, 1996, J BIOL CHEM, V271, P3336; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Weitmann S, 2001, BIOCHEMISTRY-US, V40, P10853, DOI 10.1021/bi011176w; Whitlock GG, 1999, NEURON, V23, P337, DOI 10.1016/S0896-6273(00)80784-9; Xu MQ, 2001, METHODS, V24, P257, DOI 10.1006/meth.2001.1187; Yan ECY, 2003, P NATL ACAD SCI USA, V100, P9262, DOI 10.1073/pnas.1531970100	50	74	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24283	24290		10.1074/jbc.M311166200	http://dx.doi.org/10.1074/jbc.M311166200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15007073	hybrid			2022-12-25	WOS:000221702500053
J	Lund, IK; Andersen, HS; Iversen, LF; Olsen, OH; Moller, KB; Pedersen, AK; Ge, Y; Holsworth, DD; Newman, MJ; Axe, FU; Moller, NPH				Lund, IK; Andersen, HS; Iversen, LF; Olsen, OH; Moller, KB; Pedersen, AK; Ge, Y; Holsworth, DD; Newman, MJ; Axe, FU; Moller, NPH			Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; COMPETITIVE INHIBITOR; INSULIN SENSITIVITY; PTP1B INHIBITORS; MOLECULAR-BASIS; 1B INHIBITORS; BINDING-SITE; RECEPTOR; DISCOVERY	Protein-tyrosine phosphatases (PTPs) are considered important therapeutic targets because of their pivotal role as regulators of signal transduction and thus their implication in several human diseases such as diabetes, cancer, and autoimmunity. In particular, PTP1B has been the focus of many academic and industrial laboratories because it was found to be an important negative regulator of insulin and leptin signaling, and hence a potential therapeutic target in diabetes and obesity. As a result, significant progress has been achieved in the design of highly selective and potent PTP1B inhibitors. In contrast, little attention has been given to other potential drug targets within the PTP family. Guided by x-ray crystallography, molecular modeling, and enzyme kinetic analyses with wild type and mutant PTPs, we describe the development of a general, low molecular weight, non-peptide, non-phosphorus PTP inhibitor into an inhibitor that displays more than 100-fold selectivity for PTPbeta over PTP1B. Of note, our structure-based design principles, which are based on extensive bioinformatics analyses of the PTP family, are general in nature. Therefore, we anticipate that this strategy, here applied to PTPbeta, in principle can be used in the design and development of selective inhibitors of many, if not most PTPs.	Novo Nordisk AS, Signal Transduct, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Prot Sci, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, MedChem Res 2, DK-2760 Malov, Denmark; Novo Nordisk AS, Haemostasis Biochem, DK-2760 Malov, Denmark; Ontogen Corp, Carlsbad, CA 92009 USA	Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk	Moller, NPH (corresponding author), Novo Nordisk AS, Signal Transduct, Bldg 9S2 18, DK-2880 Bagsvaerd, Denmark.	nphm@novonordisk.com						Andersen HS, 2000, J BIOL CHEM, V275, P7101, DOI 10.1074/jbc.275.10.7101; Andersen HS, 2002, J MED CHEM, V45, P4443, DOI 10.1021/jm0209026; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Andersen JN, 2004, TOP CURR GENET, V5, P201; Andersen JN, 2004, FASEB J, V18, P8, DOI 10.1096/fj.02-1212rev; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Blaskovich MA, 2002, EXPERT OPIN THER PAT, V12, P871; Bleasdale JE, 2001, BIOCHEMISTRY-US, V40, P5642, DOI 10.1021/bi002865v; CHANG G, 1989, J AM CHEM SOC, V111, P4379, DOI 10.1021/ja00194a035; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; Cheng A, 2002, EUR J BIOCHEM, V269, P1050, DOI 10.1046/j.0014-2956.2002.02756.x; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Evans J L, 1999, Expert Opin Investig Drugs, V8, P139, DOI 10.1517/13543784.8.2.139; Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992; GAITS F, 1994, CELL MOL BIOL, V40, P677; GEWALD K, 1966, CHEM BER-RECL, V99, P94, DOI 10.1002/cber.19660990116; Ghosh AK, 1998, TETRAHEDRON LETT, V39, P947, DOI 10.1016/S0040-4039(97)10666-9; Groves MR, 1998, BIOCHEMISTRY-US, V37, P17773, DOI 10.1021/bi9816958; Guo XL, 2002, J BIOL CHEM, V277, P41014, DOI 10.1074/jbc.M207347200; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; Iversen LF, 2002, J BIOL CHEM, V277, P19982, DOI 10.1074/jbc.M200567200; Iversen LF, 2001, BIOCHEMISTRY-US, V40, P14812, DOI 10.1021/bi011389l; Jia ZC, 2001, J MED CHEM, V44, P4584, DOI 10.1021/jm010266w; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Johnson TO, 2002, NAT REV DRUG DISCOV, V1, P696, DOI 10.1038/nrd895; Kar S, 2003, CARCINOGENESIS, V24, P411, DOI 10.1093/carcin/24.3.411; Keane MM, 1996, CANCER RES, V56, P4236; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Larsen SD, 2003, BIOORG MED CHEM LETT, V13, P971, DOI 10.1016/S0960-894X(02)01065-X; LEACH AR, 1992, J COMPUT CHEM, V13, P730, DOI 10.1002/jcc.540130608; Liu G, 2003, J MED CHEM, V46, P3437, DOI 10.1021/jm034088d; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; MITSUNOBU O, 1981, SYNTHESIS-STUTTGART, P1, DOI 10.1055/s-1981-29317; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Moller N P, 2000, Curr Opin Drug Discov Devel, V3, P527; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497; NIMITZ JS, 1981, J ORG CHEM, V46, P211, DOI 10.1021/jo00314a057; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pathak MK, 2001, J IMMUNOL, V167, P3391, DOI 10.4049/jimmunol.167.6.3391; Peters GH, 2000, J BIOL CHEM, V275, P18201, DOI 10.1074/jbc.M910273199; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Sarmiento M, 2000, J MED CHEM, V43, P146, DOI 10.1021/jm990329z; Skorey K, 1997, J BIOL CHEM, V272, P22472, DOI 10.1074/jbc.272.36.22472; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Sun JP, 2003, J BIOL CHEM, V278, P12406, DOI 10.1074/jbc.M212491200; Szczepankiewicz BG, 2003, J AM CHEM SOC, V125, P4087, DOI 10.1021/ja0296733; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; van Huijsduijnen RH, 2002, DRUG DISCOV TODAY, V7, P1013, DOI 10.1016/S1359-6446(02)02438-8; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Vijayakumar M, 1999, PROTEINS, V34, P497, DOI 10.1002/(SICI)1097-0134(19990301)34:4<497::AID-PROT9>3.0.CO;2-G; Wang WQ, 2003, CURR TOP MED CHEM, V3, P739, DOI 10.2174/1568026033452302; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang ZY, 2003, EXPERT OPIN INV DRUG, V12, P223, DOI 10.1517/eoid.12.2.223.21411; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616	67	32	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24226	24235		10.1074/jbc.M313027200	http://dx.doi.org/10.1074/jbc.M313027200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15024017	hybrid			2022-12-25	WOS:000221702500047
J	Park, YJ; Dyer, PN; Tremethick, DJ; Luger, K				Park, YJ; Dyer, PN; Tremethick, DJ; Luger, K			A new fluorescence resonance energy transfer approach demonstrates that the histone variant H2AZ stabilizes the histone octamer within the nucleosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY MAMMALIAN DEVELOPMENT; HIGH SALT CONCENTRATION; RNA-POLYMERASE-II; CORE PARTICLE; RECOMBINANT HISTONES; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; DNA INTERACTIONS; TARGET SITES; CHROMATIN	Nucleosomes are highly dynamic macromolecular complexes that are assembled and disassembled in a modular fashion. One important way in which this dynamic process can be modulated is by the replacement of major histones with their variants, thereby affecting nucleosome structure and function. Here we use fluorescence resonance energy transfer between fluorophores attached to various defined locations within the nucleosome to dissect and compare the structural transitions of a H2A.Z containing and a canonical nucleosome in response to increasing ionic strength. We show that the peripheral regions of the DNA dissociate from the surface of the histone octamer at relatively low ionic strength, under conditions where the dimer-tetramer interaction remains unaffected. At around 550 mM NaCl, the (H2A-H2B) dimer dissociates from the (H3-H4)(2) tetramer-DNA complex. Significantly, this latter transition is stabilized in nucleosomes that have been reconstituted with the essential histone variant H2A.Z. Our studies firmly establish fluorescence resonance energy transfer as a valid method to study nucleosome stability, and shed new light on the biological function of H2A.Z.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Australian Natl Univ, John Curtin Sch Med Res, Chromatin & Transcript Regulat Grp, Canberra, ACT 2601, Australia	Colorado State University; Australian National University; John Curtin School of Medical Research	Luger, K (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	kluger@lamar.colostate.edu	Park, Young-Jun/AAF-6249-2021	Park, Young-Jun/0000-0003-2901-6949; Tremethick, David/0000-0001-5274-8078; SCHNIZER-LUGER, KAROLINE/0000-0001-5136-5331	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061909] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061909, GM61909] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 2001, J BIOL CHEM, V276, P41945, DOI 10.1074/jbc.M108217200; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; Anderson JD, 2000, J MOL BIOL, V296, P979, DOI 10.1006/jmbi.2000.3531; Ausio J, 2002, BIOCHEMISTRY-US, V41, P5945, DOI 10.1021/bi020059d; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; BURTON DR, 1978, NUCLEIC ACIDS RES, V5, P3643, DOI 10.1093/nar/5.10.3643; CHUNG DG, 1986, BIOCHEMISTRY-US, V25, P5036, DOI 10.1021/bi00366a010; Clarkson MJ, 1999, NATURE, V399, P694, DOI 10.1038/21436; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Dyer PN, 2004, METHOD ENZYMOL, V375, P23; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; ESHAGHPOUR H, 1980, BIOCHEMISTRY-US, V19, P1797, DOI 10.1021/bi00550a011; Faast R, 2001, CURR BIOL, V11, P1183, DOI 10.1016/S0960-9822(01)00329-3; Fairclough R H, 1978, Methods Enzymol, V48, P347; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Gottesfeld JM, 2001, BIOCHEMISTRY-US, V40, P10927, DOI 10.1021/bi0109966; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Khrapunov SN, 1997, BBA-GENE STRUCT EXPR, V1351, P213, DOI 10.1016/S0167-4781(96)00199-6; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; LEE KP, 1982, CAN J BIOCHEM CELL B, V60, P379, DOI 10.1139/o82-045; LOUTERS L, 1985, BIOCHEMISTRY-US, V24, P3080, DOI 10.1021/bi00334a002; LOUTERS L, 1984, BIOCHEMISTRY-US, V23, P547, DOI 10.1021/bi00298a023; Luger K, 1999, METHOD ENZYMOL, V304, P3; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MAEDER AW, 1996, THESIS SWISS FEDERAL; Malik HS, 2003, NAT STRUCT BIOL, V10, P882, DOI 10.1038/nsb996; OOHARA I, 1987, J MOL BIOL, V196, P399, DOI 10.1016/0022-2836(87)90700-5; OOHARA I, 1987, J MOL BIOL, V196, P389, DOI 10.1016/0022-2836(87)90699-1; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; PUHL HL, 1993, J MOL BIOL, V229, P827, DOI 10.1006/jmbi.1993.1089; Rangasamy D, 2003, EMBO J, V22, P1599, DOI 10.1093/emboj/cdg160; RASMUSSEN SR, 1991, ANAL BIOCHEM, V198, P138, DOI 10.1016/0003-2697(91)90518-X; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; RICHMOND TJ, 1988, J MOL BIOL, V199, P161, DOI 10.1016/0022-2836(88)90386-5; SAMSO M, 1993, BIOCHEMISTRY-US, V32, P4609, DOI 10.1021/bi00068a018; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; THOMSON JA, 1989, J BIOL CHEM, V264, P11614; VANHOLDE KE, 1988, CHROMATIN SERIES MOL; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Widlund HR, 2000, BIOCHEMISTRY-US, V39, P3835, DOI 10.1021/bi991957l; WILHELM ML, 1980, BIOCHEMISTRY-US, V19, P4327, DOI 10.1021/bi00559a028; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; YAGER TD, 1989, BIOCHEMISTRY-US, V28, P2271, DOI 10.1021/bi00431a045	53	170	178	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24274	24282		10.1074/jbc.M313152200	http://dx.doi.org/10.1074/jbc.M313152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15020582	hybrid			2022-12-25	WOS:000221702500052
J	Rose, JJ; Foley, JF; Murphy, PM; Venkatesan, S				Rose, JJ; Foley, JF; Murphy, PM; Venkatesan, S			On the mechanism and significance of ligand-induced internalization of human neutrophil chemokine receptors CXCR1 and CXCR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; CELL-SURFACE EXPRESSION; LIPID RAFTS; SIGNAL-TRANSDUCTION; LEADING-EDGE; CHEMOATTRACTANT RECEPTORS; MEMBRANE MICRODOMAINS; BIOLOGICAL-MEMBRANES; ANCHORED PROTEINS	It is well established that leukocyte chemotactic receptors, a subset of G protein-coupled receptors, undergo endocytosis after stimulation by ligand. However, the significance of this phenomenon to cell motility and other important leukocyte functions induced by chemoattractants has not been clearly defined. Here we show that in primary human neutrophils, the threshold levels of agonist required for endocytosis of the chemotactic receptors CXCR1 and CXCR2 were similar to10-fold or higher than those needed for maximal chemotactic and calcium flux responses. Moreover, when stimulated by agonists at concentrations that are high enough for chemotaxis but too low for receptor endocytosis, neutrophil CXCR1 and CXCR2 could be reactivated in response to repeated application of the same agonist. Both receptors were excluded from Triton X-100-insoluble lipid rafts, and at high agonist concentrations were rapidly endocytosed by a clathrin/rab5/dynamin-dependent pathway. These data support the conclusion that neutrophil migration in response to CXCR1 or CXCR2 agonists is not dependent on endocytosis of CXCR1 or CXCR2. Rather than being integral to the process of cell migration, receptor endocytosis may be a terminal stop signal when cells reach the focus of inflammation where the chemoattractant concentrations are the highest.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; NIAID, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Venkatesan, S (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bldg 10,Rm 6A05, Bethesda, MD 20892 USA.	aradhana@helix.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000528, ZIAAI000749, ZIAAI000615, Z01AI000749, Z01AI000615, ZIAAI000528] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; Asagoe K, 1998, J IMMUNOL, V160, P4518; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Benmerah A, 1999, J CELL SCI, V112, P1303; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; BUCCI C, 1995, FEBS LETT, V366, P65, DOI 10.1016/0014-5793(95)00477-Q; CAIN TJ, 1995, BBA-BIOMEMBRANES, V1235, P69, DOI 10.1016/0005-2736(94)00308-C; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Devreotes P, 2003, J BIOL CHEM, V278, P20445, DOI 10.1074/jbc.R300010200; Dzenko KA, 2001, J NEUROSCI, V21, P9214, DOI 10.1523/JNEUROSCI.21-23-09214.2001; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Fan GH, 2003, BLOOD, V101, P2115, DOI 10.1182/blood-2002-07-1965; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Feniger-Barish R, 2000, BLOOD, V95, P1551, DOI 10.1182/blood.V95.5.1551.005a36_1551_1559; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Higgins MK, 2002, TRENDS BIOCHEM SCI, V27, P257, DOI 10.1016/S0968-0004(02)02089-3; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Horejsi V, 2003, IMMUNOL REV, V191, P148, DOI 10.1034/j.1600-065X.2003.00001.x; Huang YE, 2003, MOL BIOL CELL, V14, P1913, DOI 10.1091/mbc.E02-10-0703; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Khandaker MH, 1998, J IMMUNOL, V161, P1930; Kim JY, 1997, J BIOL CHEM, V272, P27313, DOI 10.1074/jbc.272.43.27313; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LEE J, 1992, J BIOL CHEM, V267, P16283; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; MCKAY DA, 1991, J CELL SCI, V100, P473; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MERESSE S, 1995, J CELL SCI, V108, P3349; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Millan J, 2001, EUR J IMMUNOL, V31, P467, DOI 10.1002/1521-4141(200102)31:2<467::AID-IMMU467>3.0.CO;2-1; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Murphy PM, 2000, PHARMACOL REV, V52, P145; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Nieto M, 1997, J EXP MED, V186, P153, DOI 10.1084/jem.186.1.153; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Pierini LM, 2003, J BIOL CHEM, V278, P10831, DOI 10.1074/jbc.M212386200; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Richardson RM, 2003, J IMMUNOL, V170, P2904, DOI 10.4049/jimmunol.170.6.2904; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Roepstorff K, 2002, J BIOL CHEM, V277, P18954, DOI 10.1074/jbc.M201422200; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; Sambrano GR, 2002, NATURE, V420, P708, DOI 10.1038/nature01305; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Schade AE, 2002, J IMMUNOL, V168, P2233, DOI 10.4049/jimmunol.168.5.2233; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SCHMITT M, 1990, BIOCHEM SOC T, V18, P219, DOI 10.1042/bst0180219; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Seveau S, 2001, MOL BIOL CELL, V12, P3550, DOI 10.1091/mbc.12.11.3550; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Triantafilou M, 2002, J CELL SCI, V115, P2603; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Unkeless J C, 1995, Semin Immunol, V7, P37, DOI 10.1016/1044-5323(95)90006-3; van Buul JD, 2003, J BIOL CHEM, V278, P30302, DOI 10.1074/jbc.M304764200; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Venkatesan S, 2002, J BIOL CHEM, V277, P2287, DOI 10.1074/jbc.M108321200; Venkatesan S, 2003, MOL BIOL CELL, V14, P3305, DOI 10.1091/mbc.e02-11-0714; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; WALTER RJ, 1984, EXP CELL RES, V154, P613, DOI 10.1016/0014-4827(84)90186-1; WALTER RJ, 1987, J LEUKOCYTE BIOL, V41, P377, DOI 10.1002/jlb.41.5.377; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; Xiao Z, 1999, J BIOL CHEM, V274, P1440, DOI 10.1074/jbc.274.3.1440; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	92	101	103	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24372	24386		10.1074/jbc.M401364200	http://dx.doi.org/10.1074/jbc.M401364200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15028716	hybrid			2022-12-25	WOS:000221702500063
J	Bhasin, M; Raghava, GPS				Bhasin, M; Raghava, GPS			Classification of nuclear receptors based on amino acid composition and dipeptide composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; SUBCELLULAR-LOCALIZATION; SEQUENCE; PROTEINS; LOCATION; DOMAIN; SVM	Nuclear receptors are key transcription factors that regulate crucial gene networks responsible for cell growth, differentiation, and homeostasis. Nuclear receptors form a superfamily of phylogenetically related proteins and control functions associated with major diseases (e.g. diabetes, osteoporosis, and cancer). In this study, a novel method has been developed for classifying the subfamilies of nuclear receptors. The classification was achieved on the basis of amino acid and dipeptide composition from a sequence of receptors using support vector machines. The training and testing was done on a non-redundant data set of 282 proteins obtained from the NucleaRDB data base (1). The performance of all classifiers was evaluated using a 5-fold cross validation test. In the 5-fold cross-validation, the data set was randomly partitioned into five equal sets and evaluated five times on each distinct set while keeping the remaining four sets for training. It was found that different subfamilies of nuclear receptors were quite closely correlated in terms of amino acid composition as well as dipeptide composition. The overall accuracy of amino acid composition-based and dipeptide composition-based classifiers were 82.6 and 97.5%, respectively. Therefore, our results prove that different subfamilies of nuclear receptors are predictable with considerable accuracy using amino acid or dipeptide composition. Furthermore, based on above approach, an online web service, NRpred, was developed, which is available at www.imtech.res.in/raghava/nrpred.	Inst Microbial Technol, Bioinformat Ctr, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Raghava, GPS (corresponding author), Inst Microbial Technol, Bioinformat Ctr, Sector 39A, Chandigarh 160036, India.	raghava@imtech.res.in	Raghava, Gajendra/B-1717-2009; Raghava, Gajendra P.S./AAA-2413-2022; Bhasin, Manoj/B-3018-2009	Raghava, Gajendra P.S./0000-0002-8902-2876; Bhasin, Manoj/0000-0001-5172-420X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARGOS P, 1982, EUR J BIOCHEM, V128, P565; Bhasin M, 2004, BIOINFORMATICS, V20, P421, DOI 10.1093/bioinformatics/btg424; BHASIN M, 2004, IN PRESS NUCL ACIDS; BRENDEL V, 1992, MATH COMPUT MODEL, V16, P37, DOI 10.1016/0895-7177(92)90150-J; Cai CZ, 2004, PROTEINS, V55, P66, DOI 10.1002/prot.20045; Cai CZ, 2003, MATH BIOSCI, V185, P111, DOI 10.1016/S0025-5564(03)00096-8; Cai YD, 2004, J THEOR BIOL, V226, P373, DOI 10.1016/j.jtbi.2003.08.015; Chou KC, 2003, J CELL BIOCHEM, V90, P1250, DOI 10.1002/jcb.10719; Chou KC, 2002, J BIOL CHEM, V277, P45765, DOI 10.1074/jbc.M204161200; Chou KC, 2001, PROTEINS, V43, P246, DOI 10.1002/prot.1035; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Grassmann J, 1999, Proc Int Conf Intell Syst Mol Biol, P106; Han LY, 2004, RNA, V10, P355, DOI 10.1261/rna.5890304; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; Hua SJ, 2001, BIOINFORMATICS, V17, P721, DOI 10.1093/bioinformatics/17.8.721; Hua SJ, 2001, J MOL BIOL, V308, P397, DOI 10.1006/jmbi.2001.4580; Joachims T, 1999, ADVANCES IN KERNEL METHODS, P169; Karchin R, 2002, BIOINFORMATICS, V18, P147, DOI 10.1093/bioinformatics/18.1.147; Krogh A, 1996, ADV NEUR IN, V8, P917; Laudet V, 2002, NUCL RECEPTORS FACTS; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RECZKO M, 1994, NUCLEIC ACIDS RES, V22, P3616; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; Robinson-Rechavi M, 2003, METHOD ENZYMOL, V364, P95; Robinson-Rechavi M, 2003, J CELL SCI, V116, P585, DOI 10.1242/jcs.00247; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Shepherd AJ, 2003, PROTEINS, V50, P290, DOI 10.1002/prot.10290; Ward JJ, 2003, BIOINFORMATICS, V19, P1650, DOI 10.1093/bioinformatics/btg223	30	160	165	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23262	23266		10.1074/jbc.M401932200	http://dx.doi.org/10.1074/jbc.M401932200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039428	hybrid			2022-12-25	WOS:000221570900059
J	Butenas, S; Orfeo, T; Gissel, MT; Brummel, KE; Mann, KG				Butenas, S; Orfeo, T; Gissel, MT; Brummel, KE; Mann, KG			The significance of circulating factor IXa in blood	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; DEEP-VEIN THROMBOSIS; HEPARIN-COFACTOR-II; RECEPTOR-RELATED PROTEIN; FACTOR-X ACTIVATION; ANTITHROMBIN-III; PROTHROMBIN ACTIVATION; MYOCARDIAL-INFARCTION; SERINE PROTEASES; FACTOR-VII	The presence of activation peptides (AP) of the vitamin K-dependent proteins in the phlebotomy blood of human subjects suggests that active serine proteases may circulate in blood as well. The goal of the current study was to evaluate the influence of trace amounts of key coagulation proteases on tissue factor-independent thrombin generation using three models of coagulation. With procoagulants and select coagulation inhibitors at mean physiological concentrations, concentrations of factor IXa, factor Xa, and thrombin were set either equal to those of their AP or to values that would result based upon the rates of AP/enzyme generation and steady state enzyme inhibition. In the latter case, numerical simulation predicts that sufficient thrombin to produce a solid clot would be generated in similar to2 min. Empirical data from the synthetic plasma suggest clotting times of 3-5 min, which are similar to that observed in contact pathway-inhibited whole blood (4.3 min) initiated with the same concentrations of factors IXa and Xa and thrombin. Numerical simulations performed with the concentrations of two of the enzymes held constant and one varied suggest that the presence of any pair of enzymes is sufficient to yield rapid clot formation. Modeling of states (numerical simulation and whole blood) where only one circulating protease is present at steady state concentration shows significant thrombin generation only for factor IXa. The addition of factor Xa and thrombin has little effect (if any) on thrombin generation induced by factor IXa alone. These data indicate that 1) concentrations of active coagulation enzymes circulating in vivo are significantly lower than can be predicted from the concentrations of their AP, and 2) expected trace amounts of factor IXa can trigger thrombin generation in the absence of tissue factor.	Univ Vermont, Dept Biochem, Burlington, VT 05405 USA	University of Vermont	Mann, KG (corresponding author), Univ Vermont, Dept Biochem, Given Bldg,Rm C401,89 Beaumont Ave, Burlington, VT 05405 USA.	Kenneth.Mann@uvm.edu			NHLBI NIH HHS [R01 HL34575, T32 HL07594] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007594, R01HL034575] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ardissino D, 2001, BLOOD, V98, P2726, DOI 10.1182/blood.V98.9.2726; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAUER KA, 1989, BLOOD, V74, P2007; BAUER KA, 1984, BLOOD, V64, P791; BAUER KA, 1990, BLOOD, V76, P731; Bauer KA, 2000, THROMB HAEMOSTASIS, V84, P396; BAUER KA, 1988, BLOOD, V71, P1418; Bauer KA, 1999, BEST PRACT RES CL HA, V12, P387, DOI 10.1053/beha.1999.0032; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; BONEU B, 1991, THROMB HAEMOSTASIS, V65, P28; Brummel KE, 2002, BLOOD, V100, P148, DOI 10.1182/blood.V100.1.148; Bucek RA, 2003, BRIT J HAEMATOL, V120, P123, DOI 10.1046/j.1365-2141.2003.03984.x; Butenas S, 1997, J BIOL CHEM, V272, P21527, DOI 10.1074/jbc.272.34.21527; Butenas S, 1997, THROMB HAEMOSTASIS, V78, P1193; Cawthern KM, 1998, BLOOD, V91, P4581, DOI 10.1182/blood.V91.12.4581.412k12_4581_4592; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; Ho GY, 1997, J BIOL CHEM, V272, P16838, DOI 10.1074/jbc.272.27.16838; Ho GY, 1996, J BIOL CHEM, V271, P9497, DOI 10.1074/jbc.271.16.9497; Hockin MF, 2002, J BIOL CHEM, V277, P18322, DOI 10.1074/jbc.M201173200; HOEK JA, 1989, THROMB HAEMOSTASIS, V62, P1050; ICHINOSE A, 1994, HEMOSTASIS THROMBOSI, P19; Jenny NS, 1998, THROMBOSIS HEMORRHAG, P3; JONES KC, 1994, J BIOL CHEM, V269, P23367; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KOCKUM C, 1980, THROMB RES, V19, P589, DOI 10.1016/0049-3848(80)90031-6; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; LAMMLE B, 1985, CLIN HAEMATOL, V14, P281; LAU HK, 1979, J BIOL CHEM, V254, P8751; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LEROYMATHERON C, 1994, THROMB RES, V74, P399, DOI 10.1016/0049-3848(94)90155-4; MANNUCCI PM, 1994, BLOOD, V84, P1314; MANNUCCI PM, 1992, THROMB HAEMOSTASIS, V67, P200; MARI D, 1995, BLOOD, V85, P3144, DOI 10.1182/blood.V85.11.3144.bloodjournal85113144; MARUYAMA I, 1985, J BIOL CHEM, V260, P5432; MERLINI PA, 1994, CIRCULATION, V90, P61, DOI 10.1161/01.CIR.90.1.61; Miller GJ, 1996, THROMB HAEMOSTASIS, V75, P767; Miller GJ, 1998, THROMB HAEMOSTASIS, V79, P549; Minnema MC, 2000, ARTERIOSCL THROM VAS, V20, P2489, DOI 10.1161/01.ATV.20.11.2489; MIZUOCHI T, 1981, J BIOCHEM-TOKYO, V90, P1023, DOI 10.1093/oxfordjournals.jbchem.a133554; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; Narita M, 1998, BLOOD, V91, P555, DOI 10.1182/blood.V91.2.555.555_555_560; OWEN J, 1989, THROMB HAEMOSTASIS, V62, P807; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; SANTAGOSTINO E, 1994, THROMB HAEMOSTASIS, V71, P737; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; TRIPODI A, 1994, THROMB HAEMOSTASIS, V73, P548; vantVeer C, 1997, J BIOL CHEM, V272, P4367, DOI 10.1074/jbc.272.7.4367	52	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22875	22882		10.1074/jbc.M400531200	http://dx.doi.org/10.1074/jbc.M400531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039440	hybrid			2022-12-25	WOS:000221570900013
J	Dolgachev, V; Farooqui, MS; Kulaeva, OI; Tainsky, MA; Nagy, B; Hanada, K; Separovic, D				Dolgachev, V; Farooqui, MS; Kulaeva, OI; Tainsky, MA; Nagy, B; Hanada, K; Separovic, D			De novo ceramide accumulation due to inhibition of its conversion to complex sphingolipids in apoptotic photosensitized cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERAPY-INDUCED APOPTOSIS; CULTURED HUMAN KERATINOCYTES; MOUSE EMBRYONIC FIBROBLASTS; EPIDERMOID CARCINOMA-CELLS; PHOTODYNAMIC THERAPY; SERINE PALMITOYLTRANSFERASE; SPHINGOMYELIN SYNTHASE; LYMPHOMA-CELLS; GLUCOSYLCERAMIDE SYNTHASE; SILICON PHTHALOCYANINE	The oxidative stress induced by photodynamic therapy (PDT) with the photosensitizer phthalocyanine 4 is accompanied by increases in ceramide mass. To assess the regulation of de novo sphingolipid metabolism during PDT-induced apoptosis, Jurkat human T lymphoma and Chinese hamster ovary cells were labeled with [C-14] serine, a substrate of serine palmitoyltransferase (SPT), the enzyme catalyzing the initial step in the sphingolipid biosynthesis. A substantial elevation in [C-14] ceramide with a concomitant decrease in [C-14] sphingomyelin was detected. The labeling of [C-14] ceramide was completely abrogated by the SPT inhibitor ISP-1. In addition, ISP-1 partly suppressed PDT-induced apoptosis. Pulse-chase experiments showed that the contribution of sphingomyelin degradation to PDT-initiated increase in de novo ceramide was absent or minor. PDT had no effect on either mRNA amounts of the SPT subunits LCB1 and LCB2, LCB1 protein expression, or SPT activity in Jurkat cells. Moreover in Chinese hamster ovary cells LCB1 protein underwent substantial photodestruction, and SPT activity was profoundly inhibited after treatment. We next examined whether PDT affects conversion of ceramide to complex sphingolipids. Sphingomyelin synthase, as well as glucosylceramide synthase, was inactivated by PDT in both cell lines in a dose-dependent manner. These results are the first to show that in the absence of SPT up-regulation PDT induces accumulation of de novo ceramide by inhibiting its conversion to complex sphingolipids.	Eugene Applebaum Coll Pharm & Hlth Sci, Dept Fundamental & Appl Sci, Detroit, MI 48201 USA; Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA; Univ Zagreb, Fac Sci, Zagreb 10000, Croatia; Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan	Barbara Ann Karmanos Cancer Institute; Wayne State University; University of Zagreb; National Institute of Infectious Diseases (NIID)	Separovic, D (corresponding author), Eugene Applebaum Coll Pharm & Hlth Sci, Dept Fundamental & Appl Sci, Rm 5142,259 Mack Ave, Detroit, MI 48201 USA.	dseparovic@wayne.edu	Studitskaia, Olga/D-8551-2014	Studitskaia, Olga/0000-0001-5417-9964; Tainsky, Michael/0000-0002-0261-831X; Hanada, Kentaro/0000-0003-1383-2781	NCI NIH HHS [R29 CA77475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA077475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1991, CANCER RES, V51, P5993; Bleicher RJ, 2002, BBA-MOL CELL BIOL L, V1585, P172, DOI 10.1016/S1388-1981(02)00338-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chiu SM, 2000, INT J ONCOL, V16, P423; del Pulgar TG, 2002, BIOCHEM J, V363, P183, DOI 10.1042/0264-6021:3630183; Dolgachev V, 2003, EXP CELL RES, V288, P425, DOI 10.1016/S0014-4827(03)00235-0; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Elabbadi N, 1997, BIOCHEM J, V324, P435, DOI 10.1042/bj3240435; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Farrell AM, 1998, J LIPID RES, V39, P2031; Garzotto M, 1998, CANCER RES, V58, P2260; Gomer CJ, 1996, CANCER RES, V56, P2355; Hanada K, 2000, J BIOL CHEM, V275, P8409, DOI 10.1074/jbc.275.12.8409; Hanada K, 2000, METHOD ENZYMOL, V312, P304; HANADA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P151, DOI 10.1016/0005-2760(91)90002-Y; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hanada K, 2003, BBA-MOL CELL BIOL L, V1632, P16, DOI 10.1016/S1388-1981(03)00059-3; Hanlon JG, 2001, J PHOTOCH PHOTOBIO B, V64, P55, DOI 10.1016/S1011-1344(01)00189-0; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Herget T, 2000, J BIOL CHEM, V275, P30344, DOI 10.1074/jbc.M000714200; HOLLERAN WM, 1990, J LIPID RES, V31, P1655; Kalka K, 2000, CANCER RES, V60, P5984; Kick G, 1996, BRIT J CANCER, V74, P30, DOI 10.1038/bjc.1996.311; Kuge O, 2003, J BIOCHEM, V133, P397, DOI 10.1093/jb/mvg052; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; Luberto C, 2003, J BIOL CHEM, V278, P32733, DOI 10.1074/jbc.M300932200; Memon RA, 2001, J LIPID RES, V42, P452; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Nagy B, 2001, ARCH BIOCHEM BIOPHYS, V385, P194, DOI 10.1006/abbi.2000.2143; Nagy B, 2000, J PHOTOCH PHOTOBIO B, V57, P132, DOI 10.1016/S1011-1344(00)00088-9; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Scarlatti F, 2003, FASEB J, V17, P2339, DOI 10.1096/fj.03-0292fje; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Separovic D, 1999, BIOCHEM BIOPH RES CO, V258, P506, DOI 10.1006/bbrc.1999.0670; Separovic D, 1998, PHOTOCHEM PHOTOBIOL, V68, P101, DOI 10.1111/j.1751-1097.1998.tb03259.x; Separovic D, 1997, CANCER RES, V57, P1717; SEPAROVIC D, 2001, RRD PHOTOCHEM PHOTOB, V5, P155; Shayman JA, 2000, KIDNEY INT, V58, P11, DOI 10.1046/j.1523-1755.2000.00136.x; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Uchida Y, 2002, J LIPID RES, V43, P1293, DOI 10.1194/jlr.M100442-JLR200; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Vivekananda J, 2001, AM J PHYSIOL-LUNG C, V281, pL98, DOI 10.1152/ajplung.2001.281.1.L98; Wang HP, 2002, PHOTOCHEM PHOTOBIOL, V76, P98, DOI 10.1562/0031-8655(2002)076<0098:UROHPA>2.0.CO;2; Wang HT, 2003, UROLOGY, V61, P1047, DOI 10.1016/S0090-4295(02)02511-6; Whitacre CM, 2000, CLIN CANCER RES, V6, P2021; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; Wispriyono B, 2002, EXP CELL RES, V279, P153, DOI 10.1006/excr.2002.5599; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Yasuda S, 2003, J BIOL CHEM, V278, P4176, DOI 10.1074/jbc.M209602200; Zhao H, 2003, FASEB J, V17, P723, DOI 10.1096/fj.02-0806fje	58	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23238	23249		10.1074/jbc.M311974200	http://dx.doi.org/10.1074/jbc.M311974200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15020599	hybrid			2022-12-25	WOS:000221570900056
J	Domanski, M; Hertzog, M; Coutant, J; Gutsche-Perelroizen, I; Bontems, F; Carlier, MF; Guittet, E; van Heijenoort, C				Domanski, M; Hertzog, M; Coutant, J; Gutsche-Perelroizen, I; Bontems, F; Carlier, MF; Guittet, E; van Heijenoort, C			Coupling of folding and binding of thymosin beta 4 upon interaction with monomeric actin monitored by nuclear magnetic resonance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-15 NMR RELAXATION; PROTEIN-PROTEIN INTERACTIONS; BETA-THYMOSINS; UNSTRUCTURED PROTEINS; SPECTRAL DENSITIES; HETERONUCLEAR NMR; RECOGNITION SITES; ATOMIC-STRUCTURE; CHEMICAL-SHIFTS; ARP2/3 COMPLEX	Thymosin beta4 is a major actin-sequestering protein, yet the structural basis for its biological function is still unknown. This study provides insight regarding the way this 43-amino acid peptide, mostly unstructured in solution, binds to monomeric actin and prevents its assembly in filaments. We show here that the whole backbone of thymosin beta4 is highly affected upon binding to G-actin. The assignment of all amide protons and nitrogens of thymosin in the bound state, obtained using a combination of NMR experiments and selective labelings, shows that thymosin folds completely upon binding and displays a central extended region flanked by two N- and C-terminal helices. The cleavage of actin by subtilisin in the DNase I binding loop does not modify the structure of thymosin beta4 in the complex, showing that the backbone of the peptide is not in close proximity to segment 42 - 47 of actin. The combination of our NMR results and previously published mutation and cross-link data allows a better characterization of the binding mode of thymosins on G-actin.	CNRS, Inst Chim Subst Nat, Lab Chim & Biol Struct, F-91190 Gif Sur Yvette, France; CNRS, Lab Enzymol & Biochim Struct Dynam Cytosquelette, F-91190 Gif Sur Yvette, France; Ecole Polytech, CNRS, Inst Chim Subst Nat, Antenne Inst Chim Subst Nat, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	van Heijenoort, C (corresponding author), CNRS, Inst Chim Subst Nat, Lab Chim & Biol Struct, 1 Ave Terrasse, F-91190 Gif Sur Yvette, France.	carine@icsn.cnrs-gif.fr	VAN HEIJENOORT, Carine/N-1986-2016; van Heijenoort, Carine/AAX-1041-2021	VAN HEIJENOORT, Carine/0000-0002-2839-1037; van Heijenoort, Carine/0000-0002-2839-1037; Guittet, Eric/0000-0002-8368-6719				Boquet I, 2000, CELL, V102, P797, DOI 10.1016/S0092-8674(00)00068-4; BRUNGER AT, 1992, X PLOR SOFTWARE VERS; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; Chakrabarti P, 2002, PROTEINS, V47, P334, DOI 10.1002/prot.10085; CZISCH M, 1993, EUR J BIOCHEM, V218, P335, DOI 10.1111/j.1432-1033.1993.tb18382.x; De La Cruz EM, 2000, BIOPHYS J, V78, P2516, DOI 10.1016/S0006-3495(00)76797-X; DOIG AJ, 1995, PROTEIN SCI, V4, P1325, DOI 10.1002/pro.5560040708; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Dyson HJ, 2002, ADV PROTEIN CHEM, V62, P311; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Feinberg J, 1996, BIOCHEM BIOPH RES CO, V222, P127, DOI 10.1006/bbrc.1996.0709; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; HEINTZ D, 1993, FEBS LETT, V329, P9, DOI 10.1016/0014-5793(93)80181-S; Hertzog M, 2002, J BIOL CHEM, V277, P14786, DOI 10.1074/jbc.M112064200; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUFF T, 1995, EUR J BIOCHEM, V230, P650; JEAN C, 1994, J MUSCLE RES CELL M, V15, P278; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Karp PD, 2002, NUCLEIC ACIDS RES, V30, P56, DOI 10.1093/nar/30.1.56; KIESSLING P, 1995, BIOCHEMISTRY-US, V34, P14834, DOI 10.1021/bi00045a026; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; Markley JL, 1998, J BIOMOL NMR, V12, P1, DOI 10.1023/A:1008290618449; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; MCINTOSH LP, 1990, Q REV BIOPHYS, V23, P1, DOI 10.1017/S0033583500005400; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MUNOZ V, 1995, NAT STRUCT BIOL, V2, P380, DOI 10.1038/nsb0595-380; Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0; Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359; Ochsenbein F, 2002, PROTEIN SCI, V11, P957, DOI 10.1110/ps.4000102; Ochsenbein F, 2001, J BIOMOL NMR, V19, P3, DOI 10.1023/A:1008390606077; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Paunola E, 2002, FEBS LETT, V513, P92, DOI 10.1016/S0014-5793(01)03242-2; PENG JW, 1992, BIOCHEMISTRY-US, V31, P8571, DOI 10.1021/bi00151a027; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; PERELROIZEN I, 1995, J BIOL CHEM, V270, P1501, DOI 10.1074/jbc.270.4.1501; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PRESS WH, 1986, NUMERICAL RECIPES AR, P523; Reichert A, 1996, J BIOL CHEM, V271, P1301, DOI 10.1074/jbc.271.3.1301; SAFER D, 1991, J BIOL CHEM, V266, P4029; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; Safer D, 1997, CELL MOTIL CYTOSKEL, V38, P163, DOI 10.1002/(SICI)1097-0169(1997)38:2<163::AID-CM5>3.0.CO;2-8; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i; Simenel C, 2000, EUR J BIOCHEM, V267, P3530, DOI 10.1046/j.1432-1327.2000.01380.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; Tsai CJ, 1996, J MOL BIOL, V260, P604, DOI 10.1006/jmbi.1996.0424; van Heijenoort C, 1998, BIOCHEMISTRY-US, V37, P5060, DOI 10.1021/bi971706h; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; YU FX, 1993, J BIOL CHEM, V268, P502; ZARBOCK J, 1990, BIOCHEMISTRY-US, V29, P7814, DOI 10.1021/bi00486a006; [No title captured]	66	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23637	23645		10.1074/jbc.M311413200	http://dx.doi.org/10.1074/jbc.M311413200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039431	hybrid			2022-12-25	WOS:000221570900105
J	Komissarov, AA; Declerck, PJ; Shore, JD				Komissarov, AA; Declerck, PJ; Shore, JD			Protonation state of a single histidine residue contributes significantly to the kinetics of the reaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER LOOP INSERTION; SERPIN-PROTEASE COMPLEXES; SUBSTRATE-BINDING POCKET; CONFORMATIONAL-CHANGE; HINGE REGION; IN-VIVO; ALPHA(1)-PROTEINASE INHIBITOR; PROTEINASE INHIBITION; FLUORESCENT-PROBE; STRUCTURAL BASIS	Stopped-flow fluorometry was used to study the kinetics of the reactive center loop insertion occurring during the reaction of N-((2-(iodoacetoxy)ethyl)-N-methyl)amino-7-nitrobenz-2-oxa-3-diazole (NBD) P9 plasminogen activator inhibitor-1 (PAI-1) with tissue (tPA) and urokinase (uPA)-type plasminogen activators and human pancreatic elastase at pH 5.5-8.5. The limiting rate constants of reactive center loop insertion (k(lim)) and concentrations of proteinase at half-saturation (K-0.5) for tPA and uPA and the specificity constants (k(lim)/K-0.5) for elastase were determined. The pH dependences of k(lim)/K-0.5 reflected inactivation of each enzyme due to protonation of His(57) of the catalytic triad. However, the specificity of the inhibitory reaction with tPA and uPA was notably higher than that for the substrate reaction catalyzed by elastase. pH dependences of klim and K0.5 obtained for tPA revealed an additional ionizable group (pK(a), 6.0-6.2) affecting the reaction. Protonation of this group resulted in a significant increase in both klim and K0.5 and a 4.6-fold decrease in the specificity of the reaction of tPA with NBD P9 PAI-1. Binding of monoclonal antibody MA-55F4C12 to PAI-1 induced a decrease in klim and K0.5 at any pH but did not affect either the pKa of the group or an observed decrease in k(lim)/K-0.5 due to protonation of the group. In contrast to tPA, the klim and K0.5 for the reactions of uPA with NBD P9 PAI-1 or its complex with the monoclonal antibody were independent of pH in the 6.5-8.5 range. Since slightly acidic pH is a feature of a number of malignant tumors, alterations in PAI-1/tPA kinetics could play a role in the cancerogenesis. Changes in the protonation state of His(188), which is placed closely to the S1 site and is unique for tPA, has been proposed to contribute to the observed pH dependences of k(lim) and K-0.5.	Henry Ford Hlth Syst, Dept Pathol, Div Biochem Res, Detroit, MI 48202 USA; Univ Louvain, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium	Henry Ford Health System; Henry Ford Hospital	Komissarov, AA (corresponding author), Henry Ford Hlth Sci Ctr, Dept Pathol, Div Biochem Res, 1 Ford Pl,5D, Detroit, MI 48202 USA.	akomiss1@hfhs.org	Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105	NHLBI NIH HHS [HL54930] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; ASHBY BS, 1966, LANCET, V2, P312; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bijnens AP, 2000, J BIOL CHEM, V275, P6375, DOI 10.1074/jbc.275.9.6375; Bijnens AP, 2001, J BIOL CHEM, V276, P44912, DOI 10.1074/jbc.M103077200; BJORQUIST P, 1994, BBA-PROTEIN STRUCT M, V1209, P191, DOI 10.1016/0167-4838(94)90184-8; BOOTH NA, 1994, BAILLIERE CLIN HAEM, V7, P559, DOI 10.1016/S0950-3536(05)80099-X; Bousquet JA, 2003, BIOCHEM J, V370, P345, DOI 10.1042/BJ20020890; Briand L, 1997, PROTEIN ENG, V10, P551, DOI 10.1093/protein/10.5.551; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; Chobert JM, 1998, BIOCHEM BIOPH RES CO, V246, P847, DOI 10.1006/bbrc.1998.8627; Coombs GS, 1998, J BIOL CHEM, V273, P4323, DOI 10.1074/jbc.273.8.4323; De Taeye B, 2003, BIOCHEM BIOPH RES CO, V307, P529, DOI 10.1016/S0006-291X(03)01217-8; De Taeye B, 2003, J BIOL CHEM, V278, P23899, DOI 10.1074/jbc.M302226200; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; Gettins PGW, 2002, FEBS LETT, V523, P2, DOI 10.1016/S0014-5793(02)02924-1; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gils A, 2004, THROMB HAEMOSTASIS, V91, P425, DOI 10.1160/TH03-12-0764; GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Helmlinger G, 2002, CLIN CANCER RES, V8, P1284; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Huber K, 2001, THROMB RES, V103, pS7, DOI 10.1016/S0049-3848(01)00293-6; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Ibarra CA, 2004, J BIOL CHEM, V279, P3643, DOI 10.1074/jbc.M310601200; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; Komissarov AA, 2002, J BIOL CHEM, V277, P43858, DOI 10.1074/jbc.M204110200; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; Leskovac V, 2003, COMPREHENSIVE ENZYME, P283; LINDAHL TL, 1990, BIOCHEM J, V265, P109, DOI 10.1042/bj2650109; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Mellet P, 2000, J BIOL CHEM, V275, P10788, DOI 10.1074/jbc.275.15.10788; OLSON ST, 1982, J BIOL CHEM, V257, P4891; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; Peterson FC, 2001, BIOCHEMISTRY-US, V40, P6284, DOI 10.1021/bi010100x; Renatus M, 1997, J BIOL CHEM, V272, P21713, DOI 10.1074/jbc.272.35.21713; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VAUGHAN DE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P221, DOI 10.1016/0167-4838(93)90008-F; Verhamme I, 1999, J BIOL CHEM, V274, P17511, DOI 10.1074/jbc.274.25.17511; Vindigni A, 1998, PROTEIN SCI, V7, P1728, DOI 10.1002/pro.5560070807; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WIMAN B, 1995, THROMB HAEMOSTASIS, V74, P71; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	74	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23007	23013		10.1074/jbc.M401383200	http://dx.doi.org/10.1074/jbc.M401383200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15033993	hybrid			2022-12-25	WOS:000221570900028
J	Stockli, J; Honing, S; Rohrer, J				Stockli, J; Honing, S; Rohrer, J			The acidic cluster of the CK2 site of the cation-dependent mannose 6-phosphate receptor (CD-MPR) but not its phosphorylation is required for GGA1 and AP-1 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; CASEIN KINASE-II; VHS DOMAINS; CYTOPLASMIC DOMAIN; ASSEMBLY PROTEINS; STRUCTURAL BASIS; PLASMA-MEMBRANE; GAMMA-ADAPTIN; CLATHRIN; TRAFFICKING	Lysosomal biogenesis depends on proper transport of lysosomal enzymes by the cation-dependent mannose 6-phosphate receptor (CD-MPR) from the trans-Golgi network (TGN) to endosomes. Trafficking of the CD-MPR is mediated by sorting signals in its cytoplasmic tail. GGA1 (Golgi-localizing, gamma-ear-containing, ARF-binding protein-1) binds to CD-MPR in the TGN and targets the receptor to clathrin-coated pits for transport from the TGN to endosomes. The motif of the CD-MPR that interacts with GGA1 was shown to be (DXXLL65)-D-61. Reports on increased affinity of cargo, when phosphorylated by casein kinase 2 (CK2), to GGAs focused our interest on the effect of the CD-MPR CK2 site on binding to GGA1. Here we demonstrate that Glu(58) and Glu(59) of the CK2 site are essential for high affinity GGA1 binding in vitro, whereas the phosphorylation of Ser(57) of the CD-MPR has no influence on receptor binding to GGA1. Furthermore, the in vivo interaction between GGA1 and CD-MPR was abolished only when all residues involved in GGA1 binding were mutated, namely, Glu(58), Glu(59), Asp(61), Leu(64), and Leu(65). In contrast, the binding of adaptor protein-1 (AP-1) to CD-MPR required all the glutamates surrounding the phosphorylation site, namely, Glu(55), Glu(56), Glu(58), and Glu(59), but like GGA1 binding, was independent of the phosphorylation of Ser(57). The binding affinity of GGA1 to the CD-MPR was found to be 2.4-fold higher than that of AP-1. This could regulate the binding of the two proteins to the partly overlapping sorting signals, allowing AP-1 binding to the CD-MPR only when GGA1 is released upon autoinhibition by phosphorylation.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Gottingen, Inst Biochem 2, D-37073 Gottingen, Germany	University of Zurich; University of Gottingen	Rohrer, J (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	rohrer.jack@access.unizh.ch	Stoeckli, Jacqueline/Z-4443-2019; Stoeckli, Jacqueline/D-7053-2016	Stoeckli, Jacqueline/0000-0002-6446-7350; Stoeckli, Jacqueline/0000-0002-6446-7350; Rohrer, Jack/0000-0002-2058-490X				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; Collins BM, 2003, DEV CELL, V4, P321, DOI 10.1016/S1534-5807(03)00037-6; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Doray B, 2002, P NATL ACAD SCI USA, V99, P8072, DOI 10.1073/pnas.082235699; Ghosh P, 2003, J BIOL CHEM, V278, P14543, DOI 10.1074/jbc.M212543200; Ghosh P, 2003, J CELL BIOL, V160, P699, DOI 10.1083/jcb.200211080; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; HEMER F, 1993, J BIOL CHEM, V268, P17108; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Kato Y, 2002, NAT STRUCT BIOL, V9, P532, DOI 10.1038/nsb807; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNER C, 1994, J BIOL CHEM, V269, P16529; Kornfeld R, 1998, J BIOL CHEM, V273, P23203, DOI 10.1074/jbc.273.36.23203; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Medigeshi GR, 2003, TRAFFIC, V4, P802, DOI 10.1034/j.1600-0854.2003.00136.x; MESSNER DJ, 1993, ARCH BIOCHEM BIOPHYS, V306, P391, DOI 10.1006/abbi.1993.1528; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; Sambrook J, 1998, MOL CLONING LAB MANU, V2nd; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	39	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23542	23549		10.1074/jbc.M313525200	http://dx.doi.org/10.1074/jbc.M313525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044437	hybrid			2022-12-25	WOS:000221570900093
J	Ventura, C; Maioli, M; Asara, Y; Santoni, D; Scarlata, I; Cantoni, S; Perbellini, A				Ventura, C; Maioli, M; Asara, Y; Santoni, D; Scarlata, I; Cantoni, S; Perbellini, A			Butyric and retinoic mixed ester of hyaluronan A novel differentiating glycoconjugate affording a high throughput of cardiogenesis in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASES; BINDING PROTEIN; SODIUM-BUTYRATE; RXR-ALPHA; ACID; EXPRESSION; KINASE; HEART; CARDIOMYOCYTES; TRANSCRIPTION	Embryonic stem (ES) cells can differentiate into specialized cells, including cardiac myocytes, but the efficiency is typically low and the process is incompletely understood. Achieving a high throughput of cardiogenesis from pluripotent cells is therefore a major requirement for future approaches in cardiac cell therapy. Here, we developed a novel ester of hyaluronan linked to both butyric and retinoic acid (HBR), coaxing pluripotent ES cells into a cardiogenic decision. In mouse ES cells, HBR remarkably increased the expression of GATA-4 and Nkx-2.5, acting as cardiac lineage-promoting genes in different animal species, including humans. HBR also enhanced prodynorphin gene expression and the synthesis and secretion of dynorphin B, an endorphin playing a major role in ES cell cardiogenesis. These effects occurred at the transcriptional level. HBR also primed the expression of cardiac-specific transcripts and highly enhanced the yield of spontaneously beating ES-derived cardiomyocytes. These results demonstrate the potential for chemically modifying the gene program of cardiac differentiation in ES cells without the aid of gene transfer technologies and may pave the way for novel approaches in tissue engineering and myocardial regeneration.	Univ Bologna, Natl Inst Biostruct & Biosyst, Lab Mol Biol & Stem Cell Engn, I-40138 Bologna, Italy; Univ Trieste, Dept Biochem Biophys & Chem Macromol, I-34127 Trieste, Italy; Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy	University of Bologna; University of Trieste; University of Sassari	Ventura, C (corresponding author), Univ Bologna, S Orcola Malpighi Hosp, Inst Cardiol,Natl Inst Biostruct & Biosyst, Lab Mol Biol & Stem Cell Engn, Pavil 21,Via Massarenti N 9, I-40138 Bologna, Italy.	cvent@libero.it	Cantoni, Silvia/H-3938-2011	Cantoni, Silvia/0000-0002-3866-3307; MAIOLI, Margherita/0000-0003-0187-4968				BENEDETTI LM, 1991, NEW POLYM MAT, V3, P41; Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Collis L, 1998, FEBS LETT, V440, P444, DOI 10.1016/S0014-5793(98)01505-1; Coradini D, 1999, INT J CANCER, V81, P411, DOI 10.1002/(SICI)1097-0215(19990505)81:3<411::AID-IJC15>3.0.CO;2-F; Deb TB, 1996, J BIOL CHEM, V271, P2206, DOI 10.1074/jbc.271.4.2206; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; HAEGEL H, 1994, DEV IMMUNOL, V3, P239, DOI 10.1155/1994/25484; HOFLE G, 1978, ANGEW CHEM INT EDIT, V17, P569, DOI 10.1002/anie.197805691; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Klug MG, 1995, AM J PHYSIOL-HEART C, V269, pH1913, DOI 10.1152/ajpheart.1995.269.6.H1913; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Majumdar M, 2002, BIOCHEM BIOPH RES CO, V291, P829, DOI 10.1006/bbrc.2002.6491; MARYANOFF C, 1988, Patent No. 4743400; MCCUE PA, 1984, J CELL BIOL, V98, P602, DOI 10.1083/jcb.98.2.602; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; Ventura C, 2000, CIRC RES, V87, P189, DOI 10.1161/01.RES.87.3.189; Ventura C, 2003, CIRC RES, V92, P623, DOI 10.1161/01.RES.0000065169.23780.0E; Ventura C, 2003, CIRC RES, V92, P617, DOI 10.1161/01.RES.0000065168.31147.5B; WHEATLEY SC, 1993, DEVELOPMENT, V119, P295; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342	31	57	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23574	23579		10.1074/jbc.M401869200	http://dx.doi.org/10.1074/jbc.M401869200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044487	hybrid			2022-12-25	WOS:000221570900097
J	Bougie, I; Bisaillon, M				Bougie, I; Bisaillon, M			The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DNA-LIGASE; CRYSTAL-STRUCTURE; GUANYLATE INTERMEDIATE; MYCOPHENOLIC-ACID; ESCHERICHIA-COLI; DOMAIN-STRUCTURE; MECHANISM; PROTEIN; GUANYLYLTRANSFERASE	The broad spectrum antiviral nucleoside ribavirin displays activity against a variety of RNA and DNA viruses. A number of possible mechanisms have been proposed during the past 30 years to account for the antiviral activity of ribavirin, including the possibility that ribavirin might have a negative effect on the synthesis of the RNA cap structure of viral RNA transcripts. In the present study, we investigated the possibility that ribavirin can directly serve as a substrate for the vaccinia virus RNA capping enzyme. We demonstrate that ribavirin triphosphate can be used as a substrate by the capping enzyme and can form a covalent ribavirin monophosphate-enzyme intermediate reminiscent of the classical GMP-enzyme intermediate. Furthermore, our data indicate that ribavirin monophosphate can be transferred to the diphosphate end of an RNA transcript to form the unusual RpppN structure. Finally, we provide evidence that RNA transcripts that possess ribavirin as the blocking nucleoside are more stable than unblocked transcripts. However, in vitro translation assays indicate that RNA transcripts blocked with ribavirin are not translated efficiently. Our study provides the first biochemical evidences that ribavirin can directly interact with a viral capping enzyme. The ability of a purified RNA capping enzyme to utilize ribavirin as a substrate has not been previously documented and has implications for our understanding of the catalytic mechanisms of RNA capping enzymes. The biological implications of these findings for the proposed ribavirin-mediated inhibition of capping are discussed.	Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Bisaillon, M (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochim, 3001 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.	Martin.Bisaillon@USherbrooke.ca						Baker R, 2003, ANTIVIR RES, V57, P13, DOI 10.1016/S0166-3542(02)00196-1; Cameron CE, 2001, CURR OPIN INFECT DIS, V14, P757, DOI 10.1097/00001432-200112000-00015; CONG PJ, 1993, J BIOL CHEM, V268, P7256; Crotty S, 2000, NAT MED, V6, P1375, DOI 10.1038/82191; Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598; DECLERCQ E, 1993, ADV VIRUS RES, V42, P1, DOI 10.1016/S0065-3527(08)60082-2; ERIKSSON B, 1977, ANTIMICROB AGENTS CH, V11, P946, DOI 10.1128/AAC.11.6.946; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Fang SH, 2000, J HEPATOL, V33, P791, DOI 10.1016/S0168-8278(00)80312-8; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; GOSWAMI BB, 1979, BIOCHEM BIOPH RES CO, V89, P830, DOI 10.1016/0006-291X(79)91853-9; Hakansson K, 1998, P NATL ACAD SCI USA, V95, P1505, DOI 10.1073/pnas.95.4.1505; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; Jordan I, 1999, J VIROL, V73, P7903, DOI 10.1128/JVI.73.9.7903-7906.1999; Koren G, 2003, CAN MED ASSOC J, V168, P1289; Lau JYN, 2002, HEPATOLOGY, V35, P1002, DOI 10.1053/jhep.2002.32672; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Maag D, 2001, J BIOL CHEM, V276, P46094, DOI 10.1074/jbc.C100349200; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; MILLER JP, 1977, ANN NY ACAD SCI, V284, P211, DOI 10.1111/j.1749-6632.1977.tb21953.x; MULLER WEG, 1977, BIOCHEM PHARMACOL, V26, P1071, DOI 10.1016/0006-2952(77)90246-5; Myette JR, 1996, J BIOL CHEM, V271, P11936, DOI 10.1074/jbc.271.20.11936; Niedzwiecka A, 2002, J MOL BIOL, V319, P615, DOI 10.1016/S0022-2836(02)00328-5; NILES EG, 1993, VIROLOGY, V193, P319; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; OXENRIDER KA, 1993, FEBS LETT, V316, P273, DOI 10.1016/0014-5793(93)81307-L; PAGE T, 1990, INT J BIOCHEM, V22, P379, DOI 10.1016/0020-711X(90)90140-X; PRUSINER P, 1973, NATURE-NEW BIOL, V244, P116, DOI 10.1038/newbio244116a0; SCHEIDEL LM, 1987, VIROLOGY, V158, P1, DOI 10.1016/0042-6822(87)90230-3; SCHEIDEL LM, 1991, VIROLOGY, V181, P490, DOI 10.1016/0042-6822(91)90881-B; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHUMAN S, 1982, J BIOL CHEM, V257, P7237; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705; SONENBERG N, 1996, TRANSLATIONAL CONTRO; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; VENKATESAN S, 1982, P NATL ACAD SCI-BIOL, V79, P340, DOI 10.1073/pnas.79.2.340; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996; Zuckerman E, 2001, BLOOD, V97, P1555, DOI 10.1182/blood.V97.6.1555	44	54	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22124	22130		10.1074/jbc.M400908200	http://dx.doi.org/10.1074/jbc.M400908200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15037606	hybrid			2022-12-25	WOS:000221417100055
J	Chen, JS; Exton, JH				Chen, JS; Exton, JH			Regulation of phospholipase D2 activity by protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; RAT-BRAIN; SIGNALING CASCADE; PLASMA-MEMBRANE; D1; ACTIVATION; PHOSPHORYLATION; CLONING; INHIBITION; EXPRESSION	It has been well documented that protein kinase C (PKC) plays an important role in regulation of phospholipase D (PLD) activity. Although PKC regulation of PLD1 activity has been studied extensively, the role of PKC in PLD2 regulation remains to be established. In the present study it was demonstrated that phorbol 12-myristate 13-acetate (PMA) induced PLD2 activation in COS-7 cells. PLD2 was also phosphorylated on both serine and threonine residues after PMA treatment. PKC inhibitors Ro-31-8220 and bisindolylmaleimide I inhibited both PMA-induced PLD2 phosphorylation and activation. However, Go 6976, a PKC inhibitor relatively specific for conventional PKC isoforms, almost completely abolished PLD2 phosphorylation by PMA but only slightly inhibited PLD2 activation. Furthermore, time course studies showed that phosphorylation of PLD2 lagged behind its activation by PMA. Concentration curves for PMA action on PLD2 phosphorylation and activation also showed that PLD2 was activated by PMA at concentrations at which PMA didn't induce phosphorylation. A kinase-deficient mutant of pKCalpha stimulated PLD2 activity to an even higher level than wild type PKCalpha. Co-expression of wild type PKCalpha, but not PKCdelta, greatly enhanced both basal and PMA-induced PLD2 phosphorylation. A PKCdelta-specific inhibitor, rottlerin, failed to inhibit PMA-induced PLD2 phosphorylation and activation. Co-immunoprecipitation studies indicated an association between PLD2 and PKCalpha under basal conditions that was further enhanced by PMA. Time course studies of the effects of PKCalpha on PLD2 showed that as the phosphorylation of PLD2 increased, its activity declined. In summary, the data demonstrated that PLD2 is activated and phosphorylated by PMA and PKCalpha in COS-7 cells. However, the phosphorylation is not required for PKCalpha to activate PLD2. It is suggested that interaction rather than phosphorylation underscores the activation of PLD2 by PKC in vivo and that phosphorylation may contribute to the inactivation of the enzyme.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.	john.exton@vanderbilt.edu						Ahn BH, 2003, MOL CELL BIOL, V23, P3103, DOI 10.1128/MCB.23.9.3103-3115.2003; Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Czarny M, 2000, FEBS LETT, V467, P326, DOI 10.1016/S0014-5793(00)01174-1; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Han JM, 2002, J BIOL CHEM, V277, P8290, DOI 10.1074/jbc.M108343200; Hu TH, 2003, J BIOL CHEM, V278, P2348, DOI 10.1074/jbc.M210093200; Jang IH, 2003, J BIOL CHEM, V278, P18184, DOI 10.1074/jbc.M208438200; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; Koch T, 2003, J BIOL CHEM, V278, P9979, DOI 10.1074/jbc.M206709200; Kodaki T, 1997, J BIOL CHEM, V272, P11408; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Sarkar S, 2001, BIOCHEM J, V359, P599, DOI 10.1042/0264-6021:3590599; Sarri E, 2003, BIOCHEM J, V369, P319, DOI 10.1042/BJ20021347; Siddiqi AR, 2000, BBA-MOL CELL RES, V1497, P103, DOI 10.1016/S0167-4889(00)00049-5; Singh IN, 2001, BIOCHEMISTRY-US, V40, P11227, DOI 10.1021/bi010787l; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Slaaby R, 2000, BIOCHEM J, V351, P613, DOI 10.1042/0264-6021:3510613; Takuwa Y, 2002, J BIOCHEM, V131, P767, DOI 10.1093/oxfordjournals.jbchem.a003163; Watanabe H, 2000, BBA-MOL CELL RES, V1495, P121, DOI 10.1016/S0167-4889(99)00165-2; Xie Z, 2002, J BIOL CHEM, V277, P11979, DOI 10.1074/jbc.M109751200; Xie Z, 2002, METHOD ENZYMOL, V345, P255	34	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22076	22083		10.1074/jbc.M311033200	http://dx.doi.org/10.1074/jbc.M311033200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15031293	hybrid			2022-12-25	WOS:000221417100049
J	Everitt, AB; Luu, T; Cromer, B; Tierney, ML; Birnir, B; Olsen, RW; Gage, PW				Everitt, AB; Luu, T; Cromer, B; Tierney, ML; Birnir, B; Olsen, RW; Gage, PW			Conductance of recombinant GABA(A) channels is increased in cells co-expressing GABA(A) receptor-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; CULTURED HIPPOCAMPAL-NEURONS; CHLORIDE CHANNELS; GABARAP; CYTOSKELETON; GLYCINE	High conductance gamma- aminobutyric acid type A ( GABA(A)) channels (> 40 picosiemens ( pS)) have been reported in some studies on GABA(A) channels in situ but not in others, whereas recombinant GABA(A) channels do not appear to display conductances above 40 pS. Furthermore, the conductance of some native GABA(A) channels can be increased by diazepam or pentobarbital, which are effects not reported for expressed GABA(A) channels. GABARAP, a protein associated with native GABA(A) channels, has been reported to cause clustering of GABA(A) receptors and changes in channel kinetics. We have recorded single channel currents activated by GABA in L929 cells expressing alpha(1), beta(1), and gamma(2S) subunits of human GABA(A) receptors. Channel conductance was never higher than 40 pS and was not significantly increased by diazepam or pentobarbital, although open probability was increased. In contrast, in cells expressing the same three subunits together with GABARAP, channel conductance could be significantly higher than 40 pS, and channel conductance was increased by diazepam and pentobarbital. GABARAP caused clustering of receptors in L929 cells, and we suggest that there may be interactions between subunits of clustered GABA(A) receptors that make them open co- operatively to give high conductance " channels." Recombinant channels may require the influence of GABARAP and perhaps other intracellular proteins to adopt a fuller repertoire of properties of native channels.	Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Australian Natl Univ, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 2601, Australia; Lund Univ, S-22184 Lund, Sweden; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research; Australian National University; Lund University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tierney, ML (corresponding author), John Curtin Sch Med Res, GPO Box 334, Canberra, ACT 0200, Australia.	louise.tierney@anu.edu.au	Luu, Tien/C-8303-2009; Cromer, Brett/AAQ-6533-2020	Cromer, Brett/0000-0003-0743-1535; Birnir, Bryndis/0000-0002-1763-0266				Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; CURMI JP, 1993, J MEMBRANE BIOL, V136, P273; Eghbali M, 2000, MOL PHARMACOL, V58, P463, DOI 10.1124/mol.58.3.463; Eghbali M, 1997, NATURE, V388, P71, DOI 10.1038/40404; FATIMASHAD K, 1992, P ROY SOC B-BIOL SCI, V250, P99, DOI 10.1098/rspb.1992.0136; GRAY R, 1985, J NEUROPHYSIOL, V54, P134, DOI 10.1152/jn.1985.54.1.134; Guyon A, 1999, J PHYSIOL-LONDON, V516, P719, DOI 10.1111/j.1469-7793.1999.0719u.x; Khakh BS, 2000, NATURE, V406, P405, DOI 10.1038/35019066; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Kneussel M, 2002, BRAIN RES REV, V39, P74, DOI 10.1016/S0165-0173(02)00159-5; Laver DR, 1997, PROG BIOPHYS MOL BIO, V67, P99, DOI 10.1016/S0079-6107(97)00008-4; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; SMITH SM, 1989, J MEMBRANE BIOL, V108, P45, DOI 10.1007/BF01870424; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264	16	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21701	21706		10.1074/jbc.M312806200	http://dx.doi.org/10.1074/jbc.M312806200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007071	hybrid			2022-12-25	WOS:000221417100004
J	Heine, C; Koch, B; Storch, S; Kohlschutter, A; Palmer, DN; Braulke, T				Heine, C; Koch, B; Storch, S; Kohlschutter, A; Palmer, DN; Braulke, T			Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; MULTIPLE SULFATASE DEFICIENCY; MANNOSE 6-PHOSPHATE RECEPTOR; BATTEN-DISEASE; CATHEPSIN-D; METACHROMATIC LEUKODYSTROPHY; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE PROTEIN; SURFACE EXPRESSION; RETENTION SIGNAL	Variant late infantile neuronal ceroid lipofuscinosis, a lysosomal storage disorder characterized by progressive mental deterioration and blindness, is caused by mutations in a polytopic membrane protein (CLN6) with unknown intracellular localization and function. In this study, transient transfection of BHK21 cells with CLN6 cDNA and immunoblot analysis using peptide-specific CLN6 antibodies demonstrated the expression of a similar to27-kDa protein that does not undergo proteolytic processing. Cross-linking experiments revealed the presence of CLN6 dimers. Using double immunofluorescence microscopy, epitope-tagged CLN6 was shown to be retained in the endoplasmic reticulum ( ER) with no colocalization with the cis-Golgi or lysosomal markers. The translocation into the ER and proper folding were confirmed by the N-linked glycosylation of a mutant CLN6 polypeptide. Pulse-chase labeling of fibroblasts from CLN6 patients and from sheep (OCL6) and mouse (nclf) models of the disease followed by immunoprecipitation of cathepsin D indicated that neither the synthesis, sorting nor the proteolytic processing of this lysosomal enzyme was affected in CLN6-defective cells. However, the degradation of the endocytosed index protein arylsulfatase A was strongly reduced in all of the mutant CLN6 cell lines compared with controls. These data suggest that defects in the ER-resident CLN6 protein lead to lysosomal dysfunctions, which may result in lysosomal accumulation of storage material.	Univ Hamburg Hosp, Childrens Hosp, Dept Biochem, D-20246 Hamburg, Germany; Lincoln Univ, Anim & Food Sci Div, Canterbury, New Zealand	University of Hamburg; University Medical Center Hamburg-Eppendorf; Lincoln University - New Zealand	Braulke, T (corresponding author), Univ Hamburg Hosp, Childrens Hosp, Dept Biochem, Martinistr 52,Bldg W23, D-20246 Hamburg, Germany.	braulke@uke.uni-hamburg.de	Palmer, David/B-7344-2008; Braulke, Thomas/AAV-9121-2020; Kohlschütter, Alfried/ABE-3495-2021; Kohlschütter, Alfried/ABH-5710-2020	Braulke, Thomas/0000-0002-2336-8532; Kohlschütter, Alfried/0000-0002-2700-0401; Storch, Stephan/0000-0002-8807-5917	NINDS NIH HHS [NS40297] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS040297] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Braulke T, 1996, Subcell Biochem, V27, P15; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; Bronson RT, 1998, AM J MED GENET, V77, P289, DOI 10.1002/(SICI)1096-8628(19980526)77:4<289::AID-AJMG8>3.0.CO;2-I; Claussen M, 1997, ENDOCRINOLOGY, V138, P3797, DOI 10.1210/en.138.9.3797; Cook RW, 2002, AUST VET J, V80, P292, DOI 10.1111/j.1751-0813.2002.tb10847.x; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; DAMKE H, 1992, BIOCHEM J, V281, P225, DOI 10.1042/bj2810225; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; FIGURA KV, 1978, EXP CELL RES, V111, P15, DOI 10.1016/0014-4827(78)90231-8; Gao HL, 2002, AM J HUM GENET, V70, P324, DOI 10.1086/338190; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; Goebel HH, 1999, MOL GENET METAB, V66, P367, DOI 10.1006/mgme.1999.2808; Haltia M, 2003, J NEUROPATH EXP NEUR, V62, P1; Hardt B, 2003, GLYCOBIOLOGY, V13, P159, DOI 10.1093/glycob/cwg013; HASILIK A, 1980, J BIOL CHEM, V255, P4937; Heine C, 2003, BIOCHEM J, V376, P369, DOI 10.1042/BJ20030598; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; Hu W, 2003, J NEUROCHEM, V86, P470, DOI 10.1046/j.1471-4159.2003.01855.x; Isosomppi J, 2002, HUM MOL GENET, V11, P885, DOI 10.1093/hmg/11.8.885; Janes RW, 1996, FEBS LETT, V399, P75, DOI 10.1016/S0014-5793(96)01290-2; Jarvela I, 1999, HUM MOL GENET, V8, P1091, DOI 10.1093/hmg/8.6.1091; Jolly RD, 1999, MOL GENET METAB, V66, P376, DOI 10.1006/mgme.1999.2821; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; Kyttala A, 2004, MOL BIOL CELL, V15, P1313, DOI 10.1091/mbc.E03-02-0120; Lin L, 2001, J BIOL CHEM, V276, P2249, DOI 10.1074/jbc.M008562200; Lonka L, 2000, HUM MOL GENET, V9, P1691, DOI 10.1093/hmg/9.11.1691; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Maza J, 2003, CELL COMMUN ADHES, V10, P319, DOI 10.1080/15419060390263083; Meyer C, 2001, J CELL SCI, V114, P4469; Muschol N, 2002, BIOCHEM J, V368, P845, DOI 10.1042/BJ20020249; PALMER DN, 1985, BIOCHIM BIOPHYS ACTA, V834, P159, DOI 10.1016/0005-2760(85)90151-1; Palmer DN, 1997, NEUROPEDIATRICS, V28, P45, DOI 10.1055/s-2007-973666; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; PARKER KC, 1983, BIOCHEMISTRY-US, V22, P1145, DOI 10.1021/bi00274a024; Partanen S, 2003, BIOCHEM J, V369, P55, DOI 10.1042/BJ20021226; PORTER MT, 1969, P NATL ACAD SCI USA, V62, P887, DOI 10.1073/pnas.62.3.887; Ranta S, 1999, NAT GENET, V23, P233, DOI 10.1038/13868; Ren Z, 2003, J BIOL CHEM, V278, P52700, DOI 10.1074/jbc.M309585200; Ren Z, 2003, J NEUROSCI, V23, P6608; ROSORIUS O, 1993, J BIOL CHEM, V268, P21470; SAVUKOSKI M, 1998, SCIENCE, V277, P1802; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Sharp JD, 2003, HUM MUTAT, V22, P35, DOI 10.1002/humu.10227; STECKEL F, 1985, EUR J BIOCHEM, V151, P141, DOI 10.1111/j.1432-1033.1985.tb09078.x; STECKEL F, 1985, EUR J BIOCHEM, V151, P147, DOI 10.1111/j.1432-1033.1985.tb09079.x; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; Teixeira C, 2003, J NEUROL, V250, P661, DOI 10.1007/s00415-003-1050-z; Teixeira CA, 2003, HUM MUTAT, V21, P502, DOI 10.1002/humu.10207; Vines DJ, 1999, FEBS LETT, V443, P131, DOI 10.1016/S0014-5793(98)01683-4; von Bulow R, 2002, J BIOL CHEM, V277, P9455, DOI 10.1074/jbc.M111993200; Wheeler RB, 2002, AM J HUM GENET, V70, P537, DOI 10.1086/338708; Zwad O, 2002, FEBS LETT, V510, P211, DOI 10.1016/S0014-5793(01)03267-7	54	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22347	22352		10.1074/jbc.M400643200	http://dx.doi.org/10.1074/jbc.M400643200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15010453	hybrid			2022-12-25	WOS:000221417100082
J	Poncet, D; Larochette, N; Pauleau, AL; Boya, P; Jalil, AA; Cartron, PF; Vallette, F; Schnebelen, C; Bartle, LM; Skaletskaya, A; Boutolleau, D; Martinou, JC; Goldmacher, VS; Kroemer, G; Zamzami, N				Poncet, D; Larochette, N; Pauleau, AL; Boya, P; Jalil, AA; Cartron, PF; Vallette, F; Schnebelen, C; Bartle, LM; Skaletskaya, A; Boutolleau, D; Martinou, JC; Goldmacher, VS; Kroemer, G; Zamzami, N			An anti-apoptotic viral protein that recruits bax to mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCATOR; LOCALIZED INHIBITOR; CYTOCHROME-C; MEMBRANE PERMEABILIZATION; BCL-2 HOMOLOG; CELL-DEATH; OLIGOMERIZATION; RELEASE; EXPRESSION; TERMINUS	The viral mitochondria-localized inhibitor of apoptosis (vMIA), encoded by the UL37 gene of human cytomegalovirus, inhibits apoptosis-associated mitochondrial membrane permeabilization by a mechanism different from that of Bcl-2. Here we show that vMIA induces several changes in Bax that resemble those found in apoptotic cells yet take place in unstimulated, nonapoptotic vMIA-expressing cells. These changes include the constitutive localization of Bax at mitochondria, where it associates tightly with the mitochondrial membrane, forming high molecular weight aggregates that contain vMIA. vMIA recruits Bax to mitochondria but delays relocation of caspase-8-activated truncated Bidgreen fluorescent protein (GFP) (t-Bid-GFP) to mitochondria. The ability of vMIA and its deletion mutants to associate with Bax and to induce relocation of Bax to mitochondria correlates with their anti-apoptotic activity and with their ability to suppress mitochondrial membrane permeabilization. Taken together, our data indicate that vMIA blocks apoptosis via its interaction with Bax. vMIA neutralizes Bax by recruiting it to mitochondria and "freezing" its pro-apoptotic activity. These data unravel a novel strategy of subverting an intrinsic pathway of apoptotic signaling.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; INSERM, U419, F-44035 Nantes, France; Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France; Dept Biol Cellulaire, CH-1211 Geneva 4, Switzerland; ImmunoGen Inc, Cambridge, MA 02139 USA; Hop Bicetre, F-94277 Le Kremlin Bicetre, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; University of Geneva; ImmunoGen, Inc.; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr; zamzami@igr.fr	Vallette, Francois/N-2361-2018; Cartron, Pierre Francois/K-9802-2015; KROEMER, Guido/B-4263-2013; Boya, Patricia/P-8345-2019; Boutolleau, David/GRO-1697-2022; Kroemer, Guido/AAY-9859-2020; Poncet, Delphine A/A-7190-2016; Vallette, Francois/K-9047-2015; LAROCHETTE, Nathanael/R-4298-2017	KROEMER, Guido/0000-0002-9334-4405; Boya, Patricia/0000-0003-3045-951X; Poncet, Delphine A/0000-0003-0446-5262; Vallette, Francois/0000-0002-3296-8572; Cartron, Pierre-Francois/0000-0002-3393-784X; martinou, Jean-claude/0000-0002-9847-2051; LAROCHETTE, Nathanael/0000-0002-7936-678X; Vallette, Francois/0000-0003-0802-0519; JALIL, Abdelali/0000-0003-2710-8735; Goldmakher, Viktor/0000-0001-6130-4436				Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Cartron PF, 2002, HUM MOL GENET, V11, P675, DOI 10.1093/hmg/11.6.675; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Everett H, 2002, J EXP MED, V196, P1127, DOI 10.1084/jem.20011247; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hayajneh WA, 2001, VIROLOGY, V279, P233, DOI 10.1006/viro.2000.0726; HEIDI L, 2002, NAT MED, V8, P274; Huang QL, 2003, J MOL BIOL, V332, P1123, DOI 10.1016/j.jmb.2003.08.007; Huang QL, 2002, P NATL ACAD SCI USA, V99, P3428, DOI 10.1073/pnas.062525799; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McCormick AL, 2003, VIROLOGY, V316, P221, DOI 10.1016/j.virol.2003.07.003; McCormick AL, 2003, J VIROL, V77, P631, DOI 10.1128/JVI.77.1.631-641.2003; Messud-Petit F, 1998, J VIROL, V72, P7830, DOI 10.1128/JVI.72.10.7830-7839.1998; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Roucou X, 2002, BIOCHEM J, V363, P547, DOI 10.1042/0264-6021:3630547; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tschopp J, 1998, CURR OPIN GENET DEV, V8, P82, DOI 10.1016/S0959-437X(98)80066-X; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamaguchi H, 2003, CANCER RES, V63, P1483; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	51	111	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22605	22614		10.1074/jbc.M308408200	http://dx.doi.org/10.1074/jbc.M308408200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15004026	hybrid			2022-12-25	WOS:000221417100112
J	MacRaild, CA; Stewart, CR; Mok, YF; Gunzburg, MJ; Perugini, MA; Lawrence, LJ; Tirtaatmadja, V; Cooper-White, JJ; Howlett, GJ				MacRaild, CA; Stewart, CR; Mok, YF; Gunzburg, MJ; Perugini, MA; Lawrence, LJ; Tirtaatmadja, V; Cooper-White, JJ; Howlett, GJ			Non-fibrillar components of amyloid deposits mediate the self-association and tangling of amyloid fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-COMPONENT; APOLIPOPROTEIN-E; ALZHEIMER-DISEASE; PROTEIN; PATHOGENESIS; COEFFICIENT; TOXICITY; BINDING	Amyloid deposits are proteinaceous extra-cellular aggregates associated with a diverse range of disease states. These deposits are composed predominantly of amyloid fibrils, the unbranched, beta-sheet rich structures that result from the misfolding and subsequent aggregation of many proteins. In addition, amyloid deposits contain a number of non-fibrillar components that interact with amyloid fibrils and are incorporated into the deposits in their native folded state. The influence of a number of the non-fibrillar components in amyloid-related diseases is well established; however, the mechanisms underlying these effects are poorly understood. Here we describe the effect of two of the most important non-fibrillar components, serum amyloid P component and apolipoprotein E, upon the solution behavior of amyloid fibrils in an in vitro model system. Using analytical ultracentrifugation, electron microscopy, and rheological measurements, we demonstrate that these non-fibrillar components cause soluble fibrils to condense into localized fibrillar aggregates with a greatly enhanced local density of fibril entanglements. These results suggest a possible mechanism for the observed role of non-fibrillar components as mediators of amyloid deposition and deposit stability.	Univ Melbourne, Russell Grimwade Sch Biochem & Mol Biol, Parkville, Vic 3010, Australia; Univ Melbourne, Particulate Fluids Proc Ctr, Dept Chem & Biomol Engn, Parkville, Vic 3010, Australia; CSIRO, Parkville, Vic 3052, Australia	University of Melbourne; University of Melbourne; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Howlett, GJ (corresponding author), Univ Melbourne, Russell Grimwade Sch Biochem & Mol Biol, Parkville, Vic 3010, Australia.	ghowlett@unimelb.edu.au	Waddington, Lynne J/H-3500-2013; Cooper-White, Justin/B-2567-2010; Stewart, Cameron R/E-6823-2011	Cooper-White, Justin/0000-0002-1920-8229; MacRaild, Christopher/0000-0002-3694-3989; Stewart, Cameron/0000-0002-3395-7859				Botto M, 1997, NAT MED, V3, P855, DOI 10.1038/nm0897-855; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Charge SBP, 1996, J PATHOL, V179, P443; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Danielsen B, 1997, BBA-PROTEIN STRUCT M, V1339, P73, DOI 10.1016/S0167-4838(96)00218-X; DELATORRE JG, 1994, BIOPHYS J, V67, P530, DOI 10.1016/S0006-3495(94)80512-0; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; GALLO G, 1994, AM J PATHOL, V145, P526; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; Hatters DM, 2003, BIOPHYS J, V85, P3979, DOI 10.1016/S0006-3495(03)74812-7; Hatters DM, 2002, EUR BIOPHYS J BIOPHY, V31, P2, DOI 10.1007/s002490100172; Hatters DM, 2000, BIOCHEMISTRY-US, V39, P8276, DOI 10.1021/bi000002w; Hoppener JWM, 2000, NEW ENGL J MED, V343, P411; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; MacRaild CA, 2003, BIOPHYS J, V84, P2562, DOI 10.1016/S0006-3495(03)75061-9; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Medeiros LA, 2004, J BIOL CHEM, V279, P10643, DOI 10.1074/jbc.M311735200; ODOHERTY DP, 1987, BRIT J SURG, V74, P83, DOI 10.1002/bjs.1800740204; Pepys MB, 2002, NATURE, V417, P254, DOI 10.1038/417254a; PEPYS MB, 1994, P NATL ACAD SCI USA, V91, P5602, DOI 10.1073/pnas.91.12.5602; Pepys MB, 2001, PHILOS T R SOC B, V356, P203, DOI 10.1098/rstb.2000.0766; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; Schuck P, 2000, BIOPOLYMERS, V54, P328, DOI 10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; Sousa MM, 2001, AM J PATHOL, V159, P1993; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; Togashi S, 1997, LAB INVEST, V77, P525; Wang CS, 1996, BBA-LIPID LIPID MET, V1302, P224, DOI 10.1016/0005-2760(96)00065-3; Weatherall DJ, 1995, OXFORD TXB MED, V2, P1512; Westermark P, 2002, AMYLOID, V9, P197; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; YAMAKAWA H, 1973, MACROMOLECULES, V6, P407, DOI 10.1021/ma60033a018	34	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21038	21045		10.1074/jbc.M314008200	http://dx.doi.org/10.1074/jbc.M314008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15031287	hybrid			2022-12-25	WOS:000221273800060
J	Michael, A; Haq, S; Chen, X; Hsich, E; Cui, L; Walters, B; Shao, ZL; Bhattacharya, K; Kilter, H; Huggins, G; Andreucci, M; Periasamy, M; Solomon, RN; Liao, RL; Patten, R; Molkentin, JD; Force, T				Michael, A; Haq, S; Chen, X; Hsich, E; Cui, L; Walters, B; Shao, ZL; Bhattacharya, K; Kilter, H; Huggins, G; Andreucci, M; Periasamy, M; Solomon, RN; Liao, RL; Patten, R; Molkentin, JD; Force, T			Glycogen synthase kinase-3 beta regulates growth, calcium homeostasis, and diastolic function in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-HYPERTROPHY; KINASE 3-BETA; SUBSTRATE-SPECIFICITY; CA2+ HOMEOSTASIS; IN-VIVO; INSULIN; CONTRACTION; EXPRESSION; DELETION; SIZE	Glycogen synthase kinase (GSK) 3beta is a negative regulator of stress-induced cardiomyocyte hypertrophy. It is not clear, however, if GSK-3beta plays any role in regulating normal cardiac growth and cardiac function. Herein we report that a transgenic mouse expressing wild type GSK-3beta in the heart has a dramatic impairment of normal post-natal cardiomyocyte growth as well as markedly abnormal cardiac contractile function. The most striking phenotype, however, is grossly impaired diastolic relaxation, which leads to increased filling pressures of the left ventricle and massive atrial enlargement. This is due to profoundly abnormal calcium handling, leading to an inability to normalize cytosolic [Ca2+] in diastole. The alterations in calcium handling are due at least in part to direct down-regulation of the sarcoplasmic reticulum calcium ATPase (SERCA2a) by GSK-3beta, acting at the level of the SERCA2 promoter. These studies identify GSK-3beta as a regulator of normal growth of the heart and are the first of which we are aware, to demonstrate regulation of expression of SERCA2a, a critical determinant of diastolic function, by a cytosolic signaling pathway, the activity of which is dynamically modulated. De-regulation of GSK-3beta leads to severe systolic and diastolic dysfunction and progressive heart failure. Because down-regulation of SERCA2a plays a central role in the diastolic and systolic dysfunction of patients with heart failure, these findings have potential implications for the therapy of this disorder.	Tufts Univ, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Boston Univ, Med Ctr, Boston, MA 02118 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Pediat, Cincinnati, OH 45229 USA; Massachusetts Gen Hosp, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	Tufts Medical Center; Tufts University; Tufts University; Boston University; Boston University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University System of Ohio; Ohio State University	Force, T (corresponding author), Tufts Univ, New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 8486, Boston, MA 02111 USA.	tforce@tufts-nemc.org		Molkentin, Jeffery/0000-0002-3558-6529; Force, Thomas/0000-0002-0450-8659; Periasamy, Muthu/0000-0001-8834-5975	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061688, R01HL067371] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61688, HL 67371] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; Baker DL, 1998, NUCLEIC ACIDS RES, V26, P1092, DOI 10.1093/nar/26.4.1092; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Fazio S, 2000, EUR J ENDOCRINOL, V142, P211, DOI 10.1530/eje.0.1420211; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Gaussin V, 2002, P NATL ACAD SCI USA, V99, P2878, DOI 10.1073/pnas.042390499; Haq S, 2003, P NATL ACAD SCI USA, V100, P4610, DOI 10.1073/pnas.0835895100; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Haq S, 2003, NAT MED, V9, P944, DOI 10.1038/nm891; Isenberg G, 2001, CARDIOVASC RES, V49, P1, DOI 10.1016/S0008-6363(00)00284-4; Ji Y, 2000, J BIOL CHEM, V275, P38073, DOI 10.1074/jbc.M004804200; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; Lim CC, 2000, J MOL CELL CARDIOL, V32, P2075, DOI 10.1006/jmcc.2000.1239; Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Minamino T, 2002, P NATL ACAD SCI USA, V99, P3866, DOI 10.1073/pnas.062453699; Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Nagata K, 1998, CARDIOVASC RES, V37, P467, DOI 10.1016/S0008-6363(97)00278-2; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Periasamy M, 2001, J MOL CELL CARDIOL, V33, P1053, DOI 10.1006/jmcc.2001.1366; Pete G, 1999, ENDOCRINOLOGY, V140, P5478, DOI 10.1210/en.140.12.5478; Petrich BG, 2002, COLD SPRING HARB SYM, V67, P429, DOI 10.1101/sqb.2002.67.429; Plank DM, 2003, AM J PHYSIOL-HEART C, V285, pH305, DOI 10.1152/ajpheart.00425.2002; Rogers JH, 1999, J CLIN INVEST, V104, P567, DOI 10.1172/JCI6713; ROTHERMEL B, 2001, P NATL ACAD SCI USA, V98, P2947; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Schillinger W, 2003, CARDIOVASC RES, V57, P996, DOI 10.1016/S0008-6363(02)00829-5; Schubert W, 2003, J CELL BIOL, V161, P861, DOI 10.1083/jcb.200301058; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shioi T, 2003, CIRCULATION, V107, P1664, DOI 10.1161/01.CIR.0000057979.36322.88; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Thuerauf DJ, 2001, J BIOL CHEM, V276, P48309, DOI 10.1074/jbc.M107146200; Wang J, 1999, ENDOCRINOLOGY, V140, P3391, DOI 10.1210/en.140.7.3391; Wang XM, 2001, EMBO J, V20, P4349, DOI 10.1093/emboj/20.16.4349; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Weisser-Thomas J, 2003, CARDIOVASC RES, V57, P974, DOI 10.1016/S0008-6363(02)00732-0; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; WOODGETT JR, 2001, SCI STKE; Xiao GS, 2001, CIRC RES, V89, P1122, DOI 10.1161/hh2401.100742; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zarain-Herzberg Angel, 2002, TheScientificWorldJOURNAL, V2, P1469	57	100	107	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21383	21393		10.1074/jbc.M401413200	http://dx.doi.org/10.1074/jbc.M401413200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15020584	hybrid			2022-12-25	WOS:000221273800102
J	Pinte, S; Guerardel, C; Deltour-Balerdi, S; Godwin, AK; Leprince, D				Pinte, S; Guerardel, C; Deltour-Balerdi, S; Godwin, AK; Leprince, D			Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1	ONCOGENE			English	Article						HIC1; 17p13.3; MDS; BTB/POZ; promoter; CpG island; 5 '-UTR	MILLER-DIEKER-SYNDROME; DNA METHYLATION; CHROMOSOME 17P13.3; BREAST-CANCER; EXPRESSION; HYPERMETHYLATION; REGION; MOUSE; MICE; P53	The BTB/POZ transcriptional repressor HIC1 (Hypermethylated in Cancer 1) is a tumor suppressor gene located at chromosome 17p13.3, a region frequently hypermethylated or deleted in human tumors and in a contiguous-gene syndrome, the Miller-Dieker syndrome. The human and murine HIC1 genes are composed of two alternative 5' exons, 1a and 1b fused to a large second coding exon 2. Exon 1a is a noncoding exon associated with a major G-C-rich promoter whereas exon 1b is a downstream coding exon associated with a minor TATA box promoter. By human-mouse genome comparison, we have identified a short upstream conserved sequence containing G-C boxes which were shown to be functional. Transcripts initiating from this new promoter were detected in various human and mouse tissues and contained a long 5'-UTR sequence, called 1c which encompass the G-C-rich promoter associated with exon 1a and uses the same splice donor site. RT-PCR analyses of two primary breast epithelial cell lines identified two other 5'-UTRs generated by alternative splicing within exon 1c. Our results thus highlight the existence of an unexpected complex transcriptional regulation of HIC1.	Inst Pasteur, Inst Biol Lille, CNRS, UMR 8526, F-59017 Lille, France; Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Fox Chase Cancer Center	Leprince, D (corresponding author), Inst Pasteur, Inst Biol Lille, CNRS, UMR 8526, 1 Rue Calmette, F-59017 Lille, France.	dominique.leprince@ibl.fr		Leprince, Dominique/0000-0002-1999-0775	NCI NIH HHS [P50 CA83638] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083638] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bruening W, 1999, CANCER RES, V59, P4973; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Grimm C, 1999, HUM MOL GENET, V8, P697, DOI 10.1093/hmg/8.4.697; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Han BG, 2003, ONCOGENE, V22, P5325, DOI 10.1038/sj.onc.1206783; Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Liscia DS, 1999, BRIT J CANCER, V80, P821, DOI 10.1038/sj.bjc.6690427; MAKOSWALES M, 1995, NAT MED, V1, P570; Melki JR, 1999, LEUKEMIA, V13, P877, DOI 10.1038/sj.leu.2401401; Phillips NJ, 1996, CANCER LETT, V102, P85, DOI 10.1016/0304-3835(96)04169-9; Rood BR, 2002, CANCER RES, V62, P3794; Schultz DC, 1996, CANCER RES, V56, P1997; Yingling J, 2003, AM J HUM GENET, V73, P475, DOI 10.1086/378096; Yuasa Y, 2002, MECH AGEING DEV, V123, P1649, DOI 10.1016/S0047-6374(02)00100-8	22	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4023	4031		10.1038/sj.onc.1207504	http://dx.doi.org/10.1038/sj.onc.1207504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007385				2022-12-25	WOS:000221382000015
J	Broer, A; Klingel, K; Kowalczuk, S; Rasko, JEJ; Cavanaugh, J; Broer, S				Broer, A; Klingel, K; Kowalczuk, S; Rasko, JEJ; Cavanaugh, J; Broer, S			Molecular cloning of mouse amino acid transport system B-0, a neutral amino acid transporter related to Hartnup disorder	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; FUNCTIONAL-CHARACTERIZATION; GLUTAMINE TRANSPORTER; NA+; CELL; SODIUM; PATHWAYS; PHENYLALANINE; SPECIFICITY; MECHANISMS	Resorption of amino acids in kidney and intestine is mediated by transporters, which prefer groups of amino acids with similar physico-chemical properties. It is generally assumed that most neutral amino acids are transported across the apical membrane of epithelial cells by system B-0. Here we have characterized a novel member of the Na+-dependent neurotransmitter transporter family (B(0)AT1) isolated from mouse kidney, which shows all properties of system B-0. Flux experiments showed that the transporter is Na+-dependent, electrogenic, and actively transports most neutral amino acids but not anionic or cationic amino acids. Superfusion of mB(0)AT1-expressing oocytes with neutral amino acids generated inward currents, which were proportional to the fluxes observed with labeled amino acids. In situ hybridization showed strong expression in intestinal microvilli and in the proximal tubule of the kidney. Expression of mouse B(0)AT1 was restricted to kidney, intestine, and skin. It is generally assumed that mutations of the system B-0 transporter underlie autosomal recessive Hartnup disorder. In support of this notion mB(0)AT1 is located on mouse chromosome 13 in a region syntenic to human chromosome 5p15, the locus of Hartnup disorder. Thus, the human homologue of this transporter is an excellent functional and positional candidate for Hartnup disorder.	Australian Natl Univ, Div Biochem & Mol Biol, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia; Univ Tubingen, Dept Mol Pathol, D-72076 Tubingen, Germany; Univ Sydney, Centenary Inst Canc Med & Cell Biol, Newton, NSW 2042, Australia; Royal Prince Alfred Hosp, Sydney Canc Ctr, Newton, NSW 2042, Australia; Canberra Hosp, Med Genet Res Inst, Woden, ACT 2607, Australia	Australian National University; Eberhard Karls University of Tubingen; University of Sydney; Centenary Institute; Australian National University; Canberra Hospital	Broer, S (corresponding author), Australian Natl Univ, Div Biochem & Mol Biol, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia.	stefan.broeer@anu.edu.au	Rasko, John EJ/F-5754-2013; Broer, Stefan/A-1286-2008; Cavanaugh, Juleen/C-9413-2009	Broer, Stefan/0000-0002-8040-1634; rasko, John/0000-0003-2975-807X				Avissar NE, 2001, AM J PHYSIOL-CELL PH, V281, pC963, DOI 10.1152/ajpcell.2001.281.3.C963; BARON DN, 1956, LANCET, V271, P421; Broer A, 2000, BIOCHEM J, V346, P705, DOI 10.1042/0264-6021:3460705; Broer A, 2002, J PHYSIOL-LONDON, V539, P3, DOI 10.1013/jphysiol.2001.013303; Broer A, 1999, J NEUROCHEM, V73, P2184; Broer S, 2002, PFLUG ARCH EUR J PHY, V444, P457, DOI 10.1007/s00424-002-0840-y; Broer S, 1997, J BIOL CHEM, V272, P30096, DOI 10.1074/jbc.272.48.30096; Broer Stefan, 2003, Methods Mol Biol, V227, P245, DOI 10.1385/1-59259-387-9:245; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P83, DOI 10.1007/BF00378645; Carninci P, 1998, P NATL ACAD SCI USA, V95, P520, DOI 10.1073/pnas.95.2.520; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Chen Z, 2003, J PHYSIOL-LONDON, V546, P349, DOI 10.1113/jphysiol.2002.026500; CHESNEY RW, 2001, METABOLIC MOL BASES, P4971; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN HN, 1966, FED PROC, V25, P850; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; DOYLE FA, 1992, BIOCHIM BIOPHYS ACTA, V1104, P55, DOI 10.1016/0005-2736(92)90131-5; Feldman DH, 2000, J BIOL CHEM, V275, P24518, DOI 10.1074/jbc.M907582199; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; Hyde R, 2003, BIOCHEM J, V373, P1, DOI 10.1042/BJ20030405; KANAI Y, 1994, J BIOL CHEM, V269, P20599; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; KLINGEL K, 1992, P NATL ACAD SCI USA, V89, P314, DOI 10.1073/pnas.89.1.314; LEVY LL, 2001, METABOLIC MOL BASES, V3, P4957; LYNCH AM, 1987, BIOCHIM BIOPHYS ACTA, V899, P176, DOI 10.1016/0005-2736(87)90398-1; MAENZ DD, 1992, J BIOL CHEM, V267, P22079; MUNCK BG, 1994, J PHYSIOL-LONDON, V480, P99, DOI 10.1113/jphysiol.1994.sp020344; Nash SR, 1998, RECEPTOR CHANNEL, V6, P113; Nelson N, 1998, J NEUROCHEM, V71, P1785; Nozaki J, 2001, BIOCHEM BIOPH RES CO, V284, P255, DOI 10.1006/bbrc.2001.4961; Palacin M, 2000, CURR OPIN NEPHROL HY, V9, P547, DOI 10.1097/00041552-200009000-00015; Palacin M, 2001, CURR OPIN GENET DEV, V11, P328, DOI 10.1016/S0959-437X(00)00198-2; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pineda M, 2004, BIOCHEM J, V377, P665, DOI 10.1042/BJ20030956; Potter SJ, 2002, J INHERIT METAB DIS, V25, P437, DOI 10.1023/A:1021286714582; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; SCHULTZ SG, 1970, PHYSIOL REV, V50, P637, DOI 10.1152/physrev.1970.50.4.637; SEPULVEDA FV, 1978, J PHYSIOL-LONDON, V282, P73, DOI 10.1113/jphysiol.1978.sp012449; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; Sloan JL, 1999, J BIOL CHEM, V274, P23740, DOI 10.1074/jbc.274.34.23740; Slominski A, 2002, FEBS LETT, V511, P102, DOI 10.1016/S0014-5793(01)03319-1; SOUBA WW, 1992, BIOCHEM BIOPH RES CO, V188, P746, DOI 10.1016/0006-291X(92)91119-B; STEVENS BR, 1985, J MEMBRANE BIOL, V87, P27, DOI 10.1007/BF01870696; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; WASSERMAN JC, 1994, AM J PHYSIOL-RENAL, V267, pF688, DOI 10.1152/ajprenal.1994.267.4.F688; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	50	191	198	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24467	24476		10.1074/jbc.M400904200	http://dx.doi.org/10.1074/jbc.M400904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044460	hybrid			2022-12-25	WOS:000221702500074
J	Lamkanfi, M; Kalai, M; Saelens, X; Declercq, W; Vandenabeele, P				Lamkanfi, M; Kalai, M; Saelens, X; Declercq, W; Vandenabeele, P			Caspase-1 activates nuclear factor of the kappa-enhancer in B cells independently of its enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1-BETA CONVERTING-ENZYME; ZINC-FINGER PROTEIN; GAMMA-INDUCING FACTOR; GENE-EXPRESSION; LYMPHOCYTE-ACTIVATION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; DEFICIENT MICE; INHIBITS TNF	The proteolytic activity of caspases is involved in apoptosis and inflammation. In this regard, caspase-1 is required for pro-interleukin (IL)-1beta and pro-IL-18 maturation. We report here on a novel function of caspase-1 as an activator of nuclear factor of the kappa-enhancer in B-cells (NF-kappaB) and p38 mitogen-activated protein kinase ( MAPK). This function is not shared by the murine caspase-1 homologues caspase-11 and -12. In contrast to pro-IL-1beta maturation, caspase-1-induced NF-kappaB activation is not inhibited by the virus-derived caspase-1 inhibitor cytokine response modifier A and is equally induced by the enzymatically inactive caspase-1 C285A mutant. Although the general NF-kappaB-inhibiting protein A20 inhibits caspase-1-derived activation of NF-kappaB, dominant-negative forms of TRAF2 and RIP1 have no effect. We demonstrate that caspase-1 interacts with RIP2 and that dominant-negative forms of RIP2 and IkappaB kinase complex-beta inhibit caspase-1-mediated NF-kappaB activation. Structure-function analysis shows that the caspase recruitment domain of caspase-1 mediates the activation of NF-kappaB and p38 MAPK. These data demonstrate that caspase-1 contributes to inflammation by two distinct pathways: proteolysis of pro-IL-1beta, and RIP2-dependent activation of NF-kappaB and p38 MAPK mediated by the caspase recruitment domain.	State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signalling & Cell Death, B-9052 Zwijnaarde, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University	Vandenabeele, P (corresponding author), State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signalling & Cell Death, Technol Pk 927, B-9052 Zwijnaarde, Belgium.	peter.vandenabeele@dmbr.ugent.be	Vandenabeele, Peter/C-8597-2009; Saelens, Xavier/N-5728-2015; Vandenabeele, Peter/AAD-5793-2022	Vandenabeele, Peter/0000-0002-6669-8822; , Xavier/0000-0002-3861-6965				Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beisner DR, 2003, J IMMUNOL, V171, P247, DOI 10.4049/jimmunol.171.1.247; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Cornelis GR, 2001, NAT MED, V7, P21, DOI 10.1038/83298; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; DeValck D, 1997, BIOCHEM BIOPH RES CO, V238, P590, DOI 10.1006/bbrc.1997.7343; Druilhe A, 2001, CELL DEATH DIFFER, V8, P649, DOI 10.1038/sj.cdd.4400881; Faas MM, 2002, CLIN EXP IMMUNOL, V127, P337, DOI 10.1046/j.1365-2249.2002.01765.x; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hersh D, 1999, P NATL ACAD SCI USA, V96, P2396, DOI 10.1073/pnas.96.5.2396; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Hilbi H, 1998, J BIOL CHEM, V273, P32895, DOI 10.1074/jbc.273.49.32895; HOPKINS SJ, 1989, J IMMUNOL METHODS, V120, P271, DOI 10.1016/0022-1759(89)90252-4; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Huang FP, 2003, J NEUROSCI RES, V73, P698, DOI 10.1002/jnr.10654; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Jaattela M, 1996, J IMMUNOL, V156, P1166; Kabra NH, 2001, P NATL ACAD SCI USA, V98, P6307, DOI 10.1073/pnas.111158698; Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kitamura M, 1999, EUR J IMMUNOL, V29, P1647; Klinkenberg M, 2001, FEBS LETT, V498, P93, DOI 10.1016/S0014-5793(01)02504-2; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; LAMKANFI M, 2003, CASPASES THEIR ROLE, P1; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; O'Reilly SM, 2003, BIOCHEM BIOPH RES CO, V303, P586, DOI 10.1016/S0006-291X(03)00389-9; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Ogushi I, 2003, HEPATOLOGY, V38, P335, DOI 10.1053/jhep.2003.50298; Olson NE, 2003, J IMMUNOL, V170, P6065, DOI 10.4049/jimmunol.170.12.6065; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Ruckdeschel K, 2001, J IMMUNOL, V166, P1823, DOI 10.4049/jimmunol.166.3.1823; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Sabroe I, 2003, J IMMUNOL, V171, P1630, DOI 10.4049/jimmunol.171.4.1630; Scheller C, 2002, EUR J IMMUNOL, V32, P2471, DOI 10.1002/1521-4141(200209)32:9<2471::AID-IMMU2471>3.0.CO;2-E; Song GY, 2001, AM J PHYSIOL-CELL PH, V281, pC662, DOI 10.1152/ajpcell.2001.281.2.C662; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang QD, 2003, J BIOL CHEM, V278, P51091, DOI 10.1074/jbc.M306541200; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Yoo NJ, 2002, BIOCHEM BIOPH RES CO, V299, P652, DOI 10.1016/S0006-291X(02)02714-6; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100	85	119	126	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24785	24793		10.1074/jbc.M400985200	http://dx.doi.org/10.1074/jbc.M400985200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15039421	hybrid			2022-12-25	WOS:000221702500109
J	Graham, NA; Asthagiri, AR				Graham, NA; Asthagiri, AR			Epidermal growth factor-mediated T-cell factor/lymphoid enhancer factor transcriptional activity is essential but not sufficient for cell cycle progression in nontransformed mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; BETA-CATENIN; E-CADHERIN; NEOPLASTIC TRANSFORMATION; NUCLEAR TRANSLOCATION; ACTIVATION; INHIBITION; EXPRESSION; INSULIN; COMPLEX	Because beta-catenin target genes such as cyclin D1 are involved in cell cycle progression, we examined whether beta-catenin has a more pervasive role in normal cell proliferation, even upon stimulation by non-Wnt ligands. Here, we demonstrate that epidermal growth factor (EGF) stimulates T-cell factor/lymphoid enhancer factor (Tcf/Lef) transcriptional activity in nontransformed mammary epithelial cells (MCF-10A) and that its transcriptional activity is essential for EGF-mediated progression through G(1)/S phase. Thus, expression of dominant-negative Tcf4 blocks EGF-mediated Tcf/Lef transcriptional activity and bromodeoxyuridine uptake. In fact, the importance of EGF-mediated Tcf/Lef transcriptional activity for cell cycle progression may lie further upstream at the G(1)/S phase transition. We demonstrate that dominant-negative Tcf4 inhibits a reporter of cyclin D1 promoter activity in a dose-dependent manner. Importantly, dominant-negative Tcf4 suppresses EGF- mediated cell cycle activity specifically by thwarting EGF- mediated Tcf/Lef transcriptional activity, not by broader effects on EGF signaling. Thus, although expression of dominant-negative Tcf4 blocks EGF- mediated TOPFLASH activation, it has no effect on either EGF receptor or ERK phosphorylation, further underscoring the fact that Tcf/ Lef-mediated transcription is essential for cell cycle progression, even when other pro-mitogenic signals are at normal levels. Yet, despite its essential role, Tcf/Lef transcriptional activity alone is not sufficient for cell cycle progression. Serum also stimulates Tcf/ Lef transcriptional activation in MCF-10A cells but is unable to promote DNA synthesis. Taken together, our data support a model wherein EGF promotes Tcf/ Lef transcriptional activity, and this signal is essential but not sufficient for cell cycle activity.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Asthagiri, AR (corresponding author), CALTECH, Div Chem & Chem Engn, Mail Code 210-41, Pasadena, CA 91125 USA.	anand@cheme.caltech.edu	Graham, Nicholas A./X-2738-2019; Graham, Nicholas/GYD-5066-2022	Graham, Nicholas A./0000-0002-6811-1941; Graham, Nicholas/0000-0002-6811-1941				Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Asthagiri AR, 2000, J CELL SCI, V113, P4499; Barker N, 2000, BIOESSAYS, V22, P961; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Chenn A, 2002, SCIENCE, V298, P766, DOI 10.1126/science.1079328; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Hari L, 2002, J CELL BIOL, V159, P867, DOI 10.1083/jcb.200209039; Hendriks B, 2002, BIOL RES, V35, P277, DOI 10.4067/S0716-97602002000200019; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Monga SPS, 2002, CANCER RES, V62, P2064; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Orsulic S, 1999, J CELL SCI, V112, P1237; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; Sakanaka C, 2002, J BIOCHEM, V132, P697, DOI 10.1093/oxfordjournals.jbchem.a003276; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474; Zhu AJ, 1999, DEVELOPMENT, V126, P2285; Zhu AJ, 1996, J CELL SCI, V109, P3013	57	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23517	23524		10.1074/jbc.M314055200	http://dx.doi.org/10.1074/jbc.M314055200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15026412	Green Accepted, hybrid			2022-12-25	WOS:000221570900090
J	Petkovic, V; Moghini, C; Paoletti, S; Uguccioni, M; Gerber, B				Petkovic, V; Moghini, C; Paoletti, S; Uguccioni, M; Gerber, B			Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5 - A human chemokine with a regulatory role	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR SOLUTION STRUCTURE; VMIP-II; EOTAXIN RECEPTOR; MOLECULAR-CLONING; EXPRESSION; BINDING; EOSINOPHILS; CELLS; ACTIVATION; RESPONSIVENESS	Eotaxin-3 (CCL26), like eotaxin (CCL11) and eotaxin-2 (CCL24), has long been considered a specific agonist for CC chemokine receptor 3 (CCR3), attracting and activating eosinophils, basophils, and Th2 type T lymphocytes. Although not characterized extensively yet, its expression profile coincides with a potential role in allergic inflammation. We recently reported that eotaxin-3 is an antagonist for CCR2 (Ogilvie, P., Paoletti, S., Clark-Lewis, I., and Uguccioni, M. (2003) Blood 102, 789-784). In the present report, we provide evidence that eotaxin-3 acts as a natural antagonist on CCR1 and -5 as well. Eotaxin-3 bound to cells transfected with either CCR1 or -5 as well as to monocytes expressing both receptors. Further, it inhibited chemotaxis, the release of free intracellular calcium, and actin polymerization when cells were stimulated with known agonists of CCR1 and -5. An analysis of its three-dimensional structure indicated the presence of two distinct epitopes that may be involved in specific binding to CCR1, -2, -3, and -5. Taken together, our data thus indicate eotaxin-3 to be the first human chemokine that features broadband antagonistic activities, suggesting that it may have a modulatory rather than an inflammatory function. Further, eotaxin-3 may play an unrecognized role in the polarization of cellular recruitment by attracting Th2 lymphocytes as well as eosinophils and basophils via CCR3, while concomitantly blocking the recruitment of Th1 lymphocytes and monocytes via CCR1, -2, and -5.	Inst Biomed Res, CH-6500 Bellinzona, Switzerland	Universita della Svizzera Italiana	Gerber, B (corresponding author), Inselspital Bern, Clin Rheumatol & Clin Immunol Allergol, Div Allergol, Sahlihaus 1, CH-3010 Bern, Switzerland.	basil.gerber@dkf6.unibe.ch	Paoletti, Samantha/AAG-8152-2021	Paoletti, Samantha/0000-0001-7982-6478; Uguccioni, Mariagrazia/0000-0002-9570-7011				Baysal C, 2001, PROTEINS, V43, P150, DOI 10.1002/1097-0134(20010501)43:2<150::AID-PROT1027>3.0.CO;2-M; Berkman N, 2001, AM J RESP CELL MOL, V24, P682, DOI 10.1165/ajrcmb.24.6.4301; Blanpain C, 1999, BLOOD, V94, P1899; Blaszczyk J, 2000, BIOCHEMISTRY-US, V39, P14075, DOI 10.1021/bi0009340; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Booth V, 2002, BIOCHEMISTRY-US, V41, P10418, DOI 10.1021/bi026020q; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Dieu-Nosjean MC, 1999, J LEUKOCYTE BIOL, V66, P252, DOI 10.1002/jlb.66.2.252; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Dulkys Y, 2001, J INVEST DERMATOL, V116, P498, DOI 10.1046/j.1523-1747.2001.01299.x; Fernandez EJ, 2000, BIOCHEMISTRY-US, V39, P12837, DOI 10.1021/bi001166f; Gerber BO, 1997, CURR BIOL, V7, P836, DOI 10.1016/S0960-9822(06)00371-X; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Guan E, 2001, J BIOL CHEM, V276, P12404, DOI 10.1074/jbc.M006327200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Kim KS, 1996, FEBS LETT, V395, P277, DOI 10.1016/0014-5793(96)01024-1; Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Lin CL, 1998, EUR J IMMUNOL, V28, P4114, DOI 10.1002/(SICI)1521-4141(199812)28:12<4114::AID-IMMU4114>3.0.CO;2-C; Lindow M, 2003, J VIROL, V77, P7393, DOI 10.1128/JVI.77.13.7393-7400.2003; Liwang AC, 1999, PROTEIN SCI, V8, P2270; Loetscher P, 2001, J LEUKOCYTE BIOL, V69, P881; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; LOETSCHER P, 2000, J BIOL CHEM, V10, P10; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Luttichau HR, 2001, EUR J IMMUNOL, V31, P1217; Martinelli R, 2001, J BIOL CHEM, V276, P42957, DOI 10.1074/jbc.M103933200; Mayer KL, 2000, BIOCHEMISTRY-US, V39, P8382, DOI 10.1021/bi000523j; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Mochizuki M, 1998, J IMMUNOL, V160, P60; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nibbs RJB, 2000, J IMMUNOL, V164, P1488, DOI 10.4049/jimmunol.164.3.1488; Ogilvie P, 2001, BLOOD, V97, P1920, DOI 10.1182/blood.V97.7.1920; Ogilvie P, 2003, BLOOD, V102, P789, DOI 10.1182/blood-2002-09-2773; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sasaki M, 2003, J IMMUNOL, V170, P588, DOI 10.4049/jimmunol.170.1.588; Shao WP, 2001, EUR J BIOCHEM, V268, P2948, DOI 10.1046/j.1432-1327.2001.02184.x; Shinkai A, 1999, J IMMUNOL, V163, P1602; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; Sozzani S, 1997, J IMMUNOL, V159, P1993; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; Wan YT, 2002, EUR J PHARMACOL, V456, P1, DOI 10.1016/S0014-2999(02)02621-3; Weber C, 2000, J LEUKOCYTE BIOL, V67, P699, DOI 10.1002/jlb.67.5.699; Ye JP, 2000, J BIOL CHEM, V275, P27250; Ye JQ, 2001, BIOCHEMISTRY-US, V40, P7820, DOI 10.1021/bi010252s; Zhu Z, 2002, J IMMUNOL, V168, P2953, DOI 10.4049/jimmunol.168.6.2953; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	54	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23357	23363		10.1074/jbc.M309283200	http://dx.doi.org/10.1074/jbc.M309283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039444	hybrid			2022-12-25	WOS:000221570900071
J	Sommer, BJ; Barycki, JJ; Simpson, MA				Sommer, BJ; Barycki, JJ; Simpson, MA			Characterization of human UDP-glucose dehydrogenase - Cys-276 is required for the second of two successive oxidations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE DIPHOSPHOGLUCOSE DEHYDROGENASE; SITES REACTIVITY; HYALURONAN; CANCER; LIVER; MECHANISM; GENE; MORPHOGENESIS; INHIBITION; ENCODES	UDP-glucose dehydrogenase (UGDH) catalyzes two oxidations of UDP-glucose to yield UDP-glucuronic acid. Pathological overproduction of extracellular matrix components may be linked to the availability of UDPglucuronic acid; therefore UGDH is an intriguing therapeutic target. Specific inhibition of human UGDH requires detailed knowledge of its catalytic mechanism, which has not been characterized. In this report, we have cloned, expressed, and affinity-purified the human enzyme and determined its steady state kinetic parameters. The human enzyme is active as a hexamer with values for K-m and V-max that agree well with those reported for a bovine homolog. We used crystal coordinates for Streptococcus pyogenes UGDH in complex with NAD(+) cofactor and UDP- glucose substrate to generate a model of the enzyme active site. Based on this model, we selected Cys-276 and Lys-279 as likely catalytic residues and converted them to serine and alanine, respectively. Enzymatic activity of C276S and K279A point mutants was not measurable under normal assay conditions. Rate constants measured over several hours demonstrated that K279A continued to turn over, although 250-fold more slowly than wild type enzyme. C276S, however, performed only a single round of oxidation, indicating that it is essential for the second oxidation. This result is consistent with the postulated role of Cys-276 as a catalytic residue and supports its position in the reaction mechanism for the human enzyme. Lys-279 is likely to have a role in positioning active site residues and in maintaining the hexameric quaternary structure.	Univ Nebraska, Beadle Ctr N241, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Simpson, MA (corresponding author), Univ Nebraska, Beadle Ctr N241, Dept Biochem, Lincoln, NE 68588 USA.	msimpson2@unl.edu			NCRR NIH HHS [IP20 RR18759] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aaltomaa S, 2002, UROL INT, V69, P266, DOI 10.1159/000066123; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Campbell RE, 1997, J BIOL CHEM, V272, P3416, DOI 10.1074/jbc.272.6.3416; Campbell RE, 1999, J ORG CHEM, V64, P9487, DOI 10.1021/jo991092h; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P7012, DOI 10.1021/bi000181h; FRANZEN JS, 1973, BIOCHEM BIOPH RES CO, V50, P517, DOI 10.1016/0006-291X(73)90870-X; FRANZEN JS, 1980, BIOCHIM BIOPHYS ACTA, V614, P242, DOI 10.1016/0005-2744(80)90214-4; FRANZEN JS, 1980, BIOCHEMISTRY-US, V19, P6080, DOI 10.1021/bi00567a021; FRANZEN JS, 1976, BIOCHEMISTRY-US, V15, P5665, DOI 10.1021/bi00670a036; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Ge X, 1998, J AM CHEM SOC, V120, P6613, DOI 10.1021/ja9805977; Hacker U, 1997, DEVELOPMENT, V124, P3565; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14224, DOI 10.1073/pnas.172522499; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lapointe J, 1999, ENDOCRINOLOGY, V140, P4486, DOI 10.1210/en.140.10.4486; Nelsestuen G L, 1971, J Biol Chem, V246, P3824; ORDMAN AB, 1977, BIOCHIM BIOPHYS ACTA, V481, P25, DOI 10.1016/0005-2744(77)90133-4; ORDMAN AB, 1977, J BIOL CHEM, V252, P1320; RIDLEY WP, 1975, J BIOL CHEM, V250, P8761; Ropponen K, 1998, CANCER RES, V58, P342; SCHILLER JG, 1972, CARBOHYD RES, V25, P403, DOI 10.1016/S0008-6215(00)81651-1; Simpson MA, 2002, AM J PATHOL, V161, P849, DOI 10.1016/S0002-9440(10)64245-9; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Stewart DC, 1998, PLANT PHYSIOL, V116, P349, DOI 10.1104/pp.116.1.349; Turner W, 2002, ARCH BIOCHEM BIOPHYS, V407, P209, DOI 10.1016/S0003-9861(02)00500-3; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670	28	46	47	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23590	23596		10.1074/jbc.M401928200	http://dx.doi.org/10.1074/jbc.M401928200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044486	hybrid			2022-12-25	WOS:000221570900099
J	Andersen, ES; Contera, SA; Knudsen, B; Damgaard, CK; Besenbacher, F; Kjems, J				Andersen, ES; Contera, SA; Knudsen, B; Damgaard, CK; Besenbacher, F; Kjems, J			Role of the trans-activation response element in dimerization of HIV-1 RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ATOMIC-FORCE MICROSCOPY; 1ST STRAND TRANSFER; LOOP-LOOP COMPLEX; REVERSE TRANSCRIPTION; NUCLEOCAPSID PROTEIN; BINDING-SITES; GENOMIC RNA; VISUALIZATION; GAG	The HIV-1 genome consists of two identical RNA strands that are linked together through non-covalent interactions. A major determinant for efficient dimerization of the two RNA strands is the interaction between palindromic sequences in the dimerization initiation site. Here we use an interplay of bioinformatics, biochemistry, and atomic force microscopy to describe another conserved palindrome in the trans-activation response element ( TAR) that functions as a strong dimerization site when transiently exposed to the viral nucleocapsid protein. In conjunction with the DIS interaction, the TAR dimerization induces the formation of a 65-nm higher-order circular structure in the dimeric HIV-1 RNA. Our results provide a molecular model for the role of TAR in packaging and reverse transcription of the viral genome. The unique structure of the TARTAR dimer renders it an intriguing therapeutic target for the treatment of HIV-1 infection.	Aarhus Univ, Interdisciplinary Nanosci Ctr, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Phys & Astron, DK-8000 Aarhus C, Denmark; Aarhus Univ, Bioinformat Res Ctr, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University	Kjems, J (corresponding author), Aarhus Univ, Interdisciplinary Nanosci Ctr, DK-8000 Aarhus C, Denmark.	kjems@biobase.dk	Damgaard, Christian/AAR-4075-2020; Damgaard, Christian K/G-7360-2015; Damgaard, Christian/AAP-3147-2021; Andersen, Ebbe S/O-3936-2014; Contera, Sonia Antoranz/B-6543-2012; Besenbacher, Flemming/A-9623-2010; Kjems, Jorgen/I-3490-2016	Damgaard, Christian/0000-0003-4940-0868; Andersen, Ebbe S/0000-0002-6236-8164; Contera, Sonia Antoranz/0000-0002-2371-1206; Kjems, Jorgen/0000-0003-4128-9317				Andersen ES, 2003, J VIROL, V77, P3020, DOI 10.1128/JVI.77.5.3020-3030.2003; Balakrishnan M, 2003, J VIROL, V77, P4710, DOI 10.1128/JVI.77.8.4710-4721.2003; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Berkhout B, 1998, VIROLOGY, V249, P211, DOI 10.1006/viro.1998.9321; Berkhout B, 2000, Adv Pharmacol, V48, P29; Bonin M, 2001, BIOL CHEM, V382, P1157, DOI 10.1515/BC.2001.145; Bonin M, 2000, RNA, V6, P563, DOI 10.1017/S1355838200992318; COFFIN JM, 1997, RETROVIRUSES, P121; Damgaard CK, 2004, J MOL BIOL, V336, P369, DOI 10.1016/j.jmb.2003.12.010; Damgaard CK, 1998, NUCLEIC ACIDS RES, V26, P3667, DOI 10.1093/nar/26.16.3667; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; Feng YX, 1999, J VIROL, V73, P4251, DOI 10.1128/JVI.73.5.4251-4256.1999; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; Hansma HG, 1996, NUCLEIC ACIDS RES, V24, P713, DOI 10.1093/nar/24.4.713; Henn A, 2001, P NATL ACAD SCI USA, V98, P5007, DOI 10.1073/pnas.071372498; Hoglund S, 1997, VIROLOGY, V233, P271, DOI 10.1006/viro.1997.8585; Jeeninga RE, 1998, NUCLEIC ACIDS RES, V26, P5472, DOI 10.1093/nar/26.23.5472; JENSEN TH, 1995, GENE, V162, P235, DOI 10.1016/0378-1119(95)00328-4; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Kiselyova OI, 2001, J GEN VIROL, V82, P1503, DOI 10.1099/0022-1317-82-6-1503; KJEMS J, 1998, ANAL RNA PROTEIN COM, P26; Knudsen B, 2003, NUCLEIC ACIDS RES, V31, P3423, DOI 10.1093/nar/gkg614; Kolb FA, 2001, J MOL BIOL, V309, P605, DOI 10.1006/jmbi.2001.4677; Kolb FA, 2000, EMBO J, V19, P5905, DOI 10.1093/emboj/19.21.5905; Laughrea M, 2001, VIROLOGY, V281, P109, DOI 10.1006/viro.2000.0778; Masquida B, 2000, RNA, V6, P9, DOI 10.1017/S1355838200992082; Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P298; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; Smith BL, 1997, J STRUCT BIOL, V119, P109, DOI 10.1006/jsbi.1997.3864; TEMIN HM, 1991, TRENDS GENET, V7, P71, DOI 10.1016/0168-9525(91)90048-U; van Wamel JLB, 1998, VIROLOGY, V244, P245, DOI 10.1006/viro.1998.9096; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; YOU JC, 1994, J BIOL CHEM, V269, P31491	34	66	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22243	22249		10.1074/jbc.M314326200	http://dx.doi.org/10.1074/jbc.M314326200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15014074	hybrid			2022-12-25	WOS:000221417100071
J	Hamon, S; Le Sommer, C; Mereau, AS; Allo, MR; Hardy, S				Hamon, S; Le Sommer, C; Mereau, AS; Allo, MR; Hardy, S			Polypyrimidine tract-binding protein is involved in vivo in repression of a composite internal/3 '-terminal exon of the Xenopus alpha-tropomyosin pre-mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE SELECTION; SEQUENCES; GENE; ACTIVATION; UPSTREAM; IDENTIFICATION; MECHANISMS; EXPRESSION; ELEMENT; EVENTS	The Xenopus alpha(fast)-tropomyosin gene contains, at its 3'-end, a composite internal/3'-terminal exon (exon 9A9'), which is subjected to three different patterns of splicing according to the cell type. Exon 9A9' is included as a terminal exon in the myotome and as an internal exon in adult striated muscles, whereas it is skipped in nonmuscle cells. We have developed an in vivo model based on transient expression of minigenes encompassing the regulated exon 9A9' in Xenopus oocytes and embryos. We first show that the different alpha-tropomyosin minigenes recapitulate the splicing pattern of the endogenous gene and constitute valuable tools to seek regulatory sequences involved in exon 9A9' usage. A mutational analysis led to the identification of an intronic element that is involved in the repression of exon 9A9' in nonmuscle cells. This element harbors four polypyrimidine track-binding protein (PTB) binding sites that are essential for the repression of exon 9A9'. We show using UV cross-linking and immunoprecipitation experiments that Xenopus PTB (XPTB) interacts with these PTB binding sites. Finally, we show that depletion of endogenous XPTB in Xenopus embryos using a morpholino-based translational inhibition strategy resulted in exon 9A9' inclusion in embryonic epidermal cells. These results demonstrate that XPTB is required in vivo to repress the terminal exon 9A9' and suggest that PTB could be a major actor in the repression of regulated 3'-terminal exon.	Univ Rennes 1, Fac Med, CNRS, UMR 6061, F-35043 Rennes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Hardy, S (corresponding author), Univ Rennes 1, Fac Med, CNRS, UMR 6061, F-35043 Rennes, France.	serge.hardy@univ-rennes1.fr		MEREAU, AGNES/0000-0002-5603-757X				Ashiya M, 1997, RNA, V3, P996; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Carroll D, 1999, ADV MOLEC BIOL, P173; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; Chesnel F, 1997, DEV BIOL, V188, P122, DOI 10.1006/dbio.1997.8631; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; Cote J, 2001, J BIOL CHEM, V276, P8535, DOI 10.1074/jbc.M008924200; Duriez P, 2000, DNA CELL BIOL, V19, P365; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Faber J., 1994, NORMAL TABLE XENOPUS, P2; FU XD, 1995, RNA, V1, P663; Gooding C, 1998, RNA, V4, P85; GRANDIN N, 1992, J CELL SCI, V101, P55; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Gromak N, 2003, RNA, V9, P443, DOI 10.1261/rna.2191903; Hardy S, 1999, MECH DEVELOP, V87, P199, DOI 10.1016/S0925-4773(99)00148-3; HARDY S, 1991, EUR J BIOCHEM, V202, P431, DOI 10.1111/j.1432-1033.1991.tb16392.x; HARLAND R, 1988, DEVELOPMENT, V102, P837; Heasman J, 2000, DEV BIOL, V222, P124, DOI 10.1006/dbio.2000.9720; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; JONAS EA, 1989, DEVELOPMENT, V106, P399; KRIEG P, 1984, J MOL BIOL, V180, P615, DOI 10.1016/0022-2836(84)90030-5; Le Guiner C, 2001, J BIOL CHEM, V276, P43677, DOI 10.1074/jbc.M107381200; LEESMILLER JP, 1990, MOL CELL BIOL, V10, P1729, DOI 10.1128/MCB.10.4.1729; LIN CH, 1995, RNA, V1, P234; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Lou H, 1999, MOL CELL BIOL, V19, P78; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; Moreira A, 1998, GENE DEV, V12, P2522, DOI 10.1101/gad.12.16.2522; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; Perez I, 1997, RNA, V3, P764; PETERSON ML, 1994, MOL CELL BIOL, V14, P7891, DOI 10.1128/MCB.14.12.7891; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Southby J, 1999, MOL CELL BIOL, V19, P2699; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; WALLACE RA, 1973, J EXP ZOOL, V184, P321, DOI 10.1002/jez.1401840305; Zhang L, 1999, RNA, V5, P117, DOI 10.1017/S1355838299981530	49	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22166	22175		10.1074/jbc.M313809200	http://dx.doi.org/10.1074/jbc.M313809200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15010470	hybrid			2022-12-25	WOS:000221417100061
J	Tomas-Cobos, L; Casadome, L; Mas, G; Sanz, P; Posas, F				Tomas-Cobos, L; Casadome, L; Mas, G; Sanz, P; Posas, F			Expression of the HXT1 low affinity glucose transporter requires the coordinated activities of the HOG and glucose signalling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNF1 PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; MAP KINASE; OSMOTIC-STRESS; GENE-EXPRESSION; YEAST; TRANSCRIPTION; ACTIVATION; REPRESSOR; MTH1	Expression of the HXT1 gene, which encodes a low affinity glucose transporter in Saccharomyces cerevisiae, is regulated positively in response to glucose by the general glucose induction pathway, involving the Snf3/Rgt2 membrane glucose sensors, the SCF-Grr1 ubiquitination complex and the Rgt1 transcription factor. In this study we show that, in addition to the glucose signaling pathway, regulation of HXT1 expression also requires the HOG pathway. Deletion of components in the glucose signaling pathway or in the HOG pathway results in impaired HXT1 expression. Genetic analyses showed that, whereas the glucose signaling pathway regulates HXT1 through modulation of the Rgt1 transcription factor, the HOG pathway modulates HXT1 through regulation of the Sko1-Tup1-Ssn6 complex. Coordinated regulation of the two signaling pathways is required for expression of HXT1 by glucose and in response to osmostress.	Inst Biomed Valencia, Valencia 46010, Spain; Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, Barcelona 08003, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Pompeu Fabra University	Sanz, P (corresponding author), Inst Biomed Valencia, Jaime Roig 11, Valencia 46010, Spain.	sanz@ibv.csic.es	Sanz, Pascual/K-2751-2014; Martin, Gloria Mas/J-8712-2015; Posas, Francesc/K-1364-2013; Tomas-Cobos, Lidia/Q-2707-2018	Sanz, Pascual/0000-0002-2399-4103; Martin, Gloria Mas/0000-0003-0730-3541; Posas, Francesc/0000-0002-4164-7076; Tomas-Cobos, Lidia/0000-0002-4996-6987				Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; Amoros M, 2001, MOL MICROBIOL, V39, P1523, DOI 10.1046/j.1365-2958.2001.02339.x; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; de Nadal E, 2003, MOL CELL BIOL, V23, P229, DOI 10.1128/MCB.23.1.229-237.2003; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Flick KM, 2003, MOL BIOL CELL, V14, P3230, DOI 10.1091/mbc.E03-03-0135; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gancedo JM., 1997, YEAST SUGAR METABOLI, P359; Garcia-Gimeno MA, 2000, MOL CELL BIOL, V20, P4340, DOI 10.1128/MCB.20.12.4340-4349.2000; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Goldstein A, 1975, Methods Enzymol, V42, P504; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Kim JH, 2003, MOL CELL BIOL, V23, P5208, DOI 10.1128/MCB.23.15.5208-5216.2003; Kishi T, 1998, MOL GEN GENET, V257, P143, DOI 10.1007/s004380050633; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Kuchin S, 2000, P NATL ACAD SCI USA, V97, P7916, DOI 10.1073/pnas.140109897; Lafuente MJ, 2000, MOL MICROBIOL, V35, P161, DOI 10.1046/j.1365-2958.2000.01688.x; Lakshmanan J, 2003, CURR GENET, V44, P19, DOI 10.1007/s00294-003-0423-2; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Marquez JA, 1998, EMBO J, V17, P2543, DOI 10.1093/emboj/17.9.2543; Mayordomo I, 2001, YEAST, V18, P1309, DOI 10.1002/yea.780; Mosley AL, 2003, J BIOL CHEM, V278, P10322, DOI 10.1074/jbc.M212802200; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Ozcan S, 1996, MOL CELL BIOL, V16, P6419; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Posas F, 1998, MOL CELL BIOL, V18, P5788, DOI 10.1128/MCB.18.10.5788; Proft M, 1999, MOL CELL BIOL, V19, P537; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Proft M, 2001, EMBO J, V20, P1123, DOI 10.1093/emboj/20.5.1123; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Schmidt MC, 1999, MOL CELL BIOL, V19, P4561; SCHULLER HJ, 1991, J BACTERIOL, V173, P2045, DOI 10.1128/jb.173.6.2045-2052.1991; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tomas-Cobos L, 2002, BIOCHEM J, V368, P657, DOI 10.1042/BJ20020984; Yale J, 2001, J BIOL CHEM, V276, P15996, DOI 10.1074/jbc.M008209200	45	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22010	22019		10.1074/jbc.M400609200	http://dx.doi.org/10.1074/jbc.M400609200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15014083	hybrid			2022-12-25	WOS:000221417100042
J	Vrontou, E; Karamanou, S; Baud, C; Sianidis, G; Economou, A				Vrontou, E; Karamanou, S; Baud, C; Sianidis, G; Economou, A			Global co-ordination of protein translocation by the SecA IRA1 switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT ATP-BINDING; ESCHERICHIA-COLI; PREPROTEIN TRANSLOCASE; SIGNAL PEPTIDES; MEMBRANE; SECYEG; DOMAIN; HYDROLYSIS; COMMUNICATION; MECHANISM	SecA, the dimeric ATPase subunit of protein translocase, contains a DEAD helicase catalytic core that binds to a regulatory C-terminal domain. We now demonstrate that IRA1, a conserved helix-loop-helix structure in the C-domain, controls C-domain conformation through direct interdomain contacts. C-domain conformational changes are transmitted to the DEAD motor and alter its conformation. These interactions establish DEAD motor/C-domain conformational cross-talk that requires a functional IRA1. IRA1-controlled binding/release cycles of the C-domain to the DEAD motor couple this crosstalk to protein translocation chemistries, i.e. DEAD motor affinities for ligands (nucleotides, preprotein signal peptides, and SecYEG, the integral membrane component of translocase) and ATP turnover. IRA1-mediated global co-ordination of SecA catalysis is essential for protein translocation.	Univ Crete, Fdn Res & Technol, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Crete, Greece; Univ Crete, Dept Biol, GR-71110 Iraklion, Crete, Greece	University of Crete; University of Crete	Economou, A (corresponding author), Univ Crete, Fdn Res & Technol, Inst Mol Biol & Biotechnol, POB 1527, GR-71110 Iraklion, Crete, Greece.	aeconomo@imbb.forth.gr	Karamanou, Spyridoula/H-7485-2018; Economou, Anastassios/P-8292-2017	Karamanou, Spyridoula/0000-0002-8803-1404; Economou, Anastassios/0000-0002-1770-507X				Baud C, 2002, J BIOL CHEM, V277, P13724, DOI 10.1074/jbc.M200047200; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Dapic V, 2000, J BIOL CHEM, V275, P25000, DOI 10.1074/jbc.M001100200; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; den Blaauwen T, 1999, FEBS LETT, V458, P145, DOI 10.1016/S0014-5793(99)01139-4; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; Ding HY, 2001, BIOCHEMISTRY-US, V40, P1835, DOI 10.1021/bi002058w; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; Economou A, 1998, MOL MICROBIOL, V27, P511, DOI 10.1046/j.1365-2958.1998.00713.x; Economou A, 2002, MOL MEMBR BIOL, V19, P159, DOI 10.1080/09687680210152609; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hirano M, 1996, BIOCHEM BIOPH RES CO, V229, P90, DOI 10.1006/bbrc.1996.1762; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; JAROSIK GP, 1991, J BACTERIOL, V173, P860, DOI 10.1128/jb.173.2.860-868.1991; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KOONIN EV, 1992, FEBS LETT, V298, P6, DOI 10.1016/0014-5793(92)80009-6; Kourtz L, 2000, MOL MICROBIOL, V37, P1342, DOI 10.1046/j.1365-2958.2000.02078.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Miller A, 1998, J BIOL CHEM, V273, P11409, DOI 10.1074/jbc.273.19.11409; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Sharma V, 2003, P NATL ACAD SCI USA, V100, P2243, DOI 10.1073/pnas.0538077100; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; Singleton MR, 2003, EMBO J, V22, P4579, DOI 10.1093/emboj/cdg441; Song M, 1997, J BIOCHEM-TOKYO, V122, P1010; Triplett TL, 2001, J BIOL CHEM, V276, P19648, DOI 10.1074/jbc.M100098200; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	39	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22490	22497		10.1074/jbc.M401008200	http://dx.doi.org/10.1074/jbc.M401008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007058	hybrid			2022-12-25	WOS:000221417100099
J	Kuzmin, EV; Karpova, OV; Elthon, TE; Newton, KJ				Kuzmin, EV; Karpova, OV; Elthon, TE; Newton, KJ			Mitochondrial respiratory deficiencies signal up-regulation of genes for heat shock proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABNORMAL GROWTH MUTANT; ZEA-MAYS; T-TOXIN; CAENORHABDITIS-ELEGANS; MOLECULAR CHAPERONES; ALTERNATIVE OXIDASE; STRESS-RESPONSE; COMPLEX-I; MAIZE; EXPRESSION	The consequences of mitochondrial dysfunction are not limited to the development of oxidative stress or initiation of apoptosis but can result in the establishment of stress tolerance. Using maize mitochondrial mutants, we show that permanent mitochondrial deficiencies trigger novel Ca2+-independent signaling pathways, leading to constitutive expression of genes for molecular chaperones, heat shock proteins (HSPs) of different classes. The signaling to activate hsp genes appears to originate from a reduced mitochondrial transmembrane potential. Upon depolarization of mitochondrial membranes in transient assays, gene induction for mitochondrial HSPs occurred more rapidly than that for cytosolic HSPs. We also demonstrate that in the nematode Caenorhabditis elegans transcription of hsp genes can be induced by RNA interference of nuclear respiratory genes. In both organisms, activation of hsp genes in response to mitochondrial impairment is distinct from their responses to heat shock and is not associated with oxidative stress. Thus, mitochondria-to-nucleus signaling to express a hsp gene network is apparently a widespread retrograde mechanism to facilitate cell defense and survival.	Univ Missouri, Dept Biol Sci, Columbia, MO 65211 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA	University of Missouri System; University of Missouri Columbia; University of Nebraska System; University of Nebraska Lincoln	Kuzmin, EV (corresponding author), Univ Missouri, Dept Biol Sci, 324 Tucker Hall, Columbia, MO 65211 USA.	bioscek@mchsi.com; newtonk@missouri.edu						ANDREWS DL, 1993, PLANT PHYSIOL, V101, P407, DOI 10.1104/pp.101.2.407; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Curtis MJ, 2002, PLANT J, V29, P295, DOI 10.1046/j.0960-7412.2001.01213.x; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Downs CA, 1998, FEBS LETT, V430, P246, DOI 10.1016/S0014-5793(98)00669-3; Dutilleul C, 2003, PLANT CELL, V15, P1212, DOI 10.1105/tpc.009464; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Gagliardi D, 1995, PLANT MOL BIOL, V29, P841, DOI 10.1007/BF00041173; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GuhaThakurta D, 2002, GENOME RES, V12, P701, DOI 10.1101/gr.228902; HOLDEN MJ, 1984, PLANT PHYSIOL, V75, P235, DOI 10.1104/pp.75.1.235; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; HUNT MD, 1991, EMBO J, V10, P1045, DOI 10.1002/j.1460-2075.1991.tb08043.x; Jones A, 2000, TRENDS PLANT SCI, V5, P225, DOI 10.1016/S1360-1385(00)01605-8; JONES D, 1986, J BIOL CHEM, V261, P2006; Kahlert S, 2002, FEBS LETT, V529, P351, DOI 10.1016/S0014-5793(02)03394-X; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Karpova OV, 1999, PLANT J, V17, P511, DOI 10.1046/j.1365-313X.1999.00401.x; Karpova OV, 2002, PLANT CELL, V14, P3271, DOI 10.1105/tpc.005603; KLEIN RR, 1985, PLANT PHYSIOL, V77, P912, DOI 10.1104/pp.77.4.912; Kliebenstein DJ, 1998, PLANT PHYSIOL, V118, P637, DOI 10.1104/pp.118.2.637; LAUER MKC, 1990, NEW BIOL, V2, P107; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; LEVINGS CS, 1993, PLANT CELL, V5, P1285, DOI 10.2307/3869781; Low D, 2000, PLANTA, V211, P575, DOI 10.1007/s004250000315; Lund AA, 1998, PLANT PHYSIOL, V116, P1097, DOI 10.1104/pp.116.3.1097; Magnard JL, 1996, PLANT PHYSIOL, V111, P1085, DOI 10.1104/pp.111.4.1085; MARIENFELD JR, 1994, GENETICS, V138, P855; Mittler R, 1999, PLANT MOL BIOL, V39, P1025, DOI 10.1023/A:1006110223774; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; NEWTON KJ, 1990, PLANT CELL, V2, P107, DOI 10.1105/tpc.2.2.107; Newton KJ, 1996, DEV GENET, V19, P277, DOI 10.1002/(SICI)1520-6408(1996)19:3<277::AID-DVG11>3.0.CO;2-X; NEWTON KJ, 1998, MITOCHONDRIAL DNA MU, P365; Nieto-Sotelo J, 2002, PLANT CELL, V14, P1621, DOI 10.1105/tpc.010487; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; PRASAD TK, 1992, PLANT MOL BIOL, V18, P873, DOI 10.1007/BF00019202; Queitsch C, 2000, PLANT CELL, V12, P479, DOI 10.1105/tpc.12.4.479; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; REID GA, 1982, J BIOL CHEM, V257, P3056; RHOADS DM, 1995, J BIOENERG BIOMEMBR, V27, P437, DOI 10.1007/BF02110006; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; SUBBAIAH CC, 1994, PLANT PHYSIOL, V105, P369, DOI 10.1104/pp.105.1.369; Sung DY, 2001, PLANT PHYSIOL, V126, P789, DOI 10.1104/pp.126.2.789; Tawe WN, 1998, NUCLEIC ACIDS RES, V26, P1621, DOI 10.1093/nar/26.7.1621; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Tsang WY, 2003, BBA-MOL BASIS DIS, V1638, P91, DOI 10.1016/S0925-4439(03)00079-6; Wagner AM, 1997, BIOSCIENCE REP, V17, P319, DOI 10.1023/A:1027388729586; Waters ER, 1996, J EXP BOT, V47, P325, DOI 10.1093/jxb/47.3.325; Young TE, 2001, PLANT PHYSIOL, V127, P777, DOI 10.1104/pp.010160; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445	54	72	88	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20672	20677		10.1074/jbc.M400640200	http://dx.doi.org/10.1074/jbc.M400640200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016808	hybrid			2022-12-25	WOS:000221273800017
J	Li, LB; Chen, NH; Ramamoorthy, S; Chi, LM; Cui, XN; Wang, LJC; Reith, MEA				Li, LB; Chen, NH; Ramamoorthy, S; Chi, LM; Cui, XN; Wang, LJC; Reith, MEA			The role of N-glycosylation in function and surface trafficking of the human dopamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOREPINEPHRINE TRANSPORTER; SEROTONIN TRANSPORTER; CELL-LINES; BINDING; NA+; INHIBITOR; OLIGOMERIZATION; RECOGNITION; EXPRESSION; RESIDUES	The present study addressed the role of N-linked glycosylation of the human dopamine transporter (DAT) in its function with the help of mutants, in which canonical N-glycosylation sites have been removed (N181Q, N181Q, N188Q, and N181Q, N188Q, N205Q), expressed in human embryonic kidney-293 cells. Removal of canonical sites produced lower molecular weight species as did enzymatic deglycosylation or blockade of glycosylation, and all three canonical sites were found to carry sugars. Prevention of N-glycosylation reduced both surface and intracellular DAT. Although partially or non-glycosylated DAT was somewhat less represented at the surface, no evidence was found for preferential exclusion of such material from the plasma membrane, indicating that glycosylation is not essential for DAT expression. Non-glycosylated DAT was less stable at the surface as revealed by apparently enhanced endocytosis, consonant with weaker DAT immunofluorescence at the cell surface and stronger presence in cytosol in confocal analysis of the double and triple mutant. Non-glycosylated DAT did not transport dopamine as efficiently as wild-type DAT as judged from the sharp reduction in uptake V-max, and prevention of N-glycosylation enhanced the potency of cocaine-like drugs in inhibiting dopamine uptake into intact cells without changing their affinity for DAT when measured in membrane preparations prepared from these cells. Thus, non-glycosylated DAT at the cell surface displays appreciably reduced catalytic activity and altered inhibitor sensitivity compared with wild type.	Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA; NYU, Dept Psychiat, Millhauser Labs, New York, NY 10016 USA; Med Univ S Carolina, Dept Physiol Neurosci, Charleston, SC 29425 USA; Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Peoria, IL 61605 USA	Illinois State University; New York University; Medical University of South Carolina; University of Illinois System; University of Illinois Peoria	Reith, MEA (corresponding author), Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA.	maarten.reith@med.nyu.edu	Reith, Maarten E./AAD-2303-2019	Reith, Maarten E./0000-0002-1900-842X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011978] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 11978] Funding Source: Medline; NIMH NIH HHS [MH 062612] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMEJDKICHAB N, 1992, J NEUROCHEM, V59, P1795, DOI 10.1111/j.1471-4159.1992.tb11012.x; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; Bonisch H, 1998, METHOD ENZYMOL, V296, P259; BONNET JJ, 1986, EUR J PHARMACOL, V121, P199, DOI 10.1016/0014-2999(86)90491-7; Chen NH, 1997, J NEUROCHEM, V68, P1968; Chen NH, 2001, J NEUROCHEM, V77, P1116, DOI 10.1046/j.1471-4159.2001.00312.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Deken Scott L., 2002, P193; DEVES R, 1989, METHOD ENZYMOL, V171, P113; ESHLEMAN AJ, 1995, J PHARMACOL EXP THER, V274, P276; GRIGORIADIS DE, 1989, J NEUROSCI, V9, P2664; Hahn Maureen K., 2002, P111; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; Li LB, 1999, J NEUROCHEM, V72, P1095, DOI 10.1046/j.1471-4159.1999.0721095.x; Li LB, 2002, N-S ARCH PHARMACOL, V365, P303, DOI 10.1007/s00210-001-0526-6; LI LB, 2000, SOC NEUR ABSTR, V26, P1168; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Melikian HE, 1999, J NEUROSCI, V19, P7699; Melikian HE, 1996, MOL PHARMACOL, V50, P266; Nguyen TT, 1996, J NEUROCHEM, V67, P645; Ozaslan D, 2003, J BIOL CHEM, V278, P43991, DOI 10.1074/jbc.M306360200; PATEL A, 1993, J NEUROCHEM, V61, P496; Patel Amrat P., 2002, P355; SCHOMIG E, 1988, N-S ARCH PHARMACOL, V337, P633; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; TATE CG, 1994, J BIOL CHEM, V269, P26303; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Vaughan RA, 1996, J NEUROCHEM, V66, P2146; WANG LC, 2000, NAUNYNSCHMIEDEBERGS; ZIMANYI I, 1989, N-S ARCH PHARMACOL, V340, P626, DOI 10.1007/BF00717737; [No title captured]	36	125	130	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21012	21020		10.1074/jbc.M311972200	http://dx.doi.org/10.1074/jbc.M311972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15024013	hybrid			2022-12-25	WOS:000221273800057
J	Kim, EK; Miller, I; Aja, S; Landree, LE; Pinn, M; McFadden, J; Kuhajda, FP; Moran, TH; Ronnett, GV				Kim, EK; Miller, I; Aja, S; Landree, LE; Pinn, M; McFadden, J; Kuhajda, FP; Moran, TH; Ronnett, GV			C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; SKELETAL-MUSCLE; BODY-WEIGHT; GENE-EXPRESSION; ENERGY-CHARGE; GLUCOSE; CELL; METABOLISM; NEURONS; LEPTIN	Energy homeostasis and feeding are regulated by the central nervous system. C75, a fatty acid synthase (FAS) inhibitor, causes weight loss and anorexia, implying a novel central nervous system pathway(s) for sensing energy balance. AMP-activated protein kinase (AMPK), a sensor of peripheral energy balance, is phosphorylated and activated when energy sources are low. Here, we identify a role for hypothalamic AMPK in the regulation of feeding behavior and in mediating the anorexic effects of C75. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR), an activator of AMPK, increased food intake, whereas compound C, an inhibitor of AMPK, decreased food intake. C75 rapidly reduced the level of the phosphorylated AMPK alpha subunit (pAMPKalpha) in the hypothalamus, even in fasted mice that had elevated hypothalamic pAMPKalpha levels. Furthermore, AICAR reversed both the C75-induced anorexia and the decrease in hypothalamic pAMPKalpha levels. C75 elevated hypothalamic neuronal ATP levels, which may contribute to the mechanism by which C75 decreased AMPK activity. C75 reduced the levels of pAMPKalpha and phosphorylated cAMP response element-binding protein (pCREB) in the arcuate nucleus neurons of the hypothalamus, suggesting a mechanism for the reduction in NPY expression seen with C75 treatment. These data indicate that modulation of FAS activity in the hypothalamus can alter energy perception via AMPK, which functions as a physiological energy sensor in the hypothalamus.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; FASgen Inc, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Ronnett, GV (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 1006B Preclin Teaching Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	gronnett@jhmi.edu						Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Clegg DJ, 2002, DIABETES, V51, P3196, DOI 10.2337/diabetes.51.11.3196; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kim EK, 2002, AM J PHYSIOL-ENDOC M, V283, pE867, DOI 10.1152/ajpendo.00178.2002; Kumar MV, 2002, P NATL ACAD SCI USA, V99, P1921, DOI 10.1073/pnas.042683699; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Landree LE, 2004, J BIOL CHEM, V279, P3817, DOI 10.1074/jbc.M310991200; Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200; Leff T, 2003, BIOCHEM SOC T, V31, P224; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Musi N, 2001, DIABETES, V50, P921, DOI 10.2337/diabetes.50.5.921; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; Ruderman NB, 2003, ENDOCRINOLOGY, V144, P5166, DOI 10.1210/en.2003-0849; SABINA RL, 1985, J BIOL CHEM, V260, P6107; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Sheriff S, 1997, MOL PHARMACOL, V51, P597, DOI 10.1124/mol.51.4.597; Shimizu-Albergine M, 2001, J NEUROSCI, V21, P1238; Shimokawa T, 2002, P NATL ACAD SCI USA, V99, P66, DOI 10.1073/pnas.012606199; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Turnley AM, 1999, J NEUROCHEM, V72, P1707, DOI 10.1046/j.1471-4159.1999.721707.x; Wilding JPH, 2002, DIABETIC MED, V19, P619, DOI 10.1046/j.1464-5491.2002.00790.x; Winder W W, 2000, Diabetes Technol Ther, V2, P441, DOI 10.1089/15209150050194305; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Winder WW, 2001, J APPL PHYSIOL, V91, P1017, DOI 10.1152/jappl.2001.91.3.1017; WITTERS LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P413, DOI 10.1006/abbi.1994.1058; Woods SC, 2000, ANNU REV PSYCHOL, V51, P255, DOI 10.1146/annurev.psych.51.1.255; Wortman MD, 2003, NAT MED, V9, P483, DOI 10.1038/nm0503-483; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	51	300	312	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19970	19976		10.1074/jbc.M402165200	http://dx.doi.org/10.1074/jbc.M402165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15028725	hybrid			2022-12-25	WOS:000221164500071
J	Gascoyne, DM; Thomas, GR; Latchman, DS				Gascoyne, DM; Thomas, GR; Latchman, DS			The effects of Brn-3a on neuronal differentiation and apoptosis are differentially modulated by EWS and its oncogenic derivative EWS/Fli-1	ONCOGENE			English	Article						POU domain; Ewing's sarcoma; neuronal differentiation	TRANSCRIPTION FACTORS BRN-3A; RNA-POLYMERASE-II; DNA-BINDING; POU TRANSCRIPTION; GENE-EXPRESSION; FUSION PROTEIN; EWS/ETS FUSIONS; GROWTH ARREST; EWING FAMILY; CELL-LINES	The Brn-3 family of POU (Pit-Oct-Unc) homeodomain transcription factors regulate differentiation of neuronal cell types. The transcriptional activator Brn-3a is expressed in Ewing's sarcomas, which also express characteristic chimaeric proteins as a consequence of fusion of the TET family gene EWS to one of several ETS genes. We have previously demonstrated a physical interaction between Brn-3a and EWS proteins, and show here that the C-terminal POU domain but not N-terminal activation domain of Brn-3a can interact in vitro with the RNA-binding domain of EWS. Likely due to POU domain homology, the related factor Brn-3b can also interact with EWS, but to a lesser extent than Brn-3a. Importantly, Brn-3a but not Brn-3b interacts in vitro with chimaeric EWS/Fli-1, EWS/ATF-1 and EWS/ERG proteins. Furthermore, overexpression of EWS/Fli-1 but not EWS or Fli-1 inhibits Brn-3a-associated growth arrest and neurite outgrowth in neuronal cells, and specifically inhibits Brn-3a-dependent activation of p21 and SNAP-25 transcription. In contrast, upregulation of Bcl-2 expression and inhibition of apoptosis by Brn-3a is antagonized more by EWS than by EWS/Fli-1. These data demonstrate that oncogenic rearrangement of EWS to produce EWS/Fli-1 may enhance the antiapoptotic effect of Brn-3a and inhibit its ability to promote neuronal differentiation.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EHUCL, England	University of London; University College London	Gascoyne, DM (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EHUCL, England.	d.gascoyne@ich.ucl.ac.uk			Medical Research Council [G9901318] Funding Source: Medline; MRC [G9901318] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; Budram-Mahadeo V, 2002, ONCOGENE, V21, P6123, DOI 10.1038/sj.onc.1205842; Chansky HA, 2001, CANCER RES, V61, P3586; COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Ensor E, 2001, J BIOL CHEM, V276, P5204, DOI 10.1074/jbc.M007068200; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; Frass B, 2002, BBA-GENE STRUCT EXPR, V1579, P207, DOI 10.1016/S0167-4781(02)00540-7; Gascoyne DM, 2003, J BIOL CHEM, V278, P18022, DOI 10.1074/jbc.M301812200; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Huang EJ, 1999, DEVELOPMENT, V126, P2869; Im YH, 2000, CANCER RES, V60, P1536; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Li KKC, 2000, J BIOL CHEM, V275, P23053, DOI 10.1074/jbc.M002961200; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MAO XH, 1994, J BIOL CHEM, V269, P18216; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; Melot T, 2001, EUR J BIOCHEM, V268, P3483, DOI 10.1046/j.1432-1327.2001.02251.x; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Morris PJ, 1997, NEUROREPORT, V8, P2041, DOI 10.1097/00001756-199705260-00047; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; OHNO T, 1994, ONCOGENE, V9, P3087; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Perez-Sanchez C, 2002, NUCLEIC ACIDS RES, V30, P4872, DOI 10.1093/nar/gkf610; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; Rossow KL, 2001, CANCER RES, V61, P2690; Ryabinin AE, 1995, J MOL NEUROSCI, V6, P201, DOI 10.1007/BF02736765; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Smith MD, 1996, INT J CANCER, V67, P653; Smith MD, 2001, MOL CELL NEUROSCI, V17, P460, DOI 10.1006/mcne.2000.0927; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Smith MD, 1998, NUCLEIC ACIDS RES, V26, P4100, DOI 10.1093/nar/26.18.4100; Teitell MA, 1999, LAB INVEST, V79, P1535; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; Thomas GR, 2002, CANCER BIOL THER, V1, P428, DOI 10.4161/cbt.1.4.23; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Wagner KD, 2003, GENE, V305, P217, DOI 10.1016/S0378-1119(02)01231-3; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099	59	21	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3830	3840		10.1038/sj.onc.1207497	http://dx.doi.org/10.1038/sj.onc.1207497			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021903				2022-12-25	WOS:000221242500010
J	Herbst, A; Salghetti, SE; Kim, SY; Tansey, WP				Herbst, A; Salghetti, SE; Kim, SY; Tansey, WP			Multiple cell-type-specific elements regulate Myc protein stability	ONCOGENE			English	Article						Myc; Myc box; ubiquitin; proteasome; transcription	ACTIVATION-DOMAIN FUNCTION; C-MYC; IN-VIVO; UBIQUITIN; PROTEASOME; DEGRADATION; ONCOPROTEIN; PROTEOLYSIS; TRANSACTIVATION; EXPRESSION	Myc is a highly unstable transcription factor that is destroyed by ubiquitin (Ub)-mediated proteolysis. We have previously identified an amino-terminal 'degron' within Myc that signals its destruction; this degron spans the transcriptional activation domain of Myc, and includes two highly conserved regions called Myc boxes I and II. We now report the identification of a second element-the D-element-which is also required for Myc proteolysis. The centrally located D-element is distinct from the PEST domain in Myc, but includes Myc box III, a third highly conserved region with no previously known function. We show that deletion of the D-element stabilizes the Myc protein without affecting its ubiquitylation, and report that the D-element and the degron act in a cell-type-specific manner to direct Myc proteolysis. These data thus demonstrate that Myc stability is regulated at both the ubiquitylation and postubiquitylation levels, and reveal that substrates of the Ub-proteasome system can be targeted for destruction differently in different cell types.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Genet Program, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Tansey, WP (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	tansey@cshl.edu			NCI NIH HHS [CA-13106, CA45508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508, P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Chen L, 2000, ARCH BIOCHEM BIOPHYS, V374, P306, DOI 10.1006/abbi.1999.1603; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; CONKLIN DS, 1993, MOL CELL BIOL, V13, P2041, DOI 10.1128/MCB.13.4.2041; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Herbst A, 2000, MOL BIOL REP, V27, P203, DOI 10.1023/A:1011008018565; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; MORTIMER RK, 1986, GENETICS, V113, P35; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; PRASAD I, 1976, J VIROL, V18, P436, DOI 10.1128/JVI.18.2.436-444.1976; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rudolph C, 1999, ANAL BIOCHEM, V269, P66, DOI 10.1006/abio.1999.3095; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; Sherman F., 1986, METHODS YEAST GENETI; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tworkowski KA, 2002, ONCOGENE, V21, P8515, DOI 10.1038/sj.onc.1205976; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889	47	40	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3863	3871		10.1038/sj.onc.1207492	http://dx.doi.org/10.1038/sj.onc.1207492			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021906				2022-12-25	WOS:000221242500013
J	Zuber, C; Fan, JY; Guhl, B; Roth, J				Zuber, C; Fan, JY; Guhl, B; Roth, J			Misfolded proinsulin accumulates in expanded pre-Golgi intermediates and endoplasmic reticulum subdomains in pancreatic beta cells of Akita mice	FASEB JOURNAL			English	Article						electron microscopy; protein quality control; protein folding disease; ERAD	UNFOLDED-PROTEIN-RESPONSE; CLASS-I MOLECULES; QUALITY-CONTROL; ER DEGRADATION; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; GENE; COMPARTMENT; PROTEASOME; RETENTION	A missense mutation of the insulin 2 gene (Cys96Tyr) in Akita mice disrupting one of the two interchain disulfide bonds results in intracellular accumulation of misfolded proinsulin. We analyzed the secretory pathway of pancreatic beta cells by electron microscopy and morphometry and identified sites of proinsulin accumulation by quantitative immunogold electron microscopy in this protein-folding disease. In Akita mice beta cells, the volume density of dilated endoplasmic reticulum subdomains was increased by 2.9- fold, resulting in a 1.7-fold increased volume density of the entire rough endoplasmic reticulum. The volume density of pre-Golgi intermediates was increased by 4.9-fold, and that of the Golgi apparatus was increase by 3.4-fold. The relative labeling intensity for proinsulin was 2.1-fold higher in dilated endoplasmic reticulum subdomains and 2.9- fold higher in pre-Golgi intermediates as compared with narrow endoplasmic reticulum, resulting in a significantly different distribution pattern between Akita and control mice beta cells (X-2= 29.97, P < 0.001). The numerical density of insulin secretory granules was equal in Akita and control mice beta cells. However, their volume density and average volume were reduced to 20% and their average diameter to 58% in Akita mice. Together, these data demonstrate that misfolded proinsulin accumulates mainly in pre-Golgi intermediates and to a lesser extent in dilated endoplasmic reticulum subdomains, providing evidence for the importance of pre-Golgi intermediates in a protein folding disease.	Univ Zurich, Dept Pathol, Div Cell & Mol Pathol, CH-8091 Zurich, Switzerland	University of Zurich	Roth, J (corresponding author), Univ Zurich, Dept Pathol, Div Cell & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	juergen.roth@usz.ch						ALANEN A, 1985, EUR J IMMUNOL, V15, P235, DOI 10.1002/eji.1830150306; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BUNZLI HF, 1972, H-S Z PHYSIOL CHEM, V353, P451, DOI 10.1515/bchm2.1972.353.1.451; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fan JY, 2003, HISTOCHEM CELL BIOL, V120, P455, DOI 10.1007/s00418-003-0597-1; FARQUHAR M, 1907, GOLGI APPARTUS, P63; Greenfield JJA, 1999, J CELL SCI, V112, P1477; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hauri HP, 2000, J CELL SCI, V113, P587; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; Izumi T, 2003, DIABETES, V52, P409, DOI 10.2337/diabetes.52.2.409; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kayo T, 1998, J CLIN INVEST, V101, P2112, DOI 10.1172/JCI1842; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; Menzel R, 1997, YEAST, V13, P1211, DOI 10.1002/(SICI)1097-0061(199710)13:13<1211::AID-YEA168>3.0.CO;2-8; Mezzacasa A, 2002, TRAFFIC, V3, P833, DOI 10.1034/j.1600-0854.2002.31108.x; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PALADE GE, 1956, J BIOPHYS BIOCHEM CY, V2, P417, DOI 10.1083/jcb.2.4.417; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTH J, 2000, ANTIGEN RETRIEVAL TE, P275; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; SARASTE J, 1991, J CELL SCI, V100, P415; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Spiliotis ET, 2002, MOL BIOL CELL, V13, P1566, DOI 10.1091/mbc.01-07-0322; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; Takewaka T, 1999, J BIOCHEM-TOKYO, V125, P507, DOI 10.1093/oxfordjournals.jbchem.a022314; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wojcik C, 1996, EUR J CELL BIOL, V71, P311; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yoshioka M, 1997, DIABETES, V46, P887, DOI 10.2337/diabetes.46.5.887; Zuber C, 2001, P NATL ACAD SCI USA, V98, P10710, DOI 10.1073/pnas.191359198	64	57	57	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					917	+		10.1096/fj.03-1210fje	http://dx.doi.org/10.1096/fj.03-1210fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033933				2022-12-25	WOS:000220522800018
J	Majee, M; Maitra, S; Dastidar, KG; Pattnaik, S; Chatterjee, A; Hait, NC; Das, KP; Majumder, AL				Majee, M; Maitra, S; Dastidar, KG; Pattnaik, S; Chatterjee, A; Hait, NC; Das, KP; Majumder, AL			A novel salt-tolerant L-myo-inositol-1-phosphate synthase from Porteresia coarctata (Roxb.) Tateoka, a halophytic wild rice - Molecular cloning, bacterial overexpression, characterization, and functional introgression into tobacco-conferring salt tolerance phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1-PHOSPHATE SYNTHASE; INOSITOL-1-PHOSPHATE SYNTHASE; MYOINOSITOL METABOLISM; CRYSTAL-STRUCTURE; INO1 GENE; PLANT; YEAST; EXPRESSION; SALINITY; STRESS	L-myo-Inositol-1-phosphatesynthase (EC5.5.1.4, MIPS), an evolutionarily conserved enzyme protein, catalyzes the synthesis of inositol, which is implicated in a number of metabolic reactions in the biological kingdom. Here we report on the isolation of the gene (PINO1) for a novel salt-tolerant MIPS from the wild halophytic rice, Porteresia coarctata (Roxb.) Tateoka. Identity of the PINO1 gene was confirmed by functional complementation in a yeast inositol auxotrophic strain. Comparison of the nucleotide and deduced amino acid sequences of PINO1 with that of the homologous gene from Oryza sativa L. (RINO1) revealed distinct differences in a stretch of 37 amino acids, between amino acids 174 and 210. Purified bacterially expressed PINO1 protein demonstrated a salt-tolerant character in vitro compared with the salt-sensitive RINO1 protein as with those purified from the native source or an expressed salt-sensitive mutant PINO1 protein wherein amino acids 174-210 have been deleted. Analysis of the salt effect on oligomerization and tryptophan fluorescence of the RINO1 and PINO1 proteins revealed that the structure of PINO1 protein is stable toward salt environment. Furthermore, introgression of PINO1 rendered transgenic tobacco plants capable of growth in 200-300 mM NaCl with retention of similar to40-80% of the photosynthetic competence with concomitant increased inositol production compared with unstressed control. MIPS protein isolated from PINO1 transgenics showed salt-tolerant property in vitro confirming functional expression in planta of the PINO1 gene. To our knowledge, this is the first report of a salt-tolerant MIPS from any source.	Bose Inst, Dept Chem, Kolkata 700054, India	Department of Science & Technology (India); Bose Institute	Majumder, AL (corresponding author), Bose Inst, Dept Chem, Centenary Bldg,P-1-12,C I T Scheme 7 M, Kolkata 700054, India.	lahiri@bic.boseinst.ernet.in		Das, Kali/0000-0001-7686-9077; Majee, Manoj/0000-0002-9156-2951				ADHIKARI J, 1987, PLANT PHYSIOL, V85, P611, DOI 10.1104/pp.85.3.611; Apse MP, 2002, CURR OPIN BIOTECH, V13, P146, DOI 10.1016/S0958-1669(02)00298-7; Bachhawat N, 1999, J MOL BIOL, V291, P531, DOI 10.1006/jmbi.1999.2980; Bachhawat N, 2000, TRENDS GENET, V16, P111, DOI 10.1016/S0168-9525(99)01966-6; BARNETT JEG, 1970, BIOCHEM J, V119, P183, DOI 10.1042/bj1190183; BIELESKI RL, 1977, AUST J PLANT PHYSIOL, V4, P1, DOI 10.1071/PP9770001; Biswas B B, 1984, Subcell Biochem, V10, P237; BOHNERT HJ, 1995, PLANT CELL, V7, P1099, DOI 10.1105/tpc.7.7.1099; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen LJ, 2000, BIOCHEMISTRY-US, V39, P12415, DOI 10.1021/bi001517q; Chen LJ, 1998, J BACTERIOL, V180, P3785, DOI 10.1128/JB.180.15.3785-3792.1998; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Chun JA, 2003, PLANTA, V216, P874, DOI 10.1007/s00425-002-0940-0; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; Hait NC, 2002, PLANT SCI, V162, P559, DOI 10.1016/S0168-9452(01)00591-X; Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IMHOFF V, 1973, PHYTOCHEMISTRY, V12, P331, DOI 10.1016/0031-9422(73)80014-7; Ishitani M, 1996, PLANT J, V9, P537, DOI 10.1046/j.1365-313X.1996.09040537.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jin XS, 2003, ACTA CRYSTALLOGR D, V59, P1154, DOI 10.1107/S0907444903008205; JOHNSON MD, 1989, J BIOL CHEM, V264, P1274; KLIG LS, 1984, P NATL ACAD SCI-BIOL, V81, P3816, DOI 10.1073/pnas.81.12.3816; Kniewel Ryan, 2002, Journal of Structural and Functional Genomics, V2, P129, DOI 10.1023/A:1021293408654; Lackey KH, 2003, PLANT PHYSIOL, V132, P2240, DOI 10.1104/pp.103.020610; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Loewus FA, 2000, PLANT SCI, V150, P1, DOI 10.1016/S0168-9452(99)00150-8; Lohia A, 1999, MOL BIOCHEM PARASIT, V98, P67, DOI 10.1016/S0166-6851(98)00147-9; Low NH, 1996, J AOAC INT, V79, P724; Majumder AL, 1997, BBA-LIPID LIPID MET, V1348, P245, DOI 10.1016/S0005-2760(97)00122-7; MAJUMDER AL, 1981, MOL GEN GENET, V184, P347, DOI 10.1007/BF00352503; Majumder AL, 2003, FEBS LETT, V553, P3, DOI 10.1016/S0014-5793(03)00974-8; Nelson DE, 1998, PLANT CELL, V10, P753; Nelson DE, 1999, PLANT PHYSIOL, V119, P165, DOI 10.1104/pp.119.1.165; NISHIGUCHI R, 1987, MOL GEN GENET, V206, P1, DOI 10.1007/BF00326529; Norman RA, 2002, STRUCTURE, V10, P393, DOI 10.1016/S0969-2126(02)00718-9; OSTREM JA, 1987, PLANT PHYSIOL, V84, P1270, DOI 10.1104/pp.84.4.1270; PROCUNIER JD, 1991, BARLEY GENET NEWSL, V20, P74; RayChaudhuri A, 1997, PLANT PHYSIOL, V115, P727, DOI 10.1104/pp.115.2.727; Raychaudhuri A, 1996, PLANT CELL ENVIRON, V19, P1437, DOI 10.1111/j.1365-3040.1996.tb00023.x; Sambrook J., 1989, MOL CLONING, pA1; Sheveleva EV, 1998, PLANT PHYSIOL, V117, P831, DOI 10.1104/pp.117.3.831; Smart CC, 1997, PLANT MOL BIOL, V33, P811, DOI 10.1023/A:1005754425440; Stein AJ, 2002, J BIOL CHEM, V277, P9484, DOI 10.1074/jbc.M109371200; Stein AJ, 2000, ACTA CRYSTALLOGR D, V56, P348, DOI 10.1107/S0907444999016777; STRASSER RJ, 1995, PHOTOCHEM PHOTOBIOL, V61, P32, DOI 10.1111/j.1751-1097.1995.tb09240.x; Wang WX, 2003, PLANTA, V218, P1, DOI 10.1007/s00425-003-1105-5; Yamada A, 2002, PLANT CELL PHYSIOL, V43, P903, DOI 10.1093/pcp/pcf108; Zhu JK, 2001, TRENDS PLANT SCI, V6, P66, DOI 10.1016/S1360-1385(00)01838-0	51	125	135	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28539	28552		10.1074/jbc.M310138200	http://dx.doi.org/10.1074/jbc.M310138200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15016817	hybrid			2022-12-25	WOS:000222265400090
J	Que-Gewirth, NLS; Ribeiro, AA; Kalb, SR; Cotter, RJ; Bulach, DM; Adler, B; Saint Girons, I; Werts, C; Raetz, CRH				Que-Gewirth, NLS; Ribeiro, AA; Kalb, SR; Cotter, RJ; Bulach, DM; Adler, B; Saint Girons, I; Werts, C; Raetz, CRH			A methylated phosphate group and four amide-linked acyl chains in Leptospira interrogans lipid A - The membrane anchor of an unusual lipopolysaccharide that activates TLR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE ACYLTRANSFERASE; LYME-DISEASE SPIROCHETE; ACID-DEFICIENT MUTANT; ESCHERICHIA-COLI; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; SALMONELLA-TYPHIMURIUM; BORRELIA-BURGDORFERI; TREPONEMA-PALLIDUM; RHIZOBIUM-LEGUMINOSARUM; NMR-SPECTROSCOPY	Leptospira interrogans differs from other spirochetes in that it contains homologs of all the Escherichia coli lpx genes required for the biosynthesis of the lipid A anchor of lipopolysaccharide (LPS). LPS from L. interrogans cells is unusual in that it activates TLR2 rather than TLR4. The structure of L. interrogans lipid A has now been determined by a combination of matrix-assisted laser desorption ionization time-of-flight mass spectrometry, NMR spectroscopy, and biochemical studies. Lipid A was released from LPS of L. interrogans serovar Pomona by 100 C hydrolysis at pH 4.5 in the presence of SDS. Following purification by anion exchange and thin layer chromatography, the major component was shown to have a molecular weight of 1727. Mild hydrolysis with dilute NaOH reduced this to 1338, consistent with the presence of four N-linked and two O-linked acyl chains. The lipid A molecules of both the virulent and nonvirulent forms of L. interrogans serovar Icterohaemorrhagiae ( strain Verdun) were identical to those of L. interrogans Pomona by the above criteria. Given the selectivity of L. interrogans LpxA for 3-hydroxylaurate, we propose that L. interrogans lipid A is acylated with R-3-hydroxylaurate at positions 3 and 3' and with R-3-hydroxypalmitate at positions 2 and 2'. The hydroxyacyl chain composition was validated by gas chromatography and mass spectrometry of fatty acid methyl esters. Intact hexa-acylated lipid A of L. interrogans Pomona was also analyzed by NMR, confirming the presence a beta-1',6-linked disaccharide of 2,3-diamino-2,3-dideoxy-D-glucopyranose units. Two secondary unsaturated acyl chains are attached to the distal residue. The 1-position of the disaccharide is derivatized with an axial phosphate moiety, but the 4'-OH is unsubstituted. H-1 and P-31 NMR analyses revealed that the 1-phosphate group is methylated. Purified L. interrogans lipid A is inactive against human THP-1 cells but does stimulate tumor necrosis factor production by mouse RAW264.7 cells.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke NMR Spect Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA; Monash Univ, Dept Microbiol, Australian Bacterial Pathogenesis Program, Clayton, Vic 3800, Australia; Inst Pasteur, Unite Bacteriol Mol & Med, F-75015 Paris, France	Duke University; Duke University; Duke University; Johns Hopkins University; Monash University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu	Bulach, Dieter M/D-5793-2011; WERTS, Catherine/AAD-5447-2020	Bulach, Dieter M/0000-0001-9823-6078; WERTS, Catherine/0000-0003-3079-5476; Kalb, Suzanne/0000-0002-8067-136X	NCI NIH HHS [P30-CA-14236, P30 CA014236] Funding Source: Medline; NIGMS NIH HHS [R37 GM051796-08, R01 GM051310, GM-51310, GM-51796, R01 GM051796, GM-54882, R37 GM051796] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R01GM051310, R01GM051796, R37GM051796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler B, 1989, FEMS Microbiol Immunol, V1, P213; ADLER B, 2003, PROKARYOTES; AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Akins DR, 1998, J CLIN INVEST, V101, P2240, DOI 10.1172/JCI2325; Armitage JP, 1999, ADV MICROB PHYSIOL, V41, P229, DOI 10.1016/S0065-2911(08)60168-X; ARONDEL V, 1993, J BIOL CHEM, V268, P16002; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; Beermann C, 2000, BIOCHEM BIOPH RES CO, V267, P897, DOI 10.1006/bbrc.1999.2057; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brade H., 1999, ENDOTOXIN HLTH DIS; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; Bulach DM, 2000, J MOL MICROB BIOTECH, V2, P375; Carty SM, 1999, J BIOL CHEM, V274, P9677, DOI 10.1074/jbc.274.14.9677; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; CUI Z, 1993, J BIOL CHEM, V268, P16655; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; de la Pena-Moctezuma A, 2001, FEMS IMMUNOL MED MIC, V31, P73, DOI 10.1111/j.1574-695X.2001.tb01589.x; ELLINGHAUSEN HC, 1965, AM J VET RES, V26, P45; FARR RW, 1995, CLIN INFECT DIS, V21, P1, DOI 10.1093/clinids/21.1.1; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; HINCKLEY MB, 2004, IN PRESS FASEB J; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; JOHNSON RC, 1967, J BACTERIOL, V94, P27, DOI 10.1128/JB.94.1.27-31.1967; JOHNSON RC, 1973, APPL MICROBIOL, V26, P118, DOI 10.1128/AEM.26.1.118-119.1973; Kanipes MI, 2001, J BIOL CHEM, V276, P1156, DOI 10.1074/jbc.M009019200; KASS LR, 1967, P NATL ACAD SCI USA, V58, P1168, DOI 10.1073/pnas.58.3.1168; KATES M, 1993, BIOCHIM BIOPHYS ACTA, V1169, P46, DOI 10.1016/0005-2760(93)90080-S; Levett PN, 2001, CLIN MICROBIOL REV, V14, P296, DOI 10.1128/CMR.14.2.296-326.2001; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Manthey CL, 1994, J ENDOTOXIN RES, V1, P84; MARR RS, 1990, J BIOL CHEM, V265, P20057; MIDWINTER A, 1994, INFECT IMMUN, V62, P5477, DOI 10.1128/IAI.62.12.5477-5482.1994; Norris SJ, 2001, J MOL MICROB BIOTECH, V3, P37; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Porcella SF, 2001, J CLIN INVEST, V107, P651, DOI 10.1172/JCI12484; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; Que Nanette L. S., 2002, Journal of Endotoxin Research, V8, P165; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; RADOLF JD, 1995, INFECT IMMUN, V63, P4244, DOI 10.1128/IAI.63.11.4244-4252.1995; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RANDO RR, 1968, J BIOL CHEM, V243, P5627; Ren SX, 2003, NATURE, V422, P888, DOI 10.1038/nature01597; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; Schultz CP, 1998, J BIOL CHEM, V273, P15661, DOI 10.1074/jbc.273.25.15661; SHIMIZU T, 1987, MICROBIOL IMMUNOL, V31, P717, DOI 10.1111/j.1348-0421.1987.tb03133.x; Shumyatsky Gleb, 1994, Gene Expression, V4, P29; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; Steeghs L, 2001, EMBO J, V20, P6937, DOI 10.1093/emboj/20.24.6937; Steeghs L, 1998, NATURE, V392, P449, DOI 10.1038/33046; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; Sweet CR, 2004, J BIOL CHEM, V279, P25400, DOI 10.1074/jbc.M400596200; Sweet CR, 2002, J BIOL CHEM, V277, P18281, DOI 10.1074/jbc.M201057200; Sweet CR, 2004, J BIOL CHEM, V279, P25411, DOI 10.1074/jbc.M400597200; TAKAYAMA K, 1987, INFECT IMMUN, V55, P2311, DOI 10.1128/IAI.55.9.2311-2313.1987; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; Takeda K, 2003, CELL MICROBIOL, V5, P143, DOI 10.1046/j.1462-5822.2003.00264.x; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; TOEWS ML, 1979, P NATL ACAD SCI USA, V76, P5544, DOI 10.1073/pnas.76.11.5544; VINH T, 1986, J GEN MICROBIOL, V132, P103; VINH TU, 1989, J GEN MICROBIOL, V135, P2663; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14186, DOI 10.1074/jbc.M200408200; WECKESSER J, 1988, FEMS MICROBIOL LETT, V54, P143, DOI 10.1016/0378-1097(88)90174-7; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030; Wyckoff TJO, 1999, J BIOL CHEM, V274, P27047, DOI 10.1074/jbc.274.38.27047; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	85	104	106	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25420	25429		10.1074/jbc.M400598200	http://dx.doi.org/10.1074/jbc.M400598200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15044492	Green Accepted, hybrid			2022-12-25	WOS:000221827900065
J	Rao, CV; Li, X; Manna, SK; Lei, ZM; Aggarwal, BB				Rao, CV; Li, X; Manna, SK; Lei, ZM; Aggarwal, BB			Human chorionic gonadotropin decreases proliferation and invasion of breast cancer MCF-7 cells by inhibiting NF-kappa B and AP-1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RAT MAMMARY-GLANDS; LUTEINIZING-HORMONE; EPITHELIAL-CELLS; MONOCLONAL-ANTIBODIES; RECEPTOR; GROWTH; HCG; CARCINOMA; RISK	The epidemiological data suggest that breast cancer risk decreases in women who complete full-term pregnancy at a young age. Studies on a rat breast cancer model indicate that human chorionic gonadotropin (hCG), a hormone that is present in very high levels during pregnancy, could be responsible for this decrease. These findings, as well as those demonstrating the presence of functional luteinizing hormone (LH)/hCG receptors in human breast cells, prompted us to investigate the anti-proliferative and anti-invasive effects of hCG in human breast cancer MCF-7 cells by down-regulating NF-kappaB and AP-1 transcription factors. Treatment of MCF-7 cells with highly purified hCG resulted in a modest dose-dependent and hormone-specific decrease in cell proliferation. hCG treatment also decreased cell invasion, which was more dramatic than the decrease in cell proliferation. These hCG actions were abrogated when receptor synthesis was inhibited by treatment with antisense hCG/LH receptor phosphorothioate oligodeoxynucleotide. hCG treatment prevented the tumor necrosis factor-dependent NF-kappaB and AP-1 activation, which paralleled a decrease in the phosphorylation and degradation of IkappaBalpha. The findings that hCG treatment increased cAMP synthesis and activated cAMP-dependent protein kinase, dibutyryl cAMP mimicked hCG in preventing NF-kappaB activation, and dideoxyadenosine, an adenylate cyclase inhibitor, prevented the hCG effect on NF-kappaB suggested that the hCG actions are mediated via the cAMP-dependent protein kinase A signaling pathway. In summary, our results demonstrate that hCG has anti-proliferative and anti-invasive effects in MCF-7 cells by down-regulating NF-kappaB and AP-1. These findings support the premise that hCG could be responsible for the pregnancy-induced protection against breast cancer in women.	Univ Louisville, Hlth Sci Ctr, Dept Obstet Gynecol & Womens Hlth, Div Res, Louisville, KY 40292 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Louisville; University of Texas System; UTMD Anderson Cancer Center	Rao, CV (corresponding author), Univ Louisville, Hlth Sci Ctr, Dept Obstet Gynecol & Womens Hlth, Div Res, 438 MDR Bldg,511 S Floyd St, Louisville, KY 40292 USA.	cvrao001@gwise.louisville.edu	Aggarwal, Bharat B/G-3388-2013					ALVARADO MV, 1994, IN VITRO CELL DEV-AN, V30A, P4; ALVARADO MV, 1994, ENDOCRINE, V2, P1107; ALVARADO MV, 1993, J HISTOCHEM CYTOCHEM, V41, P29, DOI 10.1177/41.1.8417109; Bieche I, 1998, CLIN CANCER RES, V4, P671; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; CHOCHUNG YS, 1991, PHARMACOL THERAPEUT, V50, P1, DOI 10.1016/0163-7258(91)90071-S; CHOCHUNG YS, 1974, CANCER RES, V34, P3492; CHOCHUNG YS, 1974, SCIENCE, V183, P87, DOI 10.1126/science.183.4120.87; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Funaro A, 2003, J CLIN ENDOCR METAB, V88, P5537, DOI 10.1210/jc.2003-030977; Gebauer G, 2003, BREAST CANCER RES TR, V77, P125, DOI 10.1023/A:1021301001208; Guzman RC, 1999, P NATL ACAD SCI USA, V96, P2520, DOI 10.1073/pnas.96.5.2520; HO TY, 1994, ELECTROPHORESIS, V15, P746, DOI 10.1002/elps.11501501102; Hoon DSB, 1996, INT J CANCER, V69, P369, DOI 10.1002/(SICI)1097-0215(19961021)69:5<369::AID-IJC3>3.0.CO;2-3; Hu Y. L., 1999, Breast J, V5, P186, DOI 10.1046/j.1524-4741.1999.98067.x; HUANG Y, 1999, MOL CARCINOG, V24, P8; Huynh H, 1998, INT J ONCOL, V13, P571; Jiang XS, 2002, INT J ONCOL, V20, P77; Jiang XS, 2002, INT J ONCOL, V20, P735; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; Lambe M, 1996, CANCER CAUSE CONTROL, V7, P533, DOI 10.1007/BF00051886; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Lei ZM, 2001, CANCER AND PREGNANCY, P209; Lei ZM., 2001, PRINCIPLES PRACTICE, P1096; Lojun S, 1997, BIOL REPROD, V57, P1202, DOI 10.1095/biolreprod57.5.1202; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; Manna SK, 2000, J BIOL CHEM, V275, P13307, DOI 10.1074/jbc.275.18.13307; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Meduri G, 2003, CANCER-AM CANCER SOC, V97, P1810, DOI 10.1002/cncr.11294; Meduri G, 1997, CANCER RES, V57, P857; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PLANCHON P, 1995, MOL CELL ENDOCRINOL, V111, P219, DOI 10.1016/0303-7207(95)03572-O; Pond-Tor S, 2002, BREAST CANCER RES TR, V72, P45, DOI 10.1023/A:1014964903540; Rao CV, 2000, OBSTET GYNECOL, V96, P783, DOI 10.1016/S0029-7844(00)00983-2; Rao CV, 2001, SEMIN REPROD MED, V19, P7, DOI 10.1055/s-2001-13906; RUSSO IH, 2002, J SOC GYNECOL INVE S, V9, pA245; Russo Irma H., 1993, P537; RUSSO J, 1995, J CELL BIOCHEM, P58; SHAFIE SM, 1981, J NATL CANCER I, V67, P51; Silva EG, 2002, BREAST CANCER RES TR, V76, P125, DOI 10.1023/A:1020528722842; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Srivastava P, 1997, CARCINOGENESIS, V18, P1799, DOI 10.1093/carcin/18.9.1799; Srivastava P, 1998, ANTICANCER RES, V18, P4003; Srivastava P, 1998, INT J ONCOL, V13, P465; Steel R.G., 1980, PRINCIPLES PROCEDURE, P481; Tanaka Y, 2000, ONCOLOGY-BASEL, V59, P19, DOI 10.1159/000055283; Tao YX, 1997, LIFE SCI, V60, P1297, DOI 10.1016/S0024-3205(97)00073-8; TRAPIDO EJ, 1983, CANCER, V51, P946, DOI 10.1002/1097-0142(19830301)51:5<946::AID-CNCR2820510530>3.0.CO;2-2; You SJ, 1998, CANCER RES, V58, P1498	55	47	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25503	25510		10.1074/jbc.M400683200	http://dx.doi.org/10.1074/jbc.M400683200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15044447	hybrid			2022-12-25	WOS:000221827900075
J	Toyoshima, Y; Karas, M; Yakar, S; Dupont, J; Helman, L; LeRoith, D				Toyoshima, Y; Karas, M; Yakar, S; Dupont, J; Helman, L; LeRoith, D			TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SIGNALING PATHWAYS; INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; BAD PHOSPHORYLATION; HEMATOPOIETIC-CELLS; INHIBITS APOPTOSIS; NIH-3T3 CELLS; GENE-PRODUCT; RECEPTOR; ACTIVATION	Insulin-like growth factor-I (IGF-I) receptors and insulin receptors belong to the same subfamily of receptor tyrosine kinases and share a similar set of intracellular signaling pathways, despite their distinct biological actions. In the present study, we evaluated T cell death-associated gene 51 (TDAG51), which we previously identified by cDNA microarray analysis as a gene specifically induced by IGF-I. We characterized the signaling pathways by which IGF-I induces TDAG51 gene expression and the functional role of TDAG51 in IGF-I signaling in NIH-3T3 (NWTb3) cells, which overexpress the human IGF-I receptor. Treatment with IGF-I increased TDAG51 mRNA and protein levels in NWTb3 cells. This effect of IGF-I was specifically mediated by the IGF-IR, because IGF-I did not induce TDAG51 expression in NIH-3T3 cells overexpressing a dominant-negative IGF-I receptor. Through the use of specific inhibitors of various protein kinases, we found that IGF-I induced TDAG51 expression via the p38 MAPK pathway. The ERK, JNK, and phosphatidylinositol 3-kinase pathways were not involved in IGF-I-induced regulation of TDAG51. To assess the role of TDAG51 in IGF-I signaling, we used small interfering RNA ( siRNA) expression vectors directed at two different target sites to reduce the level of TDAG51 protein. In cells expressing these siRNA vectors, TDAG51 protein levels were decreased by 75 - 80%. Furthermore, TDAG51 siRNA expression abolished the ability of IGF-I to rescue cells from serum starvation-induced apoptosis. These findings suggest that TDAG51 plays an important role in the anti-apoptotic effects of IGF-I.	NIDDK, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Bethesda, MD 20892 USA; NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LeRoith, D (corresponding author), NIDDK, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Rm 8D12,Bldg 10,MSC 1758, Bethesda, MD 20892 USA.	derek@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01SC006892, ZIASC006892] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMO M, 1992, BIOFACTORS, V3, P151; Allen RT, 1998, CELL MOL LIFE SCI, V54, P427, DOI 10.1007/s000180050171; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DAmbrosio C, 1997, CANCER RES, V57, P3264; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delaney CL, 1999, J NEUROBIOL, V41, P540, DOI 10.1002/(SICI)1097-4695(199912)41:4<540::AID-NEU9>3.0.CO;2-P; Dunn SE, 1997, CANCER RES, V57, P2687; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; Dupont J, 2001, J BIOL CHEM, V276, P26699, DOI 10.1074/jbc.M102664200; Gagnon A, 2001, ENDOCRINOLOGY, V142, P205, DOI 10.1210/en.142.1.205; Gomes I, 1999, J NEUROCHEM, V73, P612, DOI 10.1046/j.1471-4159.1999.0730612.x; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; Hinz T, 2001, CELL SIGNAL, V13, P345, DOI 10.1016/S0898-6568(01)00141-3; Hossain GS, 2003, J BIOL CHEM, V278, P30317, DOI 10.1074/jbc.M212897200; Hsing AY, 1996, CANCER RES, V56, P5146; Karas M, 1999, MOL BIOL CELL, V10, P4441, DOI 10.1091/mbc.10.12.4441; KATO H, 1993, J BIOL CHEM, V268, P2655; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LEVYTOLEDANO R, 1993, BIOCHIM BIOPHYS ACTA, V1220, P1, DOI 10.1016/0167-4889(93)90090-C; Li JY, 2003, TRENDS MOL MED, V9, P414, DOI 10.1016/j.molmed.2003.08.006; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; Mockridge JW, 2000, BIOCHEM BIOPH RES CO, V273, P322, DOI 10.1006/bbrc.2000.2934; Neef R, 2002, CANCER RES, V62, P5920; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Rho J, 2001, MOL CELL BIOL, V21, P8365, DOI 10.1128/MCB.21.24.8365-8370.2001; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SELL C, 1995, CANCER RES, V55, P303; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Thimmaiah KN, 2003, CANCER RES, V63, P364; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Worley BS, 2001, CANCER RES, V61, P6868; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; Wu YP, 2004, GROWTH HORM IGF RES, V14, P52, DOI 10.1016/j.ghir.2003.08.003; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	47	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25898	25904		10.1074/jbc.M400661200	http://dx.doi.org/10.1074/jbc.M400661200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15037619	Green Submitted, hybrid			2022-12-25	WOS:000221827900122
J	Brasseur, G; Lemesle-Meunier, D; Reinaud, F; Meunier, B				Brasseur, G; Lemesle-Meunier, D; Reinaud, F; Meunier, B			Q(O) site deficiency can be compensated by extragenic mutations in the hinge region of the iron-sulfur protein in the bc(1) complex of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME B(6)F COMPLEX; PROTONMOTIVE Q-CYCLE; TEMPERATURE-SENSITIVE MUTANTS; SCALE DOMAIN MOVEMENT; CATALYTIC CENTER-N; COB-BOX REGION; UBIQUINOL OXIDATION; ELECTRON-TRANSFER; RHODOBACTER-CAPSULATUS; RHODOPSEUDOMONAS-SPHAEROIDES	The mitochondrial bc(1) complex catalyzes the oxidation of ubiquinol and the reduction of cytochrome (cyt) c. The cyt b mutation A144F has been introduced in yeast by the biolistic method. This residue is located in the cyt b cd(1) amphipathic helix in the quinol-oxidizing (Q(o)) site. The resulting mutant was respiration-deficient and was affected in the quinol binding and electron transfer rates at the Q(o) site. An intragenic suppressor mutation was selected (A144F+F179L) that partially alleviated the defect of quinol oxidation of the original mutant A144F. The suppressor mutation F179L, located at less than 4 Angstrom from A144F, is likely to compensate directly the steric hindrance caused by phenylalanine at position 144. A second set of suppressor mutations was obtained, which also partially restored the quinol oxidation activity of the bc(1) complex. They were located about 20 Angstrom from A144F in the hinge region of the iron-sulfur protein (ISP) between residues 85 and 92. This flexible region is crucial for the movement of the ISP between cyt b and cyt c(1) during enzyme turnover. Our results suggested that the compensatory effect of the mutations in ISP was due to the repositioning of this subunit on cyt b during quinol oxidation. This genetic and biochemical study thus revealed the close interaction between the cyt b cd(1) helix in the quinol-oxidizing Q(o) site and the ISP via the flexible hinge region and that fine-tuning of the Q(o) site catalysis can be achieved by subtle changes in the linker domain of the ISP.	CNRS, Lab Bioenerget & Ingn Prot, F-13402 Marseille 20, France; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of London; University College London	Brasseur, G (corresponding author), CNRS, Lab Bioenerget & Ingn Prot, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	brasseur@ucl.ac.uk		Meunier, Brigitte/0000-0002-6988-4663				ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BECKMANN JD, 1989, J BIOL CHEM, V264, P3713; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; Brasseur G, 1997, BIOCHEMISTRY-US, V36, P11685, DOI 10.1021/bi970777d; BRASSEUR G, 1995, J BIOL CHEM, V270, P29356, DOI 10.1074/jbc.270.49.29356; BRASSEUR G, 1994, FEBS LETT, V354, P23, DOI 10.1016/0014-5793(94)01077-3; Brasseur G, 2001, BBA-BIOENERGETICS, V1506, P89, DOI 10.1016/S0005-2728(01)00186-4; BRUEL C, 1995, J BIOL CHEM, V270, P22321, DOI 10.1074/jbc.270.38.22321; Bruel C, 1996, J BIOENERG BIOMEMBR, V28, P59; Brugna M, 2000, P NATL ACAD SCI USA, V97, P2069, DOI 10.1073/pnas.030539897; CHEVILLOTTEBRIVET P, 1980, EUR J BIOCHEM, V111, P161; COPPEE JY, 1994, J BIOL CHEM, V269, P4221; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15791, DOI 10.1021/bi990961u; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; Darrouzet E, 2003, BIOCHEMISTRY-US, V42, P1499, DOI 10.1021/bi026656h; Darrouzet E, 2002, J BIOL CHEM, V277, P3471, DOI 10.1074/jbc.M107974200; Darrouzet E, 2000, BIOCHEMISTRY-US, V39, P15475, DOI 10.1021/bi000750l; Darrouzet E, 2001, TRENDS BIOCHEM SCI, V26, P445, DOI 10.1016/S0968-0004(01)01897-7; de Vitry C, 1999, PLANT CELL, V11, P2031, DOI 10.1105/tpc.11.10.2031; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DEGLIESPOSTI M, 1991, ARCH BIOCHEM BIOPHYS, V289, P303; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; Ding H, 1995, BIOCHEMISTRY-US, V34, P15997, DOI 10.1021/bi00049a013; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; DUJARDIN G, 1980, MOL GEN GENET, V179, P469, DOI 10.1007/BF00271736; Dutton P L, 1978, Methods Enzymol, V54, P411; Furbacher P. N., 1996, P221; Ghosh M, 2001, BIOCHEMISTRY-US, V40, P327, DOI 10.1021/bi001708t; Gisi U, 2002, PEST MANAG SCI, V58, P859, DOI 10.1002/ps.565; Gray KA, 1995, ANOXYGENIC PHOTOSYNT, P747; Guerin B, 1979, Methods Enzymol, V55, P149; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Junemann S, 1998, J BIOL CHEM, V273, P21603, DOI 10.1074/jbc.273.34.21603; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; KROGER A, 1973, EUR J BIOCHEM, V34, P358, DOI 10.1111/j.1432-1033.1973.tb02767.x; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; Lee TX, 2001, BBA-BIOENERGETICS, V1504, P235, DOI 10.1016/S0005-2728(00)00253-X; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MATSUURA K, 1983, J BIOL CHEM, V258, P1571; Meunier B, 2001, BIOCHEM J, V354, P407, DOI 10.1042/0264-6021:3540407; MEUNIER D, 1977, J THEOR BIOL, V64, P137, DOI 10.1016/0022-5193(77)90117-5; MEUNIERLEMESLE D, 1980, EUR J BIOCHEM, V111, P151; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; Obungu VH, 2000, BBA-BIOENERGETICS, V1457, P36, DOI 10.1016/S0005-2728(99)00116-4; OHNISHI T, 1972, FEBS LETT, V24, P305, DOI 10.1016/0014-5793(72)80378-8; Rudolph F B, 1979, Methods Enzymol, V63, P138; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yan JS, 2003, J BIOL CHEM, V278, P20925, DOI 10.1074/jbc.M212616200; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	69	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24203	24211		10.1074/jbc.M311576200	http://dx.doi.org/10.1074/jbc.M311576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15039445	hybrid			2022-12-25	WOS:000221702500044
J	Lee, SB; Varnai, P; Balla, A; Jalink, K; Rhee, SG; Balla, T				Lee, SB; Varnai, P; Balla, A; Jalink, K; Rhee, SG; Balla, T			The pleckstrin homology domain of phosphoinositide-specific phospholipase C delta(4) is not a critical determinant of the membrane localization of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DELTA 4; INOSITOL 1,4,5-TRISPHOSPHATE; HIGH-AFFINITY; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; BILAYER-MEMBRANES; PH DOMAINS; BINDING; KINASE; PLC; PROTEIN	The inositol lipid and phosphate binding properties and the cellular localization of phospholipase Cdelta(4) (PLCdelta(4)) and its isolated pleckstrin homology (PH) domain were analyzed in comparison with the similar features of the PLCdelta(1) protein. The isolated PH domains of both proteins showed plasma membrane localization when expressed in the form of a green fluorescent protein fusion construct in various cells, although a significantly lower proportion of the PLCdelta(4) PH domain was membrane-bound than in the case of PLCdelta(1)PH-GFP. Both PH domains selectively recognized phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2), but a lower binding of PLCdelta(4)PH to lipid vesicles containing PI(4,5)P-2 was observed. Also, higher concentrations of inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) were required to displace the PLCdelta(4)PH from the lipid vesicles, and a lower Ins(1,4,5)P-3 affinity of PLCdelta(4)PH was found in direct Ins(1,4,5)P-3 binding assays. In sharp contrast to the localization of its PH domain, the full-length PLCdelta(4) protein localized primarily to intracellular membranes mostly to the endoplasmic reticulum ( ER). This ER localization was in striking contrast to the well documented PH domain-dependent plasma membrane localization of PLCdelta(1). A truncated PLCdelta(4) protein lacking the entire PH domain still showed the same ER localization as the full-length protein, indicating that the PH domain is not a critical determinant of the localization of this protein. Most important, the full-length PLCdelta(4) enzyme still showed binding to PI(4,5)P-2-containing micelles, but Ins(1,4,5)P-3 was significantly less potent in displacing the enzyme from the lipid than with the PLCdelta(1) protein. These data suggest that although structurally related, PLCdelta(1) and PLCdelta(4) are probably differentially regulated in distinct cellular compartments by PI(4,5)P-2 and that the PH domain of PLCdelta(4) does not act as a localization signal.	NICHHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA; NHLI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Semmelweis Univ, Dept Physiol, Fac Med, H-1444 Budapest, Hungary; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Semmelweis University; Netherlands Cancer Institute	Balla, T (corresponding author), NICHHD, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A35,49 Convent Dr, Bethesda, MD 20892 USA.	tambal@box-t.nih.gov		Balla, Andras/0000-0002-6450-2793; Jalink, Kees/0000-0001-7019-3440; Balla, Tamas/0000-0002-9077-3335	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Dundr M, 2002, SCIENCE, V298, P1623, DOI 10.1126/science.1076164; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Fukami K, 2001, SCIENCE, V292, P920, DOI 10.1126/science.1059042; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Ghosh S, 1997, PROTEIN EXPRES PURIF, V9, P262, DOI 10.1006/prep.1996.0682; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; Kanematsu T, 2000, EUR J BIOCHEM, V267, P2731, DOI 10.1046/j.1432-1327.2000.01291.x; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Lee SB, 1996, J BIOL CHEM, V271, P25, DOI 10.1074/jbc.271.1.25; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Mao YX, 2001, CELL, V104, P433, DOI 10.1016/S0092-8674(01)00230-6; MELDRUM E, 1991, EUR J BIOCHEM, V196, P159, DOI 10.1111/j.1432-1033.1991.tb15799.x; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Philip F, 2002, FEBS LETT, V531, P28, DOI 10.1016/S0014-5793(02)03411-7; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Singh SM, 2003, PROTEIN SCI, V12, P1934, DOI 10.1110/ps.0358803; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Tabellini G, 2003, EXP CELL RES, V287, P143, DOI 10.1016/S0014-4827(03)00115-0; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Varnai P, 2002, J BIOL CHEM, V277, P27412, DOI 10.1074/jbc.M109672200; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417	42	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24362	24371		10.1074/jbc.M312772200	http://dx.doi.org/10.1074/jbc.M312772200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15037625	hybrid			2022-12-25	WOS:000221702500062
J	Schlattner, U; Gehring, F; Vernoux, N; Tokarska-Schlattner, M; Neumann, D; Marcillat, O; Vial, C; Wallimann, T				Schlattner, U; Gehring, F; Vernoux, N; Tokarska-Schlattner, M; Neumann, D; Marcillat, O; Vial, C; Wallimann, T			C-terminal lysines determine phospholipid interaction of sarcomeric mitochondrial creatine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION; MEMBRANE-BINDING; HEART-MITOCHONDRIA; LAURDAN FLUORESCENCE; ENERGY-METABOLISM; RESPIRATORY-CHAIN; CELL-DEATH; CARDIOLIPIN; ISOENZYMES; PROTEIN	High affinity interaction between octameric mitochondrial creatine kinase (MtCK) and the phospholipid cardiolipin in the inner mitochondrial membrane plays an important role in metabolite channeling between MtCK and inner membrane adenylate translocator, which itself is tightly bound to cardiolipin. Three C-terminal basic residues revealed as putative cardiolipin anchors in the x-ray structures of MtCK and corresponding to lysines in human sarcomeric MtCK (sMtCK) were exchanged by in vitro mutagenesis (K369A/E, K379Q/A/E, K380Q/A/E) to yield double and triple mutants. sMtCK proteins were bacterially expressed, purified to homogeneity, and verified for structural integrity by enzymatic activity, gel filtration chromatography, and CD spectroscopy. Interaction with cardiolipin and other acidic phospholipids was quantitatively analyzed by light scattering, surface plasmon resonance, and fluorescence spectroscopy. All mutant sMtCKs showed a strong decrease in vesicle cross-linking, membrane affinity, binding capacity, membrane ordering capability, and binding-induced changes in protein structure as compared with wild type. These effects did not depend on the nature of the replacing amino acid but on the number of exchanged lysines. They were moderate for Lys-379/Lys-380 double mutants but pronounced for triple mutants, with a 30-fold lower membrane affinity and an entire lack of alterations in protein structure compared with wild-type sMtCK. However, even triple mutants partially maintained an increased order of cardiolipin-containing membranes. Thus, the three C-terminal lysines determine high affinity sMtCK/cardiolipin interaction and its effects on MtCK structure, whereas low level binding and some effect on membrane fluidity depend on other structural components. These results are discussed in regard to MtCK microcompartments and evolution.	Swiss Fed Inst Technol, Inst Cell Biol, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland; Univ Lyon 1, UMR 5013, CNRS, F-69622 Villeurbanne, France	Swiss Federal Institutes of Technology Domain; ETH Zurich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Schlattner, U (corresponding author), Swiss Fed Inst Technol, Inst Cell Biol, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland.	uwe.schlattner@cell.biol.ethz.ch	Schlattner, Uwe/D-1267-2009; Wallimann, Theo/C-6047-2008	Schlattner, Uwe/0000-0003-1159-5911; Wallimann, Theo/0000-0003-4957-5836; Tokarska-Schlattner, Malgorzata/0000-0003-4401-7050; Neumann, Dietbert/0000-0002-4316-684X				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; BEYER K, 1985, BIOCHEMISTRY-US, V24, P3821, DOI 10.1021/bi00336a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brdiczka D, 1998, BIOFACTORS, V8, P235, DOI 10.1002/biof.5520080311; Chamberlin ME, 1997, J EXP BIOL, V200, P2789; CHENEVAL D, 1988, EUR J BIOCHEM, V171, P1, DOI 10.1111/j.1432-1033.1988.tb13750.x; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Dolder M, 2003, J BIOL CHEM, V278, P17760, DOI 10.1074/jbc.M208705200; Eder M, 2000, PROTEINS, V39, P216, DOI 10.1002/(SICI)1097-0134(20000515)39:3<216::AID-PROT40>3.0.CO;2-#; Ellington WR, 2001, ANNU REV PHYSIOL, V63, P289, DOI 10.1146/annurev.physiol.63.1.289; Ellington WR, 1998, FEBS LETT, V425, P75, DOI 10.1016/S0014-5793(98)00204-X; FritzWolf K, 1996, NATURE, V381, P341, DOI 10.1038/381341a0; Fyfe PK, 2004, BBA-BIOENERGETICS, V1608, P11, DOI 10.1016/j.bbabio.2003.09.014; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Granjon T, 2001, BIOCHEMISTRY-US, V40, P6016, DOI 10.1021/bi002293e; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Kabsch W, 1997, CURR OPIN STRUC BIOL, V7, P811, DOI 10.1016/S0959-440X(97)80151-0; Kay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937; Khuchua ZA, 1998, J BIOL CHEM, V273, P22990, DOI 10.1074/jbc.273.36.22990; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kornacker M, 2001, INT J CANCER, V94, P513, DOI 10.1002/ijc.1502; KUZNETSOV AV, 1986, BIOCHEM BIOPH RES CO, V134, P359, DOI 10.1016/0006-291X(86)90571-1; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Matthews RT, 1998, J NEUROSCI, V18, P156; McAuley KE, 1999, P NATL ACAD SCI USA, V96, P14706, DOI 10.1073/pnas.96.26.14706; MULLER M, 1985, J BIOL CHEM, V260, P3839; OGorman E, 1997, J CELL SCI, V110, P1403; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Pineda AO, 2001, GENE, V265, P115, DOI 10.1016/S0378-1119(01)00352-3; Pineda AO, 1999, EUR J BIOCHEM, V264, P67, DOI 10.1046/j.1432-1327.1999.00577.x; PRATT R, 1987, PATHOLOGY, V19, P162, DOI 10.3109/00313028709077128; ROJO M, 1991, FEBS LETT, V281, P123, DOI 10.1016/0014-5793(91)80374-C; ROJO M, 1991, J BIOL CHEM, V266, P20290; SAKS VA, 1985, J BIOL CHEM, V260, P7757; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Schlattner U, 2000, J BIOENERG BIOMEMBR, V32, P123, DOI 10.1023/A:1005576831968; Schlattner U, 1998, MOL CELL BIOCHEM, V184, P125, DOI 10.1023/A:1006851330913; Schlattner U, 2000, J BIOL CHEM, V275, P17314, DOI 10.1074/jbc.M001919200; Schlattner U, 2001, J BIOL CHEM, V276, P48027, DOI 10.1074/jbc.M106524200; Schlattner U, 2000, BIOL CHEM, V381, P1063, DOI 10.1515/BC.2000.131; SCHLATTNER U, 2004, IN PRESS ENCY BIOL C; SCHNYDER T, 1994, J STRUCT BIOL, V112, P136, DOI 10.1006/jsbi.1994.1015; Soboll S, 1999, J MOL CELL CARDIOL, V31, P857, DOI 10.1006/jmcc.1998.0925; Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694; Stachowiak O, 1998, MOL CELL BIOCHEM, V184, P141, DOI 10.1023/A:1006803431821; Stachowiak O, 1996, BIOCHEMISTRY-US, V35, P15522, DOI 10.1021/bi961838v; STADHOUDERS AM, 1994, P NATL ACAD SCI USA, V91, P5089, DOI 10.1073/pnas.91.11.5089; Tiivel T, 2000, MOL CELL BIOCHEM, V208, P119, DOI 10.1023/A:1007002323492; Tokarska-Schlattner M, 2002, MOL PHARMACOL, V61, P516, DOI 10.1124/mol.61.3.516; Vacheron MJ, 1997, ARCH BIOCHEM BIOPHYS, V344, P316, DOI 10.1006/abbi.1997.0181; Ventura-Clapier R, 1998, MOL CELL BIOCHEM, V184, P231, DOI 10.1023/A:1006840508139; Vyssokikh MY, 2003, ACTA BIOCHIM POL, V50, P389; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Walter MC, 2000, NEUROLOGY, V54, P1848, DOI 10.1212/WNL.54.9.1848; Wendt S, 2003, J BIOL CHEM, V278, P1125, DOI 10.1074/jbc.M208572200; WYSS M, 1995, BIOCHEM J, V309, P255, DOI 10.1042/bj3090255; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200	63	57	58	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24334	24342		10.1074/jbc.M314158200	http://dx.doi.org/10.1074/jbc.M314158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044463	hybrid			2022-12-25	WOS:000221702500059
J	Bolam, DN; Xie, HF; Pell, G; Hogg, D; Galbraith, G; Henrissat, B; Gilbert, HJ				Bolam, DN; Xie, HF; Pell, G; Hogg, D; Galbraith, G; Henrissat, B; Gilbert, HJ			X4 modules represent a new family of carbohydrate-binding modules that display novel properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENS SUBSP CELLULOSA; LIGAND-BINDING; PSEUDOMONAS XYLANASE; CALCIUM-BINDING; DOMAIN; RECOGNITION; FIMI; MECHANISM; CONTAINS; COMPLEX	The hydrolysis of the plant cell wall by microbial glycoside hydrolases and esterases is the primary mechanism by which stored organic carbon is utilized in the biosphere, and thus these enzymes are of considerable biological and industrial importance. Plant cell wall-degrading enzymes in general display a modular architecture comprising catalytic and non-catalytic modules. The X4 modules in glycoside hydrolases represent a large family of non-catalytic modules whose function is unknown. Here we show that the X4 modules from a Cellvibrio japonicus mannanase (Man5C) and arabinofuranosidase (Abf62A) bind to polysaccharides, and thus these proteins comprise a new family of carbohydrate-binding modules (CBMs), designated CBM35. The Man5C-CBM35 binds to galactomannan, insoluble amorphous mannan, glucomannan, and manno-oligosaccharides but does not interact with crystalline mannan, cellulose, cello-oligosaccharides, or other polysaccharides derived from the plant cell wall. Man5C-CBM35 also potentiates mannanase activity against insoluble amorphous mannan. Abf62A-CBM35 interacts with unsubstituted oat-spelt xylan but not substituted forms of the hemicellulose or xylo-oligosaccharides, and requires calcium for binding. This is in sharp contrast to other xylan-binding CBMs, which interact in a calcium-independent manner with both xylo-oligosaccharides and decorated xylans.	Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France	Newcastle University - UK; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Gilbert, HJ (corresponding author), Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Agr Bldg, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@Newcastle.ac.uk	Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588; Bolam, David/0000-0003-0314-3122				Abou-Hachem M, 2002, BIOCHEMISTRY-US, V41, P5720, DOI 10.1021/bi012094a; BLACK GW, 1995, BIOCHEM J, V307, P191, DOI 10.1042/bj3070191; Bolam DN, 2001, BIOCHEMISTRY-US, V40, P2468, DOI 10.1021/bi002564l; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2002, MOL MICROBIOL, V43, P187, DOI 10.1046/j.1365-2958.2002.02730.x; Boraston AB, 1999, ROY SOC CH, P202; Brett CT, 1996, PHYSL BIOCH PLANT CE; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; Coutinho PM, 1999, ROY SOC CH, P3; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; DIN N, 1994, P NATL ACAD SCI USA, V91, P11383, DOI 10.1073/pnas.91.24.11383; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; FERREIRA LMA, 1993, BIOCHEM J, V294, P349, DOI 10.1042/bj2940349; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; GLAUDEMANS CPJ, 1958, J AM CHEM SOC, V43, P941; Halstead JR, 2000, FEMS MICROBIOL LETT, V192, P197, DOI 10.1016/S0378-1097(00)00432-8; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; Johnson PE, 1998, BIOCHEMISTRY-US, V37, P12772, DOI 10.1021/bi980978x; JOSELEAU JP, 1992, PROGR BIOTECHNOL, V7, P1; KELLETT LE, 1990, BIOCHEM J, V272, P369, DOI 10.1042/bj2720369; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Linder M, 1996, J BIOL CHEM, V271, P21268, DOI 10.1074/jbc.271.35.21268; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; Notenboom V, 2001, BIOCHEMISTRY-US, V40, P6248, DOI 10.1021/bi0101704; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; TAKEO K, 1984, ELECTROPHORESIS, V5, P187, DOI 10.1002/elps.1150050402; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	36	64	65	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22953	22963		10.1074/jbc.M313317200	http://dx.doi.org/10.1074/jbc.M313317200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15004012	hybrid			2022-12-25	WOS:000221570900022
J	Finlay, GA; York, B; Karas, RH; Fanburg, BL; Zhang, HB; Kwiatkowski, DJ; Noonan, DJ				Finlay, GA; York, B; Karas, RH; Fanburg, BL; Zhang, HB; Kwiatkowski, DJ; Noonan, DJ			Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-beta and ERK-1/2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 GENE-PRODUCT; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; TSC2 GENE; IN-VITRO; ER ALPHA; ESTRADIOL; SCLEROSIS; KINASE; PROLIFERATION; TRANSCRIPTION	The mechanisms that regulate the diverse responses to estrogen (E-2) are unknown. Loss of function of the tuberous sclerosis 2 gene (TSC2), a tumor suppressor gene, has been associated with a growth-promoting effect of E-2. We hypothesized that tuberin, the protein product of TSC2, binds to estrogen receptors ( ER) and regulates the growth effect of E-2. An in vivo association between full-length tuberin and ERalpha was observed in HEK 293 cells and ELT-3 smooth muscle cells. In contrast, poor association was observed between tuberin and ERbeta. Complex formation with ERalpha and the C-terminal end of tuberin was also observed in vivo and in vitro, indicating that binding between ERalpha and tuberin occurs at the C-terminal end of the tuberin molecule. We examined the effect of tuberin expression in ELT-3 smooth muscle cells on the growth response to E-2. The growth-promoting effect of E-2 in tuberin-null ELT-3 smooth muscle cells was ERalpha-specific, associated with up-regulation and activation of platelet-derived growth factor receptor-beta (PDGFRbeta) and activation of the signaling intermediate, extracellular signal-regulated kinase-1/-2 (ERK-1/ 2). In contrast, the expression of tuberin in ELT-3 smooth muscle cells resulted in significant abrogation of E-2-stimulated growth. In parallel with this observation, the expression of tuberin in ELT-3 cells also resulted in significant inhibition of PDGFRbeta and ERK-1/ 2 activation in response to E-2. These results demonstrate that tuberin binds specifically to ERalpha and inhibits E-2-induced proliferation of ELT-3 cells. Furthermore, the opposing effects of tuberin on estrogen-induced activation of PDGFRbeta and ERK-1/-2 suggest a pivotal role for tuberin in directing the signaling events that dictate the growth response to E-2.	Tufts Univ New England Med Ctr, Tupper Res Inst, Dept Med, Div Pulm & Crit Care, Boston, MA 02111 USA; Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Tufts Univ New England Med Ctr, Tupper Res Inst, Dept Med, Mol Cardiol Res Inst, Boston, MA 02111 USA; Brigham & Womens Hosp, Longwood Med Res Inst, Boston, MA 02111 USA	Tufts Medical Center; University of Kentucky; Tufts Medical Center; Harvard University; Brigham & Women's Hospital	Finlay, GA (corresponding author), Tufts Univ New England Med Ctr, Pulm Crit Care & Sleep Div, NEMC 257,750 Washington St, Boston, MA 02111 USA.	gfinlay@tufts-nemc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067321, K08HL074113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031535, R01NS031535] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO8 HL74113-01, HL67321] Funding Source: Medline; NINDS NIH HHS [NS31535] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGER U, 1990, AM J CLIN PATHOL, V93, P609, DOI 10.1093/ajcp/93.5.609; Burroughs KD, 2000, BIOL REPROD, V63, P1322, DOI 10.1095/biolreprod63.5.1322; Catania MG, 2001, J NEUROPATH EXP NEUR, V60, P711, DOI 10.1093/jnen/60.7.711; Chen DB, 2004, ENDOCRINOLOGY, V145, P113, DOI 10.1210/en.2003-0547; Do DD, 1996, CARDIOVASC RES, V32, P980; Espinosa E, 1996, BIOCHEM BIOPH RES CO, V221, P8, DOI 10.1006/bbrc.1996.0535; FARHAT MY, 1992, BRIT J PHARMACOL, V107, P679, DOI 10.1111/j.1476-5381.1992.tb14506.x; Farnell YZ, 2003, J STEROID BIOCHEM, V84, P453, DOI 10.1016/S0960-0760(03)00066-9; Finlay GA, 2003, AM J PHYSIOL-CELL PH, V285, pC409, DOI 10.1152/ajpcell.00482.2002; FISCHERDZOGA K, 1983, EXP MOL PATHOL, V39, P355, DOI 10.1016/0014-4800(83)90064-3; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gee AC, 1999, MOL ENDOCRINOL, V13, P1912, DOI 10.1210/me.13.11.1912; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Govindarajan B, 2003, CLIN CANCER RES, V9, P3469; Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hart SM, 2002, BIOL RES, V35, P295, DOI 10.4067/S0716-97602002000200021; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; HOWE SR, 1995, ENDOCRINOLOGY, V136, P4996, DOI 10.1210/en.136.11.4996; HOWE SR, 1995, AM J PATHOL, V146, P1568; Huang HJ, 2002, MOL ENDOCRINOL, V16, P1778, DOI 10.1210/me.2002-0089; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Keyes LE, 1996, J CELL PHYSIOL, V166, P22, DOI 10.1002/(SICI)1097-4652(199601)166:1<22::AID-JCP3>3.0.CO;2-I; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kugoh H, 2002, MOL CARCINOGEN, V33, P131, DOI 10.1002/mc.10034; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; LIPPMAN M, 1976, CANCER RES, V36, P4595; Logginidou H, 2000, CHEST, V117, P25, DOI 10.1378/chest.117.1.25; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Mendelsohn ME, 2002, AM J CARDIOL, V90, p3F, DOI 10.1016/S0002-9149(02)02418-9; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Noonan DJ, 2002, ARCH BIOCHEM BIOPHYS, V398, P132, DOI 10.1006/abbi.2001.2682; OHORI NP, 1991, AM J CLIN PATHOL, V96, P529; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Prifti S, 2003, GYNECOL ENDOCRINOL, V17, P423, DOI 10.1080/09513590312331290338; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Strizheva GD, 2001, AM J RESP CRIT CARE, V163, P253, DOI 10.1164/ajrccm.163.1.2005004; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Treeck O, 2003, EUR J CANCER, V39, P1302, DOI 10.1016/S0959-8049(02)00777-3; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; VARGAS R, 1993, BRIT J PHARMACOL, V109, P612, DOI 10.1111/j.1476-5381.1993.tb13616.x; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Zeng M, 2001, BIOTECHNIQUES, V31, P260, DOI 10.2144/01312bm04; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	59	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23114	23122		10.1074/jbc.M401912200	http://dx.doi.org/10.1074/jbc.M401912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039427	hybrid			2022-12-25	WOS:000221570900041
J	Vranka, JA; Sakai, LY; Bachinger, HP				Vranka, JA; Sakai, LY; Bachinger, HP			Prolyl 3-hydroxylase 1, enzyme characterization and identification of a novel family of enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; MEMBRANE-ASSOCIATED PROTEOGLYCAN; HUMAN PROLYL 4-HYDROXYLASE; HYPOXIA-INDUCIBLE FACTOR; COVALENT STRUCTURE; MOLECULAR-CLONING; BETA-SUBUNIT; COLLAGEN; PURIFICATION; 3-HYDROXYLASE	The collagen prolyl hydroxylases are enzymes that are required for proper collagen biosynthesis, folding, and assembly. They reside within the endoplasmic reticulum and belong to the group of 2-oxoglutarate and iron-dependent dioxygenases. Although prolyl 4-hydroxylase has been characterized as an alpha(2)beta(2) tetramer in which protein disulfide isomerase is the beta subunit with two different alpha subunit isoforms, little is known about the enzyme prolyl 3-hydroxylase (P3H). It was initially characterized and shown to have an enzymatic activity distinct from that of prolyl 4-hydroxylase, but no amino acid sequences or genes were ever reported for the mammalian enzyme. Here we report the characterization of a novel prolyl 3-hydroxylase enzyme isolated from embryonic chicks. The primary structure of the enzyme, which we now call P3H1, demonstrates that P3H1 is a member of a family of prolyl 3-hydroxylases, which share the conserved residues present in the active site of prolyl 4-hydroxylase and lysyl hydroxylase. P3H1 is the chick homologue of mammalian leprecan or growth suppressor 1. Two other P3H family members are the genes previously called MLAT4 and GRCB. In this study we demonstrate prolyl 3-hydroxylase activity of the purified enzyme P3H1 on a full-length procollagen substrate. We also show it to specifically interact with denatured collagen and to exist in a tight complex with other endoplasmic reticulum-resident proteins. Immunohistochemistry with a monoclonal antibody specific for chick P3H1 localizes P3H1 specifically to tissues that express fibrillar collagens, suggesting that other P3H family members may be responsible for modifying basement membrane collagens.	Shriners Hosp Children, Res Dept, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Bachinger, HP (corresponding author), Shriners Hosp Children, Res Dept, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	hpb@shcc.org						ARAVIND L, 2001, GENOME BIOL, V2; BERG RA, 1973, BIOCHEMISTRY-US, V12, P3395, DOI 10.1021/bi00742a005; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; COLIGAN JE, 1996, CURRENT PROTOCOLS PR, V1; Dann CE, 2002, P NATL ACAD SCI USA, V99, P15351, DOI 10.1073/pnas.202614999; DEHM P, 1972, BIOCHIM BIOPHYS ACTA, V264, P375, DOI 10.1016/0304-4165(72)90302-9; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fietzek P P, 1976, Int Rev Connect Tissue Res, V7, P1; FIETZEK PP, 1972, EUR J BIOCHEM, V30, P163, DOI 10.1111/j.1432-1033.1972.tb02083.x; GAILL F, 1995, J MOL BIOL, V246, P284, DOI 10.1006/jmbi.1994.0084; GRYDER RM, 1975, J BIOL CHEM, V250, P2470; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jenkins CL, 2003, J AM CHEM SOC, V125, P6422, DOI 10.1021/ja034015j; Kaul SC, 2000, ONCOGENE, V19, P3576, DOI 10.1038/sj.onc.1203696; Kefalides N A, 1973, Int Rev Connect Tissue Res, V6, P63; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Mizuno K, 2004, J BIOL CHEM, V279, P282, DOI 10.1074/jbc.M308181200; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; REXRODT FW, 1973, EUR J BIOCHEM, V38, P384, DOI 10.1111/j.1432-1033.1973.tb03071.x; RHODES RK, 1978, BIOCHEMISTRY-US, V17, P3442, DOI 10.1021/bi00610a003; RISTELI J, 1978, ANAL BIOCHEM, V84, P423, DOI 10.1016/0003-2697(78)90060-X; RISTELI J, 1977, EUR J BIOCHEM, V73, P485, DOI 10.1111/j.1432-1033.1977.tb11341.x; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; TRYGGVASON K, 1979, BIOCHEM J, V183, P303, DOI 10.1042/bj1830303; TRYGGVASON K, 1977, BIOCHEM BIOPH RES CO, V76, P275, DOI 10.1016/0006-291X(77)90722-7; Wassnehove-McCarthy DJ, 1999, J BIOL CHEM, V274, P25004, DOI 10.1074/jbc.274.35.25004; Zeng BF, 1998, BIOCHEM J, V330, P109, DOI 10.1042/bj3300109	39	138	146	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23615	23621		10.1074/jbc.M312807200	http://dx.doi.org/10.1074/jbc.M312807200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044469	hybrid			2022-12-25	WOS:000221570900102
J	Wigelsworth, DJ; Krantz, BA; Christensen, KA; Lacy, DB; Juris, SJ; Collier, RJ				Wigelsworth, DJ; Krantz, BA; Christensen, KA; Lacy, DB; Juris, SJ; Collier, RJ			Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN CR3 CD11B/CD18; I-DOMAIN; LETHAL FACTOR; EDEMA FACTOR; CELLULAR RECEPTOR; DEPENDENT PROCESS; CRYSTAL-STRUCTURE; A-DOMAIN; MACROPHAGES; MUTATIONS	The protective antigen (PA) moiety of anthrax toxin binds to cellular receptors and mediates entry of the two enzymatic moieties of the toxin into the cytosol. Two PA receptors, anthrax toxin receptor (ATR)/tumor endothelial marker 8 (TEM8) and capillary morphogenesis protein 2 (CMG2), have been identified. We expressed and purified the von Willebrand A (VWA) domain of CMG2 and examined its interactions with monomeric and heptameric forms of PA. Monomeric PA bound a stoichiometric equivalent of CMG2, whereas the heptameric prepore form bound 7 eq. The K-d of the VWA domain-PA interaction is 170 pM when liganded by Mg2+, reflecting a 1000-fold tighter interaction than most VWA domains with their endogenous ligands. The dissociation rate constant is extremely slow, indicating a 30-h lifetime for the CMG2.PA monomer complex. CMG2 metal ion-dependent adhesion site (MIDAS) was studied kinetically and thermodynamically. The association rate constant (similar to10(5) M-1 s(-1)) is virtually identical in the presence or absence of Mg2+ or Ca2+, but the dissociation rate of metal ion liganded complex is up to 4 orders of magnitude slower than metal ion free complex. Residual affinity (K(d)similar to960 nM) in the absence of divalent metal ions allowed the free energy for the contribution of the metal ion to be calculated as 5 kcal mol(-1), demonstrating that the metal ion-dependent adhesion site is directly coordinated by CMG2 and PA in the binding interface. The high affinity of the VWA domain for PA supports its potency in neutralizing anthrax toxin, demonstrating its potential utility as a novel therapeutic for anthrax.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Collier, RJ (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	john_collier@hms.harvard.edu	Lacy, D. Borden/AFQ-2203-2022; Christensen, Kenneth/S-1670-2019; Christensen, Kenneth/A-3235-2009	Christensen, Kenneth/0000-0002-3736-5500; Lacy, Borden/0000-0003-2273-8121; Krantz, Bryan/0000-0002-4911-5824; Collier, R John/0000-0002-2427-4239	NIAID NIH HHS [F32 AI062204, F32 AI062204-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI062204] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; BARNARD A, 1995, CURRENT PROTOCOLS PR, V5, P1; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Bradley KA, 2003, J BIOL CHEM, V278, P49342, DOI 10.1074/jbc.M307900200; Croney JC, 2003, FEBS LETT, V550, P175, DOI 10.1016/S0014-5793(03)00870-6; Cunningham K, 2002, P NATL ACAD SCI USA, V99, P7049, DOI 10.1073/pnas.062160399; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Liddington R, 1998, STRUCT FOLD DES, V6, P937, DOI 10.1016/S0969-2126(98)00094-X; Lupher ML, 2001, J IMMUNOL, V167, P1431, DOI 10.4049/jimmunol.167.3.1431; McCleverty CJ, 2003, BIOCHEM J, V372, P121, DOI 10.1042/BJ20021273; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Mourez M, 2003, P NATL ACAD SCI USA, V100, P13803, DOI 10.1073/pnas.2436299100; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; Rosovitz MJ, 2003, J BIOL CHEM, V278, P30936, DOI 10.1074/jbc.M301154200; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259	29	134	139	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23349	23356		10.1074/jbc.M401292200	http://dx.doi.org/10.1074/jbc.M401292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044490	hybrid			2022-12-25	WOS:000221570900070
J	Hislop, JN; Marley, A; von Zastrow, M				Hislop, JN; Marley, A; von Zastrow, M			Role of mammalian vacuolar protein-sorting proteins in endocytic trafficking of a non-ubiquitinated G protein-coupled receptor to lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; ENDOSOMAL TRAFFICKING; ENDOPLASMIC-RETICULUM; HRS; COMPLEX; ATPASE; TSG101; DESENSITIZATION; MACHINERY; ARRESTINS	Many signaling receptors require covalent modification by ubiquitin for agonist-induced down-regulation via endocytic trafficking to lysosomes, a process that is mediated by a conserved set of endosome-associating proteins also required for vacuolar protein-sorting (VPS) in yeast. The delta opioid receptor (DOR) is a G protein-coupled receptor that can undergo agonist-induced proteolysis via endocytic trafficking to lysosomes but does not require covalent modification by ubiquitin to do so. This raises the question of whether lysosomal down-regulation of this "ubiquitination-independent" GPCR is mediated by a completely distinct biochemical mechanism or if similar VPS machinery is involved. Agonist-induced proteolysis of DOR was significantly inhibited by dominant negative mutant versions of Vps4/Skd1, an AAA-family ATPase required for a late step in lysosomal sorting of ubiquitinated membrane cargo. Furthermore, overexpression and interfering RNA-mediated knockdown indicated that lysosomal trafficking of opioid receptors is also dependent on Hrs, a VPS protein that mediates an early step in lysosomal sorting of ubiquitinated cargo. However, interfering RNA-mediated knockdown of Tsg101, a VPS protein that is essential for an intermediate step of the conserved lysosomal sorting mechanism, did not detectably affect agonist-induced proteolysis of DOR in the same cells in which ( ubiquitination-dependent) lysosomal trafficking of epidermal growth factor receptors was clearly inhibited. These results indicate that opioid receptors, despite their ability to undergo efficient agonist-induced trafficking to lysosomes in the absence of covalent modification by ubiquitin, utilize some (Vps4 and Hrs) but perhaps not all ( Tsg101) of the VPS machinery required for lysosomal sorting of ubiquitinated membrane cargo.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hislop, JN (corresponding author), Univ Calif San Francisco, Dept Psychiat, N-216 Genentech Hall,600 16th St, San Francisco, CA 94143 USA.	jhislop@itsa.ucsf.edu			NIDA NIH HHS [R01 DA010711, R01 DA012864] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010711, R01DA012864] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bean AJ, 2000, J BIOL CHEM, V275, P15271, DOI 10.1074/jbc.275.20.15271; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Goodman O B Jr, 1998, Adv Pharmacol, V42, P429; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Raiborg C, 2002, CELL STRUCT FUNCT, V27, P403, DOI 10.1247/csf.27.403; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Raiborg C, 2001, BIOCHEM SOC T, V29, P472, DOI 10.1042/BST0290472; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shukla A, 2001, AM J PHYSIOL-RENAL, V281, pF546, DOI 10.1152/ajprenal.2001.281.3.F546; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Strous GJ, 1999, J CELL SCI, V112, P1417; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; Tanzi GO, 2003, J VIROL, V77, P8440, DOI 10.1128/JVI.77.15.8440-8447.2003; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	55	101	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22522	22531		10.1074/jbc.M311062200	http://dx.doi.org/10.1074/jbc.M311062200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15024011	hybrid			2022-12-25	WOS:000221417100103
J	Kelly, JM; Waterhouse, NJ; Cretney, E; Browne, KA; Ellis, S; Trapani, JA; Smyth, MJ				Kelly, JM; Waterhouse, NJ; Cretney, E; Browne, KA; Ellis, S; Trapani, JA; Smyth, MJ			Granzyme M mediates a novel form of perforin-dependent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE SERINE PROTEASES; CYTOTOXIC LYMPHOCYTES; CASPASE ACTIVATION; DNA FRAGMENTATION; INDUCE APOPTOSIS; IN-VIVO; MET-ASE; PURIFICATION; EXPRESSION; PATHWAY	Cell death is mediated by cytotoxic lymphocytes through various granule serine proteases released with perforin. The unique protease activity, restricted expression, and distinct gene locus of granzyme M suggested this enzyme might have a novel biological function or trigger a novel form of cell death. Herein, we demonstrate that in the presence of perforin, the protease activity of granzyme M rapidly and effectively induces target cell death. In contrast to granzyme B, cell death induced by granzyme M does not feature obvious DNA fragmentation, occurs independently of caspases, caspase activation, and perturbation of mitochondria and is not inhibited by overexpression of Bcl-2. These data raise the likelihood that granzyme M represents a third major and specialized perforin-dependent cell death pathway that plays a significant role in death mediated by NK cells.	Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 8006, Australia	Peter Maccallum Cancer Center	Smyth, MJ (corresponding author), Peter MacCallum Canc Ctr, Canc Immunol Program, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	m.smyth@pmci.unimelb.edu.au	Waterhouse, Nigel/I-9813-2016; Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240; Ellis, Sarah/0000-0002-5772-6051; Trapani, Joseph/0000-0003-0983-1532				BAKER E, 1994, IMMUNOGENETICS, V40, P235, DOI 10.1007/BF00167085; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Beresford PJ, 1999, IMMUNITY, V10, P585, DOI 10.1016/S1074-7613(00)80058-8; Browne KA, 1999, MOL CELL BIOL, V19, P8604; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Davis JE, 2000, CELL DEATH DIFFER, V7, P973, DOI 10.1038/sj.cdd.4400725; Davis JE, 2001, EUR J IMMUNOL, V31, P39, DOI 10.1002/1521-4141(200101)31:1<39::AID-IMMU39>3.0.CO;2-1; Edwards HM, 1999, J BIOL CHEM, V274, P30468, DOI 10.1074/jbc.274.43.30468; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Fujiki K, 2002, IMMUNOGENETICS, V54, P604, DOI 10.1007/s00251-002-0506-0; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Jans DA, 1999, J BIOL CHEM, V274, P3953, DOI 10.1074/jbc.274.7.3953; Johnson H, 2003, BLOOD, V101, P3093, DOI 10.1182/blood-2002-08-2485; Kelly JM, 1996, IMMUNOGENETICS, V44, P340, DOI 10.1007/BF02602778; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; LIU CC, 1994, BIOCHEM BIOPH RES CO, V201, P318, DOI 10.1006/bbrc.1994.1704; NAKAJIMA H, 1995, J EXP MED, V181, P1037, DOI 10.1084/jem.181.3.1037; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Pardo J, 2001, J IMMUNOL, V167, P1222, DOI 10.4049/jimmunol.167.3.1222; PEITSCH MC, 1994, METHOD ENZYMOL, V244, P80; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; PILAT D, 1994, GENOMICS, V24, P445, DOI 10.1006/geno.1994.1651; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Ruefli AA, 2000, BLOOD, V95, P2378, DOI 10.1182/blood.V95.7.2378.007k10_2378_2385; Rukamp BJ, 2004, ARCH BIOCHEM BIOPHYS, V422, P9, DOI 10.1016/j.abb.2003.12.005; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; Shresta S, 1999, IMMUNITY, V10, P595, DOI 10.1016/S1074-7613(00)80059-X; SHRESTA S, 1995, IMMUNOL REV, V146, P211, DOI 10.1111/j.1600-065X.1995.tb00690.x; SIMON MM, 1994, METHOD ENZYMOL, V244, P68; Smyth MJ, 1998, J VIROL, V72, P1; Smyth MJ, 1996, J LEUKOCYTE BIOL, V60, P555, DOI 10.1002/jlb.60.5.555; Smyth MJ, 2003, J IMMUNOL, V171, P515, DOI 10.4049/jimmunol.171.2.515; SMYTH MJ, 1992, J BIOL CHEM, V267, P24418; SMYTH MJ, 1993, J IMMUNOL, V151, P6195; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; Sun JR, 1999, BIOCHEM BIOPH RES CO, V261, P251, DOI 10.1006/bbrc.1999.0989; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Sutton VR, 1997, J IMMUNOL, V158, P5783; Trapani JA, 2000, CURR OPIN IMMUNOL, V12, P323, DOI 10.1016/S0952-7915(00)00094-7; Trapani JA, 1998, CELL DEATH DIFFER, V5, P488, DOI 10.1038/sj.cdd.4400373; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Vujanovic N L, 2001, Int Rev Immunol, V20, P415, DOI 10.3109/08830180109054415; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Waterhouse NJ, 2002, TISSUE ANTIGENS, V59, P175, DOI 10.1034/j.1399-0039.2002.590301.x; Woodard SL, 1998, J IMMUNOL, V160, P4988; Zhang D, 2001, P NATL ACAD SCI USA, V98, P5746, DOI 10.1073/pnas.101329598	57	106	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22236	22242		10.1074/jbc.M401670200	http://dx.doi.org/10.1074/jbc.M401670200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15028722	hybrid			2022-12-25	WOS:000221417100070
J	Neely, A; Garcia-Olivares, J; Voswinkel, S; Horstkott, H; Hidalgo, P				Neely, A; Garcia-Olivares, J; Voswinkel, S; Horstkott, H; Hidalgo, P			Folding of active calcium channel beta(1b)-subunit by size-exclusion chromatography and its role on channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; CA2+ CHANNELS; ALPHA(1C) SUBUNIT; SKELETAL-MUSCLE; AMINO-TERMINUS; INACTIVATION; MODULATION; EXPRESSION; ACTIVATION; DELETIONS	Voltage- gated calcium channels mediate the influx of Ca2+ ions into eukaryotic cells in response to membrane depolarization. They are hetero- multimer membrane proteins formed by at least three subunits, the pore forming alpha(1)-subunit and the auxiliary beta- and alpha(2)delta- subunits. The beta- subunit is essential for channel performance because it regulates two distinct features of voltage- gated calcium channels, the surface expression and the channel activity. Four beta- subunit genes have been cloned, beta(1-4), with molecular masses ranging from 52 to 78 kDa, and several splice variants have been identified. The beta(1b)- subunit, expressed at high levels in mammalian brain, has been used extensively to study the interaction between the pore forming alpha(1)- and the regulatory beta- subunit. However, structural characterization has been impaired for its tendency to form aggregates when expressed in bacteria. We applied an on- column refolding procedure based on size exclusion chromatography to fold the beta(1b)- subunit of the voltage gated- calcium channels from Escherichia coli inclusion bodies. The beta(1b)- subunit refolds into monomers, as shown by sucrose gradient analysis, and binds to a glutathione S- transferase protein fused to the known target in the alpha(1)- subunit (the alpha- interaction domain). Using the cut-open oocyte voltage clamp technique, we measured gating and ionic currents in Xenopus oocytes expressing cardiac alpha(1)- subunit (alpha(1C)) co-injected with folded- beta(1b)- protein or beta(1b)- cRNA. We demonstrate that the co- expression of the alpha(1C)- subunit with either folded- beta(1b)- protein or beta(1b)- cRNA increases ionic currents to a similar extent and with no changes in charge movement, indicating that the beta(1b)- subunit primarily modulates channel activity, rather than expression.	Rhein Westfal TH Aachen, Inst Physiol, D-52074 Aachen, Germany; Univ Valparaiso, Ctr Neurociencia Valparaiso, Valparaiso 2349400, Chile; Ctr Estudios Cient, Valdivia 509000, Chile	RWTH Aachen University; Universidad de Valparaiso	Hidalgo, P (corresponding author), Rhein Westfal TH Aachen, Inst Physiol, Pauwelsstr 30, D-52074 Aachen, Germany.	patty@physiology.rwth-aachen.de	Neely, Alan/A-8715-2009; Hidalgo, Patricia/I-7506-2013	Hidalgo, Patricia/0000-0002-4162-6590; Neely, Alan/0000-0002-6007-2159				Batas B, 1999, J BIOTECHNOL, V68, P149, DOI 10.1016/S0168-1656(98)00197-7; Batas B, 1999, J CHROMATOGR A, V864, P229, DOI 10.1016/S0021-9673(99)01030-4; Batas D, 1996, BIOTECHNOL BIOENG, V50, P16; Bezanilla F, 1998, METHOD ENZYMOL, V293, P331; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Dzhura I, 2003, BIOPHYS J, V85, P274, DOI 10.1016/S0006-3495(03)74473-7; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Garcia R, 2002, J PHYSIOL-LONDON, V545, P407, DOI 10.1113/jphysiol.2002.027433; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; Jones SW, 2002, J PHYSIOL-LONDON, V545, P334, DOI 10.1113/jphysiol.2002.033001; Khan RH, 1998, BIOTECHNOL PROGR, V14, P722, DOI 10.1021/bp980071q; LEMAIRE M, 1989, ANAL BIOCHEM, V177, P50, DOI 10.1016/0003-2697(89)90012-2; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; Noceti F, 1996, J GEN PHYSIOL, V108, P143, DOI 10.1085/jgp.108.3.143; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; WEI XY, 1994, J BIOL CHEM, V269, P1635; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348	26	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21689	21694		10.1074/jbc.M312675200	http://dx.doi.org/10.1074/jbc.M312675200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016803	hybrid			2022-12-25	WOS:000221417100002
J	Okeley, NM; Gelb, MH				Okeley, NM; Gelb, MH			A designed probe for acidic phospholipids reveals the unique enriched anionic character of the cytosolic face of the mammalian plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C2 DOMAIN; K-RAS; ELECTROSTATIC INTERACTION; NUCLEAR-ENVELOPE; BINDING DOMAIN; HIGH-AFFINITY; A(2); PROTEIN; CELLS; TRANSLOCATION	It is generally accepted that the cytosolic face of the plasma membrane of mammalian cells is enriched in acidic phospholipids due to an asymmetric distribution of neutral and anionic phospholipids in the two bilayer leaflets. However, the phospholipid asymmetry across intracellular membranes is not known. Two models have been proposed for the selective targeting of K- Ras4B, which contains a C- terminal farnesyl cysteine methyl ester adjacent to a polybasic peptide segment, to the cytosolic face of the plasma membrane. One involves electrostatic interaction of the lipidated polybasic domain with anionic phospholipids in the plasma membrane, and the other involves binding of K- Ras4B to a specific protein receptor. To address this issue, we prepared by semi- synthesis a green fluorescent protein variant that is linked to a farnesylated, polybasic peptide corresponding to the K- Ras4B C terminus as well as a variant that contains an all- D amino acid version of the K- Ras4B peptide. As expected based on electrostatics, both constructs showed preferential in vitro binding to anionic phospholipid vesicles versus those composed only of zwitterionic phospholipid. Both constructs fully targeted to the plasma membrane when microinjected into live Chinese hamster ovary and Madin- Darby canine kidney cells. Because the all- D amino acid peptide should be devoid of binding affinity to a putative highly specific K- Ras membrane receptor, these results support an electrostatic basis for the targeting of K- Ras4B to the plasma membrane, and they support an intracellular landscape of phospholipids in which the cytosolic face of the plasma membrane is the most enriched in acidic phospholipids.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.	gelb@chem.washington.edu		gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL50040, HL71405] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bruckheimer EM, 1996, J LEUKOCYTE BIOL, V59, P784, DOI 10.1002/jlb.59.6.784; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Chiang CF, 2001, ARCH BIOCHEM BIOPHYS, V394, P229, DOI 10.1006/abbi.2001.2537; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Diaz C, 1996, J MEMBRANE BIOL, V151, P1, DOI 10.1007/s002329900051; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ETEMADI AH, 1980, BIOCHIM BIOPHYS ACTA, V604, P423; Gerber SH, 2001, J BIOL CHEM, V276, P32288, DOI 10.1074/jbc.C100108200; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; GLOUSHANKOVA NA, 1994, P NATL ACAD SCI USA, V91, P8597, DOI 10.1073/pnas.91.18.8597; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Hofemeister H, 2000, MOL BIOL CELL, V11, P3233, DOI 10.1091/mbc.11.9.3233; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; Jansen B, 1999, P NATL ACAD SCI USA, V96, P14019, DOI 10.1073/pnas.96.24.14019; JOHNSON BH, 1994, BIO-TECHNOL, V12, P1357, DOI 10.1038/nbt1294-1357; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Leventis R, 1998, BIOCHEMISTRY-US, V37, P7640, DOI 10.1021/bi973077h; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; PLETJUSHKINA OJ, 1994, EXP CELL RES, V212, P201, DOI 10.1006/excr.1994.1135; Pomorski T, 2001, SEMIN CELL DEV BIOL, V12, P139, DOI 10.1006/scdb.2000.0231; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874; XUE CB, 1992, TETRAHEDRON LETT, V33, P1435, DOI 10.1016/S0040-4039(00)91640-X; Yakhnin AV, 1998, PROTEIN EXPRES PURIF, V14, P382, DOI 10.1006/prep.1998.0981; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	52	38	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21833	21840		10.1074/jbc.M313469200	http://dx.doi.org/10.1074/jbc.M313469200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007075	hybrid			2022-12-25	WOS:000221417100021
J	Qi, XM; Tang, J; Pramanik, R; Schultz, RM; Shirasawa, S; Sasazuki, T; Han, JH; Chen, G				Qi, XM; Tang, J; Pramanik, R; Schultz, RM; Shirasawa, S; Sasazuki, T; Han, JH; Chen, G			P38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PROTEIN-KINASE ACTIVATION; C-JUN; ONCOGENIC RAS; INCREASING COMPLEXITY; GROWTH-INHIBITION; CARCINOMA CELLS; MAMMALIAN-CELLS; AP-1 ACTIVITY; TUMOR-GROWTH	ras is the most characterized oncogene in human cancer, and yet there are no effective therapeutics to selectively target this oncogene. Our previous work demonstrated the inhibitory activity of the p38 pathway in Ras proliferative signaling in experimental NIH 3T3 cells (Chen, G., Hitomi, M., Han, J., and Stacey, D. W. (2000) J. Biol. Chem. 275, 38973-38980). Here we explore the therapeutic potential of p38 kinase activation in human colon cancer cells with and without endogenous K-ras activation. p38 activation by both adenovirus-mediated gene delivery of constitutively active p38 activator MKK6 and by arsenite selectively induces cell death in K-ras-activated human colon cancer HCT116 cells but not in the K-ras-disrupted HCT116-derived sublines. The cell death-inducing effect of MKK6 is not because of its selective activation of p38 kinase or its downstream transcription factor substrates, ATF-2 or c-Jun, in K-ras-activated cells. Rather, cell death in K-ras-activated cells is linked to the down-regulation of vitamin D receptor (VDR) by an AP-1-dependent mechanism. Forced VDR expression in K-ras-activated cells inhibits p38 activation-induced cell death, and inhibition of endogenous VDR protein expression in K-ras-disrupted cells increased the arsenite-induced toxicity. Analysis of an additional two human colon cancer cell lines with and without K-ras mutation also showed a K-ras- and VDR-dependent toxicity of MKK6. Hence, p38 pathway activation selectively induces cell death in K-ras- mutated human colon cancer cells by mechanisms involving the suppression of VDR activity.	Loyola Univ, Dept Radiat Oncol, Maywood, IL 60153 USA; Loyola Univ, Program Mol & Cellular Biochem, Maywood, IL 60153 USA; Loyola Univ, Program Mol Biol, Maywood, IL 60153 USA; Loyola Univ, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA; Int Med Ctr Japan, Res Inst, Shinjuku Ku, Tokyo 1628655, Japan; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; National Center for Global Health & Medicine - Japan; Scripps Research Institute	Chen, G (corresponding author), Loyola Univ, Dept Radiat Oncol, 114B Bldg 1,B303 Hines,2160 S 1st Ave, Maywood, IL 60153 USA.	gchen1@lumc.edu	Han, J/G-4671-2010		NATIONAL CANCER INSTITUTE [R01CA091576] Funding Source: NIH RePORTER; NCI NIH HHS [CA91576] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; ALROY I, 1995, MOL CELL BIOL, V15, P5789; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Baba I, 2000, CANCER RES, V60, P6886; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chang MY, 1999, EXP CELL RES, V248, P589, DOI 10.1006/excr.1999.4436; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GALANG CK, 1994, ONCOGENE, V9, P2913; GARLAND CF, 1989, LANCET, V2, P1176, DOI 10.1016/s0140-6736(89)91789-3; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Gupta S, 2000, MOL CELL BIOL, V20, P9294, DOI 10.1128/MCB.20.24.9294-9306.2000; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hayakawa J, 2003, J BIOL CHEM, V278, P20582, DOI 10.1074/jbc.M210992200; Hewison M, 1996, J IMMUNOL, V156, P4391; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jehan F, 1997, P NATL ACAD SCI USA, V94, P10138, DOI 10.1073/pnas.94.19.10138; Jin CY, 2002, MOL CELL BIOL, V22, P4815, DOI 10.1128/MCB.22.13.4815-4826.2002; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kim MS, 2003, CANCER RES, V63, P5454; Kitamura S, 2001, INT J CANCER, V94, P335, DOI 10.1002/ijc.1470; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; Koller E, 2000, TRENDS PHARMACOL SCI, V21, P142, DOI 10.1016/S0165-6147(00)01448-6; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; Ohmori M, 1997, CANCER RES, V57, P4714; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Okumura K, 1999, CANCER RES, V59, P2445; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Qi XM, 2004, J BIOL CHEM, V279, P6769, DOI 10.1074/jbc.M311492200; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Schilli MB, 1998, J INVEST DERMATOL, V111, P598, DOI 10.1046/j.1523-1747.1998.00350.x; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SHABAHANG M, 1993, CANCER RES, V53, P3712; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; STUMPF WE, 1979, SCIENCE, V206, P1188, DOI 10.1126/science.505004; Tang J, 2003, J VIROL, V77, P5975, DOI 10.1128/JVI.77.10.5975-5984.2003; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	75	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22138	22144		10.1074/jbc.M313964200	http://dx.doi.org/10.1074/jbc.M313964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15037631	hybrid			2022-12-25	WOS:000221417100057
J	Shaner, L; Trott, A; Goeckeler, JL; Brodsky, JL; Morano, KA				Shaner, L; Trott, A; Goeckeler, JL; Brodsky, JL; Morano, KA			The function of the yeast molecular chaperone Sse1 is mechanistically distinct from the closely related Hsp70 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; ATP HYDROLYTIC ACTIVITY; ENDOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGE; SUBSTRATE-BINDING; SACCHAROMYCES-CEREVISIAE; PEPTIDE COMPLEXES; STRUCTURAL BASIS; ACTIVE-SITE; HSP110	The Sse1/Hsp110 molecular chaperones are a poorly understood subgroup of the Hsp70 chaperone family. Hsp70 can refold denatured polypeptides via a C-terminal peptide binding domain (PBD), which is regulated by nucleotide cycling in an N-terminal ATPase domain. However, unlike Hsp70, both Sse1 and mammalian Hsp110 bind unfolded peptide substrates but cannot refold them. To test the in vivo requirement for interdomain communication, SSE1 alleles carrying amino acid substitutions in the ATPase domain were assayed for their ability to complement sse1Delta yeast. Surprisingly, all mutants predicted to abolish ATP hydrolysis (D8N, K69Q, D174N, D203N) complemented the temperature sensitivity of sse1Delta and lethality of sse1Deltasse2Delta cells, whereas mutations in predicted ATP binding residues (G205D, G233D) were non-functional. Complementation ability correlated well with ATP binding assessed in vitro. The extreme C terminus of the Hsp70 family is required for substrate targeting and heterocomplex formation with other chaperones, but mutant Sse1 proteins with a truncation of up to 44 C-terminal residues that were not included in the PBD were active. Remarkably, the two domains of Sse1, when expressed in trans, functionally complement the sse1Delta growth phenotype and interact by coimmunoprecipitation analysis. In addition, a functional PBD was required to stabilize the Sse1 ATPase domain, and stabilization also occurred in trans. These data represent the first structure-function analysis of this abundant but ill defined chaperone, and establish several novel aspects of Sse1/Hsp110 function relative to Hsp70.	Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	University of Texas System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Morano, KA (corresponding author), Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA.	kevin.a.morano@uth.tmc.edu	Gimenez, Luis E Diaz/D-9291-2011	Goeckeler-Fried, Jennifer/0000-0001-5940-9917; Morano, Kevin/0000-0002-5992-0253	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK060835] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-60835] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiyar A, 1996, Methods Mol Biol, V57, P177; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Chou CC, 2003, J BIOL CHEM, V278, P30311, DOI 10.1074/jbc.M304563200; CRAIG EA, 1994, COLD SPRING HARBOR M, V26, P31; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; Craven RA, 1997, TRENDS CELL BIOL, V7, P277, DOI 10.1016/S0962-8924(97)01079-9; Davis JE, 1999, P NATL ACAD SCI USA, V96, P9269, DOI 10.1073/pnas.96.16.9269; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; Easton DP, 2000, CELL STRESS CHAPERON, V5, P276, DOI 10.1379/1466-1268(2000)005<0276:THAGSP>2.0.CO;2; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Goeckeler JL, 2002, MOL BIOL CELL, V13, P2760, DOI 10.1091/mbc.02-04-0051; Han WJ, 2003, BIOCHEM J, V369, P627, DOI 10.1042/BJ20020943; Ishihara K, 2003, J BIOL CHEM, V278, P25143, DOI 10.1074/jbc.M302975200; Kaiser C., 1994, METHODS YEAST GENETI; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; McClellan AJ, 2000, GENETICS, V156, P501; McClellan AJ, 1998, MOL BIOL CELL, V9, P3533, DOI 10.1091/mbc.9.12.3533; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Moro F, 2003, FEBS LETT, V533, P119, DOI 10.1016/S0014-5793(02)03752-3; MUKAI H, 1993, GENE, V132, P57; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Oh HJ, 1999, J BIOL CHEM, V274, P15712, DOI 10.1074/jbc.274.22.15712; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; Santoro N, 1998, MOL CELL BIOL, V18, P6340, DOI 10.1128/MCB.18.11.6340; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHIRAYAMA M, 1993, MOL GEN GENET, V240, P323, DOI 10.1007/BF00280382; Sousa MC, 1998, BIOCHEMISTRY-US, V37, P15392, DOI 10.1021/bi981510x; Wang XY, 2000, FEBS LETT, V465, P98, DOI 10.1016/S0014-5793(99)01733-0; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	38	71	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21992	22001		10.1074/jbc.M313739200	http://dx.doi.org/10.1074/jbc.M313739200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15028727	hybrid			2022-12-25	WOS:000221417100040
J	Fernandez, FJ; Vega, MC; Lehmann, F; Sandmeier, E; Gehring, H; Christen, P; Wilmanns, M				Fernandez, FJ; Vega, MC; Lehmann, F; Sandmeier, E; Gehring, H; Christen, P; Wilmanns, M			Structural studies of the catalytic reaction pathway of a hyperthermophilic histidinol-phosphate aminotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; DECARBOXYLASE COBD ENZYME; THERMUS-THERMOPHILUS HB8; ESCHERICHIA-COLI; THERMOTOGA-MARITIMA; ASPARTATE-AMINOTRANSFERASE; SALMONELLA-ENTERICA; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; PROTEIN STRUCTURES	In histidine biosynthesis, histidinol-phosphate aminotransferase catalyzes the transfer of the amino group from glutamate to imidazole acetol-phosphate producing 2-oxoglutarate and histidinol phosphate. In some organisms such as the hyperthermophile Thermotoga maritima, specific tyrosine and aromatic amino acid transaminases have not been identified to date, suggesting an additional role for histidinol-phosphate aminotransferase in other transamination reactions generating aromatic amino acids. To gain insight into the specific function of this transaminase, we have determined its crystal structure in the absence of any ligand except phosphate, in the presence of covalently bound pyridoxal 5'-phosphate, of the coenzyme histidinol phosphate adduct, and of pyridoxamine 5'-phosphate. The enzyme accepts histidinol phosphate, tyrosine, tryptophan, and phenylalanine, but not histidine, as substrates. The structures provide a model of how these different substrates could be accommodated by histidinol-phosphate aminotransferase. Some of the structural features of the enzyme are more preserved between the T. maritima enzyme and a related threonine-phosphate decarboxylase from S. typhimurium than with histidinol-phosphate aminotransferases from different organisms.	DESY, EMBL, D-22603 Hamburg, Germany; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Zurich	Wilmanns, M (corresponding author), DESY, EMBL, Notkestr 85,Bldg 25A, D-22603 Hamburg, Germany.	wilmanns@embl-hamburg.de	Vega, M. Cristina/C-3640-2011; Fernandez, Francisco J./C-3647-2011	Vega, M. Cristina/0000-0003-0628-8378; Wilmanns, Matthias/0000-0002-4643-5435; Fernandez, Francisco J./0000-0002-5015-1849				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Banfield MJ, 2001, ACTA CRYSTALLOGR D, V57, P1518, DOI 10.1107/S0907444901012604; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; BRAUNSTEIN AE, 1964, VITAM HORM, V22, P451, DOI 10.1016/S0083-6729(08)60348-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; Cheong CG, 2002, BIOCHEMISTRY-US, V41, P4798, DOI 10.1021/bi012111w; Cheong CG, 2002, BIOCHEMISTRY-US, V41, P9079, DOI 10.1021/bi020294w; Cho Y, 2003, J BIOL CHEM, V278, P8333, DOI 10.1074/jbc.M212124200; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Douangamath A, 2002, STRUCTURE, V10, P185, DOI 10.1016/S0969-2126(02)00702-5; Haruyama K, 2001, BIOCHEMISTRY-US, V40, P4633, DOI 10.1021/bi002769u; HAYASHI H, 1993, BIOCHEMISTRY-US, V32, P12229, DOI 10.1021/bi00096a036; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Jaenicke R, 1996, ADV PROTEIN CHEM, V48, P181; Jaenicke R, 2001, METHOD ENZYMOL, V334, P438; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; MALASHKEVICH VN, 1995, NAT STRUCT BIOL, V2, P548, DOI 10.1038/nsb0795-548; Matsui I, 2000, J BIOL CHEM, V275, P4871, DOI 10.1074/jbc.275.7.4871; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McClelland M, 2000, NUCLEIC ACIDS RES, V28, P4974, DOI 10.1093/nar/28.24.4974; METHA PK, 2000, ADV ENZYMOL RELAT AR, V74, P129; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; NESTER EW, 1976, J BACTERIOL, V126, P699, DOI 10.1128/JB.126.2.699-705.1976; NOVOGRODSKY A, 1963, J BIOL CHEM, V238, P1903; Okamoto A, 1996, J BIOCHEM-TOKYO, V119, P135; Omi R, 2002, J BIOCHEM, V132, P759, DOI 10.1093/oxfordjournals.jbchem.a003284; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oue S, 1997, J BIOCHEM-TOKYO, V121, P161; POWELL JT, 1978, EUR J BIOCHEM, V87, P391, DOI 10.1111/j.1432-1033.1978.tb12388.x; POWELL JT, 1978, J BACTERIOL, V136, P1; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SCHIRCH L, 1975, J BIOL CHEM, V250, P1939; Sivaraman J, 2001, J MOL BIOL, V311, P761, DOI 10.1006/jmbi.2001.4882; Sterner R, 2001, CRIT REV BIOCHEM MOL, V36, P39, DOI 10.1080/20014091074174; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; WEIGENT DA, 1976, J BIOL CHEM, V251, P6974; Westhead DR, 1999, PROTEIN SCI, V8, P897	48	13	19	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21478	21488		10.1074/jbc.M400291200	http://dx.doi.org/10.1074/jbc.M400291200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15007066	Green Published, hybrid			2022-12-25	WOS:000221273800113
J	Filippova, N; Wotring, VE; Weiss, DS				Filippova, N; Wotring, VE; Weiss, DS			Evidence that the TM1-TM2 loop contributes to the rho 1 GABA receptor pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; SINGLE-CHANNEL CONDUCTANCE; MEMBRANE-SPANNING SEGMENT; CONSERVED M2 LEUCINE; GATED ION CHANNELS; GLYCINE RECEPTOR; NONCOMPETITIVE ANTAGONIST; CYSTEINE-SUBSTITUTION; FUNCTIONAL EXPRESSION; LINING RESIDUES	Considerable evidence indicates the second transmembrane domain (TM2) of the gamma-aminobutyric acid (GABA) receptor lines the integral ion pore. To further delineate the structures that constitute the ion pore and selectivity filter of the rho1 GABA receptor, we used the substituted cysteine accessibility method with charged reagents to identify anion- and cation-accessible surfaces. Twenty-one consecutive residues were mutated to cysteine, one at a time, in the presumed intracellular end of the first transmembrane domain (TM1; Ala(271)-Met(276)), the entire linker connecting TM1 to TM2 (Leu(277)- Arg(287)), and the presumed intracellular end of TM2 (Ala(288)-Ala(291)). Positively (MTSEA(+)) and negatively (pCMBS(-)) charged sulfhydryl reagents, as well as Cd2+, were added extracellularly to test accessibility of the engineered cysteines. Four of the mutants, all at the intracellular end of TM2 (R287C, V289C, P290C, A291C), were accessible to positively charged reagents, whereas seven mutants (A271C, T272C, L277C, W279C, V280C, P290C, A291C) were functionally modified by negatively charged pCMBS(-). These seven modified residues were at the intracellular end of TM2, in the TM1-TM2 linker, and at the intracellular end of TM1. In nearly all cases ( excluding P290C), the rate and the degree of modification were state-dependent, with greater accessibility in the presence of agonist. Select cysteine mutants were combined with a point mutation (A291E) that converted the pore from chloride- to non-selective. In this case, positively charged reagents could modify residues in the TM1-TM2 linker (Leu(277) and Val(280)), supporting the notion that the modifying reagents were reaching their target through the pore. Taken together, our results suggest that, up to its intracellular end, the TM2 domain is not charge selective. In addition, we propose that the TM1-TM2 linker and the intracellular end of TM1 are along the pathway of the permeating ion. These findings may lend new insights into the structure of the GABA receptor pore.	Univ Alabama, Sch Med, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Weiss, DS (corresponding author), Univ Alabama, Sch Med, Dept Neurobiol, 1719 6th Ave So CIRC410, Birmingham, AL 35294 USA.	dweiss@nrc.uab.edu		Filippova, Natalia/0000-0003-2128-5511; Wotring, Virginia/0000-0002-3391-3899				AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMIN J, 1994, MOL PHARMACOL, V45, P317; AMIN J, 1994, RECEPTOR CHANNEL, V2, P227; Bertaccini E, 2002, PROTEIN ENG, V15, P443, DOI 10.1093/protein/15.6.443; Chang YC, 1999, BIOPHYS J, V77, P2542, DOI 10.1016/S0006-3495(99)77089-X; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KAMMANN M, 1989, NUCLEIC ACIDS RES, V12, P4445; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; Keramidas A, 2002, J GEN PHYSIOL, V119, P393, DOI 10.1085/jgp.20028552; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; Leite JF, 2002, BIOCHEMISTRY-US, V41, P6140, DOI 10.1021/bi015895m; Leite JF, 2001, MOL CELL NEUROSCI, V17, P777, DOI 10.1006/mcne.2001.0984; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WHITE BH, 1991, J BIOL CHEM, V266, P21595; WHITE BH, 1992, J BIOL CHEM, V267, P15770; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Wotring VE, 2003, J PHYSIOL-LONDON, V548, P527, DOI 10.1113/jphysiol.2002.032045; Wotring VE, 1999, J PHYSIOL-LONDON, V521, P327, DOI 10.1111/j.1469-7793.1999.00327.x; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195	38	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20906	20914		10.1074/jbc.M401012200	http://dx.doi.org/10.1074/jbc.M401012200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15007065	hybrid			2022-12-25	WOS:000221273800043
J	Heung, LJ; Luberto, C; Plowden, A; Hannun, YA; Del Poeta, M				Heung, LJ; Luberto, C; Plowden, A; Hannun, YA; Del Poeta, M			The sphingolipid pathway regulates Pkc1 through the formation of diacylglycerol in Cryptococcus neoformans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; YEAST SACCHAROMYCES-CEREVISIAE; NF-KAPPA-B; HUMAN MELANOGENESIS; DIGLYCERIDE KINASE; MOUSE FIBROBLASTS; PLASMA-MEMBRANE; SPHINGOMYELIN; CERAMIDE	The sphingolipid biosynthetic pathway generates bioactive molecules crucial to the regulation of mammalian and fungal physiological and pathobiological processes. In previous studies (Luberto, C., Toffaletti, D. L., Wills, E. A., Tucker, S. C., Casadevall, A., Perfect, J. R., Hannun, Y. A., and Del Poeta, M. (2001) Genes Dev. 15, 201-212), we demonstrated that an enzyme of the fungal sphingolipid pathway, Ipc1 (inositol-phosphorylceramide synthase-1), regulates melanin, a pigment required for the pathogenic fungus Cryptococcus neoformans to cause disease. In this study, we investigated the mechanism by which Ipc1 regulates melanin production. Because Ipc1 also catalyzes the production of diacylglycerol (DAG), a physiological activator of the classical and novel isoforms of mammalian protein kinase C (PKC), and because it has been suggested that PKC is required for melanogenesis in mammalian cells, we investigated whether Ipc1 regulates melanin in C. neoformans through the production of DAG and the subsequent activation of Pkc1, the fungal homolog of mammalian PKC. The results show that modulation of Ipc1 regulates the levels of DAG in C. neoformans cells. Next, we demonstrated that C. neoformans Pkc1 is a DAG-activated serine/threonine kinase and that the C1 domain of Pkc1 is necessary for this activation. Finally, through both pharmacological and genetic approaches, we found that inhibition of Pkc1 abolishes melanin formation in C. neoformans. This study identifies a novel signaling pathway in which C. neoformans Ipc1 plays a key role in the activation of Pkc1 through the formation of DAG. Importantly, this pathway is essential for melanin production with implications for the pathogenicity of C. neoformans.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Del Poeta, M (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,BSB 503, Charleston, SC 29425 USA.	delpoeta@musc.edu	Heung, Lena/AAH-5866-2021	Heung, Lena/0000-0002-6655-575X	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056168, R21AI051924] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 17677] Funding Source: Medline; NHLBI NIH HHS [HL 43707] Funding Source: Medline; NIAID NIH HHS [AI 51924, AI 56168] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alspaugh JA, 2002, EUKARYOT CELL, V1, P75, DOI 10.1128/EC.1.1.75-84.2002; Alspaugh JA, 1997, GENE DEV, V11, P3206, DOI 10.1101/gad.11.23.3206; ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; BERNERT JT, 1981, BIOCHIM BIOPHYS ACTA, V666, P99, DOI 10.1016/0005-2760(81)90095-3; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Casadevall A, 1998, CRYPTOCOCCUS NEOFORM; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; D'Souza CA, 2001, MOL CELL BIOL, V21, P3179, DOI 10.1128/MCB.21.9.3179-3191.2001; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Franzot SP, 1999, BIOCHEM J, V340, P25, DOI 10.1042/0264-6021:3400025; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; Gorlach JM, 2002, MICROBIOL-SGM, V148, P213, DOI 10.1099/00221287-148-1-213; HANNUN YA, 1985, J BIOL CHEM, V260, P39; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; HATCH GM, 1992, J BIOL CHEM, V267, P12443; HUBBARD SR, 1991, SCIENCE, V254, P1776; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jacoby JJ, 1997, FEBS LETT, V417, P219, DOI 10.1016/S0014-5793(97)01287-8; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KWONCHUNG KJ, 1982, J BACTERIOL, V150, P1414, DOI 10.1128/JB.150.3.1414-1421.1982; KWONCHUNG KJ, 1992, MED MYCOL, P821; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Luberto C, 2003, J CLIN INVEST, V112, P1080, DOI 10.1172/JCI200318309; Luberto C, 2001, GENE DEV, V15, P201, DOI 10.1101/gad.856001; Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760; MARGGRAF WD, 1982, BIOCHIM BIOPHYS ACTA, V710, P314, DOI 10.1016/0005-2760(82)90114-X; MARGGRAF WD, 1981, BIOCHIM BIOPHYS ACTA, V664, P61, DOI 10.1016/0005-2760(81)90028-X; Marini NJ, 1996, EMBO J, V15, P3040, DOI 10.1002/j.1460-2075.1996.tb00667.x; McDade HC, 2001, MED MYCOL, V39, P151, DOI 10.1080/714030997; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Nosanchuk JD, 1999, MOL CELL BIOL, V19, P745; Obeid LA, 2002, BBA-MOL CELL BIOL L, V1585, P163, DOI 10.1016/S1388-1981(02)00337-2; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; Paravicini G, 1996, YEAST, V12, P741, DOI 10.1002/(SICI)1097-0061(19960630)12:8<741::AID-YEA967>3.0.CO;2-G; PARK HY, 1993, J BIOL CHEM, V268, P11742; Park HY, 1999, J BIOL CHEM, V274, P16470, DOI 10.1074/jbc.274.23.16470; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; Perry DK, 2000, METHOD ENZYMOL, V312, P22; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; Salas SD, 1996, J EXP MED, V184, P377, DOI 10.1084/jem.184.2.377; Schmitz HP, 2003, CURR GENET, V43, P245, DOI 10.1007/s00294-003-0403-6; Schmitz HP, 2002, MOL MICROBIOL, V44, P829, DOI 10.1046/j.1365-2958.2002.02925.x; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; Signorelli P, 2001, FASEB J, V15, P2401, DOI 10.1096/fj.01-0244com; SIMON AJ, 1991, P ROY SOC B-BIOL SCI, V243, P165, DOI 10.1098/rspb.1991.0027; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOFFALETTI DL, 1993, J BACTERIOL, V175, P1405, DOI 10.1128/JB.175.5.1405-1411.1993; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tsegaye Y, 2002, PLATELETS, V13, P31, DOI 10.1080/09537100120111531; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WILLIAMSON PR, 1994, J BACTERIOL, V176, P656, DOI 10.1128/jb.176.3.656-664.1994; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zhang SR, 1999, GENE, V227, P231, DOI 10.1016/S0378-1119(98)00590-3	62	75	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21144	21153		10.1074/jbc.M312995200	http://dx.doi.org/10.1074/jbc.M312995200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15014071	hybrid			2022-12-25	WOS:000221273800072
J	Kou, HP; Pugh, BF				Kou, HP; Pugh, BF			Engineering dimer-stabilizing mutations in the TATA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; GENE-EXPRESSION; TERMINAL DOMAIN; MINOR-GROOVE; DNA-BINDING; TBP; TRANSCRIPTION; DIMERIZATION	The TATA-binding protein (TBP) plays a central role in assembling eukaryotic transcription complexes and is subjected to extensive regulation including auto-inhibition of its DNA binding activity through dimerization. Previously, we have shown that mutations that disrupt TBP dimers in vitro have three detectable phenotypes in vivo, including decreased steady-state levels of the mutants, transcriptional derepression, and toxicity toward cell growth. In an effort to more precisely define the multimeric structure of TBP in vivo, the crystallographic dimer structure was used to design mutations that might enhance dimer stability. These mutations were found to enhance dimer stability in vitro and significantly suppress in vivo phenotypes arising from a dimer-destabilizing mutation. Although it is conceivable that phenotypes associated with dimer-destabilizing mutants could arise through defective interactions with other cellular factors, intragenic suppression of these phenotypes by mutations designed to stabilize dimers provides compelling evidence for a crystallographic dimer configuration in vivo.	Penn State Univ, Dept Biochem & Mol Biol, N Frear Lab 452, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Pugh, BF (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, N Frear Lab 452, University Pk, PA 16802 USA.	bfp2@psu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059055] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059055, GM 059055] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blair WS, 1997, MOL CELL BIOL, V17, P2888, DOI 10.1128/MCB.17.5.2888; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2633, DOI 10.1021/bi9922998; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; Chitikila C, 2002, MOL CELL, V10, P871, DOI 10.1016/S1097-2765(02)00683-4; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; Coleman RA, 1999, MOL CELL, V4, P451, DOI 10.1016/S1097-2765(00)80453-0; Darst RP, 2003, J BIOL CHEM, V278, P13216, DOI 10.1074/jbc.M211445200; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; ICARDLIEPKALNS C, 1993, BIOCHEM BIOPH RES CO, V193, P453, DOI 10.1006/bbrc.1993.1645; Jackson-Fisher AJ, 1999, BIOCHEMISTRY-US, V38, P11340, DOI 10.1021/bi990911p; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; KATO K, 1994, NUCLEIC ACIDS RES, V22, P1179, DOI 10.1093/nar/22.7.1179; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kou HP, 2003, MOL CELL BIOL, V23, P3186, DOI 10.1128/MCB.23.9.3186-3201.2003; Lee M, 2001, GENETICS, V158, P87; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331	28	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20966	20973		10.1074/jbc.M401535200	http://dx.doi.org/10.1074/jbc.M401535200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15020592	hybrid			2022-12-25	WOS:000221273800051
J	Narizhneva, NV; Byers-Ward, VJ; Quinn, MJ; Zidar, FJ; Plow, EF; Topol, EJ; Byzova, TV				Narizhneva, NV; Byers-Ward, VJ; Quinn, MJ; Zidar, FJ; Plow, EF; Topol, EJ; Byzova, TV			Molecular and functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated with the risk of premature, familial myocardial infarction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN E-DEFICIENT; HUMAN-PLATELETS; RECEPTOR; EXPRESSION; FIBRINOGEN; INHIBITION; THROMBIN; BINDING; GENE; GLYCOPROTEIN	A serine (Ser-700) amino acid rather than an asparagine (Asn-700) at residue 700 of thrombospondin-1 has been linked to an increased risk for development of premature, familial heart attacks. We now have identified both functional and structural differences between the Ser-700 and Asn-700 thrombospondin-1 variants. The Ser-700 variant increased the rate and extent of platelet aggregation and showed increased surface expression on platelets compared with the Asn-700 variant. These differences could be ascribed to an enhanced interaction of the Ser-700 variant with fibrinogen on the platelet surface and are consistent with a prothrombotic phenotype in Ser-700 individuals. The Ser-700 variant thrombospondin-1 was conformationally more labile than the Asn-700 variant as demonstrated by increased susceptibility to proteolytic digestion and enhanced susceptibility to unfolding by denaturants. These data suggest a potential molecular and cellular basis for a genetic risk factor associated with early onset myocardial infarction.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Topol, EJ (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	topole@ccf.org		Byzova, Tatiana/0000-0002-2615-875X; Topol, Eric/0000-0002-1478-4729	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071625] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071625, HL 071625] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JC, 1997, INT J BIOCHEM CELL B, V29, P861, DOI 10.1016/S1357-2725(96)00171-9; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Adler A J, 1973, Methods Enzymol, V27, P675; AIKEN ML, 1987, BLOOD, V69, P58; AIKEN ML, 1987, SEMIN THROMB HEMOST, V13, P307, DOI 10.1055/s-2007-1003506; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; Boekholdt SM, 2002, ARTERIOSCL THROM VAS, V22, pE24, DOI 10.1161/01.ATV.0000046235.22451.66; Bonnefoy A, 2001, J BIOL CHEM, V276, P5605, DOI 10.1074/jbc.M010091200; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Calara F, 2001, J PATHOL, V195, P257, DOI 10.1002/path.915; CASTELLINO FJ, 1993, METHOD ENZYMOL, V223, P168; Chen H, 1996, BIOCHEM J, V318, P959, DOI 10.1042/bj3180959; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; HAGEN I, 1975, BIOCHIM BIOPHYS ACTA, V392, P242, DOI 10.1016/0304-4165(75)90006-9; Hang LW, 2003, J CLIN LAB ANAL, V17, P57, DOI 10.1002/jcla.10068; Hannah BLA, 2003, J BIOL CHEM, V278, P8929, DOI 10.1074/jbc.M211185200; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; LAWLER J, 1985, J BIOL CHEM, V260, P3762; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; LAWLER JW, 1977, THROMB HAEMOSTASIS, V37, P355; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; LEGRAND C, 1992, BLOOD, V79, P1995; LEGRAND C, 1994, ARTERIOSCLER THROMB, V14, P1784, DOI 10.1161/01.ATV.14.11.1784; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; MOSHER DF, 1990, ANNU REV MED, V41, P85; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Peyvandi F, 2003, BLOOD, V102, p801A; PLOW EF, 1982, P NATL ACAD SCI-BIOL, V79, P3711, DOI 10.1073/pnas.79.12.3711; Riessen R, 1998, AM HEART J, V135, P357, DOI 10.1016/S0002-8703(98)70105-X; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; Takeoka S, 2001, J HUM GENET, V46, P57, DOI 10.1007/s100380170109; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; WOLFF R, 1986, J BIOL CHEM, V261, P6840; YAMADA Y, 2004, NEW ENGL J MED, V347, P1916	49	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21651	21657		10.1074/jbc.M311090200	http://dx.doi.org/10.1074/jbc.M311090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15007078	hybrid, Green Accepted			2022-12-25	WOS:000221273800132
J	Parker, G; Taylor, R; Jones, D; McClain, D				Parker, G; Taylor, R; Jones, D; McClain, D			Hyperglycemia and inhibition of glycogen synthase in streptozotocin-treated mice - Role of O-linked N-acetylglucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXOSAMINE BIOSYNTHESIS PATHWAY; INDUCED INSULIN-RESISTANCE; NITRIC-OXIDE SYNTHASE; HUMAN SKELETAL-MUSCLE; IN-VIVO; ADIPOSE-TISSUE; NUCLEOCYTOPLASMIC PROTEINS; PHOSPHORYLATION SITES; GLUCOSE DISPOSAL; DOWN-REGULATION	Glycogen synthase is post-translationally modified by both phosphate and O-linked N-acetylglucosamine (O-GlcNAc). In 3T3-L1 adipocytes exposed to high concentrations of glucose, O-GlcNAc contributes to insulin resistance of glycogen synthase. We sought to determine whether O-GlcNAc also regulates glycogen synthase in vivo. Glycogen synthase activity in fat pad extracts was inhibited in streptozotocin (STZ)-treated diabetic mice. The half-maximal activation concentration for glucose 6-phosphate (A(0.5)) was increased to 830+/-120 muM compared with 240+/-20 muM in control mice (C, p<0.01), while the basal glycogen synthase activity (%I-form) was decreased to 2.4 +/- 1.4% compared with 10.1 +/- 1.8% in controls (p<0.01). Glycogen synthase activity remained inhibited after compensatory insulin treatment. After insulin treatment kinetic parameters of glycogen synthase were more closely correlated with blood glucose (A(0.5), r(2)=0.70; %I-form, r(2)=0.59) than insulin levels (A(0.5), r(2)=0.04; %I-form, r(2)=0.09). Hyperglycemia also resulted in an increase in the level of O-GlcNAc on glycogen synthase (16.1+/-1.8 compared with 7.0+/-0.9 arbitrary intensity units for controls, p<0.01), even though the level of phosphorylation was identical in diabetic and control mice either with (STZ: 2.9 +/- 1.0 and C: 3.2 +/- 0.8) or without (STZ: 12.2 +/- 2.8 and C: 13.8 +/- 3.0 arbitrary intensity units) insulin treatment. In all mice the percent activation of glycogen synthase that could be achieved in vitro by recombinant protein phosphatase 1 (230 +/- 30%) was significantly greater in the presence of beta-D-N-acetylglucosaminidase (410 +/- 60%, p<0.01). This synergistic stimulation of glycogen synthase due to co-digestion by protein phosphatase 1 and beta-D-N-acetylglucosaminidase was more pronounced in STZ-diabetic mice (310+/-70%) compared with control mice (100+/-10%, p<0.05). The findings demonstrate that O-GlcNAc has a role in the regulation of glycogen synthase both in normoglycemia and diabetes.	Univ Utah, Div Endocrinol, Sch Med, Salt Lake City, UT 84132 USA; Vet Affairs Med Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)	McClain, D (corresponding author), Univ Utah, Div Endocrinol, Sch Med, 30 N,2030 E, Salt Lake City, UT 84132 USA.	donald.mcclain@hsc.utah.edu		McClain, Don/0000-0002-3310-2359	NIDDK NIH HHS [R01 DK 43526] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043526] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKATSUKA A, 1983, ARCH BIOCHEM BIOPHYS, V220, P426, DOI 10.1016/0003-9861(83)90432-0; CAMICI M, 1984, J BIOL CHEM, V259, P3429; CHANG AY, 1972, CAN J BIOCHEM CELL B, V50, P714, DOI 10.1139/o72-099; Clark RJ, 2003, J BIOL CHEM, V278, P44230, DOI 10.1074/jbc.M303810200; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Crosson SM, 2003, J CLIN INVEST, V111, P1423, DOI 10.1172/JCI200317975; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; Federici M, 2002, CIRCULATION, V106, P466, DOI 10.1161/01.CIR.0000023043.02648.51; FernandezNovell JM, 1996, EUR J BIOCHEM, V238, P570, DOI 10.1111/j.1432-1033.1996.0570z.x; Ferrer JC, 2003, FEBS LETT, V546, P127, DOI 10.1016/S0014-5793(03)00565-9; GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hawkins M, 1996, DIABETES, V45, P1734, DOI 10.2337/diabetes.45.12.1734; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Hiromura M, 2003, J BIOL CHEM, V278, P14046, DOI 10.1074/jbc.M300789200; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; Kang HT, 2003, J BIOL CHEM, V278, P51223, DOI 10.1074/jbc.M307332200; KASLOW HR, 1984, AM J PHYSIOL, V247, pE581, DOI 10.1152/ajpendo.1984.247.5.E581; KASLOW HR, 1979, J BIOL CHEM, V254, P4674; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Lauro D, 1998, NAT GENET, V20, P294, DOI 10.1038/3112; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Majumdar G, 2003, AM J PHYSIOL-ENDOC M, V285, pE584, DOI 10.1152/ajpendo.00140.2003; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MARSHALL S, 2002, CURR OPIN ENDOCRINOL, V9, P160; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; McClain DA, 2002, J DIABETES COMPLICAT, V16, P72, DOI 10.1016/S1056-8727(01)00188-X; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; MCCLAIN DA, 2001, CURR OPIN ENDOCRINOL, V8, P186; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Obici S, 2002, J CLIN INVEST, V109, P1599, DOI 10.1172/JCI0215258; Park KS, 2000, METABOLISM, V49, P962, DOI 10.1053/meta.2000.7717; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; ROACH PJ, 1976, J BIOL CHEM, V251, P1913; Roduit R, 2001, DIABETES, V50, P1970, DOI 10.2337/diabetes.50.9.1970; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Rumberger JM, 2003, J BIOL CHEM, V278, P28547, DOI 10.1074/jbc.M302793200; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; Singh LP, 2001, J DIABETES COMPLICAT, V15, P88, DOI 10.1016/S1056-8727(00)00140-9; Singh LP, 2000, J INVEST MED, V48, P251; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; Skurat AV, 2000, DIABETES, V49, P1096, DOI 10.2337/diabetes.49.7.1096; THORBURN AW, 1990, J CLIN INVEST, V85, P522, DOI 10.1172/JCI114468; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; VILLARPALASI C, 1991, BIOCHIM BIOPHYS ACTA, V1095, P261, DOI 10.1016/0167-4889(91)90109-B; Virkamaki A, 1997, ENDOCRINOLOGY, V138, P2501, DOI 10.1210/en.138.6.2501; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wells L, 2002, MOL CELL PROTEOMICS, V1, P791, DOI 10.1074/mcp.M200048-MCP200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Yki-Jarvinen H, 1998, METABOLISM, V47, P449, DOI 10.1016/S0026-0495(98)90058-0; YKIJARVINEN H, 1987, J CLIN INVEST, V80, P95, DOI 10.1172/JCI113069	58	62	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20636	20642		10.1074/jbc.M312139200	http://dx.doi.org/10.1074/jbc.M312139200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15014073	hybrid			2022-12-25	WOS:000221273800013
J	Parsa, CJ; Kim, J; Riel, RU; Pascal, LS; Thompson, RB; Petrofski, JA; Matsumoto, A; Stamler, JS; Koch, WJ				Parsa, CJ; Kim, J; Riel, RU; Pascal, LS; Thompson, RB; Petrofski, JA; Matsumoto, A; Stamler, JS; Koch, WJ			Cardioprotective effects of erythropoietin in the reperfused ischemic heart - A potential role for cardiac fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; JAK-STAT PATHWAY; RECEPTOR; ACTIVATION; APOPTOSIS; HYPOXIA; PROTECTS; INJURY; CELLS; PHOSPHORYLATION	Erythropoietin has recently been shown to have effects beyond hematopoiesis such as prevention of neuronal and cardiac apoptosis secondary to ischemia. In this study, we evaluated the in vivo protective potential of erythropoietin in the reperfused rabbit heart following ventricular ischemia. We show that "preconditioning" with erythropoietin activates cell survival pathways in myocardial tissue in vivo and adult rabbit cardiac fibroblasts in vitro. These pathways, activated by erythropoietin in both whole hearts and cardiac fibroblasts, are also activated acutely by ischemia/reperfusion injury. Moreover, in vivo studies indicate that erythropoietin treatment either prior to or during ischemia significantly enhances cardiac function and recovery, including left ventricular contractility, following myocardial ischemia/reperfusion. Our data indicate that a contributing in vivo cellular mechanism of this protection is mitigation of myocardial cell apoptosis. This results in decreased infarct size as evidenced by area at risk studies following in vivo ischemia/reperfusion injury, translating into more viable myocardium and less ventricular dysfunction. Therefore, erythropoietin treatment may offer novel protection against ischemic heart disease and may act, at least in part, by direct action on cardiac fibroblasts and myocytes to alter survival and ventricular remodeling.	Thomas Jefferson Univ, Jefferson Med Coll, Ctr Translat Med, Philadelphia, PA 19107 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pulm Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Jefferson University; Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Koch, WJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Ctr Translat Med, 1025 Walnut St,Room 410, Philadelphia, PA 19107 USA.	walter.koch@jefferson.edu		Stamler, Jonathan/0000-0002-6866-1572; Matsumoto, Akio/0000-0002-3402-6992	NHLBI NIH HHS [F32 HL 70505, R01 HL 56205, R01 HL 59533] Funding Source: Medline; NIEHS NIH HHS [R01 ES 09206] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059533, R01HL056205, F32HL070505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009206] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BECKER LC, 1987, PROG CARDIOVASC DIS, V30, P23, DOI 10.1016/0033-0620(87)90009-0; Bolli R, 1997, CIRC RES, V81, P42, DOI 10.1161/01.RES.81.1.42; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chong Zhao Zhong, 2003, Current Drug Targets - Cardiovascular & Haematological Disorders, V3, P141, DOI 10.2174/1568006033481483; Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200; EGHBALI M, 1988, J MOL CELL CARDIOL, V20, P267, DOI 10.1016/S0022-2828(88)80059-2; ERSLEV AJ, 1989, ADV EXP MED BIOL, V271, P1; Figueroa YG, 2002, EXP HEMATOL, V30, P1419, DOI 10.1016/S0301-472X(02)00934-7; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Guillard C, 2003, J BIOL CHEM, V278, P11050, DOI 10.1074/jbc.M208834200; Hattori R, 2001, J MOL CELL CARDIOL, V33, P1929, DOI 10.1006/jmcc.2001.1456; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; JELKMANN W, 1994, CLIN INVESTIGATOR, V72, pS3; Kajstura J, 1996, LAB INVEST, V74, P86; Kim J, 2002, J BIOL CHEM, V277, P32116, DOI 10.1074/jbc.M204895200; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; Lin YP, 2002, BLOOD, V100, P3990, DOI 10.1182/blood-2002-02-0504; Matsui T, 2001, CIRCULATION, V104, P330; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; Miller BA, 1996, J CLIN INVEST, V98, P1728, DOI 10.1172/JCI118971; Mori M, 2003, J CELL PHYSIOL, V195, P290, DOI 10.1002/jcp.10245; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; PAFFETTLUGASSY N, 2002, BLOOD, V100, P2277; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Semenza GL, 2000, J CLIN INVEST, V106, P809, DOI 10.1172/JCI11223; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1; Veinot JP, 1997, HUM PATHOL, V28, P485, DOI 10.1016/S0046-8177(97)90039-3; White DC, 2000, P NATL ACAD SCI USA, V97, P5428, DOI 10.1073/pnas.090091197; Wierenga ATJ, 2003, EXP HEMATOL, V31, P398, DOI 10.1016/S0301-472X(03)00045-6; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798; YTREHUS K, 1994, AM J PHYSIOL-HEART C, V267, pH2383, DOI 10.1152/ajpheart.1994.267.6.H2383; Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912	38	157	178	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20655	20662		10.1074/jbc.M314099200	http://dx.doi.org/10.1074/jbc.M314099200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15020586	hybrid			2022-12-25	WOS:000221273800015
J	Podar, K; Mostoslavsky, G; Sattler, M; Tai, YT; Hayashi, T; Catley, LP; Hideshima, T; Mulligan, RC; Chauhan, D; Anderson, KC				Podar, K; Mostoslavsky, G; Sattler, M; Tai, YT; Hayashi, T; Catley, LP; Hideshima, T; Mulligan, RC; Chauhan, D; Anderson, KC			Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE RECEPTOR GP130; GRB2 BINDING-SITE; GROWTH-FACTOR; TYROSINE KINASE; GENE HCK; C-MET; SRC; ACTIVATION; TRANSFORMATION; PHOSPHATASES	Interleukin-6 (LI-6) is a known growth and survival factor in multiple myeloma via activation of extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling cascade. In this report we show that Grb2-associated binder ( Gab) family adapter proteins Gab1 and Gab2 are expressed by multiple myeloma cells; and that interleukin-6 induces their tyrosine phosphorylation and association with downstream signaling molecules. We further demonstrate that these events are Src family tyrosine kinase-dependent and specifically identify the role of hematopoietic cell kinase (Hck) as a new Gab family adapter protein kinase. Conversely, inhibition of Src family tyrosine kinases by the pyrazolopyrimidine PP2, as in kinase-inactive Hck mutants, significantly reduces IL-6-triggered activation of extracellular signal-regulated kinase and AKT-1, leading to significant reduction of multiple myeloma cell proliferation and survival. Taken together, these results delineate a key role for Hck-mediated phosphorylation of Gab1 and Gab2 docking proteins in IL-6-induced proliferation and survival of multiple myeloma cells and identify tyrosine kinases and downstream adapter proteins as potential new therapeutic targets in multiple myeloma.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, 44 Binney St, Boston, MA 02115 USA.	Kenneth_Anderson@dfci.harvard.edu	Podar, Klaus/ABD-1112-2020; Catley, Laurence/E-5313-2013	Podar, Klaus/0000-0002-7414-3632; Mostoslavsky, Gustavo/0000-0002-0784-2169	PHS HHS [P01 78378] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hallek M, 1997, EXP HEMATOL, V25, P1367; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KLEIN B, 1992, HEMATOL ONCOL CLIN N, V6, P273, DOI 10.1016/S0889-8588(18)30344-7; KLEIN B, 1989, BLOOD, V73, P517; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Ogata A, 1997, J IMMUNOL, V159, P2212; Pellicena P, 2002, FRONT BIOSCI-LANDMRK, V7, pD256, DOI 10.2741/pellicen; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Podar K, 2003, J BIOL CHEM, V278, P5794, DOI 10.1074/jbc.M208636200; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schaeffer M, 2001, MOL CELL BIOL, V21, P8068, DOI 10.1128/MCB.21.23.8068-8081.2001; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Taguchi T, 2000, EXP HEMATOL, V28, P55, DOI 10.1016/S0301-472X(99)00127-7; Tai YT, 2000, J IMMUNOL METHODS, V235, P11, DOI 10.1016/S0022-1759(99)00199-4; Tai YT, 2000, J IMMUNOL, V165, P6347, DOI 10.4049/jimmunol.165.11.6347; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Traxler P, 1997, J MED CHEM, V40, P3601, DOI 10.1021/jm970124v; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; von Laue S, 2000, J ENDOCRINOL, V165, P301, DOI 10.1677/joe.0.1650301; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	48	55	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21658	21665		10.1074/jbc.M305783200	http://dx.doi.org/10.1074/jbc.M305783200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15010462	hybrid			2022-12-25	WOS:000221273800133
J	Seeber, S; Humeny, A; Herkert, M; Rau, T; Eschenhagen, T; Becker, CM				Seeber, S; Humeny, A; Herkert, M; Rau, T; Eschenhagen, T; Becker, CM			Formation of molecular complexes by N-methyl-D-aspartate receptor subunit NR2B and ryanodine receptor 2 in neonatal rat myocard	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONOTROPIC GLUTAMATE RECEPTORS; DENSITY PROTEIN PSD-95; NMDA RECEPTORS; CENTRAL NEURONS; EXPRESSION; BRAIN; IDENTIFICATION; LOCALIZATION; POTENTIATION; CLONING	The N-methyl-D-aspartate ( NMDA) receptor is a glutamate gated cation channel prevalent in the postsynaptic membranes of central nervous system neurons. The neurotransmitter receptor complex is thought to represent a tetramer where variable NR2 or NR3 polypeptides form heteromeric assemblies with an obligatory NR1 subunit. Recently, we showed that cardiac myocytes from perinatal rats transiently express the NMDA receptor subunit NR2B, the function of which in heart is unknown. To characterize the cardiac NR2B protein, we determined its subcellular distribution and specific molecular interaction partners. By immunostaining of rat heart tissue slices and acutely dissociated cardiac myocytes, the NR2B antigen was localized at the sarcomeric Z-bands. Using immunoprecipitation of detergent-solubilized NR2B protein and subsequent analysis employing matrix-assisted laser desorption/ionization time of flight mass spectrometry, ryanodine receptor 2 was identified as a molecular interaction partner of the cardiac NR2B polypeptide. Differences in antibody recognition indicate that the cardiac NR2B polypeptide carries a structurally altered C terminus as compared with the NR2B variant prevalent in central nervous system. Based on its localization and protein interaction, the function of cardiac NR2B protein may relate to mechanosensitivity or play a role in the regulation of the contractile apparatus of neonatal heart.	Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, D-91054 Erlangen, Germany; Univ Klinikum Eppendorf, Inst Expt & Klin Pharmakol, D-20246 Hamburg, Germany	University of Erlangen Nuremberg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Becker, CM (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Fahrstr 17, D-91054 Erlangen, Germany.	CMB@biochem.uni-erlangen.de						Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bonk T, 2001, NEUROSCIENTIST, V7, P6, DOI 10.1177/107385840100700104; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; COHEN RA, 1994, NEUROL RES, V16, P443; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; Dunah AW, 2000, MOL BRAIN RES, V79, P77, DOI 10.1016/S0169-328X(00)00102-9; ENDO M, 1989, FOLIA PHARMACOL JPN, V94, P329, DOI 10.1254/fpj.94.329; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gill SS, 1998, BRAIN RES BULL, V46, P429, DOI 10.1016/S0361-9230(98)00012-4; Gill SS, 2001, TOXICOL PATHOL, V29, P208, DOI 10.1080/019262301317052486; Herkert M, 1998, EUR J NEUROSCI, V10, P1553, DOI 10.1046/j.1460-9568.1998.00164.x; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, RENAL PHYSIOL BIOCH, V17, P182; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; ISHII T, 1993, J BIOL CHEM, V268, P2836; Jiang XB, 2000, DEVELOPMENT, V127, P1607; Klein M, 1998, GENE, V208, P259, DOI 10.1016/S0378-1119(98)00005-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Koulen P, 1998, J NEUROSCI, V18, P10136; Kullmann DM, 2000, CELL MOL LIFE SCI, V57, P1551, DOI 10.1007/PL00000640; Leung JC, 2002, AM J PHYSIOL-REG I, V283, pR964, DOI 10.1152/ajpregu.00629.2001; Matsuda K, 2002, MOL BRAIN RES, V100, P43, DOI 10.1016/S0169-328X(02)00173-0; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Niethammer M, 1996, J NEUROSCI, V16, P2157; Nishi M, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-23-j0003.2001; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; Rutter AR, 2002, J NEUROCHEM, V81, P1298, DOI 10.1046/j.1471-4159.2002.00923.x; SAID SI, 1995, NEUROSCIENCE, V65, P943, DOI 10.1016/0306-4522(95)00021-A; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Seeber S, 2000, J NEUROCHEM, V75, P2472, DOI 10.1046/j.1471-4159.2000.0752472.x; Takai H, 2003, EXP MOL PATHOL, V75, P89, DOI 10.1016/S0014-4800(03)00030-3; WEBSTER KA, 1992, J MOL CELL CARDIOL, V24, P741, DOI 10.1016/0022-2828(92)93388-Z; WINTER CR, 1995, LIFE SCI, V57, P1925, DOI 10.1016/0024-3205(95)02179-M	38	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21062	21068		10.1074/jbc.M313009200	http://dx.doi.org/10.1074/jbc.M313009200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15010472	hybrid			2022-12-25	WOS:000221273800063
J	Li, B; Zhuang, L; Trueb, B				Li, B; Zhuang, L; Trueb, B			Zyxin interacts with the SH3 domains of the cytoskeletal proteins LIM-nebulette and Lasp-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTININ; NEBULIN; BINDING; GENE; MUSCLE; IDENTIFICATION; LOCALIZATION; MYOPALLADIN; RECOGNITION; COMPLEXITY	Zyxin is a versatile component of focal adhesions in eukaryotic cells. Here we describe a novel binding partner of zyxin, which we have named LIM-nebulette. LIM-nebulette is an alternative splice variant of the sarcomeric protein nebulette, which, in contrast to nebulette, is expressed in non-muscle cells. It displays a modular structure with an N-terminal LIM domain, three nebulin-like repeats, and a C-terminal SH3 domain and shows high similarity to another cytoskeletal protein, Lasp-1 (LIM and SH3 protein-1). Co-precipitation studies and results obtained with the two-hybrid system demonstrate that LIM-nebulette and Lasp-1 interact specifically with zyxin. Moreover, the SH3 domain from LIM-nebulette is both necessary and sufficient for zyxin binding. The SH3 domains from Lasp-1 and nebulin can also interact with zyxin, but the SH3 domains from more distantly related proteins such as vinexin and sorting nexin 9 do not. On the other hand, the binding site in zyxin is situated at the extreme N terminus as shown by site-directed mutagenesis. LIM-nebulette and Lasp-1 use the same linear binding motif. This motif shows some similarity to a class II binding site but does not contain the classical PXXP sequence. LIM-nebulette reveals a subcellular distribution at focal adhesions similar to Lasp-1. Thus, LIM-nebulette, Lasp-1, and zyxin may play an important role in the organization of focal adhesions.	Univ Bern, ITI Res Inst, CH-3010 Bern, Switzerland	University of Bern	Trueb, B (corresponding author), Univ Bern, ITI Res Inst, POB 54, CH-3010 Bern, Switzerland.	beat.trueb@iti.unibe.ch	Trueb, Beat/AAL-9621-2020	Trueb, Beat/0000-0001-8684-6856				Arimura T, 2000, HUM GENET, V107, P440, DOI 10.1007/s004390000389; Bang ML, 2001, J CELL BIOL, V153, P413, DOI 10.1083/jcb.153.2.413; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Butt E, 2003, J BIOL CHEM, V278, P15601, DOI 10.1074/jbc.M209009200; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Chew CS, 2000, J CELL SCI, V113, P2035; Chew CS, 2002, J CELL SCI, V115, P4787, DOI 10.1242/jcs.00174; Costa G L, 1996, Methods Mol Biol, V57, P239; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; Fradelizi J, 2001, NAT CELL BIOL, V3, P699, DOI 10.1038/35087009; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hobert O, 1996, ONCOGENE, V12, P1577; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Katoh M, 2003, INT J MOL MED, V12, P405; LABEIT S, 1995, J MOL BIOL, V248, P308, DOI 10.1016/S0022-2836(95)80052-2; Li B, 2003, J CELL SCI, V116, P1359, DOI 10.1242/jcs.00309; Li B, 2001, J BIOL CHEM, V276, P33328, DOI 10.1074/jbc.M100789200; Luo G, 1997, CELL MOTIL CYTOSKEL, V38, P75; Ma K, 2002, FEBS LETT, V532, P273, DOI 10.1016/S0014-5793(02)03655-4; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; Mayer BJ, 2001, J CELL SCI, V114, P1253; Millevoi S, 1998, J MOL BIOL, V282, P111, DOI 10.1006/jmbi.1998.1999; Moncman CL, 1999, CELL MOTIL CYTOSKEL, V44, P1, DOI 10.1002/(SICI)1097-0169(199909)44:1<1::AID-CM1>3.0.CO;2-8; MONCMAN CL, 1995, CELL MOTIL CYTOSKEL, V32, P205, DOI 10.1002/cm.970320305; Pelin K, 1999, P NATL ACAD SCI USA, V96, P2305, DOI 10.1073/pnas.96.5.2305; Politou AS, 2002, J MOL BIOL, V316, P305, DOI 10.1006/jmbi.2001.5312; Politou AS, 1998, J MOL BIOL, V276, P189, DOI 10.1006/jmbi.1997.1521; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Rottner K, 2001, MOL BIOL CELL, V12, P3103, DOI 10.1091/mbc.12.10.3103; Schmeichel KL, 1998, BIOCHEM J, V331, P885, DOI 10.1042/bj3310885; Schreiber V, 1998, GENE, V207, P171, DOI 10.1016/S0378-1119(97)00622-7; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200; Zamir E, 2001, J CELL SCI, V114, P3583; Zumbrunn J, 1996, EUR J BIOCHEM, V241, P657, DOI 10.1111/j.1432-1033.1996.00657.x	39	87	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20401	20410		10.1074/jbc.M310304200	http://dx.doi.org/10.1074/jbc.M310304200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004028	hybrid			2022-12-25	WOS:000221164500119
J	Nishizawa, H; Matsuda, M; Yamada, Y; Kawai, K; Suzuki, E; Makishima, M; Kitamura, T; Shimomura, I				Nishizawa, H; Matsuda, M; Yamada, Y; Kawai, K; Suzuki, E; Makishima, M; Kitamura, T; Shimomura, I			Musclin, a novel skeletal muscle-derived secretory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAUSES INSULIN-RESISTANCE; EXPRESSION; RECEPTOR; PROTEIN; PEPTIDE; OBESITY	Skeletal muscle is involved in the homeostasis of glucose and lipid metabolism. We hypothesized that the skeletal muscle produces and secretes bioactive factor(s), similar to adipocytokines secreted by fat tissue. Here, we report the identification of a novel secretory factor, musclin, by signal sequence trap of mouse skeletal muscle cDNAs. Musclin cDNA encoded 130 amino acids, including NH2-terminal 30-amino acid signal sequence. Musclin protein contained a region homologous to natriuretic peptide family, and KKKR, a putative serine protease cleavage site, similar to the natriuretic peptide family. Full-length musclin protein and KKKR-dependent cleaved form were secreted in media of musclin cDNA-transfected mammalian cell cultures. Musclin mRNA was expressed almost exclusively in the skeletal muscle of mice. Musclin mRNA levels in skeletal muscle were markedly low in fasted, increased upon re-feeding, and were low in streptozotocin-treated insulin-deficient mice. Musclin mRNA expression was induced at late stage in the differentiation of C2C12 myocytes. In myocytes, insulin increased, while epinephrine, isoproterenol, and forskolin reduced musclin mRNA, all of which are known to increase the cellular content of cyclic AMP, a counter-regulator to insulin. Pathologically, overexpression of musclin mRNA was noted in the muscles of obese insulin-resistant KKAy mice. Functionally, recombinant musclin significantly attenuated insulin-stimulated glucose uptake and glycogen synthesis in myocytes. In conclusion, we identified musclin, a novel skeletal muscle-derived secretory factor. Musclin expression level is tightly regulated by nutritional changes and its physiological role could be linked to glucose metabolism.	Osaka Univ, Grad Sch Med, Grad Sch Frontier Biosci, Dept Med & Pathophysiol, Suita, Osaka 5650871, Japan; Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, PREST, Kawaguchi, Saitama 3320012, Japan; Japan Soc Promot Sci, 21st Century COE Program, Tokyo 1028471, Japan	Osaka University; University of Tokyo; Japan Science & Technology Agency (JST); Japan Society for the Promotion of Science	Shimomura, I (corresponding author), Osaka Univ, Grad Sch Med, Grad Sch Frontier Biosci, Dept Med & Pathophysiol, 2-2 Yamadaoka H2, Suita, Osaka 5650871, Japan.	ichi@fbs.osaka-u.ac.jp	Kitamura, Toshio/AAA-2071-2021					Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Eto T, 1999, CLIN EXP PHARMACOL P, V26, P371, DOI 10.1046/j.1440-1681.1999.03047.x; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kojima T, 1999, NAT BIOTECHNOL, V17, P487, DOI 10.1038/8666; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nishizawa H, 2002, DIABETES, V51, P2734, DOI 10.2337/diabetes.51.9.2734; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; Schmitt M, 2003, CLIN SCI, V105, P141, DOI 10.1042/CS20030044; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Thomas G, 2003, J BIOL CHEM, V278, P50563, DOI 10.1074/jbc.M307310200; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	15	111	130	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19391	19395		10.1074/jbc.C400066200	http://dx.doi.org/10.1074/jbc.C400066200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15044443	hybrid			2022-12-25	WOS:000221164500003
J	Babic, I; Jakymiw, A; Fujita, DJ				Babic, I; Jakymiw, A; Fujita, DJ			The RNA binding protein Sam68 is acetylated in tumor cell lines, and its acetylation correlates with enhanced RNA binding activity	ONCOGENE			English	Article						acetylation; Sam68; RNA binding; breast cancer; gene expression	HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-LOCALIZATION SIGNAL; KH-DOMAIN; POSTTRANSCRIPTIONAL REGULATION; TRANSCRIPTIONAL ACTIVITY; MAMMALIAN PROTEINS; CYCLE PROGRESSION; HIV REPLICATION; SRC SUBSTRATE; COFACTOR CBP	Sam68 ((S) under bar rc-(a) under bar ssociated in mitosis; 68 kDa) is a member of the STAR ((s) under bar ignal (t) under bar ransduction and (a) under bar ctivation of RNA) family of KH domain-containing RNA binding proteins. Accumulating evidence suggests that it plays an important role in cell cycle control. Tyrosine phosphorylation by Src family kinases and breast tumor kinase can negatively regulate its RNA binding activity. To date, there are no reports of a factor, such as a phosphatase, which can positively regulate Sam68 association with RNA. Acetylation is a reversible post-translational modification known to influence the activity of DNA binding proteins. However, acetylation of a cellular RNA binding protein as a mechanism for regulating its activity has not yet been reported. Here we demonstrate Sam68 to be acetylated in vivo. A screen of several human mammary epithelial cell lines revealed variations in Sam68 acetylation. Interestingly, the highest level of acetylation was found in tumorigenic breast cancer cell lines. The screen also showed a positive correlation between Sam68 acetylation and its ability to bind RNA. The acetyltransferase CBP was shown to acetylate Sam68 and enhance its binding to poly(U) RNA. These results suggest that Sam68 association with RNA substrates may be positively regulated by acetylation, and that enhanced acetylation and RNA binding activity of Sam68 may play a role in tumor cell proliferation.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	Fujita, DJ (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.	ibabic@ucalgary.ca; dfujita@ucalgary.ca		Jakymiw, Andrew/0000-0001-6431-8753				Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Arning S, 1996, RNA, V2, P794; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen TP, 1998, MOL CELL BIOL, V18, P4863, DOI 10.1128/MCB.18.8.4863; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; CRUZALVAREZ M, 1987, J BIOL CHEM, V262, P13377; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Grossman JS, 1998, RNA, V4, P613, DOI 10.1017/S1355838298971448; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Hong W, 2002, MOL CANCER RES, V1, P48; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; Li QH, 2002, FEBS LETT, V525, P145, DOI 10.1016/S0014-5793(02)03103-4; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Mueller F, 2003, BRIT J CANCER, V88, P699, DOI 10.1038/sj.bjc.6600790; Perrotti D, 2002, ONCOGENE, V21, P8577, DOI 10.1038/sj.onc.1206085; Reddy TR, 2000, ONCOGENE, V19, P3570, DOI 10.1038/sj.onc.1203676; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Reddy TR, 2002, J BIOL CHEM, V277, P5778, DOI 10.1074/jbc.M106836200; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stoss O, 2001, J BIOL CHEM, V276, P8665, DOI 10.1074/jbc.M006851200; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; VOGEL LB, 1995, J BIOL CHEM, V270, P2506, DOI 10.1074/jbc.270.6.2506; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; Wu J, 1999, J BIOL CHEM, V274, P29202, DOI 10.1074/jbc.274.41.29202; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	46	62	65	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3781	3789		10.1038/sj.onc.1207484	http://dx.doi.org/10.1038/sj.onc.1207484			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021911				2022-12-25	WOS:000221242500005
J	Kamio, M; Yoshida, T; Ogata, H; Douchi, T; Nagata, Y; Inoue, M; Hasegawa, M; Yonemitsu, Y; Yoshimura, A				Kamio, M; Yoshida, T; Ogata, H; Douchi, T; Nagata, Y; Inoue, M; Hasegawa, M; Yonemitsu, Y; Yoshimura, A			SOC1 inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein	ONCOGENE			English	Article						cytokine; SOCS; papilloma viruses; interferon gamma; E7; proteasome	HUMAN PAPILLOMAVIRUS TYPE-16; SENDAI-VIRUS; SIGNAL-TRANSDUCTION; GROWTH-SUPPRESSION; NEGATIVE REGULATOR; GENE-TRANSFER; CELL-LINES; BOX MOTIF; INTERFERON; SOCS-1	Human papilloma viruses (HPVs) are small double-stranded DNA viruses that infect mucosal and cutaneous epithelium and induce cervical cancer. It has been shown that interferon (IFN)gamma suppresses proliferation of HPV-infected cells by suppressing expression of HPV E7. Here, we found that IFNgamma induces not only suppression of E7 transcription but also proteasome-dependent degradation. Suppressor of cytokine signaling-1 (SOCS1)/JAB, a suppressor of cytokine signaling, is known to be induced by IFNgamma, and functions as an antioncogene against various hematopoietic oncogenic proteins. SOCS1 contains the SOCS-box, which is shown to recruit ubiquitin transferase to the molecules that interact with SOCS1. We found that SOCS1 interacted with HPV E7 protein and induced ubiquitination and degradation of E7 in a SOCS-box-dependent manner. SOCS1 overexpression also increased Rb protein levels and suppressed proliferation of cervical cancer cell lines infected with HPV. Moreover, E7 protein levels were higher and Rb protein levels were lower in SOCS1-deficient fibroblasts infected with retrovirus vector carrying E7 gene than in wild-type fibroblasts. E7 induced anchorage-independent growth in SOCS1-deficient fibroblasts, but not in wild-type cells. These data suggested that SOCS1 plays an important role in regulating the levels of E7 protein and their transforming potential, and could be a new therapeutic tool for HPV-mediated tumors.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kagoshima Univ, Fac Med, Dept Obstet & Gynecol, Kagoshima 8900054, Japan; DNAVEC Res Inc, Tsukuba, Ibaraki, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol,Higash Ku, Fukuoka 8128582, Japan	Kyushu University; Kagoshima University; DNAVEC Corporation; Kyushu University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013					BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Gross G, 1997, INTERVIROLOGY, V40, P368, DOI 10.1159/000150569; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Ilangumaran S, 2003, J BIOL CHEM, V278, P41871, DOI 10.1074/jbc.M308382200; Jeon JH, 2002, EXP MOL MED, V34, P496, DOI 10.1038/emm.2002.69; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kato A, 1996, GENES CELLS, V1, P569, DOI 10.1046/j.1365-2443.1996.d01-261.x; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Kim KY, 2000, J GEN VIROL, V81, P695, DOI 10.1099/0022-1317-81-3-695; Kolakofsky D, 1998, J VIROL, V72, P891, DOI 10.1128/JVI.72.2.891-899.1998; Koromilas AE, 2001, CYTOKINE GROWTH F R, V12, P157, DOI 10.1016/S1359-6101(00)00023-X; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; MUNGER K, 1989, J VIROL, V63, P4417; Nagai H, 2003, J HUM GENET, V48, P65, DOI 10.1007/s100380300008; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Sakai Y, 1999, FEBS LETT, V456, P221, DOI 10.1016/S0014-5793(99)00960-6; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; SELVEY LA, 1994, J GEN VIROL, V75, P1647, DOI 10.1099/0022-1317-75-7-1647; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI13568; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAN TMC, 1995, CANCER RES, V55, P4599; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Um SJ, 2000, INT J CANCER, V85, P416, DOI 10.1002/(SICI)1097-0215(20000201)85:3<416::AID-IJC19>3.3.CO;2-V; Venturini F, 1999, NUCLEIC ACIDS RES, V27, P1585, DOI 10.1093/nar/27.7.1585; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WOODWORTH CD, 1992, CANCER RES, V52, P456; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yonemitsu Y, 1998, INT J ONCOL, V12, P1277; Yonemitsu Y, 2000, NAT BIOTECHNOL, V18, P970, DOI 10.1038/79463; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	48	59	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3107	3115		10.1038/sj.onc.1207453	http://dx.doi.org/10.1038/sj.onc.1207453			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15021916	Bronze			2022-12-25	WOS:000220845200015
J	Abal, M; Bras-Goncalves, R; Judde, JG; Fsihi, H; de Cremoux, P; Louvard, D; Magdelenat, H; Robine, S; Poupon, MF				Abal, M; Bras-Goncalves, R; Judde, JG; Fsihi, H; de Cremoux, P; Louvard, D; Magdelenat, H; Robine, S; Poupon, MF			Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line	ONCOGENE			English	Article						colorectal cancer; irinotecan; p53-dependent sensitivity; cdk-inh1; CYC-202; Roscovitine	COLORECTAL-CANCER; TOPOISOMERASE-I; CARCINOMA CELLS; MICROSATELLITE INSTABILITY; DIFFERENT P53; DNA-DAMAGE; CAMPTOTHECIN; APOPTOSIS; CYTOTOXICITY; XENOGRAFTS	Mutations in the tumor-suppressor gene p53 have been associated with advanced colorectal cancer (CRC). Irinotecan (CPT-11), a DNA topoisomerase 1 inhibitor, has been recently incorporated to the adjuvant therapy. Since the DNA-damage checkpoint depends on p53 activation, the status of p53 might critically influence the response to CPT-11. We analysed the sensitivity to CPT-11 in the human colon cancer cell line HT29 (mut p53) and its wild-type (wt)-p53 stably transfected subclone HT29-A4. Cell-cycle analysis in synchronised cells demonstrated the activation of transfected wt-p53 and a p21(WAF1/CIP1)-dependent cell-cycle blockage in the S phase. Activated wt-p53 increased apoptosis and enhanced sensitivity to CPT-11. In p53-deficient cells, cDNA-macroarray analysis and western blotting showed an accumulation of the cyclin-dependent kinase (cdk) 1/cyclin B complex. Subsequent p53-independent activation of the cdk-inhibitor (cdk-I) p21(WAF1/CIP1) prevented cell-cycle progression. Cdk1 induction was exploited in vivo to improve the sensitivity to CPT-11 by additional treatment with the cdk-I CYC-202. We demonstrate a gain of sensitivity to CPT-11 in a p53-mutated colon cancer model either by restoring wild-type p53 function or by sequential treatment with cdk-Is. Considering that mutations in p53 are among the most common genetic alterations in CRC, a therapeutic approach specifically targeting p53-deficient tumors could greatly improve the treatment outcomes.	Inst Curie, UMR 147, CNRS, F-75248 Paris, France; Inst Curie, Transfer Lab, CNRS, F-75248 Paris, France; Inst Curie, UMR 144, CNRS, F-75248 Paris, France; Inst Curie, Dept Tumor Biol, CNRS, Med Sect, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Poupon, MF (corresponding author), Inst Curie, UMR 147, CNRS, Rue Ulm, F-75248 Paris, France.	Marie-France.Poupon@curie.fr	FSIHI, Hafida/H-9852-2014	Abal Posada, Miguel/0000-0003-3533-7781				Arends JW, 2000, J PATHOL, V190, P412; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Bras-Goncalves RA, 2001, GASTROENTEROLOGY, V120, P874, DOI 10.1053/gast.2001.22440; Bras-Goncalves RA, 2000, BRIT J CANCER, V82, P913, DOI 10.1054/bjoc.1999.1019; Chauvier D, 2002, INT J ONCOL, V20, P855; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fishman A D, 2001, Clin Colorectal Cancer, V1, P20, DOI 10.3816/CCC.2001.n.002; Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KJELDSEN E, 1992, J MOL BIOL, V228, P1025, DOI 10.1016/0022-2836(92)90310-G; Lansiaux A, 2001, ANTICANCER RES, V21, P471; Liu WM, 1998, INT J ONCOL, V12, P793; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Magrini R, 2002, INT J CANCER, V101, P23, DOI 10.1002/ijc.10565; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; Motwani M, 2001, CLIN CANCER RES, V7, P4209; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Pocard M, 1996, ONCOGENE, V12, P875; Rougier P, 2001, Clin Colorectal Cancer, V1, P87, DOI 10.3816/CCC.2001.n.008; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 2001, ONCOGENE, V20, P1852, DOI 10.1038/sj.onc.1204264; SHIMIZU T, 1995, CANCER RES, V55, P228; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Sobrero A, 2000, EUR J CANCER, V36, P559, DOI 10.1016/S0959-8049(99)00314-7; TANIZAWA A, 1994, J NATL CANCER I, V86, P836, DOI 10.1093/jnci/86.11.836; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vanhoefer U, 2001, J CLIN ONCOL, V19, P1501, DOI 10.1200/JCO.2001.19.5.1501; Whitacre CM, 1999, CLIN CANCER RES, V5, P665; Xie XJ, 2000, CANCER CHEMOTH PHARM, V45, P362, DOI 10.1007/s002800051003	32	37	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1737	1744		10.1038/sj.onc.1207299	http://dx.doi.org/10.1038/sj.onc.1207299			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001986				2022-12-25	WOS:000220029300009
J	Heroult, M; Bernard-Pierrot, I; Delbe, J; Hamma-Kourbali, Y; Katsoris, M; Barritault, D; Papadimitriou, E; Plouet, J; Courty, J				Heroult, M; Bernard-Pierrot, I; Delbe, J; Hamma-Kourbali, Y; Katsoris, M; Barritault, D; Papadimitriou, E; Plouet, J; Courty, J			Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis	ONCOGENE			English	Article						HARP; angiogenesis; VEGF; inhibition	MELANOMA CELL-ADHESION; FACTOR GENE-EXPRESSION; C-TERMINAL PEPTIDES; IN-VITRO; THERAPEUTIC IMPLICATIONS; POTENT INHIBITOR; TUBE FORMATION; TUMOR-GROWTH; PLEIOTROPHIN; HARP	Heparin affin regulatory peptide (HARP) is an heparin-binding molecule involved in the regulation of cell proliferation and differentiation. Here, we report that HARP inhibited the biological activity induced by the 165-amino-acid form of vascular endothelial growth factor (VEGF(165)) on human umbilical vein endothelial cells. Endothelial-cell proliferation induced by VEGF(165) showed about 50% inhibition in the presence of HARP in a concentration of 3 nM. In similar range of concentrations, HARP blocked tube formation induced by VEGF(165) in three-dimensional angiogenesis assay. In vivo studies showed that HARP inhibited the VEGF(165)-induced Matrigel(TM) infiltration of endothelial cells. We then investigated the mechanisms of this inhibition and shown that HARP inhibited the binding of I-125-VEGF(165) to the VEGF receptors of endothelial cells. Additional studies using VEGF soluble receptors indicated that binding of I-125-VEGF(165) to kinase insert domain-containing receptor and neuropilin receptor was inhibited by HARP, but conversely the binding of I-125-VEGF(165) to fms-like tyrosine kinase I receptor was unaffected. A competitive affinity-binding assay demonstrated that HARP interacted directly with VEGF(165) with a dissociation coefficient of 1.38 nM. Binding assay using deletion mutants of HARP revealed that the thrombospondin type-1 repeats domains were involved in this interaction. These data demonstrate for the first time that the angiogenic factor HARP can also negatively regulates the angiogenic activity of VEGF(165).	Univ Paris 12, Lab Rech Croissance Cellulaire Reaparat & Regener, FRE 2412, CNRS, F-94010 Ceteil, France; Univ Patras, Dept Biol, Div Genet Cell & Dev Biol, GR-26504 Patras, Greece; Univ Patras, Mol Pharmacol Lab, Dept Pharm, GR-26504 Patras, Greece; CNRS, Lab Biol Mol Eucaryote, UPR 9006, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Patras; University of Patras; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Courty, J (corresponding author), Univ Paris 12, Lab Rech Croissance Cellulaire Reaparat & Regener, FRE 2412, CNRS, Ave Gen de Gaulle, F-94010 Ceteil, France.	courty@univ-paris12.f	Hamma-Kourbali, Yamina/R-3692-2018; Delbe, Jean/R-3680-2018; Papadimitriou, Evangelia/ABG-1356-2020; Courty, Jose/Q-3702-2018; Papadimitriou, Evangelia/F-3396-2010	Hamma-Kourbali, Yamina/0000-0002-2754-8928; Papadimitriou, Evangelia/0000-0001-6429-4325; 				Bernard-Pierrot I, 2002, J BIOL CHEM, V277, P32071, DOI 10.1074/jbc.M202747200; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Choudhuri R, 1997, CANCER RES, V57, P1814; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Delbe J, 1999, PATHOL BIOL, V47, P352; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1; Ledoux D, 1997, J HISTOCHEM CYTOCHEM, V45, P1239, DOI 10.1177/002215549704500907; MAIONE TE, 1991, CANCER RES, V51, P2077; Milhiet PE, 1998, J ENDOCRINOL, V158, P389, DOI 10.1677/joe.0.1580389; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Papadimitriou E, 2001, BIOCHEM BIOPH RES CO, V282, P306, DOI 10.1006/bbrc.2001.4574; Papadimitriou E, 2000, BIOCHEM BIOPH RES CO, V274, P242, DOI 10.1006/bbrc.2000.3126; Pipili-Synetos E, 1998, BRIT J PHARMACOL, V125, P1252, DOI 10.1038/sj.bjp.0702191; PLOUET J, 1990, J BIOL CHEM, V265, P22071; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; Robinson CJ, 2001, J CELL SCI, V114, P853; SEDDON AP, 1994, PROTEIN EXPRES PURIF, V5, P14, DOI 10.1006/prep.1994.1002; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Shimo T, 1998, J BIOCHEM-TOKYO, V124, P130, DOI 10.1093/oxfordjournals.jbchem.a022071; Souttou B, 2001, J CELL PHYSIOL, V187, P59, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1051>3.0.CO;2-F; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tomanek RJ, 2000, ANAT RECORD, V261, P126, DOI 10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4; Vacherot F, 1999, PROSTATE, V38, P126, DOI 10.1002/(SICI)1097-0045(19990201)38:2<126::AID-PROS6>3.0.CO;2-C	49	66	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1745	1753		10.1038/sj.onc.1206879	http://dx.doi.org/10.1038/sj.onc.1206879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001987				2022-12-25	WOS:000220029300010
J	Hans, A; Bajramovic, JJ; Syan, S; Perret, E; Dunia, I; Brahic, M; Gonzalez-Dunia, D				Hans, A; Bajramovic, JJ; Syan, S; Perret, E; Dunia, I; Brahic, M; Gonzalez-Dunia, D			Persistent, non-cytolytic infection of neurons by Borna disease virus interferes with ERK 1/2 signaling and abrogates BDNF-induced synaptogenesis	FASEB JOURNAL			English	Article						neurotrophin; mitogen-activated protein kinase (MAPK)	ACTIVATED PROTEIN-KINASE; ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC DISEASE; NEUROTRANSMITTER RELEASE; HIPPOCAMPAL-NEURONS; BIPOLAR DISORDER; GENE-EXPRESSION; NEUROTROPHINS; SCHIZOPHRENIA; TRANSMISSION	Infection of the central nervous system by Borna disease virus (BDV) provides a unique model to study the mechanisms whereby a persistent viral infection can impair neuronal function and cause behavioral diseases reminiscent of mood disorders, schizophrenia, or autism in humans. In the present work, we studied the effect of BDV infection on the response of hippocampal neurons, the main target for this virus, to the neurotrophin BDNF. We showed that persistent infection did not affect neuronal survival or morphology. However, it blocked BDNF-induced ERK 1/2 phosphorylation, despite normal expression of the TrkB BDNF receptor. In addition, BDNF-induced expression of synaptic vesicle proteins was abrogated, which resulted in severely impaired synaptogenesis and defects in synaptic organization. Thus, we provide the first evidence that a virus can interfere specifically with neurotrophin-regulated neuroplasticity, thereby hampering proper neuronal connectivity. These results may help to understand the behavioral disorders associated with BDV infection.	CHU Purpan, INSERM, U563, F-31059 Toulouse 3, France; Inst Pasteur, CNRS, URA 1930, Unite Virus Lents, Paris, France; Inst Pasteur, Ctr Imagerie Dynam, Paris, France; Univ Paris 07, CNRS, Inst Jacques Monod, Paris, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Gonzalez-Dunia, D (corresponding author), CHU Purpan, INSERM, U563, CPTP Bat B,Pl Dr Baylac, F-31059 Toulouse 3, France.	Daniel.Dunia@toulouse.inserm.fr	Bajramovic, Jeffrey/AAF-6695-2020; Dunia, Daniel/K-1090-2014	Dunia, Daniel/0000-0002-2837-7120; Bajramovic, Jeffrey/0000-0002-6504-3437				Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Bajramovic JJ, 2003, J VIROL, V77, P12222, DOI 10.1128/JVI.77.22.12222-12231.2003; Bajramovic JJ, 2002, J VIROL, V76, P6268, DOI 10.1128/JVI.76.12.6268-6286.2002; Bode L, 2003, CLIN MICROBIOL REV, V16, P534, DOI 10.1128/CMR.16.3.534-545.2003; BODE L, 1995, NAT MED, V1, P232, DOI 10.1038/nm0395-232; Bode L, 2001, MOL PSYCHIATR, V6, P481, DOI 10.1038/sj.mp.4000909; CARBONE KM, 1993, J VIROL, V67, P1453, DOI 10.1128/JVI.67.3.1453-1460.1993; Carbone KM, 2001, CLIN MICROBIOL REV, V14, P513, DOI 10.1128/CMR.14.3.513-527.2001; DELATORRE JC, 1994, J VIROL, V68, P7669, DOI 10.1128/JVI.68.12.7669-7675.1994; Dietrich DE, 1998, PHARMACOPSYCHIATRY, V31, P77, DOI 10.1055/s-2007-979305; Dunia I, 1996, J CELL BIOL, V132, P701, DOI 10.1083/jcb.132.4.701; GonzalezDunia D, 1997, BRAIN RES BULL, V44, P647, DOI 10.1016/S0361-9230(97)00276-1; GonzalezDunia D, 1997, J VIROL, V71, P3208, DOI 10.1128/JVI.71.4.3208-3218.1997; GOSZTONYI G, 1995, BORNA DIS, P39; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hans A, 2001, J BIOL CHEM, V276, P7258, DOI 10.1074/jbc.M005107200; Hornig M, 1999, P NATL ACAD SCI USA, V96, P12102, DOI 10.1073/pnas.96.21.12102; Hornig M, 2001, CURR TOP MICROBIOL, V253, P157; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Ikuta Kazuyoshi, 2002, P87; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lipkin WI, 2001, TRENDS MICROBIOL, V9, P295, DOI 10.1016/S0966-842X(01)02071-6; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.0.CO;2-0; Masliah E, 2001, NEUROLOGY, V56, P127, DOI 10.1212/WNL.56.1.127; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; Planz O, 2001, J VIROL, V75, P4871, DOI 10.1128/JVI.75.10.4871-4877.2001; Planz Oliver, 2002, P179; Pletnikov Mikhail V., 2002, P125; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; ROTT R, 1985, SCIENCE, V228, P755, DOI 10.1126/science.3922055; ROTT R, 1995, BORNA DIS, P17; SCHNEEMANN A, 1995, VIROLOGY, V210, P1, DOI 10.1006/viro.1995.1311; Schwemmle M, 1997, J BIOL CHEM, V272, P21818, DOI 10.1074/jbc.272.35.21818; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Small DH, 2001, NAT REV NEUROSCI, V2, P595, DOI 10.1038/35086072; Takei N, 1997, J NEUROCHEM, V68, P370; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Vawter MP, 2002, MOL PSYCHIATR, V7, P571, DOI 10.1038/sj.mp.4001158; Vicario-Abejon C, 1998, J NEUROSCI, V18, P7256; Wu GY, 2001, NAT NEUROSCI, V4, P151, DOI 10.1038/83976; YOLKEN RH, 1995, CLIN MICROBIOL REV, V8, P131, DOI 10.1128/CMR.8.1.131; Zocher M, 2000, J NEUROVIROL, V6, P462, DOI 10.3109/13550280009091947	48	52	60	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					863	+		10.1096/fj.03-0764fje	http://dx.doi.org/10.1096/fj.03-0764fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033926				2022-12-25	WOS:000220522800010
J	De Crescenzo, G; Pham, PL; Durocher, Y; Chao, H; O'Connor-McCourt, MD				De Crescenzo, G; Pham, PL; Durocher, Y; Chao, H; O'Connor-McCourt, MD			Enhancement of the antagonistic potency of transforming growth factor-alpha receptor extracellular domains by coiled coil-induced homo- and heterodimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA RECEPTOR; LIGAND-BINDING; BETAGLYCAN; MUTAGENESIS; METASTASIS; MEMBRANE; COMPLEX; CELLS; SITE	Transforming growth factor-beta (TGF-beta) plays a causal role in several human pathologies including fibrotic diseases and metastasis. TGF-beta signaling is mediated through its interaction with three types of cell surface receptors, RI, RII, and RIII. The soluble ectodomains of RII and RIII bind to TGF-beta, making them attractive candidates to sequester TGF-beta and inhibit its activity. To optimize the activity of the ectodomains, we studied the effect of artificially dimerizing them upon their kinetics of binding to TGF-beta using an optical biosensor and studied their antagonistic potencies using an in vitro signaling assay. We fused the RII ectodomain and the membrane-proximal ligand-binding domain of the RIII ectodomain to de novo designed heterodimerizing coil strands and demonstrated that the coil strands within the fusion proteins were capable of promoting the dimerization of the coil-tagged ectodomains. Our results indicate that coiled coil-induced dimerization of the ectodomains stabilized their interaction with TGF-beta as compared with the monomeric ectodomains. Also, in contrast to the monomeric ectodomains, which did not block signaling, the coiled coil-induced dimers were characterized by antagonistic potencies in the low nanomolar range.	Natl Res Council Canada, Biotechnol Res Inst, Hlth Sector, Cell Signaling & Proteom Grp, Montreal, PQ H4P 2R2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Bioproc Platform, Montreal, PQ H4P 2R2, Canada; Helix BioPharma Corp, Aurora, ON L4G 6X7, Canada	National Research Council Canada; National Research Council Canada	O'Connor-McCourt, MD (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Hlth Sector, Cell Signaling & Proteom Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	maureen.o'connor@nrc.ca	Durocher, Yves/K-8709-2019					ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; BORDER WA, 1993, AM J KIDNEY DIS, V22, P105, DOI 10.1016/S0272-6386(12)70175-0; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; De Crescenzo G, 2001, J BIOL CHEM, V276, P29632, DOI 10.1074/jbc.M009765200; De Crescenzo G, 2003, J MOL BIOL, V328, P1173, DOI 10.1016/S0022-2836(03)00360-7; De Crescenzo G, 2003, BIOCHEMISTRY-US, V42, P1754, DOI 10.1021/bi0268450; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; FUKUSHIMA D, 1993, J BIOL CHEM, V268, P22710; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Komesli S, 1998, EUR J BIOCHEM, V254, P505, DOI 10.1046/j.1432-1327.1998.2540505.x; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Pepin MC, 1995, FEBS LETT, V377, P368, DOI 10.1016/0014-5793(95)01378-4; PEPIN MC, 1994, P NATL ACAD SCI USA, V91, P6997, DOI 10.1073/pnas.91.15.6997; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Zhu HJ, 1999, J BIOL CHEM, V274, P11773, DOI 10.1074/jbc.274.17.11773	24	33	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26013	26018		10.1074/jbc.M400655200	http://dx.doi.org/10.1074/jbc.M400655200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15044491	hybrid			2022-12-25	WOS:000222003000012
J	Tio, L; Villarreal, L; Atrian, S; Capdevila, M				Tio, L; Villarreal, L; Atrian, S; Capdevila, M			Functional differentiation in the mammalian metallothionein gene family - Metal binding features of mouse MT4 and comparison with its paralog MT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-INHIBITORY FACTOR; TERMINAL SEQUENCE 1-29; COPPER-METALLOTHIONEIN; LIVER METALLOTHIONEIN; BETA-DOMAIN; IN-VIVO; ALZHEIMERS-DISEASE; CU+ BINDING; PROTEIN; CADMIUM	This paper reports on the characterization of the metal binding abilities of mammalian MT4 and their comparison with those of the well known MT1. Heterologous Escherichia coli expression in cultures supplemented with zinc, cadmium, or copper was achieved for MT4 and for its separate alphaMT4 and betaMT4 domains as well as for MT1 and its alphaMT1 domain in cadmium-enriched medium. The in vivo conformed metal complexes and the in vitro substituted zinc/cadmium and zinc/copper MT4 aggregates were characterized. Biosynthesis of MT4 and betaMT4 in Cd(II)-supplemented medium revealed that these peptides failed to form the same homometallic species as MT1, thus appearing less effective for cadmium coordination. Conversely, the entire MT4 and both of its domains showed better Cu(I) binding properties than MT1, affording Cu-10-MT4, Cu-5-alphaMT4 and Cu-7-betaMT4, stoichiometries that make the domain dependence toward Cu(I) clear. Overall results allow consideration of MT4 as a novel copper-thionein, made up of two copper-thionein domains, the first of this class reported in mammals, and by extension in vertebrates. Furthermore, the in silico protein sequence analyses corroborated the copper-thionein nature of the MT4 peptides. As a consequence, there is the suggestion of a possible physiological role played by MT4 related with copper requirements in epithelial differentiating tissues, where MT4 is expressed.	Univ Barcelona, Fac Biol, Dept Genet, E-08028 Barcelona, Spain; Univ Autonoma Barcelona, Dept Quim, Fac Ciencies, Barcelona 08193, Spain	University of Barcelona; Autonomous University of Barcelona	Atrian, S (corresponding author), Univ Barcelona, Fac Biol, Dept Genet, Avd Diagonal 645, E-08028 Barcelona, Spain.	satrian@ub.edu	Capdevila, Mercè/F-5374-2015; Capdevila, Mercè/ABG-4588-2020	Capdevila, Mercè/0000-0002-2246-0994; Capdevila, Mercè/0000-0002-2246-0994; Tio Barrera, Laura/0000-0003-1408-7381; Villarreal, Laura/0000-0002-4040-3280				Bertini I, 2000, EUR J BIOCHEM, V267, P1008, DOI 10.1046/j.1432-1327.2000.01093.x; BIRCHMEIER W, 1971, FEBS LETT, V18, P209, DOI 10.1016/0014-5793(71)80446-5; Bofill R, 2001, J BIOL INORG CHEM, V6, P405, DOI 10.1007/s007750100216; Bofill R, 1999, J INORG BIOCHEM, V73, P57, DOI 10.1016/S0162-0134(98)10091-0; BONGERS J, 1988, ANAL CHEM, V60, P2683, DOI 10.1021/ac00175a008; Capdevila M, 1997, CELL MOL LIFE SCI, V53, P681, DOI 10.1007/s000180050088; Chang CC, 1998, PROTEIN ENG, V11, P41, DOI 10.1093/protein/11.1.41; Chang CC, 1996, PROTEIN ENG, V9, P1165, DOI 10.1093/protein/9.12.1165; Cols N, 1999, PROTEIN ENG, V12, P265, DOI 10.1093/protein/12.3.265; Cols N, 1997, J INORG BIOCHEM, V68, P157, DOI 10.1016/S0162-0134(97)00085-8; Domenech J, 2003, FEBS LETT, V533, P72, DOI 10.1016/S0014-5793(02)03754-7; Fabris D, 1996, J AM CHEM SOC, V118, P12242, DOI 10.1021/ja962863r; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Gerhardsson L, 2002, J TRACE ELEM MED BIO, V16, P261, DOI 10.1016/S0946-672X(02)80055-4; HOLLAND PW, 1994, DEV S, V43, P125; KAGI JHR, 1960, J BIOL CHEM, V235, P3460; Li H, 1996, BIOCHEMISTRY-US, V35, P13929, DOI 10.1021/bi961401n; Liang LC, 1996, MOL REPROD DEV, V43, P25, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;25::AID-MRD4&gt;3.0.CO;2-W; Lundin LG, 1999, SEMIN CELL DEV BIOL, V10, P523, DOI 10.1006/scdb.1999.0333; NIELSON KB, 1985, J BIOL CHEM, V260, P8698; NIELSON KB, 1984, J BIOL CHEM, V259, P4941; OKADA Y, 1985, FEBS LETT, V183, P375, DOI 10.1016/0014-5793(85)80813-9; OKADA Y, 1986, CHEM PHARM BULL, V34, P986; OTVOS JD, 1980, P NATL ACAD SCI-BIOL, V77, P7094, DOI 10.1073/pnas.77.12.7094; Palacios O, 2003, J BIOL INORG CHEM, V8, P831, DOI 10.1007/s00775-003-0481-4; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Pawlak KP, 2002, TALANTA, V57, P1011, DOI 10.1016/S0039-9140(02)00137-6; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; Romero-Isart N, 2002, J BIOL CHEM, V277, P37023, DOI 10.1074/jbc.M205730200; Santovito G, 2001, PROTIST, V152, P219, DOI 10.1078/1434-4610-00061; Schlake T, 2001, MECH DEVELOP, V109, P419, DOI 10.1016/S0925-4773(01)00538-X; Suzuki KT, 2002, J INORG BIOCHEM, V88, P173, DOI 10.1016/S0162-0134(01)00376-2; Syring RA, 2000, COMP BIOCHEM PHYS C, V125, P325, DOI 10.1016/S0742-8413(99)00114-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUJI S, 1992, EMBO J, V11, P4843, DOI 10.1002/j.1460-2075.1992.tb05590.x; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Valls M, 2001, J BIOL CHEM, V276, P32835, DOI 10.1074/jbc.M102151200; Valls M, 2000, FEBS LETT, V467, P189, DOI 10.1016/S0014-5793(00)01149-2; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; WINGE DR, 1991, METHOD ENZYMOL, V205, P458; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	44	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24403	24413		10.1074/jbc.M401346200	http://dx.doi.org/10.1074/jbc.M401346200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15033980	hybrid			2022-12-25	WOS:000221702500066
J	Mahon, MJ; Segre, GV				Mahon, MJ; Segre, GV			Stimulation by parathyroid hormone of a NHERF-1-assembled complex consisting of the parathyroid hormone I receptor, phospholipase C beta, and actin increases intracellular calcium in opossum kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PDZ-INTERACTING DOMAIN; OK CELLS; PHOSPHATE-TRANSPORT; PLASMA-MEMBRANE; SIGNALING COMPLEXES; CYTOSOLIC CALCIUM; PROTEIN; INHIBITION; EXPRESSION	Parathyroid hormone (PTH) binds its cognate G-protein-coupled receptor (PTH1R) and signals through both adenylyl cyclase and phospholipase C ( PLC). C-terminal determinants of the PTH1R interact with the Na+/H+ exchanger regulatory factor 1 (NHERF-1) by binding the first of two PDZ (psd95, discs-large, ZO-1) domains. Compared with wild-type opossum kidney (OK) cells, OKH cells, a sub-clone, do not display PTH-mediated increases of [Ca2+](i) and express NHERF-1 at markedly lower levels. Stable expression of NHERF-1 in the OKH parent (OKH-N1) restores the PTH-mediated increase of [Ca2+](i) that arises from an influx of extracellular calcium and is both PLC-dependent and pertussis toxin-sensitive. From a morphological perspective, NHERF-1 and the PTH1R co-localize to apical patches of OKH-N1 cells, an expression pattern that is absent in OKH cells and depends on a direct NHERF-1-PTH1R interaction in OKH-N1 cells. Actin and PLCbeta1 and -beta3 co-localize with NHERF-1 and the PTH1R in OKH-N1 cell apical patches. Actin is also an integral component of the NHERF-1-assembled complex because cytochalasin D disrupts apical localization of both NHERF-1 and the PTH1R and inhibits the PTH-mediated increase of [Ca2+](i). Expression of the first PDZ domain of NHERF-1 acts as a dominant-negative interactor by blocking apical localization of the PTH1R and inhibiting PTH-elicited increases of [Ca2+](i). Thus, NHERF-1 assembles a signaling complex in the apical domains of OK cells that contains the PTH1R, PLCbeta, and the actin cytoskeleton. Disruption of this complex blocks the PTH mediated increases of intracellular calcium.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Segre, GV (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St, Boston, MA 02114 USA.	segre@helix.mgh.harvard.edu						ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Amizuka N, 1997, ENDOCRINOLOGY, V138, P469, DOI 10.1210/en.138.1.469; Ba JM, 2003, AM J PHYSIOL-RENAL, V285, pF1233, DOI 10.1152/ajprenal.00249.2003; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; Brown D, 2000, AM J PHYSIOL-RENAL, V278, pF192, DOI 10.1152/ajprenal.2000.278.2.F192; COLE JA, 1989, AM J PHYSIOL, V256, pF672, DOI 10.1152/ajprenal.1989.256.4.F672; FADDA GZ, 1993, KIDNEY INT, V43, P554, DOI 10.1038/ki.1993.82; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; GOLIGORSKY MS, 1986, AM J PHYSIOL, V251, pF938, DOI 10.1152/ajprenal.1986.251.5.F938; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hernando N, 2002, P NATL ACAD SCI USA, V99, P11957, DOI 10.1073/pnas.182412699; HRUSKA KA, 1986, AM J PHYSIOL, V251, pF188, DOI 10.1152/ajprenal.1986.251.2.F188; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; KAUFMANN M, 1994, ENDOCRINOLOGY, V134, P1173, DOI 10.1210/en.134.3.1173; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Lotscher M, 1996, KIDNEY INT, V49, P1010, DOI 10.1038/ki.1996.145; Mahon MJ, 2003, MOL ENDOCRINOL, V17, P2355, DOI 10.1210/me.2003-0043; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; MALMSTROM K, 1988, BIOCHEM J, V251, P207, DOI 10.1042/bj2510207; Mery L, 2002, J CELL SCI, V115, P3497; MIYAUCHI A, 1990, AM J PHYSIOL, V259, pF485, DOI 10.1152/ajprenal.1990.259.3.F485; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Pfister MF, 1999, AM J PHYSIOL-RENAL, V276, pF720, DOI 10.1152/ajprenal.1999.276.5.F720; Pfister MF, 1997, J BIOL CHEM, V272, P20125, DOI 10.1074/jbc.272.32.20125; Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909; RANGANATHAN R, 1997, CURR BIOL, V7, P770; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P624, DOI 10.1007/BF00370606; RESHKIN SJ, 1991, J MEMBRANE BIOL, V124, P227, DOI 10.1007/BF01994356; Shenolikar S, 2002, P NATL ACAD SCI USA, V99, P11470, DOI 10.1073/pnas.162232699; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; TANAKA H, 1995, AM J PHYSIOL-RENAL, V268, pF330, DOI 10.1152/ajprenal.1995.268.2.F330; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Traebert M, 2000, AM J PHYSIOL-RENAL, V278, pF792, DOI 10.1152/ajprenal.2000.278.5.F792; Tsunoda S, 1999, CELL CALCIUM, V26, P165, DOI 10.1054/ceca.1999.0070; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Weinman EJ, 2001, AM J PHYSIOL-RENAL, V281, pF374, DOI 10.1152/ajprenal.2001.281.2.F374	44	101	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23550	23558		10.1074/jbc.M313229200	http://dx.doi.org/10.1074/jbc.M313229200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15037630	hybrid			2022-12-25	WOS:000221570900094
J	McInnes, KJ; Kenyon, CJ; Chapman, KE; Livingstone, DEW; Macdonald, LJ; Walker, BR; Andrew, R				McInnes, KJ; Kenyon, CJ; Chapman, KE; Livingstone, DEW; Macdonald, LJ; Walker, BR; Andrew, R			5 alpha-reduced glucocorticoids, novel endogenous activators of the glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; RAT-LIVER; PHOSPHOENOLPYRUVATE CARBOXYKINASE; IN-VIVO; METABOLISM; BINDING; CORTICOSTERONE; DEXAMETHASONE; EXPRESSION; OBESITY	Metabolism of glucocorticoids to A-ring-reduced dihydro- and tetrahydro-derivatives by means of hepatic 5alpha- and 5beta-reductases has long been regarded as a pathway of irreversible inactivation. However, 5alpha-reduced metabolites of other steroids, e. g. testosterone and aldosterone, have significant biological activity. We investigated whether 5alpha-reduced metabolites of corticosterone are glucocorticoid receptor (GR) agonists. Corticosterone, 5alpha-tetrahydrocorticosterone (5alphaTHB), and 5alpha-dihydrocorticosterone (5alphaDHB) were similarly effective in displacing tritiated dexamethasone from binding sites in hepatocytes, whereas 5beta-reduced metabolites were less effective in binding. 5alphaTHB had glucocorticoid receptor agonist effects in vitro and in vivo. After transient co-transfection of hGR and a murine mammary tumor virus-luciferase reporter into HeLa cells, 5alphaTHB was active to a comparable extent as corticosterone (28-fold versus 37-fold induction, respectively, at 1 muM) and additive to the effect of corticosterone. 5beta-Reduced metabolites did not activate GR. In H4IIE hepatoma cells, both 5alpha-THB and corticosterone induced mRNA expression of tyrosine aminotransferase and phosphoenolpyruvate carboxykinase (6.0- versus 10.1-fold and 3.5- versus 3.9-fold at 1 muM, respectively), an effect that was inhibited by RU486. To assess in vivo glucocorticoid activity, suppression of plasma ACTH was demonstrated in adrenalectomized rats after intraperitoneal administration of vehicle (ACTH trough 80.2 pM), corticosterone (5 mg/kg; 22 pM, p < 0.001) or 5 alpha THB (5 mg/kg; 51.3 pM, p < 0.005). Similar endogenous concentrations of corticosterone and 5alphaTHB were detected in rat liver homogenates by gas chromatography mass spectrometry. We conclude that 5alpha-reduced glucocorticoids bind to and activate GR. Transcription of glucocorticoid-regulated genes in tissues that express 5alpha-reductases will thus be influenced by intracellular levels of both corticosterone and its 5alpha-reduced metabolites.	Univ Edinburgh, Western Gen Hosp, Endocrinol Unit, Sch Mol & Clin Med, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Andrew, R (corresponding author), Univ Edinburgh, Western Gen Hosp, Endocrinol Unit, Sch Mol & Clin Med, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	Ruth.Andrew@ed.ac.uk	Andrew, Ruth/C-2727-2008	Andrew, Ruth/0000-0002-6916-2994; Chapman, Karen/0000-0001-7777-6817				ALDUJAILI EAS, 1981, STEROIDS, V37, P157, DOI 10.1016/S0039-128X(81)80015-3; AMBELLAN E, 1981, J STEROID BIOCHEM, V14, P421, DOI 10.1016/0022-4731(81)90352-6; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; Andrew R, 1998, J CLIN ENDOCR METAB, V83, P1806, DOI 10.1210/jc.83.5.1806; BAXTER JD, 1971, P NATL ACAD SCI USA, V68, P932, DOI 10.1073/pnas.68.5.932; Best R, 1997, CLIN ENDOCRINOL, V47, P231, DOI 10.1046/j.1365-2265.1997.2471061.x; CARLSTEDTDUKE J, 1977, EUR J BIOCHEM, V73, P231, DOI 10.1111/j.1432-1033.1977.tb11311.x; DUBROVSKY BO, 1987, BRAIN RES BULL, V19, P635, DOI 10.1016/0361-9230(87)90049-9; GOLF SW, 1984, STEROIDS, V43, P85, DOI 10.1016/0039-128X(84)90060-6; Grange T, 2001, ONCOGENE, V20, P3028, DOI 10.1038/sj.onc.1204327; Kenyon CJ, 1985, ADRENAL GLAND HYPERT, P209; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; LEFEBVRE YA, 1982, BIOCHEM J, V202, P225, DOI 10.1042/bj2020225; Livingstone DEW, 2000, ENDOCRINOLOGY, V141, P560, DOI 10.1210/en.141.2.560; MANSER T, 1982, CELL, V29, P257, DOI 10.1016/0092-8674(82)90110-6; MELVILLE J, 1998, J ENDOCRINOL S, V156, P286; MURPHY BP, 1963, J CLIN ENDOCR METAB, V23, P293, DOI 10.1210/jcem-23-3-293; NORMINGTON K, 1992, J BIOL CHEM, V267, P19548; Nyirenda MJ, 1998, J CLIN INVEST, V101, P2174, DOI 10.1172/JCI1567; Rapkin AJ, 1997, OBSTET GYNECOL, V90, P709, DOI 10.1016/S0029-7844(97)00417-1; RATKA A, 1989, NEUROENDOCRINOLOGY, V50, P117, DOI 10.1159/000125210; ROSZAK AW, 1990, J STEROID BIOCHEM, V37, P201, DOI 10.1016/0960-0760(90)90328-I; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SEKIHARA H, 1978, ENDOCRINOLOGY, V103, P1450, DOI 10.1210/endo-103-4-1450; SIITERI PK, 1974, J CLIN ENDOCR METAB, V38, P113, DOI 10.1210/jcem-38-1-113; STEWART PM, 1990, LANCET, V335, P431, DOI 10.1016/0140-6736(90)90664-Q; Voice MW, 1996, BIOCHEM J, V317, P621, DOI 10.1042/bj3170621	30	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22908	22912		10.1074/jbc.M402822200	http://dx.doi.org/10.1074/jbc.M402822200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044432	hybrid			2022-12-25	WOS:000221570900017
J	Noon, LA; Clark, AJL; Peter, JK				Noon, LA; Clark, AJL; Peter, JK			A peroxisome proliferator-response element in the murine mc2-r promoter regulates its transcriptional activation during differentiation of 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; ACTH RECEPTOR GENE; ADENOSINE 3'-5'-CYCLIC MONOPHOSPHATE; 9-CIS RETINOIC ACID; PPAR-GAMMA RECEPTOR; ADRENOCORTICOTROPIC HORMONE; PITUITARY-ADENOMAS; ADIPOSE-TISSUE; NUCLEAR RECEPTOR; TUMOR-CELLS	Adrenocorticotropic hormone can stimulate lipolysis and suppress leptin expression in murine adipocytes. These effects are mediated via the melanocortin 2 receptor (MC2-R), which is expressed when 3T3-L1 cells are induced to undergo adipogenesis. In this study, we have characterized the mc2-r promoter in the murine adipocyte, one of the few extra-adrenal sites of expression and a cell type that lacks steroidogenic factor 1 (SF-1), a transcription factor that is required for mc2-r expression in adrenal cells. Transcriptional regulation of the mc2-r in the absence of SF-1 was investigated by 5' deletion analysis of the murine mc2-r promoter in both undifferentiated and differentiated 3T3-L1 cells. The results revealed the presence of a 59-base pair regulatory region within the promoter containing an adipocyte-specific enhancer. The ability of this region to confer enhanced activity in the adipocyte was mapped to a peroxisome proliferator-response element (PPRE)-like sequence that bound to peroxisome proliferator-activated receptor gamma (PPARgamma) and its heterodimeric partner retinoid X receptor alpha (RXRalpha) in adipocyte nuclear extracts. Co-transfection of PPARgamma2/RXRalpha with the pMC2-R(-112/+105)GL3 reporter resulted in transcriptional activation in preadipocytes, and this response required an intact PPRE. Mutation of the PPRE to prevent PPARgamma/RXRalpha binding resulted in a complete abrogation of the pMC2-R(-112/+105)GL3 reporter activity in day 3 differentiated 3T3-L1 cells, demonstrating a key role played by this site in regulating MC2-R expression in the murine adipocyte. These data highlight a novel mechanism for mc2-r transcription, which may have significance in both adrenal and extra-adrenal sites of expression.	Univ London, Mol Endocrinol Ctr, William Harvey Res Inst, London EC1A 7BE, England	University of London; Queen Mary University London	Peter, JK (corresponding author), Univ London, Mol Endocrinol Ctr, William Harvey Res Inst, London EC1A 7BE, England.	p.j.king@qmul.ac.uk	Noon, Luke A/H-4141-2014	Noon, Luke A/0000-0002-0502-4322				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Beuschlein F, 2002, ENDOCRINOLOGY, V143, P3122, DOI 10.1210/en.143.8.3122; Bland ML, 2000, P NATL ACAD SCI USA, V97, P14488, DOI 10.1073/pnas.97.26.14488; BOSCARO M, 1988, J CLIN ENDOCR METAB, V66, P255, DOI 10.1210/jcem-66-2-255; Boston BA, 1996, ENDOCRINOLOGY, V137, P2043, DOI 10.1210/en.137.5.2043; Boston BA, 1999, ANN NY ACAD SCI, V885, P75; BOUSQUETMELOU A, 1995, J LIPID RES, V36, P451; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; Cammas FM, 1997, MOL ENDOCRINOL, V11, P867, DOI 10.1210/me.11.7.867; Chhajlani V, 1996, BIOCHEM MOL BIOL INT, V38, P73; Clyne CD, 2002, J BIOL CHEM, V277, P20591, DOI 10.1074/jbc.M201117200; Fowkes RC, 2003, J MOL ENDOCRINOL, V31, P263, DOI 10.1677/jme.0.0310263; Frohnert BI, 1999, J BIOL CHEM, V274, P3970, DOI 10.1074/jbc.274.7.3970; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; GRUNFELD C, 1985, ENDOCRINOLOGY, V116, P113, DOI 10.1210/endo-116-1-113; Heaney AP, 2002, NAT MED, V8, P1281, DOI 10.1038/nm784; Heaney AP, 2003, J CLIN INVEST, V111, P1381, DOI 10.1172/JCI200316575; Kim YC, 1999, BIOCHEM BIOPH RES CO, V266, P1, DOI 10.1006/bbrc.1999.1704; King PJ, 1998, ENDOCR RES, V24, P397, DOI 10.3109/07435809809032621; Kiwaki K, 2003, J COMP PHYSIOL B, V173, P675, DOI 10.1007/s00360-003-0377-1; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Lotfi CFP, 1997, J BIOL CHEM, V272, P29886, DOI 10.1074/jbc.272.47.29886; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Marchal R, 1998, BIOCHEM BIOPH RES CO, V247, P28, DOI 10.1006/bbrc.1998.8733; MASUI H, 1971, P NATL ACAD SCI USA, V68, P3206, DOI 10.1073/pnas.68.12.3206; Morris DG, 2003, J CLIN ENDOCR METAB, V88, P6080, DOI 10.1210/jc.2002-022048; Nanbu-Wakao R, 2002, MOL ENDOCRINOL, V16, P1565, DOI 10.1210/me.16.7.1565; Nankova BB, 2003, NEUROSCI LETT, V344, P149, DOI 10.1016/S0304-3940(03)00361-6; Naville D, 1997, BIOCHEM BIOPH RES CO, V230, P7, DOI 10.1006/bbrc.1996.5911; Naville D, 1999, BIOCHEM BIOPH RES CO, V255, P28, DOI 10.1006/bbrc.1998.9891; Norman D, 2003, MOL CELL ENDOCRINOL, V200, P99, DOI 10.1016/S0303-7207(02)00410-0; O'Shaughnessy PJ, 2003, ENDOCRINOLOGY, V144, P3279, DOI 10.1210/en.2003-0277; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAMACHANDRAN J, 1976, BIOCHIM BIOPHYS ACTA, V428, P339, DOI 10.1016/0304-4165(76)90041-6; Sarkar D, 2000, ENDOCR J, V47, P63, DOI 10.1507/endocrj.47.63; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SIMPSON ER, 1983, CAN J BIOCHEM CELL B, V61, P692, DOI 10.1139/o83-088; Slominski A, 1996, J CLIN ENDOCR METAB, V81, P2746, DOI 10.1210/jc.81.7.2746; Smith SR, 2003, DIABETES, V52, P2914, DOI 10.2337/diabetes.52.12.2914; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WHITE JE, 1958, J CLIN INVEST, V37, P1556, DOI 10.1172/JCI103748; WHITESIDE ST, 1992, NUCLEIC ACIDS RES, V20, P1531, DOI 10.1093/nar/20.7.1531; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	48	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22803	22808		10.1074/jbc.M401861200	http://dx.doi.org/10.1074/jbc.M401861200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15028712	hybrid			2022-12-25	WOS:000221570900005
J	Assem, M; Schuetz, EG; Leggas, M; Sun, DX; Yasuda, K; Reid, G; Zelcer, N; Adachi, M; Strom, S; Evans, RM; Moore, DD; Borst, P; Schuetz, JD				Assem, M; Schuetz, EG; Leggas, M; Sun, DX; Yasuda, K; Reid, G; Zelcer, N; Adachi, M; Strom, S; Evans, RM; Moore, DD; Borst, P; Schuetz, JD			Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; NUCLEAR RECEPTOR; BILE-ACIDS; IN-VIVO; P-GLYCOPROTEIN; HYDROXYSTEROID SULFOTRANSFERASE; LITHOCHOLIC ACID; DRUG-METABOLISM; GENE-EXPRESSION; PROTEIN-3 MRP3	The ABC transporter, Mrp4, transports the sulfated steroid DHEA-s, and sulfated bile acids interact with Mrp4 with high affinity. Hepatic Mrp4 levels are low, but increase under cholestatic conditions. We therefore inferred that up-regulation of Mrp4 during cholestasis is a compensatory mechanism to protect the liver from accumulation of hydrophobic bile acids. We determined that the nuclear receptor CAR is required to coordinately up-regulate hepatic expression of Mrp4 and an enzyme known to sulfate hydroxy-bile acids and steroids, Sult2a1. CAR activators increased Mrp4 and Sult2a1 expression in primary human hepatocytes and HepG2, a human liver cell line. Sult2a1 was down-regulated in Mrp4-null mice, further indicating an inter-relation between Mrp4 and Sult2a1 gene expression. Based on the hydrophilic nature of sulfated bile acids and the Mrp4 capability to transport sulfated steroids, our findings suggest that Mrp4 and Sult2a1 participate in an integrated pathway mediating elimination of sulfated steroid and bile acid metabolites from the liver.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Netherlands Cancer Institute; Netherlands Cancer Institute; Baylor College of Medicine; Howard Hughes Medical Institute; Salk Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schuetz, JD (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale Ave, Memphis, TN 38105 USA.	John.schuetz@stjude.org	Strom, Stephen C/A-6501-2008; Leggas, Markos/E-6618-2011; Schuetz, John D/N-2692-2018; Schuetz, Erin/N-8087-2018; Evans, Ronald/AAF-4001-2019; Zelcer, Noam/C-6393-2009	Leggas, Markos/0000-0003-4314-4533; Evans, Ronald/0000-0002-9986-5965; Reid, Glen/0000-0001-6465-5223; Strom, Stephen/0000-0002-2889-3387; Zelcer, Noam/0000-0001-6935-7532	NCI NIH HHS [P30 CA21745, CA77545] Funding Source: Medline; NIEHS NIH HHS [ES058571] Funding Source: Medline; NIGMS NIH HHS [GM60346, GM60904, U01-GM61393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM060904, R01GM060346, R01GM060904, U01GM061393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 2002, J BIOL CHEM, V277, P38998, DOI 10.1074/jbc.M203262200; ANDERSON KE, 1986, CLIN PHARMACOL THER, V39, P510, DOI 10.1038/clpt.1986.88; Araya Z, 1999, BBA-MOL CELL BIOL L, V1438, P47, DOI 10.1016/S1388-1981(99)00031-1; CAPRON JP, 1975, DIGESTION, V12, P43, DOI 10.1159/000197653; Cherrington NJ, 2003, DRUG METAB DISPOS, V31, P1315, DOI 10.1124/dmd.31.11.1315; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; GADACZ TR, 1976, GASTROENTEROLOGY, V70, P1125; Guo GL, 2003, J BIOL CHEM, V278, P45062, DOI 10.1074/jbc.M307145200; Handschin C, 2003, PHARMACOL REV, V55, P649, DOI 10.1124/pr.55.4.2; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; Imai Y, 2003, MOL PHARMACOL, V64, P610, DOI 10.1124/mol.64.3.610; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kitada H, 2003, J BIOL CHEM, V278, P17838, DOI 10.1074/jbc.M210634200; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Lamba JK, 2003, HUM MOL GENET, V12, P99, DOI 10.1093/hmg/ddg011; Lecureur V, 2000, MOL PHARMACOL, V57, P24; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; Ostrow J. Donald, 1993, P673; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PIPER WN, 1986, ARCH BIOCHEM BIOPHYS, V246, P143, DOI 10.1016/0003-9861(86)90457-1; Raftogianis RB, 1997, BIOCHEM BIOPH RES CO, V239, P298, DOI 10.1006/bbrc.1997.7466; Rius M, 2003, HEPATOLOGY, V38, P374, DOI 10.1053/jhep.2003.50331; Schuetz E, 2002, MOL PHARMACOL, V62, P439, DOI 10.1124/mol.62.3.439; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Shimizu C, 2003, ENDOCRINOLOGY, V144, P1186, DOI 10.1210/en.2002-221011; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Song CS, 1998, J BIOL CHEM, V273, P21856, DOI 10.1074/jbc.273.34.21856; Sonoda J, 2002, P NATL ACAD SCI USA, V99, P13801, DOI 10.1073/pnas.212494599; St-Pierre MV, 2001, J EXP BIOL, V204, P1673; Staudinger JL, 2003, DRUG METAB DISPOS, V31, P523, DOI 10.1124/dmd.31.5.523; Stieger B, 2000, GASTROENTEROLOGY, V118, P422, DOI 10.1016/S0016-5085(00)70224-1; STRAUTNIEKS SS, 2003, J NAT GENET, V20, P233; Strott CA, 2002, ENDOCR REV, V23, P703, DOI 10.1210/er.2001-0040; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Wagner M, 2003, GASTROENTEROLOGY, V125, P825, DOI 10.1016/S0016-5085(03)01068-0; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang RX, 2003, HEPATOLOGY, V38, P1489, DOI 10.1016/j.hep.2003.09.037; Wang RX, 2001, P NATL ACAD SCI USA, V98, P2011, DOI 10.1073/pnas.031465498; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xiong H, 2002, DRUG METAB DISPOS, V30, P918, DOI 10.1124/dmd.30.8.918; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886; Zelcer N, 2003, BIOCHEM J, V369, P23, DOI 10.1042/BJ20021081; ZELCER N, 2003, THESIS NETHERLANDS C; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999	50	198	208	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22250	22257		10.1074/jbc.M314111200	http://dx.doi.org/10.1074/jbc.M314111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15004017	hybrid			2022-12-25	WOS:000221417100072
J	Westin, MAK; Alexson, SEH; Hunt, MC				Westin, MAK; Alexson, SEH; Hunt, MC			Molecular cloning and characterization of two mouse peroxisome proliferator-activated receptor alpha (PPAR alpha)-regulated peroxisomal Acyl-CoA thioesterases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; FATTY-ACID OXIDATION; BETA-OXIDATION; ADAPTIVE RESPONSE; MESSENGER-RNA; EXPRESSION; METABOLISM; IDENTIFICATION; PURIFICATION; EICOSANOIDS	Peroxisomes are organelles that function in the beta-oxidation of long- and very long- chain acyl- CoAs, bile acid- CoA intermediates, prostaglandins, leukotrienes, thromboxanes, dicarboxylic fatty acids, pristanic acid, and xenobiotic carboxylic acids. The very long- and long- chain acyl- CoAs are mainly chain- shortened and then transported to mitochondria for further metabolism. We have now identified and characterized two peroxisomal acyl- CoA thioesterases, named PTE- Ia and PTE- Ic, that hydrolyze acyl- CoAs to the free fatty acid and coenzyme A. PTE- Ia and PTE- Ic show 82% sequence identity at the amino acid level, and a putative peroxisomal type 1 targeting signal of - AKL was identified at the carboxyl- terminal end of both proteins. Localization experiments using green fluorescent fusion protein showed PTE- Ia and PTE- Ic to be localized in peroxisomes. Despite their high level of sequence identity, we show that PTE- Ia is mainly active on long- chain acyl-CoAs, whereas PTE- Ic is mainly active on medium- chain acyl- CoAs. Lack of regulation of enzyme activity by free CoASH suggests that PTE- Ia and PTE- Ic regulate intra-peroxisomal levels of acyl- CoA, and they may have a function in termination of beta- oxidation of fatty acids of different chain lengths. Tissue expression studies revealed that PTE- Ia is highly expressed in kidney, whereas PTE- Ic is most highly expressed in spleen, brain, testis, and proximal and distal intestine. Both PTE- Ia and PTE- Ic were highly up- regulated in mouse liver by treatment with the peroxisome proliferator WY- 14,643 and by fasting in a peroxisome proliferator- activated receptor alpha- dependent manner. These data show that PTE- Ia and PTE- Ic have different functions based on different substrate specificities and tissue expression.	Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Chem, SE-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Hunt, MC (corresponding author), Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Chem, C1-74, SE-14186 Stockholm, Sweden.	mary.hunt@labmed.ki.se		Watter, Maria/0000-0001-9047-5517; Hunt, Mary/0000-0001-6415-2992				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DICZFALUSY U, 1991, J CLIN INVEST, V88, P978, DOI 10.1172/JCI115401; FALANY CN, 1994, J BIOL CHEM, V269, P19375; Falany CN, 1997, J LIPID RES, V38, P1139; Ferdinandusse S, 1999, BIOCHEM BIOPH RES CO, V263, P213, DOI 10.1006/bbrc.1999.1340; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FURUTANI M, 1995, BIOCHEM J, V311, P203, DOI 10.1042/bj3110203; Garcia-Blanco MA, 2003, J CLIN INVEST, V112, P474, DOI 10.1172/JCI200319462; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Hiltunen JK, 2000, BBA-MOL CELL BIOL L, V1484, P117, DOI 10.1016/S1388-1981(00)00013-5; Huhtinen K, 2002, J BIOL CHEM, V277, P3424, DOI 10.1074/jbc.M109040200; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Hunt MC, 2000, J LIPID RES, V41, P814; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jones JM, 2000, BIOCHEM BIOPH RES CO, V275, P233, DOI 10.1006/bbrc.2000.3285; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Legakis JE, 2001, TRAFFIC, V2, P252, DOI 10.1034/j.1600-0854.2001.90165.x; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; NEMALI MR, 1988, CANCER RES, V48, P5316; Ofman R, 2002, BIOCHEM BIOPH RES CO, V290, P629, DOI 10.1006/bbrc.2001.6245; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Tilton GB, 2004, J BIOL CHEM, V279, P7487, DOI 10.1074/jbc.M309532200; van Roermund CWT, 2003, CELL MOL LIFE SCI, V60, P1838, DOI 10.1007/s00018-003-3076-x; van Roermund CWT, 2000, J CELL BIOL, V150, P489, DOI 10.1083/jcb.150.3.489; Van Veldhoven PP, 1999, ADV EXP MED BIOL, V466, P261; Wanders RJA, 2001, BIOCHEM SOC T, V29, P250, DOI 10.1042/0300-5127:0290250; Watanabe W, 1997, BIOCHEM BIOPH RES CO, V238, P234, DOI 10.1006/bbrc.1997.7217; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x	38	34	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21841	21848		10.1074/jbc.M313863200	http://dx.doi.org/10.1074/jbc.M313863200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007068	hybrid			2022-12-25	WOS:000221417100022
J	McInerney, P; O'Donnell, M				McInerney, P; O'Donnell, M			Functional uncoupling of twin polymerases - Mechanism of polymerase dissociation from a lagging-strand block	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; ONE HOLOENZYME PARTICLE; 2 DNA-POLYMERASES; III HOLOENZYME; LEADING-STRAND; SLIDING CLAMPS; BETA-CLAMP; LESION; REPAIR; TAU	Replication forks are constantly subjected to events that lead to fork stalling, stopping, or collapse. Using a synthetic rolling circle DNA substrate, we demonstrate that a block to the lagging-strand polymerase does not compromise helicase or leading-strand polymerase activity. In fact, lagging-strand synthesis also continues. Thus, the blocked lagging-strand enzyme quickly dissociates from the block site and resumes synthesis on new primed sites. Furthermore, studies in which the lagging polymerase is continuously blocked show that the leading polymerase continues unabated even as it remains attached to the lagging-strand enzyme. Hence, upon encounter of a block to the lagging stand, the polymerases functionally uncouple yet remain physically associated. Further study reveals that naked single-stranded DNA results in disruption of a stalled polymerase from its beta-DNA substrate. Thus, as the replisome advances, the single-stranded DNA loop that accumulates on the lagging-strand template releases the stalled lagging-strand polymerase from beta after SSB protein is depleted. The lagging-strand polymerase is then free to continue Okazaki fragment production.	Rockefeller Univ, Howard Hughes Med Inst, Lab DNA Replicat, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	O'Donnell, M (corresponding author), 1230 York Ave, New York, NY 10021 USA.	odonnel@mail.rockefeller.edu		O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM 62540, GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839, R01GM062540] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Berdichevsky A, 2002, MOL CELL, V10, P917, DOI 10.1016/S1097-2765(02)00679-2; Courcelle J, 2003, ANNU REV GENET, V37, P611, DOI 10.1146/annurev.genet.37.110801.142616; Courcelle J, 1999, J BACTERIOL, V181, P916, DOI 10.1128/JB.181.3.916-922.1999; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Falkenberg M, 2000, P NATL ACAD SCI USA, V97, P3896, DOI 10.1073/pnas.97.8.3896; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Higuchi K, 2003, GENES CELLS, V8, P437, DOI 10.1046/j.1365-2443.2003.00646.x; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Kadyrov FA, 2002, NUCLEIC ACIDS RES, V30, P4387, DOI 10.1093/nar/gkf576; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Leu FP, 2003, MOL CELL, V11, P315, DOI 10.1016/S1097-2765(03)00042-X; Li XJ, 2000, J BIOL CHEM, V275, P34757, DOI 10.1074/jbc.M006556200; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pages V, 2003, SCIENCE, V300, P1300, DOI 10.1126/science.1083964; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; Pham P, 2001, NATURE, V409, P366, DOI 10.1038/35053116; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; RUPP WD, 1971, J MOL BIOL, V61, P25, DOI 10.1016/0022-2836(71)90204-X; RUPP WD, 1968, J MOL BIOL, V31, P291, DOI 10.1016/0022-2836(68)90445-2; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Wagner J, 2000, EMBO REP, V1, P484; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	39	95	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21543	21551		10.1074/jbc.M401649200	http://dx.doi.org/10.1074/jbc.M401649200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15014081	hybrid			2022-12-25	WOS:000221273800120
J	Rusch, D; Zhong, HJ; Forman, SA				Rusch, D; Zhong, HJ; Forman, SA			Gating allosterism at a single class of etomidate sites on alpha(1)beta(2)gamma(2L) GABA(A) receptors accounts for both direct activation and agonist modulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; GENERAL ANESTHETIC ETOMIDATE; NICOTINIC ACETYLCHOLINE-RECEPTORS; A RECEPTOR; HIPPOCAMPAL-NEURONS; RECOMBINANT GABA(A); KINETIC-PROPERTIES; GLYCINE RECEPTORS; AMINO-ACID; VOLATILE ANESTHETICS	At clinical concentrations, the potent intravenous general anesthetic etomidate enhances gamma-aminobutyric acid, type A (GABA(A)) receptor activity elicited with low gamma-aminobutyric acid (GABA) concentrations, whereas much higher etomidate concentrations activate receptors in the absence of GABA. Therefore, GABA(A) receptors may possess two types of etomidate sites: high affinity GABA-modulating sites and low affinity channel-activating sites. However, GABA modulation and direct activation share stereoselectivity for the (R)(+)-etomidate isomer and display parallel dependence on GABA(A) beta subunit isoforms, suggesting that these two actions may be mediated by a single class of etomidate site(s) that exert one or more molecular effects. In this study, we assessed GABA modulation by etomidate using leftward shifts of electrophysiological GABA concentration responses in cells expressing human alpha(1)beta(2)gamma(2L) receptors. Etomidate at up to 100 muM reduced GABA EC50 values by over 100-fold but without apparent saturation, indicating the absence of high affinity etomidate sites. In experiments using a partial agonist, P4S, etomidate both reduced EC50 and increased maximal efficacy, demonstrating that etomidate shifts the GABA(A) receptor gating equilibrium toward open states. Results were quantitatively analyzed using equilibrium receptor gating models, wherein a postulated class of equivalent etomidate sites both directly activates receptors and enhances agonist gating. A Monod-Wyman-Changeux co-agonist mechanism with two equivalent etomidate sites that allosterically enhance GABA(A) receptor gating independently of agonist binding most simply accounts for direct activation and agonist modulation. This model also correctly predicts the actions of etomidate on GABA(A) receptors containing a point mutation that increases constitutive gating activity.	Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; Univ Hosp Schleswig Holstein, Dept Anesthesia & Crit Care, D-24105 Kiel, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Kiel; Schleswig Holstein University Hospital	Forman, SA (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, CLN-3, Boston, MA 02114 USA.	saforman@partners.org	Forman, Stuart/Q-6590-2019	Forman, Stuart/0000-0001-6340-2478	NIGMS NIH HHS [R01 GM 66724, P01 GM 58448] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058448, R01GM066724] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aistrup GL, 1999, MOL PHARMACOL, V55, P39, DOI 10.1124/mol.55.1.39; Akk G, 2003, J PHYSIOL-LONDON, V546, P641, DOI 10.1113/jphysiol.2002.032300; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; ARDEN JR, 1986, ANESTHESIOLOGY, V65, P19, DOI 10.1097/00000542-198607000-00004; Bai DL, 1999, J NEUROSCI, V19, P10635, DOI 10.1523/JNEUROSCI.19-24-10635.1999; Banks MI, 1999, ANESTHESIOLOGY, V90, P120, DOI 10.1097/00000542-199901000-00018; BAUMANN A, J NEUROSCI, V23, P11158; Belelli D, 2003, NEUROPHARMACOLOGY, V45, P57, DOI 10.1016/S0028-3908(03)00144-8; Belelli D, 1997, P NATL ACAD SCI USA, V94, P11031, DOI 10.1073/pnas.94.20.11031; Bianchi MT, 2003, J NEUROSCI, V23, P10934; Boileau AJ, 2003, NEUROPHARMACOLOGY, V44, P1003, DOI 10.1016/S0028-3908(03)00114-X; Carlson BX, 2000, MOL PHARMACOL, V57, P474, DOI 10.1124/mol.57.3.474; Carlson BX, 1997, ANESTHESIA BIOL FDN, P259; CASH DJ, 1988, BIOCHEMISTRY-US, V27, P4580, DOI 10.1021/bi00412a053; Cestari IN, 2000, J NEUROCHEM, V74, P827, DOI 10.1046/j.1471-4159.2000.740827.x; Chang CSS, 2003, J BIOL CHEM, V278, P42821, DOI 10.1074/jbc.M306978200; Chang YC, 1999, BIOPHYS J, V77, P2542, DOI 10.1016/S0006-3495(99)77089-X; Chang YC, 1996, J NEUROSCI, V16, P5415; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Dalziel JE, 1999, EUR J PHARMACOL, V385, P283, DOI 10.1016/S0014-2999(99)00710-4; Edelstein SJ, 1996, EXPERIENTIA, V52, P1083, DOI 10.1007/BF01952106; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; Findlay GS, 2001, NEUROSCI LETT, V305, P76, DOI 10.1016/S0304-3940(01)01879-1; Forman SA, 1999, MOL PHARMACOL, V55, P102, DOI 10.1124/mol.55.1.102; Forman SA, 1999, BIOCHEMISTRY-US, V38, P14559, DOI 10.1021/bi9914457; Greenfield LJ, 2002, NEUROPHARMACOLOGY, V42, P502, DOI 10.1016/S0028-3908(01)00196-4; HALL AC, 1994, BRIT J PHARMACOL, V112, P906, DOI 10.1111/j.1476-5381.1994.tb13166.x; Hall DA, 2000, MOL PHARMACOL, V58, P1412, DOI 10.1124/mol.58.6.1412; HillVenning C, 1997, BRIT J PHARMACOL, V120, P749, DOI 10.1038/sj.bjp.0700927; Husain SS, 2003, J MED CHEM, V46, P1257, DOI 10.1021/jm020465v; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; JONES MV, 1992, J PHYSIOL-LONDON, V449, P279, DOI 10.1113/jphysiol.1992.sp019086; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; Krasowski MD, 2001, NEUROPHARMACOLOGY, V41, P952, DOI 10.1016/S0028-3908(01)00141-1; Krasowski MD, 2001, J PHARMACOL EXP THER, V297, P338; Kurata Y, 1999, MOL PHARMACOL, V55, P1011, DOI 10.1124/mol.55.6.1011; Lambert JJ, 1996, CELL MOL NEUROBIOL, V16, P155, DOI 10.1007/BF02088174; Li XS, 2000, J NEUROSCI, V20, P899, DOI 10.1523/JNEUROSCI.20-03-00899.2000; MACDONALD RL, 1989, J PHYSIOL-LONDON, V417, P483, DOI 10.1113/jphysiol.1989.sp017814; Mascia MP, 1996, BRIT J PHARMACOL, V119, P1331, DOI 10.1111/j.1476-5381.1996.tb16042.x; McGurk KA, 1998, BRIT J PHARMACOL, V124, P13, DOI 10.1038/sj.bjp.0701787; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; MIHIC SJ, 1994, EUR J PHARM-MOLEC PH, V268, P209; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Moody EJ, 1997, J NEUROCHEM, V69, P1310; O'Shea SM, 2000, BRAIN RES, V852, P344, DOI 10.1016/S0006-8993(99)02151-4; Petrini EM, 2003, J BIOL CHEM, V278, P16271, DOI 10.1074/jbc.M213081200; Pistis M, 1997, BRIT J PHARMACOL, V122, P1707, DOI 10.1038/sj.bjp.0701563; Reynolds DS, 2003, NEUROPHARMACOLOGY, V44, P190, DOI 10.1016/S0028-3908(02)00370-2; Scheller M, 2002, J NEUROSCI, V22, P8411; Scheller M, 2001, ANESTHESIOLOGY, V95, P123, DOI 10.1097/00000542-200107000-00022; Serafini R, 2000, J PHYSIOL-LONDON, V524, P649, DOI 10.1111/j.1469-7793.2000.00649.x; Steinbach JH, 2001, J PHYSIOL-LONDON, V537, P715; Thompson SA, 1999, BRIT J PHARMACOL, V127, P1349, DOI 10.1038/sj.bjp.0702687; Tomlin SL, 1998, ANESTHESIOLOGY, V88, P708, DOI 10.1097/00000542-199803000-00022; Topf N, 2003, ANESTHESIOLOGY, V98, P306, DOI 10.1097/00000542-200302000-00007; TURNER DM, 1989, J PHARMACOL EXP THER, V248, P960; TWYMAN RE, 1992, J PHYSIOL-LONDON, V456, P215, DOI 10.1113/jphysiol.1992.sp019334; UCHIDA I, 1995, NEUROSCI LETT, V185, P203, DOI 10.1016/0304-3940(95)11263-V; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; WEISS DS, 1989, J NEUROSCI, V9, P1314; Whiting PJ, 1995, INT REV NEUROBIOL, V38, P95, DOI 10.1016/S0074-7742(08)60525-5; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Williams DB, 2002, J NEUROSCI, V22, P7417; Yang J, 1996, NEUROSCIENCE, V73, P69, DOI 10.1016/0306-4522(96)00018-8; Zhou Q, 1998, J PHYSIOL-LONDON, V507, P335, DOI 10.1111/j.1469-7793.1998.335bt.x	69	100	102	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20982	20992		10.1074/jbc.M400472200	http://dx.doi.org/10.1074/jbc.M400472200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016806	hybrid			2022-12-25	WOS:000221273800053
J	Stefansson, A; Armulik, A; Nilsson, IM; von Heijne, G; Johansson, S				Stefansson, A; Armulik, A; Nilsson, IM; von Heijne, G; Johansson, S			Determination of N- and C-terminal borders of the transmembrane domain of integrin subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; CELL-ADHESION; BETA-SUBUNIT; ACTIVATION; MODULATION; SEQUENCE; PROTEINS; RECEPTOR; CLONING	Previous studies on the membrane-cytoplasm interphase of human integrin subunits have shown that a conserved lysine in subunits alpha(2), alpha(5), beta(1), and beta(2) is embedded in the plasma membrane in the absence of interacting proteins (Armulik, A., Nilsson, I., von Heijne, G., and Johansson, S. (1999) in J. Biol. Chem. 274, 37030-37034). Using a glycosylation mapping technique, we here show that alpha(10) and beta(8), two subunits that deviate significantly from the integrin consensus sequences in the membrane-proximal region, were found to have the conserved lysine at a similar position in the lipid bilayer. Thus, this organization at the C-terminal end of the transmembrane (TM) domain seems likely to be general for all 24 integrin subunits. Furthermore, we have determined the N-terminal border of the TM domains of the alpha(2), alpha(5), alpha(10), beta(1), and beta(8) subunits. The TM domain of subunit beta(8) is found to be 22 amino acids long, with a second basic residue (Arg(684)) positioned just inside the membrane at the exoplasmic side, whereas the lipid-embedded domains of the other subunits are longer, varying from 25 (alpha(2)) to 29 amino acids (alpha(10)). These numbers implicate that the TM region of the analyzed integrins (except beta(8)) would be tilted or bent in the membrane. Integrin signaling by transmembrane conformational change may involve alteration of the position of the segment adjacent to the conserved lysine. To test the proposed "piston" model for signaling, we forced this region at the C-terminal end of the alpha(5) and beta(1) TM domains out of the membrane into the cytosol by replacing Lys-Leu with Lys-Lys. The mutation was found to not alter the position of the N-terminal end of the TM domain in the membrane, indicating that the TM domain is not moving as a piston. Instead the shift results in a shorter and therefore less tilted or bent TM alpha-helix.	Uppsala Univ, Dept Med Biochem & Microbiol, BMC, SE-75123 Uppsala, Sweden; Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden	Uppsala University; Stockholm University	Johansson, S (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, BMC, SE-75123 Uppsala, Sweden.	staffan.johansson@imbim.uu.se	von Heijne, Gunnar/F-5576-2011; Nilsson, IngMarie/H-2887-2012; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; Carnwall, Anne/0000-0003-0668-3095; Keller, Annika/0000-0003-1466-3633				Adair BD, 2002, P NATL ACAD SCI USA, V99, P14059, DOI 10.1073/pnas.212498199; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; Armulik A, 1999, J BIOL CHEM, V274, P37030, DOI 10.1074/jbc.274.52.37030; ARMULIK A, 2004, IN PRESS MOL BIOL CE; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Dempski RE, 2002, CURR OPIN CHEM BIOL, V6, P844, DOI 10.1016/S1367-5931(02)00390-3; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Gottschalk KE, 2002, PROTEIN SCI, V11, P1800, DOI 10.1110/ps.4120102; Humphries MJ, 2003, CURR OPIN STRUC BIOL, V13, P236, DOI 10.1016/S0959-440X(03)00035-6; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Leisner TM, 1999, J BIOL CHEM, V274, P12945, DOI 10.1074/jbc.274.18.12945; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Li RH, 2002, BIOCHEMISTRY-US, V41, P15618, DOI 10.1021/bi026822l; LILJESTROM P, 1991, J VIROL, V65, P147; MOYLE M, 1991, J BIOL CHEM, V266, P19650; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Schneider D, 2004, J BIOL CHEM, V279, P9840, DOI 10.1074/jbc.M312749200; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; Xiong YM, 2003, J IMMUNOL, V171, P1042, DOI 10.4049/jimmunol.171.2.1042	33	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21200	21205		10.1074/jbc.M400771200	http://dx.doi.org/10.1074/jbc.M400771200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016834	hybrid			2022-12-25	WOS:000221273800079
J	Turk, K; Puhar, A; Neese, F; Bill, E; Gunter, F; Steuber, J				Turk, K; Puhar, A; Neese, F; Bill, E; Gunter, F; Steuber, J			NADH oxidation by the Na+-translocating NADH : quinone oxidoreductase from Vibrio cholerae - Functional role of the NqrF subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-I; UBIQUINONE OXIDOREDUCTASE; NADHUBIQUINONE OXIDOREDUCTASE; BENZOATE 1,2-DIOXYGENASE; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; STRUCTURAL GENES; REDUCTASE; ALGINOLYTICUS; FERREDOXIN	The Na+-translocating NADH: quinone oxidoreductase from Vibrio cholerae is a six subunit enzyme containing four flavins and a single motif for the binding of a Fe-S cluster on its NqrF subunit. This study reports the production of a soluble variant of NqrF (NqrF') and its individual flavin and Fe-S-carrying domains using V. cholerae or Escherichia coli as expression hosts. NqrF' and the flavin domain each contain 1 mol of FAD/mol of enzyme and exhibit high NADH oxidation activity (20,000 mumol min(-1) mg(-1)). EPR, visible absorption, and circular dichroism spectroscopy indicate that the Fe-S cluster in NqrF' and its Fe-S domain is related to 2Fe ferredoxins of the vertebrate-type. The addition of NADH to NqrF' results in the formation of a neutral flavosemiquinone and a partial reduction of the Fe-S cluster. The NqrF subunit harbors the active site of NADH oxidation and acts as a converter between the hydride donor NADH and subsequent one-electron reaction steps in the Na+-translocating NADH: quinone oxidoreductase complex. The observed electron transfer NADH-->FAD-->[2Fe-2S] in NqrF requires positioning of the FAD and the Fe-S cluster in close proximity in accordance with a structural model of the subunit.	ETH Zentrum, Inst Mikrobiol, CH-8092 Zurich, Switzerland; Max Planck Inst Bioanorgan Chem, D-45470 Mulheim, Germany; Univ Konstanz, Fachbereich Biol, D-78457 Constance, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Max Planck Society; University of Konstanz	Steuber, J (corresponding author), ETH Zentrum, Inst Mikrobiol, CH-8092 Zurich, Switzerland.	fritz-steuber@micro.biol.ethz.ch	Fritz, Guenter/E-2933-2013; Neese, Frank/J-4959-2014	Fritz, Guenter/0000-0002-4571-8812; Neese, Frank/0000-0003-4691-0547; Puhar, Andrea/0000-0002-9915-002X				Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Barquera B, 2001, FEBS LETT, V492, P45, DOI 10.1016/S0014-5793(01)02224-4; Barquera B, 2002, P NATL ACAD SCI USA, V99, P10322, DOI 10.1073/pnas.162361299; Barquera B, 2002, BIOCHEMISTRY-US, V41, P3781, DOI 10.1021/bi011873o; Barquera B, 2003, J AM CHEM SOC, V125, P265, DOI 10.1021/ja0207201; BEATTIE P, 1994, FEBS LETT, V356, P333, DOI 10.1016/0014-5793(94)01275-X; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1978, Methods Enzymol, V54, P435; Bogachev AV, 2002, BBA-BIOENERGETICS, V1556, P113, DOI 10.1016/S0005-2728(02)00342-0; CHANCE B, 1954, SCIENCE, V120, P767, DOI 10.1126/science.120.3124.767; CHENG H, 1994, BIOCHEMISTRY-US, V33, P3155, DOI 10.1021/bi00177a003; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; Fato R, 1996, BIOCHEMISTRY-US, V35, P2705, DOI 10.1021/bi9516034; Gemperli AC, 2003, P NATL ACAD SCI USA, V100, P839, DOI 10.1073/pnas.0237328100; Gemperli AC, 2002, J BIOL CHEM, V277, P33811, DOI 10.1074/jbc.M204860200; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; HAMASHIMA H, 1990, MICROBIOL IMMUNOL, V34, P703, DOI 10.1111/j.1348-0421.1990.tb01047.x; Hase CC, 1999, P NATL ACAD SCI USA, V96, P3183, DOI 10.1073/pnas.96.6.3183; Hayashi M, 2001, FEBS LETT, V488, P5, DOI 10.1016/S0014-5793(00)02404-2; HAYASHI M, 1995, FEBS LETT, V363, P75, DOI 10.1016/0014-5793(95)00283-F; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; HUNT J, 1993, J BIOL CHEM, V268, P18685; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P15109, DOI 10.1021/bi972001i; Karlsson A, 2002, J MOL BIOL, V318, P261, DOI 10.1016/S0022-2836(02)00039-6; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; LU GG, 1995, J MOL BIOL, V248, P931, DOI 10.1006/jmbi.1995.0273; Macheroux P, 1999, METH MOL B, V131, P1; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; McLean KJ, 2003, BIOCHEM J, V372, P317, DOI 10.1042/BJ20021692; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; Muller A, 1998, STRUCTURE, V6, P269, DOI 10.1016/S0969-2126(98)00031-8; Nakayama Y, 1998, FEBS LETT, V422, P240, DOI 10.1016/S0014-5793(98)00016-7; Neese F, 1996, J AM CHEM SOC, V118, P8692, DOI 10.1021/ja960125x; Neese F., 1995, QUANT CHEM PROGR EXC, V136, P5; Padan E, 2001, BBA-BIOENERGETICS, V1505, P144, DOI 10.1016/S0005-2728(00)00284-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PfenningerLi XD, 1996, BIOCHEMISTRY-US, V35, P6233, DOI 10.1021/bi953032l; RICH PR, 1995, FEBS LETT, V375, P5, DOI 10.1016/0014-5793(95)01164-A; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Steuber J, 2003, J BIOL CHEM, V278, P26817, DOI 10.1074/jbc.M301682200; Steuber J, 2000, MOL MICROBIOL, V35, P428, DOI 10.1046/j.1365-2958.2000.01712.x; Steuber J, 2002, EUR J BIOCHEM, V269, P1287, DOI 10.1046/j.1432-1033.2002.02770.x; Steuber J, 1997, EUR J BIOCHEM, V249, P770, DOI 10.1111/j.1432-1033.1997.t01-2-00770.x; TA DT, 1992, J BIOL CHEM, V267, P11120; TOKUDA H, 1982, J BIOL CHEM, V257, P7; Wolfe MD, 2002, BIOCHEMISTRY-US, V41, P9611, DOI 10.1021/bi025912n; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zhou WD, 1999, BIOCHEMISTRY-US, V38, P16246, DOI 10.1021/bi991664s	54	48	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21349	21355		10.1074/jbc.M311692200	http://dx.doi.org/10.1074/jbc.M311692200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15010474	hybrid			2022-12-25	WOS:000221273800098
J	Vojta, A; Alavi, M; Becker, T; Hormann, F; Kuchler, M; Soll, J; Thomson, R; Schleiff, E				Vojta, A; Alavi, M; Becker, T; Hormann, F; Kuchler, M; Soll, J; Thomson, R; Schleiff, E			The protein translocon of the plastid envelopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER ENVELOPE; IMPORT; COMPONENT; HOMOLOGS; RECEPTOR; TOC34; GTP; IDENTIFICATION; CHLOROPLASTS	The Toc and Tic translocon facilitate import of preproteins into chloroplasts. In the past, it was speculated that several translocon subunits act specifically for different types of precursor proteins or in different tissues. To generate a comprehensive picture of the expression and tissue-specific localization of the translocon subunits, their transcript levels were analyzed in roots and leaves. Certain Tocs and Tics were found to be tissue-specific. The protein composition of the transloci in the envelope membranes of chloroplasts was analyzed to describe the function and possible stoichiometry. In contrast to Tic subunits, several Toc subunits seem to have a high turnover.	LMU Munchen, D-80638 Munich, Germany	University of Munich	Schleiff, E (corresponding author), LMU Munchen, Menzinger Str 67,Room 223, D-80368 Munich, Germany.	schleiff@LRZ.uni-muenchen.de	Vojta, Aleksandar/S-2086-2017; Becker, Thomas/AAS-9404-2020; Schleiff, Enrico/C-5105-2017	Vojta, Aleksandar/0000-0002-4627-1821; Schleiff, Enrico/0000-0002-0518-3489; thomson, rowena/0000-0002-4373-6283; Alavi, Marcel/0000-0002-1319-3062				Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; Chew O, 2004, FEBS LETT, V557, P109, DOI 10.1016/S0014-5793(03)01457-1; Gutensohn M, 2000, PLANT J, V23, P771, DOI 10.1046/j.1365-313x.2000.00849.x; Hiltbrunner A, 2001, BIOCHEM CELL BIOL, V79, P629, DOI 10.1139/bcb-79-5-629; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Jackson-Constan D, 2001, PLANT PHYSIOL, V125, P1567, DOI 10.1104/pp.125.4.1567; Jelic M, 2003, BIOCHEMISTRY-US, V42, P5906, DOI 10.1021/bi034001q; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1998, J CELL BIOL, V143, P991, DOI 10.1083/jcb.143.4.991; Kubis S, 2003, PLANT CELL, V15, P1859, DOI 10.1105/tpc.012955; Kuchler M, 2002, EMBO J, V21, P6136, DOI 10.1093/emboj/cdf621; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; Schleiff E, 2003, J CELL BIOL, V160, P541, DOI 10.1083/jcb.200210060; Schleiff E, 2003, P NATL ACAD SCI USA, V100, P4604, DOI 10.1073/pnas.0730860100; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; Sohrt K, 2000, J CELL BIOL, V148, P1213, DOI 10.1083/jcb.148.6.1213; Soll J, 2004, NAT REV MOL CELL BIO, V5, P198, DOI 10.1038/nrm1333; Stahl T, 1999, J BIOL CHEM, V274, P37467, DOI 10.1074/jbc.274.52.37467; Sveshnikova N, 2000, P NATL ACAD SCI USA, V97, P4973, DOI 10.1073/pnas.080491597	21	56	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21401	21405		10.1074/jbc.M401968200	http://dx.doi.org/10.1074/jbc.M401968200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15033972	hybrid			2022-12-25	WOS:000221273800104
J	Koller, D; Ittner, LM; Muff, R; Husmann, K; Fischer, JA; Born, W				Koller, D; Ittner, LM; Muff, R; Husmann, K; Fischer, JA; Born, W			Selective inactivation of adrenomedullin over calcitonin gene-related peptide receptor function by the deletion of amino acids 14-20 of the mouse calcitonin-like receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY-MODIFYING PROTEINS; AMINO-TERMINUS; COUPLED RECEPTORS; BINDING; HETERODIMERS	The receptors for the neuropeptide calcitonin (CT) gene-related peptide (CGRP) and the multifunctional peptide hormone adrenomedullin ( AM) are calcitonin-like receptor (CLR)/receptor-activity-modifying protein (RAMP) 1 and CLR/RAMP2 heterodimers, respectively. Here, the amino acid sequence TRNKIMT, corresponding to the residues 14-20 of the N terminus of the mouse (m) CLR, was found to be required for a functional mCLR/RAMP2 AM receptor. The deletion of amino acids 14-20 (Delta14-20) or their substitution by alanine (14-20A) did not affect the heterodimerization of the mCLR with mRAMP1 or mRAMP2, and the levels of expression at the surface of transiently transfected COS-7 cells were not altered. In mRAMP1/mCLR- or mRAMP1/mCLR-(Delta14-20)-expressing cells CGRP stimulated cAMP formation with EC50 values of 0.12 +/- 0.01 and 1.5 +/- 0.4 nM, respectively. In mRAMP2/mCLR-expressing cells the EC50 of AM was 0.8 +/- 0.2 nM. However, in cells expressing mRAMP2/mCLR-(Delta14-20) up to 10(-6) M AM failed to stimulate cAMP production. In mRAMP2/mCLR-(14-20A) expressing cells the cAMP response to AM was minimally restored, and the EC50 was >100 nM. In conclusion, the deletion of the amino acid sequence TRNKIMT of the extreme N terminus of the mCLR maintained CGRP receptor function of mRAMP1/receptor heterodimers, but AM no longer activated the mutant mCLR-(Delta14-20) in the presence of mRAMP2. The TRNKIMT sequence is required for normal mCLR/mRAMP2 association, and as a consequence, high affinity AM binding signaling the activation of adenylyl cyclase.	Univ Zurich, Klin Balgrist, Dept Orthopaed Surg, Res Lab Calcium Metab, CH-8008 Zurich, Switzerland; Univ Zurich, Klin Balgrist, Dept Med, Res Lab Calcium Metab, CH-8008 Zurich, Switzerland	University of Zurich; University of Zurich	Born, W (corresponding author), Univ Zurich, Klin Balgrist, Dept Orthopaed Surg, Res Lab Calcium Metab, Forchstr 340, CH-8008 Zurich, Switzerland.	wborn@balgrist.unizh.ch	Muff, Roman/A-4247-2009	Ittner, Lars/0000-0001-6738-3825				Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; Dong MQ, 2004, J BIOL CHEM, V279, P1167, DOI 10.1074/jbc.M305719200; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; Gujer R, 2001, BIOCHEMISTRY-US, V40, P5392, DOI 10.1021/bi002497v; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; Koller D, 2002, FEBS LETT, V531, P464, DOI 10.1016/S0014-5793(02)03585-8; Leuthauser K, 2000, BIOCHEM J, V351, P347, DOI 10.1042/0264-6021:3510347; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Wimalawansa SJ, 1996, ENDOCR REV, V17, P533, DOI 10.1210/er.17.5.533	12	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20387	20391		10.1074/jbc.M313058200	http://dx.doi.org/10.1074/jbc.M313058200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15007076	hybrid			2022-12-25	WOS:000221164500117
J	Pan, Z; Hirata, Y; Nagaraj, RY; Zhao, JY; Nishi, M; Hayek, SM; Bhat, MB; Takeshima, H; Ma, JJ				Pan, Z; Hirata, Y; Nagaraj, RY; Zhao, JY; Nishi, M; Hayek, SM; Bhat, MB; Takeshima, H; Ma, JJ			Co-expression of MG29 and ryanodine receptor leads to apoptotic cell death - Effect mediated by intracellular Ca2+ release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CALCIUM-RELEASE; MICE LACKING; CHANNEL; MITSUGUMIN29; SYNAPTOPHYSIN; RETICULUM	Perturbation of intracellular Ca2+ homeostasis has been shown to regulate the process of cell proliferation and apoptosis. Our previous studies show that mitsugumin 29 (MG29), a synaptophysin-related protein localized in the triad junction of skeletal muscle, serves an essential role in muscle Ca2+ signaling by regulating the process of store-operated Ca2+ entry. Here we report a functional interaction between MG29 and the ryanodine receptor (RyR)/Ca2+ release channel. The purified MG29 protein enhances activity of the RyR/Ca2+ release channel incorporated into the lipid bilayer membrane. Co-expression of MG29 and RyR in Chinese hamster ovary cells leads to apoptotic cell death resulting from depletion of intracellular Ca2+ stores, despite neither protein expression alone exhibits any significant effect on cell viability. In transient expression studies, the presence of RyR in the endoplasmic reticulum leads to retention of MG29 from the plasma membrane into the intracellular organelles. This functional interaction between MG29 and RyR could have important implications in the Ca2+ signaling processes of muscle cells. Our data also show that perturbation of intracellular Ca2+ homeostasis can serve as a key signal in the initiation of apoptosis.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Tohoku Univ, Dept Biochem, Sendai, Miyagi 9808575, Japan; Cleveland Clin Fdn, Ctr Anesthesiol Res, Cleveland, OH 44106 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Tohoku University; Cleveland Clinic Foundation	Ma, JJ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA.	maj2@umdnj.edu	hayek, salim/T-5679-2019	Pan, Zui/0000-0003-4105-901X; Takeshima, Hiroshi/0000-0003-4525-3725	NCI NIH HHS [R01 CA 95739] Funding Source: Medline; NHLBI NIH HHS [R01 HL 69000] Funding Source: Medline; NIA NIH HHS [R01 AG 15556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095739] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; Brandt NR, 1999, ARCH BIOCHEM BIOPHYS, V371, P348, DOI 10.1006/abbi.1999.1444; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Ferrara C, 2002, PEDIATR RADIOL, V32, P413, DOI 10.1007/s00247-001-0617-z; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; IREDALE PA, 1993, BRIT J PHARMACOL, V110, P1305, DOI 10.1111/j.1476-5381.1993.tb13960.x; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; Komazaki S, 1999, DEV DYNAM, V215, P87, DOI 10.1002/(SICI)1097-0177(199906)215:2<87::AID-DVDY1>3.0.CO;2-Y; Lee EH, 2004, AM J PHYSIOL-CELL PH, V286, pC179, DOI 10.1152/ajpcell.00176.2003; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; Meissner G, 2002, FRONT BIOSCI, V7, pD2072, DOI 10.2741/meissner; Nagaraj RY, 2000, PHYSIOL GENOMICS, V4, P43, DOI 10.1152/physiolgenomics.2000.4.1.43; Nishi M, 1999, J CELL BIOL, V147, P1473, DOI 10.1083/jcb.147.7.1473; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Pan Z, 2002, NAT CELL BIOL, V4, P379, DOI 10.1038/ncb788; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKEKURA H, 1995, J MUSCLE RES CELL M, V16, P465, DOI 10.1007/BF00126431; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Takeshima H, 1998, BIOCHEM J, V331, P317, DOI 10.1042/bj3310317; Xiao BL, 2002, J BIOL CHEM, V277, P41778, DOI 10.1074/jbc.M208210200	27	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19387	19390		10.1074/jbc.C400030200	http://dx.doi.org/10.1074/jbc.C400030200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15039443	hybrid			2022-12-25	WOS:000221164500002
J	Thore, S; Dyachok, O; Tengholm, A				Thore, S; Dyachok, O; Tengholm, A			Oscillations of phospholipase C activity triggered by depolarization and Ca2+ influx in insulin-secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; PLASMA-MEMBRANE; INOSITOL 1,4,5-TRISPHOSPHATE; INS-1 CELLS; GLUCOSE; CALCIUM; ISLETS; CARBAMYLCHOLINE; ACTIVATION; DYNAMICS	Phospholipase C (PLC) is a ubiquitous enzyme involved in the regulation of a variety of cellular processes. Its dependence on Ca2+ is well recognized, but it is not known how PLC activity is affected by physiological variations of the cytoplasmic Ca2+ concentration ([Ca2+](i)). Here, we applied evanescent wave microscopy to monitor PLC activity in parallel with [Ca2+](i) in individual insulin-secreting INS-1 cells using the phosphatidylinositol 4,5-bisphosphate- and inositol 1,4,5-trisphosphate-binding pleckstrin homology domain from PLCdelta(1) fused to green fluorescent protein (PHPLCdelta1-GFP) and the Ca2+ indicator fura red. In resting cells, PHPLCdelta1-GFP was located predominantly at the plasma membrane. Activation of PLC by muscarinic or purinergic receptor stimulation resulted in PHPLCdelta1-GFP translocation from the plasma membrane to the cytoplasm, detected as a decrease in evanescent wave-excited PHPLCdelta1-GFP fluorescence. Using this translocation as a measure of PLC activity, we found that depolarization by raising extracellular [K+] triggered activation of the enzyme. This effect could be attributed both to a rise of [Ca2+](i) and to depolarization per se, because some translocation persisted during depolarization in a Ca2+-deficient medium containing the Ca2+ chelator EGTA. Moreover, oscillations of [Ca2+](i) resulting from depolarization with Ca2+ influx evoked concentration-dependent periodic activation of PLC. We conclude that PLC activity is under tight dynamic control of [Ca2+](i). In insulin-secreting beta-cells, this mechanism provides a link between Ca2+ influx and release from intracellular stores that may be important in the regulation of insulin secretion.	Uppsala Univ, Ctr Biomed, Dept Med Cell Biol, SE-75123 Uppsala, Sweden	Uppsala University	Tengholm, A (corresponding author), Uppsala Univ, Ctr Biomed, Dept Med Cell Biol, Box 571, SE-75123 Uppsala, Sweden.	anders.tengholm@medcellbiol.uu.se	Dyachok, Oleg/B-5935-2017					Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BEST L, 1987, BIOCHIM BIOPHYS ACTA, V927, P112, DOI 10.1016/0167-4889(87)90073-5; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; BIDEN TJ, 1993, J BIOL CHEM, V268, P11065; Dorff G, 2002, BIOCHEM BIOPH RES CO, V293, P842, DOI 10.1016/S0006-291X(02)00311-X; Dryselius S, 1999, AM J PHYSIOL-ENDOC M, V276, pE512, DOI 10.1152/ajpendo.1999.276.3.E512; DYACHOK O, 2004, IN PRESS CELL CALCIU; Fridlyand LE, 2003, AM J PHYSIOL-ENDOC M, V285, pE138, DOI 10.1152/ajpendo.00194.2002; Gasa R, 1999, DIABETES, V48, P1035, DOI 10.2337/diabetes.48.5.1035; Gilon P, 1999, J BIOL CHEM, V274, P20197, DOI 10.1074/jbc.274.29.20197; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; Gromada J, 1996, BIOCHEM J, V314, P339, DOI 10.1042/bj3140339; Hellman B., 1992, NUTR REGULATION INSU, P213; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Herbst M, 2002, CELL CALCIUM, V31, P115, DOI 10.1054/ceca.2001.0266; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Liu YJ, 1996, ARCH BIOCHEM BIOPHYS, V334, P295, DOI 10.1006/abbi.1996.0458; Liu YJ, 1998, J PHYSIOL-LONDON, V508, P471, DOI 10.1111/j.1469-7793.1998.471bq.x; LIU YJ, 1995, CELL CALCIUM, V18, P165, DOI 10.1016/0143-4160(95)90007-1; MATHIAS PCF, 1985, CELL BIOCHEM FUNCT, V3, P173, DOI 10.1002/cbf.290030303; Mitchell CJ, 2001, J BIOL CHEM, V276, P19072, DOI 10.1074/jbc.M101406200; Nash MS, 2001, BIOCHEM J, V356, P137, DOI 10.1042/0264-6021:3560137; Pinton P, 2002, J BIOL CHEM, V277, P37702, DOI 10.1074/jbc.M204478200; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Roderick HL, 2003, CURR BIOL, V13, pR425, DOI 10.1016/S0960-9822(03)00358-0; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Teruel MN, 1999, J NEUROSCI METH, V93, P37, DOI 10.1016/S0165-0270(99)00112-0; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; WORLEY JF, 1994, J BIOL CHEM, V269, P14359; Xu C, 2003, J CELL BIOL, V161, P779, DOI 10.1083/jcb.200301070; Zawalich WS, 1996, AM J PHYSIOL-ENDOC M, V271, pE409, DOI 10.1152/ajpendo.1996.271.3.E409	38	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19396	19400		10.1074/jbc.C400088200	http://dx.doi.org/10.1074/jbc.C400088200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15044448	hybrid			2022-12-25	WOS:000221164500004
J	Hughey, RP; Bruns, JB; Kinlough, CL; Harkleroad, KL; Tong, QS; Carattino, MD; Johnson, JP; Stockand, JC; Kleyman, TR				Hughey, RP; Bruns, JB; Kinlough, CL; Harkleroad, KL; Tong, QS; Carattino, MD; Johnson, JP; Stockand, JC; Kleyman, TR			Epithelial sodium channels are activated by furin-dependent proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNELS; PROPROTEIN CONVERTASE; HISTIDINE-RESIDUES; SERINE PROTEASES; OPEN PROBABILITY; XENOPUS-OOCYTES; GAMMA-SUBUNIT; ALPHA-SUBUNIT; PORE REGION; CELL-LINE	Epithelial Na+ channels (ENaCs) are activated by extracellular trypsin or by co-expression with channel-activating proteases, although there is no direct evidence that these proteases activate ENaC by cleaving the channel. We previously demonstrated that the alpha and gamma subunits of ENaC are cleaved during maturation near consensus sites for furin cleavage. Using site-specific mutagenesis of channel subunits, ENaC expression in furin-deficient cells, and furin-specific inhibitors, we now report that ENaC cleavage correlates with channel activity. Channel activity in furin-deficient cells was rescued by expression of furin. Our data provide the first example of a vertebrate ion channel that is a substrate for furin and whose activity is dependent on its proteolysis.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Health San Antonio	Kleyman, TR (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	kleyman@pitt.edu		Stockand, James/0000-0002-3817-4319	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054787, R01DK065161, R01DK059594, R56DK065161, R01DK054354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54354, DK65161, DK59594, DK54787] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Booth RE, 2003, J BIOL CHEM, V278, P41367, DOI 10.1074/jbc.M305400200; Bridges RJ, 2001, AM J PHYSIOL-LUNG C, V281, pL16, DOI 10.1152/ajplung.2001.281.1.L16; Bruns JB, 2003, AM J PHYSIOL-RENAL, V285, pF600, DOI 10.1152/ajprenal.00095.2003; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; GORDON VM, 1995, INFECT IMMUN, V63, P82, DOI 10.1128/IAI.63.1.82-87.1995; Guipponi M, 2002, HUM MOL GENET, V11, P2829, DOI 10.1093/hmg/11.23.2829; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Mbikay M, 1997, P NATL ACAD SCI USA, V94, P6842, DOI 10.1073/pnas.94.13.6842; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Sheng SH, 2004, J BIOL CHEM, V279, P9743, DOI 10.1074/jbc.M311952200; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Simpkins KL, 2003, J NEUROSCI, V23, P11322; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Tsuji A, 2002, PROTEIN ENG, V15, P123, DOI 10.1093/protein/15.2.123; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	39	328	333	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18111	18114		10.1074/jbc.C400080200	http://dx.doi.org/10.1074/jbc.C400080200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	15007080	hybrid			2022-12-25	WOS:000221041500004
J	Bondos, SE; Catanese, DJ; Tan, XX; Bicknell, A; Li, LK; Matthews, KS				Bondos, SE; Catanese, DJ; Tan, XX; Bicknell, A; Li, LK; Matthews, KS			Hox transcription factor ultrabithorax Ib physically and genetically interacts with disconnected interacting protein 1, a double-stranded RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; DROSOPHILA DEVELOPMENT; FUNCTIONAL-CHARACTERIZATION; HOMEODOMAIN PROTEIN; VISUAL-SYSTEM; GENE; DOMAIN; COMPLEX; SPECIFICITY; KINASE	The Hox protein family consists of homeodomain-containing transcription factors that are primary determinants of cell fate during animal development. Specific Hox function appears to rely on protein-protein interactions; however, the partners involved in these interactions and their function are largely unknown. Disconnected Interacting Protein 1 (DIP1) was isolated in a yeast two-hybrid screen of a 0-12-h Drosophila embryo library designed to identify proteins that interact with Ultrabithorax (Ubx), a Drosophila Hox protein. The Ubx.DIP1 physical interaction was confirmed using phage display, immunoprecipitation, pull-down assays, and gel retardation analysis. Ectopic expression of DIP1 in wing and haltere imaginal discs malforms the adult structures and enhances a decreased Ubx expression phenotype, establishing a genetic interaction. Ubx can generate a ternary complex by simultaneously binding its target DNA and DIP1. A large region of Ubx, including the repression domain, is required for interaction with DIP1. These more variable sequences may be key to the differential Hox function observed in vivo. The Ubx.DIP1 interaction prevents transcriptional activation by Ubx in a modified yeast one-hybrid assay, suggesting that DIP1 may modulate transcriptional regulation by Ubx. The DIP1 sequence contains two dsRNA-binding domains, and DIP1 binds double-stranded RNA with a 1000-fold higher affinity than either single-stranded RNA or double-stranded DNA. The strong interaction of Ubx with an RNA-binding protein suggests a wider range of proteins may influence Ubx function than previously appreciated.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Rice University	Matthews, KS (corresponding author), Rice Univ, Dept Biochem & Cell Biol, 6100 S Main St, Houston, TX 77005 USA.	ksm@rice.edu		Bondos, Sarah/0000-0002-9673-4169	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008208, R01GM022441] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32-GM08208, GM22441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; Biggin MD, 1997, DEVELOPMENT, V124, P4425; Bondos SE, 2003, ANAL BIOCHEM, V316, P223, DOI 10.1016/S0003-2697(03)00059-9; Bondos SE, 2001, CRIT REV EUKAR GENE, V11, P145; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPOS AR, 1995, J NEUROBIOL, V28, P313, DOI 10.1002/neu.480280305; Cassiday LA, 2002, NUCLEIC ACIDS RES, V30, P4118, DOI 10.1093/nar/gkf512; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; Chan SK, 1996, EMBO J, V15, P2476, DOI 10.1002/j.1460-2075.1996.tb00605.x; Chariot A, 1999, BIOCHEM PHARMACOL, V58, P1851, DOI 10.1016/S0006-2952(99)00234-8; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHRISTEN B, 1992, MECH DEVELOP, V39, P73, DOI 10.1016/0925-4773(92)90027-H; DeSousa D, 2003, J BIOL CHEM, V278, P38040, DOI 10.1074/jbc.M303512200; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; Galant R, 2002, DEVELOPMENT, V129, P3115; Galant R, 2002, NATURE, V415, P910, DOI 10.1038/nature717; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GOLEMIS E, 1999, CURRENT PROTOCOLS MO; Graba Y, 1997, BIOESSAYS, V19, P379, DOI 10.1002/bies.950190505; GRABA Y, 1992, EMBO J, V11, P3375, DOI 10.1002/j.1460-2075.1992.tb05416.x; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; Grenier JK, 2000, P NATL ACAD SCI USA, V97, P704, DOI 10.1073/pnas.97.2.704; Ho CK, 1996, VIROLOGY, V217, P272, DOI 10.1006/viro.1996.0114; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; KRAUSS V, 2001, 17 EUR DROS RES C ED; Krovat BC, 1996, J BIOL CHEM, V271, P28112, DOI 10.1074/jbc.271.45.28112; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Li LK, 1997, BIOCHEMISTRY-US, V36, P7003, DOI 10.1021/bi962966m; Li LK, 1996, BIOCHEMISTRY-US, V35, P9832, DOI 10.1021/bi9606049; Li XL, 1999, EMBO J, V18, P198, DOI 10.1093/emboj/18.1.198; Li XL, 1999, P NATL ACAD SCI USA, V96, P6802, DOI 10.1073/pnas.96.12.6802; LOPEZ AJ, 1991, P NATL ACAD SCI USA, V88, P9924, DOI 10.1073/pnas.88.22.9924; Manak JR, 1994, DEVELOPMENT S, V120, P61; MartinezLaborda A, 1996, MOL GEN GENET, V250, P540, DOI 10.1007/s004380050107; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Moraitis MI, 2001, BIOCHEMISTRY-US, V40, P8109, DOI 10.1021/bi0028643; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Ronshaugen M, 2002, NATURE, V415, P914, DOI 10.1038/nature716; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shanmugam K, 1997, J BIOL CHEM, V272, P19081, DOI 10.1074/jbc.272.30.19081; Shashidhara LS, 1999, DEV BIOL, V212, P491, DOI 10.1006/dbio.1999.9341; Soehnge H, 1996, P NATL ACAD SCI USA, V93, P13262, DOI 10.1073/pnas.93.23.13262; STELLER H, 1987, CELL, V50, P1139, DOI 10.1016/0092-8674(87)90180-2; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Tan XX, 2002, BIOCHEMISTRY-US, V41, P2774, DOI 10.1021/bi011967y; Tian B, 2001, J BIOL CHEM, V276, P9936, DOI 10.1074/jbc.M007328200; Tsao KL, 1996, GENE, V169, P59, DOI 10.1016/0378-1119(95)00762-8; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vigano MA, 1998, MOL CELL BIOL, V18, P6201, DOI 10.1128/MCB.18.11.6201; Weatherbee SD, 1998, GENE DEV, V12, P1474, DOI 10.1101/gad.12.10.1474; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Wiellette EL, 1999, DEVELOPMENT, V126, P5373; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5; Xing YY, 1997, NAT STRUCT BIOL, V4, P24, DOI 10.1038/nsb0197-24; Zhu AH, 1996, J BIOL CHEM, V271, P20993, DOI 10.1074/jbc.271.35.20993	74	24	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26433	26444		10.1074/jbc.M312842200	http://dx.doi.org/10.1074/jbc.M312842200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15039447	hybrid			2022-12-25	WOS:000222003000065
J	Guo, Y; Cheong, NE; Zhang, ZJ; De Rose, R; Deng, Y; Farber, SA; Fernandes-Alnemri, T; Alnemri, ES				Guo, Y; Cheong, NE; Zhang, ZJ; De Rose, R; Deng, Y; Farber, SA; Fernandes-Alnemri, T; Alnemri, ES			Tim50, a component of the mitochondrial translocator, regulates mitochondrial integrity and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; RNA-POLYMERASE-II; C-TERMINAL DOMAIN; SERINE-PROTEASE; APOPTOSIS PROTEINS; CASPASE ACTIVATION; MAMMALIAN-CELLS; OUTER-MEMBRANE; IAP PROTEINS; NEURAL CREST	In yeast, Tim50 along with Tim23 regulate translocation of presequence-containing proteins across the mitochondrial inner membrane. Here, we describe the identification and characterization of a novel human mitochondrial inner membrane protein homologous to the yeast Tim50. We demonstrate that human Tim50 possesses phosphatase activity and is present in a complex with human Tim23. Down-regulation of human Tim50 expression by RNA interference increases the sensitivity of human cell lines to death stimuli by accelerating the release of cytochrome c from the mitochondria. Furthermore, injection of Tim50-specific morpholino antisense oligonucleotides during early zebrafish embryonic development causes neurodegeneration, dysmorphic hearts, and reduced motility as a result of increased cell death. These observations indicate that loss of Tim50 in vertebrates causes mitochondrial membrane permeabilization and dysfunction followed by cytoplasmic release of cytochrome c along with other mitochondrial inducers of cell death. Thus Tim50 is important for both mitochondrial function and early neuronal development.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldgg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.	E_Alnemri@lac.jci.tju.edu	Farber, Steven A/G-5851-2012; Alnemri, Emad S/B-4526-2010	Farber, Steven A/0000-0002-8037-7312; 	NCI NIH HHS [CA85421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; Chacinska A, 2003, EMBO J, V22, P5370, DOI 10.1093/emboj/cdg532; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; DEL PL, 1997, SCIENCE, V278, P687; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Endo T, 2002, BBA-MOL CELL RES, V1592, P3, DOI 10.1016/S0167-4889(02)00259-8; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Fishman MC, 2001, SCIENCE, V294, P1290, DOI 10.1126/science.1066652; Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1; FurutaniSeiki M, 1996, DEVELOPMENT, V123, P229; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Hukriede NA, 1999, P NATL ACAD SCI USA, V96, P9745, DOI 10.1073/pnas.96.17.9745; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jensen RE, 2002, BBA-MOL CELL RES, V1592, P25, DOI 10.1016/S0167-4889(02)00261-6; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; MCMULLIN TW, 1987, MOL CELL BIOL, V7, P4414, DOI 10.1128/MCB.7.12.4414; MILLER JB, 1989, J BIOL CHEM, V264, P13122; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Motz C, 2002, J MOL BIOL, V323, P729, DOI 10.1016/S0022-2836(02)00995-6; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Parichy DM, 2003, DEV BIOL, V256, P221, DOI 10.1016/S0012-1606(03)00016-2; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; THISSE C, 1995, DEV BIOL, V172, P86, DOI 10.1006/dbio.1995.0007; Tokatlidis K, 2000, BIOCHEM SOC T, V28, P495, DOI 10.1042/0300-5127:0280495; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE, V4th Edn; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Zeller J, 1999, DEVELOPMENT, V126, P3461; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	64	70	82	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24813	24825		10.1074/jbc.M402049200	http://dx.doi.org/10.1074/jbc.M402049200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044455	hybrid			2022-12-25	WOS:000221702500112
J	Borisenko, GG; Martin, I; Zhao, Q; Amoscato, AA; Tyurina, YY; Kagan, VE				Borisenko, GG; Martin, I; Zhao, Q; Amoscato, AA; Tyurina, YY; Kagan, VE			Glutathione propagates oxidative stress triggered by Myeloperoxidase in HL-60 cells - Evidence for glutathionyl radical-induced peroxidation of phospholipids and cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID RESIDUES; THIYL RADICALS; PHENOXYL RADICALS; SINK HYPOTHESIS; ONE-ELECTRON; KINETICS; NITROXIDE; SUPEROXIDE; MECHANISM; THIOLS	(G)lutathione acts as a universal scavenger of free radicals at the expense of the formation of the glutathionyl radicals (GS(circle)). Here we demonstrated that GS(circle) radicals specifically interact with a reporter molecule, paramagnetic and non-fluorescent 4-((9-acridinecarbonyl)amino)-2,2,6,6-tetramethylpiperidine-1-oxyl (Ac-Tempo), and convert it into a non-paramagnetic fluorescent product, identified as 4-((9-acridinecarbonyl) amino)-2,2,6,6-tetramethylpiperidine (Ac-piperidine). Horseradish peroxidase-, myeloperoxidase-, and cyclooxygenase-catalyzed oxidation of phenol in the presence of H2O2 and GSH caused the generation of phenoxyl radicals and GS(circle) radicals, of which only the latter reacted with Ac-Tempo. Oxidation of several other phenolic compounds (e.g. etoposide and tyrosine) was accompanied by the formation of GS(circle) radicals along with a characteristic fluorescence response from Ac-Tempo. In myeloperoxidase-rich HL-60 cells treated with H2O2 and phenol, fluorescence microscopic imaging of Ac-Tempo revealed the production of GS(circle) radicals. A thiol-blocking reagent, N-ethylmaleimide, as well as myeloperoxidase inhibitors (succinyl acetone and azide), blocked formation of fluorescent acridine-piperidine. H2O2/phenol-induced peroxidation of major classes of phospholipids in HL-60 cells was completely inhibited by Ac-Tempo, indicating that GS(circle) radicals were responsible for phospholipid peroxidation. Thus, GSH, commonly viewed as a universal free radical scavenger and major intracellular antioxidant, acts as a pro-oxidant during myeloperoxidase-catalyzed metabolism of phenol in HL-60 cells.	Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Biotechnol & Bioengn, Mass Spectrometry Facil, Pittsburgh, PA 15219 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Kings Coll London, Div Life Sci, London SE1 8WA, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of London; King's College London	Borisenko, GG (corresponding author), 3343 Forbes Ave, Pittsburgh, PA 15260 USA.	grigoryb@yahoo.com; Kagan@pitt.edu		Tyurina, Yulia/0000-0003-0287-2091; Kagan, Valerian E./0000-0002-7245-1885	NHLBI NIH HHS [HL7075, HL64145] Funding Source: Medline; NINDS NIH HHS [F05 NS043922] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F05NS043922] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barton DHR, 1998, TETRAHEDRON LETT, V39, P7483, DOI 10.1016/S0040-4039(98)01628-1; BLOUGH NV, 1988, J AM CHEM SOC, V110, P1915, DOI 10.1021/ja00214a041; Burner U, 1997, FEBS LETT, V411, P269, DOI 10.1016/S0014-5793(97)00713-8; CHALVARDJIAN A, 1970, ANAL BIOCHEM, V36, P225, DOI 10.1016/0003-2697(70)90352-0; Day BW, 1999, CHEM RES TOXICOL, V12, P28, DOI 10.1021/tx980137r; de Menezes SL, 2001, J BIOL CHEM, V276, P39879, DOI 10.1074/jbc.M104012200; Ferreri C, 2001, J AM CHEM SOC, V123, P4459, DOI 10.1021/ja0040969; Ford E, 2002, FREE RADICAL BIO MED, V32, P1314, DOI 10.1016/S0891-5849(02)00850-X; Galati G, 2002, TOXICOLOGY, V177, P91, DOI 10.1016/S0300-483X(02)00198-1; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; Herbelin SE, 1998, J PHYS CHEM B, V102, P8170, DOI 10.1021/jp980977e; Kagan VE, 1999, MOL PHARMACOL, V56, P494, DOI 10.1124/mol.56.3.494; Kapiotis S, 1997, ARTERIOSCL THROM VAS, V17, P2855, DOI 10.1161/01.ATV.17.11.2855; KOPPENOL WH, 1993, FREE RADICAL BIO MED, V14, P91, DOI 10.1016/0891-5849(93)90513-T; KWAK HS, 1995, P NATL ACAD SCI USA, V92, P4582, DOI 10.1073/pnas.92.10.4582; Pogocki D, 2001, FREE RADICAL BIO MED, V31, P98, DOI 10.1016/S0891-5849(01)00559-7; POU S, 1993, ANAL BIOCHEM, V212, P85, DOI 10.1006/abio.1993.1295; Ritov VB, 1996, BBA-BIOMEMBRANES, V1283, P127, DOI 10.1016/0005-2736(96)00083-1; ROSEN GM, 1977, BIOCHEM PHARMACOL, V26, P675, DOI 10.1016/0006-2952(77)90049-1; ROSS D, 1984, BIOCHEM BIOPH RES CO, V125, P109, DOI 10.1016/S0006-291X(84)80341-1; Samuni A, 2002, J AM CHEM SOC, V124, P8719, DOI 10.1021/ja017587h; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SCHONEICH C, 1992, ARCH BIOCHEM BIOPHYS, V292, P456, DOI 10.1016/0003-9861(92)90016-P; SCHREIBER J, 1989, J BIOL CHEM, V264, P7936; Sprinz H, 2000, BBA-MOL CELL BIOL L, V1483, P91, DOI 10.1016/S1388-1981(99)00175-4; Stoyanovsky DA, 1996, ARCH BIOCHEM BIOPHYS, V330, P3, DOI 10.1006/abbi.1996.0219; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; Van Kessel W S, 1977, Biochim Biophys Acta, V486, P524; Villegas I, 2002, FREE RADICAL RES, V36, P769, DOI 10.1080/10715760290032575; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; Zhang H, 2002, J BIOL CHEM, V277, P1013, DOI 10.1074/jbc.M108585200; Zhang RL, 1999, FREE RADICAL BIO MED, V26, P1245, DOI 10.1016/S0891-5849(98)00328-1; ZHAO R, 1994, J AM CHEM SOC, V116, P12010, DOI 10.1021/ja00105a048	34	51	52	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23453	23462		10.1074/jbc.M400119200	http://dx.doi.org/10.1074/jbc.M400119200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039448	hybrid			2022-12-25	WOS:000221570900082
J	Hanafusa, H; Torii, S; Yasunaga, T; Matsumoto, K; Nishida, E				Hanafusa, H; Torii, S; Yasunaga, T; Matsumoto, K; Nishida, E			Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor sprouty	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PHOSPHOTYROSINE PHOSPHATASE; DOCKING-PROTEIN; MAP KINASE; ACTIVATION; TRANSDUCTION; SHPTP2; SEVENLESS; PATHWAY; SH-PTP2	Src homology 2-containing phosphotyrosine phosphatase (Shp2) functions as a positive effector in receptor tyrosine kinase (RTK) signaling immediately proximal to activated receptors. However, neither its physiological substrate(s) nor its mechanism of action in RTK signaling has been defined. In this study, we demonstrate that Sprouty (Spry) is a possible target of Shp2. Spry acts as a conserved inhibitor of RTK signaling, and tyrosine phosphorylation of Spry is indispensable for its inhibitory activity. Shp2 was able to dephosphorylate fibroblast growth factor receptor-induced phosphotyrosines on Spry both in vivo and in vitro. Shp2-mediated dephosphorylation of Spry resulted in dissociation of Spry from Grb2. Furthermore, Shp2 could reverse the inhibitory effect of Spry on FGF-induced neurite outgrowth and MAP kinase activation. These findings suggest that Shp2 acts as a positive regulator in RTK signaling by dephosphorylating and inactivating Spry.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Nagoya Univ, Inst Adv Res, Grad Sch Sci, Dept Mol Biol,Chikusa Ku, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Kyoto University; Kyoto University; Nagoya University; Japan Science & Technology Agency (JST)	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp		Torii, Satoru/0000-0003-4841-7131				Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2002, J BIOL CHEM, V277, P9498, DOI 10.1074/jbc.M110547200; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Herbst R, 1999, EMBO J, V18, P6950, DOI 10.1093/emboj/18.24.6950; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	32	123	125	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22992	22995		10.1074/jbc.M312498200	http://dx.doi.org/10.1074/jbc.M312498200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15031289	hybrid			2022-12-25	WOS:000221570900026
J	Lauhon, CT; Erwin, WM; Ton, GN				Lauhon, CT; Erwin, WM; Ton, GN			Substrate specificity for 4-thiouridine modification in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-GUANINE TRANSGLYCOSYLASE; IN-VITRO BIOSYNTHESIS; STRUCTURAL REQUIREMENTS; MODIFIED NUCLEOSIDES; ENZYMATIC FORMATION; CROSS-LINKING; GROWTH DELAY; NIFS GENE; RECOGNITION; SEQUENCE	The biosynthesis of 4-thiouridine (s(4)U) in Escherichia coli tRNA requires the action of both the thiamin pathway enzyme ThiI and the cysteine desulfurase IscS. IscS catalyzes sulfur transfer from L-cysteine to ThiI, which utilizes Mg-ATP to activate uridine 8 in tRNA and transfers sulfur to give s(4)U. In this work, we show through deletion analysis of unmodified E. coli tRNA(Phe) that the minimum substrate for s(4)U modification is a mini-helix comprising the stacked acceptor and T stems containing an internal bulged region. The size of the bulged loop must be at least 4 nucleotides and contain the target uridine as the first nucleotide. Replacement of the T loop sequence with a tetraloop in the deletion substrate increases activity and shows that the TPsiC primary sequence is not a recognition element. An unmodified tRNAPhe transcript in which the 3'-terminal ACCA sequence is removed to give a blunt terminus has < 0.1% activity, although the addition of a single overhanging base essentially restores activity. In addition, reducing the distance of the 3' terminus relative to U8 by as little as 1 bp severely impairs activity. By dissecting a minimal RNA substrate in the T loop region, a two-piece system consisting of a substrate RNA and a "guide" RNA is efficiently modified. Our results indicate that outside of the modified U8, there is no primary sequence requirement for substrate recognition. However, the secondary and tertiary structure restrictions appear sufficient to explain why s(4)U modification is limited in the cell to tRNA.	Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Lauhon, CT (corresponding author), Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA.	clauhon@facstaff.wisc.edu			NIGMS NIH HHS [GM57002] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057002] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529; Bjork GR, 1995, TRNA STRUCTURE BIOSY, P165; BLONDEL MO, 1988, BIOCHEM BIOPH RES CO, V150, P979, DOI 10.1016/0006-291X(88)90725-5; Chavatte L, 2002, EMBO J, V21, P5302, DOI 10.1093/emboj/cdf484; CURNOW AW, 1995, J BIOL CHEM, V270, P17264, DOI 10.1074/jbc.270.29.17264; Dirheimer G., 1995, P93; EDQVIST J, 1995, BIOCHIMIE, V77, P54, DOI 10.1016/0300-9084(96)88104-1; EMILSSON V, 1992, NUCLEIC ACIDS RES, V20, P4499, DOI 10.1093/nar/20.17.4499; FAVRE A, 1969, BIOCHEM BIOPH RES CO, V37, P266, DOI 10.1016/0006-291X(69)90729-3; Flint DH, 1996, J BIOL CHEM, V271, P16068; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; Gu XR, 1996, BIOCHEMISTRY-US, V35, P11652, DOI 10.1021/bi9612125; HARA H, 1970, BIOCHEM BIOPH RES CO, V38, P305, DOI 10.1016/0006-291X(70)90713-8; HARADA F, 1972, FEBS LETT, V19, P352, DOI 10.1016/0014-5793(72)80078-4; HARRIS CL, 1989, ANAL BIOCHEM, V176, P57, DOI 10.1016/0003-2697(89)90271-6; Hiley SL, 2002, EMBO J, V21, P4691, DOI 10.1093/emboj/cdf462; HOLMES WM, 1992, J BIOL CHEM, V267, P13440; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; Ishitani R, 2003, CELL, V113, P383, DOI 10.1016/S0092-8674(03)00280-0; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; KRAMER GF, 1988, J BACTERIOL, V170, P2344, DOI 10.1128/jb.170.5.2344-2351.1988; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; LIPSETT MN, 1972, J BIOL CHEM, V247, P1458; Madore E, 1999, EUR J BIOCHEM, V266, P1128, DOI 10.1046/j.1432-1327.1999.00965.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Mueller EG, 1998, NUCLEIC ACIDS RES, V26, P2606, DOI 10.1093/nar/26.11.2606; Mueller EG, 1999, PROTEIN SCI, V8, P2424; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; PERSSON BC, 1993, MOL MICROBIOL, V8, P1011, DOI 10.1111/j.1365-2958.1993.tb01645.x; PETERSON ET, 1992, BIOCHEMISTRY-US, V31, P10380, DOI 10.1021/bi00157a028; Qian Q, 1997, J MOL BIOL, V266, P283, DOI 10.1006/jmbi.1996.0789; Qin PZ, 2003, BIOCHEMISTRY-US, V42, P6772, DOI 10.1021/bi027222p; Redlak M, 1997, BIOCHEMISTRY-US, V36, P8699, DOI 10.1021/bi9701538; SCHEIT KH, 1973, EUR J BIOCHEM, V33, P545, DOI 10.1111/j.1432-1033.1973.tb02714.x; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; Shigi N, 2002, J BIOL CHEM, V277, P39128, DOI 10.1074/jbc.M207323200; Soderberg T, 2000, BIOCHEMISTRY-US, V39, P6546, DOI 10.1021/bi992775u; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; SZWEYKOWSKAKULINSKA Z, 1992, EMBO J, V11, P1907, DOI 10.1002/j.1460-2075.1992.tb05243.x; THOMAS G, 1975, BIOCHEM BIOPH RES CO, V66, P1454, DOI 10.1016/0006-291X(75)90522-7; TREMBLAY TL, 1986, BIOCHEM CELL BIOL, V64, P315, DOI 10.1139/o86-044; Urbonavicius J, 2001, EMBO J, V20, P4863, DOI 10.1093/emboj/20.17.4863; Watanabe M, 2001, J BIOL CHEM, V276, P2387, DOI 10.1074/jbc.M005043200; Webb E, 1997, J BACTERIOL, V179, P4399, DOI 10.1128/jb.179.13.4399-4402.1997; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Wright CM, 2002, CHEM COMMUN, P2708, DOI 10.1039/b208626c; Yu YT, 1997, P NATL ACAD SCI USA, V94, P6030, DOI 10.1073/pnas.94.12.6030; YUAN Y, 1995, EMBO J, V14, P159, DOI 10.1002/j.1460-2075.1995.tb06986.x; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	55	27	27	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23022	23029		10.1074/jbc.M401757200	http://dx.doi.org/10.1074/jbc.M401757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15037613	hybrid			2022-12-25	WOS:000221570900030
J	Sato, Y; Zhang, YW; Androutsellis-Theotokis, A; Rudnick, G				Sato, Y; Zhang, YW; Androutsellis-Theotokis, A; Rudnick, G			Analysis of transmembrane domain 2 of rat serotonin transporter by cysteine scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE TRANSPORTER; FUNCTIONAL CONSEQUENCES; GABA TRANSPORTER-1; COCAINE BINDING; OLIGOMERIZATION; SUBSTRATE; MUTATIONS; RESIDUES; CLONING; RECOGNITION	The second transmembrane domain (TM2) of neurotransmitter transporters has been invoked to control oligomerization and surface expression. This transmembrane domain lies between TM1 and TM3, which have both been proposed to contain residues that contribute to the substrate binding site. Rat serotonin transporter (SERT) TM2 was investigated by cysteine scanning mutagenesis. Six mutants in which cysteine replaced an endogenous TM2 residue had low transport activity, and two were inactive. Most of the reduction in transport activity was due to decreased surface expression. In contrast, M124C and G128C showed increased activity and surface expression. Random mutagenesis at positions 124 and 128 revealed that hydrophobic residues at these positions also increased activity. When modeled as an alpha-helix, positions where mutation to cysteine strongly affects expression levels clustered on the face of TM2 surrounding the leucine heptad repeat conserved within this transporter family. 2-( Aminoethyl)methanethiosulfonate hydrobromide (MTSEA)-biotin labeled A116C and Y136C but not F117C, M135C, or Y134C, suggesting that these residues may delimit the transmembrane domain. None of the cysteine substitution mutants from 117 through 135 were sensitive to [2-( trimethylammonium) ethyl] methanethiosulfonate bromide (MTSET) or MTSEA. However, treatment with MTSEA increased 5-hydroxytryptamine transport by A116C. Activation of A116C by MTSEA was observed only in mutants containing Cys to Ile mutation at position 357, suggesting that modification of Cys-116 activated transport by compensating for a disruption in transport in response to Cys-357 replacement. The reactivity of A116C toward MTSEA was substantially increased in the presence of substrates but not inhibitors. This increase required Na+ and Cl-, and was likely to result from conformational changes during the transport process.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Rudnick, G (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,POB 3333, New Haven, CT 06510 USA.	gary.rudnick@yale.edu		ZHANG, YUAN-WEI/0000-0002-4276-9251; Androutsellis-Theotokis, Andreas/0000-0002-1985-4589				Adkins EM, 2001, MOL PHARMACOL, V59, P514, DOI 10.1124/mol.59.3.514; Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; ASBERG M, 1993, CLIN NEUROPHARMACOL, V16, pS32; Barker EL, 1999, J NEUROSCI, V19, P4705; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; Chang AS, 1998, BIOCHEM BIOPH RES CO, V249, P416, DOI 10.1006/bbrc.1998.9158; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Gainetdinov RR, 2003, ANNU REV PHARMACOL, V43, P261, DOI 10.1146/annurev.pharmtox.43.050802.112309; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kocabas AM, 2003, J NEUROCHEM, V85, P1513, DOI 10.1046/j.1471-4159.2003.01793.x; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Lin ZC, 1999, MOL PHARMACOL, V56, P434, DOI 10.1124/mol.56.2.434; Ni YG, 2001, J BIOL CHEM, V276, P30942, DOI 10.1074/jbc.M104653200; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; RUDNICK G, 1991, MOL PHARMACOL, V40, P421; Rudnick G., 2002, TRANSMEMBRANE TRANSP, P125; Rudnick Gary, 2002, P25; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Sora I, 2001, P NATL ACAD SCI USA, V98, P5300, DOI 10.1073/pnas.091039298; TALVENHEIMO J, 1979, J BIOL CHEM, V254, P4631; TATE CG, 1994, J BIOL CHEM, V269, P26303; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; WALL SC, 1993, MOL PHARMACOL, V43, P264; WALL SC, 1995, MOL PHARMACOL, V47, P544; Wu XH, 2003, MOL PHARMACOL, V63, P653, DOI 10.1124/mol.63.3.653	35	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22926	22933		10.1074/jbc.M312194200	http://dx.doi.org/10.1074/jbc.M312194200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044496				2022-12-25	WOS:000221570900019
J	White, JA; Blackmore, PF; Schoenbach, KH; Beebe, SJ				White, JA; Blackmore, PF; Schoenbach, KH; Beebe, SJ			Stimulation of capacitative calcium entry in HL-60 cells by nanosecond pulsed electric fields	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NEUTROPHIL GRANULOCYTES; GENE-TRANSFER; ELECTROPORATION; RECEPTOR; ELECTROCHEMOTHERAPY; ELECTROMANIPULATION; SUBMICROSECOND; ACTIVATION; CHANNELS	Nanosecond pulsed electric fields (nsPEFs) are hypothesized to affect intracellular structures in living cells providing a new means to modulate cell signal transduction mechanisms. The effects of nsPEFs on the release of internal calcium and activation of calcium influx in HL-60 cells were investigated by using real time fluorescent microscopy with Fluo-3 and fluorometry with Fura-2. nsPEFs induced an increase in intracellular calcium levels that was seen in all cells. With pulses of 60 ns duration and electric fields between 4 and 15 kV/cm, intracellular calcium increased 200-700 nM, respectively, above basal levels (similar to100 nM), while the uptake of propidium iodide was absent. This suggests that increases in intracellular calcium were not because of plasma membrane electroporation. nsPEF and the purinergic agonist UTP induced calcium mobilization in the presence and absence of extracellular calcium with similar kinetics and appeared to target the same inositol 1,4,5-trisphosphate- and thapsigargin-sensitive calcium pools in the endoplasmic reticulum. For cells exposed to either nsPEF or UTP in the absence of extracellular calcium, there was an electric field-dependent or UTP dose-dependent increase in capacitative calcium entry when calcium was added to the extracellular media. These findings suggest that nsPEFs, like ligand-mediated responses, release calcium from similar internal calcium pools and thus activate plasma membrane calcium influx channels or capacitative calcium entry.	Eastern Virginia Med Sch, Dept Physiol Sci, Norfolk, VA 23529 USA; Old Dominion Univ, Program Biomed Sci, Norfolk, VA 23529 USA; Old Dominion Univ, Ctr Bioelect, Norfolk, VA 23529 USA; Eastern Virginia Med Sch, Ctr Pediat Res, Norfolk, VA 23510 USA; Childrens Hosp Kings Daughters, Norfolk, VA 23510 USA	Eastern Virginia Medical School; Old Dominion University; Old Dominion University; Eastern Virginia Medical School	Beebe, SJ (corresponding author), Eastern Virginia Med Sch, Dept Physiol Sci, Norfolk, VA 23529 USA.	sbeebe@chkd.com						Alemany R, 2000, MOL PHARMACOL, V58, P491, DOI 10.1124/mol.58.3.491; Beebe SJ, 2003, DNA CELL BIOL, V22, P785, DOI 10.1089/104454903322624993; Beebe SJ, 2003, FASEB J, V17, P1493, DOI 10.1096/fj.02-0859fje; Beebe SJ, 2002, IEEE T PLASMA SCI, V30, P286, DOI 10.1109/TPS.2002.1003872; BELEHRADEK M, 1993, CANCER-AM CANCER SOC, V72, P3694, DOI 10.1002/1097-0142(19931215)72:12<3694::AID-CNCR2820721222>3.0.CO;2-2; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bobanovic F, 1999, FASEB J, V13, P365, DOI 10.1096/fasebj.13.2.365; Buescher ES, 2003, IEEE T DIELECT EL IN, V10, P788, DOI 10.1109/TDEI.2003.1237328; CHANG DC, 1992, GUIDE ELECTROPORATIO, P1; Deng JD, 2003, BIOPHYS J, V84, P2709, DOI 10.1016/S0006-3495(03)75076-0; DEV SB, 1994, CANCER TREAT REV, V20, P105, DOI 10.1016/0305-7372(94)90013-2; Dev SB, 2000, IEEE T PLASMA SCI, V28, P206, DOI 10.1109/27.842905; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Gallois A, 1998, EUR J PHARMACOL, V361, P293, DOI 10.1016/S0014-2999(98)00728-6; Gowrishankar TR, 2003, P NATL ACAD SCI USA, V100, P3203, DOI 10.1073/pnas.0636434100; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; Harper JL, 2003, BIOCHEM PHARMACOL, V65, P329, DOI 10.1016/S0006-2952(02)01488-0; Heiner I, 2003, CELL CALCIUM, V33, P533, DOI 10.1016/S0143-4160(03)00058-7; Heiner I, 2003, BIOCHEM J, V371, P1045, DOI 10.1042/BJ20021975; Heller R, 1996, CANCER-AM CANCER SOC, V77, P964, DOI 10.1002/(SICI)1097-0142(19960301)77:5<964::AID-CNCR24>3.0.CO;2-0; Itagaki K, 2003, J BIOL CHEM, V278, P27540, DOI 10.1074/jbc.M301763200; Klinker JF, 1996, GEN PHARMACOL, V27, P33, DOI 10.1016/0306-3623(95)00107-7; Lee H, 1997, J BIOL CHEM, V272, P21831, DOI 10.1074/jbc.272.35.21831; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; Nilius B, 2003, CELL CALCIUM, V33, P293, DOI 10.1016/S0143-4160(03)00042-3; Schoenbach KH, 2002, IEEE T PLASMA SCI, V30, P293, DOI 10.1109/TPS.2002.1003873; Schoenbach KH, 2001, BIOELECTROMAGNETICS, V22, P440, DOI 10.1002/bem.71; Suh BC, 2000, BRIT J PHARMACOL, V131, P489, DOI 10.1038/sj.bjp.0703581; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; TSONG TY, 1991, BIOPHYS J, V60, P297, DOI 10.1016/S0006-3495(91)82054-9; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Verghese MW, 1996, J BIOL CHEM, V271, P15597, DOI 10.1074/jbc.271.26.15597; Vernier PT, 2003, BIOCHEM BIOPH RES CO, V310, P286, DOI 10.1016/j.bbrc.2003.08.140; Weaver J.C., 1996, CRC HDB BIOL EFFECTS, P247; Weaver JC, 1999, ADV DRUG DELIVER REV, V35, P21, DOI 10.1016/S0169-409X(98)00061-1; WEAVER JC, 2000, BIOMEDICAL ENG HDB, P1431; WONG TK, 1982, BIOCHEM BIOPH RES CO, V107, P584, DOI 10.1016/0006-291X(82)91531-5; Zimmermann U, 2000, IEEE T PLASMA SCI, V28, P72, DOI 10.1109/27.842868	39	170	190	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22964	22972		10.1074/jbc.M311135200	http://dx.doi.org/10.1074/jbc.M311135200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15026420	hybrid, Green Published			2022-12-25	WOS:000221570900023
J	Zhu, QS; Casey, JR				Zhu, QS; Casey, JR			The substrate anion selectivity filter in the human erythrocyte Cl-/HCO3- exchange protein, AE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTITUTED-CYSTEINE ACCESSIBILITY; CARBONIC-ANHYDRASE-II; BAND-3 PROTEIN; TRANSPORT PROTEIN; MEMBRANE DOMAIN; BINDING-SITE; PLASMODIUM-FALCIPARUM; SCANNING MUTAGENESIS; TERMINAL REGION; LINING RESIDUES	AE1 facilitates Cl-/HCO3- exchange across the erythrocyte membrane. To identify residues involved in substrate selection and translocation, we prepared an array of single cysteine mutants in an otherwise cysteineless background. These mutants spanning the C-terminal portion of the AE1 membrane domain from Phe(806)Cys(885) were characterized for functional activity when expressed in human embryonic kidney 293 cells by measurement of changes of intracellular pH associated with bicarbonate transport. To identify residues involved in substrate translocation, transport activity was assessed for each mutant before and after treatment with the following sulfhydryl reagents: anionic parachloromercuibenzenesulfonate; permeant (2-aminoethyl) methanethiosulfonate; and cationic [2-(trimethylammonium) ethyl] methanethiosulfonate ( MTSET). Among the 80 mutants, only certain key residues in the Val(849)Leu(863) region were inhibited by the sulfhydryl reagent, consistent with direct involvement of these sites in anion transport. In the last two transmembrane segments, only mutants in the extracellular portion of the transmembrane segments could be inhibited by sulfhydryl reagent, suggesting that the outer portions line the translocation channel and the inner portions have some other role. Sensitivity to cationic MTSET and effects of Cl- identified the substrate charge filter as Ser(852)-Leu(857).	Univ Alberta, Dept Physiol, Canadian Inst Hlth Res Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Casey, JR (corresponding author), Univ Alberta, Dept Physiol, Canadian Inst Hlth Res Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada.	joe.casey@ualberta.ca	Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BRAHM J, 1977, J GEN PHYSIOL, V70, P283, DOI 10.1085/jgp.70.3.283; BRUCE LJ, 1993, BIOCHEM J, V293, P317, DOI 10.1042/bj2930317; BRUCE LJ, 1994, J BIOL CHEM, V269, P16155; Bruce LJ, 2003, BLOOD, V101, P4180, DOI 10.1182/blood-2002-09-2824; Bruce LJ, 1999, BEST PRACT RES CL HA, V12, P637, DOI 10.1053/beha.1999.0046; CANFIELD VA, 1984, BIOCHIM BIOPHYS ACTA, V778, P379, DOI 10.1016/0005-2736(84)90382-1; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; CRANDALL I, 1993, P NATL ACAD SCI USA, V90, P4703, DOI 10.1073/pnas.90.10.4703; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FALKE JJ, 1986, BIOCHEMISTRY-US, V25, P7888, DOI 10.1021/bi00372a015; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; FROHLICH O, 1986, BIOCHIM BIOPHYS ACTA, V864, P169, DOI 10.1016/0304-4157(86)90010-9; FROHLICH O, 1982, J MEMBRANE BIOL, V65, P111, DOI 10.1007/BF01870474; Goel VK, 2003, P NATL ACAD SCI USA, V100, P5164, DOI 10.1073/pnas.0834959100; Hille B., 1991, IONIC CHANNELS EXCIT; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; Jay DG, 1996, CELL, V86, P853, DOI 10.1016/S0092-8674(00)80160-9; JENNINGS ML, 1985, J GEN PHYSIOL, V86, P653, DOI 10.1085/jgp.86.5.653; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; JENNINGS ML, 1986, J BIOL CHEM, V261, P9002; Jennings ML, 1998, BIOCHEM CELL BIOL, V76, P807; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; JENNINGS ML, 1989, ANN NY ACAD SCI, V574, P84; Jin XR, 2003, BIOCHEMISTRY-US, V42, P12927, DOI 10.1021/bi0350809; JONES GS, 1985, J GEN PHYSIOL, V86, P721, DOI 10.1085/jgp.86.5.721; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KAY MMB, 1994, ANN NY ACAD SCI, V719, P419, DOI 10.1111/j.1749-6632.1994.tb56847.x; KNAUF PA, 1989, METHOD ENZYMOL, V173, P432; LANDOLTMARTICORENA C, 1995, MOL MEMBR BIOL, V12, P173, DOI 10.3109/09687689509027505; LEPKE S, 1976, BIOCHIM BIOPHYS ACTA, V455, P353, DOI 10.1016/0005-2736(76)90311-4; LOW PS, 1985, SCIENCE, V227, P531, DOI 10.1126/science.2578228; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; OKUBO K, 1994, J BIOL CHEM, V269, P1918; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; RAO A, 1979, BIOCHEMISTRY-US, V18, P4505, DOI 10.1021/bi00588a008; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SALHANY JM, 1987, J BIOL CHEM, V262, P15965; Salhany JM, 2001, BLOOD CELL MOL DIS, V27, P901, DOI 10.1006/bcmd.2001.0464; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Schulz G. E., 1979, PRINCIPLES PROTEIN S, P31; SHAMI Y, 1978, BIOCHIM BIOPHYS ACTA, V508, P357, DOI 10.1016/0005-2736(78)90337-1; SILVERTHORN DU, 2001, HUMAN PHYSL INTEGRAL, P443; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; Tang XB, 1999, J BIOL CHEM, V274, P3557, DOI 10.1074/jbc.274.6.3557; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x; WANG DN, 1994, EMBO J, V13, P3230, DOI 10.1002/j.1460-2075.1994.tb06624.x; Zhang DC, 2000, BLOOD, V96, P2925; Zhu QS, 2003, FASEB J, V17, pA465; Zhu QS, 2003, J BIOL CHEM, V278, P3112, DOI 10.1074/jbc.M207797200	59	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23565	23573		10.1074/jbc.M401380200	http://dx.doi.org/10.1074/jbc.M401380200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044489	hybrid			2022-12-25	WOS:000221570900096
J	Degryse, B; Neels, JG; Czekay, RP; Aertgeerts, K; Kamikubo, Y; Loskutoff, DJ				Degryse, B; Neels, JG; Czekay, RP; Aertgeerts, K; Kamikubo, Y; Loskutoff, DJ			The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; SMOOTH-MUSCLE-CELLS; UROKINASE RECEPTOR; CYTOSKELETON REORGANIZATION; ENDOTHELIAL-CELLS; ALPHA(2)-MACROGLOBULIN RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; ENDOCYTIC RECEPTOR; INDUCE CHEMOTAXIS; LIGAND-BINDING	Although plasminogen activator inhibitor-1 (PAI-1) is known to stimulate cell migration, little is known about underlying mechanisms. We show that both active and inactive (e.g. cleaved) PAI-1 can activate the Jak/Stat signaling system and stimulate cell migration in chemotaxis, haptotaxis, chemokinesis, and wound healing assays. Moreover, antibodies to the LDL receptor-related protein (LRP) and an LRP antagonist ( RAP) blocked these motogenic effects of PAI-1, while a PAI-1 mutant that did not bind to LRP failed to activate the Jak/Stat signaling pathway or to stimulate cell migration. PAI-1 had no chemotactic effect on LRP-deficient cells. These results indicate that LRP is a signaling molecule, that it mediates the migration-promoting activity of PAI-1, and that this activity does not require intact, biologically active PAI-1. Activation of this LRP-dependent signaling pathway by PAI-1 may begin to explain how the inhibitor stimulates cell migration in a variety of normal and pathological processes.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Loskutoff, DJ (corresponding author), Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, 10550 N Torrey Pines Rd,VB-3, La Jolla, CA 92037 USA.	loskutof@scripps.edu	Neels, Jaap G/F-5534-2010	Neels, Jaap G/0000-0002-5900-8395	NHLBI NIH HHS [HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Chapman HA, 2001, THROMB HAEMOSTASIS, V86, P124; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Degryse B, 2001, ONCOGENE, V20, P2032, DOI 10.1038/sj.onc.1204261; Degryse B, 2001, FEBS LETT, V505, P249, DOI 10.1016/S0014-5793(01)02797-1; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197; Degryse Bernard, 2003, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V2, P237, DOI 10.2174/1568014033483734; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; Horn IR, 1998, THROMB HAEMOSTASIS, V80, P822; JI ZS, 1993, J BIOL CHEM, V268, P10160; KIRCHHEIMER JC, 1990, J IMMUNOL, V145, P1518; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Neels JG, 2000, BLOOD, V96, P3459, DOI 10.1182/blood.V96.10.3459.h8003459_3459_3465; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; Orr AW, 2003, J CELL BIOL, V161, P1179, DOI 10.1083/jcb.200302069; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Palmieri D, 2002, J BIOL CHEM, V277, P40950, DOI 10.1074/jbc.M202333200; PEPPER MS, 1992, J CELL PHYSIOL, V153, P129, DOI 10.1002/jcp.1041530117; Podor TJ, 2000, J BIOL CHEM, V275, P19788, DOI 10.1074/jbc.M908079199; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Sarafanov AG, 2001, J BIOL CHEM, V276, P11970, DOI 10.1074/jbc.M008046200; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; SLIVKA SR, 1991, BLOOD, V77, P1013; Stahl A, 1997, INT J CANCER, V71, P116, DOI 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.3.CO;2-Z; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; vanLeeuwen RTJ, 1996, FIBRINOLYSIS, V10, P59, DOI 10.1016/S0268-9499(96)80081-6; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 2000, J CELL SCI, V113, P123; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILLNOW TE, 1994, J CELL SCI, V107, P719; Wyne KL, 1996, ARTERIOSCL THROM VAS, V16, P407, DOI 10.1161/01.ATV.16.3.407	54	157	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22595	22604		10.1074/jbc.M313004200	http://dx.doi.org/10.1074/jbc.M313004200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15001579	hybrid			2022-12-25	WOS:000221417100111
J	Kalinin, AE; Idler, WW; Marekov, LN; McPhie, P; Bowers, B; Steinert, PM; Steven, AC				Kalinin, AE; Idler, WW; Marekov, LN; McPhie, P; Bowers, B; Steinert, PM; Steven, AC			Co-assembly of envoplakin and periplakin into oligomers and Ca-2 +-dependent vesicle binding - Implications for cornified cell envelope formation in stratified squamous epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL LINKER PROTEIN; LINKING FACTOR MACF; INTERMEDIATE-FILAMENTS; CROSS-LINKING; PLAKIN FAMILY; DESMOPLAKIN; PLECTIN; ACTIN; GENE; MICROTUBULES	Plakin family members envoplakin and periplakin have been shown to be part of the cornified cell envelope in terminally differentiating stratified squamous epithelia. In the present study, purified recombinant human envoplakin and periplakin were used to investigate their properties and interactions. We found that envoplakin was insoluble at physiological conditions in vitro, and co- assembly with periplakin was required for its solubility. Envoplakin and periplakin formed soluble complexes with equimolar stoichiometry. Chemical cross- linking revealed that the major soluble form of all periplakin constructs and of envoplakin/ periplakin rod domains was a dimer, although co- assembly of the full-length proteins resulted in formation of higher order oligomers. Electron microscopy of rotary- shadowed periplakin demonstrated thin flexible molecules with an average contour length of 88 nm for the rod- plus- tail fragment, and immunolabeling EM confirmed the molecule as a parallel, in- register, dimer. Both periplakin and envoplakin/ periplakin oligomers were able to bind synthetic lipid vesicles whose composition mimicked the cytoplasmic side of the plasma membrane of eukaryotic cells. This binding was dependent on anionic phospholipids and Ca2+. These findings raise the possibility that envoplakin and periplakin bind to the plasma membrane upon elevation of intracellular [ Ca2+] in differentiating keratinocytes, where they serve as a scaffold for cornified cell envelope assembly.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kalinin, AE (corresponding author), NIAMS, Skin Biol Lab, NIH, 9000 Rockville Pike,Bldg 50,Rm 1527, Bethesda, MD 20892 USA.	kalinina@mail.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041086, ZIAAR027015, Z01AR027015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK024942] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aho S, 1998, GENOMICS, V48, P242, DOI 10.1006/geno.1997.5188; Aho S, 2004, CELL TISSUE RES, V316, P87, DOI 10.1007/s00441-003-0769-2; Aho S, 1999, GENOMICS, V56, P160, DOI 10.1006/geno.1998.5704; DiColandrea T, 2000, J CELL BIOL, V151, P573, DOI 10.1083/jcb.151.3.573; Feng GJ, 2003, J BIOL CHEM, V278, P33400, DOI 10.1074/jbc.M305866200; FOISNER R, 1987, J MOL BIOL, V198, P515, DOI 10.1016/0022-2836(87)90297-X; FOISNER R, 1988, J CELL BIOL, V106, P723, DOI 10.1083/jcb.106.3.723; Fuchs E, 2001, GENE DEV, V15, P1, DOI 10.1101/gad.861501; GERLACH E, 1963, BIOCHEM Z, V337, P477; GREEN KJ, 1992, INT J BIOL MACROMOL, V14, P145, DOI 10.1016/S0141-8130(05)80004-2; Kalinin A, 2001, J CELL SCI, V114, P3069; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Karakesisoglou I, 2000, J CELL BIOL, V149, P195, DOI 10.1083/jcb.149.1.195; Karashima T, 2002, J CELL SCI, V115, P5027, DOI 10.1242/jcs.00191; Kazerounian S, 2002, EXP DERMATOL, V11, P428, DOI 10.1034/j.1600-0625.2002.110506.x; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Leung CL, 1999, J CELL BIOL, V147, P1275, DOI 10.1083/jcb.147.6.1275; Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8; MA ASP, 1986, J CELL BIOL, V103, P41, DOI 10.1083/jcb.103.1.41; Maatta A, 2000, J BIOL CHEM, V275, P19857, DOI 10.1074/jbc.M001028200; Maatta A, 2001, MOL CELL BIOL, V21, P7047, DOI 10.1128/MCB.21.20.7047-7053.2001; Marekov LN, 1998, J BIOL CHEM, V273, P17763, DOI 10.1074/jbc.273.28.17763; Nemes Z, 1999, J BIOL CHEM, V274, P11013, DOI 10.1074/jbc.274.16.11013; OKEEFE EJ, 1989, J BIOL CHEM, V264, P8310; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Ruhrberg C, 1997, J CELL BIOL, V139, P1835, DOI 10.1083/jcb.139.7.1835; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; STORCH S, 1999, THESIS G AUGUST U GO; Sun DM, 2001, J CELL SCI, V114, P161; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; SWARTZENDRUBER DC, 1987, J INVEST DERMATOL, V88, P709, DOI 10.1111/1523-1747.ep12470383; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; van den Heuvel APJ, 2002, J CELL SCI, V115, P3957, DOI 10.1242/jcs.00069; Yang YM, 1999, CELL, V98, P229, DOI 10.1016/S0092-8674(00)81017-X; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5	41	23	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22773	22780		10.1074/jbc.M313660200	http://dx.doi.org/10.1074/jbc.M313660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15033990	hybrid			2022-12-25	WOS:000221417100129
J	Scheller, C; Ullrich, A; McPherson, K; Hefele, B; Knoferle, J; Lamla, S; Olbrich, ARM; Stocker, H; Arasteh, K; ter Meulen, V; Rethwilm, A; Koutsilieri, E; Dittmer, U				Scheller, C; Ullrich, A; McPherson, K; Hefele, B; Knoferle, J; Lamla, S; Olbrich, ARM; Stocker, H; Arasteh, K; ter Meulen, V; Rethwilm, A; Koutsilieri, E; Dittmer, U			CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BACTERIAL-DNA; IMMUNE-ACTIVATION; GAMMA PRODUCTION; IL-2 PRODUCTION; KAPPA-B; EXPRESSION; MOTIFS; COMBINATION; INDUCTION	CpG oligodeoxynucleotides (CpG ODNs) stimulate immune cells via the Toll-like receptor 9 (TLR9). In this study, we have investigated the effects of CpG ODNs on latent human immunodeficiency virus (HIV) infection in human T cells. Treatment of the latently infected T cell line ACH-2 with CpG ODNs 2006 or 2040 stimulated HIV replication, whereas no effects were evident when ODNs without the CpG motif were used. CpG-induced virus reactivation was blocked by chloroquine, indicating the involvement of TLR9. In contrast to the responsiveness of ACH-2 cells, CpG ODNs failed to activate HIV provirus in the latently infected Jurkat clone J1.1. We also studied the effects of CpG ODNs on productive HIV infection and found enhancement of viral replication in A3.01 T cells, whereas again no stimulating effects were observed in Jurkat T cells. CpG ODN treatment activated NF-kappaB in ACH-2 cells, which was similarly triggered in uninfected A3.01 T cells following exposure to CpG ODNs, indicating that TLR9-induced signal transduction was not dependent on proviral infection. Our study demonstrates that CpG ODNs directly trigger the activation of NF-kappaB and reactivation of latent HIV in human T cells. Our results point to a novel role for CpG ODNs as stimulators of HIV replication and open new avenues to eradicate the latent viral reservoirs in HIV-infected patients treated with antiretroviral therapy.	Univ Wurzburg, Inst Virol & Immunobiol, D-97078 Wurzburg, Germany; Univ Wurzburg, Dept Dermatol, D-97080 Wurzburg, Germany; UK Essen, Inst Virol, D-45122 Essen, Germany; Vivantes Auguste Viktoria Klinikum, D-12157 Berlin, Germany	University of Wurzburg; University of Wurzburg; University of Duisburg Essen	Scheller, C (corresponding author), Univ Wurzburg, Inst Virol & Immunobiol, Versbacher Str 7, D-97078 Wurzburg, Germany.	scheller@vim.uni-wuerzburg.de	McPherson, Kirsty G/E-6331-2017; Stoecker, Horst/F-8382-2012	McPherson, Kirsty G/0000-0003-3083-6303; Stoecker, Horst/0000-0002-3282-3664				Agrawal S, 2003, J IMMUNOL, V171, P1621, DOI 10.4049/jimmunol.171.4.1621; Bendigs S, 1999, EUR J IMMUNOL, V29, P1209, DOI 10.1002/(SICI)1521-4141(199904)29:04<1209::AID-IMMU1209>3.0.CO;2-J; Cafaro A, 2001, VACCINE, V19, P2862, DOI 10.1016/S0264-410X(01)00002-0; Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481; Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; Corral RS, 2000, VACCINE, V19, P234, DOI 10.1016/S0264-410X(00)00172-9; Deml L, 1999, CLIN CHEM LAB MED, V37, P199, DOI 10.1515/CCLM.1999.037; Equils O, 2003, J IMMUNOL, V170, P5159, DOI 10.4049/jimmunol.170.10.5159; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FOLKS T, 1985, P NATL ACAD SCI USA, V82, P4539, DOI 10.1073/pnas.82.13.4539; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Iho S, 1999, J IMMUNOL, V163, P3642; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jorgensen JB, 2001, FISH SHELLFISH IMMUN, V11, P673, DOI 10.1006/fsim.2001.0344; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kranzer K, 2000, IMMUNOLOGY, V99, P170, DOI 10.1046/j.1365-2567.2000.00964.x; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krieg AM, 1998, J IMMUNOL, V161, P2428; Lipford GB, 2000, IMMUNOLOGY, V101, P46, DOI 10.1046/j.1365-2567.2000.00077.x; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Moss RB, 2000, J INTERF CYTOK RES, V20, P1131, DOI 10.1089/107999000750053807; Olbrich ARM, 2003, J VIROL, V77, P10658, DOI 10.1128/JVI.77.19.10658-10662.2003; Olbrich ARM, 2002, J VIROL, V76, P11397, DOI 10.1128/JVI.76.22.11397-11404.2002; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PEREZ VL, 1991, J IMMUNOL, V147, P3145; Prins JM, 1999, AIDS, V13, P2405, DOI 10.1097/00002030-199912030-00012; Rotchford K, 2000, SEX TRANSM DIS, V27, P243, DOI 10.1097/00007435-200005000-00001; SCHELLER C, 2002, J BIOL CHEM, V19, P19; Sulkowski MS, 1998, J INFECT DIS, V178, P1642, DOI 10.1086/314491; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; TOKUNAGA T, 1984, J NATL CANCER I, V72, P955; Trevani AS, 2003, EUR J IMMUNOL, V33, P3164, DOI 10.1002/eji.200324334; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; WEISS A, 1984, J IMMUNOL, V133, P123; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yi AK, 1999, INT IMMUNOL, V11, P2015, DOI 10.1093/intimm/11.12.2015; Yi AK, 1998, J IMMUNOL, V160, P1240; Yi AK, 1998, J IMMUNOL, V160, P4755; Yi AK, 2001, INT IMMUNOL, V13, P1391, DOI 10.1093/intimm/13.11.1391; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	49	44	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21897	21902		10.1074/jbc.M311609200	http://dx.doi.org/10.1074/jbc.M311609200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016800	hybrid			2022-12-25	WOS:000221417100029
J	Venkatraman, A; Landar, A; Davis, AJ; Chamlee, L; Sanderson, T; Kim, H; Page, G; Pompilius, M; Ballinger, S; Darley-Usmar, V; Bailey, SM				Venkatraman, A; Landar, A; Davis, AJ; Chamlee, L; Sanderson, T; Kim, H; Page, G; Pompilius, M; Ballinger, S; Darley-Usmar, V; Bailey, SM			Modification of the mitochondrial proteome in response to the stress of ethanol-dependent hepatotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-NATIVE ELECTROPHORESIS; CHRONIC ALCOHOL-CONSUMPTION; FATTY-ACID-COMPOSITION; HEPATIC MITOCHONDRIAL; BETA-OXIDATION; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; DNA DAMAGE; LIVER; METABOLISM	Mitochondria are particularly susceptible to increased formation of reactive oxygen and nitrogen species in the cell that can occur in response to pathological and xenobiotic stimuli. Proteomics can give insights into both mechanism of pathology and adaptation to stress. Herein we report the use of proteomics to evaluate alterations in the levels of mitochondrial proteins following chronic ethanol exposure in an animal model. Forty-three proteins showed differential expression, 13 increased and 30 decreased, as a consequence of chronic ethanol. Of these proteins, 25 were not previously known to be affected by chronic ethanol emphasizing the power of proteomic approaches in revealing global responses to stress. Both nuclear and mitochondrially encoded gene products of the oxidative phosphorylation complexes in mitochondria from ethanol-fed rats were decreased suggesting an assembly defect in this integrated metabolic pathway. Moreover mtDNA damage was increased by ethanol demonstrating that the effects of ethanol consumption extend beyond the proteome to encompass mtDNA. Taken together, we have demonstrated that chronic ethanol consumption extends to a modification of the mitochondrial proteome far broader than realized previously. These data also suggest that the response of mitochondria to stress may not involve non-discriminate changes in the proteome but is restricted to those metabolic pathways that have a direct role in a specific pathology.	Univ Alabama Birmingham, Sch Publ Hlth, Dept Environm Hlth Sci, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Proteom Lab 2D, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bailey, SM (corresponding author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Environm Hlth Sci, 1530 3rd Ave S,Ryals Bldg,Rm 623, Birmingham, AL 35294 USA.	sbailey@uab.edu	Darley-Usmar, Victor/F-7656-2010; Landar, Aimee/F-7269-2010; Debiasi, Laura/ABB-9981-2020	Landar, Aimee/0000-0003-2306-9214; Page, Grier/0000-0003-2582-3786; Bailey, Shannon/0000-0003-0002-3424; Darley-Usmar, Victor/0000-0001-8921-7086; Pompilius, Melissa/0000-0002-3006-7930	NCI NIH HHS [P30 CA-13148] Funding Source: Medline; NCRR NIH HHS [S10 RR16849, S10 RR11329] Funding Source: Medline; PHS HHS [13682, 13395] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011329, S10RR016849] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Arteel GE, 2003, GASTROENTEROLOGY, V124, P778, DOI 10.1053/gast.2003.50087; Bailey SM, 1998, HEPATOLOGY, V28, P1318, DOI 10.1002/hep.510280521; Bailey SM, 2001, ALCOHOL CLIN EXP RES, V25, P726, DOI 10.1111/j.1530-0277.2001.tb02273.x; Bailey SM, 1999, FREE RADICAL BIO MED, V27, P891, DOI 10.1016/S0891-5849(99)00138-0; Bailey SM, 2003, FREE RADICAL RES, V37, P585, DOI 10.1080/1071576031000091711; Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Baraona E, 1998, RECENT DEV ALCOHOL, V14, P97, DOI 10.1007/0-306-47148-5_5; Baraona E, 2002, ALCOHOL CLIN EXP RES, V26, P883, DOI 10.1111/j.1530-0277.2002.tb02618.x; Brookes PS, 2002, PROTEOMICS, V2, P969, DOI 10.1002/1615-9861(200208)2:8<969::AID-PROT969>3.0.CO;2-3; Cahill A, 1999, HEPATOLOGY, V30, P881, DOI 10.1002/hep.510300434; Cahill A, 1997, BIOCHEM BIOPH RES CO, V235, P286, DOI 10.1006/bbrc.1997.6774; Cahill A, 1996, ALCOHOL CLIN EXP RES, V20, P1362, DOI 10.1111/j.1530-0277.1996.tb01135.x; COLEMAN WB, 1990, BIOCHIM BIOPHYS ACTA, V1019, P142, DOI 10.1016/0005-2728(90)90136-R; COLEMAN WB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P178, DOI 10.1016/S0005-2728(05)80235-X; Cox KB, 2001, HUM MOL GENET, V10, P2069, DOI 10.1093/hmg/10.19.2069; CUNNINGHAM CC, 1990, ALCOHOL ALCOHOLISM, V25, P127, DOI 10.1093/oxfordjournals.alcalc.a044987; Cunningham CC, 2001, BIOL SIGNAL RECEPT, V10, P271; CUNNINGHAM CC, 1982, BIOCHIM BIOPHYS ACTA, V712, P225, DOI 10.1016/0005-2760(82)90338-1; Devreese B, 2002, ELECTROPHORESIS, V23, P2525, DOI 10.1002/1522-2683(200208)23:15<2525::AID-ELPS2525>3.0.CO;2-I; Eaton S, 1997, EUR J CLIN INVEST, V27, P719, DOI 10.1046/j.1365-2362.1997.1780727.x; Eaton S, 2002, PROG LIPID RES, V41, P197, DOI 10.1016/S0163-7827(01)00024-8; FRENCH SW, 1971, RES COMMUN CHEM PATH, V2, P567; FROMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101, DOI 10.1016/0163-7258(95)00012-6; Garesse R, 2001, GENE, V263, P1, DOI 10.1016/S0378-1119(00)00582-5; GRUNNET N, 1986, ALCOHOL CLIN EXP RES, V10, pS64, DOI 10.1111/j.1530-0277.1986.tb05182.x; Gurvitz A, 1999, BIOCHEM J, V344, P903, DOI 10.1042/0264-6021:3440903; Hanson BJ, 2001, ELECTROPHORESIS, V22, P950, DOI 10.1002/1522-2683()22:5<950::AID-ELPS950>3.0.CO;2-D; Hoek JB, 2002, ALCOHOL, V27, P63, DOI 10.1016/S0741-8329(02)00215-X; HOEK JB, 1994, CURR TOP BIOENERG, V17, P197; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; Knight-Lozano CA, 2002, CIRCULATION, V105, P849, DOI 10.1161/hc0702.103977; Koteish A, 2001, SEMIN LIVER DIS, V21, P89, DOI 10.1055/s-2001-12932; KULIELKA E, 1994, ARCH BIOCHEM BIOPHYS, V309, P377; LIEBER CS, 1982, ALCOHOL CLIN EXP RES, V6, P523, DOI 10.1111/j.1530-0277.1982.tb05017.x; Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L; Mansouri A, 1999, GASTROENTEROLOGY, V117, P181, DOI 10.1016/S0016-5085(99)70566-4; McKallip RJ, 2003, J BIOL CHEM, V278, P43818, DOI 10.1074/jbc.M304467200; MICELI JN, 1973, LIPIDS, V8, P722, DOI 10.1007/BF02531839; Murray J, 2003, J BIOL CHEM, V278, P13619, DOI 10.1074/jbc.C300064200; NIJTMANS LGJ, 1995, BBA-MOL CELL RES, V1265, P117, DOI 10.1016/0167-4889(94)00203-Q; Patel VB, 2002, ARCH BIOCHEM BIOPHYS, V398, P41, DOI 10.1006/abbi.2001.2701; RABINOWITZ JL, 1991, ALCOHOL, V8, P241, DOI 10.1016/0741-8329(91)90289-9; Ren Y, 2003, J BIOL CHEM, V278, P111, DOI 10.1074/jbc.M209261200; RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Rouach H, 1997, HEPATOLOGY, V25, P351; SALASPURO MP, 1981, HEPATOLOGY, V1, P33, DOI 10.1002/hep.1840010106; Santoni V, 2000, ELECTROPHORESIS, V21, P1054, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.3.CO;2-#; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Schagger H, 1996, Methods Enzymol, V264, P555, DOI 10.1016/S0076-6879(96)64048-8; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schuler A Michele, 2002, ILAR J, V43, P57; Shepherd D., 1969, METHODS ENZYMOL, V13, P11, DOI [10.1016/0076-6879(69)13006-2, DOI 10.1016/0076-6879(69)13006-2]; Shimomura Y, 2004, BIOCHEM BIOPH RES CO, V313, P381, DOI 10.1016/j.bbrc.2003.07.022; SPACH PI, 1982, BIOCHEM J, V202, P445, DOI 10.1042/bj2020445; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; THAYER WS, 1979, J BIOL CHEM, V254, P7717; Venkatraman A, 2004, AM J PHYSIOL-GASTR L, V286, pG521, DOI 10.1152/ajpgi.00399.2003; Venkatraman A, 2003, HEPATOLOGY, V38, P141, DOI 10.1053/jhep.2003.50293; Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Wan YJY, 2001, HEPATOL RES, V19, P117, DOI 10.1016/S1386-6346(00)00089-9; Wharton DC., 1967, METHOD ENZYMOL, P245; WIELAND P, 1995, BIOCHEM BIOPH RES CO, V213, P815, DOI 10.1006/bbrc.1995.2202; Wright G, 2001, EXP CELL RES, V263, P107, DOI 10.1006/excr.2000.5096	66	137	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22092	22101		10.1074/jbc.M402245200	http://dx.doi.org/10.1074/jbc.M402245200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15033988	hybrid			2022-12-25	WOS:000221417100051
J	Ahmmed, GU; Mehta, D; Vogel, S; Holinstat, M; Paria, BC; Tiruppathi, C; Malik, AB				Ahmmed, GU; Mehta, D; Vogel, S; Holinstat, M; Paria, BC; Tiruppathi, C; Malik, AB			Protein kinase C alpha phosphorylates the TRPC1 channel and regulates store-operated Ca2+ entry in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ENDOGENOUSLY EXPRESSED TRP1; CALCIUM-ENTRY; CATION CHANNELS; FUNCTIONAL-ROLE; SHAPE CHANGE; ACTIVATION; DEPLETION; INFLUX; PERMEABILITY	The TRPC1 ( transient receptor potential canonical-1) channel is a constituent of the nonselective cation channel that mediates Ca2+ entry through store-operated channels (SOCs) in human endothelial cells. We investigated the role of protein kinase Calpha (PKCalpha) phosphorylation of TRPC1 in regulating the opening of SOCs. Thrombin or thapsigargin added to the external medium activated Ca2+ entry after Ca2+ store depletion, which we monitored by changes in cellular Fura 2 fluorescence. Internal application of the metabolism-resistant analog of inositol 1,4,5-trisphosphate (IP3) activated an inward cationic current within 1 min, which we recorded using the whole cell patch clamp technique. La3+ or Gd3+ abolished the current, consistent with the known properties of SOCs. Pharmacological (Go6976) or genetic (kinase-defective mutant) inhibition of PKCalpha markedly inhibited IP3-induced activation of the current. Thrombin or thapsigargin also activated La3+-sensitive Ca2+ entry in a PKCalpha-dependent manner. We determined the effects of a specific antibody directed against an extracellular epitope of TRPC1 to address the functional importance of TRPC1. External application of the antibody blocked thrombin- or IP3-induced Ca2+ entry. In addition, we showed that thrombin or thapsigargin induced phosphorylation of TRPC1 within 1 min. Thrombin failed to induce TRPC1 phosphorylation in the absence of PKCalpha activation. Phosphorylation of TRPC1 and the resulting Ca2+ entry were essential for the increase in permeability induced by thrombin in confluent endothelial monolayers. These results demonstrate that PKCalpha phosphorylation of TRPC1 is an important determinant of Ca2+ entry in human endothelial cells.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mehta, D (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	dmehta@uic.edu		Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL 46350, HL 67424, R01 HL071794, HL 45638, HL 71794] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046350, R01HL067424, R01HL071794, R01HL045638] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmmed GU, 2001, CIRC RES, V89, P1005, DOI 10.1161/hh2301.100801; Ahmmed GU, 2000, CIRC RES, V86, P558, DOI 10.1161/01.RES.86.5.558; Akiba S, 2002, BIOCHEM PHARMACOL, V63, P1969, DOI 10.1016/S0006-2952(02)00988-7; Albert AP, 2002, J PHYSIOL-LONDON, V544, P113, DOI 10.1113/jphysiol.2002.022574; Antoniotti S, 2002, FEBS LETT, V510, P189, DOI 10.1016/S0014-5793(01)03256-2; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brough GH, 2001, FASEB J, V15, P1727, DOI 10.1096/fj.01-0108com; Brownlow SL, 2004, CELL CALCIUM, V35, P107, DOI 10.1016/j.ceca.2003.08.002; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; GERICKE M, 1993, PFLUG ARCH EUR J PHY, V422, P552, DOI 10.1007/BF00374001; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Huber A, 1998, FEBS LETT, V425, P317, DOI 10.1016/S0014-5793(98)00248-8; Kondo I, 2000, JPN J PHARMACOL, V82, P210, DOI 10.1254/jjp.82.210; Kwan HY, 2003, CIRC RES, V92, P286, DOI 10.1161/01.RES.0000054625.24468.08; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma R, 2002, AM J PHYSIOL-CELL PH, V283, pC1390, DOI 10.1152/ajpcell.00141.2002; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Mene P, 1997, DIABETOLOGIA, V40, P521, DOI 10.1007/s001250050710; MONTELL C, 2001, SCI STKE, V90, P1; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Ng LC, 2001, CIRC RES, V89, P923, DOI 10.1161/hh2201.100315; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Ong HL, 2002, BIOCHEM J, V364, P641, DOI 10.1042/BJ20020061; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Paria BC, 2003, J BIOL CHEM, V278, P37195, DOI 10.1074/jbc.M304287200; PARIA BC, 2002, FASEB J, V16, pA673; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Qian F, 2002, DIABETES, V51, pS183, DOI 10.2337/diabetes.51.2007.S183; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2002, J BIOL CHEM, V277, P42157, DOI 10.1074/jbc.M207320200; Sandoval R, 2001, J PHYSIOL-LONDON, V533, P433, DOI 10.1111/j.1469-7793.2001.0433a.x; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; Siflinger-Birnboim A, 2003, AM J PHYSIOL-LUNG C, V284, pL435, DOI 10.1152/ajplung.00106.2002; Singh BB, 2001, FASEB J, V15, P1652, DOI 10.1096/fj.00-0749fje; Sinkins WG, 1998, BIOCHEM J, V331, P331, DOI 10.1042/bj3310331; Sweeney M, 2002, AM J PHYSIOL-LUNG C, V283, pL144, DOI 10.1152/ajplung.00412.2001; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7; Tojyo Y, 1997, Nihon Yakurigaku Zasshi, V110, P163; Trepakova ES, 2001, J BIOL CHEM, V276, P7782, DOI 10.1074/jbc.M010104200; Vanden Abeele F, 2003, CELL CALCIUM, V33, P357, DOI 10.1016/S0143-4160(03)00049-6; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Xu HS, 2003, J BIOL CHEM, V278, P11520, DOI 10.1074/jbc.M211061200; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84	56	144	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20941	20949		10.1074/jbc.M313975200	http://dx.doi.org/10.1074/jbc.M313975200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016832	hybrid			2022-12-25	WOS:000221273800048
J	Ito, A; Sasaguri, Y; Kitada, S; Kusaka, Y; Kuwano, K; Masutomi, K; Mizuki, E; Akao, T; Ohba, M				Ito, A; Sasaguri, Y; Kitada, S; Kusaka, Y; Kuwano, K; Masutomi, K; Mizuki, E; Akao, T; Ohba, M			A Bacillus thuringiensis crystal protein with selective cytocidal action to human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-ENDOTOXIN; CANCER-CELLS; CYTOTOXICITY; TOXICITY; ISOLATE	Bacillus thuringiensis crystal proteins, well known to be toxic to certain insects but not pathogenic to mammals, are used as insecticidal proteins in agriculture and forest management. We here identified a crystal protein that is non-insecticidal and non-hemolytic but has strong cytocidal activity against various human cells with a markedly divergent target specificity, e. g. highly cytotoxic to HepG2 and Jurkat and less cytotoxic to the normal hepatocyte (HC) and HeLa. In slices of liver and colon cancer tissues, the toxin protein preferentially killed the cancer cells, leaving other cells unaffected. The cytocidal effect of the protein is non-apoptotic with swelling and fragmentation of the susceptible cells, although the apoptotic process does occur when the cell damage proceeded slowly. The amino acid sequence deduced from the nucleotide sequence of the cloned gene of the protein has little sequence homology with the insecticidal crystal proteins of B. thuringiensis. These observations raise the presence of a new group of the B. thuringiensis toxin and the possibility of new applications for the protein in the medical field.	Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan; Univ Occupat & Environm Hlth, Dept Pathol & Cell Biol, Fukuoka 8078555, Japan; Fukuoka Inst Technol Ctr, Biotechnol & Food Res Inst, Fukuoka 8390861, Japan; Kyushu Univ, Fac Agr, Dept Appl Genet & Pest Management, Fukuoka 8128581, Japan	Kyushu University; University of Occupational & Environmental Health - Japan; Fukuoka Institute of Technology; Kyushu University	Ito, A (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan.	a.itoscc@mbox.nc.kyushu-u.ac.jp						BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BROWN KL, 1992, J BACTERIOL, V174, P549, DOI 10.1128/jb.174.2.549-557.1992; Crickmore N, 1998, MICROBIOL MOL BIOL R, V62, P807, DOI 10.1128/MMBR.62.3.807-813.1998; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; GOODMAN NS, 1967, J BACTERIOL, V94, P485, DOI 10.1128/JB.94.2.485-.1967; HAIDER MZ, 1989, BIOCHIM BIOPHYS ACTA, V978, P216, DOI 10.1016/0005-2736(89)90118-1; Heiss P, 1997, ANTICANCER RES, V17, P3177; Kim HS, 2000, J APPL MICROBIOL, V89, P16, DOI 10.1046/j.1365-2672.2000.01087.x; LECADET MM, 1966, B SOC CHIM BIOL, V48, P631; Lee DW, 2000, BIOCHEM BIOPH RES CO, V272, P218, DOI 10.1006/bbrc.2000.2765; Lee DW, 2001, BBA-PROTEIN STRUCT M, V1547, P57, DOI 10.1016/S0167-4838(01)00169-8; MAHILLON J, 1994, GENETICA, V93, P13, DOI 10.1007/BF01435236; MEADOWS MP, 1992, APPL ENVIRON MICROB, V58, P1344, DOI 10.1128/AEM.58.4.1344-1350.1992; Mizuki E, 1999, J APPL MICROBIOL, V86, P477, DOI 10.1046/j.1365-2672.1999.00692.x; Mizuki E, 2000, CLIN DIAGN LAB IMMUN, V7, P625, DOI 10.1128/CDLI.7.4.625-634.2000; OHBA M, 1986, J INVERTEBR PATHOL, V47, P12, DOI 10.1016/0022-2011(86)90158-8; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; TOJO A, 1983, APPL ENVIRON MICROB, V45, P576, DOI 10.1128/AEM.45.2.576-580.1983	18	79	88	1	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21282	21286		10.1074/jbc.M401881200	http://dx.doi.org/10.1074/jbc.M401881200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15026424	hybrid			2022-12-25	WOS:000221273800089
J	Kikuma, T; Ohtsu, M; Utsugi, T; Koga, S; Okuhara, K; Eki, T; Fujimori, F; Murakami, Y				Kikuma, T; Ohtsu, M; Utsugi, T; Koga, S; Okuhara, K; Eki, T; Fujimori, F; Murakami, Y			Dbp9p, a member of the DEAD box protein family, exhibits DNA helicase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION FACTOR-4A; RNA HELICASE; SACCHAROMYCES-CEREVISIAE; ATP HYDROLYSIS; HELA-CELLS; INTERACTS; BINDING; BIOGENESIS; NUCLEOLUS; DED1P	The yeast Dbp9p is a member of the DEAD box family of RNA helicases, which are thought to be involved in RNA metabolism. Dbp9p seems to function in ribosomal RNA biogenesis, but it has not been biochemically characterized. To analyze the enzymatic characteristics of the protein, we expressed a recombinant Dbp9p in Escherichia coli and purified it to homogeneity. The purified protein exhibited RNA unwinding and binding activity in the absence of NTP, and this activity was abolished by a mutation in the RNA-binding domain. We then characterized the ATPase activity of Dbp9p with respect to cofactor specificity; the activity was found to be severely inhibited by yeast total RNA and moderately inhibited by poly(U), poly(A), and poly(C) but to be stimulated by yeast genomic DNA and salmon sperm DNA. In addition, Dbp9p exhibited DNA-DNA and DNA-RNA helicase activity in the presence of ATP. These results indicate that Dbp9p has biochemical characteristics unique among DEAD box proteins.	Sci Univ Tokyo, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan; Toyohashi Univ Technol, Dept Ecol Engn, Aichi 4418580, Japan	Tokyo University of Science; Toyohashi University of Technology	Murakami, Y (corresponding author), Sci Univ Tokyo, Fac Ind Sci & Technol, Dept Biol Sci & Technol, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	yasufumi@rs.noda.tus.ac.jp	Ohtsu, Masaya/F-3271-2011					Bayliss CD, 1996, J VIROL, V70, P794, DOI 10.1128/JVI.70.2.794-800.1996; BLUM S, 1992, P NATL ACAD SCI USA, V89, P7664, DOI 10.1073/pnas.89.16.7664; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; Daugeron MC, 2001, RNA, V7, P1317, DOI 10.1017/S1355838201010640; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Du MX, 2002, BIOCHEM J, V363, P147, DOI 10.1042/0264-6021:3630147; FLORESROZAS H, 1993, J BIOL CHEM, V268, P21372; Huang YL, 2002, J BIOL CHEM, V277, P12810, DOI 10.1074/jbc.M200182200; Iost I, 1999, J BIOL CHEM, V274, P17677, DOI 10.1074/jbc.274.25.17677; Jones PG, 1996, P NATL ACAD SCI USA, V93, P76, DOI 10.1073/pnas.93.1.76; Leary DJ, 2001, FEBS LETT, V509, P145, DOI 10.1016/S0014-5793(01)03143-X; LIANG L, 1994, DEVELOPMENT, V120, P1201; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Liu HY, 2002, J BIOL CHEM, V277, P2637, DOI 10.1074/jbc.M109016200; Nakagawa T, 2001, J BIOL CHEM, V276, P31487, DOI 10.1074/jbc.M104003200; ODay CL, 1996, J BIOL CHEM, V271, P33261, DOI 10.1074/jbc.271.52.33261; Oh JY, 1999, NUCLEIC ACIDS RES, V27, P2753, DOI 10.1093/nar/27.13.2753; Okanami M, 1998, NUCLEIC ACIDS RES, V26, P2638, DOI 10.1093/nar/26.11.2638; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1991, MOL CELL BIOL, V11, P3463, DOI 10.1128/MCB.11.7.3463; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; STRAUSS EJ, 1991, GENE DEV, V5, P629, DOI 10.1101/gad.5.4.629; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; TUTEJA N, 1992, NUCLEIC ACIDS RES, V20, P5329, DOI 10.1093/nar/20.20.5329; Valdez BC, 2000, EUR J BIOCHEM, V267, P6395, DOI 10.1046/j.1432-1327.2000.01727.x; Yan XM, 2003, MOL CELL BIOL, V23, P414, DOI 10.1128/MCB.23.1.414-423.2003; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zirwes RF, 2000, MOL BIOL CELL, V11, P1153, DOI 10.1091/mbc.11.4.1153	32	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20692	20698		10.1074/jbc.M400231200	http://dx.doi.org/10.1074/jbc.M400231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15028736	hybrid			2022-12-25	WOS:000221273800020
J	Minami, T; Murakami, T; Horiuchi, K; Miura, M; Noguchi, T; Miyazaki, J; Hamakubo, T; Aird, WC; Kodama, T				Minami, T; Murakami, T; Horiuchi, K; Miura, M; Noguchi, T; Miyazaki, J; Hamakubo, T; Aird, WC; Kodama, T			Interaction between Hex and GATA transcription factors in vascular endothelial cells inhibits flk-1/KDR-mediated vascular endothelial growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; ADHESION MOLECULE-1; FUNCTIONAL INTERACTION; MEGAKARYOCYTIC DIFFERENTIATION; THROMBIN STIMULATION; SELF-ASSOCIATION; ACTIVATION; PROMOTER	Recent evidence supports a role for GATA transcription factors as important signal intermediates in differentiated endothelial cells. The goal of this study was to identify proteins that interact with endothelial-derived GATA transcription factors. Using yeast two-hybrid screening, we identified hematopoietically expressed homeobox (Hex) as a GATA-binding partner in endothelial cells. The physical association between Hex and GATA was confirmed with immunoprecipitation in cultured cells. Hex overexpression resulted in decreased flk-1/KDR expression, both at the level of the promoter and the endogenous gene, and attenuated vascular endothelial growth factor-mediated tube formation in primary endothelial cell cultures. In electrophoretic mobility shift assays, Hex inhibited the binding of GATA-2 to the flk-1/KDR 5'-untranslated region GATA motif. Finally, in RNase protection assays, transforming growth factor beta1, which has been previously shown to decrease flk-1 expression by interfering with GATA binding activity, was shown to increase Hex expression in endothelial cells. Taken together, the present study provides evidence for a novel association between Hex and GATA and suggests that transforming growth factor beta-mediated repression of flk-1/KDR and vascular endothelial growth factor signaling involves the inducible formation of inhibitory Hex-GATA complexes.	Univ Tokyo, Adv Sci & Technol Res Ctr, Meguro Ku, Tokyo 1538904, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648604, Japan; Osaka Univ, Sch Med, Div Stem Cell Regulat Res, Suita, Osaka 5650871, Japan; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Mol & Vasc Med, Boston, MA 02215 USA	University of Tokyo; Nagoya University; Osaka University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Minami, T (corresponding author), Univ Tokyo, Adv Sci & Technol Res Ctr, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan.	minami@med.rcast.u-tokyo.ac.jp	Miyazaki, Jun-ichi/N-1976-2015	Miyazaki, Jun-ichi/0000-0003-2475-589X; HORIUCHI, KEIKO/0000-0003-4811-5133	NHLBI NIH HHS [HL 63609-02, HL 65216-02, HL 60585-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065216, P50HL063609, R01HL060585] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIRD WC, 1994, J BIOL CHEM, V269, P883; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Blokzijl A, 2002, CURR BIOL, V12, P35, DOI 10.1016/S0960-9822(01)00623-6; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Chang AN, 2002, P NATL ACAD SCI USA, V99, P9237, DOI 10.1073/pnas.142302099; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Chiba T, 1999, AM J PATHOL, V155, P1319, DOI 10.1016/S0002-9440(10)65234-0; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Heyer J, 1999, P NATL ACAD SCI USA, V96, P12595, DOI 10.1073/pnas.96.22.12595; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Minami T, 2001, J BIOL CHEM, V276, P5395, DOI 10.1074/jbc.M008798200; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nakagawa T, 2003, ARTERIOSCL THROM VAS, V23, P231, DOI 10.1161/01.ATV.0000052670.55321.87; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; Osada H., 1997, Leukemia (Basingstoke), V11, P307; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; Pellizzari L, 2000, NUCLEIC ACIDS RES, V28, P2503, DOI 10.1093/nar/28.13.2503; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Schaefer LK, 2001, J BIOL CHEM, V276, P43074, DOI 10.1074/jbc.M102552200; Sekiguchi K, 2001, CIRC RES, V88, P52, DOI 10.1161/01.RES.88.1.52; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Simoncini T, 2000, CIRC RES, V87, P19, DOI 10.1161/01.RES.87.1.19; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Umetani M, 2001, ARTERIOSCL THROM VAS, V21, P917, DOI 10.1161/01.ATV.21.6.917; van Wering HM, 2002, J BIOL CHEM, V277, P27659, DOI 10.1074/jbc.M203645200; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang DF, 2000, J BIOL CHEM, V275, P15905, DOI 10.1074/jbc.M001847200; Wang J, 2002, J CELL PHYSIOL, V190, P238, DOI 10.1002/JCP.10059; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Zhang WJ, 2002, J BIOL CHEM, V277, P45435, DOI 10.1074/jbc.M208056200	49	44	46	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20626	20635		10.1074/jbc.M308730200	http://dx.doi.org/10.1074/jbc.M308730200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016828	hybrid			2022-12-25	WOS:000221273800012
J	Chiarugi, P; Taddei, ML; Schiavone, N; Papucci, L; Giannoni, E; Fiaschi, T; Capaccioli, S; Raugei, G; Ramponi, G				Chiarugi, P; Taddei, ML; Schiavone, N; Papucci, L; Giannoni, E; Fiaschi, T; Capaccioli, S; Raugei, G; Ramponi, G			LMW-PTP is a positive regulator of tumor onset and growth	ONCOGENE			English	Article						LMW-PTP; tumor onset; tumor progression; ephrin receptors; cell adhesion	PROTEIN-TYROSINE-PHOSPHATASE; HUMAN BREAST-CANCER; FACTOR RECEPTOR; BETA-CATENIN; E-CADHERIN; CELL-PROLIFERATION; EPH RECEPTORS; KINASE; PHOSPHORYLATION; EXPRESSION	Low molecular weight protein tyrosine phosphatases (LMW-PTPs) are an enzyme family that plays a key role in cell proliferation control by dephosphorylating/inactivating both tyrosine kinase receptors ( such as PDGF, insulin, and ephrin receptors) and docking proteins (such, as beta-catenin) endowed with both adhesion and transcriptional activity. Besides being a frequent event in human tumors, overexpression of LMW-PTP has been recently demonstrated to be sufficient to induce neoplastic transformation. We recently demonstrated that overexpression of LMW-PTP strongly potentiates the stability of cell-cell contacts at the adherens junction level, which powerfully suggests that LMW-PTP may also contribute to cancer invasivity. Focusing on mechanisms by which LMW-PTP is involved in cancer onset and progression, the emerging picture is that LMW-PTP strongly increases fibronectin-mediated cell adhesion and mobility but, paradoxically, decreases cell proliferation. Nevertheless, LMW-PTP-transfected NIH3T3 fibroblasts engrafted in nude mice induce the onset of larger fibrosarcomas, which are endowed with higher proliferation activity as compared to mock-transfected controls. Quite opposite effects have been obtained with engrafted fibroblasts transfected with a dominant-negative form of LMW-PTP. Notably, in sarcoma extracts, LMW-PTP overexpression greatly influences the ephrin A2 (EphA2) but not PDGF receptor or beta-catenin tyrosine phosphorylation. The high association of dephosphorylated EphA2 overexpression with most human cancers and our observation that cell growth stimulation by LMW-PTP overexpression is restricted to the in vivo model, strongly suggest that LMW-PTP oncogenic potential is mediated by its EphA2 tyrosine dephosphorylating activity.	Univ Florence, Dept Biochem Sci, Ctr Res Transfer & High Educ Study Mol & Clin Lev, I-50134 Florence, Italy; Univ Florence, Dept Expt Pathol & Oncol, I-50121 Florence, Italy	University of Florence; University of Florence	Raugei, G (corresponding author), Univ Florence, Dept Biochem Sci, Ctr Res Transfer & High Educ Study Mol & Clin Lev, Viale Morgagni 50, I-50134 Florence, Italy.	raugei@scibio.unifi.it	Giannoni, Elisa/AAE-2092-2020; Chiarugi, Paola/CDD-7988-2022	Giannoni, Elisa/0000-0001-7136-1098; Papucci, Laura/0000-0002-8450-7428; Schiavone, Nicola/0000-0002-1592-4244; raugei, giovanni/0000-0003-1294-786X; Chiarugi, Paola/0000-0001-7655-2969				Albini A, 2001, CANCER RES, V61, P8171; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Bonvini P, 2001, CANCER RES, V61, P1671; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Bruce V, 1999, BRAIN RES, V821, P169, DOI 10.1016/S0006-8993(99)01112-9; Bucciantini M, 1998, FEBS LETT, V422, P213, DOI 10.1016/S0014-5793(98)00009-X; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; Chiarugi P, 2000, J BIOL CHEM, V275, P37619, DOI 10.1074/jbc.M006375200; COBB BS, 1993, ONCOGENE, V8, P2897; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; EASTY DJ, 1995, CANCER RES, V55, P2528; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kikawa KD, 2002, J BIOL CHEM, V277, P39274, DOI 10.1074/jbc.M207127200; Kopreski MS, 1996, ANTICANCER RES, V16, P3037; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Liekens S, 2001, INT J CANCER, V92, P161, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1183>3.0.CO;2-K; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Orsulic S, 2000, J CELL SCI, V113, P1793; Papucci L, 2002, ANTISENSE NUCLEIC A, V12, P21, DOI 10.1089/108729002753670238; Park EK, 2002, MOL CELL BIOL, V22, P3404, DOI 10.1128/MCB.22.10.3404-3414.2002; Ramponi G, 1997, BBA-PROTEIN STRUCT M, V1341, P137, DOI 10.1016/S0167-4838(97)00087-3; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; Raugei G, 2002, CELL MOL LIFE SCI, V59, P941, DOI 10.1007/s00018-002-8481-z; Rigacci S, 1999, FEBS LETT, V459, P191, DOI 10.1016/S0014-5793(99)01234-X; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; SOMMERS CL, 1994, CANCER RES, V54, P3544; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Taddei ML, 2002, CANCER RES, V62, P6489; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Varelias A, 2002, CANCER, V95, P862, DOI 10.1002/cncr.10749; YAGEL S, 1989, CANCER RES, V49, P3553; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zantek ND, 2001, CLIN CANCER RES, V7, P3640; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4	48	87	89	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3905	3914		10.1038/sj.onc.1207508	http://dx.doi.org/10.1038/sj.onc.1207508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021900	Bronze			2022-12-25	WOS:000221382000003
J	Maglich, JM; Watson, J; McMillen, PJ; Goodwin, B; Willson, TM; Moore, JT				Maglich, JM; Watson, J; McMillen, PJ; Goodwin, B; Willson, TM; Moore, JT			The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE-ANDROSTANE RECEPTOR; MICROSOMAL-ENZYME INDUCERS; PREGNANE-X RECEPTOR; HUMAN CYP2B6 GENE; MOLECULAR-CLONING; LIVER; RATS; INDUCTION; SULFOTRANSFERASES; EXCRETION	The orphan nuclear receptor CAR (NR1I3) has been characterized as a central component in the coordinate response to xenobiotic and endobiotic stress. In this study, we demonstrate that CAR plays a pivotal function in energy homeostasis and establish an unanticipated metabolic role for this nuclear receptor. Wild-type mice treated with the synthetic CAR agonist 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) exhibited decreased serum concentration of the thyroid hormone (TH) thyroxine (T-4). However, treatment of Car(-/-) mice with TCPOBOP failed to elicit these changes. To examine whether CAR played a role in the regulation of TH levels under physiological conditions, wild-type and Car(-/-) mice were fasted for 24 h, a process known to alter TH metabolism in mammals. As expected, the serum triiodothyronine and T4 concentrations decreased in wild-type mice. However, triiodothyronine and T4 levels in fasted Car(-/-) mice remained significantly higher than those in fasted wild-type animals. Concomitant with the changes in serum TH levels, both CAR agonist treatment and fasting induced the expression of CAR target genes (notably, Cyp2b10, Ugt1a1, Sultn, Sult1a1, and Sult2a1) in a receptor-dependent manner. Importantly, the Ugt1a1, Sultn, Sult1a1, and Sult2a1 genes encode enzymes that are capable of metabolizing TH. An attenuated reduction in TH levels during fasting, as observed in Car(-/-) mice, would be predicted to increase weight loss during caloric restriction. Indeed, when Car(-/-) animals were placed on a 40% caloric restriction diet for 12 weeks, Car(-/-) animals lost over twice as much weight as their wild-type littermates. Thus, CAR participates in the molecular mechanisms contributing to homeostatic resistance to weight loss. These data imply that CAR represents a novel therapeutic target to uncouple metabolic rate from food intake and has implications in obesity and its associated disorders.	GlaxoSmithKline, High Throughput Biol, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Biosci Support, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Genet Res, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, High Throughput Chem, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Moore, JT (corresponding author), GlaxoSmithKline, High Throughput Biol, 5 Moore Dr,Venture 116-1B, Res Triangle Pk, NC 27709 USA.	John.T.Moore@gsk.com	feinstein, doug/M-9414-2019					Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Brown BL, 1995, TOXICOL LETT, V81, P39, DOI 10.1016/0378-4274(95)03407-2; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; Chopra M, 2002, B WORLD HEALTH ORGAN, V80, P952; Diwan BA, 1996, CARCINOGENESIS, V17, P37, DOI 10.1093/carcin/17.1.37; Findlay KAB, 2000, J CLIN ENDOCR METAB, V85, P2879, DOI 10.1210/jc.85.8.2879; Glatt H, 2000, TOXICOL LETT, V112, P341, DOI 10.1016/S0378-4274(99)00214-3; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Harvey CB, 2002, THYROID, V12, P441, DOI 10.1089/105072502760143791; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honma W, 2001, DRUG METAB DISPOS, V29, P274; Hood A, 2003, TOXICOL APPL PHARM, V188, P6, DOI 10.1016/S0041-008X(02)00071-6; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; HURD RE, 1993, ENDOCRINOLOGY, V133, P1951, DOI 10.1210/en.133.5.1951; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kester MHA, 1999, J CLIN ENDOCR METAB, V84, P1357, DOI 10.1210/jc.84.4.1357; KINLAW WB, 1985, J CLIN INVEST, V75, P1238, DOI 10.1172/JCI111821; KONG ANT, 1993, BIOCHIM BIOPHYS ACTA, V1171, P315, DOI 10.1016/0167-4781(93)90073-M; Krotkiewski M, 2000, INT J OBESITY, V24, pS116, DOI 10.1038/sj.ijo.0801294; Larson P. R., 1992, TXB ENDOCRINOLOGY, P357; Li X, 2001, J ENDOCRINOL, V171, P525, DOI 10.1677/joe.0.1710525; Li XY, 1999, BIOCHEM BIOPH RES CO, V263, P632, DOI 10.1006/bbrc.1999.1419; LIVOLSI VA, 1989, PATHOLOGY THYROID; Locker J, 2003, HEPATOLOGY, V38, P314, DOI 10.1053/jhep.2003.50299; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; MOL JA, 1985, ENDOCRINOLOGY, V117, P8, DOI 10.1210/endo-117-1-8; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; O'Connor JC, 2002, TOXICOL SCI, V69, P79, DOI 10.1093/toxsci/69.1.79; Pugh TD, 1999, NEUROBIOL AGING, V20, P157, DOI 10.1016/S0197-4580(99)00043-3; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Rosenbaum M, 2000, AM J CLIN NUTR, V71, P1421; RUTGERS M, 1989, ENDOCRINOLOGY, V125, P2175, DOI 10.1210/endo-125-4-2175; Sakakibara Y, 1995, J BIOL CHEM, V270, P30470, DOI 10.1074/jbc.270.51.30470; Shiraki T, 2003, J BIOL CHEM, V278, P11344, DOI 10.1074/jbc.M212859200; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Vansell NR, 2002, TOXICOL SCI, V65, P184, DOI 10.1093/toxsci/65.2.184; Vansell NR, 2002, DRUG METAB DISPOS, V30, P240, DOI 10.1124/dmd.30.3.240; Visser TJ, 1996, ACTA MED AUST, V23, P10; VISSER TJ, 1990, THYROID GLAND, P255; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; WU SY, 1990, ACTA ENDOCRINOL-COP, V122, P175, DOI 10.1530/acta.0.1220175; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	47	184	192	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19832	19838		10.1074/jbc.M313601200	http://dx.doi.org/10.1074/jbc.M313601200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004031	hybrid			2022-12-25	WOS:000221164500055
J	Barsyte-Lovejoy, D; Mao, DYL; Penn, LZ				Barsyte-Lovejoy, D; Mao, DYL; Penn, LZ			c-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism	ONCOGENE			English	Article						c-Myc oncogene; transcription; repression; growth arrest; RNA polymerase II	MEDIATED TRANSCRIPTIONAL REPRESSION; CDK INHIBITOR P15(INK4B); GROWTH ARREST GENES; DIHYDROFOLATE-REDUCTASE; ENDOPLASMIC-RETICULUM; FACTORS C/EBP; CAD PROMOTER; FACTOR MIZ-1; CELL-GROWTH; DNA-DAMAGE	The c-Myc cellular oncogene has diverse activities, including transformation, proliferation, and apoptosis. These activities are dependent on the ability of c-Myc to regulate gene transcription. c-Myc downregulates the GADD45a and GADD153 (DDTI3) genes that are induced in response to genotoxic stresses and that encode protein products with antiproliferative activities. We show that c-Myc represses the expression of GADD45a and GADD153 in response to thapsigargin, a nongenotoxic stress, as well as other endoplasmic reticulum ( ER) stress agents. c-Myc represses both the basal expression and the magnitude of ER stress induction of GADD gene transcription. This repression requires the minimal promoter region of GADD45a and GADD153 and is not dependent on the ER stress element or p53-binding sites in the regulatory regions of these genes. Further analysis by chromatin immunoprecipitation shows that c-Myc binds to the minimal promoter region of GADD45a and GADD153 in vivo. c-Myc-associated protein X (Max) is also bound to both GADD gene promoters, whereas c-Myc interacting zinc-finger protein 1(Miz-1) is bound to the GADD153, but not GADD45a, promoter. RNA polymerase II(RNAPII) is recruited to the GADD gene promoters in the presence and absence of c-Myc, which suggests that c-Myc represses these genes through a post-RNAPII recruitment mechanism.	Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Penn, LZ (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	lpenn@uhnres.utoronto.ca		Penn, Linda/0000-0001-8133-5459				Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Bowen H, 2003, J BIOL CHEM, V278, P36017, DOI 10.1074/jbc.M304301200; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chen CH, 1996, ONCOGENE, V13, P1659; Cheng CH, 2003, MOL CELL BIOL, V23, P1961, DOI 10.1128/MCB.23.6.1961-1967.2003; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Corey LL, 2003, GENE DEV, V17, P1392, DOI 10.1101/gad.1071803; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Graunke DM, 1999, NUCLEIC ACIDS RES, V27, P3881, DOI 10.1093/nar/27.19.3881; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Izumi H, 2001, J CELL SCI, V114, P1533; Kime L, 2003, BIOCHEM J, V370, P291, DOI 10.1042/BJ20021679; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Piluso D, 2002, J BIOL CHEM, V277, P46799, DOI 10.1074/jbc.M206226200; PRICE BD, 1992, CANCER RES, V52, P3814; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Ziegelbauer J, 2001, MOL CELL, V8, P339, DOI 10.1016/S1097-2765(01)00313-6; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	52	52	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3481	3486		10.1038/sj.onc.1207487	http://dx.doi.org/10.1038/sj.onc.1207487			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15021909				2022-12-25	WOS:000220975000023
J	Lin, MW; Yang, SR; Huang, MH; Wu, SN				Lin, MW; Yang, SR; Huang, MH; Wu, SN			Stimulatory actions of caffeic acid phenethyl ester, a known inhibitor of NF-kappa B activation, on Ca2+-activated K+ current in pituitary GH(3) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; GH3 CELLS; APOPTOSIS; CAPE; INVOLVEMENT; EXPRESSION; AGENTS; STRESS; INJURY; LINE	Caffeic acid phenethyl ester (CAPE), a phenolic antioxidant derived from the propolis of honeybee hives, is known to be an inhibitor of activation of nuclear transcript factor NF-kappaB. Its effects on ion currents have been investigated in pituitary GH(3) cells. This compound increased Ca2+-activated K+ current (I-K(Ca)) in a concentration-dependent manner with an EC50 value of 14 +/- 2 muM. However, the magnitude of CAPE-induced stimulation of I-K(Ca) was attenuated in GH(3) cells preincubated with 2,2'-azo-bis-(2-amidinopropane) hydrochloride (100 muM) or t-butyl hydroperoxide (1 mM). CAPE (50 muM) slightly suppressed voltage-dependent L-type Ca2+ current. In inside-out configuration, CAPE (20 muM) applied to the intracellular face of the detached patch enhanced the activity of large conductance Ca2+-activated K+ (BKCa) channels with no modification in single-channel conductance. After BKCa channel activity was increased by CAPE (20 muM), subsequent application of nordihydroguaiaretic acid (20 muM) did not further increase the channel activity. CAPE-stimulated channel activity was dependent on membrane potential. CAPE could also increase Ca2+ sensitivity of BKCa channels in these cells. Its increase in the open probability could primarily involve a decrease in the mean closed time. In current-clamp conditions, CAPE hyperpolarized the membrane potential and reduced the firing of action potentials. The stimulatory effects on these channels may partly contribute to the underlying mechanisms through which this compound influences the functional activities of neurons or neuroendocrine cells. Caution has to be used in attributing its response in the activation of NF-kappaB.	Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 701, Taiwan	National Cheng Kung University	Wu, SN (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, 1 Univ Rd, Tainan 701, Taiwan.	snwu@mail.ncku.edu.tw	Wu, Sheng-Nan/B-9224-2009	Wu, Sheng-Nan/0000-0002-5208-3253				Amodio R, 2003, INT J DEV NEUROSCI, V21, P379, DOI 10.1016/S0736-5748(03)00090-X; BHIMANI RS, 1993, CANCER RES, V53, P4528; Chen YJ, 2001, ANTI-CANCER DRUG, V12, P143, DOI 10.1097/00001813-200102000-00008; CHIAO C, 1995, CANCER RES, V55, P3576; Cicala C, 2003, LIFE SCI, V73, P73, DOI 10.1016/S0024-3205(03)00235-2; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; GRANDISON L, 1994, MOL CELL ENDOCRINOL, V106, P9; Gribkoff VK, 2001, NAT MED, V7, P471, DOI 10.1038/86546; GRIBKOFF VK, 2001, NEUROSCIENTIST, V12, P1023; GRUNBERGER D, 1988, EXPERIENTIA, V44, P230, DOI 10.1007/BF01941717; Hong KW, 2003, J PHARMACOL EXP THER, V306, P1182, DOI 10.1124/jpet.103.052365; Huang MH, 2002, LIFE SCI, V70, P1185, DOI 10.1016/S0024-3205(01)01489-8; Ilhan A, 1999, EUR J CARDIO-THORAC, V16, P458, DOI 10.1016/S1010-7940(99)00246-8; Irmak MK, 2003, CELL BIOCHEM FUNCT, V21, P283, DOI 10.1002/cbf.1024; Jaiswal AK, 1997, CANCER RES, V57, P440; Joo JH, 2003, BIOCHEM BIOPH RES CO, V307, P274, DOI 10.1016/S0006-291X(03)01199-9; Kinoshita K, 2003, AM J PHYSIOL-GASTR L, V285, pG483, DOI 10.1152/ajpgi.00038.2003; Kodal H, 2000, INVEST OPHTH VIS SCI, V41, P4262; LANG DG, 1990, J PHYSIOL-LONDON, V425, P117, DOI 10.1113/jphysiol.1990.sp018095; Lee YJ, 2003, BIOCHEM PHARMACOL, V66, P2281, DOI 10.1016/j.bcp.2003.07.014; Leu Tzeng-Horng, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P357, DOI 10.2174/1568011024606370; Lo YK, 2001, PFLUG ARCH EUR J PHY, V442, P547, DOI 10.1007/s004240100576; Massaeli H, 1999, FREE RADICAL BIO MED, V26, P1524, DOI 10.1016/S0891-5849(99)00018-0; Montpied P, 2003, MOL BRAIN RES, V115, P111, DOI 10.1016/S0169-328X(03)00178-5; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Platoshyn O, 2002, AM J PHYSIOL-CELL PH, V283, pC1298, DOI 10.1152/ajpcell.00592.2001; Sheu SJ, 2003, INVEST OPHTH VIS SCI, V44, P1237, DOI 10.1167/iovs.02-0330; Tang XD, 2004, NAT STRUCT MOL BIOL, V11, P171, DOI 10.1038/nsmb725; Wu SN, 2000, J MEMBRANE BIOL, V178, P205, DOI 10.1007/s002320010028; Wu SN, 1999, J INVEST MED, V47, P484; Wu SN, 2000, J INVEST MED, V48, P259; Wu SN, 2000, MOL PHARMACOL, V57, P865; Wu SN, 2003, CURR MED CHEM, V10, P649, DOI 10.2174/0929867033457863; Wu SN, 2003, CHEM RES TOXICOL, V16, P15, DOI 10.1021/tx020067v; Wu SN, 2001, CHINESE J PHYSIOL, V44, P161; Yamamura H, 1999, J PHARMACOL EXP THER, V291, P140	36	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26885	26892		10.1074/jbc.M400356200	http://dx.doi.org/10.1074/jbc.M400356200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15039450	hybrid			2022-12-25	WOS:000222120400012
J	Ueda, Y; Wang, SZ; Dumont, N; Yi, JY; Koh, Y; Arteaga, CL				Ueda, Y; Wang, SZ; Dumont, N; Yi, JY; Koh, Y; Arteaga, CL			Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TGF-BETA; TRANSGENIC MICE; CANCER-CELLS; SIGNALING NETWORK; MAMMARY-GLAND; GROWTH-FACTOR-BETA-1 TRANSGENE; PHOSPHATIDYLINOSITOL-3 KINASE; TUMOR SUPPRESSION; COLON-CANCER	We have examined overexpression of the human epidermal growth factor receptor 2 (HER2) to determine if it modifies the anti-proliferative effect of transforming growth factor (TGF)-beta against MCF-10A human mammary epithelial cells. Exogenous TGF-beta inhibited cell proliferation and induced Smad-dependent transcriptional reporter activity in both MCF-10A/HER2 and MCF-10A/vector control cells. Ligand-induced reporter activity was 7-fold higher in HER2-overexpressing cells. In wound closure and transwell assays, TGF-beta induced motility of HER2-transduced, but not control cells. The HER2-blocking antibody trastuzumab ( Herceptin) prevented TGF-beta-induced cell motility. Expression of a constitutively active TGF-beta type I receptor (ALK5(T204D)) induced motility of MCF-10A/HER2 but not MCF-10A/vector cells. TGF-beta-induced motility was blocked by coincubation with either the phosphatidylinositol 3-kinase inhibitor LY294002, the mitogen-activated protein kinase ( MAPK) inhibitor U0126, the p38 MAPK inhibitor SB202190, and an integrin beta(1) blocking antibody. Rac1 activity was higher in HER2-overexpressing cells, where both Rac1 and Pak1 proteins were constitutively associated with HER2. Both exogenous TGF-beta and transduction with constitutively active ALK5 enhanced this association. TGF-beta induced actin stress fibers as well as lamellipodia within the leading edge of wounds. Herceptin blocked basal and TGF-beta-stimulated Rac1 activity but did not repress TGF-beta-stimulated transcriptional reporter activity. These data suggest that 1) overexpression of HER2 in nontumorigenic mammary epithelial is permissive for the ability of TGF-beta to induce cell motility and Rac1 activity, and 2) HER2 and TGF-beta signaling cooperate in the induction of cellular events associated with tumor progression.	Vanderbilt Univ, Sch Med, Div Oncol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Ingram Comprehens Canc Ctr, Breast Canc Res Program, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Div Oncol, Dept Med, 2220 Pierce Ave,777 PRB, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu	Yin, Ji-Ye/AAE-6794-2020		NCI NIH HHS [CA68485, P50 CA98131, R01 CA62212] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA062212, P50CA098131] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; Barnes NL, 2000, INT J BIOCHEM CELL B, V32, P895, DOI 10.1016/S1357-2725(00)00024-8; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bottinger EP, 1997, CANCER RES, V57, P5564; Chakrabarty S, 2001, J CELL PHYSIOL, V186, P47, DOI 10.1002/1097-4652(200101)186:1<47::AID-JCP1009>3.0.CO;2-A; COFFEY RJ, 1988, CANCER RES, V48, P1596; Coppock DL, 1998, GENOMICS, V54, P460, DOI 10.1006/geno.1998.5605; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Czerwenka KF, 2001, CANCER DETECT PREV, V25, P268; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535-6108(03)00135-1; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Engle SJ, 1999, CANCER RES, V59, P3379; Friedline JA, 1998, AM J PATHOL, V152, P23; Go C, 1999, CANCER RES, V59, P2861; Gorska AE, 1998, CELL GROWTH DIFFER, V9, P229; Gorska AE, 2003, AM J PATHOL, V163, P1539, DOI 10.1016/S0002-9440(10)63510-9; Grignani F, 1998, CANCER RES, V58, P14; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; Kang K, 1996, Exp Dermatol, V5, P218, DOI 10.1111/j.1600-0625.1996.tb00120.x; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; Miller LJ, 2000, CANCER INVEST, V18, P293, DOI 10.3109/07357900009012171; MOSES HL, 1981, CANCER RES, V41, P2842; Moulder SL, 2001, CANCER RES, V61, P8887; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Song QH, 2000, J CELL BIOCHEM, V77, P186, DOI 10.1002/(SICI)1097-4644(20000501)77:2<186::AID-JCB3>3.0.CO;2-M; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; TOH Y, 1994, J BIOL CHEM, V269, P22958; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	60	123	131	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24505	24513		10.1074/jbc.M400081200	http://dx.doi.org/10.1074/jbc.M400081200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044465	hybrid			2022-12-25	WOS:000221702500079
J	Alam, N; Stieglitz, KA; Caban, MD; Gourinath, S; Tsuruta, H; Kantrowitz, ER				Alam, N; Stieglitz, KA; Caban, MD; Gourinath, S; Tsuruta, H; Kantrowitz, ER			240s loop interactions stabilize the T state of Escherichia coli aspartate transcarbamoylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BISUBSTRATE ANALOG N-(PHOSPHONACETYL)-L-ASPARTATE; PHOSPHONACETYL-L-ASPARTATE; RAY SOLUTION SCATTERING; CRYSTAL-STRUCTURES; RESIDUES 230-245; HETEROTROPIC INTERACTIONS; ALLOSTERIC INTERACTIONS; QUATERNARY STRUCTURE; REGULATORY CHAIN; EFFECTOR BINDING	Here the functional and structural importance of interactions involving the 240s loop of the catalytic chain for the stabilization of the T state of aspartate transcarbamoylase were tested by replacement of Lys-244 with Asn and Ala. For the K244A and K244N mutant enzymes, the aspartate concentration required to achieve half-maximal specific activity was reduced to 8.4 and 4.0 mM, respectively, as compared with 12.4 mM for the wild-type enzyme. Both mutant enzymes exhibited dramatic reductions in homotropic cooperativity and the ability of the heterotropic effectors to modulate activity. Small angle x-ray scattering studies showed that the unligated structure of the mutant enzymes, and the structure of the mutant enzymes ligated with N-phosphonacetyl-L-aspartate, were similar to that observed for the unligated and N-phosphonacetyl-L-aspartate-ligated wild-type enzyme. A saturating concentration of carbamoyl phosphate alone has little influence on the small angle x-ray scattering of the wild-type enzyme. However, carbamoyl phosphate was able to shift the structure of the two mutant enzymes dramatically toward R, establishing that the mutations had destabilized the T state of the enzyme. The x-ray crystal structure of K244N enzyme showed that numerous local T state stabilizing interactions involving 240s loop residues were lost. Furthermore, the structure established that the mutation induced additional alterations at the subunit interfaces, the active site, the relative position of the domains of the catalytic chains, and the allosteric domain of the regulatory chains. Most of these changes reflect motions toward the R state structure. However, the K244N mutation alone only changes local conformations of the enzyme to an R-like structure, without triggering the quaternary structural transition. These results suggest that loss of cooperativity and reduction in heterotropic effects is due to the dramatic destabilization of the T state of the enzyme by this mutation in the 240s loop of the catalytic chain.	Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA	Boston College; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Kantrowitz, ER (corresponding author), Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA.	evan.kantrowitz@bc.edu		Stieglitz, Kimberly/0000-0001-6086-3682	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER; NCRR NIH HHS [P41RR01209] Funding Source: Medline; NIGMS NIH HHS [GM26237] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER DP, 1993, BIOCHEMISTRY-US, V32, P10150, DOI 10.1021/bi00089a034; BETHELL MR, 1968, P NATL ACAD SCI USA, V60, P1442, DOI 10.1073/pnas.60.4.1442; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; Chan RS, 2002, J BIOL CHEM, V277, P49755, DOI 10.1074/jbc.M208919200; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P680; EISENSTEIN E, 1990, BIOCHEMISTRY-US, V29, P3724, DOI 10.1021/bi00467a019; GERHART JC, 1963, COLD SPRING HARB SYM, V28, P491, DOI 10.1101/SQB.1963.028.01.065; GERHART JC, 1968, BIOCHEMISTRY-US, V7, P538, DOI 10.1021/bi00842a600; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1965, BIOCHEMISTRY-US, V4, P1054, DOI 10.1021/bi00882a012; GERHART JC, 1962, J BIOL CHEM, V237, P891; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P389, DOI 10.1021/bi00454a013; GOUAUX JE, 1989, P NATL ACAD SCI USA, V86, P8212, DOI 10.1073/pnas.86.21.8212; GOUAUX JE, 1989, BIOCHEMISTRY-US, V28, P1798, DOI 10.1021/bi00430a056; HERVE G, 1985, J MOL BIOL, V185, P189, DOI 10.1016/0022-2836(85)90190-1; Jin L, 2000, BIOCHEMISTRY-US, V39, P8058, DOI 10.1021/bi000418+; Jin L, 1999, PROTEINS, V37, P729, DOI 10.1002/(SICI)1097-0134(19991201)37:4<729::AID-PROT21>3.0.CO;2-F; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KE HM, 1984, P NATL ACAD SCI USA, V81, P4027; KIM KH, 1987, J MOL BIOL, V196, P853, DOI 10.1016/0022-2836(87)90410-4; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KOSMAN RP, 1993, PROTEINS, V15, P147, DOI 10.1002/prot.340150206; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; KRAUSE KL, 1985, P NATL ACAD SCI USA, V82, P1643, DOI 10.1073/pnas.82.6.1643; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P268, DOI 10.1021/bi00401a041; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MIDDLETON SA, 1986, P NATL ACAD SCI USA, V83, P5866, DOI 10.1073/pnas.83.16.5866; MIDDLETON SA, 1988, BIOCHEMISTRY-US, V27, P8653, DOI 10.1021/bi00423a022; MIDDLETON SA, 1989, BIOCHEMISTRY-US, V28, P1617, DOI 10.1021/bi00430a029; MOODY MF, 1979, J MOL BIOL, V133, P517, DOI 10.1016/0022-2836(79)90405-4; NEWTON CJ, 1990, P NATL ACAD SCI USA, V87, P2309, DOI 10.1073/pnas.87.6.2309; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; ROBEY EA, 1985, P NATL ACAD SCI USA, V82, P361, DOI 10.1073/pnas.82.2.361; Sakash JB, 2000, J BIOL CHEM, V275, P752, DOI 10.1074/jbc.275.2.752; Schomaker V, 1998, ACTA CRYSTALLOGR B, V54, P507, DOI 10.1107/S0108768198003243; SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; TANNER JJ, 1993, PROTEIN SCI, V2, P927, DOI 10.1002/pro.5560020606; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; West JM, 2004, J BIOL CHEM, V279, P945, DOI 10.1074/jbc.M304018200; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46; Williams MK, 1998, BBA-PROTEIN STRUCT M, V1429, P249, DOI 10.1016/S0167-4838(98)00234-9; Williams MK, 1998, J MOL BIOL, V281, P121, DOI 10.1006/jmbi.1998.1923; YATES RA, 1956, J BIOL CHEM, V221, P757	55	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23302	23310		10.1074/jbc.M401637200	http://dx.doi.org/10.1074/jbc.M401637200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15014067	hybrid			2022-12-25	WOS:000221570900064
J	Cai, WH; Hisatsune, C; Nakamura, K; Nakamura, T; Inoue, T; Mikoshiba, K				Cai, WH; Hisatsune, C; Nakamura, K; Nakamura, T; Inoue, T; Mikoshiba, K			Activity-dependent expression of inositol 1,4,5-trisphosphate receptor type 1 in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; BACKPROPAGATING ACTION-POTENTIALS; LONG-TERM DEPRESSION; PYRAMIDAL NEURONS; CA2+ RELEASE; INTRACELLULAR CALCIUM; FUNCTIONAL EXPRESSION; TYPE-1 RECEPTOR; NERVOUS-SYSTEM; L-FIBROBLASTS	There are several lines of evidence showing that synaptic activity regulates the level of expression of inositol 1,4,5-trisphosphate receptor type 1 (IP(3)R1) in neurons. In this study, we examined the effect of chronic activity blockade on the localization and level of IP(3)R1 expression in cultured hippocampal neurons. We found that chronic blockade of NMDA receptors (NMDARs), one of the major Ca2+-permeable ion channels, increased the number of neurons that express a high level of IP(3)R1 without any apparent changes in its intracellular localization. Interestingly, this up-regulation was time-dependent; there was no clear change in IP(3)R1 expression level up to day 5 of the NMDAR blockade, but expression increased at day 6, and the increased expression level persisted for at least a week. The up-regulation of IP(3)R1 depended on transcription and protein synthesis and required cAMP-dependent protein kinase activity. Moreover, although most of the control neurons did not respond to the metabotropic glutamate receptor (mGluR) stimulation, the 2-amino-5-phosphonopentanoic acid-treated neurons with high IP(3)R1 expression became sensitive to mGluR stimulation. Furthermore, we also found that hippocampal neurons transiently overexpressing green fluorescent protein-tagged IP(3)R1 released Ca2+ in response to mGluR and muscarinic acetylcholine receptor stimulation. These findings suggested that chronic NMDAR blockade increased the IP(3)R1 expression and enhanced sensitivity to mGluR stimulation. The change in IP(3)R1 expression level in response to alteration of synaptic activity may be an important determinant of the sensitivity of Ca2+ stores to G-protein-coupled receptor stimulation and would help to maintain intracellular Ca2+ homeostasis in hippocampal neurons.	Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan; Japan Sci & Technol Agcy, ICORP, Calcium Oscillat Project, Chiyoda Ku, Tokyo 1020084, Japan	University of Tokyo; RIKEN; Japan Science & Technology Agency (JST)	Hisatsune, C (corresponding author), Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.	chihiro@brain.riken.go.jp	Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015; Hisatsune, Chihiro/C-6661-2017	Inoue, Takafumi/0000-0002-2728-0060; Hisatsune, Chihiro/0000-0001-7811-7784				Ango F, 2002, MOL CELL NEUROSCI, V20, P323, DOI 10.1006/mcne.2002.1100; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; Crump FT, 2001, J NEUROSCI, V21, P5079, DOI 10.1523/JNEUROSCI.21-14-05079.2001; Davis RJ, 1999, BIOCHEM J, V341, P813, DOI 10.1042/0264-6021:3410813; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; Fujii S, 2000, LEARN MEMORY, V7, P312, DOI 10.1101/lm.34100; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Garcia MA, 1999, FEBS LETT, V444, P27, DOI 10.1016/S0014-5793(99)00021-6; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; Itoh S, 2001, BRAIN RES, V901, P237, DOI 10.1016/S0006-8993(01)02373-3; Kapur A, 2001, NEUROSCIENCE, V107, P59, DOI 10.1016/S0306-4522(01)00293-7; Kohrmann M, 1999, J NEUROSCI RES, V58, P831; Larkum ME, 2003, J PHYSIOL-LONDON, V549, P471, DOI 10.1113/jphysiol.2002.037614; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mackrill JJ, 1996, BIOCHEM J, V318, P871, DOI 10.1042/bj3180871; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; Nakamura T, 2000, J NEUROSCI, V20, P8365, DOI 10.1523/JNEUROSCI.20-22-08365.2000; Nakamura T, 1999, NEURON, V24, P727, DOI 10.1016/S0896-6273(00)81125-3; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; OGURA A, 1987, NEUROSCI LETT, V78, P69, DOI 10.1016/0304-3940(87)90563-5; Ohkawa N, 1999, GENE, V229, P11, DOI 10.1016/S0378-1119(99)00048-7; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; Reyes M, 1996, J NEUROSCI, V16, P5951; Roche KW, 1999, J BIOL CHEM, V274, P25953, DOI 10.1074/jbc.274.36.25953; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; SEYMOURLAURENT KJ, 1995, J NEUROSCI, V15, P2592; SHARP AH, 1993, J NEUROSCI, V13, P3051; Shimada M, 1999, NEUROSCI RES, V33, P275, DOI 10.1016/S0168-0102(99)00017-6; SIMPSON PB, 1994, J NEUROCHEM, V63, P2369; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Thrower EC, 2002, J BIOL CHEM, V277, P15801, DOI 10.1074/jbc.M110139200; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; Xiang Y, 2002, NAT NEUROSCI, V5, P843, DOI 10.1038/nn899; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180; Yokoyama K, 2002, EMBO J, V21, P83, DOI 10.1093/emboj/21.1.83; Yoshida Y, 2003, J PHARMACOL SCI, V92, P245	50	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23691	23698		10.1074/jbc.M313296200	http://dx.doi.org/10.1074/jbc.M313296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15016804	hybrid			2022-12-25	WOS:000221570900111
J	Cotton, NJH; Stoddard, B; Parson, WW				Cotton, NJH; Stoddard, B; Parson, WW			Oxidative inhibition of human soluble catechol-O-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-ACTIVITY ALLELE; RAY CRYSTAL-STRUCTURE; S-GLUTATHIOLATION; GENETIC-POLYMORPHISM; COMT ACTIVITY; ASSOCIATION; VARIANT; SCHIZOPHRENIA; EXPRESSION; PROTEINS	A common polymorphism in the human gene for catechol-O-methyltransferase results in replacement of Val-108 by Met in the soluble form of the protein ( s-COMT) and has been linked to breast cancer and neuropsychiatric disorders. The 108M and 108V variants are reported to differ in their thermal stability, with 108M COMT losing catalytic activity more rapidly. Because human s-COMT contains seven cysteine residues and includes CXXC and CXXS motifs that are associated with thiol-disulfide redox reactions, we examined the effects of reducing and oxidizing conditions on the enzyme. In the absence of a reductant 108M s-COMT lost activity more rapidly than 108V, whereas in the presence of 4 mM dithiothreitol (DTT) we found no significant differences in the stability of the two variants at 37 C. DTT also restored most of the activity that was lost upon incubation at 37 C in the absence of DTT. Mass spectrometry showed that cysteines 188 and 191 formed an intramolecular disulfide bond when s-COMT was incubated with oxidized glutathione, whereas cysteines 69, 95, 157, and 173 formed protein-glutathione adducts. Replacing Cys-95 by serine protected 108M s-COMT against inactivation in the absence of a reductant; C33S and Cys-188 mutations had little effect, and C69S was destabilizing. The sequences surrounding the reactive cysteine residues of human s-COMT and other proteins that form glutathione adducts at identified sites all include Pro and/or Gly and most include a hydrogen-bonding residue, suggesting that glutathiolation at conserved sites plays a physiologically important role.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Parson, WW (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	parsonb@u.washington.edu			NIGMS NIH HHS [5-T32-GM08268, R01GM49857] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008268, R01GM049857] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKSOY S, 1993, PHARMACOGENETICS, V3, P116, DOI 10.1097/00008571-199304000-00008; ALDEN RG, 1995, J AM CHEM SOC, V117, P12284, DOI 10.1021/ja00154a031; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; ASSICOT M, 1970, European Journal of Biochemistry, V12, P490, DOI 10.1111/j.1432-1033.1970.tb00877.x; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Bonifacio MJ, 2002, MOL PHARMACOL, V62, P795, DOI 10.1124/mol.62.4.795; BORCHARDT RT, 1974, ANAL BIOCHEM, V58, P382, DOI 10.1016/0003-2697(74)90206-1; BOUDIKOVA B, 1990, CLIN PHARMACOL THER, V48, P381, DOI 10.1038/clpt.1990.166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bray NJ, 2003, AM J HUM GENET, V73, P152, DOI 10.1086/376578; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; Caplan JF, 2004, J BIOL CHEM, V279, P7740, DOI 10.1074/jbc.M313049200; Celli N, 2003, J CHROMATOGR B, V787, P405, DOI 10.1016/S1570-0232(02)00706-7; Chai YC, 2003, EXP EYE RES, V76, P155, DOI 10.1016/S0014-4835(02)00309-3; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; Dawling S, 2001, CANCER RES, V61, P6716; Ellingson T, 1999, J CHROMATOGR B, V729, P347, DOI 10.1016/S0378-4347(99)00125-5; Enoch MA, 2003, PSYCHIAT GENET, V13, P33, DOI 10.1097/00041444-200303000-00006; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Fiser A, 2000, BIOINFORMATICS, V16, P251, DOI 10.1093/bioinformatics/16.3.251; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Fomenko DE, 2002, PROTEIN SCI, V11, P2285, DOI 10.1110/ps.0218302; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goodman JE, 2002, PHARMACOGENETICS, V12, P517, DOI 10.1097/00008571-200210000-00003; Graf WD, 2001, NEUROLOGY, V57, P410, DOI 10.1212/WNL.57.3.410; GROSSMAN MH, 1992, LIFE SCI, V50, P473, DOI 10.1016/0024-3205(92)90386-4; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; Horton JR, 2001, STRUCTURE, V9, P837, DOI 10.1016/S0969-2126(01)00643-8; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; HUH MMO, 1979, J BIOL CHEM, V254, P299; Humphries KM, 2002, J BIOL CHEM, V277, P43505, DOI 10.1074/jbc.M207088200; Karayiorgou M, 1997, P NATL ACAD SCI USA, V94, P4572, DOI 10.1073/pnas.94.9.4572; Kauhanen J, 2000, ALCOHOL CLIN EXP RES, V24, P135, DOI 10.1097/00000374-200002000-00001; Kirov G, 1998, MOL PSYCHIATR, V3, P342, DOI 10.1038/sj.mp.4000385; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Kleinman WA, 2003, BIOCHEM PHARMACOL, V65, P741, DOI 10.1016/S0006-2952(02)01560-5; KONISHI K, 1991, ARCH BIOCHEM BIOPHYS, V289, P90, DOI 10.1016/0003-9861(91)90446-P; Kotler M, 1999, AM J MED GENET, V88, P628, DOI 10.1002/(SICI)1096-8628(19991215)88:6<628::AID-AJMG10>3.0.CO;2-E; Lachman HM, 1996, AM J MED GENET, V67, P468, DOI 10.1002/(SICI)1096-8628(19960920)67:5<468::AID-AJMG5>3.0.CO;2-G; Lautala P, 2001, MOL PHARMACOL, V59, P393, DOI 10.1124/mol.59.2.393; Lerner Christian, 2001, Angew Chem Int Ed Engl, V40, P4040; LEVITT M, 1995, COMPUT PHYS COMMUN, V91, P215, DOI 10.1016/0010-4655(95)00049-L; Li T, 1997, PHARMACOGENETICS, V7, P349, DOI 10.1097/00008571-199710000-00002; LOTTA T, 1995, BIOCHEMISTRY-US, V34, P4202, DOI 10.1021/bi00013a008; Lyon RP, 2002, BIOCHEMISTRY-US, V41, P10920, DOI 10.1021/bi0262810; Mallis RJ, 2000, FEBS LETT, V482, P237, DOI 10.1016/S0014-5793(00)02022-6; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Mannisto P T, 1992, Prog Drug Res, V39, P291; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Matsui A, 2000, CANCER LETT, V150, P23, DOI 10.1016/S0304-3835(99)00368-7; Mitrunen K, 2001, CANCER EPIDEM BIOMAR, V10, P635; Nolan KA, 2000, PSYCHIAT GENET, V10, P117, DOI 10.1097/00041444-200010030-00003; Palmatier MA, 1999, BIOL PSYCHIAT, V46, P557, DOI 10.1016/S0006-3223(99)00098-0; Papolos DF, 1998, MOL PSYCHIATR, V3, P346, DOI 10.1038/sj.mp.4000410; Reddy S, 2000, BIOCHEM J, V347, P821, DOI 10.1042/0264-6021:3470821; SCANLON PD, 1979, SCIENCE, V203, P63, DOI 10.1126/science.758679; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Shifman S, 2002, AM J HUM GENET, V71, P1296, DOI 10.1086/344514; SPIELMAN RS, 1981, AM J MED GENET, V10, P279, DOI 10.1002/ajmg.1320100311; Strous RD, 1997, PSYCHIAT RES, V69, P71, DOI 10.1016/S0165-1781(96)03111-3; Syvanen AC, 1997, PHARMACOGENETICS, V7, P65; TENHUNEN J, 1994, EUR J BIOCHEM, V223, P1049, DOI 10.1111/j.1432-1033.1994.tb19083.x; Tenhunen J, 1999, CANCER LETT, V144, P75, DOI 10.1016/S0304-3835(99)00197-4; TERRY CJ, 1993, EMBO J, V12, P735, DOI 10.1002/j.1460-2075.1993.tb05707.x; Tiihonen J, 1999, MOL PSYCHIATR, V4, P286, DOI 10.1038/sj.mp.4000509; TILGMANN C, 1990, FEBS LETT, V264, P95, DOI 10.1016/0014-5793(90)80774-D; Ulmanen I, 1997, EUR J BIOCHEM, V243, P452, DOI 10.1111/j.1432-1033.1997.0452a.x; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; VILBOIS F, 1994, EUR J BIOCHEM, V222, P377, DOI 10.1111/j.1432-1033.1994.tb18876.x; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; Wang T, 2001, MOL PSYCHIATR, V6, P109, DOI 10.1038/sj.mp.4000803; Ward NE, 2002, METHOD ENZYMOL, V353, P89; WEINSHILBOUM RM, 1977, AM J HUM GENET, V29, P125; Weisz J, 2000, AM J PATHOL, V156, P1841, DOI 10.1016/S0002-9440(10)65057-2; Woycechowsky KJ, 2000, CURR OPIN CHEM BIOL, V4, P533, DOI 10.1016/S1367-5931(00)00128-9; Xie T, 1999, MOL PHARMACOL, V56, P31, DOI 10.1124/mol.56.1.31; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546	81	32	42	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23710	23718		10.1074/jbc.M401086200	http://dx.doi.org/10.1074/jbc.M401086200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15031283	hybrid			2022-12-25	WOS:000221570900113
J	Lee, SJ; Richardson, CC				Lee, SJ; Richardson, CC			The linker region between the helicase and primase domains of the gene 4 protein of bacteriophage T7 - Role in helicase conformation and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND DNA-SYNTHESIS; RNA PRIMER SYNTHESIS; DEOXYRIBONUCLEIC-ACID; CRYSTAL-STRUCTURE; NUCLEOTIDE-BINDING; HEXAMER FORMATION; ESCHERICHIA-COLI; PHAGE T7; REPLICATION; POLYMERASE	The gene 4 protein of bacteriophage T7 provides both helicase and primase activities. The C-terminal helicase domain is responsible for DNA-dependent dTTP hydrolysis, translocation, and DNA unwinding whereas the N-terminal primase domain is responsible for template-directed oligoribonucleotide synthesis. A 26 amino acid linker region (residues 246-271) connects the two domains and is essential for the formation of functional hexamers. In order to further dissect the role of the linker region, three residues (Ala(257), Pro(259), and Asp(263)) that was disordered in the crystal structure of the hexameric helicase fragment were substituted with all amino acids, and the altered proteins were analyzed for their ability to support growth of T7 phage lacking gene 4. The in vivo screening revealed Ala(257) and Asp(263) to be essential whereas Pro259 could be replaced with any amino acid without loss of function. Selected gene 4 proteins with substitution for Ala257 or Asp263 were purified and examined for their ability to unwind DNA, hydrolyze dTTP, translocate on ssDNA, and oligomerize. In the presence of Mg2+, all of the altered proteins oligomerize. However, in the absence of divalent ion, alterations at position 257 increase the extent of oligomerization whereas those at position 263 reduce oligomer formation. Although dTTP hydrolysis activity is reduced only 2-3-fold, none of the altered gene 4 proteins can translocate effectively on single-strand DNA, and they cannot mediate the unwinding of duplex DNA. Primer synthesis catalyzed by the altered proteins is relatively normal on a short DNA template but it is severely impaired on longer templates where translocation is required. The results suggest that the linker region not only connects the two domains of the gene 4 protein and participates in oligomerization, but also contributes to helicase activity by mediating conformations within the functional hexamer.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	ccr@hms.harvard.edu						Ahnert P, 2000, EMBO J, V19, P3418, DOI 10.1093/emboj/19.13.3418; Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; Bird LE, 2000, BIOCHEMISTRY-US, V39, P171, DOI 10.1021/bi9918801; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; Frick DN, 1999, J BIOL CHEM, V274, P35889, DOI 10.1074/jbc.274.50.35889; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; Frick DN, 2001, ANNU REV BIOCHEM, V70, P39, DOI 10.1146/annurev.biochem.70.1.39; Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; HUBER HE, 1986, J BIOL CHEM, V261, P5006; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; Kato M, 2003, MOL CELL, V11, P1349, DOI 10.1016/S1097-2765(03)00195-3; Kato M, 2001, J BIOL CHEM, V276, P21809, DOI 10.1074/jbc.M101470200; Kornberg A., 1992, DNA REPLICATION; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lee SJ, 2001, J BIOL CHEM, V276, P49419, DOI 10.1074/jbc.M108443200; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; PATEL SS, 1995, BIOPHYS J, V68, pS186; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Picha KM, 1998, J BIOL CHEM, V273, P27315, DOI 10.1074/jbc.273.42.27315; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; Rosenberg AH, 1996, J BIOL CHEM, V271, P26819, DOI 10.1074/jbc.271.43.26819; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825	38	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23384	23393		10.1074/jbc.M400857200	http://dx.doi.org/10.1074/jbc.M400857200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044475	hybrid, Green Published			2022-12-25	WOS:000221570900074
J	Pennaneach, V; Barbier, V; Regazzoni, K; Fotedar, R; Fotedar, A				Pennaneach, V; Barbier, V; Regazzoni, K; Fotedar, R; Fotedar, A			Rb inhibits E2F-1-induced cell death in a LXCXE-dependent manner by active repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; UBIQUITIN-PROTEASOME PATHWAY; RETINOBLASTOMA GENE-PRODUCT; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; LARGE SUBUNIT; CYCLE ARREST; S-PHASE; FAMILY PROTEINS; ATPASE ACTIVITY	Rb (retinoblastoma protein) inhibits E2F-1-induced cell death. We now show that the ability of Rb to inhibit E2F-1-induced cell death is dependent on a functional LXCXE-binding site in Rb, thereby suggesting that proteins that bind the LXCXE-binding site in Rb may regulate the anti-apoptotic activity of Rb. HDAC1, an LXCXE protein that plays a critical role in Rb-mediated transcription repression, abrogates the effect of Rb on E2F-1-induced cell death. In contrast, RF-Cp145, another LXCXE protein, cooperates with Rb to inhibit E2F-1-induced cell death. Both proteins exert their effect in an LXCXE-dependent manner. Rb regulates E2F-induced cell death by acting upstream of p73. Rb represses the p73 promoter. Our results further suggest a model in which Rb-E2F-1 complexes mediate the anti-apoptotic activity of Rb through active repression of target genes without recruiting HDAC1.	Inst Biol Struct, F-38027 Grenoble 1, France; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Fotedar, A (corresponding author), Inst Biol Struct, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	fotedar@ibs.fr		Pennaneach, Vincent/0000-0002-2518-0517	NATIONAL CANCER INSTITUTE [R01CA074435, R01CA092321] Funding Source: NIH RePORTER; NCI NIH HHS [CA092321, CA74435] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson LA, 2003, MOL CELL BIOL, V23, P721, DOI 10.1128/MCB.23.2.721-732.2003; Anderson LA, 2002, J BIOL CHEM, V277, P29550, DOI 10.1074/jbc.M200513200; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cai JS, 1998, P NATL ACAD SCI USA, V95, P11607, DOI 10.1073/pnas.95.20.11607; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Laj A, 1999, MOL CELL BIOL, V19, P6632; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Pennaneach V, 2001, MOL CELL, V7, P715, DOI 10.1016/S1097-2765(01)00217-9; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Podust VN, 1998, J BIOL CHEM, V273, P12935, DOI 10.1074/jbc.273.21.12935; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	56	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23376	23383		10.1074/jbc.M309809200	http://dx.doi.org/10.1074/jbc.M309809200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15016799	hybrid			2022-12-25	WOS:000221570900073
J	Yamada, NA; Hinz, JM; Kopf, VL; Segalle, KD; Thompson, LH				Yamada, NA; Hinz, JM; Kopf, VL; Segalle, KD; Thompson, LH			XRCC3 ATPase activity is required for normal XRCC3-Rad51C complex dynamics and homologous recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; HUMAN RAD51; CHROMOSOMAL INSTABILITY; PARALOGS; MUTANTS; DAMAGE	Homologous recombinational repair preserves chromosomal integrity by removing double-strand breaks, cross-links, and other DNA damage. In eukaryotic cells, the Rad51 paralogs (XRCC2/3, Rad51B/C/D) are involved in this process, although their exact functions are largely undetermined. All five paralogs contain ATPase motifs, and XRCC3 exists in a single complex with Rad51C. To examine the function of this Rad51C-XRCC3 complex, we generated mammalian expression vectors that produce human wild-type XRCC3 or mutant XRCC3 with either a nonconservative mutation (K113A) or a conservative mutation (K113R) in the GKT Walker A box of the ATPase motif. The three vectors were independently transfected into Xrcc3-deficient irs1SF Chinese hamster ovary cells. Wild-type XRCC3 complemented irs1SF cells, albeit to varying degrees, whereas ATPase mutants had no complementing activity, even when the mutant protein was expressed at comparable levels to that in wild-type-complemented clones. Because of dysfunction of the mutants, we propose that ATP binding and hydrolyzing activities of XRCC3 are essential. We tested in vitro complex formation by wild-type and mutant XRCC3 with His6-tagged Rad51C upon co-expression in bacteria, nickel-affinity purification, and Western blotting. Wild-type and K113A mutant XRCC3 formed stable complexes with Rad51C and co-purified with Rad51C, whereas the K113R mutant did not and was predominantly insoluble. The addition of 5 mM ATP but not ADP also abolished complex formation by the wild-type proteins. These results suggest that XRCC3 probably regulates the dissociation and formation of Rad51C-XRCC3 complex through ATP binding and hydrolysis with both processes being essential for the ability of the complex to participate in homologous recombinational repair.	Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Thompson, LH (corresponding author), Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA.	thompson14@llnl.gov	Classen, Scott/AAY-8176-2020		NCI NIH HHS [P01 CA92584-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Gaymes TJ, 2002, ONCOGENE, V21, P2525, DOI 10.1038/sj.onc.1205331; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; Lio YC, 2003, J BIOL CHEM, V278, P2469, DOI 10.1074/jbc.M211038200; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Liu YL, 2004, SCIENCE, V303, P243, DOI 10.1126/science.1093037; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Miller KA, 2002, J BIOL CHEM, V277, P8406, DOI 10.1074/jbc.M108306200; Morrison C, 1999, MOL CELL BIOL, V19, P6891; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Raffii S, 2003, HUM MOL GENET, V12, P915, DOI 10.1093/hmg/ddg102; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Thompson LH, 2004, MOL B INT U, P107; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Wiese C, 2002, NUCLEIC ACIDS RES, V30, P1001, DOI 10.1093/nar/30.4.1001; Yokoyama H, 2003, J BIOL CHEM, V278, P2767, DOI 10.1074/jbc.M210899200; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	30	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23250	23254		10.1074/jbc.M402247200	http://dx.doi.org/10.1074/jbc.M402247200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15037616	Green Submitted, hybrid			2022-12-25	WOS:000221570900057
J	Faillace, MP; Bernabeu, RO; Korenbrot, JI				Faillace, MP; Bernabeu, RO; Korenbrot, JI			Cellular processing of cone photoreceptor cyclic GMP-gated ion channels - A role for the S4 structural motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; N-LINKED GLYCOSYLATION; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; ROD PHOTORECEPTORS; ACTIVATED CHANNEL; CATION CHANNEL; VOLTAGE SENSOR; ELECTROSTATIC INTERACTIONS; TIGER SALAMANDER	We examined cellular protein processing and functional expression of photoreceptor cyclic nucleotide-gated (CNG) ion channels. In a mammalian cell line, wild type bovine cone photoreceptor channel alpha subunits (bCNGA3) convert from an unglycosylated state, at 90 kDa, to two glycosylated states at 93 and 102 kDa as they transit within the cell to their final location at the plasma membrane. Glycosylation per se is not required to yield functional channels, yet it is a milestone that distinguishes sequential steps in channel protein maturation. CNG ion channels are not gated by membrane voltage although their structure includes the transmembrane S4 motif known to function as the membrane voltage sensor in all voltage-gated ion channels. S4 must be functionally important because its natural mutation in cone photoreceptor CNG channels is associated with achromatopsia, a human autosomal inherited loss of cone function. Point mutation of specific, not all, charged and neutral residues within S4 cause failure of functional channel expression. Cellular channel protein processing fails in every one of the non-functional S4 mutations we studied. Mutant proteins do not reach the 102-kDa glycosylated state and do not arrive at the plasma membrane. They remain trapped within the endoplasmic reticulum and fail to transit out to the Golgi apparatus. Coexpression of cone CNG beta subunit (CNGB3) does not rescue the consequence of S4 mutations in CNGA3. It is likely that an intact S4 is required for proper protein folding and/or assembly in the endoplasmic reticulum membrane.	Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Korenbrot, JI (corresponding author), Univ Calif San Francisco, Sch Med, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.	juan@itsa.ucsf.edu	Faillace, Paula/AGW-7438-2022					Accili EA, 1997, J BIOL CHEM, V272, P25824, DOI 10.1074/jbc.272.41.25824; Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Benndorf K, 1999, J GEN PHYSIOL, V114, P477, DOI 10.1085/jgp.114.4.477; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Chen J, 2000, J BIOL CHEM, V275, P36465, DOI 10.1074/jbc.M007034200; COLAMARTINO G, 1991, J PHYSIOL-LONDON, V440, P189, DOI 10.1113/jphysiol.1991.sp018703; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Deutsch C, 2003, NEURON, V40, P265, DOI 10.1016/S0896-6273(03)00506-3; Deutsch C, 2002, ANNU REV PHYSIOL, V64, P19, DOI 10.1146/annurev.physiol.64.081501.155934; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Ding CL, 1997, AM J PHYSIOL-CELL PH, V272, pC1335, DOI 10.1152/ajpcell.1997.272.4.C1335; GORDON SE, 1995, NEURON, V14, P857, DOI 10.1016/0896-6273(95)90229-5; Hagen V, 1999, J PHOTOCH PHOTOBIO B, V53, P91, DOI 10.1016/S1011-1344(99)00131-1; HAYNES LW, 1995, J GEN PHYSIOL, V106, P507, DOI 10.1085/jgp.106.3.507; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Horn R, 2000, J GEN PHYSIOL, V116, P461, DOI 10.1085/jgp.116.3.461; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Kramer RH, 2001, J EXP BIOL, V204, P2921; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; Mannikko R, 2002, NATURE, V419, P837, DOI 10.1038/nature01038; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; Mottig H, 2001, J GEN PHYSIOL, V118, P183, DOI 10.1085/jgp.118.2.183; Much B, 2003, J BIOL CHEM, V278, P43781, DOI 10.1074/jbc.M306958200; Ohyama T, 2002, J GEN PHYSIOL, V119, P341, DOI 10.1085/jgp.20028565; Ohyama T, 2000, J GEN PHYSIOL, V116, P735, DOI 10.1085/jgp.116.6.735; Papazian DM, 1999, NEURON, V23, P7, DOI 10.1016/S0896-6273(00)80746-1; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; Peng CH, 2003, J BIOL CHEM, V278, P24617, DOI 10.1074/jbc.M301699200; PEROZO E, 1994, BIOPHYS J, V66, P345, DOI 10.1016/S0006-3495(94)80783-0; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; PICONES A, 1995, BIOPHYS J, V69, P120, DOI 10.1016/S0006-3495(95)79881-2; PICONES A, 1992, J GEN PHYSIOL, V100, P647, DOI 10.1085/jgp.100.4.647; Rho SH, 2000, FEBS LETT, V478, P246, DOI 10.1016/S0014-5793(00)01863-9; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SASAVAGE NL, 1982, J BIOL CHEM, V257, P678; Sautter A, 1997, MOL BRAIN RES, V48, P171, DOI 10.1016/S0169-328X(97)00155-1; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Smith-Maxwell CJ, 1998, J GEN PHYSIOL, V111, P421, DOI 10.1085/jgp.111.3.421; Tang CY, 1997, J GEN PHYSIOL, V109, P301, DOI 10.1085/jgp.109.3.301; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Trankner D, 2004, J NEUROSCI, V24, P138, DOI 10.1523/JNEUROSCI.3883-03.2004; Trudeau MC, 2003, J BIOL CHEM, V278, P18705, DOI 10.1074/jbc.R300001200; Tu L, 2000, BIOCHEMISTRY-US, V39, P824, DOI 10.1021/bi991740r; Wang MH, 1999, J PHYSIOL-LONDON, V521, P315, DOI 10.1111/j.1469-7793.1999.00315.x; Wei JY, 1998, J MOL NEUROSCI, V10, P53, DOI 10.1007/BF02737085; Weitz D, 2002, NEURON, V36, P881, DOI 10.1016/S0896-6273(02)01098-X; Wells GB, 1997, BIOPHYS J, V72, P127, DOI 10.1016/S0006-3495(97)78652-1; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; Wissinger B, 2001, AM J HUM GENET, V69, P722, DOI 10.1086/323613; WOHLFART P, 1989, J BIOL CHEM, V264, P20934; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Zheng J, 2002, NEURON, V36, P891, DOI 10.1016/S0896-6273(02)01099-1; Zhong HM, 2002, NATURE, V420, P193, DOI 10.1038/nature01201; ZIMMERMAN AL, 1992, J PHYSIOL-LONDON, V449, P759, DOI 10.1113/jphysiol.1992.sp019112	62	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22643	22653		10.1074/jbc.M400035200	http://dx.doi.org/10.1074/jbc.M400035200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15024024	hybrid			2022-12-25	WOS:000221417100116
J	Nuscher, B; Kamp, F; Mehnert, T; Odoy, S; Haass, C; Kahle, PJ; Beyer, K				Nuscher, B; Kamp, F; Mehnert, T; Odoy, S; Haass, C; Kahle, PJ; Beyer, K			alpha-synuclein has a high affinity for packing defects in a bilayer membrane - A thermodynamics study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; ISOTHERMAL TITRATION CALORIMETRY; SPERM ADHESIVE PROTEIN; HELIX-COIL TRANSITION; PARKINSONS-DISEASE; FIBRIL FORMATION; BETA-SYNUCLEIN; LIPID-BINDING; DIPALMITOYLPHOSPHATIDYLCHOLINE VESICLES; PHOSPHOLIPID-VESICLES	A number of neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, are characterized by the intracellular deposition of fibrillar aggregates that contain a high proportion of alpha-synuclein (alphaS). The interaction with the membrane-water interface strongly modulates folding and aggregation of the protein. The present study investigates the lipid binding and the coil-helix transition of alphaS, using titration calorimetry, differential scanning calorimetry, and circular dichroism spectroscopy. Titration of the protein with small unilamellar vesicles composed of zwitterionic phospholipids below the chain melting temperature of the lipids yielded exceptionally large exothermic heat values. The sigmoidal titration curves were evaluated in terms of a simple model that assumes saturable binding sites at the vesicle surface. The cumulative heat release and the ellipticity were linearly correlated as a result of simultaneous binding and helix folding. There was no heat release and folding of alphaS in the presence of large unilamellar vesicles, indicating that a small radius of curvature is necessary for the alphaS-membrane interaction. The heat release and the negative heat capacity of the protein-vesicle interaction could not be attributed to the coil-helix transition of the protein alone. We speculate that binding and helix folding of alphaS depends on the presence of defect structures in the membrane-water interface, which in turn results in lipid ordering in the highly curved vesicular membranes. This will be discussed with regard to a possible role of the protein for the stabilization of synaptic vesicle membranes.	Univ Munich, Dept Biochem, Inst Stoffwechselbiochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany	University of Munich	Beyer, K (corresponding author), Univ Munich, Dept Biochem, Inst Stoffwechselbiochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.	kbeyer@med.uni-muenchen.de						BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; Barenholz Y, 1999, CHEM PHYS LIPIDS, V102, P29, DOI 10.1016/S0009-3084(99)00072-9; Barenholz Y., 1984, PHYSL MEMBRANE FLUID, V1, P131; Bevington PR, 1969, DATA REDUCTION ERROR; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; BRECKENRIDGE WC, 1973, BIOCHIM BIOPHYS ACTA, V320, P681, DOI 10.1016/0304-4165(73)90148-7; Bussell R, 2003, J MOL BIOL, V329, P763, DOI 10.1016/S0022-2836(03)00520-5; Cabin DE, 2002, J NEUROSCI, V22, P8797; Cevc G., 1987, PHOSPHOLIPID BILAYER; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; CHOU PY, 1971, BIOPOLYMERS, V10, P657, DOI 10.1002/bip.360100406; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; EICHBERG J, 1964, BIOCHEM J, V92, P91, DOI 10.1042/bj0920091; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; EPAND RM, 1990, J BIOL CHEM, V265, P20829; GABER BP, 1982, BIOCHIM BIOPHYS ACTA, V685, P87, DOI 10.1016/0005-2736(82)90038-4; Gazzara JA, 1997, J LIPID RES, V38, P2134; GLABE CG, 1985, J CELL BIOL, V100, P794, DOI 10.1083/jcb.100.3.794; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; JAHNIG F, 1981, BIOPHYS J, V36, P329, DOI 10.1016/S0006-3495(81)84735-2; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Kahle PJ, 2002, J NEUROCHEM, V82, P449, DOI 10.1046/j.1471-4159.2002.01020.x; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; KENNEDY L, 1989, BIOCHEMISTRY-US, V28, P9153, DOI 10.1021/bi00449a029; KING RJ, 1986, BIOCHIM BIOPHYS ACTA, V879, P1, DOI 10.1016/0005-2760(86)90259-6; KODAMA M, 1993, BIOCHIM BIOPHYS ACTA, V1169, P90; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; LICHTENBERG D, 1984, LIPIDS, V19, P395, DOI 10.1007/BF02537400; Lopez MM, 2002, P NATL ACAD SCI USA, V99, P1298, DOI 10.1073/pnas.032665199; Lotharius J, 2002, J BIOL CHEM, V277, P38884, DOI 10.1074/jbc.M205518200; MICHAELSON DM, 1983, BIOCHEM J, V211, P155, DOI 10.1042/bj2110155; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; NAGY A, 1976, BRAIN RES, V109, P285, DOI 10.1016/0006-8993(76)90531-X; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Necula M, 2003, J BIOL CHEM, V278, P46674, DOI 10.1074/jbc.M308231200; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Park JY, 2003, BIOCHEMISTRY-US, V42, P3696, DOI 10.1021/bi020604a; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ramakrishnan M, 2003, BIOCHEMISTRY-US, V42, P12919, DOI 10.1021/bi035048e; SCHOLTZ JM, 1992, ANNU REV BIOPH BIOM, V21, P95, DOI 10.1146/annurev.bb.21.060192.000523; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; SCHULLERY SE, 1980, BIOCHEMISTRY-US, V19, P3919, DOI 10.1021/bi00558a005; SEELIG J, 1993, BIOCHEMISTRY-US, V32, P9714, DOI 10.1021/bi00088a025; Seelig J, 1997, BBA-REV BIOMEMBRANES, V1331, P103, DOI 10.1016/S0304-4157(97)00002-6; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; SUREWICZ WK, 1986, J BIOL CHEM, V261, P6191; SUURKUUSK J, 1976, BIOCHEMISTRY-US, V15, P1393, DOI 10.1021/bi00652a007; TANFORD C, 1962, J AM CHEM SOC, V84, P4240, DOI 10.1021/ja00881a009; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2002, J BIOL CHEM, V277, P11970, DOI 10.1074/jbc.M109541200; VANDIJCK PWM, 1978, BIOCHIM BIOPHYS ACTA, V506, P183, DOI 10.1016/0005-2736(78)90389-9; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WETTERAU JR, 1982, J BIOL CHEM, V257, P961; Wieprecht T, 2002, BIOPHYS CHEM, V96, P191, DOI 10.1016/S0301-4622(02)00025-X; Wieprecht T, 2002, CURR TOP MEMBR, V52, P31; Wieprecht T, 1999, BIOCHEMISTRY-US, V38, P10377, DOI 10.1021/bi990913+; Wieprecht T, 2000, BIOCHEMISTRY-US, V39, P15297, DOI 10.1021/bi001774v; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9; Zhu M, 2003, J BIOL CHEM, V278, P16873, DOI 10.1074/jbc.M210136200; Zhu M, 2003, J BIOL CHEM, V278, P40186, DOI 10.1074/jbc.M305326200	76	187	188	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21966	21975		10.1074/jbc.M401076200	http://dx.doi.org/10.1074/jbc.M401076200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15028717	hybrid			2022-12-25	WOS:000221417100037
J	Smith, MJ; Smith, BRE; Lawrence, MB; Snapp, KR				Smith, MJ; Smith, BRE; Lawrence, MB; Snapp, KR			Functional analysis of the combined role of the O-linked branching enzyme core 2 beta 1-6-N-glucosaminyltransferase and dimerization of P-selectin glycoprotein ligand-1 in rolling on P-selectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION; FUCOSYL-TRANSFERASE; TYROSINE SULFATION; HUMAN NEUTROPHILS; DEFICIENT MICE; AMINO-TERMINUS; SHEAR-FLOW; FUCT-VII; IN-VIVO; PSGL-1	Leukocyte P-selectin glycoprotein ligand-1 (PSGL-1) is expressed as a homodimer and mediates leukocyte rolling through interactions with endothelial P-selectin. Previous studies have shown that PSGL-1 must be properly modified by specific glycosyltransferases including alpha1,3-fucosyltransferase-VII, core 2 beta1-6-N-glucosaminyltransferase (C2GlcNAcT-I), one or more alpha2,3-sialytransferases, and a tyrosulfotransferase. In addition, dimerization of PSGL-1 through its sole extracellular cysteine (Cys(320)) is essential for rolling on P-selectin under shear conditions. In this report, we measured the contributions of both C2GlcNAcT-I glycosylation and dimerization of PSGL-1 to adhesive bonds formed during tethering and rolling of transfected cell lines on purified P-selectin. Tethering to P-selectin under flow increased with dimerization compared with cells expressing monomeric PSGL-1 (referred to as C320A). The rolling defects (decreased cellular accumulation, PSGL-1/P-selectin bond strengths and tethering rates, and increased velocities and skip distance) demonstrated by transfectants expressing monomeric PSGL-1 could be overcome by increasing the substrate P-selectin site density and by overexpressing C2GlcNAcT-I in C320A transfectants. Two molecular weight variants of PSGL-1 were isolated from cell lines transfected with PSGL-1, C320A, and/or C2GlcNAcT-I cDNAs, and these differences in electrophoretic mobility appeared to correlate with C2GlcNAcT-I expression. C320A transfectants expressing low molecular weight PSGL-1 had lower C2GlcNAcT-I levels ( measured by reactivity to core 2 specific linkage antibody, CHO-131) and compromised rolling on P-selectin ( regardless of site density) compared with C320A cells with high levels of C2GlcNAcT-I and high molecular weight PSGL-1. Both C2GlcNAcT-I glycosylation and PSGL-1 dimerization increased the rate of tethering to P-selectin under flow, whereas C2GlcNAcT-I levels primarily influenced tether bond strength.	Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22903 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Virginia; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lawrence, MB (corresponding author), Univ Virginia, Dept Biomed Engn, Box 800759, Charlottesville, VA 22903 USA.	mbl2a@virginia.edu			NHLBI NIH HHS [HL064381, HL054614] Funding Source: Medline; NIGMS NIH HHS [GM060563] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054614, R01HL054614, R01HL064381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060563] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; Bullard DC, 1996, J EXP MED, V183, P2329, DOI 10.1084/jem.183.5.2329; Cheezum MK, 2001, BIOPHYS J, V81, P2378, DOI 10.1016/S0006-3495(01)75884-5; Doggett TA, 2002, BIOPHYS J, V83, P194, DOI 10.1016/S0006-3495(02)75161-8; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; Jung U, 1996, AM J PHYSIOL-HEART C, V271, pH2740, DOI 10.1152/ajpheart.1996.271.6.H2740; KAPLANSKI G, 1993, BIOPHYS J, V64, P1922, DOI 10.1016/S0006-3495(93)81563-7; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; Kumar R, 1996, BLOOD, V88, P3872, DOI 10.1182/blood.V88.10.3872.bloodjournal88103872; Kunkel EJ, 1996, CIRC RES, V79, P1196, DOI 10.1161/01.RES.79.6.1196; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Li X, 1998, J EXP MED, V188, P1385, DOI 10.1084/jem.188.7.1385; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; Park EYH, 2002, BIOPHYS J, V82, P1835, DOI 10.1016/S0006-3495(02)75534-3; Pierres A, 1996, P NATL ACAD SCI USA, V93, P15114, DOI 10.1073/pnas.93.26.15114; Poppe L, 1997, J AM CHEM SOC, V119, P1727, DOI 10.1021/ja9610702; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Puri KD, 1998, NATURE, V392, P930, DOI 10.1038/31954; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Ramachandran V, 2001, P NATL ACAD SCI USA, V98, P10166, DOI 10.1073/pnas.171248098; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Smith MJ, 1999, BIOPHYS J, V77, P3371, DOI 10.1016/S0006-3495(99)77169-9; Smith MJ, 2002, BIOPHYS J, V83, P2320, DOI 10.1016/S0006-3495(02)73992-1; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; Snapp KR, 1998, J CELL BIOL, V142, P263, DOI 10.1083/jcb.142.1.263; Snapp KR, 2001, BLOOD, V97, P3806, DOI 10.1182/blood.V97.12.3806; Snapp KR, 1997, BLOOD, V89, P896, DOI 10.1182/blood.V89.3.896; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Sperandio M, 2001, BLOOD, V97, P3812, DOI 10.1182/blood.V97.12.3812; VARKI A, 1999, ESSENTIALS GLYCOBIOL, P404; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Wagers AJ, 1997, J IMMUNOL, V159, P1917; Wagers AJ, 1996, BLOOD, V88, P2125, DOI 10.1182/blood.V88.6.2125.bloodjournal8862125; Walcheck B, 2002, BLOOD, V99, P4063, DOI 10.1182/blood-2001-12-0265; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677	41	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21984	21991		10.1074/jbc.M402731200	http://dx.doi.org/10.1074/jbc.M402731200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15026421	hybrid			2022-12-25	WOS:000221417100039
J	Zhang, J; Anastasiadis, PZ; Liu, Y; Thompson, EA; Fields, AP				Zhang, J; Anastasiadis, PZ; Liu, Y; Thompson, EA; Fields, AP			Protein kinase C (PKC) beta II induces cell invasion through a Ras/Mek-, PKC iota/Rac1-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; SELECTIVE CYCLOOXYGENASE-2 INHIBITOR; COLON-CANCER CELLS; RAS TRANSFORMATION; LIVER METASTASIS; COLORECTAL-CANCER; F-ACTIN; CARCINOGENESIS; EXPRESSION; POLARITY	Protein kinase C betaII (PKCbetaII) promotes colon carcinogenesis. Expression of PKCbetaII in the colon of transgenic mice induces hyperproliferation and increased susceptibility to colon cancer. To determine molecular mechanisms by which PKCbetaII promotes colon cancer, we established rat intestinal epithelial (RIE) cells stably expressing PKCbetaII. Here we show that RIE/PKCbetaII cells acquire an invasive phenotype that is blocked by the PKCbeta inhibitor LY379196. Invasion is not observed in RIE cells expressing a kinase-deficient PKCbetaII, indicating that PKCbetaII activity is required for the invasive phenotype. PKCbetaII induces activation of K-Ras and the Ras effector, Rac1, in RIE/PKCbetaII cells. PKCbetaII-mediated invasion is blocked by the Mek inhibitor, U0126, and by expression of either dominant negative Rac1 or kinase-deficient atypical PKCiota. Expression of constitutively active Rac1 induces Mek activation and invasion in RIE cells, indicating that Rac1 is the critical downstream effector of PKCbetaII-mediated invasion. Taken together, our results define a novel PKCbetaII-->Ras-->PKCiota/Rac1-->Mek signaling pathway that induces invasion in intestinal epithelial cells. This pathway provides a plausible mechanism by which PKCbetaII promotes colon carcinogenesis.	Mayo Clin, Ctr Comprehens Canc, Jacksonville, FL 32224 USA	Mayo Clinic	Fields, AP (corresponding author), Mayo Clin, Ctr Comprehens Canc, Griffin Canc Res Bldg,Rm 312,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu						Alahari SK, 2003, EXP CELL RES, V288, P415, DOI 10.1016/S0014-4827(03)00233-7; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; BAUM CL, 1990, CANCER RES, V50, P3915; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Calvert PM, 2002, ANN INTERN MED, V137, P603, DOI 10.7326/0003-4819-137-7-200210010-00012; Chen WS, 2001, INT J CANCER, V91, P894, DOI 10.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.3.CO;2-R; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; CRAVEN PA, 1992, CANCER RES, V52, P2216; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dubois R, 1997, ADV EXP MED BIOL, V400, P487; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Fields Alan P, 2003, Methods Mol Biol, V233, P519; Fujimoto K, 2001, EXP CELL RES, V266, P239, DOI 10.1006/excr.2000.5229; Gokmen-Polar Y, 2001, CANCER RES, V61, P1375; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y; KARGMAN SL, 1995, CANCER RES, V55, P2556; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kiley SC, 1999, CANCER RES, V59, P3230; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MARSHALL CJ, 1989, INT J CANCER, P29; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; Murray NR, 2002, J CELL BIOL, V157, P915, DOI 10.1083/jcb.200201127; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Murray NR, 1999, J CELL BIOL, V145, P699, DOI 10.1083/jcb.145.4.699; MURRAY NR, 1997, PROTEIN KINASE C, P97; Nagatsuka I, 2002, INT J CANCER, V100, P515, DOI 10.1002/ijc.10508; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sheng HM, 1997, CELL GROWTH DIFFER, V8, P463; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; Tomozawa S, 1999, BRIT J CANCER, V81, P1274, DOI 10.1038/sj.bjc.6694262; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Yamauchi T, 2003, ANTICANCER RES, V23, P245; Yu WS, 2003, J BIOL CHEM, V278, P11167, DOI 10.1074/jbc.M211424200	46	117	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22118	22123		10.1074/jbc.M400774200	http://dx.doi.org/10.1074/jbc.M400774200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15037605	hybrid			2022-12-25	WOS:000221417100054
J	Sivashanmugam, P; Tang, L; Daaka, Y				Sivashanmugam, P; Tang, L; Daaka, Y			Interleukin 6 mediates the lysophosphatidic acid-regulated cross-talk between stromal and epithelial prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; REACTIVE STROMA; KAPPA-B; ACTIVATION; GROWTH; REQUIREMENT; MECHANISMS	The interaction between stromal and epithelial cells is critical for the initiation and progression of prostate cancer, but the molecular determinants responsible for the cross-talk between these two cell types remain largely unknown. Here, we used a co-culture cell assay to identify messengers involved in the cross-talk between human prostate stromal PS30 and epithelial LNCaP cells. Stimulation with lysophosphatidic acid (LPA) activates the mitogenic ERK signaling pathway in PS30, but not LNCaP, cells. The co-culture of PS30 and LNCaP cells results in the activation of ERK in LNCaP cells and that is further increased in response to stimulation with LPA. Physiologic relevance of the interaction between PS30 and LNCaP cells is demonstrated using LNCaP xenograft tumor assays. Animals implanted with a mixture of both cell types develop larger tumors with higher frequency compared with those injected with LNCaP cells alone. Conditioned medium transfer experiments reveal the PS30-derived inducing factor is soluble and promotes mitogenic ERK and STAT3 signaling pathways in LNCaP cells. Protein analysis demonstrates that treatment of the PS30 cells with LPA induces synthesis of interleukin 6 (IL-6). Antibody neutralization experiments reveal that IL-6 is responsible for the LPA-induced mitogenic signaling and growth of the LNCaP cells. Our findings reveal that the LPA-regulated secretion of IL-6 is an important messenger linking stromal and epithelial prostate cells, which may be exploited for the effective treatment of patients with advanced prostate cancer.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University	Daaka, Y (corresponding author), Duke Univ, Med Ctr, Dept Surg, 2607, Durham, NC 27710 USA.	daaka001@mc.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017952] Funding Source: NIH RePORTER; NIA NIH HHS [AG 17952] Funding Source: Medline; NIDDK NIH HHS [DK 60917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayala G, 2003, CLIN CANCER RES, V9, P4792; Barki-Harrington L, 2001, J UROLOGY, V165, P2121, DOI 10.1016/S0022-5347(05)66305-7; Barki-Harrington L, 2003, BIOCHEM J, V371, P581, DOI 10.1042/BJ20021708; Berger AP, 2003, PROSTATE, V57, P57, DOI 10.1002/pros.10279; Bookout AL, 2003, J BIOL CHEM, V278, P37569, DOI 10.1074/jbc.M306276200; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Browatzki M, 2000, BASIC RES CARDIOL, V95, P98, DOI 10.1007/s003950050170; Chung TDK, 1999, PROSTATE, V38, P199; Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335; Daaka Y., 2004, SCI STKE, V216, pr; Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Huang CD, 2003, AM J RESP CELL MOL, V28, P330, DOI 10.1165/rcmb.2002-0040OC; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kranzhofer R, 1999, ARTERIOSCL THROM VAS, V19, P1623, DOI 10.1161/01.ATV.19.7.1623; Kue PF, 2000, J UROLOGY, V164, P2162, DOI 10.1016/S0022-5347(05)66990-X; Kue PF, 2002, INT J CANCER, V102, P572, DOI 10.1002/ijc.10734; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Price DT, 2000, J UROLOGY, V164, P2145, DOI 10.1016/S0022-5347(05)66987-X; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Steiner H, 2003, AM J PATHOL, V162, P655, DOI 10.1016/S0002-9440(10)63859-X; Sung SY, 2002, DIFFERENTIATION, V70, P506, DOI 10.1046/j.1432-0436.2002.700905.x; Tuxhorn JA, 2002, CANCER RES, V62, P3298; Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Zerbini LF, 2003, CANCER RES, V63, P2206	30	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21154	21159		10.1074/jbc.M313776200	http://dx.doi.org/10.1074/jbc.M313776200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15024019	hybrid			2022-12-25	WOS:000221273800073
J	Kawasaki, K; Ernst, RK; Miller, SI				Kawasaki, K; Ernst, RK; Miller, SI			3-O-deacylation of lipid A by PagL, a PhoP/PhoQ-regulated deacylase of Salmonella typhimurium, modulates signaling through Toll-like receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ANTIMICROBIAL PEPTIDES; CUTTING EDGE; PHOP-PHOQ; LPS GENE; LIPOPOLYSACCHARIDE; MD-2; MICE; TLR4; TRANSDUCTION	Toll-like receptor 4 (TLR4)-mediated responses, which are induced by the lipid A portion of lipopolysaccharide, are important for host defense against Salmonellae infection. A variety of different data indicate that the acylation state of lipid A can alter TLR4-mediated responses. The S. typhimurium virulence gene product PhoP/PhoQ signals the presence of host microenvironments to regulate the expression of a lipid A 3-O-deacylase, PagL, and a lipid A palmitoyltransferase, PagP. We now demonstrate that 3-O-deacylation and palmitoylation of lipid A decreases its ability to induce TLR4-mediated signaling. Deacylated lipid A, deacylated and palmitoylated lipid A, palmitoylated lipid A, and unmodified lipid A species were purified from Escherichia coli heterologously expressing PagL and/or PagP. The purified lipid A preparations showed spectra of a single lipid A species on mass spectrometry and gave a single band on thin layer chromatography. The activity of purified lipid A species was examined using human and mouse cell lines that express recombinant human TLR4. Compared with unmodified lipid A, the modified lipid A species are 30-100-fold less active in the ability to induce NF-kappaB-dependent reporter activation. These results suggest that the lipid A modifications reduce TLR4-signaling as part of Salmonellae adaptation to host environments.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Miller, SI (corresponding author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.	millersi@u.washington.edu		Ernst, Robert/0000-0001-5016-8694	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030479] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 30479] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; Bader MW, 2003, MOL MICROBIOL, V50, P219, DOI 10.1046/j.1365-2958.2003.03675.x; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; CROSS AS, 1989, J EXP MED, V169, P2021, DOI 10.1084/jem.169.6.2021; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Gomi K, 2002, J IMMUNOL, V168, P2939, DOI 10.4049/jimmunol.168.6.2939; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hohmann EL, 1996, J INFECT DIS, V173, P1408, DOI 10.1093/infdis/173.6.1408; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; Kawasaki K, 2001, J IMMUNOL, V166, P11, DOI 10.4049/jimmunol.166.1.11; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Que NLS, 2000, J BIOL CHEM, V275, P28006; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHERER CA, 2001, PRINCIPLES BACTERIAL, P265; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Stover AG, 2004, J BIOL CHEM, V279, P4440, DOI 10.1074/jbc.M310760200; Tanamoto K, 2000, J IMMUNOL, V164, P3149, DOI 10.4049/jimmunol.164.6.3149; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Yi EC, 2000, ANALYST, V125, P651, DOI 10.1039/b000368i; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	33	128	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20044	20048		10.1074/jbc.M401275200	http://dx.doi.org/10.1074/jbc.M401275200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15014080	hybrid			2022-12-25	WOS:000221164500080
J	Cheng, NL; Janumyan, YM; Didion, L; Van Hofwegen, C; Yang, E; Knudson, CM				Cheng, NL; Janumyan, YM; Didion, L; Van Hofwegen, C; Yang, E; Knudson, CM			Bcl-2 inhibition of T-cell proliferation is related to prolonged T-cell survival	ONCOGENE			English	Article						apoptosis; Bax; proliferation; T cells; quiescent; p27; Bcl-2	CYCLE ENTRY; TRANSGENIC MICE; PARADOXICAL INHIBITION; REDUCES PROLIFERATION; IN-VIVO; C-MYC; EXPRESSION; DEATH; APOPTOSIS; BAX	Bcl-2 promotes oncogenesis by inhibiting cell death. Bcl-2 also inhibits proliferation and suppresses tumorigenesis in some settings. To clarify the role of the antiproliferative function of Bcl-2, mice expressing a mutant form of Bcl-2 reported to lack antiproliferative activity were generated (tyrosine 28 to alanine, Bcl-2-Y28A). As expected, both wild type (WT) and Bcl-2-Y28A inhibited apoptosis similarly. In contrast to previous results in cell lines, Bcl-2-Y28A inhibited T-cell proliferation identical to WT-Bcl-2. Significantly, both Bcl-2-Y28A and WT-Bcl-2 inhibited proliferation of T cells isolated from older animals, but not proliferation of T cells from immature mice. Instead, inhibition of cell activation correlated with T-cell size, p27 levels, and RNA content, all indicators of quiescent G0 arrest. Consistent with this model, Bcl-2 inhibition of T-cell proliferation was reversed by expression of Bax, again correlating cell proliferation with cell size. These experiments do not support genetically separate effects of Bcl-2 on apoptosis and proliferation. Instead, the data support a model in which Bcl-2 and Bax regulate T-cell proliferation by changes in T-cell size and by increasing the markers of quiescent G0 arrest. These changes likely result from prolonged T-cell survival.	Univ Iowa, Roy J & Lucille P Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Pediat, Nashville, TN 37232 USA	University of Iowa; Vanderbilt University; Vanderbilt University	Knudson, CM (corresponding author), Univ Iowa, Roy J & Lucille P Carver Coll Med, Dept Pathol, 3160 ML, Iowa City, IA 52242 USA.	c-knudson@uiowa.edu		Knudson, Charles Michael/0000-0003-3964-5466; Janumyan, Yelena/0000-0001-9860-6366	NATIONAL CANCER INSTITUTE [R01CA078443, R01CA088967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA88967, 1R01CA78443] Funding Source: Medline; NIGMS NIH HHS [T32GM08554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bairey O, 1999, CLIN CANCER RES, V5, P2860; Buglioni S, 1999, INT J CANCER, V84, P545, DOI 10.1002/(SICI)1097-0215(19991222)84:6<545::AID-IJC1>3.0.CO;2-2; Bureau F, 2002, BLOOD, V99, P3683, DOI 10.1182/blood.V99.10.3683; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; DARZYNKIEWICZ Z, 1980, P NATL ACAD SCI-BIOL, V77, P6696, DOI 10.1073/pnas.77.11.6696; de la Coste A, 1999, CANCER RES, V59, P5017; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; Greider C, 2002, ONCOGENE, V21, P7765, DOI 10.1038/sj.onc.1205928; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hogarth LA, 1999, BLOOD, V93, P2671, DOI 10.1182/blood.V93.8.2671.408k26_2671_2678; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Kaklamanis L, 1998, BRIT J CANCER, V77, P1864, DOI 10.1038/bjc.1998.310; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Knudson CM, 2001, CANCER RES, V61, P659; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Luke JJ, 2003, CELL DEATH DIFFER, V10, P740, DOI 10.1038/sj.cdd.4401233; MacCarthy-Morrogh L, 1999, BIOCHEM SOC T, V27, P785, DOI 10.1042/bst0270785; Manne U, 1997, INT J CANCER, V74, P346, DOI 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO;2-9; MARVEL J, 1994, ONCOGENE, V9, P1117; Meterissian SH, 2001, ANN SURG ONCOL, V8, P533, DOI 10.1245/aso.2001.8.6.533; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; OFNER D, 1995, BRIT J CANCER, V72, P981, DOI 10.1038/bjc.1995.446; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1997, J IMMUNOL, V159, P2301; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Rossiter H, 2001, CANCER RES, V61, P3619; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Uhlmann EJ, 1996, CANCER RES, V56, P2506; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0	43	43	43	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3770	3780		10.1038/sj.onc.1207478	http://dx.doi.org/10.1038/sj.onc.1207478			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15034548				2022-12-25	WOS:000221242500004
J	Weinmann, M; Jendrossek, V; Handrick, R; Guner, D; Goecke, B; Belka, C				Weinmann, M; Jendrossek, V; Handrick, R; Guner, D; Goecke, B; Belka, C			Molecular ordering of hypoxia-induced apoptosis: critical involvement of the mitochondrial death pathway in a FADD/caspase-8 independent manner	ONCOGENE			English	Article						hypoxia; apoptosis; mitochondria; FADD; Bcl-2; caspase-8	DRUG-INDUCED APOPTOSIS; NEURONAL CELL-DEATH; TYROSINE KINASE LCK; IONIZING-RADIATION; CYTOCHROME-C; LYMPHOMA-CELLS; P53-DEPENDENT APOPTOSIS; DIFFERENTIAL REGULATION; CASPASE-3 ACTIVATION; SERUM DEPRIVATION	Dys-regulated growth and improper angiogenesis commonly lead to areas of hypoxia in human tumors. Hypoxia is known to be associated with a worse outcome since a lack of oxygen interferes with the efficacy of chemotherapy or radiotherapy. In parallel, hypoxia-induced apoptosis may also impose a selection pressure favoring growth of more resistant tumor cells. However, the mechanisms of hypoxia-induced apoptosis and the relative contribution of intrinsic and extrinsic apoptotic pathways are not understood. Therefore, Jurkat cell lines with defined defects in the extrinsic or intrinsic signaling cascades were used to evaluate the role of either pathway for induction of apoptosis under hypoxic conditions. Jurkat cells were incubated in hypoxia and the rate of apoptosis induction was determined by Western blotting, fluorescence microscopy and flow cytometry. Hypoxia-induced apoptosis was not affected by lack of caspase-8 or FADD, whereas overexpression of Bcl-2 or expression of dominant-negative caspase-9 mutant rendered the cells resistant to hypoxia-induced apoptosis. These results suggest that hypoxia-induced apoptosis mainly relies on intrinsic, mitochondrial pathways, whereas extrinsic pathways have no significant implications in this process. Thus, in human tumors, hypoxia will mainly lead to the selection of hypoxia-resistant cells with defects in mitochondrial apoptosis signaling pathways.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Charite Berlin, Dept Radiat Oncol, Berlin, Germany	Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seylerstr 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de	Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				Alarcon R M, 2001, Novartis Found Symp, V240, P115; Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; Banasiak KJ, 1999, MOL BRAIN RES, V72, P214, DOI 10.1016/S0169-328X(99)00189-8; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Belka C, 2003, STRAHLENTHER ONKOL, V179, P141, DOI 10.1007/s00066-003-1047-7; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Chao W, 2002, J BIOL CHEM, V277, P31639, DOI 10.1074/jbc.M204104200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Gibson ME, 2001, MOL MED, V7, P644, DOI 10.1007/BF03401871; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jendrossek V, 2003, FASEB J, V17, P1547, DOI 10.1096/fj.02-0947fje; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Khurana P, 2002, NEUROCHEM RES, V27, P931, DOI 10.1023/A:1020347732741; Kim CY, 1997, CANCER RES, V57, P4200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; KISCHKEL FC, 2001, J BIOL CHEM, V2, P2; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 2002, J BIOL CHEM, V277, P42802, DOI 10.1074/jbc.M207765200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOPEZHERNANDEZ FJ, 2003, CELL DEATH DIFFER, V24, P24; Malhotra R, 2001, AM J PHYSIOL-CELL PH, V281, pC1596, DOI 10.1152/ajpcell.2001.281.5.C1596; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mogi M, 2001, LAB INVEST, V81, P177, DOI 10.1038/labinvest.3780225; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shimizu S, 1996, CANCER RES, V56, P2161; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Steinbach JP, 2003, CELL DEATH DIFFER, V10, P823, DOI 10.1038/sj.cdd.4401252; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Tsujimoto Yoshihide, 1997, Leukemia (Basingstoke), V11, P380; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yaniv G, 2002, CARDIOVASC RES, V54, P611, DOI 10.1016/S0008-6363(02)00264-X; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zhu H, 2000, CELL DEATH DIFFER, V7, P773, DOI 10.1038/sj.cdd.4400721	64	50	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3757	3769		10.1038/sj.onc.1207481	http://dx.doi.org/10.1038/sj.onc.1207481			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15034549				2022-12-25	WOS:000221242500003
J	Krause, F; Scheckhuber, CQ; Werner, A; Rexroth, S; Reifschneider, NH; Dencher, NA; Osiewacz, HD				Krause, F; Scheckhuber, CQ; Werner, A; Rexroth, S; Reifschneider, NH; Dencher, NA; Osiewacz, HD			Supramolecular organization of cytochrome c oxidase- and alternative oxidase-dependent respiratory chains in the filamentous fungus Podospora anserina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-PHOSPHORYLATION COMPLEXES; MITOCHONDRIAL-DNA REARRANGEMENTS; MEMBRANE-PROTEIN COMPLEXES; SENESCENCE; COPPER; YEAST; GENE; ELECTROPHORESIS; SUPERCOMPLEXES; PURIFICATION	To elucidate the molecular basis of the link between respiration and longevity, we have studied the organization of the respiratory chain of a wild-type strain and of two long-lived mutants of the filamentous fungus Podospora anserina. This established aging model is able to respire by either the standard or the alternative pathway. In the latter pathway, electrons are directly transferred from ubiquinol to the alternative oxidase and thus bypass complexes III and IV. We show that the cytochrome c oxidase pathway is organized according to the mammalian "respirasome" model (Schagger, H., and Pfeiffer, K. (2000) EMBO J. 19, 1777-1783). In contrast, the alternative pathway is composed of distinct super-complexes of complexes I and III (i.e. I-2 and I2III2), which have not been described so far. Enzymatic analysis reveals distinct functional properties of complexes I and III belonging to either cytochrome c oxidase- or alternative oxidase- dependent pathways. By a gentle colorless-native PAGE, almost all of the ATP synthases from mitochondria respiring by either pathway were preserved in the dimeric state. Our data are of significance for the understanding of both respiratory pathways as well as lifespan control and aging.	Tech Univ Darmstadt, Dept Chem, D-64287 Darmstadt, Germany; Goethe Univ Frankfurt, Inst Bot, D-60439 Frankfurt, Germany	Technical University of Darmstadt; Goethe University Frankfurt	Krause, F (corresponding author), Tech Univ Darmstadt, Dept Chem, Petersenstr 22, D-64287 Darmstadt, Germany.	f_krause@pop.tu-darmstadt.de	Osiewacz, Heinz D./D-3454-2011; Dencher, Norbert/G-6640-2014; Rexroth, Sascha/H-3702-2011; Scheckhuber, Christian Q./A-6462-2012	Rexroth, Sascha/0000-0003-3819-2127; Scheckhuber, Christian Q./0000-0002-2924-7547				Affourtit C, 2002, FEBS LETT, V510, P121, DOI 10.1016/S0014-5793(01)03261-6; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; ARRETZ M, 1994, J BIOL CHEM, V269, P4959; Borghouts C, 2000, CURR GENET, V37, P268, DOI 10.1007/s002940050528; Borghouts C, 1997, P NATL ACAD SCI USA, V94, P10768, DOI 10.1073/pnas.94.20.10768; Borghouts C, 2002, INT J BIOCHEM CELL B, V34, P1355, DOI 10.1016/S1357-2725(02)00078-X; Borghouts C, 1998, MOL GEN GENET, V260, P492, DOI 10.1007/s004380050922; Borghouts C, 2001, MOL CELL BIOL, V21, P390, DOI 10.1128/MCB.21.2.390-399.2001; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; Dufour E, 2000, P NATL ACAD SCI USA, V97, P4138, DOI 10.1073/pnas.070501997; ELTHON TE, 1989, PLANT PHYSIOL, V89, P1311, DOI 10.1104/pp.89.4.1311; Esser K., 1974, BACTERIA BACTERIOPHA, P531; Eubel H, 2003, PLANT PHYSIOL, V133, P274, DOI 10.1104/pp.103.024620; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FRESE D, 1992, MECH AGEING DEV, V65, P277, DOI 10.1016/0047-6374(92)90041-B; GrandierVazeille X, 1996, ANAL BIOCHEM, V242, P248, DOI 10.1006/abio.1996.0460; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; Joseph-Horne T, 2001, BBA-BIOENERGETICS, V1504, P179, DOI 10.1016/S0005-2728(00)00251-6; KUCK U, 1985, CURR GENET, V9, P373, DOI 10.1007/BF00421608; KUONEN DR, 1986, ANAL BIOCHEM, V153, P221, DOI 10.1016/0003-2697(86)90084-9; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Lorin S, 2001, MOL MICROBIOL, V42, P1259, DOI 10.1046/j.1365-2958.2001.02690.x; MARBACH K, 1994, CURR GENET, V26, P184, DOI 10.1007/BF00313809; Maxwell DP, 1999, P NATL ACAD SCI USA, V96, P8271, DOI 10.1073/pnas.96.14.8271; Neff D, 1999, BIOCHEM BIOPH RES CO, V259, P569, DOI 10.1006/bbrc.1999.0820; Osiewacz HD, 2002, AGEING RES REV, V1, P425, DOI 10.1016/S1568-1637(02)00010-7; Osiewacz HD, 2002, GENE, V286, P65, DOI 10.1016/S0378-1119(01)00804-6; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; PRILLINGER H, 1977, MOL GEN GENET, V156, P333, DOI 10.1007/BF00267190; Rexroth S, 2003, ELECTROPHORESIS, V24, P2814, DOI 10.1002/elps.200305543; RIZET G, 1953, CR HEBD ACAD SCI, V237, P838; SCHAGGER H, 1990, EUR J BIOCHEM, V190, P123, DOI 10.1111/j.1432-1033.1990.tb15554.x; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schagger H, 2001, IUBMB LIFE, V52, P119, DOI 10.1080/15216540152845911; Schagger H, 2001, J BIOL CHEM, V276, P37861; SCHULTE E, 1988, MOL GEN GENET, V211, P342, DOI 10.1007/BF00330614; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; Stumpferl SW, 2004, EUKARYOT CELL, V3, P200, DOI 10.1128/EC.3.1.200-211.2004; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131	41	101	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26453	26461		10.1074/jbc.M402756200	http://dx.doi.org/10.1074/jbc.M402756200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15044453	hybrid			2022-12-25	WOS:000222003000067
J	Galijatovic, A; Beaton, D; Nguyen, N; Chen, SJ; Bonzo, J; Johnson, R; Maeda, S; Karin, M; Guengerich, FP; Tukey, RH				Galijatovic, A; Beaton, D; Nguyen, N; Chen, SJ; Bonzo, J; Johnson, R; Maeda, S; Karin, M; Guengerich, FP; Tukey, RH			The human CYP1A1 gene is regulated in a developmental and tissue-specific fashion in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; AH DIOXIN RECEPTOR; TRANSCRIPTIONAL ACTIVATION; MESSENGER-RNA; STRUCTURAL GENE; CYTOCHROMES P450; DNA RECOGNITION; PHORBOL ESTERS; MOUSE CYP1A-1; INDUCTION	Regulation and expression of human CYP1A1 is demonstrated in transgenic mice. We have developed two transgenic mouse lines. One mouse strain (CYPLucR) carries a functional human CYP1A1 promoter (-1612 to +293)-luciferase reporter gene, and the other strain (CYP1A1N) expresses CYP1A1 under control of the full-length human CYP1A1 gene and 9 kb of flanking regulatory DNA. With CYPLucR(+/-) mice, 2,3,7,8-tetra-chlordibenzo-p-dioxin ( TCDD) and several other aryl hydrocarbon receptor ligands induced hepatocyte-specific luciferase activity. When other tissues were examined, TCDD induced luciferase activity in brain with limited induction in lung and no detectable luciferase activity in kidney. Treatment of CYP1A1N(+/-) mice with TCDD resulted in induction of human CYP1A1 in liver and lung, while mouse Cyp1a1 was induced in liver, lung, and kidney. Although induced CYP1A1/Cyp1a1 could not be detected by Western blot analysis in brains from CYP1A1N(+/-) mice, induction in brain was verified by detection of CYP1A1/Cyp1a1 RNA. The administration of TCDD to nursing mothers to examine the effect of lactational exposure via milk demonstrated prominent induction of luciferase activity in livers of CYPLucR(+/-) newborn pups with limited induction in brain. However, TCDD treatment of adult CYPLucR(+/-) mice led to a 7-10-fold induction of brain luciferase activity. Combined these results indicate that tissue-specific and developmental factors are controlling aryl hydrocarbon receptor-mediated induction of human CYP1A1.	Univ Calif San Diego, Dept Pharmacol, Lab Environm Toxicol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem, Lab Environm Toxicol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biochem, Lab Environm Toxicol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Vanderbilt University; Vanderbilt University	Tukey, RH (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Environm Toxicol, La Jolla, CA 92093 USA.	rtukey@ucsd.edu	Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639; Bonzo, Jessica/0000-0003-2403-9981; Chen, Shujuan/0000-0002-1068-195X	NATIONAL CANCER INSTITUTE [R37CA090426, R01CA090426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NCI NIH HHS [CA55353, CA90426] Funding Source: Medline; NIEHS NIH HHS [ES10337] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allen SW, 2001, DRUG METAB DISPOS, V29, P1074; BOUCHER PD, 1995, MOL CELL BIOL, V15, P5144; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Campbell SJ, 1996, J CELL SCI, V109, P2619; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; Chen YH, 1996, J BIOL CHEM, V271, P26261, DOI 10.1074/jbc.271.42.26261; CHEN YT, 1982, DNA-J MOLEC CELL BIO, V1, P231, DOI 10.1089/dna.1.1982.1.231; Cheung YL, 1999, CANCER LETT, V139, P199, DOI 10.1016/S0304-3835(99)00045-2; CONNEY AH, 1982, CANCER RES, V42, P4875; Corchero J, 2001, PHARMACOGENETICS, V11, P1, DOI 10.1097/00008571-200102000-00001; Dey A, 1999, BIOCHEM PHARMACOL, V58, P525, DOI 10.1016/S0006-2952(99)00110-0; Ding XX, 2003, ANNU REV PHARMACOL, V43, P149, DOI 10.1146/annurev.pharmtox.43.100901.140251; Dzeletovic N, 1997, J BIOL CHEM, V272, P12705, DOI 10.1074/jbc.272.19.12705; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Iba MM, 2003, ARCH TOXICOL, V77, P547, DOI 10.1007/s00204-003-0488-1; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; JONES SN, 1991, NUCLEIC ACIDS RES, V19, P6547, DOI 10.1093/nar/19.23.6547; KAHL GF, 1980, DEV PHARMACOL THERAP, V1, P137, DOI 10.1159/000455531; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KOURI RE, 1980, GENETIC DIFFERENCES, P21; Lahvis GP, 1998, BIOCHEM PHARMACOL, V56, P781, DOI 10.1016/S0006-2952(98)00134-8; NEBERT DW, 1972, FED PROC, V31, P1315; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; OKINO ST, 1992, J BIOL CHEM, V267, P6991; PENDURTHI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P65, DOI 10.1006/abbi.1993.1481; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; QUATTROCHI LC, 1989, MOL PHARMACOL, V36, P66; QUATTROCHI LC, 1993, MOL PHARMACOL, V43, P504; RAUNIO H, 1983, CANCER RES, V43, P782; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Sanderson JT, 1996, TOXICOL APPL PHARM, V137, P316, DOI 10.1006/taap.1996.0086; Shimada T, 2003, TOXICOL APPL PHARM, V187, P1, DOI 10.1016/S0041-008X(02)00035-2; Soucek P, 1995, BIOCHEMISTRY-US, V34, P16013, DOI 10.1021/bi00049a015; Strassburg CP, 1997, CANCER RES, V57, P2979; TUKEY RH, 1984, BIOCHEMISTRY-US, V23, P6003, DOI 10.1021/bi00320a016; TUKEY RH, 1981, J BIOL CHEM, V256, P6969; TUKEY RH, 1982, CELL, V31, P275, DOI 10.1016/0092-8674(82)90427-5; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; Zaher H, 1998, BIOCHEM PHARMACOL, V55, P235, DOI 10.1016/S0006-2952(97)00476-0; Zhang S, 2003, ENVIRON HEALTH PERSP, V111, P1877, DOI 10.1289/ehp.6322	44	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23969	23976		10.1074/jbc.M400973200	http://dx.doi.org/10.1074/jbc.M400973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15037607	hybrid			2022-12-25	WOS:000221702500018
J	Shi, JH; Wei, Z; Song, JX				Shi, JH; Wei, Z; Song, JX			Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme - Defining the extra domain as a new target for design of highly specific protease inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARS-CORONAVIRUS; GENOME SEQUENCE; NMR; PROTEINASE; CONFORMATIONS; PEPTIDES; LIGANDS; PROGRAM	The severe acute respiratory syndrome (SARS) 3C-like protease consists of two distinct folds, namely the N-terminal chymotrypsin fold containing the domains I and II hosting the complete catalytic machinery and the C-terminal extra helical domain III unique for the coronavirus 3CL proteases. Previously the functional role of this extra domain has been completely unknown, and it was believed that the coronavirus 3CL proteases share the same enzymatic mechanism with picornavirus 3C proteases, which contain the chymotrypsin fold but have no extra domain. To understand the functional role of the extra domain and to characterize the enzyme-substrate interactions by use of the dynamic light scattering, circular dichroism, and NMR spectroscopy, we 1) dissected the full-length SARS 3CL protease into two distinct folds and subsequently investigated their structural and dimerization properties and 2) studied the structural and binding interactions of three substrate peptides with the entire enzyme and its two dissected folds. The results lead to several findings; 1) although two dissected parts folded into the native-like structures, the chymotrypsin fold only had weak activity as compared with the entire enzyme, and 2) although the chymotrypsin fold remained a monomer within a wide range of protein concentrations, the extra domain existed as a stable dimer even at a very low concentration. This observation strongly indicates that the extra domain contributes to the dimerization of the SARS 3CL protease, thus, switching the enzyme from the inactive form ( monomer) to the active form ( dimer). This discovery not only separates the coronavirus 3CL protease from the picornavirus 3C protease in terms of the enzymatic mechanism but also defines the dimerization interface on the extra helical domain as a new target for design of the specific protease inhibitors. Furthermore, the determination of the preferred solution conformation of the substrate peptide S1 together with the NMR differential line-broadening and transferred nuclear Overhauser enhancement study allows us to pinpoint the bound structure of the S1 peptide.	Natl Univ Singapore, Dept Biol Sci, Singapore 119260, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore	National University of Singapore; National University of Singapore	Song, JX (corresponding author), Natl Univ Singapore, Dept Biol Sci, 10 Kent Ridge Crescent, Singapore 119260, Singapore.	bchsj@nus.edu.sg	shi, jiahai/D-7650-2013; Song, Jianxing/H-8026-2012; Shi, Jiahai/AAH-1103-2019; Song, Jianxing/J-3617-2013	shi, jiahai/0000-0002-6467-8289; Shi, Jiahai/0000-0002-6467-8289; Song, Jianxing/0000-0003-0224-6322				Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327; [Anonymous], 1996, CIRCULAR DICHROISM C; Barrette-Ng IH, 2002, J BIOL CHEM, V277, P39960, DOI 10.1074/jbc.M206978200; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BIRDSALL B, 1984, BIOCHEMISTRY-US, V23, P4733, DOI 10.1021/bi00315a032; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DIMAIO J, 1990, J BIOL CHEM, V265, P21698; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200; Hegyi A, 2002, J GEN VIROL, V83, P581, DOI 10.1099/0022-1317-83-3-581; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krieger E, 2002, BIOINFORMATICS, V18, P315, DOI 10.1093/bioinformatics/18.2.315; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9; LaPlante SR, 1999, J BIOL CHEM, V274, P18618, DOI 10.1074/jbc.274.26.18618; Lu YQ, 1997, VIROLOGY, V230, P335, DOI 10.1006/viro.1997.8479; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Ng LFP, 2000, VIROLOGY, V272, P27, DOI 10.1006/viro.2000.0330; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Song JX, 1999, NAT STRUCT BIOL, V6, P129, DOI 10.1038/5815; Song JX, 2002, BIOPOLYMERS, V65, P373, DOI 10.1002/bip.10253; Song JX, 1998, BIOCHEM CELL BIOL, V76, P177; Song JX, 1998, J MOL BIOL, V280, P167, DOI 10.1006/jmbi.1998.1826; Song JX, 1997, BIOCHEMISTRY-US, V36, P3760, DOI 10.1021/bi962720h; Sykes Brian D., 1993, Current Opinion in Biotechnology, V4, P392, DOI 10.1016/0958-1669(93)90003-F; Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0; WAGNER G, 1982, J MOL BIOL, V155, P347, DOI 10.1016/0022-2836(82)90009-2; WAGNER G, 1993, J BIOMOL NMR, V3, P375; WUTHRICK K, 1986, NMR PROTEINS NUCL AC; Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100; Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	42	142	150	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24765	24773		10.1074/jbc.M311744200	http://dx.doi.org/10.1074/jbc.M311744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15037623	hybrid, Green Published			2022-12-25	WOS:000221702500107
J	Topp, JD; Gray, NW; Gerard, RD; Horazdovsky, BF				Topp, JD; Gray, NW; Gerard, RD; Horazdovsky, BF			Alsin is a Rab5 and Rac1 guanine nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							AMYOTROPHIC-LATERAL-SCLEROSIS; METABOTROPIC GLUTAMATE-RECEPTOR; TRANSGENIC MOUSE MODEL; LONG-TERM DEPRESSION; MOTOR-NEURON DEATH; SYNAPTIC VESICLES; BINDING-PROTEIN; NMDA RECEPTOR; RHO-GTPASES; RAPID REDISTRIBUTION	ALS2 is the gene mutated in a recessive juvenile form of amyotrophic lateral sclerosis ( ALS2). ALS2 encodes a large protein termed alsin, which contains a number of predicted cell signaling and protein trafficking sequence motifs. To gain insight into the overall function of alsin and to begin to evaluate its role in motor neuron maintenance, we examined the subcellular localization of alsin and the biochemical activities associated with its individual subdomains. We found that the Vps9p domain of alsin has Rab5 guanine nucleotide exchange activity. In addition, alsin interacted specifically with and acted as a guanine nucleotide exchange factor for Rac1. Immunofluorescence and fractionation experiments in both fibroblasts and neurons revealed that alsin is a cytosolic protein, with a significant portion associated with small, punctate membrane structures. Many of these membrane structures also contained Rab5 or Rac1. Upon overexpression of full-length alsin, the overexpressed material was largely cytosolic, indicating that the association with membrane structures could be saturated. We also found that alsin was present in membrane ruffles and lamellipodia. These data suggest that alsin is involved in membrane transport events, potentially linking endocytic processes and actin cytoskeleton remodeling.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Mayo Clin Canc Ctr, Rochester, MN 55905 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	Mayo Clinic; Mayo Clinic; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Horazdovsky, BF (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	horazdovsky.bruce@mayo.edu		Gray, Noah/0000-0002-4672-7403	NIGMS NIH HHS [R01 GM067206] Funding Source: Medline; NINDS NIH HHS [NS07424] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007424] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albasanz JL, 2002, MOL BRAIN RES, V99, P54; Allison DW, 1998, J NEUROSCI, V18, P2423; Aoki K, 1999, MOL MED, V5, P224, DOI 10.1007/BF03402119; Barbieri MA, 2003, J BIOL CHEM, V278, P32027, DOI 10.1074/jbc.M304324200; Barker PA, 2002, TRENDS NEUROSCI, V25, P379, DOI 10.1016/S0166-2236(02)02199-9; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BENHAMIDA M, 1990, BRAIN, V113, P347; Bernstein BW, 1998, MOL BRAIN RES, V53, P236, DOI 10.1016/S0169-328X(97)00319-7; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Bolis A, 2003, EUR J NEUROSCI, V18, P2417, DOI 10.1046/j.1460-9568.2003.02938.x; Bonhoeffer T, 2002, NEURON, V35, P1019, DOI 10.1016/S0896-6273(02)00906-6; Brown R. H., 2001, HARRISONS PRINCIPLES, P2412; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Chance PF, 1998, AM J HUM GENET, V62, P633, DOI 10.1086/301769; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Cole N, 1999, SEMIN NEUROL, V19, P407, DOI 10.1055/s-2008-1040855; Colicos MA, 2001, CELL, V107, P605, DOI 10.1016/S0092-8674(01)00579-7; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dailey ME, 1996, J NEUROSCI, V16, P2983; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; Devon RS, 2003, CLIN GENET, V64, P210, DOI 10.1034/j.1399-0004.2003.00138.x; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; Fiala JC, 1998, J NEUROSCI, V18, P8900; Fourgeaud L, 2003, J BIOL CHEM, V278, P12222, DOI 10.1074/jbc.M205663200; Gallo G, 2000, J NEUROBIOL, V44, P159, DOI 10.1002/1097-4695(200008)44:2<159::AID-NEU6>3.0.CO;2-H; GERARD RD, 1995, DNA CLONING PRACTICA; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Gray NW, 2003, CURR BIOL, V13, P510, DOI 10.1016/S0960-9822(03)00136-2; Gros-Louis F, 2003, ANN NEUROL, V53, P144, DOI 10.1002/ana.10422; Guegn C, 2001, J NEUROSCI, V21, P6569, DOI 10.1523/JNEUROSCI.21-17-06569.2001; Haataja L, 2002, J BIOL CHEM, V277, P8321, DOI 10.1074/jbc.M105363200; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hama H, 1999, J BIOL CHEM, V274, P15284, DOI 10.1074/jbc.274.21.15284; Hand CK, 2002, MUSCLE NERVE, V25, P135; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HART MJ, 1994, J BIOL CHEM, V269, P62; Hentati A, 1998, NEUROGENETICS, V2, P55, DOI 10.1007/s100480050052; HENTATI A, 1994, NAT GENET, V7, P425, DOI 10.1038/ng0794-425; Hirai H, 2000, J NEUROSCI, V20, P5217, DOI 10.1523/JNEUROSCI.20-14-05217.2000; Hong S., 1998, Society for Neuroscience Abstracts, V24, P478; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Hosler BA, 2000, JAMA-J AM MED ASSOC, V284, P1664, DOI 10.1001/jama.284.13.1664; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Lee SH, 2002, NEURON, V36, P661, DOI 10.1016/S0896-6273(02)01024-3; Lee SH, 2001, NEUROPHARMACOLOGY, V41, P680, DOI 10.1016/S0028-3908(01)00124-1; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Morales M, 2000, NEURON, V27, P539, DOI 10.1016/S0896-6273(00)00064-7; Mundell SJ, 2001, J NEUROCHEM, V78, P546, DOI 10.1046/j.1471-4159.2001.00421.x; Murase S, 2002, NEURON, V35, P91, DOI 10.1016/S0896-6273(02)00764-X; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Nishiki T, 2001, NEUROSCIENCE, V107, P363, DOI 10.1016/S0306-4522(01)00370-0; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Roberts RL, 1999, J CELL SCI, V112, P3667; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Saito K, 2002, J BIOL CHEM, V277, P3412, DOI 10.1074/jbc.M106276200; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Shaw PJ, 2001, NAT GENET, V29, P103, DOI 10.1038/ng1001-103; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; Shupliakov O, 2002, P NATL ACAD SCI USA, V99, P14476, DOI 10.1073/pnas.212381799; SIDDIQUE T, 1991, NEW ENGL J MED, V324, P1381, DOI 10.1056/NEJM199105163242001; Sin WC, 2002, NATURE, V419, P475, DOI 10.1038/nature00987; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Spaargaren M, 1999, MOL BIOL CELL, V10, P3239, DOI 10.1091/mbc.10.10.3239; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Vukosavic S, 2000, J NEUROSCI, V20, P9119; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Xiao MY, 2001, NEUROPHARMACOLOGY, V41, P664, DOI 10.1016/S0028-3908(01)00134-4; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhou Q, 2001, P NATL ACAD SCI USA, V98, P1261, DOI 10.1073/pnas.031573798; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	113	154	156	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24612	24623		10.1074/jbc.M313504200	http://dx.doi.org/10.1074/jbc.M313504200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15033976	hybrid			2022-12-25	WOS:000221702500091
J	Roberts, DM; Liao, RLP; Wisedchaisri, G; Hol, WGJ; Sherman, DR				Roberts, DM; Liao, RLP; Wisedchaisri, G; Hol, WGJ; Sherman, DR			Two sensor kinases contribute to the hypoxic response of Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT SYSTEM; GENE-EXPRESSION; PROTEIN; DEVR; VIRULENCE; SITE	Current estimates indicate that nearly a third of the world's population is latently infected with Mycobacterium tuberculosis. Reduced oxygen tension and nitric oxide exposure are two conditions encountered by bacilli in vivo that may promote latency. In vitro exposure to hypoxia or nitric oxide results in bacterial stasis with concomitant induction of a 47-gene regulon controlled by the transcription factor DosR. In this report we demonstrate that both the dosS gene adjacent to dosR and another gene, dosT (Rv2027c), encode sensor kinases, each of which can autophosphorylate at a conserved histidine and then transfer phosphate to an aspartate residue of DosR. Mutant bacteria lacking both sensors are unable to activate expression of DosR-regulated genes. These data indicate that DosR/DosS/DosT comprise a two-component signaling system that is required for the M. tuberculosis genetic response to hypoxia and nitric oxide, two conditions that produce reversible growth arrest in vitro and may contribute to latency in vivo.	Univ Washington, Sch Publ Hlth & Community Med, Dept Pathobiol, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Biomol Struct & Design Grad Program, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Sherman, DR (corresponding author), Univ Washington, Sch Publ Hlth & Community Med, Dept Pathobiol, Seattle, WA 98195 USA.	dsherman@u.washington.edu		Wisedchaisri, Goragot/0000-0002-6967-5925	NCI NIH HHS [CA65656] Funding Source: Medline; NIAID NIH HHS [R01 AI047744, AI47744, AI07509] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI047744, R01AI047744] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bloom BR, 1998, NEW ENGL J MED, V338, P677, DOI 10.1056/NEJM199803053381008; Boon C, 2002, J BACTERIOL, V184, P6760, DOI 10.1128/JB.184.24.6760-6767.2002; Brekasis D, 2003, EMBO J, V22, P4856, DOI 10.1093/emboj/cdg453; CANETTI G, 1955, TUBERCLE BACILLUS PU, P111; Choi HS, 2002, AM J RESP CRIT CARE, V166, P178, DOI 10.1164/rccm.2201023; CORPER H. J., 1933, AMER REV TUBERC, V28, P856; Dasgupta N, 2000, TUBERCLE LUNG DIS, V80, P141, DOI 10.1054/tuld.2000.0240; DOCK W, 1946, AM REV TUBERC PULM, V53, P297; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; ENARSON DA, 1996, TUBERCULOSIS, P55; Fenhalls G, 2002, INFECT IMMUN, V70, P6330, DOI 10.1128/IAI.70.11.6330-6338.2002; Florczyk MA, 2003, INFECT IMMUN, V71, P5332, DOI 10.1128/IAI.71.9.5332-5343.2003; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Hoch JA, 1995, 2 COMPONENT SIGNAL T; KLOSE KE, 1993, J MOL BIOL, V232, P67, DOI 10.1006/jmbi.1993.1370; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; Malhotra V, 2004, FEMS MICROBIOL LETT, V231, P237, DOI 10.1016/S0378-1097(04)00002-3; Mdluli K, 1996, J INFECT DIS, V174, P1085, DOI 10.1093/infdis/174.5.1085; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; O'Toole R, 2003, RES MICROBIOL, V154, P387, DOI 10.1016/S0923-2508(03)00081-0; Ohno H, 2003, CELL MICROBIOL, V5, P637, DOI 10.1046/j.1462-5822.2003.00307.x; Parish T, 2003, INFECT IMMUN, V71, P1134, DOI 10.1128/IAI.71.3.1134-1140.2003; Park HD, 2003, MOL MICROBIOL, V48, P833, DOI 10.1046/j.1365-2958.2003.03474.x; Saini DK, 2002, PROTEIN EXPRES PURIF, V25, P203, DOI 10.1006/prep.2002.1628; Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498; Shi LB, 2003, P NATL ACAD SCI USA, V100, P241, DOI 10.1073/pnas.0136863100; Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205; WAYNE LG, 1977, INFECT IMMUN, V17, P528, DOI 10.1128/IAI.17.3.528-530.1977; WAYNE LG, 1982, INFECT IMMUN, V37, P1042, DOI 10.1128/IAI.37.3.1042-1049.1982; Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139; Yuan Y, 1998, P NATL ACAD SCI USA, V95, P9578, DOI 10.1073/pnas.95.16.9578; Yuan Y., 1996, J BACTERIOL, V178, P4484, DOI DOI 10.1128/JB.178.15.4484-4492.1996	33	201	225	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23082	23087		10.1074/jbc.M401230200	http://dx.doi.org/10.1074/jbc.M401230200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15033981	Green Accepted, hybrid			2022-12-25	WOS:000221570900037
J	Perkinton, MS; Standen, CL; Lau, KF; Kesavapany, S; Byers, HL; Ward, M; McLoughlin, DM; Miller, CCJ				Perkinton, MS; Standen, CL; Lau, KF; Kesavapany, S; Byers, HL; Ward, M; McLoughlin, DM; Miller, CCJ			The c-Abl tyrosine kinase phosphorylates the Fe65 adaptor protein to stimulate Fe65/amyloid precursor protein nuclear signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; CARBOXYL-TERMINAL DOMAIN; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; CYTOPLASMIC DOMAIN; CLEAVAGE; APP; INTERACTS; FAMILY	The amyloid precursor protein (APP) is proteolytically processed to release a C-terminal domain that signals to the nucleus to regulate transcription of responsive genes. The APP C terminus binds to a number of phosphotyrosine binding (PTB) domain proteins and one of these, Fe65, stimulates APP nuclear signaling. Fe65 is an adaptor protein that contains a number of protein-protein interaction domains. These include two PTB domains, the second of which binds APP, and a WW domain that binds proline-rich ligands. One ligand for the Fe65WW domain is the tyrosine kinase c-Abl. Here, we show that active c-Abl stimulates APP/Fe65-mediated gene transcription and that this effect is mediated by phosphorylation of Fe65 on tyrosine 547 within its second PTB domain. The homologous tyrosine within the motif Tyr-(Leu/Met)-Gly is conserved in a variety of PTB domains, and this suggests that PTB tyrosine phosphorylation occurs in other proteins. As such, PTB domain phosphorylation may represent a novel mechanism for regulating the function of this class of protein.	Kings Coll London, Inst Psychiat, Dept Neurosci, London SE5 8AF, England; Kings Coll London, Inst Psychiat, Old Age Psychiat Sect, London SE5 8AF, England; Kings Coll London, Inst Psychiat, Proteome Sci Plc, London SE5 8AF, England	University of London; King's College London; University of London; King's College London; University of London; King's College London	Miller, CCJ (corresponding author), Kings Coll London, Inst Psychiat, Dept Neurosci, POB PO37,De Crespigny Pk,Denmark Hill, London SE5 8AF, England.	chris.miller@iop.kcl.ac.uk	Miller, Christopher/H-5733-2012	Miller, Christopher/0000-0002-5130-1845; Lau, Kwok-Fai/0000-0002-0193-1152; McLoughlin, Declan/0000-0003-4574-2799; Ward, Malcolm/0000-0003-2164-6938	Medical Research Council [G0000749] Funding Source: Medline; MRC [G0000749] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Biederer T, 2002, J NEUROSCI, V22, P7340; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 2000, J CELL SCI, V113, P1857; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Kesavapany S, 2002, NEUROSCIENCE, V115, P951, DOI 10.1016/S0306-4522(02)00422-0; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kinoshita A, 2002, J NEUROCHEM, V82, P839, DOI 10.1046/j.1471-4159.2002.01016.x; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Lau KF, 2000, NEUROREPORT, V11, P3607, DOI 10.1097/00001756-200011090-00041; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Matsuda S, 2001, J NEUROSCI, V21, P6597; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; McLoughlin DM, 2001, J BIOL CHEM, V276, P9303, DOI 10.1074/jbc.M010023200; McLoughlin DM, 1996, FEBS LETT, V397, P197; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Robakis NK, 2003, AMYLOID, V10, P80, DOI 10.3109/13506120309041729; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Russo C, 2002, ANN NY ACAD SCI, V973, P323, DOI 10.1111/j.1749-6632.2002.tb04660.x; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Standen CL, 2003, MOL CELL NEUROSCI, V24, P851, DOI 10.1016/j.mcn.2003.07.002; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	50	62	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22084	22091		10.1074/jbc.M311479200	http://dx.doi.org/10.1074/jbc.M311479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15031292	Green Published, hybrid			2022-12-25	WOS:000221417100050
J	McConkey, M; Gillin, H; Webster, CRL; Anwer, MS				McConkey, M; Gillin, H; Webster, CRL; Anwer, MS			Cross-talk between protein kinases C zeta and B in cyclic AMP-mediated sodium taurocholate co-transporting polypeptide translocation in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; 3-KINASE LIPID PRODUCTS; BILE-ACID UPTAKE; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; NA+/TAUROCHOLATE COTRANSPORT; GLUT4 TRANSLOCATION; SIGNALING PATHWAY	Cyclic AMP stimulates taurocholate (TC) uptake and sodium taurocholate co-transporting polypeptide (Ntcp) translocation in hepatocytes via the phosphoinositide-3 kinase (PI3K) signaling pathway. The aim of the present study was to determine whether protein kinase (PK) Czeta, one of the downstream mediators of the PI3K signaling pathway, is involved in cAMP-mediated stimulation of TC uptake. Studies were conducted in isolated rat hepatocytes and in HuH-7 cells stably transfected with rat liver Ntcp (HuH-Ntcp cells). Studies in hepatocytes showed that cAMP activates PKCzeta in a PI3K-dependent manner without inducing translocation of PKCzeta to the plasma membrane. Inhibition of cAMP-induced PKCzeta activity by myristoylated PKC (zeta/lambda) pseudosubstrate, a specific inhibitor of PKCzeta, and Go6850, a PKC inhibitor, resulted in inhibition of cAMP-induced increases in TC uptake and Ntcp translocation. Studies in HuH-Ntcp cells showed that inhibition of cAMP-induced PKCzeta activation by dominant-negative (DN) PKCzeta resulted in inhibition of cAMP-induced increases in TC uptake and Ntcp translocation. DN PKCzeta also inhibited wild-type PKCzeta-induced increases in PKCzeta activity, TC uptake, and Ntcp translocation. Myristoylated PKC (zeta/lambda) pseudosubstrate and DN PKCzeta also inhibited cAMP-induced activation of PKB in hepatocytes and HuH-Ntcp cells, respectively. Neither DN PKB nor constitutively active PKB affected cAMP-induced activation of PKCzeta, and wild-type PKCzeta did not activate PKB. Taken together, these results suggest that cAMP-induced activation of PKB is dependent on cAMP-induced stimulation of PKCzeta. It is proposed that cAMP-induced Ntcp translocation involves the activation of the PI3K/PKCzeta signaling pathway followed by the activation of the PI3K/PKB signaling pathway.	Tufts Univ, Sch Vet Med, Dept Biomed Sci, North Grafton, MA 01536 USA; Tufts Univ, Sch Vet Med, Dept Clin Sci, North Grafton, MA 01536 USA	Tufts University; Tufts University	Anwer, MS (corresponding author), 200 Westboro Rd, North Grafton, MA 01536 USA.	sawkat.anwer@tufts.edu			NIDDK NIH HHS [DK 33436, DK 02721] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002721, R01DK033436] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; Anwer MS, 1998, CURR OPIN GASTROEN, V14, P182, DOI 10.1097/00001574-199805000-00002; ANWER MS, 1978, H-S Z PHYSIOL CHEM, V359, P181; ANWER MS, 1976, H-S Z PHYSIOL CHEM, V357, P1477, DOI 10.1515/bchm2.1976.357.2.1477; Bandyopadhyay G, 2000, ENDOCRINOLOGY, V141, P4120, DOI 10.1210/en.141.11.4120; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766; Beuers U, 2003, J BIOL CHEM, V278, P17810, DOI 10.1074/jbc.M209898200; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Calcerrada MC, 2002, FEBS LETT, V514, P361, DOI 10.1016/S0014-5793(02)02401-8; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Dranoff JA, 1999, HEPATOLOGY, V30, P223, DOI 10.1002/hep.510300136; Elmendorf JS, 2002, J MEMBRANE BIOL, V190, P167, DOI 10.1007/s00232-002-1035-3; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Feranchak AP, 1999, J BIOL CHEM, V274, P30979, DOI 10.1074/jbc.274.43.30979; HAYAKAWA T, 1990, AM J PHYSIOL, V259, pG727, DOI 10.1152/ajpgi.1990.259.5.G727; Hernandez R, 2001, FEBS LETT, V494, P225, DOI 10.1016/S0014-5793(01)02353-5; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; Hodgkinson CP, 2002, BIOCHEMISTRY-US, V41, P10351, DOI 10.1021/bi026065r; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mao ML, 2000, BIOCHEM J, V352, P475, DOI 10.1042/0264-6021:3520475; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Meier PJ, 2000, NEWS PHYSIOL SCI, V15, P89; Miguel BG, 2000, BIOCHEM BIOPH RES CO, V274, P596, DOI 10.1006/bbrc.2000.3194; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; Mukhopadhayay S, 1997, AM J PHYSIOL-GASTR L, V273, pG842, DOI 10.1152/ajpgi.1997.273.4.G842; Mukhopadhyay S, 1998, HEPATOLOGY, V28, P1629, DOI 10.1002/hep.510280624; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Sauvage M, 2000, EUR J BIOCHEM, V267, P955, DOI 10.1046/j.1432-1327.2000.01084.x; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Trauner M, 1999, J HEPATOL, V31, P165, DOI 10.1016/S0168-8278(99)80179-2; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Webster CRL, 1999, AM J PHYSIOL-GASTR L, V277, pG1165, DOI 10.1152/ajpgi.1999.277.6.G1165; Webster CRL, 2002, J BIOL CHEM, V277, P28578, DOI 10.1074/jbc.M201937200; Webster CRL, 2002, AM J PHYSIOL-GASTR L, V283, pG727, DOI 10.1152/ajpgi.00410.2001; Webster CRL, 2000, J BIOL CHEM, V275, P29754, DOI 10.1074/jbc.M002831200	51	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20882	20888		10.1074/jbc.M309988200	http://dx.doi.org/10.1074/jbc.M309988200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15007074	hybrid			2022-12-25	WOS:000221273800040
J	Pires, VMR; Henshaw, JL; Prates, JAM; Bolam, DN; Ferreira, LMA; Fontes, CMGA; Henrissat, B; Planas, A; Gilbert, HJ; Czjzek, M				Pires, VMR; Henshaw, JL; Prates, JAM; Bolam, DN; Ferreira, LMA; Fontes, CMGA; Henrissat, B; Planas, A; Gilbert, HJ; Czjzek, M			The crystal structure of the family 6 carbohydrate binding module from Cellvibrio mixtus endoglucanase 5A in complex with oligosaccharides reveals two distinct binding sites with different ligand Specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAN-BINDING; DOMAINS; RECOGNITION; XYLANASE; CENC	Glycoside hydrolases that release fixed carbon from the plant cell wall are of considerable biological and industrial importance. These hydrolases contain noncatalytic carbohydrate binding modules (CBMs) that, by bringing the appended catalytic domain into intimate association with its insoluble substrate, greatly potentiate catalysis. Family 6 CBMs (CBM6) are highly unusual because they contain two distinct clefts ( cleft A and cleft B) that potentially can function as binding sites. Henshaw et al. ( Henshaw, J., Bolam, D. N., Pires, V. M. R., Czjzek, M., Henrissat, B., Ferreira, L. M. A., Fontes, C. M. G. A., and Gilbert, H. J. (2003) J. Biol. Chem. 279, 21552 - 21559) show that CmCBM6 contains two binding sites that display both similarities and differences in their ligand specificity. Here we report the crystal structure of CmCBM6 in complex with a variety of ligands that reveals the structural basis for the ligand specificity displayed by this protein. In cleft A the two faces of the terminal sugars of beta-linked oligosaccharides stack against Trp-92 and Tyr-33, whereas the rest of the binding cleft is blocked by Glu-20 and Thr-23, residues that are not present in CBM6 proteins that bind to the internal regions of polysaccharides in cleft A. Cleft B is solvent-exposed and, therefore, able to bind ligands because the loop, which occludes this region in other CBM6 proteins, is much shorter and flexible ( lacks a conserved proline) in CmCBM6. Subsites 2 and 3 of cleft B accommodate cellobiose (Glc-beta-1,4-Glc), subsite 4 will bind only to a beta-1,3-linked glucose, whereas subsite 1 can interact with either a beta-1,3- or beta-1,4-linked glucose. These different specificities of the subsites explain how cleft B can accommodate beta-1,4-beta- 1,3- or beta-1,3-beta-1,4-linked gluco-configured ligands.	CNRS, Unite Mixte Rech 6098, Lab Architecture & Fonct Macromol Biol, F-13402 Marseille 20, France; Fac Med Vet, CIISA, P-1300477 Lisbon, Portugal; Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; Univ Ramon Llull, Inst Quim Sarria, Biochem Lab, Barcelona 08017, Spain	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Universidade de Lisboa; Newcastle University - UK; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Universitat Ramon Llull; Institut Quimic de Sarria	Czjzek, M (corresponding author), CNRS, Unite Mixte Rech 6098, Lab Architecture & Fonct Macromol Biol, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	czjzek@afmb.cnrs-mrs.fr	Pires, Virginia/J-4799-2013; Henrissat, Bernard/J-2475-2012; Prates, José A M/K-9934-2013; PLANAS, ANTONI/I-4803-2015	Pires, Virginia/0000-0003-1307-3797; Henrissat, Bernard/0000-0002-3434-8588; Prates, José A M/0000-0003-1032-5987; PLANAS, ANTONI/0000-0001-7073-3320; Fontes, Carlos/0000-0002-1219-9753; Ferreira, Luis/0000-0002-3543-9166; Bolam, David/0000-0003-0314-3122				Abou Hachem M, 2000, BIOCHEM J, V345, P53, DOI 10.1042/0264-6021:3450053; ATKINS EDT, 1992, PROGR BIOTECHNOL, V7, P39; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boraston AB, 2003, J MOL BIOL, V327, P659, DOI 10.1016/S0022-2836(03)00152-9; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P14679, DOI 10.1021/bi015760g; Brett CT, 1996, PHYSL BIOCH PLANT CE; Brun E, 2000, BIOCHEMISTRY-US, V39, P2445, DOI 10.1021/bi992079u; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; GILBERT HJ, 2001, CARBOHYDRATE BIOENGI; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Henrissat B, 2000, PLANT PHYSIOL, V124, P1515, DOI 10.1104/pp.124.4.1515; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; Johnson PE, 1999, J MOL BIOL, V287, P609, DOI 10.1006/jmbi.1999.2627; Lehtio J, 2003, P NATL ACAD SCI USA, V100, P484, DOI 10.1073/pnas.212651999; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Pell G, 2004, J BIOL CHEM, V279, P11777, DOI 10.1074/jbc.M311947200; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; ROUSSEL A, 1991, SILICON GRAPHICS GEO, V88; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; Tomme P, 1996, BIOCHEMISTRY-US, V35, P13885, DOI 10.1021/bi961185i; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Zverlov VV, 2001, MICROBIOL-SGM, V147, P621, DOI 10.1099/00221287-147-3-621	29	61	63	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21560	21568		10.1074/jbc.M401599200	http://dx.doi.org/10.1074/jbc.M401599200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15010454	hybrid			2022-12-25	WOS:000221273800122
J	Yao, J; Li, Q; Chen, J; Muallem, S				Yao, J; Li, Q; Chen, J; Muallem, S			Subpopulation of store-operated Ca2+ channels regulate Ca2+-induced Ca2+ release in non-excitable cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; CYCLIC ADP-RIBOSE; ADENINE-DINUCLEOTIDE PHOSPHATE; INOSITOL TRISPHOSPHATE RECEPTORS; SALIVARY-GLAND CELLS; PAROTID ACINAR; RYANODINE RECEPTOR; CYTOSOLIC CA2+; 2-AMINOETHOXYDIPHENYL BORATE; POLARIZED EXPRESSION	Ca2+-induced Ca2+ release (CICR) is a well characterized activity in skeletal and cardiac muscles mediated by the ryanodine receptors. The present study demonstrates CICR in the non-excitable parotid acinar cells, which resembles the mechanism described in cardiac myocytes. Partial depletion of internal Ca2+ stores leads to a minimal activation of Ca2+ influx. Ca2+ influx through this pathway results in an explosive mobilization of Ca2+ from the majority of the stores by CICR. Thus, stimulation of parotid acinar cells in Ca2+-free medium with 0.5 muM carbachol releases similar to5% of the Ca2+ mobilizable by 1 mM carbachol. Addition of external Ca2+ induced the same Ca2+ release observed in maximally stimulated cells. Similar results were obtained by a short treatment with 2.5-10 muM cyclopiazonic acid, an inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase pump. The Ca2+ release induced by the addition of external Ca2+ was largely independent of IP(3)Rs because it was reduced by only similar to30% by the inhibition of the inositol 1,4,5-trisphosphate receptors with caffeine or heparin. Measurements of Ca2+-activated outward current and [Ca2+](i) suggested that most CICR triggered by Ca2+ influx occurred away from the plasma membrane. Measurement of the response to several concentrations of cyclopiazonic acid revealed that Ca2+ influx that regulates CICR is associated with a selective portion of the internal Ca2+ pool. The minimal activation of Ca2+ influx by partial store depletion was confirmed by the measurement of Mn2+ influx. Inhibition of Ca2+ influx with SKF96365 or 2-aminoethoxydiphenyl borate prevented activation of CICR observed on addition of external Ca2+. These findings provide evidence for activation of CICR by Ca2+ influx in non-excitable cells, demonstrate a previously unrecognized role for Ca2+ influx in triggering CICR, and indicate that CICR in non-excitable cells resembles CICR in cardiac myocytes with the exception that in cardiac cells Ca2+ influx is mediated by voltage-regulated Ca2+ channels whereas in non-excitable cells Ca2+ influx is mediated by store-operated channels.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	SHMUEL.MUALLEM@utsouthwestern.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 12309] Funding Source: Medline; NIDDK NIH HHS [DK 38938] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashby MC, 2002, J CELL BIOL, V158, P283, DOI 10.1083/jcb.200112025; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; DiJulio DH, 1997, J BIOL CHEM, V272, P15687, DOI 10.1074/jbc.272.25.15687; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Fitzsimmons TJ, 2000, BIOCHEM J, V351, P265, DOI 10.1042/0264-6021:3510265; FOSKETT JK, 1989, P NATL ACAD SCI USA, V86, P167, DOI 10.1073/pnas.86.1.167; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; Giovannucci DR, 2002, J PHYSIOL-LONDON, V540, P469, DOI 10.1113/jphysiol.2001.013453; Harmer AR, 2001, BIOCHEM J, V353, P555, DOI 10.1042/0264-6021:3530555; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; Krause E, 1999, J BIOL CHEM, V274, P36957, DOI 10.1074/jbc.274.52.36957; Krause E, 2002, J BIOL CHEM, V277, P11696, DOI 10.1074/jbc.M107794200; Lee BS, 2002, J MEMBRANE BIOL, V189, P181, DOI 10.1007/s00232-002-1012-x; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Leite MF, 1999, BIOCHEM J, V337, P305, DOI 10.1042/0264-6021:3370305; Leite MF, 2002, GASTROENTEROLOGY, V122, P415, DOI 10.1053/gast.2002.30982; Li Q, 2003, J BIOL CHEM, V278, P47554, DOI 10.1074/jbc.M308306200; Mak DOD, 2001, J GEN PHYSIOL, V117, P435, DOI 10.1085/jgp.117.5.435; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Ozawa T, 1997, J MEMBRANE BIOL, V156, P231, DOI 10.1007/s002329900203; Ross D, 2002, CELL CALCIUM, V32, P307, DOI 10.1016/S0143-4160(02)00198-7; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; Shin DM, 2001, J BIOL CHEM, V276, P44146, DOI 10.1074/jbc.M105203200; Sneyd J, 2003, BIOPHYS J, V85, P1392, DOI 10.1016/S0006-3495(03)74572-X; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOESCU EC, 1992, J BIOL CHEM, V267, P23467; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; Yamaki H, 1998, J DENT RES, V77, P1807, DOI 10.1177/00220345980770100801; Zhang XJ, 1999, BIOCHEM J, V340, P519, DOI 10.1042/0264-6021:3400519; Zhang XJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1306, DOI 10.1152/ajpcell.1997.273.4.C1306; ZHAO H, 1995, J BIOL CHEM, V270, P19599, DOI 10.1074/jbc.270.33.19599	42	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21511	21519		10.1074/jbc.M314028200	http://dx.doi.org/10.1074/jbc.M314028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016819	hybrid			2022-12-25	WOS:000221273800116
J	Han, SY; Iliopoulos, D; Druck, T; Guler, G; Grubbs, CJ; Pereira, M; Zhang, ZQ; You, M; Lubet, RA; Fong, LYY; Huebner, K				Han, SY; Iliopoulos, D; Druck, T; Guler, G; Grubbs, CJ; Pereira, M; Zhang, ZQ; You, M; Lubet, RA; Fong, LYY; Huebner, K			CpG methylation in the Fhit regulatory region: relation to Fhit expression in murine tumors	ONCOGENE			English	Article						CpG island methylation; Fhit promoter; epigenetics; tumor suppressor; gene inactivation; homozygous deletion	DNA METHYLATION; GENE-EXPRESSION; BLADDER-CANCER; LUNG; PROFILE; BREAST; INACTIVATION; BREAKPOINT; CARCINOMA; 3P14.2	To determine if: (1) 5' CpG island methylation is related to Fhit inactivation; (2) there are tumor or carcinogen-specific methylation patterns, we examined 35 CpG sites in the promoter, exon and intron 1 of the mouse Fhit gene. In primary tumors of lung, urinary bladder and tongue, induced by different carcinogens, 15-35% of sites were methylated, with specific methylation patterns associated with each cancer type, suggesting cancer- or tissue-specific methylation patterns. The methylation patterns were associated with reduced Fhit expression, as determined by immunohistochemical analyses. Methylation of rat Fhit 5' CpGs in mammary adenocarcinomas, detected by methylation specific PCR amplification, also correlated with reduced gene expression. Thus, there was an overall association between promoter/exon 1 methylation and decreased Fhit expression. In contrast, in cancer- derived cell lines 70-95% of the CpG sites were methylated. This is the first detailed study of the relationship between Fhit 5' CpG island methylation and Fhit expression in murine tumors, our main models for preclinical cancer studies, and provides evidence that loss of Fhit expression and methylation are correlated in these mouse models and these models will be useful to examine the complex relationships among gene expression, methylation patterns and organ specific city.	Thomas Jefferson Univ, Kimmel Canc Ctr, BLSB 1008, Philadelphia, PA 19107 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; Med Coll Ohio, Dept Pathol, Toledo, OH 43699 USA; Washington Univ, Dept Surg, St Louis, MO USA; NCI, Div Canc Prevent & Control, DCPC, Rockville, MD 20852 USA; Hacettepe Univ, Dept Pathol, TR-06100 Ankara, Turkey	Jefferson University; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hacettepe University	Huebner, K (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, BLSB 1008, 233 S 10th St, Philadelphia, PA 19107 USA.	K_Huebner@mail.jci.tju.edu	GULER, GULNUR/I-9887-2013; Iliopoulos, Dimitrios/AAE-9106-2019	Fong, Louise/0000-0001-7654-7035	NCI NIH HHS [N01-CN-15128, N01-CN-25007, N01-CN-15113, CA77738, CA56036] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA056036, P01CA077738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Baffa R, 2000, AM J PATHOL, V156, P419, DOI 10.1016/S0002-9440(10)64745-1; BAYLIN SB, 1986, CANCER RES, V46, P2917; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Druck T, 1997, CANCER RES, V57, P504; Druck T, 1998, ONCOL RES, V10, P341; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Esteller M, 2001, CANCER RES, V61, P3225; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Glover TW, 1998, CANCER RES, V58, P3409; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Grubbs CJ, 2000, CANCER RES, V60, P5599; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Ingvarsson S, 1999, CANCER RES, V59, P2682; Kolomietz E, 2003, LEUKEMIA, V17, P1313, DOI 10.1038/sj.leu.2402969; LUBET RA, 2003, UNPUB CARCINOGENESIS; Maruyama R, 2001, CANCER RES, V61, P8659; Nigro JM, 2001, AM J PATHOL, V158, P1253, DOI 10.1016/S0002-9440(10)64076-X; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paz MF, 2003, CANCER RES, V63, P1114; Pekarsky Y, 1998, CANCER RES, V58, P3401; Skopelitou AS, 2001, IN VIVO, V15, P169; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Sozzi G, 1998, CANCER RES, V58, P5032; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Sutherland JE, 2001, MUTAT RES-FUND MOL M, V479, P225, DOI 10.1016/S0027-5107(01)00163-4; Tanaka H, 1998, CANCER RES, V58, P3429; WARY KK, 1993, CANCER RES, V53, P1498; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	33	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3990	3998		10.1038/sj.onc.1207526	http://dx.doi.org/10.1038/sj.onc.1207526			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007387				2022-12-25	WOS:000221382000011
J	Muraki, M; Ohkawara, B; Hosoya, T; Onogi, H; Koizumi, J; Koizumi, T; Sumi, K; Jun-ichiro, Y; Murray, MV; Kimura, H; Furuichi, K; Shibuya, H; Krainer, AR; Suzuki, M; Hagiwara, M				Muraki, M; Ohkawara, B; Hosoya, T; Onogi, H; Koizumi, J; Koizumi, T; Sumi, K; Jun-ichiro, Y; Murray, MV; Kimura, H; Furuichi, K; Shibuya, H; Krainer, AR; Suzuki, M; Hagiwara, M			Manipulation of alternative splicing by a newly developed inhibitor of Clks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; SPINAL MUSCULAR-ATROPHY; PROTEIN-KINASE; SR PROTEINS; SERINE-RICH; IN-VIVO; DROSOPHILA-MELANOGASTER; NUCLEAR SPECKLES; HUMAN-DISEASE; CELL-CYCLE	The regulation of splice site usage provides a versatile mechanism for controlling gene expression and for the generation of proteome diversity, playing an essential role in many biological processes. The importance of alternative splicing is further illustrated by the increasing number of human diseases that have been attributed to mis-splicing events. Appropriate spatial and temporal generation of splicing variants demands that alternative splicing be subjected to extensive regulation, similar to transcriptional control. The Clk (Cdc2-like kinase) family has been implicated in splicing control and consists of at least four members. Through extensive screening of a chemical library, we found that a benzothiazole compound, TG003, had a potent inhibitory effect on the activity of Clk1/Sty. TG003 inhibited SF2/ASF-dependent splicing of beta-globin pre-mRNA in vitro by suppression of Clk-mediated phosphorylation. This drug also suppressed serine/arginine-rich protein phosphorylation, dissociation of nuclear speckles, and Clk1/Sty-dependent alternative splicing in mammalian cells. Consistently, administration of TG003 rescued the embryonic defects induced by excessive Clk activity in Xenopus. Thus, TG003, a novel inhibitor of Clk family will be a valuable tool to dissect the regulatory mechanisms involving serine/arginine-rich protein phosphorylation signaling pathways in vivo, and may be applicable for the therapeutic manipulation of abnormal splicing.	Tokyo Med & Dent Univ, Sch Biomed Sci, Gene Express Lab, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Tokyo, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol & Cellular Biol, Tokyo, Japan; Gifu Univ, Grad Sch Med, Div Regenerat & Adv Med Sci, Gifu 5011193, Japan; Yamanouchi Pharmaceut Co Ltd, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Kyoto Univ, Grad Sch Med, Horizontal Med Res Org, Nucl Funct & Dynam Unit, Kyoto 6068501, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Gifu University; Astellas Pharmaceuticals; Cold Spring Harbor Laboratory; Kyoto University	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Sch Biomed Sci, Gene Express Lab, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	m.hagiwara.end@mri.tmd.ac.jp	Kimura, Hiroshi/B-9524-2015; Hosoya, Takamitsu/N-7762-2015	Kimura, Hiroshi/0000-0003-0854-083X; Hosoya, Takamitsu/0000-0002-7270-351X; Krainer, Adrian/0000-0001-9024-9501; Ohkawara, Bisei/0000-0002-1987-458X				Andreassi C, 2001, HUM MOL GENET, V10, P2841, DOI 10.1093/hmg/10.24.2841; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER J, 1994, P NATL ACAD SCI USA, V91, P12105, DOI 10.1073/pnas.91.25.12105; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Cao WH, 1997, RNA, V3, P1456; Cartegni L, 2003, NAT STRUCT BIOL, V10, P120, DOI 10.1038/nsb887; Celotto AM, 2002, RNA, V8, P718, DOI 10.1017/S1355838202021064; Chang JG, 2001, P NATL ACAD SCI USA, V98, P9808, DOI 10.1073/pnas.171105098; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Du C, 1998, MOL CELL, V2, P741, DOI 10.1016/S1097-2765(00)80289-0; Duncan PI, 1997, MOL CELL BIOL, V17, P5996, DOI 10.1128/MCB.17.10.5996; Epstein PM, 1998, METHODS, V14, P21, DOI 10.1006/meth.1997.0562; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; GUPTA AK, 1995, CAN J CHEM, V73, P1278, DOI 10.1139/v95-157; HAGIWARA M, 1987, MOL PHARMACOL, V31, P523; Hanamura A, 1998, RNA, V4, P430; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; Katsu R, 2002, J BIOL CHEM, V277, P44220, DOI 10.1074/jbc.M206504200; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kojima T, 2001, J BIOL CHEM, V276, P32247, DOI 10.1074/jbc.M103790200; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAWCZAK M, 1992, HUM GENET, V90, P41; Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913; Lai MC, 2003, BIOCHEM J, V371, P937, DOI 10.1042/BJ20021827; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Lee K, 1996, J BIOL CHEM, V271, P27299, DOI 10.1074/jbc.271.44.27299; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; Mayeda A, 1999, METH MOL B, V118, P309; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Nayler O, 1998, J BIOL CHEM, V273, P34341, DOI 10.1074/jbc.273.51.34341; Nayler O, 1997, BIOCHEM J, V326, P693, DOI 10.1042/bj3260693; Neugebauer KM, 1997, GENE DEV, V11, P1148, DOI 10.1101/gad.11.9.1148; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Philips AV, 2000, CELL MOL LIFE SCI, V57, P235, DOI 10.1007/PL00000687; Pilch B, 2001, CANCER RES, V61, P6876; RABINOW L, 1993, GENETICS, V134, P1175; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; ROTH MB, 1991, J CELL BIOL, V115, P5877; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547; Soret J, 2003, CANCER RES, V63, P8203; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; STOSS O, 2000, GENE THER MOL BIOL, V5, P9; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	59	212	228	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24246	24254		10.1074/jbc.M314298200	http://dx.doi.org/10.1074/jbc.M314298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15010457	hybrid			2022-12-25	WOS:000221702500049
J	Galili, L; Herz, K; Dym, O; Padan, E				Galili, L; Herz, K; Dym, O; Padan, E			Unraveling functional and structural interactions between transmembrane domains IV and XI of NhaA Na+/H+ antiporter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL CROSS-LINKING; DEPENDENT CONFORMATIONAL-CHANGE; ION-TRANSPORT; SCANNING MUTAGENESIS; LACTOSE PERMEASE; MOLECULAR RULERS; DIMER INTERFACE; ACID-RESIDUES; PH RESPONSE; PROTEIN	A functionally important, interface domain between transmembrane segments (TMSs) IV and XI of the NhaA Na+/H+ antiporter of Escherichia coli has been unraveled. Scanning by single Cys replacements identified new mutations (F136C, G125C, and A137C) that cluster in one face of TMS IV and increase dramatically the Km of the antiporter. Whereas G125C, in addition, causes a drastic alkaline shift to the pH dependence of the antiporter, G338C alleviates the pH control of NhaA. Scanning by double Cys replacements ( 21 pairs of one replacement per TMS) identified genetically eight pairs of residues that showed very strong negative complementation. Cross-linking of the double mutants identified six double mutants (T132C/G338C, D133C/G338C, F136C/ S342C, T132C/S342C, A137C/S342C, and A137C/G338C) of which pronounced intramolecular cross-linking defined an interface domain between the two TMSs. Remarkably, cross-linking by a short and rigid reagent (N, N'-o-phenylenedimaleimide) revived the Li+/H+ antiport activity, whereas a shorter reagent (1,2-ethanediyl bismethanethiosulfonate) revived both Na+/H+ and Li+/H+ antiporter activities and even the pH response of the dead mutant T132C/G338C. Hence, cross-linking at this position restores an active conformation of NhaA.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Padan, E (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	etana@vms.huji.ac.il						Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAREAGA CL, 1992, BIOPHYS J, V62, P209, DOI 10.1016/S0006-3495(92)81806-4; Dahaoui S, 1999, J PHYS CHEM A, V103, P6240, DOI 10.1021/jp990641k; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Galili L, 2002, BIOCHEMISTRY-US, V41, P609, DOI 10.1021/bi011655v; Geertsma ER, 2003, J MOL BIOL, V332, P1165, DOI 10.1016/j.jmb.2003.07.010; Gerchman Y, 1999, J BIOL CHEM, V274, P24617, DOI 10.1074/jbc.274.35.24617; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KLEYWEGT GJ, 2001, O INT TABLES CRYSTAL, P353; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwaw I, 2000, BIOCHEMISTRY-US, V39, P3134, DOI 10.1021/bi992509g; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Padan E, 2003, SODIUM-HYDROGEN EXCHANGER: FROM MOLECULE TO ITS ROLE IN DISEASE, P91; PADAN E, 1989, J BIOL CHEM, V264, P20297; Padan E, 2001, BBA-BIOENERGETICS, V1505, P144, DOI 10.1016/S0005-2728(00)00284-X; Padan E, 1998, FEBS LETT, V441, P53, DOI 10.1016/S0014-5793(98)01524-5; PINNER E, 1993, J BIOL CHEM, V268, P1729; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Rimon A, 2002, BIOCHEMISTRY-US, V41, P14897, DOI 10.1021/bi0261342; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; ROSEN BP, 1986, ANNU REV MICROBIOL, V40, P263, DOI 10.1146/annurev.mi.40.100186.001403; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; Tsuboi Y, 2003, J BIOL CHEM, V278, P21467, DOI 10.1074/jbc.M301932200; Tzubery T, 2004, J BIOL CHEM, V279, P3265, DOI 10.1074/jbc.M309021200; van Montfort BA, 2002, J BIOL CHEM, V277, P14717, DOI 10.1074/jbc.M201533200; Venturi M, 2000, J BIOL CHEM, V275, P4734, DOI 10.1074/jbc.275.7.4734; Venturi M., 2002, PRACTICAL GUIDE MEMB, P179; Wakabayashi S, 2003, SODIUM-HYDROGEN EXCHANGER: FROM MOLECULE TO ITS ROLE IN DISEASE, P35; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002	51	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23104	23113		10.1074/jbc.M400288200	http://dx.doi.org/10.1074/jbc.M400288200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039449	hybrid			2022-12-25	WOS:000221570900040
J	Anderluh, G; Gokce, I; Lakey, JH				Anderluh, G; Gokce, I; Lakey, JH			A natively unfolded toxin domain uses its receptor as a folding template	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; FILAMENTOUS PHAGE INFECTION; GROUP-A COLICINS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; CIRCULAR-DICHROISM; ENDONUCLEASE COLICINS; IMMUNITY PROTEIN; RECOGNITION SITE; TOLA	Natively unfolded proteins range from molten globules to disordered coils. They are abundant in eukaryotic genomes and commonly involved in molecular interactions. The essential N-terminal translocation domains of colicin toxins from Escherichia coli are disordered bacterial proteins that bind at least one protein of the Tol or Ton family. The colicin N translocation domain (ColN-(1-90)), which binds to the C-terminal domain of TolA (TolA-(296-421)), shows a disordered far-UV CD spectrum, no near-UV CD signal, and non-cooperative thermal unfolding. As expected, TolA-(296-421) displays both secondary structure in far-UV CD and tertiary structure in near-UV CD. Furthermore it shows a cooperative unfolding transition at 65 degreesC. CD spectra of the 1:1 complex show both increased secondary structure and colicin N-specific near-UV CD signals. A new cooperative thermal transition at 35 degreesC is followed by the unchanged unfolding behavior of TolA-(296-421). Fluorescence and surface plasmon resonance confirm that the new unfolding transition accompanies dissociation of ColN-(1-90). Hence upon binding the disordered structure of ColN-(1-90) converts to a cooperatively folded domain without altering the TolA-(296-421) structure.	Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Ljubljana, Biotech Fac, Dept Biol, Ljubljana 1000, Slovenia; Gaziosmanpasa Univ, Dept Chem, TR-60240 Tokat, Turkey	Newcastle University - UK; University of Ljubljana; Gaziosmanpasa University	Lakey, JH (corresponding author), Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	j.h.lakey@ncl.ac.uk	Anderluh, Gregor/C-6905-2014	Anderluh, Gregor/0000-0002-9916-8465				Anderluh G, 2003, J BIOL CHEM, V278, P21860, DOI 10.1074/jbc.M300411200; Anderluh G, 2003, PROTEIN EXPRES PURIF, V28, P173, DOI 10.1016/S1046-5928(02)00681-2; Bienkiewicz EA, 2000, J MOL BIOL, V297, P119, DOI 10.1006/jmbi.2000.3545; Braun V, 2002, BIOCHIMIE, V84, P365, DOI 10.1016/S0300-9084(02)01427-X; COLLINS ES, 2002, J MOL BIOL, V122, P145; CRAIG S, 1989, INT J PEPT PROT RES, V33, P256; Deprez C, 2002, BIOCHEMISTRY-US, V41, P2589, DOI 10.1021/bi0157262; Derouiche R, 1996, EMBO J, V15, P6408, DOI 10.1002/j.1460-2075.1996.tb01032.x; Dover LG, 2000, BIOCHEMISTRY-US, V39, P8632, DOI 10.1021/bi000160n; Dubuisson JF, 2002, J BACTERIOL, V184, P4620, DOI 10.1128/JB.184.16.4620-4625.2002; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Eker F, 2003, J AM CHEM SOC, V125, P8178, DOI 10.1021/ja034625j; ELKOUHEN R, 1993, EUR J BIOCHEM, V214, P635; Evans LJA, 1996, BIOCHEMISTRY-US, V35, P13180, DOI 10.1021/bi960990u; Evans LJA, 1996, BIOCHEMISTRY-US, V35, P15143, DOI 10.1021/bi9615497; Evans LJA, 1996, J MOL BIOL, V255, P559, DOI 10.1006/jmbi.1996.0047; Fasman G.D., 1996, CIRCULAR DICHROISM C; GELI V, 1986, MOL GEN GENET, V202, P455, DOI 10.1007/BF00333276; Gokce I, 2000, J MOL BIOL, V304, P621, DOI 10.1006/jmbi.2000.4232; James R, 2002, BIOCHIMIE, V84, P381, DOI 10.1016/S0300-9084(02)01450-5; JAMES R, 1988, J GEN MICROBIOL, V134, P2525; James R, 1996, MICROBIOL-SGM, V142, P1569, DOI 10.1099/13500872-142-7-1569; Kerr B, 2002, NATURE, V418, P171, DOI 10.1038/nature00823; Kleanthous C, 1999, NAT STRUCT BIOL, V6, P243, DOI 10.1038/6683; Kleanthous C, 1998, MOL MICROBIOL, V28, P227, DOI 10.1046/j.1365-2958.1998.00811.x; Kurisu G, 2003, NAT STRUCT BIOL, V10, P948, DOI 10.1038/nsb997; Lakey JH, 2001, CURR TOP MICROBIOL, V257, P131; Lazzaroni JC, 2002, BIOCHIMIE, V84, P391, DOI 10.1016/S0300-9084(02)01419-0; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Lubkowski J, 1999, STRUCTURE, V7, P711, DOI 10.1016/S0969-2126(99)80092-6; Mosbahi K, 2002, NAT STRUCT BIOL, V9, P476, DOI 10.1038/nsb797; Pappu RV, 2002, PROTEIN SCI, V11, P2437, DOI 10.1110/ps.0217402; Park SH, 1997, PROTEIN SCI, V6, P1694, DOI 10.1002/pro.5560060809; Pilpel Y, 2003, BIOCHEMISTRY-US, V42, P3519, DOI 10.1021/bi0266176; PILSL H, 1995, J BACTERIOL, V177, P6966, DOI 10.1128/jb.177.23.6966-6972.1995; POLITOU AS, 1994, BIOCHEMISTRY-US, V33, P4730, DOI 10.1021/bi00181a604; PUGSLEY AP, 1984, MICROBIOL SCI, V1, P168; PUGSLEY AP, 1987, MOL MICROBIOL, V1, P317, DOI 10.1111/j.1365-2958.1987.tb01938.x; Raggett EM, 1998, MOL MICROBIOL, V28, P1335, DOI 10.1046/j.1365-2958.1998.00899.x; Rakin A, 1996, MICROBIOL-UK, V142, P3415, DOI 10.1099/13500872-142-12-3415; Riechmann L, 1997, CELL, V90, P351, DOI 10.1016/S0092-8674(00)80342-6; Schendel SL, 1997, J BACTERIOL, V179, P3683, DOI 10.1128/jb.179.11.3683-3690.1997; Soelaiman S, 2001, MOL CELL, V8, P1053, DOI 10.1016/S1097-2765(01)00396-3; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Vetter IR, 1998, STRUCTURE, V6, P863, DOI 10.1016/S0969-2126(98)00088-4; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; WILMSEN HU, 1990, EUR BIOPHYS J, V18, P149, DOI 10.1007/BF02427374; Zakharov SD, 2002, BBA-BIOMEMBRANES, V1565, P333, DOI 10.1016/S0005-2736(02)00579-5	50	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22002	22009		10.1074/jbc.M313603200	http://dx.doi.org/10.1074/jbc.M313603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15004032	hybrid			2022-12-25	WOS:000221417100041
J	Cuppoletti, J; Tewari, KP; Sherry, AM; Ferrante, CJ; Malinowska, DH				Cuppoletti, J; Tewari, KP; Sherry, AM; Ferrante, CJ; Malinowska, DH			Sites of protein kinase A activation of the human ClC-2Cl(-) channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNELS; CL-CHANNEL; ARACHIDONIC-ACID; CELLS; PHOSPHORYLATION; PKA; PH	Human ClC- 2 Cl- ( hClC- 2) channels are activated by protein kinase A ( PKA) and low extracellular pH(o). Both of these effects are prevented by the PKA inhibitor, myristoylated PKI. The aims of the present study were to identify the PKA phosphorylation site( s) important for PKA activation of hClC- 2 at neutral and low pH(o) and to examine the relationship between PKA and low pH(o) activation. Recombinant hClC- 2 with point mutations of consensus phosphorylation sites was prepared and stably expressed in HEK- 293 cells. The responses to forskolin plus isobutylmethylxanthine at neutral and acidic pH(o) were studied by whole cell patch clamp in the presence and absence of phosphatase inhibitors. The double phosphorylation site ( RRAT655( A) plus RGET691( A)) mutant hClC- 2 lost PKA activation and low pH(o) activation. Either RRAT or RGET was sufficient for PKA activation of hClC- 2 at pH(o) 7.4, as long as phosphatase inhibitors ( cyclosporin A or endothal) were present. At pHo 6 only RGET was needed for PKA activation of hClC- 2. Low pH(o) activation of hClC- 2 Cl- channel activity was PKA- dependent, retained in RGET( A) mutant hClC- 2, but lost in RRAT( A) mutant hClC- 2. RRAT655( D) mutant hClC- 2 was constitutively active and was further activated by PKA at pH(o) 7.4 and 6.0, consistent with the above findings. These results show that activation of hClC- 2 is differentially regulated by PKA at two sites, RRAT655 and RGET691. Either RRAT655 or RGET691 was sufficient for activation at pH(o) 7.4. RGET, but not RRAT, was sufficient for activation at pH(o) 6.0. However, in the RGET691( D) mutant, there was PKA activation at pH(o) 6.0.	Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Cuppoletti, J (corresponding author), Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA.	John.Cuppoletti@uc.edu			NHLBI NIH HHS [HL58399] Funding Source: Medline; NIDDK NIH HHS [DK43816] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043816] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baba Y, 2003, J AM CHEM SOC, V125, P9740, DOI 10.1021/ja034694y; Brockdorff J, 1997, CYTOKINE, V9, P333, DOI 10.1006/cyto.1996.0173; Cuppoletti J, 2001, AM J PHYSIOL-CELL PH, V281, pC46, DOI 10.1152/ajpcell.2001.281.1.C46; Fritsch J, 1997, AM J PHYSIOL-CELL PH, V272, pC778, DOI 10.1152/ajpcell.1997.272.3.C778; Furukawa T, 2002, J PHYSIOL-LONDON, V540, P883; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kajita H, 2000, J PHYSIOL-LONDON, V523, P313, DOI 10.1111/j.1469-7793.2000.t01-1-00313.x; KLOSE KE, 1993, J MOL BIOL, V232, P67, DOI 10.1006/jmbi.1993.1370; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; OMKUMAR RV, 1994, J BIOL CHEM, V269, P6810; Park K, 2001, J MEMBRANE BIOL, V182, P31, DOI 10.1007/s00232-001-0026-0; PURVES FC, 1991, J VIROL, V65, P5757, DOI 10.1128/JVI.65.11.5757-5764.1991; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P3879, DOI 10.1073/pnas.95.7.3879; Sherry AM, 1997, AM J PHYSIOL-CELL PH, V273, pC384, DOI 10.1152/ajpcell.1997.273.2.C384; Stroffekova K, 1998, AM J PHYSIOL-CELL PH, V275, pC1113, DOI 10.1152/ajpcell.1998.275.4.C1113; Tewari KP, 2000, AM J PHYSIOL-CELL PH, V279, pC40, DOI 10.1152/ajpcell.2000.279.1.C40; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; ZHANG B, 1991, J BIOL CHEM, V266, P990	18	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21849	21856		10.1074/jbc.M312567200	http://dx.doi.org/10.1074/jbc.M312567200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15010473	hybrid			2022-12-25	WOS:000221417100023
J	Galigniana, MD; Harrell, JM; O'Hagen, HM; Ljungman, M; Pratt, WB				Galigniana, MD; Harrell, JM; O'Hagen, HM; Ljungman, M; Pratt, WB			Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; TETRATRICOPEPTIDE REPEAT DOMAIN; PEPTIDYLPROLYL ISOMERASE DOMAIN; WILD-TYPE P53; GLUCOCORTICOID-RECEPTOR; MUTANT P53; IN-VIVO; CYTOPLASMIC DYNEIN; INTRACELLULAR-LOCALIZATION; CHAPERONE MACHINERY	The tumor suppressor protein p53 is known to be transported to the nucleus along microtubular tracks by cytoplasmic dynein. However, the connection between p53 and the dynein motor protein complex has not been established. Here, we show that hsp90.binding immunophilins link p53.hsp90 complexes to dynein and that prevention of that linkage in vivo inhibits the nuclear movement of p53. First, we show that p53.hsp90 hetero-complexes from DLD-1 human colon cancer cells contain an immunophilin (FKBP52, CyP-40, or PP5) as well as dynein. p53.hsp90.immunophilin.dynein complexes can be formed by incubating immunopurified p53 with rabbit reticulocyte lysate, and we show by peptide competition that the immunophilins link via their tetratricopeptide repeat domains to p53-bound hsp90 and by means of their PPIase domains to the dynein complex. The linkage of immunophilins to the dynein motor is indirect by means of the dynamitin component of the dynein-associated dynactin complex, and we show that purified FKBP52 binds directly by means of its PPIase domain to purified dynamitin. By using a temperature-sensitive mutant of p53 where cytoplasmic-nuclear movement occurs by shift to permissive temperature, we show that p53 movement is impeded when p53 binding to hsp90 is inhibited by the hsp90 inhibitor radicicol. Also, nuclear movement of p53 is inhibited when immunophilin binding to dynein is competed for by expression of a PPIase domain fragment in the same manner as when dynein linkage to cargo is dissociated by expression of dynamitin. This is the first demonstration of the linkage between an hsp90-chaperoned transcription factor and the system for its retrograde movement to the nucleus both in vitro and in vivo.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Buenos Aires, Programa Regulac Hormonal & Metab, Consejo Nacl Invest Cient & Tecn, Fac Ciencias Exactas & Nat,Dept Quim Biol, Buenos Aires, DF, Argentina	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	mgali@umich.edu		O'Hagan, Heather/0000-0001-9750-5088; GALIGNIANA, MARIO/0000-0002-9130-8574	NCI NIH HHS [CA82376, CA28010] Funding Source: Medline; NIDDK NIH HHS [P60DK20572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082376, R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; GANNON JV, 1991, NATURE, V349, P802; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Harrell JM, 2002, BIOCHEMISTRY-US, V41, P5581, DOI 10.1021/bi020073q; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Komarova EA, 1997, CANCER RES, V57, P5217; LEBIHAN S, 1993, BIOCHEM BIOPH RES CO, V195, P600, DOI 10.1006/bbrc.1993.2088; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; Merchant AK, 1996, ONCOGENE, V13, P2631; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; OwensGrillo JK, 1996, BIOCHEMISTRY-US, V35, P15249, DOI 10.1021/bi9615349; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pirkl F, 2001, J MOL BIOL, V308, P795, DOI 10.1006/jmbi.2001.4595; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Uberti D, 1999, MOL BRAIN RES, V65, P167, DOI 10.1016/S0169-328X(98)00339-8; Vallee RB, 1998, TRENDS CELL BIOL, V8, P490, DOI 10.1016/S0962-8924(98)01379-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	52	119	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22483	22489		10.1074/jbc.M402223200	http://dx.doi.org/10.1074/jbc.M402223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15004035	Green Published, hybrid			2022-12-25	WOS:000221417100098
J	Ishiyama, N; Creuzenet, C; Lam, JS; Berghuis, AM				Ishiyama, N; Creuzenet, C; Lam, JS; Berghuis, AM			Crystal structure of WbpP, a genuine UDP-N-acetylglucosamine 4-epimerase from Pseudomonas aeruginosa - Substrate specificity in UDP-hexose 4-epimerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLCNAC C4 EPIMERASE; GALACTOSE 4-EPIMERASE; ESCHERICHIA-COLI; O-ANTIGEN; MOLECULAR-STRUCTURE; ACTIVE-SITE; SEROTYPE O6; PROTEIN; GLUCOSE; BIOSYNTHESIS	The O antigen of lipopolysaccharide in Gram-negative bacteria plays a critical role in bacterium-host interactions, and for pathogenic bacteria it is a major virulence factor. In Pseudomonas aeruginosa serotype O6 one of the initial steps in O-antigen biosynthesis is catalyzed by a saccharide epimerase, WbpP. WbpP is a member of the UDP-hexose 4-epimerase family of enzymes and exists as a homo-dimer. This enzyme preferentially catalyzes the conversion between UDP-GlcNAc and UDP-GalNAc above UDP-Glc and UDP-Gal, using NAD(+) as a cofactor. The crystal structures of WbpP in complex with cofactor and either UDP-Glc or UDP-GalNAc were determined at 2.5 and 2.1 Angstrom, respectively, which represents the first structural studies of a genuine UDP-GlcNAc 4-epimerase. These structures in combination with complementary mutagenesis studies suggest that the basis for the differential substrate specificity of WbpP is a consequence of the presence of a pliable solvent network in the active site. This information allows for a comprehensive analysis of the relationship between sequence and substrate specificity for UDP-hexose 4-epimerases and enables the formulation of consensus sequences that predict substrate specificity of UDP-hexose 4-epimerases yet to be biochemically characterized. Furthermore, the examination indicates that as little as one residue can dictate substrate specificity. Nonetheless, phylogenetic analysis suggests that this substrate specificity is an evolutionary and highly conserved property within UDP-hexose 4-epimerases.	McGill Univ, Dept Biochem, Montreal, PQ H3A 1A4, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 1A4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada	McGill University; McGill University; Western University (University of Western Ontario); University of Guelph	Berghuis, AM (corresponding author), McGill Univ, Dept Biochem, 740 Dr Penfield Ave,Rm 5202, Montreal, PQ H3A 1A4, Canada.	albert.berghuis@mcgill.ca	Berghuis, Albert M/A-6495-2008	Berghuis, Albert/0000-0002-2663-025X; Ishiyama, Noboru/0000-0002-1426-6083				Allard STM, 2001, CELL MOL LIFE SCI, V58, P1650, DOI 10.1007/PL00000803; BAUER AJ, 1992, PROTEINS, V12, P372, DOI 10.1002/prot.340120409; Belanger M, 1999, MICROBIOL-UK, V145, P3505, DOI 10.1099/00221287-145-12-3505; Bengoechea JA, 2002, J BACTERIOL, V184, P4277, DOI 10.1128/JB.184.15.4277-4287.2002; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; Downey J. S., 1998, FRONT BIOSCI, V3, pd468; Du X, 1999, BLOOD CELL MOL DIS, V25, P328, DOI 10.1006/bcmd.1999.0262; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Heumann D, 2002, CLIN CHIM ACTA, V323, P59, DOI 10.1016/S0009-8981(02)00180-8; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNIREL YA, 1990, CRIT REV MICROBIOL, V17, P273, DOI 10.3109/10408419009105729; Kowal P, 2002, BIOCHEMISTRY-US, V41, P15410, DOI 10.1021/bi026384i; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lerouge I, 2002, FEMS MICROBIOL REV, V26, P17, DOI 10.1111/j.1574-6976.2002.tb00597.x; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; Lopez  AB, 2003, MOL BIOCHEM PARASIT, V128, P51, DOI 10.1016/S0166-6851(03)00049-5; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Samuel J, 2002, NAT PROD REP, V19, P261, DOI 10.1039/b100492l; Shaw MP, 2003, MOL BIOCHEM PARASIT, V126, P173, DOI 10.1016/S0166-6851(02)00243-8; Soldo B, 2003, GENE, V319, P65, DOI 10.1016/S0378-1119(03)00793-5; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P10685, DOI 10.1021/bi9704313; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6294, DOI 10.1021/bi970025j; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 2002, J BIOL CHEM, V277, P27528, DOI 10.1074/jbc.M204413200; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	34	70	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22635	22642		10.1074/jbc.M401642200	http://dx.doi.org/10.1074/jbc.M401642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016816	hybrid			2022-12-25	WOS:000221417100115
J	Lau, EK; Paavola, CD; Johnson, Z; Gaudry, JP; Geretti, E; Borlat, F; Kungl, AJ; Proudfoot, AE; Handel, TM				Lau, EK; Paavola, CD; Johnson, Z; Gaudry, JP; Geretti, E; Borlat, F; Kungl, AJ; Proudfoot, AE; Handel, TM			Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1 - Implications for structure and function in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; HEPARAN-SULFATE; CHEMOTACTIC PROTEIN-1; NATURAL ANTAGONIST; RECEPTOR-BINDING; SURFACE; INTERLEUKIN-8; ACTIVATION; RANTES; OLIGOMERIZATION	In a recent study, we demonstrated that glycosaminoglycan ( GAG) binding and oligomerization are essential for the in vivo function of the chemokines MCP-1/CCL2, RANTES/CCL5, and MIP-1beta/CCL4 (1). Binding to the GAG chains of cell surface proteoglycans is thought to facilitate the formation of high localized concentrations of chemokines, which in turn provide directional signals for leukocyte migration. To understand the molecular details of the chemokine-GAG interaction, in the present study we identified the GAG binding epitopes of MCP-1/CCL2 by characterizing a panel of surface alanine mutants in a series of heparin-binding assays. Using sedimentation equilibrium and cross-linking methods, we also observed that addition of heparin octasaccharide induces tetramer formation of MCP-1/CCL2. Although MCP-1/CCL2 forms a dimer in solution, both a dimer and tetramer have been observed by x-ray crystallography, providing a glimpse of the putative heparin-bound state. When the GAG binding residues are mapped onto the surface of the tetramer, the pattern that emerges is a continuous ring of basic residues encircling the tetramer, creating a positively charged surface well suited for binding GAGs. The structure also suggests several possible functional roles for GAG-induced oligomerization beyond retention of chemokines at the site of production.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Graz Univ, Inst Pharmaceut Chem & Pharmaceut Technol, Dept Prot Chem & Biophys, A-8010 Graz, Austria	University of California System; University of California Berkeley; University of Graz	Handel, TM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 239 Hildebrand Hall, Berkeley, CA 94720 USA.	handel@annapurna.berkeley.edu		Johnson, Zoe/0000-0002-4120-2579; Kungl, Andreas/0000-0003-3362-797X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037113] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37113] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali S, 2001, BIOCHEM J, V358, P737, DOI 10.1042/0264-6021:3580737; Appay V, 2000, INT IMMUNOL, V12, P1173, DOI 10.1093/intimm/12.8.1173; Appay V, 1999, J BIOL CHEM, V274, P27505, DOI 10.1074/jbc.274.39.27505; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAGGIOLINI M, 1991, BIOCHEM SOC T, V19, P55, DOI 10.1042/bst0190055; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chakravarty L, 1998, J BIOL CHEM, V273, P29641, DOI 10.1074/jbc.273.45.29641; Cohn E. J., 1943, PROTEINS AMINO ACIDS; D'Ambrosio D, 2003, J IMMUNOL METHODS, V273, P3, DOI 10.1016/S0022-1759(02)00414-3; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Devalaraja MN, 1999, TRENDS PHARMACOL SCI, V20, P151, DOI 10.1016/S0165-6147(99)01342-5; Duensing TD, 1999, INFECT IMMUN, V67, P4463, DOI 10.1128/IAI.67.9.4463-4468.1999; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; Koopmann W, 1997, J BIOL CHEM, V272, P10103; Kunkel EJ, 2002, ADV EXP MED BIOL, V512, P65; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Middleton J, 2002, BLOOD, V100, P3853, DOI 10.1182/blood.V100.12.3853; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Ogilvie P, 2001, BLOOD, V97, P1920, DOI 10.1182/blood.V97.7.1920; Ogilvie P, 2003, BLOOD, V102, P789, DOI 10.1182/blood-2002-09-2773; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Patel DD, 2001, CLIN IMMUNOL, V99, P43, DOI 10.1006/clim.2000.4997; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; Roscic-Mrkic B, 2003, BLOOD, V102, P1169, DOI 10.1182/blood-2003-02-0488; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; Shriver Z, 2002, TRENDS CARDIOVAS MED, V12, P71, DOI 10.1016/S1050-1738(01)00150-5; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; Stringer SE, 1999, J BIOL CHEM, V274, P25455, DOI 10.1074/jbc.274.36.25455; Swaminathan GJ, 2003, STRUCTURE, V11, P521, DOI 10.1016/S0969-2126(03)00070-4; Van Damme J, 1999, Chem Immunol, V72, P42, DOI 10.1159/000058725; Vives RR, 2002, BIOCHEMISTRY-US, V41, P14779, DOI 10.1021/bi026459i; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025; Zhuang P, 1997, J BIOL CHEM, V272, P6858, DOI 10.1074/jbc.272.11.6858	58	159	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22294	22305		10.1074/jbc.M311224200	http://dx.doi.org/10.1074/jbc.M311224200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15033992	hybrid			2022-12-25	WOS:000221417100077
J	Mills, KV; Manning, JS; Garcia, AM; Wuerdeman, LA				Mills, KV; Manning, JS; Garcia, AM; Wuerdeman, LA			Protein splicing of a Pyrococcus abyssi intein with a C-terminal glutamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MINI-INTEIN; IDENTIFICATION; CLEAVAGE; INHIBITION; MODULATION; STABILITY; MECHANISM; REVEALS; RINGS	Protein splicing involves the excision of an intervening polypeptide sequence, the intein, from a precursor protein and the concomitant ligation of the flanking polypeptides, the exteins, by a peptide bond. Most reported inteins have a C-terminal asparagine residue, and it has been shown that cyclization of this residue is coupled to peptide bond cleavage between the intein and C-extein. We show that the intein interrupting the DNA polymerase II DP2 subunit in Pyrococcus abyssi, which has a C-terminal glutamine, is capable of facilitating protein splicing. Substitution of an asparagine for the C-terminal glutamine moderately improves the rate and extent of protein splicing. However, substitution of an alanine for the penultimate histidine residue, with either asparagine or glutamine in the C-terminal position, prevents protein splicing and facilitates cleavage at the intein N terminus. The intein facilitates in vitro protein splicing only at temperatures above 30degreesC and can be purified as a nonspliced precursor. This temperature dependence has enabled us to characterize the optimal in vitro splicing conditions and determine the rate constants for splicing as a function of temperature.	Coll Holy Cross, Dept Chem, Worcester, MA 01610 USA	College of the Holy Cross	Mills, KV (corresponding author), Coll Holy Cross, Dept Chem, 1 Coll St, Worcester, MA 01610 USA.	kmills@holycross.edu						Amitai G, 2004, J BIOL CHEM, V279, P3121, DOI 10.1074/jbc.M311343200; Amitai G, 2003, MOL MICROBIOL, V47, P61, DOI 10.1046/j.1365-2958.2003.03283.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HC, 1954, J AM CHEM SOC, V76, P467, DOI 10.1021/ja01631a041; Chen LX, 2000, J BIOL CHEM, V275, P20431, DOI 10.1074/jbc.M000178200; CHILDERS SE, 1992, APPL ENVIRON MICROB, V58, P3949, DOI 10.1128/AEM.58.12.3949-3953.1992; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; Ding Y, 2003, J BIOL CHEM, V278, P39133, DOI 10.1074/jbc.M306197200; Evans TC, 1999, J BIOL CHEM, V274, P3923, DOI 10.1074/jbc.274.7.3923; Ghosh I, 2001, J BIOL CHEM, V276, P24051, DOI 10.1074/jbc.M011049200; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martin DD, 2001, BIOCHEMISTRY-US, V40, P1393, DOI 10.1021/bi001786g; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; Mills KV, 1998, P NATL ACAD SCI USA, V95, P3543, DOI 10.1073/pnas.95.7.3543; Mills KV, 2001, J BIOL CHEM, V276, P10832, DOI 10.1074/jbc.M011149200; NICHOLS NM, 1942, BIOCHEMISTRY-US, V42, P15301; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Paulus H, 1998, CHEM SOC REV, V27, P375, DOI 10.1039/a827375z; Perler FB, 2002, NUCLEIC ACIDS RES, V30, P383, DOI 10.1093/nar/30.1.383; Pietrokovski S, 1998, CURR BIOL, V8, pR634, DOI 10.1016/S0960-9822(07)00409-5; SHAO Y, 1995, BIOCHEMISTRY-US, V34, P10844, DOI 10.1021/bi00034a017; Sircar SSG, 1927, J CHEM SOC, P1252, DOI 10.1039/jr9270001252; Sircar SSG, 1927, J CHEM SOC, P600, DOI 10.1039/jr9270000600; Southworth MW, 2000, EMBO J, V19, P5019, DOI 10.1093/emboj/19.18.5019; Southworth MW, 1999, BIOTECHNIQUES, V27, P110, DOI 10.2144/99271st04; Wang SL, 1997, J BIOL CHEM, V272, P11869, DOI 10.1074/jbc.272.18.11869; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Yamamoto K, 2001, BIOCHEM BIOPH RES CO, V280, P898, DOI 10.1006/bbrc.2000.4202	34	46	46	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20685	20691		10.1074/jbc.M400887200	http://dx.doi.org/10.1074/jbc.M400887200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15024006	hybrid			2022-12-25	WOS:000221273800019
J	Chantome, A; Pance, A; Gauthier, N; Vandroux, D; Chenu, J; Solary, E; Jeannin, JF; Reveneau, S				Chantome, A; Pance, A; Gauthier, N; Vandroux, D; Chenu, J; Solary, E; Jeannin, JF; Reveneau, S			Casein kinase II-mediated phosphorylation of NF-kappa B p65 subunit enhances inducible nitric-oxide synthase gene transcription in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MOUSE MACROPHAGES; P65/RELA SUBUNIT; ACTIVATION; INDUCTION; ALPHA; EXPRESSION; BINDING; CK2; DOMAIN	Nitric oxide ( NO) produced by inducible nitric-oxide synthase (NOSII) is mainly regulated at the transcriptional level by the nuclear factor-kappaB (NF-kappaB). In the present study, we further analyzed the role of NF-kappaB in the in vivo transcriptional regulation of NOSII gene by comparing two clones isolated from the EMT-6 mouse mammary cancer cell line. In response to interleukin (IL)-1beta or lipopolysaccharide (LPS), EMT-6 clone J (EMT-6J) cells produce 3-fold more NO than EMT-6 clone H (EMT-6H) cells, an effect correlated with enhanced activation of NF-kappaB in EMT-6J cells. In response to IL-1beta, the kinetics of degradation of NF-kappaB inhibitors IkappaB-alpha and IkappaB-beta, the nucleo-cytoplasmic shuttling of the transcription factor and its binding to a specific DNA sequence were similar in both clones. In contrast, an IL-1beta-induced phosphorylation of serine residues in NF-kappaB p65 subunit was observed in EMT-6J, but not in EMT-6H, cells. This IL-1beta-induced phosphorylation of p65 was specifically prevented by pretreatment of EMT-6J cells with the casein kinase II inhibitor DRB. Small interfering RNA-mediated depletion of casein kinase II-alpha subunit also decreased NF-kappaB transcriptional activity and NOSII gene transcription in IL-1beta and LPS-stimulated EMT-6J cells to the levels observed in EMT-6H cells treated in the same conditions. Altogether, these data indicate that casein kinase II-mediated phosphorylation of p65 subunit can enhance the transcriptional activity of NF-kappaB in vivo. This post-translational modification of the transcription factor can be responsible for increased NOSII gene transcription and NO production in tumor cells exposed to either IL-1beta or LPS.	Fac Med, Ecole Prat Hautes Etud, INSERM, U517,Canc Immunotherapy Lab, F-21079 Dijon, France; Fac Med, Inst Federat Rech IFR100, Lab Physiopathol & Pharmacol Cardiovasc Expt, F-21079 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut Agro; AgroSup Dijon; Universite de Bourgogne	Reveneau, S (corresponding author), Fac Med, Ecole Prat Hautes Etud, INSERM, U517,Canc Immunotherapy Lab, 7 Blvd Jeanne Arc,BP 87900, F-21079 Dijon, France.	sylvie.reveneau@u-bourgogne.fr	Pance, Alena/AAH-2878-2021	Pance, Alena/0000-0002-9017-2644; Solary, Eric/0000-0002-8629-1341				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; De Ridder M, 2003, BRIT J CANCER, V88, P120, DOI 10.1038/sj.bjc.6600678; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DONG ZY, 1994, CANCER RES, V54, P789; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Filhol O, 2003, MOL CELL BIOL, V23, P975, DOI 10.1128/MCB.23.3.975-987.2003; Gao JJ, 1998, J IMMUNOL, V161, P4803; Gerecitano J, 1999, J INTERF CYTOK RES, V19, P393, DOI 10.1089/107999099314108; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Ginis I, 2002, J CEREBR BLOOD F MET, V22, P142, DOI 10.1097/00004647-200202000-00002; Goldring CEP, 2000, FASEB J, V14, P2393; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Hassa PO, 2003, J BIOL CHEM, V278, P45145, DOI 10.1074/jbc.M307957200; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; KILBOURN RG, 1992, J NATL CANCER I, V84, P1672, DOI 10.1093/jnci/84.21.1672; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Lind DS, 1997, J SURG RES, V69, P283, DOI 10.1006/jsre.1997.5015; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Maxwell AJ, 2002, NITRIC OXIDE-BIOL CH, V6, P101, DOI 10.1006/niox.2001.0394; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Pahan K, 2001, J BIOL CHEM, V276, P7899, DOI 10.1074/jbc.M008262200; Pance A, 2002, FASEB J, V16, P631, DOI 10.1096/fj.01-0450fje; Perrella MA, 1999, J BIOL CHEM, V274, P9045, DOI 10.1074/jbc.274.13.9045; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sawada T, 1997, J IMMUNOL, V158, P5267; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Taylor BS, 2000, SHOCK, V13, P413, DOI 10.1097/00024382-200006000-00001; Van den Berge DL, 2001, BRIT J CANCER, V84, P1122, DOI 10.1054/bjoc.2000.1719; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	59	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23953	23960		10.1074/jbc.M313731200	http://dx.doi.org/10.1074/jbc.M313731200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15033982	hybrid			2022-12-25	WOS:000221702500016
J	Barker, TH; Pallero, MA; MacEwen, MW; Tilden, SG; Woods, A; Murphy-Ullrich, JE; Hagood, JS				Barker, TH; Pallero, MA; MacEwen, MW; Tilden, SG; Woods, A; Murphy-Ullrich, JE; Hagood, JS			Thrombospondin-1-induced focal adhesion disassembly in fibroblasts requires Thy-1 surface expression, lipid raft integrity, and Src activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; PROTEIN-TYROSINE KINASES; RECEPTOR-RELATED PROTEIN; LUNG FIBROBLASTS; GROWTH-FACTOR; DIFFERENTIAL EXPRESSION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; ANCHORED PROTEINS; SUBPOPULATIONS	The hep I peptide of thrombospondin-1 is known to induce the disassembly of focal adhesions, a critical step in regulating cellular adhesive changes needed for cell motility. Fibroblasts that are heterogeneous with respect to the surface expression of Thy-1 differ markedly in morphology, cytoskeletal organization, and migration, suggesting differential regulation of focal adhesion dynamics. Here we demonstrate that disassembly of focal adhesions mediated by both full-length thrombospondin-1 and the hep I peptide in fibroblasts requires the expression of Thy-1, although it does not appear to function as a stable member of the hep I receptor complex. Consistent with a known function of Thy-1 in regulating lipid raft-associated signaling, intact lipid rafts are necessary for hep I-mediated focal adhesion disassembly. Furthermore, we establish Src family kinase (SFK) activation as a novel component required for hep I-induced signaling leading to focal adhesion disassembly. hep I induces transient phosphorylation of SFKs in Thy-1-expressing fibroblasts only. Therefore, we conclude that Thy-1 surface expression is required for thrombospondin-1-induced focal adhesion disassembly in fibroblasts through an SFK-dependent mechanism. This represents a novel role for Thy-1 in the regulation of fibroblast-matrix interactions critical to tissue homeostasis and remodeling.	Univ Alabama Birmingham, Dept Pediat, Div Pulm, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Adhes, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Matrix Res Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Biomed Implant Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Engn, Dept Biomed Engn, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Hagood, JS (corresponding author), Univ Alabama Birmingham, Dept Pediat, Div Pulm, 1600 7th Ave S, Birmingham, AL 35294 USA.	Jhagood@peds.uab.edu			NHLBI NIH HHS [HL65348] Funding Source: Medline; NIAMS NIH HHS [P60 AR 20614, AR46378] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614, R03AR046378] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; Barker TH, 2004, EXP CELL RES, V295, P488, DOI 10.1016/j.yexcr.2004.01.026; Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Borrello MA, 1996, CELL IMMUNOL, V173, P198, DOI 10.1006/cimm.1996.0268; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; Durrheim GA, 2001, CELL BIOL INT, V25, P33, DOI 10.1006/cbir.2000.0675; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; FIRER MA, 1995, ISRAEL J MED SCI, V31, P382; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Goicoechea S, 2002, J BIOL CHEM, V277, P37219, DOI 10.1074/jbc.M202200200; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; Greenwood JA, 1998, J BIOL CHEM, V273, P1755, DOI 10.1074/jbc.273.3.1755; Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; Haeryfar SMM, 2001, INT IMMUNOPHARMACOL, V1, P689, DOI 10.1016/S1567-5769(01)00002-9; Hagood JS, 2002, AM J RESP CELL MOL, V26, P702, DOI 10.1165/ajrcmb.26.6.4547; Hagood JS, 2001, CHEST, V120, p64S, DOI 10.1378/chest.120.1_suppl.S64; Hagood JS, 1999, AM J PHYSIOL-LUNG C, V277, pL218, DOI 10.1152/ajplung.1999.277.1.L218; HE HT, 1991, J EXP MED, V173, P515, DOI 10.1084/jem.173.2.515; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; LANCKI DW, 1995, J IMMUNOL, V154, P4363; Leyton L, 2001, CURR BIOL, V11, P1028, DOI 10.1016/S0960-9822(01)00262-7; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; MCINTOSH JC, 1994, EUR RESPIR J, V7, P2131, DOI 10.1183/09031936.94.07122131; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; NarisawaSaito M, 1996, CLIN EXP IMMUNOL, V106, P86, DOI 10.1046/j.1365-2249.1996.d01-800.x; Orr AW, 2003, J CELL BIOL, V161, P1179, DOI 10.1083/jcb.200302069; Orr AW, 2002, J BIOL CHEM, V277, P20453, DOI 10.1074/jbc.M112091200; PENNEY DP, 1992, ANAT RECORD, V232, P432, DOI 10.1002/ar.1092320312; PHIPPS RP, 1989, AM J RESP CELL MOL, V1, P65, DOI 10.1165/ajrcmb/1.1.65; Saalbach A, 2000, J INVEST DERMATOL, V115, P882, DOI 10.1046/j.1523-1747.2000.00104.x; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; STEFANOVA I, 1991, J IMMUNOL, V147, P1587; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; TIVERON MC, 1992, NATURE, V355, P745, DOI 10.1038/355745a0; TIVERON MC, 1994, J CELL SCI, V107, P1783	41	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23510	23516		10.1074/jbc.M402169200	http://dx.doi.org/10.1074/jbc.M402169200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15033989	hybrid			2022-12-25	WOS:000221570900089
J	Jha, BK; Mitra, N; Rana, R; Surolia, A; Salunke, DM; Datta, K				Jha, BK; Mitra, N; Rana, R; Surolia, A; Salunke, DM; Datta, K			pH and cation-induced thermodynamic stability of human hyaluronan binding protein 1 regulates its hyaluronan affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING FACTOR SF2; UNSTRUCTURED PROTEINS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; P-32 PROTEIN; CELL-SURFACE; LOCALIZATION; CARTILAGE; CLONING; GC1Q-R	Hyaluronan-binding protein 1 (HABP1) is a trimeric protein with high negative charges distributed asymmetrically along the faces of the molecule. Recently, we have reported that HABP1 exhibits a high degree of structural flexibility, which can be perturbed by ions under in vitro conditions near physiological pH (Jha, B. K., Salunke, D. M., and Datta, K. ( 2003) J. Biol. Chem. 278, 27464 - 27472). Here, we report the effect of ionic strength and pH on thermodynamic stability of HABP1. Trimeric HABP1 was shown to unfold reversibly upon dissociation ruling out the possibility of existence of folded monomer. An increase in ionic concentration (0.05 - 1 M) or decrease in pH ( pH 8.0 - pH 5.0) induced an unusually high thermodynamic stability of HABP1 as reflected in the gradual increase in transition midpoint temperature, enthalpy of transition, and conformational entropy. Our studies suggest that the presence of counter ions in the molecular environment of HABP1 leads to dramatic reduction of the intramolecular electrostatic repulsion either by de-ionizing the charged amino acid residues or by direct binding leading to a more stable conformation. A regulation on cellular HA-HABP1 interaction by changes in pH and ionic strength may exist, because the more stable conformation attained at higher ionic strength or at acidic pH showed maximum affinity toward HA as probed either in solid phase binding assay on HA-immobilized plates or an in-solution binding assay using intrinsic fluorescence of HABP1.	Jawaharlal Nehru Univ, SES, Biochem Lab 103, New Delhi 110067, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Natl Inst Immunol, Struct Biol Unit, New Delhi 110067, India; Jawaharlal Nehru Univ, Special Ctr Mol Med, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi; Indian Institute of Science (IISC) - Bangalore; Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Jawaharlal Nehru University, New Delhi	Datta, K (corresponding author), Jawaharlal Nehru Univ, SES, Biochem Lab 103, New Delhi 110067, India.	kdatta@mail.jnu.ac.in	jha, babal k/B-1803-2010; SUROLIA, AVADESHA/C-5442-2009	jha, babal k/0000-0002-7660-5255; Mitra, Nivedita/0000-0003-3799-5681				Apetri AC, 2003, J BIOL CHEM, V278, P22187, DOI 10.1074/jbc.M302130200; Backmann J, 1998, J MOL BIOL, V284, P817, DOI 10.1006/jmbi.1998.2216; BAGSHAW CR, 1988, SPECTROPHOTOMETRY SP, P91; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Deb TB, 1996, J BIOL CHEM, V271, P2206, DOI 10.1074/jbc.271.4.2206; DSOUZA M, 1985, BIOCHEM INT, V10, P43; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; FRASER JRE, 1996, EXTRACELLULAR MATRIX, V2, P141; FREIRE E, 1978, BIOPOLYMERS, V17, P1257, DOI 10.1002/bip.1978.360170512; Fukuda K, 1996, J PHARMACOL EXP THER, V277, P1672; Ghebrehiwet B, 2002, IMMUNOBIOLOGY, V205, P421, DOI 10.1078/0171-2985-00143; Ghebrehiwet B, 2001, IMMUNOL REV, V180, P65, DOI 10.1034/j.1600-065X.2001.1800106.x; Ghebrehiwet B, 1998, IMMUNOBIOLOGY, V199, P225, DOI 10.1016/S0171-2985(98)80029-6; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; GITTELMAN MS, 1990, BIOCHEMISTRY-US, V29, P7011, DOI 10.1021/bi00482a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; GUPTA S, 1991, EUR J CELL BIOL, V56, P58; GUPTA S, 1991, EXP CELL RES, V195, P386, DOI 10.1016/0014-4827(91)90388-B; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; Jekow P, 1999, EUR J BIOCHEM, V264, P724, DOI 10.1046/j.1432-1327.1999.00601.x; Jha BK, 2003, J BIOL CHEM, V278, P27464, DOI 10.1074/jbc.M206696200; Jha BK, 2002, EUR J BIOCHEM, V269, P298, DOI 10.1046/j.0014-2956.2001.02654.x; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Li X, 2000, Genome Inform Ser Workshop Genome Inform, V11, P172; Lommer BS, 2002, J BIOL CHEM, V277, P7108, DOI 10.1074/jbc.M109045200; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; McCrary BS, 1996, J MOL BIOL, V264, P784, DOI 10.1006/jmbi.1996.0677; Nishimura C, 2001, BIOCHEMISTRY-US, V40, P2113, DOI 10.1021/bi000861k; Pace CN, 1995, METHOD ENZYMOL, V259, P538; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; RANGANATHAN S, 1994, MOL REPROD DEV, V38, P69, DOI 10.1002/mrd.1080380112; Ranganathan S, 1995, CELL MOL BIOL RES, V41, P467; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Salminen T, 1996, PROTEIN SCI, V5, P1014; Saunders AJ, 2000, BIOPOLYMERS, V53, P293, DOI 10.1002/(SICI)1097-0282(20000405)53:4<293::AID-BIP2>3.3.CO;2-K; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; Srinivas VR, 2001, BBA-GEN SUBJECTS, V1527, P102, DOI 10.1016/S0304-4165(01)00153-2; STURTEVANT JM, 1981, BIOCHEMISTRY-US, V20, P3792, DOI 10.1021/bi00516a019; Swaminathan CP, 1998, J AM CHEM SOC, V120, P5153, DOI 10.1021/ja9733696; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; XIE D, 1993, J MOL BIOL, V232, P5, DOI 10.1006/jmbi.1993.1364	51	8	8	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23061	23072		10.1074/jbc.M310676200	http://dx.doi.org/10.1074/jbc.M310676200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15004022	hybrid			2022-12-25	WOS:000221570900035
J	Kuo, WL; Duke, CJ; Abe, MK; Kaplan, EL; Gomes, S; Rosner, MR				Kuo, WL; Duke, CJ; Abe, MK; Kaplan, EL; Gomes, S; Rosner, MR			ERK7 expression and kinase activity is regulated by the ubiquitin-proteosome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PROTEASOME PATHWAY; DEGRADATION; COMPLEX; LIGASE; FAMILY; DOMAIN; MEMBER; SCF	ERK7 is a unique member of the extracellular signal-regulated kinase (ERK) subfamily of MAP kinases. Although ERK7 shares a TEY motif in the activation loop of the kinase, it displays constitutive activation, nuclear localization, and growth inhibitory properties that are regulated by its C-terminal domain. Because ERK7 is expressed at low levels compared with ERK2 and its activity is dependent upon its expression level, we investigated the mechanism by which ERK7 expression is regulated. We now show that ERK7 expression is regulated by ubiquitination and rapid proteosomal turnover. Furthermore, both the kinase domain and the C-terminal tail are independently degraded at a rate comparable with that of the intact protein. Analysis of a series of chimeras between ERK2 and ERK7 reveal that the N-terminal 20 amino acids of the kinase domain are a primary determinant of ERK7 degradation. Fusion of the N-terminal 20 amino acids is both necessary and sufficient to cause proteolytic degradation of both ERK2 and green fluorescent protein. Finally, ERK7 is stabilized by an N-terminal mutant of Cullin-1 suggesting that ERK7 is ubiquitinated by the Skip1-Cullin-F box complex. These results indicate that ERK7 is a highly regulated enzyme whose cellular expression and kinase activation level is tightly controlled by the ubiquitinproteosome pathway.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60615 USA; Univ Chicago, Dept Pediat, Chicago, IL 60615 USA	University of Chicago; University of Chicago	Rosner, MR (corresponding author), Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60615 USA.	m-rosner@uchicago.edu			NHLBI NIH HHS [HL73132, HL07605] Funding Source: Medline; NIGMS NIH HHS [GM61038] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061038] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe MK, 2002, J BIOL CHEM, V277, P16733, DOI 10.1074/jbc.M112483200; Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Abe MK, 1999, MOL CELL BIOL, V19, P1301; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Brickley DR, 2002, J BIOL CHEM, V277, P43064, DOI 10.1074/jbc.M207604200; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Gaiano N, 1999, NAT NEUROSCI, V2, P812, DOI 10.1038/12186; Henrich LM, 2003, MOL CELL BIOL, V23, P5979, DOI 10.1128/MCB.23.17.5979-5988.2003; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	17	34	36	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23073	23081		10.1074/jbc.M313696200	http://dx.doi.org/10.1074/jbc.M313696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15033983	hybrid			2022-12-25	WOS:000221570900036
J	Moody, TW; Mantey, SA; Pradhan, TK; Schumann, M; Nakagawa, T; Martinez, A; Fuselier, J; Coy, DH; Jensen, RT				Moody, TW; Mantey, SA; Pradhan, TK; Schumann, M; Nakagawa, T; Martinez, A; Fuselier, J; Coy, DH; Jensen, RT			Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIN-RELEASING-PEPTIDE; LUNG-CANCER; EXPRESSED RECEPTORS; DOWN-REGULATION; BINDING-SITES; NEUROMEDIN-B; SUBTYPE 3; GROWTH; INTERNALIZATION; AUTOCRINE	Mammalian bombesin (BN) receptors are among those most frequently overexpressed by a number of common tumors including prostate, breast, lung, and colon cancers. The aim of this study was to develop a camptothecin-bombesin (CPT-BN) conjugate that interacts with all classes of BN receptors and possibly functions as a prodrug via a labile linker with site-specific cytotoxicity for cancer cells bearing these receptors. CPT was coupled to analogs of [D-Tyr(6), beta-Ala(11), Phe(13), Nle(14)] BN-(6 - 14) (BA0) using carbamate linkers (L1 and L2) with built-in nucleophile-assisted releasing groups for intracellular cleavage of free cytotoxic agents. One conjugate, CPT-L2-BA3, bound to all three BN receptor classes with high affinity and functioned as a full agonist at each. I-125-CPT-L2-BA3 was rapidly internalized by cells expressing each BN receptor class and, using fluorescent imaging, was found to co-localize with BN receptors initially and later to be internalized in cytoplasmic compartments. HPLC analysis of internalized ligand showed that 40% was intact, 25% was metabolized by releasing free CPT, and 35% was metabolized to other breakdown products. CPT-L2-BA3 inhibited the growth of NCI-H1299 non-small cell lung cancer cells in 3-(4,5-dimethylthiazol-2- yl)- 2.5-diphenyl-2H-tetrazolium bromide (MTT) and clonal growth assays. CPT-L2-BA3 was cytotoxic in an MTT assay for cells transfected with each class of BN receptor; however, it had significantly less effect in cells lacking BN receptors. These results indicate that CTP-L2-BA3 is a potent agonist that is cytotoxic for cells overexpressing any of the three BN receptor classes and functions as a prodrug for receptor-mediated cytoxicity. It therefore should be a useful prototype to explore the effectiveness of tumor-specific cytotoxicity delivery using a receptor-mediated mechanism.	NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20892 USA; Tulane Univ, Hlth Sci Ctr, Dept Med, Peptide Res Labs, New Orleans, LA 70112 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tulane University	Jensen, RT (corresponding author), NIDDK, Digest Dis Branch, NIH, Bldg 10,Rm 9C203,10 Ctr Dr MSC 1804, Bethesda, MD 20892 USA.	robertj@intra.niddk.nih.gov	Martinez, Alfredo/GQH-5998-2022; Schumann, Michael/K-6426-2013	Martinez, Alfredo/0000-0003-4882-4044; Schumann, Michael/0000-0001-6391-9979	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK053100, ZIADK053100] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akeson M, 1997, J BIOL CHEM, V272, P17405, DOI 10.1074/jbc.272.28.17405; BENYA RV, 1992, MOL PHARMACOL, V42, P1058; BENYA RV, 1994, MOL PHARMACOL, V46, P235; BENYA RV, 1995, MOL PHARMACOL, V47, P10; Bunnett NW, 1996, HISTOCHEM J, V28, P811, DOI 10.1007/BF02272154; Cha SW, 2000, TOXICOL LETT, V115, P173, DOI 10.1016/S0378-4274(00)00176-4; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; de Groot FMH, 2001, CURR MED CHEM, V8, P1093; Dubowchik GM, 1999, PHARMACOL THERAPEUT, V83, P67, DOI 10.1016/S0163-7258(99)00018-2; Fuselier JA, 2003, BIOORG MED CHEM LETT, V13, P799, DOI 10.1016/S0960-894X(03)00016-7; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; GUINEE DG, 1994, AM J CLIN PATHOL, V102, P406, DOI 10.1093/ajcp/102.4.406; Hoffman TJ, 2001, NUCL MED BIOL, V28, P527, DOI 10.1016/S0969-8051(01)00209-8; JENSEN RT, 1983, AM J PHYSIOL, V245, pG186, DOI 10.1152/ajpgi.1983.245.2.G186; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; Kwekkeboom D, 2000, J NUCL MED, V41, P1704; Langer M., 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P71, DOI 10.2174/1568011013354877; Lango MN, 2002, J NATL CANCER I, V94, P375; MAHMOUD S, 1991, CANCER RES, V51, P1798; MANTEY S, 1993, MOL PHARMACOL, V43, P762; Mantey SA, 1997, J BIOL CHEM, V272, P26062, DOI 10.1074/jbc.272.41.26062; Moody TW, 2003, CURR PHARM DESIGN, V9, P495, DOI 10.2174/1381612033391621; MOODY TW, 1995, LIFE SCI, V56, P521, DOI 10.1016/0024-3205(94)00481-7; Moody TW, 1996, J CELL BIOCHEM, P247; Patterson LH, 1999, ANTI-CANCER DRUG DES, V14, P473; Pradhan TK, 1998, EUR J PHARMACOL, V343, P275, DOI 10.1016/S0014-2999(97)01527-6; PRESTON SR, 1993, CANCER RES, V53, P5090; PRESTON SR, 1995, BRIT J CANCER, V71, P1087, DOI 10.1038/bjc.1995.210; Reubi JC, 2003, ENDOCR REV, V24, P389, DOI 10.1210/er.2002-0007; Reubi JC, 2002, CLIN CANCER RES, V8, P1139; Schally AV, 2003, LIFE SCI, V72, P2305, DOI 10.1016/S0024-3205(03)00113-9; Schally AV, 1999, EUR J ENDOCRINOL, V141, P1, DOI 10.1530/eje.0.1410001; Schally AV, 2001, FRONT NEUROENDOCRIN, V22, P248, DOI 10.1006/frne.2001.0217; Siegfried JM, 1999, PULM PHARMACOL THER, V12, P291, DOI 10.1006/pupt.1999.0210; SLICE LW, 1994, J BIOL CHEM, V269, P21755; Slice LW, 1998, RECEPTOR CHANNEL, V6, P201; Sun BD, 2000, REGUL PEPTIDES, V90, P77, DOI 10.1016/S0167-0115(00)00114-2; Tokita K, 2002, MOL PHARMACOL, V61, P1435, DOI 10.1124/mol.61.6.1435; VARGA JM, 1977, NATURE, V267, P56, DOI 10.1038/267056a0; Williams BY, 1998, MOL PHARMACOL, V54, P889, DOI 10.1124/mol.54.5.889; Wu JM, 1996, MOL PHARMACOL, V50, P1355; ZACHARY I, 1987, EMBO J, V6, P2233, DOI 10.1002/j.1460-2075.1987.tb02495.x	42	73	74	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23580	23589		10.1074/jbc.M401938200	http://dx.doi.org/10.1074/jbc.M401938200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15016826	hybrid			2022-12-25	WOS:000221570900098
J	Nienhaus, K; Kriegl, JM; Nienhaus, GU				Nienhaus, K; Kriegl, JM; Nienhaus, GU			Structural dynamics in the active site of murine neuroglobin and its effects on ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; HEME-PROTEINS; LOW PH; HEMOGLOBIN; EXPRESSION; MYOGLOBIN; BRAIN; PLANT; DETERMINANTS; CONNECTION	We have examined the effects of active site residues on ligand binding to the heme iron of mouse neuroglobin using steady-state and time-resolved visible spectroscopy. Absorption spectra of the native protein, mutants H64L and K67L and double mutant H64L/K67L were recorded for the ferric and ferrous states over a wide pH range (pH 4-11), which allowed us to identify a number of different species with different ligands at the sixth coordination, to characterize their spectroscopic properties, and to determine the pK values of active site residues. In flash photolysis experiments on CO-ligated samples, reaction intermediates and the competition of ligands for the sixth coordination were studied. These data provide insights into structural changes in the active site and the role of the key residues His(64) and Lys(67). His(64) interferes with exogenous ligand access to the heme iron. Lys(67) sequesters the distal pocket from the solvent. The heme iron is very reactive, as inferred from the fast ligand binding kinetics and the ability to bind water or hydroxyl ligands to the ferrous heme. Fast bond formation favors geminate rebinding; yet the large fraction of bimolecular rebinding observed in the kinetics implies that ligand escape from the distal pocket is highly efficient. Even slight pH variations cause pronounced changes in the association rate of exogenous ligands near physiological pH, which may be important in functional processes.	Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Ulm, Dept Biophys, D-89081 Ulm, Germany	University of Illinois System; University of Illinois Urbana-Champaign; Ulm University	Nienhaus, GU (corresponding author), Univ Illinois, Dept Phys, 1110 W Green, Urbana, IL 61801 USA.	uli@uiuc.edu	Nienhaus, Gerd Ulrich/G-8698-2012	Nienhaus, Gerd Ulrich/0000-0002-5027-3192				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Arredondo-Peter R, 1998, PLANT PHYSIOL, V118, P1121, DOI 10.1104/pp.118.4.1121; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Bhattacharya S, 1997, BIOPHYS J, V73, P3230, DOI 10.1016/S0006-3495(97)78348-6; BOSCHCOV P, 1983, BIOORG CHEM, V12, P34, DOI 10.1016/0045-2068(83)90005-6; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Du WH, 2003, J AM CHEM SOC, V125, P8080, DOI 10.1021/ja034584r; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; Eaton W A, 1981, Methods Enzymol, V76, P175; GERSONDE K, 1986, EUR J BIOCHEM, V157, P393, DOI 10.1111/j.1432-1033.1986.tb09681.x; Hankeln T, 2002, J BIOL CHEM, V277, P29012, DOI 10.1074/jbc.M204009200; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Hvitved AN, 2001, J BIOL CHEM, V276, P34714, DOI 10.1074/jbc.M105175200; Johnson JB, 1996, BIOPHYS J, V71, P1563, DOI 10.1016/S0006-3495(96)79359-1; Kriegl JM, 2002, P NATL ACAD SCI USA, V99, P7992, DOI 10.1073/pnas.082244399; Lamb DC, 1998, J AM CHEM SOC, V120, P2981, DOI 10.1021/ja973781l; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Lide D.R., 1994, CRC HDB CHEM PHYS; Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203; Muller JD, 1999, BIOPHYS J, V77, P1036, DOI 10.1016/S0006-3495(99)76954-7; Nienhaus GU, 1997, PHYSICA D, V107, P297, DOI 10.1016/S0167-2789(97)00097-3; NIENHAUS GU, 1992, P NATL ACAD SCI USA, V89, P2902, DOI 10.1073/pnas.89.7.2902; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9647, DOI 10.1021/bi034788k; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; PEYTON DH, 1988, BIOCHIM BIOPHYS ACTA, V954, P82, DOI 10.1016/0167-4838(88)90058-1; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; SAGE JT, 1991, BIOCHEMISTRY-US, V30, P1227, DOI 10.1021/bi00219a010; SAGE JT, 1991, BIOCHEMISTRY-US, V30, P1237, DOI 10.1021/bi00219a011; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Uno T, 2004, J BIOL CHEM, V279, P5886, DOI 10.1074/jbc.M311748200; VALLONE B, 2004, IN PRESS PROTEINS; Venis S, 2001, LANCET, V358, P2055, DOI 10.1016/S0140-6736(01)07148-3; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123; Zhu YH, 2002, BLOOD, V100, P2494, DOI 10.1182/blood-2002-01-0280	50	88	92	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22944	22952		10.1074/jbc.M401561200	http://dx.doi.org/10.1074/jbc.M401561200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15016813	hybrid			2022-12-25	WOS:000221570900021
J	Podojil, JR; Kin, NW; Sanders, VM				Podojil, JR; Kin, NW; Sanders, VM			CD86 and beta(2)-adrenergic receptor signaling pathways, respectively, increase Oct-2 and OCA-B expression and binding to the 3 '-IgH enhancer in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COSTIMULATORY MOLECULES B7-1; ANTIBODY-RESPONSES; RISK-ASSESSMENT; TRANSCRIPTION; ACTIVATION; IMMUNE; LIGAND; CD40; NOREPINEPHRINE	Stimulation of CD86 (formerly known as B7-2) and/or the beta(2)-adrenergic receptor on a CD40 ligand/interleukin-4-activated B cell increased the rate of mature IgG(1) transcription. To identify the mechanism responsible for this effect, we determined whether CD86 and/or beta(2)-adrenergic receptor stimulation regulated transcription factor expression and binding to the 3'-IgH enhancer in vitro and in vivo. We showed that CD86 stimulation increased the nuclear localization of NF-kappaB1 (p50) and phosphorylated RelA (p65) and increased Oct-2 expression and binding to the 3'-IgH enhancer, in a protein kinase C-dependent manner. These effects were lost when CD86-deficient or NF-kappaB1-deficient B cells were used. CD86 stimulation also increased the level of IkappaB-alpha phosphorylation but in a protein kinase C-independent manner. beta(2)-Adrenergic receptor stimulation increased CREB phosphorylation, OCA-B expression, and OCA-B binding to the 3'-IgH enhancer in a protein kinase A-dependent manner, an effect lost when beta(2)-adrenergic receptor-deficient B cells were used. Also, the beta(2)-adrenergic receptor-induced increase in the level of mature IgG1 transcript was lost when OCA-B-deficient B cells were used. These data are the first to show that CD86 stimulation up-regulates the expression of the transcription factor Oct-2 in a protein kinase C- and NF-kappaB1-dependent manner, and that beta(2)-adrenergic receptor stimulation up-regulates the expression of the coactivator OCA-B in a protein kinase A-dependent manner to cooperate with Oct-2 binding to the 3'-IgH enhancer.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Sanders, VM (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, 2194 Graves Hall,333 W 10th St, Columbus, OH 43210 USA.	Sanders.302@osu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037326, T32AI055411, R29AI037326, R01AI047420] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37326, T32 AI55411, AI47420] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Bendall HH, 1997, J BIOL CHEM, V272, P28826, DOI 10.1074/jbc.272.46.28826; BERBERICH I, 1994, J IMMUNOL, V153, P4357; CHU CC, 1993, J EXP MED, V178, P1381, DOI 10.1084/jem.178.4.1381; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Ferguson SE, 1996, J IMMUNOL, V156, P4576; FINE DP, 1988, J LAB CLIN MED, V112, P487; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; Goldstein MD, 1996, MOL IMMUNOL, V33, P541, DOI 10.1016/0161-5890(96)00005-3; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; Hathcock KS, 1996, ADV IMMUNOL, V62, P131, DOI 10.1016/S0065-2776(08)60429-0; Jeannin P, 1997, J BIOL CHEM, V272, P15613, DOI 10.1074/jbc.272.25.15613; Kaku H, 2002, INT IMMUNOL, V14, P1055, DOI 10.1093/intimm/dxf072; Kasprowicz DJ, 2000, J IMMUNOL, V165, P680, DOI 10.4049/jimmunol.165.2.680; Khamlichi AA, 2000, ADV IMMUNOL, V75, P317, DOI 10.1016/S0065-2776(00)75008-5; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; Kim U, 2000, J IMMUNOL, V165, P6825, DOI 10.4049/jimmunol.165.12.6825; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; Kohm AP, 2000, J IMMUNOL, V165, P725, DOI 10.4049/jimmunol.165.2.725; Kohm AP, 2000, IMMUNOL TODAY, V21, P539, DOI 10.1016/S0167-5699(00)01747-3; Kohm AP, 1999, J IMMUNOL, V162, P5299; Kohm AP, 2002, J IMMUNOL, V168, P6314, DOI 10.4049/jimmunol.168.12.6314; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LAYTON JE, 1984, J EXP MED, V160, P1850, DOI 10.1084/jem.160.6.1850; LENSCHOW DJ, 1994, J IMMUNOL, V153, P1990; LENSCHOW DJ, 1993, P NATL ACAD SCI USA, V90, P11054, DOI 10.1073/pnas.90.23.11054; Lin SC, 1998, MOL CELL BIOL, V18, P5523, DOI 10.1128/MCB.18.9.5523; Lumsden JM, 2003, J IMMUNOL, V170, P781, DOI 10.4049/jimmunol.170.2.781; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUSTER MI, 1992, FUND APPL TOXICOL, V18, P200, DOI 10.1016/0272-0590(92)90047-L; LUSTER MI, 1993, FUND APPL TOXICOL, V21, P71, DOI 10.1006/faat.1993.1074; NOELLE RJ, 1991, FASEB J, V5, P2770, DOI 10.1096/fasebj.5.13.1833257; Pinaud E, 2001, IMMUNITY, V15, P187, DOI 10.1016/S1074-7613(01)00181-9; Podojil JR, 2003, J IMMUNOL, V170, P5143, DOI 10.4049/jimmunol.170.10.5143; ROBBINS JB, 1995, J INFECT DIS, V171, P1387, DOI 10.1093/infdis/171.6.1387; ROY M, 1995, EUR J IMMUNOL, V25, P596, DOI 10.1002/eji.1830250243; Sanders V. M., 2001, PSYCHONEUROIMMUNOLOG, V1, P161; Sanders VM, 1997, J IMMUNOL, V158, P4200; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; STACK RM, 1994, J IMMUNOL, V152, P5723; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; Stevens S, 2000, J IMMUNOL, V164, P6372, DOI 10.4049/jimmunol.164.12.6372; Stevens S, 2000, J IMMUNOL, V164, P5306, DOI 10.4049/jimmunol.164.10.5306; Suvas S, 2002, J BIOL CHEM, V277, P7766, DOI 10.1074/jbc.M105902200; Warren WD, 1999, MOL IMMUNOL, V36, P31, DOI 10.1016/S0161-5890(98)00114-X; Wolf I, 1998, J BIOL CHEM, V273, P28831, DOI 10.1074/jbc.273.44.28831	50	56	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23394	23404		10.1074/jbc.M313096200	http://dx.doi.org/10.1074/jbc.M313096200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15024018	hybrid			2022-12-25	WOS:000221570900075
J	Rahaman, A; Srinivasan, N; Shamala, N; Shaila, MS				Rahaman, A; Srinivasan, N; Shamala, N; Shaila, MS			Phosphoprotein of the rinderpest virus forms a tetramer through a coiled coil region important for biological function - A structural insight	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; RESPIRATORY SYNCYTIAL VIRUS; CASEIN KINASE-II; N-TERMINAL DOMAIN; P-PROTEIN; ACIDIC DOMAIN; TRANSCRIPTIONAL ACTIVITY; RNA-POLYMERASE; PHOSPHORYLATION; COMPLEX	Phosphoprotein ( P) of negative sense RNA viruses functions as a transcriptional transactivator of the viral polymerase ( L). We report here the characterization of oligomeric P protein of rinderpest virus (RPV) and provide a structural basis for its multimerization. By size exclusion chromatography and dynamic light scattering analyses we show that bacterially expressed P protein exists as an oligomer, thus excluding the role of phosphorylation in P protein oligomerization. Gel filtration analyses of various parts of the P protein, also expressed in Escherichia coli, revealed that the predicted coiled coil region in the C-terminal domain is responsible for P protein oligomerization. Dynamic light scattering analysis confirmed the oligomeric nature of the coiled coil region of P. Chemical cross-linking analysis suggested that the C-terminal coiled coil region exists as a tetramer. The tetramer is formed by coiled coil interaction as shown by circular dichroism spectral analysis. Based on sequence homology, we propose a three-dimensional structure of the multimerization domain of RPV P using the crystal structure for multimerization domain of sendai virus (SeV) P as a template. Four-stranded coiled coil structure of the model is stabilized by a series of interactions predominantly between short nonpolar side chains emerging from different strands. In an in vivo replication/transcription system using a synthetic minigenome of RPV, we show that multimerization is essential for P protein function(s), and the multimerization domain is highly conserved between two morbilliviruses namely RPV and peste de petits ruminants virus. These results are discussed in the context of biological functions of P protein among various negative-stranded RNA viruses.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Phys, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Shaila, MS (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	shaila@mcbl.iisc.ernet.in						Akey DL, 2001, BIOCHEMISTRY-US, V40, P6352, DOI 10.1021/bi002829w; Asenjo A, 2000, FEBS LETT, V467, P279, DOI 10.1016/S0014-5793(00)01171-6; BANERJEE AK, 1987, CELL, V48, P363, DOI 10.1016/0092-8674(87)90184-X; BARIK S, 1992, P NATL ACAD SCI USA, V89, P6570, DOI 10.1073/pnas.89.14.6570; BARIK S, 1995, VIROLOGY, V213, P405, DOI 10.1006/viro.1995.0013; Baron MD, 1997, J VIROL, V71, P1265, DOI 10.1128/JVI.71.2.1265-1271.1997; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Chattopadhyay A, 2004, VIRUS GENES, V28, P169, DOI 10.1023/B:VIRU.0000016855.25662.95; Chattopadhyay D, 1997, VIROLOGY, V239, P11, DOI 10.1006/viro.1997.8838; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Choudhary SK, 2002, VIROLOGY, V302, P373, DOI 10.1006/viro.2002.1668; Curran J, 1999, ADV VIRUS RES, V54, P403, DOI 10.1016/S0065-3527(08)60373-5; CURRAN J, 1995, J VIROL, V69, P849, DOI 10.1128/JVI.69.2.849-855.1995; Curran J, 1996, VIROLOGY, V221, P130, DOI 10.1006/viro.1996.0359; DAS T, 1995, J BIOL CHEM, V270, P24100, DOI 10.1074/jbc.270.41.24100; Dupuy LC, 1999, J VIROL, V73, P8384, DOI 10.1128/JVI.73.10.8384-8392.1999; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fields B. N, 1996, FIELDS VIROLOGY, V1, P1177; GAO Y, 1995, J VIROL, V69, P7718, DOI 10.1128/JVI.69.12.7718-7723.1995; Gao Y, 1996, BIOCHEMISTRY-US, V35, P14569, DOI 10.1021/bi9613133; GAO Y, 1995, EMBO J, V14, P1240, DOI 10.1002/j.1460-2075.1995.tb07107.x; Gigant B, 2000, J GEN VIROL, V81, P1757, DOI 10.1099/0022-1317-81-7-1757; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARTY RN, 1995, J GEN VIROL, V76, P2863, DOI 10.1099/0022-1317-76-11-2863; Karlin D, 2002, VIROLOGY, V296, P251, DOI 10.1006/viro.2001.1296; Kaushik R, 2004, J GEN VIROL, V85, P687, DOI 10.1099/vir.0.19702-0; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; Pattnaik AK, 1997, J VIROL, V71, P8167, DOI 10.1128/JVI.71.11.8167-8175.1997; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sedlmeier R, 1998, ADV VIRUS RES, V50, P101, DOI 10.1016/S0065-3527(08)60807-6; Shaji D, 1999, VIROLOGY, V258, P415, DOI 10.1006/viro.1999.9740; Spadafora D, 1996, J VIROL, V70, P4538, DOI 10.1128/JVI.70.7.4538-4548.1996; SRINIVASAN N, 1993, PROTEIN ENG, V6, P501, DOI 10.1093/protein/6.5.501; TAKACS AM, 1992, J VIROL, V66, P5842, DOI 10.1128/JVI.66.10.5842-5848.1992; Tarbouriech N, 2000, VIROLOGY, V266, P99, DOI 10.1006/viro.1999.0066; Tarbouriech N, 2000, NAT STRUCT BIOL, V7, P777; Villanueva N, 2000, J GEN VIROL, V81, P129, DOI 10.1099/0022-1317-81-1-129; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019	43	34	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23606	23614		10.1074/jbc.M400673200	http://dx.doi.org/10.1074/jbc.M400673200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15037604	hybrid			2022-12-25	WOS:000221570900101
J	Bahou, WF; Scudder, L; Rubenstein, D; Jesty, J				Bahou, WF; Scudder, L; Rubenstein, D; Jesty, J			A shear-restricted pathway of platelet procoagulant activity is regulated by IQGAP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN; THROMBIN; PROTEIN; CDC42; ACTIVATION; RAC1; RELEASE; DOMAIN	Circulating blood platelets regulate the initial phase of the hemostatic response through adhesive and aggregatory events and by providing the necessary procoagulant surface for prothrombinase complex assembly and thrombin generation. The signaling pathway(s) that regulate platelet procoagulant activity are largely unknown, although they are distinct from platelet aggregatory signals linked to fibrinogen ligation to the conformationally active alpha(IIB)beta(3) integrin. We describe a novel intracellular signaling mechanism involving platelet IQGAP1 that specifically regulates the development of platelet procoagulant activity under conditions of mechanical shear stress. Murine platelets that are deficient in IQGAP1 demonstrate increased prothrombinase activity compared with wild-type littermate controls when activated by a physiological shear stress of 16 dynes/cm(2) (shear rates of 1600 s(-1)) (p < 0.0001), corresponding to similar to 2.5 times the normal shear stress, or similar to 40% degree of stenosis in coronary arteries. The exaggerated prothrombinase activity is not associated with enhanced platelet microvesiculation ( cytoskeletal proteolysis) and occurs independently of the intracellular calcium release, [Ca2+](i), but it is specifically coupled to the alpha-granule exocytic pathway without concomitant effects on aminophospholipid exposure. These observations identify platelet IQGAP1 as an important modulator of normal hemostasis and as an appropriate pharmacological target for control of platelet procoagulant function.	SUNY Stony Brook, Hlth Sci Ctr T15 040, Div Hematol, Dept Med, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; SUNY Stony Brook, Genet Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bahou, WF (corresponding author), SUNY Stony Brook, Hlth Sci Ctr T15 040, Div Hematol, Dept Med, Stony Brook, NY 11794 USA.	wbahou@notes.cc.sunysb.edu	Rubenstein, David/H-3570-2011	Rubenstein, David/0000-0002-9495-9049	NHLBI NIH HHS [HL49141, HL53665] Funding Source: Medline; PHS HHS [M01 10710-5] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049141, R01HL053665] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberio L, 2000, BLOOD, V95, P1694, DOI 10.1182/blood.V95.5.1694.005k24_1694_1702; Andersen H, 1999, P NATL ACAD SCI USA, V96, P11189, DOI 10.1073/pnas.96.20.11189; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Brill S, 1996, MOL CELL BIOL, V16, P4869; Bucki R, 1998, BIOCHEMISTRY-US, V37, P15383, DOI 10.1021/bi9805238; DACHARYPRIGENT J, 1995, BIOCHEMISTRY-US, V34, P11625, DOI 10.1021/bi00036a039; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; GAFFET P, 1995, BIOCHEMISTRY-US, V34, P10448; Gnatenko DV, 2003, BLOOD, V101, P2285, DOI 10.1182/blood-2002-09-2797; Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515; HO YH, 2004, J BIOL CHEM, V274, P464; Jesty J, 2003, PLATELETS, V14, P143, DOI 10.1080/0953710031000092839; Jesty J, 1999, ANAL BIOCHEM, V272, P64, DOI 10.1006/abio.1999.4148; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li SH, 2000, MOL CELL BIOL, V20, P697, DOI 10.1128/MCB.20.2.697-701.2000; Li ZG, 2003, J BIOL CHEM, V278, P4347, DOI 10.1074/jbc.M208579200; MACNEIL S, 1984, BIOSCIENCE REP, V4, P643, DOI 10.1007/BF01121017; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; Miyazaki Y, 1996, BLOOD, V88, P3456, DOI 10.1182/blood.V88.9.3456.bloodjournal8893456; Osman MA, 2002, J CELL BIOL, V159, P601, DOI 10.1083/jcb.200205084; Reed GL, 2000, BLOOD, V96, P3334; Schmidt VA, 2003, BLOOD, V101, P3021, DOI 10.1182/blood-2002-09-2807; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692	31	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22571	22577		10.1074/jbc.M402561200	http://dx.doi.org/10.1074/jbc.M402561200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15026422	hybrid			2022-12-25	WOS:000221417100108
J	Iwanyshyn, WM; Han, GS; Carman, GM				Iwanyshyn, WM; Han, GS; Carman, GM			Regulation of phospholipid synthesis in Saccharomyces cerevisiae by zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DIACYLGLYCEROL PYROPHOSPHATE PHOSPHATASE; CDP-CHOLINE PATHWAY; PROTEIN-KINASE-A; PHOSPHATIDYLSERINE SYNTHASE ACTIVITY; COORDINATE REGULATION; PHOSPHATIDYLINOSITOL SYNTHASE; PHOSPHATIDYLCHOLINE SYNTHESIS; FUNCTIONAL-CHARACTERIZATION; STRUCTURAL GENE; CTP SYNTHETASE	Zinc is an essential nutrient required for the growth and metabolism of eukaryotic cells. In this work, we examined the effects of zinc depletion on the regulation of phospholipid synthesis in the yeast Saccharomyces cerevisiae. Zinc depletion resulted in a decrease in the activity levels of the CDP-diacylglycerol pathway enzymes phosphatidylserine synthase, phosphatidylserine decarboxylase, phosphatidylethanolamine methyltransferase, and phospholipid methyltransferase. In contrast, the activity of phosphatidylinositol synthase was elevated in response to zinc depletion. The level of Aut7p, a marker for the induction of autophagy, was also elevated in zinc-depleted cells. For the CHO1-encoded phosphatidylserine synthase, the reduction in activity in response to zinc depletion was controlled at the level of transcription. This regulation was mediated through the UAS(INO) element and by the transcription factors Ino2p, Ino4p, and Opi1p that are responsible for the inositol-mediated regulation of UAS(INO)-containing genes involved in phospholipid synthesis. Analysis of the cellular composition of the major membrane phospholipids showed that zinc depletion resulted in a 66% decrease in phosphatidylethanolamine and a 29% increase in phosphatidylinositol. A zrt1Delta zrt2Delta mutant ( defective in the plasma membrane zinc transporters Zrt1p and Zrt2p) grown in the presence of zinc exhibited a phospholipid composition similar to that of wild type cells depleted for zinc. These results indicated that a decrease in the cytoplasmic levels of zinc was responsible for the alterations in phospholipid composition.	Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001; AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; ASHBURNER BP, 1995, P NATL ACAD SCI USA, V92, P9722, DOI 10.1073/pnas.92.21.9722; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BAELEE M, 1990, J BIOL CHEM, V265, P7221; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogdanov M, 1999, J BIOL CHEM, V274, P36827, DOI 10.1074/jbc.274.52.36827; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CARSON MA, 1984, J BIOL CHEM, V259, P6267; Choi HS, 2004, J BIOL CHEM, V279, P12081, DOI 10.1074/jbc.M400297200; Choi MG, 2003, J BIOL CHEM, V278, P23610, DOI 10.1074/jbc.M303337200; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; CLEJAN S, 1981, LIPIDS, V16, P454, DOI 10.1007/BF02535014; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; DRISCOLL ER, 1992, LIPIDS, V27, P972, DOI 10.1007/BF02535574; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; GAYNOR PM, 1990, BIOCHIM BIOPHYS ACTA, V1045, P156, DOI 10.1016/0005-2760(90)90145-N; GOMEZMUNOZ A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P49, DOI 10.1016/0005-2760(92)90200-F; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Griac P, 1999, NUCLEIC ACIDS RES, V27, P2043, DOI 10.1093/nar/27.9.2043; Guerinot ML, 1999, CURR OPIN PLANT BIOL, V2, P244, DOI 10.1016/S1369-5266(99)80042-9; HAID A, 1983, METHOD ENZYMOL, V96, P192; Han GS, 2004, J BIOL CHEM, V279, P5338, DOI 10.1074/jbc.M311779200; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HROMY MJ, 1986, J BIOL CHEM, V261, P15572; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jiranek V, 1998, MICROBIOL-UK, V144, P2739, DOI 10.1099/00221287-144-10-2739; JOHANNING GL, 1989, J NUTR, V119, P1654, DOI 10.1093/jn/119.11.1654; JOHNSTON CN, 2002, THESIS RUTGERS U NEW; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; KIYONO K, 1987, J BIOCHEM-TOKYO, V102, P1089, DOI 10.1093/oxfordjournals.jbchem.a122147; KLIG LS, 1984, P NATL ACAD SCI-BIOL, V81, P3816, DOI 10.1073/pnas.81.12.3816; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KODAKI T, 1987, J BIOL CHEM, V262, P15428; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; LAMPING E, 1995, GENETICS, V137, P55; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; LESTER RL, 1993, ADV LIPID RES, V26, P253; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2003, J BIOL CHEM, V278, P15065, DOI 10.1074/jbc.M300568200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; MENON AK, 1992, J BIOL CHEM, V267, P15277; Miyabe S, 2000, BIOCHEM BIOPH RES CO, V276, P879, DOI 10.1006/bbrc.2000.3580; MORASH SC, 1994, J BIOL CHEM, V269, P28769; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; NIES DH, 1995, J IND MICROBIOL, V14, P186, DOI 10.1007/BF01569902; NIKAWA J, 1987, EUR J BIOCHEM, V167, P7, DOI 10.1111/j.1432-1033.1987.tb13297.x; NIKAWA J, 1984, EUR J BIOCHEM, V143, P251, DOI 10.1111/j.1432-1033.1984.tb08366.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; Oshiro J, 2003, J BIOL CHEM, V278, P31495, DOI 10.1074/jbc.M305452200; Oshiro J, 2000, J BIOL CHEM, V275, P40887, DOI 10.1074/jbc.M008144200; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; Oteiza PL, 1996, P SOC EXP BIOL MED, V213, P85, DOI 10.3181/00379727-213-44040; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Park TS, 2003, J BIOL CHEM, V278, P20785, DOI 10.1074/jbc.M301394200; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULLER HJ, 1995, FEBS LETT, V370, P149, DOI 10.1016/0014-5793(95)00818-T; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Shen HF, 1996, J BIOL CHEM, V271, P789, DOI 10.1074/jbc.271.2.789; Sreenivas A, 2003, J BIOL CHEM, V278, P20673, DOI 10.1074/jbc.M300132200; Sreenivas A, 2001, J BIOL CHEM, V276, P29915, DOI 10.1074/jbc.M105147200; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; SUMMERS EF, 1988, GENETICS, V120, P909; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Wagner C, 1999, YEAST, V15, P843, DOI 10.1002/(SICI)1097-0061(199907)15:10A<843::AID-YEA424>3.0.CO;2-M; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; WALSH CT, 1994, ENVIRON HEALTH PERSP, V102, P5, DOI 10.2307/3431820; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WHITE MJ, 1991, J BIOL CHEM, V266, P863; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; WU WI, 1994, J BIOL CHEM, V269, P29495; WU WI, 1993, J BIOL CHEM, V268, P13830; Wu WI, 1996, BIOCHEMISTRY-US, V35, P3790, DOI 10.1021/bi952808f; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Yamashita S, 1997, BBA-LIPID LIPID MET, V1348, P228, DOI 10.1016/S0005-2760(97)00102-1; Yu Y, 2002, J BIOL CHEM, V277, P34978, DOI 10.1074/jbc.M205316200; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	136	68	69	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21976	21983		10.1074/jbc.M402047200	http://dx.doi.org/10.1074/jbc.M402047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15028711	hybrid			2022-12-25	WOS:000221417100038
J	Koch, M; Schulze, J; Hansen, U; Ashwodt, T; Keene, DR; Brunken, WJ; Burgeson, RE; Bruckner, P; Bruckner-Tuderman, L				Koch, M; Schulze, J; Hansen, U; Ashwodt, T; Keene, DR; Brunken, WJ; Burgeson, RE; Bruckner, P; Bruckner-Tuderman, L			A novel marker of tissue junctions, collagen XXII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; ALPHA-7-BETA-1 INTEGRIN; MYOTENDINOUS JUNCTION; MUSCULAR-DYSTROPHY; FAMILY; EXPRESSION; IDENTIFICATION; DOMAIN; MEMBER; TENDON	Here we describe a novel specific component of tissue junctions, collagen XXII. It was first identified by screening an EST data base and subsequently expressed as a recombinant protein and characterized as an authentic tissue component. The COL22A1 gene on human chromosome 8q24.2 encodes a collagen that structurally belongs to the FACIT protein family (fibril-associated collagens with interrupted triple helices). Collagen XXII exhibits a striking restricted localization at tissue junctions such as the myotendinous junction in skeletal and heart muscle, the articular cartilage-synovial fluid junction, or the border between the anagen hair follicle and the dermis in the skin. It is deposited in the basement membrane zone of the myotendinous junction and the hair follicle and associated with the extrafibrillar matrix in cartilage. In situ hybridization of myotendinous junctions revealed that muscle cells produce collagen XXII, and functional tests demonstrated that collagen XXII acts as a cell adhesion ligand for skin epithelial cells and fibroblasts. This novel gene product, collagen XXII, is the first specific extracellular matrix protein present only at tissue junctions.	Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Boston, MA 02129 USA; Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Shriners Hosp Children, Portland, OR 97201 USA; Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA; Univ Munster, Dept Biochem, D-48129 Munster, Germany	University of Freiburg; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Cologne; Tufts University; Tufts University; Tufts University; University of Munster	Bruckner-Tuderman, L (corresponding author), Univ Freiburg, Dept Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	bruckner_tuderman@haut.ukl.uni-freiburg.de	Bruckner, Peter/F-4817-2019; Koch, Manuel/AAG-9914-2021	Bruckner, Peter/0000-0002-5566-5611; Koch, Manuel/0000-0002-2962-7814; Brunken, William J/0000-0001-7330-1814	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039502] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS039502, R01 NS039502-03, R01 NS39502] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; BAO ZZ, 1993, J CELL SCI, V106, P579; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; Brent AE, 2003, CELL, V113, P235, DOI 10.1016/S0092-8674(03)00268-X; Chiquet M, 2003, MATRIX BIOL, V22, P73, DOI 10.1016/S0945-053X(03)00004-0; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; Dogic D, 1999, CURR TOPICS PATHOL, V93, P75; Edom-Vovard F, 2002, DEV BIOL, V247, P351, DOI 10.1006/dbio.2002.0707; Edom-Vovard F, 2001, MECH DEVELOP, V108, P203, DOI 10.1016/S0925-4773(01)00483-X; Fitzgerald J, 2001, FEBS LETT, V505, P275, DOI 10.1016/S0014-5793(01)02754-5; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; Kardon G, 1998, DEVELOPMENT, V125, P4019; Kassner A, 2003, MATRIX BIOL, V22, P131, DOI 10.1016/S0945-053X(03)00008-8; Klatt AR, 2000, J BIOL CHEM, V275, P3999, DOI 10.1074/jbc.275.6.3999; Koch M, 2000, J CELL BIOL, V151, P221, DOI 10.1083/jcb.151.2.221; KOCH M, 1995, J CELL BIOL, V130, P1005, DOI 10.1083/jcb.130.4.1005; Koch M, 2001, J BIOL CHEM, V276, P23120, DOI 10.1074/jbc.M009912200; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; Miosge N, 1999, LAB INVEST, V79, P1591; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nawrotzki R, 2003, HUM MOL GENET, V12, P483, DOI 10.1093/hmg/ddg047; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; Panteleyev AA, 2001, J CELL SCI, V114, P3419; Paulsson M, 1999, BIOCHEM SOC T, V27, P824, DOI 10.1042/bst0270824; Pegoraro E, 2002, AM J PATHOL, V160, P2135, DOI 10.1016/S0002-9440(10)61162-5; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; Sato K, 2002, J BIOL CHEM, V277, P37678, DOI 10.1074/jbc.M205347200; Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051; Vainzof M, 2003, BRAZ J MED BIOL RES, V36, P543, DOI 10.1590/S0100-879X2003000500001; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; WU JJ, 1992, J BIOL CHEM, V267, P23007	40	122	127	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22514	22521		10.1074/jbc.M400536200	http://dx.doi.org/10.1074/jbc.M400536200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016833	Green Accepted, hybrid			2022-12-25	WOS:000221417100102
J	Nimonkar, AV; Boehmer, PE				Nimonkar, AV; Boehmer, PE			Role of protein-protein interactions during herpes simplex virus type 1 recombination-dependent replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ORIGIN-BINDING-PROTEIN; HELICASE-PRIMASE; FUNCTIONAL INTERACTION; UL8 SUBUNIT; IN-VITRO; POLYMERASE; BACTERIOPHAGE-T7; ICP8; FORK	Recombination-dependent replication is an integral part of the process by which double-strand DNA breaks are repaired to maintain genome integrity. It also serves as a means to replicate genomic termini. We reported previously on the reconstitution of a recombination-dependent replication system using purified herpes simplex virus type 1 proteins (Nimonkar A. V., and Boehmer, P. E. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 10201 10206). In this system, homologous pairing by the viral single-strand DNA-binding protein (ICP8) is coupled to DNA synthesis by the viral DNA polymerase and helicase-primase in the presence of a DNA-relaxing enzyme. Here we show that DNA synthesis in this system is dependent on the viral polymerase processivity factor (UL42). Moreover, although DNA synthesis is strictly dependent on topoisomerase I, it is only stimulated by the viral helicase in a manner that requires the helicase-loading protein (UL8). Furthermore, we have examined the dependence of DNA synthesis in the viral system on species-specific protein-protein interactions. Optimal DNA synthesis was observed with the herpes simplex virus type 1 replication proteins, ICP8, DNA polymerase (UL30/UL42), and helicase-primase (UL5/UL52/UL8). Interestingly, substitution of each component with functional homologues from other systems for the most part did not drastically impede DNA synthesis. In contrast, recombination-dependent replication promoted by the bacteriophage T7 replisome was disrupted by substitution with the replication proteins from herpes simplex virus type 1. These results show that although DNA synthesis performed by the T7 replisome is dependent on cognate protein-protein interactions, such interactions are less important in the herpes simplex virus replisome.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Boehmer, PE (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.	pboehmer@molbio.med.miami.edu		Boehmer, Paul/0000-0003-4479-0529	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062643] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62643] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boehmer PE, 2003, PROG NUCLEIC ACID RE, V75, P139, DOI 10.1016/S0079-6603(03)75005-3; Boehmer PE, 2003, IUBMB LIFE, V55, P13, DOI 10.1080/1521654031000070645; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1996, METHOD ENZYMOL, V275, P16; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; ENQUIST LW, 1973, J MOL BIOL, V75, P185, DOI 10.1016/0022-2836(73)90016-8; FAIRMAN M, 1988, BIOCHIM BIOPHYS ACTA, V951, P382, DOI 10.1016/0167-4781(88)90110-8; Falkenberg M, 1998, J BIOL CHEM, V273, P32154, DOI 10.1074/jbc.273.48.32154; Falkenberg M, 1997, J BIOL CHEM, V272, P22766, DOI 10.1074/jbc.272.36.22766; Falkenberg M, 2000, P NATL ACAD SCI USA, V97, P3896, DOI 10.1073/pnas.97.8.3896; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gourves AS, 2000, J BIOL CHEM, V275, P10864, DOI 10.1074/jbc.275.15.10864; Hamatake RK, 1997, J GEN VIROL, V78, P857, DOI 10.1099/0022-1317-78-4-857; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; Huang KJ, 2002, J BIOL CHEM, V277, P21071, DOI 10.1074/jbc.M201785200; Jackson SA, 2003, P NATL ACAD SCI USA, V100, P7871, DOI 10.1073/pnas.1230643100; JENSEN DE, 1976, J BIOL CHEM, V251, P7215; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2933; KAMAKAKA RT, 1994, MOL CELL BIOL, V14, P5114, DOI 10.1128/MCB.14.8.5114; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM YT, 1992, J BIOL CHEM, V267, P15022; KODADEK T, 1991, J BIOL CHEM, V266, P9712; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; LeGac NT, 1996, J BIOL CHEM, V271, P21645; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; Makhov AM, 2003, P NATL ACAD SCI USA, V100, P898, DOI 10.1073/pnas.0237171100; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; Milatovic D, 2002, J NEUROVIROL, V8, P295, DOI 10.1080/13550280290100743; Miller ES, 2003, MICROBIOL MOL BIOL R, V67, P86, DOI 10.1128/MMBR.67.1.86-156.2003; NAKAI H, 1988, J BIOL CHEM, V263, P9831; Nimonkar AV, 2003, NUCLEIC ACIDS RES, V31, P5275, DOI 10.1093/nar/gkg740; Nimonkar AV, 2003, P NATL ACAD SCI USA, V100, P10201, DOI 10.1073/pnas.1534569100; ODONNELL ME, 1987, J BIOL CHEM, V262, P4252; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; RABKIN SD, 1990, J VIROL, V64, P4957, DOI 10.1128/JVI.64.10.4957-4967.1990; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; Sampson DA, 2000, J BIOL CHEM, V275, P2931, DOI 10.1074/jbc.275.4.2931; Severini A, 1996, J VIROL, V70, P3169, DOI 10.1128/JVI.70.5.3169-3175.1996; SKALITER R, 1994, P NATL ACAD SCI USA, V91, P10665, DOI 10.1073/pnas.91.22.10665; SMILEY JR, 1980, VIROLOGY, V102, P83, DOI 10.1016/0042-6822(80)90072-0; Trego KS, 2003, J VIROL, V77, P12646, DOI 10.1128/JVI.77.23.12646-12659.2003; Valyi-Nagy T, 2000, VIROLOGY, V278, P309, DOI 10.1006/viro.2000.0678; WOBBE CR, 1987, PHILOS T ROY SOC B, V317, P439, DOI 10.1098/rstb.1987.0071; WOHLRAB F, 1991, P NATL ACAD SCI USA, V88, P6432, DOI 10.1073/pnas.88.15.6432; Xu LW, 2002, J BIOL CHEM, V277, P14321, DOI 10.1074/jbc.M112418200; Zhu YL, 2003, J VIROL, V77, P10147, DOI 10.1128/JVI.77.18.10147-10153.2003	51	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21957	21965		10.1074/jbc.M400832200	http://dx.doi.org/10.1074/jbc.M400832200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15026409	hybrid			2022-12-25	WOS:000221417100036
J	Budovskaya, YV; Stephan, JS; Reggiori, F; Klionsky, DJ; Herman, PK				Budovskaya, YV; Stephan, JS; Reggiori, F; Klionsky, DJ; Herman, PK			The Ras/cAMP-dependent protein kinase signaling pathway regulates an early step of the autophagy process in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; STATIONARY-PHASE ENTRY; ADENYLATE-CYCLASE; AMINOPEPTIDASE-I; RAS PROTEINS; YEAST; VACUOLE; CYTOPLASM; MUTANTS; TOR	When faced with nutrient deprivation, Saccharomyces cerevisiae cells enter into a nondividing resting state, known as stationary phase. The Ras/PKA (cAMP-dependent protein kinase) signaling pathway plays an important role in regulating the entry into this resting state and the subsequent survival of stationary phase cells. The survival of these resting cells is also dependent upon autophagy, a membrane trafficking pathway that is induced upon nutrient deprivation. Autophagy is responsible for targeting bulk protein and other cytoplasmic constituents to the vacuolar compartment for their ultimate degradation. The data presented here demonstrate that the Ras/PKA signaling pathway inhibits an early step in autophagy because mutants with elevated levels of Ras/PKA activity fail to accumulate transport intermediates normally associated with this process. Quantitative assays indicate that these increased levels of Ras/PKA signaling activity result in an essentially complete block to autophagy. Interestingly, Ras/PKA activity also inhibited a related process, the cytoplasm to vacuole targeting (Cvt) pathway that is responsible for the delivery of a subset of vacuolar proteins in growing cells. These data therefore indicate that the Ras/PKA signaling pathway is not regulating a switch between the autophagy and Cvt modes of transport. Instead, it is more likely that this signaling pathway is controlling an activity that is required during the early stages of both of these membrane trafficking pathways. Finally, the data suggest that at least a portion of the Ras/PKA effects on stationary phase survival are the result of the regulation of autophagy activity by this signaling pathway.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Program Mol Cellular & Dev Biol, Columbus, OH 43210 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Herman, PK (corresponding author), Ohio State Univ, Dept Mol Genet, 484 W 12th Ave,Rm 984, Columbus, OH 43210 USA.	herman.81@osu.edu	Budovskaya, Yelena/D-2254-2011; Reggiori, Fulvio/U-8327-2019; stephan, joseph/AAC-4889-2020	Reggiori, Fulvio/0000-0003-2652-2686; stephan, joseph/0000-0001-7804-0115; Budovskaya, Yelena/0000-0002-1047-693X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396, R01GM065227] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 65227, GM 53396, R01 GM065227, R01 GM053396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001; Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Baba M, 1995, CELL STRUCT FUNCT, V20, P465, DOI 10.1247/csf.20.465; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; Budovskaya YV, 2002, J BIOL CHEM, V277, P287, DOI 10.1074/jbc.M109263200; Chang YW, 2001, GENETICS, V157, P17; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; Gerhardt B, 1998, J BIOL CHEM, V273, P15818, DOI 10.1074/jbc.273.25.15818; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; Herman PK, 2002, CURR OPIN MICROBIOL, V5, P602, DOI 10.1016/S1369-5274(02)00377-6; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; Howard SC, 2003, GENETICS, V165, P1059; Howard SC, 2002, J BIOL CHEM, V277, P19488, DOI 10.1074/jbc.M201878200; Howard SC, 2001, GENETICS, V159, P77; Hutchins MU, 2001, J BIOL CHEM, V276, P20491, DOI 10.1074/jbc.M101150200; IIDA H, 1984, J CELL BIOL, V98, P1185, DOI 10.1083/jcb.98.4.1185; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; Kaiser C., 1994, METHODS YEAST GENETI; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Khalfan WA, 2002, CURR OPIN CELL BIOL, V14, P468, DOI 10.1016/S0955-0674(02)00343-5; Kim J, 2000, INT REV CYTOL, V198, P153; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; KLEKAMP MS, 1982, J BIOL CHEM, V257, P8432; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Klionsky DJ, 1998, J BIOL CHEM, V273, P10807, DOI 10.1074/jbc.273.18.10807; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lorberg A, 2003, CURR TOP MICROBIOL, V279, P1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MATSUMOTO K, 1983, EXP CELL RES, V146, P151, DOI 10.1016/0014-4827(83)90333-6; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; MORISHITA T, 1995, SCIENCE, V270, P1213, DOI 10.1126/science.270.5239.1213; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pedruzzi I, 2000, EMBO J, V19, P2569, DOI 10.1093/emboj/19.11.2569; Pedruzzi I, 2003, MOL CELL, V12, P1607, DOI 10.1016/S1097-2765(03)00485-4; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Reggiori F, 2003, J BIOL CHEM, V278, P5009, DOI 10.1074/jbc.M210436200; Reinders A, 1998, GENE DEV, V12, P2943, DOI 10.1101/gad.12.18.2943; Schmelzle T, 2004, MOL CELL BIOL, V24, P338, DOI 10.1128/MCB.24.1.338-351.2004; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 1998, CURR OPIN CELL BIOL, V10, P523, DOI 10.1016/S0955-0674(98)80068-9; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; SIKORSKI RS, 1989, GENETICS, V122, P19; Stromhaug PE, 2001, TRAFFIC, V2, P524, DOI 10.1034/j.1600-0854.2001.20802.x; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; THIELE DJ, 1986, MOL CELL BIOL, V6, P1158, DOI 10.1128/MCB.6.4.1158; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRUMBLY RJ, 1983, J BACTERIOL, V156, P36, DOI 10.1128/JB.156.1.36-48.1983; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Varmus H., 1993, GENES BIOL CANC; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WINGE DR, 1985, J BIOL CHEM, V260, P4464	86	159	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20663	20671		10.1074/jbc.M400272200	http://dx.doi.org/10.1074/jbc.M400272200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016820	hybrid, Green Accepted			2022-12-25	WOS:000221273800016
J	Leung, SW; Wloga, EH; Castro, AF; Nguyen, T; Bronson, RT; Yamasaki, L				Leung, SW; Wloga, EH; Castro, AF; Nguyen, T; Bronson, RT; Yamasaki, L			A dynamic switch in Rb+/- mediated neuroendocrine tumorigenesis	ONCOGENE			English	Article						Rb; tumorigenesis; pituitary	RETINOBLASTOMA GENE; PITUITARY-TUMORS; MICE LACKING; DNA-REPLICATION; TARGETED DISRUPTION; MICROARRAY ANALYSIS; DEFICIENT CELLS; CHIMERIC MICE; G(1) CONTROL; LUNG-CANCER	Rb+/- mice develop a complex spectrum of neuroendocrine tumors on a mixed genetic (129Sv x C57BL/6) background. To understand how the 129Sv and C57BL/6 contributions affect Rb+/- tumorigenesis, we serially backcrossed Rb+/- animals to the 129Sv or C57BL/6 strain, and analysed their pathological profiles. Strikingly, the length of survival and the penetrance, severity and multiplicity of neuroendocrine tumors switch dramatically between Rb+/- animals from the two genetic backgrounds. In fact, the 129Sv background significantly enhances both the initiation and progression of tumorigenesis in the intermediate lobe of the pituitary (ILP) in Rb+/- animals. This is due to the surprising fact that ILPs from wild-type 129Sv animals are inherently abnormal, and thus greatly predisposed to neoplasia. This is likely to explain the high incidence of ILP tumors, an otherwise rare tumor type in wild-type mice, in numerous knockout studies performed on the 129Sv strain, and raises the intriguing possibility that the classic Rb+/- neuroendocrine tumors may fade away in another as of yet unidentified inbred strain. Finally, we have increased the utility of the Rb+/- tumor model, since Rb+/- animals on the C57BL/6 background develop high-penetrance tumors of the anterior lobe of the pituitary, a class of tumors estimated to occur in 20-25% of humans.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA	Columbia University; Tufts University	Yamasaki, L (corresponding author), Columbia Univ, Dept Biol Sci, 1102 Fairchild Bldg,Mail Code 2428, New York, NY 10027 USA.	ly63@columbia.edu			NATIONAL CANCER INSTITUTE [R01CA079646] Funding Source: NIH RePORTER; NCI NIH HHS [5-R01-CA79646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asa SL, 2002, NAT REV CANCER, V2, P836, DOI 10.1038/nrc926; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; GARY KA, 1992, INT J DEV NEUROSCI, V10, P131, DOI 10.1016/0736-5748(92)90041-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HU NP, 1994, ONCOGENE, V9, P1021; Humbert PO, 2000, GENE DEV, V14, P690; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knudson AG, 1997, ANN NY ACAD SCI, V833, P58, DOI 10.1111/j.1749-6632.1997.tb48593.x; Kratzke RA, 1996, CANCER RES, V56, P3415; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; OKAMOTO A, 1995, CANCER RES, V55, P1448; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Simpson DJ, 2000, CANCER RES, V60, P1211; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; YAMASAKI L, 2003, SIGNAL TRANSDUCTION, P209; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	59	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3296	3307		10.1038/sj.onc.1207457	http://dx.doi.org/10.1038/sj.onc.1207457			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15021915				2022-12-25	WOS:000220975000004
J	Tarbe, NG; Rio, MC; Weidle, UH				Tarbe, NG; Rio, MC; Weidle, UH			SMAGP, a new small trans-membrane glycoprotein altered in cancer	ONCOGENE			English	Article						SMAGP; cancer; cell-cell junction; protein 4.1; MAGUK; glycosylation	CELL-CELL ADHESION; GENOMIC ORGANIZATION; SORTING SIGNALS; METASTASIS; TUMOR; CARCINOMA; BREAST; GENE; PREDICTION; EXPRESSION	Using the Affymetrix array technology, we previously identified an EST strongly expressed in several metastatic cell lines. In the present study, we cloned the corresponding cDNA that encodes a new glycoprotein composed of 97 amino acids and containing a trans-membrane domain. Therefore, we named it SMAGP for Small trans-Membrane And Glycosylated Protein. SMAGP is strongly conserved during evolution. It is expressed by normal epithelia of various organs, the protein being notably localized to the lateral face of the plasma membrane of cohesive well-polarized epithelial cells. In addition, SMAGP contains binding domains for the protein 4.1 and the PDZ domain of MAGUK proteins. Similar protein features are observed in several cell-surface proteins involved via ternary complexes in intercellular processes leading to cytoskeleton assembly as well as intracellular signalling. Thus, SMAGP might similarly be involved in a scaffolding protein complex, and therefore participate in the epithelium organization or in subsequent functions. Immunohistochemical data obtained using human breast, colon and lung cancer samples sustain this hypothesis since they showed that, in both primary tumours and metastases, reduced expression and/or cytoplasmic redistribution of SMAGP is superimposable with low histological tumour differentiation features, namely a lack of epithelial cell polarity and disorganized tissue phenotype.	Univ Strasbourg 1, INSERM, U596,CNRS,UMR 7104, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France; Roche Diagnost GmbH, Pharma Res, D-82377 Penzberg, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Roche Holding	Rio, MC (corresponding author), Univ Strasbourg 1, INSERM, U596,CNRS,UMR 7104, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.	rio@igbmc.u-strasbg.fr						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Biederer T, 2001, J BIOL CHEM, V276, P47869, DOI 10.1074/jbc.M105287200; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; BRATTAIN MG, 1981, CANCER RES, V41, P1751; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; FUKUDA M, 1987, J BIOL CHEM, V262, P11952; Greenwood E, 2003, NAT REV CANCER, V3, P549, DOI 10.1038/nrc1155; Grille SJ, 2003, CANCER RES, V63, P2172; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Hunter KW, 2001, CANCER RES, V61, P8866; Jeanplong F, 2001, MOL CELL BIOCHEM, V220, P31, DOI 10.1023/A:1010801511963; Jensen LJ, 2002, J MOL BIOL, V319, P1257, DOI 10.1016/S0022-2836(02)00379-0; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; MATZKU S, 1983, INVAS METAST, V3, P109; Nawrocki B, 1998, AM J PATHOL, V153, P1521, DOI 10.1016/S0002-9440(10)65740-9; NERI A, 1982, J NATL CANCER I, V68, P507; Nestl A, 2001, CANCER RES, V61, P1569; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Rogers GR, 1997, GENOMICS, V39, P127, DOI 10.1006/geno.1996.4501; Rosel M, 1998, ONCOGENE, V17, P1989, DOI 10.1038/sj.onc.1202079; Skubitz Amy P N, 2002, Cancer Treat Res, V107, P305; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Sy Man-Sun, 1997, Current Opinion in Oncology, V9, P108; Tarbe N, 2002, ANTICANCER RES, V22, P2015; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; Welch DR, 1997, CLIN EXP METASTAS, V15, P272, DOI 10.1023/A:1018477516367; Wurfel J, 1999, ONCOGENE, V18, P2323, DOI 10.1038/sj.onc.1202542; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	8	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3395	3403		10.1038/sj.onc.1207469	http://dx.doi.org/10.1038/sj.onc.1207469			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15021913				2022-12-25	WOS:000220975000014
J	Nakagami, H; Kiegerl, S; Hirt, H				Nakagami, H; Kiegerl, S; Hirt, H			OMTK1, a novel MAPKKK, channels oxidative stress signaling through direct MAPK interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CASCADE; PLANTS; DISTINCT; PATHWAY; YEAST; STE5; TRANSDUCTION; ARABIDOPSIS; COMPONENTS	In common with other eukaryotes, plants utilize mitogen-activated protein kinase (MAPK) cascades to mediate responses to a wide variety of stimuli. In contrast to other eukaryotes, plants have an unusually large number of MAPK components, such as more than 20 MAPKs, 10 MAPK kinases (MAPKKs), and 60 MAPKK kinases (MAPKKKs) in Arabidopsis (MAPK Group (2002) Trends Plant Sci. 7, 301-308). Presently it is mostly unknown how MAPK signaling specificity is generated in plants. Here we have isolated OMTK1 (oxidative stress-activated MAP triple-kinase 1), a novel MAPKKK from alfalfa ( Medicago sativa). In plant protoplasts, OMTK1 showed basal kinase activity and was found to induce cell death. Among a panel of hormones and stresses tested, only H2O2 was found to activate OMTK1. Out of four MAPKs, OMTK1 specifically activated MMK3 resulting in an increased cell death rate. Pull-down analysis between recombinant proteins indicated that OMTK1 directly interacts with MMK3 and that OMTK1 and MMK3 are part of a protein complex in vivo. These results indicate that OMTK1 plays a MAPK scaffolding role and functions in activation of H2O2-induced cell death in plants.	Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Hirt, H (corresponding author), Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, Dr Bohrgasse 9, A-1030 Vienna, Austria.	heribert.hirt@univie.ac.at	Nakagami, Hirofumi/A-4122-2011; Hirt, Heribert/A-2061-2013	Nakagami, Hirofumi/0000-0003-2569-7062; 				Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Bogre L, 1999, PLANT CELL, V11, P101, DOI 10.1105/tpc.11.1.101; Cardinale F, 2000, J BIOL CHEM, V275, P36734, DOI 10.1074/jbc.M007418200; Cardinale F, 2002, PLANT CELL, V14, P703, DOI 10.1105/tpc.010256; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; CHOI KY, 1994, CELL, V78, P499; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Elion EA, 2001, J CELL SCI, V114, P3967; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Ichimura K, 1998, BIOCHEM BIOPH RES CO, V253, P532, DOI 10.1006/bbrc.1998.9796; Ito M, 1999, MOL CELL BIOL, V19, P7539; Jonak C, 2002, CURR OPIN PLANT BIOL, V5, P415, DOI 10.1016/S1369-5266(02)00285-6; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Kiegerl S, 2000, PLANT CELL, V12, P2247, DOI 10.1105/tpc.12.11.2247; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Kovtun Y, 1998, NATURE, V395, P716, DOI 10.1038/27240; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Neill S, 2002, CURR OPIN PLANT BIOL, V5, P388, DOI 10.1016/S1369-5266(02)00282-0; O'Rourke SM, 2002, TRENDS GENET, V18, P405, DOI 10.1016/S0168-9525(02)02723-3; Ouaked F, 2003, EMBO J, V22, P1282, DOI 10.1093/emboj/cdg131; PRINTEN JA, 1994, GENETICS, V138, P609; RAABE T, 2002, SCI STKE; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Tena G, 2001, CURR OPIN PLANT BIOL, V4, P392, DOI 10.1016/S1369-5266(00)00191-6; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247	28	105	118	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26959	26966		10.1074/jbc.M312662200	http://dx.doi.org/10.1074/jbc.M312662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15033984	hybrid			2022-12-25	WOS:000222120400021
J	Henn, V; Edemir, B; Stefan, E; Wiesner, B; Lorenz, D; Theilig, F; Schmitt, R; Vossebein, L; Tamma, G; Beyermann, M; Krause, E; Herberg, FW; Valenti, G; Bachmann, S; Rosenthal, W; Klussmann, E				Henn, V; Edemir, B; Stefan, E; Wiesner, B; Lorenz, D; Theilig, F; Schmitt, R; Vossebein, L; Tamma, G; Beyermann, M; Krause, E; Herberg, FW; Valenti, G; Bachmann, S; Rosenthal, W; Klussmann, E			Identification of a novel A-kinase anchoring protein 18 isoform and evidence for its role in the vasopressin-induced aquaporin-2 shuttle in renal principal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER PERMEABILITY; CYCLIC-AMP; SUBCELLULAR-LOCALIZATION; MEDIATED TRANSLOCATION; REGULATORY SUBUNIT; PLASMA-MEMBRANE; CAMP; PHOSPHORYLATION; CHANNELS; KIDNEY	Arginine vasopressin (AVP) increases the water permeability of renal collecting duct principal cells by inducing the fusion of vesicles containing the water channel aquaporin-2 (AQP2) with the plasma membrane AQP2 shuttle). This event is initiated by activation of vasopressin V2 receptors, followed by an elevation of cAMP and the activation of protein kinase A (PKA). The tethering of PKA to subcellular compartments by protein kinase A anchoring proteins (AKAPs) is a prerequisite for the AQP2 shuttle. During the search for AKAP(s) involved in the shuttle, a new splice variant of AKAP18, AKAP18delta, was identified. AKAP18delta functions as an AKAP in vitro and in vivo. In the kidney, it is mainly expressed in principal cells of the inner medullary collecting duct, closely resembling the distribution of AQP2. It is present in both the soluble and particulate fractions derived from renal inner medullary tissue. Within the particulate fraction, AKAP18delta was identified on the same intracellular vesicles as AQP2 and PKA. AVP not only recruited AQP2, but also AKAP18delta to the plasma membrane. The elevation of cAMP caused the dissociation of AKAP18delta and PKA. The data suggest that AKAP18delta is involved in the AQP2 shuttle.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Humboldt Univ, Univ Med Berlin, Charite, Inst Anat, D-10117 Berlin, Germany; Univ Kassel, Biochem Abt, D-34132 Kassel, Germany; Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Free Univ Berlin, Univ Med Berlin, Charite, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universitat Kassel; Universita degli Studi di Bari Aldo Moro; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Klussmann, E (corresponding author), Forschungsinst Mol Pharmakol, Campus Berlin Buch,Robert Rossle Str 10, D-13125 Berlin, Germany.	klussmann@fmp-berlin.de	Herberg, Friedrich W/B-5572-2015; Edemir, Bayram/AAF-6845-2020; Theilig, Franziska/K-9566-2015; Schmitt, Roland/AAP-4609-2021; Tamma, Grazia/F-8823-2016	Herberg, Friedrich W/0000-0001-7117-7653; Theilig, Franziska/0000-0001-8810-4717; Tamma, Grazia/0000-0002-8890-0278; VALENTI, GIOVANNA/0000-0003-0233-0778; Stefan, Eduard/0000-0003-3650-4713; Schmitt, Roland/0000-0003-4415-8355				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Altier C, 2002, J BIOL CHEM, V277, P33598, DOI 10.1074/jbc.M202476200; Alto NM, 2003, P NATL ACAD SCI USA, V100, P4445, DOI 10.1073/pnas.0330734100; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; Brown RL, 2003, BIOCHEM BIOPH RES CO, V306, P394, DOI 10.1016/S0006-291X(03)00982-3; Burns-Hamuro LL, 2003, P NATL ACAD SCI USA, V100, P4072, DOI 10.1073/pnas.2628038100; Cantrell AR, 2002, MOL CELL NEUROSCI, V21, P63, DOI 10.1006/mcne.2002.1162; CARR DW, 1992, J BIOL CHEM, V267, P13376; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DANSFIELD DT, 1997, EMBO J, V16, P35; Francis SH, 2002, FRONT BIOSCI-LANDMRK, V7, pD580, DOI 10.2741/francis; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; Gouraud S, 2002, J CELL SCI, V115, P3667, DOI 10.1242/jcs.00053; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; Hausken ZE, 1998, METH MOL B, V88, P47; Herberg FW, 2000, J MOL BIOL, V298, P329, DOI 10.1006/jmbi.2000.3662; Holroyd C, 1999, MOL BIOL CELL, V10, P3035, DOI 10.1091/mbc.10.9.3035; Hulme JT, 2003, P NATL ACAD SCI USA, V100, P13093, DOI 10.1073/pnas.2135335100; Hulme JT, 2002, J BIOL CHEM, V277, P4079, DOI 10.1074/jbc.M109814200; Jo I, 1997, BBA-BIOMEMBRANES, V1324, P91, DOI 10.1016/S0005-2736(96)00213-1; Jo IH, 2001, AM J PHYSIOL-RENAL, V281, pF958; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; Kamsteeg EJ, 2000, J CELL BIOL, V151, P919, DOI 10.1083/jcb.151.4.919; Katsura T, 1997, AM J PHYSIOL-RENAL, V272, pF816; Klussmann E, 2000, REV PHYSIOL BIOCH P, V141, P33, DOI 10.1007/BFb0119577; Klussmann E, 2001, KIDNEY INT, V60, P446, DOI 10.1046/j.1523-1755.2001.060002446.x; Klussmann E, 1999, J BIOL CHEM, V274, P4934, DOI 10.1074/jbc.274.8.4934; Klussmann E, 2001, J BIOL CHEM, V276, P20451, DOI 10.1074/jbc.M010270200; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; Lande MB, 1996, J BIOL CHEM, V271, P5552, DOI 10.1074/jbc.271.10.5552; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; LIEBENHOFF U, 1995, FEBS LETT, V365, P209, DOI 10.1016/0014-5793(95)00476-P; Lorenz D, 2003, EMBO REP, V4, P88, DOI 10.1038/sj.embor.embor711; Lu H, 2004, AM J PHYSIOL-RENAL, V286, pF233, DOI 10.1152/ajprenal.00179.2003; Maric K, 1998, AM J PHYSIOL-RENAL, V275, pF796, DOI 10.1152/ajprenal.1998.275.5.F796; Maric K, 2001, BIOPHYS J, V80, P1783, DOI 10.1016/S0006-3495(01)76148-6; Marples D, 1998, AM J PHYSIOL-RENAL, V274, pF384, DOI 10.1152/ajprenal.1998.274.2.F384; Morello JP, 2001, ANNU REV PHYSIOL, V63, P607, DOI 10.1146/annurev.physiol.63.1.607; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Nishimoto G, 1999, AM J PHYSIOL-RENAL, V276, pF254, DOI 10.1152/ajprenal.1999.276.2.F254; Oliveria SF, 2003, J CELL BIOL, V160, P101, DOI 10.1083/jcb.200209127; Procino G, 2003, FASEB J, V17, P1886, DOI 10.1096/fj.02-0870fje; Sambrook J, 2001, MOL CLONING LAB MANU; Shukla A, 2001, AM J PHYSIOL-RENAL, V281, pF546, DOI 10.1152/ajprenal.2001.281.3.F546; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; Smith PJ, 2002, SIGHT SOUND, V12, P32; Storm R, 2003, AM J PHYSIOL-RENAL, V284, pF189, DOI 10.1152/ajprenal.00245.2002; Tamma G, 2003, J CELL SCI, V116, P3285, DOI 10.1242/jcs.00640; Tamma G, 2003, J CELL SCI, V116, P1519, DOI 10.1242/jcs.00355; TAMMA G, 2001, AM J PHYSIOL, V281, pR1092; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; Trotter KW, 1999, J CELL BIOL, V147, P1481, DOI 10.1083/jcb.147.7.1481; Valenti G, 1996, J BIOL CHEM, V271, P24365, DOI 10.1074/jbc.271.40.24365; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; Wang L, 2001, P NATL ACAD SCI USA, V98, P3220, DOI 10.1073/pnas.051633398; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345; Zakhary DR, 2000, J BIOL CHEM, V275, P41389, DOI 10.1074/jbc.M004212200; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	65	105	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26654	26665		10.1074/jbc.M312835200	http://dx.doi.org/10.1074/jbc.M312835200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15037626	hybrid, Green Published			2022-12-25	WOS:000222003000092
J	Gorski, JP; Wang, AM; Lovitch, D; Law, D; Powell, K; Midura, RJ				Gorski, JP; Wang, AM; Lovitch, D; Law, D; Powell, K; Midura, RJ			Extracellular bone acidic glycoprotein-75 defines condensed mesenchyme regions to be mineralized and localizes with bone sialoprotein during intramembranous bone formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIBIAL MARROW ABLATION; MATRIX VESICLES; COLLAGEN FIBRILS; IN-VITRO; GENE-EXPRESSION; MESSENGER-RNA; TENASCIN-C; RAT BONE; N-RAP; PROTEIN	Bone acidic glycoprotein-75 is expressed very early during in vivo models of intramembranous bone formation, highly enriched in condensing osteogenic mesenchyme after marrow ablation and the osteoprogenitor layer of tibial periosteum. Bone sialoprotein accumulates within bone acidic glycoprotein-75-enriched matrix areas at a later stage in both models. Decalcification of initial sites of mineralization consistently revealed focal immunostaining for bone acidic glycoprotein-75 underneath these sites suggesting that mineralization occurs within bone acidic glycoprotein-75-enriched matrix areas. Ultrastructural immunolocalization of bone acidic glycoprotein-75 does not support a direct association with banded collagen fibrils, but rather suggests it is a component of a separate, amorphous scaffold occupying interfibrillar spaces. Double immunogold labeling demonstrated that a sizeable proportion of bone sialoprotein particles were located within a 50-nm radius of bone acidic glycoprotein-75. These results define bone acidic glycoprotein-75 as the earliest bone-restricted, extracellular marker of osteogenic mesenchyme. Based on this early bone-restricted expression pattern and a previously documented propensity of bone acidic glycoprotein-75 to form supramolecular complexes through self-association, bone acidic glycoprotein-75 may serve a key structural role in setting boundary limits of condensing osteogenic mesenchyme.	Univ Missouri, Sch Dent, Dept Oral Biol, Bone Biol Res Program, Kansas City, MO 64108 USA; Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, Kansas City, MO 64108 USA; Cleveland Clin & Fdn, Orthopaed Res Ctr, Cleveland, OH 44195 USA; Cleveland Clin & Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Missouri System; University of Missouri Kansas City	Gorski, JP (corresponding author), Univ Missouri, Sch Dent, Dept Oral Biol, Bone Biol Res Program, 650 E 25th St, Kansas City, MO 64108 USA.	Gorskij@umkc.edu			NIAMS NIH HHS [AR-45171] Funding Source: Medline; NIDCR NIH HHS [DE-11197, DE-14619] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE014619, R03DE011197] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; BHARGAVA U, 1988, BONE, V9, P155, DOI 10.1016/8756-3282(88)90005-1; BIANCO P, 1993, J HISTOCHEM CYTOCHEM, V41, P193, DOI 10.1177/41.2.8419459; BONNUCI E, 1989, CONNECT TISSUE RES, V22, P43; BONUCCI E, 1992, BONE MINER, V17, P219, DOI 10.1016/0169-6009(92)90740-5; Bonucci E, 1995, Connect Tissue Res, V33, P157, DOI 10.3109/03008209509016996; BONUCCI E, 1978, CALC TISS RES, V25, P179, DOI 10.1007/BF02010766; BONUCCI E, 1988, CLIN ORTHOP RELAT R, P243; Bonucci E., 1992, CALCIFICATION BIOL S, P19; BOSKEY AL, 1995, ANN NY ACAD SCI, V760, P249, DOI 10.1111/j.1749-6632.1995.tb44635.x; BOSKEY AL, 1992, CLIN ORTHOP RELAT R, P244; CHEN JK, 1992, J BONE MINER RES, V7, P987; CHEN Y, 1992, J BIOL CHEM, V267, P24871; Deak F, 1997, J BIOL CHEM, V272, P9268; Fell HB, 1925, J MORPHOL PHYSIOL, V40, P417, DOI 10.1002/jmor.1050400302; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; Gorski JP, 2003, J BONE MINER RES, V18, pS196; Gorski JP, 1996, CONNECT TISSUE RES, V35, P137, DOI 10.3109/03008209609029184; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; Gorski JP, 1997, J CELL BIOCHEM, V64, P547; Gorski JP, 1998, CRIT REV ORAL BIOL M, V9, P201, DOI 10.1177/10454411980090020401; Gorski JP, 2000, BONE, V27, P103, DOI 10.1016/S8756-3282(00)00295-7; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; Herrera AH, 2000, CELL MOTIL CYTOSKEL, V45, P211, DOI 10.1002/(SICI)1097-0169(200003)45:3<211::AID-CM4>3.3.CO;2-P; HIRAKAWA K, 1994, J BONE MINER RES, V9, P1551; Hoshi K, 1999, J BONE MINER RES, V14, P273, DOI 10.1359/jbmr.1999.14.2.273; HULTENBY K, 1994, EUR J CELL BIOL, V63, P230; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; Irie K, 1998, ANAT RECORD, V252, P554; Jee W., 1983, HISTOLOGY CELL TISSU, V5, P200; JEE WSS, 1988, BONE, V9, P381, DOI 10.1016/8756-3282(88)90120-2; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; KASUGAI S, 1992, J CELL PHYSIOL, V152, P467, DOI 10.1002/jcp.1041520305; Koyama E, 1996, J ORTHOPAED RES, V14, P403, DOI 10.1002/jor.1100140310; KOYAMA E, 1995, DEV DYNAM, V203, P152, DOI 10.1002/aja.1002030204; LAW DJ, 1993, AM J PATHOL, V142, P1513; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Magnuson SK, 1997, J BONE MINER RES, V12, P200, DOI 10.1359/jbmr.1997.12.2.200; MAJESKA RJ, 1975, BIOCHIM BIOPHYS ACTA, V391, P51, DOI 10.1016/0005-2744(75)90151-5; MCCULLOCH CAG, 1989, ANAT REC, V223, P27, DOI 10.1002/ar.1092230105; MCQUILLAN DJ, 1995, BONE, V16, P415; Midura RJ, 2004, J BIOL CHEM, V279, P25464, DOI 10.1074/jbc.M312409200; Midura RJ, 2003, J BIOL CHEM, V278, P51462, DOI 10.1074/jbc.M307567200; Nefussi JR, 1997, J HISTOCHEM CYTOCHEM, V45, P493, DOI 10.1177/002215549704500402; Piecha D, 2002, BIOCHEM J, V367, P715, DOI 10.1042/BJ20021069; Qin CL, 2001, EUR J ORAL SCI, V109, P133, DOI 10.1034/j.1600-0722.2001.00001.x; Riminucci M, 1998, J BONE MINER RES, V13, P1852, DOI 10.1359/jbmr.1998.13.12.1852; RIMINUCCI M, 1995, CALCIFIED TISSUE INT, V57, P277, DOI 10.1007/BF00298883; SATO M, 1992, FASEB J, V6, P2966, DOI 10.1096/fasebj.6.11.1644260; SATOMURA K, 1991, ACTA ANAT, V142, P97; SAUREN YMHF, 1989, BONE, V10, P287, DOI 10.1016/8756-3282(89)90066-5; Schinke T, 1999, NAT GENET, V21, P150, DOI 10.1038/5928; SCHWARTZ Z, 1989, BONE, V10, P53, DOI 10.1016/8756-3282(89)90147-6; STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420; SUVA LJ, 1993, J BONE MINER RES, V8, P379; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200; WANG A, 1999, T 45 ANN M ORTH RES, P209; Wang AM, 2000, J BIOL CHEM, V275, P11082, DOI 10.1074/jbc.275.15.11082; WUTHIER RE, 1989, CONNECT TISSUE RES, V22, P653, DOI 10.3109/03008208909114117; Zhang RQ, 2001, BIOCHEMISTRY-US, V40, P14898, DOI 10.1021/bi0107445; Zhu JX, 2001, HISTOCHEM J, V33, P25, DOI 10.1023/A:1017587712914; ZIMMERMANN B, 1984, HISTOCHEMISTRY, V81, P353, DOI 10.1007/BF00514329	64	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25455	25463		10.1074/jbc.M312408200	http://dx.doi.org/10.1074/jbc.M312408200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15004029	hybrid			2022-12-25	WOS:000221827900069
J	Kilili, KG; Atanassova, N; Vardanyan, A; Clatot, N; Al-Sabarna, K; Kanellopoulos, PN; Makris, AM; Kampranis, SC				Kilili, KG; Atanassova, N; Vardanyan, A; Clatot, N; Al-Sabarna, K; Kanellopoulos, PN; Makris, AM; Kampranis, SC			Differential roles of Tau class glutathione S-transferases in oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YAP-1 TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; LIPID-PEROXIDATION; ARABIDOPSIS-THALIANA; TARGET GENE; YEAST; PROTEIN; P1-1; DETOXIFICATION; EXPRESSION	The plant glutathione S-transferase BI-GST has been identified as a potent inhibitor of Bax lethality in yeast, a phenotype associated with oxidative stress and disruption of mitochondrial functions. Screening of a tomato two-hybrid library for BI-GST interacting proteins identified five homologous Tau class GSTs, which readily form heterodimers between them and BI-GST. All six LeGSTUs were found to be able to protect yeast cells from prooxidant-induced cell death. The efficiency of each LeGSTU was prooxidant-specific, indicating a different role for each LeGSTU in the oxidative stress-response mechanism. The prooxidant protective effect of all six proteins was suppressed in the absence of YAP1, a transcription factor that regulates hydroperoxide homeostasis in Saccharomyces cerevisiae, suggesting a role for the LeGSTUs in the context of the YAP1-dependent stress-responsive machinery. The different LeGSTUs exhibited varied substrate specificity and showed activity against oxidative stress by-products, indicating that their prooxidant protective function is likely related to the minimization of oxidative damage. Taken together, these results indicate that Tau class GSTs participate in a broad network of catalytic and regulatory functions involved in the oxidative stress response.	Mediterranean Agron Inst Chania, Khania 73100, Greece	CIHEAM; CIHEAM IAM Chania	Kampranis, SC (corresponding author), Mediterranean Agron Inst Chania, Alsyllion Agrokepiou, Khania 73100, Greece.	antonios@maich.gr	Kampranis, Sotirios C/G-8374-2016	Kampranis, Sotirios C/0000-0001-6208-1684				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alfenito MR, 1998, PLANT CELL, V10, P1135, DOI 10.1105/tpc.10.7.1135; Belles-Boix E, 2000, FEBS LETT, V482, P19, DOI 10.1016/S0014-5793(00)02016-0; Board PG, 1997, BIOCHEM J, V328, P929; BOYLAND E, 1969, BIOCHEM J, V115, P985, DOI 10.1042/bj1150985; BROPHY PM, 1990, BIOCHEM CELL BIOL, V68, P1288, DOI 10.1139/o90-191; Caccuri AM, 1996, J BIOL CHEM, V271, P16193, DOI 10.1074/jbc.271.27.16193; Charizanis C, 1999, MOL GEN GENET, V261, P740, DOI 10.1007/s004380050017; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Coggan M, 2002, BIOCHEM J, V366, P323, DOI 10.1042/bj20011878; Collinson EJ, 2002, J BIOL CHEM, V277, P16712, DOI 10.1074/jbc.M111686200; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Cummins I, 1999, PLANT J, V18, P285, DOI 10.1046/j.1365-313X.1999.00452.x; Dixon DP, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews3004; Dixon DP, 1998, CURR OPIN PLANT BIOL, V1, P258, DOI 10.1016/S1369-5266(98)80114-3; Dixon DP, 1999, PLANT MOL BIOL, V40, P997, DOI 10.1023/A:1006257305725; Edwards R, 2000, TRENDS PLANT SCI, V5, P193, DOI 10.1016/S1360-1385(00)01601-0; ESTERBAUER H, 1986, BIOCHIM BIOPHYS ACTA, V876, P154, DOI 10.1016/0005-2760(86)90329-2; Evans MV, 1998, J BACTERIOL, V180, P483, DOI 10.1128/JB.180.3.483-490.1998; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; Gronwald JW, 1998, PLANT PHYSIOL, V117, P877, DOI 10.1104/pp.117.3.877; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Habig W H, 1981, Methods Enzymol, V77, P398; Hoeberichts FA, 2001, PLANT MOL BIOL, V45, P641, DOI 10.1023/A:1010625203485; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; IVANETICH KM, 1990, BIOCHEM PHARMACOL, V39, P1999, DOI 10.1016/0006-2952(90)90621-Q; Jemth P, 1996, BIOCHEM J, V316, P131, DOI 10.1042/bj3160131; Johansson AS, 2001, J BIOL CHEM, V276, P33061, DOI 10.1074/jbc.M104539200; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; KUSHNIR S, 1995, P NATL ACAD SCI USA, V92, P10580, DOI 10.1073/pnas.92.23.10580; Kushnir S, 2001, PLANT CELL, V13, P89, DOI 10.1105/tpc.13.1.89; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; Lo Bello M, 2001, J BIOL CHEM, V276, P42138; MAGER WH, 1993, BIOCHEM J, V290, P1; McGonigle B, 2000, PLANT PHYSIOL, V124, P1105, DOI 10.1104/pp.124.3.1105; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; *QIAG, 1999, QIAEXPRESSIONIST HDB; RICCI G, 1994, ANAL BIOCHEM, V218, P463, DOI 10.1006/abio.1994.1209; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; Roxas VP, 1997, NAT BIOTECHNOL, V15, P988, DOI 10.1038/nbt1097-988; SANDERMANN H, 1992, TRENDS BIOCHEM SCI, V17, P82, DOI 10.1016/0968-0004(92)90507-6; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Tan KL, 1996, BIOCHEM J, V315, P727, DOI 10.1042/bj3150727; Tan KL, 1996, BIOCHEM J, V319, P315, DOI 10.1042/bj3190315; Thom R, 2002, BIOCHEMISTRY-US, V41, P7008, DOI 10.1021/bi015964x; Toby GG, 2001, METHODS, V24, P201, DOI 10.1006/meth.2001.1182; Turella P, 2003, J BIOL CHEM, V278, P42294, DOI 10.1074/jbc.M305569200; ULMASOV T, 1995, PLANT PHYSIOL, V108, P919, DOI 10.1104/pp.108.3.919; Wheeler GL, 2003, J BIOL CHEM, V278, P49920, DOI 10.1074/jbc.M310156200; Whittington AT, 1996, GENOMICS, V33, P105, DOI 10.1006/geno.1996.0165; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	58	96	105	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24540	24551		10.1074/jbc.M309882200	http://dx.doi.org/10.1074/jbc.M309882200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15037622	hybrid			2022-12-25	WOS:000221702500083
J	Krishnamurthy, P; Ross, DD; Nakanishi, T; Bailey-Dell, K; Zhou, S; Mercer, KE; Sarkadi, B; Sorrentino, BP; Schuetz, JD				Krishnamurthy, P; Ross, DD; Nakanishi, T; Bailey-Dell, K; Zhou, S; Mercer, KE; Sarkadi, B; Sorrentino, BP; Schuetz, JD			The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER RESISTANCE PROTEIN; ACUTE MYELOID-LEUKEMIA; MOUSE HEPATOMA-CELLS; MULTIDRUG-RESISTANCE; TRANSPORTER ABCG2; DRUG-RESISTANCE; IN-VIVO; EXPRESSION; DAMAGE; EFFLUX	Our studies demonstrate that the ABC transporter and marker of stem and progenitor cells known as the breast cancer resistance protein (BCRP or ABCG2) confers a strong survival advantage under hypoxic conditions. We show that, under hypoxia, progenitor cells from Bcrp(-/-) mice have a reduced ability to form colonies as compared with progenitor cells from Bcrp(+/+) mice. Blocking BCRP function in Bcrp(+/+) progenitor cells markedly reduces survival under hypoxic conditions. However, blocking heme biosynthesis reverses the hypoxic susceptibility of Bcrp(-/-) progenitor cells, a finding that indicates that heme molecules (i.e. porphyrins) are detrimental to Bcrp(-/-) cells under hypoxia. BCRP specifically binds heme, and cells lacking BCRP accumulate porphyrins. Finally, Bcrp expression is up-regulated by hypoxia, and we demonstrate that this up-regulation involves the hypoxia-inducible transcription factor complex HIF-1. Collectively, our findings suggest that cells can, upon hypoxic demand, use BCRP to reduce heme or porphyrin accumulation, which can be detrimental to cells. Our findings have implications for the survival of stem cells and tumor cells in hypoxic environments.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Div Expt Hematol, Memphis, TN 38105 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Greenebaum Canc Ctr, Program Expt Therapeut, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Hungarian Acad Sci, Res Grp, Inst Hematol & Immunol, Natl Med Ctr,Dept Mol Cell Biol, H-1518 Budapest, Hungary	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; Hungarian Academy of Sciences	Schuetz, JD (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	John.schuetz@stjude.org	Schuetz, John D/N-2692-2018; Sarkadi, Balazs/I-5024-2013; Nakanishi, Takeo/C-3891-2015	Nakanishi, Takeo/0000-0002-6561-7138; Zhou, Sheng/0000-0001-5902-5868	NCI NIH HHS [CA77545, P30 CA21745] Funding Source: Medline; NHLBI NIH HHS [HL67366] Funding Source: Medline; NIEHS NIH HHS [ES068571] Funding Source: Medline; NIGMS NIH HHS [GM60346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077545] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott BL, 2002, BLOOD, V100, P4594, DOI 10.1182/blood-2002-01-0271; Alison MR, 2003, J PATHOL, V200, P547, DOI 10.1002/path.1411; Allen JD, 2002, MOL CANCER THER, V1, P427; ANTOLIN I, 1994, ANAT REC, V239, P349, DOI 10.1002/ar.1092390402; Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; BAILLY JD, 1995, LEUKEMIA, V9, P799; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Bates SE, 2001, J BIOENERG BIOMEMBR, V33, P503, DOI 10.1023/A:1012879205914; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; Blokhina O, 2003, ANN BOT-LONDON, V91, P179, DOI 10.1093/aob/mcf118; Bodo A, 2003, J BIOL CHEM, V278, P23529, DOI 10.1074/jbc.M303515200; Bohm F, 2001, J PHOTOCH PHOTOBIO B, V65, P177, DOI 10.1016/S1011-1344(01)00259-7; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bunting KD, 2002, STEM CELLS, V20, P11, DOI 10.1002/stem.200011; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CANET GH, 2003, J CLIN INVEST, V112, P126; CIPOLLESCHI MG, 1993, BLOOD, V82, P2031; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Ejendal KFK, 2002, CURR PROTEIN PEPT SC, V3, P503, DOI 10.2174/1389203023380521; Feuring-Buske M, 2001, BLOOD, V97, P3882, DOI 10.1182/blood.V97.12.3882; Furuya KN, 1997, J BIOL CHEM, V272, P11518; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; Hofer T, 2003, BLOOD, V101, P348, DOI 10.1182/blood-2002-03-0773; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kim M, 2002, CLIN CANCER RES, V8, P22; Kubota H, 2003, P NATL ACAD SCI USA, V100, P6487, DOI 10.1073/pnas.0631767100; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lim H W, 1989, Immunol Ser, V46, P671; Lin KT, 1997, BIOCHEM BIOPH RES CO, V230, P115, DOI 10.1006/bbrc.1996.5897; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; Maliepaard M, 2001, CANCER RES, V61, P3458; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Orth K, 2000, LANGENBECK ARCH SURG, V385, P488, DOI 10.1007/s004230000174; Otake M, 2003, BRIT J CANCER, V89, P730, DOI 10.1038/sj.bjc.6601135; Ozvegy C, 2001, BIOCHEM BIOPH RES CO, V285, P111, DOI 10.1006/bbrc.2001.5130; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; PERDEW GH, 1990, BIOCHEMISTRY-US, V29, P6210, DOI 10.1021/bi00478a014; PISKORSKAPLISZCZYNSKA J, 1991, ARCH BIOCHEM BIOPHYS, V290, P362, DOI 10.1016/0003-9861(91)90552-T; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Rabindran SK, 2000, CANCER RES, V60, P47; Ross DD, 2000, LEUKEMIA, V14, P467, DOI 10.1038/sj.leu.2401694; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; SANDBERG S, 1980, BIOCHIM BIOPHYS ACTA, V593, P187, DOI 10.1016/0005-2728(80)90056-0; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Suzuki M, 2003, J BIOL CHEM, V278, P22644, DOI 10.1074/jbc.M212399200; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wierdl M, 2003, MOL PHARMACOL, V64, P279, DOI 10.1124/mol.64.2.279; Wulf GG, 2001, BLOOD, V98, P1166, DOI 10.1182/blood.V98.4.1166; Zamber CP, 2003, PHARMACOGENETICS, V13, P19, DOI 10.1097/00008571-200301000-00004; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886; Zelcer N, 2003, J BIOL CHEM, V278, P23538, DOI 10.1074/jbc.M303504200; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	56	520	548	1	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24218	24225		10.1074/jbc.M313599200	http://dx.doi.org/10.1074/jbc.M313599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044468	hybrid			2022-12-25	WOS:000221702500046
J	Van Dyke, MW; Nelson, LD; Weilbaecher, RG; Mehta, DV				Van Dyke, MW; Nelson, LD; Weilbaecher, RG; Mehta, DV			Stm1p, a G(4) quadruplex and purine motif triplex nucleic acid-binding protein, interacts with ribosomes and subtelomeric Y ' DNA in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-ANTIGEN HELICASE; YEAST GENE-PRODUCT; G-QUARTET DNA; TELOMERIC DNA; BUDDING YEAST; IN-VIVO; G4 DNA; AFFINITY PURIFICATION; FUNCTIONAL-ANALYSIS; MESSENGER-RNAS	The Saccharomyces cerevisiae protein Stm1 was originally identified as a G4 quadruplex and purine motif triplex nucleic acid-binding protein. However, more recent studies have suggested a role for Stm1p in processes ranging from antiapoptosis to telomere maintenance. To better understand the biological role of Stm1p and its potential for G*G multiplex binding, we used epitope-tagged protein and immunological methods to identify the subcellular localization and protein and nucleic acid partners of Stm1p in vivo. Indirect immunofluorescence microscopy indicated that Stm1p is primarily a cytoplasmic protein, although a small percentage is also present in the nucleus. Conventional immunoprecipitation found that Stm1p is associated with ribosomal proteins and rRNA. This association was verified by rate zonal separation through sucrose gradients, which showed that Stm1p binds exclusively to mature 80 S ribosomes and polysomes. Chromatin immunoprecipitation experiments found that Stm1p preferentially binds telomere-proximal Y' element DNA sequences. Taken together, our data suggest that Stm1p is primarily a ribosome-associated protein, but one that can also interact with DNA, especially subtelomeric sequences. We discuss the implications of our findings in relation to prior genetic, genomic, and proteomic studies that have identified STM1 and/or Stm1p as well as the possible biological role of Stm1p.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 79, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Van Dyke, MW (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 79, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mvandyke@mdanderson.org	Van Dyke, Michael W./AAY-6751-2020	Van Dyke, Michael W./0000-0003-0306-4002				Agazie YM, 1996, BIOCHEM J, V316, P461, DOI 10.1042/bj3160461; Arimondo PB, 2000, NUCLEIC ACIDS RES, V28, P4832, DOI 10.1093/nar/28.24.4832; Arthanari H, 2001, CHEM BIOL, V8, P221, DOI 10.1016/S1074-5521(01)00007-2; Ball CA, 2001, NUCLEIC ACIDS RES, V29, P80, DOI 10.1093/nar/29.1.80; Baran N, 1997, NUCLEIC ACIDS RES, V25, P297, DOI 10.1093/nar/25.2.297; BaudinBaillieu A, 1997, MOL CELL BIOL, V17, P5023, DOI 10.1128/MCB.17.9.5023; BEHE MJ, 1995, NUCLEIC ACIDS RES, V23, P689, DOI 10.1093/nar/23.4.689; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P1881, DOI 10.1073/pnas.68.8.1881; Bourns BD, 1998, MOL CELL BIOL, V18, P5600, DOI 10.1128/MCB.18.9.5600; BURKE D, 2000, METHODS YEAST GENET; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Ciotti P, 2001, EUR J BIOCHEM, V268, P225, DOI 10.1046/j.1432-1327.2001.01859.x; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Drawid A, 2000, J MOL BIOL, V301, P1059, DOI 10.1006/jmbi.2000.3968; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Erlitzki R, 1997, J BIOL CHEM, V272, P15881, DOI 10.1074/jbc.272.25.15881; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; Gasch AP, 2001, MOL BIOL CELL, V12, P2987, DOI 10.1091/mbc.12.10.2987; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Guieysse AL, 1997, J MOL BIOL, V267, P289, DOI 10.1006/jmbi.1997.0884; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; Harrington C, 1997, J BIOL CHEM, V272, P24631, DOI 10.1074/jbc.272.39.24631; Hata H, 1998, GENETICS, V148, P571; Hayashi N, 2002, MOL GENET GENOMICS, V267, P806, DOI 10.1007/s00438-002-0712-3; Hua SJ, 2001, J MOL BIOL, V308, P397, DOI 10.1006/jmbi.2001.4580; Hughes TR, 2000, P NATL ACAD SCI USA, V97, P6457, DOI 10.1073/pnas.97.12.6457; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Inada T, 2002, RNA, V8, P948, DOI 10.1017/S1355838202026018; Isalan M, 2001, BIOCHEMISTRY-US, V40, P830, DOI 10.1021/bi001728v; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jimenez-Garcia E, 1998, J BIOL CHEM, V273, P24640, DOI 10.1074/jbc.273.38.24640; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Kopel V, 1996, NUCLEIC ACIDS RES, V24, P330, DOI 10.1093/nar/24.2.330; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Crom S, 2002, NUCLEIC ACIDS RES, V30, P76, DOI 10.1093/nar/30.1.76; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Ligr M, 2001, MOL BIOL CELL, V12, P2422, DOI 10.1091/mbc.12.8.2422; Lin YC, 2001, J BIOL CHEM, V276, P47671, DOI 10.1074/jbc.M104989200; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; Longhese MP, 2000, GENETICS, V155, P1577; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Louis EJ, 1995, YEAST, V11, P1553, DOI 10.1002/yea.320111604; Lu Q, 2000, NUCLEIC ACIDS RES, V28, P2993, DOI 10.1093/nar/28.15.2993; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; Muniyappa K, 2000, MOL CELL BIOL, V20, P1361, DOI 10.1128/MCB.20.4.1361-1369.2000; Musso M, 2000, NUCLEIC ACIDS RES, V28, P4090, DOI 10.1093/nar/28.21.4090; Musso M, 1998, BIOCHEMISTRY-US, V37, P3086, DOI 10.1021/bi9717486; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nelson LD, 2000, J BIOL CHEM, V275, P5573, DOI 10.1074/jbc.275.8.5573; Oliver AW, 2000, J MOL BIOL, V301, P575, DOI 10.1006/jmbi.2000.3991; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; ROONEY SM, 1995, P NATL ACAD SCI USA, V92, P2141, DOI 10.1073/pnas.92.6.2141; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Sarig G, 1997, BIOCHEM BIOPH RES CO, V237, P617, DOI 10.1006/bbrc.1997.7198; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034; Simonsson T, 1998, NUCLEIC ACIDS RES, V26, P1167, DOI 10.1093/nar/26.5.1167; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; Takaku H, 2001, BIOCHEM BIOPH RES CO, V284, P194, DOI 10.1006/bbrc.2001.4951; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Uliel L, 2000, J BIOL CHEM, V275, P33134, DOI 10.1074/jbc.M005542200; UTSUGI T, 1995, BBA-GENE STRUCT EXPR, V1263, P285, DOI 10.1016/0167-4781(95)00123-X; Vasquez KM, 2002, P NATL ACAD SCI USA, V99, P5848, DOI 10.1073/pnas.082193799; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; Wen JD, 2002, BIOCHEMISTRY-US, V41, P11438, DOI 10.1021/bi020276e; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P541; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zain R, 2003, CELL MOL LIFE SCI, V60, P862, DOI 10.1007/s00018-003-3046-3; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	94	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24323	24333		10.1074/jbc.M401981200	http://dx.doi.org/10.1074/jbc.M401981200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044472	hybrid			2022-12-25	WOS:000221702500058
J	Garriga-Canut, M; Orkin, SH				Garriga-Canut, M; Orkin, SH			Transforming acidic coiled-coil protein 3 (TACC3) controls friend of GATA-1 (FOG-1) subcellular localization and regulates the association between GATA-1 and FOG-1 during hematopoiesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; ZINC-FINGER PROTEIN; ERYTHROID LINEAGE; BINDING-PROTEIN; EXPRESSION; GENE; CELLS; DIFFERENTIATION; FAMILY; COFACTOR	Physical association between the transcription factor GATA-1 and the cofactor, Friend of GATA-1 (FOG-1), is essential for the differentiation of two blood cell types, erythroid cells and megakaryocytes. However, little is known regarding the mechanisms that modulate their interaction within cells. In the present study, we have identified TACC3 as a FOG-1-interacting protein. Transforming acidic coiled-coil protein 3 ( TACC3), a protein that is highly expressed in hematopoietic cells, has been reported to have a critical role in the expansion of immature hematopoietic progenitors. We show that TACC3 affects FOG-1 nuclear localization, altering the interaction between GATA-1 and FOG-1. However, GATA-1 competes with TACC3 in the interaction with FOG-1. We observe that high levels of TACC3 inhibit the function of FOG-1 as a transcriptional cofactor of GATA-1. Furthermore, forced expression of TACC3 to levels similar to those found in progenitor cells delays terminal maturation of MEL and G1ER cells, two cell models of erythroid cell development. We suggest a role for TACC3 in regulating the cellular distribution of FOG-1 and thus the direct interaction of GATA-1 and FOG-1 as a mechanism to control the transition between expansion of multipotential progenitor cell populations and final stages of erythroid maturation.	Harvard Univ, Sch Med, Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	Orkin, SH (corresponding author), Childrens Hosp, Div Hematol, 300 Longwood Ave, Boston, MA 02115 USA.	stuart_orkin@dfci.harvard.edu						Cantor AB, 2002, MOL CELL BIOL, V22, P4268, DOI 10.1128/MCB.22.12.4268-4279.2002; Chang AN, 2002, P NATL ACAD SCI USA, V99, P9237, DOI 10.1073/pnas.142302099; Chen F, 2000, CURR BIOL, V10, P758, DOI 10.1016/S0960-9822(00)00571-6; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Deconinck AE, 2000, DEVELOPMENT, V127, P2031; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; Dovat S, 2002, GENE DEV, V16, P2985, DOI 10.1101/gad.1040502; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Hsu LC, 2001, CANCER RES, V61, P7713; Katz SG, 2002, MOL CELL BIOL, V22, P3121, DOI 10.1128/MCB.22.9.3121-3128.2002; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; Klein C, 2000, J EXP MED, V191, P1699, DOI 10.1084/jem.191.10.1699; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; McKeveney PJ, 2001, BRIT J HAEMATOL, V112, P1016, DOI 10.1046/j.1365-2141.2001.02644.x; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; Orkin SH, 1998, INT J DEV BIOL, V42, P927; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Sadek CM, 2003, GENE EXPR PATTERNS, V3, P203, DOI 10.1016/S1567-133X(02)00066-2; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Suwabe N, 1998, BLOOD, V92, P4108, DOI 10.1182/blood.V92.11.4108.423k29_4108_4118; Thomas RC, 1996, EXP CELL RES, V223, P227, DOI 10.1006/excr.1996.0076; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; ZON LI, 1993, BLOOD, V81, P3234	44	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23597	23605		10.1074/jbc.M313987200	http://dx.doi.org/10.1074/jbc.M313987200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15037632	hybrid			2022-12-25	WOS:000221570900100
J	Gibson, KJC; Gilleron, M; Constant, P; Brando, T; Puzo, G; Besra, GS; Nigou, J				Gibson, KJC; Gilleron, M; Constant, P; Brando, T; Puzo, G; Besra, GS; Nigou, J			Tsukamurella paurometabola lipoglycan, a new lipoarabinomannan variant with pro-inflammatory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-BOVIS BCG; GORDONA-AURANTIACA RHODOCOCCUS; BACILLUS-CALMETTE-GUERIN; SURFACTANT PROTEIN-A; MYO-INOSITOL ANCHOR; CYTOKINE PRODUCTION; TUBERCULOSIS H37RV; IDENTIFICATION; INFECTION; RECEPTOR	The genus Tsukamurella is a member of the phylogenetic group nocardioform actinomycetes and is closely related to the genus Mycobacterium. The mycobacterial cell envelope contains lipoglycans, and of particular interest is lipoarabinomannan, one of the most potent mycobacterial immunomodulatory molecules. We have investigated the presence of lipoglycans in Tsukamurella paurometabola and report here the isolation and structural characterization of a new lipoarabinomannan variant, designated TpaLAM. Matrix-assisted laser desorption ionization-mass spectrometric analysis revealed that TpaLAM had an average molecular mass of 12.5 kDa and consequently was slightly smaller than Mycobacterium tuberculosis lipoarabinomannan. Using a range of chemical degradations, NMR experiments, capillary electrophoresis, and mass spectrometry analyses, TpaLAM revealed an original carbohydrate structure. Indeed, TpaLAM contained a mannosylphosphatidylmyo-inositol (MPI) anchor glycosylated by a linear (alpha1-->6)-Manp mannan domain, which is further substituted by an (alpha1-->5)-Araf chain. Half of the Araf units are further substituted at the O-2 position by a Manp-(alpha1-->2)-Manp-(alpha1--> dimannoside motif. Altogether, TpaLAM appears to be the most elaborated non-mycobacterial LAM molecule identified to date. TpaLAM was found to induce the pro-inflammatory cytokine tumor necrosis factor (TNF)-alpha when tested with either human or murine monocyte/macrophage cell lines. This induction was completely abrogated in the presence of an anti-toll-like receptor-2 (TLR-2) antibody, suggesting that TLR-2 participates in the mediation of TNF-alpha production in response to TpaLAM. Moreover, we established that the lipomannan core of TpaLAM is the primary moiety responsible for the observed TNF-alpha inducing activity. This conclusively demonstrates that a linear (alpha1-->6)-Manp chain, linked to the MPI anchor, is sufficient in providing pro-inflammatory activity.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; CNRS, Dept Mol Mech Mycobacterial Infect, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse 4, France	University of Birmingham; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Besra, GS (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	g.besra@bham.ac.uk	Nigou, Jérôme/D-6802-2019	Nigou, Jérôme/0000-0002-6233-2487; Besra, Gurdyal/0000-0002-5605-0395; GILLERON, Martine/0000-0002-2581-3302				ADAMS LB, 1993, INFECT IMMUN, V61, P4173, DOI 10.1128/IAI.61.10.4173-4181.1993; BARNES PF, 1992, J IMMUNOL, V149, P541; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BOCK K, 1974, J CHEM SOC        P2, V2, P293; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P66; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COLLINS MD, 1988, INT J SYST BACTERIOL, V38, P385, DOI 10.1099/00207713-38-4-385; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; Flaherty C, 1996, ZBL BAKT-INT J MED M, V285, P11, DOI 10.1016/S0934-8840(96)80017-X; Flaherty C, 1999, SYST APPL MICROBIOL, V22, P530, DOI 10.1016/S0723-2020(99)80005-8; Garton NJ, 2002, J BIOL CHEM, V277, P31722, DOI 10.1074/jbc.M203008200; Gibson KJC, 2003, BIOCHEM J, V372, P821, DOI 10.1042/BJ20030197; Gibson KJC, 2003, MICROBIOL-SGM, V149, P1437, DOI 10.1099/mic.0.26161-0; Gilleron M, 2000, J BIOL CHEM, V275, P677, DOI 10.1074/jbc.275.1.677; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; Gilleron M, 1997, J BIOL CHEM, V272, P117; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; GILLERON M, 2001, GLYCANS CELL INTERAC, P113; GOODFELLOW M, 1989, BERGEYS MANUAL SYSTE, V4, P2350; Granel F, 1996, CLIN INFECT DIS, V23, P839, DOI 10.1093/clinids/23.4.839; Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200; IKEDAFUJITA T, 1987, MICROBIOL IMMUNOL, V31, P289, DOI 10.1111/j.1348-0421.1987.tb03091.x; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645; LECHEVALIER HA, 1986, BERGEYS MANUAL SYSTE, V4, P2348; Ludwiczak P, 2002, MICROBIOL-SGM, V148, P3029, DOI 10.1099/00221287-148-10-3029; MCNEILL MM, 1994, CLIN MICROBIOL REV, V7, P357, DOI 10.1128/CMR.7.3.357-417.1994; Means TK, 1999, J IMMUNOL, V163, P6748; Nigou J, 1999, GLYCOCONJUGATE J, V16, P257, DOI 10.1023/A:1007046609341; Nigou J, 2000, J MOL BIOL, V299, P1353, DOI 10.1006/jmbi.2000.3821; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRAUSER H, 1967, PUBL FAC U PURKYNE B, V196, P196; PRINZ G, 1985, J CLIN MICROBIOL, V22, P472, DOI 10.1128/JCM.22.3.472-474.1985; Rey D, 1997, PATHOL BIOL, V45, P60; REY O, 1995, AIDS, V9, P1379, DOI 10.1097/00002030-199512000-00014; SERIANNI AS, 1984, J ORG CHEM, V49, P3292, DOI 10.1021/jo00192a009; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SHAPIRO CL, 1992, CLIN INFECT DIS, V14, P200, DOI 10.1093/clinids/14.1.200; Sidobre S, 2002, BIOCHEM J, V365, P89, DOI 10.1042/BJ20011659; Sidobre S, 2000, J BIOL CHEM, V275, P2415, DOI 10.1074/jbc.275.4.2415; Sutcliffe IC, 1995, ARCH ORAL BIOL, V40, P1119, DOI 10.1016/0003-9969(95)00086-0; Sutcliffe IC, 2000, ANTON LEEUW INT J G, V78, P195, DOI 10.1023/A:1026562610490; TSUKAMUR.M, 1971, J GEN MICROBIOL, V68, P15, DOI 10.1099/00221287-68-1-15; TSUKAMURA M, 1982, J CLIN MICROBIOL, V16, P604, DOI 10.1128/JCM.16.4.604-607.1982; VENISSE A, 1993, J BIOL CHEM, V268, P12401; Vercellone A, 1998, FRONT BIOSCI-LANDMRK, V3, pE149; Vignal C, 2003, J IMMUNOL, V171, P2014, DOI 10.4049/jimmunol.171.4.2014	56	28	29	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22973	22982		10.1074/jbc.M310906200	http://dx.doi.org/10.1074/jbc.M310906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15031299	hybrid			2022-12-25	WOS:000221570900024
J	Joyce, MG; Girvan, HM; Munro, AW; Leys, D				Joyce, MG; Girvan, HM; Munro, AW; Leys, D			A single mutation in cytochrome P450BM3 induces the conformational rearrangement seen upon substrate binding in the wild-type enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVOCYTOCHROME P-450 BM3; CRYSTAL-STRUCTURE; MYCOBACTERIUM-TUBERCULOSIS; HYDROXYLATION; MECHANISM; ACID; HEME; DOMAIN	The multidomain fatty-acid hydroxylase flavocytochrome P450 BM3 has been studied as a paradigm model for eukaryotic microsomal P450 enzymes because of its homology to eukaryotic family 4 P450 enzymes and its use of a eukaryotic-like diflavin reductase redox partner. High-resolution crystal structures have led to the proposal that substrate-induced conformational changes lead to removal of water as the sixth ligand to the heme iron. Concomitant changes in the heme iron spin state and heme iron reduction potential help to trigger electron transfer from the reductase and to initiate catalysis. Surprisingly, the crystal structure of the substrate-free A264E heme domain mutant reveals the enzyme to be in the conformation observed for substrate-bound wild-type P450, but with the iron in the low-spin state. This provides strong evidence that the spin-state shift observed upon substrate binding in wild-type P450 BM3 not only is caused indirectly by structural changes in the protein, but is a direct consequence of the presence of the substrate itself, similar to what has been observed for P450cam. The crystal structure of the palmitoleate-bound A264E mutant reveals that substrate binding promotes heme ligation by Glu(264), with little other difference from the palmitoleate-bound wild-type structure observable. Despite having a protein-derived sixth heme ligand in the substrate-bound form, the A264E mutant is catalytically active, providing further indication for structural rearrangement of the active site upon reduction of the heme iron, including displacement of the glutamate ligand to allow binding of dioxygen.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Leys, D (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	dl37@le.ac.uk	Munro, Andrew/G-5639-2019	Munro, Andrew/0000-0002-4642-180X; Girvan, Hazel/0000-0003-2299-8644				BODDUPALLI SS, 1992, ARCH BIOCHEM BIOPHYS, V292, P20, DOI 10.1016/0003-9861(92)90045-X; Colas C, 2003, CHEM REV, V103, P2305, DOI 10.1021/cr0204303; Cupp-Vickery J, 2000, P NATL ACAD SCI USA, V97, P3050, DOI 10.1073/pnas.050406897; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; Georgopapadakou NH, 1998, CURR OPIN MICROBIOL, V1, P547, DOI 10.1016/S1369-5274(98)80087-8; Girvan HM, 2004, J BIOL CHEM, V279, P23274, DOI 10.1074/jbc.M401716200; Guengerich FP, 2002, DRUG METAB REV, V34, P7, DOI 10.1081/DMR-120001386; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; Lee DS, 2003, J BIOL CHEM, V278, P9761, DOI 10.1074/jbc.M211575200; Leys D, 2003, J BIOL CHEM, V278, P5141, DOI 10.1074/jbc.M209928200; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; MILES JS, 1992, BIOCHEM J, V288, P503, DOI 10.1042/bj2880503; Modi S, 1996, NAT STRUCT BIOL, V3, P414, DOI 10.1038/nsb0596-414; Modi S, 1997, BIOCHEMISTRY-US, V36, P4461, DOI 10.1021/bi962633p; Munro AW, 1999, BIOCHEM SOC T, V27, P190, DOI 10.1042/bst0270190; Munro AW, 2002, TRENDS BIOCHEM SCI, V27, P250, DOI 10.1016/S0968-0004(02)02086-8; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NARHI LO, 1987, J BIOL CHEM, V262, P6683; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Noble MA, 1999, BIOCHEM J, V339, P371, DOI 10.1042/0264-6021:3390371; Okita RT, 2001, CURR DRUG METAB, V2, P265; Oliver CF, 1997, BIOCHEMISTRY-US, V36, P1567, DOI 10.1021/bi962826c; Ost TWB, 2001, BIOCHEMISTRY-US, V40, P13421, DOI 10.1021/bi010716m; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Roussel A, 1992, TURBO FRODO BIOGRAPH; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029	31	55	57	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23287	23293		10.1074/jbc.M401717200	http://dx.doi.org/10.1074/jbc.M401717200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15020590	hybrid			2022-12-25	WOS:000221570900062
J	Cumming, RC; Andon, NL; Haynes, PA; Park, M; Fischer, WH; Schubert, D				Cumming, RC; Andon, NL; Haynes, PA; Park, M; Fischer, WH; Schubert, D			Protein disulfide bond formation in the cytoplasm during oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SULFINIC ACID; REDOX REGULATION; TYROSINE PHOSPHATASES; ENDOPLASMIC-RETICULUM; MASS-SPECTROMETRY; HYDROGEN-PEROXIDE; MIXED DISULFIDES; LIVING CELLS; IDENTIFICATION; THIOREDOXIN	The majority of disulfide- linked cytosolic proteins are thought to be enzymes that transiently form disulfide bonds while catalyzing oxidation- reduction ( redox) processes. Recent evidence indicates that reactive oxygen species can act as signaling molecules by promoting the formation of disulfide bonds within or between select redox- sensitive proteins. However, few studies have attempted to examine global changes in disulfide bond formation following reactive oxygen species exposure. Here we isolate and identify disulfide- bonded proteins ( DSBP) in a mammalian neuronal cell line ( HT22) exposed to various oxidative insults by sequential nonreducing/ reducing two- dimensional SDS- PAGE combined with mass spectrometry. By using this strategy, several known cytosolic DSBP, such as peroxiredoxins, thioredoxin reductase, nucleoside- diphosphate kinase, and ribonucleotide-diphosphate reductase, were identified. Unexpectedly, a large number of previously unknown DSBP were also found, including those involved in molecular chaperoning, translation, glycolysis, cytoskeletal structure, cell growth, and signal transduction. Treatment of cells with a wide range of hydrogen peroxide concentrations either promoted or inhibited disulfide bonding of select DSBP in a concentration- dependent manner. Decreasing the ratio of reduced to oxidized glutathione also promoted select disulfide bond formation within proteins from cytoplasmic extracts. In addition, an epitope- tagged version of the molecular chaperone HSP70 forms mixed disulfides with both beta4-spectrin and adenomatous polyposis coli protein in the cytosol. Our findings indicate that disulfide bond formation within families of cytoplasmic proteins is dependent on the nature of the oxidative insult and may provide a common mechanism used to control multiple physiological processes.	Salk Inst Biol Studies, Cellular Neurobiol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92037 USA; Torrey Mesa Res Inst, Prot & Metabolite Dynam Dept, San Diego, CA 92121 USA	Salk Institute; Salk Institute	Schubert, D (corresponding author), Salk Inst Biol Studies, Cellular Neurobiol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schubert@salk.edu	Cumming, Robert/G-2185-2010	Haynes, Paul/0000-0003-1472-8249				Andon NL, 2002, PROTEOMICS, V2, P1156, DOI 10.1002/1615-9861(200209)2:9<1156::AID-PROT1156>3.0.CO;2-4; Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; BRODIE AE, 1990, ARCH BIOCHEM BIOPHYS, V276, P212, DOI 10.1016/0003-9861(90)90028-W; Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Chaudhuri AR, 2001, BIOCHEMISTRY-US, V40, P8834, DOI 10.1021/bi0101603; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; COAN C, 1992, ARCH BIOCHEM BIOPHYS, V295, P369, DOI 10.1016/0003-9861(92)90530-A; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Gasdaska JR, 1996, BIOCHEM PHARMACOL, V52, P1741, DOI 10.1016/S0006-2952(96)00595-3; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Ishige K, 2001, FREE RADICAL BIO MED, V30, P433, DOI 10.1016/S0891-5849(00)00498-6; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lind C, 2002, ARCH BIOCHEM BIOPHYS, V406, P229, DOI 10.1016/S0003-9861(02)00468-X; Linke K, 2003, ANTIOXID REDOX SIGN, V5, P425, DOI 10.1089/152308603768295168; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Maher P, 2000, CELL MOL LIFE SCI, V57, P1287, DOI 10.1007/PL00000766; Manalo DJ, 2002, BIOCHEMISTRY-US, V41, P2580, DOI 10.1021/bi0159682; MANNERVIK B, 1983, BIOCHEM J, V213, P519, DOI 10.1042/bj2130519; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Nystrom T, 2002, AGEING RES REV, V1, P693, DOI 10.1016/S1568-1637(02)00028-4; Ramsby ML, 1999, METH MOL B, V112, P53; RHEE SG, 2000, SCI STKE, V53, P1; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; SAADATZADEH MR, 2004, IN PRESS J BIOL CHEM, V279; Sagara Y, 1998, FREE RADICAL BIO MED, V24, P1375, DOI 10.1016/S0891-5849(97)00457-7; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Shenton D, 2003, BIOCHEM J, V374, P513, DOI 10.1042/BJ20030414; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SOMMER A, 1974, P NATL ACAD SCI USA, V71, P3946, DOI 10.1073/pnas.71.10.3946; Song EJ, 2000, BIOCHEMISTRY-US, V39, P10090, DOI 10.1021/bi000267a; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; Tan S, 2001, J CELL BIOL, V152, P997, DOI 10.1083/jcb.152.5.997; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Thomas JA, 2001, EXP GERONTOL, V36, P1519, DOI 10.1016/S0531-5565(01)00137-1; Vignols F, 2003, J BIOL CHEM, V278, P4516, DOI 10.1074/jbc.M210080200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	57	341	354	3	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21749	21758		10.1074/jbc.M312267200	http://dx.doi.org/10.1074/jbc.M312267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15031298	hybrid			2022-12-25	WOS:000221417100010
J	Leonoudakis, D; Conti, LR; Anderson, S; Radeke, CM; McGuire, LMM; Adams, ME; Froehner, SC; Yates, JR; Vandenberg, CA				Leonoudakis, D; Conti, LR; Anderson, S; Radeke, CM; McGuire, LMM; Adams, ME; Froehner, SC; Yates, JR; Vandenberg, CA			Protein trafficking and anchoring complexes revealed by proteomic analysis of inward rectifier potassium channel (Kir2.x)-associated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPSE-ASSOCIATED PROTEIN-97; AMINO-ACID-SEQUENCES; NMDA RECEPTOR; GUANYLATE KINASES; PDZ DOMAINS; POSTSYNAPTIC DENSITY; MOLECULAR CHARACTERIZATION; IDENTIFICATION TECHNOLOGY; EXCITATORY SYNAPSES; CLUSTERING ACTIVITY	Inward rectifier potassium (Kir) channels play important roles in the maintenance and control of cell excitability. Both intracellular trafficking and modulation of Kir channel activity are regulated by protein-protein interactions. We adopted a proteomics approach to identify proteins associated with Kir2 channels via the channel C-terminal PDZ binding motif. Detergent-solubilized rat brain and heart extracts were subjected to affinity chromatography using a Kir2.2 C-terminal matrix to purify channel-interacting proteins. Proteins were identified with multidimensional high pressure liquid chromatography coupled with electrospray ionization tandem mass spectrometry, N-terminal microsequencing, and immunoblotting with specific antibodies. We identified eight members of the MAGUK family of proteins (SAP97, PSD-95, Chapsyn-110, SAP102, CASK, Dlg2, Dlg3, and Pals2), two isoforms of Veli (Veli-1 and Veli-3), Mint1, and actin-binding LIM protein (abLIM) as Kir2.2-associated brain proteins. From heart extract purifications, SAP97, CASK, Veli-3, and Mint1 also were found to associate with Kir2 channels. Furthermore, we demonstrate for the first time that components of the dystrophin-associated protein complex, including alpha1-, beta1-, and beta2-syntrophin, dystrophin, and dystrobrevin, interact with Kir2 channels, as demonstrated by immunoaffinity purification and affinity chromatography from skeletal and cardiac muscle and brain. Affinity pull-down experiments revealed that Kir2.1, Kir2.2, Kir2.3, and Kir4.1 all bind to scaffolding proteins but with different affinities for the dystrophin-associated protein complex and SAP97, CASK, and Veli. Immunofluorescent localization studies demonstrated that Kir2.2 co-localizes with syntrophin, dystrophin, and dystrobrevin at skeletal muscle neuromuscular junctions. These results suggest that Kir2 channels associate with protein complexes that may be important to target and traffic channels to specific subcellular locations, as well as anchor and stabilize channels in the plasma membrane.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Scripps Research Institute; University of Washington; University of Washington Seattle	Vandenberg, CA (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	vandenbe@lifesci.ucsb.edu			NINDS NIH HHS [NS33145, NS43377] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033145, R01NS043377] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; Albrecht DE, 2002, NEUROSIGNALS, V11, P123, DOI 10.1159/000065053; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Becamel C, 2002, EMBO J, V21, P2332, DOI 10.1093/emboj/21.10.2332; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1998, J NEUROSCI, V18, P8805; Brown S, 2001, IUBMB LIFE, V51, P359; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cai C, 2002, J BIOL CHEM, V277, P31484, DOI 10.1074/jbc.M204354200; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Connors NC, 2002, J NEUROSCI, V22, P4321, DOI 10.1523/JNEUROSCI.22-11-04321.2002; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Dalloz C, 2003, HUM MOL GENET, V12, P1543, DOI 10.1093/hmg/ddg170; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; El-Hussein AE, 2000, SCIENCE, V290, P1364; El-Husseini AE, 2000, J BIOL CHEM, V275, P23904, DOI 10.1074/jbc.M909919199; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gee SH, 1998, J NEUROSCI, V18, P128; Horio Y, 1996, FEBS LETT, V379, P239, DOI 10.1016/0014-5793(95)01519-1; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Hunt CA, 1996, J NEUROSCI, V16, P1380; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Inanobe A, 2002, AM J PHYSIOL-CELL PH, V282, pC1396, DOI 10.1152/ajpcell.00615.2001; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Karnak D, 2002, J BIOL CHEM, V277, P46730, DOI 10.1074/jbc.M208781200; Karschin C, 1996, J NEUROSCI, V16, P3559; Karschin C, 1997, MOL CELL NEUROSCI, V10, P131, DOI 10.1006/mcne.1997.0655; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Laverty HG, 1998, GENOMICS, V53, P29, DOI 10.1006/geno.1998.5479; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonoudakis D, 2004, J BIOL CHEM, V279, P19051, DOI 10.1074/jbc.M400284200; Leonoudakis D, 2001, J CELL SCI, V114, P987; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Misawa H, 2001, J BIOL CHEM, V276, P9264, DOI 10.1074/jbc.M009334200; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Niethammer M, 1996, J NEUROSCI, V16, P2157; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Raab-Graham KF, 1998, J BIOL CHEM, V273, P19699, DOI 10.1074/jbc.273.31.19699; Roof DJ, 1997, J CELL BIOL, V138, P575, DOI 10.1083/jcb.138.3.575; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; TAKAHASHI N, 1994, J BIOL CHEM, V269, P23274; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; VANDENBERG CA, 1994, ION CHANNELS CARDIOV, P145; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Wu HJ, 1998, J CELL SCI, V111, P2365; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	76	163	173	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22331	22346		10.1074/jbc.M400285200	http://dx.doi.org/10.1074/jbc.M400285200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15024025	hybrid			2022-12-25	WOS:000221417100081
J	Chung, MK; Lee, H; Mizuno, A; Suzuki, M; Caterina, MJ				Chung, MK; Lee, H; Mizuno, A; Suzuki, M; Caterina, MJ			TRPV3 and TRPV4 mediate warmth-evoked currents in primary mouse keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNEL; VANILLOID RECEPTOR; EPOXYEICOSATRIENOIC ACIDS; CAPSAICIN-RECEPTOR; ACTIVATE TRPV4; ION-CHANNEL; EXPRESSION; HEAT; PROTEIN; PAIN	Recently, a family of temperature-activated ion channels has been identified in mammalian and nonmammalian species that appear to contribute to thermosensation. Two of these proteins, TRPV3 and TRPV4, are ion channels activated by modest increases in ambient temperature. Localization studies have indicated that both proteins, in addition to being expressed in sensory neurons, are also expressed in skin keratinocytes. These and other findings have suggested that keratinocytes might act in concert with sensory neurons to perceive our thermal environment. In this study, we demonstrate that primary keratinocytes isolated from mouse skin exhibit two distinct heat-evoked current responses to mild increases in ambient temperature. The more common of these response types bears considerable similarity to responses mediated by recombinant TRPV4, is absent in mice lacking this ion channel, and is restored upon TRPV4 reintroduction. The second, rarer response strongly resembles those mediated by recombinant TRPV3. Together, these findings demonstrate that keratinocytes can indeed act as thermosensory cells and that they do so via at least two distinct transduction mechanisms.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Jichi Med Sch, Dept Pharmacol, Minami Kawachi, Tochigi 3290498, Japan	Johns Hopkins University; Johns Hopkins University; Jichi Medical University	Caterina, MJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 408 Biophys Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	caterina@jhmi.edu	Chung, Man-Kyo/S-7433-2019	Chung, Man-Kyo/0000-0001-7637-1148; , Hyosang/0000-0002-3200-8678				Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; Denda M, 2002, J INVEST DERMATOL, V119, P1034, DOI 10.1046/j.1523-1747.2002.19505.x; Denda M, 2001, BIOCHEM BIOPH RES CO, V285, P1250, DOI 10.1006/bbrc.2001.5299; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; Guler AD, 2002, J NEUROSCI, V22, P6408; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENSEL H, 1960, J PHYSIOL-LONDON, V153, P113, DOI 10.1113/jphysiol.1960.sp006522; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; Inoue K, 2002, BIOCHEM BIOPH RES CO, V291, P124, DOI 10.1006/bbrc.2002.6393; Khodorova A, 2003, NAT MED, V9, P1055, DOI 10.1038/nm885; Komuves L, 2002, J CELL PHYSIOL, V192, P45, DOI 10.1002/jcp.10107; Ladd PA, 2003, J BIOL CHEM, V278, P35184, DOI 10.1074/jbc.M301666200; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Paladini RD, 1998, J CELL BIOL, V142, P1035, DOI 10.1083/jcb.142.4.1035; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Souslova V, 2000, NATURE, V407, P1015, DOI 10.1038/35039526; Southall MD, 2003, J PHARMACOL EXP THER, V304, P217, DOI 10.1124/jpet.102.040675; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Strotmann R, 2003, J BIOL CHEM, V278, P26541, DOI 10.1074/jbc.M302590200; Suzuki M, 2003, J BIOL CHEM, V278, P51448, DOI 10.1074/jbc.M308212200; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; TRON VA, 1990, J CLIN INVEST, V85, P1085, DOI 10.1172/JCI114539; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; WATT FM, 1984, J CELL BIOL, V99, P2211, DOI 10.1083/jcb.99.6.2211; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Xu HS, 2003, J BIOL CHEM, V278, P11520, DOI 10.1074/jbc.M211061200; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882	40	212	227	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21569	21575		10.1074/jbc.M401872200	http://dx.doi.org/10.1074/jbc.M401872200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15004014	hybrid			2022-12-25	WOS:000221273800123
J	Zhang, MS; MacDonald, AI; Hoyt, MA; Coffino, P				Zhang, MS; MacDonald, AI; Hoyt, MA; Coffino, P			Proteasomes begin ornithine decarboxylase digestion at the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE; INTRACELLULAR DEGRADATION; 26S PROTEASOME; PROTEIN; RECOGNITION; MECHANISMS; EXPRESSION; SEQUENCE; SIC1	Proteasomes denature folded protein substrates and thread them through a narrow pore that leads to the sequestered sites of proteolysis. Whether a protein substrate initiates insertion from its N or C terminus or in a random orientation has not been determined for any natural substrate. We used the labile enzyme ornithine decarboxylase (ODC), which is recognized by the proteasome via a 37-residue C-terminal tag, to answer this question. Three independent approaches were used to assess orientation as follows. 1) The 461-residue ODC protein chain was interrupted at position 305. The C-terminal fragment was degraded by purified proteasomes, but because processivity requires continuity of the polypeptide chain, the N-terminal fragment was spared. 2) A proteasome-inhibitory viral sequence prevented degradation when introduced near the C terminus but not when inserted elsewhere in ODC. 3) A bulky tightly folded protein obstructed in vivo degradation most effectively when positioned near the C terminus. These data demonstrate that the proteasome initiates degradation of this native substrate at the C terminus. The co-localization of entry site and degradation tag to the ODC C terminus suggests that recognition tags determine the site for initiating entry. Flexibility of a polypeptide terminus may promote the initiation of degradation.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Coffino, P (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, 513 Parnassus Ave, San Francisco, CA 94143 USA.	pcoffin@itsa.ucsf.edu		Coffino, Philip/0000-0003-0344-5083	NIGMS NIH HHS [R01 GM 45335] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045335] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Collinet B, 2000, J BIOL CHEM, V275, P17428, DOI 10.1074/jbc.M000666200; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; Hoyt MA, 2003, J BIOL CHEM, V278, P12135, DOI 10.1074/jbc.M211802200; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSTON JA, 1995, J BIOL CHEM, V270, P8172, DOI 10.1074/jbc.270.14.8172; LAUX G, 1988, EMBO J, V7, P769, DOI 10.1002/j.1460-2075.1988.tb02874.x; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Leonchiks A, 1998, FEBS LETT, V440, P365, DOI 10.1016/S0014-5793(98)01488-4; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; Matouschek A, 2003, CURR OPIN STRUC BIOL, V13, P98, DOI 10.1016/S0959-440X(03)00010-1; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; OSTERMAN AL, 1995, BIOCHEMISTRY-US, V34, P13431, DOI 10.1021/bi00041a021; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Reid BG, 2001, P NATL ACAD SCI USA, V98, P3768, DOI 10.1073/pnas.071043698; ROSENBERGHASSON Y, 1991, BIOCHEM J, V277, P683, DOI 10.1042/bj2770683; Sambrook J, 2001, MOL CLONING LAB MANU; SCHWEITZER BI, 1989, J BIOL CHEM, V264, P20786; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Verma R, 2001, MOL CELL, V8, P439, DOI 10.1016/S1097-2765(01)00308-2; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158; Zhang MS, 2004, J BIOL CHEM, V279, P8635, DOI 10.1074/jbc.M310449200; Zhu C, 1999, J BIOL CHEM, V274, P26425, DOI 10.1074/jbc.274.37.26425	40	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20959	20965		10.1074/jbc.M314043200	http://dx.doi.org/10.1074/jbc.M314043200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016805	hybrid			2022-12-25	WOS:000221273800050
J	Yamamoto, Y; Irie, K; Asada, M; Mino, A; Mandai, K; Takai, Y				Yamamoto, Y; Irie, K; Asada, M; Mino, A; Mandai, K; Takai, Y			Direct binding of the human homologue of the Drosophila disc large tumor suppressor gene to seven-pass transmembrane proteins, tumor endothelial marker 5 (TEM5), and a novel TEM5-like protein	ONCOGENE			English	Article						hDlg; TEM5; tumor suppressor; G-protein-coupled receptor; PDZ domain	COUPLED RECEPTORS; CELL-ADHESION; GUANYLATE KINASES; K+ CHANNELS; SAP97; MEMBRANE; FAMILY; JUNCTIONS; DLG; PROLIFERATION	The human homologue of the Drosophila discs large tumor suppressor gene ( hDlg) is a member of the membrane-associated guanylate kinase family with three PSD-95/Dlg/ZO-1 (PDZ) domains. hDlg has been shown to bind tumor suppressor proteins, adenomatous polyposis coli (APC) and protein tyrosine phosphatase and tensin homologue ( PTEN), and several viral oncoproteins, and has been implicated in the negative regulation of cell proliferation. hDlg has furthermore been shown to localize at the plasma membrane of synapses and to scaffold cell surface receptors and channels. In epithelial cells, hDlg localizes at the basolateral plasma membrane, but its localization mechanism is unknown. We searched here for a transmembrane protein that directly bound to hDlg. hDlg bound tumor endothelial marker 5 (TEM5), a seven-pass transmembrane protein that is homologous to the family B of G-protein-coupled receptors (GPCRs). TEM5 has previously been reported to display elevated expression during tumor angiogenesis and neoangiogenesis. The PDZ domains of hDlg bound the C-terminal PDZ-binding motif of TEM5. The expression of TEM5 was detected in endothelial cells of embryonic liver, where hDlg colocalized with TEM5. hDlg furthermore bound a novel seven-pass transmembrane protein, which was homologous to TEM5, and was named here a TEM5-like protein (TEM5-like). These results suggest that hDlg localizes at the plasma membrane through TEM5 and TEM5-like and furthermore scaffolds these GPCRs in endothelial cells during tumor angiogenesis and neoangiogenesis.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp		Mandai, Kenji/0000-0002-0115-6635				BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budnik V, 1996, CURR OPIN NEUROBIOL, V6, P858, DOI 10.1016/S0959-4388(96)80038-9; Cai C, 2002, J BIOL CHEM, V277, P31484, DOI 10.1074/jbc.M204354200; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Fredriksson R, 2003, BIOCHEM BIOPH RES CO, V301, P725, DOI 10.1016/S0006-291X(03)00026-3; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Murata M, 2001, AM J PHYSIOL-HEART C, V281, pH2575, DOI 10.1152/ajpheart.2001.281.6.H2575; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Reuver SM, 1998, J CELL SCI, V111, P1071; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	31	37	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3889	3897		10.1038/sj.onc.1207495	http://dx.doi.org/10.1038/sj.onc.1207495			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021905				2022-12-25	WOS:000221382000001
J	Rae, FK; Martinez, G; Gillinder, KR; Smith, A; Shooter, G; Forrest, AR; Grimmond, SM; Little, MH				Rae, FK; Martinez, G; Gillinder, KR; Smith, A; Shooter, G; Forrest, AR; Grimmond, SM; Little, MH			Anlaysis of complementary expression profiles following WT1 induction versus repression reveals the cholesterol/fatty acid synthetic pathways as a possible major target of WT1	ONCOGENE			English	Article						WT1; mevalonate; cholesterol; expression profiling	TUMOR-SUPPRESSOR GENE; DENSITY-LIPOPROTEIN RECEPTOR; WILMS-TUMOR; ORNITHINE-DECARBOXYLASE; MUTANT PROTEINS; BINDING; CELLS; MUTATIONS; RAS; WILMS-TUMOR-1	The Wilms' tumour suppressor gene, WT1, encodes a zinc-finger protein that is mutated in Wilms' tumours and other malignancies. WT1 is one of the earliest genes expressed during kidney development. WT1 proteins can activate and repress putative target genes in vitro, although the in vivo relevance of such target genes often remains unverified. To better understand the role of WT1 in tumorigenesis and kidney development, we need to identify downstream target genes. In this study, we have expression pro. led human embryonic kidney 293 cells stably transfected to allow inducible WT1 expression and mouse mesonephric M15 cells transfected with a WT1 antisense construct to abolish endogenous expression of all WT1 isoforms to identify WT1-responsive genes. The complementary overlap between the two cell lines revealed a pronounced repression of genes involved in cholesterol biosynthesis by WT1. This pathway is transcriptionally regulated by the sterol responsive element-binding proteins (SREBPs). Here, we provide evidence that the C-terminal end of the WT1 protein can directly interact with SREBP, suggesting that WT1 may modify the transcriptional function of SREBPs via a direct protein-protein interaction. Therefore, the tumour suppressor activities of WT1 may be achieved by repressing the mevalonate pathway, thereby controlling cellular proliferation and promoting terminal differentiation.	Univ Queensland, Queensland Biosci Precinct, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland	Little, MH (corresponding author), Univ Queensland, Queensland Biosci Precinct, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	m.little@imb.uq.edu.au	Little, Melissa H/A-6170-2010; Grimmond, Sean/K-3246-2019; Gillinder, Kevin/I-6224-2013; Smith, Aaron/A-8329-2010; Forrest, Alistair/A-6597-2008; Grimmond, Sean M/J-5304-2016	Little, Melissa H/0000-0003-0380-2263; Grimmond, Sean/0000-0002-8102-7998; Gillinder, Kevin/0000-0002-1221-9718; Forrest, Alistair/0000-0003-4543-1675; Grimmond, Sean M/0000-0002-8102-7998				Bassa BV, 1999, BBA-MOL CELL RES, V1449, P137, DOI 10.1016/S0167-4889(99)00007-5; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Denoyelle C, 2003, CELL SIGNAL, V15, P327, DOI 10.1016/S0898-6568(02)00124-9; DENYS P, 1967, ARCH FR PEDIATR, V24, P729; DRASH A, 1970, J PEDIATR-US, V76, P585, DOI 10.1016/S0022-3476(70)80409-7; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grimmond S, 2000, HUM MOL GENET, V9, P1553, DOI 10.1093/hmg/9.10.1553; Gurates B, 2002, J CLIN ENDOCR METAB, V87, P4369, DOI 10.1210/jc.2002-020522; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; HEWITT SM, 1995, CANCER RES, V55, P5386; Holmes G, 1997, BIOCHEM BIOPH RES CO, V233, P723, DOI 10.1006/bbrc.1997.6545; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; KingUnderwood L, 1996, BLOOD, V87, P2171, DOI 10.1182/blood.V87.6.2171.bloodjournal8762171; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LADANYI M, 1994, CANCER RES, V54, P2837; Ladomery M, 2003, J CELL SCI, V116, P1539, DOI 10.1242/jcs.00324; Ladomery MR, 1999, J BIOL CHEM, V274, P36520, DOI 10.1074/jbc.274.51.36520; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lee TH, 2001, PHYSIOL GENOMICS, V7, P187, DOI 10.1152/physiolgenomics.00046.2001; Li RS, 1999, EXP CELL RES, V247, P257, DOI 10.1006/excr.1998.4361; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; Llorente-Cortes V, 2002, CIRCULATION, V106, P3104, DOI 10.1161/01.CIR.0000041434.28573.0B; Lopez D, 2001, ENDOCRINOLOGY, V142, P5097, DOI 10.1210/en.142.12.5097; LUO XN, 1995, ONCOGENE, V11, P743; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Oda H, 1999, KIDNEY INT, V56, pS2, DOI 10.1046/j.1523-1755.1999.07101.x; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1994, HUM MOL GENET, V3, P1633, DOI 10.1093/hmg/3.9.1633; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REDDY JC, 1995, J BIOL CHEM, V270, P29976; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Sakakura Y, 2001, BIOCHEM BIOPH RES CO, V286, P176, DOI 10.1006/bbrc.2001.5375; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; Simms LA, 1995, EUR J CANCER, V31A, P2270, DOI 10.1016/0959-8049(95)00474-2; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; Valerius MT, 2002, P NATL ACAD SCI USA, V99, P8090, DOI 10.1073/pnas.122229199	56	22	23	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3067	3079		10.1038/sj.onc.1207360	http://dx.doi.org/10.1038/sj.onc.1207360			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15021918				2022-12-25	WOS:000220845200011
J	Tambe, Y; Isono, T; Haraguchi, S; Yoshioka-Yamashita, A; Yutsudo, M; Inoue, H				Tambe, Y; Isono, T; Haraguchi, S; Yoshioka-Yamashita, A; Yutsudo, M; Inoue, H			A novel apoptotic pathway induced by the drs tumor suppressor gene	ONCOGENE			English	Article						drs; apoptosis; endoplasmic reticulum caspase-12; ASY/Nogo-B/RTN-x(S)	ENDOPLASMIC-RETICULUM STRESS; MESSENGER-RNA; DOWN-REGULATION; CYTOCHROME-C; CASPASE-12; RECEPTOR; PROTEIN; CELLS; BCL-2; SELECTINS	The drs gene was originally isolated as a suppressor against v-src transformation. Expression of drs mRNA was markedly downregulated in a variety of human cancer cell lines and tissues, suggesting that the drs gene acts as a tumor suppressor. In this study, we found that ectopic expression of the Drs protein induced apoptosis in human cancer cell lines. Analyses using deletion mutants of drs revealed that both the C-terminal region and the three consensus repeats in the N-terminal region are essential for the induction of apoptosis. Caspase-12, -9, and -3 were sequentially activated by drs, and specific inhibitors of caspase-3 and -9 suppressed drs-induced apoptosis. The release of cytochrome c from the mitochondria into the cytoplasm was not observed in apoptosis by drs, suggesting that the mitochondrial pathway does not mediate drs-induced apoptosis. Furthermore, we found that the Drs protein can interact with ASY/Nogo-B/RTN-x(S), an apoptosis-inducing protein localized in the endoplasmic reticulum, and that coexpression of these genes increased the efficiency of apoptosis. These results indicated that Drs induces apoptosis by a novel pathway mediated by ASY/Nogo-B/RTN-x(S), caspase-12, -9, and -3.	Shiga Univ Med Sci, Dept Microbiol, Shiga 5202192, Japan; Shiga Univ Med Sci, Cent Res Lab, Shiga 5202192, Japan; Osaka Univ, Microbial Dis Res Inst, Osaka 5650871, Japan	Shiga University of Medical Science; Shiga University of Medical Science; Osaka University	Inoue, H (corresponding author), Shiga Univ Med Sci, Dept Microbiol, Shiga 5202192, Japan.	hirokazu@belle.shiga-med.ac.jp						Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kim CJ, 2003, HUM PATHOL, V34, P654, DOI 10.1016/S0046-8177(03)00240-5; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li Q, 2001, ONCOGENE, V20, P3929, DOI 10.1038/sj.onc.1204536; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Mukaisho K, 2002, JPN J CANCER RES, V93, P888, DOI 10.1111/j.1349-7006.2002.tb01334.x; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Oertle T, 2003, ONCOGENE, V22, P1390, DOI 10.1038/sj.onc.1206278; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Pan J, 1996, FEBS LETT, V383, P21; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Rudner J, 2001, J CELL SCI, V114, P4161; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shimakage M, 2000, INT J CANCER, V87, P5, DOI 10.1002/1097-0215(20000701)87:1<5::AID-IJC2>3.0.CO;2-Y; Shimakage M, 2002, HUM PATHOL, V33, P615, DOI 10.1053/hupa.2002.125373; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Yamashita A, 1999, ONCOGENE, V18, P4777, DOI 10.1038/sj.onc.1202852	36	37	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					2977	2987		10.1038/sj.onc.1207419	http://dx.doi.org/10.1038/sj.onc.1207419			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15021917				2022-12-25	WOS:000220845200001
J	Wei, L; Taffet, GE; Khoury, DS; Bo, J; Li, Y; Yatani, A; Delaughter, MC; Klevitsky, R; Hewett, TE; Robbins, J; Michael, LH; Schneider, MD; Entman, ML; Schwartz, RJ				Wei, L; Taffet, GE; Khoury, DS; Bo, J; Li, Y; Yatani, A; Delaughter, MC; Klevitsky, R; Hewett, TE; Robbins, J; Michael, LH; Schneider, MD; Entman, ML; Schwartz, RJ			Disruption of Rho signaling results in progressive atrioventricular conduction defects while ventricular function remains preserved	FASEB JOURNAL			English	Article						Rho GDI alpha transgenic mouse; cardiac contractile function; atrial arrhythmias; connexin 40	CARDIAC MYOCYTE HYPERTROPHY; JUNCTION PROTEIN CONNEXIN40; GTP-BINDING PROTEINS; CONTRACTILE FAILURE; TRANSGENIC MICE; FAMILY GTPASES; BUNDLE-BRANCH; HEART-FAILURE; SYSTEM; MOUSE	Recent studies suggest that RhoA and Rac1 mediate hypertrophic signals in cardiac myocyte hypertrophy. However, effects on cardiac function caused by inhibition of their activity in the heart have yet to be evaluated. Cardiac-specific inhibition of Rho family protein activities was achieved by expressing Rho GDIalpha, an endogenous specific GDP dissociation inhibitor for Rho family proteins, using the alpha-myosin heavy-chain promoter. Increased expression of Rho GDIa led to atrial arrhythmias and mild ventricular hypertrophy in adult mice (4-7 months). However, left ventricular systolic and diastolic function was largely preserved before and after the development of cardiac hypertrophy, indicating that Rho GTPases are not required to maintain ventricular contractile function under basal physiological condition. Electrocardiography and intracardiac electrophysiological studies revealed first-degree atrioventricular (AV) block in the transgenic heart at 1 week of age, which further progressed into second-degree AV block at 4 weeks of age before the development of cardiac hypertrophy. Expression of connexin 40 dramatically decreased from 1 week to 4 weeks of age in the transgenic heart, which may contribute in part to the conduction defects in the transgenic mice. This study provides novel evidence for an important role of Rho GTPases in regulating AV conduction.	Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, DeBakey Heart Ctr, Houston, TX 77030 USA; Baylor Coll Med, Cardiol Sect, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Newark, NJ 07103 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Rutgers State University New Brunswick; Rutgers State University Medical Center; Cincinnati Children's Hospital Medical Center	Wei, L (corresponding author), Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, 1 Baylor Plaza,Room 506D, Houston, TX 77030 USA.	lwei@bcm.tmc.edu	Hewett, Timothy/G-1023-2011; Hewett, Timothy E/E-3241-2011; Hewett, Timothy Edwin/GLT-1556-2022	Schneider, Michael/0000-0001-9645-1938	NHLBI NIH HHS [R01 HL072897-01, R01 HL072897] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072897] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; Aronow BJ, 2001, PHYSIOL GENOMICS, V6, P19, DOI 10.1152/physiolgenomics.2001.6.1.19; Berul CI, 1996, CIRCULATION, V94, P2641, DOI 10.1161/01.CIR.94.10.2641; Bevilacqua LM, 2000, J INTERV CARD ELECTR, V4, P459, DOI 10.1023/A:1009800328836; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Clerk A, 2000, CIRC RES, V86, P1019, DOI 10.1161/01.RES.86.10.1019; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; GOURDIE RG, 1993, J CELL SCI, V105, P985; Guerrero PA, 1997, J CLIN INVEST, V99, P1991, DOI 10.1172/JCI119367; Gulick J, 1997, CIRC RES, V80, P655, DOI 10.1161/01.RES.80.5.655; Hagendorff A, 1999, CIRCULATION, V99, P1508, DOI 10.1161/01.CIR.99.11.1508; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; Kasahara H, 2001, J CLIN INVEST, V108, P189, DOI 10.1172/JCI200112694; Kirchhoff S, 1998, CURR BIOL, V8, P299, DOI 10.1016/S0960-9822(98)70114-9; Laufs U, 2000, CIRCULATION, V102, P3104; Laufs U, 2002, CARDIOVASC RES, V53, P911, DOI 10.1016/S0008-6363(01)00540-5; Moorman AFM, 1998, CIRC RES, V82, P629, DOI 10.1161/01.RES.82.6.629; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Patel R, 2001, CIRCULATION, V104, P317, DOI 10.1161/hc2801.094031; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Simon AM, 1998, CURR BIOL, V8, P295, DOI 10.1016/S0960-9822(98)70113-7; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Sussman MA, 2000, J CLIN INVEST, V105, P875, DOI 10.1172/JCI8497; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Taffet GE, 1996, AM J PHYSIOL-HEART C, V270, pH2204; Takemoto M, 2001, J CLIN INVEST, V108, P1429, DOI 10.1172/JCI200113350; Tamaddon HS, 2000, CIRC RES, V87, P929, DOI 10.1161/01.RES.87.10.929; Thomas SA, 1998, CIRCULATION, V97, P686, DOI 10.1161/01.CIR.97.7.686; UEDA T, 1990, J BIOL CHEM, V265, P9373; VAN AL, 1997, GENE DEV, V11, P2295; van Rijen HVM, 2001, CIRCULATION, V103, P1591; Verheule S, 1999, J CARDIOVASC ELECTR, V10, P1380, DOI 10.1111/j.1540-8167.1999.tb00194.x; Wei L, 2002, DEVELOPMENT, V129, P1705; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037	41	39	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					857	+		10.1096/fj.03-0664fje	http://dx.doi.org/10.1096/fj.03-0664fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033930				2022-12-25	WOS:000220522800015
J	Sadlier, DM; Connolly, SB; Kieran, NE; Roxburgh, S; Brazil, DP; Kairaitis, L; Wang, Y; Harris, DCH; Doran, P; Brady, HR				Sadlier, DM; Connolly, SB; Kieran, NE; Roxburgh, S; Brazil, DP; Kairaitis, L; Wang, Y; Harris, DCH; Doran, P; Brady, HR			Sequential extracellular matrix-focused and baited-global cluster analysis of serial transcriptomic profiles identifies candidate modulators of renal tubulointerstitial fibrosis in murine adriamycin-induced nephropathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TENASCIN-C EXPRESSION; BETA-BINDING-PROTEIN; GROWTH-FACTOR-BETA; GENE-EXPRESSION; UP-REGULATION; TGF-BETA; MESANGIAL CELLS; IN-VIVO; ENDOGLIN; SPARC	Transcriptome analysis using microarray technology represents a powerful unbiased approach for delineating pathogenic mechanisms in disease. Here molecular mechanisms of renal tubulointerstitial fibrosis (TIF) were probed by monitoring changes in the renal transcriptome in a glomerular disease-dependent model of TIF ( adriamycin nephropathy) using Affymetrix (mu74av2) microarray coupled with sequential primary biological function-focused and secondary "baited"-global cluster analysis of gene expression profiles. Primary cluster analysis focused on mRNAs encoding matrix proteins and modulators of matrix turnover as classified by Onto-Compare and Gene Ontology and identified both molecules and pathways already implicated in the pathogenesis of TIF ( e. g. transforming growth factor beta1-CTGF-fibronectin- 1 pathway) and novel TIF-associated genes ( e. g. SPARC and Matrilin-2). Specific gene expression patterns identified by primary extracellular matrix-focused cluster analysis were then used as bioinformatic bait in secondary global clustering, with which to search the renal transcriptome for novel modulators of TIF. Among the genes clustering with ECM proteins in the latter analysis were endoglin, clusterin, and gelsolin. In several notable cases ( e. g. claudin-1 and meprin-1beta) the pattern of gene expression identified in adriamycin nephropathy in vivo was replicated during transdifferentiation of renal tubule epithelial cells to a fibroblast-like phenotype in vitro on exposure to transforming growth factor-beta and epidermal growth factor suggesting a role in fibrogenesis. The further exploration of these complex gene networks should shed light on the core molecular pathways that underpin TIF in renal disease.	Univ Coll Dublin, Mater Misericordiae Univ Hosp, Dept Med & Therapeut, Conway Inst Biomol & Biomed Res, Dublin 7, Ireland; Dublin Mol Med Ctr, Dublin, Ireland; Univ Sydney, Westmead Millenium Inst, Ctr Transplantat & Renal Res, Sydney, NSW 2006, Australia	Mater Misericordiae University Hospital; University College Dublin; Trinity College Dublin; University College Dublin; University of Sydney; Westmead Institute for Medical Research	Sadlier, DM (corresponding author), Univ Coll Dublin, Mater Misericordiae Univ Hosp, Dept Med & Therapeut, Conway Inst Biomol & Biomed Res, 44 Eccles St, Dublin 7, Ireland.	dsadlier.genome@mater.ie	Harris, David/W-4786-2019	Doran, Peter/0000-0003-2064-5335; Brazil, Derek/0000-0003-1375-1076				Anders HJ, 2003, KIDNEY INT, V63, P401, DOI 10.1046/j.1523-1755.2003.00750.x; Aoyama I, 2002, NEPHRON, V92, P635, DOI 10.1159/000064108; Ashburner M, 2001, GENOME RES, V11, P1425; Atula T, 2003, ANTICANCER RES, V23, P3051; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Crean John KG, 2001, Expert Opin Ther Targets, V5, P519; DELACHAPELLE A, 1992, NAT GENET, V2, P157, DOI 10.1038/ng1092-157; Devarajan P, 2002, AM J KIDNEY DIS, V39, P625, DOI 10.1053/ajkd.2002.31420; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; Eikmans M, 2003, J PATHOL, V200, P526, DOI 10.1002/path.1417; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FLOEGE J, 1993, AM J PATHOL, V142, P637; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; Francki A, 2001, TRENDS CARDIOVAS MED, V11, P32, DOI 10.1016/S1050-1738(01)00081-0; Frank S, 2002, J BIOL CHEM, V277, P19071, DOI 10.1074/jbc.M202146200; Gore-Hyer E, 2002, AM J PHYSIOL-RENAL, V283, pF707, DOI 10.1152/ajprenal.00007.2002; GOUGOS A, 1988, J IMMUNOL, V141, P1925; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Gupta S, 2000, KIDNEY INT, V58, P1389, DOI 10.1046/j.1523-1755.2000.00301.x; HAVERTY TP, 1988, J CELL BIOL, V107, P1359, DOI 10.1083/jcb.107.4.1359; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jahkola T, 1998, BRIT J CANCER, V78, P1507, DOI 10.1038/bjc.1998.714; Jin K, 2002, NEUROCHEM RES, V27, P1105, DOI 10.1023/A:1020913123054; JOMARY C, 1993, MOL BRAIN RES, V20, P274, DOI 10.1016/0169-328X(93)90052-Q; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Kieran NE, 2003, KIDNEY INT, V64, P480, DOI 10.1046/j.1523-1755.2003.00106.x; Klatt AR, 2001, J BIOL CHEM, V276, P17267, DOI 10.1074/jbc.M100587200; Kruse MN, 2004, BIOCHEM J, V378, P383, DOI 10.1042/BJ20031163; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Leuenberger B, 2003, BIOCHEM J, V369, P659, DOI 10.1042/BJ20021398; MAURY CPJ, 1990, FEBS LETT, V276, P75, DOI 10.1016/0014-5793(90)80510-P; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Miki R, 2001, P NATL ACAD SCI USA, V98, P2199, DOI 10.1073/pnas.041605498; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Okada H, 1996, CONTRIB NEPHROL, V118, P147; Okamoto Y, 2001, AM J PATHOL, V159, P639, DOI 10.1016/S0002-9440(10)61735-X; Pichler RH, 1996, AM J PATHOL, V148, P1153; Piecha D, 2002, BIOCHEM J, V367, P715, DOI 10.1042/BJ20021069; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Rees WD, 1999, J NUTR, V129, P1532, DOI 10.1093/jn/129.8.1532; Ricardo SD, 1996, AM J PHYSIOL-RENAL, V270, pF669, DOI 10.1152/ajprenal.1996.270.4.F669; Rodriguez-Barbero A, 2001, BIOCHEM BIOPH RES CO, V282, P142, DOI 10.1006/bbrc.2001.4526; Rodriguez-Pena A, 2001, NEPHROL DIAL TRANSPL, V16, P34, DOI 10.1093/ndt/16.suppl_1.34; Rodriguez-Pena A, 2002, HYPERTENSION, V40, P713, DOI 10.1161/01.HYP.0000037429.73954.27; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; SANCHEZLOZADA LG, 2003, KIDNEY INT S86, V64, P9; Santilli G, 2003, J BIOL CHEM, V278, P38214, DOI 10.1074/jbc.C300252200; Sarwal M, 2003, NEW ENGL J MED, V349, P125, DOI 10.1056/NEJMoa035588; Spangenberg C, 1998, GENOMICS, V48, P178, DOI 10.1006/geno.1997.5170; Strutz F, 2000, NEPHROL DIAL TRANSPL, V15, P1729, DOI 10.1093/ndt/15.11.1729; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Taneda S, 2003, J AM SOC NEPHROL, V14, P968, DOI 10.1097/01.ASN.0000054498.83125.90; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; Truong LD, 1996, NEPHRON, V72, P579, DOI 10.1159/000188943; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Twal WO, 2001, J CELL SCI, V114, P4587; Visapaa H, 2003, UROLOGY, V61, P845, DOI 10.1016/S0090-4295(02)02404-4; Wang Y, 2000, KIDNEY INT, V58, P1797, DOI 10.1046/j.1523-1755.2000.00342.x; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Yoshida T, 2002, KIDNEY INT, V61, P1646, DOI 10.1046/j.1523-1755.2002.00341.x	66	43	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29670	29680		10.1074/jbc.M313408200	http://dx.doi.org/10.1074/jbc.M313408200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15033991	hybrid			2022-12-25	WOS:000222445300103
J	Sweet, CR; Ribeiro, AA; Raetz, CRH				Sweet, CR; Ribeiro, AA; Raetz, CRH			Oxidation and transamination of the 3 ''-position of UDP-N-acetylglucosamine by enzymes from Acidithiobacillus ferrooxidans - Role in the formation of lipid a molecules with four amide-linked acyl chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; THIOBACILLUS-FERROOXIDANS; RHODOPSEUDOMONAS-VIRIDIS; A COMPONENT; ACID; LIPOPOLYSACCHARIDE; IDENTIFICATION; BIOSYNTHESIS; PROTEIN; EXPRESSION	Lipid A, a major component of the outer membranes of Escherichia coli and other Gram-negative bacteria, is usually constructed around a beta-1',6-linked glucosamine disaccharide backbone. However, in organisms like Acidithiobacillus ferrooxidans, Leptospira interrogans, Mesorhizobium loti, and Legionella pneumophila, one or both glucosamine residues are replaced with the sugar 2,3-diamino-2,3-dideoxy-D-glucopyranose. We now report the identification of two proteins, designated GnnA and GnnB, involved in the formation of the 2,3-diamino2,3-dideoxy-D-glucopyranose moiety. The genes encoding these proteins were recognized because of their location between lpxA and lpxB in A. ferrooxidans. Based upon their sequences, the 313-residue GnnA protein was proposed to catalyze the NAD(+)-dependent oxidation of the glucosamine 3-OH of UDP-GlcNAc, and the 369-residue GnnB protein was proposed to catalyze the subsequent transamination to form UDP2-acetamido-3-amino2,3-dideoxy-alpha-D-glucopyranose (UDP-GlcNAc3N). Both gnnA and gnnB were cloned and expressed in E. coli using pET23c+. In the presence of L-glutamate and NAD(+), both proteins were required for the conversion of [alpha-P-32]UDP-GlcNAc to a novel, less negatively charged sugar nucleotide shown to be [alpha-P-32]UDP-GlcNAc3N. The latter contained a free amine, as judged by modification with acetic anhydride. Using recombinant GnnA and GnnB, similar to0.4 mg of the presumptive UDP-GlcNAc3N was synthesized. The product was purified and subjected to NMR analysis to confirm the replacement of the GlcNAc 3-OH group with an equatorial NH2. As shown in the accompanying papers ( Sweet, C. R., Williams, A. H., Karbarz, M. J., Werts, C., Kalb, S. R., Cotter, R. J., and Raetz, C. R. H. (2004) J. Biol. Chem. 279, 25411-25419; Que-Gewirth, N. L. S., Ribeiro, A. A., Kalb, S. R., Cotter, R. J., Bulach, D. M., Adler, B., Saint Girons, I., Werts, C., and Raetz, C. R. H. ( 2004) J. Biol. Chem. 279, 25420-25429), UDP-GlcNAc3N is selectively acylated by LpxAs of A. ferrooxidans, L. interrogans, and M. loti. UDP-GlcNAc3N may be useful as a substrate analog for diverse enzymes that utilize UDP-GlcNAc.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, NMR Spect Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NCI NIH HHS [P30-CA-14236] Funding Source: Medline; NIGMS NIH HHS [GM-51310] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Basu SS, 2000, ANAL BIOCHEM, V280, P173, DOI 10.1006/abio.2000.4479; BERG JM, 2002, BIOCHEMISTRY-US, P495; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Breazeale SD, 2003, J BIOL CHEM, V278, P24731, DOI 10.1074/jbc.M304043200; Breazeale SD, 2002, J BIOL CHEM, V277, P2886, DOI 10.1074/jbc.M109377200; Chen HW, 1999, J AM CHEM SOC, V121, P7166, DOI 10.1021/ja991213v; Clausen T, 1996, J MOL BIOL, V262, P202, DOI 10.1006/jmbi.1996.0508; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; Creuzenet C, 2000, J BIOL CHEM, V275, P34873, DOI 10.1074/jbc.M006369200; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Hallis TM, 1999, ACCOUNTS CHEM RES, V32, P579, DOI 10.1021/ar9602056; HASELBERGER A, 1987, TRIANGLE, V26, P33; He XMM, 2002, ANNU REV BIOCHEM, V71, P701, DOI 10.1146/annurev.biochem.71.110601.135339; INGLEDEW WJ, 1982, BIOCHIM BIOPHYS ACTA, V683, P89, DOI 10.1016/0304-4173(82)90007-6; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; KEILICH G, 1976, CARBOHYD RES, V51, P129, DOI 10.1016/S0008-6215(00)84042-2; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; MORAN AP, 1991, EUR J BIOCHEM, V198, P459, DOI 10.1111/j.1432-1033.1991.tb16036.x; OKUDA S, 1986, BIOCHEM J, V239, P733, DOI 10.1042/bj2390733; PARK JW, 1983, B KOR CHEM SOC, V4, P68; Plotz BM, 2000, J BIOL CHEM, V275, P11222, DOI 10.1074/jbc.275.15.11222; Que-Gewirth NLS, 2004, J BIOL CHEM, V279, P25420, DOI 10.1074/jbc.M400598200; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rawlings DE, 1999, MICROBIOL-UK, V145, P5, DOI 10.1099/13500872-145-1-5; ROPPEL J, 1975, CARBOHYD RES, V40, P31, DOI 10.1016/S0008-6215(00)82666-X; ROSENTHAL SN, 1976, ADV PHYS ORG CHEM, V13, P280; RUSSA R, 1995, ARCH MICROBIOL, V163, P345, DOI 10.1007/BF00404207; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SILVERMAN MP, 1959, J BACTERIOL, V77, P642, DOI 10.1128/JB.77.5.642-647.1959; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sweet CR, 2001, FASEB J, V15, pA194; Sweet CR, 2001, J BIOL CHEM, V276, P19565, DOI 10.1074/jbc.M101868200; Sweet CR, 2004, J BIOL CHEM, V279, P25411, DOI 10.1074/jbc.M400597200; SWEET CR, 2002, THESIS DUKE U DURHAM; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; TOMASIEWICZ HG, 1987, J BACTERIOL, V169, P5735, DOI 10.1128/jb.169.12.5735-5744.1987; Trefzer A, 1999, NAT PROD REP, V16, P283, DOI 10.1039/a804431g; VANHALBEEK H, 1996, ENCY NMR, V2, P1107; WECKESSER J, 1988, FEMS MICROBIOL LETT, V54, P143, DOI 10.1016/0378-1097(88)90174-7; YOKOTA A, 1987, ARCH MICROBIOL, V149, P106, DOI 10.1007/BF00425074; Zahringer U, 1995, Prog Clin Biol Res, V392, P113; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93	48	46	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25400	25410		10.1074/jbc.M400596200	http://dx.doi.org/10.1074/jbc.M400596200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15044494	hybrid			2022-12-25	WOS:000221827900063
J	Guay, J; Bateman, K; Gordon, R; Mancini, J; Riendeau, D				Guay, J; Bateman, K; Gordon, R; Mancini, J; Riendeau, D			Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E-2 (PGE(2)) response in the central nervous system associated with the induction of microsomal PGE(2) synthase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADJUVANT-INDUCED ARTHRITIS; RHEUMATOID SYNOVIAL-CELLS; THERMAL HYPERALGESIA; CONSCIOUS MICE; SPINAL-CORD; PERIPHERAL INFLAMMATION; ENDOTHELIAL-CELLS; PAIN PERCEPTION; UP-REGULATION; CYCLOOXYGENASE-2	Peripheral inflammation involves an increase in cyclooxygenase-2 (COX-2)-mediated prostaglandin ( PG) synthesis in the central nervous system (CNS), which contributes to allodynia and hyperalgesia. In the present study we have determined the changes in prostanoid tissue levels and in expression of terminal prostanoid synthases in both the CNS and inflamed peripheral tissue during carrageenan-induced paw inflammation in the rat. Prostanoid levels were measured by liquid chromatography-mass spectrometry and enzyme expression at the RNA level by quantitative PCR analysis during both the early (1-6 h) and late (12 and 24 h) phases of the inflammatory response. In the paw, the early phase was associated with increases in PGE(2) and thromboxane (TX)B-2 levels and with a peak of COX-2 expression that preceded that of microsomal prostaglandin-E-2 synthase-1 (mPGES-1). COX-2 and mPGES-1 remained elevated during the late phase, and PGE2 continued to further increase through 24 h. The cytosolic PGE(2) synthase (cPGES) showed a small transient increase during the early phase, whereas mPGES-2 expression was not affected by inflammation. In the cerebrospinal fluid, elevated levels of PGE(2), 6-keto-PGF(1alpha), PGD(2), and TXB2 were detected during the early phase. PGE(2) levels also increased in the spinal cord and, to a lesser extent, in the brain and remained elevated in both the cerebrospinal fluid and the spinal cord during the late phase. The expression of mPGES-1 was strongly up-regulated in the brain and spinal cord during inflammation, whereas no change was detected for the expression of cPGES, mPGES-2, COX-1, and terminal PGD, TX, or PGI synthases. The results show that the carrageenan-induced edema in the paw elicits an early phase of COX-2 induction in the CNS leading to an increase synthesis in PGD(2), 6-keto-PGF(1alpha), and TXB2 in addition to the major PGE(2) response. The data also indicate that the up-regulation of mPGES-1 contributes to COX-2-mediated PGE(2) production in the CNS during peripheral inflammation.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ H9H 3L1, Canada; Merck Frosst Ctr Therapeut Res, Dept Med Chem, Kirkland, PQ H9H 3L1, Canada; Merck Frosst Ctr Therapeut Res, Dept Pharmacol, Kirkland, PQ H9H 3L1, Canada	Merck & Company; Merck & Company; Merck & Company	Riendeau, D (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ H9H 3L1, Canada.	denis_riendeau@merck.com		Bateman, Kevin/0000-0002-4026-6685				ABDELHALIM MS, 1980, PROSTAGLANDINS, V19, P249, DOI 10.1016/0090-6980(80)90023-4; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; Ciceri P, 2002, J PHARMACOL EXP THER, V302, P846, DOI 10.1124/jpet.302.3.846; Claveau D, 2003, J IMMUNOL, V170, P4738, DOI 10.4049/jimmunol.170.9.4738; Daher JB, 2003, BRAIN RES, V962, P207, DOI 10.1016/S0006-8993(02)04056-8; Dirig DM, 1998, J PHARMACOL EXP THER, V285, P1031; Doi Y, 2002, NEUROREPORT, V13, P93, DOI 10.1097/00001756-200201210-00022; Eguchi N, 1999, P NATL ACAD SCI USA, V96, P726, DOI 10.1073/pnas.96.2.726; Ek M, 2001, NATURE, V410, P430, DOI 10.1038/35068632; Engblom D, 2002, J COMP NEUROL, V452, P205, DOI 10.1002/cne.10380; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Hay CH, 1997, NEUROSCIENCE, V78, P843, DOI 10.1016/S0306-4522(96)00598-2; HORIGUCHI S, 1986, EUR J PHARMACOL, V122, P173, DOI 10.1016/0014-2999(86)90100-7; Hosoi M, 1997, PAIN, V71, P303, DOI 10.1016/S0304-3959(97)03380-0; Hu JB, 2002, J BIOL CHEM, V277, P30253, DOI 10.1074/jbc.M202679200; Ibuki T, 2003, J NEUROCHEM, V86, P318, DOI 10.1046/j.1471-4159.2003.01848.x; Ichitani Y, 1997, NEUROREPORT, V8, P2949, DOI 10.1097/00001756-199709080-00028; Inoue W, 2002, NEUROSCI RES, V44, P51, DOI 10.1016/S0168-0102(02)00083-4; Ivanov AI, 2002, AM J PHYSIOL-REG I, V283, pR1104, DOI 10.1152/ajpregu.00347.2002; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kojima F, 2002, J RHEUMATOL, V29, P1836; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; Matsuoka Y, 2003, P NATL ACAD SCI USA, V100, P4132, DOI 10.1073/pnas.0633341100; MINAMI T, 1992, PAIN, V50, P223, DOI 10.1016/0304-3959(92)90166-9; MINAMI T, 1994, PAIN, V57, P217, DOI 10.1016/0304-3959(94)90226-7; Moore AH, 2004, J NEUROIMMUNOL, V148, P32, DOI 10.1016/j.jneuroim.2003.11.001; Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163-7827(03)00037-7; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Nakano H, 2001, BRIT J PHARMACOL, V133, P438, DOI 10.1038/sj.bjp.0704092; Nantel F, 1999, BRIT J PHARMACOL, V128, P853, DOI 10.1038/sj.bjp.0702866; Riendeau D, 1997, BRIT J PHARMACOL, V121, P105, DOI 10.1038/sj.bjp.0701076; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Schuligoi R, 2003, NEUROSCIENCE, V116, P1043, DOI 10.1016/S0306-4522(02)00783-2; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Turnbach ME, 2002, PAIN, V97, P33, DOI 10.1016/S0304-3959(01)00487-0; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Ueno A, 2000, LIFE SCI, V66, pPL155, DOI 10.1016/S0024-3205(00)00420-3; Ueno A, 2001, BIOCHEM PHARMACOL, V62, P157, DOI 10.1016/S0006-2952(01)00654-2; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V264, P428, DOI 10.1016/0003-9861(88)90308-6; Vasquez E, 2001, J NEUROSCI, V21, P9001, DOI 10.1523/JNEUROSCI.21-22-09001.2001; Vidensky S, 2003, NEUROMOL MED, V3, P15, DOI 10.1385/NMM:3:1:15; Yaksh TL, 2001, J NEUROSCI, V21, P5847, DOI 10.1523/JNEUROSCI.21-16-05847.2001; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001; Yamamoto T, 1997, NEUROREPORT, V8, P2179, DOI 10.1097/00001756-199707070-00018; Zhang Y, 1997, J PHARMACOL EXP THER, V283, P1069	52	195	210	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24866	24872		10.1074/jbc.M403106200	http://dx.doi.org/10.1074/jbc.M403106200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044444	hybrid			2022-12-25	WOS:000221702500118
J	Hammarton, TC; Engstler, M; Mottram, JC				Hammarton, TC; Engstler, M; Mottram, JC			The Trypanosoma brucei cyclin, CYC2, is required for cell cycle progression through G(1) phase and for maintenance of procyclic form cell morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE COMPLEXES; SACCHAROMYCES-CEREVISIAE; RNA INTERFERENCE; CDK COMPLEX; PHO85; PROTEIN; YEAST; DIFFERENTIATION; EXPRESSION; GENE	CYC2 is an essential PHO80-like cyclin that forms a complex with the cdc2-related kinase CRK3 in Trypanosoma brucei. In both procyclic and bloodstream form T. brucei, knock-down of CYC2 by RNA interference (RNAi) led to an accumulation of cells in G(1) phase. Additionally, in procyclic cells, but not in bloodstream form cells, CYC2 RNAi induced a specific cell elongation at the posterior end. The G(1) block, as well as the posterior end elongation in the procyclic form, was irreversible once established. Staining for tyrosinated alpha-tubulin and morphometric analyses showed that the posterior end elongation occurred through active microtubule extension, with no repositioning of the kinetoplast. Hence, these cells can be classified as exhibiting the "nozzle" phenotype as has been described for cells that ectopically express TbZFP2, a zinc finger protein that is involved in the differentiation of the bloodstream form to procyclic form. Within the tsetse fly, procyclic trypanosomes differentiate to elongated mesocyclic cells. However, although mesocyclic trypanosomes isolated from tsetse flies also show active microtubule extension at the posterior end, the kinetoplast is coincidentally repositioned such that it always lies approximately midway between the nucleus and posterior end of the cell. Thus, in the procyclic form CYC2 has dual functionality and is required for both cell cycle progression through G(1) and for the maintenance of correct cell morphology, whereas in the bloodstream form only a role for CYC2 in G(1) progression is evident.	Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland; Univ Munich, Dept Biol 1, D-80638 Munich, Germany	University of Glasgow; University of Munich	Mottram, JC (corresponding author), Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.	j.mottram@udcf.gla.ac.uk	Engstler, Markus/E-6054-2010; Hammarton, Tansy/A-5632-2011	Hammarton, Tansy/0000-0002-0799-6600; Mottram, Jeremy/0000-0001-5574-3766				Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Carroll AS, 2002, TRENDS BIOCHEM SCI, V27, P87, DOI 10.1016/S0968-0004(01)02040-0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CONLON I, 2003, J BIOL, V2, P1; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; Grunfelder CG, 2002, TRAFFIC, V3, P547, DOI 10.1034/j.1600-0854.2002.30805.x; Hammarton Tansy C, 2003, Prog Cell Cycle Res, V5, P91; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Hendriks EF, 2001, EMBO J, V20, P6700, DOI 10.1093/emboj/20.23.6700; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KANG S, 1993, GENETICS, V133, P193; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Lahoz EG, 1999, MOL CELL BIOL, V19, P353; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; Lenburg ME, 2001, GENETICS, V157, P39; Li ZY, 2003, J BIOL CHEM, V278, P20652, DOI 10.1074/jbc.M301635200; McKean PG, 2003, CURR OPIN MICROBIOL, V6, P600, DOI 10.1016/j.mib.2003.10.010; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; Miller ME, 2001, J CELL SCI, V114, P1811; Mottram JC, 1996, BIOCHEM J, V316, P833, DOI 10.1042/bj3160833; Ogbadoyi EO, 2003, MOL BIOL CELL, V14, P1769, DOI 10.1091/mbc.E02-08-0525; Ploubidou A, 1999, J CELL SCI, V112, P4641; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rupes I, 2002, TRENDS GENET, V18, P479, DOI 10.1016/S0168-9525(02)02745-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shemer R, 2002, MOL CELL BIOL, V22, P5395, DOI 10.1128/MCB.22.15.5395-5404.2002; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Tennyson CN, 1998, MOL MICROBIOL, V28, P69, DOI 10.1046/j.1365-2958.1998.00773.x; Timms MW, 2002, MOL BIOL CELL, V13, P3747, DOI 10.1091/mbc.E02-05-0266; Van den Abbeele J, 1999, PARASITOLOGY, V118, P469, DOI 10.1017/S0031182099004217; Van Hellemond JJ, 2000, J BIOL CHEM, V275, P8315, DOI 10.1074/jbc.275.12.8315; Van Hellemond JJ, 2000, MOL BIOCHEM PARASIT, V111, P275, DOI 10.1016/S0166-6851(00)00318-2; Vassella E, 2001, MOL MICROBIOL, V41, P33, DOI 10.1046/j.1365-2958.2001.02471.x; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; Wharton W, 2000, J BIOL CHEM, V275, P33981, DOI 10.1074/jbc.M005600200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODWARD R, 1990, J CELL SCI, V95, P49	40	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24757	24764		10.1074/jbc.M401276200	http://dx.doi.org/10.1074/jbc.M401276200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15039435	hybrid			2022-12-25	WOS:000221702500106
J	Sato, SB; Ishii, K; Makino, A; Iwabuchi, K; Yamaji-Hasegawa, A; Senoh, Y; Nagaoka, I; Sakuraba, H; Kobayashi, T				Sato, SB; Ishii, K; Makino, A; Iwabuchi, K; Yamaji-Hasegawa, A; Senoh, Y; Nagaoka, I; Sakuraba, H; Kobayashi, T			Distribution and transport of cholesterol-rich membrane domains monitored by a membrane-impermeant fluorescent polyethylene glycol-derivatized cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; GOLGI-APPARATUS; TRANSBILAYER MOVEMENT; LIPID RAFTS; PERFRINGOLYSIN-O; LIVING CELLS; PHOSPHATIDYLSERINE; LOCALIZATION; MICRODOMAINS; CAVEOLAE	Cholesterol-rich membrane domains function in various membrane events as diverse as signal transduction and membrane traffic. We studied the interaction of a fluorescein ester of polyethylene glycol-derivatized cholesterol (fPEG-Chol) with cholesterol-rich membranes both in cells and in model membranes. Unlike filipin and other cholesterol probes, this molecule could be applied as an aqueous dispersion to various samples. When added to live cells, fPEG-Chol distributed exclusively in the outer plasma membrane leaflet and was enriched in microdomains that dynamically clustered by the activation of receptor signaling. The surface-bound fPEG-Chol was slowly internalized via clathrin-independent pathway into endosomes together with lipid raft markers. Noteworthy, fPEG-Chol could be microinjected in the living cells in which we found Golgi apparatus as the sole major organelle to be labeled. PEG-Chol, thus, provides a novel, sensitive probe for unraveling the dynamics of cholesterol-rich microdomains in living cells.	RIKEN, Wako, Saitama 3510198, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan; Tokyo Metropolitan Org Med Res, Dept Clin Genet, Bunkyo Ku, Tokyo 1138613, Japan; Inst Natl Sci Appl, INSERM, U585, F-69621 Villeurbanne, France	RIKEN; Kyoto University; Juntendo University; Tokyo Metropolitan Institute of Medical Science; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon	Sato, SB (corresponding author), RIKEN, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	sbsato@em.biophys.kyoto-u.ac.jp; kobayasi@riken.jp	Kobayashi, Toshihide/B-6298-2015; KOBAYASHI, TOSHIHIDE/S-8313-2019	Kobayashi, Toshihide/0000-0002-4811-7270; KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270				Baba T, 2001, TRAFFIC, V2, P501, DOI 10.1034/j.1600-0854.2001.20707.x; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Blom TS, 2001, BIOCHEMISTRY-US, V40, P14635, DOI 10.1021/bi0156714; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Endo TA, 1996, EXP CELL RES, V228, P341, DOI 10.1006/excr.1996.0334; Hao MM, 2002, J BIOL CHEM, V277, P609, DOI 10.1074/jbc.M108861200; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; Ishiwata H, 1997, BBA-MOL CELL RES, V1359, P123, DOI 10.1016/S0167-4889(97)00061-X; John K, 2002, BIOPHYS J, V83, P1525, DOI 10.1016/S0006-3495(02)73922-2; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; KOBAYASHI T, 1988, CELL, V55, P797, DOI 10.1016/0092-8674(88)90135-3; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; Kobayashi T, 2001, BIOL CHEM, V382, P483, DOI 10.1515/BC.2001.059; KOBAYASHI T, 1991, J CELL BIOL, V113, P235, DOI 10.1083/jcb.113.2.235; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Kuwabara PE, 2002, TRENDS GENET, V18, P193, DOI 10.1016/S0168-9525(02)02640-9; Liscum L, 2000, TRAFFIC, V1, P218, DOI 10.1034/j.1600-0854.2000.010304.x; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; MIYAZAWA A, 1988, MOL IMMUNOL, V25, P1025; Mobius W, 2003, TRAFFIC, V4, P222; Mobius W, 2002, J HISTOCHEM CYTOCHEM, V50, P43; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; NICHOLS JW, 1982, BIOCHEMISTRY-US, V21, P1720, DOI 10.1021/bi00537a003; NORMAN AW, 1972, J BIOL CHEM, V247, P1918; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Ringerike T, 2002, J CELL SCI, V115, P1331; Roepstorff K, 2002, J BIOL CHEM, V277, P18954, DOI 10.1074/jbc.M201422200; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Rothblat GH, 1999, J LIPID RES, V40, P781; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sugii S, 2003, J LIPID RES, V44, P1033, DOI 10.1194/jlr.D200036-JLR200; TASSET C, 1992, ANTIMICROB AGENTS CH, V36, P1525, DOI 10.1128/AAC.36.7.1525; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Waugh MG, 2001, BIOCHEM SOC T, V29, P509, DOI 10.1042/BST0290509	42	84	84	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23790	23796		10.1074/jbc.M313568200	http://dx.doi.org/10.1074/jbc.M313568200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15026415	hybrid			2022-12-25	WOS:000221570900122
J	Flores-Diaz, M; Higuita, JC; Florin, I; Okada, T; Pollesello, P; Bergman, T; Thelestam, M; Mori, K; Alape-Giron, A				Flores-Diaz, M; Higuita, JC; Florin, I; Okada, T; Pollesello, P; Bergman, T; Thelestam, M; Mori, K; Alape-Giron, A			A cellular UDP-glucose deficiency causes overexpression of glucose/oxygen-regulated proteins independent of the endoplasmic reticulum stress elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING TRANSCRIPTION FACTOR-6; HEAT-SHOCK PROTEINS; NF-Y CBF; MESSENGER-RNA; TRANSMEMBRANE PROTEIN; CHAPERONE PROTEIN; COUPLED RECEPTOR; OXIDATIVE STRESS; POINT MUTATION; BINDING-SITE	A low level of UDP- Glc occurs in cells exposed to hypoxia or glucose starvation. This work reveals that a 65% reduction in the cellular UDP- Glc level causes upregulation of the mitochondrial chaperone GRP75 and the endoplasmic reticulum ( ER) resident chaperones GRP58, ERp72, GRP78, GRP94, GRP170, and calreticulin. Conditions that cause misfolding of proteins within the ER activate the transcription factors ATF6alpha/beta and induce translation of the transcription factors XBP- 1/ TREB5 and ATF4/ CREB2. These transcription factors induce the overexpression of ER chaperones and CHOP/ GADD153. However, the 65% decrease in the cellular UDP- Glc level does not cause activation of ATF6alpha, splicing of XBP- 1/ TREB5, induction of ATF4/ CREB2, or expression of CHOP/ GADD153. The activity of the promoters of the ER chaperones is increased in UDP- Glc-deficient cells, but the activity of the CHOP/ GADD153 promoter is not affected, in comparison with their respective activities in cells having compensated for the UDP- Glc deficiency. The results demonstrate that the unfolded protein response remains functionally intact in cells with a 65% decrease in the cellular UDP- Glc level and provide evidence that this decrease is a stress signal in mammalian cells, which triggers the coordinate overexpression of mitochondrial and ER chaperones, independently of the ER stress elements.	Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Univ Costa Rica, Fac Med, Dept Bioquim, San Jose 2060, Costa Rica; Univ Costa Rica, Fac Microbiol, Inst Clodoniro Picado, San Jose 2060, Costa Rica; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068304, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Orion Pharma, Res & Dev, NMR Lab, Drug Design Unit, FIN-02101 Espoo, Finland	Karolinska Institutet; Karolinska Institutet; Universidad Costa Rica; Universidad Costa Rica; Kyoto University; Kyoto University; Orion Corporation	Alape-Giron, A (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden.	aalape@cariari.ucr.ac.cr	Mori, Kazutoshi/K-6106-2015; Pollesello, Piero/I-6884-2019	Pollesello, Piero/0000-0001-6994-768X; Okada, Tetsuya/0000-0002-2513-1301				Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BERGMAN T, 1987, EUR J BIOCHEM, V169, P9, DOI 10.1111/j.1432-1033.1987.tb13573.x; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Boehmelt G, 2000, EMBO J, V19, P5092, DOI 10.1093/emboj/19.19.5092; BOHRINGER J, 1995, J BACTERIOL, V177, P413; Brown JM, 1998, CANCER RES, V58, P1408; Bush KT, 2000, J CLIN INVEST, V106, P621, DOI 10.1172/JCI10968; Bush KT, 1999, AM J PHYSIOL-RENAL, V277, pF211, DOI 10.1152/ajprenal.1999.277.2.F211; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Fasolato C, 1998, MOL BIOL CELL, V9, P1513, DOI 10.1091/mbc.9.6.1513; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Flores-Diaz M, 1998, J BIOL CHEM, V273, P24433, DOI 10.1074/jbc.273.38.24433; FloresDiaz M, 1997, J BIOL CHEM, V272, P23784, DOI 10.1074/jbc.272.38.23784; Freeman K, 2001, GENOMICS, V78, P124, DOI 10.1006/geno.2001.6662; GREEN JM, 1995, HYBRIDOMA, V14, P347, DOI 10.1089/hyb.1995.14.347; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Haze K, 2001, BIOCHEM J, V355, P19, DOI 10.1042/0264-6021:3550019; Higuita JC, 2003, BIOCHEM J, V370, P995, DOI 10.1042/BJ20021320; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Kaneda S, 2000, J BIOCHEM-TOKYO, V128, P529, DOI 10.1093/oxfordjournals.jbchem.a022783; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; KOONG AC, 1994, INT J RADIAT ONCOL, V28, P661, DOI 10.1016/0360-3016(94)90191-0; Kuznetsov G, 1998, NEW ENGL J MED, V339, P1688, DOI 10.1056/NEJM199812033392307; Lazarowski ER, 2003, MOL PHARMACOL, V63, P1190, DOI 10.1124/mol.63.5.1190; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; MAAS C, 1990, EMBO J, V9, P3447, DOI 10.1002/j.1460-2075.1990.tb07552.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MASSA SM, 1995, CEREBROVASCULAR BRAI, V8, P95; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MENORET A, 1994, INT J CANCER, V56, P400, DOI 10.1002/ijc.2910560319; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; Pollesello P, 1995, NMR BIOMED, V8, P190, DOI 10.1002/nbm.1940080503; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; ROLL DE, 1991, MOL CELL BIOCHEM, V103, P141; Sarto C, 2000, ELECTROPHORESIS, V21, P1218, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1218::AID-ELPS1218>3.3.CO;2-8; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Singh B, 1997, EXP CELL RES, V234, P205, DOI 10.1006/excr.1997.3609; Takano S, 1997, EXP CELL RES, V237, P38, DOI 10.1006/excr.1997.3754; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tsukamoto Y, 1998, LAB INVEST, V78, P699; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Vondracek MT, 2002, INT J CANCER, V99, P776, DOI 10.1002/ijc.10408; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; ZISNER H, 1998, GENE DEV, V12, P982	73	35	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21724	21731		10.1074/jbc.M312791200	http://dx.doi.org/10.1074/jbc.M312791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15020602	hybrid			2022-12-25	WOS:000221417100007
J	Hasegawa, M; Cahill, GM				Hasegawa, M; Cahill, GM			Regulation of the circadian oscillator in Xenopus retinal photoreceptors by protein kinases sensitive to the stress-activated protein kinase inhibitor, SB 203580	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLTRANSFERASE ACTIVITY; CHICK PINEAL CELLS; DROSOPHILA CLOCK GENE; CYCLIC-AMP; SUBSTRATE-SPECIFICITY; CELLULAR STRESSES; SAP KINASES; DOUBLE-TIME; I-EPSILON; LIGHT	Circadian rhythms are generated by transcriptional and translational feedback loops. Stress- activated protein kinases ( SAPKs) are known to regulate transcription factors in response to a variety of extracellular stimuli. In the present study, we examined whether the SAPKs play a role in the circadian system in cultured Xenopus retinal photoreceptor layers. A 6- h pulse of SB 203580, an inhibitor of SAPKs, reset the circadian rhythm of melatonin in a phase- dependent manner similar to dark pulses. This phase- shifting effect was dose-dependent over the range of 1 - 100 mu M. Treatment with SB 203580 also affected light- induced phase shifts, and light had no effect on the circadian oscillator in the presence of 100 mu M SB 203580. In- gel kinase assays showed that SB 203580 selectively inhibited a small group of protein kinases in the photoreceptor cells. These SB 203580- sensitive kinases correspond to two isoforms of phosphorylated p38 MAPK and three isoforms of c- Jun N- terminal kinase ( JNK). Further in vitro study demonstrated that SB 203580 also inhibited casein kinase Iepsilon ( CKIepsilon), which has been shown to regulate circadian rhythms in several organisms. However, a pharmacological inhibition of CKI reset the circadian oscillator in a phase- dependent manner distinct from that of SB 203580. This argues against a primary role of CKI in the phase- shifting effects of SB 203580. These results suggest that SB 203580 affects the circadian system by inhibiting p38 MAPKs or JNKs and that these protein kinases are candidate cellular signals in the regulation of the circadian oscillator in the Xenopus retinal photoreceptors.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA	University of Houston System; University of Houston	Hasegawa, M (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.	hasegawa@uh.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049757] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH49757] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Akashi M, 2000, GENE DEV, V14, P645; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BINKLEY S, 1979, NATURE, V281, P479, DOI 10.1038/281479a0; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; CAHILL GM, 1991, J NEUROSCI, V11, P2959; Cermakian N, 2002, CURR BIOL, V12, P844, DOI 10.1016/S0960-9822(02)00835-7; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; DUNLAP JC, 1988, P NATL ACAD SCI USA, V85, P1096, DOI 10.1073/pnas.85.4.1096; ESKIN A, 1984, P NATL ACAD SCI-BIOL, V81, P7637, DOI 10.1073/pnas.81.23.7637; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAMM HE, 1980, P NATL ACAD SCI-BIOL, V77, P4998, DOI 10.1073/pnas.77.8.4998; Harada Y, 2000, J BIOL CHEM, V275, P37078, DOI 10.1074/jbc.M004706200; Hasegawa M, 1998, J NEUROCHEM, V70, P1523; Hasegawa M, 1999, J NEUROCHEM, V72, P1812, DOI 10.1046/j.1471-4159.1999.0721812.x; HASEGAWA M, 2004, IN PRESS J BIOL RHYT; Hayashi Y, 2003, J BIOL CHEM, V278, P25166, DOI 10.1074/jbc.M212726200; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IUVONE PM, 1983, BRAIN RES, V273, P111, DOI 10.1016/0006-8993(83)91099-5; IUVONE PM, 1986, LIFE SCI, V38, P331; JOHNSON CH, 1990, J BIOL RHYTHM, V5, P159, DOI 10.1177/074873049000500207; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu Y, 2000, P NATL ACAD SCI USA, V97, P234, DOI 10.1073/pnas.97.1.234; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; PROVENCIO I, 1995, BRAIN RES, V694, P183, DOI 10.1016/0006-8993(95)00694-L; ROLLAG MD, 1976, ENDOCRINOLOGY, V98, P482, DOI 10.1210/endo-98-2-482; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sanada K, 2000, J NEUROSCI, V20, P986, DOI 10.1523/JNEUROSCI.20-03-00986.2000; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yadav G, 2003, J NEUROSCI, V23, P10021; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; ZATZ M, 1991, AM J PHYSIOL, V261, pR1424; ZATZ M, 1991, AM J PHYSIOL, V260, pR769, DOI 10.1152/ajpregu.1991.260.4.R769; ZATZ M, 1988, BRAIN RES, V438, P199, DOI 10.1016/0006-8993(88)91339-X; ZAWILSKA J, 1989, J PHARMACOL EXP THER, V250, P86	53	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22738	22746		10.1074/jbc.M401389200	http://dx.doi.org/10.1074/jbc.M401389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15028715	hybrid			2022-12-25	WOS:000221417100125
J	Hori, T; Yokomizo, T; Ago, H; Sugahara, M; Ueno, G; Yamamoto, M; Kumasaka, T; Shimizu, T; Miyano, M				Hori, T; Yokomizo, T; Ago, H; Sugahara, M; Ueno, G; Yamamoto, M; Kumasaka, T; Shimizu, T; Miyano, M			Structural basis of leukotriene B-4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase catalytic mechanism and a possible Src homology 3 domain binding loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; QUINONE OXIDOREDUCTASE; CRYSTAL-STRUCTURE; CDNA CLONING; LIPOXIN A(4); PROTEIN; IDENTIFICATION; INACTIVATION; PURIFICATION; CYCLOOXYGENASE	The bifunctional leukotriene B-4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase (LTB412-HD/PGR) is an essential enzyme for eicosanoid inactivation. It is involved in the metabolism of the E and F series of 15-oxo-prostaglandins (15-oxo-PGs), leukotriene B-4 (LTB4), and 15-oxo-lipoxin A4 (15-oxo-LXA4). Some nonsteroidal anti-inflammatory drugs (NSAIDs), which primarily act as cyclooxygenase inhibitors also inhibit LTB4 12-HD/PGR activity. Here we report the crystal structure of the LTB4 12-HD/PGR, the binary complex structure with NADP(+), and the ternary complex structure with NADP(+) and 15-oxo-PGE(2). In the ternary complex, both in the crystalline form and in solution, the enolate anion intermediate accumulates as a brown chromophore. PGE(2) contains two chains, but only the omega-chain of 15-oxo-PGE(2) was defined in the electron density map in the ternary complex structure. The omega-chain was identified at the hydrophobic pore on the dimer interface. The structure showed that the 15-oxo group forms hydrogen bonds with the 2'-hydroxyl group of nicotine amide ribose of NADP(+) and a bound water molecule to stabilize the enolate intermediate during the reductase reaction. The electron-deficient C13 atom of the conjugated enolate may be directly attacked by a hydride from the NADPH nicotine amide in a stereospecific manner. The moderate recognition of 15-oxo-PGE(2) is consistent with a broad substrate specificity of LTB4 12-HD/PGR. The structure also implies that a Src homology domain 3 may interact with the left-handed proline-rich helix at the dimer interface and regulate LTB4 12HD/PGR activity by disruption of the substrate binding pore to accommodate the omega-chain.	SPring8, RIKEN Harima Inst, Struct Biophys Inst, Mikazuki, Hyogo 6795148, Japan; SPring8, RIKEN Harima Inst, Highthroughput Factory, Mikazuki, Hyogo 6795148, Japan; SPring8, RIKEN Harima Inst, Coherent Xray Opt Lab, Mikazuki, Hyogo 6795148, Japan; Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Bunkyo Ku, Tokyo 1130033, Japan	Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Miyano, M (corresponding author), SPring8, RIKEN Harima Inst, Struct Biophys Inst, 1-1-1 Kouto, Mikazuki, Hyogo 6795148, Japan.	miyano@spring8.or.jp	Shimizu, Takao/AAV-7052-2021; Miyano, Masashi/R-2785-2016; Kumasaka, Takashi/D-7428-2018; Yamamoto, Masaki/B-7844-2015; Yokomizo, Takehiko/P-5673-2016	Miyano, Masashi/0000-0003-2253-6175; Kumasaka, Takashi/0000-0001-9289-1557; Yamamoto, Masaki/0000-0002-1311-1768; Yokomizo, Takehiko/0000-0002-5219-1553; Ago, Hideo/0000-0002-9040-488X				Airenne TT, 2003, J MOL BIOL, V327, P47, DOI 10.1016/S0022-2836(03)00038-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; BOLL W, 1993, J BIOL CHEM, V268, P12901; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clarke A. R., 1998, COMPREHENSIVE BIOL C, VIII, P1; Clish CB, 2000, J BIOL CHEM, V275, P25372, DOI 10.1074/jbc.M002863200; Clish CB, 2001, BIOCHEM BIOPH RES CO, V288, P868, DOI 10.1006/bbrc.2001.5841; Dick RA, 2001, J BIOL CHEM, V276, P40803, DOI 10.1074/jbc.M105487200; EKLUND H, 1979, J BIOL CHEM, V254, P3458; ENSOR CM, 1995, J LIPID MEDIAT CELL, V12, P313, DOI 10.1016/0929-7855(95)00040-W; Ensor CM, 1998, BIOCHEM J, V330, P103, DOI 10.1042/bj3300103; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HANSEN HS, 1979, BIOCHIM BIOPHYS ACTA, V574, P136, DOI 10.1016/0005-2760(79)90092-4; HANSSON G, 1981, FEBS LETT, V130, P107, DOI 10.1016/0014-5793(81)80676-X; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Hoozemans JJM, 2003, CURR DRUG TARGETS, V4, P461, DOI 10.2174/1389450033490902; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILLER TA, 1983, AM J PHYSIOL, V245, pG601, DOI 10.1152/ajpgi.1983.245.5.G601; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Nordling E, 2002, EUR J BIOCHEM, V269, P4267, DOI 10.1046/j.1432-1033.2002.03114.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parnova R G, 2000, Membr Cell Biol, V13, P287; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; Primiano T, 1998, CARCINOGENESIS, V19, P999, DOI 10.1093/carcin/19.6.999; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; Ricchi P, 2003, BRIT J CANCER, V88, P803, DOI 10.1038/sj.bjc.6600829; Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Shimomura Y, 2003, J BACTERIOL, V185, P4211, DOI 10.1128/JB.185.14.4211-4218.2003; Sugahara Mitsuaki, 2002, Tanpakushitsu Kakusan Koso, V47, P1026; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THORN JM, 1995, J MOL BIOL, V249, P785, DOI 10.1006/jmbi.1995.0337; Yamamoto T, 2001, EUR J BIOCHEM, V268, P6105, DOI 10.1046/j.0014-2956.2001.02462.x; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128; Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	49	49	53	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22615	22623		10.1074/jbc.M312655200	http://dx.doi.org/10.1074/jbc.M312655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007077	hybrid			2022-12-25	WOS:000221417100113
J	Mitin, NY; Ramocki, MB; Zullo, AJ; Der, CJ; Konieczny, SF; Taparowsky, EJ				Mitin, NY; Ramocki, MB; Zullo, AJ; Der, CJ; Konieczny, SF; Taparowsky, EJ			Identification and characterization of rain, a novel Ras-interacting protein with a unique subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; PLASMA-MEMBRANE; BINDING DOMAIN; MYOSIN V; R-RAS; TRANSFORMATION; ACTIVATION; EFFECTOR; AF-6; KINASE	The Ras small GTPase functions as a signaling node and is activated by extracellular stimuli. Upon activation, Ras interacts with a spectrum of functionally diverse downstream effectors and stimulates multiple cytoplasmic signaling cascades that regulate cellular proliferation, differentiation, and apoptosis. In addition to the association of Ras with the plasma membrane, recent studies have established an association of Ras with Golgi membranes. Whereas the effectors of signal transduction by activated, plasma membrane-localized Ras are well characterized, very little is known about the effectors used by Golgi-localized Ras. In this study, we report the identification of a novel Ras-interacting protein, Rain, that may serve as an effector for endomembrane-associated Ras. Rain does not share significant sequence similarity with any known mammalian proteins, but contains a Ras-associating domain that is found in RalGDS, AF-6, and other characterized Ras effectors. Rain interacts with Ras in a GTP-dependent manner in vitro and in vivo, requires an intact Ras core effector-binding domain for this interaction, and thus fits the definition of a Ras effector. Unlike other Ras effectors, however, Rain is localized to perinuclear, juxta-Golgi vesicles in intact cells and is recruited to the Golgi by activated Ras. Finally, we found that Rain cooperates with activated Raf and causes synergistic transformation of NIH3T3 cells. Taken together, these observations support a role for Rain as a novel protein that can serve as an effector of endomembrane-localized Ras.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of North Carolina; University of North Carolina Chapel Hill	Taparowsky, EJ (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	ejt@bilbo.bio.purdue.edu		Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978, T32CA009634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041115] Funding Source: NIH RePORTER; NCI NIH HHS [CA09634, CA42978] Funding Source: Medline; NIAMS NIH HHS [AR41115] Funding Source: Medline; NIGMS NIH HHS [GM08737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asada M, 2003, J BIOL CHEM, V278, P4103, DOI 10.1074/jbc.M209832200; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Boettner B, 2003, GENETICS, V165, P159; BOS JL, 1989, CANCER RES, V49, P4682; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; LopezBarahona M, 1996, ONCOGENE, V12, P463; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mitin N, 2001, METHOD ENZYMOL, V333, P232; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; PRASAD R, 1993, CANCER RES, V53, P5624; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Radziwill G, 2003, MOL CELL BIOL, V23, P4663, DOI 10.1128/MCB.23.13.4663-4672.2003; RDRIGUEZVICIANA P, 1997, CELL, V89, P457; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rogers SL, 1999, J CELL BIOL, V146, P1265, DOI 10.1083/jcb.146.6.1265; Shirouzu M, 1999, BIOCHEMISTRY-US, V38, P5103, DOI 10.1021/bi9820053; Solski PA, 2002, CELL GROWTH DIFFER, V13, P363; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	43	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22353	22361		10.1074/jbc.M312867200	http://dx.doi.org/10.1074/jbc.M312867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15031288	hybrid			2022-12-25	WOS:000221417100083
J	Walker, F; Orchard, SG; Jorissen, RN; Hall, NE; Zhang, HH; Hoyne, PA; Adams, TE; Johns, TG; Ward, C; Garrett, TPJ; Zhu, HJ; Nerrie, M; Scott, AM; Nice, EC; Burgess, AW				Walker, F; Orchard, SG; Jorissen, RN; Hall, NE; Zhang, HH; Hoyne, PA; Adams, TE; Johns, TG; Ward, C; Garrett, TPJ; Zhu, HJ; Nerrie, M; Scott, AM; Nice, EC; Burgess, AW			CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; EGF RECEPTOR; CRYSTAL-STRUCTURE; LIGAND-BINDING; EXTRACELLULAR REGION; IMAGING MICROSCOPY; CARCINOMA-CELLS; ACTIVATION; PROTEIN; DOMAIN	Recent crystallographic data on the isolated extracellular domain of the epidermal growth factor receptor ( EGFR) have suggested a model for its activation by ligand. We have tested this model in the context of the full-length EGFR displayed at the cell surface, by introducing mutations in two regions (CR1 and CR2) of the extracellular domain thought to be critical for regulation of receptor activation. Mutations in the CR1 and CR2 domains have opposing effects on ligand binding affinity, receptor dimerization, tyrosine kinase activation, and signaling competence. Tyr(246) is a critical residue in the CR1 loop, which is implicated in the positioning and stabilization of the receptor dimer interface after ligand binding; mutations of Tyr(246) impair or abolish receptor function. Mutations in CR2, which weaken the interaction that restricts the receptor to the tethered ( inactive) state, enhance responsiveness to EGF by increasing affinity for the ligand. However, weakening of the CR1/CR2 interaction does not result in spontaneous activation of the receptors' kinase. We have used an antibody (mAb 806), which recognizes a transition state of the EGF receptor between the negatively constrained, tethered state and the fully active back-to-back dimer conformation, to follow conformational changes in the wild-type and mutant EGF receptors after ligand binding. Our results suggest that EGFR on the cell surface can be untethered, but this form is inactive; thus, untethering of the receptor is not sufficient for activation, and ligand binding is essential for the correct positioning of the two receptor subunits to achieve kinase activation.	Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; CSIRO, Hlth Sci & Nutr, Parkville, Vic 3052, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia	Ludwig Institute for Cancer Research; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Walter & Eliza Hall Institute	Burgess, AW (corresponding author), Ludwig Inst Canc Res, PO Royal Melbourne Hosp, Melbourne, Vic 3050, Australia.	tony.burgess@ludwig.edu.au	Nice, Edouard C/B-1026-2011; Orchard, Suzanne/GXF-5346-2022; Johns, Terrance/C-2441-2008; Adams, Timothy E/I-6231-2012	Orchard, Suzanne/0000-0003-0211-3183; Johns, Terrance/0000-0002-8874-4543; Adams, Timothy E/0000-0003-3436-0066; Scott, Andrew/0000-0002-6656-295X; Zhu, Hong-Jian/0000-0002-1478-995X; Hall, Nathan/0000-0001-8942-0498; Jorissen, Robert/0000-0001-9634-2803				Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Bastiaens PIH, 1999, TRENDS CELL BIOL, V9, P48, DOI 10.1016/S0962-8924(98)01410-X; BERKERS JAM, 1992, J RECEPTOR RES, V12, P71, DOI 10.3109/10799899209066025; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; BURGESS AW, 1983, EMBO J, V2, P2065, DOI 10.1002/j.1460-2075.1983.tb01701.x; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Elleman TC, 2001, BIOCHEMISTRY-US, V40, P8930, DOI 10.1021/bi010037b; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GILL GN, 1984, J BIOL CHEM, V259, P7755; Gulliford T, 1999, CELL SIGNAL, V11, P245, DOI 10.1016/S0898-6568(98)00058-8; Holbrook MR, 2000, BIOCHEM J, V352, P99, DOI 10.1042/0264-6021:3520099; HOSOI K, 1989, P NATL ACAD SCI USA, V86, P4510, DOI 10.1073/pnas.86.12.4510; Johns TG, 2003, P NATL ACAD SCI USA, V100, P15871, DOI 10.1073/pnas.2036503100; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Jungbluth AA, 2003, P NATL ACAD SCI USA, V100, P639, DOI 10.1073/pnas.232686499; KNUTSON VP, 1983, J BIOL CHEM, V258, P2139; Luwor RB, 2001, CANCER RES, V61, P5355; Mattoon D, 2004, P NATL ACAD SCI USA, V101, P923, DOI 10.1073/pnas.0307286101; Mishima K, 2001, CANCER RES, V61, P5349; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; OLSON JE, 1990, J BIOL CHEM, V265, P1847; Ringerike T, 1998, J BIOL CHEM, V273, P16639, DOI 10.1074/jbc.273.27.16639; Roepstorff K, 2002, J BIOL CHEM, V277, P18954, DOI 10.1074/jbc.M201422200; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Sherrill JM, 1996, BIOCHEMISTRY-US, V35, P5705, DOI 10.1021/bi9602268; STOCKERT E, 1995, ANN SCI REPORT LUDWI, P226; STOCKERT E, 1997, ANN SCI REPORT LUDWI, P212; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; TODARO GJ, 1976, NATURE, V264, P26, DOI 10.1038/264026a0; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VanderHeyden MAG, 1997, FEBS LETT, V410, P265, DOI 10.1016/S0014-5793(97)00599-1; Walker F, 1998, GROWTH FACTORS, V16, P53, DOI 10.3109/08977199809017491; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WALKER F, 1991, J BIOL CHEM, V266, P2746; Wouters FS, 2001, TRENDS CELL BIOL, V11, P203, DOI 10.1016/S0962-8924(01)01982-1; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424	48	75	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22387	22398		10.1074/jbc.M401244200	http://dx.doi.org/10.1074/jbc.M401244200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016810	hybrid			2022-12-25	WOS:000221417100087
J	Chen, BC; Chang, YS; Kang, JC; Hsu, MJ; Sheu, JR; Chen, TL; Teng, CM; Lin, CH				Chen, BC; Chang, YS; Kang, JC; Hsu, MJ; Sheu, JR; Chen, TL; Teng, CM; Lin, CH			Peptidoglycan induces nuclear factor-kappa B activation and cyclooxygenase-2 expression via Ras, Raf-1, and ERK in RAW 264.7 macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; TRANSCRIPTIONAL REGULATION; LIPOTEICHOIC ACID; PROINFLAMMATORY MEDIATORS; BACTERIAL PEPTIDOGLYCAN; PROSTAGLANDIN SYNTHASE; STAPHYLOCOCCUS-AUREUS; SIGNAL-TRANSDUCTION	In this study, we investigated the signaling pathway involved in cyclooxygenase-2 (COX-2) expression caused by peptidoglycan (PGN), a cell wall component of the Gram-positive bacterium Staphylococcus aureus, in RAW 264.7 macrophages. PGN caused dose- and time-dependent increases in COX-2 expression, which was attenuated by a Ras inhibitor ( manumycin A), a Raf-1 inhibitor (GW 5074), and an MEK inhibitor (PD 098059). Treatment of RAW 264.7 macrophages with PGN caused time-dependent activations of Ras, Raf-1, and ERK. The PGN-induced increase in Ras activity was inhibited by manumycin A. Raf-1 phosphorylation at Ser-338 by PGN was inhibited by manumycin A and GW 5074. The PGN-induced increase in ERK activity was inhibited by manumycin A, GW 5074, and PD 098059. Stimulation of cells with PGN activated IkappaB kinase alpha/beta (IKalpha/beta), IkappaBalpha phosphorylation, IkappaBalpha degradation, and kappaB-luciferase activity. Treatment of macrophages with an NF-kappaB inhibitor (pyrrolidine dithiocarbamate), an IkappaBalpha phosphorylation inhibitor (Bay 117082), and IkappaB protease inhibitors (L-1-tosylamido-2-phenylethyl chloromethyl ketone and calpain inhibitor I) all inhibited PGN-induced COX-2 expression. The PGN-mediated increase in the activities of IKKalpha/beta and kappaB-luciferase were also inhibited by the Ras dominant negative mutant (RasN17), manumycin A, GW 5074, and PD 098059. Further studies revealed that PGN induced the recruitment of p85alpha and Ras to Toll-like receptor 2 in a time-dependent manner. Our data demonstrate for the first time that PGN activates the Ras/Raf-1/ERK pathway, which in turn initiates IKKalpha/beta and NF-kappaB activation, and ultimately induces COX-2 expression in RAW 264.7 macrophages.	Taipei Med Univ, Sch Resp Therapy, Taipei 110, Taiwan; Taipei Med Univ, Grad Inst Biomed Technol, Taipei 110, Taiwan; Taipei Med Univ, Sch Med, Dept Pharmacol, Taipei 110, Taiwan; Taipei Med Univ, Wan Fang Hosp, Dept Anesthesiol, Taipei 110, Taiwan; Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei 110, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; National Taiwan University	Lin, CH (corresponding author), Taipei Med Univ, Sch Resp Therapy, 250 Wu Hsing St, Taipei 110, Taiwan.	chlin@tmu.edu.tw		Lin, Chien-Huang/0000-0002-0916-8737; TENG, CHE-MING/0000-0002-9719-7334; Hsu, Ming-Jen/0000-0001-9688-8494				Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BHAKDI S, 1991, INFECT IMMUN, V59, P4614, DOI 10.1128/IAI.59.12.4614-4620.1991; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; BONE RC, 1994, ARCH INTERN MED, V154, P26, DOI 10.1001/archinte.154.1.26; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen BC, 1998, J BIOL CHEM, V273, P29754, DOI 10.1074/jbc.273.45.29754; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chiang LL, 2003, J PHARM PHARMACOL, V55, P115, DOI 10.1111/j.2042-7158.2003.tb02441.x; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Elgavish A, 2000, J CELL PHYSIOL, V182, P232, DOI 10.1002/(SICI)1097-4652(200002)182:2<232::AID-JCP12>3.3.CO;2-X; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; GEPPERT TD, 1994, MOL MED, V1, P93; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Hinz B, 2002, J PHARMACOL EXP THER, V300, P367, DOI 10.1124/jpet.300.2.367; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Lin CH, 2002, EUR J PHARMACOL, V450, P1, DOI 10.1016/S0014-2999(02)02002-2; Lin CH, 2001, BRIT J PHARMACOL, V134, P543, DOI 10.1038/sj.bjp.0704290; Lin CH, 2000, MOL PHARMACOL, V57, P36; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MATTSSON E, 1993, FEMS IMMUNOL MED MIC, V7, P281, DOI 10.1016/0928-8244(93)90023-W; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; MITCHELL JA, 1995, BIOCHEM PHARMACOL, V50, P1535, DOI 10.1016/0006-2952(95)00212-X; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Musial A, 2001, J BIOL CHEM, V276, P24268, DOI 10.1074/jbc.M100725200; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Paul A, 1999, CELL SIGNAL, V11, P491, DOI 10.1016/S0898-6568(99)00018-2; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Sheng HM, 2001, CANCER RES, V61, P2670; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Varga EV, 2002, EUR J PHARMACOL, V451, P101, DOI 10.1016/S0014-2999(02)02220-3; Vasselon T, 2002, INFECT IMMUN, V70, P1033, DOI 10.1128/IAI.70.3.1033-1041.2002; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wang QL, 2001, INFECT IMMUN, V69, P2270, DOI 10.1128/IAI.69.4.2270-2276.2001; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Xu ZJ, 2001, J IMMUNOL, V167, P6975, DOI 10.4049/jimmunol.167.12.6975; Yadav PN, 2003, J PHARMACOL EXP THER, V305, P925, DOI 10.1124/jpet.103.049171; Yeo SJ, 2003, J BIOL CHEM, V278, P40590, DOI 10.1074/jbc.M306280200; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	66	80	82	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20889	20897		10.1074/jbc.M311279200	http://dx.doi.org/10.1074/jbc.M311279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15007072	hybrid			2022-12-25	WOS:000221273800041
J	Kwok, SC; Hodges, RS				Kwok, SC; Hodges, RS			Stabilizing and destabilizing clusters in the hydrophobic core of long two-stranded alpha-helical coiled-coils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO DESIGN; AMINO-ACID SUBSTITUTIONS; LEUCINE-ZIPPER; OLIGOMERIZATION-STATE; ION-PAIRS; ENERGETIC CONTRIBUTION; SECONDARY STRUCTURE; PROTEIN STABILITY; AQUEOUS-SOLUTION; TROPOMYOSIN	Detailed sequence analyses of the hydrophobic core residues of two long two-stranded alpha-helical coiled-coils that differ dramatically in sequence, function, and length were performed ( tropomyosin of 284 residues and the coiled-coil domain of the myosin rod of 1086 residues). Three types of regions were present in the hydrophobic core of both proteins: stabilizing clusters and destabilizing clusters, defined as three or more consecutive core residues of either stabilizing (Leu, Ile, Val, Met, Phe, and Tyr) or destabilizing (Gly, Ala, Cys, Ser, Thr, Asn, Gln, Asp, Glu, His, Arg, Lys, and Trp) residues, and intervening regions that consist of both stabilizing and destabilizing residues in the hydrophobic core but no clusters. Subsequently, we designed a series of two-stranded coiled-coils to determine what defines a destabilizing cluster and varied the length of the destabilizing cluster from 3 to 7 residues to determine the length effect of the destabilizing cluster on protein stability. The results showed a dramatic destabilization, caused by a single Leu to Ala substitution, on formation of a 3-residue destabilizing cluster (DeltaT(m) of 17 - 21 degreesC) regardless of the stability of the coiled-coil. Any further substitution of Leu to Ala that increased the size of the destabilizing cluster to 5 or 7 hydrophobic core residues in length had little effect on stability (DeltaT(m) of 1.4 - 2.8 degreesC). These results suggested that the contribution of Leu to protein stability is context-dependent on whether the hydrophobe is in a stabilizing cluster or its proximity to neighboring destabilizing and stabilizing clusters.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hodges, RS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.	robert.hodges@uchsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061855] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 61855] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Choy WY, 2003, J AM CHEM SOC, V125, P1748, DOI 10.1021/ja021179b; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Dragan AI, 2002, J MOL BIOL, V321, P891, DOI 10.1016/S0022-2836(02)00699-X; GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P510, DOI 10.1038/nsb0696-510; GOODMAN EM, 1991, BIOCHEMISTRY-US, V30, P11615, DOI 10.1021/bi00114a002; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hill RB, 2000, ACCOUNTS CHEM RES, V33, P745, DOI 10.1021/ar970004h; Hitchcock-DeGregori SE, 2002, BIOCHEMISTRY-US, V41, P15036, DOI 10.1021/bi026519k; HODGES R S, 1988, Peptide Research, V1, P19; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; Holtzer ME, 1997, BIOPHYS J, V73, P1031, DOI 10.1016/S0006-3495(97)78136-0; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Karplus PA, 1997, PROTEIN SCI, V6, P1302; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; Kohn WD, 1997, J MOL BIOL, V267, P1039, DOI 10.1006/jmbi.1997.0930; Kohn WD, 1998, J MOL BIOL, V283, P993, DOI 10.1006/jmbi.1998.2125; Kwok SC, 2003, J BIOL CHEM, V278, P35248, DOI 10.1074/jbc.M305306200; KWOK SC, 1999, PEPTIDES 1998, P34; Landis C, 1999, J BIOL CHEM, V274, P31279, DOI 10.1074/jbc.274.44.31279; LAVIGNE P, 1995, J MOL BIOL, V254, P505, DOI 10.1006/jmbi.1995.0634; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; Liu J, 2002, J MOL BIOL, V318, P877, DOI 10.1016/S0022-2836(02)00138-9; Lu M, 1999, J MOL BIOL, V288, P743, DOI 10.1006/jmbi.1999.2707; Lu SM, 2004, PROTEIN SCI, V13, P714, DOI 10.1110/ps.03443204; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LYU PCC, 1992, J MOL BIOL, V223, P343, DOI 10.1016/0022-2836(92)90735-3; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Mant CT, 1997, METHOD ENZYMOL, V289, P426; McClain DL, 2001, J MOL BIOL, V313, P371, DOI 10.1006/jmbi.2001.5044; Merrifield B, 1997, METHOD ENZYMOL, V289, P3; Micklatcher C, 1999, CURR OPIN CHEM BIOL, V3, P724, DOI 10.1016/S1367-5931(99)00031-9; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; Monera OD, 1996, J BIOL CHEM, V271, P3995; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; Paulucci AA, 2002, J BIOL CHEM, V277, P39574, DOI 10.1074/jbc.M204749200; Perry SV, 2001, J MUSCLE RES CELL M, V22, P5, DOI 10.1023/A:1010303732441; Regan L, 2003, CURR OPIN STRUC BIOL, V13, P479, DOI 10.1016/S0959-440X(03)00111-8; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Shortle D, 2001, SCIENCE, V293, P487, DOI 10.1126/science.1060438; Singh A, 2003, BIOCHEMISTRY-US, V42, P14114, DOI 10.1021/bi0348462; SKOLNICK J, 1983, MACROMOLECULES, V16, P1069, DOI 10.1021/ma00241a008; SKOLNICK J, 1986, BIOCHEMISTRY-US, V25, P6192, DOI 10.1021/bi00368a054; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; STELLWAGEN E, 1992, BIOPOLYMERS, V32, P1193, DOI 10.1002/bip.360320909; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; Suarez MC, 2001, BIOCHEMISTRY-US, V40, P1300, DOI 10.1021/bi0020978; TIDOR B, 1994, PROTEINS, V19, P310, DOI 10.1002/prot.340190406; Tripet B, 2002, J STRUCT BIOL, V137, P220, DOI 10.1006/jsbi.2002.4475; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; Wagschal K, 1999, PROTEIN SCI, V8, P2312; Weiss A, 1999, J MOL BIOL, V290, P61, DOI 10.1006/jmbi.1999.2865; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; XIONG HY, 1995, P NATL ACAD SCI USA, V92, P6349, DOI 10.1073/pnas.92.14.6349; Yang JX, 1997, PROTEIN SCI, V6, P1264, DOI 10.1002/pro.5560060614; Zhou N.-E., 1993, PEPTIDES BIOL CHEM, P217; ZHOU NE, 1993, BIOCHEMISTRY-US, V32, P6190, DOI 10.1021/bi00075a011; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1993, BIOCHEMISTRY-US, V32, P3178, DOI 10.1021/bi00063a033; ZHOU NE, 1994, PROTEIN PEPTIDE LETT, V1, P114; ZHU BY, 1993, PROTEIN SCI, V2, P383	70	88	89	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21576	21588		10.1074/jbc.M401074200	http://dx.doi.org/10.1074/jbc.M401074200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15020585	hybrid			2022-12-25	WOS:000221273800124
J	Yang, N; Huang, Y; Jiang, J; Frank, SJ				Yang, N; Huang, Y; Jiang, J; Frank, SJ			Caveolar and lipid raft localization of the growth hormone receptor and its signaling elements - Impact on growth hormone signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PLASMA-MEMBRANE CHOLESTEROL; JAK2 TYROSINE KINASE; GH RECEPTOR; INSULIN-RECEPTOR; IM-9 CELLS; FACTOR-I; INTERLEUKIN-2 RECEPTOR; NUCLEAR TRANSLOCATION; CYTOPLASMIC DOMAIN	The growth hormone receptor (GHR) is a cell surface receptor that mediates the somatogenic and metabolic effects of the growth hormone (GH). GHR signaling is transduced via the receptor-associated cytoplasmic tyrosine kinase called Janus protein kinase 2 (JAK2). The major intracellular signaling systems activated by JAK2 in response to GH include the signal transducer and activator of transcription ( STAT) 5 and extracellular signal-regulated kinase (ERK)-1 and -2 pathways. In this report, we investigate the role of cholesterol-rich plasma membrane microdomains (caveolae and lipid rafts) in GH signaling. By subcellular fractionation of the GH-responsive 3T3-F442A murine preadipocyte, we found dramatic enrichment (6.7-fold) of plasma membrane GHR in the caveolae membranes ( CM). JAK2 was also represented in the CM fraction, but was less enriched (2.5-fold) than GHR. ERK1/2 and the important ERK pathway upstream small adaptor protein, Grb2 (growth factor receptor-bound protein 2), were also enriched in caveolae (2.3- and 8.3-fold, respectively), but STAT5 was barely detected in the same fraction. Correspondingly, GH-induced tyrosine-phosphorylated GHR, JAK2, and ERK1/2 were highly represented in the CM fraction, whereas tyrosine-phosphorylated STAT5 was enriched in the non-membranous fraction of the post-nuclear supernatant. Additionally, GH induced further accumulation of GHR, Grb2, and SHC proteins in the CM fraction. Interestingly, treatment of the cells with the caveolae-disrupting agent, methyl-beta-cyclodextrin (mbetaCD), selectively inhibited GH-induced ERK1/2 activation but not STAT5 phosphorylation; repletion of cholesterol in mbetaCD-treated cells restored GH-induced ERK activation. Comparison of 3T3-F442A cells with the GHR-expressing human IM-9 lymphoblasts revealed similar enrichment of GHR in the lipid raft fraction of IM-9 as in the CM fraction of 3T3-F442A, but there were dramatic differences in the ERKs and Grb2. The IM-9 cell, in which ERKs are not activated by GH, displayed no enrichment of ERKs and Grb2 in the lipid raft fraction. Our results suggest that localization of GHRs in the CM fraction of the plasma membrane plays important roles in signaling.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Med Serv, Endocrinol Sect, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Frank, SJ (corresponding author), Univ Alabama, Dept Cell Biol, 1530 3rd Ave S,BDB 861, Birmingham, AL 35294 USA.	sjfrank@uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046395, R01DK058259, R29DK046395, R56DK058259, R01DK046395] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 58259, DK 46395] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASAKAWA K, 1986, BIOCHEM J, V238, P379, DOI 10.1042/bj2380379; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; Biedi C, 2003, ENDOCRINOLOGY, V144, P5497, DOI 10.1210/en.2003-0417; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Frank SJ, 2002, CYTOKINE REFERENCE O, P1; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Goebel J, 2002, J LEUKOCYTE BIOL, V72, P199; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Guan R, 2001, ENDOCRINOLOGY, V142, P1137, DOI 10.1210/en.142.3.1137; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; He K, 2003, MOL ENDOCRINOL, V17, P2211, DOI 10.1210/me.2003-0256; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Huang Y, 2003, J BIOL CHEM, V278, P18902, DOI 10.1074/jbc.M300939200; Huo HR, 2003, J BIOL CHEM, V278, P11561, DOI 10.1074/jbc.M211785200; Ikonen E, 2000, TRAFFIC, V1, P212, DOI 10.1034/j.1600-0854.2000.010303.x; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Kim SO, 2002, ENDOCRINOLOGY, V143, P4856, DOI 10.1210/en.2002-220565; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Kim YN, 2002, ENDOCRINOLOGY, V143, P1726, DOI 10.1210/en.143.5.1726; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; LESNIAK MA, 1974, J BIOL CHEM, V249, P1661; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; Liang L, 2000, ENDOCRINOLOGY, V141, P3328, DOI 10.1210/en.141.9.3328; Liu LJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1550, DOI 10.1152/ajpcell.00555.2002; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Lobie PE, 1999, EXP CELL RES, V246, P47, DOI 10.1006/excr.1998.4288; Love DW, 1998, ENDOCRINOLOGY, V139, P1965, DOI 10.1210/en.139.4.1965; Marmor MD, 2001, BLOOD, V98, P1489, DOI 10.1182/blood.V98.5.1489; Matko J, 2002, EUR J BIOCHEM, V269, P1199, DOI 10.1046/j.0014-2956.2002.02759.x; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; Razani B, 2001, EXP CELL RES, V271, P36, DOI 10.1006/excr.2001.5372; Sadir R, 2001, CYTOKINE, V14, P19, DOI 10.1006/cyto.2000.0854; Saltiel AR, 2003, TRAFFIC, V4, P711, DOI 10.1034/j.1600-0854.2003.00119.x; Shah BH, 2002, TRENDS ENDOCRIN MET, V13, P1, DOI 10.1016/S1043-2760(01)00539-2; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 2002, METHOD ENZYMOL, V353, P131; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; SOTIROPOULOS A, 1995, FEBS LETT, V369, P169, DOI 10.1016/0014-5793(95)00734-Q; Subramaniam PS, 2002, J IMMUNOL, V169, P1959, DOI 10.4049/jimmunol.169.4.1959; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; Woelfle J, 2003, J BIOL CHEM, V278, P22696, DOI 10.1074/jbc.M301362200; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Yoon M, 2003, BIOCHEM BIOPH RES CO, V308, P101, DOI 10.1016/S0006-291X(03)01341-X; Zhang Y, 2001, J BIOL CHEM, V276, P24565, DOI 10.1074/jbc.M101281200; Zhang Y, 1999, J BIOL CHEM, V274, P33072, DOI 10.1074/jbc.274.46.33072	78	53	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20898	20905		10.1074/jbc.M400625200	http://dx.doi.org/10.1074/jbc.M400625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15010456	hybrid			2022-12-25	WOS:000221273800042
J	Zhang, JJ; Zhang, YL; Zhu, L; Suzuki, M; Inouye, M				Zhang, JJ; Zhang, YL; Zhu, L; Suzuki, M; Inouye, M			Interference of mRNA function by sequence-specific endoribonuclease PemK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLE1 PLASMID REPLICATION; ESCHERICHIA-COLI; STABLE MAINTENANCE; CELL-DEATH; STABILITY SYSTEM; ADDICTION SYSTEM; BACTERIOPHAGE P1; DNA-REPLICATION; GENE-EXPRESSION; PROTEIN	In Escherichia coli, programmed cell death is mediated through the system called "addiction module," which consists of a pair of genes encoding a stable toxin and a labile antitoxin. The pemI-pemK system is an addiction module present on plasmid R100. It helps to maintain the plasmid by post-segregational killing in E. coli population. Here we demonstrate that purified PemK, the toxin encoded by the pemI-pemK addiction module, inhibits protein synthesis in an E. coli cell-free system, whereas the addition of PemI, the antitoxin against PemK, resumes the protein synthesis. Further studies reveal that PemK is a sequence-specific endoribonuclease that cleaves mRNAs to inhibit protein synthesis, whereas PemI blocks the endoribonuclease activity of PemK. PemK cleaves only single-stranded RNA preferentially at the 5' or 3' side of the A residue in the "UAH" sequences (where H is C, A, or U). Upon induction, PemK cleaves cellular mRNAs to effectively block protein synthesis in E. coli. The pemK homologue genes have been identified on the genomes of a wide range of bacteria. We propose that PemK and its homologues form a novel endoribonuclease family that interferes with mRNA function by cleaving cellular mRNAs in a sequence-specific manner.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.	inouye@rwja.umdnj.edu	Zhu, Ling/M-3887-2013	Zhu, Ling/0000-0003-0776-1630; Zhang, Junjie/0000-0001-8809-1485				Afif H, 2001, MOL MICROBIOL, V41, P73, DOI 10.1046/j.1365-2958.2001.02492.x; Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Bahassi EM, 1999, J BIOL CHEM, V274, P10936, DOI 10.1074/jbc.274.16.10936; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; BRAVO A, 1987, MOL GEN GENET, V210, P101, DOI 10.1007/BF00337764; Briani F, 2001, PLASMID, V45, P1, DOI 10.1006/plas.2000.1497; CESARENI G, 1991, TRENDS GENET, V7, P230, DOI 10.1016/0168-9525(91)90370-6; Christensen SK, 2003, J MOL BIOL, V332, P809, DOI 10.1016/S0022-2836(03)00922-7; Christensen SK, 2003, MOL MICROBIOL, V48, P1389, DOI 10.1046/j.1365-2958.2003.03512.x; Christensen SK, 2001, P NATL ACAD SCI USA, V98, P14328, DOI 10.1073/pnas.251327898; Dao-Thi MH, 2002, J BIOL CHEM, V277, P3733, DOI 10.1074/jbc.M105505200; DAVISON J, 1984, GENE, V28, P1, DOI 10.1016/0378-1119(84)90082-9; de la Cueva-Mendez G, 2003, EMBO J, V22, P246, DOI 10.1093/emboj/cdg026; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; Gazit E, 1999, J BIOL CHEM, V274, P16813, DOI 10.1074/jbc.274.24.16813; Gotfredsen M, 1998, MOL MICROBIOL, V29, P1065, DOI 10.1046/j.1365-2958.1998.00993.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hargreaves D, 2002, STRUCTURE, V10, P1425, DOI 10.1016/S0969-2126(02)00856-0; Hargreaves D, 2002, ACTA CRYSTALLOGR D, V58, P355, DOI 10.1107/S0907444901020753; Hayes CS, 2003, MOL CELL, V12, P903, DOI 10.1016/S1097-2765(03)00385-X; Jung YH, 1996, MOL BIOL REP, V22, P195, DOI 10.1007/BF00988728; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; Kampranis SC, 1999, J MOL BIOL, V293, P733, DOI 10.1006/jmbi.1999.3182; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; Magnuson P, 1996, J BIOL CHEM, V271, P18705, DOI 10.1074/jbc.271.31.18705; Marianovsky I, 2001, J BIOL CHEM, V276, P5975, DOI 10.1074/jbc.M008832200; MASUDA YJ, 1993, J BACTERIOL, V175, P6850, DOI 10.1128/jb.175.21.6850-6856.1993; MIZUNO T, 1984, P NATL ACAD SCI-BIOL, V81, P1966, DOI 10.1073/pnas.81.7.1966; NAKANO ET, 1987, J VIROL, V61, P302, DOI 10.1128/JVI.61.2.302-307.1987; Pedersen K, 2002, MOL MICROBIOL, V45, P501, DOI 10.1046/j.1365-2958.2002.03027.x; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Puerta-Fernandez E, 2003, FEMS MICROBIOL REV, V27, P75, DOI 10.1016/S0168-6445(03)00020-2; RUIZECHEVARRIA MJ, 1991, MOL MICROBIOL, V5, P2685, DOI 10.1111/j.1365-2958.1991.tb01977.x; RUIZECHEVARRIA MJ, 1995, J MOL BIOL, V247, P568, DOI 10.1006/jmbi.1995.0163; Santos-Sierra S, 2003, PLASMID, V50, P120, DOI 10.1016/S0147-619X(03)00048-9; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; Sierra SS, 1998, FEMS MICROBIOL LETT, V168, P51; SMITH JS, 1992, J BIOL CHEM, V267, P15071; TAM JE, 1989, J BACTERIOL, V171, P2353, DOI 10.1128/jb.171.5.2353-2360.1989; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOMIZAWA J, 1982, CELL, V31, P575, DOI 10.1016/0092-8674(82)90313-0; TSUCHIMOTO S, 1989, MOL GEN GENET, V215, P463, DOI 10.1007/BF00427044; TSUCHIMOTO S, 1992, J BACTERIOL, V174, P4205, DOI 10.1128/JB.174.13.4205-4211.1992; TSUCHIMOTO S, 1993, MOL GEN GENET, V237, P81, DOI 10.1007/BF00282787; TSUCHIMOTO S, 1988, J BACTERIOL, V170, P1461, DOI 10.1128/jb.170.4.1461-1466.1988; Zhang JJ, 2003, J BIOL CHEM, V278, P32300, DOI 10.1074/jbc.M304767200; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7	49	106	119	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20678	20684		10.1074/jbc.M314284200	http://dx.doi.org/10.1074/jbc.M314284200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15024022	hybrid			2022-12-25	WOS:000221273800018
J	Carretero, J; Medina, PP; Pio, R; Montuenga, LM; Sanchez-Cespedes, M				Carretero, J; Medina, PP; Pio, R; Montuenga, LM; Sanchez-Cespedes, M			Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene	ONCOGENE			English	Article						LKB1/STK11; Peutz-Jeghers syndrome; lung adenocarcinomas	PEUTZ-JEGHERS-SYNDROME; SYNDROME KINASE LKB1; SOMATIC MUTATIONS; TOBACCO-SMOKE; DNA-DAMAGE; GROWTH; ADENOCARCINOMA; PATTERNS; ARREST; COMMON	Germline mutations of the LKB1 gene are responsible for Peutz-Jeghers syndrome (PJS), an autosomal dominant inherited disorder bestowing an increased risk of cancer. We have recently demonstrated that LKB1 inactivating mutations are not confined to PJS, but also appear in lung adenocarcinomas of sporadic origin, including primary tumors and lung cancer cell lines. To accurately determine the frequency of inactivating LKB1 gene mutations in lung tumors we have sequenced the complete coding region of LKB1 in 21 additional lung cancer cell lines. Here we describe the mutational status of LKB1 gene in 30 lung cancer cell lines from different histopathological types, including 11 lung adenocarcinomas (LADs) and 11 small cell lung cancers (SCLCs). LKB1 gene alterations were present in six (54%) of the LAD cell lines tested but in none of the other histological types. Similar to our previous observations in primary tumors, all point mutations were of the nonsense or frameshift type, leading to an abnormal, truncated protein. Moreover, 2 cell lines (A427 and H2126) harbored large gene deletions that spanned several exons. Hence, we have identified additional lung cancer cell lines carrying inactivating mutations of the LKB1 tumor suppressor gene, further attesting to the significance of this gene in the development of LADs and providing new natural LKB1 knockouts for studies of the biological function of the LKB1 protein.	CNIO, Mol Pathol Program, Lymphoma & Lung Canc Grp, Madrid 28029, Spain; Univ Navarra, Sch Med, Fdn Appl Med Res, Dept Biochem, E-31080 Pamplona, Spain; Univ Navarra, Sch Med, Fdn Appl Med Res, Dept Histol & Pathol, E-31080 Pamplona, Spain; Univ Navarra, Sch Med, Fdn Appl Med Res, Div Oncol, E-31080 Pamplona, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); University of Navarra; University of Navarra; University of Navarra	Sanchez-Cespedes, M (corresponding author), CNIO, Mol Pathol Program, Lymphoma & Lung Canc Grp, Calle Melchor Fernandez Almagro 3, Madrid 28029, Spain.	msanchez@cnio.es	Pio, Ruben/F-5353-2017; Carretero, Julian/N-5214-2014; Montuenga, Luis M/AAF-7783-2020; Vico, Pedro Pablo Medina/D-1688-2013; Sanchez-Cespedes, Montse/H-8485-2012	Pio, Ruben/0000-0002-6831-6111; Carretero, Julian/0000-0001-7269-8506; Montuenga, Luis M/0000-0002-8739-1387; Vico, Pedro Pablo Medina/0000-0002-7834-7093; Sanchez-Cespedes, Montse/0000-0002-6045-5627				Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Miyaki M, 2000, CANCER RES, V60, P6311; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Sanchez-Cespedes M, 2003, LUNG CANCER, V40, P111, DOI 10.1016/S0169-5002(03)00033-3; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031	24	106	109	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4037	4040		10.1038/sj.onc.1207502	http://dx.doi.org/10.1038/sj.onc.1207502			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021901	Green Published			2022-12-25	WOS:000221382000017
J	Bentin, T; Hamzavi, R; Salomonsson, J; Roy, H; Ibba, M; Nielsen, PE				Bentin, T; Hamzavi, R; Salomonsson, J; Roy, H; Ibba, M; Nielsen, PE			Photoreactive bicyclic amino acids as substrates for mutant Escherichia coli phenylalanyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO INCORPORATION; GENETIC-CODE; PROTEINS; ANALOGS; FUNCTIONALITY; SPECIFICITY	Unnatural amino acids carrying reactive groups that can be selectively activated under non-invasive biologically benign conditions are of interest in protein engineering as biological tools for the analysis of protein-protein and protein-nucleic acids interactions. The double ring system phenylalanine analogues benzofuranylalanine and benzotriazolylalanine were synthesized, and their photolability was tested by UV irradiation at 254, 320, and 365 nm. Although both showed photo reactivity, benzofuranylalanine appeared as the most promising compound because this amino acid was activated by UVA (long wavelength) irradiation. These amino acids were also tested for in vitro charging of tRNAPhe and for protein mutagenesis via the phenylalanyl-tRNA synthetase variant alphaA294G that is able to facilitate in vivo protein synthesis using a range of para-substituted phenylalanine analogues. The results demonstrate that benzofuranylalanine, but not benzotriazolylalanine, is a substrate for phenylalanine tRNA synthetase alphaA294G, and matrix-assisted laser desorption ionization time-of-flight analysis showed it to be incorporated into a model protein with high efficiency. The in vivo incorporation into a target protein of a bicyclic phenylalanine analogue, as described here, demonstrates the applicability of phenylalanine tRNA synthetase variants in expanding the scope of protein engineering.	Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, DK-2200 Copenhagen N, Denmark; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	University of Copenhagen; University System of Ohio; Ohio State University	Nielsen, PE (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, Blegdamsvej 3C, DK-2200 Copenhagen N, Denmark.	pen@imbg.ku.dk	Roy, Hemant/AAC-9096-2020	/0000-0001-8771-330X				Behrens C, 2000, TETRAHEDRON, V56, P9443, DOI 10.1016/S0040-4020(00)00828-0; Chin JW, 2003, SCIENCE, V301, P964, DOI 10.1126/science.1084772; Datta D, 2002, J AM CHEM SOC, V124, P5652, DOI 10.1021/ja0177096; Furter R, 1998, PROTEIN SCI, V7, P419; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; IBBA M, 1994, BIOCHEMISTRY-US, V33, P7107, DOI 10.1021/bi00189a013; IBBA M, 1995, FEBS LETT, V364, P272, DOI 10.1016/0014-5793(95)00408-2; KATRITZKY AR, 1993, SYNTHETIC COMMUN, V23, P2019, DOI 10.1080/00397919308009862; Kirshenbaum K, 2002, CHEMBIOCHEM, V3, P235, DOI 10.1002/1439-7633(20020301)3:2/3<235::AID-CBIC235>3.0.CO;2-7; Kohrer C, 2001, P NATL ACAD SCI USA, V98, P14310, DOI 10.1073/pnas.251438898; Kowal AK, 2001, P NATL ACAD SCI USA, V98, P2268, DOI 10.1073/pnas.031488298; Kwon I, 2003, J AM CHEM SOC, V125, P7512, DOI 10.1021/ja0350076; MAGLIERY TJ, 2003, TRANSLATIONAL MECH; RAMABHADRAN TV, 1976, P NATL ACAD SCI USA, V73, P59, DOI 10.1073/pnas.73.1.59; Sakamoto M, 2000, CHEM COMMUN, P1201, DOI 10.1039/b002396p; Sharma N, 2000, FEBS LETT, V467, P37, DOI 10.1016/S0014-5793(00)01120-0; Wang H, 2000, J AM CHEM SOC, V122, P5849, DOI 10.1021/ja994464c; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; Wolfson AD, 2002, P NATL ACAD SCI USA, V99, P5965, DOI 10.1073/pnas.092152799; YANIV M, 1969, NATURE, V223, P1331, DOI 10.1038/2231331a0; Zhang ZW, 2004, SCIENCE, V303, P371, DOI 10.1126/science.1089509	22	21	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19839	19845		10.1074/jbc.M401278200	http://dx.doi.org/10.1074/jbc.M401278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004015	Green Published, hybrid			2022-12-25	WOS:000221164500056
J	Marchal, S; Gorren, ACF; Sorlie, M; Andersson, KK; Mayer, B; Lange, R				Marchal, S; Gorren, ACF; Sorlie, M; Andersson, KK; Mayer, B; Lange, R			Evidence of two distinct oxygen complexes of reduced endothelial nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-L-ARGININE; LOW-TEMPERATURE; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; OXYFERRO COMPLEX; DIOXYGEN COMPLEX; SINGLE-TURNOVER; REDOX ROLE; TETRAHYDROBIOPTERIN; HEME	Oxygen binding to the oxygenase domain of reduced endothelial nitric oxide synthase (eNOS) results in two distinct species differing in their Soret and visible absorbance maxima and in their capacity to exchange oxygen by CO. At 7degreesC, heme-oxy I (with maxima at 420 and 560 nm) is formed very rapidly (k(on) approximate to 2.5.10(6) M-1.s(-1)) in the absence of substrate but in the presence of pterin cofactor. It is capable of exchanging oxygen with CO at -30degreesC. Heme-oxy II is formed more slowly (k(on) approximate to 3.10(5) M-1.s(-1)) in the presence of substrate, regardless of the presence of pterin. It is also formed in the absence of both substrate and pterin. In contrast to heme-oxy I, it cannot exchange oxygen with CO at cryogenic temperature. In the presence of arginine, heme-oxy II is characterized by absorbance maxima near 432, 564, and 597 nm. When arginine is replaced by N-hydroxyarginine, and also in the absence of both substrate and pterin, its absorbance maxima are blue-shifted to 428, 560, and 593 nm. Heme-oxy I seems to resemble the ferrous dioxygen complex observed in many hemoproteins, including cytochrome P450. Heme-oxy II, which is the oxygen complex competent for product formation, appears to represent a distinct conformation in which the electronic configuration is essentially locked in the ferric superoxide complex.	Univ Montpellier 2, INSERM, U431, Dept Biol Sante, F-34095 Montpellier, France; Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria; Agr Univ Norway, Dept Chem & Biotechnol, N-1432 As, Norway; Univ Oslo, Dept Biochem, N-0316 Oslo, Norway	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Graz; Norwegian University of Life Sciences; University of Oslo	Lange, R (corresponding author), Univ Montpellier 2, INSERM, U431, Dept Biol Sante, Pl Eugene Bataillon, F-34095 Montpellier 5, France.	lange@montp.inserm.fr	MARCHAL, stéphane/M-4324-2017; Mayer, Bernd/B-9391-2008; Andersson, K Kristoffer/F-9624-2010	MARCHAL, stéphane/0000-0002-1101-7890; Mayer, Bernd/0000-0002-2921-3494; Gorren, Antonius Cornelis Franciscus/0000-0003-3476-6162				Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Bec N, 2000, J INORG BIOCHEM, V81, P207, DOI 10.1016/S0162-0134(00)00104-5; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Gorren ACF, 2000, BIOCHEMISTRY-US, V39, P11763, DOI 10.1021/bi0007775; Gorren ACF, 2002, METHOD ENZYMOL, V353, P114; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; Gorren ACF, 2001, NITRIC OXIDE-BIOL CH, V5, P176, DOI 10.1006/niox.2001.0332; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Groves JT, 2000, CURR OPIN CHEM BIOL, V4, P687, DOI 10.1016/S1367-5931(00)00146-0; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; Hagedoorn PL, 2001, J BIOL CHEM, V276, P22850, DOI 10.1074/jbc.M009458200; Hemmens B, 1998, METH MOL B, V100, P1; Hurshman AR, 2003, BIOCHEMISTRY-US, V42, P13287, DOI 10.1021/bi035491p; IGNARRO LJ, 1990, HYPERTENSION, V16, P477, DOI 10.1161/01.HYP.16.5.477; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KORTH HG, 1994, J BIOL CHEM, V269, P17776; Lange R, 2001, J INORG BIOCHEM, V87, P191, DOI 10.1016/S0162-0134(01)00330-0; LARROQUE C, 1980, FEBS LETT, V115, P175, DOI 10.1016/0014-5793(80)81161-6; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Raman CS, 2001, BIOCHEMISTRY-US, V40, P13448, DOI 10.1021/bi010957u; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; SHARROCK M, 1976, BIOCHIM BIOPHYS ACTA, V420, P8, DOI 10.1016/0005-2795(76)90340-8; SONO M, 1985, J BIOL CHEM, V260, P5530; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Sorlie M, 2003, J BIOL CHEM, V278, P48602, DOI 10.1074/jbc.M305682200; TUCKEY RC, 1982, J BIOL CHEM, V257, P9309; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Wang ZQ, 2002, J BIOL CHEM, V277, P12830, DOI 10.1074/jbc.M111967200; Wei CC, 2003, J BIOL CHEM, V278, P46668, DOI 10.1074/jbc.M307682200; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200	43	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19824	19831		10.1074/jbc.M313587200	http://dx.doi.org/10.1074/jbc.M313587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004019	hybrid			2022-12-25	WOS:000221164500054
J	Yang, YG; Cortes, U; Patnaik, S; Jasin, M; Wang, ZQ				Yang, YG; Cortes, U; Patnaik, S; Jasin, M; Wang, ZQ			Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks	ONCOGENE			English	Article						poly(ADP-ribose) polymerase-1; Rad51; homologous recombination; DNA double-strand break repair; replication stall and progression	SISTER-CHROMATID EXCHANGES; HOMOLOGY-DIRECTED REPAIR; POLY(ADP-RIBOSE) POLYMERASE; S-PHASE; RECOMBINATION; DAMAGE; RAD51; STABILITY; PROTEIN; GENOME	Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant DNA end-sensing and binding molecule. Inactivation of PARP-1 by chemicals and genetic mutations slows cell proliferation, increases sister chromatid exchange (SCE), micronuclei formation and chromosome instability, and shortens telomeres. Given its affinity to DNA breaks and temporal occupation on DNA strand break sites, PARP-1 is proposed to prevent inappropriate DNA recombination. We investigated the potential role of PARP-1 in repair of DNA double-strand breaks (DSBs) and stalled replication forks. PARP-1-/- embryonic stem cells and embryonic fibroblast cells exhibited normal repair of DNA DSBs by either homologous recombination (HR) or nonhomologous end-joining(NHEJ) pathways. Inactivation of PARP-1 did not interfere with gene-targeting efficiency in ES cells. However, PARP-1-/- cells were hypersensitive to the replication damage agent hydroxyurea (HU)-induced cell death and exhibited enhanced SCE formation. Ablation of PARP-1 delayed reactivation of stalled replication forks imposed by HU and re-entry into the G2-M phase after HU release. These data indicate that PARP-1 is dispensable in HR induced by DSBs, but is involved in the repair and reactivation of stalled replication forks.	Int Agcy Res Canc, F-69008 Lyon, France; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	World Health Organization; International Agency for Research on Cancer (IARC); Memorial Sloan Kettering Cancer Center	Wang, ZQ (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	zqwang@iarc.fr	Yang, Yungui/ABF-2507-2021					Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; CORTES F, 1993, MUTAT RES, V303, P71, DOI 10.1016/0165-7992(93)90097-F; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; COX MM, 2002, MUTAT RES, V10, P107; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Henrie MS, 2003, DNA REPAIR, V2, P151, DOI 10.1016/S1568-7864(02)00199-4; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; IKUSHIMA T, 1990, CHROMOSOMA, V99, P360, DOI 10.1007/BF01731724; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Menissier-de Murcia J, 2001, MOL CELL BIOL, V21, P1828; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; RAINALDI G, 1984, CHROMOSOMA, V90, P46, DOI 10.1007/BF00352277; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Tong WM, 2000, COLD SPRING HARB SYM, V65, P583, DOI 10.1101/sqb.2000.65.583; Tong WM, 2002, CANCER RES, V62, P6990; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wesierska-Gadek J, 1999, CANCER RES, V59, P28	45	189	195	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3872	3882		10.1038/sj.onc.1207491	http://dx.doi.org/10.1038/sj.onc.1207491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021907				2022-12-25	WOS:000221242500014
J	Andrabi, SA; Sayeed, I; Siemen, D; Wolf, G; Horn, TFW				Andrabi, SA; Sayeed, I; Siemen, D; Wolf, G; Horn, TFW			Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for antiapoptotic effects of melatonin	FASEB JOURNAL			English	Article						patch clamp; intracellular calcium; TMRM; NMDA; apoptosis; fluo-4	CEREBRAL-ARTERY OCCLUSION; TRANSIENT FOREBRAIN ISCHEMIA; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; CYCLOSPORINE-A; CYTOCHROME-C; CELL-DEATH; OXIDATIVE STRESS; STRIATAL NEURONS; BRAIN-DAMAGE	Melatonin, the secretory product of the pineal gland, is known to be neuroprotective in cerebral ischemia, which is so far mostly attributed to its antioxidant properties. Here we show that melatonin directly inhibits the mitochondrial permeability transition pore (mtPTP). mtPTP contributes to the pathology of ischemia by releasing calcium and cytochrome c (cyt c) from mitochondria. Consistently, NMDA-induced calcium rises were diminished by melatonin in cultured mouse striatal neurons, similar to the pattern seen with cyclosporine A (CsA). When the mouse striatal neurons were subjected to oxygen-glucose deprivation (OGD), melatonin strongly prevented the OGD-induced loss of the mitochondrial membrane potential. To assess the direct effect of melatonin on the mtPTP activity at the single channel level, recordings from the inner mitochondrial membrane were obtained by a patch-clamp approach using rat liver mitoplasts. Melatonin strongly inhibited mtPTP currents in a dose-dependent manner with an IC50 of 0.8 muM. If melatonin is an inhibitor of the mtPTP, it should prevent mitochondrial cyt c release as seen in stroke models. Rats underwent middle cerebral artery occlusion (MCAO) for 2 h followed by reperfusion. Melatonin (10 mg/kg ip) or vehicle was given at the time of occlusion and at the time of reperfusion. Indeed, infarct area in the brain sections of melatonin-treated animals displayed a considerably decreased cyt c release along with less activation of caspase-3 and apoptotic DNA fragmentation. Melatonin treatment diminished the loss of neurons and decreased the infarct volume as compared with untreated MCAO rats. Our findings suggest that the direct inhibition of the mtPTP by melatonin may essentially contribute to its anti-apoptotic effects in transient brain ischemia.	Otto Von Guericke Univ, Inst Med Neurobiol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurol, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Horn, TFW (corresponding author), Otto Von Guericke Univ, Inst Med Neurobiol, Leipziger Str 44, D-39120 Magdeburg, Germany.	thomas.horn@medizin.uni-magdeburg.de	Andrabi, Shaida/I-6167-2012	Andrabi, Shaida/0000-0002-3305-2638				ACUNACASTROVIEJ.D, 1997, LIFE SCI, V60, P23; Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; Back T, 2000, ANN NEUROL, V47, P485, DOI 10.1002/1531-8249(200004)47:4<485::AID-ANA12>3.3.CO;2-#; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Chung SY, 2003, J PINEAL RES, V34, P95, DOI 10.1034/j.1600-079X.2003.00010.x; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; Cuzzocrea S, 2000, J PINEAL RES, V29, P217, DOI 10.1034/j.1600-0633.2002.290404.x; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Halestrap AP, 1999, BIOCHEM SOC SYMP, V66, P181, DOI 10.1042/bss0660181; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Harms C, 2000, FASEB J, V14, P1814, DOI 10.1096/fj.99-0899com; Horn TFW, 2002, FASEB J, V16, P1611, DOI 10.1096/fj.02-0126com; HORTNAGL H, 1991, N-S ARCH PHARMACOL, V344, P213, DOI 10.1007/BF00167221; HUERTODELGADILLO L, 1994, J PINEAL RES, V17, P55, DOI 10.1111/j.1600-079X.1994.tb00114.x; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Joo WS, 1998, NEUROREPORT, V9, P4123, DOI 10.1097/00001756-199812210-00022; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; Kunduzova OR, 2003, FASEB J, V17, P872, DOI 10.1096/fj.02-0504fje; Lapin IP, 1998, J PINEAL RES, V24, P215; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu W, 2001, BRAIN RES, V916, P239, DOI 10.1016/S0006-8993(01)03006-2; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lorenz P, 2003, NITRIC OXIDE-BIOL CH, V9, P64, DOI 10.1016/j.niox.2003.09.005; Loupatatzis C, 2002, CELL PHYSIOL BIOCHEM, V12, P269, DOI 10.1159/000067897; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matsumoto S, 2002, LIFE SCI, V72, P591, DOI 10.1016/S0024-3205(02)02267-1; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; Nakatsuka H, 1999, BRAIN RES, V849, P216, DOI 10.1016/S0006-8993(99)01971-X; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Pei Z, 2002, J PINEAL RES, V32, P168, DOI 10.1034/j.1600-079x.2002.1o847.x; Pei Z, 2003, STROKE, V34, P770, DOI 10.1161/01.STR.0000057460.14810.3E; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; Pennartz CMA, 2002, NATURE, V416, P286, DOI 10.1038/nature728; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; Qian T, 1999, TOXICOL APPL PHARM, V154, P117, DOI 10.1006/taap.1998.8580; Reichert SA, 2001, J NEUROSCI, V21, P6608, DOI 10.1523/JNEUROSCI.21-17-06608.2001; REITER RJ, 1992, BIOESSAYS, V14, P169, DOI 10.1002/bies.950140307; Shen YX, 2002, J PINEAL RES, V32, P163, DOI 10.1034/j.1600-079x.2002.1o839.x; SIEMEN, 2002, REST NEURO NEUROSCI, V20, P275; SIESJO BK, 1985, PROG BRAIN RES, V63, P121; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SIMON RP, 1984, J CEREBR BLOOD F MET, V4, P350, DOI 10.1038/jcbfm.1984.52; Smaili SS, 1999, CELL CALCIUM, V26, P121, DOI 10.1054/ceca.1999.0061; Szewczyk A, 2002, PHARMACOL REV, V54, P101, DOI 10.1124/pr.54.1.101; Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Wang XD, 2001, GENE DEV, V15, P2922; Yoo YM, 2002, J PINEAL RES, V33, P146, DOI 10.1034/j.1600-079X.2002.02899.x; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	75	258	278	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					869	+		10.1096/fj.03-1031fje	http://dx.doi.org/10.1096/fj.03-1031fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033929				2022-12-25	WOS:000220522800013
J	Sweet, CR; Williams, AH; Karbarz, MJ; Werts, C; Kalb, SR; Cotter, RJ; Raetz, CRH				Sweet, CR; Williams, AH; Karbarz, MJ; Werts, C; Kalb, SR; Cotter, RJ; Raetz, CRH			Enzymatic synthesis of lipid A molecules with four amide-linked acyl chains - LpxA acyltransferases selective for an analog of UDP-N-acetylglucosamine in which an amine replaces the 3 ''-hydroxyl group	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CARRIER PROTEIN; ENDOTOXIN BIOSYNTHESIS; 1ST STEP; PRECURSORS; GLCNAC; ACETYLTRANSFERASE; SPECIFICITY; VARIABILITY; EXPRESSION	LpxA of Escherichia coli catalyzes the acylation of the glucosamine 3-OH group of UDP-GlcNAc, using R-3-hydroxymyristoyl-acyl carrier protein (ACP) as the donor substrate. We now demonstrate that LpxA in cell extracts of Mesorhizobium loti and Leptospira interrogans, which synthesize lipid A molecules containing 2,3-diamino2,3-dideoxy-D-glucopyranose (GlcN3N) units in place of glucosamine, do not acylate UDP-GlcNAc. Instead, these LpxA acyltransferases require a UDP-GlcNAc derivative ( designated UDP 2-acetamido-3-amino-2,3-dideoxy-alpha-D-glucopyranose or UDP-GlcNAc3N), characterized in the preceding paper (Sweet, C. R., Ribeiro, A. A., and Raetz, C. R. H. (2004) J. Biol. Chem. 279, 25400-25410), in which an amine replaces the glucosamine 3-OH group. L. interrogans LpxA furthermore displays absolute selectivity for 3-hydroxylauroyl-ACP as the donor, whereas M. loti LpxA functions almost equally well with 10-, 12-, and 14-carbon 3-hydroxyacyl-ACPs. The substrate selectivity of L. interrogans LpxA is consistent with the structure of L. interrogans lipid A. The mechanism of L. interrogans LpxA appears to be similar to that of E. coli LpxA, given that the essential His(125) residue of E. coli LpxA is conserved and is also required for acyltransferase activity in L. interrogans. Acidithiobacillus ferrooxidans (an organism that makes lipid A molecules containing both GlcN and GlcN3N) has an ortholog of LpxA that is selective for UDP-GlcNAc3N, but the enzyme also catalyzes the acylation of UDPGlcNAc at a slow rate. E. coli LpxA acylates UDP-GlcNAc and UDP-GlcNAc3N at comparable rates in vitro. However, UDP-GlcNAc3N is not synthesized in vivo, because E. coli lacks gnnA and gnnB. When the latter are supplied together with A. ferrooxidans lpxA, E. coli incorporates a significant amount of GlcN3N into its lipid A.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Inst Pasteur, Unite Bacteriol Mol & Med, F-75015 Paris, France; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA	Duke University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu	WERTS, Catherine/AAD-5447-2020	WERTS, Catherine/0000-0003-3079-5476; Kalb, Suzanne/0000-0002-8067-136X	NIGMS NIH HHS [GM-51310, R01 GM051796, R01 GM051310, R37 GM051796, GM-54882, GM-51796, R37 GM051796-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R37GM051796, R01GM051310, R01GM051796] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; Beaman TW, 1997, BIOCHEMISTRY-US, V36, P489, DOI 10.1021/bi962522q; Caroff M, 2001, J ENDOTOXIN RES, V7, P63, DOI 10.1177/09680519010070011101; Caroff M, 2000, FEBS LETT, V477, P8, DOI 10.1016/S0014-5793(00)01720-8; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; Dotson GD, 1998, J BACTERIOL, V180, P330, DOI 10.1128/JB.180.2.330-337.1998; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee BI, 2003, PROTEINS, V53, P772, DOI 10.1002/prot.10436; MOHAN S, 1994, J BIOL CHEM, V269, P32896; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Que-Gewirth NLS, 2004, J BIOL CHEM, V279, P25420, DOI 10.1074/jbc.M400598200; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Ren SX, 2003, NATURE, V422, P888, DOI 10.1038/nature01597; RUSSA R, 1995, ARCH MICROBIOL, V163, P345, DOI 10.1007/BF00404207; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SILVERMAN MP, 1959, J BACTERIOL, V77, P642, DOI 10.1128/JB.77.5.642-647.1959; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sweet CR, 2004, J BIOL CHEM, V279, P25400, DOI 10.1074/jbc.M400596200; Sweet CR, 2002, J BIOL CHEM, V277, P18281, DOI 10.1074/jbc.M201057200; Sweet CR, 2001, J BIOL CHEM, V276, P19565, DOI 10.1074/jbc.M101868200; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Wang XG, 2002, STRUCTURE, V10, P581, DOI 10.1016/S0969-2126(02)00741-4; WECKESSER J, 1988, FEMS MICROBIOL LETT, V54, P143, DOI 10.1016/0378-1097(88)90174-7; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; Wyckoff TJO, 1999, J BIOL CHEM, V274, P27047, DOI 10.1074/jbc.274.38.27047; YOKOTA A, 1987, ARCH MICROBIOL, V149, P106, DOI 10.1007/BF00425074; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zarrouk H, 1997, J BACTERIOL, V179, P3756, DOI 10.1128/jb.179.11.3756-3760.1997; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	42	32	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25411	25419		10.1074/jbc.M400597200	http://dx.doi.org/10.1074/jbc.M400597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15044493	hybrid, Green Accepted			2022-12-25	WOS:000221827900064
J	Johnson, JD; Han, ZQ; Otani, K; Ye, HG; Zhang, Y; Wu, H; Horikawa, Y; Misler, S; Bell, GI; Polonsky, KS				Johnson, JD; Han, ZQ; Otani, K; Ye, HG; Zhang, Y; Wu, H; Horikawa, Y; Misler, S; Bell, GI; Polonsky, KS			RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL RYANODINE RECEPTOR; INTRACELLULAR CA2+ STORES; BETA-CELL APOPTOSIS; DIABETES-MELLITUS; RELEASE CHANNELS; GLUCOSE; INSULIN; GROWTH; DEATH; INHIBITION	Cells are programmed to die when critical signaling and metabolic pathways are disrupted. Inhibiting the type 2 ryanodine receptor (RyR2) in human and mouse pancreatic beta-cells markedly increased apoptosis. This mode of programmed cell death was not associated with robust caspase-3 activation prompting a search for an alternative mechanism. Increased calpain activity and calpain gene expression suggested a role for a calpain-dependent death pathway. Using a combination of pharmacological and genetic approaches, we demonstrated that the calpain-10 isoform mediated ryanodine-induced apoptosis. Apoptosis induced by the fatty acid palmitate and by low glucose also required calpain-10. Ryanodine-induced calpain activation and apoptosis were reversed by glucagon-like peptide or short-term exposure to high glucose. Thus RyR2 activity seems to play an essential role in beta-cell survival in vitro by suppressing a death pathway mediated by calpain-10, a type 2 diabetes susceptibility gene with previously unknown function.	Washington Univ, Dept Internal Med, St Louis, MO 63110 USA; Univ Chicago, Dept Biochem, Chicago, IL 60637 USA; Univ Calif Los Angeles, Dept Pharmacol, Los Angeles, CA 90210 USA; Gunma Univ, Dept Cell Biol, Gunma 3718511, Japan	Washington University (WUSTL); University of Chicago; University of California System; University of California Los Angeles; Gunma University	Polonsky, KS (corresponding author), Washington Univ, Dept Internal Med, St Louis, MO 63110 USA.	polonsky@im.wustl.edu	Johnson, James/B-3919-2008	Johnson, James/0000-0002-7523-9433	NIDDK NIH HHS [DK-31842, DK-20595, P60 DK-20579, DK-47486] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031842, R01DK031842, R01DK047486, P60DK020579, P60DK020595] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi R, 2003, MOL GENET GENOMICS, V269, P797, DOI 10.1007/s00438-003-0892-5; Araki E, 2003, INTERNAL MED, V42, P7, DOI 10.2169/internalmedicine.42.7; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Drucker DJ, 2003, MOL ENDOCRINOL, V17, P161, DOI 10.1210/me.2002-0306; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; Federici M, 2001, FASEB J, V15, P22; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Islam MS, 2002, DIABETES, V51, P1299, DOI 10.2337/diabetes.51.5.1299; Johnson JD, 2004, FASEB J, V18, P878, DOI 10.1096/fj.03-1280fje; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; Johnson JD, 2002, J NEUROENDOCRINOL, V14, P144, DOI 10.1046/j.0007-1331.2001.00756.x; Johnson JD, 2002, AM J PHYSIOL-CELL PH, V282, pC635, DOI 10.1152/ajpcell.00044.2001; Johnson JD, 2002, AM J PHYSIOL-ENDOC M, V282, pE810, DOI 10.1152/ajpendo.00038.2001; Johnson JD, 2000, BIOCHEM CELL BIOL, V78, P217, DOI 10.1139/bcb-78-3-217; Komazaki S, 1998, CELL TISSUE RES, V294, P467, DOI 10.1007/s004410051198; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; Maedler K, 2001, DIABETES, V50, P1683, DOI 10.2337/diabetes.50.8.1683; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Masumiya H, 2001, J BIOL CHEM, V276, P39727, DOI 10.1074/jbc.M106557200; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; MODY I, 1995, TRENDS PHARMACOL SCI, V16, P356, DOI 10.1016/S0165-6147(00)89070-7; Moritz W, 2002, FASEB J, V16, P745, DOI 10.1096/fj.01-0403fje; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pacher P, 2002, P NATL ACAD SCI USA, V99, P2380, DOI 10.1073/pnas.032423699; Paraskevas S, 2001, ANN SURG, V233, P124, DOI 10.1097/00000658-200101000-00018; Podesta M, 2002, FASEB J, V16, P310, DOI 10.1096/fj.02-0520fje; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Sreenan SK, 2001, DIABETES, V50, P2013, DOI 10.2337/diabetes.50.9.2013; Srinivasan S, 2002, AM J PHYSIOL-ENDOC M, V283, pE784, DOI 10.1152/ajpendo.00177.2002; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Yang HT, 2002, P NATL ACAD SCI USA, V99, P9225, DOI 10.1073/pnas.142651999; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245; Zhou YP, 2003, METABOLISM, V52, P528, DOI 10.1053/meta.2003.50091	42	106	142	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24794	24802		10.1074/jbc.M401216200	http://dx.doi.org/10.1074/jbc.M401216200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044459	hybrid			2022-12-25	WOS:000221702500110
J	Lin, MT; Chang, CC; Chen, ST; Chang, HL; Su, JL; Chau, YP; Kuo, ML				Lin, MT; Chang, CC; Chen, ST; Chang, HL; Su, JL; Chau, YP; Kuo, ML			Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappa B-dependent XIAP up-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; HUMAN SKIN FIBROBLASTS; IMMEDIATE-EARLY GENE; HEPARAN-SULFATE PROTEOGLYCANS; ANGIOGENIC FACTOR CYR61; VEIN ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; INTEGRIN ALPHA(6)BETA(1); PLASMINOGEN-ACTIVATOR; MEDIATED SECRETION	The aggressiveness of a tumor is partly attributed to its resistance to chemotherapeutic agent-induced apoptosis. Cysteine-rich 61 (Cyr61), from the CCN gene family, is a secreted and matrix-associated protein, which is involved in many cellular activities such as growth and differentiation. Here we established a cell model system to examine whether stable expression of Cyr61 in MCF-7 cells can confer resistance to apoptosis and identify possible participating mechanisms. We showed that stable cell lines overexpressing Cyr61 had acquired a remarkable resistance to apoptosis induced by paclitaxel, adriamycin, and beta-lapachone. Most interesting, gel shift and reporter assays showed that the Cyr61-overexpressing cells had significantly increased NF-kappaB activity compared with neo control cells. Blockage of NF-kappaB activity in Cyr61-expressing cells by transfecting with a dominant negative (DN)-IkappaB or with an NF-kappaB decoy rendered them more susceptible to anti-cancer drugs-induced apoptosis. In addition, several NF-kappaB-regulated anti-apoptotic genes were examined, and we found that only XIAP showed a significant 3-4-fold increase in mRNA and protein in Cyr61-overexpressing cells but not in neo control cells. Treatment with inhibitor of apoptosis protein ( XIAP)specific antisense, but not sense, oligonucleotides abolished the apoptosis resistance of the Cyr61-overexpressing cells. At the same time, transfection of these stable cells with DN-IkappaB to block NF-kappaB activity also effectively reduced the elevated XIAP level. Function-neutralizing antibodies to alpha(v)beta(3) and alpha(v)beta(5) could inhibit Cyr61-mediated NF-kappaB activation as well as XIAP expression. Taken together, our data suggested that Cyr61 plays an important role in resistance to chemotherapeutic agent-induced apoptosis in human breast cancer MCF-7 cells by a mechanism involving the activation of the integrins/NF-kappaB/XIAP signaling pathway.	Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Pediat, Taipei 100, Taiwan; Natl Hlth Res Inst, Canc Res Div, VGH Taipei, Cooperat Lab, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Inst Anat, Taipei 112, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University	Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, 1,Sect 1,Jen Ai Rd, Taipei 100, Taiwan.	toxkml@ha.mc.ntu.edu.tw	Kuo, Min-Liang/C-4872-2009	KUO, MIN-LIANG/0000-0002-7139-0144; Chen, Szu-Ta/0000-0002-9715-1221; LIN, MING-TSAN/0000-0001-7313-7057				Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Ben-Neriah Y, 2003, MOL CELL, V12, P1344, DOI 10.1016/S1097-2765(03)00493-3; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Chawla-Sarkar M, 2003, J BIOL CHEM, V278, P39461, DOI 10.1074/jbc.M306111200; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Dai Y, 2003, ONCOGENE, V22, P7108, DOI 10.1038/sj.onc.1206863; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Gong LJ, 2003, ONCOGENE, V22, P4702, DOI 10.1038/sj.onc.1206583; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Guo GZ, 2004, ONCOGENE, V23, P535, DOI 10.1038/sj.onc.1207149; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; Huang YH, 2004, CANCER CELL, V5, P1, DOI 10.1016/S1535-6108(03)00340-4; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kasof GM, 2001, ONCOGENE, V20, P7965, DOI 10.1038/sj.onc.1204985; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Kikuchi E, 2003, CANCER RES, V63, P107; Kim EH, 2004, ONCOGENE, V23, P446, DOI 10.1038/sj.onc.1207025; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kirito K, 2002, J BIOL CHEM, V277, P8329, DOI 10.1074/jbc.M109824200; Kolesnikova TV, 1998, ONCOGENE, V16, P747, DOI 10.1038/sj.onc.1201572; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Laurent M, 2003, FASEB J, V17, P1919, DOI 10.1096/fj.02-1023fje; Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Levkau B, 2001, CIRC RES, V88, P282, DOI 10.1161/01.RES.88.3.282; Li CG, 2003, J CELL SCI, V116, P2677, DOI 10.1242/jcs.00470; Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200; Liu H, 2003, J NATL CANCER I, V95, P1586, DOI 10.1093/jnci/djg080; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P52598, DOI 10.1074/jbc.M308941200; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Munzert G, 2002, BLOOD, V100, P3749, DOI 10.1182/blood.V100.10.3749; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pilarsky CP, 1998, PROSTATE, V36, P85; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Qi H, 2003, CANCER RES, V63, P7076; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Schober JM, 2003, J BIOL CHEM, V278, P25808, DOI 10.1074/jbc.M301534200; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; SMITH JB, 1995, J BIOL CHEM, V270, P16756, DOI 10.1074/jbc.270.28.16756; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Tergaonkar V, 2003, MOL CELL BIOL, V23, P8070, DOI 10.1128/MCB.23.22.8070-8083.2003; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj/onc/1205131; Tsai MS, 2000, CANCER RES, V60, P5603; Tsai PW, 2003, J BIOL CHEM, V278, P5750, DOI 10.1074/jbc.M204863200; Uno K, 2003, BLOOD, V101, P3658, DOI 10.1182/blood-2002-06-1770; Wang QD, 2003, J BIOL CHEM, V278, P51091, DOI 10.1074/jbc.M306541200; Xiao CW, 2003, ENDOCRINOLOGY, V144, P623, DOI 10.1210/en.2001-211024; Xie D, 2001, CANCER RES, V61, P8917; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Yang L, 2003, CANCER RES, V63, P6815; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	86	162	176	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24015	24023		10.1074/jbc.M402305200	http://dx.doi.org/10.1074/jbc.M402305200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044484	hybrid			2022-12-25	WOS:000221702500023
J	Ajtai, K; Garamszegi, SP; Watanabe, S; Ikebe, M; Burghardt, TP				Ajtai, K; Garamszegi, SP; Watanabe, S; Ikebe, M; Burghardt, TP			The myosin cardiac loop participates functionally in the actomyosin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; ESSENTIAL LIGHT-CHAIN; X-RAY STRUCTURES; HEAVY-MEROMYOSIN; MOTOR DOMAIN; CHIMERIC SUBSTITUTIONS; 50/20-KDA JUNCTION; CRYSTAL-STRUCTURE; TRYPTIC CLEAVAGE	The motor protein myosin in association with actin transduces chemical free energy in ATP into work in the form of actin translation against an opposing force. Mediating the actomyosin interaction in myosin is an actin binding site distributed among several peptides on the myosin surface including surface loops contributing to affinity and actin regulation of myosin ATPase. A structured surface loop on beta-cardiac myosin, the cardiac or C-loop, was recently demonstrated to affect myosin ATPase and was indirectly implicated in the actomyosin interaction. The C-loop is a conserved feature of all myosin isoforms with crystal structures, suggesting that it is an essential part of the core energy transduction machinery. It is shown here that proteolytic digestion of the C-loop in beta-cardiac myosin eliminates actin-activated myosin ATPase and reduces actomyosin affinity in rigor more than 100-fold. Studies of C-loop function in smooth muscle myosin were also undertaken using site-directed mutagenesis. Mutagenesis of a single charged residue in the C-loop of smooth muscle myosin alters actomyosin affinity and doubles myosin in vitro motility and actin-activated ATPase velocities, thereby involving a charged region of the loop in the actomyosin interaction. It appears likely that the C-loop is an essential electrostatic binding site for actin involved in modulation of actomyosin affinity and regulation of actomyosin ATPase velocity.	Mayo Clin Rochester, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	Mayo Clinic; University of Massachusetts System; University of Massachusetts Worcester	Burghardt, TP (corresponding author), Mayo Clin Rochester, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.	burghardt@mayo.edu			NIAMS NIH HHS [R01 AR049277, AR049277, AR41653] Funding Source: Medline; NIGMS NIH HHS [GM55834] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049277, R01AR041653] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ajtai K, 2001, BIOCHEMISTRY-US, V40, P12078, DOI 10.1021/bi0112098; APPLEGATE D, 1984, BIOCHEMISTRY-US, V23, P6626, DOI 10.1021/bi00321a053; BALINT M, 1975, J BIOL CHEM, V250, P6168; BALINT M, 1978, ARCH BIOCHEM BIOPHYS, V190, P793, DOI 10.1016/0003-9861(78)90339-9; Berger CEM, 2001, J BIOL CHEM, V276, P23240, DOI 10.1074/jbc.M100524200; Blanchoin L, 1996, J BIOL CHEM, V271, P12380, DOI 10.1074/jbc.271.21.12380; Bobkov AA, 1996, P NATL ACAD SCI USA, V93, P2285, DOI 10.1073/pnas.93.6.2285; BRANT DA, 1967, J MOL BIOL, V23, P47, DOI 10.1016/S0022-2836(67)80066-4; Conibear PB, 1998, BIOPHYS J, V75, P926, DOI 10.1016/S0006-3495(98)77581-2; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Ellison PA, 2003, J BIOL CHEM, V278, P4410, DOI 10.1074/jbc.M211016200; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Fiske CH, 1925, J BIOL CHEM, V66, P375; Fujita H, 1997, J CLIN INVEST, V99, P1010, DOI 10.1172/JCI119228; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GOODY RS, 1983, BIOCHIM BIOPHYS ACTA, V726, P13, DOI 10.1016/0304-4173(83)90009-5; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; IKEBE M, 1987, J BIOL CHEM, V262, P13828; Joel PB, 2001, J BIOL CHEM, V276, P2998, DOI 10.1074/jbc.M006930200; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kinose F, 1996, J CELL BIOL, V134, P895, DOI 10.1083/jcb.134.4.895; Knetsch MLW, 1999, J BIOL CHEM, V274, P20133, DOI 10.1074/jbc.274.29.20133; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Kollmar M, 2002, EMBO J, V21, P2517, DOI 10.1093/emboj/21.11.2517; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Li XD, 2003, J BIOL CHEM, V278, P29435, DOI 10.1074/jbc.M301784200; Lowey S, 2002, TRENDS CARDIOVAS MED, V12, P348, DOI 10.1016/S1050-1738(02)00181-0; Luther HP, 2001, J CELL BIOCHEM, V80, P596, DOI 10.1002/1097-4644(20010315)80:4<596::AID-JCB1014>3.0.CO;2-Y; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MANNHERZ HG, 1992, J MOL BIOL, V226, P899, DOI 10.1016/0022-2836(92)90641-V; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; Mendelson R, 1997, P NATL ACAD SCI USA, V94, P8533, DOI 10.1073/pnas.94.16.8533; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; Milligan RA, 1996, P NATL ACAD SCI USA, V93, P21, DOI 10.1073/pnas.93.1.21; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; MUHLRAD A, 1982, P NATL ACAD SCI-BIOL, V79, P958, DOI 10.1073/pnas.79.4.958; Murphy CT, 1999, BIOCHEMISTRY-US, V38, P3785, DOI 10.1021/bi9826815; Murphy CT, 2000, J MUSCLE RES CELL M, V21, P139, DOI 10.1023/A:1005610007209; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; ONISHI H, 1995, P NATL ACAD SCI USA, V92, P704, DOI 10.1073/pnas.92.3.704; Onishi H, 2000, P NATL ACAD SCI USA, V97, P11203, DOI 10.1073/pnas.200362897; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; Root DD, 2002, CELL BIOCHEM BIOPHYS, V37, P97, DOI 10.1385/CBB:37:2:097; Root DD, 2002, BIOCHEMISTRY-US, V41, P1786, DOI 10.1021/bi015869o; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Sata M, 1996, J CLIN INVEST, V98, P2866, DOI 10.1172/JCI119115; Schaub MC, 1998, CARDIOVASC RES, V37, P381, DOI 10.1016/S0008-6363(97)00258-7; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; STRAUSS JD, 1996, BIOCH SMOOTH MUSCLE, P341; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; YAMAMOTO K, 1979, J BIOCHEM-TOKYO, V86, P1869, DOI 10.1093/oxfordjournals.jbchem.a132710; Yamashita H, 2000, J BIOL CHEM, V275, P28045; YOUNT RG, 1995, BIOPHYS J, V68, pS44	66	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23415	23421		10.1074/jbc.M310775200	http://dx.doi.org/10.1074/jbc.M310775200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15020589	hybrid			2022-12-25	WOS:000221570900077
J	Chen, QY; Cai, SS; Shadrach, KG; Prestwich, GD; Hollyfield, JG				Chen, QY; Cai, SS; Shadrach, KG; Prestwich, GD; Hollyfield, JG			Spacrcan binding to hyaluronan and other glycosaminoglycans - Molecular and biochemical studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERPHOTORECEPTOR MATRIX; EPITHELIUM-DERIVED FACTOR; PIGMENT-EPITHELIUM; GROWTH-FACTOR; MOUSE RETINA; N-SYNDECAN; PROTEIN; RAT; IDENTIFICATION; LOCALIZATION	Photoreceptors project from the outer retinal surface into a specialized glycocalyx, the interphotoreceptor matrix (IPM), which contains hyaluronan ( HA) and two novel proteoglycans, Spacr and Spacrcan. This matrix must be stable enough to function in the attachment of the retina to the outer eye wall yet porous enough to allow movement of metabolites between these tissues. How this matrix is organized is not known. HA is a potential candidate in IPM organization since biochemical studies show that these proteoglycans bind HA. RHAMM ( receptor for HA-mediated motility)-type HA binding motifs (HABMs) are present in their deduced amino acid sequence and may be the sites of this HA interaction. To test this hypothesis, we subcloned three fragments of mouse Spacrcan that contain the putative HABMs. We found that each recombinant fragment binds HA. Binding decreased when residues in the HABMs were mutated. This provides direct evidence that the RHAMM-type HABMs in Spacrcan are involved in hyaluronan binding. Since chondroitin sulfate and heparan sulfate proteoglycans are important for retinal development and function, we also evaluated the binding of these recombinant proteins to heparin and chondroitin sulfates, the glycosaminoglycan side chain of these proteoglycans. We found that each recombinant protein bound to both heparin and chondroitin sulfates. Binding to chondroitin sulfates involved these HABMs, because mutagenesis reduced binding. Binding to heparin was probably not mediated through these HABMs since heparin binding persisted following their mutagenesis. These studies provide the first evidence defining the sites of protein-carbohydrate interaction of molecules present in the IPM.	Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84108 USA	Cleveland Clinic Foundation; Utah System of Higher Education; University of Utah	Chen, QY (corresponding author), Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	chenq2@ccf.org			NATIONAL CANCER INSTITUTE [R43CA081820] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY002362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004336] Funding Source: NIH RePORTER; NCI NIH HHS [R43 CA81820] Funding Source: Medline; NEI NIH HHS [EY02362] Funding Source: Medline; NIDCD NIH HHS [DC 04336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Acharya S, 1998, J BIOL CHEM, V273, P31599, DOI 10.1074/jbc.273.47.31599; Acharya S, 2000, J BIOL CHEM, V275, P6945, DOI 10.1074/jbc.275.10.6945; Berndt C, 2001, J CELL BIOCHEM, V82, P246, DOI 10.1002/jcb.1119; Beuckmann CT, 1996, J NEUROSCI, V16, P6119; Cai SS, 2004, ANAL BIOCHEM, V326, P33, DOI 10.1016/j.ab.2003.11.017; CARRI NG, 1988, J NEUROSCI RES, V19, P428, DOI 10.1002/jnr.490190407; Chen QY, 2003, EXP EYE RES, V76, P1, DOI 10.1016/S0014-4835(02)00273-7; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; Chia JS, 2001, INFECT IMMUN, V69, P6987, DOI 10.1128/IAI.69.11.6987-6998.2001; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DELLONELARKIN G, 2001, EMEDICINE; ENOCH JM, 1971, INVEST OPHTH VISUAL, V10, P959; EVANKO S, 2001, GLYCOFORUM SCI HYALU; Foletta VC, 2001, J COMP NEUROL, V435, P354, DOI 10.1002/cne.1035; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; HAGEMAN GS, 1991, PROGR RETINAL RES, V10, P207; Henle J., 1855, HDB SYSTEMATISCHEN A, V2, P636; Herrmann JL, 2000, FEBS LETT, V473, P358, DOI 10.1016/S0014-5793(00)01553-2; HEWITT AT, 1990, EXP EYE RES, V50, P79; Hollyfield JG, 1999, INVEST OPHTH VIS SCI, V40, P2767; HOLLYFIELD JG, 1989, RETINA-J RET VIT DIS, V9, P59, DOI 10.1097/00006982-198909010-00008; HOLLYFIELD JG, 1990, EXP EYE RES, V51, P107, DOI 10.1016/0014-4835(90)90177-V; Inatani M, 2002, INVEST OPHTH VIS SCI, V43, P1616; Inatani M, 2002, PROG RETIN EYE RES, V21, P429, DOI 10.1016/S1350-9462(02)00009-5; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Karakousis PC, 2001, MOL VIS, V7, P154; Lee JW, 2000, EXP EYE RES, V71, P341, DOI 10.1006/exer.2000.0888; LI AR, 1995, J NEUROSCI, V15, P385; LIOU GIH, 1991, PROG CLIN BIOL RES, V362, P115; McBride JW, 2000, INFECT IMMUN, V68, P13, DOI 10.1128/IAI.68.1.13-18.2000; Mieziewska K, 1996, MICROSC RES TECHNIQ, V35, P463; Padgett LC, 1997, EXP EYE RES, V64, P927, DOI 10.1006/exer.1997.0287; Plantner JJ, 1998, CURR EYE RES, V17, P132, DOI 10.1076/ceyr.17.2.132.5610; Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552; POUYANI T, 1994, BIOCONJUGATE CHEM, V5, P339, DOI 10.1021/bc00028a010; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; RIPELLINO JA, 1988, J CELL BIOL, V106, P845, DOI 10.1083/jcb.106.3.845; RIPELLINO JA, 1989, J CELL BIOL, V108, P1899, DOI 10.1083/jcb.108.5.1899; SHERMAN MY, 1992, EMBO J, V11, P71; Shu XZ, 2002, BIOMACROMOLECULES, V3, P1304, DOI 10.1021/bm025603c; SIDMAN RL, 1954, J HISTOCHEM CYTOCHEM, V2, P413, DOI 10.1177/2.6.413; SWEATT AJ, 1991, EXP EYE RES, V53, P479, DOI 10.1016/0014-4835(91)90165-B; TURLEY EA, 1999, GLYCOFORUM SCI HYALU; van Lith-Verhoeven JJC, 2004, INVEST OPHTH VIS SCI, V45, P30, DOI 10.1167/iovs.03-0392; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P3658, DOI 10.1073/pnas.96.7.3658; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WU YQ, 1995, PROTEIN EXPRES PURIF, V6, P447, DOI 10.1006/prep.1995.1060; YANG BH, 1994, J CELL BIOCHEM, V56, P455, DOI 10.1002/jcb.240560406; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YAO XY, 1990, INVEST OPHTH VIS SCI, V31, P2051	51	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23142	23150		10.1074/jbc.M401584200	http://dx.doi.org/10.1074/jbc.M401584200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044457	hybrid			2022-12-25	WOS:000221570900044
J	Fornes, A; Nunez, E; Aragon, C; Lopez-Corcuera, B				Fornes, A; Nunez, E; Aragon, C; Lopez-Corcuera, B			The second intracellular loop of the glycine transporter 2 contains crucial residues for glycine transport and phorbol ester-induced regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DOPAMINE TRANSPORTER; PROTEIN-KINASE-C; TRANSMEMBRANE DOMAIN-I; SEROTONIN TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; GABA TRANSPORTER; CONFORMATIONAL EQUILIBRIUM; RECOMBINANT GLYT1; COCAINE BINDING; SYNTAXIN 1A	Na+ and Cl--coupled glycine transporters control the availability of glycine neurotransmitter in the synaptic cleft of inhibitory glycinergic pathways. In this report, we have investigated the involvement of the second intracellular loop of the neuronal glycine transporter 2 (GLYT2) on the protein conformational equilibrium and the regulation by 4alpha-phorbol 12 myristate 13-acetate (PMA). By substituting several charged (Lys-415, Lys-418, and Lys-422) and polar (Thr-419 and Ser-420) residues for different amino acids and monitoring plasma membrane expression and kinetic behavior, we found that residue Lys-422 is crucial for glycine transport. The introduction of a negative charge in 422, and to a lower extent in neighboring N-terminal residues, dramatically increases transporter voltage dependence as assessed by response to high potassium depolarizing conditions. In addition, [2-(trimethylammonium) ethyl] methanethiosulfonate accessibility revealed a conformational connection between Lys-422 and the glycine binding/permeation site. Finally, we show that the mutation of positions Thr-419, Ser-420, and mainly Lys-422 to acidic residues abolishes the PMA-induced inhibition of transport activity and the plasma membrane transporter internalization. Our results establish a new structural basis for the action of PMA on GLYT2 and suggest a complex nature of the PMA action on this glycine transporter.	Univ Autonoma Madrid, Ctr Biol Mol SeveroOchoa, Fac Ciencias, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Lopez-Corcuera, B (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol SeveroOchoa, Fac Ciencias, CSIC, E-28049 Madrid, Spain.	blopez@cbm.uam.es	Corcuera, Beatriz López/D-5188-2009; Aragon, Carmen/K-9783-2014	Corcuera, Beatriz López/0000-0002-0383-4241; Aragon, Carmen/0000-0001-8287-9386				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; Aragon C, 2003, EUR J PHARMACOL, V479, P249, DOI 10.1016/j.ejphar.2003.08.074; Barker EL, 1999, J NEUROSCI, V19, P4705; Beckman ML, 1998, J NEUROSCI, V18, P6103; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Chen NH, 2004, J BIOL CHEM, V279, P5508, DOI 10.1074/jbc.M306294200; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Geerlings A, 2000, FEBS LETT, V470, P51, DOI 10.1016/S0014-5793(00)01297-7; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; Gomeza J, 2003, NEURON, V40, P785, DOI 10.1016/S0896-6273(03)00672-X; Gomeza J, 2003, NEURON, V40, P797, DOI 10.1016/S0896-6273(03)00673-1; GONOVALEWSKY V, 1999, J BIOL CHEM, V274, P23020; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; LIU QR, 1993, J BIOL CHEM, V268, P22802; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; Loland CJ, 2004, J BIOL CHEM, V279, P3228, DOI 10.1074/jbc.M304755200; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; Lopez-Corcuera B, 2001, MOL MEMBR BIOL, V18, P13, DOI 10.1080/09687680120521; Lopez-Corcuera B, 2001, J BIOL CHEM, V276, P43463, DOI 10.1074/jbc.M107438200; Lopez-Corcuera B, 1998, J NEUROCHEM, V71, P2211; MacAulay N, 2003, J BIOL CHEM, V278, P28771, DOI 10.1074/jbc.M213023200; Martinez-Maza R, 2001, J BIOL CHEM, V276, P2168, DOI 10.1074/jbc.M006774200; Melikian HE, 1999, J NEUROSCI, V19, P7699; Nelson N, 1998, J NEUROCHEM, V71, P1785; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Nunez E, 2000, BRIT J PHARMACOL, V129, P200, DOI 10.1038/sj.bjp.0703049; Nunez E, 2000, BRIT J PHARMACOL, V129, P802, DOI 10.1038/sj.bjp.0703100; Ponce J, 2000, J BIOL CHEM, V275, P13856, DOI 10.1074/jbc.275.18.13856; QUIAN Y, 1997, J NEUROSCI, V17, P45; Quick MW, 1997, J NEUROSCI, V17, P2967; Reith MEA, 2001, J BIOL CHEM, V276, P29012, DOI 10.1074/jbc.M011785200; Roux MJ, 2000, NEURON, V25, P373, DOI 10.1016/S0896-6273(00)80901-0; Roux MJ, 2001, J BIOL CHEM, V276, P17699, DOI 10.1074/jbc.M009196200; Sakai N, 2000, NEUROCHEM INT, V36, P567, DOI 10.1016/S0197-0186(99)00160-6; SATO K, 1995, J NEUROCHEM, V65, P1967; SZATKOWSKI MS, 1989, J PHYSIOL-LONDON, V409, P103, DOI 10.1113/jphysiol.1989.sp017487; Willoughby D, 1999, PFLUG ARCH EUR J PHY, V438, P741, DOI 10.1007/s004240051101; ZAFRA F, 1995, J NEUROSCI, V15, P3952; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zhou YG, 2004, J BIOL CHEM, V279, P13800, DOI 10.1074/jbc.M311579200; Zomot E, 2003, J BIOL CHEM, V278, P42950, DOI 10.1074/jbc.M209307200	48	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22934	22943		10.1074/jbc.M401337200	http://dx.doi.org/10.1074/jbc.M401337200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15010455	hybrid			2022-12-25	WOS:000221570900020
J	Hashimoto, M; Bar-on, P; Ho, G; Takenouchi, T; Rockenstein, E; Crews, L; Masliah, E				Hashimoto, M; Bar-on, P; Ho, G; Takenouchi, T; Rockenstein, E; Crews, L; Masliah, E			beta-synuclein regulates Akt activity in neuronal cells - A possible mechanism for neuroprotection in Parkinson's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEWY BODY DISEASE; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; NERVOUS-SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-DEGRADATION; SUBSTANTIA-NIGRA; KINASE-ACTIVITY; AGGREGATION	Recent studies have shown that the neurodegenerative process in disorders with Lewy body formation, such as Parkinson's disease and dementia with Lewy bodies, is associated with alpha-synuclein accumulation and that beta-synuclein might protect the central nervous system from the neurotoxic effects of alpha-synuclein. However, the mechanisms are unclear. The main objective of the present study was to investigate the potential involvement of the serine threonine kinase Akt ( also known as protein kinase B) signaling pathway in the mechanisms of beta-synuclein neuroprotection. For this purpose, Akt activity and cell survival were analyzed in synuclein-transfected B103 neuroblastoma cells and primary cortical neurons. beta-Synuclein transfection resulted in increased Akt activity and conferred protection from the neurotoxic effects of rotenone. Down-regulation of Akt expression resulted in an increased susceptibility to rotenone toxicity, whereas transfection with a lentiviral vector encoding for beta-synuclein was protective. The effects of beta-synuclein on the Akt pathway appear to be by direct interaction between these molecules and were independent of upstream signaling molecules. Taken together, these results indicate that the mechanisms of beta-synuclein neuroprotection might involve direct interactions between beta-synuclein and Akt and suggest that this signaling pathway could be a potential therapeutic target for neurological conditions associated with parkinsonism and alpha-synuclein aggregation.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Natl Inst Agrobiol Sci, Lab Anim Cell Biol, Tsukuba, Ibaraki 3050602, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institute of Agrobiological Sciences - Japan	Masliah, E (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.	emasliah@ucsd.edu	Crews, Leslie/B-7584-2014	Crews, Leslie/0000-0003-0704-0067	NIA NIH HHS [AG022074, AG10435, AG5131, AG18440] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018440, P01AG022074, P50AG005131, R37AG018440, P01AG010435] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn BH, 2002, J BIOL CHEM, V277, P12334, DOI 10.1074/jbc.M110414200; AKOPIAN AN, 1995, J BIOL CHEM, V270, P21264, DOI 10.1074/jbc.270.36.21264; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buchman VL, 1998, J NEUROSCI, V18, P9335; Cohen G, 2000, ANN NY ACAD SCI, V899, P112; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; da Costa CA, 2003, J BIOL CHEM, V278, P37330, DOI 10.1074/jbc.M306083200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Doong H, 2003, J BIOL CHEM, V278, P28490, DOI 10.1074/jbc.M209682200; Elkon H, 2001, CELL MOL NEUROBIOL, V21, P771, DOI 10.1023/A:1015160323009; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Hashimoto M, 2003, J NEUROCHEM, V85, P1468, DOI 10.1046/j.1471-4159.2003.01791.x; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; Hoglinger GU, 2003, J NEUROCHEM, V86, P1297, DOI 10.1046/j.1471-4159.2003.01952.x; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jia TL, 1999, CANCER RES, V59, P742; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kowall NW, 2000, NEUROREPORT, V11, P211, DOI 10.1097/00001756-200001170-00041; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; McKeith IG, 2000, NEUROL CLIN, V18, P865, DOI 10.1016/S0733-8619(05)70230-9; Nakagomi S, 2003, J NEUROSCI, V23, P5187; NAKAJO S, 1993, EUR J BIOCHEM, V217, P1057, DOI 10.1111/j.1432-1033.1993.tb18337.x; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Opazo P, 2003, J NEUROSCI, V23, P3679; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735; Takeda A, 1998, LAB INVEST, V78, P1169; Takenouchi T, 2001, MOL CELL NEUROSCI, V17, P141, DOI 10.1006/mcne.2000.0923; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2002, J BIOL CHEM, V277, P11970, DOI 10.1074/jbc.M109541200; Vila M, 2000, J NEUROCHEM, V74, P721, DOI 10.1046/j.1471-4159.2000.740721.x; Wakabayashi K, 1997, ACTA NEUROPATHOL, V93, P7, DOI 10.1007/s004010050576	48	78	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23622	23629		10.1074/jbc.M313784200	http://dx.doi.org/10.1074/jbc.M313784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15026413	hybrid			2022-12-25	WOS:000221570900103
J	Sandegren, L; Sjoberg, BM				Sandegren, L; Sjoberg, BM			Distribution, sequence homology, and homing of group I Introns among T-even-like bacteriophages - Evidence for recent transfer of old introns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC ENDONUCLEASE; OPEN READING FRAMES; THYMIDYLATE SYNTHASE GENE; SELF-SPLICING INTRONS; RIBONUCLEOTIDE REDUCTASE; ENCODED ENDONUCLEASE; MARKER EXCLUSION; CO-CONVERSION; CLEAVAGE SITE; MINOR-GROOVE	Self-splicing group I introns are being found in an increasing number of bacteriophages. Most introns contain an open reading frame coding for a homing endonuclease that confers mobility to both the intron and the homing endonuclease gene (HEG). The frequent occurrence of intron/HEG has raised questions whether group I introns are spread via horizontal transfer between phage populations. We have determined complete sequences for the known group I introns among T-even-like bacteriophages together with sequences of the intron-containing genes td, nrdB, and nrdD from phages with and without introns. A previously uncharacterized phage isolate, U5, is shown to contain all three introns, the only phage besides T4 found with a "full set" of these introns. Sequence analysis of td and nrdB genes from intron-containing and intronless phages provides evidence that recent horizontal transmission of introns has occurred among the phages. The fact that several of the HEGs have suffered deletions rendering them non-functional implies that the homing endonucleases are of no selective advantage to the phage and are rapidly degenerating and probably dependent upon frequent horizontal transmissions for maintenance within the phage populations. Several of the introns can home to closely related intronless phages during mixed infections. However, the efficiency of homing varies and is dependent on homology in regions flanking the intron insertion site. The occurrence of optional genes flanking the respective intron-containing gene can strongly affect the efficiency of homing. These findings give further insight into the mechanisms of propagation and evolution of group I introns among the T-even-like bacteriophages.	Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, Svante Arrhenius Vag 16,F3, SE-10691 Stockholm, Sweden.	britt-marie.sjoberg@molbio.su.se	Sandegren, Linus/K-4638-2013	Sandegren, Linus/0000-0001-7382-9782; Sjoberg, Britt-Marie/0000-0001-5953-3360				Abedon Stephen T., 1994, P397; ALDNTHALER M, 2003, NUCLEIC ACIDS RES, V31, P3071; BECHHOFER DH, 1994, P NATL ACAD SCI USA, V91, P11669, DOI 10.1073/pnas.91.24.11669; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Belle A, 2002, GENE DEV, V16, P351, DOI 10.1101/gad.960302; BELLPEDERSEN D, 1990, NUCLEIC ACIDS RES, V18, P3763, DOI 10.1093/nar/18.13.3763; BELLPEDERSEN D, 1989, GENE, V82, P119, DOI 10.1016/0378-1119(89)90036-X; BELLPEDERSEN D, 1991, P NATL ACAD SCI USA, V88, P7719, DOI 10.1073/pnas.88.17.7719; BRYK M, 1995, J MOL BIOL, V247, P197, DOI 10.1006/jmbi.1994.0133; BRYK M, 1993, EMBO J, V12, P2141, DOI 10.1002/j.1460-2075.1993.tb05862.x; Busse I, 2003, PROTIST, V154, P57, DOI 10.1078/143446103764928495; Chevalier BS, 2001, NUCLEIC ACIDS RES, V29, P3757, DOI 10.1093/nar/29.18.3757; CHU FK, 1990, P NATL ACAD SCI USA, V87, P3574, DOI 10.1073/pnas.87.9.3574; CHU FK, 1991, NUCLEIC ACIDS RES, V19, P6863, DOI 10.1093/nar/19.24.6863; CHU FK, 1984, P NATL ACAD SCI-BIOL, V81, P3049, DOI 10.1073/pnas.81.10.3049; CLYMAN J, 1992, GENE DEV, V6, P1269, DOI 10.1101/gad.6.7.1269; Desplats C, 2002, J BACTERIOL, V184, P2789, DOI 10.1128/JB.184.10.2789-2804.2002; Eddy S, 1992, THESIS U COLORADO BO; EDDY SR, 1991, GENE DEV, V5, P1032, DOI 10.1101/gad.5.6.1032; Edgell DR, 2000, J BACTERIOL, V182, P5281, DOI 10.1128/JB.182.19.5281-5289.2000; Foley S, 2000, J VIROL, V74, P611, DOI 10.1128/JVI.74.2.611-618.2000; Goddard MR, 1999, P NATL ACAD SCI USA, V96, P13880, DOI 10.1073/pnas.96.24.13880; GOODRICHBLAIR H, 1994, NUCLEIC ACIDS RES, V22, P3715, DOI 10.1093/nar/22.18.3715; GOODRICHBLAIR H, 1990, CELL, V63, P417, DOI 10.1016/0092-8674(90)90174-D; GOTT JM, 1988, GENE DEV, V2, P1791, DOI 10.1101/gad.2.12b.1791; GOTT JM, 1986, CELL, V47, P81, DOI 10.1016/0092-8674(86)90368-5; Hendrix RW, 1999, P NATL ACAD SCI USA, V96, P2192, DOI 10.1073/pnas.96.5.2192; Holst-Jensen A, 1999, MOL BIOL EVOL, V16, P114, DOI 10.1093/oxfordjournals.molbev.a026031; Jurica MS, 1999, CELL MOL LIFE SCI, V55, P1304, DOI 10.1007/s000180050372; Kadyrov FA, 1997, FEBS LETT, V415, P75, DOI 10.1016/S0014-5793(97)01098-3; Kutter E, 1995, VIRUS GENES, V11, P285, DOI 10.1007/BF01728666; Landthaler M, 2002, NUCLEIC ACIDS RES, V30, P1935, DOI 10.1093/nar/30.9.1935; Landthaler M, 1999, P NATL ACAD SCI USA, V96, P7005, DOI 10.1073/pnas.96.12.7005; Lazarevic V, 1998, P NATL ACAD SCI USA, V95, P1692, DOI 10.1073/pnas.95.4.1692; Liu QQ, 2003, J MOL BIOL, V334, P13, DOI 10.1016/j.jmb.2003.09.027; Loizos N, 1996, J MOL BIOL, V255, P412, DOI 10.1006/jmbi.1996.0034; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MIKKONEN M, 1995, MICROBIOL-UK, V141, P2183, DOI 10.1099/13500872-141-9-2183; Miller ES, 2003, MICROBIOL MOL BIOL R, V67, P86, DOI 10.1128/MMBR.67.1.86-156.2003; Monod C, 1997, J MOL BIOL, V267, P237, DOI 10.1006/jmbi.1996.0867; Mueller JE, 1996, GENE DEV, V10, P351, DOI 10.1101/gad.10.3.351; Mueller JE, 1996, GENE DEV, V10, P2158, DOI 10.1101/gad.10.17.2158; Parker MM, 1996, GENETICS, V143, P1057; Parker MM, 1999, GENETICS, V153, P1513; QUIRK SM, 1989, CELL, V56, P455, DOI 10.1016/0092-8674(89)90248-1; QUIRK SM, 1989, NUCLEIC ACIDS RES, V17, P301, DOI 10.1093/nar/17.1.301; Rudi K, 2002, J BACTERIOL, V184, P666, DOI 10.1128/JB.184.3.666-671.2002; RUSSELL RL, 1974, GENETICS, V78, P989; SHARMA M, 1994, J BACTERIOL, V176, P6439, DOI 10.1128/JB.176.21.6439-6448.1994; SHARMA M, 1992, P NATL ACAD SCI USA, V89, P6658, DOI 10.1073/pnas.89.14.6658; SHUB DA, 1988, P NATL ACAD SCI USA, V85, P1151, DOI 10.1073/pnas.85.4.1151; SJOBERG BM, 1986, EMBO J, V5, P2031, DOI 10.1002/j.1460-2075.1986.tb04460.x; Tetart F, 1998, J MOL BIOL, V282, P543, DOI 10.1006/jmbi.1998.2047; Tetart F, 2001, J BACTERIOL, V183, P358, DOI 10.1128/JB.183.1.358-366.2001; vanSinderen D, 1996, MOL MICROBIOL, V19, P1343, DOI 10.1111/j.1365-2958.1996.tb02478.x; YOUNG P, 1994, J BIOL CHEM, V269, P20229	56	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22218	22227		10.1074/jbc.M400929200	http://dx.doi.org/10.1074/jbc.M400929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15026408	hybrid			2022-12-25	WOS:000221417100068
J	Zdebik, AA; Cuffe, JE; Bertog, M; Korbmacher, C; Jentsch, TJ				Zdebik, AA; Cuffe, JE; Bertog, M; Korbmacher, C; Jentsch, TJ			Additional disruption of the ClC-2Cl(-) channel does not exacerbate the cystic fibrosis phenotype of cystic fibrosis transmembrane conductance regulator mouse models	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CHLORIDE CHANNEL; FETAL LUNG; EPITHELIAL-CELLS; DISEASE SEVERITY; CL-CONDUCTANCE; EXPRESSION; MICE; SECRETION; CFTR; GENE	Cystic fibrosis is a fatal inherited disease that is caused by mutations in the gene encoding a cAMP-activated chloride channel, the cystic fibrosis transmembrane conductance regulator (CFTR). It has been suggested that the cystic fibrosis phenotype might be modulated by the presence of other Cl- channels that are co-expressed with CFTR in some epithelial cells. Because the broadly expressed plasma membrane Cl- channel, ClC-2, is present in the tissues whose function is compromised in cystic fibrosis, we generated mice with a disruption of both Cl- channel genes. No morphological changes in their intestine, lung, or pancreas, tissues affected by cystic fibrosis, were observed in these mice. The mortality was not increased over that observed with a complete lack of functional CFTR. Surprisingly, mice expressing mutant CFTR ( deletion of phenylalanine 508), survived longer when ClC-2 was disrupted additionally. Currents across colonic epithelia were investigated in Ussing chamber experiments. The disruption of ClC-2, in addition to CFTR, did not decrease Cl- secretion. Colon expressing wild-type CFTR even secreted more Cl- when ClC-2 was disrupted, although CFTR transcript levels were unchanged. It is concluded that ClC-2 is unlikely to be a candidate rescue channel in cystic fibrosis. Our data are consistent with a model in which ClC-2 is located in the basolateral membrane.	ZMNH, D-20246 Hamburg, Germany; Univ Oxford, Univ Lab Physiol, Oxford OX1 3PT, England	University of Oxford	Jentsch, TJ (corresponding author), ZMNH, Falkenried 94, D-20246 Hamburg, Germany.	Jentsch@zmnh.uni-hamburg.de		Jentsch, Thomas/0000-0002-3509-2553; Bertog, Marko/0000-0002-1504-9582				Blaisdell CJ, 2004, AM J PHYSIOL-LUNG C, V286, pL420, DOI 10.1152/ajplung.00113.2003; Blaisdell CJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1248, DOI 10.1152/ajplung.2000.278.6.L1248; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; Catalan M, 2002, AM J PHYSIOL-GASTR L, V283, pG1004, DOI 10.1152/ajpgi.00158.2002; Chu SJ, 1999, AM J PHYSIOL-LUNG C, V276, pL614, DOI 10.1152/ajplung.1999.276.4.L614; Cuffe JE, 2002, J PHYSIOL-LONDON, V539, P209, DOI 10.1113/jphysiol.2001.013159; Duan D, 2000, CIRC RES, V86, pE63, DOI 10.1161/01.RES.86.4.e63; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; French PJ, 1996, J CLIN INVEST, V98, P1304, DOI 10.1172/JCI118917; Grubb Barbara R., 1999, Physiological Reviews, V79, pS193; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Guggino WB, 1999, CELL, V96, P607, DOI 10.1016/S0092-8674(00)80570-X; Gyomorey K, 2000, AM J PHYSIOL-CELL PH, V279, pC1787, DOI 10.1152/ajpcell.2000.279.6.C1787; Gyomorey K, 2000, PEDIATR RES, V48, P731; Haug K, 2003, NAT GENET, V33, P527, DOI 10.1038/ng1121; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; Kajita H, 2000, J PHYSIOL-LONDON, V523, P313, DOI 10.1111/j.1469-7793.2000.t01-1-00313.x; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Kunzelmann E, 1997, PFLUG ARCH EUR J PHY, V435, P178, DOI 10.1007/s004240050498; Kunzelmann K, 2001, NEWS PHYSIOL SCI, V16, P167; LEVESQUE PC, 1992, CIRC RES, V71, P1002, DOI 10.1161/01.RES.71.4.1002; Lipecka J, 2002, AM J PHYSIOL-CELL PH, V282, pC805, DOI 10.1152/ajpcell.00291.2001; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Murray CB, 1996, AM J PHYSIOL-LUNG C, V271, pL829, DOI 10.1152/ajplung.1996.271.5.L829; MURRAY CB, 1995, AM J RESP CELL MOL, V12, P597, DOI 10.1165/ajrcmb.12.6.7766424; Nehrke K, 2002, J BIOL CHEM, V277, P23604, DOI 10.1074/jbc.M202900200; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P3879, DOI 10.1073/pnas.95.7.3879; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; Speake T, 2002, J PHYSIOL-LONDON, V539, P385, DOI 10.1113/jphysiol.2001.014548; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; TANIMURA A, 1995, J BIOL CHEM, V270, P25252, DOI 10.1074/jbc.270.42.25252; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Verkman AS, 2003, AM J PHYSIOL-CELL PH, V284, pC2, DOI 10.1152/ajpcell.00417.2002; ZEIHER BG, 1995, J CLIN INVEST, V96, P2051, DOI 10.1172/JCI118253	43	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22276	22283		10.1074/jbc.M309899200	http://dx.doi.org/10.1074/jbc.M309899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007059	hybrid			2022-12-25	WOS:000221417100075
J	Henshaw, JL; Bolam, DN; Pires, VMR; Czjzek, M; Henrissat, B; Ferreira, LMA; Fontes, CMGA; Gilbert, HJ				Henshaw, JL; Bolam, DN; Pires, VMR; Czjzek, M; Henrissat, B; Ferreira, LMA; Fontes, CMGA; Gilbert, HJ			The family 6 carbohydrate binding module CmCBM6-2 contains two ligand-binding sites with distinct specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVIDANS XYLANASE 10A; CRYSTAL-STRUCTURE; CATALYTIC-ACTIVITY; GLUCAN-BINDING; DOMAIN; COMPLEX; RECOGNITION; REVEALS; OLIGOSACCHARIDE; MECHANISM	The microbial degradation of the plant cell wall is an important biological process, representing a major component of the carbon cycle. Enzymes that mediate the hydrolysis of this composite structure are modular proteins that contain non-catalytic carbohydrate binding modules (CBMs) that enhance catalytic activity. CBMs are grouped into sequence-based families, and in a previous study we showed that a family 6 CBM (CBM6) that interacts with xylan contains two potential ligand binding clefts, designated cleft A and cleft B. Mutagenesis and NMR studies showed that only cleft A in this protein binds to xylan. Family 6 CBMs bind to a range of polysaccharides, and it was proposed that the variation in ligand specificity observed in these proteins reflects the specific cleft that interacts with the target carbohydrate. Here the biochemical properties of the C-terminal cellulose binding CBM6 (CmCBM6-2) from Cellvibrio mixtus endoglucanase 5A were investigated. The CBM binds to the beta1,4-beta1,3-mixed linked glucans lichenan and barley beta-glucan, cello-oligosaccharides, insoluble forms of cellulose, the beta1,3-glucan laminarin, and xylooligosaccharides. Mutagenesis studies, informed by the crystal structure of the protein ( presented in the accompanying paper, Pires, V. M. R., Henshaw, J. L., Prates, J. A. M., Bolam, D., Ferreira, L. M. A. Fontes, C. M. G. A., Henrissat, B., Planas, A., Gilbert, H. J., Czjzek, M. ( 2004) J. Biol. Chem. 279, 21560 - 21568), show that both cleft A and B can accommodate cello-oligosaccharides and laminarin displays a preference for cleft A, whereas xylooligosaccharides exhibit absolute specificity for this site, and the beta1,4,-beta1,3-mixed linked glucans interact only with cleft B. The binding of CmCBM6-2 to insoluble cellulose involves synergistic interactions between cleft A and cleft B. These data show that CmCBM6-2 contains two binding sites that display differences in ligand specificity, supporting the view that distinct binding clefts with different specificities can contribute to the variation in ligand recognition displayed by family 6 CBMs. This is in sharp contrast to other CBM families, where variation in ligand binding is a result of changes in the topology of a single carbohydrate-binding site.	Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; CIISA, Fac Med Vet, P-1199 Lisbon, Portugal; CNRS, UMR6098, F-13402 Marseille, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France	Newcastle University - UK; Universidade de Lisboa; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Gilbert, HJ (corresponding author), Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@Newcastle.ac.uk	Pires, Virginia/J-4799-2013; Henrissat, Bernard/J-2475-2012	Pires, Virginia/0000-0003-1307-3797; Henrissat, Bernard/0000-0002-3434-8588; Bolam, David/0000-0003-0314-3122; Ferreira, Luis/0000-0002-3543-9166; Fontes, Carlos/0000-0002-1219-9753				Abou Hachem M, 2000, BIOCHEM J, V345, P53, DOI 10.1042/0264-6021:3450053; Allouch J, 2003, J BIOL CHEM, V278, P47171, DOI 10.1074/jbc.M308313200; BLACK GW, 1995, BIOCHEM J, V307, P191, DOI 10.1042/bj3070191; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2003, J MOL BIOL, V327, P659, DOI 10.1016/S0022-2836(03)00152-9; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P14679, DOI 10.1021/bi015760g; Boraston AB, 2000, BIOCHEM J, V350, P933, DOI 10.1042/0264-6021:3500933; Boraston AB, 1999, ROY SOC CH, P202; BRETT CT, 1996, TOPICS PLANT FUNCTIO, V1; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; Coutinho PM, 1999, ROY SOC CH, P3; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; DIN N, 1994, P NATL ACAD SCI USA, V91, P11383, DOI 10.1073/pnas.91.24.11383; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; FERREIRA LMA, 1990, BIOCHEM J, V269, P261, DOI 10.1042/bj2690261; Fontes CMGA, 1998, APPL MICROBIOL BIOT, V49, P552, DOI 10.1007/s002530051212; Freelove ACJ, 2001, J BIOL CHEM, V276, P43010, DOI 10.1074/jbc.M107143200; Fujimoto Z, 2000, J MOL BIOL, V300, P575, DOI 10.1006/jmbi.2000.3877; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Notenboom V, 2002, BIOCHEMISTRY-US, V41, P4246, DOI 10.1021/bi015865j; Pell G, 2003, BIOCHEMISTRY-US, V42, P9316, DOI 10.1021/bi0347510; Pires VMR, 2004, J BIOL CHEM, V279, P21560, DOI 10.1074/jbc.M401599200; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; Robert X, 2003, STRUCTURE, V11, P973, DOI 10.1016/S0969-2126(03)00151-5; Scharpf M, 2002, BIOCHEMISTRY-US, V41, P4255, DOI 10.1021/bi015866b; Simpson PJ, 1999, STRUCTURE, V7, P853, DOI 10.1016/S0969-2126(99)80108-7; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Skov LK, 2002, J BIOL CHEM, V277, P47741, DOI 10.1074/jbc.M207860200; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Williamson MP, 1997, BIOCHEMISTRY-US, V36, P7535, DOI 10.1021/bi9702896; WOOD TM, 1988, METHOD ENZYMOL, V160, P19; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011; Zverlov VV, 2001, MICROBIOL-SGM, V147, P621, DOI 10.1099/00221287-147-3-621	43	82	84	1	22	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21552	21559		10.1074/jbc.M401620200	http://dx.doi.org/10.1074/jbc.M401620200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15004011	hybrid			2022-12-25	WOS:000221273800121
J	Ye, S; Vakonakis, I; Ioerger, TR; LiWang, AC; Sacchettini, JC				Ye, S; Vakonakis, I; Ioerger, TR; LiWang, AC; Sacchettini, JC			Crystal structure of circadian clock protein KaiA from Synechococcus elongatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN; PHOSPHORYLATION; EXPRESSION; PROGRAM; SYSTEMS	The circadian clock found in Synechococcus elongatus, the most ancient circadian clock, is regulated by the interaction of three proteins, KaiA, KaiB, and KaiC. While the precise function of these proteins remains unclear, KaiA has been shown to be a positive regulator of the expression of KaiB and KaiC. The 2.0-Angstrom structure of KaiA of S. elongatus reported here shows that the protein is composed of two independently folded domains connected by a linker. The NH2-terminal pseudo-receiver domain has a similar fold with that of bacterial response regulators, whereas the COOH-terminal four-helix bundle domain is novel and forms the interface of the 2-fold-related homodimer. The COOH-terminal four-helix bundle domain has been shown to contain the KaiC binding site. The structure suggests that the KaiB binding site is covered in the dimer interface of the KaiA "closed" conformation, observed in the crystal structure, which suggests an allosteric regulation mechanism.	Texas A&M Univ, Ctr Struct Biol, Dept Biochem & Biophys, College Stn, TX 77843 USA; Inst Biosci & Technol, Ctr Struct Biol, Houston, TX 77030 USA; Texas A&M Univ, Dept Comp Sci, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	LiWang, AC (corresponding author), Texas A&M Univ, Ctr Struct Biol, Dept Biochem & Biophys, College Stn, TX 77843 USA.	andy-liwang@tamu.edu; sacchett@tamu.edu	LiWang, Andy/AAE-5205-2020	LiWang, Andy/0000-0003-4741-6946	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062410, R56GM064576, R01GM064576] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 064576, GM 62410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BUNNING E, 1973, P NATL ACAD SCI USA, V70, P3387, DOI 10.1073/pnas.70.12.3387; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; Claridge-Chang A, 2001, NEURON, V32, P657, DOI 10.1016/S0896-6273(01)00515-3; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Durbin R., 1998, BIOL SEQUENCE ANAL P; Dvornyk V, 2003, P NATL ACAD SCI USA, V100, P2495, DOI 10.1073/pnas.0130099100; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Hayashi F, 2003, GENES CELLS, V8, P287, DOI 10.1046/j.1365-2443.2003.00633.x; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki H, 2002, P NATL ACAD SCI USA, V99, P15788, DOI 10.1073/pnas.222467299; Iwasaki H, 1999, EMBO J, V18, P1137, DOI 10.1093/emboj/18.5.1137; Kageyama H, 2003, J BIOL CHEM, V278, P2388, DOI 10.1074/jbc.M208899200; Kitayama Y, 2003, EMBO J, V22, P2127, DOI 10.1093/emboj/cdg212; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leipe DD, 2000, GENOME RES, V10, P5; LIANG DC, 1994, BIOPHYS CHEM, V50, P63, DOI 10.1016/0301-4622(94)85020-8; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mori T, 2002, P NATL ACAD SCI USA, V99, P17203, DOI 10.1073/pnas.262578499; Nishimura H, 2002, MICROBIOL-SGM, V148, P2903, DOI 10.1099/00221287-148-9-2903; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAO GM, 1995, J MOL EVOL, V40, P136, DOI 10.1007/BF00167109; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Taniguchi Y, 2001, FEBS LETT, V496, P86, DOI 10.1016/S0014-5793(01)02408-5; Vakonakis L, 2004, P NATL ACAD SCI USA, V101, P1479, DOI 10.1073/pnas.0305516101; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; Williams SB, 2002, P NATL ACAD SCI USA, V99, P15357, DOI 10.1073/pnas.232517099; Xu Y, 2003, EMBO J, V22, P2117, DOI 10.1093/emboj/cdg168; Yan OY, 1998, P NATL ACAD SCI USA, V95, P8660, DOI 10.1073/pnas.95.15.8660	36	81	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20511	20518		10.1074/jbc.M400077200	http://dx.doi.org/10.1074/jbc.M400077200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15007067	hybrid			2022-12-25	WOS:000221164500130
J	Engel, S; Vyazmensky, M; Vinogradov, M; Berkovich, D; Bar-Ilan, A; Qimron, U; Rosiansky, Y; Barak, Z; Chipman, DM				Engel, S; Vyazmensky, M; Vinogradov, M; Berkovich, D; Bar-Ilan, A; Qimron, U; Rosiansky, Y; Barak, Z; Chipman, DM			Role of a conserved arginine in the mechanism of acetohydroxyacid synthase - Catalysis of condensation with a specific ketoacid substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETOLACTATE SYNTHASE; PYRUVATE DECARBOXYLASE; THIAMIN DIPHOSPHATE; CRYSTAL-STRUCTURE; ACID SYNTHASE; ENZYME; ACTIVATION; OXIDASE; SITE	The thiamin diphosphate (ThDP)-dependent biosynthetic enzyme acetohydroxyacid synthase (AHAS) catalyzes decarboxylation of pyruvate and specific condensation of the resulting ThDP-bound two-carbon intermediate, hydroxyethyl-ThDP anion/enamine (HEThDP-), with a second ketoacid, to form acetolactate or acetohydroxybutyrate. Whereas the mechanism of formation of HEThDP- from pyruvate is well understood, the role of the enzyme in control of the carboligation reaction of HEThDP- is not. Recent crystal structures of yeast AHAS from Duggleby's laboratory suggested that an arginine residue might interact with the second ketoacid substrate. Mutagenesis of this completely conserved residue in Escherichia coli AHAS isozyme II (Arg(276)) confirms that it is required for rapid and specific reaction of the second ketoacid. In the mutant proteins, the normally rapid second phase of the reaction becomes rate-determining. A competing alternative nonnatural but stereospecific reaction of bound HEThDP- with benzaldehyde to form phenylacetylcarbinol (Engel, S., Vyazmensky, M., Geresh, S., Barak, Z., and Chipman, D. M. (2003) Biotechnol. Bioeng. 84, 833-840) provides a new tool for studying the fate of HEThDP- in AHAS, since the formation of the new product has a very different dependence on active site modifications than does acetohydroxyacid acid formation. The effects of mutagenesis of four different residues in the site on the rates and specificities of the normal and unnatural reactions support a critical role for Arg276 in the stabilization of the transition states for ligation of the incoming second ketoacid with HEThDP- and/or for the breaking of the product-ThDP bond. This information makes it possible to engineer the active site so that it efficiently and preferentially catalyzes a new reaction.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Biotechnol Engn, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Chipman, DM (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, POB 653, IL-84105 Beer Sheva, Israel.	chipman@bgumail.bgu.ac.il	Engel, Stanislav/G-2799-2013; Gazit, Ehud/AHE-9332-2022	Engel, Stanislav/0000-0001-5916-5190; Qimron, Udi/0000-0003-2169-5270				Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; AULABAUGH A, 1990, BIOCHEMISTRY-US, V29, P2824, DOI 10.1021/bi00463a027; Bar-Ilan A, 2001, BIOCHEMISTRY-US, V40, P11946, DOI 10.1021/bi0104524; BARAK Z, 1987, J BACTERIOL, V169, P3750, DOI 10.1128/jb.169.8.3750-3756.1987; Bowen TL, 1997, GENE, V188, P77, DOI 10.1016/S0378-1119(96)00779-2; CHANG YY, 1988, J BACTERIOL, V170, P3937, DOI 10.1128/jb.170.9.3937-3945.1988; Chipman D, 1998, BBA-PROTEIN STRUCT M, V1385, P401, DOI 10.1016/S0167-4838(98)00083-1; CISKANIK LM, 1985, BIOCHEMISTRY-US, V24, P3357; CROUT DHG, 1990, J CHEM SOC PERK T 1, P1367, DOI 10.1039/p19900001367; CROUT DHG, 1991, J CHEM SOC PERK T 2, P53, DOI 10.1039/p29910000053; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; Engel S, 2003, BIOTECHNOL BIOENG, V83, P833, DOI 10.1002/bit.10728; GOLLOP N, 1989, BIOCHEMISTRY-US, V28, P6310, DOI 10.1021/bi00441a024; GREEN JBA, 1989, FEBS LETT, V246, P1, DOI 10.1016/0014-5793(89)80241-8; Hill CM, 1997, BIOCHEM J, V327, P891, DOI 10.1042/bj3270891; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huebner Gerhard, 1998, Biochimica et Biophysica Acta, V1385, P221; Ibdah M, 1996, BIOCHEMISTRY-US, V35, P16282, DOI 10.1021/bi961588i; KRAMPITZ LO, 1948, ARCH BIOCHEM, V17, P81; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; MAZUR BJ, 1989, ANNU REV PLANT PHYS, V40, P441, DOI 10.1146/annurev.pp.40.060189.002301; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; Pang SS, 2002, J MOL BIOL, V317, P249, DOI 10.1006/jmbi.2001.5419; Pang SS, 2004, J BIOL CHEM, V279, P2242, DOI 10.1074/jbc.M304038200; Pang SS, 2003, J BIOL CHEM, V278, P7639, DOI 10.1074/jbc.M211648200; Schloss J. V., 1996, BIOCH PHYSL THIAMIN, P580; Tittmann K, 2003, BIOCHEMISTRY-US, V42, P7885, DOI 10.1021/bi034465o; TSE JMT, 1993, BIOCHEMISTRY-US, V32, P10398, DOI 10.1021/bi00090a015; Yoon TY, 2002, BIOCHEM BIOPH RES CO, V293, P433, DOI 10.1016/S0006-291X(02)00249-8	29	45	47	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24803	24812		10.1074/jbc.M401667200	http://dx.doi.org/10.1074/jbc.M401667200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044456	hybrid			2022-12-25	WOS:000221702500111
J	Groffen, AJA; Brian, EC; Dudok, JJ; Kampmeijer, J; Toonen, RF; Verhage, M				Groffen, AJA; Brian, EC; Dudok, JJ; Kampmeijer, J; Toonen, RF; Verhage, M			Ca2+-induced recruitment of the secretory vesicle protein DOC2B to the target membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE C2 PROTEIN; DEPENDENT PHOSPHOLIPID-BINDING; KINASE-C; CA2+-DEPENDENT EXOCYTOSIS; IN-VIVO; RELEASE; CELLS; DIACYLGLYCEROL; DOC2-ALPHA; MODULATOR	Ca2+-dependent fusion of transport vesicles at their target can be enhanced by intracellular Ca2+ and diacylglycerol. Diacylglycerol induces translocation of the vesicle priming factor Munc13 and association of the secretory vesicle protein DOC2B to the membrane. Here we demonstrate that a rise in intracellular Ca2+ is sufficient for a Munc13-independent recruitment of DOC2B to the target membrane. This novel mechanism occurred readily in the absence of Munc13 and was not influenced by DOC2B mutations that abolish Munc13 binding. Purified DOC2B ( expressed as a bacterial fusion protein) bound phospholipids in a Ca2+-dependent way, suggesting that the translocation is the result of a C2 domain activation mechanism. Ca2+-induced translocation was also observed in cultured neurons expressing DOC2B-enhanced green fluorescent protein. In this case, however, various degrees of membrane association occurred under resting conditions, suggesting that physiological Ca2+ concentrations modulate DOC2B localization. Depolarization of the neurons induced a complete translocation of DOC2B-enhanced green fluorescent protein to the target membrane within 5 s. We hypothesize that this novel Ca2+-induced activity of DOC2B functions synergistically with diacylglycerol-induced Munc13 binding to enhance exocytosis during episodes of high secretory activity.	Vrije Univ Amsterdam, Ctr Neurogenom & Cognit Res, Dept Funct Genom, NL-1081 HV Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Groffen, AJA (corresponding author), Vrije Univ Amsterdam, Ctr Neurogenom & Cognit Res, Dept Funct Genom, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	sander@cncr.vu.nl	Groffen, A.J.A./C-1118-2009	Groffen, A.J.A./0000-0003-0046-4027; verhage, matthijs/0000-0002-6085-7503; Dudok, Jacobus/0000-0002-7407-2491; Toonen, Ruud/0000-0002-9900-4233				Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Bollmann JH, 2000, SCIENCE, V289, P953, DOI 10.1126/science.289.5481.953; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Duncan RR, 1999, J BIOL CHEM, V274, P27347, DOI 10.1074/jbc.274.39.27347; Duncan RR, 2000, BIOCHIMIE, V82, P421, DOI 10.1016/S0300-9084(00)00214-5; Fisher SA, 1997, TRENDS NEUROSCI, V20, P170, DOI 10.1016/S0166-2236(96)01001-6; Fukuda M, 2000, BIOCHEM BIOPH RES CO, V276, P626, DOI 10.1006/bbrc.2000.3520; Hori T, 1999, J NEUROSCI, V19, P7262, DOI 10.1523/JNEUROSCI.19-17-07262.1999; Kojima T, 1996, J BIOCHEM-TOKYO, V120, P671; Mochida S, 1998, P NATL ACAD SCI USA, V95, P11418, DOI 10.1073/pnas.95.19.11418; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Orita S, 2001, METHOD ENZYMOL, V329, P83; Orita S, 1997, J BIOL CHEM, V272, P16081, DOI 10.1074/jbc.272.26.16081; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Sakaguchi G, 1995, BIOCHEM BIOPH RES CO, V217, P1053, DOI 10.1006/bbrc.1995.2876; Sakaguchi G, 1999, EUR J NEUROSCI, V11, P4262, DOI 10.1046/j.1460-9568.1999.00855.x; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	27	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23740	23747		10.1074/jbc.M400731200	http://dx.doi.org/10.1074/jbc.M400731200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15033971	Green Published, hybrid			2022-12-25	WOS:000221570900116
J	Leulliot, N; Quevillon-Cheruel, S; Sorel, I; Graille, M; Meyer, P; Liger, D; Blondeau, K; Janin, J; van Tilbeurgh, H				Leulliot, N; Quevillon-Cheruel, S; Sorel, I; Graille, M; Meyer, P; Liger, D; Blondeau, K; Janin, J; van Tilbeurgh, H			Crystal structure of yeast allantoicase reveals a repeated jelly roll motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ALLANTOATE AMIDINOHYDROLASE; CHLAMYDOMONAS-REINHARDTII; 3-DIMENSIONAL STRUCTURE; MOLECULAR-CLONING; NEUROSPORA-CRASSA; DEGRADING ENZYMES; SEQUENCE; GENE; DEGRADATION	Allantoicase (EC 3.5.3.4) catalyzes the conversion of allantoate into ureidoglycolate and urea, one of the final steps in the degradation of purines to urea. The mechanism of most enzymes involved in this pathway, which has been known for a long time, is unknown. In this paper we describe the three-dimensional crystal structure of the yeast allantoicase determined at a resolution of 2.6 Angstrom by single anomalous diffraction. This constitutes the first structure for an enzyme of this pathway. The structure reveals a repeated jelly roll beta-sheet motif, also present in proteins of unrelated biochemical function. Allantoicase has a hexameric arrangement in the crystal (dimer of trimers). Analysis of the protein sequence against the structural data reveals the presence of two totally conserved surface patches, one on each jelly roll motif. The hexameric packing concentrates these patches into conserved pockets that probably constitute the active site.	Univ Paris 11, CNRS, Unite Mixte Rech 8619, Inst Biochim & Biophys Mol & Cellulaire, F-91405 Orsay, France; Lab Enzymol & Biochim Struct, CNRS, Unite Propre Rech 9063, F-91198 Gif Sur Yvette, France; Univ Paris 11, CNRS, Unite Mixte Rech 8621, Inst Genet & Microbiol, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	van Tilbeurgh, H (corresponding author), Univ Paris 11, CNRS, Unite Mixte Rech 8619, Inst Biochim & Biophys Mol & Cellulaire, Batiment 430, F-91405 Orsay, France.	herman@lebs.cnrs-gif.fr	Meyer, Philippe/AAC-6038-2019; Leulliot, Nicolas/AAA-7160-2019; Janin, Joel/I-2958-2012; GRAILLE, Marc/D-3242-2014	Meyer, Philippe/0000-0002-6220-0679; Leulliot, Nicolas/0000-0003-0283-4298; GRAILLE, Marc/0000-0002-7853-5852				Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; Au SWN, 2002, J MOL BIOL, V316, P955, DOI 10.1006/jmbi.2002.5399; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; COOPER TG, 1979, GENETICS, V92, P383; COOPER TG, 1984, ADV ENZYMOL RAMB, V56, P91; Fuentes-Prior P, 2002, CURR PROTEIN PEPT SC, V3, P313, DOI 10.2174/1389203023380639; FUJIWARA S, 1995, BIOCHEM J, V312, P315, DOI 10.1042/bj3120315; GASKELL A, 1995, STRUCTURE, V3, P1197, DOI 10.1016/S0969-2126(01)00255-6; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hayashi S, 2000, CELL BIOCHEM BIOPHYS, V32, P123, DOI 10.1385/CBB:32:1-3:123; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; LEE FJS, 1991, YEAST, V7, P993, DOI 10.1002/yea.320070912; LEE H, 1990, BIOCHEMISTRY-US, V29, P8779, DOI 10.1021/bi00489a039; Manoj N, 2001, PROTEIN ENG, V14, P735, DOI 10.1093/protein/14.10.735; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; McIninch JK, 2003, J BIOL CHEM, V278, P50091, DOI 10.1074/jbc.M303828200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nishihara K, 2000, APPL ENVIRON MICROB, V66, P884, DOI 10.1128/AEM.66.3.884-889.2000; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Piedras P, 2003, PLANT SCI, V165, P423, DOI 10.1016/S0168-9452(03)00203-6; Piedras P, 2000, ARCH BIOCHEM BIOPHYS, V378, P340, DOI 10.1006/abbi.2000.1833; RAY MVL, 1993, BIO-TECHNOL, V11, P64, DOI 10.1038/nbt0193-64; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Timm DE, 1999, STRUCTURE, V7, P1023, DOI 10.1016/S0969-2126(99)80170-1; VANVUUREN HJJ, 1991, J BACTERIOL, V173, P7186, DOI 10.1128/jb.173.22.7186-7195.1991; Vigetti D, 2000, ARCH BIOCHEM BIOPHYS, V379, P90, DOI 10.1006/abbi.2000.1863; Vigetti D, 2000, GENE, V256, P253, DOI 10.1016/S0378-1119(00)00342-5; Vigetti D, 2002, FEBS LETT, V512, P323, DOI 10.1016/S0014-5793(02)02264-0; Vigetti D, 2001, BBA-GENE STRUCT EXPR, V1519, P117, DOI 10.1016/S0167-4781(01)00207-X; VOGELS GD, 1976, BACTERIOL REV, V40, P403, DOI 10.1128/MMBR.40.2.403-468.1976; Westhead DR, 1999, PROTEIN SCI, V8, P897; YOO HS, 1985, MOL CELL BIOL, V5, P2279, DOI 10.1128/MCB.5.9.2279; YOO HS, 1991, GENE, V104, P55, DOI 10.1016/0378-1119(91)90464-M	38	21	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23447	23452		10.1074/jbc.M401336200	http://dx.doi.org/10.1074/jbc.M401336200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15020593	Green Published, hybrid			2022-12-25	WOS:000221570900081
J	Locke, D; Koreen, IV; Liu, JY; Harris, AL				Locke, D; Koreen, IV; Liu, JY; Harris, AL			Reversible pore block of connexin channels by cyclodextrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GAP-JUNCTION CHANNELS; BETA-CYCLODEXTRIN; BINDING-PROTEIN; SELECTIVE PERMEABILITY; EXTRACELLULAR LOOP; CHARGE SELECTIVITY; KLEBSIELLA-OXYTOCA; OUTER-MEMBRANE; MALTODEXTRIN; AMYLASE	Cyclodextrins (CDs), a series of hollow cyclic glucosaccharides, can reversibly block molecular permeation through channels formed by connexin-32 and/or connexin-26 reconstituted into liposomes. The character of the block changes as a function of the size of the CD relative to the connexin pore diameter, suggesting that the block occurs via entry of the CD into the pore lumen and occlusion of the permeability pathway. The block occurs only when the CD is applied to the side of the pore that is normally cytoplasmic and not from the side that is normally extracellular. The block is potentiated when organic analytes are sequestered in the hydrophobic interior of the CDs. CDs may be useful as molecular tools with which to explore the structure of the connexin pore and to alter molecular movement through connexin channels.	UMDNJ, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Locke, D (corresponding author), UMDNJ, New Jersey Med Sch, Dept Physiol & Pharmacol, Med Sci Bldg I-643,185 S Orange Ave, Newark, NJ 07103 USA.	lockeda@umdnj.edu		Harris, Andrew/0000-0002-3782-0550	NIGMS NIH HHS [GM36044, GM61406] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061406, R01GM036044] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 1998, J BIOL CHEM, V273, P19859, DOI 10.1074/jbc.273.31.19859; Ahmad S, 2002, BIOCHEM J, V365, P693, DOI 10.1042/bj20011572; Albers E, 1995, CRIT REV THER DRUG, V12, P311, DOI 10.1615/CritRevTherDrugCarrierSyst.v12.i4.20; ALONSO DOV, 1991, BIOPOLYMERS, V31, P1631, DOI 10.1002/bip.360311317; Anibarro M, 2001, CARBOHYD RES, V333, P251, DOI 10.1016/S0008-6215(01)00131-8; Bakshi MS, 1996, J SOLUTION CHEM, V25, P411, DOI 10.1007/BF00972896; Beahm DL, 2002, BIOPHYS J, V82, P2016, DOI 10.1016/S0006-3495(02)75550-1; BENESI HA, 1949, J AM CHEM SOC, V71, P2703, DOI 10.1021/ja01176a030; BETTINETTI G, 1991, J PHARM SCI, V80, P1162, DOI 10.1002/jps.2600801214; BEVANS C, 1995, BIOPHYS J, V68, P204; Bevans CG, 1999, J BIOL CHEM, V274, P3711, DOI 10.1074/jbc.274.6.3711; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Bevans CG, 1999, J BIOL CHEM, V274, P3720, DOI 10.1074/jbc.274.6.3720; BEVANS CG, 1996, MOL BIOL CELL, V7, P281; Beyer EC, 2000, BRAZ J MED BIOL RES, V33, P391, DOI 10.1590/S0100-879X2000000400004; Braesicke K, 2000, J MOL GRAPH MODEL, V18, P143, DOI 10.1016/S1093-3263(00)00046-2; BRINK PR, 2000, GAP JUNCTIONS MOL BA, P43; Cao FL, 1998, J CELL SCI, V111, P31; Contreras JE, 2003, P NATL ACAD SCI USA, V100, P11388, DOI 10.1073/pnas.1434298100; Duan XQ, 2001, J MOL BIOL, V306, P1115, DOI 10.1006/jmbi.2001.4456; Easton C. J., 1999, MODIFIED CYCLODEXTRI; Ebihara L, 2003, NEWS PHYSIOL SCI, V18, P100, DOI 10.1152/nips.01431.2002; EBIHARA L, 1995, BIOPHYS J, V68, P1796, DOI 10.1016/S0006-3495(95)80356-5; EBIHARA L, 1993, J GEN PHYSIOL, V102, P59, DOI 10.1085/jgp.102.1.59; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Enkvetchakul D, 2003, J PHYSIOL-LONDON, V553, P95, DOI 10.1113/jphysiol.2003.047910; Evenas J, 2001, J MOL BIOL, V309, P961, DOI 10.1006/jmbi.2001.4695; Falk MM, 1998, J BIOL CHEM, V273, P7856, DOI 10.1074/jbc.273.14.7856; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; Goldberg GS, 1998, EXP CELL RES, V239, P82, DOI 10.1006/excr.1997.3872; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Gu LQ, 2000, P NATL ACAD SCI USA, V97, P3959, DOI 10.1073/pnas.97.8.3959; Gu LQ, 1999, NATURE, V398, P686, DOI 10.1038/19491; Gu LQ, 2001, J GEN PHYSIOL, V118, P481, DOI 10.1085/jgp.118.5.481; Harris AL, 1998, GAP JUNCTIONS, P60; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Harris AL, 2001, METH MOL B, V154, P357; HARRIS AL, 1989, J MEMBRANE BIOL, V109, P243, DOI 10.1007/BF01870281; HARRIS AL, 1992, MOL BRAIN RES, V15, P269, DOI 10.1016/0169-328X(92)90118-U; HILLE B, 1975, J GEN PHYSIOL, V66, P535, DOI 10.1085/jgp.66.5.535; Hong EJ, 1996, ARCH PHARM RES, V19, P264, DOI 10.1007/BF02976238; Hu XG, 1999, FEBS LETT, V451, P113, DOI 10.1016/S0014-5793(99)00558-X; Immel S, 2000, STARCH-STARKE, V52, P1; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; Kam Y, 1998, BBA-BIOMEMBRANES, V1372, P384, DOI 10.1016/S0005-2736(98)00075-3; Kamionka A, 2001, FEMS MICROBIOL LETT, V204, P55, DOI 10.1111/j.1574-6968.2001.tb10862.x; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kim DY, 1999, J BIOL CHEM, V274, P5581, DOI 10.1074/jbc.274.9.5581; KNEGTEL RMK, 1995, J BIOL CHEM, V270, P29256, DOI 10.1074/jbc.270.49.29256; Kokkinou A, 2000, CARBOHYD RES, V328, P135, DOI 10.1016/S0008-6215(00)00091-4; Koreen IV, 2004, BIOPHYS J, V86, p583A; KOVAL M, 1995, J CELL BIOL, V130, P987, DOI 10.1083/jcb.130.4.987; Kronengold J, 2003, J GEN PHYSIOL, V122, P389, DOI 10.1085/jgp.200308861; LARSON SB, 1994, J MOL BIOL, V235, P1560, DOI 10.1006/jmbi.1994.1107; LI S, 1992, CHEM REV, V92, P1457, DOI 10.1021/cr00014a009; Locke D, 2002, MOL BIOL CELL, V13, p352A; MANZUNA B, 1997, J MOL STRUC-THEOCHEM, V419, P133; Mele A, 1997, EUR MASS SPECTROM, V3, P347, DOI 10.1255/ejms.166; MIKAMI B, 1993, BIOCHEMISTRY-US, V32, P6836, DOI 10.1021/bi00078a006; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Musa H, 2003, BIOPHYS J, V84, P205, DOI 10.1016/S0006-3495(03)74843-7; Musa H, 2001, BIOPHYS J, V81, P3253, DOI 10.1016/S0006-3495(01)75960-7; MUSA H, 2003, INT GAP JUNC M, P107; Nakata Y, 2002, BIOPOLYMERS, V64, P72, DOI 10.1002/bip.10133; Nicholson BJ, 2000, BRAZ J MED BIOL RES, V33, P369, DOI 10.1590/S0100-879X2000000400002; Niessen H, 2000, J CELL SCI, V113, P1365; OLLIVON M, 1986, ANAL BIOCHEM, V152, P262, DOI 10.1016/0003-2697(86)90408-2; Orlik F, 2003, BIOPHYS J, V85, P876, DOI 10.1016/S0006-3495(03)74527-5; Pajatsch M, 1999, J BIOL CHEM, V274, P25159, DOI 10.1074/jbc.274.35.25159; Pajatsch M, 1998, J BACTERIOL, V180, P2630, DOI 10.1128/JB.180.10.2630-2635.1998; Plum A, 2000, CURR BIOL, V10, P1083, DOI 10.1016/S0960-9822(00)00690-4; Purnick PEM, 2000, BIOPHYS J, V79, P2403, DOI 10.1016/S0006-3495(00)76485-X; Rekharsky MV, 1998, CHEM REV, V98, P1875, DOI 10.1021/cr970015o; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; Rong P, 2002, DEVELOPMENT, V129, P167; SAUVE DM, 1995, ANAL BIOCHEM, V226, P382, DOI 10.1006/abio.1995.1242; Schmidt AK, 1998, BIOCHEMISTRY-US, V37, P5909, DOI 10.1021/bi9729918; Schneider HJ, 1998, CHEM REV, V98, P1755, DOI 10.1021/cr970019t; SCHULTZ SG, 1961, J GEN PHYSIOL, V44, P1189, DOI 10.1085/jgp.44.6.1189; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; Skerrett IM, 2002, J CELL BIOL, V159, P349, DOI 10.1083/jcb.200207060; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; Suchyna TM, 1999, BIOPHYS J, V77, P2968, DOI 10.1016/S0006-3495(99)77129-8; SUGAWARA E, 1994, J BIOL CHEM, V269, P17981; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; Trexler EB, 2000, BIOPHYS J, V79, P3036, DOI 10.1016/S0006-3495(00)76539-8; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; Valiunas V, 1999, PFLUG ARCH EUR J PHY, V437, P846, DOI 10.1007/s004240050854; VEENSTRA RD, 1995, CIRC RES, V77, P1156, DOI 10.1161/01.RES.77.6.1156; Verselis V.K., 2000, ADV MOL CEL, V30, P129; Wallqvist A, 1998, J AM CHEM SOC, V120, P427, DOI 10.1021/ja972053v; WERNER R, 1989, P NATL ACAD SCI USA, V86, P5380, DOI 10.1073/pnas.86.14.5380; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; White TW, 2002, SCIENCE, V295, P319, DOI 10.1126/science.1067582; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; Yi ZP, 1999, PHYS CHEM CHEM PHYS, V1, P441, DOI 10.1039/a807916a; Zhou XW, 1997, BIOPHYS J, V72, P1946, DOI 10.1016/S0006-3495(97)78840-4; ZIMMER DB, 1987, J BIOL CHEM, V262, P7751	103	28	31	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22883	22892		10.1074/jbc.M401980200	http://dx.doi.org/10.1074/jbc.M401980200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044473	hybrid			2022-12-25	WOS:000221570900014
J	Webb, AI; Dunstone, MA; Chen, WS; Aguilar, MI; Chen, QY; Jackson, H; Chang, L; Kjer-Nielsen, L; Beddoe, T; McCluskey, J; Rossjohn, J; Purcell, AW				Webb, AI; Dunstone, MA; Chen, WS; Aguilar, MI; Chen, QY; Jackson, H; Chang, L; Kjer-Nielsen, L; Beddoe, T; McCluskey, J; Rossjohn, J; Purcell, AW			Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; T-CELL RESPONSES; REDUCED PEPTIDE-BOND; HISTOCOMPATIBILITY MOLECULE HLA-A2; CHORIOMENINGITIS VIRUS-INFECTION; TESTIS ANTIGEN NY-ESO-1; VACCINE DESIGN; CRYSTAL-STRUCTURES; IMMUNE-RESPONSES; ANTIBODY-RESPONSES	NY-ESO-1, a commonly expressed tumor antigen of the cancer-testis family, is expressed by a wide range of tumors but not found in normal adult somatic tissue, making it an ideal cancer vaccine candidate. Peptides derived from NY-ESO-1 have shown preclinical and clinical trial promise; however, biochemical features of these peptides have complicated their formulation and led to heterogeneous immune responses. We have taken a rational approach to engineer an HLA A2-restricted NY-ESO-1-derived T cell epitope with improved formulation and immunogenicity to the wild type peptide. To accomplish this, we have solved the x-ray crystallographic structures of HLA A2 complexed to NY-ESO (157-165) and two analogues of this peptide in which the C-terminal cysteine residue has been substituted to alanine or serine. Substitution of cysteine by serine maintained peptide conformation yet reduced complex stability, resulting in poor cytotoxic T lymphocyte recognition. Conversely, substitution with alanine maintained complex stability and cytotoxic T lymphocyte recognition. Based on the structures of the three HLA A2 complexes, we incorporated 2-aminoisobutyric acid, an isostereomer of cysteine, into the epitope. This analogue is impervious to oxidative damage, cysteinylation, and dimerization of the peptide epitope upon formulation that is characteristic of the wild type peptide. Therefore, this approach has yielded a potential therapeutic molecule that satiates the hydrophobic F pocket of HLA A2 and exhibited superior immunogenicity relative to the wild type peptide.	Monash Univ, Sch Biomed Sci, Prot Crystallog Unit, Clayton, Vic 3800, Australia; Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Austin & Repatriat Med Ctr, Ludwig Inst Canc Res, T Cell Lab, Heidelberg, Vic 3084, Australia; Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Univ Melbourne, ImmunoID, Parkville, Vic 3010, Australia	Monash University; Monash University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; University of Melbourne; University of Melbourne	Rossjohn, J (corresponding author), Monash Univ, Sch Biomed Sci, Prot Crystallog Unit, Clayton, Vic 3800, Australia.	jamie.rossjohn@med.monash.edu.au; apurcell@unimelb.edu.au	Purcell, Anthony/AAH-1942-2019; Beddoe, Travis/F-3415-2014; Chen, Weisan/E-7828-2012; Rossjohn, Jamie/F-9032-2013; McCluskey, James/A-1291-2007; Dunstone, Michelle/I-2895-2014	Purcell, Anthony/0000-0003-0532-8331; Beddoe, Travis/0000-0003-4550-2277; Chen, Weisan/0000-0002-5221-9771; Rossjohn, Jamie/0000-0002-2020-7522; McCluskey, James/0000-0002-8597-815X; Dunstone, Michelle/0000-0002-6026-648X				Apostolopoulos V, 2002, J MOL BIOL, V318, P1293, DOI 10.1016/S0022-2836(02)00196-1; Baratin M, 2002, J PEPT SCI, V8, P327, DOI 10.1002/psc.391; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Blanchet JS, 2001, J IMMUNOL, V167, P5852, DOI 10.4049/jimmunol.167.10.5852; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Bouvier M, 1998, PROTEINS, V33, P97, DOI 10.1002/(SICI)1097-0134(19981001)33:1<97::AID-PROT9>3.0.CO;2-I; Brooks JM, 1998, J IMMUNOL, V161, P5252; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calbo S, 2000, J IMMUNOTHER, V23, P125, DOI 10.1097/00002371-200001000-00015; Chang L, 2003, TISSUE ANTIGENS, V62, P408, DOI 10.1034/j.1399-0039.2003.00122.x; Chen JL, 2000, J IMMUNOL, V165, P948, DOI 10.4049/jimmunol.165.2.948; Chen WS, 1999, J EXP MED, V189, P1757, DOI 10.1084/jem.189.11.1757; Collaborative Computational Project No. 4, 1994, ACTA CRYSTALLOGR D, V50, P750; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; Deng YP, 1997, J IMMUNOL, V158, P1507; Dutoit V, 2002, J CLIN INVEST, V110, P1813, DOI 10.1172/JCI200216428; Engelhard VH, 2002, IMMUNOL REV, V188, P136, DOI 10.1034/j.1600-065X.2002.18812.x; Ercolini AM, 2003, J IMMUNOL, V170, P4273, DOI 10.4049/jimmunol.170.8.4273; GARBOCZI DN, 1994, J MOL BIOL, V239, P581, DOI 10.1006/jmbi.1994.1398; Gnjatic S, 2003, P NATL ACAD SCI USA, V100, P8862, DOI 10.1073/pnas.1133324100; Gnjatic S, 2002, P NATL ACAD SCI USA, V99, P11813, DOI 10.1073/pnas.142417699; Gold JS, 2003, J IMMUNOL, V170, P5188, DOI 10.4049/jimmunol.170.10.5188; GUICHARD G, 1995, J BIOL CHEM, V270, P26057, DOI 10.1074/jbc.270.44.26057; Guichard G, 1996, J MED CHEM, V39, P2030, DOI 10.1021/jm9509511; Guichard G, 2000, J MED CHEM, V43, P3803, DOI 10.1021/jm000909s; Hillig RC, 2001, J MOL BIOL, V310, P1167, DOI 10.1006/jmbi.2001.4816; Huarte E, 2002, CLIN CANCER RES, V8, P2336; Jager D, 2001, J CLIN PATHOL, V54, P669, DOI 10.1136/jcp.54.9.669; Jager E, 2000, P NATL ACAD SCI USA, V97, P12198, DOI 10.1073/pnas.220413497; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Jager E, 2000, P NATL ACAD SCI USA, V97, P4760, DOI 10.1073/pnas.97.9.4760; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Kjer-Nielsen L, 2002, J IMMUNOL, V169, P5153, DOI 10.4049/jimmunol.169.9.5153; Kourilsky P, 2001, Int Rev Immunol, V20, P575, DOI 10.3109/08830180109045579; Krebs S, 1998, J BIOL CHEM, V273, P19072, DOI 10.1074/jbc.273.30.19072; Krebs S, 1998, J PEPT SCI, V4, P378, DOI 10.1002/(SICI)1099-1387(199809)4:6<378::AID-PSC157>3.0.CO;2-B; Lamas JR, 1998, INT IMMUNOL, V10, P259, DOI 10.1093/intimm/10.3.259; Levitsky V, 1996, J EXP MED, V183, P915, DOI 10.1084/jem.183.3.915; LIPFORD GB, 1995, VACCINE, V13, P313, DOI 10.1016/0264-410X(95)93320-9; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; Meziere C, 1997, J IMMUNOL, V159, P3230; Micheletti F, 1999, IMMUNOLOGY, V96, P411; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; Ostankovitch M, 1998, J IMMUNOL, V161, P200; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Platsoucas CD, 2003, ANTICANCER RES, V23, P1969; Poenaru S, 1999, J MED CHEM, V42, P2318, DOI 10.1021/jm981123l; Purcell AW, 2003, J PEPT SCI, V9, P255, DOI 10.1002/psc.456; Reid SW, 1996, J EXP MED, V184, P2279, DOI 10.1084/jem.184.6.2279; Reinelt S, 2001, J BIOL CHEM, V276, P24525, DOI 10.1074/jbc.M102772200; Romero P, 2001, CLIN CANCER RES, V7, p766S; Rudolph MG, 2001, IMMUNITY, V14, P231, DOI 10.1016/S1074-7613(01)00105-4; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9; SETTE A, 1994, J IMMUNOL, V153, P5586; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Sliz P, 2001, J IMMUNOL, V167, P3276, DOI 10.4049/jimmunol.167.6.3276; Stemmer C, 1999, J BIOL CHEM, V274, P5550, DOI 10.1074/jbc.274.9.5550; Sylvester-Hvid C, 2002, TISSUE ANTIGENS, V59, P251, DOI 10.1034/j.1399-0039.2002.590402.x; Tangri S, 2001, J EXP MED, V194, P833, DOI 10.1084/jem.194.6.833; Terasawa H, 2002, CLIN CANCER RES, V8, P41; Valmori D, 2000, CANCER RES, V60, P4499; vanderBurg SH, 1996, J IMMUNOL, V156, P3308; vanderMost RG, 1996, J IMMUNOL, V157, P5543; Zarour HM, 2002, CANCER RES, V62, P213; Zeng G, 2002, CANCER RES, V62, P3630	68	57	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23438	23446		10.1074/jbc.M314066200	http://dx.doi.org/10.1074/jbc.M314066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15004033	hybrid			2022-12-25	WOS:000221570900080
J	Yamasaki, T; Izumi, S; Ide, H; Ohyama, Y				Yamasaki, T; Izumi, S; Ide, H; Ohyama, Y			Identification of a novel rat microsomal vitamin D-3 25-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							25-HYDROXYVITAMIN D-3-1-ALPHA-HYDROXYLASE GENE; D-3 1-ALPHA-HYDROXYLASE GENE; D-DEFICIENCY RICKETS; ESCHERICHIA-COLI; LIVER MICROSOMES; MOLECULAR-CLONING; CATALYTIC-PROPERTIES; PARATHYROID-HORMONE; SEX-DIFFERENCES; MESSENGER-RNA	Vitamin D-3 requires the 25-hydroxylation in the liver and the subsequent 1alpha-hydroxylation in the kidney to exert its biological activity. Vitamin D-3 25-hydroxylation is hence an essential modification step for vitamin D-3 activation. Until now, three cytochrome P450 molecular species (CYP27A1, CYP2C11, and CYP2D25) have been characterized well as vitamin D-3 25-hydroxylases. However, their physiological role remains unclear because of their broad substrate specificities and low activities toward vitamin D-3 relative to other substrates. In this study, we purified vitamin D-3 25-hydroxylase from female rat liver microsomes. The activities of the purified fraction toward vitamin D-3 and 1alpha-hydroxyvitamin D-3 were 1.1 and 13 nmol/min/nmol of P450, respectively. The purified fraction showed a few protein bands in a 50-60-kDa range on SDS-PAGE, typical for a cytochrome P450. The tryptic peptide mass fingerprinting of a protein band (56 kDa) with matrix-assisted laser desorption ionization/time of flight mass spectrometry identified this band as CYP2J3. CYP2J3 was heterologously expressed in Escherichia coli. Purified recombinant CYP2J3 showed strong 25-hydroxylation activities toward vitamin D-3 and 1alpha-hydroxyvitamin D-3 with turnover numbers of 3.3 and 22, respectively, which were markedly higher than those of P450s previously characterized as 25-hydroxylases. Quantitative PCR analysis showed that CYP2J3 mRNA is expressed at a level similar to that of CYP27A1 without marked sexual dimorphism. These results strongly suggest that CYP2J3 is the principal P450 responsible for vitamin D-3 25-hydroxylation in rat liver.	Hiroshima Univ, Dept Math & Life Sci, Grad Sch Psychol, Higashihiroshima 7398526, Japan	Hiroshima University	Ohyama, Y (corresponding author), Hiroshima Univ, Dept Math & Life Sci, Grad Sch Psychol, Higashihiroshima 7398526, Japan.	ohyama@sci.hiroshima-u.ac.jp	Ide, Hiroshi/G-9042-2019					AKIYOSHISHIBATA M, 1994, EUR J BIOCHEM, V224, P335, DOI 10.1111/j.1432-1033.1994.00335.x; ANDERSSON S, 1983, J BIOL CHEM, V258, P6777; ANDERSSON S, 1986, J BIOL CHEM, V261, P6932; Araya Z, 2003, BBA-MOL CELL BIOL L, V1632, P40, DOI 10.1016/S1388-1981(03)00062-3; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AXEN E, 1992, BIOCHEM J, V287, P725, DOI 10.1042/bj2870725; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BJORKHEM I, 1978, J BIOL CHEM, V253, P842; BJORKHEM I, 2001, METABOLIC MOL BASES, P2961; Brenza HL, 1998, P NATL ACAD SCI USA, V95, P1387, DOI 10.1073/pnas.95.4.1387; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; Capdevila JH, 2001, BIOCHEM BIOPH RES CO, V285, P571, DOI 10.1006/bbrc.2001.5167; Capdevila JH, 2000, J LIPID RES, V41, P163; Cheng JB, 2003, J BIOL CHEM, V278, P38084, DOI 10.1074/jbc.M307028200; Coon M J, 1978, Methods Enzymol, V52, P109; Cuatrecasas P., 1971, METHOD ENZYMOL, V22, P345; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; GONZALEZ FJ, 1995, ANNU REV PHARMACOL, V35, P369, DOI 10.1146/annurev.pa.35.040195.002101; GUO YD, 1993, P NATL ACAD SCI USA, V90, P8668, DOI 10.1073/pnas.90.18.8668; HAYASHI S, 1986, J BIOCHEM-TOKYO, V99, P1753, DOI 10.1093/oxfordjournals.jbchem.a135653; HAYASHI S, 1988, J BIOCHEM-TOKYO, V103, P863, DOI 10.1093/oxfordjournals.jbchem.a122362; Hosseinpour F, 2000, J BIOL CHEM, V275, P34650, DOI 10.1074/jbc.M004185200; Hosseinpour F, 2002, BBA-MOL CELL BIOL L, V1580, P133, DOI 10.1016/S1388-1981(01)00192-5; Inoue E, 2000, BIOCHEM BIOPH RES CO, V269, P623, DOI 10.1006/bbrc.2000.2340; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kagawa N, 2003, STEROIDS, V68, P205, DOI 10.1016/S0039-128X(02)00168-X; Kitanaka S, 1998, NEW ENGL J MED, V338, P653, DOI 10.1056/NEJM199803053381004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LARSON JR, 1991, P NATL ACAD SCI USA, V88, P9141, DOI 10.1073/pnas.88.20.9141; LicadColes E, 1997, ARCH BIOCHEM BIOPHYS, V338, P35, DOI 10.1006/abbi.1996.9795; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADHOK TC, 1979, BIOCHEM J, V184, P491, DOI 10.1042/bj1840491; MASUMOTO O, 1988, J BIOL CHEM, V263, P14256; Murayama A, 1999, ENDOCRINOLOGY, V140, P2224, DOI 10.1210/en.140.5.2224; Nelson DR, 2003, ARCH BIOCHEM BIOPHYS, V409, P18, DOI 10.1016/S0003-9861(02)00553-2; Nishihara K, 1998, APPL ENVIRON MICROB, V64, P1694; Nishihara K, 2000, APPL ENVIRON MICROB, V66, P884, DOI 10.1128/AEM.66.3.884-889.2000; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OHYAMA Y, 1991, J BIOCHEM-TOKYO, V109, P389, DOI 10.1093/oxfordjournals.jbchem.a123391; OHYAMA Y, 1989, FEBS LETT, V255, P405, DOI 10.1016/0014-5793(89)81133-0; Ohyama Y, 1997, METHOD ENZYMOL, V282, P186; Omdahl JL, 2002, ANNU REV NUTR, V22, P139, DOI 10.1146/annurev.nutr.22.120501.150216; OMURA T, 1964, J BIOL CHEM, V239, P2379; Postlind H, 1997, BIOCHEM BIOPH RES CO, V241, P491, DOI 10.1006/bbrc.1997.7551; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; SAAREM K, 1987, BIOCHEM J, V247, P73, DOI 10.1042/bj2470073; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sawada N, 2000, BIOCHEM BIOPH RES CO, V273, P977, DOI 10.1006/bbrc.2000.3050; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shinki T, 1999, P NATL ACAD SCI USA, V96, P8253, DOI 10.1073/pnas.96.14.8253; Shinki T, 1997, P NATL ACAD SCI USA, V94, P12920, DOI 10.1073/pnas.94.24.12920; StArnaud R, 1997, J BONE MINER RES, V12, P1552, DOI 10.1359/jbmr.1997.12.10.1552; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; Sutton ALM, 2003, MOL ENDOCRINOL, V17, P777, DOI 10.1210/me.2002-0363; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; TANIGUCHI H, 2002, SAIBO KOGAKU, V21, P524; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; vonWachenfeldt C, 1997, ARCH BIOCHEM BIOPHYS, V339, P107, DOI 10.1006/abbi.1996.9859; Wikvall K, 2001, INT J MOL MED, V7, P201; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOSHIOKA H, 1987, J BIOL CHEM, V262, P1706	65	42	45	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22848	22856		10.1074/jbc.M311346200	http://dx.doi.org/10.1074/jbc.M311346200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15026419	hybrid			2022-12-25	WOS:000221570900010
J	Dowds, TA; Masumoto, J; Zhu, L; Inohara, N; Nunez, G				Dowds, TA; Masumoto, J; Zhu, L; Inohara, N; Nunez, G			Cryopyrin-induced interleukin 1 beta secretion in monocytic cells - Enhanced activity of disease-associated mutants and requirement for ASC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CASPASE RECRUITMENT DOMAIN; MUCKLE-WELLS-SYNDROME; SPECK-LIKE PROTEIN; CUTTING EDGE; ACTIVATION; PYRIN; FAMILY; APOPTOSIS; PYPAF1	Several autoinflammatory disorders are associated with missense mutations within the nucleotide-binding oligomerization domain of cryopyrin. The mechanism by which cryopyrin mutations cause inflammatory disease remains elusive. To understand the molecular bases of these diseases, we generated constructs to express three common cryopyrin disease-associated mutations, R260W, D303N, and E637G, and compared their activity with that of the wild-type protein. All cryopyrin mutant proteins tested were found to induce potent NF-kappaB activity when compared with the wild-type protein. This activation was dependent on the expression of ASC, an adaptor protein previously suggested to mediate cryopyrin signaling. When the disease-associated mutants were expressed in monocytic THP-1 cells ( which express endogenous ASC), each induced spontaneous IL-1beta secretion, whereas wild-type protein did not. In the absence of stimuli, wild-type cryopyrin was unable to bind to ASC, whereas the three mutants co-immunoprecipitated with ASC, suggesting a mechanism involved in the constitutive activation of mutant proteins. The induction of cryopyrin activity by enforced oligomerization in THP-1 cells resulted in ASC binding and the secretion of IL-1beta, an effect that was abolished by the inhibition of ASC expression with small interfering RNAs. Thus, cryopyrin-mediated IL-1beta secretion requires ASC in monocytic cells. Further, these results indicate that cryopyrin disease-associated mutants are constitutively active and able to induce NF-kappaB activation and IL-1beta secretion at least in part by an increased ability to interact with ASC.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.	bclx@umich.edu	Nuñez, Gabriel/A-7160-2014		NATIONAL CANCER INSTITUTE [T32CA088784, R01CA064556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060421] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556, T32-CA88784] Funding Source: Medline; NIDDK NIH HHS [DK-61707] Funding Source: Medline; NIGMS NIH HHS [GM-60421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Albrecht M, 2003, BIOINFORMATICS, V19, P2171, DOI 10.1093/bioinformatics/btg370; Albrecht M, 2003, FEBS LETT, V554, P520, DOI 10.1016/S0014-5793(03)01222-5; COGSWELL JP, 1994, J IMMUNOL, V153, P712; Dowds TA, 2003, BIOCHEM BIOPH RES CO, V302, P575, DOI 10.1016/S0006-291X(03)00221-3; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Hawkins PN, 2004, ARTHRITIS RHEUM-US, V50, P607, DOI 10.1002/art.20033; Hawkins PN, 2003, NEW ENGL J MED, V348, P2583, DOI 10.1056/NEJM200306193482523; Hull KM, 2003, CURR OPIN RHEUMATOL, V15, P61, DOI 10.1097/00002281-200301000-00011; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 2001, J HISTOCHEM CYTOCHEM, V49, P1269, DOI 10.1177/002215540104901009; Moffett P, 2002, EMBO J, V21, P4511, DOI 10.1093/emboj/cdf453; Neven B, 2004, BLOOD, V103, P2809, DOI 10.1182/blood-2003-07-2531; O'Connor W, 2003, J IMMUNOL, V171, P6329, DOI 10.4049/jimmunol.171.12.6329; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stehlik C, 2003, J IMMUNOL, V171, P6154, DOI 10.4049/jimmunol.171.11.6154; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019	24	179	187	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21924	21928		10.1074/jbc.M401178200	http://dx.doi.org/10.1074/jbc.M401178200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15020601	hybrid			2022-12-25	WOS:000221417100032
J	Tremuth, L; Kreis, S; Melchior, C; Hoebeke, J; Ronde, P; Plancon, S; Takeda, K; Kieffer, N				Tremuth, L; Kreis, S; Melchior, C; Hoebeke, J; Ronde, P; Plancon, S; Takeda, K; Kieffer, N			A fluorescence cell biology approach to map the second integrin-binding site of talin to a 130-amino acid sequence within the rod domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; ADHESION PLAQUES; ACTIN-BINDING; I/LWEQ MODULE; PROTEIN; CONTAINS; FRET; LOCALIZATION; DISRUPTION; ANTIBODIES	The cytoskeletal protein talin, which provides a direct link between integrins and actin filaments, has been shown to contain two distinct binding sites for integrin beta subunits. Here, we report the precise delimitation and a first functional analysis of the talin rod domain integrin-binding site. Partially overlapping cDNAs covering the entire human talin gene were transiently expressed as DsRed fusion proteins in Chinese hamster ovary cells expressing alpha(IIb)beta(3), linked to green fluorescent protein (GFP). Two-color fluorescence analysis of the transfected cells, spread on fibrinogen, revealed distinct subcellular staining patterns including focal adhesion, actin filament, and granular labeling for different talin fragments. The rod domain fragment G (residues 1984-2344), devoid of any known actin- or vinculin-binding sites, colocalized with beta(3)-GFP in focal adhesions. Direct in vitro interaction of fragment G with native platelet integrin alpha(IIb)beta(3) or with the recombinant wild type, but not the Y747A mutant beta(3) cytoplasmic tail, linked to glutathione S-transferase, was demonstrated by surface plasmon resonance analysis and pull-down assays, respectively. Here, we demonstrate for the first time the in vivo relevance of this interaction by fluorescence resonance energy transfer between beta(3)-GFP and DsRed-talin fragment G. Further in vitro pull-down studies allowed us to map out the integrin-binding site within fragment G to a stretch of 130 residues (fragment J, residues 1984-2113) that also localized to focal adhesions. Finally, we show by a cell biology approach that this integrin-binding site within the talin rod domain is important for beta(3)-cytoskeletal interactions but does not participate in alpha(IIb)beta(3) activation.	Univ Luxembourg, Lab Biol & Physiol Integree, CNRS, GDRE ITI, L-1511 Luxembourg, Luxembourg; Inst Biol Mol & Cellulaire, CNRS, UPR 9021, F-67000 Strasbourg, France; Univ Louis Pasteur Strasbourg 1, CNRS, UMR 7034, F-67401 Illkirch Graffenstaden, France; Inst Gilbert Laustriat IFR 85, F-67401 Illkirch Graffenstaden, France	University of Luxembourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kieffer, N (corresponding author), Univ Luxembourg, Lab Biol & Physiol Integree, CNRS, GDRE ITI, 162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	kieffer@cu.lu		Kreis, Stephanie/0000-0003-1865-3889				ALBIGESRIZO C, 1995, J CELL SCI, V108, P3317; Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; Barsukov IL, 2003, J BIOL CHEM, V278, P31202, DOI 10.1074/jbc.M303850200; Bass MD, 1999, BIOCHEM J, V341, P257, DOI 10.1042/0264-6021:3410257; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; Bastiaens PIH, 1996, P NATL ACAD SCI USA, V93, P8407, DOI 10.1073/pnas.93.16.8407; Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006-3495(03)75126-1; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2003, NAT CELL BIOL, V5, P694, DOI 10.1038/ncb0803-694; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Coutts AS, 2003, J CELL SCI, V116, P897, DOI 10.1242/jcs.00278; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1351, DOI 10.1083/jcb.113.6.1351; Erickson MG, 2003, BIOPHYS J, V85, P599, DOI 10.1016/S0006-3495(03)74504-4; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; GOLDMANN WH, 1994, J STRUCT BIOL, V112, P3, DOI 10.1006/jsbi.1994.1002; Hemmings L, 1996, J CELL SCI, V109, P2715; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Isenberg G, 1998, FEBS LETT, V426, P165, DOI 10.1016/S0014-5793(98)00336-6; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Liu SC, 2000, J CELL SCI, V113, P3563; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; McCann RO, 1999, BIOCHEM BIOPH RES CO, V266, P135, DOI 10.1006/bbrc.1999.1776; McCann RO, 1997, P NATL ACAD SCI USA, V94, P5679, DOI 10.1073/pnas.94.11.5679; MCLACHLAN AD, 1994, J MOL BIOL, V235, P1278, DOI 10.1006/jmbi.1994.1081; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mizuno H, 2001, BIOCHEMISTRY-US, V40, P2502, DOI 10.1021/bi002263b; MOLONY L, 1987, J BIOL CHEM, V262, P7790; Monkley SJ, 2000, DEV DYNAM, V219, P560, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1079>3.0.CO;2-Y; Monkley SJ, 2001, BIOCHEM BIOPH RES CO, V286, P880, DOI 10.1006/bbrc.2001.5497; NIGGLI V, 1994, EUR J BIOCHEM, V224, P951, DOI 10.1111/j.1432-1033.1994.00951.x; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Plancon S, 2001, BIOCHEM J, V357, P529, DOI 10.1042/0264-6021:3570529; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Seelig A, 2000, J BIOL CHEM, V275, P17954, DOI 10.1074/jbc.M002264200; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Ulmer TS, 2003, BIOCHEMISTRY-US, V42, P8307, DOI 10.1021/bi034384s; Winkler J, 1997, EUR J BIOCHEM, V243, P430, DOI 10.1111/j.1432-1033.1997.0430a.x; Woodside DG, 2002, J BIOL CHEM, V277, P39401, DOI 10.1074/jbc.M207657200; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179; Xing BD, 2001, J BIOL CHEM, V276, P44373, DOI 10.1074/jbc.M108587200; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200	52	55	60	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22258	22266		10.1074/jbc.M400947200	http://dx.doi.org/10.1074/jbc.M400947200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15031296	hybrid, Green Published			2022-12-25	WOS:000221417100073
J	Yoshizaki, T; Maegawa, H; Egawa, K; Ugi, S; Nishio, Y; Imamura, T; Kobayashi, T; Tamura, S; Olefsky, JM; Kashiwagi, A				Yoshizaki, T; Maegawa, H; Egawa, K; Ugi, S; Nishio, Y; Imamura, T; Kobayashi, T; Tamura, S; Olefsky, JM; Kashiwagi, A			Protein Phosphatase-2C alpha as a positive regulator of insulin sensitivity through direct activation of phosphatidylinositol 3-kinase in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFECTING GLUCOSE-TRANSPORT; TYROSINE-PHOSPHATASE; KINASE-ACTIVITY; RESISTANCE; RECEPTOR; EXPRESSION; 2C; PHOSPHORYLATION; OVEREXPRESSION; STIMULATION	During differentiation, expression of protein phosphatase-2Calpha (PP2Calpha) is increased in 3T3-L1 adipocytes. To elucidate the role of PP2Calpha in insulin signaling, we overexpressed wild-type (WT) PP2Calpha by adenovirus-mediated gene transfer in 3T3-L1 adipocytes. Overexpression of PP2Calpha-WT enhanced the insulin sensitivity of glucose uptake without any changes in the early steps of insulin signaling. Infection with adenovirus 5 expressing PP2Calpha-WT increased phosphatidylinositol 3-kinase (PI3K) activities in the immunoprecipitate using antibody against the p85 or p110 subunit under both basal and insulin-stimulated conditions, followed by activation of downstream steps in the PI3K pathway, such as phosphorylation of Akt, glycogen synthase kinase-3, and atypical protein kinase C. In contrast, overexpression of the phosphatase-defective mutant PP2Calpha(R174G) did not produce such effects. Furthermore, overexpression of PP2Calpha-WT (but not PP2Calpha(R174G)) decreased the P-32-labeled phosphorylation state as well as the gel mobility shift of the p85 subunit, suggesting that dephosphorylation of the p85 subunit by PP2Calpha activation might stimulate PI3K catalytic activity. Moreover, knockdown of PP2Calpha by transfection of small interfering RNA led to a significant decrease in Akt phosphorylation. In addition, microinjection of anti-PP2Calpha antibody or PP2Calpha small interfering RNA led to decreased insulin-stimulated GLUT4 translocation. In conclusion, PP2Calpha is a new positive regulator of insulin sensitivity that acts through a direct activation of PI3K in 3T3-L1 adipocytes.	Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan; Tohoku Univ, Dept Biochem, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan; Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92037 USA	Shiga University of Medical Science; Tohoku University; Tohoku University; University of California System; University of California San Diego	Maegawa, H (corresponding author), Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan.	maegawa@belle.shiga-med.ac.jp	Kashiwagi, Atsunori/H-8712-2019	Maegawa, Hiroshi/0000-0002-4611-8149				Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Egawa K, 2002, J BIOL CHEM, V277, P38863, DOI 10.1074/jbc.M203132200; Egawa K, 2001, J BIOL CHEM, V276, P10207, DOI 10.1074/jbc.M009489200; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Guthridge MA, 1997, MOL CELL BIOL, V17, P5485, DOI 10.1128/MCB.17.9.5485; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P9294; Imamura T, 1999, MOL CELL BIOL, V19, P6765; KAHN CR, 1978, METABOLISM, V27, P1893; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; KLUMPP S, 1994, J BIOL CHEM, V269, P32774; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Lammers R, 1997, FEBS LETT, V404, P37, DOI 10.1016/S0014-5793(97)00080-X; Li JP, 2002, AM J PHYSIOL-ENDOC M, V282, pE1334, DOI 10.1152/ajpendo.00516.2001; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Lifschitz-Mercer B, 2001, HISTOCHEM CELL BIOL, V116, P31; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; Marley AE, 1996, BIOCHEM J, V320, P801, DOI 10.1042/bj3200801; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; Rosen ED, 2000, GENE DEV, V14, P1293; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; TAKAI A, 1991, BIOCHEM J, V275, P233, DOI 10.1042/bj2750233; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Usui I, 2003, J BIOL CHEM, V278, P13765, DOI 10.1074/jbc.M208904200; WENK J, 1992, FEBS LETT, V297, P135, DOI 10.1016/0014-5793(92)80344-G; Zabolotny JM, 2001, P NATL ACAD SCI USA, V98, P5187, DOI 10.1073/pnas.071050398	46	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22715	22726		10.1074/jbc.M313745200	http://dx.doi.org/10.1074/jbc.M313745200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016818	hybrid			2022-12-25	WOS:000221417100123
J	James, DJ; Salaun, C; Brandie, FM; Connell, JMC; Chamberlain, LH				James, DJ; Salaun, C; Brandie, FM; Connell, JMC; Chamberlain, LH			Neomycin prevents the wortmannin inhibition of insulin-stimulated glut4 translocation and glucose transport in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; SUBCELLULAR-LOCALIZATION; PHOSPHOLIPASE-C; HUMAN PLATELETS; ACTIVATION; 4,5-BISPHOSPHATE; CELLS	Insulin stimulates the movement of the facilitative glucose transporter glucose transporter-4 (Glut4) from an intracellular compartment to the plasma membrane in adipocytes and muscle cells, resulting in an increased rate of glucose uptake. Insulin-stimulated Glut4 translocation and glucose transport are abolished by wortmannin, a specific inhibitor of phosphatidylinositol 3'-kinase (PI3K). Here, we demonstrate that neomycin, a drug that masks the cellular substrate of PI3K, phosphatidylinositol 4,5-bisphosphate (PIP2), prevents wortmannin inhibition of insulin-stimulated Glut4 translocation and glucose transport without activating protein kinase B, a downstream effector of PI3K. These results suggest that PIP2 may have an important regulatory function in insulin-stimulated Glut4 translocation and glucose transport.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Welcome Lab Cell Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Western Infirm, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow; University of Glasgow	Chamberlain, LH (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Welcome Lab Cell Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	l.chamberlain@bio.gla.ac.uk		s, hema/0000-0002-3440-9475; Salaun, Christine/0000-0003-3002-6810				Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Arbuzova A, 2000, BBA-BIOMEMBRANES, V1464, P35, DOI 10.1016/S0005-2736(99)00243-6; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Clodi M, 1998, ENDOCRINOLOGY, V139, P4984, DOI 10.1210/en.139.12.4984; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Eichhorn J, 2001, BIOCHEM BIOPH RES CO, V282, P615, DOI 10.1006/bbrc.2001.4616; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; Hajduch E, 2001, FEBS LETT, V492, P199, DOI 10.1016/S0014-5793(01)02242-6; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Heijnen HFG, 1997, J CELL BIOL, V138, P323, DOI 10.1083/jcb.138.2.323; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; JOUNEAUX C, 1994, J BIOL CHEM, V269, P1845; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kwik J, 2003, P NATL ACAD SCI USA, V100, P13964, DOI 10.1073/pnas.2336102100; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Lawrence JTR, 2003, P NATL ACAD SCI USA, V100, P13320, DOI 10.1073/pnas.2232129100; Lawrence JTR, 2001, MOL CELL BIOL, V21, P5276, DOI 10.1128/MCB.21.15.5276-5285.2001; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; OKADA T, 1994, J BIOL CHEM, V269, P3568; Ono H, 2001, MOL ENDOCRINOL, V15, P1411, DOI 10.1210/me.15.8.1411; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Sorbara LR, 1997, BIOCHEM J, V328, P511; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Tengholm A, 2002, CURR BIOL, V12, P1871, DOI 10.1016/S0960-9822(02)01223-X; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Zheng Q, 2004, NEUROCHEM INT, V44, P243, DOI 10.1016/S0197-0186(03)00149-9	41	13	13	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20567	20570		10.1074/jbc.C400096200	http://dx.doi.org/10.1074/jbc.C400096200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15024008	hybrid			2022-12-25	WOS:000221273800004
J	Kaeser, MD; Iggo, RD				Kaeser, MD; Iggo, RD			Promoter-specific p53-dependent histone acetylation following DNA damage	ONCOGENE			English	Article						chromatin immunoprecipitation; p53; p21; MDM2; PUMA; histone acetyltransferase	CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; CANCER CELLS; P53 PROTEIN; BINDING; EXPRESSION; COMPLEX; GENE; PHOSPHORYLATION	We have used chromatin immunoprecipitation (ChIP) to measure p53-dependent histone acetylation at the p21, MDM2, and PUMA promoters. The pattern of histone acetylation was different at each promoter. H3 and H4 acetylation increased at both the p21 and PUMA promoters in response to p53 activation, whereas there was only a minimal increase in H4 acetylation and no increase in H3 acetylation at the MDM2 promoter. The high p53 occupancy of the p21, MDM2 and PUMA promoters has been attributed to the presence of two p53 binding sites in these promoters, but mutation of the p53 binding sites in integrated p21 promoter constructs showed that the two sites in the p21 promoter do not cooperate to stabilize p53 binding. Despite 10-fold higher p53 binding to the proximal than the distal site in the p21 promoter, both sites showed similar patterns of H3 and H4 acetylation. Mutation of the binding sites showed that acetylation of the proximal, low-affinity site requires p53 binding to that site but not to the distal, high-affinity site. Since low-affinity p53 binding sites can confer strong acetylation, the DNA binding affinity in vitro is an unreliable guide to the likely importance of p53 in regulating candidate target genes in vivo.	Swiss Inst Expt Canc Res, Oncogene Grp, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Iggo, RD (corresponding author), Swiss Inst Expt Canc Res, Oncogene Grp, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	richard.iggo@isrec.unil.ch	Iggo, Richard/G-3546-2014	Kaeser, Matthias/0000-0003-0050-9408				Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; ANDERSON CW, 2003, HDB CELL SIGNALING, V3, P237; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jackson P, 1998, ONCOGENE, V16, P283, DOI 10.1038/sj.onc.1201491; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Winkler GS, 2002, P NATL ACAD SCI USA, V99, P3517, DOI 10.1073/pnas.022042899; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Zhao RB, 2000, GENE DEV, V14, P981; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	41	45	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4007	4013		10.1038/sj.onc.1207536	http://dx.doi.org/10.1038/sj.onc.1207536			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007388	Bronze			2022-12-25	WOS:000221382000013
J	Tu, XM; Wang, CC				Tu, XM; Wang, CC			The involvement of two cdc2-related kinases (CRKs) in Trypanosoma brucei cell cycle regulation and the distinctive stage-specific phenotypes caused by CRK3 depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-MEXICANA; RNA INTERFERENCE; PROTEIN-KINASE; LIFE-CYCLE; FUNCTIONAL-CHARACTERIZATION; AFRICAN TRYPANOSOMES; GENOME SEGREGATION; DNA-REPLICATION; GENE-EXPRESSION; CYTOKINESIS	Cyclin-dependent protein kinases are among the key regulators of eukaryotic cell cycle progression. Potential functions of the five cdc2-related kinases (CRK) in Trypanosoma brucei were analyzed using the RNA interference (RNA(i)) technique. In both the procyclic and bloodstream forms of T. brucei, CRK1 is apparently involved in controlling the G(1)/S transition, whereas CRK3 plays an important role in catalyzing cells across the G(2)/M junction. A knockdown of CRK1 caused accumulation of cells in the G(1) phase without apparent phenotypic change, whereas depletion of CRK3 enriched cells of both forms in the G(2)/M phase. However, two distinctive phenotypes were observed between the CRK3-deficient procyclic and bloodstream forms. The procyclic form has a majority of the cells containing a single enlarged nucleus plus one kinetoplast. There is also an enhanced population of anucleated cells, each containing a single kinetoplast known as the zoids (0N1K). The CRK3-depleted bloodstream form has an increased number of one nucleus-two kinetoplast cells (1N2K) and a small population containing aggregated multiple nuclei and multiple kinetoplasts. Apparently, these two forms have different mechanisms in cell cycle regulation. Although the procyclic form can be driven into cytokinesis and cell division by kinetoplast segregation without a completed mitosis, the bloodstream form cannot enter cytokinesis under the same condition. Instead, it keeps going through another G(1) phase and enters a new S phase resulting in an aggregate of multiple nuclei and multiple kinetoplasts in an undivided cell. The different leakiness in cell cycle regulation between two stage-specific forms of an organism provides an interesting and useful model for further understanding the evolution of cell cycle control among the eukaryotes.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu	Tu, Xiaoming/G-5090-2018		NIAID NIH HHS [R01 AI 2178] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bastin P, 2000, J CELL SCI, V113, P3321; DAS A, 1994, J CELL SCI, V107, P3477; Gomez EB, 1998, MOL BIOCHEM PARASIT, V91, P337, DOI 10.1016/S0166-6851(97)00218-1; Gomez EB, 2001, MOL BIOCHEM PARASIT, V113, P97, DOI 10.1016/S0166-6851(00)00382-0; Grant KM, 1998, J BIOL CHEM, V273, P10153, DOI 10.1074/jbc.273.17.10153; Hammarton Tansy C, 2003, Prog Cell Cycle Res, V5, P91; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Hassan P, 2001, MOL BIOCHEM PARASIT, V113, P189, DOI 10.1016/S0166-6851(01)00220-1; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3; Kohl L, 2003, EMBO J, V22, P5336, DOI 10.1093/emboj/cdg518; Kuntzel H, 1996, BIOL CHEM, V377, P481; Li ZY, 2003, J BIOL CHEM, V278, P20652, DOI 10.1074/jbc.M301635200; Li ZY, 2002, J BIOL CHEM, V277, P42686, DOI 10.1074/jbc.M207183200; Li ZY, 2002, J BIOL CHEM, V277, P15486, DOI 10.1074/jbc.M109029200; Lillico SG, 2002, FEMS MICROBIOL LETT, V211, P123, DOI 10.1111/j.1574-6968.2002.tb11213.x; MATTHEWS KR, 1995, J CELL SCI, V108, P2231; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; Morris JC, 2001, MOL BIOCHEM PARASIT, V117, P111, DOI 10.1016/S0166-6851(01)00334-6; Mottram JC, 1996, MOL MICROBIOL, V22, P573, DOI 10.1046/j.1365-2958.1996.00136.x; MOTTRAM JC, 1995, GENE, V162, P147, DOI 10.1016/0378-1119(95)00350-F; MOTTRAM JC, 1993, J BIOL CHEM, V268, P21044; Mutomba MC, 1997, MOL BIOCHEM PARASIT, V90, P491, DOI 10.1016/S0166-6851(97)00197-7; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Ploubidou A, 1999, J CELL SCI, V112, P4641; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; Timms MW, 2002, MOL BIOL CELL, V13, P3747, DOI 10.1091/mbc.E02-05-0266; Van Hellemond JJ, 2000, J BIOL CHEM, V275, P8315, DOI 10.1074/jbc.275.12.8315; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; Wang YX, 1998, MOL BIOCHEM PARASIT, V96, P139, DOI 10.1016/S0166-6851(98)00121-2; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODWARD R, 1990, J CELL SCI, V95, P49	36	90	90	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20519	20528		10.1074/jbc.M312862200	http://dx.doi.org/10.1074/jbc.M312862200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15010459	hybrid			2022-12-25	WOS:000221164500131
J	Smith, RA; Anderson, DJ; Preston, BD				Smith, RA; Anderson, DJ; Preston, BD			Purifying selection masks the mutational flexibility of HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT RNA-POLYMERASE; AMINO-ACID SUBSTITUTIONS; ACTIVE-SITE; ESCHERICHIA-COLI; DRUG-RESISTANCE; MOLECULAR CLONE; HEPATITIS-C; NUCLEOTIDE-SEQUENCE; CONSERVED MOTIFS	DNA and RNA polymerases share a core architecture composed of three structurally conserved motifs: A, B, and C. Although the amino acid sequences of these motifs are highly conserved between closely related organisms, variation across broader evolutionary distances suggests that only a few residues in each motif are indispensable for polymerase function. To test this, we constructed libraries of human immunodeficiency virus type-1 (HIV-1) containing random single amino acid replacements in motif B of reverse transcriptase (RT), and we used selection in culture to assess RT function. Despite the nearly absolute constancy of motif B in vivo, virus replicating in culture tolerated a range of conservative and nonconservative substitutions at 10 of the 11 amino acid positions examined. These included residues that are invariant across all retroviral subfamilies and highly conversed in diverse retroelements. Several mutants retained wild type infectivity, and serial passage experiments revealed replacements that were neutral or even beneficial to viral fitness. In addition, a number of the selected variants exhibited altered susceptibility to the nucleoside analog inhibitors AZT and 3TC. Taken together, these data indicate that HIV-1 tolerates a range of substitutions at conserved RT residues and that selection against slightly deleterious mutations ( purifying selection) in vivo masks a large repertoire of viable phenotypic variants. This mutational flexibility likely contributes to HIV-1 evolution in response to changing selection pressures in infected individuals.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Preston, BD (corresponding author), Univ Washington, Dept Pathol, K-072 Hlth Sci Bldg,Box 357705,1959 NE Pacific St, Seattle, WA 98195 USA.	bradp@u.washington.edu		Anderson, Donovan/0000-0002-9387-8431	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010139, R01AI034834] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34834, F32 AI10139] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Arts EJ, 1996, ANTIMICROB AGENTS CH, V40, P527, DOI 10.1128/AAC.40.3.527; BISWAS SK, 1994, J VIROL, V68, P1819, DOI 10.1128/JVI.68.3.1819-1826.1994; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Caliendo AM, 1996, J VIROL, V70, P2146, DOI 10.1128/JVI.70.4.2146-2153.1996; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cook RF, 1998, J VIROL, V72, P1383, DOI 10.1128/JVI.72.2.1383-1393.1998; D'Aquila Richard T., 2002, Top HIV Med, V10, P21; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; FASSBENDER S, 1994, EMBO J, V13, P2075, DOI 10.1002/j.1460-2075.1994.tb06482.x; Frost SDW, 2000, J VIROL, V74, P6262, DOI 10.1128/JVI.74.14.6262-6268.2000; Gao HQ, 1998, J MOL BIOL, V277, P559, DOI 10.1006/jmbi.1998.1624; Glick E, 2001, EMBO J, V20, P7303, DOI 10.1093/emboj/20.24.7303; GRAUR D, 2000, FUNDAMENTALS MOL EVO, P41; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Harris D, 1998, J BIOL CHEM, V273, P33624, DOI 10.1074/jbc.273.50.33624; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; HOLLAND JJ, 1991, J VIROL, V65, P2960, DOI 10.1128/JVI.65.6.2960-2967.1991; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang W, 2003, J VIROL, V77, P1512, DOI 10.1128/JVI.77.2.1512-1523.2003; Iversen AKN, 1996, J VIROL, V70, P1086, DOI 10.1128/JVI.70.2.1086-1090.1996; Kantor R, 2001, NUCLEIC ACIDS RES, V29, P296, DOI 10.1093/nar/29.1.296; Kaushik N, 2000, BIOCHEMISTRY-US, V39, P2912, DOI 10.1021/bi991376w; Kim B, 1996, J BIOL CHEM, V271, P4872, DOI 10.1074/jbc.271.9.4872; KIMURA M, 1991, P NATL ACAD SCI USA, V88, P5969, DOI 10.1073/pnas.88.14.5969; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; KORNBERG A, 1992, DNA REPLICATION, P553; Kosalaraksa P, 1999, J VIROL, V73, P5356, DOI 10.1128/JVI.73.7.5356-5363.1999; Lai VCH, 1999, J VIROL, V73, P10129, DOI 10.1128/JVI.73.12.10129-10136.1999; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Maeda Y, 1998, J INFECT DIS, V177, P1207, DOI 10.1086/515282; Meyer PR, 2003, J VIROL, V77, P6127, DOI 10.1128/JVI.77.11.6127-6137.2003; MILLER AD, 1984, J VIROL, V49, P214, DOI 10.1128/JVI.49.1.214-222.1984; MINDICH L, 1988, J VIROL, V62, P1180, DOI 10.1128/JVI.62.4.1180-1185.1988; NAJERA I, 1995, J VIROL, V69, P23; Nijhuis M, 1999, AIDS, V13, P2349, DOI 10.1097/00002030-199912030-00006; O'Reilly EK, 1998, VIROLOGY, V252, P287, DOI 10.1006/viro.1998.9463; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; Quinones-Mateu ME, 1998, J VIROL, V72, P9002; RACANIELLO VR, 1981, P NATL ACAD SCI-BIOL, V78, P4887, DOI 10.1073/pnas.78.8.4887; Rausch JW, 2000, J BIOL CHEM, V275, P13879, DOI 10.1074/jbc.275.18.13879; Resch W, 2002, J VIROL, V76, P8659, DOI 10.1128/JVI.76.17.8659-8666.2002; RETHWILM A, 1990, NUCLEIC ACIDS RES, V18, P733, DOI 10.1093/nar/18.4.733; Rouzine IM, 2001, MICROBIOL MOL BIOL R, V65, P151, DOI 10.1128/MMBR.65.1.151-185.2001; SANKAR S, 1992, J BIOL CHEM, V267, P10168; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; Schmit JC, 1996, J INFECT DIS, V174, P962, DOI 10.1093/infdis/174.5.962; Shinkai A, 2001, J BIOL CHEM, V276, P18836, DOI 10.1074/jbc.M011472200; Singh K, 2000, PROTEIN ENG, V13, P635, DOI 10.1093/protein/13.9.635; Smith RA, 1999, ANTIMICROB AGENTS CH, V43, P2077, DOI 10.1128/AAC.43.8.2077; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Svarovskaia ES, 2003, FRONT BIOSCI-LANDMRK, V8, pD117, DOI 10.2741/957; Swingler S, 1997, J VIROL, V71, P4372, DOI 10.1128/JVI.71.6.4372-4377.1997; Weiss KK, 2000, BIOCHEMISTRY-US, V39, P10684, DOI 10.1021/bi000788y; Wrobel JA, 1998, P NATL ACAD SCI USA, V95, P638, DOI 10.1073/pnas.95.2.638; ZHAO TM, 1995, J VIROL, V69, P2024, DOI 10.1128/JVI.69.4.2024-2030.1995	65	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26726	26734		10.1074/jbc.M314038200	http://dx.doi.org/10.1074/jbc.M314038200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15014075	hybrid			2022-12-25	WOS:000222003000099
J	Daly, NL; Ekberg, JA; Thomas, L; Adams, DJ; Lewis, RJ; Craik, DJ				Daly, NL; Ekberg, JA; Thomas, L; Adams, DJ; Lewis, RJ; Craik, DJ			Structures of mu O-conotoxins from Conus marmoreus - Inhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; 3-DIMENSIONAL SOLUTION STRUCTURE; NMR STRUCTURE CALCULATION; BIOLOGICAL-ACTIVITY; CYSTINE KNOT; SMALL-CELLS; PAIN; EXPRESSION; CURRENTS; PROTEINS	The muO-conotoxins are an intriguing class of conotoxins targeting various voltage-dependent sodium channels and molluscan calcium channels. In the current study, we have shown MrVIA and MrVIB to be the first known peptidic inhibitors of the transient tetrodotoxin-resistant (TTX-R) Na+ current in rat dorsal root ganglion neurons, in addition to inhibiting tetrodotoxin-sensitive Na+ currents. Human TTX-R sodium channels are a therapeutic target for indications such as pain, highlighting the importance of the muO-conotoxins as potential leads for drug development. Furthermore, we have used NMR spectroscopy to provide the first structural information on this class of conotoxins. MrVIA and MrVIB are hydrophobic peptides that aggregate in aqueous solution but were solubilized in 50% acetonitrile/water. The three-dimensional structure of MrVIB consists of a small beta-sheet and a cystine knot arrangement of the three-disulfide bonds. It contains four backbone "loops" between successive cysteine residues that are exposed to the solvent to varying degrees. The largest of these, loop 2, is the most disordered part of the molecule, most likely due to flexibility in solution. This disorder is the most striking difference between the structures of MrVIB and the known delta- and omega-conotoxins, which along with the muO-conotoxins are members of the O superfamily. Loop 2 of omega-conotoxins has previously been shown to contain residues critical for binding to voltage-gated calcium channels, and it is interesting to speculate that the flexibility observed in MrVIB may accommodate binding to both sodium and molluscan calcium channels.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	rlewis@imb.uq.edu.au; d.craik@imb.uq.edu.au	Ekberg, Jenny/AAV-2006-2020; Adams, David John/K-3578-2019; Lewis, Richard/T-8763-2019; Daly, Norelle L/D-4302-2013; Adams, David/J-9125-2014; Craik, David/B-1695-2010; Lewis, Richard J/E-8674-2013	Adams, David John/0000-0002-7030-2288; Lewis, Richard/0000-0003-3470-923X; Daly, Norelle L/0000-0002-4697-6602; Adams, David/0000-0002-7030-2288; Craik, David/0000-0003-0007-6796; Lewis, Richard J/0000-0003-3470-923X; Ekberg, Jenny/0000-0001-5151-4966				Adams DJ, 1999, DRUG DEVELOP RES, V46, P219; Akopian AN, 1999, NAT NEUROSCI, V2, P541, DOI 10.1038/9195; Atkinson RA, 2000, BIOCHEMISTRY-US, V39, P3908, DOI 10.1021/bi992651h; Brock JA, 1998, J PHYSIOL-LONDON, V512, P211, DOI 10.1111/j.1469-7793.1998.211bf.x; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Carter AJ, 1998, AMINO ACIDS, V14, P159, DOI 10.1007/BF01345257; Chuang RSI, 1998, NAT NEUROSCI, V1, P668, DOI 10.1038/3669; Coward K, 2000, PAIN, V85, P41, DOI 10.1016/S0304-3959(99)00251-1; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Cummins TR, 2000, J NEUROSCI, V20, P8754; Dutton JL, 2002, J BIOL CHEM, V277, P48849, DOI 10.1074/jbc.M208842200; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; Eglen RM, 1999, TRENDS PHARMACOL SCI, V20, P337, DOI 10.1016/S0165-6147(99)01372-3; ELLIOTT AA, 1993, J PHYSIOL-LONDON, V463, P39, DOI 10.1113/jphysiol.1993.sp019583; FAINZILBER M, 1995, BIOCHEMISTRY-US, V34, P5364, DOI 10.1021/bi00016a007; Fjell J, 2000, NEUROREPORT, V11, P199, DOI 10.1097/00001756-200001170-00039; Flinn JP, 1999, BBA-PROTEIN STRUCT M, V1434, P177, DOI 10.1016/S0167-4838(99)00165-X; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; Hill JM, 1997, STRUCTURE, V5, P571, DOI 10.1016/S0969-2126(97)00212-8; Hill JM, 2000, EUR J BIOCHEM, V267, P4649, DOI 10.1046/j.1432-1327.2000.01507.x; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jones RM, 2000, CURR PHARM DESIGN, V6, P1249, DOI 10.2174/1381612003399653; Kohno T, 2002, J BIOL CHEM, V277, P36387, DOI 10.1074/jbc.M206833200; Lai J, 2002, PAIN, V95, P143, DOI 10.1016/S0304-3959(01)00391-8; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; MCINTOSH JM, 1995, J BIOL CHEM, V270, P16796, DOI 10.1074/jbc.270.28.16796; Middleton RE, 2002, BIOCHEMISTRY-US, V41, P14734, DOI 10.1021/bi026546a; Nielsen KJ, 1996, J MOL BIOL, V263, P297, DOI 10.1006/jmbi.1996.0576; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Porreca F, 1999, P NATL ACAD SCI USA, V96, P7640, DOI 10.1073/pnas.96.14.7640; Rabert DK, 1998, PAIN, V78, P107, DOI 10.1016/S0304-3959(98)00120-1; Ragsdale DS, 1998, BRAIN RES REV, V26, P16, DOI 10.1016/S0165-0173(97)00054-4; Rho JM, 1999, EPILEPSIA, V40, P1471, DOI 10.1111/j.1528-1157.1999.tb02029.x; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200; Rush AM, 1998, J PHYSIOL-LONDON, V511, P771, DOI 10.1111/j.1469-7793.1998.771bg.x; Saab CY, 2002, NEUROSCI LETT, V331, P79, DOI 10.1016/S0304-3940(02)00860-1; Sangameswaran L, 1996, J BIOL CHEM, V271, P5953, DOI 10.1074/jbc.271.11.5953; Scholz A, 2000, PAIN, V89, P47, DOI 10.1016/S0304-3959(00)00345-6; Shembalkar PK, 2001, EUR J PAIN, V5, P319, DOI 10.1053/eujp.2001.0251; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Tanaka M, 1998, NEUROREPORT, V9, P967, DOI 10.1097/00001756-199804200-00003; TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4; Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129; Terlau H, 1996, J NEUROPHYSIOL, V76, P1423, DOI 10.1152/jn.1996.76.3.1423; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC	50	79	86	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25774	25782		10.1074/jbc.M313002200	http://dx.doi.org/10.1074/jbc.M313002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15044438	hybrid			2022-12-25	WOS:000221827900107
J	Wang, XD; Shou, JY; Wong, P; French, DM; Gao, WQ				Wang, XD; Shou, JY; Wong, P; French, DM; Gao, WQ			Notch1-expressing cells are indispensable for prostatic branching morphogenesis during development and re-growth following castration and androgen replacement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL STEM-CELLS; TRANSGENIC MICE; BACTERIAL NITROREDUCTASE; EXPRESSION PATTERNS; MOUSE PROSTATE; BASAL-CELLS; NOTCH-GENE; INNER-EAR; ABLATION; DROSOPHILA	Notch expression is frequently associated with progenitor cells, and its function is crucial for development. Our recent work showing that Notch1 is selectively expressed in basal epithelial cells of the prostate and higher Notch1 expression during development suggests that Notch1-expressing cells may define progenitor cells in the prostate. To test this hypothesis, we have generated a transgenic mouse line in which the Notch1-expressing cells can be ablated in a controlled manner. Specific targeting was achieved by expressing the bacterial nitroreductase, an enzyme that catalyzes its substrate into a cytotoxin capable of inducing apoptosis, under the Notch1 promoter. Cell death in transgenic prostate was confirmed by histological analyses including terminal dUTP nick-end labeling and caspase 3 immunocytochemical staining. We evaluated the consequences of ablation of Notch1-expressing cells in two systems, organ culture of early postnatal prostates and re-growth of prostate in castrated mice triggered by hormone replacement. Our data show that elimination of Notch1-expressing cells inhibited the branching morphogenesis, growth, and differentiation of early postnatal prostate in culture and impaired prostate re-growth triggered by hormone replacement in castrated mice. Furthermore, we found that Notch1 expression following castration and hormone replacement was concomitant with known basal cell markers p63 and cytokeratin 14 and was high in the proliferative human prostate epithelial cells. Taken together, these data suggest that Notch1-expressing cells define the progenitor cells in the prostatic epithelial cell lineage, which are indispensable for prostatic development and re-growth.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Gao, WQ (corresponding author), Genentech Inc, Dept Mol Oncol, MS 72,1 DNA Way, San Francisco, CA 94080 USA.	gao@gene.com	Gao, Wei/GXH-0380-2022; Thomson, Axel/A-7893-2013	Shou, Jianyong/0000-0002-3752-7215				Abate-Shen C, 2003, CANCER RES, V63, P3886; Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Abate-Shen Cory, 2002, Trends Genet, V18, pS1, DOI 10.1016/S0168-9525(02)02683-5; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bilsland AE, 2003, ONCOGENE, V22, P370, DOI 10.1038/sj.onc.1206168; Bonkhoff H, 1996, PROSTATE, V28, P98; BORRELLI E, 1989, NATURE, V339, P538, DOI 10.1038/339538a0; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; COFFEY DS, 1968, ARCH BIOCHEM BIOPHYS, V124, P184, DOI 10.1016/0003-9861(68)90319-6; Collins AT, 2001, J CELL SCI, V114, P3865; Cui W, 1999, GENE THER, V6, P764, DOI 10.1038/sj.gt.3300873; Drabek D, 1997, GENE THER, V4, P93, DOI 10.1038/sj.gt.3300366; Eddison M, 2000, P NATL ACAD SCI USA, V97, P11692, DOI 10.1073/pnas.97.22.11692; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Farrell ER, 1999, DEVELOPMENT, V126, P273; Foster CS, 2002, J PATHOL, V197, P551, DOI 10.1002/path.1194; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; GAO WQ, 1988, NEURON, V1, P269, DOI 10.1016/0896-6273(88)90075-X; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hayward SW, 1996, ANN NY ACAD SCI, V784, P50, DOI 10.1111/j.1749-6632.1996.tb16227.x; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; HAYWARD SW, 1992, J CELL SCI, V102, P361; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Hidalgo A, 1997, DEVELOPMENT, V124, P3253; Hudson DL, 2000, LAB INVEST, V80, P1243, DOI 10.1038/labinvest.3780132; Ilio KY, 1998, J ANDROL, V19, P718; ISAACS JT, 1989, PROSTATE S, V2, P33; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; KNOX RJ, 1988, BIOCHEM PHARMACOL, V37, P4661, DOI 10.1016/0006-2952(88)90335-8; Lewis AK, 1998, MECH DEVELOP, V78, P159, DOI 10.1016/S0925-4773(98)00165-8; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; Lipinski KS, 2001, GENE THER, V8, P274, DOI 10.1038/sj.gt.3301403; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; Maillard I, 2003, CANCER CELL, V3, P203, DOI 10.1016/S1535-6108(03)00052-7; Marker PC, 2003, DEV BIOL, V253, P165, DOI 10.1016/S0012-1606(02)00031-3; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; PEEHL DM, 1988, IN VITRO CELL DEV B, V24, P530; Reiter RE, 1998, P NATL ACAD SCI USA, V95, P1735, DOI 10.1073/pnas.95.4.1735; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Robey E, 1999, ANNU REV IMMUNOL, V17, P283, DOI 10.1146/annurev.immunol.17.1.283; Robey E, 1997, CURR OPIN GENET DEV, V7, P551, DOI 10.1016/S0959-437X(97)80085-8; Saito M, 2001, NAT BIOTECHNOL, V19, P746, DOI 10.1038/90795; Schalken JA, 2003, UROLOGY, V62, P11, DOI 10.1016/S0090-4295(03)00758-1; Shigenaga A, 1997, DEV GROWTH DIFFER, V39, P429; Shou JY, 2001, CANCER RES, V61, P7291; SUGIMURA Y, 1986, BIOL REPROD, V34, P961, DOI 10.1095/biolreprod34.5.961; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Tran CP, 2002, MOL CANCER RES, V1, P113; Tsujimura A, 2002, J CELL BIOL, V157, P1257, DOI 10.1083/jcb.200202067; Wang BE, 2003, J BIOL CHEM, V278, P18506, DOI 10.1074/jbc.M300968200; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang YZ, 2001, DIFFERENTIATION, V68, P270, DOI 10.1046/j.1432-0436.2001.680414.x; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; Weinstein BM, 2002, COLD SPRING HARB SYM, V67, P155, DOI 10.1101/sqb.2002.67.155; WELSHONS WJ, 1965, SCIENCE, V150, P1122, DOI 10.1126/science.150.3700.1122	60	71	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24733	24744		10.1074/jbc.M401602200	http://dx.doi.org/10.1074/jbc.M401602200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15028713	hybrid			2022-12-25	WOS:000221702500104
J	Williams, TM; Lee, H; Cheung, MWC; Cohen, AW; Razani, B; Iyengar, P; Scherer, PE; Pestell, RG; Lisanti, MP				Williams, TM; Lee, H; Cheung, MWC; Cohen, AW; Razani, B; Iyengar, P; Scherer, PE; Pestell, RG; Lisanti, MP			Combined loss of INK4a and Caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis - Role of INK4a/CAV-1 in mammary epithelial cell hyperplasia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P42/44 MAP KINASE; TUMOR-SUPPRESSOR GENE; RICH MEMBRANE DOMAINS; SRC TYROSINE KINASES; NULL MICE; H-RAS; PANCREATIC-CANCER; SOMATIC MUTATIONS; TRANSFORMED-CELLS; CDK INHIBITORS	Tumorigenesis is a multistep process that involves a series of genetic changes or "multiple hits," leading to alterations in signaling, proliferation, immortalization, and transformation. Many of the molecular factors that govern tumor initiation and progression remain unknown. Here, we evaluate the transformation suppressor potential of caveolin-1 (Cav-1) and its ability to cooperate with a well established tumor suppressor, the INK4a locus. To study the effects of loss of caveolin- 1 on cellular transformation, we established immortalized primary mouse embryonic fibroblasts (MEFs) expressing and lacking caveolin-1 by interbreeding Cav-1 (+/+) and Cav-1 (-/-) mice with INK4a (-/-) mice. Analysis of these cells reveals that loss of caveolin- 1 confers a significant growth advantage, as measured via cellular proliferation and cell cycle analysis. Loss of caveolin-1 in the INK4a (-/-) genetic background results in constitutive hyperactivation of the p42/44 MAP kinase cascade, decreased expression of p21(Cip1), as well as cyclin D1 and PCNA overexpression, consistent with their hyperproliferative phenotype. Importantly, in cells lacking Cav-1 expression, transformation by activated onco-genes (H-Ras(G12V) or v-Src) results in increased tumor growth in vivo (up to > 40-fold). Finally, INK4a (-/-)/Cav-1 (-/-) mice demonstrate disturbed mammary epithelial ductal morphology, with hyperplasia, increased side- branching, and fibrosis. Our results provide important new evidence for the transformation suppressor properties of Cav-1 and the first molecular genetic evidence that Cav-1 cooperates with a tumor suppressor, namely the INK4a genetic locus.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Georgetown University	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Williams, Terence M/I-9614-2014; Lisanti, Michael P/C-6866-2013; Scherer, Philipp E/K-7819-2012; Lisanti, Michael/B-6131-2018	Scherer, Philipp E/0000-0003-0680-3392; Lisanti, Michael/0000-0003-2034-1382; Razani, Babak/0000-0002-7172-9240	NATIONAL CANCER INSTITUTE [R01CA070896, R01CA075503, P30CA051008, R01CA086072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA75503, R01CA70896, R01CA86072, P30 CA51008-13] Funding Source: Medline; NIDDK NIH HHS [T32-DK07513] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hayashi K, 2001, CANCER RES, V61, P2361; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HIRAMA T, 1995, BLOOD, V86, P841; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park DS, 2002, MOL BIOL CELL, V13, P3416, DOI 10.1091/mbc.02-05-0071; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; QUELLE DE, 1995, CELL, V83, P993; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SUBRAMANIAM A, 1990, J BIOL CHEM, V265, P13986; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505	48	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24745	24756		10.1074/jbc.M402064200	http://dx.doi.org/10.1074/jbc.M402064200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044451	hybrid			2022-12-25	WOS:000221702500105
J	Prokop, S; Shirotani, K; Edbauer, D; Haass, C; Steiner, H				Prokop, S; Shirotani, K; Edbauer, D; Haass, C; Steiner, H			Requirement of PEN-2 for stabilization of the presenilin N-/C-terminal fragment heterodimer within the gamma-secretase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; DISEASE-ASSOCIATED PRESENILIN-1; BETA-PEPTIDE PRODUCTION; ALZHEIMERS-DISEASE; APH-1 INTERACTS; WILD-TYPE; IN-VIVO; NICASTRIN; NOTCH; EXPRESSION	gamma-Secretase is a protease complex composed of presenilin (PS), nicastrin (NCT), APH-1, and PEN-2, which catalyzes intramembrane cleavage of several type I transmembrane proteins including the Alzheimer's disease-associated beta-amyloid precursor protein. We generated stable RNA interference-mediated PEN-2 knockdown cells to probe mutant PEN-2 variants for functional activity. Knockdown of PEN-2 was associated with impaired NCT maturation and deficient PS1 endoproteolysis, which was efficiently rescued by wild type or N-terminally tagged PEN-2 but not by C-terminally tagged PEN-2 or by the C-terminally truncated PEN-2-DeltaC mutant. Although the latter mutants rescued the PS1 holoprotein accumulation associated with the PEN-2 knockdown, they failed to restore normal levels of the PS1 N- and C-terminal fragments and to maturate NCT. PEN-2-DeltaC was highly unstable and rapidly turned over by proteasomal degradation consistent with its failure to become stably incorporated into the gamma-secretase complex. In addition, expression of PEN-2-DeltaC caused a selective instability of the PS1 N-/C-terminal fragment heterodimer that underwent proteasomal degradation, whereas NCT and APH-1 were stable. Interestingly, when we knocked down PEN-2 in the background of the endoproteolysis-deficient PS1 Deltaexon9 mutant, immature NCT still accumulated, demonstrating that PEN-2 is also required for gamma-secretase complex maturation when PS endoproteolysis cannot occur. Taken together, our data suggest that PEN-2 is required for the stabilization of the PS fragment heterodimer within the gamma-secretase complex following PS endoproteolysis. This function critically depends on the PEN-2 C terminus. Moreover, our data show that PEN-2 is generally required for gamma-secretase complex maturation independent of its activity in PS1 endoproteolysis.	Univ Munich, Dept Biochem, Adolf Butenandt Inst, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany	University of Munich	Haass, C (corresponding author), Univ Munich, Dept Biochem, Adolf Butenandt Inst, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.	chaass@med.uni-muenchen.de; hsteiner@med.uni-muenchen.de	Prokop, Stefan/Y-1257-2019; Edbauer, Dieter/M-9906-2019	Prokop, Stefan/0000-0002-5633-2149; Edbauer, Dieter/0000-0002-7186-4653				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Capell A, 1997, J NEUROCHEM, V69, P2432; Cervantes S, 2001, FEBS LETT, V505, P81, DOI 10.1016/S0014-5793(01)02785-5; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Dick LR, 1997, J BIOL CHEM, V272, P182; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Goutte C, 2000, DEVELOPMENT, V127, P2481; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; LaPointe CF, 2000, J BIOL CHEM, V275, P1502, DOI 10.1074/jbc.275.2.1502; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li T, 2003, J NEUROSCI, V23, P3272; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; PerezTur J, 1995, NEUROREPORT, V7, P297; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; SHIROTANI K, 2004, IN PRESS J NEUROCHEM; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	48	105	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23255	23261		10.1074/jbc.M401789200	http://dx.doi.org/10.1074/jbc.M401789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039426	hybrid			2022-12-25	WOS:000221570900058
J	Thoden, JB; Timson, DJ; Reece, RJ; Holden, HM				Thoden, JB; Timson, DJ; Reece, RJ; Holden, HM			Molecular structure of human galactose mutarotase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUS E COLI; ESCHERICHIA-COLI; ALDOSE 1-EPIMERASE; LACTOCOCCUS-LACTIS; PENICILLIUM-NOTATUM; POLYOL ACCUMULATION; HIGHER PLANTS; PURIFICATION; METABOLISM; MECHANISM	Galactose mutarotase catalyzes the conversion of beta-D-galactose to alpha-D-galactose during normal galactose metabolism. The enzyme has been isolated from bacteria, plants, and animals and is present in the cytoplasm of most cells. Here we report the x-ray crystallographic analysis of human galactose mutarotase both in the apoform and complexed with its substrate, beta-D-galactose. The polypeptide chain folds into an intricate array of 29 beta-strands, 25 classical reverse turns, and 2 small alpha-helices. There are two cis-peptide bonds at Arg-78 and Pro-103. The sugar ligand sits in a shallow cleft and is surrounded by Asn-81, Arg-82, His-107, His-176, Asp-243, Gln-279, and Glu-307. Both the side chains of Glu-307 and His-176 are in the proper location to act as a catalytic base and a catalytic acid, respectively. These residues are absolutely conserved among galactose mutarotases. To date, x-ray models for three mutarotases have now been reported, namely that described here and those from Lactococcus lactis and Caenorhabditis elegans. The molecular architectures of these enzymes differ primarily in the loop regions connecting the first two beta-strands. In the human protein, there are six extra residues in the loop compared with the bacterial protein for an approximate longer length of 9 Angstrom. In the C. elegans protein, the first 17 residues are missing, thereby reducing the total number of beta-strands by one.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Queens Univ Belfast, Sch Biol & Biochem, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Wisconsin System; University of Wisconsin Madison; Queens University Belfast; University of Manchester	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu	Timson, David/I-4014-2019	Timson, David/0000-0002-0985-8818	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047814, R01DK047814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bailey J F, 1975, Methods Enzymol, V41, P471; BAILEY JM, 1965, BIOCHIM BIOPHYS ACTA, V94, P124, DOI 10.1016/0926-6585(65)90015-4; BAILEY JM, 1966, SCIENCE, V152, P1270, DOI 10.1126/science.152.3726.1270; BAILEY JM, 1969, J BIOL CHEM, V244, P781; BAILEY JM, 1967, J BIOL CHEM, V242, P4263; Beebe JA, 2003, BIOCHEMISTRY-US, V42, P4414, DOI 10.1021/bi020639a; Beebe JA, 1998, BIOCHEMISTRY-US, V37, P14989, DOI 10.1021/bi9816047; BENTLEY R, 1960, J BIOL CHEM, V235, P1219; BENTLEY R, 1960, J BIOL CHEM, V235, P1225; BOUFFARD GG, 1994, J MOL BIOL, V244, P269, DOI 10.1006/jmbi.1994.1728; DVORNIK D, 1973, SCIENCE, V182, P1146, DOI 10.1126/science.182.4117.1146; Erlandson KA, 2001, APPL ENVIRON MICROB, V67, P1445, DOI 10.1128/AEM.67.4.1445-1452.2001; GATZ C, 1986, J BACTERIOL, V168, P31, DOI 10.1128/jb.168.1.31-39.1986; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; HUCHO F, 1971, EUR J BIOCHEM, V23, P489, DOI 10.1111/j.1432-1033.1971.tb01645.x; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JONES TA, 1992, MOL REPLACEMENT; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KESTON AS, 1954, SCIENCE, V120, P355, DOI 10.1126/science.120.3113.355-a; KESTON AS, 1963, ARCH BIOCHEM BIOPHYS, V102, P306, DOI 10.1016/0003-9861(63)90184-X; KINOSHITA JH, 1962, BIOCHIM BIOPHYS ACTA, V62, P176, DOI 10.1016/0006-3002(62)90508-5; KLEYWEGT GJ, 1994, 1 M AP FINAL MODEL; LI LK, 1965, ARCH BIOCHEM BIOPHYS, V110, P156, DOI 10.1016/0003-9861(65)90167-0; LIN LR, 1991, EXP EYE RES, V52, P93, DOI 10.1016/0014-4835(91)90132-X; MASKELL DJ, 1992, MOL MICROBIOL, V6, P3051, DOI 10.1111/j.1365-2958.1992.tb01763.x; MOLLET B, 1991, J BACTERIOL, V173, P4464, DOI 10.1128/JB.173.14.4464-4473.1991; NAVAZA J, 1987, ACTA CRYSTALLOGR A, V43, P645, DOI 10.1107/S0108767387098787; Novelli G, 2000, MOL GENET METAB, V71, P62, DOI 10.1006/mgme.2000.3073; Petry KG, 1998, TRENDS GENET, V14, P98, DOI 10.1016/S0168-9525(97)01379-6; POOLMAN B, 1990, J BACTERIOL, V172, P4037, DOI 10.1128/jb.172.7.4037-4047.1990; ROUSSEL A, 1992, BIOGRAPHICS; Thoden JB, 2003, PROTEIN SCI, V12, P1051, DOI 10.1110/ps.0243203; Thoden JB, 2002, J BIOL CHEM, V277, P20854, DOI 10.1074/jbc.M201415200; Thoden JB, 2002, J BIOL CHEM, V277, P45458, DOI 10.1074/jbc.M208395200; Timson DJ, 2003, FEBS LETT, V543, P21, DOI 10.1016/S0014-5793(03)00364-8; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Tsakiris S, 2002, PHARMACOL TOXICOL, V91, P254, DOI 10.1034/j.1600-0773.2002.910506.x; WALLENFELS K, 1965, BIOCHEM Z, V343, P307; WALLENFELS K, 1965, BIOCHEM Z, V343, P294	40	33	35	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23431	23437		10.1074/jbc.M402347200	http://dx.doi.org/10.1074/jbc.M402347200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15026423	hybrid			2022-12-25	WOS:000221570900079
J	Annabi, B; Thibeault, S; Moumdjian, R; Beliveau, R				Annabi, B; Thibeault, S; Moumdjian, R; Beliveau, R			Hyaluronan cell surface binding is induced by type I collagen and regulated by caveolae in glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; CENTRAL-NERVOUS-SYSTEM; EXTRACELLULAR-MATRIX; PROTEIN-KINASE; LIPID RAFTS; TRANSMEMBRANE DOMAIN; SULFATE PROTEOGLYCAN; TUMOR PROGRESSION; ENDOTHELIAL-CELLS; CD44 EXPRESSION	Hyaluronan ( HA) is a component of the brain extracellular matrix environment that is synthesized and secreted by glioma cells. The primary cell surface receptor for HA is CD44, a membrane glycoprotein that is functionally regulated by a membrane type 1 matrix metalloproteinase (MT1-MMP). Both CD44 and MT1-MMP are partially located in Triton X-100-insoluble domains, but no functional link has yet been established between them. In the present study, we studied the regulation of HA cell surface binding in U-87 glioma cells. We show that an MMP-dependent mechanism regulates the intrinsic cell surface binding of HA as ilomastat, a broad MMP inhibitor, increased HA binding to glioma cells. HA binding was also rapidly and specifically up-regulated by 3-fold by type I collagen in U-87 cells, which also induced a significant morphological reorganization associated with the activation of a latent form of MMP-2 through a MT1-MMP-mediated mechanism. Interestingly, caveolae depletion with a cell surface cholesterol-depleting agent beta-cyclodextrin triggered an additional increase (9-fold) in the binding of HA, in synergy with type I collagen. On the other hand, HA cell surface binding was diminished by the MEK inhibitor PD98059 and by the overexpression of a recombinant, wild type MT1-MMP, whereas its cytoplasmic-deleted form had no effect. Taken together, our results suggest that MT1-MMP regulates, through its cytoplasmic domain, the cell surface functions of CD44 in a collagen-rich pericellular environment. Additionally, we describe a new molecular mechanism regulating the invasive potential of glioma cells involving a MT1-MMP/CD44/caveolin interaction, which could represent a potential target for anti-cancer therapies.	Univ Quebec, Dept Chem, Oncol Mol Lab, Montreal, PQ H3C 3P8, Canada; Univ Quebec, Hop St Justine, Ctr Cancerol Charles Bruneau, Mol Med Lab, Montreal, PQ H3C 3P8, Canada; Univ Montreal, Notre Dame Hosp, Dept Surg, Montreal, PQ H2L 4M1, Canada	University of Quebec; University of Quebec Montreal; Universite de Montreal; University of Quebec; University of Quebec Montreal; Universite de Montreal	Beliveau, R (corresponding author), Univ Quebec, Mol Med Lab, CP 8888,Succursalle Ctr Ville, Montreal, PQ H3C 3P8, Canada.	oncomol@nobel.si.uqam.ca						Akiyama Y, 2001, J NEURO-ONCOL, V53, P115, DOI 10.1023/A:1012297132047; Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Annabi B, 2002, BBA-MOL CELL RES, V1542, P209, DOI 10.1016/S0167-4889(01)00187-2; Annabi B, 2001, BIOCHEM J, V359, P325, DOI 10.1042/0264-6021:3590325; ASHER R, 1991, J NEUROSCI RES, V28, P410, DOI 10.1002/jnr.490280314; Beaulieu E, 1999, NEUROSURGERY, V45, P1432, DOI 10.1097/00006123-199912000-00033; Bernardo MM, 2002, J BIOL CHEM, V277, P11201, DOI 10.1074/jbc.M111021200; BERTOLOTTO A, 1990, J NEUROL SCI, V100, P113, DOI 10.1016/0022-510X(90)90021-E; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; CARTER WG, 1988, J BIOL CHEM, V263, P4193; Demeule Michel, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P441, DOI 10.2174/1568011023353930; Dome B, 2001, VIRCHOWS ARCH, V439, P628; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Enegd B, 2002, NEUROSURGERY, V50, P1311, DOI 10.1097/00006123-200206000-00023; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; Fujisaki T, 1999, CANCER RES, V59, P4427; Gal I, 2003, J BIOL CHEM, V278, P11150, DOI 10.1074/jbc.M210661200; GALARDY RE, 1994, CANCER RES, V54, P4715; Gingras D, 1998, BIOCHEM BIOPH RES CO, V247, P888, DOI 10.1006/bbrc.1998.8885; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Gunthert U, 1998, ADV EXP MED BIOL, V451, P43; Guo C, 2003, J BIOL CHEM, V278, P46699, DOI 10.1074/jbc.M307238200; GUSTAFSON S, 1991, BIOCHIM BIOPHYS ACTA, V1091, P36, DOI 10.1016/0167-4889(91)90218-M; ISACKE CM, 1994, J CELL SCI, V107, P2353; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jaworski DM, 1996, CANCER RES, V56, P2293; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Knutson JR, 1996, MOL BIOL CELL, V7, P383, DOI 10.1091/mbc.7.3.383; KUPPNER MC, 1992, INT J CANCER, V50, P572, DOI 10.1002/ijc.2910500414; Lamy S, 2002, CANCER RES, V62, P381; Leigh CJ, 1996, HUM PATHOL, V27, P1288, DOI 10.1016/S0046-8177(96)90339-1; Lesley J, 2000, J BIOL CHEM, V275, P26967; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Lewis CA, 2001, BIOCHEM J, V357, P843, DOI 10.1042/0264-6021:3570843; Liu D, 1996, J EXP MED, V183, P1987, DOI 10.1084/jem.183.5.1987; Lokeshwar Vinata, 2001, ScientificWorldJournal, V1, P106, DOI 10.1100/tsw.2001.120; Maidment SL, 1997, ANTICANCER RES, V17, P4145; Maleski M, 1997, GLIA, V20, P193, DOI 10.1002/(SICI)1098-1136(199707)20:3<193::AID-GLIA3>3.0.CO;2-9; McCurdy LH, 2003, J VIROL, V77, P1747, DOI 10.1128/JVI.77.3.1747-1756.2003; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; NAGASAKA S, 1995, J NEUROSURG, V82, P858, DOI 10.3171/jns.1995.82.5.0858; NAOT D, 1997, ADV CANCER RES, V71, P241; Nutt CL, 2001, CANCER RES, V61, P7056; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Oku N, 2003, BIOL PHARM BULL, V26, P1235, DOI 10.1248/bpb.26.1235; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; PERSCHL A, 1995, J CELL SCI, V108, P1033; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Rahmanian M, 1997, EXP CELL RES, V237, P223, DOI 10.1006/excr.1997.3792; Ranuncolo SM, 2002, J SURG ONCOL, V79, P30, DOI 10.1002/jso.10045; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Samuelsson C, 1998, GLYCOCONJUGATE J, V15, P169, DOI 10.1023/A:1006920323095; SATTAR A, 1994, J INVEST DERMATOL, V103, P576, DOI 10.1111/1523-1747.ep12396880; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Silva WI, 1999, INT J DEV NEUROSCI, V17, P705, DOI 10.1016/S0736-5748(99)00040-4; SILVER FH, 1980, J BIOL CHEM, V255, P9427; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; Sugahara KN, 2003, J BIOL CHEM, V278, P32259, DOI 10.1074/jbc.M300347200; Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.0.CO;2-T; Thylen A, 1999, CANCER-AM CANCER SOC, V86, P2000, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2000::AID-CNCR17>3.3.CO;2-E; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Uekita T, 2004, J BIOL CHEM, V279, P12734, DOI 10.1074/jbc.M309957200; WEST DC, 1989, CIBA F SYMP, V143, P187; Xu Y, 2003, J BIOL CHEM, V278, P8661, DOI 10.1074/jbc.M208181200; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x; Zhang H, 1998, J NEUROSCI, V18, P2370	74	61	62	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21888	21896		10.1074/jbc.M313694200	http://dx.doi.org/10.1074/jbc.M313694200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016831	hybrid			2022-12-25	WOS:000221417100028
J	Nomura, K; Kanemura, H; Satoh, T; Kataoka, T				Nomura, K; Kanemura, H; Satoh, T; Kataoka, T			Identification of a novel domain of Ras and Rap1 that directs their differential subcellular localizations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-EPSILON; GTP-BINDING PROTEINS; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; GOLGI-APPARATUS; PLASMA-MEMBRANE; ACTIVATION; COLOCALIZATION; SWITCH; TARGET	The small GTPase Ha-Ras and Rap1A exhibit high mutual sequence homology and share various target proteins. However, they exert distinct biological functions and exhibit differential subcellular localizations; Rap1A is predominantly localized in the perinuclear region including the Golgi apparatus and endosomes, whereas Ha-Ras is predominantly localized in the plasma membrane. Here, we have identified a small region in Rap1A that is crucial for its perinuclear localization. Analysis of a series of Ha-Ras-Rap1A chimeras shows that Ha-Ras carrying a replacement of amino acids 46-101 with that of Rap1 exhibits the perinuclear localization. Subsequent mutational studies indicate that Rap1A-type substitutions within five amino acids at positions 85-89 of Ha-Ras, such as NNTKS85-89TAQST, NN85-86TA, and TKS87-89QST, are sufficient to induce the perinuclear localization of Ha-Ras. In contrast, substitutions of residues surrounding this region, such as FAI82-84YSI and FEDI90-93FNDL, have no effect on the plasma membrane localization of Ha-Ras. A chimeric construct consisting of amino acids 1-134 of Rap1A and 134-189 of Ha-Ras, which harbors both the palmitoylation and farnesylation sites of Ha-Ras, exhibits the perinuclear localization like Rap1A. Introduction of a Ha-Ras-type substitution into amino acids 85-89 (TAQST85-89NNTKS) of this chimeric construct causes alteration of its predominant subcellular localization site from the perinuclear region to the plasma membrane. These results indicate that a previously uncharacterized domain spanning amino acids 85-89 of Rap1A plays a pivotal role in its perinuclear localization. Moreover, this domain acts dominantly over COOH-terminal lipid modification of Ha-Ras, which has been considered to be essential and sufficient for the plasma membrane localization.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Kataoka, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kataoka@kobe-u.ac.jp	Satoh, Takaya/K-2628-2014					Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Caloca MJ, 2003, J BIOL CHEM, V278, P33465, DOI 10.1074/jbc.M302807200; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Gurung R, 2003, J BIOL CHEM, V278, P11376, DOI 10.1074/jbc.M209991200; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Okada T, 1999, MOL CELL BIOL, V19, P6057; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; Sarafian V, 1998, INT J CANCER, V75, P105, DOI 10.1002/(SICI)1097-0215(19980105)75:1<105::AID-IJC16>3.3.CO;2-L; SATOH T, 1992, J BIOL CHEM, V267, P24149; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Song CH, 2002, ONCOGENE, V21, P8105, DOI 10.1038/sj.onc.1206003; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wienecke R, 1996, ONCOGENE, V13, P913; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000	28	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22664	22673		10.1074/jbc.M314169200	http://dx.doi.org/10.1074/jbc.M314169200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15031297	hybrid			2022-12-25	WOS:000221417100118
J	Su, X; Mancuso, DJ; Bickel, PE; Jenkins, CM; Gross, RW				Su, X; Mancuso, DJ; Bickel, PE; Jenkins, CM; Gross, RW			Small interfering RNA knockdown of calcium-independent phospholipases A2 beta or gamma inhibits the hormone-induced differentiation of 3T3-L1 preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CLONAL EXPANSION; ACTIVATED-RECEPTOR-GAMMA; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; C/EBP-ALPHA; GENE-EXPRESSION; SMOOTH-MUSCLE; MESSENGER-RNA; ADIPOGENESIS; A(2)	Alterations in lipid secondary messenger generation and lipid metabolic flux are essential in promoting the differentiation of adipocytes. To determine whether specific subtypes of intracellular phospholipases A(2) ( PLA(2)s) facilitate hormone- induced differentiation of 3T3- L1 cells into adipocytes, we examined alterations in the mRNA level, protein mass, and activity of three previously characterized mammalian intracellular PLA(2)s. Hormone- induced differentiation of 3T3- L1 cells resulted in 7.3 +/- 0.5- and 7.4 +/- 1.4- fold increases of mRNA encoding the calcium- independent phospholipases, iPLA(2)beta and iPLA(2)gamma, respectively. In contrast, the temporally coordinated loss of at least 90% of cPLA(2)alpha mRNA was manifest. Western analysis demonstrated the near absence of both iPLA(2)beta and iPLA(2)gamma protein mass in resting 3T3- L1 cells that increased dramatically during differentiation. In vitro measurement of PLA2 activities demonstrated an increase in both iPLA(2)beta and iPLA(2)gamma activities that were discriminated using the chiral mechanism based inhibitors ( S)- and ( R)- BEL, respectively. Remarkably, treatment of 3T3- L1 cells with small interfering RNA directed against either iPLA(2)beta or iPLA(2)gamma prevented hormone- induced differentiation. Moreover, analysis of the temporally programmed expression of transcription factors demonstrated that the small interfering RNA knockdown of iPLA(2)beta or iPLA(2)gamma resulted in down- regulation of the expression of peroxisome proliferator- activated receptor gamma and the CCAAT enhancer- binding protein alpha ( C/ EBP alpha). No alterations in the expression of the early stage transcription factors C/ EBP beta and C/ EBP delta were observed. Collectively, these results demonstrate prominent alterations in intracellular PLA(2)s during 3T3- L1 cell differentiation into adipocytes and identify the requirement of iPLA(2)beta and iPLA(2)gamma for the adipogenic program that drives resting 3T3- L1 cells into adipocytes after hormone stimulation.	Washington Univ, Sch Med, Dept Internal Med, Div Bioorgan Chem & Mol Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Chem, Div Bioorgan Chem & Mol Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Div Bioorgan Chem & Mol Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, Div Bioorgan Chem & Mol Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gross, RW (corresponding author), 660 S Euclid Ave,Campus Box 8020, St Louis, MO 63110 USA.	dwamser@pcg.wustl.edu	Bickel, Perry/Q-9185-2019		NHLBI NIH HHS [5P01HL57278-07] Funding Source: Medline; NIDDK NIH HHS [R01DK59577] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Ferry G, 2003, J BIOL CHEM, V278, P18162, DOI 10.1074/jbc.M301158200; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; FROST SC, 1985, J BIOL CHEM, V260, P2646; GAO G, 1990, J BIOL CHEM, V265, P2431; Gomez FE, 2002, BIOCHEMISTRY-US, V41, P5473, DOI 10.1021/bi012177r; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; GROSS RW, 1992, TRENDS CARDIOVAS MED, V2, P115, DOI 10.1016/1050-1738(92)90016-L; GROSS RW, 1995, J LIPID MEDIAT CELL, V12, P131, DOI 10.1016/0929-7855(95)00014-H; Han XL, 2001, ANAL BIOCHEM, V295, P88, DOI 10.1006/abio.2001.5178; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; Hichami A, 2002, EUR J BIOCHEM, V269, P5557, DOI 10.1046/j.1432-1033.2002.03261.x; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; IZAWA T, 1994, AM J PHYSIOL, V266, pE418, DOI 10.1152/ajpendo.1994.266.3.E418; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Miller CW, 1996, ENDOCRINOLOGY, V137, P5641, DOI 10.1210/en.137.12.5641; MIYAKE R, 1992, BIOCHIM BIOPHYS ACTA, V1165, P167, DOI 10.1016/0005-2760(92)90183-V; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; Nosjean O, 2002, CELL SIGNAL, V14, P573, DOI 10.1016/S0898-6568(01)00281-9; Ntambi JM, 1996, DIFFERENTIATION, V60, P151, DOI 10.1007/s002580050145; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Ramanadham S, 1996, BIOCHEMISTRY-US, V35, P5464, DOI 10.1021/bi952652j; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shi H, 2000, PHYSIOL GENOMICS, V3, P75, DOI 10.1152/physiolgenomics.2000.3.2.75; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VASSAUX G, 1992, J BIOL CHEM, V267, P11092; VASSAUX G, 1992, ENDOCRINOLOGY, V131, P2393, DOI 10.1210/en.131.5.2393; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Xue JC, 1996, MOL CELL BIOL, V16, P1567	55	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21740	21748		10.1074/jbc.M314166200	http://dx.doi.org/10.1074/jbc.M314166200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15024020	hybrid			2022-12-25	WOS:000221417100009
J	Zhang, Y; Griffin, K; Mondal, N; Parvin, JD				Zhang, Y; Griffin, K; Mondal, N; Parvin, JD			Phosphorylation of histone H2A inhibits transcription on chromatin templates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ACETYLATION; GENE; H3; KINASE; P300; RECRUITMENT; ACTIVATION; CODE; MSK1	The regulation of gene expression via the histone code has, for the most part, revealed that histone modifications cause the recruitment of adaptor proteins that indirectly regulate the synthesis of RNA. Using purified factors to assemble and modify the chromatin and to transcribe the DNA, we investigated whether modifications of histones may directly impact the RNA polymerase II transcription process. We screened proteins known to modify histones for effects on transcription, and we found that the mitogen- and stress- induced kinase, MSK1, inhibited RNA synthesis. Inhibition of transcription by MSK1 was most sensitive when the template was in chromatin, as naked DNA templates were resistant to the effects of MSK1. We found that MSK1 phosphorylated histone H2A on serine 1, and mutation of serine 1 to alanine blocked the inhibition of transcription by MSK1. Furthermore, we found that acetylation of histone H3 by the p300 and CREB- binding protein associated factor, PCAF, suppressed the kinase- dependent inhibition of transcription. These results suggest that acetylation of histones may stimulate transcription by suppressing an inhibitory phosphorylation by a kinase as MSK1.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Parvin, JD (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, HMS-NRB 630,77 Ave Louis Pasteur, Boston, MA 02115 USA.	JParvin@rics.bwh.harvard.edu	Zhang, Ye/D-5015-2011; Parvin, Jeffrey D/C-8955-2009	Zhang, Ye/0000-0002-3494-7206; 	NIGMS NIH HHS [GM-53504] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053504] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; BOFFA LC, 1981, J BIOL CHEM, V256, P9612; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; Mondal N, 2001, NATURE, V413, P435, DOI 10.1038/35096590; Mondal N, 2003, NUCLEIC ACIDS RES, V31, P5016, DOI 10.1093/nar/gkg705; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; RYAN CA, 1999, CURRENT PROTOCOLS MO; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419	27	46	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21866	21872		10.1074/jbc.M400099200	http://dx.doi.org/10.1074/jbc.M400099200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15010469	hybrid			2022-12-25	WOS:000221417100025
J	Liu, JJ; Lewellyn, AL; Chen, LG; Maller, JL				Liu, JJ; Lewellyn, AL; Chen, LG; Maller, JL			The polo box is required for multiple functions of Plx1 in mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; XENOPUS EGG EXTRACTS; KINASE PLX1; CELL-CYCLE; CDC25 PHOSPHATASE; M-PHASE; SUBCELLULAR-LOCALIZATION; SPINDLE CHECKPOINT; PHOSPHORYLATION; ACTIVATION	Polo-like kinases comprise a family of evolutionarily conserved serine/threonine protein kinases that play multiple roles in cell cycle regulation. In addition to the N-terminal catalytic domain, polo-like kinases have one or two highly conserved C-terminal non-catalytic regions, termed polo boxes. These motifs are required for targeting these kinases to subcellular mitotic structures. Here we report that kinase-dead Xenopus polo-like kinase (Plx1NA) functions as a competitor of endogenous Plx1 for polo box binding site(s) and inhibits the activation of Cdc25C and the G(2)-M transition in vivo. However, kinase-dead Plx1 with a point mutation in the polo box region (Plx1NAWF) did not have inhibitory effects. The ability of Plx1NA to block activation of the anaphase-promoting complex/cyclosome also requires an intact polo box. Microinjection of Plx1NA but not Plx1NAWF mRNA into Xenopus embryos caused cleavage arrest and formation of monopolar spindles, an effect previously seen in embryos injected with anti-Plx1 antibody. Spindle assembly experiments in vitro also showed that only monopolar spindles formed in Xenopus egg extracts supplemented with recombinant Plx1NA and that the spindle assembly process was delayed. Taken together, these results indicate that the polo box is required for Plx1 function in both the G(2)-M and the metaphase/anaphase transitions during the cell cycle.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.	jim.maller@uchsc.edu			NCI NIH HHS [CA 46934] Funding Source: Medline; NIGMS NIH HHS [GM 26743-24] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL BIOL, V153, P663, DOI 10.1083/jcb.153.4.663; Duncan PI, 2001, EXP CELL RES, V270, P78, DOI 10.1006/excr.2001.5333; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Fang GW, 1999, PHILOS T ROY SOC B, V354, P1583, DOI 10.1098/rstb.1999.0502; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Frazier JA, 1998, J CELL BIOL, V143, P737, DOI 10.1083/jcb.143.3.737; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; Golsteyn R M, 1996, Prog Cell Cycle Res, V2, P107; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Peters JM, 1999, EXP CELL RES, V248, P339, DOI 10.1006/excr.1999.4443; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Reimann JDR, 2002, NATURE, V416, P850, DOI 10.1038/416850a; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V260, P193, DOI 10.1006/bbrc.1999.0884; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Song S, 2000, MOL CELL BIOL, V20, P286, DOI 10.1128/MCB.20.1.286-298.2000; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; SUNKEL CE, 1988, J CELL SCI, V89, P25; Taieb FE, 2001, CURR BIOL, V11, P508, DOI 10.1016/S0960-9822(01)00145-2; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Vorlaufer E, 1998, MOL BIOL CELL, V9, P1817, DOI 10.1091/mbc.9.7.1817; Wassmann K, 2003, EMBO J, V22, P797, DOI 10.1093/emboj/cdg071; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	61	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21367	21373		10.1074/jbc.M400482200	http://dx.doi.org/10.1074/jbc.M400482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016807	hybrid			2022-12-25	WOS:000221273800100
J	Skerrett, IM; Di, WL; Kasperek, EM; Kelsell, DP; Nicholson, BJ				Skerrett, IM; Di, WL; Kasperek, EM; Kelsell, DP; Nicholson, BJ			Aberrant gating, but a normal expression pattern, underlies the recessive phenotype of the deafness mutant Connexin26M34T	FASEB JOURNAL			English	Article						Connexin26; gap junction; channel gating	MUTATIONS; CONNEXIN-26	Mutations in the gene GJB2, encoding the gap junction protein Connexin26 (Cx26), are the most prevalent cause of inherited hearing loss, and Cx26M34T was one of the first mutations linked to deafness (Kelsell et al., 1997; Nature 387, 80-83). We report the first characterization of the gating properties of M34T, which had previously been reported to be nonfunctional. Although homotypic mutant channels did not produce detectable currents, heterotypic pairings with wtCx26 confirmed that M34T formed intercellular channels, although the gating properties were altered. Cx26M34T displayed an inverted response to transjunctional voltage (Vj), mediating currents that activate in a time- and Vj-dependent manner. These characteristics suggest that the channel population is only partially open at rest, consistent with previous reports that dye transfer in M34T-expressing cells is reduced or abolished ( e. g., Thonnissen et al., Human Genet. 111, 190-197). To investigate the controversial recessive/dominant behavior of this mutant, we coexpressed M34T with wtCx26 RNA at equimolar levels, mimicking the situation in heterozygotic individuals. Under these conditions, M34T did not significantly reduce Cx26/Cx26 coupling, or alter the electrophysiological properties of the wt channels, consistent with the recessive nature of the allele. Overexpression of the mutant did have some inhibitory effects on conductance, possibly explaining some of the previous reports in exogenous expression systems and some patients. Consistent with its electrophysiological behavior, we also show that M34T localizes to cell junctions in both transfected HeLa cells and patient-derived tissue.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA; Barts & London Queen Marys Sch Med & Dent, Ctr Cutaneous Res, London E1 2AT, England	University of Texas System; University of Texas Health San Antonio; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of London; Queen Mary University London	Nicholson, BJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	nicholsonb@uthscsa.edu	Kelsell, David P/F-8767-2011	Nicholson, Bruce/0000-0003-1649-7173; Kelsell, David/0000-0002-9910-7144				BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Cohen-Salmon M, 2002, CURR BIOL, V12, P1106, DOI 10.1016/S0960-9822(02)00904-1; Cucci RA, 2000, GENET TEST, V4, P335, DOI 10.1089/109065700750065063; Di WL, 2001, J INVEST DERMATOL, V117, P958, DOI 10.1046/j.0022-202x.2001.01468.x; Griffith AJ, 2000, AM J HUM GENET, V67, P745, DOI 10.1086/303045; Houseman MJ, 2001, J MED GENET, V38, P20, DOI 10.1136/jmg.38.1.20; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kelsell DP, 2001, AM J HUM GENET, V68, P559, DOI 10.1086/318803; Kikuchi Toshihiko, 2000, Medical Electron Microscopy, V33, P51, DOI 10.1007/s007950070001; Kudo T, 2003, HUM MOL GENET, V12, P995, DOI 10.1093/hmg/ddg116; Martin PEM, 1999, HUM MOL GENET, V8, P2369, DOI 10.1093/hmg/8.13.2369; NICHOLSON BJ, 1993, PROG CELL R, V3, P3; Oh S, 1997, NEURON, V19, P927, DOI 10.1016/S0896-6273(00)80973-3; Oshima A, 2003, J BIOL CHEM, V278, P1807, DOI 10.1074/jbc.M207713200; Scott DA, 1998, NATURE, V391, P32, DOI 10.1038/34079; Skerrett IM, 2001, CELL COMMUN ADHES, V8, P179, DOI 10.3109/15419060109080720; Skerrett IM, 2001, METH MOL B, V154, P225; Skerrett IM, 2000, CURR TOP MEMBR, V49, P249; Smith RJH, 2001, ARCH OTOLARYNGOL, V127, P941, DOI 10.1001/archotol.127.8.941; Thonnissen E, 2002, HUM GENET, V111, P190, DOI 10.1007/s00439-002-0750-2; White TW, 1998, NATURE, V394, P630, DOI 10.1038/29202	21	35	39	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					860	+		10.1096/fj.03-0763fje	http://dx.doi.org/10.1096/fj.03-0763fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033936				2022-12-25	WOS:000220522800004
J	Kort, R; Hellingwerf, KJ; Ravelli, RBG				Kort, R; Hellingwerf, KJ; Ravelli, RBG			Initial events in the photocycle of photoactive yellow protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOPHILIC PHOTOTROPHIC BACTERIUM; P-COUMARIC ACID; ECTOTHIORHODOSPIRA-HALOPHILA; STRUCTURAL-CHANGES; PRIMARY PHOTOREACTION; ANGSTROM RESOLUTION; EARLY INTERMEDIATE; RADIATION-DAMAGE; PROTON-TRANSFER; ACTIVE-SITE	The light-induced isomerization of a double bond is the key event that allows the conversion of light energy into a structural change in photoactive proteins for many light-mediated biological processes, such as vision, photosynthesis, photomorphogenesis, and photo movement. Cofactors such as retinals, linear tetrapyrroles, and 4-hydroxy-cinnamic acid have been selected by nature that provide the essential double bond to transduce the light signal into a conformational change and eventually, a physiological response. Here we report the first events after light excitation of the latter chromophore, containing a single ethylene double bond, in a low temperature crystallographic study of the photoactive yellow protein. We measured experimental phases to overcome possible model bias, corrected for minimized radiation damage, and measured absorption spectra of crystals to analyze the photoproducts formed. The data show a mechanism for the light activation of photoactive yellow protein, where the energy to drive the remainder of the conformational changes is stored in a slightly strained but fully cis-chromophore configuration. In addition, our data indicate a role for backbone rearrangements during the very early structural events.	Univ Amsterdam, Swammerdam Inst Life Sci, Microbiol Lab, NL-1018 WV Amsterdam, Netherlands; European Synchrotron Radiat Facil, F-38043 Grenoble, France; European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France	University of Amsterdam; European Synchrotron Radiation Facility (ESRF); European Molecular Biology Laboratory (EMBL)	Kort, R (corresponding author), Univ Amsterdam, Swammerdam Inst Life Sci, Microbiol Lab, Nieuwe Achtergracht 166, NL-1018 WV Amsterdam, Netherlands.	rkort@science.uva.nl	Kort, Remco/ABH-1915-2021	Kort, Remco/0000-0003-3674-598X; Ravelli, Raimond/0000-0001-6056-5888				BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berglund GI, 2002, NATURE, V417, P463, DOI 10.1038/417463a; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Bourgeois D, 2002, J APPL CRYSTALLOGR, V35, P319, DOI 10.1107/S0021889802003837; Brodersen DE, 2000, ACTA CRYSTALLOGR D, V56, P431, DOI 10.1107/S0907444900000834; Brudler R, 2001, NAT STRUCT BIOL, V8, P265, DOI 10.1038/85021; Burmeister WP, 2000, ACTA CRYSTALLOGR D, V56, P328, DOI 10.1107/S0907444999016261; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Devanathan S, 1998, BIOCHEMISTRY-US, V37, P11563, DOI 10.1021/bi9803776; Devanathan S, 1999, BIOPHYS J, V77, P1017, DOI 10.1016/S0006-3495(99)76952-3; Diederichs K, 2003, ACTA CRYSTALLOGR D, V59, P903, DOI 10.1107/S0907444903006516; DIEDERICHS K, 2003, ACTA CRYSTALLOGR D, V11, P217; Edman K, 1999, NATURE, V401, P822, DOI 10.1038/44623; Essen LO, 1998, NATURE, V392, P131, DOI 10.1038/32294; Fabiola F, 2002, PROTEIN SCI, V11, P1415, DOI 10.1110/ps.4890102; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Getzoff ED, 2003, NAT STRUCT BIOL, V10, P663, DOI 10.1038/nsb958; Groot ML, 2003, BIOCHEMISTRY-US, V42, P10054, DOI 10.1021/bi034878p; HOFF WD, 1992, PHOTOCHEM PHOTOBIOL, V56, P529, DOI 10.1111/j.1751-1097.1992.tb02197.x; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Imamoto Y, 1997, J BIOL CHEM, V272, P12905, DOI 10.1074/jbc.272.20.12905; Imamoto Y, 1996, BIOCHEMISTRY-US, V35, P14047, DOI 10.1021/bi961342d; Imamoto Y, 2001, BIOCHEMISTRY-US, V40, P6047, DOI 10.1021/bi002437p; Imamoto Y, 2001, BIOCHEMISTRY-US, V40, P8997, DOI 10.1021/bi010021l; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; Kort R, 1996, EMBO J, V15, P3209, DOI 10.1002/j.1460-2075.1996.tb00685.x; Kort R, 2003, PHOTOCHEM PHOTOBIOL, V78, P131, DOI 10.1562/0031-8655(2003)078<0131:COPIIC>2.0.CO;2; Kriminski S, 2003, ACTA CRYSTALLOGR D, V59, P697, DOI 10.1107/S0907444903002713; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Matsui Y, 2002, J MOL BIOL, V324, P469, DOI 10.1016/S0022-2836(02)01110-5; MCREE DE, 1986, J BIOL CHEM, V261, P3850; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; MURRAY J, 2004, IN PRESS J APPL CRYS; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; Ravelli RBG, 2000, BIOPHYS J, V78, p484A; Ravelli RBG, 2002, J SYNCHROTRON RADIAT, V9, P355, DOI 10.1107/S0909049502014541; Ravelli RBG, 2003, STRUCTURE, V11, P217, DOI 10.1016/S0969-2126(03)00006-6; Ravelli RBG, 2000, STRUCTURE, V8, P315, DOI 10.1016/S0969-2126(00)00109-X; Ren Z, 2001, BIOCHEMISTRY-US, V40, P13788, DOI 10.1021/bi0107142; Royant A, 2000, NATURE, V406, P645, DOI 10.1038/35020599; Royant A, 2001, PHOTOCHEM PHOTOBIOL, V74, P794, DOI 10.1562/0031-8655(2001)074<0794:SCOBSL>2.0.CO;2; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P195, DOI 10.1107/S0907444901019291; Sergi A, 2001, J PHYS CHEM B, V105, P4386, DOI 10.1021/jp002270+; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Thompson MJ, 2003, J AM CHEM SOC, V125, P8186, DOI 10.1021/ja0294461; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Weik M, 2000, P NATL ACAD SCI USA, V97, P623, DOI 10.1073/pnas.97.2.623; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035	54	61	63	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26417	26424		10.1074/jbc.M311961200	http://dx.doi.org/10.1074/jbc.M311961200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15026418	hybrid			2022-12-25	WOS:000222003000063
J	Ando, K; Ozaki, T; Yamamoto, H; Furuya, K; Hosoda, M; Hayashi, S; Fukuzawa, M; Nakagawara, A				Ando, K; Ozaki, T; Yamamoto, H; Furuya, K; Hosoda, M; Hayashi, S; Fukuzawa, M; Nakagawara, A			Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; WILD-TYPE P53; DNA-DAMAGE; PROTEIN-KINASE; SUBCELLULAR-LOCALIZATION; SERINE/THREONINE KINASE; CANCER-CELLS; PROGNOSTIC-SIGNIFICANCE; NUCLEAR TRANSLOCATION; BINDING PROTEIN	Polo-like kinase 1 (Plk1) has an important role in the regulation of M phase of the cell cycle. In addition to its cell cycle-regulatory function, Plk1 has a potential role in tumorigenesis. Here we found for the first time that Plk1 physically binds to the tumor suppressor p53 in mammalian cultured cells, and inhibits its transactivation activity as well as its pro-apoptotic function. During the cisplatin-induced apoptosis in human neuroblastoma SH-SY5Y cells, the expression level of Plk1 was significantly decreased both at mRNA and protein levels, whereas cisplatin treatment caused a remarkable stabilization of p53. Systematic immunoprecipitation analyses using a series of deletion mutants of p53 revealed that a sequence-specific DNA-binding region of p53 is required and sufficient for the physical interaction with Plk1. The ectopically overexpressed Plk1 was co-localized with the endogenous p53 in mammalian cell nucleus, as shown by confocal laser microscopy. Expression of exogenous Plk1 and p53 in p53-deficient lung carcinoma H1299 cells greatly decreased the p53-mediated transcription from the p53-responsive p21(WAF1), MDM2, and BAX promoters, whereas the kinase-deficient mutant form of Plk1 failed to reduce the transcriptional activity of p53. Consistent with the luciferase reporter analysis, Plk1 had an ability to block the p53-dependent induction of the endogenous p21(WAF1). In addition, Plk1 inhibited the pro-apoptotic function of p53 in H1299 cells. Intriguingly, Plk1-mediated repression of p53 was attenuated with ATM. Thus, our present findings strongly suggest that p53 is a critical target of Plk1, and its function is abrogated through the physical interaction with Plk1.	Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Nihon Univ, Sch Med, Dept Surg 1, Tokyo 1738610, Japan	Chiba Cancer Center; Nihon University	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-ccri.chuo.chiba.jp	Hosoda, Mitsuchika/A-7534-2012					Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; BRAUNINGER A, 1995, ONCOGENE, V11, P1793; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; DANG CV, 1989, J BIOL CHEM, V264, P18019; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lane HA, 1997, TRENDS CELL BIOL, V7, P63, DOI 10.1016/S0962-8924(96)10051-9; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee MG, 2003, J BIOL CHEM, V278, P41047, DOI 10.1074/jbc.M307031200; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Lin J, 2001, J BIOL CHEM, V276, P35037, DOI 10.1074/jbc.M104379200; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nakamura Y, 1997, EUR J CANCER, V33, P1986, DOI 10.1016/S0959-8049(97)00333-X; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Prives C, 1999, J PATHOL, V187, P112; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Ree AH, 2003, ONCOGENE, V22, P8952, DOI 10.1038/sj.onc.1207000; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Song S, 2000, MOL CELL BIOL, V20, P286, DOI 10.1128/MCB.20.1.286-298.2000; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; Taniguchi E, 2002, J BIOL CHEM, V277, P48884, DOI 10.1074/jbc.M206307200; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	68	212	234	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25549	25561		10.1074/jbc.M314182200	http://dx.doi.org/10.1074/jbc.M314182200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15024021	hybrid			2022-12-25	WOS:000221827900081
J	Kumar, A; Vaid, A; Syin, C; Sharma, P				Kumar, A; Vaid, A; Syin, C; Sharma, P			PfPKB, a novel protein kinase B-like enzyme from Plasmodium falciparum - I. Identification, characterization, and possible role in parasite development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MALARIA PARASITES; SACCHAROMYCES-CEREVISIAE; INHIBITORS; ACTIVATION; GENOME; HOMOLOG; DIFFERENTIATION; PHOSPHORYLATION; MECHANISM; RESOURCE	Extracellular signals control various important functions of a eukaryotic cell, which is often achieved by regulating a battery of protein kinases and phosphatases. Protein Kinase B (PKB) is an important member of the phosphatidylinositol 3-kinase-dependent signaling pathways in several eukaryotes, but the role of PKB in protozoan parasites is not known. We have identified a protein kinase B homologue in Plasmodium falciparum (PfPKB) that is expressed mainly in the schizonts and merozoites. Even though PfPKB shares high sequence homology with PKB catalytic domain, it lacks a pleckstrin homology domain typically found at the N terminus of the mammalian enzyme. Biochemical studies performed to understand the mechanism of PfPKB catalytic activation suggested (i) its activation is dependent on autophosphorylation of a serine residue (Ser-271) in its activation loop region and (ii) PfPKB has an unusual N-terminal region that was found to negatively regulate its catalytic activity. We also identified an inhibitor of PfPKB activity that also inhibits P. falciparum growth, suggesting that this enzyme may be important for the development of the parasite.	Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India; US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); US Food & Drug Administration (FDA)	Sharma, P (corresponding author), Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India.	pushkar@nii.res.in		Kumar, Amit/0000-0003-1732-440X				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bahl A, 2003, NUCLEIC ACIDS RES, V31, P212, DOI 10.1093/nar/gkg081; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Bhattacharyya MK, 2002, INT J PARASITOL, V32, P739, DOI 10.1016/S0020-7519(02)00007-3; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Bracchi-Ricard V, 2000, BIOCHEM J, V347, P255, DOI 10.1042/0264-6021:3470255; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Deng WS, 2002, MOL MICROBIOL, V44, P1141, DOI 10.1046/j.1365-2958.2002.02948.x; Doerig C, 2002, INT J PARASITOL, V32, P1575, DOI 10.1016/S0020-7519(02)00186-8; Dorin D, 1999, J BIOL CHEM, V274, P29912, DOI 10.1074/jbc.274.42.29912; Dorin D, 2001, EUR J BIOCHEM, V268, P2600, DOI 10.1046/j.1432-1327.2001.02151.x; Fujita M, 1998, CURR GENET, V33, P248, DOI 10.1007/s002940050333; Garcia-Echeverria C, 2000, MED RES REV, V20, P28, DOI 10.1002/(SICI)1098-1128(200001)20:1<28::AID-MED2>3.3.CO;2-U; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Kappes B, 1999, PARASITOL TODAY, V15, P449, DOI 10.1016/S0169-4758(99)01527-6; Kissinger JC, 2002, NATURE, V419, P490, DOI 10.1038/419490a; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Le Roch K, 2000, J BIOL CHEM, V275, P8952, DOI 10.1074/jbc.275.12.8952; Li JL, 2000, MOL BIOCHEM PARASIT, V109, P157, DOI 10.1016/S0166-6851(00)00242-5; Li JL, 2000, BBA-GENE STRUCT EXPR, V1491, P341, DOI 10.1016/S0167-4781(00)00032-4; Madeira L, 2003, BIOCHEM BIOPH RES CO, V306, P995, DOI 10.1016/S0006-291X(03)01074-X; Mamoun CB, 2001, MOL MICROBIOL, V39, P26, DOI 10.1046/j.1365-2958.2001.02222.x; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pascuccelli V, 1999, MOL BIOCHEM PARASIT, V102, P21, DOI 10.1016/S0166-6851(99)00076-6; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Silva-Neto MAC, 2002, J BIOL CHEM, V277, P14085, DOI 10.1074/jbc.M107903200; Syin C, 2001, EUR J BIOCHEM, V268, P4842, DOI 10.1046/j.1432-1327.2001.02403.x; TODA T, 1988, GENE DEV, V2, P517, DOI 10.1101/gad.2.5.517; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Woodard CL, 2003, J MED CHEM, V46, P3877, DOI 10.1021/jm0300983; Xiao ZL, 2001, BIOORG MED CHEM LETT, V11, P2875, DOI 10.1016/S0960-894X(01)00578-9; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6	41	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24255	24264		10.1074/jbc.M312855200	http://dx.doi.org/10.1074/jbc.M312855200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15024016	hybrid			2022-12-25	WOS:000221702500050
J	Petropoulos, H; Gianakopoulos, PJ; Ridgeway, AG; Skerjanc, IS				Petropoulos, H; Gianakopoulos, PJ; Ridgeway, AG; Skerjanc, IS			Disruption of Meox or Gli activity ablates skeletal myogenesis in P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR 2C; CUBITUS-INTERRUPTUS; MUSCLE DEVELOPMENT; PARAXIAL MESODERM; OTHERS EXPRESSION; REPRESSION DOMAIN; PAX-3 EXPRESSION; GENE-EXPRESSION; SONIC HEDGEHOG; SHH	Gli2 and Meox1 are transcription factors that are expressed in the developing somite and play roles in the commitment of cells to the skeletal muscle lineage. To further define their roles in regulating myogenesis, the function of wild type and dominant-negative forms of Gli2 and Meox1 were examined in the context of differentiating P19 stem cells. We found that Gli2 overexpression up-regulated transcript levels of Meox1 and, conversely, Meox1 overexpression resulted in the up-regulation of Gli2 transcripts. Furthermore, dominant-negative forms of either Meox1 or Gli2 disrupted the ability of P19 cells to commit to the muscle lineage and to properly express either Gli2 or Meox1, respectively. Finally, Pax3 transcripts were induced by Gli2 overexpression and lost in the presence of either mutants Meox1 or Gli2. Taken together, these results support the existence of a regulatory loop between Gli2, Meox1, and Pax3 that is essential for specification of mesodermal cells into the muscle lineage.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Western University (University of Western Ontario); Harvard University; Harvard Medical School	Skerjanc, IS (corresponding author), Univ Western Ontario, Dept Biochem, Med Sci Bldg, London, ON N6A 5C1, Canada.	skerjanc@uwo.ca	Skerjanc, Ilona/AAN-3318-2020					ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Bailey P, 2001, CURR OPIN CELL BIOL, V13, P679, DOI 10.1016/S0955-0674(00)00271-4; BOBER E, 1994, DEVELOPMENT, V120, P603; Borycki AG, 2000, DEVELOPMENT, V127, P2075; Borycki AG, 1999, DEVELOPMENT, V126, P1665; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Candia AF, 1996, INT J DEV BIOL, V40, P1179; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Capdevila J, 1998, DEV BIOL, V193, P182, DOI 10.1006/dbio.1997.8806; EPSTEIN DJ, 1993, P NATL ACAD SCI USA, V90, P532, DOI 10.1073/pnas.90.2.532; GeorgeWeinstein M, 1997, DEV BIOL, V185, P14, DOI 10.1006/dbio.1997.8542; GOULDING M, 1994, DEVELOPMENT, V120, P957; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Karlstrom RO, 1999, GENE DEV, V13, P388, DOI 10.1101/gad.13.4.388; Kim JH, 2001, CLIN GENET, V59, P306, DOI 10.1034/j.1399-0004.2001.590503.x; LinJones J, 1996, DEV BIOL, V174, P407, DOI 10.1006/dbio.1996.0084; Mankoo BS, 2003, DEVELOPMENT, V130, P4655, DOI 10.1242/dev.00687; Mankoo BS, 1999, NATURE, V400, P69, DOI 10.1038/21892; Mansouri A, 1998, CRIT REV ONCOGENESIS, V9, P141, DOI 10.1615/CritRevOncog.v9.i2.40; Marine JC, 1997, MECH DEVELOP, V63, P211, DOI 10.1016/S0925-4773(97)00050-6; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; Mo R, 1997, DEVELOPMENT, V124, P113; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; Park HL, 2000, DEVELOPMENT, V127, P1593; Petropoulos H, 2002, J BIOL CHEM, V277, P15393, DOI 10.1074/jbc.M112141200; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; Ridgeway AG, 2000, J BIOL CHEM, V275, P32398, DOI 10.1074/jbc.M004349200; RIDGEWAY AG, 2001, J BIOL CHEM, V21, P21; RUIZ IAA, 2002, NAT REV NEUROSCI, V3, P24, DOI DOI 10.1038/NRN704; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; Skerjanc IS, 2000, FEBS LETT, V472, P53, DOI 10.1016/S0014-5793(00)01438-1; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Smith ST, 1996, DEVELOPMENT, V122, P3141; Stamataki D, 2001, FEBS LETT, V499, P274, DOI 10.1016/S0014-5793(01)02556-X; STERN HM, 1995, DEVELOPMENT, V121, P3675; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155; Teboul L, 2003, GENE DEV, V17, P2870, DOI 10.1101/gad.1117603; Teboul L, 2002, DEVELOPMENT, V129, P4571; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; vanEeden FJM, 1996, DEVELOPMENT, V123, P153; Wagner J, 2000, DEV BIOL, V228, P86, DOI 10.1006/dbio.2000.9921; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Wilton S, 1999, IN VITRO CELL DEV-AN, V35, P175; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3	55	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23874	23881		10.1074/jbc.M312612200	http://dx.doi.org/10.1074/jbc.M312612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15039437	hybrid			2022-12-25	WOS:000221702500007
J	Hainzl, O; Wegele, H; Richter, K; Buchner, J				Hainzl, O; Wegele, H; Richter, K; Buchner, J			Cns1 is an activator of the Ssa1 ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; EUKARYOTIC DNAJ HOMOLOG; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONE; ESSENTIAL PROTEIN; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; CITRATE SYNTHASE; GLOBAL ANALYSIS; HSP90 ATPASE	Hsp90 is a key mediator in the folding process of a growing number of client proteins. The molecular chaperone cooperates with many co-chaperones and partner proteins to fulfill its task. In Saccharomyces cerevisiae, several co-chaperones of Hsp90 interact with Hsp90 via a tetratricopeptide repeat (TPR) domain. Here we show that one of these proteins, Cns1, binds both to Hsp90 and to the yeast Hsp70 protein Ssa1 with comparable affinities. This is reminiscent of Sti1, another TPR-containing co-chaperone. Unlike Sti1, Cns1 exhibits no influence on the ATPase of Hsp90. However, it activates the ATPase of Ssa1 up to 30-fold by accelerating the rate-limiting ATP hydrolysis step. This stimulating effect is mediated by the N-terminal TPR-containing part of Cns1, whereas the C-terminal part showed no effect. Competition experiments allow the conclusion that Hsp90 and Ssa1 compete for binding to the single TPR domain of Cns1. Taken together, Cns1 is a potent cochaperone of Ssa1. Our findings highlight the importance of the regulation of Hsp70 function in the context of the Hsp90 chaperone cycle.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Richter, Klaus/A-2673-2010; Buchner, Johannes/A-2651-2010	Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BAUR A, 1994, YEAST, V10, P131, DOI 10.1002/yea.320100113; Birnby DA, 2000, GENETICS, V155, P85; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Bolivar F, 1979, Methods Enzymol, V68, P245; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, J BIOL CHEM, V269, P9798; Dolinski KJ, 1998, MOL CELL BIOL, V18, P7344, DOI 10.1128/MCB.18.12.7344; Duina AA, 1996, YEAST, V12, P943, DOI 10.1002/(SICI)1097-0061(199608)12:10<943::AID-YEA997>3.0.CO;2-3; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Haslbeck M, 2003, J CHROMATOGR B, V786, P127, DOI 10.1016/S1570-0232(02)00716-X; HONORE B, 1992, J BIOL CHEM, V267, P8485; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Marsh JA, 1998, MOL CELL BIOL, V18, P7353, DOI 10.1128/MCB.18.12.7353; Mayr C, 2000, J BIOL CHEM, V275, P34140, DOI 10.1074/jbc.M005251200; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MUCKE M, 1994, BIOCHEMISTRY-US, V33, P14608; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Richter K, 2003, J BIOL CHEM, V278, P10328, DOI 10.1074/jbc.M213094200; SANGER F, 1949, BIOCHEM J, V45, P563, DOI 10.1042/bj0450563; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; Warth R, 1997, BIOL CHEM, V378, P381, DOI 10.1515/bchm.1997.378.5.381; Wegele H, 2003, J CHROMATOGR B, V786, P109, DOI 10.1016/S1570-0232(02)00724-9; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; Wegele H., 2004, REV PHYSL BIOCH PHAR; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	56	41	43	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23267	23273		10.1074/jbc.M402189200	http://dx.doi.org/10.1074/jbc.M402189200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044454	hybrid			2022-12-25	WOS:000221570900060
J	Liang, M; Melchior, F; Feng, XH; Lin, X				Liang, M; Melchior, F; Feng, XH; Lin, X			Regulation of Smad4 sumoylation and transforming growth factor-beta signaling by protein inhibitor of activated STAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED PROTEOLYSIS; NUCLEAR-PORE COMPLEX; SUMO-1 MODIFICATION; ANDROGEN RECEPTOR; GENE ACTIVATION; PIAS PROTEINS; DEPENDENT TRANSCRIPTION; PROTEASOME PATHWAY; E3 LIGASE; TGF-BETA	The tumor suppressor, Smad4/DPC4, is a common signal transducer in transforming growth factor-beta (TGF-beta) signaling. In this study, we demonstrated that the protein inhibitor of activated STAT1 (PIAS1) regulates the signaling potential of Smad4 through a sumoylation-dependent mechanism. PIAS1 was shown to be an E3 ligase for Smad4 sumoylation in vitro and in vivo. PIAS1 physically interacted with Smad4 in a TGF-beta-inducible manner. A minimal SUMO E3 ligase domain and Smad4-binding domain were defined on PIAS1 protein. The RING finger domain of PIAS1 was essential for its E3 ligase function. Although PIAS1 enhanced the Smad4-dependent transcriptional activation of TGF-beta signaling, a mutant lacking the RING domain inhibited the sumoylation of Smad4 in a dominant negative manner and, as a result, abolished the transcriptional response of TGF-beta. These data demonstrate that PIAS1 protein positively modulates TGF-beta responses as a SUMO E3 ligase for Smad4.	Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Baylor College of Medicine; Baylor College of Medicine; Max Planck Society	Lin, X (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, 1 Baylor Plaza,Rm 131D, Houston, TX 77030 USA.	xialin@bcm.tmc.edu	Melchior, Frauke/E-2014-2014	Melchior, Frauke/0000-0001-9546-8797	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63773] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Bashir T, 2003, ADV CANCER RES, V88, P101, DOI 10.1016/S0065-230X(03)88305-7; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Doherty FJ, 2002, ESSAYS BIOCHEM, V38, P51, DOI 10.1042/bse0380051; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Fuchs SY, 2002, CANCER BIOL THER, V1, P337; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 2002, MOL CELL, V10, P441, DOI 10.1016/S1097-2765(02)00653-6; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sharma MJ, 2003, EMBO J, V22, P6101, DOI 10.1093/emboj/cdg585; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	46	65	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22857	22865		10.1074/jbc.M401554200	http://dx.doi.org/10.1074/jbc.M401554200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15028714	hybrid			2022-12-25	WOS:000221570900011
J	Miranda, TB; Miranda, M; Frankel, A; Clarke, S				Miranda, TB; Miranda, M; Frankel, A; Clarke, S			PRMT7 is a member of the protein arginine methyltransferase family with a distinct substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-METHYLTRANSFERASE; ENDOGENOUS METHYLARGININES; IDENTIFICATION; BINDING; METHYLATION; TRANSCRIPTION; GENERATION; INTERACTS; RNA	We have identified a mammalian arginine N-methyl-transferase, PRMT7, that can catalyze the formation of omega-N-G-monomethylarginine in peptides. This protein is encoded by a gene on human chromosome 16q22.1 (human locus AK001502). We expressed a full-length human cDNA construct in Escherichia coli as a glutathione S-transferase (GST) fusion protein. We found that GST-tagged PRMT7 catalyzes the S-adenosyl-[methyl-H-3]-L-methionine-dependent methylation of the synthetic peptide GGPGGRGGPGG-NH2 (R1). The radiolabeled peptide was purified by high-pressure liquid chromatography and acid hydrolyzed to free amino acids. When the hydrolyzed products were separated by high-resolution cation-exchange chromatography, we were able to detect one tritiated species which co-migrated with an omega-N-G-monomethylarginine standard. Surprisingly, GST-PRMT7 was not able to catalyze the in vitro methylation of a GST-fibrillarin (amino acids 1-148) fusion protein (GST-GAR), a methyl-accepting substrate for the previously characterized PRMT1, PRMT3, PRMT4, PRMT5, and PRMT6 enzymes. Nor was it able to methylate myelin basic protein or histone H2A, in vitro substrates of PRMT5. This specificity distinguishes PRMT7 from all of the other known arginine methyltransferases. An additional unique feature of PRMT7 is that it seems to have arisen from a gene duplication event and contains two putative AdoMet-binding motifs. To see if both motifs were necessary for activity, each putative domain was expressed as a GST-fusion and tested for activity with peptides R1 and R2 (acetyl-GGRGG-NH2). These truncated proteins were enzymatically inactive, suggesting that both domains are required for functionality.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	clarke@mbi.ucla.edu			NIGMS NIH HHS [GM26020, GM07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020, T32GM007185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Altschuler L, 1999, J INTERF CYTOK RES, V19, P189, DOI 10.1089/107999099314333; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Cardounel AJ, 2002, J BIOL CHEM, V277, P33995, DOI 10.1074/jbc.M108983200; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; Gros L, 2003, CANCER RES, V63, P164; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Katz JE, 2003, MOL CELL PROTEOMICS, V2, P525, DOI 10.1074/mcp.M300037-MCP200; Leiper J, 1999, CARDIOVASC RES, V43, P542, DOI 10.1016/S0008-6363(99)00162-5; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Qi C, 2002, J BIOL CHEM, V277, P28624, DOI 10.1074/jbc.M201053200; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509; Zhu W, 2002, J BIOL CHEM, V277, P35787, DOI 10.1074/jbc.C200346200	28	151	153	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22902	22907		10.1074/jbc.M312904200	http://dx.doi.org/10.1074/jbc.M312904200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044439	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000221570900016
J	Evert, BA; Salmon, TB; Song, BW; Jingjing, L; Siede, W; Doetsch, PW				Evert, BA; Salmon, TB; Song, BW; Jingjing, L; Siede, W; Doetsch, PW			Spontaneous DNA damage in Saccharomyces cerevisiae elicits phenotypic properties similar to cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; CHECKPOINT RESPONSE; ABASIC SITES; BASE-DAMAGE; YEAST; RAD53; REMOVAL; ARREST; CYCLE; GENE	To determine the spectrum of effects elicited by specific levels of spontaneous DNA damage, a series of isogenic Saccharomyces cerevisiae strains defective in base excision repair (BER) and nucleotide excision repair (NER) were analyzed. In log phase of growth, when compared with wild type (WT) or NER-defective cells, BER-defective cells and BER/NER-defective cells possess elevated levels of unrepaired, spontaneous oxidative DNA damage. This system allowed establishment of a range of similar to400 to 1400 Ntg1p-recognized DNA lesions per genome necessary to provoke profound biological changes similar in many respects to the phenotypic properties of cancer cells. The BER/NER-defective cells are genetically unstable, exhibiting mutator and hyper-recombinogenic phenotypes. They also exhibit aberrations in morphology, DNA content, and growth characteristics compared with WT, BER-defective, and NER-defective cells. The BER/NER-defective cells also possess increased levels of intracellular reactive oxygen species, activate the yeast checkpoint response pathway via Rad53p phosphorylation in stationary phase, and show profound changes in transcription patterns, a subset of which can be ascribed to responses resulting from unrepaired DNA damage. By establishing a relationship between specific levels of spontaneous DNA damage and the ensuing deleterious biological consequences, these yeast DNA excision repair-defective strains are an informative model for gauging the progressive biological consequences of spontaneous DNA damage accumulation and may have relevancy for delineating underlying mechanisms in tumorigenesis.	Emory Univ, Dept Biochem, Rollins Res Ctr, Atlanta, GA 30322 USA; Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA; Emory Univ, Div Canc Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA; Univ N Texas, Dept Cell Biol & Genet, Ft Worth, TX 76107 USA	Emory University; Emory University; Emory University; Emory University; University of North Texas System; University of North Texas Health Science Center	Doetsch, PW (corresponding author), Emory Univ, Dept Biochem, Rollins Res Ctr, Rm 4013,1510 Clifton Rd, Atlanta, GA 30322 USA.	medpwd@emory.edu			NCI NIH HHS [CA87381] Funding Source: Medline; NIEHS NIH HHS [ES11163] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011163] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aguilaniu H, 2001, J BIOL CHEM, V276, P35396, DOI 10.1074/jbc.M101796200; Basrai MA, 1999, MOL CELL BIOL, V19, P7041; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1988, DNA REPAIR LABORATOR, P347; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Chial HJ, 1999, P NATL ACAD SCI USA, V96, P10200, DOI 10.1073/pnas.96.18.10200; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Doetsch PW, 2001, PROG NUCLEIC ACID RE, V68, P29; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P2; Gancedo JM, 2001, FEMS MICROBIOL REV, V25, P107, DOI 10.1016/S0168-6445(00)00056-5; Gellon L, 2001, MOL GENET GENOMICS, V265, P1087, DOI 10.1007/s004380100507; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Greene CN, 1997, MOL CELL BIOL, V17, P2844, DOI 10.1128/MCB.17.5.2844; GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Jiang YW, 2003, MOL BIOL CELL, V14, P5116, DOI 10.1091/mbc.E03-06-0375; JINKSROBERTSON S, 1993, METHOD ENZYMOL, V224, P631; JONG AY, 1995, ANAL BIOCHEM, V227, P32, DOI 10.1006/abio.1995.1249; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; Matunis MJ, 2002, MOL CELL, V10, P441, DOI 10.1016/S1097-2765(02)00653-6; Meadows KL, 2003, NUCLEIC ACIDS RES, V31, P5560, DOI 10.1093/nar/gkg749; Memisoglu A, 2000, MUTAT RES-FUND MOL M, V451, P39, DOI 10.1016/S0027-5107(00)00039-7; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; O'Rourke TW, 2002, MOL CELL BIOL, V22, P4086, DOI 10.1128/MCB.22.12.4086-4093.2002; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Qi HY, 2003, J BIOL CHEM, V278, P15136, DOI 10.1074/jbc.M212808200; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; Sambrook J, 2001, MOL CLONING LAB MANU; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Siede W, 1996, J BACTERIOL, V178, P5841, DOI 10.1128/jb.178.19.5841-5843.1996; SNOWDEN A, 1990, BIOCHEMISTRY-US, V29, P7251, DOI 10.1021/bi00483a013; Swanson RL, 1999, MOL CELL BIOL, V19, P2929; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Torres-Ramos CA, 2000, MOL CELL BIOL, V20, P3522, DOI 10.1128/MCB.20.10.3522-3528.2000; You HJ, 1999, BIOCHEMISTRY-US, V38, P11298, DOI 10.1021/bi991121i; Zhang H, 2003, J BIOL CHEM, V278, P9382, DOI 10.1074/jbc.M300061200	47	54	58	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22585	22594		10.1074/jbc.M400468200	http://dx.doi.org/10.1074/jbc.M400468200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15020594	hybrid			2022-12-25	WOS:000221417100110
J	He, ZG; Richardson, CC				He, ZG; Richardson, CC			Effect of single-stranded DNA-binding proteins on the helicase and primase activities of the bacteriophage T7 gene 4 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; TEMPLATE RECOGNITION; CRYSTAL-STRUCTURE; PRIMER SYNTHESIS; IN-VITRO; REPLICATION; POLYMERASE; PURIFICATION; MECHANISM; ROLES	Gene 4 protein (gp4) of bacteriophage T7 provides two essential functions at the T7 replication fork, primase and helicase activities. Previous studies have shown that the single-stranded DNA-binding protein of T7, encoded by gene 2.5, interacts with gp4 and modulates its multiple functions. To further characterize the interactions between gp4 and gene 2.5 protein (gp2.5), we have examined the effect of wild-type and altered gene 2.5 proteins as well as Escherichia coli single-stranded DNA-binding (SSB) protein on the ability of gp4 to synthesize primers, hydrolyze dTTP, and unwind duplex DNA. Wild-type gp2.5 and E. coli SSB protein stimulate primer synthesis and DNA-unwinding activities of gp4 at low concentrations but do not significantly affect single-stranded DNA-dependent hydrolysis of dTTP. Neither protein inhibits the binding of gp4 to single-stranded DNA. The variant gene 2.5 proteins, gp2.5-F232L and gp2.5-Delta26C, inhibit primase, dTTPase, and helicase activities proportional to their increased affinities for DNA. Interestingly, wild-type gp2.5 stimulates the unwinding activity of gp4 except at very high concentrations, whereas E. coli SSB protein is highly inhibitory at relative low concentrations.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	ccr@hms.harvard.edu	He, Zheng-Guo/P-3647-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54397] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; BARRY J, 1994, J BIOL CHEM, V269, P330; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; Chowdhury K, 2000, P NATL ACAD SCI USA, V97, P12469, DOI 10.1073/pnas.230448397; Curth U, 1996, NUCLEIC ACIDS RES, V24, P2706, DOI 10.1093/nar/24.14.2706; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Frick DN, 1999, J BIOL CHEM, V274, P35889, DOI 10.1074/jbc.274.50.35889; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; Frick DN, 2001, ANNU REV BIOCHEM, V70, P39, DOI 10.1146/annurev.biochem.70.1.39; Genschel J, 2000, BIOL CHEM, V381, P183, DOI 10.1515/BC.2000.025; Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303; He ZG, 2003, J BIOL CHEM, V278, P29538, DOI 10.1074/jbc.M304318200; HINTON DM, 1985, J BIOL CHEM, V260, P2851; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; Hyland EM, 2003, J BIOL CHEM, V278, P7247, DOI 10.1074/jbc.M210605200; Kato M, 2003, MOL CELL, V11, P1349, DOI 10.1016/S1097-2765(03)00195-3; Kato M, 2001, J BIOL CHEM, V276, P21809, DOI 10.1074/jbc.M101470200; Kim DE, 2002, J MOL BIOL, V321, P807, DOI 10.1016/S0022-2836(02)00733-7; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kong DC, 1998, J BIOL CHEM, V273, P6556, DOI 10.1074/jbc.273.11.6556; Kusakabe T, 1998, EMBO J, V17, P1542, DOI 10.1093/emboj/17.5.1542; Kusakabe T, 1997, J BIOL CHEM, V272, P5943, DOI 10.1074/jbc.272.9.5943; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MYERS TW, 1988, J BIOL CHEM, V263, P17006; NAKAI H, 1988, J BIOL CHEM, V263, P9831; PATEL SS, 1992, J BIOL CHEM, V267, P15013; Reddy MS, 2001, J BIOL CHEM, V276, P45959, DOI 10.1074/jbc.M103523200; Rezende LF, 2003, J BIOL CHEM, V278, P29098, DOI 10.1074/jbc.M303374200; Rezende LF, 2002, J BIOL CHEM, V277, P50643, DOI 10.1074/jbc.M207359200; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; RIGLER MN, 1995, J BIOL CHEM, V270, P8910, DOI 10.1074/jbc.270.15.8910; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; Tabor S., 1996, Richardson, Method for Nucleic Acid Hybridization Using Single-stranded DNA Binding Protein, Patent No. 5534407; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740	49	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22190	22197		10.1074/jbc.M401100200	http://dx.doi.org/10.1074/jbc.M401100200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15044449	Green Published, hybrid			2022-12-25	WOS:000221417100064
J	Liu, Y; Kim, BO; Kao, CH; Jung, CY; Dalton, JT; He, JJ				Liu, Y; Kim, BO; Kao, CH; Jung, CY; Dalton, JT; He, JJ			Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; NUCLEAR-RECEPTOR; TRANSACTIVATION DOMAIN; LXXLL MOTIF; HISTONE ACETYLTRANSFERASE; MEDIATED TRANSCRIPTION; ESTROGEN-RECEPTOR; COACTIVATOR	Upon binding to androgen, androgen receptor ( AR) can activate expression of target genes through its direct binding to the androgen- responsive elements ( AREs), which are located within the target gene promoters and/ or enhancers. A number of cellular proteins have been identified as co- regulators to regulate this transactivation process. One common structural feature among these co- regulators is the presence of the LXXLL motif ( X, any amino acid), the so- called nuclear receptor ( NR) box, through which binding of these regulatory proteins to AR occurs. We have recently shown that Tip110 functions to potentiate the transactivation activity of human immunodeficiency virus type I ( HIV- 1) Tat protein. In this study, we report that Tip110 is a potent AR- binding protein that can suppress AR activity. Tip110 bound to AR in an NR box- dependent manner and inhibited AREs- mediated reporter gene expression. The inhibitory effects were abolished by removal of the NR box. Moreover, knock- down of the constitutive Tip110 expression significantly augmented AR transcriptional activation. In agreement with these findings, Tip110 overexpression blocked the prostate- specific antigen ( PSA) gene, a well characterized target gene of AR from expression in LNCaP cells. Further analysis revealed that Tip110 prevented the complex formation between AR and AREs. Taken together, these results indicate that Tip110 is a negative regulator of AR transcriptional activation, and may be directly involved in AR- related developmental, physiological, and pathological processes.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Urol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Ohio State Univ, Coll Pharm, Div Pharmaceut, Columbus, OH 43210 USA; Walther Canc Inst, Indianapolis, IN 46206 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; University System of Ohio; Ohio State University; Walther Cancer Institute	He, JJ (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, R2 302,950 W Walnut St, Indianapolis, IN 46202 USA.	jjhe@iupui.edu		Dalton, James T/0000-0002-3915-7326	NCI NIH HHS [R01CA74042] Funding Source: Medline; NIMH NIH HHS [R01MH65158] Funding Source: Medline; NINDS NIH HHS [R01NS39804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Brawer MK, 2000, SEMIN SURG ONCOL, V18, P3, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<3::AID-SSU2>3.3.CO;2-9; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; Hayes SA, 2001, CANCER RES, V61, P2112; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JENSTER G, 1992, J STEROID BIOCHEM, V41, P671, DOI 10.1016/0960-0760(92)90402-5; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kelly C, 1996, CHILD PSYCHOL PSYCHI, V1, P59; Knudsen KE, 1999, CANCER RES, V59, P2297; Ko L, 2002, MOL ENDOCRINOL, V16, P128, DOI 10.1210/me.16.1.128; Liu Y, 2002, J BIOL CHEM, V277, P23854, DOI 10.1074/jbc.M200773200; Liu YP, 1996, J BIOL CHEM, V271, P10391, DOI 10.1074/jbc.271.17.10391; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; ONATE SA, 1995, SCIENCE, V270, P1354; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Roy AK, 1999, VITAM HORM, V55, P309; Sharma M, 2001, MOL ENDOCRINOL, V15, P1918, DOI 10.1210/me.15.11.1918; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang CH, 2003, J BIOL CHEM, V278, P32423, DOI 10.1074/jbc.M207862200; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Whitesell L, 1999, METHODS, V18, P296, DOI 10.1006/meth.1999.0787; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang SB, 1997, BIOCHEM BIOPH RES CO, V231, P784, DOI 10.1006/bbrc.1997.6197; Zhang YX, 2002, ONCOGENE, V21, P5609, DOI 10.1038/sj.onc.1205638; Zhu ZX, 2001, BIOCHEM BIOPH RES CO, V284, P828, DOI 10.1006/bbrc.2001.5029	54	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21766	21773		10.1074/jbc.M314321200	http://dx.doi.org/10.1074/jbc.M314321200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15031286	hybrid			2022-12-25	WOS:000221417100012
J	Zhang, XP; Lester, RL; Dickson, RC				Zhang, XP; Lester, RL; Dickson, RC			Pil1p and Lsp1p negatively regulate the 3-phosphoinositide-dependent protein kinase-like kinase Pkh1p and downstream signaling pathways Pkc1p and Ypk1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL INTEGRITY; SACCHAROMYCES-CEREVISIAE; STRESS-RESPONSE; HEAT-STRESS; YEAST; ENDOCYTOSIS; GENES; SPHINGOLIPIDS; MAINTENANCE; GROWTH	The Saccharomyces cerevisiae homologs, Pkh1/2p, of the mammalian 3-phosphoinositide-dependent protein kinase 1 (PDK1) regulate the Pkc1-MAP kinase cascade and the partially parallel Ypk1/2p pathway(s) that control growth and cell integrity. Mammalian PDK1 is regulated by 3-phosphoinositides, whereas Pkh1/2p are regulated by sphingolipid long-chain bases (LCBs). Recently Pkh1/2p were found to complex with two related proteins, Pil1p (Ygr086) and Lsp1p (Yp1004). Because these two proteins are not related to any known protein we sought to characterize their functions. We show that Pkh1p phosphorylates both proteins in vitro in a reaction that is only weakly regulated by LCBs. In contrast, LCBs inhibit phosphorylation of Pil1p by Pkh2p, whereas LCBs stimulate phosphorylation of Lsp1p by Pkh2p. We find that Pil1p and Lsp1p downregulate resistance to heat stress and, specifically, that they down-regulate the activity of the Pkc1p-MAP and Ypk1p pathways during heat stress. Pil1p and Lsp1p are thus the first proteins identified as regulators of Pkh1/2p. An unexpected finding was that the level of Ypk1p is greatly reduced in pkc1Delta cells, indicating that Pkc1p controls the level of Ypk1p. Homologs of Pil1p and Lsp1p are widespread in nature, and our results suggest that they may be negative regulators of PDK-like protein kinases and their downstream cellular pathways that control cell growth and survival.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Dickson, RC (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	bobd@uky.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Brachmann CB, 1998, YEAST, V14, P115; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Ferguson-Yankey SR, 2002, YEAST, V19, P573, DOI 10.1002/yea.861; Friant S, 2000, EMBO J, V19, P2834, DOI 10.1093/emboj/19.12.2834; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Gelperin D, 2002, GENETICS, V161, P1453; Hearn JD, 2003, J BIOL CHEM, V278, P3679, DOI 10.1074/jbc.M209170200; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huang DQ, 2002, MOL CELL BIOL, V22, P5076, DOI 10.1128/MCB.22.14.5076-5088.2002; Inagaki M, 1999, MOL CELL BIOL, V19, P8344; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Lawlor MA, 2001, J CELL SCI, V114, P2903; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Roelants FM, 2002, MOL BIOL CELL, V13, P3005, DOI 10.1091/mbc.E02-04-0201; Schmelzle T, 2002, MOL CELL BIOL, V22, P1329, DOI 10.1128/MCB.22.5.1329-1339.2002; Sun YD, 2000, MOL CELL BIOL, V20, P4411, DOI 10.1128/MCB.20.12.4411-4419.2000; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824	37	90	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22030	22038		10.1074/jbc.M400299200	http://dx.doi.org/10.1074/jbc.M400299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016821	hybrid			2022-12-25	WOS:000221417100044
J	Mielke, C; Christensen, MO; Barthelmes, HU; Boege, F				Mielke, C; Christensen, MO; Barthelmes, HU; Boege, F			Enhanced processing of UVA-irradiated DNA by human topoisomerase II in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR; DAMAGE; ENZYME; RADIATION; MOBILITY; POISONS; ALPHA; BETA; FORM	Solar UV light induces a variety of DNA lesions in the genome. Enhanced cleavage of such base modifications by topoisomerase II has been demonstrated in vitro, but it is unclear what will arise from an interplay of these mechanisms in the genome of a living cell exposed to UV light. To address this question, we have subjected cells expressing biofluorescent topoisomerase IIalpha or IIbeta to DNA base modifications inflicted by a UVA laser at 364 nm through a confocal microscope in a locally confined manner. At DNA sites thus irradiated, we observed rapid, long term (>90 min) accumulation of topoisomerase IIalpha and IIbeta, which was accompanied by a decrease in mobility but not immobilization of the enzyme. The catalytic topoisomerase II inhibitor ICRF-187 prevented the effect when added to the cell culture before the UVA pulse but promoted it when added thereafter. Self-primed in situ extension with rhodamine-dUTP revealed massive DNA breakage at the UVA-exposed spot. Culturing the cells with ICRF-187 before UVA-exposure prevented such breaks. In conclusion, we show in a living cell nucleus that UVA-modified DNA is preferentially targeted and processed by topoisomerase IIalpha and IIbeta. This results in increased levels of topoisomerase II-mediated DNA breaks, but formation of immobile, stable topoisomerase II.DNA intermediates is not notably promoted. Inhibition of topoisomerase II activity by ICRF-187 greatly diminishes UVA-induced DNA breakage, implying topoisomerase IIalpha and IIbeta as endogenous co-factors modulating and possibly aggravating the impact of UVA light on the genome.	Univ Dusseldorf, Sch Med, Inst Clin Chem & Lab Diagnost, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Mielke, C (corresponding author), Univ Dusseldorf, Sch Med, Inst Clin Chem & Lab Diagnost, Moorenstr 5, D-40225 Dusseldorf, Germany.	christian.mielke@med.uniduesseldorf.de	Boege, Fritz/H-3261-2019					Andersen CL, 2002, CHROMOSOME RES, V10, P305, DOI 10.1023/A:1016571825025; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Beckman KB, 1998, ANN NY ACAD SCI, V854, P118, DOI 10.1111/j.1749-6632.1998.tb09897.x; Berneburg M, 1999, J BIOL CHEM, V274, P15345, DOI 10.1074/jbc.274.22.15345; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Christensen MO, 2002, J CELL BIOL, V157, P31, DOI 10.1083/jcb.200112023; Christensen MO, 2002, J BIOL CHEM, V277, P15661, DOI 10.1074/jbc.C200066200; Cline SD, 2003, NAT REV MOL CELL BIO, V4, P361, DOI 10.1038/nrm1101; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Douki T, 2003, BIOCHEMISTRY-US, V42, P9221, DOI 10.1021/bi034593c; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; Epe B, 2002, BIOL CHEM, V383, P467, DOI 10.1515/BC.2002.049; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Grue P, 1998, J BIOL CHEM, V273, P33660, DOI 10.1074/jbc.273.50.33660; HICKSON ID, 1990, INT J RADIAT BIOL, V58, P561, DOI 10.1080/09553009014551921; Hoogstraten D, 2002, MOL CELL, V10, P1163, DOI 10.1016/S1097-2765(02)00709-8; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Ravanat JL, 2001, J PHOTOCH PHOTOBIO B, V63, P88, DOI 10.1016/S1011-1344(01)00206-8; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Rochette PJ, 2003, NUCLEIC ACIDS RES, V31, P2786, DOI 10.1093/nar/gkg402; Sabourin M, 2000, NUCLEIC ACIDS RES, V28, P1947, DOI 10.1093/nar/28.9.1947; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; Subramanian D, 2000, METH MOL B, V95, P137; Subramanian D, 1998, CANCER RES, V58, P976; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wilstermann AM, 2001, J BIOL CHEM, V276, P46290, DOI 10.1074/jbc.M105733200	29	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20559	20562		10.1074/jbc.C400032200	http://dx.doi.org/10.1074/jbc.C400032200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15044480	hybrid			2022-12-25	WOS:000221273800002
J	Saito, H; Dhanasekaran, P; Nguyen, D; Deridder, E; Holvoet, P; Lund-Katz, S; Phillips, MC				Saito, H; Dhanasekaran, P; Nguyen, D; Deridder, E; Holvoet, P; Lund-Katz, S; Phillips, MC			alpha-Helix formation is required for high affinity binding of human apolipoprotein A-I to lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN PARTICLES; C-TERMINAL DOMAIN; CELLULAR CHOLESTEROL EFFLUX; UNILAMELLAR VESICLES; APOA-I; EXCHANGEABLE APOLIPOPROTEINS; TITRATION CALORIMETRY; AMPHIPATHIC PEPTIDES; ALANINE PEPTIDE; COIL TRANSITION	Apolipoprotein (apo) A-I is thought to undergo a conformational change during lipid association that results in the transition of random coil to alpha-helix. Using a series of deletion mutants lacking different regions along the molecule, we examined the contribution of alpha-helix formation in apoA-I to the binding to egg phosphatidylcholine (PC) small unilamellar vesicles (SUV). Binding isotherms determined by gel filtration showed that apoA-I binds to SUV with high affinity and deletions in the C-terminal region markedly decrease the affinity. Circular dichroism measurements demonstrated that binding to SUV led to an increase in alpha-helix content, but the helix content was somewhat less than in reconstituted discoidal PC . apoA-I complexes for all apoA-I variants, suggesting that the helical structure of apoA-I on SUV is different from that in discs. Isothermal titration calorimetry showed that the binding of apoA-I to SUV is accompanied by a large exothermic heat and deletions in the C-terminal regions greatly decrease the heat. Analysis of the rate of release of heat on binding, as well as the kinetics of quenching of tryptophan fluorescence by brominated PC, indicated that the opening of the N-terminal helix bundle is a rate-limiting step in apoA-I binding to the SUV surface. Significantly, the correlation of thermodynamic parameters of binding with the increase in the number of helical residues revealed that the contribution of alpha-helix formation upon lipid binding to the enthalpy and the free energy of the binding of apoA-I is - 1.1 and - 0.04 kcal/mol per residue, respectively. These results indicate that alpha-helix formation, especially in the C-terminal regions, provides the energetic source for high affinity binding of apoA-I to lipids.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Abramson Res Ctr,Div Gastroenterol & Nutr, Philadelphia, PA 19104 USA; Univ Louvain, Ctr Expt Surg & Anesthesiol, B-3000 Louvain, Belgium	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Phillips, MC (corresponding author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Abramson Res Ctr,Div Gastroenterol & Nutr, Ste 1102,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	phillipsmi@email.chop.edu	HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772; Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL 22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Corsico B, 2001, J BIOL CHEM, V276, P16978, DOI 10.1074/jbc.M011533200; Davidson WS, 1999, BIOCHEMISTRY-US, V38, P14387, DOI 10.1021/bi991428h; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; Fang YL, 2003, BIOCHEMISTRY-US, V42, P13260, DOI 10.1021/bi0354031; Fang YL, 2003, BIOCHEMISTRY-US, V42, P6881, DOI 10.1021/bi034152t; Favari E, 2002, BIOCHEM BIOPH RES CO, V299, P801, DOI 10.1016/S0006-291X(02)02745-6; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Frank PG, 2000, J LIPID RES, V41, P853; Gazzara JA, 1997, J LIPID RES, V38, P2134; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; Gorshkova IN, 2002, BIOCHEMISTRY-US, V41, P10529, DOI 10.1021/bi025807d; Gorshkova IN, 2000, BIOCHEMISTRY-US, V39, P15910, DOI 10.1021/bi0014406; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; Kiss RS, 1999, BIOCHEMISTRY-US, V38, P4327, DOI 10.1021/bi982597p; Klon AE, 2002, BIOCHEMISTRY-US, V41, P10895, DOI 10.1021/bi020315m; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Li HH, 2000, J BIOL CHEM, V275, P37048, DOI 10.1074/jbc.M005336200; Li HH, 2002, J BIOL CHEM, V277, P39093, DOI 10.1074/jbc.M206770200; Liu LJ, 2003, J BIOL CHEM, V278, P42976, DOI 10.1074/jbc.M308420200; Lopez MM, 2002, P NATL ACAD SCI USA, V99, P1298, DOI 10.1073/pnas.032665199; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lund-Katz S, 2003, FRONT BIOSCI-LANDMRK, V8, pD1044, DOI 10.2741/1077; LUNDKATZ S, 1993, J BIOL CHEM, V268, P23008; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MASSEY JB, 1979, J BIOL CHEM, V254, P9359; MCLEAN LR, 1984, BIOCHIM BIOPHYS ACTA, V776, P21, DOI 10.1016/0005-2736(84)90246-3; Mishra VK, 1998, BIOCHEMISTRY-US, V37, P10313, DOI 10.1021/bi980042o; Mishra VK, 1996, BIOCHEMISTRY-US, V35, P11210, DOI 10.1021/bi960760f; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; Oda MN, 2003, NAT STRUCT BIOL, V10, P455, DOI 10.1038/nsb931; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Panagotopulos SE, 2001, J BIOL CHEM, V276, P42965, DOI 10.1074/jbc.M106462200; Phillips JC, 1997, BIOPHYS J, V73, P2337, DOI 10.1016/S0006-3495(97)78264-X; Roberts LM, 1997, BIOCHEMISTRY-US, V36, P7615, DOI 10.1021/bi962952g; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; Rothblat GH, 1999, J LIPID RES, V40, P781; Saito H, 1997, J LIPID RES, V38, P287; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854; Schulthess G, 2000, BIOCHEMISTRY-US, V39, P12623, DOI 10.1021/bi0011633; Seelig J, 1997, BBA-REV BIOMEMBRANES, V1331, P103, DOI 10.1016/S0304-4157(97)00002-6; SEGREST JP, 1992, J LIPID RES, V33, P141; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Tricerri MA, 2000, BIOCHEMISTRY-US, V39, P14682, DOI 10.1021/bi0014251; Tricerri MA, 2002, J LIPID RES, V43, P187; Wang LB, 2003, J BIOL CHEM, V278, P37480, DOI 10.1074/jbc.M303133200; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wieprecht T, 1999, J MOL BIOL, V294, P785, DOI 10.1006/jmbi.1999.3268; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	66	112	116	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20974	20981		10.1074/jbc.M402043200	http://dx.doi.org/10.1074/jbc.M402043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15020600	hybrid			2022-12-25	WOS:000221273800052
J	Beauchemin, H; Blouin, MJ; Trudel, M				Beauchemin, H; Blouin, MJ; Trudel, M			Differential regulatory and compensatory responses in hematopoiesis/erythropoiesis in alpha- and beta-globin hemizygous mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW TRANSPLANTATION; SICKLE-CELL-DISEASE; INEFFECTIVE ERYTHROPOIESIS; THALASSEMIC ERYTHROCYTES; MOUSE MODEL; STEM-CELLS; HEMOGLOBIN; GENE; CHAINS; MUTATIONS	Characterization of hematopoiesis/erythropoiesis in thalassemias from multipotent primitive cells to mature erythrocytes is of fundamental importance and clinical relevance. We investigated this process in alpha- and beta-globin hemizygous mice, lacking the two adult tandemly organized genes from either the alpha- or beta-globin locus. Although both mice backcrossed on a homogeneous background exhibited similar reduced red blood cell (RBC) survival, beta-globin hemizygous mice had less severe reticulocyte loss and globin chain imbalance, suggesting an apparently milder thalassemia than for alpha-globin hemizygous mice. In contrast, however, beta-globin hemizygous mice displayed a more marked perturbation of hematologic parameters. Quantification of erythroid precursor subpopulations in marrow and spleen of beta-globin hemizygous mice showed more severely impaired maturation from the basophilic to orthochromatophilic erythroblasts and substantial loss of these late precursors probably as a consequence of a greater susceptibility to an excess of free alpha-chain than beta-chain. Hence, only erythroid precursors exhibiting stochastically moderate chain imbalance would escape death and mature to reticulocyte/RBC stage, leading to survival and minimal loss of reticulocytes in the beta-globin hemizygous mice. Furthermore, in response to the ineffective erythropoiesis in beta-globin hemizygous mice, a dynamic compensatory hematopoiesis was observed at earlier differentiation stage as evidenced by a significant increase of erythroid progenitors (erythroid colony-forming units similar to100-fold) as well as of multipotent primitive cells (day 12 spleen colony-forming units similar to7-fold). This early compensatory mechanism was less pronounced in alpha-globin hemizygous mice. The expansion of multipotent primitive and potentially stem cell populations, taken together with ineffective erythropoiesis and increased reticulocyte/RBC destruction could confer major cumulative advantage for gene targeting/bone marrow transplantation. Therefore, this study not only corroborated the strong potential effectiveness of transplantation for thalassemic hematopoietic therapy but also demonstrated the existence of a differential regulatory response for alpha- and beta-thalassemia.	Univ Montreal, Fac Med, Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Trudel, M (corresponding author), Univ Montreal, Fac Med, Inst Rech Clin Montreal, 110 Ouest Ave Pins, Montreal, PQ H2W 1R7, Canada.	trudelm@IRCM.qc.ca		Trudel, Marie/0000-0003-0057-2669				Ayala S, 1997, BRIT J HAEMATOL, V98, P47, DOI 10.1046/j.1365-2141.1997.1822999.x; BANK A, 1969, NATURE, V222, P295, DOI 10.1038/222295a0; BARON MH, 1991, MOL CELL BIOL, V11, P1239, DOI 10.1128/MCB.11.3.1239; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; Blouin MJ, 1999, BLOOD, V94, P1451, DOI 10.1182/blood.V94.4.1451.416k02_1451_1459; Blouin MJ, 2000, NAT MED, V6, P177, DOI 10.1038/72279; BOTHWELL TH, 1979, IRON METABOLISM MAN, P190; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P322; CIAVATTA DJ, 1995, P NATL ACAD SCI USA, V92, P9259, DOI 10.1073/pnas.92.20.9259; COLEMAN MB, 1995, J CLIN INVEST, V95, P503, DOI 10.1172/JCI117691; de Krom M, 2002, MOL CELL, V9, P1319, DOI 10.1016/S1097-2765(02)00558-0; Fabry ME, 2001, BLOOD, V97, P410, DOI 10.1182/blood.V97.2.410; FABRY ME, 1995, BLOOD, V86, P2419, DOI 10.1182/blood.V86.6.2419.bloodjournal8662419; FINCH CA, 1970, MEDICINE, V49, P17, DOI 10.1097/00005792-197001000-00002; Gell D, 2002, J BIOL CHEM, V277, P40602, DOI 10.1074/jbc.M206084200; GIARDINI C, 1995, ANNU REV MED, V46, P319; HANASH SM, 1978, P NATL ACAD SCI USA, V75, P3427, DOI 10.1073/pnas.75.7.3427; Harteveld CL, 1996, BRIT J HAEMATOL, V95, P461, DOI 10.1046/j.1365-2141.1996.d01-1926.x; HEYWOOD JD, 1966, J LAB CLIN MED, V67, P246; Imren S, 2002, P NATL ACAD SCI USA, V99, P14380, DOI 10.1073/pnas.212507099; KAPELUSHNIK J, 1995, BLOOD, V86, P3241, DOI 10.1182/blood.V86.8.3241.bloodjournal8683241; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; La Nasa G, 2002, BLOOD, V99, P4350, DOI 10.1182/blood.V99.12.4350; LOUKOPOULOS D, 1991, ANN HEMATOL, V62, P85, DOI 10.1007/BF01702920; MARTINELL J, 1981, P NATL ACAD SCI-BIOL, V78, P5056, DOI 10.1073/pnas.78.8.5056; MASALA B, 1994, METHOD ENZYMOL, V231, P21; Mathias LA, 2000, EXP HEMATOL, V28, P1343, DOI 10.1016/S0301-472X(00)00555-5; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; Pootrakul P, 2000, BLOOD, V96, P2606, DOI 10.1182/blood.V96.7.2606.h8002606_2606_2612; ROUYERFESSARD P, 1990, J BIOL CHEM, V265, P20247; RUSSELL LB, 1976, P NATL ACAD SCI USA, V73, P2843, DOI 10.1073/pnas.73.8.2843; SCHRIER SL, 1989, BLOOD, V74, P2194; SCHRIER SL, 1994, ANNU REV MED, V45, P211; SCOTT MD, 1993, J CLIN INVEST, V91, P1706, DOI 10.1172/JCI116380; SCOTT MD, 1995, BRIT J HAEMATOL, V91, P811, DOI 10.1111/j.1365-2141.1995.tb05394.x; SHAEFFER JR, 1983, J BIOL CHEM, V258, P3172; SHELTON JB, 1984, J LIQ CHROMATOGR, V7, P1969, DOI 10.1080/01483918408068849; SKOW LC, 1983, CELL, V34, P1043, DOI 10.1016/0092-8674(83)90562-7; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; TRUDEL M, 1994, BLOOD, V84, P3189; VANDENBOS C, 1993, EXP HEMATOL, V21, P350; WAGEMAKER G, 1986, EXP HEMATOL, V14, P303; WONG C, 1989, BLOOD, V73, P914	44	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19471	19480		10.1074/jbc.M309989200	http://dx.doi.org/10.1074/jbc.M309989200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004025	hybrid			2022-12-25	WOS:000221164500013
J	London, FS; Marcinkiewicz, M; Walsh, PN				London, FS; Marcinkiewicz, M; Walsh, PN			A Subpopulation of platelets responds to thrombin- or SFLLRN-stimulation with binding sites for factor IXa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-X ACTIVATION; MONOCLONAL-ANTIBODIES; FACTOR-VIII; MICROPARTICLES; SURFACE; COMPLEX	Strong agonists cause platelets to expose a procoagulant surface supporting the assembly of two important coagulation enzyme complexes. Equilibrium binding has determined the density of high affinity saturable factor IXa binding sites to be 500-600 sites/platelet. We have now used flow cytometry to visualize the binding of factor IX and IXa to thrombin- or SFLLRN-activated platelets. Concentrations of these agonists that are half-maximal or maximal in kinetic studies resulted in only a small subpopulation (4-20%) of platelets binding factor IX or IXa with the density of binding sites for factor IX being about half of that for factor IXa, consistent with previous equilibrium binding studies. A small subpopulation (5 +/- 1.5%) of platelets stimulated with either agonist also exposed annexin V binding sites, and this subpopulation of platelets also bound factor IXa. Annexin V decreased factor IXa binding in the presence or absence of factor VIIIa, and factor IXa could also decrease annexin V binding on some platelets indicating a common binding site in agreement with previous studies. All platelets binding factor IXa were positive for glycoprotein IX, at the same glycoprotein IX surface density as seen in platelets negative for factor IXa binding. These studies refine the results from equilibrium binding studies and suggest that, on average, only a small subpopulation (similar to10%) of PAR 1-stimulated platelets expose similar to6000 factor IXa binding sites/platelet.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	London, FS (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Dept Biochem, 3400 N Broad St, Philadelphia, PA 19140 USA.	flon@temple.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070683, P01HL074124, P01HL064943, R01HL046213] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 64943, HL 70683, HL 74124, HL 46213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1990, BLOOD, V75, P128; Ahmad SS, 2000, J BIOL CHEM, V275, P13071, DOI 10.1074/jbc.275.17.13071; AHMAD SS, 1989, J BIOL CHEM, V264, P3244; AHMAD SS, 1989, J CLIN INVEST, V84, P824, DOI 10.1172/JCI114242; BEVERS EM, 1985, ADV EXP MED BIOL, V192, P359; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; Colman RWCA, 2001, HEMOSTASIS THROMBOSI, P3; Falati S, 2002, NAT MED, V8, P1175, DOI 10.1038/nm782; FENG P, 1998, BLOOD S350A, V1, P1441; FRAZIER D, 1989, BLOOD, V74, P971; GILES AR, 1982, BRIT J HAEMATOL, V51, P457, DOI 10.1111/j.1365-2141.1982.tb02803.x; Hartwig J, 2003, J THROMB HAEMOST, V1, P1580, DOI 10.1046/j.1538-7836.2003.00331.x; HOFFMAN M, 1992, THROMB HAEMOSTASIS, V68, P74; Italiano JE, 1999, J CELL BIOL, V147, P1299, DOI 10.1083/jcb.147.6.1299; London F, 1996, BIOCHEMISTRY-US, V35, P16886, DOI 10.1021/bi960712v; London F, 1996, BIOCHEMISTRY-US, V35, P12146, DOI 10.1021/bi960097v; London FS, 2002, BLOOD, V100, p489A; MANN KG, 1984, PROG HEMOST THROMB, V7, P1; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8903, DOI 10.1021/bi9525031; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029; SHATTIL SJ, 1992, AM J CLIN NUTR, V56, P789; SHATTIL SJ, 1987, BLOOD, V70, P307; VANDIEIJEN G, 1985, THROMB HAEMOSTASIS, V53, P396; ZWAAL RFA, 1992, BIOCHIM BIOPHYS ACTA, V1180, P1, DOI 10.1016/0925-4439(92)90019-J	25	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19854	19859		10.1074/jbc.M310624200	http://dx.doi.org/10.1074/jbc.M310624200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15010476	hybrid			2022-12-25	WOS:000221164500058
J	Hummel, S; Osanger, A; Bajari, TM; Balasubramani, M; Halfter, W; Nimpf, J; Schneider, WJ				Hummel, S; Osanger, A; Bajari, TM; Balasubramani, M; Halfter, W; Nimpf, J; Schneider, WJ			Extracellular matrices of the avian ovarian follicle - Molecular characterization of chicken perlecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCAN; RECEPTOR-RELATED PROTEIN; BASEMENT-MEMBRANE PROTEOGLYCAN; CELL-ADHESION MOLECULES; EPIDERMAL-GROWTH-FACTOR; APOLIPOPROTEIN-VLDL-II; LAMININ-A-CHAIN; CAENORHABDITIS-ELEGANS; OOCYTE GROWTH	In egg-laying species, such as the chicken, the mode of transport of lipoprotein particles from the capillary plasma to endocytic receptors on the oocyte surface is largely unknown. Here we show by molecular characterization that the large prominent heparan sulfate proteoglycan of extracellular matrices, termed perlecan or HSPG2 ( the product of the hspg2 gene), is a component of ovarian follicles that may participate in this process. However, although normally a major HSPG of basement membranes or basal laminae, in chicken follicles, perlecan is absent from the membranous structure between the theca interna and granulosa cell layers, which to date has been considered a bona fide basement membrane. Rather, the protein is localized in the extracellular matrix of theca externa cells, which produce this HSPG. Furthermore, in chicken testes, perlecan is localized in the peritubular spaces but in less organized fashion than the classical basement membrane components, agrin and laminin. All five domains and structural hallmarks of chicken perlecan ( 4071 residues) have been conserved in its mammalian counterparts. We have produced the recombinant domain II ( containing low density lipoprotein (LDL) receptor-like binding repeats) of chicken perlecan and demonstrate its capacity to bind LDL and very low density lipoprotein ( VLDL), apolipoprotein B-containing lipoproteins ultimately destined for uptake into oocytes via members of the low density lipoprotein receptor family. Binding to perlecan heparan sulfate side chains may facilitate the interaction of lipoproteins with domain II. Based on the current results and on domain-domain interactions revealed by recent ultrastructural investigations of the LDL receptor, nidogen, and laminin (Rudenko, G., Henry, L., Henderson, K., Ichtchenko, K., Brown, M. S., Goldstein, J. L., and Deisenhofer, J. ( 2002) Science 298, 2353 - 2358 and Takagi, J., Yang, Y., Liu, J. H., Wang, J. H., and Springer, T. A. ( 2003) Nature 424, 969 - 974), we propose a novel role of perlecan in mediating plasma-to-oocyte surface transport of VLDL particles.	Med Univ Vienna, Inst Med Biochem, Univ Dept Vienna Bioctr, Max F Perutz Labs,Dept Mol Genet, A-1030 Vienna, Austria; Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15261 USA	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schneider, WJ (corresponding author), Med Univ Vienna, Inst Med Biochem, Univ Dept Vienna Bioctr, Max F Perutz Labs,Dept Mol Genet, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	wolfgang.schneider@univie.ac.at		Nimpf, Johannes/0000-0002-9273-3492	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033981] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33981] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aire TA, 1997, ONDERSTEPOORT J VET, V64, P291; Andersen OM, 2001, BIOCHEMISTRY-US, V40, P15408, DOI 10.1021/bi0110692; Bajari TM, 1998, BIOL CHEM, V379, P1053, DOI 10.1515/bchm.1998.379.8-9.1053; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 2001, INT REV CYTOL, V209, P79; Bujo H, 1997, J NUTR, V127, pS801, DOI 10.1093/jn/127.5.801S; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHAKRAVARTI S, 1995, J BIOL CHEM, V270, P404, DOI 10.1074/jbc.270.1.404; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; Costell M, 1996, FEBS LETT, V396, P127, DOI 10.1016/0014-5793(96)01082-4; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EVANS AJ, 1979, BIOCHIM BIOPHYS ACTA, V573, P184, DOI 10.1016/0005-2760(79)90185-1; EVANS AJ, 1987, J BIOL CHEM, V262, P501; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GILBERT AB, 1977, J REPROD FERTIL, V50, P179, DOI 10.1530/jrf.0.0500179; Groffen AJA, 1996, EUR J BIOCHEM, V241, P827, DOI 10.1111/j.1432-1033.1996.00827.x; HALFTER W, 1993, J NEUROSCI, V13, P2863; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HERZ J, 1994, ANN NY ACAD SCI, V737, P14, DOI 10.1111/j.1749-6632.1994.tb44298.x; Hey PJ, 1998, GENE, V216, P103, DOI 10.1016/S0378-1119(98)00311-4; Hirayama S, 2003, BIOL REPROD, V68, P1850, DOI 10.1095/biolreprod.102.012427; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; Hopf M, 2001, J MOL BIOL, V311, P529, DOI 10.1006/jmbi.2001.4878; HUMMEL S, 2003, J LIPID RES, V1, P1; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; Ito Y, 2003, ZOOL SCI, V20, P717, DOI 10.2108/zsj.20.717; JI ZS, 1993, J BIOL CHEM, V268, P10160; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; Koch S, 2002, EMBO J, V21, P5996, DOI 10.1093/emboj/cdf599; Kvansakul M, 2001, EMBO J, V20, P5342, DOI 10.1093/emboj/20.19.5342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larrain J, 1997, EXP CELL RES, V234, P405, DOI 10.1006/excr.1997.3648; LEDBETTER SR, 1987, BIOCHEMISTRY-US, V26, P988, DOI 10.1021/bi00378a003; McCarthy RA, 2002, J BIOL CHEM, V277, P25660, DOI 10.1074/jbc.M201933200; MONTELL DJ, 1989, J CELL BIOL, V109, P2441, DOI 10.1083/jcb.109.5.2441; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; MULDER M, 1993, J BIOL CHEM, V268, P9369; Mullen GP, 1999, MOL BIOL CELL, V10, P3205, DOI 10.1091/mbc.10.10.3205; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NIMPF J, 1989, P NATL ACAD SCI USA, V86, P906, DOI 10.1073/pnas.86.3.906; NIMPF J, 1988, J LIPID RES, V29, P657; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; NOONAN DM, 1993, KIDNEY INT, V43, P53, DOI 10.1038/ki.1993.10; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; OREAR JJ, 1992, J BIOL CHEM, V267, P20555; Park Y, 2003, DEV BIOL, V253, P247, DOI 10.1016/S0012-1606(02)00019-2; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; PERRY MM, 1978, J ANAT, V125, P481; PERRY MM, 1979, J CELL SCI, V39, P257; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; Recheis B, 2000, J BIOL CHEM, V275, P35320, DOI 10.1074/jbc.M005025200; Rogalski TM, 2001, BIOCHEM SOC T, V29, P171, DOI 10.1042/BST0290171; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; Romanoff A. L., 1949, AVIAN EGG; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Sambrook J, 2001, MOL CLONING LAB MANU; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHNEIDER WJ, 1990, J LIPID RES, V31, P507; Schneider WJ, 1998, BIOL CHEM, V379, P965; SHEN XY, 1993, CELL TISSUE RES, V272, P459, DOI 10.1007/BF00318552; STIFANI S, 1991, J BIOL CHEM, V266, P19079; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; Takagi J, 2003, NATURE, V424, P969, DOI 10.1038/nature01873; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; Villar MJ, 1999, J CELL BIOCHEM, V75, P665, DOI 10.1002/(SICI)1097-4644(19991215)75:4<665::AID-JCB12>3.0.CO;2-S; Voigt A, 2002, DEV DYNAM, V224, P403, DOI 10.1002/dvdy.10120; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wessel GM, 2000, BIOL REPROD, V63, P1706, DOI 10.1095/biolreprod63.6.1706; WESSEL GM, 1995, DEV BIOL, V167, P388, DOI 10.1006/dbio.1995.1033; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wilsie LC, 2003, J BIOL CHEM, V278, P15758, DOI 10.1074/jbc.M208786200; YOCHEM J, 1993, P NATL ACAD SCI USA, V90, P4572, DOI 10.1073/pnas.90.10.4572	85	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23486	23494		10.1074/jbc.M312694200	http://dx.doi.org/10.1074/jbc.M312694200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15016830	hybrid			2022-12-25	WOS:000221570900086
J	Kim, DJ; Akiyama, TE; Harman, FS; Burns, AM; Shan, WW; Ward, JM; Kennett, MJ; Gonzalez, FJ; Peters, JM				Kim, DJ; Akiyama, TE; Harman, FS; Burns, AM; Shan, WW; Ward, JM; Kennett, MJ; Gonzalez, FJ; Peters, JM			Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; GENE-EXPRESSION; LIPOPROTEIN METABOLISM; TRANSCRIPTION FACTORS; TARGETED DISRUPTION; LIPID-METABOLISM; CANCER CELLS; FATTY-ACIDS; ADULT-RAT; DELTA	The role of peroxisome proliferator-activated receptor-beta( PPARbeta) in the molecular regulation of skin carcinogenesis was examined. Increased caspase-3 activity associated with apoptosis was found in the skin of wildtype mice after tumor promotion with 12-O-tetradecanoylphorbol-13- acetate, and this effect was diminished in PPARbeta-null mice. The onset of tumor formation, tumor size, and tumor multiplicity induced from a two-stage carcinogen bioassay ( 7,12-dimethylbenz[a] anthracene/ 12-O-tetradecanoylphorbol-13- acetate) were significantly enhanced in PPARbeta-null mice compared with wild-type mice. To begin to characterize the molecular changes underlying this PPARbeta-dependent phenotype, microarray analysis was performed and a number of differentially regulated gene products were identified including ubiquitin C. Subsequent promoter analysis, reporter gene assays, site-directed mutagenesis, and electrophoretic mobility shift assays provide evidence that PPARbeta regulates ubiquitin C expression, and that ubiquitination of proteins is influenced by PPARbeta. These results strongly suggest that activation of PPARbeta-dependent target genes provides a novel strategy to inhibit tumor promotion and carcinogenesis.	Penn State Univ, Dept Vet Sci, Fenske Lab 226, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Penn State Univ, Grad Program Biochem Microbiol Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Grad Program Genet, University Pk, PA 16802 USA; Penn State Univ, Grad Program Mol Toxicol, Huck Inst Life Sci, University Pk, PA 16802 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; NCI, Vet & Tumor Pathol Sect, Ctr Canc Res, Frederick, MD 21702 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Peters, JM (corresponding author), Penn State Univ, Dept Vet Sci, Fenske Lab 226, University Pk, PA 16802 USA.	jmp21@psu.edu	Peters, Jeffrey/D-8847-2011	KIM, DAE/0000-0002-7977-9955; Peters, Jeffrey/0000-0003-2782-2998	NATIONAL CANCER INSTITUTE [Z01BC005708, ZIABC005708, R01CA089607] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA89607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Bastie C, 1999, J BIOL CHEM, V274, P21920, DOI 10.1074/jbc.274.31.21920; Bastie C, 2000, J BIOL CHEM, V275, P38768, DOI 10.1074/jbc.M006450200; Basu-Modak S, 1999, J BIOL CHEM, V274, P35881, DOI 10.1074/jbc.274.50.35881; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; Bocher V, 2002, ANN NY ACAD SCI, V967, P7; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Chawla A, 2003, P NATL ACAD SCI USA, V100, P1268, DOI 10.1073/pnas.0337331100; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Clark RB, 2002, J LEUKOCYTE BIOL, V71, P388; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195; FINCH JS, 1992, CELL GROWTH DIFFER, V3, P269; Granneman J, 1998, J NEUROSCI RES, V51, P563, DOI 10.1002/(SICI)1097-4547(19980301)51:5<563::AID-JNR3>3.0.CO;2-D; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Hansen JB, 2001, J BIOL CHEM, V276, P3175, DOI 10.1074/jbc.M005567200; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hihi AK, 2002, CELL MOL LIFE SCI, V59, P790, DOI 10.1007/s00018-002-8467-x; Jaeckel EC, 2001, ARCH OTOLARYNGOL, V127, P1253, DOI 10.1001/archotol.127.10.1253; Jehl-Pietri C, 2000, BIOCHEM J, V350, P93, DOI 10.1042/0264-6021:3500093; Kemp CJ, 1999, CARCINOGENESIS, V20, P2051, DOI 10.1093/carcin/20.11.2051; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leibowitz MD, 2000, FEBS LETT, V473, P333, DOI 10.1016/S0014-5793(00)01554-4; Lu YP, 2002, P NATL ACAD SCI USA, V99, P12455, DOI 10.1073/pnas.182429899; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Marinovic AC, 2002, J BIOL CHEM, V277, P16673, DOI 10.1074/jbc.M200501200; Marinovic AC, 2000, BIOCHEM BIOPH RES CO, V274, P537, DOI 10.1006/bbrc.2000.3171; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Michalik L, 2000, HORM RES, V54, P263, DOI 10.1159/000053269; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; Mitch WE, 1999, AM J PHYSIOL-CELL PH, V276, pC1132, DOI 10.1152/ajpcell.1999.276.5.C1132; Mitev V, 1999, EXP DERMATOL, V8, P96, DOI 10.1111/j.1600-0625.1999.tb00355.x; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Perelygin AA, 2002, J MOL EVOL, V55, P202, DOI 10.1007/s00239-002-2318-0; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Qin CH, 2003, CANCER RES, V63, P958; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Saluja I, 2001, GLIA, V33, P191, DOI 10.1002/1098-1136(200103)33:3<191::AID-GLIA1018>3.0.CO;2-M; Shearer BG, 2003, CURR MED CHEM, V10, P267, DOI 10.2174/0929867033368295; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Tiao G, 1996, J CLIN INVEST, V97, P339, DOI 10.1172/JCI118421; Tong BJ, 2000, NEOPLASIA, V2, P483, DOI 10.1038/sj.neo.7900119	58	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23719	23727		10.1074/jbc.M312063200	http://dx.doi.org/10.1074/jbc.M312063200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15033975	hybrid			2022-12-25	WOS:000221570900114
J	Lunin, VV; Munger, C; Wagner, J; Ye, Z; Cygler, M; Sacher, M				Lunin, VV; Munger, C; Wagner, J; Ye, Z; Cygler, M; Sacher, M			The structure of the MAPK scaffold, MP1, bound to its partner, p14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; BETA-ARRESTIN; RAS/RAF/MEK/ERK PATHWAY; RECEPTOR; MEK; ENDOCYTOSIS; ENDOSOMES; COMPLEX	Scaffold proteins of the mitogen-activated protein kinase (MAPK) pathway have been proposed to form an active signaling module and enhance the specificity of the transduced signal. Here, we report a 2-Angstrom resolution structure of the MAPK scaffold protein MP1 in a complex with its partner protein, p14, that localizes the complex to late endosomes. The structures of these two proteins are remarkably similar, with a five-stranded beta-sheet flanked on either side by a total of three helices. The proteins form a heterodimer in solution and interact mainly through the edge beta-strand in each protein to generate a 10-stranded beta-sheet core. Both proteins also share structural similarity with the amino-terminal regulatory domains of the membrane trafficking proteins, sec22b and Ykt6p, as well as with sedlin (a component of a Golgi-associated membrane-trafficking complex) and the sigma2 and amino-terminal portion of the mu2 subunits of the clathrin adaptor complex AP2. Because neither MP1 nor p14 have been implicated in membrane traffic, we propose that the similar protein folds allow these relatively small proteins to be involved in multiple and simultaneous protein-protein interactions. Mapping of highly conserved, surface-exposed residues on MP1 and p14 provided insight into the potential sites of binding of the signaling kinases MEK1 and ERK1 to this complex, as well as the areas potentially involved in other protein-protein interactions.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Montreal Proteom Network, Montreal, PQ H3A 1A4, Canada	National Research Council Canada	Sacher, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	michael.sacher@bri.nrc.ca						Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Bell B, 1999, J BIOL CHEM, V274, P7982, DOI 10.1074/jbc.274.12.7982; Bowman AB, 1999, J CELL BIOL, V146, P165; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Jang SB, 2002, J BIOL CHEM, V277, P49863, DOI 10.1074/jbc.M207436200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kolch Walter, 2002, Expert Opin Pharmacother, V3, P709, DOI 10.1517/14656566.3.6.709; Koonin EV, 2000, CURR BIOL, V10, pR774, DOI 10.1016/S0960-9822(00)00774-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Neuwald AF, 1999, GENOME RES, V9, P27; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pearl FMG, 2000, NUCLEIC ACIDS RES, V28, P277, DOI 10.1093/nar/28.1.277; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Sacher M, 2000, EUR J CELL BIOL, V79, P71, DOI 10.1078/S0171-9335(04)70009-6; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schwartz T, 2003, CELL, V112, P793, DOI 10.1016/S0092-8674(03)00161-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Teis D, 2003, CELL MOL LIFE SCI, V60, P2020, DOI 10.1007/s00018-003-3010-2; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P45, DOI 10.1107/S0907444902018048; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Wunderlich W, 2001, J CELL BIOL, V152, P765, DOI 10.1083/jcb.152.4.765; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X	54	58	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23422	23430		10.1074/jbc.M401648200	http://dx.doi.org/10.1074/jbc.M401648200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15016825	hybrid			2022-12-25	WOS:000221570900078
J	Alvarez-Maqueda, M; El Bekay, R; Alba, G; Monteseirin, J; Chacon, P; Vega, A; Martin-Nieto, J; Bedoya, FJ; Pintado, E; Sobrino, F				Alvarez-Maqueda, M; El Bekay, R; Alba, G; Monteseirin, J; Chacon, P; Vega, A; Martin-Nieto, J; Bedoya, FJ; Pintado, E; Sobrino, F			15-deoxy-Delta(12,14)-prostaglandin J(2) induces heme oxygenase-1 gene expression in a reactive oxygen species-dependent manner in human lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; NF-KAPPA-B; PPAR-GAMMA; HYDROGEN-PEROXIDE; PROTEIN-KINASE; T-LYMPHOCYTES; CYCLOPENTENONE PROSTAGLANDINS; NUCLEAR TRANSLOCATION; ENDOTHELIAL-CELLS; HUMAN NEUTROPHILS	15-Deoxy-Delta(12,14)-prostaglandin J(2) (15dPGJ(2)) has been proposed recently as a potent anti-inflammatory agent. However, the mechanisms by which 15dPGJ(2) mediates its therapeutic effects in vivo are unclear. We demonstrate that 15dPGJ(2) at micromolar (2.5-10 muM) concentrations induces the expression of heme oxygenase-1 (HO-1), an anti-inflammatory enzyme, at both mRNA and protein levels in human lymphocytes. In contrast, troglitazone and ciglitazone, two thiazolidinediones that mimic several effects of 15dPGJ(2) through their binding to the peroxisome proliferator-activated receptor (PPAR)-gamma, did not affect HO-1 expression, and the positive effect of 15dPGJ(2) on this process was mimicked instead by other cyclopentenone prostaglandins ( PG), such as PGD(2) (the precursor of 15dPGJ(2)) and PGA(1) and PGA(2) which do not interact with PPAR-gamma. Also, 15dPGJ(2) enhanced the intracellular production of reactive oxygen species (ROS) and increased xanthine oxidase activity in vitro. Inhibition of intracellular ROS production by N-acetylcysteine, TEMPO, Me2SO, 1,10-phenanthroline, or allopurinol resulted in a decreased 15dPGJ(2)-dependent HO-1 expression in the cells. Furthermore, buthionine sulfoximine, an inhibitor of reduced glutathione synthesis, or Fe2+/Cu2+ ions enhanced the positive effect of 15dPGJ(2) on HO-1 expression. On the other hand, the inhibition of phosphatidylinositol 3-kinase or p38 mitogen-activated protein kinase, or the blockade of transcription factor NF-kappaB activation, hindered 15dPGJ(2)-elicited HO-1 expression. Collectively, the present data suggest that 15dPGJ(2) anti-inflammatory actions at pharmacological concentrations involve the induction of HO-1 gene expression through mechanisms independent of PPAR-gamma activation and dependent on ROS produced via the xanthine/xanthine oxidase system and/or through Fenton reactions. Both phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase signaling pathways also appear implicated in modulation of HO-1 expression by 15dPGJ(2).	Univ Seville, Hosp Univ Virgen Macarena, Dept Bioquim Med & Biol Mol, E-41009 Seville, Spain; Univ Seville, Hosp Univ Virgen Macarena, Serv Inmunol & Alergia, E-41009 Seville, Spain; Univ Alicante, Dept Fisiol Genet & Microbiol, E-03080 Alicante, Spain	Hospital Universitario Virgen Macarena; University of Sevilla; Hospital Universitario Virgen Macarena; University of Sevilla; Universitat d'Alacant	Sobrino, F (corresponding author), Univ Seville, Dept Bioquim Med & Biol Mol, Avda Sanchez Pizjuan 4, E-41009 Seville, Spain.	fsobrino@us.es	Bedoya, Francisco J/R-4871-2018; El Bekay, RAJAA/AGN-6069-2022; Bekay, Rajaa El/AAZ-3959-2020; MARTÍN-NIETO, JOSÉ/R-5428-2018; Alba Jiménez, Gonzalo/K-9283-2014; Bedoya, Francisco/AAX-8812-2021	Bedoya, Francisco J/0000-0003-0262-7029; El Bekay, RAJAA/0000-0003-3332-3431; MARTÍN-NIETO, JOSÉ/0000-0002-7815-6887; Alba Jiménez, Gonzalo/0000-0002-6598-2039; Bedoya, Francisco/0000-0003-0262-7029; Vega Rioja, Antonio/0000-0003-4698-9697; Sobrino, Francisco/0000-0002-4503-5739; Pintado, Elizabeth/0000-0002-5237-5045				Alam J, 2000, J BIOL CHEM, V275, P27694; APPLEGATE LA, 1991, CANCER RES, V51, P974; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carballo M, 1999, J BIOL CHEM, V274, P17580, DOI 10.1074/jbc.274.25.17580; Carballo M, 1999, J BIOL CHEM, V274, P93, DOI 10.1074/jbc.274.1.93; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; Couturier C, 1999, J BIOL CHEM, V274, P23085, DOI 10.1074/jbc.274.33.23085; Cuzzocrea S, 2002, MOL PHARMACOL, V61, P997, DOI 10.1124/mol.61.5.997; Devadas S, 2002, J EXP MED, V195, P59, DOI 10.1084/jem.20010659; Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508; El Bekay R, 2003, BLOOD, V102, P662, DOI 10.1182/blood-2002-09-2785; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Ginn-Pease ME, 1998, FREE RADICAL BIO MED, V25, P346, DOI 10.1016/S0891-5849(98)00067-7; Gong PF, 2003, J BIOL CHEM, V278, P29693, DOI 10.1074/jbc.M304728200; Gong PF, 2002, ANTIOXID REDOX SIGN, V4, P249, DOI 10.1089/152308602753666307; GRUM CM, 1990, J LAB CLIN MED, V116, P211; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; Harris SG, 2002, J IMMUNOL, V168, P1372, DOI 10.4049/jimmunol.168.3.1372; Harris SG, 2001, EUR J IMMUNOL, V31, P1098, DOI 10.1002/1521-4141(200104)31:4<1098::AID-IMMU1098>3.0.CO;2-I; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; ITO S, 1989, PROSTAG LEUKOTR ESS, V37, P219, DOI 10.1016/0952-3278(89)90033-1; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOIZUMI T, 1995, J BIOL CHEM, V270, P21779, DOI 10.1074/jbc.270.37.21779; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; Koppal T, 2000, BRAIN RES, V867, P115, DOI 10.1016/S0006-8993(00)02270-8; Kurata SI, 1996, EUR J BIOCHEM, V239, P566, DOI 10.1111/j.1432-1033.1996.0566u.x; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; Lee TS, 2003, J BIOL CHEM, V278, P19325, DOI 10.1074/jbc.M300498200; Lennon AM, 2002, J BIOL CHEM, V277, P29681, DOI 10.1074/jbc.M201517200; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MAINES MD, 1986, J BIOL CHEM, V261, P411; MALY FE, 1989, J IMMUNOL, V142, P1260; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Menzel DB, 1998, BIOCHEM BIOPH RES CO, V250, P653, DOI 10.1006/bbrc.1998.9363; Monteseirin J, 1996, J EXP MED, V183, P2571, DOI 10.1084/jem.183.6.2571; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Morse D, 2003, J BIOL CHEM, V278, P36993, DOI 10.1074/jbc.M302942200; Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613; Muijsers RBR, 2000, BRIT J PHARMACOL, V130, P932, DOI 10.1038/sj.bjp.0703401; Naughton P, 2002, J BIOL CHEM, V277, P40666, DOI 10.1074/jbc.M203863200; Okamoto K, 2003, J BIOL CHEM, V278, P1848, DOI 10.1074/jbc.M208307200; Orie NN, 1999, LIFE SCI, V65, P2135, DOI 10.1016/S0024-3205(99)00478-6; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SANTORO MG, 1994, EXPERIENTIA, V50, P1039, DOI 10.1007/BF01923459; Sau AK, 2001, BBA-PROTEIN STRUCT M, V1544, P89, DOI 10.1016/S0167-4838(00)00207-7; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Vaidya S, 1999, J IMMUNOL, V163, P6187; van Reyk DM, 2001, FREE RADICAL BIO MED, V30, P82, DOI 10.1016/S0891-5849(00)00449-4; Wang Q, 2000, J IMMUNOL, V164, P6487, DOI 10.4049/jimmunol.164.12.6487; Wang YL, 2002, J BIOL CHEM, V277, P31781, DOI 10.1074/jbc.M204279200; Ward C, 2002, J IMMUNOL, V168, P6232, DOI 10.4049/jimmunol.168.12.6232; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; Wiesel P, 2000, J BIOL CHEM, V275, P24840, DOI 10.1074/jbc.M000835200; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	68	90	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21929	21937		10.1074/jbc.M400492200	http://dx.doi.org/10.1074/jbc.M400492200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15024026	hybrid, Green Published			2022-12-25	WOS:000221417100033
J	Le Lay, J; Matsuoka, T; Henderson, E; Stein, R				Le Lay, J; Matsuoka, T; Henderson, E; Stein, R			Identification of a novel PDX-1 binding site in the human insulin gene enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX TRANSCRIPTION FACTOR; PANCREATIC BETA-CELLS; I GENE; DIFFERENTIAL REGULATION; HOMEODOMAIN PROTEIN; DIABETES-MELLITUS; TRANSGENIC MICE; CONTROL ELEMENT; HOMEOBOX FACTOR; ISLET CELLS	Islet beta cell type-specific transcription of the insulin gene is regulated by a number of cis-acting elements found within the proximal 5'-flanking region. The control sequences conserved between mammalian insulin genes are acted upon by transcription factors, like PDX-1 and BETA-2, that are also involved in islet beta cell function and formation. In the current study, we investigated the contribution to human insulin expression of the GG2 motif found between nucleotides -145 and -140 relative to the transcription start site. Site-specific mutants were generated within GG2 that displayed a parallel increase (i.e. -144 base pair) or decrease (i.e. -141 base pair) in insulin enhancer-driven reporter and gel shift binding activity in beta cells consistent with human GG2 being under positive regulatory control. In contrast, the corresponding site in the rodent insulin gene, which only differs from the human at nucleotides -144 and -141, is negatively regulated by the Nkx2.2 transcription factor (Cissell, M. A., Zhao, L., Sussel, L., Henderson, E., and Stein, R. (2003) J. Biol. Chem. 278, 751 756). Human GG2 activator binding activity was present in nuclear extracts prepared from human islets and enriched in those from rodent beta cell lines. The human GG2 activator binding factor(s) was shown to be similar to38-40 kDa and distinct from other size-matched islet-enriched transcription factors, including Nkx2.2, Pax-4, Cdx2/3, and Isl-1. Combined DNA chromatographic purification and mass spectrometry analysis revealed that the GG2 activator was PDX-1. These results demonstrate that the GG2 element, despite its divergence from the core homeodomain consensus binding motif, is a site for PDX-1 activation in the human insulin gene.	Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37215 USA	Vanderbilt University	Stein, R (corresponding author), Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, 723 Light Hall, Nashville, TN 37215 USA.	roland.stein@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050203, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60 DK20593, R01 DK50203] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOAM DSW, 1990, J BIOL CHEM, V265, P8285; BrethertonWatt D, 1996, BIOCHEM J, V313, P495, DOI 10.1042/bj3130495; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Cissell MA, 2003, J BIOL CHEM, V278, P751, DOI 10.1074/jbc.M205905200; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V19, P4925, DOI 10.1093/nar/19.18.4925; Dumonteil E, 1998, J BIOL CHEM, V273, P19945, DOI 10.1074/jbc.273.32.19945; Edlund H, 2002, NAT REV GENET, V3, P524, DOI 10.1038/nrg841; FROMONTRACINE M, 1990, MOL ENDOCRINOL, V4, P669, DOI 10.1210/mend-4-5-669; Gadgil H, 2002, J CHROMATOGR A, V966, P99, DOI 10.1016/S0021-9673(02)00738-0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Liberzon A, 2004, NUCLEIC ACIDS RES, V32, P54, DOI 10.1093/nar/gkh156; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; Matsuoka T, 2004, P NATL ACAD SCI USA, V101, P2930, DOI 10.1073/pnas.0306233101; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Moates JM, 2003, DIABETES, V52, P403, DOI 10.2337/diabetes.52.2.403; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Samaras SE, 2002, MOL CELL BIOL, V22, P4702, DOI 10.1128/MCB.22.13.4702-4713.2002; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwitzgebel VM, 2001, MOL CELL ENDOCRINOL, V185, P99, DOI 10.1016/S0303-7207(01)00628-1; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1468, DOI 10.1210/me.9.11.1468; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; Stead JDH, 2003, GENOME RES, V13, P2101, DOI 10.1101/gr.948003; STEIN R, 2001, HDB PHYSL 7, V2, P25; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Tomonari A, 1999, BBA-GENE STRUCT EXPR, V1446, P233, DOI 10.1016/S0167-4781(99)00096-2; Tomonari A, 1996, DIABETOLOGIA, V39, P1462, DOI 10.1007/s001250050599; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; Watada H, 1996, BIOCHEM BIOPH RES CO, V229, P746, DOI 10.1006/bbrc.1996.1875; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; Yasuda T, 2002, DIABETES, V51, P224, DOI 10.2337/diabetes.51.1.224; Zhao L, 2000, J BIOL CHEM, V275, P10532, DOI 10.1074/jbc.275.14.10532	55	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22228	22235		10.1074/jbc.M312673200	http://dx.doi.org/10.1074/jbc.M312673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15028719	hybrid			2022-12-25	WOS:000221417100069
J	Mehta, R; Pearson, JT; Mahajan, S; Nath, A; Hickey, MJ; Sherman, DR; Atkins, WM				Mehta, R; Pearson, JT; Mahajan, S; Nath, A; Hickey, MJ; Sherman, DR; Atkins, WM			Adenylylation and catalytic properties of Mycobacterium tuberculosis glutamine synthetase expressed in Escherichia coli versus mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; MACROPHAGES; GROWTH; ENZYME; STATE; GENE; CULTURES	Bacterial glutamine synthetases (GSs) are complex dodecameric oligomers that play a critical role in nitrogen metabolism, converting ammonia and glutamate to glutamine. Recently published reports suggest that GS from Mycobacterium tuberculosis (MTb) may be a therapeutic target (Harth, G., and Horwitz, M. A. ( 2003) Infect. Immun. 71, 456-464). In some bacteria, GS is regulated via adenylylation of some or all of the subunits within the aggregate; catalytic activity is inversely proportional to the extent of adenylylation. The adenylylation and deadenylylation of GS are catalyzed by adenylyl transferase (ATase). Here, we demonstrate via electrospray ionization mass spectrometry that GS from pathogenic M. tuberculosis is adenylylated by the Escherichia coli ATase. The adenylyl group can be hydrolyzed by snake venom phosphodiesterase to afford the unmodified enzyme. The site of adenylylation of MTb GS by the E. coli ATase is Tyr-406, as indicated by the lack of adenylylation of the Y406F mutant, and, as expected, is based on amino acid sequence alignments. Using electrospray ionization mass spectroscopy methodology, we found that GS is not adenylylated when obtained directly from MTb cultures that are not supplemented with glutamine. Under these conditions, the highly related but non-pathogenic Mycobacterium bovis BCG yields partially (similar to25%) adenylylated enzyme. Upon the addition of glutamine to the cultures, the MTb GS becomes significantly adenylylated (similar to30%), whereas the adenylylation of M. bovis BCG GS does not change. Collectively, the results demonstrate that MTb GS is a substrate for E. coli ATase, but only low adenylylation states are accessible. This parallels the low adenylylation states observed for GS from mycobacteria and suggests the intriguing possibility that adenylylation in the pathogenic versus non-pathogenic mycobacteria is differentially regulated.	Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Atkins, WM (corresponding author), Univ Washington, Dept Med Chem, Seattle, WA 98195 USA.	winky@u.washington.edu		Nath, Abhinav/0000-0002-2895-2973	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI049780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007750, P01GM032165] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49780] Funding Source: Medline; NIGMS NIH HHS [T32 GM07750, GM32165] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELL LM, 1991, BIOCHEMISTRY-US, V30, P1413, DOI 10.1021/bi00219a035; ANDERSEN P, 1991, INFECT IMMUN, V59, P1905, DOI 10.1128/IAI.59.6.1905-1910.1991; ATKINS WM, 1999, ENCY MOL BIOL, P61; Bendt AK, 2003, PROTEOMICS, V3, P1637, DOI 10.1002/pmic.200300494; CADER BM, 1991, TECHNIQUES PROTEIN C, V2, P313; Collins DM, 2002, MICROBIOL-SGM, V148, P3019, DOI 10.1099/00221287-148-10-3019; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Cosma CL, 2003, ANNU REV MICROBIOL, V57, P641, DOI 10.1146/annurev.micro.57.030502.091033; Crick DC, 2001, GLYCOBIOLOGY, V11, p107R, DOI 10.1093/glycob/11.9.107R; Eisenberg D, 2000, BBA-PROTEIN STRUCT M, V1477, P122, DOI 10.1016/S0167-4838(99)00270-8; Fink D, 1999, MICROBIOL-UK, V145, P2313, DOI 10.1099/00221287-145-9-2313; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Gill HS, 2002, BIOCHEMISTRY-US, V41, P9863, DOI 10.1021/bi020254s; GINSBURG A, 1970, BIOCHEMISTRY-US, V9, P633, DOI 10.1021/bi00805a025; GORDON AH, 1980, NATURE, V286, P79, DOI 10.1038/286079a0; Harth G, 2000, P NATL ACAD SCI USA, V97, P418, DOI 10.1073/pnas.97.1.418; Harth G, 2003, INFECT IMMUN, V71, P456, DOI 10.1128/IAI.71.1.456-464.2003; Hingley-Wilson SM, 2003, NAT IMMUNOL, V4, P949, DOI 10.1038/ni981; HIRSCHFIELD GR, 1990, J BACTERIOL, V172, P1005, DOI 10.1128/jb.172.2.1005-1013.1990; Meister A., 1980, GLUTAMINE METABOLISM, P1; Miller BH, 2000, INFECT IMMUN, V68, P387, DOI 10.1128/IAI.68.1.387-390.2000; MUNOZCENTENO MC, 1994, BIOCHEM J, V298, P641, DOI 10.1042/bj2980641; MURA U, 1981, J BIOL CHEM, V256, P3022; Mutalik VK, 2003, J BIOL CHEM, V278, P26327, DOI 10.1074/jbc.M300129200; Parish T, 2000, J BACTERIOL, V182, P5715, DOI 10.1128/JB.182.20.5715-5720.2000; Parish T, 2001, TUBERCULOSIS, V81, P359, DOI 10.1054/tube.2001.0312; Raynaud C, 1998, MICROBIOL-SGM, V144, P577, DOI 10.1099/00221287-144-2-577; Reynaldo LP, 1996, PROTEIN SCI, V5, P2532, DOI 10.1002/pro.5560051216; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; SHAPIRO BM, 1968, J BIOL CHEM, V243, P3769; SHAPIRO BM, 1967, P NATL ACAD SCI USA, V58, P642, DOI 10.1073/pnas.58.2.642; Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498; SORENSEN AL, 1995, INFECT IMMUN, V63, P1710; STADTMAN ER, 1979, ANAL BIOCHEM, V95, P275, DOI 10.1016/0003-2697(79)90217-3; Tullius MV, 2003, INFECT IMMUN, V71, P3927, DOI 10.1128/IAI.71.7.3927-3936.2003; Tullius MV, 2001, INFECT IMMUN, V69, P6348, DOI 10.1128/IAI.69.10.6348-6363.2001; YAMASHITA MM, 1989, J BIOL CHEM, V264, P17681; YANCHUNAS J, 1994, BIOCHEMISTRY-US, V33, P14949, DOI 10.1021/bi00254a001	38	16	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22477	22482		10.1074/jbc.M401652200	http://dx.doi.org/10.1074/jbc.M401652200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15037612	hybrid			2022-12-25	WOS:000221417100097
J	Seo, JB; Moon, HM; Noh, MJ; Lee, YS; Jeong, HW; Yoo, EJ; Kim, WS; Park, J; Youn, BS; Kim, JW; Park, SD; Kim, JB				Seo, JB; Moon, HM; Noh, MJ; Lee, YS; Jeong, HW; Yoo, EJ; Kim, WS; Park, J; Youn, BS; Kim, JW; Park, SD; Kim, JB			Adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element-binding protein 1c regulates mouse adiponectin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; INDUCED INSULIN-RESISTANCE; ADIPOSE-SPECIFIC PROTEIN; LEUCINE ZIPPER PROTEIN; LEPTIN GENE-EXPRESSION; ACID SYNTHASE GENE; PLASMA-PROTEIN; TNF-ALPHA; NUTRITIONAL REGULATION; SREBP-1C EXPRESSION	Adiponectin is exclusively expressed in differentiated adipocytes and plays an important role in regulating energy homeostasis, including the glucose and lipid metabolism associated with increased insulin sensitivity. However, the control of adiponectin gene expression in adipocytes is poorly understood. We show here that levels of adiponectin mRNA and protein are reduced in the white adipose tissue of ob/ob and db/db mice and that there is a concomitant reduction of the adipocyte determination- and differentiation-dependent factor 1 (ADD1)/sterol regulatory element-binding protein 1c (SREBP1c) transcription factor. To determine whether ADD1/SREBP1c regulates adiponectin gene expression, we isolated and characterized the mouse adiponectin promoter. Analysis of the adiponectin promoter revealed putative binding sites for the adipogenic transcription factors ADD1/SREBP1c, peroxisomal proliferator-activated receptor gamma and CCAAT enhancer-binding proteins. DNase I footprinting and chromatin immunoprecipitation analyses revealed that ADD1/SREBP1c binds in vitro and in vivo to the proximal promoter containing sterol regulatory element (SRE) motifs. A luciferase reporter containing the promoter was transactivated by ADD1/SREBP1c, and introduction of SRE mutations into the construct abolished transactivation. Adenoviral overexpression of ADD1/SREBP1c also elevated adiponectin mRNA and protein levels in 3T3-L1 adipocytes. Furthermore, insulin stimulated adiponectin mRNA expression in adipocytes and augmented transactivation of the adiponectin promoter by ADD1/SREBP1c. Taken together, these data indicate that ADD1/SREBP1c controls adiponectin gene expression in differentiated adipocytes.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Korea Univ, KOMED Inst Life Sci, Seoul 136701, South Korea; Yonsei Univ, Coll Med, Inst Genet Sci, Dept Biochem & Mol Biol, Seoul 120752, South Korea; Int Vaccine Inst, Seoul 151818, South Korea	Seoul National University (SNU); Korea University; Yonsei University; Yonsei University Health System; International Vaccine Institute	Kim, JB (corresponding author), San 56-1,Sillim Dong, Seoul, South Korea.	jaebkim@snu.ac.kr	Lee, Yun Sok/B-3265-2015; Song, Minsun/I-5701-2015; Lee, Yun Sok/ABC-9195-2021	Lee, Yun Sok/0000-0001-7967-4734; Lee, Yun Sok/0000-0001-7967-4734; Kim, Jae-woo/0000-0001-5456-9495; KIM, Jae Bum/0000-0003-2337-6935				Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; BARINAGA M, 1995, SCIENCE, V269, P475, DOI 10.1126/science.7624769; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Fasshauer M, 2001, FEBS LETT, V507, P142, DOI 10.1016/S0014-5793(01)02960-X; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Gasic S, 1999, J BIOL CHEM, V274, P6770, DOI 10.1074/jbc.274.10.6770; Gustafson B, 2003, BIOCHEM BIOPH RES CO, V308, P933, DOI 10.1016/S0006-291X(03)01518-3; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halleux CM, 2001, BIOCHEM BIOPH RES CO, V288, P1102, DOI 10.1006/bbrc.2001.5904; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Kappes A, 2000, HORM METAB RES, V32, P548, DOI 10.1055/s-2007-978684; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kolehmainen M, 2001, OBES RES, V9, P706, DOI 10.1038/oby.2001.95; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Latasa MJ, 2003, MOL CELL BIOL, V23, P5896, DOI 10.1128/MCB.23.16.5896-5907.2003; Lindsay RS, 2003, DIABETES, V52, P2419, DOI 10.2337/diabetes.52.9.2419; Lindsay RS, 2002, LANCET, V360, P57, DOI 10.1016/S0140-6736(02)09335-2; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Mingrone G, 2003, ATHEROSCLEROSIS, V170, P155, DOI 10.1016/S0021-9150(03)00254-5; Mishima Y, 2001, DIABETES RES CLIN PR, V52, P119, DOI 10.1016/S0168-8227(00)00247-3; Moore GBT, 2001, BIOCHEM BIOPH RES CO, V286, P735, DOI 10.1006/bbrc.2001.5460; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; Nadler ST, 2001, J NUTR, V131, P2078, DOI 10.1093/jn/131.8.2078; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Ruan H, 2002, DIABETES, V51, P1319, DOI 10.2337/diabetes.51.5.1319; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; Saito K, 1999, GENE, V229, P67, DOI 10.1016/S0378-1119(99)00041-4; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Saltiel AR, 2001, NAT MED, V7, P887, DOI 10.1038/90911; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Seo JB, 2003, MOL ENDOCRINOL, V17, P1522, DOI 10.1210/me.2003-0028; Sewter C, 2002, DIABETES, V51, P1035, DOI 10.2337/diabetes.51.4.1035; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Statnick M A, 2000, Int J Exp Diabetes Res, V1, P81, DOI 10.1155/EDR.2000.81; Stefan N, 2002, J CLIN ENDOCR METAB, V87, P4652, DOI 10.1210/jc.2002-020694; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wu XD, 2003, DIABETES, V52, P1355, DOI 10.2337/diabetes.52.6.1355; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Zhang Y, 2002, BBA-MOL CELL BIOL L, V1584, P115, DOI 10.1016/S1388-1981(02)00298-6	68	112	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22108	22117		10.1074/jbc.M400238200	http://dx.doi.org/10.1074/jbc.M400238200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15037635	hybrid			2022-12-25	WOS:000221417100053
J	Darmoul, D; Gratio, V; Devaud, H; Laburthe, M				Darmoul, D; Gratio, V; Devaud, H; Laburthe, M			Protease-activated receptor 2 in colon cancer - Trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC TYROSINE KINASE; EGF RECEPTOR; COUPLED RECEPTORS; COLORECTAL-CANCER; DIFFERENTIAL EXPRESSION; AMPHIREGULIN ACTS; EPITHELIAL-CELLS; CARCINOMA CELLS; GASTRIC-CANCER; LINES	Several lines of evidence suggest that tumor-derived trypsin contributes to the growth and invasion of cancer cells. We have recently shown that trypsin is a potent growth factor for colon cancer cells through activation of the G protein-coupled receptor protease-activated receptor 2 (PAR2). Here, we analyzed the signaling pathways downstream of PAR2 activation that lead to colon cancer cell proliferation in HT-29 cells. Our data are consistent with the following cascade of events upon activation of PAR2 by the serine protease trypsin or the specific PAR2-activating peptide (AP2): (i) a matrix metalloproteinase-dependent release of transforming growth factor (TGF)-alpha, as demonstrated with TGF-alpha-blocking antibodies and measurement of TGF-alpha in culture medium; (ii) TGF-alpha-mediated activation of epidermal growth factor receptor (EGF-R) and subsequent EGF-R phosphorylation; and (iii) activation of ERK1/2 and subsequent cell proliferation. The links between these events are demonstrated by the fact that stimulation of cell proliferation and ERK1/2 upon activation of PAR2 is reversed by the metalloproteinase inhibitor batimastat, TGF-alpha-neutralizing antibodies, EGF-R ligand binding domain-blocking antibodies, and the EGF-R tyrosine kinase inhibitors AG1478 and PD168393. Therefore, transactivation of EGF-R appears to be a major mechanism whereby activation of PAR2 results in colon cancer cell growth. By using the Src tyrosine kinase inhibitor PP2, we further showed that Src plays a permissive role for PAR2-mediated ERK1/2 activation and cell proliferation, probably acting downstream of the EGF-R. These data explain how trypsin exerts robust trophic action on colon cancer cells and underline the critical role of EGF-R transactivation.	Univ Paris 07, INSERM, U410, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Darmoul, D (corresponding author), Univ Paris 07, INSERM, U410, F-75018 Paris, France.	darmoul@bichat.inserm.fr	LABURTHE, Marc/C-1875-2012; Darmoul, Dalila/M-5812-2018	Darmoul, Dalila/0000-0002-1206-0655				BARNARD JA, 1995, GASTROENTEROLOGY, V108, P564, DOI 10.1016/0016-5085(95)90087-X; Bernard-Perrone F, 1998, AM J PHYSIOL-GASTR L, V274, pG1077, DOI 10.1152/ajpgi.1998.274.6.G1077; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Cheng KR, 2003, CANCER RES, V63, P6744; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; D'Andrea MR, 2001, AM J PATHOL, V158, P2031, DOI 10.1016/S0002-9440(10)64675-5; Damstrup L, 1999, BRIT J CANCER, V80, P1012, DOI 10.1038/sj.bjc.6690456; Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6; Darmoul D, 2001, BRIT J CANCER, V85, P772, DOI 10.1054/bjoc.2001.1976; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; HIRAHARA F, 1995, INT J CANCER, V63, P176, DOI 10.1002/ijc.2910630205; Hiwasa T, 2002, INT J ONCOL, V20, P797; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; Ichikawa Y, 2000, CLIN CANCER RES, V6, P1385; Jin EJ, 2003, CANCER-AM CANCER SOC, V97, P703, DOI 10.1002/cncr.11087; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kawano N, 1997, HUM PATHOL, V28, P613, DOI 10.1016/S0046-8177(97)90085-X; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Kennedy AR, 2002, NUTR CANCER, V43, P174, DOI 10.1207/S15327914NC432_8; KENNEDY AR, 1994, CANCER RES, V54, pS1999; Kim J, 2002, J BIOL CHEM, V277, P32116, DOI 10.1074/jbc.M204895200; KOIVUNEN E, 1990, CANCER RES, V50, P2375; KOIVUNEN E, 1991, INT J CANCER, V47, P592, DOI 10.1002/ijc.2910470419; KOSHIKAWA N, 1994, BIOCHEM J, V303, P187, DOI 10.1042/bj3030187; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; Lukkonen A, 2000, INT J CANCER, V86, P577, DOI 10.1002/(SICI)1097-0215(20000515)86:4<577::AID-IJC21>3.3.CO;2-A; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mignatti P, 2000, ADV CANCER RES, V78, P103; MISZCZUKJAMSKA B, 1991, FEBS LETT, V294, P175, DOI 10.1016/0014-5793(91)80662-M; Miyata S, 1998, CLIN EXP METASTAS, V16, P613, DOI 10.1023/A:1006576313979; Miyata S, 1999, J BIOCHEM, V125, P1067, DOI 10.1093/oxfordjournals.jbchem.a022388; Miyata S, 2000, J BIOL CHEM, V275, P4592, DOI 10.1074/jbc.275.7.4592; O'Dwyer PJ, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.35643; Ohta T, 2003, INT J ONCOL, V23, P61; Okamoto T, 2001, J NEURAL TRANSM, V108, P125, DOI 10.1007/s007020170083; Oyama K, 2000, INT J MOL MED, V6, P543; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Sabri A, 2003, J BIOL CHEM, V278, P11714, DOI 10.1074/jbc.M213091200; SAEKI T, 1992, CANCER RES, V52, P3467; Schramek H, 2002, NEWS PHYSIOL SCI, V17, P62, DOI 10.1152/nips.01365.2001; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Williams SJ, 2001, INT J CANCER, V93, P67, DOI 10.1002/ijc.1304; Yamamoto H, 2003, J PATHOL, V199, P176, DOI 10.1002/path.1277	66	172	179	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20927	20934		10.1074/jbc.M401430200	http://dx.doi.org/10.1074/jbc.M401430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15010475	hybrid			2022-12-25	WOS:000221273800046
J	Zhao, J; Zhang, LH; Jia, LT; Zhang, L; Xu, YM; Wang, Z; Yu, CJ; Peng, WD; Wen, WH; Wang, CJ; Chen, SY; Yang, AG				Zhao, J; Zhang, LH; Jia, LT; Zhang, L; Xu, YM; Wang, Z; Yu, CJ; Peng, WD; Wen, WH; Wang, CJ; Chen, SY; Yang, AG			Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN ANTIBODY; BREAST-CANCER-CELLS; GRANZYME-B; PSEUDOMONAS EXOTOXIN; ANTITUMOR-ACTIVITY; INDUCED APOPTOSIS; TARGET-CELLS; KILLER-CELLS; GROWTH; TRANSLOCATION	Targeted cell killing is required for effective treatment of cancers. We previously described the generation of a chimeric immunocasp-3 protein and its potent selective antitumor activity (Jia, L.T., Zhang, L.H., Yu, C.J., Zhao, J., Xu, Y.M., Gui, J.H., Jin, M., Ji, Z.L., Wen, W.H., Wang, C.J., Chen, S.Y., and Yang, A.G. (2003) Cancer Res. 63, 3257-3262). Here we extend the repertoire of another chimeric pro-apoptotic protein immunoGrB, which comprises an anti-HER2 single-chain antibody, a Pseudomonas exotoxin A translocation domain and active granzyme B. Human lymphoma Jurkat cells transfected with the immunoGrB gene expression vector were able to produce and secrete the chimeric protein. The immunoGrB molecule selectively recognized and destroyed HER2-overexpressing tumor cells both in vitro and in nude mouse after intramuscular injection of the immunoGrB expression plasmid. Further in vivo study showed that intravenous administration of immunoGrB gene-modified lymphocytes led to suppression of HER2-overexpressing tumor growth and prolonged animal survival because of continuous secretion of immunoGrB molecules into blood and lymph fluid. These results demonstrate that the chimeric immunoGrB molecule, which is capable of antibody-directed targeting and granzyme B-mediated killing, has therapeutic potential against HER2 tumors, especially in cases in which caspase-dependent apoptosis is inhibited.	Fourth Mil Med Univ, Dept Biochem & Mol Biol, Xian 710032, Peoples R China; Fourth Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA	Air Force Military Medical University; Air Force Military Medical University; Baylor College of Medicine	Yang, AG (corresponding author), Fourth Mil Med Univ, Dept Biochem & Mol Biol, Xian 710032, Peoples R China.	agyang@fmmu.edu.cn	温, 家琦/GYV-3177-2022					Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; BATRA JK, 1992, P NATL ACAD SCI USA, V89, P5867, DOI 10.1073/pnas.89.13.5867; Browne KA, 2000, J BIOL CHEM, V275, P39262, DOI 10.1074/jbc.C000622200; Chen SY, 1997, NATURE, V385, P78, DOI 10.1038/385078a0; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Dela Cruz JS, 2000, J IMMUNOL, V165, P5112, DOI 10.4049/jimmunol.165.9.5112; Edwards KM, 1999, IMMUNOL CELL BIOL, V77, P76, DOI 10.1046/j.1440-1711.1999.00799.x; Elliott MJ, 1999, CANCER CHEMOTH PHARM, V44, P1, DOI 10.1007/s002800050938; Fokkema E, 2003, VIRCHOWS ARCH, V442, P349, DOI 10.1007/s00428-003-0763-9; Foy TM, 2002, SEMIN ONCOL, V29, P53, DOI 10.1053/sonc.2002.34056; Frankel AE, 2000, CLIN CANCER RES, V6, P326; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HEAD JF, 2002, EXPER OPIN THER TAR, V6, P375; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Iwasaka T, 1996, ACTA OBSTET GYN SCAN, V75, P797, DOI 10.3109/00016349609054706; Jia LT, 2003, CANCER RES, V63, P3257; Kam CM, 2000, BBA-PROTEIN STRUCT M, V1477, P307, DOI 10.1016/S0167-4838(99)00282-4; Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3; Keefe DL, 2002, CANCER-AM CANCER SOC, V95, P1592, DOI 10.1002/cncr.10854; Kolenko VM, 2000, APOPTOSIS, V5, P17, DOI 10.1023/A:1009677307458; Kreitman R J, 2001, Curr Opin Investig Drugs, V2, P1282; Leyland-Jones B, 2002, LANCET ONCOL, V3, P137, DOI 10.1016/S1470-2045(02)00676-9; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Neve RM, 2001, BIOCHEM BIOPH RES CO, V280, P274, DOI 10.1006/bbrc.2000.4104; OGATA M, 1992, J BIOL CHEM, V267, P25396; OSBORNE CK, 1985, CANCER RES, V45, P584; Pelegrin M, 1998, HUM GENE THER, V9, P2165, DOI 10.1089/hum.1998.9.15-2165; Pinkoski MJ, 2000, CELL DEATH DIFFER, V7, P17, DOI 10.1038/sj.cdd.4400604; Pinkoski MJ, 1998, BLOOD, V92, P1044; Plunkett TA, 2002, INT J CLIN PRACT, V56, P261; PRESS MF, 1994, CANCER RES, V54, P5675; PRESS MF, 1990, ONCOGENE, V5, P953; PRIOR TI, 1992, BIOCHEMISTRY-US, V31, P3555, DOI 10.1021/bi00129a001; Ranson M, 2002, ONCOLOGY-BASEL, V63, P17, DOI 10.1159/000066203; Rosenblum MG, 1999, CLIN CANCER RES, V5, P865; Rosenblum MG, 2000, INT J CANCER, V88, P267, DOI 10.1002/1097-0215(20001015)88:2<267::AID-IJC19>3.0.CO;2-G; Tan-Chiu E, 2002, ONCOLOGY-BASEL, V63, P57, DOI 10.1159/000066201; Taupiac MP, 1999, MOL MICROBIOL, V31, P1385, DOI 10.1046/j.1365-2958.1999.01280.x; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Trapani JA, 2001, GENOME BIOL, V2; Wright M, 1997, GENE THER, V4, P317, DOI 10.1038/sj.gt.3300372; Yang AG, 1997, NAT BIOTECHNOL, V15, P46, DOI 10.1038/nbt0197-46	45	44	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21343	21348		10.1074/jbc.M312648200	http://dx.doi.org/10.1074/jbc.M312648200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15004021	hybrid			2022-12-25	WOS:000221273800097
J	Potrykus, K; Wegrzyn, G; Hernandez, VJ				Potrykus, K; Wegrzyn, G; Hernandez, VJ			Direct stimulation of the lambda paQ promoter by the transcription effector guanosine-3 ',5 '-(bis)pyrophosphate in a defined in vitro system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; HISTIDINE OPERON; PPGPP; INITIATION; CII; MECHANISM; KINETICS; SUBUNIT	The bacterial response to nutritional deprivation, called the stringent response, results in the introduction of the specific nucleotide guanosine-3',5'-(bis) pyrophosphate (ppGpp). This nucleotide interacts with RNA polymerase and alters its action so that transcription from certain promoters is inhibited, whereas transcription from others seems to be activated. The exact mechanism of transcriptional stimulation by ppGpp in vivo remains unknown. A passive control model has been proposed according to which transcription inhibition during the stringent response at several very active promoters, like those for rRNA and tRNA genes, makes more free RNA polymerase (RNAP) molecules available for transcription at promoters with weak binding affinities for RNAP, thus leading to their passive activation. Among promoters whose transcription is activated by ppGpp in vivo is the histidine operon promoter (hisGp). However, in vitro it is only possible to demonstrate this effect in a coupled transcription-translation system. Here we demonstrate, using another in vivo ppGpp-stimulated promoter, the phage lambdapaQ promoter, that activation by ppGpp in a defined in vitro system is direct. A systematic study of ppGpp effects on the stimulation of paQ revealed that, as in the case of promoters inhibited by this nucleotide, ppGpp decreases the half-life of paQ open complexes. Our results also indicate that the equilibrium binding affinity of RNA polymerase to paQ seems not to be affected in the presence of ppGpp. Our data indicate that the mechanism underlying ppGpp stimulation of paQ is due to an increased rate of productive open complex formation.	SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA; Univ Gdansk, Dept Mol Biol, PL-80822 Gdansk, Poland	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Fahrenheit Universities; University of Gdansk	Hernandez, VJ (corresponding author), SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA.	vjh@buffalo.edu	Wegrzyn, Grzegorz/AAL-1179-2020; Wegrzyn, Grzegorz/ABD-6699-2020	Wegrzyn, Grzegorz/0000-0003-4042-7466; Potrykus, Katarzyna/0000-0002-4902-3348	FOGARTY INTERNATIONAL CENTER [R03TW001244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057189] Funding Source: NIH RePORTER; FIC NIH HHS [TW 01244] Funding Source: Medline; NIGMS NIH HHS [GM 57189] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker MM, 2001, J MOL BIOL, V305, P689, DOI 10.1006/jmbi.2000.4328; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; CASHEL M, 1974, ANAL BIOCHEM, V57, P100, DOI 10.1016/0003-2697(74)90056-6; CASHEL M, 1970, J BIOL CHEM, V245, P2309; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Chatterji D, 1998, GENES CELLS, V3, P279, DOI 10.1046/j.1365-2443.1998.00190.x; Choy HE, 1997, BBA-GENE STRUCT EXPR, V1353, P61, DOI 10.1016/S0167-4781(97)00042-0; Choy HE, 2000, J BIOL CHEM, V275, P6783, DOI 10.1074/jbc.275.10.6783; GILADI H, 1992, J MOL BIOL, V227, P985, DOI 10.1016/0022-2836(92)90514-K; HO YS, 1985, J BIOL CHEM, V260, P1838; HOOPES BC, 1985, P NATL ACAD SCI USA, V82, P3134, DOI 10.1073/pnas.82.10.3134; KAINZ M, 1995, J MOL BIOL, V254, P808, DOI 10.1006/jmbi.1995.0657; Lutz R, 2001, NUCLEIC ACIDS RES, V29, P3873, DOI 10.1093/nar/29.18.3873; Potrykus K, 2002, J BIOL CHEM, V277, P43785, DOI 10.1074/jbc.M208768200; RIGGS DL, 1986, P NATL ACAD SCI USA, V83, P9333, DOI 10.1073/pnas.83.24.9333; Slominska M, 1999, VIROLOGY, V262, P431, DOI 10.1006/viro.1999.9907; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; TOULOKHONOV II, 2001, J BIOL CHEM, V266, P5991; VOGEL U, 1994, J BIOL CHEM, V269, P16236; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908	21	15	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19860	19866		10.1074/jbc.M313378200	http://dx.doi.org/10.1074/jbc.M313378200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15014078	hybrid			2022-12-25	WOS:000221164500059
J	Fodor, AA; Aldrich, RW				Fodor, AA; Aldrich, RW			On evolutionary conservation of thermodynamic coupling in proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; STAPHYLOCOCCAL NUCLEASE; CORRELATED MUTATIONS; ENERGETICS; RESIDUES; DETERMINANTS; PREDICTION; STABILITY; CONTACTS; PORE	The inherent complexity of thermodynamic coupling in proteins presents a major challenge in understanding and engineering protein function. Recent work has argued that the study of proteins can be simplified by the use of correlated mutations in the evolutionary record to locate a small subset of thermodynamically coupled residues that participate in functionally important, evolutionarily conserved energetic pathways. To test this hypothesis, we examined the predictions of correlated mutation algorithms for a number of proteins for which coupling between residues has been determined by analysis of double mutant cycles. We find that correlated mutation algorithms can find residue pairs that are physically close and that physically close residue pairs tend to be thermodynamically coupled. We find little evidence, however, for the hypothesis that thermodynamic coupling is limited to the subset of evolutionarily constrained residue positions.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Beckman Ctr, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University	Aldrich, RW (corresponding author), Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Beckman Ctr, 279 Campus Dr, Stanford, CA 94305 USA.	raldrich@stanford.edu						ALTSCHUH D, 1987, J MOL BIOL, V193, P693, DOI 10.1016/0022-2836(87)90352-4; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Chen JM, 2001, BIOCHEMISTRY-US, V40, P14004, DOI 10.1021/bi011268l; DEKKER J, 2004, IN PRESS BIOINFORMAT; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FODOR A, 2004, IN PRESS PROTEINS; GOBEL U, 1994, PROTEINS, V18, P309, DOI 10.1002/prot.340180402; GREEN SM, 1992, BIOCHEMISTRY-US, V31, P5717, DOI 10.1021/bi00140a005; GREEN SM, 1993, BIOCHEMISTRY-US, V32, P10131, DOI 10.1021/bi00089a032; Hatley ME, 2003, P NATL ACAD SCI USA, V100, P14445, DOI 10.1073/pnas.1835919100; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HOROVITZ A, 1994, J MOL BIOL, V238, P133, DOI 10.1006/jmbi.1994.1275; HOROVITZ A, 1996, FOLDING DESIGN, V1, P121, DOI DOI 10.1016/S1359-0278(96)00056-9; Larson SM, 2000, J MOL BIOL, V303, P433, DOI 10.1006/jmbi.2000.4146; Larson SM, 2002, J MOL BIOL, V316, P225, DOI 10.1006/jmbi.2001.5344; Lee SY, 2004, BIOPHYS J, V86, P1105, DOI 10.1016/S0006-3495(04)74185-5; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Mirny L, 2001, J MOL BIOL, V308, P123, DOI 10.1006/jmbi.2001.4602; Mooney SD, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-24; Olmea O, 1997, FOLD DES, V2, pS25, DOI 10.1016/S1359-0278(97)00060-6; Olmea O, 1999, J MOL BIOL, V293, P1221, DOI 10.1006/jmbi.1999.3208; Plaxco KW, 2000, J MOL BIOL, V298, P303, DOI 10.1006/jmbi.1999.3663; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Schueler-Furman O, 2003, PROTEINS, V52, P225, DOI 10.1002/prot.10365; Shakhnovich E, 1996, NATURE, V379, P96, DOI 10.1038/379096a0; SHINDYALOV IN, 1994, PROTEIN ENG, V7, P349, DOI 10.1093/protein/7.3.349; Shulman AI, 2004, CELL, V116, P417, DOI 10.1016/S0092-8674(04)00119-9; Skinner MM, 1996, P NATL ACAD SCI USA, V93, P10753, DOI 10.1073/pnas.93.20.10753; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; TAYLOR WR, 1994, PROTEIN ENG, V7, P341, DOI 10.1093/protein/7.3.341; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9	35	66	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19046	19050		10.1074/jbc.M402560200	http://dx.doi.org/10.1074/jbc.M402560200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	15023994	hybrid			2022-12-25	WOS:000221041500117
J	Grotendorst, GR; Rahmanie, H; Duncan, MR				Grotendorst, GR; Rahmanie, H; Duncan, MR			Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation	FASEB JOURNAL			English	Article						myofibroblasts; TGF-beta; CTGF; fibrotic tissue	TRANSFORMING-GROWTH-FACTOR; ANCHORAGE-INDEPENDENT GROWTH; SMOOTH MUSCLE ACTIN; BETA TGF-BETA; FIBRONECTIN MESSENGER-RNAS; HUMAN DERMAL FIBROBLASTS; HUMAN SKIN FIBROBLASTS; GENE-EXPRESSION; ALPHA-5-BETA-1 INTEGRIN; COLLAGEN-SYNTHESIS	Fibroblast proliferation, differentiation into myofibroblasts, and increased collagen synthesis are key events during both normal wound repair and fibrotic lesion formation. Here we report that these biological responses to TGF-beta by fibroblasts are regulated via a CTGF-dependent pathway in concert with either EGF or IGF-2. Our studies indicate these responses to TGF-beta are mutually exclusive, and cells that are proliferating do not express alpha-SMA or elevated levels of collagen synthesis. Cells expressing alpha-SMA do not exhibit DNA synthesis but do coexpress higher levels of types I and III collagen mRNA. Thus, fibroblast proliferation and differentiation are controlled by combinatorial signaling pathways involving not only components of the TGF-beta/CTGF pathway, but also signaling events induced by EGF and IGF-2-activated receptors. Collectively, our studies indicate TGF-beta functions as a classic embryonic inducer, initiating a cascade that is controlled by other factors in the cellular environment. We propose a model for this process with regard to wound repair and fibrotic lesion formation that is likely applicable to other instances of CTGF action during embryogenesis.	Univ Miami, Sch Med, Dept Cell Biol & Anat, RMSB 2030 A, Miami, FL 33136 USA	University of Miami	Grotendorst, GR (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, RMSB 2030 A, 1600 NW 10th Ave, Miami, FL 33136 USA.	ggrotend@miami.edu			NIGMS NIH HHS [GM 65603, GM 37223] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065603, R01GM037223] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; ASSOIAN RK, 1984, CELL, V36, P35, DOI 10.1016/0092-8674(84)90071-0; Badid C, 2000, HISTOL HISTOPATHOL, V15, P269, DOI 10.14670/HH-15.269; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; Border WA, 1998, KIDNEY INT, V54, P1390, DOI 10.1046/j.1523-1755.1998.00127.x; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BRANDES ME, 1991, J CLIN INVEST, V87, P1108, DOI 10.1172/JCI115073; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Clark DA, 1998, INT J BIOCHEM CELL B, V30, P293, DOI 10.1016/S1357-2725(97)00128-3; Crean John KG, 2001, Expert Opin Ther Targets, V5, P519; Dalton SL, 1999, J BIOL CHEM, V274, P30139, DOI 10.1074/jbc.274.42.30139; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DESMOULIERE A, 1995, EXP NEPHROL, V3, P134; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; DUNCAN MR, 1989, J INVEST DERMATOL, V92, P699, DOI 10.1111/1523-1747.ep12696891; Folger PA, 2001, INVEST OPHTH VIS SCI, V42, P2534; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Gabbiani G, 1998, CARDIOVASC RES, V38, P545, DOI 10.1016/S0008-6363(98)00065-0; GABBIANI G, 1992, KIDNEY INT, V41, P530, DOI 10.1038/ki.1992.75; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Gupta S, 2000, KIDNEY INT, V58, P1389, DOI 10.1046/j.1523-1755.2000.00301.x; HALES AM, 1994, CURR EYE RES, V13, P885, DOI 10.3109/02713689409015091; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Jester JV, 1996, CORNEA, V15, P505; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Martinerie C, 2001, J CLIN ENDOCR METAB, V86, P3929, DOI 10.1210/jc.86.8.3929; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MOSES HL, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P250; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Ng JK, 1999, CURR TOP DEV BIOL, V41, P37; O'Dell SD, 1998, INT J BIOCHEM CELL B, V30, P767, DOI 10.1016/S1357-2725(98)00048-X; OKAZAKI R, 1995, BIOCHEM BIOPH RES CO, V207, P963, DOI 10.1006/bbrc.1995.1279; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Robertson G, 2001, UASGCP REP, V2001, P43; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; Schurch W, 1998, AM J SURG PATHOL, V22, P141, DOI 10.1097/00000478-199802000-00001; Shinozaki M, 1997, BIOCHEM BIOPH RES CO, V237, P292, DOI 10.1006/bbrc.1997.7134; SOMA Y, 1989, J CELL PHYSIOL, V140, P246, DOI 10.1002/jcp.1041400209; STJOHNSTON D, 1992, CELL, V68, P201; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; Takigawa M, 2003, J CELL PHYSIOL, V194, P256, DOI 10.1002/jcp.10206; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; Voci A, 1999, EUR J ENDOCRINOL, V140, P577, DOI 10.1530/eje.0.1400577; Wahab NA, 2002, J AM SOC NEPHROL, V13, P2437, DOI 10.1097/01.ASN.0000031828.58276.02; Wahl SM, 2000, CYTOKINE GROWTH F R, V11, P71, DOI 10.1016/S1359-6101(99)00030-1; WEBSTER DF, 1979, ANAL BIOCHEM, V96, P220, DOI 10.1016/0003-2697(79)90576-1; Weston BS, 2003, J AM SOC NEPHROL, V14, P601, DOI 10.1097/01.ASN.0000051600.53134.B9; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Yamamoto Y, 2002, SPINE, V27, P1852, DOI 10.1097/00007632-200209010-00009	73	225	238	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					469	479		10.1096/fj.03-0699com	http://dx.doi.org/10.1096/fj.03-0699com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003992				2022-12-25	WOS:000220522800039
J	Sodhi, A; Montaner, S; Gutkind, JS				Sodhi, A; Montaner, S; Gutkind, JS			Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis?	FASEB JOURNAL			English	Article						Kaposi's sarcoma-associated herpesvirus; human herpesvirus-8; G-protein-coupled receptor; HIV	PROTEIN-COUPLED RECEPTOR; NF-KAPPA-B; CONSTITUTIVE ACTIVITY; ENDOTHELIAL-CELLS; HERPESVIRUS; ACTIVATION; INFECTION; KINASE; INTERLEUKIN-8; ANGIOGENESIS	In 1994, the Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) was identified as the etiologic agent of Kaposi's sarcoma (KS). KSHV has since been associated with two additional AIDS-related malignancies: primary effusion lymphomas (PEL) and multicentric Castleman's disease (MCD). Although molecular characterization of the KSHV genome has revealed several candidate oncogenes, infection with KSHV alone is not sufficient to cause KS, suggestive of an accomplice in KS initiation. Recent experimental evidence supports a key role for a particular KSHV gene, a constitutively-active G-protein-coupled receptor (vGPCR), in the development of KS. However, it is unclear how a lytic gene expressed in cells destined to die can cause cancer. Here we propose that dysregulation of the viral gene program may lead to nonlytic vGPCR expression. Several candidate cofactors (e.g., HIV-1 Tat, inflammation, aborted lytic cycle progression) are identified that may trigger vGPCR dysregulation, enabling oncogenic signaling pathways up-regulated by vGPCR, combined with the paracrine secretions from vGPCR-expressing cells, to promote the initiation of KS. If KS is indeed dependent on vGPCR dysregulation, then the development of new therapeutic modalities specifically targeting this viral protein or its downstream targets may ultimately prove to be the most effective treatment strategy for this enigmatic disease.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Sodhi, A (corresponding author), NIDR, Cell Growth Regulat Sect, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Room 211, Bethesda, MD 20892 USA.	asodhi@nidcr.nih.gov; sg39v@nih.gov	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Hengge UR, 2002, LANCET INFECT DIS, V2, P281, DOI 10.1016/S1473-3099(02)00263-3; Ho HH, 2001, J BIOL CHEM, V276, P1376, DOI 10.1074/jbc.M007885200; Holst PJ, 2001, J CLIN INVEST, V108, P1789, DOI 10.1172/JCI13622; Lane BR, 2002, J VIROL, V76, P11570, DOI 10.1128/JVI.76.22.11570-11583.2002; Lee BJ, 2003, J IMMUNOL, V170, P243, DOI 10.4049/jimmunol.170.1.243; Manji KP, 2000, TROP MED INT HEALTH, V5, P85, DOI 10.1046/j.1365-3156.2000.00523.x; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; Masood R, 2002, AM J PATHOL, V160, P23, DOI 10.1016/S0002-9440(10)64344-1; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2001, CANCER RES, V61, P2641; Morris K, 2003, LANCET ONCOL, V4, P5, DOI 10.1016/S1470-2045(03)00969-0; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Nador RG, 2001, VIROLOGY, V287, P62, DOI 10.1006/viro.2001.1016; Polson AG, 2002, CANCER RES, V62, P4525; Pozniak A, 2001, ANN NY ACAD SCI, V953, P192, DOI 10.1111/j.1749-6632.2001.tb11377.x; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Sodhi A, 2000, CANCER RES, V60, P4873; Talbot SJ, 1999, VIROLOGY, V257, P84, DOI 10.1006/viro.1999.9672; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Webster-Cyriaque J, 2002, NEW ENGL J MED, V346, P1207, DOI 10.1056/NEJMoa012125; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yen-Moore A, 2000, VIROLOGY, V267, P247, DOI 10.1006/viro.1999.0125	33	53	56	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					422	427		10.1096/fj.03-1035hyp	http://dx.doi.org/10.1096/fj.03-1035hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003988				2022-12-25	WOS:000220522800035
J	Viswanathan, P; Ohn, T; Chiang, YC; Chen, JJ; Denis, CL				Viswanathan, P; Ohn, T; Chiang, YC; Chen, JJ; Denis, CL			Mouse CAF1 can function as a processive deadenylase/3 '-5 '-exonuclease in vitro but in yeast the deadenylase function of CAF1 is not required for mRNA poly(A) removal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; POP2 GENE; COMPLEX; CCR4; IDENTIFICATION; PROTEIN; EXONUCLEASE; DEGRADATION; COMPONENT; PATHWAY	The mouse CAF1 (mCAF1) is an ortholog of the yeast (y) CAF1 protein, which is a component of the CCR4-NOT complex, the major cytoplasmic deadenylase of Saccharomyces cerevisiae. Although CAF1 protein belongs to the DEDDh family of RNases, CCR4 appears to be the principle deadenylase of the CCR4-NOT complex. Here, we present evidence that mCAF1 is a processive, 3'-5'-RNase with a preference for poly(A) substrates. Like CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD family members, PAN2 and PARN, mCAF1 was not activated either by PAB1 or capped RNA substrates. The rate of deadenylation in vitro by yCCR4 and mCAF1 were both strongly influenced by secondary structures present in sequences adjacent to the poly(A) tail, suggesting that the ability of both enzymes to deadenylate might be affected by the context of the mRNA 3'-untranslated region sequences. The ability of mCAF1 to complement a ycaf1 deletion in yeast, however, did not require the RNase function of mCAF1. Importantly, yCAF1 mutations, which have been shown to block its RNase activity in vitro, did not inactivate yCAF1 in vivo, and mRNAs were deadenylated in vivo at nearly the same rate as found for wild type yCAF1. These results indicate that at least in yeast the CAF1 RNase activity is not required for its in vivo function.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Denis, CL (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, Rudman Hall, Durham, NH 03824 USA.	cldenis@cisunix.unh.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041215] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Cao D, 2003, CELL, V113, P533, DOI 10.1016/S0092-8674(03)00353-2; Cao D, 2001, RNA, V7, P1192, DOI 10.1017/S1355838201010330; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Clark LB, 2004, J BIOL CHEM, V279, P13616, DOI 10.1074/jbc.M313202200; Copeland PR, 2001, RNA, V7, P875, DOI 10.1017/S1355838201010020; Cui YJ, 2003, MOL CELL BIOL, V23, P7887, DOI 10.1128/MCB.23.21.7887-7901.2003; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dlakic M, 2000, TRENDS BIOCHEM SCI, V25, P272, DOI 10.1016/S0968-0004(00)01582-6; Doktycz MJ, 1998, P NATL ACAD SCI USA, V95, P14614, DOI 10.1073/pnas.95.25.14614; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Hata H, 1998, GENETICS, V148, P571; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; Martinez J, 2001, J BIOL CHEM, V276, P27923, DOI 10.1074/jbc.M102270200; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Mitchell P, 2003, MOL CELL, V11, P1405, DOI 10.1016/S1097-2765(03)00190-4; MIYAJIMA A, 1984, NUCLEIC ACIDS RES, V12, P6397, DOI 10.1093/nar/12.16.6397; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Shimizu-Yoshida Y, 1999, YEAST, V15, P1357, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1357::AID-YEA465>3.0.CO;2-Y; Thore S, 2003, EMBO REP, V4, P1150, DOI 10.1038/sj.embor.7400020; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Uchida N, 2004, J BIOL CHEM, V279, P1383, DOI 10.1074/jbc.M309125200; Viswanathan P, 2003, J BIOL CHEM, V278, P14949, DOI 10.1074/jbc.M211794200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	30	94	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23988	23995		10.1074/jbc.M402803200	http://dx.doi.org/10.1074/jbc.M402803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044470	hybrid			2022-12-25	WOS:000221702500020
J	Zaccheo, O; Dinsdale, D; Meacock, PA; Glynn, P				Zaccheo, O; Dinsdale, D; Meacock, PA; Glynn, P			Neuropathy target esterase and its yeast homologue degrade phosphatidylcholine to glycerophosphocholine in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDP-CHOLINE PATHWAY; SACCHAROMYCES-CEREVISIAE; MEMBRANE-LIPIDS; MAMMALIAN-CELLS; GLOBAL ANALYSIS; GROWTH; GENE; BIOSYNTHESIS; INHIBITION; EXPRESSION	Eukaryotic cells control the levels of their major membrane lipid, phosphatidylcholine (PtdCho), by balancing synthesis with degradation via deacylation to glycerophosphocholine (GroPCho). Here we present evidence that in both yeast and mammalian cells this deacylation is catalyzed by neuropathy target esterase (NTE), a protein originally identified by its reaction with organo-phosphates, which cause nerve axon degeneration. YML059c, a Saccharomyces cerevisiae protein with sequence homology to NTE, had similar catalytic properties to the mammalian enzyme in assays of microsome preparations and, like NTE, was localized to the endoplasmic reticulum. Yeast lacking YML059c were viable under all conditions examined but, unlike the wild-type strain, did not convert PtdCho to GroPCho. Despite the absence of the deacylation pathway, the net rate of [C-14]choline incorporation into PtdCho in YML059c-null yeast was not greater than that in the wild type; this was because, in the null strain diminished net uptake of extracellular choline and decreased formation of the rate-limiting intermediate, CDP-choline, resulted in a reduced rate of PtdCho synthesis. In [C-14]choline labeling experiments with cultured mammalian cell lines, production of [C-14]GroPCho was enhanced by overexpression of catalytically active NTE and was diminished by reduction of endogenous NTE activity mediated either by RNA interference or organophosphate treatment. We conclude that NTE and its homologues play a central role in membrane lipid homeostasis.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Genet, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester	Glynn, P (corresponding author), Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England.	pg8@le.ac.uk						ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Atkins J, 2000, J BIOL CHEM, V275, P24477, DOI 10.1074/jbc.M002921200; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Bauer C, 2001, MICROSC MICROANAL, V7, P530, DOI 10.1007/s10005-001-0020-4; BISCHOFF A, 1970, ACTA NEUROPATHOL, V15, P142, DOI 10.1007/BF00685267; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; Chambers J. E., 2001, HDB PESTICIDE TOXICO, P919; Chiu CH, 2001, BIOCHEM BIOPH RES CO, V287, P600, DOI 10.1006/bbrc.2001.5632; DINSDALE D, 1992, HISTOCHEM J, V24, P144, DOI 10.1007/BF01047464; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Glynn P, 1999, BIOCHEM J, V344, P625, DOI 10.1042/0264-6021:3440625; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; Howe AG, 2002, J BIOL CHEM, V277, P44100, DOI 10.1074/jbc.M206643200; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JOHNSON MK, 1969, BIOCHEM J, V114, P711, DOI 10.1042/bj1140711; JOHNSON MK, 1977, ARCH TOXICOL, V37, P113, DOI 10.1007/BF00293860; JOHNSON MK, 1974, J NEUROCHEM, V23, P785, DOI 10.1111/j.1471-4159.1974.tb04404.x; Kretzschmar D, 1997, J NEUROSCI, V17, P7425; Li Y, 2003, J BIOL CHEM, V278, P8820, DOI 10.1074/jbc.M210743200; Lin QS, 2000, BIOCHEMISTRY-US, V39, P9335, DOI 10.1021/bi000017u; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; Moser M, 2004, MOL CELL BIOL, V24, P1667, DOI 10.1128/MCB.24.4.1667-1679.2004; Moser M, 2000, MECH DEVELOP, V90, P279, DOI 10.1016/S0925-4773(99)00239-7; REYNOLDS LJ, 1991, METHOD ENZYMOL, V197, P3; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; van Tienhoven M, 2002, J BIOL CHEM, V277, P20942, DOI 10.1074/jbc.M200330200; Vance JE, 2000, BBA-MOL CELL BIOL L, V1486, P84, DOI 10.1016/S1388-1981(00)00050-0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Williams JG, 1998, J BIOL CHEM, V273, P13482, DOI 10.1074/jbc.273.22.13482; Winrow CJ, 2003, NAT GENET, V33, P477, DOI 10.1038/ng1131; Xie ZH, 2001, MOL BIOL CELL, V12, P1117, DOI 10.1091/mbc.12.4.1117	42	164	178	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24024	24033		10.1074/jbc.M400830200	http://dx.doi.org/10.1074/jbc.M400830200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044461	hybrid			2022-12-25	WOS:000221702500024
J	Girvan, HM; Marshall, KR; Lawson, RJ; Leys, D; Joyce, MG; Clarkson, J; Smith, WE; Cheesman, MR; Munro, AW				Girvan, HM; Marshall, KR; Lawson, RJ; Leys, D; Joyce, MG; Clarkson, J; Smith, WE; Cheesman, MR; Munro, AW			Flavocytochrome P450BM3 mutant A264E undergoes substrate-dependent formation of a novel heme iron ligand set	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; PARAMAGNETIC-RESONANCE SPECTROSCOPY; NITRIC-OXIDE SYNTHASE; BACILLUS-MEGATERIUM; P-450 BM3; THIOLATE LIGATION; BINDING PROPERTIES; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER	A conserved glutamate covalently attaches the heme to the protein backbone of eukaryotic CYP4 P450 enzymes. In the related Bacillus megaterium P450 BM3, the corresponding residue is Ala(264). The A264E mutant was generated and characterized by kinetic and spectroscopic methods. A264E has an altered absorption spectrum compared with the wild-type enzyme (Soret maximum at similar to420.5 nm). Fatty acid substrates produced an inhibitor-like spectral change, with the Soret band shifting to 426 nm. Optical titrations with long-chain fatty acids indicated higher affinity for A264E over the wild-type enzyme. The heme iron midpoint reduction potential in substrate-free A264E is more positive than that in wild-type P450 BM3 and was not changed upon substrate binding. EPR, resonance Raman, and magnetic CD spectroscopies indicated that A264E remains in the low-spin state upon substrate binding, unlike wild-type P450 BM3. EPR spectroscopy showed two major species in substrate-free A264E. The first has normal Cys-aqua iron ligation. The second resembles formate-ligated P450cam. Saturation with fatty acid increased the population of the latter species, suggesting that substrate forces on the glutamate to promote a Cys-Glu ligand set, present in lower amounts in the substrate-free enzyme. A novel charge-transfer transition in the near-infrared magnetic CD spectrum provides a spectroscopic signature characteristic of the new A264E heme iron ligation state. A264E retains oxygenase activity, despite glutamate coordination of the iron, indicating that structural rearrangements occur following heme iron reduction to allow dioxygen binding. Glutamate coordination of the heme iron is confirmed by structural studies of the A264E mutant (Joyce, M.G., Girvan, H.M., Munro, A.W., and Leys, D. ( 2004)J. Biol. Chem. 279, 23287-23293).	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Strathclyde, Dept Pure & Appl Chem, Glasgow G1 1XL, Lanark, Scotland; Univ E Anglia, Dept Chem Sci, Norwich NR4 7TJ, Norfolk, England	University of Leicester; University of Strathclyde; University of East Anglia	Munro, AW (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	awm9@le.ac.uk	Munro, Andrew/G-5639-2019	Munro, Andrew/0000-0002-4642-180X; Girvan, Hazel/0000-0003-2299-8644				Arnesano F, 1998, BIOCHEMISTRY-US, V37, P173, DOI 10.1021/bi971896w; Bell SG, 2003, BIOCHEM SOC T, V31, P558, DOI 10.1042/BST0310558; Bell SG, 2002, CHEM COMMUN, P490, DOI 10.1039/b110957j; Berka V, 1998, BIOCHEMISTRY-US, V37, P6136, DOI 10.1021/bi980133l; BUCHANAN JF, 1978, BIOCHEM BIOPH RES CO, V85, P1254, DOI 10.1016/0006-291X(78)91138-5; Carmichael AB, 2001, EUR J BIOCHEM, V268, P3117, DOI 10.1046/j.1432-1327.2001.02212.x; CHEESMAN MR, 1991, ADV INORG CHEM, V36, P201, DOI 10.1016/S0898-8838(08)60040-9; CHEESMAN MR, 1990, NATURE, V346, P771, DOI 10.1038/346771a0; Cheesman MR, 2001, BIOCHEMISTRY-US, V40, P10562, DOI 10.1021/bi0100081; Daff S, 1996, BIOCHEMISTRY-US, V35, P6351, DOI 10.1021/bi9522561; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; DAWSON JH, 1983, INORG CHIM A-BIOINOR, V79, P184, DOI 10.1016/S0020-1693(00)95217-4; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; Dhawan IK, 1999, BIOCHEMISTRY-US, V38, P12805, DOI 10.1021/bi991303c; Dutton P L, 1978, Methods Enzymol, V54, P411; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; Glieder A, 2002, NAT BIOTECHNOL, V20, P1135, DOI 10.1038/nbt744; Groves John T., 1995, P3; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Henne KR, 2001, BIOCHEMISTRY-US, V40, P12925, DOI 10.1021/bi011171z; Hoa GHB, 2002, BBA-PROTEIN STRUCT M, V1595, P297, DOI 10.1016/S0167-4838(01)00352-1; Hoch U, 2001, J BIOL CHEM, V276, P11339, DOI 10.1074/jbc.M009969200; Joyce MG, 2004, J BIOL CHEM, V279, P23287, DOI 10.1074/jbc.M401717200; LeBrun LA, 2002, J BIOL CHEM, V277, P12755, DOI 10.1074/jbc.M112155200; Lee DS, 2003, J BIOL CHEM, V278, P9761, DOI 10.1074/jbc.M211575200; Leys D, 2003, J BIOL CHEM, V278, P5141, DOI 10.1074/jbc.M209928200; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; MACHEROUX P, 1991, BIOCHEMISTRY-US, V30, P4612, DOI 10.1021/bi00232a036; MCKNIGHT J, 1993, EUR J BIOCHEM, V213, P683, DOI 10.1111/j.1432-1033.1993.tb17808.x; McLean MA, 1998, BIOCHEM BIOPH RES CO, V252, P166, DOI 10.1006/bbrc.1998.9584; MILES JS, 1992, BIOCHEM J, V288, P503, DOI 10.1042/bj2880503; MODI S, 1995, BIOCHEM J, V310, P939, DOI 10.1042/bj3100939; Modi S, 1996, NAT STRUCT BIOL, V3, P414, DOI 10.1038/nsb0596-414; Mowat CG, 2001, BIOCHEMISTRY-US, V40, P12292, DOI 10.1021/bi011360h; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; Munro AW, 1996, BBA-PROTEIN STRUCT M, V1296, P127, DOI 10.1016/0167-4838(96)00061-1; Munro AW, 2002, TRENDS BIOCHEM SCI, V27, P250, DOI 10.1016/S0968-0004(02)02086-8; Munro AW, 1996, EUR J BIOCHEM, V239, P403, DOI 10.1111/j.1432-1033.1996.0403u.x; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Munro AW, 1996, MOL MICROBIOL, V20, P1115, DOI 10.1111/j.1365-2958.1996.tb02632.x; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NARHI LO, 1987, J BIOL CHEM, V262, P6683; Noble MA, 1998, BIOCHEMISTRY-US, V37, P15799, DOI 10.1021/bi980462d; Noble MA, 1999, BIOCHEM J, V339, P371, DOI 10.1042/0264-6021:3390371; NOZAWA T, 1978, BIOCHIM BIOPHYS ACTA, V534, P285, DOI 10.1016/0005-2795(78)90011-9; Oliver CF, 1997, BIOCHEMISTRY-US, V36, P1567, DOI 10.1021/bi962826c; Oliver CF, 1997, BIOCHEM J, V327, P537; Ost TWB, 2001, BIOCHEMISTRY-US, V40, P13421, DOI 10.1021/bi010716m; Ost TWB, 2000, FEBS LETT, V486, P173, DOI 10.1016/S0014-5793(00)02267-5; Perera R, 2003, P NATL ACAD SCI USA, V100, P3641, DOI 10.1073/pnas.0737142100; Pochapsky TC, 1999, BIOCHEMISTRY-US, V38, P4681, DOI 10.1021/bi983030b; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RUETTINGER RT, 1981, J BIOL CHEM, V256, P5728; RUX JJ, 1991, FEBS LETT, V290, P49, DOI 10.1016/0014-5793(91)81222-T; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIMIZU T, 1975, BIOCHEMISTRY-US, V14, P4172, DOI 10.1021/bi00690a004; Sigman JA, 1999, BIOCHEMISTRY-US, V38, P11122, DOI 10.1021/bi990815o; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SONO M, 1982, J BIOL CHEM, V257, P5496; SONO M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P351, DOI 10.1016/0167-4838(91)90156-T; SUTHERLAND J, 1986, BIOCHEM J, V233, P893, DOI 10.1042/bj2330893; SVASTITS EW, 1989, BIOCHEM BIOPH RES CO, V165, P1170, DOI 10.1016/0006-291X(89)92725-3; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; THOMSON AJ, 1993, METHOD ENZYMOL, V226, P199, DOI 10.1016/0076-6879(93)26011-W; Tsai AL, 1996, J BIOL CHEM, V271, P32563, DOI 10.1074/jbc.271.51.32563; VICKERY L, 1975, BIOCHIM BIOPHYS ACTA, V386, P87, DOI 10.1016/0005-2795(75)90249-4; VICKERY L, 1976, J AM CHEM SOC, V98, P351, DOI 10.1021/ja00418a006; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Zheng YM, 2003, BIOCHEMISTRY-US, V42, P4601, DOI 10.1021/bi020667t	72	65	66	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23274	23286		10.1074/jbc.M401716200	http://dx.doi.org/10.1074/jbc.M401716200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15020591	hybrid			2022-12-25	WOS:000221570900061
J	Gustavsson, A; Yuan, M; Fallman, M				Gustavsson, A; Yuan, M; Fallman, M			Temporal dissection of beta(1)-integrin signaling indicates a role for p130Cas-Crk in filopodia formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; INVASIN-PROMOTED INTERNALIZATION; ACTIN-BASED MOTILITY; SRC FAMILY KINASES; CELL-MIGRATION; YERSINIA-PSEUDOTUBERCULOSIS; TYROSINE PHOSPHORYLATION; RHO GTPASES; N-WASP; CYTOPLASMIC TAIL	Invasin-promoted spreading of B-1-integrin-deficient cells, transfected with the X-1A- or beta(1B)-integrin splice variants, were used to dissect early beta(1)-integrin signaling events. The X-1B isoform, which has a different membrane-distal part of the cytoplasmic tail from beta(1A), is defective in signaling and function. When plated on surfaces coated with the high affinity ligand invasin, beta(1B)-integrin-expressing cells spread by forming filopodia with distinct adhesive phosphotyrosine complexes at the tips, without signs of lamellipodia. This suggested that the beta(1B)-integrin mediated a partial signaling sufficient for formation of filopodia but insufficient for lamellipodia formation. When screening for proteins present in the distal filopodial phosphotyrosine complexes of beta(1B) cells, p130Cas and the filopodia proteins vasodilator-stimulated phosphoprotein and talin were found, whereas the typical focal complex proteins focal adhesion kinase, paxillin, and vinculin were not. Invasin-promoted adhesion induced complex formation of p130Cas and the adapter Crk. Moreover, Crk together with Dock180 were present at the filopodial tips of beta(1B)-integrin-expressing cells, and there was a prominent Rac1 activation. Expression of dominant negative variants of p130Cas or CrkII blocked beta(1B)-integrin-mediated filopodia formation, indicating that this signaling scaffold is central in this process.	Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden	Umea University	Fallman, M (corresponding author), Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden.	maria.fallman@molbiol.umu.se						Abe T, 2003, J CELL SCI, V116, P155, DOI 10.1242/jcs.00208; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Allen WE, 1997, J CELL SCI, V110, P707; Alrutz MA, 2001, MOL MICROBIOL, V42, P689, DOI 10.1046/j.1365-2958.2001.02676.x; Armulik A, 2000, EXP CELL RES, V254, P55, DOI 10.1006/excr.1999.4722; Armulik A, 2002, FRONT BIOSCI-LANDMRK, V7, pD219, DOI 10.2741/armulik; Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; BOLIN I, 1982, INFECT IMMUN, V37, P506; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; BURRIDGE K, 1990, CELL DIFFER DEV, V32, P337, DOI 10.1016/0922-3371(90)90048-2; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; de Melker AA, 1999, BIOESSAYS, V21, P499, DOI 10.1002/(SICI)1521-1878(199906)21:6<499::AID-BIES6>3.0.CO;2-D; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1351, DOI 10.1083/jcb.113.6.1351; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; GOLDMANN WH, 1995, EXP CELL RES, V221, P311, DOI 10.1006/excr.1995.1380; Goldmann WH, 2002, BIOCHEM BIOPH RES CO, V290, P749, DOI 10.1006/bbrc.2001.6243; Gual P, 2002, J BIOL CHEM, V277, P43980, DOI 10.1074/jbc.M203042200; Gustavsson A, 2002, J CELL SCI, V115, P2669; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; ILLC D, 1995, NATURE, V377, P539; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kee WJ, 2000, J CELL BIOCHEM, V78, P97, DOI 10.1002/(SICI)1097-4644(20000701)78:1<97::AID-JCB9>3.0.CO;2-5; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LaFlamme SE, 1997, MATRIX BIOL, V16, P153, DOI 10.1016/S0945-053X(97)90003-2; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Liu SC, 2000, J CELL SCI, V113, P3563; Martel V, 2000, J CELL SCI, V113, P1951; McGee K, 2001, FEBS LETT, V509, P59, DOI 10.1016/S0014-5793(01)03139-8; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Reckmann I, 1997, FEBS LETT, V409, P141, DOI 10.1016/S0014-5793(97)00450-X; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, J CELL SCI, V114, P2713; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Samarin S, 2003, J CELL BIOL, V163, P131, DOI 10.1083/jcb.200303191; SAMUELS M, 1993, J CELL BIOL, V121, P909, DOI 10.1083/jcb.121.4.909; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scaplehorn N, 2002, CURR BIOL, V12, P740, DOI 10.1016/S0960-9822(02)00812-6; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Takino T, 2003, J CELL SCI, V116, P3145, DOI 10.1242/jcs.00632; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Xing BD, 2001, J BIOL CHEM, V276, P44373, DOI 10.1074/jbc.M108587200; Zamir E, 2001, J CELL SCI, V114, P3583	76	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22893	22901		10.1074/jbc.M309693200	http://dx.doi.org/10.1074/jbc.M309693200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044442	hybrid			2022-12-25	WOS:000221570900015
J	Nikolov, EN; Ivanova-Nikolova, TT				Nikolov, EN; Ivanova-Nikolova, TT			Coordination of membrane excitability through a GIRK1 signaling complex in the atria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+-CHANNEL; BETA-GAMMA-SUBUNITS; PROTEIN-KINASE-C; MUSCARINIC POTASSIUM CHANNEL; I-KACH; ARACHIDONIC-ACID; MOLECULAR-BASIS; ACTIVATION; CELLS; EXPRESSION	Control of heart rate is a complex process that integrates the function of multiple G protein-coupled receptors and ion channels. Among them, the G protein-regulated inwardly rectifying K+ (GIRK or K-ACh) channels of sinoatrial node and atria play a major role in beat-to-beat regulation of the heart rate. The atrial K-ACh channels are heterotetrameric proteins that consist of two pore-forming subunits, GIRK1 and GIRK4. Following m(2)-muscarinic acetylcholine receptor (M2R) stimulation, K-ACh channel activation is conferred by the direct binding of G protein betagamma subunits (Gbetagamma) to the channel. Here we show that atrial K-ACh channels are assembled in a signaling complex with Gbetagamma, G protein-coupled receptor kinase, cyclic adenosine monophosphate-dependent protein kinase, two protein phosphatases, PP1 and PP2A, receptor for activated C kinase 1, and actin. This complex would enable the K-ACh channels to rapidly integrate beta-adrenergic and M2R signaling in the membrane, and it provides insight into general principles governing spatial integration of different transduction pathways. Furthermore, the same complex might recruit protein kinase C (PKC) to the K-ACh channel following alpha-adrenergic receptor stimulation. Our electrophysiological recordings from single atrial K-ACh channels revealed a potent inhibition of Gbetagamma-induced channel activity by PKC, thus validating the physiological significance of the observed complex as interconnecting site where signaling molecules congregate to execute a coordinated control of membrane excitability.	E Carolina Univ, Brody Sch Med, Dept Pharmacol & Toxicol, Greenville, NC 27858 USA	University of North Carolina; East Carolina University	Ivanova-Nikolova, TT (corresponding author), E Carolina Univ, Brody Sch Med, Dept Pharmacol & Toxicol, Brody Med Sci Bldg,Rm 6S-11, Greenville, NC 27858 USA.	ivanovanikolovat@mail.ecu.edu						Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; Corey S, 1998, J BIOL CHEM, V273, P27499, DOI 10.1074/jbc.273.42.27499; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Dell EJ, 2002, J BIOL CHEM, V277, P49888, DOI 10.1074/jbc.M202755200; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Ivanova-Nikolova TT, 1998, J GEN PHYSIOL, V112, P199, DOI 10.1085/jgp.112.2.199; Ji S, 1998, J BIOL CHEM, V273, P1324, DOI 10.1074/jbc.273.3.1324; Kim D, 2000, J GEN PHYSIOL, V115, P287, DOI 10.1085/jgp.115.3.287; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KIM D, 1991, J PHYSIOL-LONDON, V437, P133, DOI 10.1113/jphysiol.1991.sp018588; KIM D, 1990, CIRC RES, V67, P1292, DOI 10.1161/01.RES.67.5.1292; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; Liao YJ, 1996, J NEUROSCI, V16, P7137; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; Mao JZ, 2004, BIOPHYS J, V86, p440A; Medina I, 2000, J BIOL CHEM, V275, P29709, DOI 10.1074/jbc.M004989200; Mullner C, 2000, J GEN PHYSIOL, V115, P547, DOI 10.1085/jgp.115.5.547; Mullner C, 2003, BIOPHYS J, V84, P1399, DOI 10.1016/S0006-3495(03)74954-6; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; Petit-Jacques J, 1999, J GEN PHYSIOL, V114, P673, DOI 10.1085/jgp.114.5.673; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pleumsamran A, 1995, J MEMBRANE BIOL, V148, P287; Rishal I, 2004, BIOPHYS J, V86, p439A; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; Yakubovich D, 2000, J PHYSIOL-LONDON, V524, P737, DOI 10.1111/j.1469-7793.2000.00737.x; Yamada M, 1998, PHARMACOL REV, V50, P723; Ye CI, 2000, BIOPHYS J, V79, P2547, DOI 10.1016/S0006-3495(00)76495-2	44	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23630	23636		10.1074/jbc.M312861200	http://dx.doi.org/10.1074/jbc.M312861200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15037627	hybrid			2022-12-25	WOS:000221570900104
J	Shen, GX; Hebbar, V; Nair, S; Xu, CJ; Li, WG; Lin, W; Keum, YS; Han, JH; Gallo, MA; Kong, ANT				Shen, GX; Hebbar, V; Nair, S; Xu, CJ; Li, WG; Lin, W; Keum, YS; Han, JH; Gallo, MA; Kong, ANT			Regulation of Nrf2 transactivation domain activity - The differential effects of mitogen-activated protein kinase cascades and synergistic stimulatory effect of Raf and CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; DRUG-METABOLIZING-ENZYMES; HEME OXYGENASE-1 GENE; NF-E2-RELATED FACTOR-2; OXIDATIVE STRESS; INDUCIBLE EXPRESSION; PHENOLIC ANTIOXIDANTS; PHASE-2 ENZYMES; SUBUNIT GENE	Transcription factor NF-E2-related factor 2 (Nrf2) regulates the induction of Phase II detoxifying enzymes as well as anti-oxidative enzymes. In this study, we investigated the transactivation potential of different Nrf2 transactivation domain regions by using the Gal4-Nrf2 chimeras and Gal4-Luc reporter co-transfection assay system in HepG2 cells. The results indicated that chimera Gal4-Nrf2-( 1-370), which contains the full transactivation domain showed very potent transactivation activity. The high transactivation activity of Gal4-Nrf2( 113 - 251) and the diminished transactivation activities of chimera Gal4-Nrf2-( 1 - 126) and Gal4-Nrf2-( 230 - 370) suggested that the Nrf2 N-terminal 113 - 251 amino acids region is critical in maintaining its transactivation activity. Overexpression of upstream MAPKs such as Raf, MEKK1, TAK1-DeltaN, and ASK1 up-regulated the transactivation activities of Gal4-Nrf2-( 1 - 370) and Gal4-Nrf2( 113 - 251) in a dose-dependent manner. Further investigation on the effects of the three MAPK pathways on Nrf2 transactivation domain activity demonstrated that both ERK and JNK signaling pathways stimulated the Gal4-Nrf2-( 1 - 370) transactivation activity while the p38 pathway played a negative role. Site-directed mutagenesis studies on potential MAPK phosphorylation sites of Gal4-Nrf2-( 113 - 251) showed no significant effect on its basal transactivation activity or the fold of induction by Raf. Interestingly, the nuclear transcription coactivator CREB-binding protein (CBP), which can bind to Nrf2 transactivation domain and can be activated by ERK cascade, showed synergistic stimulation with Raf on the transactivation activities of both the chimera Gal4-Nrf2( 1 - 370) and the full-length Nrf2. Taken together, this study clearly demonstrated that different segments of Nrf2 transactivation domain have different transactivation potential and different MAPKs have differential effects on Nrf2 transcriptional activity. It also suggested that the up-regulation of Nrf2 transactivation domain activity by upstream MAPKs such as Raf may not be mediated by direct phosphorylation of the Nrf2 transactivation domain, but rather by regulation of the transcriptional activity of coactivator CBP.	Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Med & Dent New Jersey, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Scripps Research Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Kong, ANT (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	KongT@cop.rutgers.edu	Nair, Sujit/C-4096-2015; Han, J/G-4671-2010; Kong, Ah-Ng Tony/AAX-2828-2020	Nair, Sujit/0000-0002-7322-7375; 	NATIONAL CANCER INSTITUTE [R01CA094828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005022] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA94828] Funding Source: Medline; NIEHS NIH HHS [P30 ES005022] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; Chan D, 2000, AUSTRALAS J AGEING, V19, P26; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Gusterson R, 2002, J BIOL CHEM, V277, P2517, DOI 10.1074/jbc.M104626200; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LI Y, 1992, J BIOL CHEM, V267, P15097; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Liu YZ, 1999, NEUROREPORT, V10, P1239, DOI 10.1097/00001756-199904260-00016; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Misra P, 2002, J BIOL CHEM, V277, P48745, DOI 10.1074/jbc.M208829200; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Nakaso K, 2003, FEBS LETT, V546, P181, DOI 10.1016/S0014-5793(03)00517-9; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Primiano T, 1997, Adv Pharmacol, V38, P293; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; Zhu M, 2001, BIOCHEM BIOPH RES CO, V289, P212, DOI 10.1006/bbrc.2001.5944; Zipper LM, 2000, BIOCHEM BIOPH RES CO, V278, P484, DOI 10.1006/bbrc.2000.3830; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	55	164	167	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23052	23060		10.1074/jbc.M401368200	http://dx.doi.org/10.1074/jbc.M401368200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15020583	hybrid			2022-12-25	WOS:000221570900034
J	Ju, SL; Shaltiel, G; Shamir, A; Agam, G; Greenberg, ML				Ju, SL; Shaltiel, G; Shamir, A; Agam, G; Greenberg, ML			Human 1-D-myo-inositol-3-phosphate synthase is functional in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1-PHOSPHATE SYNTHASE; INO1 GENE; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; L-MYO-INOSITOL-1-PHOSPHATE SYNTHASE; INOSITOL-1-PHOSPHATE SYNTHASE; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID BIOSYNTHESIS; VALPROATE DECREASE; LITHIUM; MYOINOSITOL	We have cloned, sequenced, and expressed a human cDNA encoding 1- D- myo- inositol- 3- phosphate ( MIP) synthase ( hINO1). The encoded 62- kDa human enzyme converted D- glucose 6- phosphate to 1- D- myo- inositol 3- phosphate, the rate- limiting step for de novo inositol biosynthesis. Activity of the recombinant human MIP synthase purified from Escherichia coli was optimal at pH 8.0 at 37degreesC and exhibited K-m values of 0.57 mM and 8 muM for glucose 6- phosphate and NAD(+), respectively. NH4+ and K+ were better activators than other cations tested ( Na+, Li+, Mg2+, Mn2+), and Zn2+ strongly inhibited activity. Expression of the protein in the yeast ino1Delta mutant lacking MIP synthase ( ino1Delta/ hINO1) complemented the inositol auxotrophy of the mutant and led to inositol excretion. MIP synthase activity and intracellular inositol were decreased about 35 and 25%, respectively, when ino1Delta/ hINO1 was grown in the presence of a therapeutically relevant concentration of the anti- bipolar drug valproate ( 0.6 mM). However, in vitro activity of purified MIP synthase was not inhibited by valproate at this concentration, suggesting that inhibition by the drug is indirect. Because inositol metabolism may play a key role in the etiology and treatment of bipolar illness, functional conservation of the key enzyme in inositol biosynthesis underscores the power of the yeast model in studies of this disorder.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA; Ben Gurion Univ Negev, Dept Clin Biochem, IL-84170 Beer Sheva, Israel; Ben Gurion Univ Negev, Stanley Res Ctr, Zlotowski Ctr Neurosci, IL-84170 Beer Sheva, Israel; Beersheva Mental Hlth Ctr, IL-84170 Beer Sheva, Israel	Wayne State University; Ben Gurion University; Ben Gurion University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.	mlgreen@sun.science.wayne.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056220] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH 56220] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADHIKARI J, 1983, FEBS LETT, V163, P46, DOI 10.1016/0014-5793(83)81159-4; ADHIKARI J, 1988, INDIAN J BIOCHEM BIO, V25, P408; Agam G, 2002, BIPOLAR DISORD, V4, P15, DOI 10.1034/j.1399-5618.4.s1.2.x; ALLISON JH, 1980, J NEUROCHEM, V34, P456, DOI 10.1111/j.1471-4159.1980.tb06619.x; ATACK JR, 1995, FEBS LETT, V361, P1, DOI 10.1016/0014-5793(95)00063-F; Bachhawat N, 1999, J MOL BIOL, V291, P531, DOI 10.1006/jmbi.1999.2980; BANKS RE, 1990, J AFFECT DISORDERS, V19, P1, DOI 10.1016/0165-0327(90)90002-P; BARNETT JEG, 1970, BIOCHEM J, V119, P183, DOI 10.1042/bj1190183; Berridge M J, 1985, Rev Clin Basic Pharm, V5 Suppl, p5S; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Chang HJ, 2002, GENETICS, V162, P29; CHEN IW, 1966, J BIOL CHEM, V241, P2194; Chen LJ, 2000, BIOCHEMISTRY-US, V39, P12415, DOI 10.1021/bi001517q; Chun JA, 2003, PLANTA, V216, P874, DOI 10.1007/s00425-002-0940-0; Davanzo P, 2001, NEUROPSYCHOPHARMACOL, V24, P359, DOI 10.1016/S0893-133X(00)00207-4; Ding DB, 2003, MOL MICROBIOL, V47, P373, DOI 10.1046/j.1365-2958.2003.03284.x; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Graves JA, 2000, GENETICS, V154, P1485; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; Griac P, 1996, J BIOL CHEM, V271, P25692, DOI 10.1074/jbc.271.41.25692; GROSSISSEROFF R, 1990, ARCH GEN PSYCHIAT, V47, P1049; Guan GM, 2003, ARCH BIOCHEM BIOPHYS, V417, P251, DOI 10.1016/S0003-9861(03)00388-6; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; Ju SL, 2003, MOL MICROBIOL, V49, P1595, DOI 10.1046/j.1365-2958.2003.03641.x; KLIG LS, 1994, YEAST, V10, P789, DOI 10.1002/yea.320100609; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEWUS MW, 1983, J REPROD FERTIL, V69, P215, DOI 10.1530/jrf.0.0690215; Lohia A, 1999, MOL BIOCHEM PARASIT, V98, P67, DOI 10.1016/S0166-6851(98)00147-9; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; MAEDA T, 1980, J BIOL CHEM, V255, P8458; Majumder AL, 1997, BBA-LIPID LIPID MET, V1348, P245, DOI 10.1016/S0005-2760(97)00122-7; Maslanski J. A., 1990, METHODS INOSITIDE RE, P113; MAUCK LA, 1980, BIOCHEMISTRY-US, V19, P3623, DOI 10.1021/bi00556a031; MCGRAW P, 1989, GENETICS, V122, P317; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Murray M, 2000, MOL MICROBIOL, V36, P651, DOI 10.1046/j.1365-2958.2000.01886.x; NACCARATO WF, 1974, ARCH BIOCHEM BIOPHYS, V164, P194, DOI 10.1016/0003-9861(74)90022-8; O'Donnell T, 2000, BRAIN RES, V880, P84, DOI 10.1016/S0006-8993(00)02797-9; PITTNER F, 1979, MOL CELL BIOCHEM, V25, P43; RayChaudhuri A, 1997, PLANT PHYSIOL, V115, P727, DOI 10.1104/pp.115.2.727; Shimon H, 1997, AM J PSYCHIAT, V154, P1148; Soares JC, 2000, PSYCHOPHARMACOLOGY, V149, P12, DOI 10.1007/s002139900341; Vaden DL, 2001, J BIOL CHEM, V276, P15466, DOI 10.1074/jbc.M004179200; VADNAL R, 1995, NEUROPSYCHOPHARMACOL, V12, P277, DOI 10.1016/0893-133X(94)00088-H; WEISSMAN MM, 1988, PSYCHOL MED, V18, P141, DOI 10.1017/S0033291700001975; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X	54	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21759	21765		10.1074/jbc.M312078200	http://dx.doi.org/10.1074/jbc.M312078200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15024000	hybrid			2022-12-25	WOS:000221417100011
J	Torii, S; Takeuchi, T; Nagamatsu, S; Izumi, T				Torii, S; Takeuchi, T; Nagamatsu, S; Izumi, T			Rab27 effector granuphilin promotes the plasma membrane targeting of insulin granules via interaction with syntaxin 1a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; EVANESCENT-WAVE MICROSCOPY; SYNAPTIC VESICLE FUSION; SECRETORY GRANULES; B-CELLS; EXOCYTOSIS; RELEASE; DOCKING; PROTEINS; MUNC-18	Secretory vesicle exocytosis is a highly regulated process involving vesicle targeting, priming, and membrane fusion. Rabs and SNAREs play a central role in executing these processes. We have shown recently that Rab27a and its effector, granuphilin, are involved in the exocytosis of insulin-containing secretory granules through a direct interaction with the plasma membrane syntaxin 1a in pancreatic beta cells. Here, we demonstrate that fluorescence-labeled insulin granules are peripherally accumulated in cells overexpressing granuphilin. The peripheral location of granules is well overlapped with both localizations of granuphilin and syntaxin 1a. The plasma membrane targeting of secretory granules is promoted by wild-type granuphilin but not by granuphilin mutants that are defective in binding to either Rab27a or syntaxin 1a. Granuphilin directly binds to the H3 domain of syntaxin 1a containing its SNARE motif. Moreover, introduction of the H3 domain into beta cells induces a dissociation of the native granuphilin-syntaxin complex and a marked reduction of newly docked granules. These results indicate that granuphilin plays a role in tethering insulin granules to the plasma membrane by an interaction with both Rab27a and syntaxin 1a. The complex formation of these three proteins may contribute to the specificity of the targeting process during the exocytosis of insulin granules.	Gunma Univ, Gene Anal Lab, Maebashi, Gumma 3718512, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Lab Gene Engn, Maebashi, Gumma 3718512, Japan; Kyorin Univ, Sch Med, Dept Biochem, Tokyo 1818611, Japan	Gunma University; Gunma University; Kyorin University	Izumi, T (corresponding author), Gunma Univ, Gene Anal Lab, Maebashi, Gumma 3718512, Japan.	tizumi@showa.gunma-u.ac.jp						BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; Hosaka M, 2002, MOL BIOL CELL, V13, P3388, DOI 10.1091/mbc.02-03-0040; Izumi T, 2003, CELL STRUCT FUNCT, V28, P465, DOI 10.1247/csf.28.465; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Marsal J, 1997, P NATL ACAD SCI USA, V94, P14871, DOI 10.1073/pnas.94.26.14871; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; Ohara-Imaizumi M, 2004, J BIOL CHEM, V279, P8403, DOI 10.1074/jbc.M308954200; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P50805, DOI 10.1074/jbc.M207988200; Ohara-Imaizumi M, 2002, BIOCHEM J, V363, P73, DOI 10.1042/0264-6021:3630073; Olofsson CS, 2002, PFLUG ARCH EUR J PHY, V444, P43, DOI 10.1007/s00424-002-0781-5; Plattner H, 1997, J CELL BIOL, V139, P1709, DOI 10.1083/jcb.139.7.1709; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Rosenmund C, 2003, CURR OPIN NEUROBIOL, V13, P509, DOI 10.1016/j.conb.2003.09.011; Shorter J, 2002, J CELL BIOL, V157, P45, DOI 10.1083/jcb.200112127; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Torii S, 2002, MOL CELL BIOL, V22, P5518, DOI 10.1128/MCB.22.15.5518-5526.2002; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; Whyte JRC, 2002, J CELL SCI, V115, P2627; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang W, 2000, J BIOL CHEM, V275, P41521, DOI 10.1074/jbc.M005479200; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	35	76	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22532	22538		10.1074/jbc.M400600200	http://dx.doi.org/10.1074/jbc.M400600200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15028737	hybrid			2022-12-25	WOS:000221417100104
J	Vultur, A; Cao, J; Arulanandam, R; Turkson, J; Jove, R; Greer, P; Craig, A; Elliott, B; Raptis, L				Vultur, A; Cao, J; Arulanandam, R; Turkson, J; Jove, R; Greer, P; Craig, A; Elliott, B; Raptis, L			Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells	ONCOGENE			English	Article						Stat3; cell confluence; cell-to-cell adhesion; breast cancer; breast carcinoma lines; rodent fibroblasts	GROWTH-FACTOR RECEPTOR; DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; E-CADHERIN; PHOSPHATIDYLINOSITOL 3-KINASE; NEOPLASTIC TRANSFORMATION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; SRC ONCOPROTEIN; KINASE-ACTIVITY	Stat3 (signal transducer and activator of transcription-3) activity is required for transformation by a number of oncogenes, while a constitutively active form of Stat3 alone is sufficient to induce neoplastic transformation. Although in most instances Stat3 is growth-promoting, the impact of cell density on Stat3 activation status and the biological importance of Stat3 during growth arrest have not been characterized. Previous results indicated that cell density alters tyrosine phosphorylation levels of cultured cells. Since signalling through Stat3 is determined by a key phosphorylation at tyr705, we examined the effects of cell density upon Stat3 activity in normal breast epithelial cells, breast carcinoma lines and normal mouse fibroblasts. Intriguingly, the results revealed a dramatic increase in Stat3, tyr705 phosphorylation and activity with cell density, which gradually declined at later stages. This activation was dependent upon cell-cell contact, since it was eliminated if cell adhesion was disrupted through calcium chelation, while it was reinstated through cell aggregation. Furthermore, this activation was suppressed following inhibition of JAKs (Janus kinases) but not inhibition of Fer, IGF1-R, or kinases of the c-Src family. On the other hand, constitutively active Stat3 in carcinoma lines, known to harbor activated Src, was blocked by pharmacological inhibitors of Src as well as JAKs. These results point to the existence of two distinct pathways of Stat3 activation in breast carcinomas, based on Src dependence. More importantly, our results suggest that Stat3 activity is upregulated during the confluence-mediated growth arrest by a signalling mechanism that requires JAKs.	Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA	Queens University - Canada; Queens University - Canada; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Raptis, L (corresponding author), Queens Univ, Dept Microbiol & Immunol, Botterell Hall,Rm 715, Kingston, ON K7L 3N6, Canada.	raptisl@post.queensu.ca	Craig, Andrew/AAC-6923-2019; Craig, Andrew/G-2312-2017	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393; Vultur, Adina/0000-0003-0068-9496				Balhoff JP, 1998, BIOCHEM BIOPH RES CO, V247, P894, DOI 10.1006/bbrc.1998.8890; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Deng JB, 2000, ENDOCRINOLOGY, V141, P2370, DOI 10.1210/en.141.7.2370; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; Huttenlocher A, 1998, J CELL BIOL, V141, P515, DOI 10.1083/jcb.141.2.515; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lin JY, 2002, CANCER RES, V62, P376; Mauro L, 2003, J CELL PHYSIOL, V194, P108, DOI 10.1002/jcp.10207; Mora LB, 2002, CANCER RES, V62, P6659; Narimatsu M, 2001, MOL CELL BIOL, V21, P6615, DOI 10.1128/MCB.21.19.6615-6625.2001; Nelson PJ, 2002, KIDNEY INT S1, V61, P99, DOI DOI 10.1046/J.1523-1755.2002.0610S1099.X; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Raptis L, 1997, EXP CELL RES, V235, P188, DOI 10.1006/excr.1997.3646; Raptis L, 1997, CELL GROWTH DIFFER, V8, P891; Raptis L, 2000, CELL GROWTH DIFFER, V11, P293; Rothen-Rutishauser B, 2002, J MEMBRANE BIOL, V188, P151, DOI 10.1007/s00232-001-0182-2; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; Stephens JM, 1996, J BIOL CHEM, V271, P10441, DOI 10.1074/jbc.271.18.10441; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Whittard JD, 2002, MATRIX BIOL, V21, P525, DOI 10.1016/S0945-053X(02)00037-9; Xu FP, 2001, EXP CELL RES, V262, P49, DOI 10.1006/excr.2000.5075; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	58	91	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2600	2616		10.1038/sj.onc.1207378	http://dx.doi.org/10.1038/sj.onc.1207378			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15007380	Green Published			2022-12-25	WOS:000220714900002
J	Lee, IH; You, JO; Ha, KS; Bae, DS; Suh, PG; Rhee, SG; Bae, YS				Lee, IH; You, JO; Ha, KS; Bae, DS; Suh, PG; Rhee, SG; Bae, YS			AHNAK-mediated activation of phospholipase C-gamma 1 through protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; A(2); CA2+; PHOSPHORYLATION; BRADYKININ; CALCIUM; GAMMA; CELLS; PLC-GAMMA-1; FIBROBLASTS	We have recently shown that phospholipase C-gamma (PLC-gamma) is activated by the central repeated units ( CRUs) of the AHNAK protein in the presence of arachidonic acid. Here we demonstrate that four central repeated units ( 4 CRUs) of AHNAK act as a scaffolding motif networking PLC-gamma and PKC-alpha. Specifically, 4 CRUs of AHNAK bind and activate PKC-alpha, which in turn stimulates the release of arachidonic acid near where PLC-gamma1 is localized. Moreover, 4 CRUs of AHNAK interacted with PLC-gamma and the concerted action of 4 CRUs with arachidonic acid stimulated PLC-gamma activity. Stimulation of NIH3T3 cells expressing 4 CRUs of AHNAK with phorbol 12-myristate 13-acetate resulted in the increased generation of total inositol phosphates (IPT) and mobilization of the intracellular calcium. Phorbol 12-myristate 13-acetate-dependent generation of IPT was completely blocked in NIH3T3 cells depleted of PLC-gamma1 by RNA interference. Furthermore, bradykinin, which normally stimulated the PLC-beta isozyme resulting in the generation of a monophasic IPT within 30 s in NIH3T3 cells, led to a biphasic pattern for generation of IPT in NIH3T3 cells expressing 4 CRUs of AHNAK. The secondary activation of PLC is likely because of the scaffolding activity of AHNAK, which is consistent with the role of 4 CRUs as a molecular linker between PLC-gamma and PKC-alpha.	Ewha Womans Univ, Ctr Cell Signaling Res, Div Mol Life Sci, Seoul 120750, South Korea; Kangweon Natl Univ, Dept Biochem, Chunchon 200701, Kangwondo, South Korea; SungKyunKwan Univ, Samsung Med Ctr, Dept Obstet & Gynecol, Seoul 135230, South Korea; POSTECH, Dept Life Sci, Pohang 790784, South Korea; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20852 USA	Ewha Womans University; Kangwon National University; Sungkyunkwan University (SKKU); Samsung Medical Center; Pohang University of Science & Technology (POSTECH); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Bae, YS (corresponding author), Ewha Womans Univ, Ctr Cell Signaling Res, Div Mol Life Sci, 11-1 Daehyun Dong, Seoul 120750, South Korea.	baeys@ewha.ac.kr	LEE, IN HYE/T-2714-2019; Suh, Pann-Ghill/F-3610-2010	LEE, IN HYE/0000-0003-2334-3594; Ha, Kwon-Soo/0000-0002-4219-1787				Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Andrade MA, 2001, J STRUCT BIOL, V134, P117, DOI 10.1006/jsbi.2001.4392; BAE SS, 2002, ADV ENZYME REGUL, V267, P195; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098; Borgonovo B, 2002, NAT CELL BIOL, V4, P955, DOI 10.1038/ncb888; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Croze E, 2000, J IMMUNOL, V165, P5127, DOI 10.4049/jimmunol.165.9.5127; Gentil BJ, 2003, J HISTOCHEM CYTOCHEM, V51, P339, DOI 10.1177/002215540305100309; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Harris BZ, 2001, J CELL SCI, V114, P3219; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0855com; Hur EM, 2004, J BIOL CHEM, V279, P5852, DOI 10.1074/jbc.M311687200; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jenkins SM, 1998, NEUROREPORT, V9, P67, DOI 10.1097/00001756-199801050-00014; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; Lal MA, 1997, AM J PHYSIOL-RENAL, V273, pF907, DOI 10.1152/ajprenal.1997.273.6.F907; Lee ZW, 1998, J BIOL CHEM, V273, P12710, DOI 10.1074/jbc.273.21.12710; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mochly-Rosen D, 1998, FASEB J, V12, P35; Moscat J, 2003, EMBO REP, V4, P31, DOI 10.1038/sj.embor.embor704; Panini SR, 2001, J LIPID RES, V42, P1678; PARK DJ, 1992, J BIOL CHEM, V267, P1496; Park TJ, 2003, CELL SIGNAL, V15, P519, DOI 10.1016/S0898-6568(02)00136-5; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Strokin M, 2003, BRIT J PHARMACOL, V139, P1014, DOI 10.1038/sj.bjp.0705326; Sussman J, 2001, J CELL BIOL, V154, P1019, DOI 10.1083/jcb.200105121	43	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26645	26653		10.1074/jbc.M311525200	http://dx.doi.org/10.1074/jbc.M311525200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15033986	hybrid			2022-12-25	WOS:000222003000091
J	Mounier, CM; Ghomashchi, F; Lindsay, MR; James, S; Singer, AG; Parton, RG; Gelb, MH				Mounier, CM; Ghomashchi, F; Lindsay, MR; James, S; Singer, AG; Parton, RG; Gelb, MH			Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A(2) occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A(2)-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-V; CROSS-TALK; LEUKOTRIENE BIOSYNTHESIS; ANTIINFLAMMATORY DRUGS; PYRROLIDINE INHIBITORS; EICOSANOID GENERATION; HUMAN NEUTROPHILS; A(2); BINDING; EXPRESSION	Stable expression of human groups IIA and X secreted phospholipases A(2) (hGIIA and hGX) in CHO-K1 and HEK293 cells leads to serum- and interleukin-1beta-promoted arachidonate release. Using mutant CHO-K1 cell lines, it is shown that this arachidonate release does not require heparan sulfate proteoglycan- or glycosylphosphatidylinositol-anchored proteins. It is shown that the potent secreted phospholipase A(2) inhibitor Me-Indoxam is cell-impermeable. By use of Me-Indoxam and the cell-impermeable, secreted phospholipase A(2) trapping agent heparin, it is shown that hGIIA liberates free arachidonate prior to secretion from the cell. With hGX-transfected CHO-K1 cells, arachidonate release occurs before and after enzyme secretion, whereas all of the arachidonate release from HEK293 cells occurs prior to enzyme secretion. Immunocytochemical studies by confocal laser and electron microscopies show localization of hGIIA to the cell surface and Golgi compartment. Additional results show that the interleukin-1beta-dependent release of arachidonate is promoted by secreted phospholipase A(2) expression and is completely dependent on cytosolic (group IVA) phospholipase A(2). These results along with additional data resolve the paradox that efficient arachidonic acid release occurs with hGIIA-transfected cells, and yet exogenously added hGIIA is poorly able to liberate arachidonic acid from mammalian cells.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Queensland; University of Queensland; University of Queensland	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Campus Box 351700, Seattle, WA 98195 USA.	gelb@chem.washington.edu	Parton, Robert G/C-5673-2009	Parton, Robert G/0000-0002-7494-5248; gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL36835, HL50040] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrami L, 2001, J BIOL CHEM, V276, P30729, DOI 10.1074/jbc.M102039200; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balboa MA, 2003, J BIOL CHEM, V278, P48059, DOI 10.1074/jbc.M305904200; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Bezzine S, 2002, J BIOL CHEM, V277, P48523, DOI 10.1074/jbc.M203137200; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Breuza L, 2002, J CELL SCI, V115, P4457, DOI 10.1242/jcs.00130; Connolly S, 2002, J MED CHEM, V45, P1348, DOI 10.1021/jm011050x; Das S, 2003, J BIOL CHEM, V278, P41431, DOI 10.1074/jbc.M304897200; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Edwards SH, 2002, BIOCHEMISTRY-US, V41, P15468, DOI 10.1021/bi020485z; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Gargalovic P, 2001, J BIOL CHEM, V276, P26164, DOI 10.1074/jbc.M011291200; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Han WK, 2003, J BIOL CHEM, V278, P24153, DOI 10.1074/jbc.M300424200; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Huwiler A, 1997, BBA-LIPID LIPID MET, V1348, P257, DOI 10.1016/S0005-2760(97)00073-8; KASSIS AI, 1980, J NUCL MED, V21, P88; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; Mihelich ED, 1999, BBA-MOL CELL BIOL L, V1441, P223, DOI 10.1016/S1388-1981(99)00157-2; MORGAN BP, 1991, J AM CHEM SOC, V113, P297, DOI 10.1021/ja00001a043; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2003, J BIOL CHEM, V278, P10657, DOI 10.1074/jbc.M211325200; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2002, J BIOL CHEM, V277, P19145, DOI 10.1074/jbc.M112385200; Murakami M, 2002, BIOCHEM BIOPH RES CO, V292, P689, DOI 10.1006/bbrc.2002.6716; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Ono T, 2002, BIOCHEM J, V363, P727, DOI 10.1042/0264-6021:3630727; Osterhout JL, 2000, J BIOL CHEM, V275, P8248, DOI 10.1074/jbc.275.11.8248; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Seno K, 2000, J MED CHEM, V43, P1041, DOI 10.1021/jm9905155; Seno K, 2001, BIOORG MED CHEM LETT, V11, P587, DOI 10.1016/S0960-894X(01)00003-8; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Snyder DW, 1999, J PHARMACOL EXP THER, V288, P1117; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Yu BZ, 1997, BIOCHEMISTRY-US, V36, P12400, DOI 10.1021/bi962972i; Zhu XD, 2001, J IMMUNOL, V167, P461, DOI 10.4049/jimmunol.167.1.461	59	128	133	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25024	25038		10.1074/jbc.M313019200	http://dx.doi.org/10.1074/jbc.M313019200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15007070	hybrid			2022-12-25	WOS:000221827900017
J	Chaudhuri, BN; Sum, C; Perry, LJ; Yeates, TO				Chaudhuri, BN; Sum, C; Perry, LJ; Yeates, TO			Crystal structure of the Apo forms of Psi 55 tRNA pseudouridine synthase from Mycobacterium tuberculosis - A hinge at the base of the catalytic cleft	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA; ESCHERICHIA-COLI; NORMAL GROWTH; ENZYMATIC FORMATION; PROTEIN MODELS; RECOGNITION; REFINEMENT; BINDING; GENE; TRUB	The three-dimensional structure of the RNA-modifying enzyme, Psi55 tRNA pseudouridine synthase from Mycobacterium tuberculosis, is reported. The 1.9-Angstrom resolution crystal structure reveals the enzyme, free of substrate, in two distinct conformations. The structure depicts an interesting mode of protein flexibility involving a hinged bending in the central beta-sheet of the catalytic module. Key parts of the active site cleft are also found to be disordered in the substrate-free form of the enzyme. The hinge bending appears to act as a clamp to position the substrate. Our structural data furthers the previously proposed mechanism of tRNA recognition. The present crystal structure emphasizes the significant role that protein dynamics must play in tRNA recognition, base flipping, and modification.	Univ Calif Los Angeles, Dept Energy, Inst Genom & Proteom, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biochem & Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Chaudhuri, BN (corresponding author), Univ Calif Los Angeles, Dept Energy, Inst Genom & Proteom, Los Angeles, CA 90095 USA.	neel@mbi.ucla.edu		Yeates, Todd/0000-0001-5709-9839	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI075320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062410] Funding Source: NIH RePORTER; NIAID NIH HHS [N01 AI-75320] Funding Source: Medline; NIGMS NIH HHS [1 P50 GM62410] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Aravind L, 1999, J MOL EVOL, V48, P291, DOI 10.1007/PL00006472; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13475, DOI 10.1021/bi00249a036; Becker HF, 1997, J MOL BIOL, V274, P505, DOI 10.1006/jmbi.1997.1417; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charette M, 2000, IUBMB LIFE, V49, P341; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Del Campo M, 2004, RNA, V10, P231, DOI 10.1261/rna.5187404; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11866, DOI 10.1021/bi9910878; Foster PG, 2000, NAT STRUCT BIOL, V7, P23; Goulding Celia W., 2002, Current Drug Targets - Infectious Disorders, V2, P121, DOI 10.2174/1568005023342551; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; Gu J, 1996, RNA, V2, P909; Gu XR, 1998, BIOCHEMISTRY-US, V37, P339, DOI 10.1021/bi971590p; Gutgsell N, 2000, RNA, V6, P1870, DOI 10.1017/S1355838200001588; Gutgsell NS, 2001, RNA, V7, P990, DOI 10.1017/S1355838201000243; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hoang C, 2001, CELL, V107, P929, DOI 10.1016/S0092-8674(01)00618-3; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOWLIN B, 1993, J APPL CRYSTALLOGR, V26, P622, DOI 10.1107/S0021889893002729; Ishitani R, 2003, CELL, V113, P383, DOI 10.1016/S0092-8674(03)00280-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kaya Y, 2003, RNA, V9, P711, DOI 10.1261/rna.5230603; Kinghorn SM, 2002, MICROBIOL-SGM, V148, P3511, DOI 10.1099/00221287-148-11-3511; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Lane BG, 1998, MODIFICATION EDITING, P1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOOMAN AC, 1987, EMBO J, V6, P2489, DOI 10.1002/j.1460-2075.1987.tb02530.x; Mueller EG, 2002, NAT STRUCT BIOL, V9, P320, DOI 10.1038/nsb0502-320; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan H, 2003, P NATL ACAD SCI USA, V100, P12648, DOI 10.1073/pnas.2135585100; Raychaudhuri S, 1998, RNA, V4, P1407, DOI 10.1017/S1355838298981146; Sanner M. F., 1995, Proceedings of the Eleventh Annual Symposium on Computational Geometry, pC6; Sivaraman J, 2004, J MOL BIOL, V335, P87, DOI 10.1016/j.jmb.2003.10.003; Sivaraman J, 2002, NAT STRUCT BIOL, V9, P353, DOI 10.1038/nsb788; Spies MA, 2002, J AM CHEM SOC, V124, P14049, DOI 10.1021/ja012272n; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yu YT, 1998, EMBO J, V17, P5783, DOI 10.1093/emboj/17.19.5783	47	22	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24585	24591		10.1074/jbc.M401045200	http://dx.doi.org/10.1074/jbc.M401045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15028724	hybrid			2022-12-25	WOS:000221702500088
J	Katoh, Y; Shiba, Y; Mitsuhashi, H; Yanagida, Y; Takatsu, H; Nakayama, K				Katoh, Y; Shiba, Y; Mitsuhashi, H; Yanagida, Y; Takatsu, H; Nakayama, K			Tollip and Tom1 form a complex and recruit ubiquitin-conjugated proteins onto early endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS; IL-1 RECEPTOR; VHS DOMAIN; GAT DOMAIN; HUMAN GGA1; CLATHRIN; HRS; GOLGI; PATHWAY; ARF	Tom1 (target of Myb1) is a protein of unknown function. Tom1 and its relative Tom1L1 have an N-terminal VHS (Vps27p/Hrs/Stam) domain followed by a GAT (GGA and Tom1) domain, both of which are also found in the GGA (Golgi-localizing, gamma-adaptin ear domain homology, ADP-ribosylation factor-binding protein) family of proteins. Although the VHS and GAT domains of GGA proteins bind to transmembrane cargo proteins and the small GTPase ADP-ribosylation factor, respectively, the VHS and GAT domains of Tom1 are unable to interact with these proteins. In this study, we show that the GAT domains of Tom1 and Tom1L1 interact with ubiquitin and Tollip (Toll-interacting protein). Ubiquitin bound the GAT domains of Tom1, Tom1L1, and GGA proteins, whereas Tollip interacted specifically with Tom1 and Tom1L1. Ubiquitin and Tollip bound to an overlapping region of the Tom1-GAT domain in a mutually exclusive manner. Tom1 was predominantly cytosolic when expressed in cells. On the other hand, Tollip was localized on early endosomes and recruited Tom1 and ubiquitinated proteins. These observations suggest that Tollip and Tom1 form a complex and regulate endosomal trafficking of ubiquitinated proteins.	Kyoto Univ, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa 9200934, Japan; RIKEN, Res Ctr Allergy & Immunol, Kanagawa 2300045, Japan; Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan	Kyoto University; University of Tsukuba; Kanazawa University; RIKEN; Kanazawa University	Nakayama, K (corresponding author), Kyoto Univ, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan.	kazunaka@pharm.kyoto-u.ac.jp	Katoh, Yohei/AAA-3378-2020; Nakayama, Kazuhisa/ABF-2924-2020; Shiba, Yoko/AAX-3885-2020	Shiba, Yoko/0000-0001-8229-541X; Katoh, Yohei/0000-0003-1649-4917; Nakayama, Kazuhisa/0000-0001-7701-7183				Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Collins BM, 2003, DEV CELL, V4, P321, DOI 10.1016/S1534-5807(03)00037-6; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hinners I, 2003, J CELL SCI, V116, P763, DOI 10.1242/jcs.00270; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Lohi O, 2002, FEBS LETT, V513, P19, DOI 10.1016/S0014-5793(01)03287-2; Nakayama K, 2003, CELL STRUCT FUNCT, V28, P431, DOI 10.1247/csf.28.431; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Seet LF, 2004, J BIOL CHEM, V279, P4670, DOI 10.1074/jbc.M311228200; Seykora JT, 2002, J BIOL CHEM, V277, P2812, DOI 10.1074/jbc.M106813200; Shiba T, 2003, NAT STRUCT BIOL, V10, P386, DOI 10.1038/nsb920; Shiba Y, 2004, J BIOL CHEM, V279, P7105, DOI 10.1074/jbc.M311702200; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Shin HW, 1997, J BIOCHEM-TOKYO, V122, P525; Suer S, 2003, P NATL ACAD SCI USA, V100, P4451, DOI 10.1073/pnas.0831133100; TAKADA K, 1995, EUR J BIOCHEM, V233, P42, DOI 10.1111/j.1432-1033.1995.042_1.x; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Takatsu H, 2002, BIOCHEM J, V365, P369, DOI 10.1042/BJ20020428; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Yamakami M, 2003, J BIOL CHEM, V278, P52865, DOI 10.1074/jbc.M306740200; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200; Zhu GY, 2003, BIOCHEMISTRY-US, V42, P6392, DOI 10.1021/bi034334n	39	113	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24435	24443		10.1074/jbc.M400059200	http://dx.doi.org/10.1074/jbc.M400059200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15047686	hybrid			2022-12-25	WOS:000221702500070
J	Furukawa, H; Doh-ura, K; Okuwaki, R; Shirabe, S; Yamamoto, K; Udono, H; Ito, T; Katamine, S; Niwa, M				Furukawa, H; Doh-ura, K; Okuwaki, R; Shirabe, S; Yamamoto, K; Udono, H; Ito, T; Katamine, S; Niwa, M			A pitfall in diagnosis of human prion diseases using detection of protease-resistant prion protein in urine - Contamination with bacterial outer membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; KLEBSIELLA-PNEUMONIAE; CEREBROSPINAL-FLUID; PORIN; SEQUENCE; BINDING	Because a definite diagnosis of prion diseases relies on the detection of the abnormal isoform of prion protein ( PrPSc), it has been urgently necessary to establish a non-invasive diagnostic test to detect PrPSc in human prion diseases. To evaluate diagnostic usefulness and reliability of the detection of protease-resistant prion protein in urine, we extensively analyzed proteinase K (PK)-resistant proteins in patients affected with prion diseases and control subjects by Western blot, a coupled liquid chromatography and mass spectrometry analysis, and N-terminal sequence analysis. The PK-resistant signal migrating around 32 kDa previously reported by Shaked et al. ( Shaked, G. M., Shaked, Y., Kariv-Inbal, Z., Halimi, M., Avraham, I., and Gabizon, R. ( 2001) J. Biol. Chem. 276, 31479 - 31482) was not observed in this study. Instead, discrete protein bands with an apparent molecular mass of similar to 37 kDa were detected in the urine of many patients affected with prion diseases and two diseased controls. Although these proteins also gave strong signals in the Western blot using a variety of anti-PrP antibodies as a primary antibody, we found that the signals were still detectable by incubation of secondary antibodies alone, i.e. in the absence of the primary anti-PrP antibodies. Mass spectrometry and N-terminal protein sequencing analysis revealed that the majority of the PK-resistant 37-kDa proteins in the urine of patients were outer membrane proteins (OMPs) of the Enterobacterial species. OMPs isolated from these bacteria were resistant to PK and the PK-resistant OMPs from the Enterobacterial species migrated around 37 kDa on SDS-PAGE. Furthermore, nonspecific binding of OMPs to antibodies could be mistaken for PrPSc. These findings caution that bacterial contamination can affect the immunological detection of prion protein. Therefore, the presence of Enterobacterial species should be excluded in the immunological tests for PrPSc in clinical samples, in particular, urine.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Pharmacol 1, Nagasaki 8528523, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Immunol, Nagasaki 8528523, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Internal Med 1, Nagasaki 8528523, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Biochem, Nagasaki 8528523, Japan; Tohoku Univ, Grad Sch Med, Dept Prion Res, Sendai, Miyagi 9808575, Japan; RIKEN, Yokohama Inst, Res Ctr Allergy & Immunol, Lab Immunochaperones, Yokohama, Kanagawa 2300045, Japan	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Tohoku University; RIKEN	Furukawa, H (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Pharmacol 1, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	hisako@net.nagasaki-u.ac.jp						ALBERTI S, 1993, INFECT IMMUN, V61, P852; ALBERTI S, 1995, INFECT IMMUN, V63, P903; Benz R., 1994, BACTERIAL CELL WALL, P397; Bieschke J, 2000, P NATL ACAD SCI USA, V97, P5468, DOI 10.1073/pnas.97.10.5468; Castellani R, 1996, NEUROLOGY, V46, P1690, DOI 10.1212/WNL.46.6.1690; Demaerel P, 1997, LANCET, V349, P847, DOI 10.1016/S0140-6736(05)61750-3; Hernandez-Alles S, 1999, MICROBIOL-UK, V145, P673, DOI 10.1099/13500872-145-3-673; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; KESSLER SW, 1975, J IMMUNOL, V115, P1617; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; Riemenschneider M, 2003, MOL PSYCHIATR, V8, P343, DOI 10.1038/sj.mp.4001220; Shaked GM, 2001, J BIOL CHEM, V276, P31479, DOI 10.1074/jbc.C100278200; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; World Health Organisation, 2000, WHO INF CONTR GUID T	15	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23661	23667		10.1074/jbc.M400187200	http://dx.doi.org/10.1074/jbc.M400187200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15031285	hybrid			2022-12-25	WOS:000221570900108
J	Ju, PC; Aubrey, KR; Vandenberg, RJ				Ju, PC; Aubrey, KR; Vandenberg, RJ			Zn2+ inhibits glycine transport by glycine transporter subtype 1b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-D-ASPARTATE; HUMAN DOPAMINE TRANSPORTER; RAT-BRAIN; SEROTONIN TRANSPORTER; ENDOGENOUS ZINC; MOLECULAR-BASIS; NMDA RECEPTORS; BINDING SITES; CLONING; ACID	In the central nervous system, glycine is a co-agonist with glutamate at the N-methyl-D-aspartate subtype of glutamate receptors and also an agonist at inhibitory, strychnine-sensitive glycine receptors. The GLYT1 subtypes of glycine transporters (GLYTs) are responsible for regulation of glycine at excitatory synapses, whereas a combination of GLYT1 and GLYT2 subtypes of glycine transporters are used at inhibitory glycinergic synapses. Zn2+ is stored in synaptic vesicles with glutamate in a number of regions of the brain and is believed to play a role in modulation of excitatory neurotransmission. In this study we have investigated the actions of Zn2+ on the glycine transporters, GLYT1b and GLYT2a, expressed in Xenopus laevis oocytes and we demonstrate that Zn2+ is a noncompetitive inhibitor of GLYT1 but has no effect on GLYT2. We have also investigated the molecular basis for these differences and the relationship between the Zn2+ and proton binding sites on GLYT1. Using site-directed mutagenesis, we identified 2 histidine residues, His-243 in the large second extracellular loop (ECL2) and His-410 in the fourth extracellular loop (ECL4), as two coordinates in the Zn2+ binding site of GLYT1b. In addition, our study suggests that the molecular determinants of proton regulation of GLYT1b are localized to the 2 histidine residues (His-410 and His-421) of ECL4. The ability of Zn2+ and protons to regulate the rate of glycine transport by interacting with residues situated in ECL4 of GLYT1b suggests that this region may influence the substrate translocation mechanism.	Univ Sydney, Inst Biomed Res, Dept Pharmacol, Sydney, NSW 2006, Australia	University of Sydney	Vandenberg, RJ (corresponding author), Univ Sydney, Inst Biomed Res, Dept Pharmacol, Sydney, NSW 2006, Australia.	robv@pharmacol.usyd.edu.au	, Karin/R-3241-2019; Aubrey, Karin/J-6526-2012; Vandenberg, Robert John/E-6018-2016	, Karin/0000-0002-1808-4041; Aubrey, Karin/0000-0002-1808-4041; Vandenberg, Robert John/0000-0003-1523-4814				Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; APRISON M. H., 1965, LIFE SCI, V4, P2075, DOI 10.1016/0024-3205(65)90325-5; ARAGON MC, 1987, FEBS LETT, V212, P87, DOI 10.1016/0014-5793(87)81562-4; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Aubrey KR, 2000, MOL PHARMACOL, V58, P129, DOI 10.1124/mol.58.1.129; Berger AJ, 1998, J NEUROPHYSIOL, V80, P3336, DOI 10.1152/jn.1998.80.6.3336; Bergeron R, 1998, P NATL ACAD SCI USA, V95, P15730, DOI 10.1073/pnas.95.26.15730; BUSSELBERG D, 1994, J NEUROPHYSIOL, V71, P1491, DOI 10.1152/jn.1994.71.4.1491; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; Danysz W, 1998, PHARMACOL REV, V50, P597; DAWSON RMC, 1986, DATA BIOMEDICAL RES; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; Hanley JG, 2000, J BIOL CHEM, V275, P840, DOI 10.1074/jbc.275.2.840; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Huang EP, 1997, P NATL ACAD SCI USA, V94, P13386, DOI 10.1073/pnas.94.25.13386; JURSKY F, 1995, J NEUROCHEM, V64, P1026; Kamdar G, 2001, J BIOL CHEM, V276, P4038, DOI 10.1074/jbc.M008483200; KIM KM, 1994, MOL PHARMACOL, V45, P608; Kinney GG, 2003, J NEUROSCI, V23, P7586; Laube B, 2002, EUR J NEUROSCI, V16, P1025, DOI 10.1046/j.1460-9568.2002.02170.x; LIU QR, 1993, J BIOL CHEM, V268, P22802; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; MacAulay N, 2001, J BIOL CHEM, V276, P40476, DOI 10.1074/jbc.M105578200; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; Mitrovic AD, 2001, J BIOL CHEM, V276, P26071, DOI 10.1074/jbc.M011318200; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Pearlman RJ, 2003, J NEUROCHEM, V84, P592, DOI 10.1046/j.1471-4159.2003.01549.x; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; Ponce J, 1998, NEUROSCI LETT, V242, P25, DOI 10.1016/S0304-3940(98)00037-8; Poyatos I, 1997, MOL BRAIN RES, V49, P63, DOI 10.1016/S0169-328X(97)00124-1; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; Roux MJ, 2000, NEURON, V25, P373, DOI 10.1016/S0896-6273(00)80901-0; Roux MJ, 2001, J BIOL CHEM, V276, P17699, DOI 10.1074/jbc.M009196200; Smicun Y, 1999, J BIOL CHEM, V274, P36058, DOI 10.1074/jbc.274.51.36058; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; Sonders MS, 1997, J NEUROSCI, V17, P960; Spike RC, 1997, NEUROSCIENCE, V77, P543, DOI 10.1016/S0306-4522(96)00501-5; Spiridon M, 1998, J PHYSIOL-LONDON, V506, P363, DOI 10.1111/j.1469-7793.1998.363bw.x; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Vandenberg RJ, 1997, MOL PHARMACOL, V51, P809, DOI 10.1124/mol.51.5.809; Vandenberg RJ, 1998, MOL PHARMACOL, V54, P189, DOI 10.1124/mol.54.1.189; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; XIE XM, 1991, NATURE, V349, P521, DOI 10.1038/349521a0; ZAFRA F, 1995, J NEUROSCI, V15, P3952	47	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22983	22991		10.1074/jbc.M312484200	http://dx.doi.org/10.1074/jbc.M312484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15031290	hybrid			2022-12-25	WOS:000221570900025
J	Miko, A; Werby, E; Sun, H; Healey, J; Zhang, L				Miko, A; Werby, E; Sun, H; Healey, J; Zhang, L			A TM2 residue in the beta 1 subunit determines spontaneous opening of homomeric and heteromeric gamma-aminobutyric acid-gated ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA SUBUNITS; GENERAL ANESTHETIC ETOMIDATE; GABA-A RECEPTORS; AMINO-ACID; FUNCTIONAL EXPRESSION; CHLORIDE CHANNELS; MOLECULAR VOLUME; ALPHA-SUBUNIT; RAT-BRAIN; DISTINCT	gamma-Aminobutyric acid type A (GABA(A)) receptors are major inhibitory neurotransmitter-gated ion channels in the central nervous system. GABA(A) receptors consist of multiple subunits and exhibit distinct pharmacological and channel properties. Of all GABA(A) receptor subunits, the beta subunit is thought to be a key component for the functionality of the receptors. Certain types of GABA(A) receptors have been found to be constitutively active. However, the molecular basis for spontaneous opening of channels of these receptors is not totally understood. In this study, we showed that channels that contain the beta1 but not beta3 subunits opened spontaneously when these subunits were expressed homomerically or co-expressed with other types of GABA(A) receptor subunits in Xenopus oocytes. Using subunit chimeras and site-directed mutagenesis, we localized a key amino acid residue, a serine at position 265, that is critical in conferring an open state of the beta1 subunit-containing GABA(A) receptors in the absence of agonist. Moreover, some point mutations of Ser-265 also produced constitutively active channels. The magnitude of spontaneous activity of these receptors was correlated with the molecular volume of the residue at 265 for both homomeric and heteromeric GABA(A) receptors, suggesting that the spontaneous activity of the beta1 subunit-containing GABA(A) receptors may be mediated through a similar molecular mechanism that is dependent on the molecular volume of the residue at 265.	NIAAA, Lab Mol & Cellular Neurobiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Zhang, L (corresponding author), NIAAA, Lab Mol & Cellular Neurobiol, NIH, Pk Bldg,Rm 150, Bethesda, MD 20892 USA.	lzhang@niaaa.nih.gov			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000007] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Beckstead MJ, 2002, J NEUROCHEM, V82, P1343, DOI 10.1046/j.1471-4159.2002.01086.x; Belelli D, 1997, P NATL ACAD SCI USA, V94, P11031, DOI 10.1073/pnas.94.20.11031; BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; Cestari IN, 1996, NEUROREPORT, V7, P943, DOI 10.1097/00001756-199603220-00023; Cestari IN, 2000, J NEUROCHEM, V74, P827, DOI 10.1046/j.1471-4159.2000.740827.x; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; Davies PA, 1997, BRIT J PHARMACOL, V120, P899, DOI 10.1038/sj.bjp.0700987; Findlay GS, 2001, NEUROSCI LETT, V305, P76, DOI 10.1016/S0304-3940(01)01879-1; HAMANN M, 1990, MOL PHARMACOL, V37, P578; HillVenning C, 1997, BRIT J PHARMACOL, V120, P749, DOI 10.1038/sj.bjp.0700927; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; Kash TL, 2003, BRAIN RES, V960, P36, DOI 10.1016/S0006-8993(02)03748-4; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; Krishek BJ, 1996, MOL PHARMACOL, V49, P494; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MALHERBE P, 1990, FEBS LETT, V260, P261, DOI 10.1016/0014-5793(90)80118-3; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MATHERS DA, 1985, CAN J PHYSIOL PHARM, V63, P1228, DOI 10.1139/y85-203; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Mortensen M, 2003, EUR J PHARMACOL, V476, P17, DOI 10.1016/S0014-2999(03)02125-3; Neelands TR, 1999, MOL PHARMACOL, V55, P168, DOI 10.1124/mol.55.1.168; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; Reynolds DS, 2003, J NEUROSCI, V23, P8608; SANNA E, 1995, MOL PHARMACOL, V47, P213; Scheller M, 2002, J NEUROSCI, V22, P8411; SIGEL E, 1989, FEBS LETT, V257, P377, DOI 10.1016/0014-5793(89)81576-5; Sigel E, 1996, TRENDS NEUROSCI, V19, P386, DOI 10.1016/S0166-2236(96)20032-3; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; TALEB O, 1987, PFLUG ARCH EUR J PHY, V409, P620, DOI 10.1007/BF00584663; Taylor PM, 2000, J NEUROSCI, V20, P1297; Taylor PM, 1999, J NEUROSCI, V19, P6360; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; Ueno S, 2001, ALCOHOL CLIN EXP RES, V25, p76S, DOI 10.1097/00000374-200105051-00014; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; Wooltorton JRA, 1997, EUR J NEUROSCI, V9, P2225, DOI 10.1111/j.1460-9568.1997.tb01641.x; Ye Q, 1998, J BIOL CHEM, V273, P3314, DOI 10.1074/jbc.273.6.3314; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; Zhang L, 2002, J BIOL CHEM, V277, P46256, DOI 10.1074/jbc.M207683200; Zhang L, 1997, J NEUROPHYSIOL, V78, P582, DOI 10.1152/jn.1997.78.2.582; ZIMMERMAN JM, 1968, J THEOR BIOL, V21, P170, DOI 10.1016/0022-5193(68)90069-6	46	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22833	22840		10.1074/jbc.M402577200	http://dx.doi.org/10.1074/jbc.M402577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15014066	hybrid			2022-12-25	WOS:000221570900008
J	Saridakis, V; Yakunin, A; Xu, XH; Anandakumar, P; Pennycooke, M; Gu, J; Cheung, F; Lew, JM; Sanishvili, R; Joachimiak, A; Arrowsmith, CH; Christendat, D; Edwards, AM				Saridakis, V; Yakunin, A; Xu, XH; Anandakumar, P; Pennycooke, M; Gu, J; Cheung, F; Lew, JM; Sanishvili, R; Joachimiak, A; Arrowsmith, CH; Christendat, D; Edwards, AM			The structural basis for methylmalonic aciduria - The crystal structure of archaeal ATP: Cobalamin adenosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; METHANOBACTERIUM-THERMOAUTOTROPHICUM; CORRINOID ADENOSYLTRANSFERASE; COMPLEMENTATION GROUP; METHIONINE SYNTHASE; GENE; IDENTIFICATION; VITAMIN-B-12; BIOSYNTHESIS; MUTANT	ATP: cobalamin adenosyltransferase MMAB was recently identified as the gene responsible for a disorder of cobalamin metabolism in humans (cblB complementation group). The crystal structure of the MMAB sequence homologue from Thermoplasma acidophilum (TA1434; GenBank(TM) identification number gi\16082403) was determined to a resolution of 1.5 Angstrom. TA1434 was confirmed to be an ATP: cobalamin adenosyltransferase, which depended absolutely on divalent metal ions (Mg2+ >Mn2+ > Co2+) and only used ATP or dATP as adenosyl donors. The apparent K-m of TA1434 was 110 muM (k(cat) = 0.23 s(-1)) for ATP, 140 muM ( k(cat) = 0.11 s(-1)) for dATP, and 3 muM ( k(cat) = 0.18 s(-1)) for cobalamin. TA1434 is a trimer in solution and in the crystal structure, with each subunit composed of a five-helix bundle. The location of disease-related point mutations and other residues conserved among the homologues of TA1434 suggest that the active site lies at the junctions between the subunits. Mutations in TA1434 that correspond to the disease-related mutations resulted in proteins that were inactive for ATP: cobalamin adenosyltransferase activity in vitro, confirming that these mutations define the molecular basis of the human disease.	Univ Toronto, Banting & Best Dept Med Res, CH Best Inst, Toronto, ON M5G 1L6, Canada; Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L6, Canada; Univ Hlth Network, Clin Genom Ctr, Toronto, ON M5G 1L7, Canada; Argonne Natl Lab, Struct Biol Ctr, Biosci Div, Argonne, IL 60439 USA; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada	University of Toronto; University of Toronto; Structural Genomics Consortium; University of Toronto; University Toronto Affiliates; University Health Network Toronto; United States Department of Energy (DOE); Argonne National Laboratory; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Edwards, AM (corresponding author), Univ Toronto, Banting & Best Dept Med Res, CH Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.	aled.edwards@utoronto.ca	Yakunin, Alexander/J-1519-2014	Arrowsmith, Cheryl/0000-0002-4971-3250; Edwards, Aled/0000-0002-4782-6016; Yakunin, Alexander/0000-0003-0813-6490				Andrews SC, 1998, ADV MICROB PHYSIOL, V40, P281, DOI 10.1016/S0065-2911(08)60134-4; Banerjee R., 1999, Chemistry and biochemistry of B12., P707; Bauer CB, 2001, BIOCHEMISTRY-US, V40, P361, DOI 10.1021/bi002145o; BOBIK TA, 1989, J BACTERIOL, V171, P1423, DOI 10.1128/jb.171.3.1423-1427.1989; Christendat D, 2000, J BIOL CHEM, V275, P24608, DOI 10.1074/jbc.C000238200; Dobson CM, 2002, HUM MOL GENET, V11, P3361, DOI 10.1093/hmg/11.26.3361; Dobson CM, 2002, P NATL ACAD SCI USA, V99, P15554, DOI 10.1073/pnas.242614799; Drennan CL, 1996, P NATL ACAD SCI USA, V93, P5550, DOI 10.1073/pnas.93.11.5550; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; FENTON WA, 1995, METABOLIC MOL BASES, P3129; Fonseca MV, 2001, J BIOL CHEM, V276, P32101, DOI 10.1074/jbc.M102510200; Fonseca MV, 2002, J BIOL CHEM, V277, P33127, DOI 10.1074/jbc.M203893200; Harding CO, 1997, AM J MED GENET, V71, P384, DOI 10.1002/(SICI)1096-8628(19970905)71:4<384::AID-AJMG3>3.0.CO;2-U; Ilari A, 2000, NAT STRUCT BIOL, V7, P38; Johnson CLV, 2001, J BACTERIOL, V183, P1577, DOI 10.1128/JB.183.5.1577-1584.2001; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leal NA, 2003, J BIOL CHEM, V278, P9227, DOI 10.1074/jbc.M212739200; Martens JH, 2002, APPL MICROBIOL BIOT, V58, P275, DOI 10.1007/s00253-001-0902-7; Raux E, 2000, CELL MOL LIFE SCI, V57, P1880, DOI 10.1007/PL00000670; Rosenblatt D. S., 2001, METABOLIC MOL BASES, V8th, P3897; Roth JR, 1996, ANNU REV MICROBIOL, V50, P137, DOI 10.1146/annurev.micro.50.1.137; SUH SJ, 1995, J BACTERIOL, V177, P921, DOI 10.1128/jb.177.4.921-925.1995	22	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23646	23653		10.1074/jbc.M401395200	http://dx.doi.org/10.1074/jbc.M401395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044458	hybrid			2022-12-25	WOS:000221570900106
J	Ancsin, JB; Kisilevsky, R				Ancsin, JB; Kisilevsky, R			A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoite protein - Significance for malarial sporozoite attachment to hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-E; FUNCTIONAL-PROPERTIES; FIBROBLAST-GROWTH; CELL-SURFACE; II-PLUS; GLYCOSAMINOGLYCAN; PROTEOGLYCANS; DOMAIN; CLEARANCE; INVASION	Circumsporozoite protein ( CSP) coats the malarial sporozoite and functions to target the liver for infection, which is the first step to developing malaria. An important tissue ligand for CSP is the glycosaminoglycan heparan sulfate ( HS) found on the surface of hepatocytes and in the basement membrane of the space of Disse. To better understand this efficient targeting process, we set out to identify and characterize the HS binding site( s) of CSP. We synthesized a series of peptides corresponding to five regions of Plasmodium falciparum CSP containing basic residues, a common requirement of HS binding sites, and screened them for heparin and HS binding activity. Only one of these peptides ( Pf 2), which contains a motif we have named region I- plus, demonstrated both high affinity heparin/ HS binding activity and the ability to block the binding of recombinant CSP to heparin- Sepharose 4B. Analysis by isothermal titration calorimetry revealed that region I- plus has a binding constant of K-d = 5.0 mum M and a stoichiometry of n = 7.8 binding sites/ heparin chain. Heparin binding was dependent on the amino acid sequence of region I- plus, and the binding sites on heparin/ HS are contained within a decasaccharide. Furthermore, HS oligosaccharides rich in sulfate and iduronic acid content ( heparin- like) are required for efficient binding. Because liver HS is exceptionally high in both these components relative to the HS of other organs, the HS structural requirements for efficient region I- plus/ HS binding are consistent with this peptide sequence functioning to target sporozoites to the liver for attachment to hepatocytes. Finally, the region I- plus heparin/ HS binding site was also discovered for two other species that infect humans, Plasmodium malariae and Plasmodium vivax, further supporting the existence of a HS binding domain in the N- terminal portion of CSP.	Queens Univ, Dept Pathol & Lab Med, Kingston, ON K7L 3N6, Canada; Kingston Gen Hosp, Syl & Molly Apps Res Ctr, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Ancsin, JB (corresponding author), Queens Univ, Dept Pathol & Lab Med, Kingston, ON K7L 3N6, Canada.	3jba1@post.queensu.ca						BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Caldwell EEO, 1996, INT J BIOCHEM CELL B, V28, P203, DOI 10.1016/1357-2725(95)00123-9; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1994, J EXP MED, V179, P695, DOI 10.1084/jem.179.2.695; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; GRESSNER AM, 1989, J CLIN CHEM CLIN BIO, V27, P141; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JI ZS, 1995, J LIPID RES, V36, P583; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; LAWLER J, 1986, BLOOD, V67, P1197; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; McCutchan TF, 1996, P NATL ACAD SCI USA, V93, P11889, DOI 10.1073/pnas.93.21.11889; MILLET P, 1994, J PARASITOL, V80, P384, DOI 10.2307/3283408; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; Pinzon-Ortiz C, 2001, J BIOL CHEM, V276, P26784, DOI 10.1074/jbc.M104038200; Pradel G, 2002, MOL MICROBIOL, V45, P637, DOI 10.1046/j.1365-2958.2002.03057.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rathore D, 2000, P NATL ACAD SCI USA, V97, P8530, DOI 10.1073/pnas.140224597; Rathore D, 2002, J BIOL CHEM, V277, P7092, DOI 10.1074/jbc.M106862200; Rathore D, 2001, BIOCHEMISTRY-US, V40, P11518, DOI 10.1021/bi0105476; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Shakibaei M, 1996, J EXP MED, V184, P1699, DOI 10.1084/jem.184.5.1699; SHIN SCJ, 1982, J PROTOZOOL, V29, P448, DOI 10.1111/j.1550-7408.1982.tb05431.x; Silverstein RL, 2002, J CELL BIOL, V159, P203, DOI 10.1083/jcb.200209138; Sinnis P, 1996, J EXP MED, V184, P945, DOI 10.1084/jem.184.3.945; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; Sinnis P, 1996, INFECT AGENT DIS, V5, P182; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SMITH PK, 1980, ANAL BIOCHEM, V109, P466, DOI 10.1016/0003-2697(80)90679-X; SOBEL M, 1992, J BIOL CHEM, V267, P8857; TAYLOR RL, 1973, BIOCHEMISTRY-US, V12, P3633, DOI 10.1021/bi00743a010; UHLINHANSEN L, 1988, J BIOL CHEM, V263, P2526; UNGUREANU E, 1976, T ROY SOC TROP MED H, V70, P482, DOI 10.1016/0035-9203(76)90133-4; Wadstrom T, 1999, J MED MICROBIOL, V48, P223, DOI 10.1099/00222615-48-3-223; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Ying P, 1997, EXP PARASITOL, V85, P168, DOI 10.1006/expr.1996.4134; Zhu H, 2001, MOL MED, V7, P517, DOI 10.1007/BF03401857; [No title captured]	52	66	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21824	21832		10.1074/jbc.M401979200	http://dx.doi.org/10.1074/jbc.M401979200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007056	hybrid			2022-12-25	WOS:000221417100020
J	Deng, XB; Mercer, SE; Shah, S; Ewton, DZ; Friedman, E				Deng, XB; Mercer, SE; Shah, S; Ewton, DZ; Friedman, E			The cyclin-dependent kinase inhibitor p27(Kip1) is stabilized in G(0) by Mirk/dyrk1B kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERACTING PROTEIN KINASE-2; ELEMENT-BINDING PROTEIN; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATOR; RESTRICTION POINT; PROGENITOR CELLS; NUCLEAR EXPORT; PHOSPHORYLATION; P27; DIFFERENTIATION	Elevated levels of the cyclin-dependent kinase (CDK) inhibitor p27 block the cell in G(0)/G(1) until mitogenic signals activate G(1) cyclins and initiate proliferation. Posttranslational regulation of p27 by different phosphorylation events is critical in allowing cells to proceed through the cell cycle. We now demonstrate that the arginine-directed kinase, Mirk/dyrk1B, is maximally active in G(0) in NIH3T3 cells, when it stabilizes p27 by phosphorylating it at Ser-10. The phospho-mimetic mutant p27-S10D was more stable, and the non-phosphorylatable mutant p27-S10A was less stable than wild-type when expressed in G(0)-arrested cells. Following phosphorylation by Mirk, p27 remains a functional CDK inhibitor, capable of binding to CDK2. Mirk did not induce the translocation of p27 from the nucleus in G(0), but instead co-localized with nuclear p27. Depletion of Mirk by RNA interference decreased the phosphorylation of p27 at Ser-10 and the stability of endogenous p27. RNA(i) to Mirk increased cell entry from G(0) into G(1) as shown by increased expression of proliferating cell nuclear antigen and decreased expression of p27. These data suggest a model in which Mirk increases the amount of nuclear p27 by stabilizing it during G(0) when Mirk is most abundant. Mitogen stimulation then causes cells to enter G(1), reduces Mirk levels (Deng, X., Ewton, D., Pawlikowski, B., Maimone, M., and Friedman, E. (2003) J. Biol. Chem. 278, 41347-41354), and initiates the translocation of p27 to the cytoplasm. In addition, depletion of Mirk by RNAi in postmitotic C2C12 myoblasts decreased protein but not mRNA levels of p27, suggesting that stabilization of p27 by Mirk also occurs during differentiation.	SUNY Syracuse, Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Friedman, E (corresponding author), SUNY Syracuse, Upstate Med Univ, Dept Pathol, 750 E Adams St, Syracuse, NY 13210 USA.	friedmae@upstate.edu			NATIONAL CANCER INSTITUTE [R01CA067405] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA67405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; Deng XB, 2003, J BIOL CHEM, V278, P41347, DOI 10.1074/jbc.M306780200; Ewton DZ, 2003, INT J CANCER, V103, P21, DOI 10.1002/ijc.10743; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Geiger JN, 2001, BLOOD, V97, P901, DOI 10.1182/blood.V97.4.901; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Lee K, 2000, CANCER RES, V60, P3631; Lee K.-M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P273; Li K, 2002, J BIOL CHEM, V277, P47052, DOI 10.1074/jbc.M205374200; Lim S, 2002, J BIOL CHEM, V277, P49438, DOI 10.1074/jbc.M206840200; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200; Zou YL, 2003, J BIOL CHEM, V278, P49573, DOI 10.1074/jbc.M307556200	30	98	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22498	22504		10.1074/jbc.M400479200	http://dx.doi.org/10.1074/jbc.M400479200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15010468	hybrid			2022-12-25	WOS:000221417100100
J	Park, JY; Kang, HW; Jeong, SW; Lee, JH				Park, JY; Kang, HW; Jeong, SW; Lee, JH			Multiple structural elements contribute to the slow kinetics of the Cav3.3 T-type channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLTAGE-DEPENDENT INACTIVATION; CARBOXYL-TERMINAL REGION; CALCIUM-CHANNELS; MOLECULAR DETERMINANTS; CA2+ CHANNELS; GATING PROPERTIES; THALAMIC NEURONS; SUBUNIT; CELLS; ALPHA(1A)	Molecular cloning and expression studies established the existence of three T- type Ca2+ channel ( Ca(v)3) alpha(1) subunits: Ca(v)3.1 ( alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 ( alpha(1I)). Although all three channels are low voltage- activated, they display considerable differences in their kinetics, with Ca(v)3.1 and Ca(v)3.2 channels activating and inactivating much faster than Ca(v)3.3 channels. The goal of the present study was to determine the structural elements that confer the distinctively slow kinetics of Ca(v)3.3 channels. To address this question, a series of chimeric channels between Ca(v)3.1 and Ca(v)3.3 channels were constructed and expressed in Xenopus oocytes. Kinetic analysis showed that the slow activation and inactivation kinetics of the Ca(v)3.3 channel were not completely abolished by substitution with any one portion of the Ca(v)3.1 channel. Likewise, the Ca(v)3.1 channel failed to acquire the slow kinetics by simply adopting one portion of the Ca(v)3.3 channel. These findings suggest that multiple structural elements contribute to the slow kinetics of Ca(v)3.3 channels	Sogang Univ, Dept Life Sci, Seoul 121742, South Korea; Yonsei Univ, Wonju Coll Med, Inst Basic Med Sci, Wonju, Kangwon Do, South Korea; Yonsei Univ, Wonju Coll Med, Dept Physiol, Wonju, Kangwon Do, South Korea	Sogang University; Yonsei University; Yonsei University	Lee, JH (corresponding author), Sogang Univ, Dept Life Sci, Shinsu Dong 1, Seoul 121742, South Korea.	jhleem@ccs.sogang.ac.kr						ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; Berjukow S, 2001, J BIOL CHEM, V276, P17076, DOI 10.1074/jbc.M010491200; Bernatchez G, 1998, BIOPHYS J, V75, P1727, DOI 10.1016/S0006-3495(98)77614-3; Berrou L, 2001, BIOPHYS J, V80, P215, DOI 10.1016/S0006-3495(01)76008-0; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; Chemin J, 2001, EUR J NEUROSCI, V14, P1678, DOI 10.1046/j.0953-816x.2001.01796.x; Chemin J, 2001, BIOPHYS J, V80, P1238, DOI 10.1016/S0006-3495(01)76100-0; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; EAHOLTZ G, 1994, NEURON, V12, P1041, DOI 10.1016/0896-6273(94)90312-3; HAGIWARA N, 1988, J PHYSIOL-LONDON, V395, P233, DOI 10.1113/jphysiol.1988.sp016916; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; Lee JH, 1999, J NEUROSCI, V19, P1912; LLINAS R, 1982, NATURE, V297, P406, DOI 10.1038/297406a0; Marksteiner R, 2001, J PHYSIOL-LONDON, V537, P27, DOI 10.1111/j.1469-7793.2001.0027k.x; Martinez ML, 1999, J MOL CELL CARDIOL, V31, P1617, DOI 10.1006/jmcc.1999.0998; McRory JE, 2001, J BIOL CHEM, V276, P3999, DOI 10.1074/jbc.M008215200; Murbartian J, 2002, FEBS LETT, V528, P272, DOI 10.1016/S0014-5793(02)03341-0; Pan ZH, 2001, NEURON, V32, P89, DOI 10.1016/S0896-6273(01)00454-8; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Randall AD, 1997, NEUROPHARMACOLOGY, V36, P879, DOI 10.1016/S0028-3908(97)00086-5; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Spaetgens RL, 1999, J BIOL CHEM, V274, P22428, DOI 10.1074/jbc.274.32.22428; Staes M, 2001, J PHYSIOL-LONDON, V530, P35, DOI 10.1111/j.1469-7793.2001.0035m.x; Stephens GJ, 2000, J PHYSIOL-LONDON, V525, P377, DOI 10.1111/j.1469-7793.2000.t01-1-00377.x; Stotz SC, 2000, J BIOL CHEM, V275, P24575, DOI 10.1074/jbc.M000399200; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; ZHOU ZF, 1994, J MOL CELL CARDIOL, V26, P1211, DOI 10.1006/jmcc.1994.1139	40	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21707	21713		10.1074/jbc.M400684200	http://dx.doi.org/10.1074/jbc.M400684200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016809	hybrid			2022-12-25	WOS:000221417100005
J	Szewczuk, LM; Forti, L; Stivala, LA; Penning, TM				Szewczuk, LM; Forti, L; Stivala, LA; Penning, TM			Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2 - A mechanistic approach to the design of COX-1 selective agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE; HIGHER OXIDATION-STATES; INHIBITS PLATELET-AGGREGATION; IN-VITRO; RED WINE; ENDOPEROXIDES; ASPIRIN; PROSTACYCLIN; BIOSYNTHESIS; ENZYME	Resveratrol ( 3,4', 5- trihydroxy- trans- stilbene) is a phytoalexin found in grapes that has anti- inflammatory, cardiovascular protective, and cancer chemopreventive properties. It has been shown to target prostaglandin H-2 synthase ( COX)- 1 and COX- 2, which catalyze the first committed step in the synthesis of prostaglandins via sequential cyclooxygenase and peroxidase reactions. Resveratrol discriminates between both COX isoforms. It is a potent inhibitor of both catalytic activities of COX- 1, the desired drug target for the prevention of cardiovascular disease, but only a weak inhibitor of the peroxidase activity of COX- 2, the isoform target for nonsteroidal anti- inflammatory drugs. We have investigated the unique inhibitory properties of resveratrol. We find that it is a potent peroxidase- mediated mechanism-based inactivator of COX- 1 only ( k(inact) = 0.069 +/- 0.004 s(-1), K-i( inact) = 1.52 +/- 0.15 muM), with a calculated partition ratio of 22. Inactivation of COX- 1 was time- and concentration- dependent, it had an absolute requirement for a peroxide substrate, and it was accompanied by a concomitant oxidation of resveratrol. Resveratrol-inactivated COX- 1 was devoid of both the cyclooxygenase and peroxidase activities, neither of which could be restored upon gel- filtration chromatography. Inactivation of COX- 1 by [ H-3] resveratrol was not accompanied by stable covalent modification as evident by both SDS-PAGE and reverse phase- high performance liquid chromatography analysis. Structure activity relationships on methoxy- resveratrol analogs showed that the m- hydroquinone moiety was essential for irreversible inactivation of COX- 1. We propose that resveratrol inactivates COX- 1 by a " hit- and- run" mechanism, and offers a basis for the design of selective COX- 1 inactivators that work through a mechanism- based event at the peroxidase active site.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Modena & Reggio Emilia, Dipartimento Chim, I-41100 Modena, Italy; Univ Pavia, Dipartimento Med Sperimentale, Sez Patol Gen, I-27100 Pavia, Italy	University of Pennsylvania; University of Pennsylvania; Universita di Modena e Reggio Emilia; University of Pavia	Penning, TM (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.	penning@pharm.med.upenn.edu	Luca, Forti/C-9876-2015; Forti, Luca/AAY-9976-2021	Luca, Forti/0000-0002-5662-7756; Forti, Luca/0000-0002-5662-7756; Penning, Trevor/0000-0002-3937-1066				AMEZCUA JL, 1979, THROMB RES, V16, P69, DOI 10.1016/0049-3848(79)90270-6; BUNTING S, 1983, BRIT MED BULL, V39, P271, DOI 10.1093/oxfordjournals.bmb.a071832; BUNTING S, 1976, PROSTAG OTH LIPID M, V12, P897, DOI 10.1016/0090-6980(76)90125-8; Cichewicz RH, 2000, J NAT PROD, V63, P29, DOI 10.1021/np990266n; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DIVI RL, 1994, BIOCHEMISTRY-US, V33, P9668, DOI 10.1021/bi00198a036; EGAN RW, 1976, J BIOL CHEM, V251, P7329; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; George HJ, 1996, PROTEIN EXPRES PURIF, V7, P19, DOI 10.1006/prep.1996.0003; Gunther MR, 2002, J BIOL CHEM, V277, P9160, DOI 10.1074/jbc.M107342200; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Johnson JL, 1998, PROSTAG OTH LIPID M, V56, P131, DOI 10.1016/S0090-6980(98)00052-5; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Kirk RI, 2000, BLOOD CELL MOL DIS, V26, P144, DOI 10.1006/bcmd.2000.0289; KITZ R, 1962, J BIOL CHEM, V237, P3245; KORBUT R, 1978, THROMB RES, V13, P489, DOI 10.1016/0049-3848(78)90134-2; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; PACEASCIAK CR, 1995, CLIN CHIM ACTA, V235, P207, DOI 10.1016/0009-8981(95)06045-1; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; Patrono C, 2001, CHEST, V119, p39S, DOI 10.1378/chest.119.1_suppl.39S; Pezet R, 2003, J AGR FOOD CHEM, V51, P5488, DOI 10.1021/jf030227o; Rouzer CA, 2003, CHEM REV, V103, P2239, DOI 10.1021/cr000068x; SAMUELSS.B, 1965, J AM CHEM SOC, V87, P3011, DOI 10.1021/ja01091a043; Selinsky BS, 2001, BIOCHEMISTRY-US, V40, P5172, DOI 10.1021/bi010045s; Stivala LA, 2001, J BIOL CHEM, V276, P22586, DOI 10.1074/jbc.M101846200; STRIEDER S, 1992, J BIOL CHEM, V267, P13870; UCHIDA K, 1994, J BIOL CHEM, V269, P2405; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wang ZR, 2002, CHINESE MED J-PEKING, V115, P378; Wang ZR, 2002, INT J MOL MED, V9, P77	38	191	197	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22727	22737		10.1074/jbc.M314302200	http://dx.doi.org/10.1074/jbc.M314302200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15020596	hybrid			2022-12-25	WOS:000221417100124
J	Cordoba-Rodriguez, R; Fang, H; Lankford, CSR; Frucht, DM				Cordoba-Rodriguez, R; Fang, H; Lankford, CSR; Frucht, DM			Anthrax lethal toxin rapidly activates caspase-1/ICE and induces extracellular release of interleukin (IL)-1 beta and IL-18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-ANTHRACIS; CONVERTING-ENZYME; MICE DEFICIENT; FACTOR CLEAVES; TNF-ALPHA; MACROPHAGES; APOPTOSIS; KINASE; PHOSPHORYLATION; INACTIVATION	Anthrax lethal toxin (LT), a critical virulence factor for Bacillus anthracis, has been demonstrated to cleave and to inactivate mitogen-activated protein kinase kinases (MAPKKs) that propagate prosurvival signals in macrophages (1-5). Whether this action of anthrax LT leads to the production of proinflammatory cytokines by macrophages has been more controversial (6, 7). We now report that anthrax LT treatment leads to the specific extracellular release of interleukin (IL)-1beta and IL-18 by the murine macrophage cell lines, RAW264.7 and J774A.1. Studies of the processing of IL-1beta reveal that the levels of activated/cleaved IL-1beta in RAW264.7 and J774.A1 cells are increased following treatment with anthrax LT. Enhanced processing of IL-1beta directly correlates with increased levels in the activation of its upstream regulator, IL-1beta-converting enzyme/Caspase-1 (ICE). The extracellular release of IL-1beta and IL-18 in response to anthrax LT is ICE-dependent, as an ICE-specific inhibitor blocks this process. These data indicate that ICE, IL-1beta, and IL-18 are downstream effectors of anthrax LT in macrophages, providing the basis for new bioassays for anthrax LT activity and representing potential therapeutic targets.	US FDA, Div Monoclonal Antibodies, Off Biotechnol, Off Pharmaceut Sci,Ctr Drug Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Frucht, DM (corresponding author), US FDA, Div Monoclonal Antibodies, Off Biotechnol, Off Pharmaceut Sci,Ctr Drug Evaluat & Res, Bldg 29B,Rm 3NN22, Bethesda, MD 20892 USA.	frucht@cber.fda.gov						BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P1049; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chopra AP, 2003, J BIOL CHEM, V278, P9402, DOI 10.1074/jbc.M211262200; Cummings RT, 2002, P NATL ACAD SCI USA, V99, P6603, DOI 10.1073/pnas.062171599; Dinarello CA, 2003, J INFECT DIS, V187, pS370, DOI 10.1086/374751; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Erwin JL, 2001, INFECT IMMUN, V69, P1175, DOI 10.1128/IAI.69.2.1175-1177.2001; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lacy DB, 2002, CURR TOP MICROBIOL, V271, P61; LEPEZUNIGA JL, 1984, CLIN IMMUNOL IMMUNOP, V31, P222, DOI 10.1016/0090-1229(84)90242-3; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Moayeri M, 2003, J CLIN INVEST, V112, P670, DOI [10.1172/JCI200317991, 10.1172/JCI17991]; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Popov SG, 2002, BIOCHEM BIOPH RES CO, V293, P349, DOI 10.1016/S0006-291X(02)00227-9; Rivera VR, 2003, ANAL BIOCHEM, V321, P125, DOI 10.1016/S0003-2697(03)00424-X; RUBARTELLI A, 1993, CYTOKINE, V5, P117, DOI 10.1016/1043-4666(93)90050-F; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; WELKOS SL, 1986, INFECT IMMUN, V51, P795, DOI 10.1128/IAI.51.3.795-800.1986	23	60	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20563	20566		10.1074/jbc.C300539200	http://dx.doi.org/10.1074/jbc.C300539200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15010463	hybrid			2022-12-25	WOS:000221273800003
J	Gonzalez-Gronow, M; Hershfield, MS; Arredondo-Vega, FX; Pizzo, SV				Gonzalez-Gronow, M; Hershfield, MS; Arredondo-Vega, FX; Pizzo, SV			Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; COMPLEXING PROTEIN; AFFINITY-CHROMATOGRAPHY; HUMAN MELANOCYTES; HUMAN PLASMA; AMINO-ACIDS; T-CELLS; CD26; PURIFICATION; EXPRESSION	Adenosine deaminase (ADA) is expressed intracellularly by all cells, but in some tissues, it is also associated with the cell surface multifunctional glycoprotein CD26/dipeptidyl peptidase IV. By modulating extracellular adenosine, this "ecto-ADA" may regulate adenosine receptor signaling implicated in various cellular functions. CD26 is expressed on the surface of human prostate cancer 1-LN cells acting as a receptor for plasminogen (Pg). Since ADA and Pg bind to CD26 at distinct but nearby sites, we investigated a possible interaction between these two proteins on the surface of 1-LN cells. Human ADA binds to CD26 on the surface 1-LN cells and immobilized CD26 isolated from the same cells with similar affinity. In both cases, ADA binding is diminished by mutation of ADA residues known to interact with CD26. ADA was also found to bind Pg 2 in the absence of CD26 via the Pg kringle 4 (K4) domain. In the presence of 1-LN cells or immobilized CD26, exogenous ADA enhances conversion of Pg 2 to plasmin by 1-LN endogenous urinary plasminogen activator (u-PA), as well as by added tissue Pg Activator (t-PA), suggesting that ADA and Pg bind simultaneously to CD26 in a ternary complex that stimulates the Pg activation by its physiologic activators. Consistent with this, in melanoma A375 cells that bind Pg, but do not express CD26, the rate of Pg activation was not affected by ADA. Thus, ADA may be a factor regulating events in prostate cancer cells that occur when Pg binds to the cell surface and is activated.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Gonzalez-Gronow, M (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	gonza002@mc.duke.edu			NATIONAL CANCER INSTITUTE [R01CA086344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020902] Funding Source: NIH RePORTER; NCI NIH HHS [CA 86344] Funding Source: Medline; NIDDK NIH HHS [DK 20902] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDY RJ, 1982, J BIOL CHEM, V257, P7922; ARAN JM, 1990, J CHROMATOGR-BIOMED, V532, P75, DOI 10.1016/S0378-4347(00)83753-6; Arredondo-Vega FX, 1998, AM J HUM GENET, V63, P1049, DOI 10.1086/302054; BERNARD AM, 1994, BIOCHEMISTRY-US, V33, P15204, DOI 10.1021/bi00254a032; Biri H, 1999, CANCER INVEST, V17, P314, DOI 10.3109/07357909909032872; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; CATANIA MV, 1991, NEUROPHARMACOLOGY, V30, P153, DOI 10.1016/0028-3908(91)90198-K; CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x; Cristalli G, 2001, MED RES REV, V21, P105, DOI 10.1002/1098-1128(200103)21:2<105::AID-MED1002>3.0.CO;2-U; DADDONA PE, 1978, J BIOL CHEM, V253, P4617; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; deVries TJ, 1996, J PATHOL, V179, P260, DOI 10.1002/(SICI)1096-9896(199607)179:3<260::AID-PATH586>3.0.CO;2-T; DINJENS WNM, 1989, J BIOL CHEM, V264, P19215; Dong RP, 1997, J IMMUNOL, V159, P6070; Dong RP, 1996, J IMMUNOL, V156, P1349; FOX DA, 1984, J IMMUNOL, V133, P1250; Franco R, 1998, IMMUNOL REV, V161, P27, DOI 10.1111/j.1600-065X.1998.tb01569.x; Gonzalez-Gronow M, 2001, BIOCHEM J, V355, P397, DOI 10.1042/0264-6021:3550397; Gonzalez-Gronow M, 1998, FIBRINOLYSIS PROTEOL, V12, P366, DOI 10.1016/S0268-9499(98)80395-0; GONZALEZGRONOW M, 1984, BIOCHEMISTRY-US, V23, P190, DOI 10.1021/bi00297a003; Hershfield MS., 2001, METABOLIC MOL BASES, V8th, P2585; HOUGHTON AN, 1988, J EXP MED, V167, P197, DOI 10.1084/jem.167.1.197; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN M, 1995, J IMMUNOL, V155, P4630; MISUMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P333, DOI 10.1016/0167-4781(92)90036-Y; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; NISHIHARA H, 1973, BIOCHIM BIOPHYS ACTA, V302, P429, DOI 10.1016/0005-2744(73)90172-1; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; Richard E, 2000, J EXP MED, V192, P1223, DOI 10.1084/jem.192.9.1223; Richard E, 2002, J BIOL CHEM, V277, P19720, DOI 10.1074/jbc.M111901200; SANTISTEBAN I, 1995, HUM MOL GENET, V4, P2081, DOI 10.1093/hmg/4.11.2081; SCHRADER WP, 1990, J BIOL CHEM, V265, P19312; Smith DD, 1997, BIOTECHNIQUES, V22, P952, DOI 10.2144/97225rr03; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, P199; Spychala J, 2000, PHARMACOL THERAPEUT, V87, P161, DOI 10.1016/S0163-7258(00)00053-X; TRITSCH GL, 1980, EUR UROL, V6, P229; Wilson MJ, 2000, J ANDROL, V21, P220	38	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20993	20998		10.1074/jbc.M401023200	http://dx.doi.org/10.1074/jbc.M401023200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016824	hybrid			2022-12-25	WOS:000221273800054
J	Toso, R; Camire, RM				Toso, R; Camire, RM			Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-CATALYZED ACTIVATION; BOVINE FACTOR-V; COAGULATION FACTOR-V; FACTOR-VIII VARIANT; FACTOR XA-BINDING; PROTHROMBINASE COMPLEX; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; PROTEIN-C; SITE	Factor V, the precursor of factor Va, circulates in plasma with little or no procoagulant activity. Activity is generated following limited proteolysis indicating that the conversion of factor V to factor Va results in appropriate structural changes, which impart cofactor function. We have produced recombinant partial B-domain-truncated derivatives of factor V (FVdes811-1491 and FVdes811-1491 with Arg(709) and Arg(1545) mutated to Gln) to investigate whether discrete proteolysis within the B-domain followed by a conformational transition is responsible for activation. Direct binding fluorescence measurements as well as steady-state kinetic assays were employed to assess the ability of these factor V derivatives to assemble and function in prothrombinase. In contrast to human factor V, single-chain B-domain-truncated factor V bound to FXa membranes with an affinity that was identical to factor Va. Additionally, it was found that, once this modified derivative was assembled in prothrombinase, it functioned in an equivalent manner to factor Va. Taken together these data support the hypothesis that proteolysis within the B-domain of factor V, although necessary, is incidental to the mechanism by which cofactor function is realized. Instead, our results are more consistent with the interpretation that proteolytic activation of factor V simply eliminates steric and/or conformational constraints contributed by the B-domain that otherwise interfere with discrete binding interactions that govern the eventual function of factor Va.	Childrens Hosp Philadelphia, Div Hematol, Abramson Res Ctr 302E, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Camire, RM (corresponding author), Childrens Hosp Philadelphia, Div Hematol, Abramson Res Ctr 302E, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	rcamire@mail.med.upenn.edu	Toso, Raffaella/I-5202-2012		NHLBI NIH HHS [P01 HL 74124-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington PR., 2002, DATA REDUCTION ERROR; BRUIN T, 1987, EUR J BIOCHEM, V170, P305, DOI 10.1111/j.1432-1033.1987.tb13700.x; Buddai SK, 2002, J BIOL CHEM, V277, P26689, DOI 10.1074/jbc.M202507200; Camire RM, 2002, J BIOL CHEM, V277, P37863, DOI 10.1074/jbc.M203692200; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; CHEN J, 1994, J BIOL CHEM, V269, P16041; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DONATH MJSH, 1995, BIOCHEM J, V312, P49, DOI 10.1042/bj3120049; Doolittle RF, 2003, J THROMB HAEMOST, V1, P1559, DOI 10.1046/j.1538-7836.2003.00278.x; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1973, BIOCHIM BIOPHYS ACTA, V310, P289, DOI 10.1016/0005-2795(73)90034-2; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; Gomori G, 1942, J LAB CLIN MED, V27, P955; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; Kalafatis M, 2003, J BIOL CHEM, V278, P33550, DOI 10.1074/jbc.M303153200; Kalafatis M, 1997, ARTERIOSCL THROM VAS, V17, P620, DOI 10.1161/01.ATV.17.4.620; KANE WH, 1990, BIOCHEMISTRY-US, V29, P6762, DOI 10.1021/bi00481a003; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; Kemball-Cook G, 1998, NUCLEIC ACIDS RES, V26, P216, DOI 10.1093/nar/26.1.216; Khan AR, 1998, PROTEIN SCI, V7, P815; Kim SW, 1999, BIOCHEMISTRY-US, V38, P11448, DOI 10.1021/bi991275y; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1981, METHOD ENZYMOL, V80, P286; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; MANN KG, 1990, BLOOD, V76, P1; MARQUETTE KA, 1995, BLOOD, V86, P3026; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; ORTEL TL, 1995, MOL BIOL THROMBOSIS, P119; Pipe SW, 1997, P NATL ACAD SCI USA, V94, P11851, DOI 10.1073/pnas.94.22.11851; PITTMAN DD, 1993, BLOOD, V81, P2925; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; Sandberg H, 2001, THROMB HAEMOSTASIS, V85, P93; SEGAL IH, 1975, ENZYME KINETICS BEHA; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Steen M, 2002, J BIOL CHEM, V277, P38424, DOI 10.1074/jbc.M204972200; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939	61	66	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21643	21650		10.1074/jbc.M402107200	http://dx.doi.org/10.1074/jbc.M402107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15004010	hybrid			2022-12-25	WOS:000221273800131
J	Wu, LQ; Zhu, HY; Nie, LH; Maki, CG				Wu, LQ; Zhu, HY; Nie, LH; Maki, CG			A link between p73 transcriptional activity and p73 degradation	ONCOGENE			English	Article						p53; p73; degradation	RING-FINGER DOMAIN; P53-RELATED PROTEIN; ONCOPROTEIN MDM2; UBIQUITIN LIGASE; P53; P63; IDENTIFICATION; ACTIVATION; TRANSACTIVATION; APOPTOSIS	The p53 family of proteins includes three members, p53, p63, and p73. The levels and stability of p53 are controlled in large part by MDM2, which can bind the p53 N-terminus and promote its degradation. Because the MDM2 gene is transcriptionally activated by p53, it forms part of an autoregulatory feedback loop that directly links the transcriptional activity of p53 with its degradation. In contrast, little is known about the mechanisms that control p63 or p73 stability. In the current study, p73 deletion or point mutants that lacked transactivation activity were stable compared to wild-type p73. A naturally occurring p73 variant (DeltaNp73) was also stable compared to wild-type p73. Finally, fusion of the VP16-transactivation domain to an inactive, stable p73 mutant restored transactivation function and rendered the mutant protein unstable. These results demonstrate that p73 transactivation activity is necessary for rapid p73 turnover, and suggest that one or more transcriptional targets of p73 may promote its degradation.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago	Maki, CG (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave,MC1105,Room G-06, Chicago, IL 60637 USA.	cmaki@rover.uchicago.edu			NCI NIH HHS [1R01CA80918-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; MELIKHOV D, 2002, EUR PHYS J C, V2, P1; Miyazaki K, 2003, BIOCHEM BIOPH RES CO, V308, P106, DOI 10.1016/S0006-291X(03)01347-0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Takada N, 1999, CANCER RES, V59, P2810; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	25	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4032	4036		10.1038/sj.onc.1207538	http://dx.doi.org/10.1038/sj.onc.1207538			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021899				2022-12-25	WOS:000221382000016
J	Graf, PCF; Martinez-Yamout, M; VanHaerents, S; Lilie, H; Dyson, HJ; Jakob, U				Graf, PCF; Martinez-Yamout, M; VanHaerents, S; Lilie, H; Dyson, HJ; Jakob, U			Activation of the redox-regulated chaperone Hsp33 by domain unfolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-SIGMA FACTOR; DISULFIDE BOND FORMATION; PROTEIN-KINASE-C; STREPTOMYCES-COELICOLOR; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ZINC; BINDING; STRESS	The molecular chaperone Hsp33 in Escherichia coli responds to oxidative stress conditions with the rapid activation of its chaperone function. On its activation pathway, Hsp33 progresses through three major conformations, starting as a reduced, zinc-bound inactive monomer, proceeding through an oxidized zinc-free monomer, and ending as a fully active oxidized dimer. While it is known that Hsp33 senses oxidative stress through its C-terminal four-cysteine zinc center, the nature of the conformational changes in Hsp33 that must take place to accommodate this activation process is largely unknown. To investigate these conformational rearrangements, we constructed constitutively monomeric Hsp33 variants as well as fragments consisting of the redox regulatory C-terminal domain of Hsp33. These proteins were studied by a combination of biochemical and NMR spectroscopic techniques. We found that in the reduced, monomeric conformation, zinc binding stabilizes the C terminus of Hsp33 in a highly compact, alpha-helical structure. This appears to conceal both the substrate-binding site as well as the dimerization interface. Zinc release without formation of the two native disulfide bonds causes the partial unfolding of the C terminus of Hsp33. This is sufficient to unmask the substrate-binding site, but not the dimerization interface, rendering reduced zinc-free Hsp33 partially active yet monomeric. Critical for the dimerization is disulfide bond formation, which causes the further unfolding of the C terminus of Hsp3 and allows the association of two oxidized Hsp33 monomers. This then leads to the formation of active Hsp33 dimers, which are capable of protecting cells against the severe consequences of oxidative heat stress.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Mol & Cellular Biol Program, La Jolla, CA 92037 USA; Univ Halle Wittenberg, Dept Biotechnol, D-06120 Halle Saale, Germany	University of Michigan System; University of Michigan; Scripps Research Institute; Scripps Research Institute; Martin Luther University Halle Wittenberg	Jakob, U (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ, Ann Arbor, MI 48109 USA.	ujakob@umich.edu	Dyson, Jane/D-4160-2011	Dyson, Jane/0000-0001-6855-3398; VanHaerents, Stephen/0000-0003-0759-4414; Graf, Paul/0000-0002-1094-7498	NIGMS NIH HHS [GM 065318, GM 43238] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043238, R01GM065318] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbirz S, 2000, J BIOL CHEM, V275, P18759, DOI 10.1074/jbc.M001089200; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Cox EH, 2000, CURR OPIN CHEM BIOL, V4, P162, DOI 10.1016/S1367-5931(99)00070-8; Farr GW, 2000, CELL, V100, P561, DOI 10.1016/S0092-8674(00)80692-3; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Graumann J, 2001, STRUCTURE, V9, P377, DOI 10.1016/S0969-2126(01)00599-8; Hoffmann JH, 2004, EMBO J, V23, P160, DOI 10.1038/sj.emboj.7600016; Hoyos B, 2002, J BIOL CHEM, V277, P23949, DOI 10.1074/jbc.M110750200; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; Kang JG, 1999, EMBO J, V18, P4292, DOI 10.1093/emboj/18.15.4292; Kim SJ, 2001, NAT STRUCT BIOL, V8, P459, DOI 10.1038/87639; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Li W, 2003, J MOL BIOL, V333, P461, DOI 10.1016/j.jmb.2003.08.038; Lutz T, 2003, EMBO J, V22, P4400, DOI 10.1093/emboj/cdg421; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; Mo HP, 2001, P NATL ACAD SCI USA, V98, P2352, DOI 10.1073/pnas.051627998; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P3852, DOI 10.1021/bi00336a006; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; Paget MSB, 2001, MOL MICROBIOL, V42, P1007, DOI 10.1046/j.1365-2958.2001.02675.x; Paget MSB, 2001, MOL MICROBIOL, V39, P1036, DOI 10.1046/j.1365-2958.2001.02298.x; Raman B, 2001, FEBS LETT, V489, P19, DOI 10.1016/S0014-5793(01)02074-9; Takemoto T, 1998, FREE RADICAL BIO MED, V24, P556, DOI 10.1016/S0891-5849(97)00287-6; Vijayalakshmi J, 2001, STRUCTURE, V9, P367, DOI 10.1016/S0969-2126(01)00597-4; Webster KA, 2001, ANTIOXID REDOX SIGN, V3, P535, DOI 10.1089/15230860152542916; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	30	76	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20529	20538		10.1074/jbc.M401764200	http://dx.doi.org/10.1074/jbc.M401764200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15023991	hybrid			2022-12-25	WOS:000221164500132
J	Makino, K; Day, CP; Wang, SC; Li, YM; Hung, MC				Makino, K; Day, CP; Wang, SC; Li, YM; Hung, MC			Upregulation of IKK alpha/IKK beta by integrin-linked kinase is required for HER2/neu-induced NF-kappa B antiapoptotic pathway	ONCOGENE			English	Article						HER2/neu; ILK; PI-3K; Akt; TNF-alpha; antiapoptotic pathway; IKK	ACTIVATED PROTEIN-KINASE; CELL-PROLIFERATION; INDUCED APOPTOSIS; MAP KINASE; AKT; PHOSPHORYLATION; HER-2/NEU; CANCER; OVEREXPRESSION; TRANSFORMATION	Constitutively active HER2/neu activates nuclear factor kappa-B (NF-kappaB) in cells and induces their resistance to apoptotic stimuli such as tumor necrosis factor-alpha (TNF-alpha). Here, we show that integrin-linked kinase (ILK), the crucial signal transducer in the integrin pathway, is involved in HER2/neu-mediated activation of NF-kappaB. Expression of HER2/neu increases ILK activity. Blocking ILK activity with a kinase-deficient mutant ILK (ILK-KD) inhibits NF-kappaB activation and sensitizes HER2/neu-transformed cells to TNF-alpha-induced apoptosis. Stable expression of ILK-KD in HER2/neu-transformed cells suppressed Akt phosphorylation and the expression of IkappaB kinase alpha and beta (IKKalpha and beta) at both the protein and mRNA levels, preventing IkappaB-alpha degradation and NF-kappaB activation. Furthermore, HER2/neu stimulated the transcriptional activity of the putative IKKbeta promoter through ILK and Akt. Our results demonstrate that upregulation of IKKalpha and IKKbeta by the ILK/Akt pathway is required for the HER2/neu-mediated NF-kappaB antiapoptotic pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 860, Japan; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Kumamoto University; University of Texas System; University of Texas Health Science Center Houston	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mail.mdanderson.org	Wang, Shao-Chun/P-9904-2019; Hung, Mien-Chie/ABD-5911-2021	Wang, Shao-Chun/0000-0002-5477-1682; Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [P01 CA 99031] Funding Source: Medline; PHS HHS [R01 58880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA099031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gary DS, 2003, J NEUROCHEM, V84, P878, DOI 10.1046/j.1471-4159.2003.01579.x; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hung MC, 1999, SEMIN ONCOL, V26, P51; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Ozes ON, 1999, NATURE, V401, P82; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	29	36	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3883	3887		10.1038/sj.onc.1207485	http://dx.doi.org/10.1038/sj.onc.1207485			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021910				2022-12-25	WOS:000221242500015
J	Meyer, T; Hendry, L; Begitt, A; John, S; Vinkemeier, U				Meyer, T; Hendry, L; Begitt, A; John, S; Vinkemeier, U			A single residue modulates tyrosine dephosphorylation, oligomerization, and nuclear accumulation of stat transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; DNA-BINDING DOMAIN; INTERFERON-GAMMA; TARGETED DISRUPTION; FUNCTIONAL-ANALYSIS; SIGNALING PATHWAY; EXPORT SIGNAL; GENE PROMOTER; VIRAL DISEASE; ACTIVATION	The NH2 terminus of Stat proteins forms a versatile protein interaction domain that is believed to use discrete surfaces to mediate oligomerization and tyrosine dephosphorylation of Stat dimers. Here we show for Stat1 and Stat5a/b that these interfaces overlap and need to be reassigned to an unrelated region of the N-domain. Unexpectedly, our study showed for Stat1 that defective oligomerization of DNA-bound dimers was associated with prolonged interferon-induced nuclear accumulation. This uncoupling of DNA binding and nuclear retention was explained by the concomitant dephosphorylation deficiency that both Stat1 and Stat5a/b have in common and that for Stat1 was due to defective dephosphorylation by the phosphatase TC45. Furthermore, diminished N-domain-mediated oligomerization affected transcriptional activation by both Stat1 and Stat5a/b in a promoter-specific manner. DNA binding analysis indicated that oligomerization of Stats on DNA may be common, irrespective of the presence of multiple canonical binding sites. Accordingly, also transcription from promoters with only a single discernable gamma-activated sequence site was negatively effected by reduced tetramerization. Thus, these results indicate that defective oligomerization cannot generally be compensated for by enhanced tyrosine phosphorylation and prolonged nuclear accumulation. In addition, these data clarify the role of DNA binding in nuclear retention of Stat1.	Kings Coll London, Dept Immunobiol, London SE1 9RT, England; Free Univ Berlin, Abt Zellulare Signalverarbeitung, Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany	University of London; King's College London; Free University of Berlin	Vinkemeier, U (corresponding author), Kings Coll London, Dept Immunobiol, 3rd Floor New Guys House,St Thomas St, London SE1 9RT, England.	vinkemeier@fmp-berlin.de		Vinkemeier, Uwe/0000-0001-6924-1783; John, Susan/0000-0002-5620-1982				Aoki N, 2002, MOL ENDOCRINOL, V16, P58, DOI 10.1210/me.16.1.58; Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; Chen XM, 2003, PROTEIN SCI, V12, P361, DOI 10.1110/ps.0218903; Chen Y, 2003, J BIOL CHEM, V278, P16520, DOI 10.1074/jbc.M210572200; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; Darnell JE, 1997, P NATL ACAD SCI USA, V94, P11767, DOI 10.1073/pnas.94.22.11767; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; John S, 1999, MOL CELL BIOL, V19, P1910; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Li XX, 1998, BIOCHIMIE, V80, P703, DOI 10.1016/S0300-9084(99)80023-6; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Ota N, 2004, NAT IMMUNOL, V5, P208, DOI 10.1038/ni1032; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang XK, 2001, J BIOL CHEM, V276, P33576, DOI 10.1074/jbc.M104978200	45	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18998	19007		10.1074/jbc.M400766200	http://dx.doi.org/10.1074/jbc.M400766200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	15010467	hybrid			2022-12-25	WOS:000221041500112
J	Watson, JEV; Doggett, NA; Albertson, DG; Andaya, A; Chinnaiyan, A; van Dekken, H; Ginzinger, D; Haqq, C; James, K; Kamkar, S; Kowbel, D; Pinkel, D; Schmitt, L; Simko, JP; Volik, S; Weinberg, VK; Paris, PL; Collins, C				Watson, JEV; Doggett, NA; Albertson, DG; Andaya, A; Chinnaiyan, A; van Dekken, H; Ginzinger, D; Haqq, C; James, K; Kamkar, S; Kowbel, D; Pinkel, D; Schmitt, L; Simko, JP; Volik, S; Weinberg, VK; Paris, PL; Collins, C			Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer	ONCOGENE			English	Article						prostate cancer; chromosome 16q; array CGH; tumor suppressor genes	FRAGILE SITE FRA16D; ALLELIC IMBALANCE; GROWTH; CARCINOMAS; BREAST; TRANSLOCATION; DYSREGULATION; MICROARRAYS; DELETIONS; SEQUENCE	We have constructed a high-resolution genomic microarray of human chromosome 16q, and used it for comparative genomic hybridization analysis of 16 prostate tumors. We demarcated 10 regions of genomic loss between 16q23.1 and 16qter that occurred in five or more samples. Mining expression array data from four independent studies allowed us to identify 11 genes that were frequently underexpressed in prostate cancer and that co-localized with a region of genomic loss. Quantitative expression analyses of these genes in matched tumor and benign tissue from 13 patients showed that six of these 11 (WWOX, WFDC1, MAF, FOXF1, MVD and the predicted novel transcript Q9H0B8 (NM_031476)) had significant and consistent downregulation in the tumors relative to normal prostate tissue expression making them candidate tumor suppressor genes.	Univ Calif San Francisco, Ctr Comprehens Canc, Collins Lab, San Francisco, CA 94143 USA; Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Med Ctr, Erasmus Med Ctr, Rotterdam, Netherlands	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Michigan System; University of Michigan; Erasmus University Rotterdam; Erasmus MC	Watson, JEV (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Collins Lab, 2340 Sutter St, San Francisco, CA 94143 USA.	vwatson@cc.ucsf.edu			NATIONAL CANCER INSTITUTE [P50CA089520] Funding Source: NIH RePORTER; NCI NIH HHS [CA89520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bednarek AK, 2001, CANCER RES, V61, P8068; Buckley PG, 2002, HUM MOL GENET, V11, P3221, DOI 10.1093/hmg/11.25.3221; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Chu LW, 2003, GENE CHROMOSOME CANC, V36, P303, DOI 10.1002/gcc.10171; Collins C, 2001, GENOME RES, V11, P1034, DOI 10.1101/gr.GR1743R; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Elo JP, 1999, BRIT J CANCER, V79, P156, DOI 10.1038/sj.bjc.6690025; Giese A, 2002, GENE, V299, P101, DOI 10.1016/S0378-1119(02)01018-1; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Han CS, 2000, GENOME RES, V10, P714, DOI 10.1101/gr.10.5.714; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kochetkova M, 2002, CANCER RES, V62, P4599; Larsen M, 1998, J BIOL CHEM, V273, P4574, DOI 10.1074/jbc.273.8.4574; Luo J, 2001, CANCER RES, V61, P4683; Magee JA, 2001, CANCER RES, V61, P5692; Mahlapuu M, 2001, DEVELOPMENT, V128, P2397; Matsuyama H, 2003, PROSTATE, V54, P103, DOI 10.1002/pros.10173; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Paige AJW, 2000, CANCER RES, V60, P1690; Paris PL, 2000, CANCER RES, V60, P3645; Paris PL, 2003, AM J PATHOL, V162, P763, DOI 10.1016/S0002-9440(10)63873-4; Rhodes DR, 2002, CANCER RES, V62, P4427; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; ROWLEY DR, 1995, J BIOL CHEM, V270, P22058, DOI 10.1074/jbc.270.37.22058; Ruijter ETG, 1999, J PATHOL, V188, P271, DOI 10.1002/(SICI)1096-9896(199907)188:3<271::AID-PATH359>3.0.CO;2-K; Smith DM, 2001, MECH DEVELOP, V102, P223, DOI 10.1016/S0925-4773(01)00293-3; Strup SE, 1999, J UROLOGY, V162, P590, DOI 10.1016/S0022-5347(05)68631-4; Toyooka KO, 2001, CANCER RES, V61, P4556; Van Dekken H, 2000, ACTA HISTOCHEM, V102, P85, DOI 10.1078/0065-1281-00540; Verhage BAJ, 2003, PROSTATE, V54, P50, DOI 10.1002/pros.10148; Wadhwa R, 2003, BIOCHEM BIOPH RES CO, V302, P735, DOI 10.1016/S0006-291X(03)00226-2; Welsh JB, 2001, CANCER RES, V61, P5974	33	77	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	2004	23	19					3487	3494		10.1038/sj.onc.1207474	http://dx.doi.org/10.1038/sj.onc.1207474			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15007382				2022-12-25	WOS:000220975000024
J	Kulinski, A; Vance, DE; Vance, JE				Kulinski, A; Vance, DE; Vance, JE			A choline-deficient diet in mice inhibits neither the CDP-choline pathway for phosphatidylcholine synthesis in hepatocytes nor apolipoprotein B secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; LOW-DENSITY LIPOPROTEINS; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; CULTURED RAT HEPATOCYTES; LIVER; BIOSYNTHESIS; PLASMA; CELLS; REQUIREMENT; METHYLATION	Phosphatidylcholine is a major component of very low density lipoproteins (VLDLs) secreted by the liver. Hepatic phosphatidylcholine is synthesized from choline via the CDP-choline pathway and from the phosphatidylethanolamine N-methyltransferase pathway. Elimination of the methyltransferase in male mice reduces hepatic VLDL secretion. Our objective was to determine whether inhibition of the CDP-choline pathway for phosphatidylcholine synthesis ( by restricting the supply of choline) also impaired VLDL secretion. In mice fed a choline-deficient ( CD), compared with a choline-supplemented, diet for 21 days, the amounts of plasma apolipoproteins (apo) B100 and B48 were reduced and the liver triacylglycerol content was increased. Hepatocytes were isolated from male mice that had been fed the CD diet for 3 or 21 days, and the cells were incubated with or without choline. The secretion of apoB100 and B48 from CD hepatocytes was not reduced, and triacylglycerol secretion was only modestly decreased, compared with that from cells supplemented with choline. Remarkably, in light of widely held assumptions, the rate of phosphatidylcholine synthesis from the CDPcholine pathway was not decreased in CD hepatocytes. Rather, there was a trend toward increased phosphatidylcholine synthesis that might be explained by enhanced CTP:phosphocholine cytidylyltransferase activity. Although the concentration of phosphocholine in CD hepatocytes was reduced, the size of the phosphocholine pool remained well above the K-m for the cytidylyltransferase. Moreover, the amount and activity of the cytidylyltransferase and methyltransferase were increased. The reduction in plasma apoB in mice deprived of dietary choline cannot, therefore, be attributed to decreased apoB secretion.	Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, HMRC 328, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, HMRC 328, Edmonton, AB T6G 2S2, Canada.	jean.vance@ualberta.ca						Best CH, 1932, J PHYSIOL-LONDON, V75, P405, DOI 10.1113/jphysiol.1932.sp002899; BLUMENSTEIN J, 1964, CAN J BIOCHEM PHYS, V42, P1183, DOI 10.1139/o64-128; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; BREMER J, 1961, BIOCHIM BIOPHYS ACTA, V46, P205, DOI 10.1016/0006-3002(61)90745-4; CHAM BE, 1976, J LIPID RES, V17, P176; CHOY PC, 1977, J BIOL CHEM, V252, P7673; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; Cui Z, 1996, J BIOL CHEM, V271, P2839, DOI 10.1074/jbc.271.5.2839; CUI Z, 1993, J BIOL CHEM, V268, P16655; DAVIS RA, 1985, J BIOL CHEM, V260, P4137; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; EAGLE H, 1955, J EXP MED, V102, P595, DOI 10.1084/jem.102.5.595; Folch J., 1959, J BIOL CHEM, V226, P495; *FOOD NUTR BOARD I, 1998, DIET REF INT THIAM R; HAINES DSM, 1970, CAN J BIOCHEM CELL B, V48, P885, DOI 10.1139/o70-139; HAINES DSM, 1965, CAN J BIOCHEM CELL B, V43, P507, DOI 10.1139/o65-059; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KUKSIS A, 1978, NUTR REV, V36, P201; LOMBARDI B, 1971, FED PROC, V30, P139; LOMBARDI B, 1968, J LIPID RES, V9, P437; MAEDA M, 1985, J BIOL CHEM, V260, P5925; MOOKERJEA S, 1975, LIPIDS, V10, P374, DOI 10.1007/BF02532440; MOOKERJEA S, 1969, CAN J BIOCHEM CELL B, V47, P125, DOI 10.1139/o69-021; MOOKERJEA S, 1971, FED PROC, V30, P143; NAGLER AL, 1968, J NUTR, V94, P13, DOI 10.1093/jn/94.1.13; Noga AA, 2003, J LIPID RES, V44, P1998, DOI 10.1194/jlr.M300226-JLR200; Noga AA, 2003, J BIOL CHEM, V278, P21851, DOI 10.1074/jbc.M301982200; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; PELECH SL, 1981, J BIOL CHEM, V256, P8283; PRITCHARD PH, 1981, BIOCHEM J, V196, P261, DOI 10.1042/bj1960261; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; RIDGWAY ND, 1987, J BIOL CHEM, V262, P17231; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHNEIDER WJ, 1978, EUR J BIOCHEM, V85, P181, DOI 10.1111/j.1432-1033.1978.tb12226.x; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; SUNDLER R, 1975, BIOCHEM J, V146, P309, DOI 10.1042/bj1460309; TERCE F, 1994, J LIPID RES, V35, P2142; TINOCO J, 1964, J LIPID RES, V5, P57; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE DE, 1979, TRENDS BIOCHEM SCI, V4, P145, DOI 10.1016/0968-0004(79)90001-X; Vermeulen PS, 1997, J LIPID RES, V38, P447; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; WEINHOLD PA, 1994, BBA-LIPID LIPID MET, V1210, P335, DOI 10.1016/0005-2760(94)90238-0; YAO Z, 1990, BIOCHEM CELL BIOL, V68, P552, DOI 10.1139/o90-079; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; YAO ZM, 1990, J BIOL CHEM, V265, P4326; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Yen CLE, 2001, FASEB J, V15, P1704, DOI 10.1096/fj.00-0800com; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	53	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23916	23924		10.1074/jbc.M312676200	http://dx.doi.org/10.1074/jbc.M312676200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15024002	hybrid			2022-12-25	WOS:000221702500012
J	Boulet, L; Ouellet, M; Bateman, KP; Ethier, D; Percival, MD; Riendeau, D; Mancini, JA; Methot, N				Boulet, L; Ouellet, M; Bateman, KP; Ethier, D; Percival, MD; Riendeau, D; Mancini, JA; Methot, N			Deletion of microsomal prostaglandin E-2 (PGE(2)) synthase-1 reduces inducible and basal PGE(2) production and alters the gastric prostanoid profile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADJUVANT-INDUCED ARTHRITIS; THIOGLYCOLATE-ELICITED MACROPHAGES; MICE LACKING; 3'-UNTRANSLATED REGION; CYCLOOXYGENASE ISOFORMS; INFLAMMATORY RESPONSE; GENE DISRUPTION; INDUCED PYRESIS; UP-REGULATION; EXPRESSION	Microsomal prostaglandin E synthase-1 (mPGES-1) is an inducible protein recently shown to be an important source of inflammatory PGE(2). Here we have used mPGES-1 wild type, heterozygote, and null mice to assess the impact of reduction or absence mPGES-1 protein on the production of PGE2 and other prostaglandins in lipopolysaccharide (LPS)-treated macrophages and mice. Thioglycollate-elicited peritoneal macrophages with mPGES-1 deficiency were found to lose their ability to produce PGE(2) upon LPS stimulation. Resident mPGES-1(-/-) peritoneal macrophages exhibited severely impaired PGE(2)-releasing activity but retained some LPS-inducible PGE(2) production capacity. Both macrophage types showed a 50% decrease in PGE(2) production with removal of one copy of the mPGES-1 gene. In vivo, mPGES-1 deletion abolished the LPS-stimulated production of PGE2 in spleen, kidney, and brain. Surprisingly, lack of mPGES-1 activity resulted in an 80 - 90% decrease in basal, cyclooxygenase-1 (COX-1)- dependent PGE(2) production in stomach and spleen, and a 50% reduction in brain and kidney. Other prostaglandins (thromboxane B-2, PGD(2), PGF(2alpha), and 6-keto-PGF(1alpha)) were significantly elevated in stomachs of mPGES-1-null mice but not in other tissues. Examination of mRNA for several terminal prostaglandin synthases did not reveal changes in expression levels associated with mPGES-1 deficiency, indicating that gastric prostaglandin changes may be due to shunting of cyclooxygenase products to other terminal synthases. These data demonstrate for the first time a dual role for mPGES-1 in both inflammatory and COX-1-mediated PGE(2) production and suggest an interdependence of prostanoid production with tissue-specific alterations of prostaglandin levels in the absence of mPGES-1.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ H9H 3L1, Canada	Merck & Company	Methot, N (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, 16711 Trans Canada Highway, Kirkland, PQ H9H 3L1, Canada.	nathalie_methot@merck.com		Bateman, Kevin/0000-0002-4026-6685				Claveau D, 2003, J IMMUNOL, V170, P4738, DOI 10.4049/jimmunol.170.9.4738; Cok SJ, 2003, J BIOL CHEM, V278, P36157, DOI 10.1074/jbc.M302547200; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Engblom D, 2003, NAT NEUROSCI, V6, P1137, DOI 10.1038/nn1137; Engblom D, 2002, J COMP NEUROL, V452, P205, DOI 10.1002/cne.10380; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Halter F, 2001, GUT, V49, P443, DOI 10.1136/gut.49.3.443; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Inoue W, 2002, NEUROSCI RES, V44, P51, DOI 10.1016/S0168-0102(02)00083-4; Ivanov AI, 2002, AM J PHYSIOL-REG I, V283, pR1104, DOI 10.1152/ajpregu.00347.2002; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kojima F, 2003, ARTHRITIS RHEUM, V48, P2819, DOI 10.1002/art.11261; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lazarus M, 2002, ARCH BIOCHEM BIOPHYS, V397, P336, DOI 10.1006/abbi.2001.2614; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Loftin CD, 2002, PROSTAG OTH LIPID M, V68-9, P177, DOI 10.1016/S0090-6980(02)00028-X; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; Nugteren D H, 1980, Adv Prostaglandin Thromboxane Res, V6, P129; OGOROCHI T, 1987, J NEUROCHEM, V48, P900, DOI 10.1111/j.1471-4159.1987.tb05602.x; OUELLET M, 1995, BIOCHEM J, V306, P247, DOI 10.1042/bj3060247; Ouellet M, 2002, PROTEIN EXPRES PURIF, V26, P489, DOI 10.1016/S1046-5928(02)00566-1; PERCIVAL MD, 1994, ARCH BIOCHEM BIOPHYS, V315, P111, DOI 10.1006/abbi.1994.1478; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; SILVER RM, 1995, J CLIN INVEST, V95, P725, DOI 10.1172/JCI117719; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163-7827(00)00008-4; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Vitzthum H, 2002, KIDNEY INT, V62, P1570, DOI 10.1046/j.1523-1755.2002.00615.x; Wallace JL, 2000, GASTROENTEROLOGY, V119, P706, DOI 10.1053/gast.2000.16510; Watanabe S, 1998, PROSTAG OTH LIPID M, V56, P7, DOI 10.1016/S0090-6980(98)00039-2; WATANABE S, 1994, J LIPID MEDIAT CELL, V10, P283; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001; Yokoyama C, 2002, CIRCULATION, V106, P2397, DOI 10.1161/01.CIR.0000034733.93020.BC	45	106	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23229	23237		10.1074/jbc.M400443200	http://dx.doi.org/10.1074/jbc.M400443200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15016822	hybrid			2022-12-25	WOS:000221570900055
J	Shinohara, T; Harada, M; Ogi, K; Maruyama, M; Fujii, R; Tanaka, H; Fukusumi, S; Komatsu, H; Hosoya, M; Noguchi, Y; Watanabe, T; Moriya, T; Itoh, Y; Hinuma, S				Shinohara, T; Harada, M; Ogi, K; Maruyama, M; Fujii, R; Tanaka, H; Fukusumi, S; Komatsu, H; Hosoya, M; Noguchi, Y; Watanabe, T; Moriya, T; Itoh, Y; Hinuma, S			Identification of a G protein-coupled receptor specifically responsive to beta-alanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-ROOT GANGLION; CAPSAICIN RECEPTOR; GLYCINE RECEPTOR; NEUROMEDIN U; AMINO-ACIDS; MOUSE-BRAIN; GABA-A; LIGAND; FAMILY; CELLS	We isolated a cDNA encoding an orphan G protein-coupled receptor, TGR7, which has been recently reported to correspond to MrgD. To search for ligands for TGR7, we screened a series of small molecule compounds by detecting the Ca2+ influx in Chinese hamster ovary cells expressing TGR7. Through this screening, we found that beta-alanine at micromolar doses specifically evoked Ca2+ influx in cells expressing human, rat, or mouse TGR7. A structural analogue, gamma-aminobutyric acid, weakly stimulated cells expressing human or rat TGR7, but another analogue, glycine, did not. In addition, beta-alanine decreased forskolin-stimulated cAMP production in cells expressing TGR7, suggesting that TGR7 couples with G proteins G(q) and G(i). In guanosine 5'-O-3-thiotriphosphate binding assays conducted using a membrane fraction of cells expressing TGR7, beta-alanine specifically increased the binding of guanosine 5'-O-3-thiotriphosphate. When a fusion protein composed of TGR7 and green fluorescent protein was expressed in cells, it localized at the plasma membrane but internalized into the cytoplasm after treatment with beta-alanine. In addition, we found that beta- [H-3] alanine more efficiently bound to TGR7-expressing cells than to control cells. From these results, we concluded that TGR7 functioned as a specific membrane receptor for beta-alanine. Quantitative PCR analysis revealed that TGR7 mRNA was predominantly expressed in the dorsal root ganglia in rats. By in situ hybridization and immunostaining, we confirmed that TGR7 mRNA was co-expressed in the small diameter neurons with P2X(3) and VR1, both in rat and monkey dorsal root ganglia. Our results suggest that TGR7 participates in the modulation of neuropathic pain.	Takeda Chem Ind Ltd, Discovery Res Labs, Div Pharmaceut Res, Tsukuba, Ibaraki 3004293, Japan	Takeda Chemical Industries	Itoh, Y (corresponding author), Takeda Chem Ind Ltd, Discovery Res Labs, Div Pharmaceut Res, 10 Wadai, Tsukuba, Ibaraki 3004293, Japan.	Ito_Yasuaki@takeda.co.jp	Smith, Peter G/G-9172-2014	Smith, Peter G/0000-0002-1931-7660; Maruyama, Minoru/0000-0002-1478-9415; Komatsu, Hidetoshi/0000-0003-1630-0537				Bender E, 2002, P NATL ACAD SCI USA, V99, P8573, DOI 10.1073/pnas.122016499; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, CURR OPIN NEUROBIOL, V9, P525, DOI 10.1016/S0959-4388(99)00009-4; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; DEFEUDIS FV, 1977, GEN PHARMACOL, V8, P177, DOI 10.1016/0306-3623(77)90046-5; Dong XZ, 2001, CELL, V106, P619, DOI 10.1016/S0092-8674(01)00483-4; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; Fujii R, 2002, J BIOL CHEM, V277, P34010, DOI 10.1074/jbc.M205883200; Fujioka R, 1999, POLYM J, V31, P1, DOI 10.1295/polymj.31.1; Fukusumi S, 2001, BBA-MOL CELL RES, V1540, P221, DOI 10.1016/S0167-4889(01)00135-5; Fukusumi S, 2003, J BIOL CHEM, V278, P46387, DOI 10.1074/jbc.M305270200; FURUYAMA T, 1992, MOL BRAIN RES, V12, P335, DOI 10.1016/0169-328X(92)90136-Y; Han SK, 2002, P NATL ACAD SCI USA, V99, P14740, DOI 10.1073/pnas.192565799; Hinuma S, 1999, J MOL MED, V77, P495, DOI 10.1007/s001090050403; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; HOSLI E, 1980, NEUROSCIENCE, V5, P145, DOI 10.1016/0306-4522(80)90080-9; HOSLI E, 1979, ADV EXP MED BIOL, V123, P205; Hosoya M, 2000, J BIOL CHEM, V275, P29528, DOI 10.1074/jbc.M004261200; Hunt SP, 2001, NAT REV NEUROSCI, V2, P83, DOI 10.1038/35053509; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Kawamata Y, 2003, J BIOL CHEM, V278, P9435, DOI 10.1074/jbc.M209706200; KONTRO P, 1983, NEUROSCIENCE, V8, P153, DOI 10.1016/0306-4522(83)90034-9; LARSSON OM, 1986, J NEUROCHEM, V47, P426; Lembo PMC, 2002, NAT NEUROSCI, V5, P201, DOI 10.1038/nn815; LIU QR, 1992, P NATL ACAD SCI USA, V89, P12145, DOI 10.1073/pnas.89.24.12145; MARKS N, 1970, J NEUROCHEM, V17, P53, DOI 10.1111/j.1471-4159.1970.tb00501.x; OGITA K, 1989, NEUROPHARMACOLOGY, V28, P1263, DOI 10.1016/0028-3908(89)90220-7; PULLAN LM, 1992, NEUROSCI LETT, V148, P199, DOI 10.1016/0304-3940(92)90838-X; Rajendra S, 1997, PHARMACOL THERAPEUT, V73, P121, DOI 10.1016/S0163-7258(96)00163-5; Robas N, 2003, J BIOL CHEM, V278, P44400, DOI 10.1074/jbc.M302456200; SARANSAARI P, 1993, NEUROSCIENCE, V53, P475, DOI 10.1016/0306-4522(93)90211-W; SCHON F, 1975, BRAIN RES, V86, P243, DOI 10.1016/0006-8993(75)90700-3; TALLAN HH, 1954, J BIOL CHEM, V211, P927; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Tominaga M, 2001, P NATL ACAD SCI USA, V98, P6951, DOI 10.1073/pnas.111025298; Usherwood P N, 1978, Adv Comp Physiol Biochem, V7, P227; WU FS, 1993, EUR J PHARM-MOLEC PH, V246, P239, DOI 10.1016/0922-4106(93)90037-A; Zylka MJ, 2003, P NATL ACAD SCI USA, V100, P10043, DOI 10.1073/pnas.1732949100	42	126	141	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23559	23564		10.1074/jbc.M314240200	http://dx.doi.org/10.1074/jbc.M314240200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15037633	hybrid			2022-12-25	WOS:000221570900095
J	Cheng, S; Afif, H; Martel-Pelletier, J; Pelletier, JP; Li, XF; Farrajota, K; Lavigne, M; Fahmi, H				Cheng, S; Afif, H; Martel-Pelletier, J; Pelletier, JP; Li, XF; Farrajota, K; Lavigne, M; Fahmi, H			Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1 beta-induced membrane-associated prostaglandin E-2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; ADJUVANT-INDUCED ARTHRITIS; TRANSCRIPTION FACTOR EGR-1; RESPONSE FACTOR-I; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); GENE-EXPRESSION; NITRIC-OXIDE; MEDIATED ADIPOGENESIS; T-LYMPHOCYTES	Membrane-associated prostaglandin (PG) E-2 synthase-1 (mPGES-1) catalyzes the conversion of PGH(2) to PGE(2), which contributes to many biological processes. Peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-activated transcription factor and plays an important role in growth, differentiation, and inflammation in different tissues. Here, we examined the effect of PPARgamma ligands on interleukin-1beta (IL-1beta)-induced mPGES-1 expression in human synovial fibroblasts. PPARgamma ligands 15-deoxy-Delta(12,14) prostaglandin J(2) (15d-PGJ(2)) and the thiazolidinedione troglitazone (TRO), but not PPARalpha ligand Wy14643, dose-dependently suppressed IL-1beta-induced PGE2 production, as well as mPGES-1 protein and mRNA expression. 15d-PGJ(2) and TRO suppressed IL-1beta-induced activation of the mPGES-1 promoter. Overexpression of wild-type PPARgamma further enhanced, whereas overexpression of a dominant negative PPARgamma alleviated, the suppressive effect of both PPARgamma ligands. Furthermore, pretreatment with an antagonist of PPARgamma, GW9662, relieves the suppressive effect of PPARgamma ligands on mPGES-1 protein expression, suggesting that the inhibition of mPGES-1 expression is mediated by PPARgamma. We demonstrated that PPARgamma ligands suppressed Egr-1-mediated induction of the activities of the mPGES-1 promoter and of a synthetic reporter construct containing three tandem repeats of an Egr-1 binding site. The suppressive effect of PPARgamma ligands was enhanced in the presence of a PPARgamma expression plasmid. Electrophoretic mobility shift and supershift assays for Egr-1 binding sites in the mPGES-1 promoter showed that both 15d-PGJ(2) and TRO suppressed IL-1beta-induced DNA-binding activity of Egr-1. These data define mPGES-1 and Egr-1 as novel targets of PPARgamma and suggest that inhibition of mPGES-1 gene transcription may be one of the mechanisms by which PPARgamma regulates inflammatory responses.	Univ Montreal, Notre Dame Hosp, Ctr Hosp, Osteoarthrit Res Unit, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada; Hop Maison Neuve Rosemont, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Fahmi, H (corresponding author), Univ Montreal, Notre Dame Hosp, Ctr Hosp, Osteoarthrit Res Unit, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.	h.fahmi@umontreal.ca	Pelletier, Jean-Pierre/AAG-2896-2019; Martel-Pelletier, Johanne/AAG-2928-2019					ALTMAN RD, 1991, SEMIN ARTHRITIS RHEU, V20, P40, DOI 10.1016/0049-0172(91)90026-V; Barthel R, 2003, MOL CELL BIOL, V23, P526, DOI 10.1128/MCB.23.2.526-533.2003; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chen F, 2003, J CELL BIOCHEM, V90, P732, DOI 10.1002/jcb.10668; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; Cippitelli M, 2003, J IMMUNOL, V170, P4578, DOI 10.4049/jimmunol.170.9.4578; Claveau D, 2003, J IMMUNOL, V170, P4738, DOI 10.4049/jimmunol.170.9.4738; Cohen EG, 2003, CLIN CANCER RES, V9, P3425; Crosby Colin G, 2003, Expert Opin Emerg Drugs, V8, P1; Cunard R, 2002, J IMMUNOL, V168, P2795, DOI 10.4049/jimmunol.168.6.2795; Cuzzocrea S, 2003, ARTHRITIS RHEUM-US, V48, P3544, DOI 10.1002/art.11351; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508; Ekstrom L, 2003, BBA-GENE STRUCT EXPR, V1627, P79, DOI 10.1016/S0167-4781(03)00077-0; Fahmi H, 2002, OSTEOARTHR CARTILAGE, V10, P100, DOI 10.1053/joca.2001.0485; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; Fahmi H, 2002, J RHEUMATOL, V29, P3; Fu MG, 2002, J BIOL CHEM, V277, P26808, DOI 10.1074/jbc.M203748200; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Jabbour HN, 2001, BRIT J CANCER, V85, P1023; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jones DC, 2003, J IMMUNOL, V171, P196, DOI 10.4049/jimmunol.171.1.196; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Martel-Pelletier J, 2003, SEMIN ARTHRITIS RHEU, V33, P155, DOI 10.1016/S0049-0172(03)00134-3; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Okada M, 2002, FASEB J, V16, P1861, DOI 10.1096/fj.02-0503com; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Qi C, 2003, J BIOL CHEM, V278, P25281, DOI 10.1074/jbc.C300175200; Reilly CM, 2000, J IMMUNOL, V164, P1498, DOI 10.4049/jimmunol.164.3.1498; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Subbaramaiah K, 2004, J BIOL CHEM, V279, P12647, DOI 10.1074/jbc.M312972200; Sugawara A, 2002, J BIOL CHEM, V277, P9676, DOI 10.1074/jbc.M104560200; Tanioka T, 2003, BIOCHEM BIOPH RES CO, V303, P1018, DOI 10.1016/S0006-291X(03)00470-4; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Vaidya S, 1999, J IMMUNOL, V163, P6187; van Rees BP, 2003, INT J CANCER, V107, P551, DOI 10.1002/ijc.11422; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P2669	56	77	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22057	22065		10.1074/jbc.M402828200	http://dx.doi.org/10.1074/jbc.M402828200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15023995	hybrid			2022-12-25	WOS:000221417100047
J	Ravanel, S; Block, MA; Rippert, P; Jabrin, S; Curien, G; Rebeille, F; Douce, R				Ravanel, S; Block, MA; Rippert, P; Jabrin, S; Curien, G; Rebeille, F; Douce, R			Methionine metabolism in plants - Chloroplasts are autonomous for de novo methionine synthesis and can import S-adenosylmethionine from the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; ADENOSYL-L-METHIONINE; FUNCTIONAL-CHARACTERIZATION; DEPENDENT METHYLTRANSFERASE; ARABIDOPSIS-THALIANA; CATHARANTHUS-ROSEUS; BIOSYNTHESIS; SYNTHASE; EXPRESSION; RECONSTITUTION	The subcellular distribution of Met and S-adenosylmethionine (AdoMet) metabolism in plant cells discloses a complex partition between the cytosol and the organelles. In the present work we show that Arabidopsis contains three functional isoforms of vitamin B-12-independent methionine synthase (MS), the enzyme that catalyzes the methylation of homocysteine to Met with 5-methyltetrahydrofolate as methyl group donor. One MS isoform is present in chloroplasts and is most likely required to methylate homocysteine that is synthesized de novo in this compartment. Thus, chloroplasts are autonomous and are the unique site for de novo Met synthesis in plant cells. The additional MS isoforms are present in the cytosol and are most probably involved in the regeneration of Met from homocysteine produced in the course of the activated methyl cycle. Although Met synthesis can occur in chloroplasts, there is no evidence that AdoMet is synthesized anywhere but the cytosol. In accordance with this proposal, we show that AdoMet is transported into chloroplasts by a carrier-mediated facilitated diffusion process. This carrier is able to catalyze the uniport uptake of AdoMet into chloroplasts as well as the exchange between cytosolic AdoMet and chloroplastic AdoMet or S-adenosylhomocysteine. The obvious function for the carrier is to sustain methylation reactions and other AdoMet-dependent functions in chloroplasts and probably to remove S-adenosylhomocysteine generated in the stroma by methyltransferase activities. Therefore, the chloroplastic AdoMet carrier serves as a link between cytosolic and chloroplastic one-carbon metabolism.	Univ Grenoble 1, Dept Reponse & Dynam Cellulaires, CEA Grenoble,INRA,CNRS,UMR 5168, Physiol Cellulaire Vegetale Lab, F-38054 Grenoble 9, France; ETH, Inst Plant Sci, Plant Biochem & Physiol Grp, CH-8092 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Swiss Federal Institutes of Technology Domain; ETH Zurich	Ravanel, S (corresponding author), Univ Grenoble 1, Dept Reponse & Dynam Cellulaires, CEA Grenoble,INRA,CNRS,UMR 5168, Physiol Cellulaire Vegetale Lab, 17 Rue Martyrs, F-38054 Grenoble 9, France.	sravanel@cea.fr		Rippert, Pascal/0000-0003-0185-0659; Ravanel, Stephane/0000-0001-9475-4222				ABEL S, 1994, PLANT J, V5, P421, DOI 10.1111/j.1365-313X.1994.00421.x; Agrimi G, 2004, BIOCHEM J, V379, P183, DOI 10.1042/BJ20031664; [Anonymous], METHODS CHLOROPLAST; Awai K, 2001, P NATL ACAD SCI USA, V98, P10960, DOI 10.1073/pnas.181331498; BLACK MT, 1987, J BIOL CHEM, V262, P9803; Block MA, 2002, EUR J BIOCHEM, V269, P240, DOI 10.1046/j.0014-2956.2001.02643.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUINSMA J, 1961, BIOCHIM BIOPHYS ACTA, V52, P576, DOI 10.1016/0006-3002(61)90418-8; BURTON E, 1969, BIOCHEM J, V111, P793, DOI 10.1042/bj1110793; BURTON EG, 1969, BIOCHEM BIOPH RES CO, V36, P228, DOI 10.1016/0006-291X(69)90319-2; Chan SY, 2003, PTERIDINES, V14, P17; Cheng ZG, 2003, PLANT CELL, V15, P2343, DOI 10.1105/tpc.013656; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Curien G, 2003, EUR J BIOCHEM, V270, P4615, DOI 10.1046/j.1432-1033.2003.03851.x; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; DRUMMOND JT, 1995, ANAL BIOCHEM, V228, P323, DOI 10.1006/abio.1995.1358; Eckermann C, 2000, BIOL CHEM, V381, P695, DOI 10.1515/BC.2000.090; EICHEL J, 1995, EUR J BIOCHEM, V230, P1053, DOI 10.1111/j.1432-1033.1995.tb20655.x; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Gakiere B., 1999, Plant Physiology, V120, P1206; Gallardo K, 2002, PHYSIOL PLANTARUM, V116, P238, DOI 10.1034/j.1399-3054.2002.1160214.x; GIOVANELLI J, 1985, PLANT PHYSIOL, V78, P555, DOI 10.1104/pp.78.3.555; GONZALEZ JC, 1992, BIOCHEMISTRY-US, V31, P6045, DOI 10.1021/bi00141a013; Hanson AD, 2001, ANNU REV PLANT PHYS, V52, P119, DOI 10.1146/annurev.arplant.52.1.119; Heldt H. W., 1980, METHOD ENZYMOL, V69, P604; Hesse H, 2003, TRENDS PLANT SCI, V8, P259, DOI 10.1016/S1360-1385(03)00107-9; Horne DW, 1997, ARCH BIOCHEM BIOPHYS, V343, P201, DOI 10.1006/abbi.1997.0167; ISEGAWA Y, 1994, PHYTOCHEMISTRY, V35, P59; Jabrin S, 2003, PLANT PHYSIOL, V131, P1431, DOI 10.1104/pp.016915; Marobbio CMT, 2003, EMBO J, V22, P5975, DOI 10.1093/emboj/cdg574; MILLS WR, 1980, PLANT PHYSIOL, V65, P1166, DOI 10.1104/pp.65.6.1166; Moffatt BA, 2001, PHYSIOL PLANTARUM, V113, P435, DOI 10.1034/j.1399-3054.2001.1130401.x; MOURIOUX G, 1981, PLANT PHYSIOL, V67, P470, DOI 10.1104/pp.67.3.470; Nikiforova V, 2002, AMINO ACIDS, V22, P259, DOI 10.1007/s007260200013; Ravanel S, 2001, P NATL ACAD SCI USA, V98, P15360, DOI 10.1073/pnas.261585098; Ravanel S, 1998, P NATL ACAD SCI USA, V95, P7805, DOI 10.1073/pnas.95.13.7805; Schroder G, 1997, PLANT MOL BIOL, V33, P211, DOI 10.1023/A:1005711720930; Teyssier E, 1996, PLANT J, V10, P903, DOI 10.1046/j.1365-313X.1996.10050903.x; WALLSGROVE RM, 1983, PLANT PHYSIOL, V71, P780, DOI 10.1104/pp.71.4.780; WHITFIELD CD, 1970, J BIOL CHEM, V245, P390; YEO EJ, 1992, J BIOL CHEM, V267, P24669; Zeh M, 2002, PLANT MOL BIOL, V48, P255, DOI 10.1023/A:1013333303554	43	187	202	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22548	22557		10.1074/jbc.M313250200	http://dx.doi.org/10.1074/jbc.M313250200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15024005	Green Published, hybrid			2022-12-25	WOS:000221417100106
J	Relic, B; Benoit, R; Franchimont, N; Ribbens, C; Kaiser, MJ; Gillet, P; Merville, MP; Bours, V; Malaise, MG				Relic, B; Benoit, R; Franchimont, N; Ribbens, C; Kaiser, MJ; Gillet, P; Merville, MP; Bours, V; Malaise, MG			15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; NITRIC-OXIDE; EXPERIMENTAL OSTEOARTHRITIS; TRANSCRIPTION FACTORS; GAMMA AGONISTS; IN-VIVO; PATHWAYS; ERK; GROWTH	We have previously shown that nuclear factor-kappaB inhibition by adenovirus expressing mutated IkappaB-alpha or by proteasome inhibitor increases human articular chondrocytes sensibility to apoptosis. Moreover, the nuclear factor-kappaB inhibitor BAY11-7085, a potent anti-inflammatory drug in rat adjuvant arthritis, is itself a proapoptotic agent for chondrocytes. In this work, we show that BAY 11-7085 but not the proteasome inhibitor MG-132 induced a rapid and sustained phosphorylation of extracellular signal-regulated kinases (ERK1/2) in human articular chondrocytes. The level of ERK1/2 phosphorylation correlated with BAY 11-7085 concentration and chondrocyte apoptosis. 15-Deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) and its precursor prostaglandin (PG) D2 but not PGE2 and PGF2alpha rescued chondrocytes from BAY 11-7085-induced apoptosis. 15d-PGJ2 markedly inhibited BAY 11-7085-induced phosphorylation of ERK1/2. BAY 11-7085 also induced ERK1/2 phosphorylation and apoptosis in human synovial fibroblasts, and these reactions were down-regulated by 15d-PGJ2. Further analysis in synovial fibroblasts showed that only molecules that suppressed BAY 11-7085-induced phosphorylation of ERK1/2 (i.e. 15d-PGJ2, PGD2, and to a lesser extent, MEK1/2 inhibitor UO126, but not prostaglandins E2 and F2alpha or peroxisome proliferator-activated receptor-gamma agonist ciglitazone) were able protect cells from apoptosis. These results suggested that the antiapoptotic effect of 15d-PGJ2 on chondrocytes and synovial fibroblasts might involve inhibition of ERK1/2 phosphorylation.	Univ Liege, Ctr Cellular & Mol Therapy, B-4000 Liege, Belgium; Univ Liege, Dept Orthoped Surg, B-4000 Liege, Belgium	University of Liege; University of Liege	Malaise, MG (corresponding author), CHU Sart Tilman B35, Dept Rheumatol, B-4000 Liege, Belgium.	michel.malaise@ulg.ac.be		BENOIT, Valerie/0000-0002-1098-9452				Aigner T, 2002, ARTHRITIS RHEUM-US, V46, P1986, DOI 10.1002/art.10554; Aoun P, 2003, EUR J PHARMACOL, V472, P65, DOI 10.1016/S0014-2999(03)01867-3; Asada S, 2001, INFLAMM RES, V50, P19, DOI 10.1007/s000110050719; Bapat S, 2001, FEBS LETT, V499, P21, DOI 10.1016/S0014-5793(01)02511-X; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Boyault S, 2001, FEBS LETT, V501, P24, DOI 10.1016/S0014-5793(01)02614-X; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Calabrese C, 2003, J BIOL CHEM, V278, P24951, DOI 10.1074/jbc.M211600200; Choi YJ, 2003, BIOCHEM BIOPH RES CO, V305, P176, DOI 10.1016/S0006-291X(03)00719-8; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kim HA, 2002, BIOCHEM BIOPH RES CO, V295, P937, DOI 10.1016/S0006-291X(02)00789-1; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pelletier JP, 2003, ARTHRITIS RHEUM-US, V48, P1582, DOI 10.1002/art.11014; Pelletier JP, 2001, J RHEUMATOL, V28, P2509; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Relic B, 2002, LAB INVEST, V82, P1661, DOI 10.1097/01.LAB.0000041714.05322.C0; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Shimada T, 2002, GUT, V50, P658, DOI 10.1136/gut.50.5.658; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Subramaniam S, 2003, J BIOL CHEM, V278, P8904, DOI 10.1074/jbc.M210037200; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Tsubouchi Y, 2001, BIOCHEM BIOPH RES CO, V283, P750, DOI 10.1006/bbrc.2001.4847; van der Kraan PM, 2002, OSTEOARTHR CARTILAGE, V10, P631, DOI 10.1053/joca.2002.0806; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Ward C, 2002, J IMMUNOL, V168, P6232, DOI 10.4049/jimmunol.168.12.6232; Xiao D, 2002, CANCER RES, V62, P3615; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Zheng B, 2003, BLOOD, V102, P1019, DOI 10.1182/blood-2002-11-3507; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	36	41	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22399	22403		10.1074/jbc.M314118200	http://dx.doi.org/10.1074/jbc.M314118200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15004016	hybrid			2022-12-25	WOS:000221417100088
J	Saran, A; Spinola, M; Pazzaglia, S; Peissel, B; Tiveron, C; Tatangelo, L; Mancuso, M; Covelli, V; Giovannelli, L; Pitozzi, V; Pignatiello, C; Milani, S; Dolara, P; Dragani, TA				Saran, A; Spinola, M; Pazzaglia, S; Peissel, B; Tiveron, C; Tatangelo, L; Mancuso, M; Covelli, V; Giovannelli, L; Pitozzi, V; Pignatiello, C; Milani, S; Dolara, P; Dragani, TA			Loss of tyrosinase activity confers increased skin tumor susceptibility in mice	ONCOGENE			English	Article						polymorphism; genetic predisposition; animal models	CANCER MODIFIER LOCI; OUTBRED MICE; COMET ASSAY; MOUSE; RESISTANCE; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; CARCINOGENESIS; MUTATION; GENETICS; DAMAGE	The tyrosinase (Tyr) gene encodes the enzyme tyrosinase that catalyses the conversion of L-tyrosine into DOPA (3,4-dihydroxyphenylalanine)- quinone. The albino mutation abrogates functional activity of tyrosinase resulting in deficiency of melanin pigment production in skin and retina. Tyr maps to a region in the central position of Chromosome 7 that contains a skin tumor-modi. er locus. We rescued the albino mutation in transgenic mice to assess a possible role of Tyr gene in two-stage skin carcinogenesis. Transgenic expression of the functional Tyr(Cys) allele in albino mice (Tyr(Ser)) caused a reduction in skin papilloma multiplicity, in four independent experiments and at three dose levels of DMBA (9,10-dimethyl-1,2- benzanthracene). In vitro mechanistic studies demonstrated that transfection of the Tyr(Cys) allele in a human squamous cell carcinoma cell line (NCI-H520) increases tyrosinase enzyme activity and confers resistance to hydrogen peroxide-induced oxidative DNA damage. These results provide direct evidence that the Tyr gene can act as a skin cancer-modifier gene, whose mechanism of action may involve modulation of oxidative DNA damage.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; ENEA CR Casaccia, Biotechnol Unit, Rome, Italy; Ist Regina Elena, Transgen Mice Serv Ctr, I-00161 Rome, Italy; Univ Florence, Dept Pharmacol, Florence, Italy; Univ Milan, Inst Med Stat & Biometry, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Florence; University of Milan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	dragani@istitutotumori.mi.it	Dragani, Tommaso A./K-4493-2016; Peissel, Bernard/E-8187-2017; Giovannelli, Lisa/H-3766-2012; milani, silvano/I-7889-2012	Dragani, Tommaso A./0000-0001-5915-4598; Peissel, Bernard/0000-0001-9233-3571; milani, silvano/0000-0002-5677-1758; Saran, Anna/0000-0002-5587-064X; Giovannelli, Lisa/0000-0002-4027-4693	Telethon [B.55] Funding Source: Medline	Telethon(Fondazione Telethon)		Angel JM, 1997, MOL CARCINOGEN, V20, P162, DOI 10.1002/(SICI)1098-2744(199710)20:2<162::AID-MC2>3.0.CO;2-P; Collins AR, 1997, MUTAT RES-FUND MOL M, V375, P183, DOI 10.1016/S0027-5107(97)00013-4; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Darvasi A, 2002, TRENDS GENET, V18, P489, DOI 10.1016/S0168-9525(02)02767-1; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Dragani TA, 2003, CANCER RES, V63, P3011; Draper N.R., 1998, APPL REGRESSION ANAL, P79; FRENKEL K, 1995, FREE RADICAL BIO MED, V19, P373, DOI 10.1016/0891-5849(95)00046-Z; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; Giovannelli L, 2003, MUTAT RES-GEN TOX EN, V538, P71, DOI 10.1016/S1383-5718(03)00090-1; Hogan B, 1994, MANIPULATING MOUSE E; Lutsenko EA, 2002, J BIOL CHEM, V277, P16895, DOI 10.1074/jbc.M201151200; Manenti G, 1997, MAMM GENOME, V8, P801, DOI 10.1007/s003359900582; Maria DA, 2003, ONCOGENE, V22, P426, DOI 10.1038/sj.onc.1206157; Mock BA, 1998, CARCINOGENESIS, V19, P1109, DOI 10.1093/carcin/19.6.1109; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Nagase H, 2001, CANCER RES, V61, P1305; Park KK, 2003, MUTAT RES-GEN TOX EN, V542, P89, DOI 10.1016/j.mrgentox.2003.09.001; Peissel B, 2000, MAMM GENOME, V11, P979, DOI 10.1007/s003350010184; Peissel B, 2001, MAMM GENOME, V12, P291, DOI 10.1007/s003350010274; PERIN F, 1994, CANCER RES, V54, P4635; Saran A, 2000, INT J CANCER, V88, P424, DOI 10.1002/1097-0215(20001101)88:3<424::AID-IJC15>3.0.CO;2-D; SEARLE AG, 1990, OPHTHALMIC PAED GEN, V11, P159, DOI 10.3109/13816819009020974; Shi YL, 2002, LIFE SCI, V70, P1595, DOI 10.1016/S0024-3205(01)01546-6; SLAGA TJ, 1995, ADV EXP MED BIOL, V369, P167; Steinmetz LM, 2002, NATURE, V416, P326, DOI 10.1038/416326a; WEI HC, 1993, CARCINOGENESIS, V14, P1195, DOI 10.1093/carcin/14.6.1195; WINDER AJ, 1994, J BIOCHEM BIOPH METH, V28, P173, DOI 10.1016/0165-022X(94)90014-0; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293	29	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4130	4135		10.1038/sj.onc.1207565	http://dx.doi.org/10.1038/sj.onc.1207565			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15007389				2022-12-25	WOS:000221520200011
J	Wlodawer, A; Li, M; Gustchina, A; Tsuruoka, N; Ashida, M; Minakata, H; Oyama, H; Oda, K; Nishino, T; Nakayama, T				Wlodawer, A; Li, M; Gustchina, A; Tsuruoka, N; Ashida, M; Minakata, H; Oyama, H; Oda, K; Nishino, T; Nakayama, T			Crystallographic and biochemical investigations of kumamolisin-As, a serine-carboxyl peptidase with collagenase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MACROMOLECULAR STRUCTURES; STRAIN NTAP-1; PROTEINASE; KUMAMOLYSIN; PURIFICATION; SPECIFICITY; REFINEMENT; EXPRESSION; INHIBITOR	Kumamolisin-As (previously called ScpA) is the first known example of a collagenase from the sedolisin family (MEROPS S53). This enzyme is active at low pH and in elevated temperatures. In this study that used x-ray crystallographic and biochemical methods, we investigated the structural basis of the preference of this enzyme for collagen and the importance of a glutamate residue in the unique catalytic triad (Ser(278)-Glu(78)-Asp(82)) for enzymatic activity. Crystal structures of the uninhibited enzyme and its complex with a covalently bound inhibitor, N-acetyl-isoleucyl-prolyl-phenylalaninal, showed the occurrence of a narrow S2 pocket and a groove that encompasses the active site and is rich in negative charges. Limited endoproteolysis studies of bovine type-I collagen as well as kinetic studies using peptide libraries randomized at P1 and P1', showed very strong preference for arginine at the P1 position, which correlated very well with the presence of a negatively charged residue in the S1 pocket of the enzyme. All of these features, together with those predicted through comparisons with fiddler crab collagenase, a serine peptidase, rationalize the enzyme's preference for collagen. A comparison of the Arrhenius plots of the activities of kumamolisin-As with either collagen or peptides as substrates suggests that collagen should be relaxed before proteolysis can occur. The E78H mutant, in which the catalytic triad was engineered to resemble that of subtilisin, showed only 0.01% activity of the wild-type enzyme, and its structure revealed that Ser(278), His(78), and Asp(82) do not interact with each other; thus, the canonical catalytic triad is disrupted.	NCI Frederick, NIH, Macromol Crystallog Lab, Prot Struct Sect, Frederick, MD 21702 USA; NCI Frederick, NIH, Sci Applicat Int Corp, Basic Res Program, Frederick, MD 21702 USA; Kanazawa Med Univ, Sch Med, Dept Biochem, Kanazawa, Ishikawa 9200293, Japan; Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan; Suntory Inst Bioorgan Res, Osaka 6188503, Japan; Kyoto Inst Technol, Fac Text Sci, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Kanazawa Medical University; Tohoku University; Suntory Holdings Ltd; Kyoto Institute of Technology	Wlodawer, A (corresponding author), NCI Frederick, NIH, Macromol Crystallog Lab, Prot Struct Sect, Frederick, MD 21702 USA.	wlodawer@ncifcrf.gov	Tsuruoka, Naoki/L-1192-2018	Tsuruoka, Naoki/0000-0003-4052-3327	NATIONAL CANCER INSTITUTE [Z01BC010348] Funding Source: NIH RePORTER; NCI NIH HHS [N01 CO 12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antal J, 2001, ANAL BIOCHEM, V288, P156, DOI 10.1006/abio.2000.4886; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Comellas-Bigler M, 2002, STRUCTURE, V10, P865, DOI 10.1016/S0969-2126(02)00772-4; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME, P105; Dauter Z, 2001, ACTA CRYSTALLOGR D, V57, P239, DOI 10.1107/S0907444900015249; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GLANVILLE RW, 1983, BIOCHEM J, V215, P183, DOI 10.1042/bj2150183; Harrington DJ, 1996, INFECT IMMUN, V64, P1885, DOI 10.1128/IAI.64.6.1885-1891.1996; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; MADIGAN MT, 2000, BIOL MICROORGANISMS; Matsushita O, 1998, J BIOL CHEM, V273, P3643, DOI 10.1074/jbc.273.6.3643; Miller EJ, 1984, EXTRACELLULAR MATRIX, P41; MURAO S, 1993, J BIOL CHEM, V268, P349; Nakayama T, 2000, J BIOSCI BIOENG, V89, P612, DOI 10.1016/S1389-1723(00)80067-5; Nicholls A., 1992, GRASP GRAPHICAL REPR; Oda K, 2000, J BIOCHEM, V128, P499, DOI 10.1093/oxfordjournals.jbchem.a022780; Okamoto M, 2001, APPL MICROBIOL BIOT, V57, P103, DOI 10.1007/s002530100731; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oyama H, 2002, J BIOCHEM, V131, P757, DOI 10.1093/oxfordjournals.jbchem.a003162; Perona JJ, 1997, BIOCHEMISTRY-US, V36, P5381, DOI 10.1021/bi9617522; SASAGAWA T, 1987, HDB HPLC SEPARATION, P53; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; Tsu CA, 1997, BIOCHEMISTRY-US, V36, P5393, DOI 10.1021/bi961753u; Tsuruoka N, 2003, INT J SYST EVOL MICR, V53, P1081, DOI 10.1099/ijs.0.02409-0; Tsuruoka N, 2003, APPL ENVIRON MICROB, V69, P162, DOI 10.1128/AEM.69.1.162-169.2003; Wlodawer A, 2003, ACTA BIOCHIM POL, V50, P81; Wlodawer A, 2001, BIOCHEMISTRY-US, V40, P15602, DOI 10.1021/bi011817n; Wlodawer A, 2001, NAT STRUCT BIOL, V8, P442, DOI 10.1038/87610	35	39	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21500	21510		10.1074/jbc.M401141200	http://dx.doi.org/10.1074/jbc.M401141200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15014068	hybrid			2022-12-25	WOS:000221273800115
J	Xie, SQ; Wang, Q; Ruan, Q; Liu, TY; Jhanwar-Uniyal, M; Guan, KL; Dai, W				Xie, SQ; Wang, Q; Ruan, Q; Liu, TY; Jhanwar-Uniyal, M; Guan, KL; Dai, W			MEK1-induced Golgi dynamics during cell cycle progression is partly mediated by Polo-like kinase-3	ONCOGENE			English	Article						Plk3; Golgi breakdown; polo-like kinases; MEK1; cell cycle	MATRIX PROTEIN GM130; MITOTIC PHOSPHORYLATION; CDC2 KINASE; FRAGMENTATION; MITOSIS; APOPTOSIS; COMPLEX; MEK1; IDENTIFICATION; ACTIVATION	MEK1, a gene product that regulates cell growth and differentiation, also plays an important role in Golgi breakdown during the cell cycle. We have recently shown that polo-like kinase (Plk3) is Golgi localized and involved in Golgi dynamics during the cell cycle. To study the mode of action of Plk3 in the Golgi fragmentation cascade, we examined functional as well as physical interactions between Plk3 and MEK1/ERKs. In HeLa cells, although a significant amount of Plk3 signals dispersed in a manner similar to those of Golgi during mitosis concentrated Plk3 was detected at spindle poles, which colocalized with phospho-MEKs and phospho-ERKs. Pull-down assays showed that Plk3 physically interacted with MEK1 and ERK2. Nocodazole activated Plk3 and its activation was blocked by MEK-specific inhibitors (PD98059 or U0126). Moreover, transfection of activated MEK1 resulted in an enhanced kinase activity of Plk3; Plk3-induced fragmentation of Golgi stacks was significantly reduced after treatment with MEK inhibitors. Consistently, ectopic expression of activated MEK1, but not kinase-dead MEK1(K97R), stimulated Plk3 to induce Golgi breakdown and the stimulation was not observed in cells expressing Plk3(K52R). Furthermore, PLK3(-/-) murine embryonic fibroblast cells exhibited a significantly less fragmentation of the Golgi complex than that in wild-type cells after exposed to nocodazole. Thus, our studies strongly suggest that Plk3 may be a key protein kinase mediating MEK1 function in the Golgi fragmentation pathway during cell division.	New York Med Coll, Dept Med, Valhalla, NY 10595 USA; Inst Canc Prevent, Valhalla, NY 10595 USA; Univ Michigan, Dept Biochem, Ann Arbor, MI 48109 USA	New York Medical College; University of Michigan System; University of Michigan	Dai, W (corresponding author), New York Med Coll, Dept Med, Valhalla, NY 10595 USA.	wei_dai@nymc.edu		Dai, Wei/0000-0003-0169-8327	NCI NIH HHS [R01-CA74229] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; Colanzi A, 2003, J CELL BIOL, V161, P27, DOI 10.1083/jcb.200208099; Jesch SA, 2001, MOL BIOL CELL, V12, P1811, DOI 10.1091/mbc.12.6.1811; Kano F, 2000, J CELL BIOL, V149, P357, DOI 10.1083/jcb.149.2.357; Kee HJ, 2003, YONSEI MED J, V44, P65, DOI 10.3349/ymj.2003.44.1.65; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Lowe M, 2000, J CELL BIOL, V149, P341, DOI 10.1083/jcb.149.2.341; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; LUCOCQ J, 1991, J CELL SCI, V100, P753; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; RUAN Q, 2004, IN PRESS EXP CELL RE; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	22	40	41	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3822	3829		10.1038/sj.onc.1207479	http://dx.doi.org/10.1038/sj.onc.1207479			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021912				2022-12-25	WOS:000221242500009
J	Gomez-Manzano, C; Balague, C; Alemany, R; Lemoine, MG; Mitlianga, P; Jiang, H; Khan, A; Alonso, M; Lang, FF; Conrad, CA; Liu, TJ; Bekele, BN; Yung, WKA; Fueyo, J				Gomez-Manzano, C; Balague, C; Alemany, R; Lemoine, MG; Mitlianga, P; Jiang, H; Khan, A; Alonso, M; Lang, FF; Conrad, CA; Liu, TJ; Bekele, BN; Yung, WKA; Fueyo, J			A novel E1A-E1B mutant adenovirus induces glioma regression in vivo	ONCOGENE			English	Article						glioma; therapy; E1A; E1B; adenovirus	CONDITIONALLY REPLICATIVE ADENOVIRUS; ONCOLYTIC ADENOVIRUS; CANCER-THERAPY; E1A PROTEINS; EFFICACY; TUMOR; CELLS; TRANSFORMATION; PATHWAY; POTENT	Malignant gliomas are the most frequently occurring primary brain tumors and are resistant to conventional therapy. Conditionally replicating adenoviruses are a novel strategy in glioma treatment. Clinical trials using E1B mutant adenoviruses have been reported recently and E1A mutant replication-competent adenoviruses are in advanced preclinical testing. Here we constructed a novel replication-selective adenovirus (CB1) incorporating a double deletion of a 24 bp Rb-binding region in the E1a gene, and a 903 bp deleted region in the E1b gene that abrogates the expression of a p53-binding E1B-55 kDa protein. CB1 exerted a potent anticancer effect in vitro in U-251 MG, U-373 MG, and D-54 MG human glioma cell lines, as assessed by qualitative and quantitative viability assays. Replication analyses demonstrated that CB1 replicates in vitro in human glioma cells. Importantly, CB1 acquired a highly attenuated replicative phenotype in both serum-starved and proliferating normal human astrocytes. In vivo experiments using intracranially implanted D-54 MG glioma xenografts in nude mice showed that a single dose of CB1 (1.5 x 10(8) PFU/tumor) significantly improved survival. Immunohistochemical analyses of expressed adenoviral proteins confirmed adenoviral replication within the tumors. The CB1 oncolytic adenovirus induces a potent antiglioma effect and could ultimately demonstrate clinical relevance and therapeutic utility.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Alabama Birmingham, Gene Therapy Ctr, Birmingham, AL 35294 USA; Inst Catala Oncol, Barcelona 08907, Spain; Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Alabama System; University of Alabama Birmingham; Catalan Institute of Oncology; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Box 316,1515 Holcombe Blvd, Houston, TX 77030 USA.	jfueyo@mdanderson.org	Alonso, Marta M/AAI-9457-2020; Mitlianga, Paraskevi/AAU-1541-2020	Alonso, Marta M/0000-0002-7520-7351; Mitlianga, Paraskevi/0000-0003-3145-5596; Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335	NCI NIH HHS [R01CA90879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; Balague C, 2001, J VIROL, V75, P7602, DOI 10.1128/JVI.75.16.7602-7611.2001; Bauerschmitz GJ, 2002, CANCER RES, V62, P1266; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Cripe TP, 2001, CANCER RES, V61, P2953; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Howe JA, 2000, MOL THER, V2, P485, DOI 10.1006/mthe.2000.0206; Jakubczak JL, 2003, CANCER RES, V63, P1490; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Lamfers MLM, 2002, CANCER RES, V62, P5736; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Ramachandra M, 2001, NAT BIOTECHNOL, V19, P1035, DOI 10.1038/nbt1101-1035; SHENK T, 1991, ADV CANCER RES, V57, P47; Suzuki K, 2001, CLIN CANCER RES, V7, P120; Tsukuda K, 2002, CANCER RES, V62, P3438; van Beusechem VW, 2002, CANCER RES, V62, P6165; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YOSHIDA K, 1995, CURR TOP MICROBIOL, V199, P113	27	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1821	1828		10.1038/sj.onc.1207321	http://dx.doi.org/10.1038/sj.onc.1207321			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	15014451				2022-12-25	WOS:000220129500003
J	Louzada, PR; Lima, ACP; Mendonca-Silva, DL; Noel, F; De Mello, FG; Ferreira, ST				Louzada, PR; Lima, ACP; Mendonca-Silva, DL; Noel, F; De Mello, FG; Ferreira, ST			Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders	FASEB JOURNAL			English	Article						amyloid; neuroprotection	EXCITATORY AMINO-ACIDS; BLOOD-BRAIN-BARRIER; LIPID-PEROXIDATION; NEURONAL DEATH; HIPPOCAMPAL-NEURONS; CALCIUM HOMEOSTASIS; IN-VITRO; PEPTIDE; RETINA; EXCITOTOXICITY	Alzheimer's disease (AD) and several other neurological disorders have been linked to the overactivation of glutamatergic transmission and excitotoxicity as a common pathway of neuronal injury. The beta-amyloid peptide (Abeta) is centrally related to the pathogenesis of AD, and previous reports have demonstrated that the blockade of glutamate receptors prevents Abeta-induced neuronal death. We show that taurine, a beta-amino acid found at high concentrations in the brain, protects chick retinal neurons in culture against the neurotoxicity of Abeta and glutamate receptor agonists. The protective effect of taurine is not mediated by interaction with glutamate receptors, as demonstrated by binding studies using radiolabeled glutamate receptor ligands. The neuroprotective action of taurine is blocked by picrotoxin, an antagonist of GABA(A) receptors. GABA and the GABA(A) receptor agonists phenobarbital and melatonin also protect neurons against Abeta-induced neurotoxicity. These results suggest that activation of GABA receptors decreases neuronal vulnerability to excitotoxic damage and that pharmacological manipulation of the excitatory and inhibitory neurotransmitter tonus may protect neurons against a variety of insults. GABAergic transmission may represent a promising target for the treatment of AD and other neurological disorders in which excitotoxicity plays a relevant role.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Farmacol Basica & Clin, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Ferreira, ST (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.	ferreira@bioqmed.uf.br	Noël, François/C-3402-2009; Paula-Lima, Andrea/I-2537-2013; Ferreira, Sergio/AAZ-1576-2020; nikkhah, elham/M-6142-2017	Noël, François/0000-0001-6813-1347; Paula-Lima, Andrea/0000-0002-0466-7561; Ferreira, Sergio/0000-0001-7160-9866; 				Abel KM, 2003, NEUROPHARMACOLOGY, V44, P729, DOI 10.1016/S0028-3908(03)00073-X; Alvarez A, 1998, J NEUROSCI, V18, P3213; ARIAS C, 1995, J NEUROSCI RES, V41, P561, DOI 10.1002/jnr.490410416; Balla A, 2001, NEUROPSYCHOPHARMACOL, V25, P157, DOI 10.1016/S0893-133X(01)00230-5; Behrens PF, 2002, BRAIN, V125, P1908, DOI 10.1093/brain/awf180; BENRABH H, 1995, BRAIN RES, V692, P57, DOI 10.1016/0006-8993(95)00648-A; Birdsall T C, 1998, Altern Med Rev, V3, P128; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butterfield DA, 2002, NEUROBIOL AGING, V23, P655; Cluskey S, 2001, J CLIN PATHOL-MOL PA, V54, P386; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; del Olmo N, 2000, BRAIN RES, V864, P298, DOI 10.1016/S0006-8993(00)02211-3; DIFAZIO MC, 1992, NEUROLOGY, V42, P402, DOI 10.1212/WNL.42.2.402; El Idrissi A, 1999, J NEUROSCI, V19, P9459; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; Forloni G, 1997, J NEUROCHEM, V68, P319; FRANDSEN A, 1990, NEUROSCI LETT, V111, P233, DOI 10.1016/0304-3940(90)90374-I; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; Green AR, 2000, NEUROPHARMACOLOGY, V39, P1483, DOI 10.1016/S0028-3908(99)00233-6; GUIDOTTI A, 1972, J NEUROCHEM, V19, P431, DOI 10.1111/j.1471-4159.1972.tb01352.x; Harkany T, 2000, EUR J NEUROSCI, V12, P2735, DOI 10.1046/j.1460-9568.2000.00164.x; Hassel B, 2001, EPILEPSY RES, V43, P153, DOI 10.1016/S0920-1211(00)00196-0; Holden C, 2003, SCIENCE, V300, P1866, DOI 10.1126/science.300.5627.1866; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Jevtovic-Todorovic V, 2001, BRAIN RES, V913, P185, DOI 10.1016/S0006-8993(01)02800-1; JOHNSTON GAR, 1980, J NEUROCHEM, V34, P241, DOI 10.1111/j.1471-4159.1980.tb04650.x; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; KIEBURTZ KD, 1991, ARCH NEUROL-CHICAGO, V48, P1281, DOI 10.1001/archneur.1991.00530240087028; KOWALL NW, 1992, NEUROBIOL AGING, V13, P537, DOI 10.1016/0197-4580(92)90053-Z; LAUNDERBACK CM, 1999, LIFE SCI, V650, P1977; Lima ACP, 2003, NEUROTOX RES, V5, P323, DOI 10.1007/BF03033152; LIMA L, 1993, J NEUROCHEM, V60, P2153, DOI 10.1111/j.1471-4159.1993.tb03500.x; Lima L, 1998, J NEUROSCI RES, V53, P377, DOI 10.1002/(SICI)1097-4547(19980801)53:3<377::AID-JNR12>3.0.CO;2-2; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lombardini JB, 1996, ADV EXP MED BIOL, V403, P343; Loureiro-dos-Santos NE, 2001, J NEUROCHEM, V77, P1136, DOI 10.1046/j.1471-4159.2001.00330.x; Louzada PR, 2001, NEUROSCI LETT, V301, P59, DOI 10.1016/S0304-3940(01)01585-3; MARK RJ, 1995, NEUROBIOL AGING, V16, P187, DOI 10.1016/0197-4580(94)00150-2; Matsuyama Y, 1983, Prog Clin Biol Res, V125, P461; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; MCBRIDE WJ, 1980, FED PROC, V39, P2701; Mills CD, 2002, EXP NEUROL, V173, P153, DOI 10.1006/exnr.2001.7828; NAGELHUS EA, 1993, NEUROSCIENCE, V54, P615, DOI 10.1016/0306-4522(93)90233-6; Noda M, 1999, NEUROSCIENCE, V92, P1465, DOI 10.1016/S0306-4522(99)00036-6; O'Byrne MB, 2000, J NEUROCHEM, V74, P2087, DOI 10.1046/j.1471-4159.2000.0742087.x; OKAMOTO K, 1983, BRAIN RES, V259, P319, DOI 10.1016/0006-8993(83)91266-0; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; POMARA N, 1992, AM J PSYCHIAT, V149, P251; Rodrigues CMP, 2001, BIOCHEM BIOPH RES CO, V281, P468, DOI 10.1006/bbrc.2001.4370; Saransaari P, 1997, NEUROSCIENCE, V79, P847, DOI 10.1016/S0306-4522(97)00038-9; Schwartz-Bloom RD, 2000, NEUROSCIENCE, V98, P471, DOI 10.1016/S0306-4522(00)00144-5; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; TADOLINI B, 1995, BIOCHEM BIOPH RES CO, V213, P820, DOI 10.1006/bbrc.1995.2203; Tamai I, 1995, BIOCHEM PHARMACOL, V50, P1783, DOI 10.1016/0006-2952(95)02046-2; Velasco I, 2002, J NEUROSCI RES, V67, P406, DOI 10.1002/jnr.10114; Zhao P, 1999, NEUROSCI LETT, V268, P25, DOI 10.1016/S0304-3940(99)00373-0	57	182	191	1	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					511	518		10.1096/fj.03-0739com	http://dx.doi.org/10.1096/fj.03-0739com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003996				2022-12-25	WOS:000220522800043
J	Ma, YY; Shimakami, T; Luo, H; Hayashi, N; Murakami, S				Ma, YY; Shimakami, T; Luo, H; Hayashi, N; Murakami, S			Mutational analysis of hepatitis C virus NS5B in the subgenomic replicon cell culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; DE-NOVO INITIATION; CRYSTAL-STRUCTURE; PROTEIN; REPLICATION; MECHANISM; IDENTIFICATION; LINE; TRANSACTIVATION; REQUIREMENTS	The hepatitis C virus (HCV) NS5B is an RNA-dependent RNA polymerase (RdRP), a central catalytic enzyme of HCV RNA replication. We previously identified five novel residues of NS5B in a JK-1 isolate indispensable for RdRP activity in vitro (Qin, W., Yamashita, T., Shirota, Y., Lin, Y., Wei, W., and Murakami, S. (2001) Hepatology 33, 728-737). We addressed the role of these residues in HCV RNA replication using a HCV replicon system derived from an M1LE isolate (Kishine, H., Sugiyama, K., Hijikata, M., Kato, N., Takahashi, H., Noshi, T., Nio, Y., Hosaka, M., Miyanari, Y., and Shimotohno, K. (2002) Biochem. Biophys. Res. Commun. 293, 993-999). The five residues of NS5B in M1LE were found to be critical for HCV replication in vivo and also indispensable for RdRP activity in vitro along with purified bacterial recombinant proteins. We also found a chimeric replicon of JK-1 and M1LE in which only the NS5B sequence derived from JK-1 could not replicate in Huh-7 cells. The residues responsible for the phenomenon were mapped by several chimeric and substituted forms of NS5B M1LE and/or JK-1 isolates in the HCV RNA replicon. Two residues, amino acids 220 and 288, were critical, and two residues, amino acids 213 and 231, were important for efficient HCV replication. Mutant JK-1 NS5B harboring all four residues of M1LE was replication-competent in the chimeric replicon and was as efficient as the original M1LE replicon. By comparing the replication competence in vivo and RdRP activity in vitro with various chimeric and mutated versions of NS5B, the HCV replication ability was found to correlate well with the RdRP activity. However, heat- and dilution-sensitive NS5Bs exhibiting weaker RdRP activity in vitro were found to be replication-incompetent, suggesting that HCV replication requires RdRP activity higher than a certain critical threshold.	Kanazawa Univ, Canc Res Inst, Dept Mol Oncol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Kanazawa, Ishikawa 9200934, Japan	Kanazawa University; Kanazawa University	Murakami, S (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Oncol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	semuraka@kenroku.kanazawa-u.ac.jp						Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Alter MJ, 1998, INFECT DIS CLIN N AM, V12, P13, DOI 10.1016/S0891-5520(05)70405-0; Bartenschlager R, 2001, ANTIVIR RES, V52, P1, DOI 10.1016/S0166-3542(01)00164-4; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2003, J VIROL, V77, P3181, DOI 10.1128/JVI.77.5.3181-3190.2003; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; DeFrancesco R, 1996, METHOD ENZYMOL, V275, P58; Dimitrova M, 2003, J VIROL, V77, P5401, DOI 10.1128/JVI.77.9.5401-5414.2003; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Francki RIB, 1991, ARCH VIROL         S, V2, P223; Gosert R, 2003, J VIROL, V77, P5487, DOI 10.1128/JVI.77.9.5487-5492.2003; Gu BH, 2003, J VIROL, V77, P5352, DOI 10.1128/JVI.77.9.5352-5359.2003; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; Ishii K, 1999, HEPATOLOGY, V29, P1227, DOI 10.1002/hep.510290448; Johnson RB, 2000, ARCH BIOCHEM BIOPHYS, V377, P129, DOI 10.1006/abbi.2000.1749; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; KATO N, 1995, BIOCHEM BIOPH RES CO, V206, P863, DOI 10.1006/bbrc.1995.1123; Kishine H, 2002, BIOCHEM BIOPH RES CO, V293, P993, DOI 10.1016/S0006-291X(02)00342-X; Labonte P, 2002, J BIOL CHEM, V277, P38838, DOI 10.1074/jbc.M204657200; Lai VCH, 1999, J VIROL, V73, P10129, DOI 10.1128/JVI.73.12.10129-10136.1999; Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1998, VIROLOGY, V249, P108, DOI 10.1006/viro.1998.9311; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; Mizutani T, 1996, J VIROL, V70, P7219, DOI 10.1128/JVI.70.10.7219-7223.1996; MURAKAMI S, 1994, VIROLOGY, V199, P243, DOI 10.1006/viro.1994.1119; Oh JW, 2000, J BIOL CHEM, V275, P17710, DOI 10.1074/jbc.M908781199; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Pietschmann T, 2001, J VIROL, V75, P1252, DOI 10.1128/JVI.75.3.1252-1264.2001; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Qin WP, 2001, HEPATOLOGY, V33, P728, DOI 10.1053/jhep.2001.22765; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Seeff LB, 1997, HEPATOLOGY, V26, pS21, DOI 10.1002/hep.510260704; SHI ST, 1997, J VIROL, V71, P6465; Shimakami T, 2004, J VIROL, V78, P2738, DOI 10.1128/JVI.78.6.2738-2748.2004; Sugiyama K, 1997, J GEN VIROL, V78, P329, DOI 10.1099/0022-1317-78-2-329; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000; [No title captured]	54	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25474	25482		10.1074/jbc.M401067200	http://dx.doi.org/10.1074/jbc.M401067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15037608	Green Submitted, hybrid			2022-12-25	WOS:000221827900071
J	Malonek, S; Rojas, MC; Hedden, P; Gaskin, P; Hopkins, P; Tudzynski, B				Malonek, S; Rojas, MC; Hedden, P; Gaskin, P; Hopkins, P; Tudzynski, B			The NADPH-cytochrome P450 reductase gene from Gibberella fujikuroi is essential for gibberellin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-SPOROTRICHIOIDES ENCODES; AMINO-ACID-SEQUENCES; SACCHAROMYCES-CEREVISIAE; OXIDOREDUCTASE GENE; HETEROLOGOUS EXPRESSION; NUCLEOTIDE-SEQUENCE; CLONING; TRANSFORMATION; HYDROXYLASE; CLUSTER	The fungus Gibberella fujikuroi is used for the commercial production of gibberellins (GAs), which it produces in very large quantities. Four of the sevenGA biosynthetic genes in this species encode cytochrome P450 monooxygenases, which function in association with NADPH-cytochrome P450 reductases (CPRs) that mediate the transfer of electrons from NADPH to the P450 monooxygenases. Only one cpr gene (cpr-Gf) was found in G. fujikuroi and cloned by a PCR approach. The encoded protein contains the conserved CPR functional domains, including the FAD, FMN, and NADPH binding motifs. cpr-Gf disruption mutants were viable but showed a reduced growth rate. Furthermore, disruption resulted in total loss of GA(3), GA(4), and GA(7) production, but low levels of non-hydroxylated C-20-GAs (GA(15) and GA(24)) were still detected. In addition, the knock-out mutants were much more sensitive to benzoate than the wild type due to loss of activity of another P450 monooxygenase, the detoxifying enzyme, benzoate p-hydroxylase. The UV-induced mutant of G. fujikuroi, SG138, which was shown to be blocked at most of the GA biosynthetic steps catalyzed by P450 monooxygenases, displayed the same phenotype. Sequence analysis of the mutant cpr allele in SG138 revealed a nonsense mutation at amino acid position 627. The mutant was complemented with the cpr-Gf and the Aspergillus niger cprA genes, both genes fully restoring the ability to produce GAs. Northern blot analysis revealed co-regulated expression of the cpr-Gf gene and the GA biosynthetic genes P450-1, P450-2, P450-4 under GA production conditions (nitrogen starvation). In addition, expression of cpr-Gf is induced by benzoate. These results indicate that CPR-Gf is the main but not the only electron donor for several P450 monooxygenases from primary and secondary metabolism.	Univ Munster, Inst Bot, D-48149 Munster, Germany; Univ Chile, Fac Ciencias, Dept Quim, Lab Bioorgan, Santiago, Chile; Rothamsted Res, Harpenden AL5 2JQ, Herts, England	University of Munster; Universidad de Chile; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Tudzynski, B (corresponding author), Univ Munster, Inst Bot, Schlossgarten 3, D-48149 Munster, Germany.	Bettina.Tudzynski@uni-muenster.de	ROJAS, MARIA CECILIA/D-8730-2014	ROJAS, MARIA CECILIA/0000-0002-6034-9779	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004161] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alexander NJ, 1998, APPL ENVIRON MICROB, V64, P221; Alexander NJ, 1999, MOL GEN GENET, V261, P977, DOI 10.1007/s004380051046; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; Backes WL, 2003, PHARMACOL THERAPEUT, V98, P221, DOI 10.1016/S0163-7258(03)00031-7; Barrero AF, 2001, J NAT PROD, V64, P222, DOI 10.1021/np0003239; BOLWELL GP, 1994, PHYTOCHEMISTRY, V37, P1491, DOI 10.1016/S0031-9422(00)89567-9; Cardoso MIL, 1997, MOL GEN GENET, V256, P674; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Coles JP, 1999, PLANT J, V17, P547, DOI 10.1046/j.1365-313X.1999.00410.x; de Vetten N, 1999, P NATL ACAD SCI USA, V96, P778, DOI 10.1073/pnas.96.2.778; DESJARDINS AE, 1992, MOL PLANT MICROBE IN, V5, P214, DOI 10.1094/MPMI-5-214; DONALDSON RP, 1991, PLANT PHYSIOL, V96, P669, DOI 10.1104/pp.96.3.669; Doyle J.J., 1990, FOCUS, V12, P13, DOI DOI 10.2307/2419362; Gaskin P., 1992, GC MS GIBBERELLINS R; GEISSMAN TA, 1966, PHYTOCHEMISTRY, V5, P933, DOI 10.1016/S0031-9422(00)82790-9; HOHN TM, 1995, MOL GEN GENET, V248, P95, DOI 10.1007/BF02456618; Ichinose H, 2002, APPL MICROBIOL BIOT, V59, P658, DOI 10.1007/s00253-002-1083-8; Kargel E, 1996, YEAST, V12, P333; Keller NP, 1997, FUNGAL GENET BIOL, V21, P17, DOI 10.1006/fgbi.1997.0970; Khan R, 2003, MOL MICROBIOL, V49, P117, DOI 10.1046/j.1365-2958.2003.03552.x; Koopmann E, 1997, P NATL ACAD SCI USA, V94, P14954, DOI 10.1073/pnas.94.26.14954; KRUGEL H, 1993, GENE, V127, P127, DOI 10.1016/0378-1119(93)90627-F; Kunic B, 2001, MOL GENET GENOMICS, V265, P930, DOI 10.1007/s004380100492; LESOT A, 1995, PLANT PHYSIOL BIOCH, V33, P751; Linnemannstons P, 1999, APPL ENVIRON MICROB, V65, P2558; Mihlan M, 2003, MOL MICROBIOL, V47, P975, DOI 10.1046/j.1365-2958.2003.03326.x; MILES JS, 1992, BIOCHEM J, V287, P195, DOI 10.1042/bj2870195; Nakayama N, 1996, J BIOCHEM-TOKYO, V119, P435; O'Donnell K, 1998, MYCOLOGIA, V90, P465, DOI 10.2307/3761407; OHKUMA M, 1995, BIOSCI BIOTECH BIOCH, V59, P1328, DOI 10.1271/bbb.59.1328; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; PUNT PJ, 1987, GENE, V56, P117, DOI 10.1016/0378-1119(87)90164-8; Rojas MC, 2001, P NATL ACAD SCI USA, V98, P5838, DOI 10.1073/pnas.091096298; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Schuler MA, 1996, CRIT REV PLANT SCI, V15, P235, DOI 10.1080/713608134; Seo JA, 2001, FUNGAL GENET BIOL, V34, P155, DOI 10.1006/fgbi.2001.1299; SUTTER TR, 1990, J BIOL CHEM, V265, P16428; SUTTER TR, 1989, BIOCHEM BIOPH RES CO, V160, P1257, DOI 10.1016/S0006-291X(89)80139-1; TRUAN G, 1994, GENE, V142, P123, DOI 10.1016/0378-1119(94)90366-2; Tudzynski B, 1996, MICROBIOL-SGM, V142, P533, DOI 10.1099/13500872-142-3-533; Tudzynski B, 2003, J BIOL CHEM, V278, P28635, DOI 10.1074/jbc.M301927200; Tudzynski B, 2002, J BIOL CHEM, V277, P21246, DOI 10.1074/jbc.M201651200; Tudzynski B, 2001, APPL ENVIRON MICROB, V67, P3514, DOI 10.1128/AEM.67.8.3514-3522.2001; Tudzynski B, 1998, FUNGAL GENET BIOL, V25, P157, DOI 10.1006/fgbi.1998.1095; TURI TG, 1992, J BIOL CHEM, V267, P2046; Urban P, 1997, J BIOL CHEM, V272, P19176, DOI 10.1074/jbc.272.31.19176; Urrutia O, 2001, PHYTOCHEMISTRY, V56, P505, DOI 10.1016/S0031-9422(00)00381-2; Uzura A, 2001, J BIOSCI BIOENG, V92, P580, DOI 10.1016/S1389-1723(01)80320-0; van den Brink HJM, 1998, FUNGAL GENET BIOL, V23, P1, DOI 10.1006/fgbi.1997.1021; van den Brink JM, 2000, MOL GEN GENET, V263, P601, DOI 10.1007/s004380051207; VANDENBRINK HJM, 1995, DNA CELL BIOL, V14, P719, DOI 10.1089/dna.1995.14.719; WARD M, 1986, MOL GEN GENET, V205, P331, DOI 10.1007/BF00430447; Warrilow AGS, 2002, BIOCHEM BIOPH RES CO, V299, P189, DOI 10.1016/S0006-291X(02)02600-1; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; XU JR, 1995, MOL PLANT MICROBE IN, V8, P74, DOI 10.1094/MPMI-8-0074; YABUSAKI Y, 1988, J BIOCHEM-TOKYO, V103, P1004, DOI 10.1093/oxfordjournals.jbchem.a122370; Yadav JS, 1999, GENE, V226, P139, DOI 10.1016/S0378-1119(98)00579-4; Yadav JS, 2000, BIOCHEM BIOPH RES CO, V268, P345, DOI 10.1006/bbrc.2000.2124; Yadav JS, 2000, CURR GENET, V37, P65, DOI 10.1007/s002940050010; Yamazaki H, 1997, ARCH BIOCHEM BIOPHYS, V342, P329, DOI 10.1006/abbi.1997.0125; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; Yoder OC, 2001, CURR OPIN PLANT BIOL, V4, P315, DOI 10.1016/S1369-5266(00)00179-5; Young C, 2001, MOL MICROBIOL, V39, P754, DOI 10.1046/j.1365-2958.2001.02265.x	64	101	115	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25075	25084		10.1074/jbc.M308517200	http://dx.doi.org/10.1074/jbc.M308517200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15037621	hybrid			2022-12-25	WOS:000221827900022
J	Horiuchi, H; Tategaki, A; Yamashita, Y; Hisamatsu, H; Ogawa, M; Noguchi, T; Aosasa, M; Kawashima, T; Akita, S; Nishimichi, N; Mitsui, N; Furusawa, S; Matsuda, H				Horiuchi, H; Tategaki, A; Yamashita, Y; Hisamatsu, H; Ogawa, M; Noguchi, T; Aosasa, M; Kawashima, T; Akita, S; Nishimichi, N; Mitsui, N; Furusawa, S; Matsuda, H			Chicken leukemia inhibitory factor maintains chicken embryonic stem cells in the undifferentiated state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-RENEWAL; GERM-LINE; ES CELLS; FUNCTIONAL EXPRESSION; FACTOR LIF; DIFFERENTIATION; ESTABLISHMENT; IL-6; ACTIVATION; RECEPTOR	Mouse embryonic stem (ES) cells can be maintained in an undifferentiated state in the presence of leukemia inhibitory factor (LIF), a member of the interleukin-6 cytokine family. In other mammals, this is not possible with LIF alone. Chicken ES-like cells (blastodermal cells) have only been cultured with mouse LIF because chicken LIF was not available. However the culture system is imperfect and chicken ES-like cells equivalent to mouse ES cells were not observed. In the present study, we cloned the cDNA-encoding chicken LIF using mRNA subtraction and RACE methodology. The chicken LIF cDNA encodes a protein with similar to40% sequence identity to mouse LIF. It has 211 amino acids including a putative N-terminal signal peptide of 24 residues. Chicken blastodermal cells were cultured in the presence of bacterially expressed chicken LIF or mouse LIF. The expression of alkaline phosphatase and embryonal carcinoma cell monoclonal antibody-1 and stage-specific embryonic antigen-1 and the activation of STAT3 were examined, all of which are indices of the undifferentiated state. Exposure in the blastodermal cells to recombinant chicken LIF but not to mouse LIF maintained the expression of these various markers. After 9 days of incubation, the blastodermal cells formed cystic embryoid bodies in the presence of mouse LIF but not in the presence of recombinant chicken LIF. We conclude that chicken LIF is able to maintain chicken ES cell cultures in the undifferentiated state.	Hiroshima Univ, Grad Sch Biosphere Sci, Dept Mol & Appl Biosci, Immunobiol Lab, Higashihiroshima 7398528, Japan; Hiroshima Ind Promot Org, Hiroshima Prefectural Inst Ind Sci & Technol, Higashihiroshima 7390046, Japan; Towakagaku Co Ltd, Inst Res & Dev, Higashihiroshima 7390046, Japan	Hiroshima University; Immuno-Biological Laboratories Co. Ltd.	Horiuchi, H (corresponding author), Hiroshima Univ, Grad Sch Biosphere Sci, Dept Mol & Appl Biosci, Immunobiol Lab, 1-4-4 Kagamiyama, Higashihiroshima 7398528, Japan.	hhori10@Hiroshima-u.ac.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANEGON I, 1990, CELL IMMUNOL, V130, P50, DOI 10.1016/0008-8749(90)90161-J; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Burdon T, 1999, CELLS TISSUES ORGANS, V165, P131, DOI 10.1159/000016693; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Etches RJ, 1996, MOL REPROD DEV, V45, P291, DOI 10.1002/(SICI)1098-2795(199611)45:3&lt;291::AID-MRD5&gt;3.0.CO;2-N; EYALGILADI H, 1976, DEV BIOL, V49, P321, DOI 10.1016/0012-1606(76)90178-0; FRAICHARD A, 1995, J CELL SCI, V108, P3181; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HAHNEL AC, 1987, J REPROD IMMUNOL, V10, P89, DOI 10.1016/0165-0378(87)90069-6; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; INOUE M, 1988, JPN J VET SCI, V50, P648; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KLASING KC, 1987, DEV COMP IMMUNOL, V11, P385, DOI 10.1016/0145-305X(87)90082-6; LE PT, 1990, J IMMUNOL, V145, P3310; LOVE J, 1994, BIO-TECHNOL, V12, P60, DOI 10.1038/nbt0194-60; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; MOREADITH RW, 1992, AM PHYS, V105, P197; NAITO M, 1994, MOL REPROD DEV, V37, P167, DOI 10.1002/mrd.1080370207; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; NICOLA NA, 1997, GROWTH FACTORS CYT B, V2, P605; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pain B, 1996, DEVELOPMENT, V122, P2339; Park TS, 2000, MOL REPROD DEV, V56, P475, DOI 10.1002/1098-2795(200008)56:4&lt;475::AID-MRD5&gt;3.0.CO;2-M; Potts JD, 1998, DEV BIOL, V204, P277, DOI 10.1006/dbio.1998.9077; ROBERTSON M, 1993, DEV GENET, V14, P165, DOI 10.1002/dvg.1020140303; ROHWEDEL J, 1994, DEV BIOL, V164, P87, DOI 10.1006/dbio.1994.1182; SALTER DW, 1987, VIROLOGY, V157, P236, DOI 10.1016/0042-6822(87)90334-5; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; SANG H, 1989, Molecular Reproduction and Development, V1, P98, DOI 10.1002/mrd.1080010204; Schat K. A., 1997, P289; SCHAUENSTEIN K, 1988, DEV COMP IMMUNOL, V12, P823, DOI 10.1016/0145-305X(88)90056-0; Schneider K, 2001, EUR J BIOCHEM, V268, P4200, DOI 10.1046/j.1432-1327.2001.02334.x; Smith A G, 1992, Semin Cell Biol, V3, P385, DOI 10.1016/1043-4682(92)90010-S; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Suemori H, 2001, DEV DYNAM, V222, P273, DOI 10.1002/dvdy.1191; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; TOMIDA M, 1984, J BIOL CHEM, V259, P978; URVEN LE, 1988, DEVELOPMENT, V103, P299; Wakamatsu Yuko, 1994, Molecular Marine Biology and Biotechnology, V3, P185; WHEELER MB, 1994, REPROD FERT DEVELOP, V6, P563, DOI 10.1071/RD9940563; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	50	43	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24514	24520		10.1074/jbc.M313231200	http://dx.doi.org/10.1074/jbc.M313231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044464	hybrid			2022-12-25	WOS:000221702500080
J	Vannini, A; Volpari, C; Di Marco, S				Vannini, A; Volpari, C; Di Marco, S			Crystal structure of the quorum-sensing protein TraM and its interaction with the transcriptional regulator TraR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY DIFFRACTION; AGROBACTERIUM-TUMEFACIENS; ANTIACTIVATOR TRAM; OPINE REGULON; IN-VITRO; DNA; AUTOINDUCER; CRYSTALLIZATION; REFINEMENT; ACTIVATION	Transfer of the tumor-inducing plasmid in Agrobacterium tumefaciens is controlled by a quorum-sensing system whose main components are the transcriptional regulator TraR and its autoinducer. This system allows bacteria to synchronize infection of the host plant when a "quorum" of cells has been reached. TraM is an A. tumefaciens protein involved in the regulation of this system because it binds to TraR and prevents it from binding DNA. As a first step to understanding the molecular basis for the regulation of TraR by TraM, we have determined the crystal structure of TraM at 1.65 resolution. This protein is packed as a dimer, with each monomer consisting mainly of two antiparallel alpha helices. Monomers are tightly associated, with a large hydrophobic area buried upon dimerization. Secondly, we characterized the TraR-TraM complex in vitro. TraM (11.4 kDa, monomer molecular mass) binds tightly TraR ( 27 kDa, monomer molecular mass) forming a stable oligomeric complex that likely accounts for two TraR and two TraM dimers.	Ist Ric Biol Mol Pietro Angeletti, Dept Biochem, I-00040 Rome, Italy		Di Marco, S (corresponding author), Ist Ric Biol Mol Pietro Angeletti, Dept Biochem, I-00040 Rome, Italy.	stefania_dimarco@merck.com	Vannini, Alessandro/E-6988-2011; Vannini, Alessandro/N-4528-2014; Di Marco, Stefania -/C-3859-2009	Vannini, Alessandro/0000-0001-7212-5425				Chai Y, 2001, MOL MICROBIOL, V40, P414, DOI 10.1046/j.1365-2958.2001.02385.x; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Farrand S. K, 1998, RHIZOBIACEAE MOL BIO, P199, DOI DOI 10.1007/978-94-011-5060-6; Fuqua C, 1996, MOL MICROBIOL, V20, P1199, DOI 10.1111/j.1365-2958.1996.tb02640.x; Hwang IY, 1999, MOL MICROBIOL, V34, P282, DOI 10.1046/j.1365-2958.1999.01595.x; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Kawabata T, 2000, PROTEINS, V41, P108, DOI 10.1002/1097-0134(20001001)41:1<108::AID-PROT130>3.3.CO;2-J; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Ledgham F, 2003, MOL MICROBIOL, V48, P199, DOI 10.1046/j.1365-2958.2003.03423.x; LESLIE AGW, 1986, DARESBURY LAB INF Q, V18, P33; Lo Conte L, 2002, NUCLEIC ACIDS RES, V30, P264; Luo ZQ, 2000, J BIOL CHEM, V275, P7713, DOI 10.1074/jbc.275.11.7713; Luo ZQ, 2003, J BACTERIOL, V185, P5665, DOI 10.1128/JB.185.19.5665-5672.2003; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Piper KR, 2000, J BACTERIOL, V182, P1080, DOI 10.1128/JB.182.4.1080-1088.2000; Piper KR, 1999, MOL MICROBIOL, V32, P1077, DOI 10.1046/j.1365-2958.1999.01422.x; Swiderska A, 2001, J BIOL CHEM, V276, P49449, DOI 10.1074/jbc.M107881200; Vannini A, 2004, ACTA CRYSTALLOGR D, V60, P146, DOI 10.1107/S0907444903022911; Vannini A, 2002, ACTA CRYSTALLOGR D, V58, P1362, DOI 10.1107/S0907444902010028; Vannini A, 2002, EMBO J, V21, P4393, DOI 10.1093/emboj/cdf459; Vlassi M, 1998, ACTA CRYSTALLOGR D, V54, P1245, DOI 10.1107/S0907444998002492; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Zhang RG, 2002, NATURE, V417, P971, DOI 10.1038/nature00833; Zhu J, 1999, P NATL ACAD SCI USA, V96, P4832, DOI 10.1073/pnas.96.9.4832; Zhu J, 2000, J BACTERIOL, V182, P3885, DOI 10.1128/JB.182.14.3885-3895.2000	30	29	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24291	24296		10.1074/jbc.M401855200	http://dx.doi.org/10.1074/jbc.M401855200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044488	hybrid			2022-12-25	WOS:000221702500054
J	Gingis-Velitski, S; Zetser, A; Flugelman, MY; Vlodavsky, I; Ilan, N				Gingis-Velitski, S; Zetser, A; Flugelman, MY; Vlodavsky, I; Ilan, N			Heparanase induces endothelial cell migration via protein kinase B/Akt activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX DEGRADATIVE ENZYMES; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; PLATELET HEPARANASE; BASEMENT-MEMBRANE; SULFATE; ANGIOGENESIS; EXPRESSION; RECEPTOR; PROTEOGLYCAN	Heparanase is a mammalian endoglycosidase that degrades heparan sulfate (HS) at specific intra-chain sites. Blood-borne neutrophils, macrophages, mast cells, and platelets exhibit heparanase activity that is thought to be stored in specific granules. The degranulated heparanase is implicated in extravasation of metastatic tumor cells and activated cells of the immune system. Degranulation and heparanase release in response to an inflammatory stimulus or platelet activation would facilitate cellular extravasation directly, by altering the composition and structural integrity of the extracellular matrix, or indirectly, by releasing HS-bound proinflammatory cytokines and chemokines. We hypothesized that in addition to such indirect effect, the released heparanase may also locally affect and activate neighboring cells such as endothelial cells. Here, we provide evidence that addition of the 65-kDa latent heparanase to endothelial cells enhances Akt signaling. Heparanase-mediated Akt phosphorylation was independent of its enzymatic activity or the presence of cell membrane HS proteoglycans and was augmented by heparin. Moreover, addition of heparanase stimulated phosphatidylinositol 3-kinase-dependent endothelial cell migration and invasion. These results suggest, for the first time, that heparanase activates endothelial cells and elicits angiogenic responses directly. This effect appears to be mediated by as yet unidentified heparanase receptor.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Lady Davies Carmel Med Ctr, Dept Cardiol, IL-34632 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services; Carmel Medical Center	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il						BARTLETT MR, 1995, IMMUNOL CELL BIOL, V73, P113, DOI 10.1038/icb.1995.19; BASHKIN P, 1990, BLOOD, V75, P2204; Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Elkin M, 2000, FASEB J, V14, P2477, DOI 10.1096/fj.00-0292com; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5; Freeman C, 1999, BIOCHEM J, V342, P361, DOI 10.1042/0264-6021:3420361; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Goldschmidt O, 2003, FASEB J, V17, P1015, DOI 10.1096/fj.02-0773com; Ihrcke NS, 1998, J CELL PHYSIOL, V175, P255, DOI 10.1002/(SICI)1097-4652(199806)175:3<255::AID-JCP3>3.0.CO;2-N; Ilan N, 1998, J CELL SCI, V111, P3621; Ilan N, 1999, J CELL SCI, V112, P3005; Kelly T, 2003, CANCER RES, V63, P8749; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; Mollinedo F, 1997, BIOCHEM J, V327, P917, DOI 10.1042/bj3270917; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Nadav L, 2002, J CELL SCI, V115, P2179; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Parish CR, 1998, IMMUNOL CELL BIOL, V76, P104, DOI 10.1046/j.1440-1711.1998.00722.x; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Rolny C, 2002, J BIOL CHEM, V277, P19315, DOI 10.1074/jbc.M111805200; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Vaday GG, 2000, J LEUKOCYTE BIOL, V67, P149, DOI 10.1002/jlb.67.2.149; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; Zetser A, 2003, CANCER RES, V63, P7733; ZETSER A, 2004, IN PRESS J CELL SCI; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	48	197	209	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23536	23541		10.1074/jbc.M400554200	http://dx.doi.org/10.1074/jbc.M400554200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044433	hybrid			2022-12-25	WOS:000221570900092
J	Herold, S; Fago, A; Weber, RE; Dewilde, S; Moens, L				Herold, S; Fago, A; Weber, RE; Dewilde, S; Moens, L			Reactivity studies of the Fe(III) and Fe(II)NO forms of human neuroglobin reveal a potential role against oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; MEDIATED OXIDATION; BINDING-PROPERTIES; REDOX REACTIONS; MYOGLOBIN; PEROXYNITRITE; HEMOGLOBIN; BRAIN; OXYGEN; ISOMERIZATION	Neuroglobin, recently discovered in the brain and in the retina of vertebrates, belongs to the class of hexaco-ordinate globins, in which the distal histidine coordinates the iron center in both the Fe(II) and Fe(III) forms. As for most other hexacoordinate globins, the physiological function of neuroglobin is still unclear, but seems to be related to neuronal survival following acute hypoxia. In this study, we have addressed the question whether human neuroglobin could act as a scavenger of toxic species, such as nitrogen monoxide, peroxynitrite, and hydrogen peroxide, which are generated at high levels in the brain during hypoxia; we have also investigated the kinetics of the reactions of its Fe(III) (metNGB) and Fe(II)NO forms with several reagents. Binding of cyanide or NO. to metNGB follows bi-exponential kinetics, showing the existence of two different protein conformations. In the presence of excess NO., metNGB is converted into NGBFe(II)NO by reductive nitrosylation, in analogy to the reactions of NO. with metmyoglobin and methemoglobin. The Fe(II)NO form of neuroglobin is oxidized to metNGB by peroxynitrite and dioxygen, two reactions that also take place in hemoglobin, albeit at lower rates. In contrast to myoglobin and hemoglobin, metNGB unexpectedly does not generate the cytotoxic ferryl form of the protein upon addition of either peroxynitrite or hydrogen peroxide. Taken together, our data indicate that human neuroglobin may be an efficient scavenger of reactive oxidizing species and thus may play a role in the cellular defense against oxidative stress.	ETH Honggerberg, Anorgan Chem Lab, CH-8093 Zurich, Switzerland; Aarhus Univ, Dept Zoophysiol, Inst Biol Sci, DK-8000 Aarhus C, Denmark; Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium	Swiss Federal Institutes of Technology Domain; ETH Zurich; Aarhus University; University of Antwerp	Herold, S (corresponding author), ETH Honggerberg, Anorgan Chem Lab, HCI H 215, CH-8093 Zurich, Switzerland.	herold@inorg.chem.ethz.ch; angela.fago@biology.au.dk	Fago, Angela/J-5946-2013	Fago, Angela/0000-0001-7315-2628				ADDISON AW, 1986, BIOCHEMISTRY-US, V25, P4104, DOI 10.1021/bi00362a018; Alayash AI, 1999, J BIOL CHEM, V274, P2029, DOI 10.1074/jbc.274.4.2029; Alayash AI, 2001, ANTIOXID REDOX SIGN, V3, P313, DOI 10.1089/152308601300185250; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Arnold EV, 1996, METHOD ENZYMOL, V269, P41; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bohle DS, 1996, METHOD ENZYMOL, V269, P302; Bolanos JP, 1999, BBA-BIOENERGETICS, V1411, P415, DOI 10.1016/S0005-2728(99)00030-4; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Du WH, 2003, J AM CHEM SOC, V125, P8080, DOI 10.1021/ja034584r; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Exner M, 2000, CHEM RES TOXICOL, V13, P287, DOI 10.1021/tx990201k; Fago A, 2003, P NATL ACAD SCI USA, V100, P12087, DOI 10.1073/pnas.2032603100; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; GALARIS D, 1989, BIOCHEM BIOPH RES CO, V160, P1162, DOI 10.1016/S0006-291X(89)80125-1; Godecke A, 1999, P NATL ACAD SCI USA, V96, P10495, DOI 10.1073/pnas.96.18.10495; HALLIEWLL B, 1999, FREE RADICAL BIO MED, P74; Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Herold S, 2003, BIOCHEMISTRY-US, V42, P14036, DOI 10.1021/bi0350349; Herold S, 2003, J BIOL CHEM, V278, P6623, DOI 10.1074/jbc.M210275200; Herold S, 2001, J AM CHEM SOC, V123, P4085, DOI 10.1021/ja010111d; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; Hoshino M, 1996, J AM CHEM SOC, V118, P5702, DOI 10.1021/ja953311w; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; Kundu S, 2003, TRENDS PLANT SCI, V8, P387, DOI 10.1016/S1360-1385(03)00163-8; Laverman LE, 2001, J AM CHEM SOC, V123, P285, DOI 10.1021/ja001696z; Lin J, 1998, ARCH BIOCHEM BIOPHYS, V352, P214, DOI 10.1006/abbi.1998.0619; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203; Parmentier S, 1999, BRIT J PHARMACOL, V127, P546, DOI 10.1038/sj.bjp.0702549; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Van Doorslaer S, 2003, J BIOL CHEM, V278, P4919, DOI 10.1074/jbc.M210617200	49	236	249	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22841	22847		10.1074/jbc.M313732200	http://dx.doi.org/10.1074/jbc.M313732200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15020597	hybrid			2022-12-25	WOS:000221570900009
J	Yakovleva, L; Handy, CJ; Sayer, JM; Pirrung, M; Jerina, DM; Shuman, S				Yakovleva, L; Handy, CJ; Sayer, JM; Pirrung, M; Jerina, DM; Shuman, S			Benzo[c]phenanthrene adducts and nogalamycin inhibit DNA transesterification by vaccinia topoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC INTERACTION; SOLUTION CONFORMATION; VIRUS TOPOISOMERASE; DIOL EPOXIDE; OPPOSITE DT; BINDING; DUPLEX; MECHANISM; COVALENT; CLEAVAGE	Vaccinia DNA topoisomerase forms a covalent DNA-(3'-phosphotyrosyl)-enzyme intermediate at a specific target site 5'-C(+5)C(+4)C(+3)T(+2)T(+1)pdown arrowN(-1) in duplex DNA. Here we study the effects of position-specific DNA intercalators on the rate and extent of single-turnover DNA transesterification. Chiral C-1 R and S trans-opened 3,4-diol 1,2-epoxide adducts of benzo[c] phenanthrene (BcPh) were introduced at single N-2-deoxyguanosine and N-6-deoxyadenosine positions within the 3'-G(+5)G(+4)G(+3)A(+2)A(+1)T(-1)A(-2) sequence of the nonscissile DNA strand. Transesterification was unaffected by BcPh intercalation between the +6 and +5 base pairs, slowed 4-fold by intercalation between the +5 and +4 base pairs, and virtually abolished by BcPh intercalation between the +4 and +3 base pairs and the +3 and +2 base pairs. Intercalation between the +2 and +1 base pairs by the +2R BcPh dA adduct abolished transesterification, whereas the overlapping +1S BcPh dA adduct slowed the rate of transesterification by a factor of 2700, with little effect upon the extent of the reaction. Intercalation at the scissile phosphodiester (between the +1 and -1 base pairs) slowed transesterification by a factor of 450. BcPh intercalation between the -1 and -2 base pairs slowed cleavage by two orders of magnitude, but intercalation between the -2 and -3 base pairs had little effect. The anthracycline drug nogalamycin, a non-covalent intercalator with preference for 5'-TG dinucleotides, inhibited the single-turnover DNA cleavage reaction of vaccinia topoisomerase with an IC50 of 0.7 muM. Nogalamycin was most effective when the drug was preincubated with DNA and when the cleavage target site was 5'-CCCTTdown arrowG instead of 5'-CCCTTdown arrowA. These findings demarcate upstream and downstream boundaries of the functional interface of vaccinia topoisomerase with its DNA target site.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; Duke Univ, Dept Chem, Durham, NC 27708 USA	Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Duke University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER; NIAID NIH HHS [AI053471] Funding Source: Medline; NIGMS NIH HHS [GM46330] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL SK, 1987, J AM CHEM SOC, V109, P2497, DOI 10.1021/ja00242a040; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1999, BIOCHEMISTRY-US, V38, P16599, DOI 10.1021/bi992001d; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P12488, DOI 10.1021/bi00097a029; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P1295, DOI 10.1021/bi00004a024; Cruse WBT, 1996, J BIOL CHEM, V271, P15558, DOI 10.1074/jbc.271.26.15558; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; FONSECA FD, 2003, P NATL ACAD SCI USA, V100, P11291; FOX KR, 1985, BIOCHIM BIOPHYS ACTA, V840, P383, DOI 10.1016/0304-4165(85)90219-3; FOX KR, 1986, BIOCHEMISTRY-US, V25, P4349, DOI 10.1021/bi00363a026; FOX KR, 1986, NUCLEIC ACIDS RES, V14, P2001, DOI 10.1093/nar/14.5.2001; Hwang Y, 1998, J VIROL, V72, P3401, DOI 10.1128/JVI.72.4.3401-3406.1998; Hwang Y, 1999, J BIOL CHEM, V274, P9160, DOI 10.1074/jbc.274.14.9160; Ilankumaran P, 2001, CHEM RES TOXICOL, V14, P1330, DOI 10.1021/tx010092l; KLEMPERER N, 1995, VIROLOGY, V206, P203, DOI 10.1016/S0042-6822(95)80035-2; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 1999, VIROLOGY, V264, P441, DOI 10.1006/viro.1999.0022; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; Krogh BO, 2001, J BIOL CHEM, V276, P20907, DOI 10.1074/jbc.M102312200; Kroth H, 2001, CHEM RES TOXICOL, V14, P708, DOI 10.1021/tx0002637; Kwon K, 2002, J BIOL CHEM, V277, P345, DOI 10.1074/jbc.M109449200; Lin CH, 2001, J MOL BIOL, V306, P1059, DOI 10.1006/jmbi.2001.4425; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; Palaniyar N, 1996, VIROLOGY, V221, P351, DOI 10.1006/viro.1996.0385; Petersen BO, 1997, VIROLOGY, V230, P197, DOI 10.1006/viro.1997.8495; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pradhan P, 2001, BIOCHEMISTRY-US, V40, P5870, DOI 10.1021/bi002896q; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; SCHURTER EJ, 1995, BIOCHEMISTRY-US, V34, P9009, DOI 10.1021/bi00028a009; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; Sekiguchi JA, 1996, J BIOL CHEM, V271, P2313, DOI 10.1074/jbc.271.4.2313; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; Sim SP, 2000, BIOCHEMISTRY-US, V39, P9928, DOI 10.1021/bi000906h; Sim SP, 1997, BIOCHEMISTRY-US, V36, P13285, DOI 10.1021/bi971261x; Smith CK, 1996, J MOL BIOL, V263, P237, DOI 10.1006/jmbi.1996.0572; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; Tian LG, 2004, STRUCTURE, V12, P31, DOI 10.1016/j.str.2003.11.025; Tian LG, 2003, MOL CELL, V12, P199, DOI 10.1016/S1097-2765(03)00263-6; Van Dross RT, 2002, ANTIMICROB AGENTS CH, V46, P2145, DOI 10.1128/AAC.46.7.2145-2154.2002; Volk DE, 2000, BIOCHEMISTRY-US, V39, P14040, DOI 10.1021/bi001669l; Williams HEL, 1999, J MOL BIOL, V290, P699, DOI 10.1006/jmbi.1999.2903; WILLIAMS LD, 1990, P NATL ACAD SCI USA, V87, P2225, DOI 10.1073/pnas.87.6.2225; Yagi H, 2002, J ORG CHEM, V67, P6678, DOI 10.1021/jo020418a; Yakovleva L, 2003, J BIOL CHEM, V278, P42170, DOI 10.1074/jbc.M308079200; Zegar IS, 1998, BIOCHEMISTRY-US, V37, P16516, DOI 10.1021/bi9817616; Zegar IS, 1996, BIOCHEMISTRY-US, V35, P6212, DOI 10.1021/bi9524732; ZHANG XL, 1990, BIOCHEMISTRY-US, V29, P9451, DOI 10.1021/bi00492a020	55	15	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23335	23342		10.1074/jbc.M401203200	http://dx.doi.org/10.1074/jbc.M401203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044474	hybrid			2022-12-25	WOS:000221570900068
J	Dubourg, B; Kamphausen, T; Weiwad, M; Jahreis, G; Feunteun, J; Fischer, G; Modjtahedi, N				Dubourg, B; Kamphausen, T; Weiwad, M; Jahreis, G; Feunteun, J; Fischer, G; Modjtahedi, N			The human nuclear SRcyp is a cell cycle-regulated cyclophilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SPLICING FACTORS; C-TERMINAL DOMAIN; PROLYL CIS/TRANS ISOMERASES; MESSENGER-RNA; INTERCHROMATIN GRANULES; POLYMERASE-II; DEPENDENT KINASES; RECOGNITION MOTIF; MITOTIC CELLS; SR PROTEINS	Cyclophilins of the Moca family (Cavarec, L., Kamphausen, T., Dubourg, B., Callebaut, I., Lemeunier, F., Metivier, D., Feunteun, J., Fischer, G., and Modjtahedi, N. (2002) J. Biol. Chem. 277, 41171-41182) are found only in organisms of the animal kingdom and share several structural and enzymatic features. The presence of serine/arginine (S/R) dipeptide repeats in their C-terminal tail suggests that these enzymes belong to the SR protein family involved in the regulation of gene expression. The function of this group of cyclophilins is currently unknown. However, their C-terminal tails contain a highly conserved polypeptide signature segment (the moca domain), which may well be involved in the functional regulation of these proteins. We report here the identification of five Cdc2-type phosphorylation sites gathered in and around the moca domain of SRcyp, a human cyclophilin belonging to the Moca family. The segment of SRcyp containing the identified sites is specifically phosphorylated in mitotic cells. This mitosis-specific phosphorylation was inhibited by treatment of the cells with roscovitine, a specific inhibitor of cyclin-dependent kinases, suggesting that the unknown activity of the moca domain of SRcyp requires mitotic regulation by the Cdc2-cyclin B kinase complex. The Cdc2-cyclin B complex was found to phosphorylate four of the five identified phosphorylation sites in vitro, providing further support for this possibility. Like many factors stored in nuclear speckles and involved in the regulation of gene expression, this nuclear cyclophilin displays a predominantly diffuse cytoplasmic distribution at the onset of mitosis. Only in late telophase is SRcyp recruited to the newly formed nuclei. The transit of SRcyp through mitotic interchromatin granule clusters, before re-entering the nucleus, suggests that the timing of the appearance of this cyclophilin in the telophasic nuclei is tightly coordinated with post-mitotic events. Human SRcyp is the first cell cycle-regulated cyclophilin to be described.	Inst Gustave Roussy PR1, Lab Genet Oncol UMR8125, F-94805 Villejuif, France; Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle Saale, Germany	UNICANCER; Gustave Roussy; Max Planck Society	Modjtahedi, N (corresponding author), Inst Gustave Roussy PR1, Lab Genet Oncol UMR8125, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	nazanine@igr.fr	MODJTAHEDI, Nazanine/D-4377-2017; Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189				Adams PD, 1996, MOL CELL BIOL, V16, P6623; ANDERSON SK, 1993, P NATL ACAD SCI USA, V90, P542, DOI 10.1073/pnas.90.2.542; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Blencowe BJ, 2003, CURR BIOL, V13, pR149, DOI 10.1016/S0960-9822(03)00079-4; BLENCOWE BJ, 1995, RNA, V1, P852; Bourquin JP, 1997, NUCLEIC ACIDS RES, V25, P2055, DOI 10.1093/nar/25.11.2055; Cavarec L, 2002, J BIOL CHEM, V277, P41171, DOI 10.1074/jbc.M203757200; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; FERREIRA JA, 1994, J CELL BIOL, V126, P11, DOI 10.1083/jcb.126.1.11; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Horowitz DS, 2002, EMBO J, V21, P470, DOI 10.1093/emboj/21.3.470; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; LESER GP, 1989, EUR J CELL BIOL, V50, P376; LOBL TJ, 1988, ANAL BIOCHEM, V170, P502, DOI 10.1016/0003-2697(88)90665-3; Ma D, 2002, J BIOL CHEM, V277, P14925, DOI 10.1074/jbc.M112293200; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Mortillaro MJ, 1998, J BIOL CHEM, V273, P8183, DOI 10.1074/jbc.273.14.8183; Nestel FP, 1996, GENE, V180, P151, DOI 10.1016/S0378-1119(96)00436-2; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Page AP, 1996, BIOCHEM J, V317, P179, DOI 10.1042/bj3170179; PAGE AP, 1995, BIOCHEMISTRY-US, V34, P11545, DOI 10.1021/bi00036a030; Parrish JZ, 2003, MOL CELL, V11, P987, DOI 10.1016/S1097-2765(03)00095-9; Patturajan M, 1998, MOL CELL BIOL, V18, P2406, DOI 10.1128/MCB.18.4.2406; Pfleger CM, 2000, GENE DEV, V14, P655; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Prasanth KV, 2003, MOL BIOL CELL, V14, P1043, DOI 10.1091/mbc.E02-10-0669; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; REUTER R, 1985, EXP CELL RES, V159, P63, DOI 10.1016/S0014-4827(85)80038-0; Santos AN, 2000, BIOL REPROD, V62, P1, DOI 10.1095/biolreprod62.1.1; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; Schiene-Fischer C, 2001, FEBS LETT, V495, P1, DOI 10.1016/S0014-5793(01)02326-2; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; Teigelkamp S, 1998, RNA, V4, P127; THIRY M, 1995, EUR J CELL BIOL, V68, P14; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER BM, 1987, J CELL SCI, V87, P269; VERHEIJEN R, 1986, J CELL SCI, V80, P103; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Wohlschlegel JA, 2001, MOL CELL BIOL, V21, P4868, DOI 10.1128/MCB.21.15.4868-4874.2001; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	53	14	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22322	22330		10.1074/jbc.M400736200	http://dx.doi.org/10.1074/jbc.M400736200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016823	hybrid			2022-12-25	WOS:000221417100080
J	Ko, M; Jang, JH; Ahn, JG; Lee, K; Chung, HY; Jeon, SH; Seong, RH				Ko, M; Jang, JH; Ahn, JG; Lee, K; Chung, HY; Jeon, SH; Seong, RH			T cell receptor signaling inhibits glucocorticoid-induced apoptosis by repressing the SRG3 expression via Ras activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEX; LOOP-HELIX PROTEINS; POSITIVE SELECTION; THYMOCYTE DEVELOPMENT; DNA-BINDING; NEGATIVE SELECTION; CD4(+)CD8(+) THYMOCYTES; GENE; DEATH; TCR	Activation of T cell antigen receptor (TCR) signaling inhibits glucocorticoid (GC)-induced apoptosis of T cells. However, the detailed mechanism regarding how activated T cells are protected from GC-induced apoptosis is unclear. Previously, we have shown that the expression level of SRG3, a murine homolog of BAF155 in humans, correlated well with the GC sensitivity of T cells either in vitro or in vivo. Intriguingly, the expression of SRG3 decreased upon positive selection in the thymus. Here we have shown that TCR signaling inhibits the SRG3 expression via Ras activation and thereby renders primary thymocytes and some thymoma cells resistant to GC-mediated apoptosis. By using pharmacological inhibitors, we have shown that Ras-mediated down-regulation of the SRG3 gene expression is mediated by MEK/ERK and phosphatidylinositol 3-kinase pathways. Moreover, TCR signals repressed the SRG3 transcription through the putative binding sites for E proteins and Ets family transcription factors in the proximal region of the SRG3 promoter. Introduction of mutations in these elements rendered the SRG3 promoter immune to the Ras or TCR signals. Taken together, these observations suggest that TCR signals result in GC desensitization in immature T cells by repressing SRG3 gene expression via Ras activation.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea; Hanyang Univ, Sch Med, Dept Pathol, Seoul 133791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Hanyang University	Seong, RH (corresponding author), Seoul Natl Univ, Sch Biol Sci, Kwanak Gu Shinlim Dong San 56-1,Bldg 105, Seoul 151742, South Korea.	rhseong@plaza.snu.ac.kr		Seong, Rho/0000-0001-5699-0718; Ko, Myunggon/0000-0002-6007-2570				AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; Ashwell JD, 1996, STEM CELLS, V14, P490, DOI 10.1002/stem.140490; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bettini M, 2002, J IMMUNOL, V169, P1713, DOI 10.4049/jimmunol.169.4.1713; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; Choi YI, 2001, P NATL ACAD SCI USA, V98, P10267, DOI 10.1073/pnas.181076198; COHEN JJ, 1984, J IMMUNOL, V132, P38; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Cowley DO, 2000, GENE DEV, V14, P366; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gong K, 2001, NAT IMMUNOL, V2, P29, DOI 10.1038/83134; GRUBER J, 1994, EUR J IMMUNOL, V24, P1115, DOI 10.1002/eji.1830240516; Han SM, 2001, J IMMUNOL, V167, P805, DOI 10.4049/jimmunol.167.2.805; Iwata M, 1996, STEM CELLS, V14, P632, DOI 10.1002/stem.140632; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; Iwata M, 1996, EUR J IMMUNOL, V26, P2081, DOI 10.1002/eji.1830260918; Jamieson CAM, 2000, P NATL ACAD SCI USA, V97, P7319, DOI 10.1073/pnas.97.13.7319; Jeon SH, 1997, J EXP MED, V185, P1827, DOI 10.1084/jem.185.10.1827; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kim DS, 2002, IMMUNITY, V16, P9, DOI 10.1016/S1074-7613(02)00264-9; Kim JK, 2001, MOL CELL BIOL, V21, P7787, DOI 10.1128/MCB.21.22.7787-7795.2001; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; Ko M, 2004, J BIOL CHEM, V279, P21916, DOI 10.1074/jbc.M402145200; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Ohoka Y, 1996, INT IMMUNOL, V8, P297, DOI 10.1093/intimm/8.3.297; Ohoka Y, 1997, J IMMUNOL, V158, P5707; OShea CC, 1996, EUR J IMMUNOL, V26, P2350, DOI 10.1002/eji.1830261012; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Pazirandeh A, 2002, FASEB J, V16, P727, DOI 10.1096/fj.01-0891fje; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; Rincon M, 2001, CURR OPIN IMMUNOL, V13, P339, DOI 10.1016/S0952-7915(00)00224-7; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Stephens GL, 2003, INT IMMUNOL, V15, P623, DOI 10.1093/intimm/dxg060; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; Thompson EB, 1999, TRENDS ENDOCRIN MET, V10, P353, DOI 10.1016/S1043-2760(99)00187-3; Tolosa E, 1998, IMMUNITY, V8, P67, DOI 10.1016/S1074-7613(00)80459-8; Vacchio MS, 2000, SEMIN IMMUNOL, V12, P475, DOI 10.1006/smim.2000.0265; Vacchio MS, 1997, J EXP MED, V185, P2033, DOI 10.1084/jem.185.11.2033; Vacchio MS, 1999, J IMMUNOL, V163, P1327; VACCHIO MS, 1994, J EXP MED, V179, P1835, DOI 10.1084/jem.179.6.1835; Wagner DH, 1996, J EXP MED, V184, P1631, DOI 10.1084/jem.184.5.1631; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Werlen G, 2000, NATURE, V406, P422, DOI 10.1038/35019094; Wilkinson B, 2002, NAT IMMUNOL, V3, P272, DOI 10.1038/ni767; Wong B, 1997, Semin Immunol, V9, P7, DOI 10.1006/smim.1996.0051; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; Yun TJ, 2001, NAT IMMUNOL, V2, P13, DOI 10.1038/83118; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZHAO Y, 1995, INT IMMUNOL, V7, P1387, DOI 10.1093/intimm/7.9.1387; ZHAO Y, 1995, J IMMUNOL, V154, P6346	71	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21903	21915		10.1074/jbc.M402144200	http://dx.doi.org/10.1074/jbc.M402144200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016814	hybrid			2022-12-25	WOS:000221417100030
J	Ahn, MY; Katsanakis, KD; Bheda, F; Pillay, TS				Ahn, MY; Katsanakis, KD; Bheda, F; Pillay, TS			Primary and essential role of the adaptor protein APS for recruitment of both c-Cbl and its associated protein CAP in insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; TYROSINE PHOSPHORYLATION; GLUT4 TRANSLOCATION; RECEPTOR SUBSTRATE; SH2 DOMAIN; KINASE; ACTIVATION; PATHWAYS; PH	APS ((a) under bar dapter protein with (P) under bar leckstrin homology and (S) under bar rc homology 2 domains) is recruited by the autophosphorylated insulin receptor and is essential for Glut4 translocation. Although both APS and CAP (c-(C) under bar bl-(a) double under bar ssociated (p) under bar rotein) interact with c-Cbl during insulin signaling, the relative importance of each protein in recruiting c-Cbl has not been clear. We performed a side-by-side comparison by ectopic expression of APS or Src homology 2-Balpha (SH2-Balpha) and CAP in Chinese hamster ovary (CHO) cells. In cells co-expressing insulin receptor and CAP, without APS, no association of the insulin receptor and CAP could be detected and no insulin-stimulated phosphorylation of Cbl was observed. Insulin-stimulated Cbl phosphorylation was reconstituted when APS was co-expressed with insulin receptor, with or without CAP. APS or SH2-Balpha and CAP interacted in the basal state, and in the case of APS this interaction was mediated by the C terminus of APS. Insulin stimulation resulted in the dissociation of APS and CAP. Similarly, insulin stimulation also resulted in the dissociation of SH2-Balpha and CAP in CHO cells. CAP was localized to the membrane in the presence of APS. Insulin stimulation resulted in the re-localization of CAP to the cytosol only when APS was co-expressed. In 3T3-L1 adipocytes, small interfering RNA-mediated knockdown of the mouse APS gene abolished the insulin-stimulated phosphorylation of c-Cbl. Taken together, these results indicate that APS plays a central role in recruiting both CAP and c-Cbl to the insulin receptor after insulin stimulation and is necessary and sufficient for the insulin-stimulated phosphorylation of c-Cbl, whereas SH2-Balpha may provide an alternative pathway for the recruitment of CAP.	Univ Nottingham, Sch Med, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England; Univ Nottingham, Sch Med, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Pillay, TS (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England.	tpillay@nottingham.ac.uk		pillay, tahir/0000-0002-9982-9710				Ahmed Z, 2000, FEBS LETT, V475, P31, DOI 10.1016/S0014-5793(00)01621-5; Ahmed Z, 2003, BIOCHEM J, V371, P405, DOI 10.1042/BJ20021589; Ahmed Z, 1999, BIOCHEM J, V341, P665, DOI 10.1042/0264-6021:3410665; Ahmed Z, 2001, BIOCHEM SOC T, V29, P529, DOI 10.1042/BST0290529; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; Govind S, 2001, J CELL BIOL, V152, P579, DOI 10.1083/jcb.152.3.579; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kotani K, 1998, BIOCHEM J, V335, P103, DOI 10.1042/bj3350103; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Minami A, 2003, DIABETES, V52, P2657, DOI 10.2337/diabetes.52.11.2657; Moodie SA, 1999, J BIOL CHEM, V274, P11186, DOI 10.1074/jbc.274.16.11186; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520; Zhang M, 2003, MOL MED, V9, P18, DOI 10.1007/BF03402103	22	55	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21526	21532		10.1074/jbc.M307740200	http://dx.doi.org/10.1074/jbc.M307740200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15031295	hybrid			2022-12-25	WOS:000221273800118
J	Suzuki, M; Takamura, Y; Maeno, M; Tochinai, S; Iyaguchi, D; Tanaka, I; Nishihira, J; Ishibashi, T				Suzuki, M; Takamura, Y; Maeno, M; Tochinai, S; Iyaguchi, D; Tanaka, I; Nishihira, J; Ishibashi, T			Xenopus laevis macrophage migration inhibitory factor is essential for axis formation and neural development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-RESPONSES; FACTOR MIF; CRYSTAL-STRUCTURE; REGULATORY ROLE; TUMOR-GROWTH; CELL-GROWTH; FACTOR GENE; CYTOKINE; TAUTOMERASE; GLUTATHIONE	Macrophage migration inhibitory factor (MIF) is an immunoregulatory cytokine involved in both acquired and innate immunity. MIF also has many functions outside the immune system, such as isomerase and oxidoreductase activities and control of cell proliferation. Considering the involvement of MIF in various intra- and extracellular events, we expected that MIF might also be important in vertebrate development. To elucidate the possible role of MIF in developmental processes, we knocked down MIF in embryos of the African clawed frog Xenopus laevis, using MIF-specific morpholino oligomers (MOs). For the synthesis of the MOs, we cloned a cDNA for a Xenopus homolog of MIF. Sequence analysis, determination of the isomerase activity, and x-ray crystallographic analysis revealed that the protein encoded by the cDNA was the ortholog of mammalian MIF. We carried out whole mount in situ hybridization of MIF mRNA and found that MIF was expressed at high levels in the neural tissues of normal embryos. Although early embryogenesis of MO-injected embryos proceeded normally until the gastrula stage, their neurulation was completely inhibited. At the tailbud stage, the MO-injected embryos lacked neural and mesodermal tissues, and also showed severe defects in their head and tail structures. Thus, MIF was found to be essential for axis formation and neural development of Xenopus embryos.	Hokkaido Univ, Grad Sch Med, Dept Mol Biochem, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Niigata Univ, Fac Sci, Dept Biol, Niigata 9502181, Japan	Hokkaido University; Hokkaido University; Niigata University	Nishihira, J (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Mol Biochem, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.	j_nisihi@med.hokudai.ac.jp	TOCHINAI, Shin/A-4303-2012	TOCHINAI, Shin/0000-0001-5808-8533				Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Braun M, 2002, J IMMUNOL, V168, P2340, DOI 10.4049/jimmunol.168.5.2340; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Denkinger CM, 2003, J IMMUNOL, V170, P1274, DOI 10.4049/jimmunol.170.3.1274; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fingerle-Rowson G, 2003, P NATL ACAD SCI USA, V100, P9354, DOI 10.1073/pnas.1533295100; Heasman J, 2000, DEV BIOL, V222, P124, DOI 10.1006/dbio.2000.9720; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Honma N, 2000, IMMUNOLOGY, V100, P84, DOI 10.1046/j.1365-2567.2000.00011.x; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Johnson WH, 1999, BIOCHEMISTRY-US, V38, P16024, DOI 10.1021/bi991825s; Kimura MA, 1985, NEUTRAL THEORY MOL E; Kleemann R, 1998, FEBS LETT, V430, P191, DOI 10.1016/S0014-5793(98)00654-1; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; KNOX WE, 1955, METHOD ENZYMOL, V2, P287, DOI 10.1016/S0076-6879(55)02202-7; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Morand EF, 2003, ARTHRITIS RHEUM, V48, P291, DOI 10.1002/art.10728; Nguyen MT, 2003, J IMMUNOL, V170, P3337, DOI 10.4049/jimmunol.170.6.3337; Nieukoop P, 1967, NORMAL TABLE XENOPUS; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; Ohkawara T, 2002, GASTROENTEROLOGY, V123, P256, DOI 10.1053/gast.2002.34236; Petrenko O, 2003, J BIOL CHEM, V278, P11078, DOI 10.1074/jbc.M211985200; Roger T, 2001, J ENDOTOXIN RES, V7, P456, DOI 10.1177/09680519010070061101; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKAI M, 1994, BIOCHEM MOL BIOL INT, V33, P439; Sasaki Y, 2002, INT J MOL MED, V10, P579; Sato A, 2003, DEV COMP IMMUNOL, V27, P401, DOI 10.1016/S0145-305X(02)00136-2; Shain DH, 1996, J BIOCHEM BIOPH METH, V31, P185, DOI 10.1016/0165-022X(95)00030-U; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Soares TA, 2000, J MOL RECOGNIT, V13, P146, DOI 10.1002/1099-1352(200005/06)13:3<146::AID-JMR497>3.0.CO;2-4; Sugimoto H, 1996, FEBS LETT, V389, P145, DOI 10.1016/0014-5793(96)00553-4; Sugimoto H, 1999, BIOCHEMISTRY-US, V38, P3268, DOI 10.1021/bi982184o; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; Watarai H, 2000, P NATL ACAD SCI USA, V97, P13251, DOI 10.1073/pnas.230445397; WISTOW GJ, 1993, P NATL ACAD SCI USA, V90, P1272, DOI 10.1073/pnas.90.4.1272; Yasuda Y, 2002, INT J MOL MED, V10, P463	47	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21406	21414		10.1074/jbc.M311416200	http://dx.doi.org/10.1074/jbc.M311416200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15024012	hybrid			2022-12-25	WOS:000221273800105
J	Liu, EB; Li, XH; Yan, F; Zhao, QP; Wu, XH				Liu, EB; Li, XH; Yan, F; Zhao, QP; Wu, XH			Cyclin-dependent kinases phosphorylate human Cdt1 and induce its degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; S-PHASE; LICENSING FACTOR; PROTEIN; PROTEOLYSIS; P65(CDC18); TRANSITION; INITIATION	Eukaryotic cells tightly control DNA replication so that replication origins fire only once during S phase within the same cell cycle. Cell cycle-regulated degradation of the replication licensing factor Cdt1 plays important roles in preventing more than one round of DNA replication per cell cycle. We have previously shown that the SCFSkp2-mediated ubiquitination pathway plays an important role in Cdt1 degradation. In this study, we demonstrate that human Cdt1 is a substrate of Cdk2 and Cdk4 both in vivo and in vitro. Overexpression of cyclin-dependent kinase inhibitors such as p21 and p27 dramatically suppresses the phosphorylation of Cdt1, disrupts the interaction of Cdt1 with the F-box protein Skp2, and blocks the degradation of Cdt1. Further analysis reveals that Cdt1 interacts with cyclin/cyclin-dependent kinase (Cdk) complexes through a cyclin/Cdk binding consensus site, located at the N terminus of Cdt1. A Cdt1 mutant carrying four amino acid substitutions at the Cdk binding site dramatically reduces associations with cyclin/Cdk complexes. This mutant is not phosphorylated, fails to bind Skp2 and is more stable than wild-type Cdt1. These data suggest that cyclin/Cdk-mediated Cdt1 phosphorylation is required for the association of Cdt1 with the SCFSkp2 ubiquitin ligase and thus is important for the cell cycle dependent degradation of Cdt1 in mammalian cells.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Wu, XH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	xiaohwu@scripps.edu						Adams PD, 1996, MOL CELL BIOL, V16, P6623; Baum B, 1998, EMBO J, V17, P5689, DOI 10.1093/emboj/17.19.5689; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Rialland M, 2002, J CELL SCI, V115, P1435; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089	26	148	151	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17283	17288		10.1074/jbc.C300549200	http://dx.doi.org/10.1074/jbc.C300549200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	15004027	hybrid			2022-12-25	WOS:000220870400050
J	Hsu, JH; Shi, YJ; Frost, P; Yan, HJ; Hoang, B; Sharma, S; Gera, J; Lichtenstein, A				Hsu, JH; Shi, YJ; Frost, P; Yan, HJ; Hoang, B; Sharma, S; Gera, J; Lichtenstein, A			Interleukin-6 activates phosphoinositol-30 kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways	ONCOGENE			English	Article						multiple myeloma; interleukin-6; AKT; phosphatidylinositol-3 '-kinase	PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; TYROSINE PHOSPHORYLATION; GROWTH-FACTORS; AKT KINASE; N-RAS; SURVIVAL; RECEPTOR; PROTOONCOGENE; APOPTOSIS; RESPONSES	The IL-6-induced activation of the phosphatidylinositol-3' kinase (PI3-K)/AKTcascade in multiple myeloma (MM) cells is critical for tumor cell proliferation and viability. Since the IL-6 receptor does not contain binding sites for the p85 regulatory portion of PI3-K, intermediate molecules must play a role. Coimmunoprecipitation studies in MM cell lines demonstrated the IL-6-induced formation of two independent PI3-K-containing complexes: one containing p21 RAS but not STAT-3 and a second containing STAT-3 but not RAS. Both complexes demonstrated IL-6-induced lipid kinase activity. IL-6 also generated kinase activity in a mutant p110 molecule that could not bind p85. Use of dominant-negative (DN) constructs confirmed the presence of two independent pathways of activation: a DN RAS prevented the IL-6-induced generation of lipid kinase activity in the mutant p110 molecule but had no effect on activity generated in the STAT-3-containing complex. In contrast, a DN p85 prevented the generation of kinase activity in the STAT-3-containing complex but had no effect on activity generated in the p110 molecule. Both DN constructs significantly prevented the IL-6-induced activation of AKT. MM cells expressing activating RAS mutations demonstrated enhanced IL-6-independent growth and constitutive PI3-K activity. These data indicate two potential independent pathways of PI3-K/AKT activation in MM cells: one mediated via signaling through RAS which is independent of p85 and a second mediated via p85 and due to a STAT-3-containing complex.	W LA VA UCLA Med Ctr, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Lichtenstein, A (corresponding author), VA W LA Hosp, W111H,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	alan.lichtenstein@med.va.gov		Gera, Joseph/0000-0002-2908-6894; Frost, Patrick/0000-0003-3348-5983				ANDERSON KC, 1989, BLOOD, V73, P1915; BILLADEAU D, 1995, CANCER RES, V55, P3640; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hsu JH, 2002, ONCOGENE, V21, P1391, DOI 10.1038/sj/onc/1205194; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Hu LP, 2003, BLOOD, V101, P3126, DOI 10.1182/blood-2002-08-2640; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Lee IS, 1997, FEBS LETT, V401, P133, DOI 10.1016/S0014-5793(96)01456-1; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; Ogata A, 1997, J IMMUNOL, V159, P2212; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Podar K, 2002, J BIOL CHEM, V277, P7875, DOI 10.1074/jbc.M109068200; PODAR K, 2003, HEMATOL J, V4, pS140; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; Tu YP, 2000, CANCER RES, V60, P6763; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53	30	43	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3368	3375		10.1038/sj.onc.1207459	http://dx.doi.org/10.1038/sj.onc.1207459			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15021914				2022-12-25	WOS:000220975000011
J	Francois, H; Placier, S; Flamant, M; Tharaux, PL; Chansel, D; Dussaule, JC; Chatziantoniou, C				Francois, H; Placier, S; Flamant, M; Tharaux, PL; Chansel, D; Dussaule, JC; Chatziantoniou, C			Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition	FASEB JOURNAL			English	Article						renal fibrosis; collagen; hypertension; endothelin	NITRIC-OXIDE SYNTHESIS; ANGIOTENSIN-II; HYPERTENSIVE-RATS; KINASE ACTIVATION; TRANSGENIC MICE; COLLAGEN GENE; EGF RECEPTOR; EXPRESSION; TRANSACTIVATION; HYPERTROPHY	Hypertension is frequently associated with the development of renal vascular and glomerular fibrosis. The purpose of the present study was to investigate whether epidermal growth factor receptor (EGFR) activation participates in the development of renal fibrosis and to test if blockade of EGFR activation would have therapeutic effects. Experiments were performed during nitric oxide (NO) deficiency-induced hypertension in rats (L-NAME model). After 4 weeks of L-NAME treatment, animals developed hypertension associated to deterioration of renal structure and function. Over the same period, EGFR was activated twofold within glomeruli. This activation was accompanied by increased activity of the mitogen-activated protein kinase (MAPK) p42/p44 pathway and exaggerated collagen I expression. Gefitinib, an EGFR-tyrosine kinase inhibitor, given concomitantly with L-NAME, normalized MAPK activation and collagen I expression and prevented the decline of renal function and the development of fibrosis. Since endothelin mediates the L-NAME-induced fibrogenesis, the endothelin-EGFR interaction was tested in transgenic mice expressing luciferase under the control of collagen I-alpha2 promoter: In renal cortex of these animals, the endothelin-induced collagen I gene activity was inhibited by an EGFR-phosphorylation inhibitor. These results provide the first evidence that EGFR activation plays an important role in the progression of renal vascular and glomerular fibrosis.	Hop Tenon, INSERM, U489, F-75020 Paris, France; Univ Paris 06, UFR St Antoine, Physiol Lab, AP HP, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Sorbonne Universite	Chatziantoniou, C (corresponding author), INSERM, U489, F-75020 Paris, France.	christos.chatziantoniou@tnn.ap-hop-paris.fr	Chatziantoniou, Christos/L-2501-2016; Tharaux, Pierre-Louis/A-9155-2009	Tharaux, Pierre-Louis/0000-0002-6062-5905; Francois, Helene/0000-0001-7436-9554				ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bancroft J, 1982, THEORY PRACTICE HIST, P131; Boffa JJ, 1999, CIRCULATION, V100, P1901, DOI 10.1161/01.CIR.100.18.1901; Boffa JJ, 2003, J AM SOC NEPHROL, V14, P1132, DOI 10.1097/01.ASN.0000060574.38107.3B; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Bouriquet N, 1996, HYPERTENSION, V27, P382, DOI 10.1161/01.HYP.27.3.382; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Brilla CG, 1996, HYPERTENSION, V28, P269, DOI 10.1161/01.HYP.28.2.269; BRILLA CG, 1991, CIRC RES, V69, P107, DOI 10.1161/01.RES.69.1.107; Buist A, 1998, BIOCHEM BIOPH RES CO, V251, P6, DOI 10.1006/bbrc.1998.9405; Chatziantoniou C, 1998, J CLIN INVEST, V101, P2780, DOI 10.1172/JCI2132; CRAWFORD DC, 1994, CIRC RES, V74, P727, DOI 10.1161/01.RES.74.4.727; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Flamant M, 2002, FASEB J, V16, P327, DOI 10.1096/fj.02-0115fje; Floege J, 1999, AM J PATHOL, V154, P169, DOI 10.1016/S0002-9440(10)65263-7; FLOEGE J, 1995, MINER ELECTROL METAB, V21, P271; Johnson DH, 2003, LUNG CANCER, V41, pS23, DOI 10.1016/S0169-5002(03)00136-3; Ju HS, 1996, MOL CELL BIOCHEM, V164, P231, DOI 10.1007/BF00408663; LI JS, 1994, HYPERTENSION, V24, P183, DOI 10.1161/01.HYP.24.2.183; Mendelsohn J, 2000, CLIN CANCER RES, V6, P747; Michel JB, 1996, J CARDIOVASC PHARM, V28, P142, DOI 10.1097/00005344-199607000-00021; Mizuno S, 1998, J CLIN INVEST, V101, P1827, DOI 10.1172/JCI1709; Moreau P, 1997, CIRCULATION, V96, P1593, DOI 10.1161/01.CIR.96.5.1593; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Richards WG, 1998, J CLIN INVEST, V101, P935, DOI 10.1172/JCI2071; Ruperez M, 2003, AM J PATHOL, V163, P1937, DOI 10.1016/S0002-9440(10)63552-3; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; Strutz F, 2000, KIDNEY INT, V57, P1521, DOI 10.1046/j.1523-1755.2000.00997.x; Suzuki H, 2003, CANCER RES, V63, P5054; Swaisland H, 2001, CLIN PHARMACOKINET, V40, P297, DOI 10.2165/00003088-200140040-00005; Takemoto M, 1997, J CLIN INVEST, V99, P278, DOI 10.1172/JCI119156; Terzi F, 2000, J CLIN INVEST, V106, P225, DOI 10.1172/JCI8315; Tharaux PL, 1999, CIRCULATION, V99, P2185, DOI 10.1161/01.CIR.99.16.2185; Vargas GA, 2000, KIDNEY INT, V57, P1426, DOI 10.1046/j.1523-1755.2000.00987.x; Wakeling AE, 2002, CANCER RES, V62, P5749; Weber KT, 2000, CIRCULATION, V102, P1342, DOI 10.1161/01.CIR.102.12.1342; WOLF G, 1991, KIDNEY INT, V39, P401, DOI 10.1038/ki.1991.52; YOSHIOKA K, 1990, J PATHOL, V162, P141, DOI 10.1002/path.1711620207; Zatz R, 1998, HYPERTENSION, V32, P958, DOI 10.1161/01.HYP.32.6.958	41	98	101	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					926	+		10.1096/fj.03-0702fje	http://dx.doi.org/10.1096/fj.03-0702fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033924				2022-12-25	WOS:000220522800008
J	Dias, FMV; Vincent, F; Pell, G; Prates, JAM; Centeno, MSJ; Tailford, LE; Ferreira, LMA; Fontes, CMGA; Davies, GJ; Gilbert, HJ				Dias, FMV; Vincent, F; Pell, G; Prates, JAM; Centeno, MSJ; Tailford, LE; Ferreira, LMA; Fontes, CMGA; Davies, GJ; Gilbert, HJ			Insights into the molecular determinants of substrate specificity in glycoside hydrolase family 5 revealed by the crystal structure and kinetics of Cellvibrio mixtus mannosidase 5A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING MODULES; FLUORESCENS SUBSP CELLULOSA; PSEUDOMONAS-CELLULOSA; BETA-MANNOSIDASE; MECHANISM; ARCHITECTURE; NUCLEOPHILE; MUTAGENESIS; REFINEMENT; MANNANASE	The enzymatic hydrolysis of the glycosidic bond is central to numerous biological processes. Glycoside hydrolases, which catalyze these reactions, are grouped into families based on primary sequence similarities. One of the largest glycoside hydrolase families is glycoside hydrolase family 5 (GH5), which contains primarily endo-acting enzymes that hydrolyze beta-mannans and beta-glucans. Here we report the cloning, characterization, and three-dimensional structure of the Cellvibrio mixtus GH5 beta-mannosidase (CmMan5A). This enzyme releases mannose from the nonreducing end of mannooligosaccharides and polysaccharides, an activity not previously observed in this enzyme family. CmMan5A contains a single glycone (-1) and two aglycone (-1 and -2) sugar-binding subsites. The -1 subsite displays absolute specificity for mannose, whereas the -1 subsite does not accommodate galactosyl side chains but will bind weakly to glucose. The +2 subsite is able to bind to decorated mannose residues. CmMan5A displays similar activity against crystalline and amorphous mannans, a property rarely attributed to glycoside hydrolases. The 1.5 Angstrom crystal structure reveals that CmMan5A adopts a (beta/alpha)(8) barrel fold, and superimposition with GH5 endo-mannanases shows that dramatic differences in the length of three loops modify the active center accessibility and thus modulate the specificity from endo to exo. The most striking and significant difference is the extended loop between strand beta8 and helix alpha8 comprising residues 378-412. This insertion forms a "double" steric barrier, formed by two short beta-strands that function to "block" the substrate binding cleft at the edge of the -1 subsite forming the "exo" active center topology of CmMan5A.	Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Tecn Lisboa, Fac Med Vet, CIISA, P-1300477 Lisbon, Portugal; Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England	Newcastle University - UK; Universidade de Lisboa; University of York - UK	Gilbert, HJ (corresponding author), Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	h.j.gilbert@ncl.ac.uk	Dias, Fernando/I-4861-2012; Vincent, Florence/F-7137-2016; Prates, José A M/K-9934-2013; Davies, Gideon J/A-9042-2011	Dias, Fernando/0000-0001-8109-2063; Prates, José A M/0000-0003-1032-5987; Davies, Gideon J/0000-0002-7343-776X; Ferreira, Luis/0000-0002-3543-9166; vincent, Florence/0000-0002-8564-4184; Centeno, Maria S. Jose/0000-0002-8586-5542; Fontes, Carlos/0000-0002-1219-9753	Biotechnology and Biological Sciences Research Council [BBS/B/05974, B20376] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERNS KI, 1965, J MOL BIOL, V11, P476, DOI 10.1016/S0022-2836(65)80004-3; Beylot MH, 2001, BIOCHEM J, V358, P599, DOI 10.1042/0264-6021:3580599; Bolam DN, 2001, BIOCHEMISTRY-US, V40, P2468, DOI 10.1021/bi002564l; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Brett CT, 1996, PHYSL BIOCH PLANT CE; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; CLARKE JH, 1991, FEMS MICROBIOL LETT, V83, P305, DOI [10.1016/0378-1097(91)90493-T, 10.1111/j.1574-6968.1991.tb04481.x]; Coutinho PM, 1999, ROY SOC CH, P3; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; Cutfield SM, 1999, J MOL BIOL, V294, P771, DOI 10.1006/jmbi.1999.3287; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; GEBLER J, 1992, J BIOL CHEM, V267, P12559; Halstead JR, 2000, FEMS MICROBIOL LETT, V192, P197, DOI 10.1016/S0378-1097(00)00432-8; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Hilge M, 1998, STRUCTURE, V6, P1433, DOI 10.1016/S0969-2126(98)00142-7; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; Hogg D, 2001, J BIOL CHEM, V276, P31186, DOI 10.1074/jbc.M010290200; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MACLEOD AM, 1994, BIOCHEMISTRY-US, V33, P6371, DOI 10.1021/bi00186a042; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McCleary B V, 1986, Adv Carbohydr Chem Biochem, V44, P147; MCCLEARY BV, 1988, METHOD ENZYMOL, V160, P523; MCCLEARY BV, 1983, CARBOHYD RES, V111, P297, DOI 10.1016/0008-6215(83)88314-1; MILLWARDSADLER SJ, 1995, BIOCHEM J, V312, P39, DOI 10.1042/bj3120039; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy T, 2002, J BACTERIOL, V184, P4925, DOI 10.1128/JB.184.17.4925-4929.2002; Oldfield TJ, 2001, ACTA CRYSTALLOGR D, V57, P82, DOI 10.1107/S0907444900014098; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sabini E, 2000, ACTA CRYSTALLOGR D, V56, P3, DOI 10.1107/S0907444999013943; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; Stoll D, 2000, BIOCHEM J, V351, P833, DOI 10.1042/0264-6021:3510833; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; WANG QP, 1993, J BIOL CHEM, V268, P14096; Williams SJ, 2000, J AM CHEM SOC, V122, P4229, DOI 10.1021/ja0002870; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z; Zechel DL, 2003, BIOCHEMISTRY-US, V42, P7195, DOI 10.1021/bi034329j	45	85	88	5	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25517	25526		10.1074/jbc.M401647200	http://dx.doi.org/10.1074/jbc.M401647200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15014076	Green Published, hybrid			2022-12-25	WOS:000221827900077
J	Eberl, H; Tittmann, P; Glockshuber, R				Eberl, H; Tittmann, P; Glockshuber, R			Characterization of recombinant, membrane-attached full-length prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATION; SCRAPIE ISOFORM; SPONGIFORM ENCEPHALOPATHIES; LIPID-MEMBRANES; NMR STRUCTURE; SPECTROSCOPIC CHARACTERIZATION; UNILAMELLAR VESICLES; ESCHERICHIA-COLI; IN-VIVO; CONVERSION	An abnormal isoform, PrPSc, of the normal cellular prion protein ( PrPC) is the major component of the causative agent of prion diseases. Both isoforms were found to possess the same covalent structures, including a C-terminal glycosylphosphatidylinositol anchor, but different secondary and tertiary structures. In this study, a variant of full-length PrP with an unpaired cysteine at the C terminus was recombinantly produced in Escherichia coli, covalently coupled to a thiol-reactive phospholipid, and incorporated into liposomes to serve as a model for studying possible changes in structure and stability of recombinant PrP upon membrane attachment. Covalent coupling of PrP to liposomes did not result in significant structural changes observable by far-UV circular dichroism. Moreover, limited proteolysis experiments failed to detect changes in the stability of liposome-bound PrP relative to soluble PrP. These data suggest that the requirement of raft localization for the PrPC to PrPSc conversion, observed previously in cell culture models, is not because of a direct influence of raft lipids on the structure and stability of membrane-bound PrPC but caused by other factors, e. g. increased local PrP concentrations or high effective concentrations of membrane-associated conversion factors. The availability of recombinant PrP covalently attached to liposomes provides the basis for systematic in vitro conversion assays with recombinant PrP on the surface of membranes. In addition, our results indicate that the three-dimensional structure of mammalian PrPC in membranes is identical to that of recombinant PrP in solution.	ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; ETH, Inst Angew Phys, Elektronenmikroscopie Zentrum, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Glockshuber, R (corresponding author), ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland.	rudi@mol.biol.ethz.ch						BALDWIN MA, 1994, PHILOS T ROY SOC B, V343, P435, DOI 10.1098/rstb.1994.0041; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Baron GS, 2003, J BIOL CHEM, V278, P14883, DOI 10.1074/jbc.M210840200; BREDEHORST R, 1986, BIOCHEMISTRY-US, V25, P5693, DOI 10.1021/bi00367a052; Brown D, 2002, INT J MED MICROBIOL, V291, P433; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Critchley P, 2004, BIOCHEM BIOPH RES CO, V313, P559, DOI 10.1016/j.bbrc.2003.12.004; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; Garnett AP, 2003, J BIOL CHEM, V278, P6795, DOI 10.1074/jbc.M209280200; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEPPNER FL, 2001, NATURE ENCY LIFE SCI; Hermanns U, 2000, BIOCHEMISTRY-US, V39, P11564, DOI 10.1021/bi000549a; HOMANS SW, 1989, BIOCHEMISTRY-US, V28, P2881, DOI 10.1021/bi00433a020; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hornemann S, 1996, J MOL BIOL, V261, P614, DOI 10.1006/jmbi.1996.0487; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kazlauskaite J, 2003, BIOCHEMISTRY-US, V42, P3295, DOI 10.1021/bi026872q; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Munoz M, 1998, ANALYST, V123, P2223, DOI 10.1039/a804560g; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pergami P, 1996, ANAL BIOCHEM, V236, P63, DOI 10.1006/abio.1996.0132; Philipps B, 2003, J MOL BIOL, V327, P239, DOI 10.1016/S0022-2836(03)00077-9; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1991, J INFECT DIS, V163, P488, DOI 10.1093/infdis/163.3.488; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Smondyrev AM, 1999, BIOPHYS J, V77, P2075, DOI 10.1016/S0006-3495(99)77049-9; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1991, FASEB J, V5, P2799, DOI 10.1096/fasebj.5.13.1916104; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; WELLER CT, 1994, BIOPOLYMERS, V34, P1155, DOI 10.1002/bip.360340905; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; Zuegg J, 2000, GLYCOBIOLOGY, V10, P959, DOI 10.1093/glycob/10.10.959	62	52	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25058	25065		10.1074/jbc.M400952200	http://dx.doi.org/10.1074/jbc.M400952200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15031284	hybrid			2022-12-25	WOS:000221827900020
J	Valverde, C; Lindell, M; Wagner, EGH; Haas, D				Valverde, C; Lindell, M; Wagner, EGH; Haas, D			A repeated GGA motif is critical for the activity and stability of the riboregulator RsmY of Pseudomonas fluorescens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN CSRA; MESSENGER-RNA TARGETS; SMALL REGULATORY RNA; ESCHERICHIA-COLI; GLOBAL REGULATION; MOLECULAR CHARACTERIZATION; SECONDARY METABOLITE; EXOPRODUCT FORMATION; 2-COMPONENT SYSTEM; EXPRESSION	The riboregulator RsmY of Pseudomonas fluorescens strain CHA0 is an example of small regulatory RNAs belonging to the global Rsm/Csr regulatory systems controlling diverse cellular processes such as glycogen accumulation, motility, or formation of extracellular products in various bacteria. By binding multiple molecules of the small regulatory protein RsmA, RsmY relieves the negative effect of RsmA on the translation of several target genes involved in the biocontrol properties of strain CHA0. RsmY and functionally related riboregulators have repeated GGA motifs predicted to be exposed in single-stranded regions, notably in the loops of hairpins. The secondary structure of RsmY was corroborated by in vivo cleavage with lead acetate. RsmY mutants lacking three or five ( out of six) of the GGA motifs showed reduced ability to derepress the expression of target genes in vivo and failed to bind the RsmA protein efficiently in vitro. The absence of GGA motifs in RsmY mutants resulted in reduced abundance of these transcripts and in a shorter half-life (less than or equal to6 min as compared with 27 min for wild type RsmY). These results suggest that both the interaction of RsmY with RsmA and the stability of RsmY strongly depend on the GGA repeats and that the ability of RsmY to interact with small regulatory proteins such as RsmA may protect this RNA from degradation.	Univ Lausanne, Dept Microbiol Fondamentale, CH-1015 Lausanne, Switzerland; Uppsala Univ, Ctr Biomed, Inst Cell & Mol Biol, SE-75124 Uppsala, Sweden	University of Lausanne; Uppsala University	Valverde, C (corresponding author), Univ Lausanne, Dept Microbiol Fondamentale, Batiment Biol, CH-1015 Lausanne, Switzerland.	cvalver@unq.edu.ar	Valverde, Claudio F/I-3375-2019	Valverde, Claudio/0000-0001-8296-1291				Aarons S, 2000, J BACTERIOL, V182, P3913, DOI 10.1128/JB.182.14.3913-3919.2000; Altier C, 2000, MOL MICROBIOL, V35, P635, DOI 10.1046/j.1365-2958.2000.01734.x; BAO Y, 1991, GENE, V109, P167, DOI 10.1016/0378-1119(91)90604-A; Barnard FM, 2004, MOL MICROBIOL, V51, P15, DOI 10.1046/j.1365-2958.2003.03788.x; Blumer C, 1999, P NATL ACAD SCI USA, V96, P14073, DOI 10.1073/pnas.96.24.14073; CASTRIC PA, 1975, CAN J MICROBIOL, V21, P613, DOI 10.1139/m75-088; Chatterjee A, 2003, MOL PLANT MICROBE IN, V16, P1106, DOI 10.1094/MPMI.2003.16.12.1106; Chatterjee A, 2002, J BACTERIOL, V184, P4089, DOI 10.1128/JB.184.15.4089-4095.2002; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P9878; Dubey AK, 2003, J BACTERIOL, V185, P4450, DOI 10.1128/JB.185.15.4450-4460.2003; GAMPER M, 1992, J MOL BIOL, V226, P943, DOI 10.1016/0022-2836(92)91044-P; Gudapaty S, 2001, J BACTERIOL, V183, P6017, DOI 10.1128/JB.183.20.6017-6027.2001; Haas D, 2003, ANNU REV PHYTOPATHOL, V41, P117, DOI 10.1146/annurev.phyto.41.052002.095656; Haas D, 2002, ANTON LEEUW INT J G, V81, P385, DOI 10.1023/A:1020549019981; Heeb S, 2002, J BACTERIOL, V184, P1046, DOI 10.1128/jb.184.4.1046-1056.2002; Heeb S, 2001, MOL PLANT MICROBE IN, V14, P1351, DOI 10.1094/MPMI.2001.14.12.1351; HEEB S, 2004, PSEUDOMONAS, V2, P239; Hershberg R, 2003, NUCLEIC ACIDS RES, V31, P1813, DOI 10.1093/nar/gkg297; HEURLIER K, 2004, IN PRESS J BACT; Johansson J, 2003, TRENDS MICROBIOL, V11, P280, DOI 10.1016/S0966-842X(03)00118-5; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lawhon SD, 2003, MOL MICROBIOL, V48, P1633, DOI 10.1046/j.1365-2958.2003.03535.x; Lease RA, 2000, MOL MICROBIOL, V38, P667, DOI 10.1046/j.1365-2958.2000.02162.x; Lindell M, 2002, RNA, V8, P534, DOI 10.1017/S1355838201020416; Liu MY, 1997, J BIOL CHEM, V272, P17502, DOI 10.1074/jbc.272.28.17502; Liu Y, 1998, MOL MICROBIOL, V29, P219, DOI 10.1046/j.1365-2958.1998.00924.x; Ma WL, 2001, J BACTERIOL, V183, P1870, DOI 10.1128/JB.183.6.1870-1880.2001; Masse E, 2002, P NATL ACAD SCI USA, V99, P4620, DOI 10.1073/pnas.032066599; Masse E, 2003, GENE DEV, V17, P2374, DOI 10.1101/gad.1127103; Moller T, 2002, GENE DEV, V16, P1696, DOI 10.1101/gad.231702; Molofsky AB, 2003, MOL MICROBIOL, V50, P445, DOI 10.1046/j.1365-2958.2003.03706.x; Pessi G, 2001, J BACTERIOL, V183, P6676, DOI 10.1128/JB.183.22.6676-6683.2001; Romeo T, 1998, MOL MICROBIOL, V29, P1321, DOI 10.1046/j.1365-2958.1998.01021.x; ROMEO T, 1993, J BACTERIOL, V175, P4744, DOI 10.1128/JB.175.15.4744-4755.1993; Sambrook J, 2001, MOL CLONING LAB MANU; SMELTZER MS, 1993, INFECT IMMUN, V61, P919, DOI 10.1128/IAI.61.3.919-925.1993; Solini A, 2001, HYPERTENSION, V37, P1492, DOI 10.1161/01.HYP.37.6.1492; Suzuki K, 2002, J BACTERIOL, V184, P5130, DOI 10.1128/JB.184.18.5130-5140.2002; Valverde C, 2003, MOL MICROBIOL, V50, P1361, DOI 10.1046/j.1365-2958.2003.03774.x; Vogel J, 2003, NUCLEIC ACIDS RES, V31, P6435, DOI 10.1093/nar/gkg867; VOISARD C, 1994, MOLECULAR ECOLOGY OF RHIZOSPHERE MICROORGANISMS, P67, DOI 10.1002/9783527615810.ch6; VOISARD C, 1989, EMBO J, V8, P351, DOI 10.1002/j.1460-2075.1989.tb03384.x; Wei BDL, 2001, MOL MICROBIOL, V40, P245, DOI 10.1046/j.1365-2958.2001.02380.x; Weilbacher T, 2003, MOL MICROBIOL, V48, P657, DOI 10.1046/j.1365-2958.2003.03459.x; Zhang AX, 2003, MOL MICROBIOL, V50, P1111, DOI 10.1046/j.1365-2958.2003.03734.x; Zuber S, 2003, MOL PLANT MICROBE IN, V16, P634, DOI 10.1094/MPMI.2003.16.7.634; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	47	82	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25066	25074		10.1074/jbc.M401870200	http://dx.doi.org/10.1074/jbc.M401870200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15031281	hybrid			2022-12-25	WOS:000221827900021
J	Baron, MJ; Bolduc, GR; Goldberg, MB; Auperin, TC; Madoff, LC				Baron, MJ; Bolduc, GR; Goldberg, MB; Auperin, TC; Madoff, LC			Alpha C protein of group B Streptococcus binds host cell surface glycosaminoglycan and enters cells by an actin-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; EPIDERMAL GROWTH-FACTOR; EPITHELIAL-CELLS; ENDOTHELIAL-CELLS; INTEGRIN ALPHA(IIB)BETA(3); NEISSERIA-GONORRHOEAE; PROTECTIVE EPITOPES; PLASMA-MEMBRANE; VIRUS TYPE-1; ANTIGEN GENE	Group B Streptococcus (GBS) colonizes mucosal surfaces of the human gastrointestinal and gynecological tracts and causes disease in a wide range of patients. Invasive illness occurs after organisms traverse an epithelial boundary and enter deeper tissues. Previously we have reported that the alpha C protein (ACP) on the surface of GBS mediates GBS entry into ME180 cervical epithelial cells and GBS translocation across layers of these cells. We now demonstrate that ACP interacts with host cell glycosaminoglycan (GAG); the interaction of ACP with ME180 cells is inhibited if cells are pretreated with sodium chlorate, an inhibitor of sulfate incorporation, or with heparitinases. The interaction is also inhibited in the presence of soluble heparin or heparan sulfate or host cell-derived GAG. In addition, ACP binds soluble heparin specifically in inhibition and dot blot assays. After interaction with host GAG, soluble ACP enters ME180 cells and fractionates to the eukaryotic cell cytosol. These events are inhibited in cells pretreated with cytochalasin D or with Clostridium difficile toxin B. These data indicate that full-length ACP interacts with ME180 cell GAG and enters the eukaryotic cell cytosol by a mechanism that involves Rho GTPase-dependent actin rearrangements. We suggest that these molecular interactions drive ACP-mediated translocation of GBS across epithelial barriers, thereby facilitating invasive GBS infection.	Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Massachusetts Gen Hosp, Div Infect Dis, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Baron, MJ (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	mbaron@partners.org	Goldberg, Marcia/U-8604-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI051114, R21AI038424, R01AI038424, R56AI038424] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38424, AI51114] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADDO JB, 1995, ARTERIOSCL THROM VAS, V15, P1466, DOI 10.1161/01.ATV.15.9.1466; Alrutz MA, 2001, MOL MICROBIOL, V42, P689, DOI 10.1046/j.1365-2958.2001.02676.x; AlvarezDominguez C, 1997, INFECT IMMUN, V65, P78; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bolduc GR, 2002, CELL MICROBIOL, V4, P751, DOI 10.1046/j.1462-5822.2002.00227.x; Boquet P, 1998, FOLIA MICROBIOL, V43, P285, DOI 10.1007/BF02818614; Bose S, 2002, VIROLOGY, V298, P73, DOI 10.1006/viro.2002.1484; Brown EL, 2001, J CLIN INVEST, V107, P845, DOI 10.1172/JCI11692; Calvet CM, 2003, J EUKARYOT MICROBIOL, V50, P97, DOI 10.1111/j.1550-7408.2003.tb00240.x; CAREY DJ, 1986, J BIOL CHEM, V261, P7518; Cornelis GR, 2002, INT J MED MICROBIOL, V291, P455; Cywes C, 2001, NATURE, V414, P648, DOI 10.1038/414648a; Dehio C, 1998, EXP CELL RES, V242, P528, DOI 10.1006/excr.1998.4116; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; GIBSON RL, 1993, INFECT IMMUN, V61, P478, DOI 10.1128/IAI.61.2.478-485.1993; Giroglou T, 2001, J VIROL, V75, P1565, DOI 10.1128/JVI.75.3.1565-1570.2001; Gravekamp C, 1996, INFECT IMMUN, V64, P3576, DOI 10.1128/IAI.64.9.3576-3583.1996; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; JACKSON LA, 1995, ANN INTERN MED, V123, P415, DOI 10.7326/0003-4819-123-6-199509150-00003; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kallman J, 1997, PEDIATR RES, V42, P799; Kallstrom H, 2001, CELL MICROBIOL, V3, P133, DOI 10.1046/j.1462-5822.2001.00095.x; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Kling DE, 1997, INFECT IMMUN, V65, P1462, DOI 10.1128/IAI.65.4.1462-1467.1997; Lachenauer CS, 2000, P NATL ACAD SCI USA, V97, P9630, DOI 10.1073/pnas.97.17.9630; Lachenauer CS, 2002, J INFECT DIS, V185, P368, DOI 10.1086/338773; LANCEFIELD RC, 1975, J EXP MED, V142, P165, DOI 10.1084/jem.142.1.165; Laquerre S, 1998, J VIROL, V72, P6119, DOI 10.1128/JVI.72.7.6119-6130.1998; Lee VT, 1998, MOL MICROBIOL, V28, P593, DOI 10.1046/j.1365-2958.1998.00822.x; Li E, 1998, J VIROL, V72, P8806, DOI 10.1128/JVI.72.11.8806-8812.1998; Li J, 1997, P NATL ACAD SCI USA, V94, P13251, DOI 10.1073/pnas.94.24.13251; Lundqvist K, 2001, BRIT J DERMATOL, V144, P254, DOI 10.1046/j.1365-2133.2001.04009.x; MADOFF LC, 1991, INFECT IMMUN, V59, P2638, DOI 10.1128/IAI.59.8.2638-2644.1991; MADOFF LC, 1991, INFECT IMMUN, V59, P204, DOI 10.1128/IAI.59.1.204-210.1991; Madoff LC, 1996, P NATL ACAD SCI USA, V93, P4131, DOI 10.1073/pnas.93.9.4131; Mercurius KO, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-18; MICHEL JL, 1992, P NATL ACAD SCI USA, V89, P10060, DOI 10.1073/pnas.89.21.10060; Nhieu GTV, 2000, CELL MICROBIOL, V2, P187; Nizet V, 1997, INFECT IMMUN, V65, P5074, DOI 10.1128/IAI.65.12.5074-5081.1997; Olsson U, 2001, DIABETES, V50, P2126, DOI 10.2337/diabetes.50.9.2126; Ozeri V, 2001, MOL MICROBIOL, V41, P561, DOI 10.1046/j.1365-2958.2001.02535.x; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; PRIME SS, 1980, CYTOBIOS, V28, P151; RUBENS CE, 1992, INFECT IMMUN, V60, P5157, DOI 10.1128/IAI.60.12.5157-5163.1992; Rudolph MG, 1999, J BIOL CHEM, V274, P30501, DOI 10.1074/jbc.274.43.30501; Sansonetti PJ, 1998, ANTON LEEUW INT J G, V74, P191, DOI 10.1023/A:1001519806727; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; Schroter CJ, 1999, J IMMUNOL METHODS, V227, P161, DOI 10.1016/S0022-1759(99)00079-4; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shafti-Keramat S, 2003, J VIROL, V77, P13125, DOI 10.1128/JVI.77.24.13125-13135.2003; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Timar J, 2002, SEMIN CANCER BIOL, V12, P173, DOI 10.1016/S1044-579X(02)00021-4; Toksoz D, 2002, HISTOL HISTOPATHOL, V17, P915, DOI 10.14670/HH-17.915; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Tyrrell GJ, 2002, MICROBIOL-SGM, V148, P3921, DOI 10.1099/00221287-148-12-3921; ValentinWeigand P, 1997, FEMS MICROBIOL LETT, V147, P69, DOI 10.1016/S0378-1097(96)00506-X; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Wilkins TD, 1996, TRENDS MICROBIOL, V4, P49, DOI 10.1016/0966-842X(96)81508-3; Winram SB, 1998, INFECT IMMUN, V66, P4932, DOI 10.1128/IAI.66.10.4932-4941.1998; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; Yanagishita M, 1994, EXS, V70, P179; Zaslaver A, 2001, J IMMUNOL, V166, P1272, DOI 10.4049/jimmunol.166.2.1272; ZHENG ZS, 1990, CANCER RES, V50, P1201	70	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24714	24723		10.1074/jbc.M402164200	http://dx.doi.org/10.1074/jbc.M402164200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044471	hybrid			2022-12-25	WOS:000221702500102
J	Cao, XW; Sudhof, TC				Cao, XW; Sudhof, TC			Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATION; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; MOUSE-BRAIN; FE65; CLEAVAGE; APP; FAMILY; TIP60; NOTCH	Amyloid-beta precursor protein (APP) forms a transcriptionally active complex with the adaptor protein Fe65 and the histone acetyltransferase Tip60, but the mechanism of transcriptional activation that is mediated by APP and Fe65 remains unclear. APP is cleaved by gamma-secretase similar to Notch, whose intracellular domain activates transcription by interacting with nuclear transcription factors. To test whether the APP intracellular domain (AICD) functions analogously, we investigated how APP and Fe65 transactivate a Gal4 fusion protein of Tip60. Consistent with the Notch paradigm, we observe that gamma-cleavage of APP and nuclear translocation of Fe65 are required for transactivation. Surprisingly, however, we find that nuclear translocation of the AICD may be dispensable and that only membrane-tethered AICD (i.e. AICD coupled to a transmembrane region) and not free AICD (i.e. soluble AICD) is a potent transactivator of transcription. Membrane-tethered AICD recruits Fe65 and mediates the activation of bound Fe65 that is then released for nuclear translocation by gamma-cleavage together with the AICD. Our data suggest that transcriptional transactivation by APP and Notch may involve distinct mechanisms; whereas the Notch intracellular domain directly functions in the nucleus, the AICD acts indirectly by activating Fe65.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestern.edu	Cao, Xinwei/N-8183-2018	Cao, Xinwei/0000-0003-0651-5243	NIMH NIH HHS [R01-MH069585] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069585] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heber S, 2000, J NEUROSCI, V20, P7951; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kesavapany S, 2002, NEUROSCIENCE, V115, P951, DOI 10.1016/S0306-4522(02)00422-0; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Koo EH, 2002, TRAFFIC, V3, P763, DOI 10.1034/j.1600-0854.2002.31101.x; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; MCGEER PL, 1992, J NEUROSCI RES, V31, P428, DOI 10.1002/jnr.490310305; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Sabo SL, 2003, J NEUROSCI, V23, P5407; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Zheng H, 1996, ANN NY ACAD SCI, V777, P421, DOI 10.1111/j.1749-6632.1996.tb34456.x	29	242	249	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24601	24611		10.1074/jbc.M402248200	http://dx.doi.org/10.1074/jbc.M402248200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044485	hybrid			2022-12-25	WOS:000221702500090
J	Parker, AKT; Gergely, FV; Taylor, CW				Parker, AKT; Gergely, FV; Taylor, CW			Targeting of inositol 1,4,5-trisphosphate receptors to the endoplasmic reticulum by multiple signals within their transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; GREEN FLUORESCENT PROTEIN; RIBOSE-MEDIATED RELEASE; LIVER EPITHELIAL-CELLS; PLASMA-MEMBRANE; IP3 RECEPTORS; TRISPHOSPHATE RECEPTORS; RYANODINE RECEPTOR; GOLGI-APPARATUS; FUNCTIONAL-PROPERTIES	Most inositol 1,4,5-trisphosphate receptors (IP3R) are expressed in the endoplasmic reticulum ( ER), where their precise distribution underlies the spatially complex Ca2+ signals evoked by extracellular stimuli. The signals that target IP3R to the ER or, less commonly, to other membranes are unknown. We expressed yellow fluorescent protein-tagged fragments of type 1 IP3R alone or fused with a plasma membrane protein to establish the determinants of ER targeting in COS-7 cells. By using a combination of confocal imaging and glycoprotein analyses, we demonstrated that any pair of the six transmembrane domains (TMD) linked by a luminal loop retains the protein within the ER, and when attached to a plasma membrane protein (ICAM-1), prevents it from reaching the medial Golgi. TMD1 or TMD2 alone were accumulated in mitochondria, whereas TMD5 and TMD6 were retained in ER, but were unable to prevent ICAM from reaching the plasma membrane. We conclude that IP3R are targeted to the ER membrane only after synthesis of TMDs 1 and 2, and that after co-translational insertion of the remaining TMDs, redundant retention signals present in any pair of TMD retain IP3R in the ER.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1PD, England	University of Cambridge; University of Cambridge	Gergely, FV (corresponding author), Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England.	fvg20@cus.cam.ac.uk; cwt1000@cam.ac.uk	Taylor, Colin/G-2447-2010	Taylor, Colin/0000-0001-7771-1044; Gergely, Fanni/0000-0002-2441-8095				Balshaw D, 1999, P NATL ACAD SCI USA, V96, P3345, DOI 10.1073/pnas.96.7.3345; Bella J, 1999, J STRUCT BIOL, V128, P69, DOI 10.1006/jsbi.1999.4143; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bhat MB, 2002, J BIOL CHEM, V277, P8597, DOI 10.1074/jbc.M107609200; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BUSH K, 1994, J BIOL CHEM, V38, P23694; Du GG, 2002, P NATL ACAD SCI USA, V99, P16725, DOI 10.1073/pnas.012688999; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; El-Daher SS, 2000, BLOOD, V95, P3412, DOI 10.1182/blood.V95.11.3412.011k03_3412_3422; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Galvan DL, 2002, J BIOL CHEM, V277, P48248, DOI 10.1074/jbc.M209990200; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Heinrich SU, 2003, EMBO J, V22, P3654, DOI 10.1093/emboj/cdg346; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1995, BIOCHEM J, V307, P859, DOI 10.1042/bj3070859; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; JOSEPH SK, 1994, J BIOL CHEM, V269, P5673; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; MAK DOD, 1994, J BIOL CHEM, V269, P29375; Mak DOD, 1997, J GEN PHYSIOL, V109, P571, DOI 10.1085/jgp.109.5.571; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; Marchant JS, 2001, EMBO J, V20, P65, DOI 10.1093/emboj/20.1.65; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Mottola G, 2000, J BIOL CHEM, V275, P24070, DOI 10.1074/jbc.M910400199; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; Petersen OH, 1999, BIOESSAYS, V21, P851, DOI 10.1002/(SICI)1521-1878(199910)21:10<851::AID-BIES7>3.3.CO;2-6; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; PRINZ T, 2002, PROTEIN TARGETING TR, P214; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Sato K, 1997, P NATL ACAD SCI USA, V94, P9693, DOI 10.1073/pnas.94.18.9693; Sato K, 2003, MOL BIOL CELL, V14, P3605, DOI 10.1091/mbc.E02-12-0777; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; Sayers LG, 1997, BIOCHEM J, V323, P273, DOI 10.1042/bj3230273; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; SEYMOURLAURENT KJ, 1995, J NEUROSCI, V15, P2592; SHARP AH, 1993, J NEUROSCI, V13, P3051; Sitsapesan R, 1998, STRUCTURE FUNCTION R; TAKEI K, 1994, NEURON, V12, P327, DOI 10.1016/0896-6273(94)90275-5; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Taylor CW, 2004, TRENDS BIOCHEM SCI, V29, P210, DOI 10.1016/j.tibs.2004.02.010; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Vazquez G, 2002, EMBO J, V21, P4531, DOI 10.1093/emboj/cdf467; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Yule DI, 1997, J BIOL CHEM, V272, P9093; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198	73	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23797	23805		10.1074/jbc.M402098200	http://dx.doi.org/10.1074/jbc.M402098200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15033979	hybrid			2022-12-25	WOS:000221570900123
J	Roberts, SC; Tancer, MJ; Polinsky, MR; Gibson, KM; Heby, O; Ullman, B				Roberts, SC; Tancer, MJ; Polinsky, MR; Gibson, KM; Heby, O; Ullman, B			Arginase plays a pivotal role in polyamine precursor metabolism in Leishmania - Characterization of gene deletion mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-DECARBOXYLASE GENE; S-ADENOSYLMETHIONINE DECARBOXYLASE; BRUCEI-RHODESIENSE INFECTIONS; TRYPANOSOMA-BRUCEI; ALPHA-DIFLUOROMETHYLORNITHINE; DONOVANI; CLONING; GLYCOSOMES; GLUCOSE; ENZYMES	The polyamine pathway of protozoan parasites has been successfully targeted in anti-parasitic therapies and is significantly different from that of the mammalian host. To gain knowledge into the metabolic routes by which parasites synthesize polyamines and their precursors, the arginase gene was cloned from Leishmania mexicana, and Deltaarg null mutants were created by double targeted gene replacement and characterized. The ARG sequence exhibited significant homology to ARG proteins from other organisms and predicted a peroxisomal targeting signal (PTS-1) that steers proteins to the glycosome, an organelle unique to Leishmania and related parasites. ARG was subsequently demonstrated to be present in the glycosome, whereas the polyamine biosynthetic enzymes, in contrast, were shown to be cytosolic. The Deltaarg knockouts expressed no ARG activity, lacked an intracellular ornithine pool, and were auxotrophic for ornithine or polyamines. The ability of the Deltaarg null mutants to proliferate could be restored by pharmacological supplementation, either with low putrescine or high ornithine or spermidine concentrations, or by complementation with an arginase episome. Transfection of an arg construct lacking the PTS-1 directed the synthesis of an arg that mislocalized to the cytosol and notably also complemented the genetic lesion and restored polyamine prototrophy to the Deltaarg parasites. This molecular, biochemical, and genetic dissection of ARG function in L. mexicana promastigotes establishes: ( i) that the enzyme is essential for parasite viability; ( ii) that Leishmania, unlike mammalian cells, expresses only one ARG activity; (iii) that the sole vital function of ARG is to provide polyamine precursors for the parasite; and (iv) that ARG is present in the glycosome, but this subcellular milieu is not essential for its role in polyamine biosynthesis.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Biochem Genet Lab, Portland, OR 97239 USA; Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden	Oregon Health & Science University; Oregon Health & Science University; Umea University	Ullman, B (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	ullmanb@ohsu.edu			NIAID NIH HHS [AI41622, AI10096] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI041622, R01AI041622] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; Bacchi C.J., 1987, P317; Bacchi CJ, 2002, MINI-REV MED CHEM, V2, P553, DOI 10.2174/1389557023405549; BACCHI CJ, 1980, SCIENCE, V210, P332, DOI 10.1126/science.6775372; BACCHI CJ, 1992, ANTIMICROB AGENTS CH, V36, P2736, DOI 10.1128/AAC.36.12.2736; BACCHI CJ, 1993, ACTA TROP, V54, P225, DOI 10.1016/0001-706X(93)90095-S; BITONTI AJ, 1987, EXP PARASITOL, V64, P237, DOI 10.1016/0014-4894(87)90148-2; BITONTI AJ, 1990, ANTIMICROB AGENTS CH, V34, P1485, DOI 10.1128/AAC.34.8.1485; BLATTNER J, 1995, FEBS LETT, V360, P310, DOI 10.1016/0014-5793(95)00128-V; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burchmore RJS, 2003, P NATL ACAD SCI USA, V100, P3901, DOI 10.1073/pnas.0630165100; CAMARGO EP, 1978, EXP PARASITOL, V46, P141, DOI 10.1016/0014-4894(78)90125-X; CARRERA L, 1994, PARASITOL RES, V80, P203, DOI 10.1007/BF00932675; Carrillo C, 1999, FEBS LETT, V454, P192, DOI 10.1016/S0014-5793(99)00804-2; CHANG CS, 1985, MOL BIOCHEM PARASIT, V16, P267, DOI 10.1016/0166-6851(85)90069-6; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; COBURN CM, 1991, MOL BIOCHEM PARASIT, V46, P169, DOI 10.1016/0166-6851(91)90210-W; COONS T, 1990, MOL BIOCHEM PARASIT, V39, P77, DOI 10.1016/0166-6851(90)90010-J; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; da Silva ER, 2002, INT J PARASITOL, V32, P727, DOI 10.1016/S0020-7519(02)00002-4; FAIRLAMB AH, 1989, PARASITOLOGY, V99, pS93, DOI 10.1017/S003118200008344X; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FREEDMAN DJ, 1993, MOL BIOCHEM PARASIT, V62, P37, DOI 10.1016/0166-6851(93)90175-W; FUNG K, 1991, MOL BIOCHEM PARASIT, V45, P261, DOI 10.1016/0166-6851(91)90093-L; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1990, J BIOL CHEM, V265, P11823; GILLIN FD, 1984, J PROTOZOOL, V31, P161, DOI 10.1111/j.1550-7408.1984.tb04308.x; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; HAMMOND DJ, 1982, BIOCHIM BIOPHYS ACTA, V718, P1, DOI 10.1016/0304-4165(82)90002-2; HANSON S, 1992, J BIOL CHEM, V267, P2350; HART DT, 1984, MOL BIOCHEM PARASIT, V13, P159, DOI 10.1016/0166-6851(84)90110-5; Heby O, 2003, BIOCHEM SOC T, V31, P415, DOI 10.1042/BST0310415; Iniesta V, 2001, J EXP MED, V193, P777, DOI 10.1084/jem.193.6.777; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; Iyer RK, 2002, MOL GENET METAB, V75, P209, DOI 10.1006/mgme.2001.3277; Jardim A, 2002, MOL BIOCHEM PARASIT, V124, P51, DOI 10.1016/S0166-6851(02)00164-0; Jiang YQ, 1999, J BIOL CHEM, V274, P3781, DOI 10.1074/jbc.274.6.3781; Kanyo ZF, 1996, NATURE, V383, P554, DOI 10.1038/383554a0; KAUR K, 1986, J PROTOZOOL, V33, P518, DOI 10.1111/j.1550-7408.1986.tb05654.x; KRASSNER SM, 1971, J PARASITOL, V57, P917, DOI 10.2307/3277829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mikus Judith, 2000, Parasitology International, V48, P265, DOI 10.1016/S1383-5769(99)00020-3; Mistry SK, 2002, AM J PHYSIOL-GASTR L, V282, pG375, DOI 10.1152/ajpgi.00386.2001; MUKHOPADHYAY R, 1995, INT J BIOCHEM CELL B, V27, P947, DOI 10.1016/1357-2725(95)00053-R; Muller S., 1988, Advances in Experimental Medicine and Biology, V250, P737; Muller S, 2001, TRENDS PARASITOL, V17, P242, DOI 10.1016/S1471-4922(01)01908-0; OPPERDOES FR, 1977, FEBS LETT, V80, P360, DOI 10.1016/0014-5793(77)80476-6; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; Parsons M, 2001, MOL BIOCHEM PARASIT, V115, P19, DOI 10.1016/S0166-6851(01)00261-4; Pegg  A., 1981, POLYAMINES BIOL MED, P3; Perozich J, 1998, BBA-PROTEIN STRUCT M, V1382, P23, DOI 10.1016/S0167-4838(97)00131-3; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; Roberts SC, 2002, J BIOL CHEM, V277, P5902, DOI 10.1074/jbc.M110118200; Roberts SC, 2001, MOL BIOCHEM PARASIT, V115, P217, DOI 10.1016/S0166-6851(01)00293-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schechter P. J., 1987, Inhibition of polyamine metabolism. Biological significance and basis for new therapies [edited by McCann, P. P.; Pegg, A. E.; Sjoerdsma, A.], P345; SEILER N, 1986, J CHROMATOGR, V379, P157, DOI 10.1016/S0378-4347(00)80684-2; Sekowska A, 2000, MICROBIOL-SGM, V146, P1815, DOI 10.1099/00221287-146-8-1815; Shih S, 1998, J BIOL CHEM, V273, P1534, DOI 10.1074/jbc.273.3.1534; Slocum RH, 1991, TECHNIQUES DIAGNOSTI, P87; SOMMER JM, 1994, FEBS LETT, V350, P125, DOI 10.1016/0014-5793(94)00747-0; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TERKUILE BH, 1992, J PROTOZOOL, V39, P555; Walker J B, 1979, Adv Enzymol Relat Areas Mol Biol, V50, P177; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; ZILBERSTEIN D, 1984, MOL BIOCHEM PARASIT, V12, P327, DOI 10.1016/0166-6851(84)90089-6; ZILBERSTEIN D, 1985, P NATL ACAD SCI USA, V82, P1716, DOI 10.1073/pnas.82.6.1716	70	125	129	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23668	23678		10.1074/jbc.M402042200	http://dx.doi.org/10.1074/jbc.M402042200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15023992	hybrid			2022-12-25	WOS:000221570900109
J	Carmody, LC; Bauman, PA; Bass, MA; Mavila, N; DePaoli-Roach, AA; Colbran, RJ				Carmody, LC; Bauman, PA; Bass, MA; Mavila, N; DePaoli-Roach, AA; Colbran, RJ			A protein phosphatase-1 gamma 1 isoform selectivity determinant in dendritic spine-associated neurabin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-TARGETING SUBUNIT; FILAMENT-BINDING PROTEIN; CATALYTIC SUBUNIT; SUBCELLULAR-LOCALIZATION; SKELETAL-MUSCLE; SPINOPHILIN; IDENTIFICATION; MOTIF; INHIBITOR-2; DOMAIN	Protein phosphatase- 1 ( PP1) catalytic subunit isoforms interact with diverse proteins, typically containing a canonical ( R/ K)( V/ I) XF motif. Despite sharing similar to 90% amino acid sequence identity, PP1beta and PP1gamma1 have distinct subcellular localizations that may be determined by selective interactions with PP1- binding proteins. Immunoprecipitation studies from brain and muscle extracts demonstrated that PP1gamma1 selectively interacts with spinophilin and neurabin, F- actin- targeting proteins, whereas PP1beta selectively interacted with G(M)/ R-GL, the striated- muscle glycogen- targeting subunit. Glutathione S- transferase ( GST) fusion proteins containing residues 146 - 493 of neurabin ( GST- Nb-( 146 - 493)) or residues 1 - 240 of G(M)/ R-GL ( GST-G(M)-( 1 - 240)) recapitulated these isoform selectivities in binding and phosphatase activity inhibition assays. Site- directed mutagenesis indicated that this isoform selectivity was not due to sequence differences between the canonical PP1- binding motifs ( neurabin, (KIKF460)-K-457; G(M)/ R-GL, (RVSF68)-R-65). A chimeric GST fusion protein containing residues 1 - 64 of G(M)/ R-GL fused to residues 457 - 493 of neurabin ( GST- G(M)/ Nb) selectively bound to and inhibited PP1gamma1, whereas a GST- Nb/ G(M) chimera containing Nb-( 146 - 460) fused to G(M)-( 69 - 240) selectively interacted with and weakly inhibited PP1 beta, implicating domain( s) C- terminal to the ( R/ K)( V/ I) XF motif as determinants of PP1 isoform selectivity. Deletion of Pro(464) and Ile(465) in neurabin ( Delta PI) to equally space a conserved cluster of amino acids from the ( R/ K)( V/ I) XF motif as in G(M)/ R-GL severely compromised the ability of neurabin to bind and inhibit both isoforms but did not affect PP1gamma1 selectivity. Further analysis of a series of C- terminal truncated GST- Nb-( 146 - 493) proteins identified residues 473 - 479 of neurabin as containing a crucial PP1gamma1- selectivity determinant. In combination, these data identify a novel PP1gamma1- selective interaction domain in neurabin that may allow for selective regulation and/ or subcellular targeting of PP1 isoforms.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN 37232 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Indiana University System; Indiana University-Purdue University Indianapolis	Colbran, RJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Rm 702,Light Hall, Nashville, TN 37232 USA.	Roger.Colbran@Vanderbilt.edu	Mavila, Nirmala/AAH-6140-2021; Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244; Carmody, Leigh/0000-0001-7941-2961	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563, R01DK036569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037508] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA68485] Funding Source: Medline; NIDDK NIH HHS [5T32DK07563, R01-DK36569] Funding Source: Medline; NINDS NIH HHS [R01-NS37508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Aschenbach WG, 2001, J BIOL CHEM, V276, P39959, DOI 10.1074/jbc.M105518200; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cohen P T, 1996, Adv Pharmacol, V36, P67; Cohen PTW, 2002, J CELL SCI, V115, P241; Colbran RJ, 2003, METHOD ENZYMOL, V366, P156; COLBRAN RJ, 2003, HDB CELL SIGNALING, V2, P397; DENT P, 1990, FEBS LETT, V259, P281, DOI 10.1016/0014-5793(90)80027-G; DEPAOLIROACH AA, 2003, HDB CELL SIGNALING, P613; DOMBRADI V, 1990, EUR J BIOCHEM, V194, P739, DOI 10.1111/j.1432-1033.1990.tb19464.x; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Enz R, 2003, BIOCHEM J, V372, P183, DOI 10.1042/BJ20021750; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Haneji T, 1998, BIOCHEM BIOPH RES CO, V248, P39, DOI 10.1006/bbrc.1998.8913; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Liu J, 2000, J BIOL CHEM, V275, P26074, DOI 10.1074/jbc.M003843200; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; PARK IK, 1994, J BIOL CHEM, V269, P28919; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Strack S, 1999, J COMP NEUROL, V413, P373; Strack S, 1997, MOL BRAIN RES, V49, P15, DOI 10.1016/S0169-328X(97)00117-4; Suzuki Y, 2001, MOL CELL BIOL, V21, P2683, DOI 10.1128/MCB.21.8.2683-2694.2001; Tang TS, 2003, J NEUROSCI, V23, P403, DOI 10.1523/JNEUROSCI.23-02-00403.2003; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; Winder DG, 2001, NAT REV NEUROSCI, V2, P461, DOI 10.1038/35081514; Wu J, 1998, FEBS LETT, V439, P185, DOI 10.1016/S0014-5793(98)01371-4; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; ZHANG ZJ, 1993, ARCH BIOCHEM BIOPHYS, V303, P402, DOI 10.1006/abbi.1993.1301; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	45	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21714	21723		10.1074/jbc.M402261200	http://dx.doi.org/10.1074/jbc.M402261200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016827	hybrid			2022-12-25	WOS:000221417100006
J	Estacion, M; Li, S; Sinkins, WG; Gosling, M; Bahra, P; Poll, C; Westwick, J; Schilling, WP				Estacion, M; Li, S; Sinkins, WG; Gosling, M; Bahra, P; Poll, C; Westwick, J; Schilling, WP			Activation of human TRPC6 channels by receptor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT RECEPTOR; CATION CHANNEL; EXCHANGER; MEMBRANE; CA2+; DIACYLGLYCEROL; ENTRY; DYE	The human TRPC6 channel was expressed in human embryonic kidney (HEK) cells, and activity was monitored using the giga-seal technique. Whole cell membrane currents with distinctive inward and outward rectification were activated by carbachol (CCh) in TRPC6-expressing cells, but not in lacZ-transfected controls. The effect of CCh was steeply dose-dependent with a K-0.5 of similar to10 muM and a Hill coefficient of 3-4. A steep concentration-response relationship was also observed when TRPC6 activity was measured using a fluorescence-based imaging plate reader (FLIPR) assay for membrane depolarization. Ionomycin, thapsigargin, and dialysis of the cell with inositol 1,4,5-trisphosphate via the patch pipette had no effect on TRPC6 currents, but exogenous application of 1-oleoyl acetyl-sn-glycerol (OAG, 30-300 muM) produced a slow increase in channel activity. The PKC activator, phorbol 12-myristate 13-acetate (PMA, 0.5 muM) had no significant acute effect on TRPC6, or on the subsequent response to OAG. In contrast, the response to CCh was blocked >90% by PMA pretreatment. To further explore the role of DAG in receptor stimulation, TRPC6 currents were monitored following the sequential addition of CCh and OAG. Surprisingly, concentrations of CCh that produced little or no response in the absence of OAG, produced increases in TRPC6 currents in the presence of OAG that were larger than the sum of either agent alone. Likewise, the response to OAG was superadditive following prior stimulation of the cells with near threshold concentrations of CCh. Overall, these results suggest that generation of DAG alone may not fully account for activation of TRPC6, and that other receptor-mediated events act synergistically with DAG to stimulate channel activity. This synergy may explain, at least in part, the steep dose-response relationship observed for CCh-induced TRPC6 currents expressed in HEK cells.	Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res, Cleveland, OH 44109 USA; Novartis Resp Res Ctr, Horsham RH12 5AB, W Sussex, England; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	MetroHealth System; Novartis; Case Western Reserve University	Schilling, WP (corresponding author), Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res, Room R-322,2500 Metrohlth Dr, Cleveland, OH 44109 USA.	wschilling@metrohealth.org	Estacion, Mark/H-2444-2011	Estacion, Mark/0000-0002-7271-1165	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052019] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52019] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert AP, 2003, J PHYSIOL-LONDON, V552, P789, DOI 10.1113/jphysiol.2003.052977; Basora N, 2003, J BIOL CHEM, V278, P31709, DOI 10.1074/jbc.M304437200; Baxter DF, 2002, J BIOMOL SCREEN, V7, P79, DOI 10.1177/108705710200700110; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Condrescu M, 1997, J GEN PHYSIOL, V109, P41, DOI 10.1085/jgp.109.1.41; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; Fang Y, 1998, AM J PHYSIOL-CELL PH, V275, pC50, DOI 10.1152/ajpcell.1998.275.1.C50; Fischer KG, 2002, NEPHROL DIAL TRANSPL, V17, P1742, DOI 10.1093/ndt/17.10.1742; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Hardie RC, 2003, ANNU REV PHYSIOL, V65, P735, DOI 10.1146/annurev.physiol.65.092101.142505; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; IWAMOTO T, 1995, J BIOL CHEM, V270, P8996, DOI 10.1074/jbc.270.15.8996; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Pei L, 2003, P NATL ACAD SCI USA, V100, P7803, DOI 10.1073/pnas.1232448100; Putney JW, 1999, BIOESSAYS, V21, P38; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Rosker C, 2004, J BIOL CHEM, V279, P13696, DOI 10.1074/jbc.M308108200; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Schulze DH, 2003, J BIOL CHEM, V278, P28849, DOI 10.1074/jbc.M300754200; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; TIBBITS GF, 1985, BIOCHIM BIOPHYS ACTA, V817, P327, DOI 10.1016/0005-2736(85)90035-5; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Whiteaker KL, 2001, J BIOMOL SCREEN, V6, P305, DOI 10.1177/108705710100600504; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Zhang L, 2001, J BIOL CHEM, V276, P13331, DOI 10.1074/jbc.M008914200	40	73	82	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22047	22056		10.1074/jbc.M402320200	http://dx.doi.org/10.1074/jbc.M402320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15023993	hybrid			2022-12-25	WOS:000221417100046
J	Frieden, M; James, D; Castelbou, C; Danckaert, A; Martinou, JC; Demaurex, N				Frieden, M; James, D; Castelbou, C; Danckaert, A; Martinou, JC; Demaurex, N			Ca2+ homeostasis during mitochondrial fragmentation and perinuclear clustering induced by hFis1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-ENTRY; ENDOPLASMIC-RETICULUM; T-LYMPHOCYTES; CELLS; ACTIVATION; CHANNELS; FISSION; STIMULATION; COMPONENT; DEPLETION	Mitochondria modulate Ca2+ signals by taking up, buffering, and releasing Ca2+ at key locations near Ca2+ release or influx channels. The role of such local interactions between channels and organelles is difficult to establish in living cells because mitochondria form an interconnected network constantly remodeled by coordinated fusion and fission reactions. To study the effect of a controlled disruption of the mitochondrial network on Ca2+ homeostasis, we took advantage of hFis1, a protein that promotes mitochondrial fission by recruiting the dynamin-related protein, Drp1.hFis1 expression in HeLa cells induced a rapid and complete fragmentation of mitochondria, which redistributed away from the plasma membrane and clustered around the nucleus. Despite the dramatic morphological alteration, hFis1-fragmented mitochondria maintained a normal transmembrane potential and pH and took up normally the Ca2+ released from intracellular stores upon agonist stimulation, as measured with a targeted ratiometric pericam probe. In contrast, hFis1-fragmented mitochondria took up more slowly the Ca2+ entering across plasma membrane channels, because the Ca2+ ions reaching mitochondria propagated faster and in a more coordinated manner in interconnected than in fragmented mitochondria. In parallel cytosolic fura-2 measurements, the capacitative Ca2+ entry (CCE) elicited by store depletion was only marginally reduced by hFis1 expression. Regardless of mitochondria shape and location, disruption of mitochondrial potential with uncouplers or oligomycin/rotenone reduced CCE by similar to35%. These observations indicate that close contact to Ca2+ influx channels is not required for CCE modulation and that the formation of a mitochondrial network facilitates Ca2+ propagation within interconnected mitochondria.	Univ Geneva, Med Ctr, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Med Ctr, Bioimaging Core Facil, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Cell Biol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva	Demaurex, N (corresponding author), Univ Geneva, Med Ctr, Dept Physiol, 1 Michel Servet, CH-1211 Geneva 4, Switzerland.	Nicolas.Demaurex@medicine.unige.ch	James, Dominic/G-6435-2016	James, Dominic/0000-0002-0452-2178; Frieden, Maud/0000-0001-7135-0874; martinou, Jean-claude/0000-0002-9847-2051; Demaurex, Nicolas/0000-0002-9933-6772				Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Filippin L, 2003, J BIOL CHEM, V278, P39224, DOI 10.1074/jbc.M302301200; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Malli R, 2003, J BIOL CHEM, V278, P10807, DOI 10.1074/jbc.M212971200; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Parekh AB, 1998, J BIOL CHEM, V273, P14925, DOI 10.1074/jbc.273.24.14925; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Prakriya M, 2003, CELL CALCIUM, V33, P311, DOI 10.1016/S0143-4160(03)00045-9; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; SAUVE R, 1987, J MEMBRANE BIOL, V96, P199, DOI 10.1007/BF01869302; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Wang GJ, 2003, J NEUROCHEM, V87, P85, DOI 10.1046/j.1471-4159.2003.01970.x; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003	23	165	170	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22704	22714		10.1074/jbc.M312366200	http://dx.doi.org/10.1074/jbc.M312366200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15024001	hybrid, Green Published			2022-12-25	WOS:000221417100122
J	Guida, L; Franco, L; Bruzzone, S; Sturla, L; Zocchi, E; Basile, G; Usai, C; De Flora, A				Guida, L; Franco, L; Bruzzone, S; Sturla, L; Zocchi, E; Basile, G; Usai, C; De Flora, A			Concentrative influx of functionally active cyclic ADP-ribose in dimethyl sulfoxide-differentiated HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATES INTRACELLULAR CALCIUM; RETINOIC ACID; MOLECULAR-IDENTIFICATION; NUCLEOSIDE TRANSPORTERS; CD38; CYCLASE; SYSTEM; 2ND-MESSENGER; PROLIFERATION; ANTIGEN	Native human HL-60 cells do not express CD38, a multifunctional ectoenzyme, which generates cyclic ADP-ribose ( cADPR), a potent calcium mobilizer. However, when HL-60 cells are induced to differentiate to granulocytes by treatment with retinoic acid ( RA), they express CD38 and accumulate cADPR. Both processes play a causal role in RA-induced differentiation. Other granulocyte differentiation-inducers, including dimethyl sulfoxide (Me2SO), fail to induce CD38 expression. We investigated whether treatment of HL-60 cells with Me2SO involves any changes in the cADPR/intracellular calcium ([Ca2+](i)) signaling system and, specifically, whether Me2SO affects those nucleoside transporters (NT) ( both equilibrative ( ENT) and concentrative (CNT)) that mediate influx of extracellular cADPR. Semiquantitative polymerase chain reaction analysis of transcripts, binding of [H-3] nitrobenzylthioinosine ( NBMPR) to intact cells, and influx experiments of extracellular cADPR ( with selective inhibitors of NT as NBMPR or in specific conditions) were performed in native and Me2SO-differentiated HL-60 cells. The native cells showed uptake of cADPR across ENT2, whereas influx of cADPR into the Me2SO-differentiated cells occurred mostly by concentrative processes mediated by CNT3 and by an NBMPR-inhibitable concentrative NT designated cs-csg. Me2SO-differentiated, but not native HL-60 cells, accumulated cADPR and showed increased [Ca2+](i) levels when grown in a transwell co-culture setting over CD38-transfected 3T3 fibroblasts where nanomolar cADPR concentrations are present in the medium. NBMPR inhibited both responses of Me2SO-induced cells. Thus, concentrative influx of extracellular cADPR across CNT3 and cs-csg NT could substitute in the absence of CD38 in eliciting cADPR-dependent [Ca2+](i) increases in granulocyte-differentiated HL-60 cells, as well as in other CD38(-) cells.	Univ Genoa, Biochem Sect, Dept Expt Med, DIMES, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy; Giannina Gaslini Inst, I-16147 Genoa, Italy; CNR, Inst Biophys, I-16149 Genoa, Italy	University of Genoa; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR)	De Flora, A (corresponding author), Univ Genoa, Biochem Sect, Dept Expt Med, DIMES, Viale Benedetto XV 1, I-16132 Genoa, Italy.	toninodf@unige.it	Bruzzone, Santina/A-4264-2015	Bruzzone, Santina/0000-0003-2034-3716; Usai, Cesare/0000-0001-8863-7759				Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Boleti H, 1997, NEUROPHARMACOLOGY, V36, P1167, DOI 10.1016/S0028-3908(97)00136-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruzzone S, 2003, BIOCHEM J, V375, P395, DOI 10.1042/BJ20030556; Bruzzone S, 2001, J BIOL CHEM, V276, P48300, DOI 10.1074/jbc.M107308200; Bruzzone S, 2001, FASEB J, V15, P10; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; DEFLORA A, 2002, CYCLIC ADP RIBOSE NA, P241; DRACH J, 1994, CANCER RES, V54, P1746; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; Franco L, 2001, J BIOL CHEM, V276, P21642, DOI 10.1074/jbc.M010536200; Franco L, 2001, AM J PHYSIOL-LUNG C, V280, pL98; Franco L, 1998, FASEB J, V12, P1507; Graeff R, 2002, BIOCHEM J, V361, P379, DOI 10.1042/bj3610379; Guida L, 2002, J BIOL CHEM, V277, P47097, DOI 10.1074/jbc.M207793200; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Guse Andreas H., 2002, Current Molecular Medicine (Hilversum), V2, P273, DOI 10.2174/1566524024605707; HEMMI H, 1982, BIOCHEM BIOPH RES CO, V109, P669, DOI 10.1016/0006-291X(82)91992-1; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; ITOH M, 1994, BIOCHEM BIOPH RES CO, V203, P1309, DOI 10.1006/bbrc.1994.2325; JARVIS SM, 1983, BIOCHEM J, V216, P661, DOI 10.1042/bj2160661; KONTANI K, 1993, J BIOL CHEM, V268, P16895; LEE CW, 1991, BIOCHEM J, V274, P85, DOI 10.1042/bj2740085; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; LEE HC, 2002, CYCLIC ADIP RIBOSE N; Mehta K., 2002, CYCLIC ADP RIBOSE NA, P409; MEHTA K, 2000, CHEM IMMUNOL, V75, P1; Munshi CB, 2002, J BIOL CHEM, V277, P49453, DOI 10.1074/jbc.M209313200; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Partida-Sanchez S, 2003, MICROBES INFECT, V5, P49, DOI 10.1016/S1286-4579(02)00055-2; Paterson A. R. P., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P14; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Soler C, 1998, J BIOL CHEM, V273, P26939, DOI 10.1074/jbc.273.41.26939; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; Verderio C, 2001, J NEUROCHEM, V78, P646, DOI 10.1046/j.1471-4159.2001.00455.x; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; Zocchi E, 2001, FASEB J, V15, P1610, DOI 10.1096/fj.00-0803fje	46	27	27	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22066	22075		10.1074/jbc.M314137200	http://dx.doi.org/10.1074/jbc.M314137200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15028729	hybrid			2022-12-25	WOS:000221417100048
J	Iwai, T; Kuramitsu, S; Masui, R				Iwai, T; Kuramitsu, S; Masui, R			The Nudix hydrolase Ndx1 from Thermus thermophilus HB8 is a diadenosine hexaphosphate hydrolase with a novel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHOINOSITOL POLYPHOSPHATE PHOSPHOHYDROLASE; ADP-RIBOSE PYROPHOSPHATASE; MANNOSE MANNOSYL HYDROLASE; ESCHERICHIA-COLI; TETRAPHOSPHATE HYDROLASE; CAENORHABDITIS-ELEGANS; MUTT FAMILY; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; MAGNETIC-RESONANCE	The ndx1 gene, which encodes a Nudix protein, was cloned from the extremely thermophilic bacterium Thermus thermophilus HB8. This gene encodes a 126-amino acid protein that includes the characteristic Nudix motif conserved among Nudix proteins. Ndx1 was overexpressed in Escherichia coli and purified. Ndx1 was stable up to 95degreesC and at extreme pH. Size exclusion chromatography indicated that Ndx1 was monomeric in solution. Ndx1 specifically hydrolyzed ( di) adenosine polyphosphates but not ATP or diadenosine triphosphate, and it always generated ATP as the product. Diadenosine hexaphosphate ( Ap(6)A), the most preferred substrate, was hydrolyzed to produce two ATP molecules, which is a novel hydrolysis mode for Ap(6)A, with a K-m of 1.4 muM and a k(cat) of 4.1 s(-1). These results indicate that Ndx1 is a ( di) adenosine polyphosphate hydrolase. Ndx1 activity required the presence of the divalent cations Mn2+ , Mg2+, Zn2+, and Co2+, whereas Ca2+, Ni2+, and Cu2+ were not able to activate Ndx1. Fluoride ion inhibited Ndx1 activity via a non- competitive mechanism. Optimal activity for Ap(6)A was observed at around pH 8.0 and about 70degreesC. We found two important residues with pK(a) values of 6.1 and 9.6 in the free enzyme and pK(a) values of 7.9 and 10.0 in the substrate- enzyme complex. Kinetic studies of proteins with amino acid substitutions suggested that Glu- 46 and Glu- 50 were conserved residues in the Nudix motif and were involved in catalysis. Trp- 26 was likely involved in enzyme- substrate interactions based on fluorescence measurements. Based on these results, the mechanism of substrate recognition and catalysis are discussed.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; RIKEN Harima Inst SPring8, Mikazuki, Hyogo 6795148, Japan	Osaka University; RIKEN	Masui, R (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan.	rmasui@bio.sci.osaka-u.ac.jp						Abdelghany HM, 2003, J BIOL CHEM, V278, P4435, DOI 10.1074/jbc.M211983200; Abdelghany HM, 2001, BBA-PROTEIN STRUCT M, V1550, P27, DOI 10.1016/S0167-4838(01)00263-1; AbdelRaheim SR, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-5; Bailey S, 2002, STRUCTURE, V10, P589, DOI 10.1016/S0969-2126(02)00746-3; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Bessman MJ, 2001, J BIOL CHEM, V276, P37834; Cartwright JL, 1999, J BIOL CHEM, V274, P8604, DOI 10.1074/jbc.274.13.8604; DIXON NE, 1980, CAN J BIOCHEM CELL B, V58, P481, DOI 10.1139/o80-064; FERSHT AR, 1909, STRUCTURE MECH PROTE, P169; Fisher DI, 2002, J BIOL CHEM, V277, P47313, DOI 10.1074/jbc.M209795200; Fletcher JI, 2002, STRUCTURE, V10, P205, DOI 10.1016/S0969-2126(02)00696-2; Fontes R, 1999, BIOCHIMIE, V81, P229, DOI 10.1016/S0300-9084(99)80056-X; FRICK DN, 1994, J BIOL CHEM, V269, P1794; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; Harris TK, 2000, BIOCHEMISTRY-US, V39, P1655, DOI 10.1021/bi9918745; Hashimoto Y, 2001, FEBS LETT, V506, P231, DOI 10.1016/S0014-5793(01)02926-X; Hoseki J, 1999, J BIOCHEM-TOKYO, V126, P951, DOI 10.1093/oxfordjournals.jbchem.a022539; Ingram SW, 1999, BIOCHEMISTRY-US, V38, P3649, DOI 10.1021/bi982951j; Jankowski J, 1999, J BIOL CHEM, V274, P23926, DOI 10.1074/jbc.274.34.23926; Legler PM, 2002, BIOCHEMISTRY-US, V41, P4655, DOI 10.1021/bi012118d; Leslie NR, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-20; LIANG P, 1991, PROTEINS, V9, P28, DOI 10.1002/prot.340090105; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; Luo JK, 1999, HYPERTENSION, V34, P872, DOI 10.1161/01.HYP.34.4.872; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Maksel D, 1998, BIOCHEM J, V329, P313, DOI 10.1042/bj3290313; Maksel D, 2001, BIOCHEM J, V357, P399, DOI 10.1042/0264-6021:3570399; Marina A, 1998, EUR J BIOCHEM, V253, P280, DOI 10.1046/j.1432-1327.1998.2530280.x; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; McLennan AG, 1999, INT J MOL MED, V4, P79; Nishimura A, 1997, GENES CELLS, V2, P401, DOI 10.1046/j.1365-2443.1997.1300328.x; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; Pintor J, 2002, PFLUG ARCH EUR J PHY, V443, P432, DOI 10.1007/s004240100696; Pintor J, 2002, J PHARMACOL EXP THER, V300, P291, DOI 10.1124/jpet.300.1.291; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Samizo K, 2001, ANAL BIOCHEM, V293, P212, DOI 10.1006/abio.2001.5146; Swarbrick JD, 2000, J MOL BIOL, V302, P1165, DOI 10.1006/jmbi.2000.4085; VINCENT JB, 1991, BIOCHEMISTRY-US, V30, P3025, DOI 10.1021/bi00226a007; WEBER DJ, 1992, J BIOL CHEM, V267, P16939; WEDLER FC, 1982, BIOCHEMISTRY-US, V21, P6389, DOI 10.1021/bi00268a011; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Xu WL, 2001, MOL MICROBIOL, V39, P286, DOI 10.1046/j.1365-2958.2001.02267.x; Yamagishi A, 1996, APPL ENVIRON MICROB, V62, P2191, DOI 10.1128/AEM.62.6.2191-2194.1996; Yang HJ, 2000, J BIOL CHEM, V275, P8844, DOI 10.1074/jbc.275.12.8844; Yang XN, 1999, J BIOL CHEM, V274, P35434, DOI 10.1074/jbc.274.50.35434; Yokoyama S, 2000, PROG BIOPHYS MOL BIO, V73, P363, DOI 10.1016/S0079-6107(00)00012-2; Yokoyama S, 2000, NAT STRUCT BIOL, V7, P943, DOI 10.1038/80712; Yoshiba S, 2003, ACTA CRYSTALLOGR D, V59, P1840, DOI 10.1107/S090744490301713X	54	18	19	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21732	21739		10.1074/jbc.M312018200	http://dx.doi.org/10.1074/jbc.M312018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15024014	hybrid			2022-12-25	WOS:000221417100008
J	Kang, DS; Ryberg, K; Morgelin, M; Leeb-Lundberg, LMF				Kang, DS; Ryberg, K; Morgelin, M; Leeb-Lundberg, LMF			Spontaneous formation of a proteolytic B1 and B2 bradykinin receptor complex with enhanced signaling capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PROTEIN-COUPLED RECEPTORS; KININ RECEPTORS; B-1 RECEPTORS; INVERSE AGONISTS; DOWN-REGULATION; SEQUESTRATION; DIMERIZATION; ENDOCYTOSIS; EXPRESSION	B1 bradykinin receptor (B1R) induction is critical in the adaptation of the kinin-mediated inflammatory response from a B2 bradykinin receptor (B2R) subtype to a B1R subtype that occurs during chronic insult. Here, we show that B1R spontaneously forms a proteolytic plasma membrane complex with B2R along with increased receptor signaling capacity. Co-expression of hemagglutinin-tagged B2R with FLAG-tagged B1R in HEK293 cells resulted in degradation of B2R as determined by the diminution of the intact 65-kDa B2R species and the appearance of proteolytic B2R products at 30-40 kDa and by the reduction in B2R bradykinin binding sites. On the other hand, the 35-kDa B1R remained intact. Receptor co-expression also led to an increase in constitutive and agonist-stimulated receptor signaling. Selective immunoprecipitation with epitope-specific antibodies revealed a spontaneously formed heterologous receptor complex, which was composed of the intact 35-kDa B1R and the B2R degradation products. Cellular fractionation, cell surface biotinylation, and immuno-electron microscopy showed that B2R.B1R complexes were present on the cell surface. This is the first evidence that a heterologous G protein-coupled receptor complex in the plasma membrane is linked to proteolytic degradation of a participating receptor, and this mechanism may contribute to the adaptation of the kinin response from a B2 type to a B1 type during chronic insult.	Lund Univ, Wallenberg Neurosci Ctr, Dept Physiol Sci, Div Mol Neurobiol,BMC, SE-22184 Lund, Sweden; Lund Univ, Dept Cell & Mol Biol, Div Mol Pathogenesis, SE-22184 Lund, Sweden; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Lund University; Lund University; University of Texas System; University of Texas Health San Antonio	Leeb-Lundberg, LMF (corresponding author), Lund Univ, Wallenberg Neurosci Ctr, Dept Physiol Sci, Div Mol Neurobiol,BMC, A12,Solvegatan 17, SE-22184 Lund, Sweden.	fredrik.leeb-lundberg@mphy.lu.se			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041659, R01GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bachvarov DR, 2001, J PHARMACOL EXP THER, V297, P19; Barki-Harrington L, 2003, BIOCHEM J, V371, P581, DOI 10.1042/BJ20021708; BASCHONG W, 1990, J ELECTRON MICR TECH, V14, P313, DOI 10.1002/jemt.1060140405; Blaukat A, 2003, AM J PHYSIOL-HEART C, V284, pH1909, DOI 10.1152/ajpheart.00034.2003; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Couture R, 2001, EUR J PHARMACOL, V429, P161, DOI 10.1016/S0014-2999(01)01318-8; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; Fathy DB, 1999, J BIOL CHEM, V274, P29603, DOI 10.1074/jbc.274.42.29603; Hecquet C, 2000, MOL PHARMACOL, V58, P828, DOI 10.1124/mol.58.4.828; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Lamb ME, 2002, BIOCHEMISTRY-US, V41, P14340, DOI 10.1021/bi020231d; Leeb-Lundberg LMF, 2001, J BIOL CHEM, V276, P8785, DOI 10.1074/jbc.M007396200; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; Ma QP, 2001, NEUROSCIENCE, V107, P665, DOI 10.1016/S0306-4522(01)00387-6; Marceau F, 1998, PHARMACOL REV, V50, P357; Mathis SA, 1996, MOL PHARMACOL, V50, P128; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; Ni AG, 2003, J BIOL CHEM, V278, P219, DOI 10.1074/jbc.M209490200; Pesquero JB, 2000, P NATL ACAD SCI USA, V97, P8140, DOI 10.1073/pnas.120035997; Phagoo SB, 1999, MOL PHARMACOL, V56, P325, DOI 10.1124/mol.56.2.325; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; TROPEA MM, 1993, J PHARMACOL EXP THER, V264, P930; von Zastrow M, 2001, PARKINSONISM RELAT D, V7, P265, DOI 10.1016/S1353-8020(00)00069-9; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wohlfart P, 1997, J PHARMACOL EXP THER, V280, P1109	31	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22102	22107		10.1074/jbc.M402572200	http://dx.doi.org/10.1074/jbc.M402572200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15033977	hybrid			2022-12-25	WOS:000221417100052
J	Khan, KMF; Howe, LR; Falcone, DJ				Khan, KMF; Howe, LR; Falcone, DJ			Extracellular matrix-induced cyclooxygenase-2 regulates macrophage proteinase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; ARTERIAL NEOINTIMA FORMATION; MEDIATED CELL-ADHESION; PLASMINOGEN-ACTIVATOR; PROSTAGLANDIN E(2); METALLOPROTEINASE PRODUCTION; TYROSINE PHOSPHORYLATION; TISSUE INHIBITOR; SIGNALING ROLE; MESSENGER-RNA	Chronic inflammatory diseases are characterized by the persistent presence of macrophages and other mononuclear cells, tissue destruction, cell proliferation, and the deposition of extracellular matrix (ECM). The tissue degradation is mediated, in part, by enhanced proteinase expression by macrophages. It has been demonstrated recently that macrophage proteinase expression can be stimulated or inhibited by purified ECM components. However, in an intact ECM the biologically active domains of matrix components may be masked either by tertiary conformation or by complex association with other matrix molecules. In an effort to determine whether a complex ECM produced by vascular smooth muscle cells (SMC) regulates macrophage degradative phenotype, we prepared insoluble SMC matrices and examined their ability to regulate proteinase expression by RAW264.7 and thioglycollate-elicited peritoneal macrophages. Here we demonstrate that macrophage engagement of SMC-ECM triggers PKC-dependent activation of MAPK(erk1/2) leading to increased expression of cyclooxygenase (COX)-2 and prostaglandin (PG) E-2 synthesis. The addition of PGE(2) to macrophage cultures stimulates their expression of both urokinase-type plasminogen activator and MMP-9, and the selective COX-2 inhibitor NS-398 blocks ECM-induced proteinase expression. Moreover, ECM-induced PGE2 and MMP-9 expression by elicited COX-2(-/-) macrophages is markedly reduced when compared with the response of either COX-2(+/-) or COX-2(+/+) macrophages. These data clearly demonstrate that SMC-ECM exerts a regulatory role on the degradative phenotype of macrophages via enhanced urokinase-type plasminogen activator and MMP-9 expression, and identify COX-2 as a targetable component of the signaling pathway leading to increased proteinase expression.	Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Vasc Biol Ctr, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA; Strang Canc Res Lab, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Falcone, DJ (corresponding author), Cornell Univ, Weill Med Coll, Dept Pathol, Rm A678,1300 York Ave, New York, NY 10021 USA.	dfalcone@med.cornell.edu		Howe, Louise/0000-0002-1468-7136	NATIONAL CANCER INSTITUTE [R01CA089578] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040819, R01HL073375] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA89578] Funding Source: Medline; NHLBI NIH HHS [R01 HL073375, R01-HL73375, R01-HL40819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aplin AE, 1998, PHARMACOL REV, V50, P197; Baker CSR, 1999, ARTERIOSCL THROM VAS, V19, P646, DOI 10.1161/01.ATV.19.3.646; Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; Carmeliet P, 1997, CIRC RES, V81, P829; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cho A, 2002, CIRC RES, V91, P845, DOI 10.1161/01.RES.0000040420.17366.2E; Cipollone F, 2003, CIRCULATION, V107, P1479, DOI 10.1161/01.CIR.0000056530.03783.81; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; CORCORAN ML, 1994, ARCH BIOCHEM BIOPHYS, V310, P481, DOI 10.1006/abbi.1994.1196; CORCORAN ML, 1995, J BIOL CHEM, V270, P10365, DOI 10.1074/jbc.270.18.10365; COTRAN R, 1999, DIS IMMUNITY ROBBINS, P189; D'Haese A, 2000, J INTERF CYTOK RES, V20, P667, DOI 10.1089/107999000414853; de Fougerolles AR, 2000, IMMUNITY, V13, P749, DOI 10.1016/S1074-7613(00)00073-X; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; EDELSON PJ, 1976, IN VITRO METHODS CEL, P333; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; Falcone DJ, 2001, BLOOD, V97, P777, DOI 10.1182/blood.V97.3.777; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; HENKIN J, 1991, PROG CARDIOVASC DIS, V34, P135, DOI 10.1016/0033-0620(91)90010-J; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Horton MR, 2000, AM J PHYSIOL-LUNG C, V279, pL707, DOI 10.1152/ajplung.2000.279.4.L707; Horton MR, 1999, J IMMUNOL, V162, P4171; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; Khan KMF, 2000, J BIOL CHEM, V275, P4492, DOI 10.1074/jbc.275.6.4492; Khan KMF, 2002, J BIOL CHEM, V277, P13778, DOI 10.1074/jbc.M111290200; Kitching AR, 1997, J EXP MED, V185, P963, DOI 10.1084/jem.185.5.963; Kost C, 1996, EUR J BIOCHEM, V236, P682, DOI 10.1111/j.1432-1033.1996.0682d.x; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; LASSILA R, 1993, EUR HEART J, V14, P94; Lepidi S, 2001, J VASC SURG, V34, P1111, DOI 10.1067/mva.2001.119401; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Mackrell PJ, 2001, SURGERY, V130, P826, DOI 10.1067/msy.2001.116669; Mizumura K, 2003, CLIN EXP ALLERGY, V33, P1244, DOI 10.1046/j.1365-2222.2003.01750.x; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MOSER TL, 1993, J BIOL CHEM, V268, P18917; NAGASE H, 1997, TXB RHEUMATOLOGY, P323; Ottino P, 2001, CURR EYE RES, V23, P77, DOI 10.1076/ceyr.23.2.77.5471; PENTLAND AP, 1995, J INVEST DERMATOL, V104, P52, DOI 10.1111/1523-1747.ep12613488; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; Pratt PF, 2003, J BIOL CHEM, V278, P51928, DOI 10.1074/jbc.M309256200; Pyo R, 2000, J CLIN INVEST, V105, P1641, DOI 10.1172/JCI8931; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Ratzinger G, 2002, J IMMUNOL, V168, P4361, DOI 10.4049/jimmunol.168.9.4361; RICHARDSON M, 1988, CLIN INVEST MED, V11, P139; SCHAFER BM, 1994, AM J PATHOL, V144, P1269; Shankavaram UT, 1997, J CELL PHYSIOL, V173, P327, DOI 10.1002/(SICI)1097-4652(199712)173:3<327::AID-JCP4>3.3.CO;2-R; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; Stemme V, 2000, EUR J VASC ENDOVASC, V20, P146, DOI 10.1053/ejvs.2000.1145; Subbaramaiah K, 2003, J BIOL CHEM, V278, P37637, DOI 10.1074/jbc.M301481200; UNKELESS JC, 1974, J EXP MED, V139, P834, DOI 10.1084/jem.139.4.834; WAHL LM, 1993, J PERIODONTOL, V64, P467; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WERB Z, 1980, J EXP MED, V152, P1537, DOI 10.1084/jem.152.6.1537; Wesley RB, 1998, ARTERIOSCL THROM VAS, V18, P432, DOI 10.1161/01.ATV.18.3.432; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576	71	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22039	22046		10.1074/jbc.M312735200	http://dx.doi.org/10.1074/jbc.M312735200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15024003	hybrid			2022-12-25	WOS:000221417100045
J	Suzuki, M; Mizuno, A				Suzuki, M; Mizuno, A			A novel human Cl- channel family related to Drosophila flightless locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONDUCTANCE CHLORIDE CHANNELS; SMOOTH-MUSCLE; CURRENTS; SELECTIVITY; ACTIVATION; MYOCYTES; CELLS; GENE	Large conductance chloride (maxi-Cl-) currents have been recorded in some cells, but there is still little information on the molecular nature of the channel underlying this conductance. We report here that tweety, a gene located in Drosophila flightless, has a structure similar to those of known channels and that human homologues of tweety (hTTYH1-3) are novel maxi-Cl- channels. hTTYH3 mRNA was found to be distributed in excitable tissues. The whole cell current of hTTYH3 was large enough to be discriminated from the control but emerged only after treatment with ionomycin. Analysis of pore mutants suggested that positively charged amino acids contributed to anion selectivity. Like a maxi-Cl- channel in situ, the hTTYH3 single channel showed 26-picosiemen linear current voltage, complex kinetics, 4,4'-diisothiocyanato-stilbene-2,2'-disulfonic acid sensitivity, subconductance, and the permeability order of I- > Br- > Cl-. Similarly, hTTYH2 encoded an ionomycin-induced maxi-Cl- channel, but TTYH1 encoded a Ca2+-independent and swelling-activated maxi-Cl- channel. Therefore, the hTTYH family encoded maxi-Cl- channels of mammals. Further studies on the hTTYH family should lead to the elucidation of physiological and pathophysiological roles of novel Cl- channel molecules.	Jichi Med Sch, Dept Pharmacol, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University	Suzuki, M (corresponding author), Jichi Med Sch, Dept Pharmacol, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	macsuz@jichi.ac.jp						Bell PD, 2003, P NATL ACAD SCI USA, V100, P4322, DOI 10.1073/pnas.0736323100; Campbell HD, 2000, GENOMICS, V68, P89, DOI 10.1006/geno.2000.6259; COULOMBE A, 1992, PFLUG ARCH EUR J PHY, V422, P143, DOI 10.1007/BF00370413; Diaz M, 2001, J PHYSIOL-LONDON, V536, P79, DOI 10.1111/j.1469-7793.2001.00079.x; DIXON DM, 1993, J MEMBRANE BIOL, V131, P143, DOI 10.1007/BF02791323; FAHMI M, 1995, AM J PHYSIOL-ENDOC M, V269, pE969, DOI 10.1152/ajpendo.1995.269.5.E969; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; GROSCHNER K, 1992, PFLUG ARCH EUR J PHY, V421, P209, DOI 10.1007/BF00374829; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Hille B., 1992, IONIC CHANNELS EXCIT, P337, DOI 10.1016/0014-5793(92)81020-M; HURNAK O, 1993, GEN PHYSIOL BIOPHYS, V12, P171; HUSSY N, 1992, J NEUROPHYSIOL, V68, P2042, DOI 10.1152/jn.1992.68.6.2042; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; KEMP PJ, 1993, AM J PHYSIOL, V265, pL323, DOI 10.1152/ajplung.1993.265.4.L323; KOKUBUN S, 1991, PFLUG ARCH EUR J PHY, V418, P204, DOI 10.1007/BF00370515; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; PACAUD P, 1992, PFLUG ARCH EUR J PHY, V421, P125, DOI 10.1007/BF00374818; PAHAPILL PA, 1992, J MEMBRANE BIOL, V125, P171; Piskorowski R, 2002, NATURE, V420, P499, DOI 10.1038/nature01199; Sabirov RZ, 2001, J GEN PHYSIOL, V118, P251, DOI 10.1085/jgp.118.3.251; Schreiber M, 1999, NAT NEUROSCI, V2, P416, DOI 10.1038/8077; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; SUN XP, 1993, AM J PHYSIOL, V264, pG774, DOI 10.1152/ajpgi.1993.264.4.G774; SUN XP, 1992, J PHYSIOL-LONDON, V448, P355, DOI 10.1113/jphysiol.1992.sp019046; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; SUZUKI M, 1991, J CLIN INVEST, V88, P735, DOI 10.1172/JCI115370; THORN P, 1987, Q J EXP PHYSIOL CMS, V72, P31, DOI 10.1113/expphysiol.1987.sp003053; WRIGHT EM, 1977, PHYSIOL REV, V57, P109, DOI 10.1152/physrev.1977.57.1.109; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	34	111	119	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22461	22468		10.1074/jbc.M313813200	http://dx.doi.org/10.1074/jbc.M313813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15010458	hybrid			2022-12-25	WOS:000221417100095
J	Tong, QS; Gamper, N; Medina, JL; Shapiro, MS; Stockand, JD				Tong, QS; Gamper, N; Medina, JL; Shapiro, MS; Stockand, JD			Direct activation of the epithelial Na+ channel by phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-bisphosphate produced by phosphoinositide 3-OH kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; POTASSIUM CHANNELS; K+ CHANNELS; GAMMA-SUBUNIT; TRANSPORT; CELLS; 3-KINASE; INSULIN; ENAC; PROTEIN	The phospholipid phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) is accepted to be a direct modulator of ion channel activity. The products of phosphoinositide 3-OH kinase (PI3K), PtdIns( 3,4) P-2 and phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3), in contrast, are not. We report here activation of the epithelial Na+ channel (ENaC) reconstituted in Chinese hamster ovary cells by PI3K. Insulin-like growth factor-I also activated reconstituted ENaC and increased Na+ reabsorption across renal A6 epithelial cell monolayers via PI3K. Neither IGF-I nor PI3K affected the levels of ENaC in the plasma membrane. The effects of PI3K and IGF-I on ENaC activity paralleled changes in the plasma membrane levels of the PI3K product phospholipids, PtdIns(3,4)P-2/PtdIns(3,4,5)P-3, as measured by evanescent field fluorescence microscopy. Both PtdIns(3,4)P-2 and PtdIns(3,4,5)P-3 activated ENaC in excised patches. Activation of ENaC by PI3K and its phospholipid products corresponded to changes in channel open probability. We conclude that PI3K directly modulates ENaC activity via PtdIns(3,4)P-2 and PtdIns(3,4,5)P-3. This represents a novel transduction pathway whereby growth factors, such as IGF-I, rapidly modulate target proteins independent of signaling elicited by kinases downstream of PI3K.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Stockand, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol 7756, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	stockand@uthscsa.edu		Gamper, Nikita/0000-0001-5806-0207; Stockand, James/0000-0002-3817-4319	NIDDK NIH HHS [R01-DK59594] Funding Source: Medline; NINDS NIH HHS [R01-NS43394] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043394] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; Blazer-Yost BL, 2003, AM J PHYSIOL-CELL PH, V284, pC1645, DOI 10.1152/ajpcell.00372.2002; BlazerYost BL, 1996, PFLUG ARCH EUR J PHY, V432, P685, DOI 10.1007/s004240050186; Booth RE, 2003, J BIOL CHEM, V278, P41367, DOI 10.1074/jbc.M305400200; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; FRUMAN D, 1998, ANNU REV BIOCHEM, V67, P507; Gamper N, 2002, PFLUG ARCH EUR J PHY, V443, P625, DOI 10.1007/s00424-001-0741-5; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Geller DS, 1998, NAT GENET, V19, P279, DOI 10.1038/966; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HILGEMANN DW, 2001, SCI STKE; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Ishii M, 2002, P NATL ACAD SCI USA, V99, P4325, DOI 10.1073/pnas.072073399; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Lhuillier L, 2002, J NEUROPHYSIOL, V88, P954, DOI 10.1152/jn.2002.88.2.954; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Loussouarn G, 2003, EMBO J, V22, P5412, DOI 10.1093/emboj/cdg526; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; MacGregor GG, 2002, P NATL ACAD SCI USA, V99, P2726, DOI 10.1073/pnas.042688899; Macrez N, 2001, CIRC RES, V89, P692, DOI 10.1161/hh2001.097864; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Ozaki S, 2000, P NATL ACAD SCI USA, V97, P11286, DOI 10.1073/pnas.210197897; Paunescu TG, 2000, AM J PHYSIOL-CELL PH, V279, pC236, DOI 10.1152/ajpcell.2000.279.1.C236; Record RD, 1998, AM J PHYSIOL-ENDOC M, V274, pE611, DOI 10.1152/ajpendo.1998.274.4.E611; Rohacs T, 2003, P NATL ACAD SCI USA, V100, P745, DOI 10.1073/pnas.0236364100; Rohatgi R, 2003, J AM SOC NEPHROL, V14, P827, DOI 10.1097/01.ASN.0000056481.66379.B2; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Stockand JD, 2002, AM J PHYSIOL-RENAL, V282, pF559, DOI 10.1152/ajprenal.00320.2001; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; TONG Q, 2004, IN PRESS AM J PHYSL; VERREY F, 1995, J MEMBRANE BIOL, V144, P93; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang J, 2001, AM J PHYSIOL-RENAL, V280, pF303, DOI 10.1152/ajprenal.2001.280.2.F303; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200; Zhainazarov AB, 2001, J NEUROPHYSIOL, V85, P2537, DOI 10.1152/jn.2001.85.6.2537; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	47	81	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22654	22663		10.1074/jbc.M401004200	http://dx.doi.org/10.1074/jbc.M401004200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15028718	hybrid			2022-12-25	WOS:000221417100117
J	Kho, PS; Wang, Z; Zhuang, L; Li, YQ; Chew, JL; Ng, HH; Liu, ET; Yu, Q				Kho, PS; Wang, Z; Zhuang, L; Li, YQ; Chew, JL; Ng, HH; Liu, ET; Yu, Q			p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CELL-CYCLE PROGRESSION; HUMAN CANCER-CELLS; TARGET GENES; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; CDNA MICROARRAY; GROWTH-FACTOR; CHROMATIN IMMUNOPRECIPITATION; CHECKPOINT KINASES	By using a genome-wide approach, we sought the identification of p53-regulated genes involved in cellular apoptosis. To this end, we assessed the transcriptional response of HCT116 colorectal cancer cells during apoptosis induced by the anticancer drug 5-fluorouracil as the function of p53 status, and we identified 230 potential targets that are regulated by p53. Previously identified p53 targets known to be involved in growth arrest and apoptosis were observed to be induced, thus validating the approach. Strikingly, we found that p53 regulates gene expression primarily through transcriptional repression (n = 189) rather than activation (n = 41), and selective blockade of p53-dependent gene repression resulted in the reduction in 5-fluorouracil-induced apoptosis. Reporter and chromatin immunoprecipitation assays demonstrated that p53 can suppress the promoter activities of three further studied candidate genes PLK, PTTG1, and CHEK1 but would only bind directly to PTTG1 and CHEK1 promoters, revealing that p53 can repress gene expression through both direct and indirect mechanisms. Moreover, RNA(i)-mediated knockdown of PLK and PTTG1 expression was sufficient to induce apoptosis, suggesting that repression of novel anti-apoptotic genes by p53 might contribute to a significant portion of the p53-dependent apoptosis. Our data support the divergent functions of p53 in regulating gene expression that play both synergistic and pleiotropic roles in p53-associated apoptosis.	Genome Inst Singapore, Mol Pharmacol Lab, Singapore 138672, Singapore; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore	Yu, Q (corresponding author), Genome Inst Singapore, Mol Pharmacol Lab, Genome Bldg 02-01,60 Biopolis St, Singapore 138672, Singapore.	yuq@gis.a-star.edu.sg	Liu, Edison/C-4141-2008; Ng, Huck Hui/A-1135-2009	Yu, Qiang/0000-0003-2132-8278				Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Anselmo AN, 2002, J BIOL CHEM, V277, P5940, DOI 10.1074/jbc.M110498200; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Guo QM, 2000, CANCER RES, V60, P5922; HALDAR S, 1994, CANCER RES, V54, P2095; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jiang DH, 1998, J CELL PHYSIOL, V175, P174, DOI 10.1002/(SICI)1097-4652(199805)175:2<174::AID-JCP7>3.3.CO;2-E; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Maxwell PJ, 2003, CANCER RES, V63, P4602; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129; Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Sawhney RS, 2003, J BIOL CHEM, V278, P19861, DOI 10.1074/jbc.M213162200; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Therrien M, 1999, P NATL ACAD SCI USA, V96, P13259, DOI 10.1073/pnas.96.23.13259; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yu Q, 2002, CANCER RES, V62, P5743; Yu Q, 2002, J BIOL CHEM, V277, P13059, DOI 10.1074/jbc.M111403200; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhao R, 2000, COLD SPRING HARB SYM, V65, P475, DOI 10.1101/sqb.2000.65.475; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200	56	128	132	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21183	21192		10.1074/jbc.M311912200	http://dx.doi.org/10.1074/jbc.M311912200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016801	hybrid			2022-12-25	WOS:000221273800077
J	Majka, J; Chung, BY; Burgers, PMJ				Majka, J; Chung, BY; Burgers, PMJ			Requirement for ATP by the DNA damage checkpoint clamp loader	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; GENOME STABILITY; YEAST; COMPLEX; FORMS; RAD24; IDENTIFICATION; PURIFICATION	The DNA damage clamp loader replication factor C (RFC-Rad24) consists of the Rad24 protein and the four small Rfc2-5 subunits of RFC. This complex loads the heterotrimeric DNA damage clamp consisting of Rad17, Mec3, and Ddc1 (Rad17/3/1) onto partial duplex DNA in an ATP-dependent manner. Interactions between the clamp loader and the clamp have been proposed to mirror those of the replication clamp loader RFC and the sliding clamp proliferating cell nuclear antigen ( PCNA). In that system, three ATP molecules bound to the Rfc2, Rfc3, and Rfc4 subunits are necessary and sufficient for efficient loading of PCNA, whereas ATP binding to Rfc1 is not required. In contrast, in this study, we show that mutant RFC-Rad24 with a rad24-K115E mutation in the ATP-binding domain of Rad24 shows defects in the ATPase of the complex and is defective for interaction with Rad17/3/1 and for loading of the checkpoint clamp. A similar defect was measured with a mutant RFC-Rad24 clamp loader carrying a rfc4K55R ATP-binding mutation, whereas the rfc4K55E clamp loader showed partial loading activity, in agreement with genetic studies of these mutants. These studies show that ATP utilization by the checkpoint clamp/clamp loader system is effectively different from that by the structurally analogous replication system.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	burgers@biochem.wustl.edu	Burgers, Peter M/AAW-6621-2021; Chung, Brian/F-8583-2010	Chung, Brian/0000-0002-6423-5226	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32431, R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bellaoui M, 2003, EMBO J, V22, P4304, DOI 10.1093/emboj/cdg406; Ben-Aroya S, 2003, P NATL ACAD SCI USA, V100, P9906, DOI 10.1073/pnas.1633757100; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Gomes XV, 2001, J BIOL CHEM, V276, P34776, DOI 10.1074/jbc.M011743200; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Huberman JA, 1999, PROG NUCLEIC ACID RE, V62, P369; Kanellis P, 2003, CURR BIOL, V13, P1583, DOI 10.1016/S0960-9822(03)00578-5; Kenna MA, 2003, MOL CELL BIOL, V23, P2999, DOI 10.1128/MCB.23.8.2999-3007.2003; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Naiki T, 2001, MOL CELL BIOL, V21, P5838, DOI 10.1128/MCB.21.17.5838-5845.2001; Naiki T, 2000, MOL CELL BIOL, V20, P5888, DOI 10.1128/MCB.20.16.5888-5896.2000; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; Schmidt SLG, 2001, J BIOL CHEM, V276, P34792, DOI 10.1074/jbc.M011671200; Schmidt SLG, 2001, J BIOL CHEM, V276, P34784, DOI 10.1074/jbc.M011633200; SCHUDDEMAT J, 1988, BIOCHIM BIOPHYS ACTA, V937, P81, DOI 10.1016/0005-2736(88)90229-5; Shiomi Y, 2002, GENES CELLS, V7, P861, DOI 10.1046/j.1365-2443.2002.00566.x; Smith CV, 1998, BIOCHEMISTRY-US, V37, P9658, DOI 10.1021/bi9801309; Venclovas C, 2002, PROTEIN SCI, V11, P2403, DOI 10.1110/ps.0214302; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yang HM, 1996, BBA-MOL CELL RES, V1310, P303, DOI 10.1016/0167-4889(95)00179-4; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100	28	29	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20921	20926		10.1074/jbc.M400898200	http://dx.doi.org/10.1074/jbc.M400898200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15014082	hybrid			2022-12-25	WOS:000221273800045
J	Peng, JM; Kim, MJ; Cheng, DM; Duong, DM; Gygi, SP; Sheng, M				Peng, JM; Kim, MJ; Cheng, DM; Duong, DM; Gygi, SP; Sheng, M			Semiquantitative proteomic analysis of rat Forebrain postsynaptic density fractions by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR SUBUNITS; DOMAIN-CONTAINING PROTEIN; LONG-TERM POTENTIATION; ABSOLUTE QUANTIFICATION; GLUTAMATE RECEPTORS; ANCHORING PROTEIN; DENDRITIC SPINES; SYNAPTIC PROTEIN; AMPA RECEPTORS; YEAST PROTEOME	The postsynaptic density (PSD) of central excitatory synapses plays a key role in postsynaptic signal transduction and contains a high concentration of glutamate receptors and associated scaffold and signaling proteins. We report here a comprehensive analysis of purified PSD fractions by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). We identified 374 different proteins that copurified with the PSD structure and discovered thirteen phosphorylated sites from eight proteins. These proteins were classified into numerous functional groups, implying that the signaling pathways in the PSD are complex and diverse. Furthermore, using quantitative mass spectrometry, we measured the molar concentration and relative stoichiometries of a number of glutamate receptor subunits and scaffold proteins in the postsynaptic density. Thus this proteomic study reveals crucial information about molecular abundance as well as molecular diversity in the PSD, and provides a basis for further studies on the molecular mechanisms of synaptic function and plasticity.	Emory Univ, Dept Human Genet, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Taplin Biol Mass Spectrometry Facil, Boston, MA 02115 USA; MIT, Picower Ctr Learning & Memory, RIKEN MIT Neurosci Res Ctr, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Emory University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); RIKEN	Peng, JM (corresponding author), Emory Univ, Dept Human Genet, Ctr Neurodegenerat Dis, 615 Michael St,505D, Atlanta, GA 30322 USA.	jpeng@genetics.emory.edu; msheng@mit.edu	Peng, Junmin/N-2614-2018	Peng, Junmin/0000-0003-0472-7648; Duong, Duc/0000-0001-5880-1888				ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Apperson ML, 1996, J NEUROSCI, V16, P6839; Barnidge DR, 2003, ANAL CHEM, V75, P445, DOI 10.1021/ac026154+; Barry MF, 2002, CURR OPIN NEUROBIOL, V12, P279, DOI 10.1016/S0959-4388(02)00329-X; BEHE P, 1995, P ROY SOC B-BIOL SCI, V262, P205, DOI 10.1098/rspb.1995.0197; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Furusawa T, 2000, BIOCHEM BIOPH RES CO, V270, P67, DOI 10.1006/bbrc.2000.2377; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Gomez LL, 2002, J NEUROSCI, V22, P7027; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Gygi SP, 2000, CURR OPIN CHEM BIOL, V4, P489, DOI 10.1016/S1367-5931(00)00121-6; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; HARRINGTON MG, 1990, METHOD ENZYMOL, V182, P488; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Husi H, 2001, TRENDS NEUROSCI, V24, P259, DOI 10.1016/S0166-2236(00)01792-6; Inoue A, 2003, CURR OPIN NEUROBIOL, V13, P332, DOI 10.1016/S0959-4388(03)00077-1; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech S, 1997, J NEUROSCI, V17, P9565; Kaufmann N, 2002, NEURON, V34, P27, DOI 10.1016/S0896-6273(02)00643-8; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kim S, 2003, J BIOL CHEM, V278, P6291, DOI 10.1074/jbc.M212287200; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Ko J, 2003, J NEUROSCI, V23, P1667; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Li KW, 2004, J BIOL CHEM, V279, P987, DOI 10.1074/jbc.M303116200; Lin JW, 1998, J NEUROSCI, V18, P2017; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lujan R, 1996, EUR J NEUROSCI, V8, P1488, DOI 10.1111/j.1460-9568.1996.tb01611.x; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Mann M, 2003, NAT BIOTECHNOL, V21, P255, DOI 10.1038/nbt0303-255; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Moffat J, 2003, DEV CELL, V5, P528, DOI 10.1016/S1534-5807(03)00301-0; Moore RE, 2002, J AM SOC MASS SPECTR, V13, P378, DOI 10.1016/S1044-0305(02)00352-5; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Penzes P, 2001, J NEUROSCI, V21, P8426, DOI 10.1523/JNEUROSCI.21-21-08426.2001; Phillips GR, 2001, NEURON, V32, P63, DOI 10.1016/S0896-6273(01)00450-0; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Rong R, 2003, NAT NEUROSCI, V6, P1153, DOI 10.1038/nn1134; Sabatini BL, 2000, NATURE, V408, P589, DOI 10.1038/35046076; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Satoh K, 2002, GENES CELLS, V7, P187, DOI 10.1046/j.1356-9597.2001.00505.x; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Steward O, 2003, NEURON, V40, P347, DOI 10.1016/S0896-6273(03)00635-4; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; TAL M, 1985, J BIOL CHEM, V260, P9976; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Valtschanoff JG, 2001, J NEUROSCI, V21, P1211; Walikonis RS, 2000, J NEUROSCI, V20, P4069; WALSH MJ, 1992, J NEUROCHEM, V59, P667, DOI 10.1111/j.1471-4159.1992.tb09421.x; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Wu K, 1997, P NATL ACAD SCI USA, V94, P13273, DOI 10.1073/pnas.94.24.13273; Wyszynski M, 1998, NEUROPHARMACOLOGY, V37, P1335, DOI 10.1016/S0028-3908(98)00120-8; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Yamauchi T, 2002, MASS SPECTROM REV, V21, P266, DOI 10.1002/mas.10033; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886; Zhou HL, 2002, NAT BIOTECHNOL, V20, P512, DOI 10.1038/nbt0502-512; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	89	357	372	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21003	21011		10.1074/jbc.M400103200	http://dx.doi.org/10.1074/jbc.M400103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15020595	hybrid			2022-12-25	WOS:000221273800056
J	Ohashi, S; Abe, H; Takahashi, T; Yamamoto, Y; Takeuchi, M; Arai, H; Nagata, K; Kita, T; Okamoto, H; Yamamoto, H; Doi, T				Ohashi, S; Abe, H; Takahashi, T; Yamamoto, Y; Takeuchi, M; Arai, H; Nagata, K; Kita, T; Okamoto, H; Yamamoto, H; Doi, T			Advanced glycation end products increase collagen-specific chaperone protein in mouse diabetic nephropathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MOLECULAR CHAPERONE; MESANGIAL CELLS; TRANSCRIPTIONAL ACTIVATION; ADVANCED GLYCOSYLATION; GLOMERULAR-LESIONS; TRANSGENIC MICE; HSP47; EXPRESSION; RECEPTOR	Advanced glycation end products (AGEs) appear to contribute to the diabetic complications. This study reports the inhibitory effect of OPB-9195 (OPB), an inhibitor of AGEs formation, and the role of a collagen-specific molecular chaperone, a 47-kDa heat shock protein (HSP47) in diabetic nephropathy. Transgenic mice carrying nitric-oxide synthase cDNA fused with insulin promoter (iNOSTg) leads to diabetes mellitus. The iNOSTg mice at 6 months of age represented diffuse glomerulosclerosis, and the expression of HSP47 was markedly increased in the mesangial area in parallel with increased expression of types I and IV collagens. OPB treatment ameliorated glomerulosclerosis in the iNOSTg mice associated with the decreased expression of HSP47 and types I and IV collagens. The expression of transforming growth factor-beta (TGF-beta) was increased in glomeruli of iNOSTg mice and decreased after treatment with OPB. To confirm these mechanisms, cultured mesangial cells were stimulated with AGEs. AGEs significantly increased the expression of HSP47, type IV collagen, and TGF-beta mRNA. Neutralizing antibody for TGF-beta inhibited the overexpression of both HSP47 and type IV collagen in vitro. In conclusion, AGEs increase the expression of HSP47 in association with collagens, both in vivo and in vitro. The processes may be mediated by TGF-beta.	Univ Tokushima, Sch Med, Dept Clin Biol & Med, Course Biol Med, Tokushima 7708503, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Biochem & Mol Vasc Biol, Kanazawa, Ishikawa 9208640, Japan; Hokuriku Univ, Fac Pharmaceut Sci, Dept Biochem, Kanazawa, Ishikawa 9201181, Japan; Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Kyoto 6068575, Japan; Kyoto Univ, Dept Cardiovasc Med, Kyoto 6068575, Japan; Tohoku Univ, Grad Sch Med, Dept Biochem, Sendai, Miyagi 9808575, Japan	Tokushima University; Kanazawa University; Hokuriku University; Kyoto University; Kyoto University; Tohoku University	Doi, T (corresponding author), Univ Tokushima, Sch Med, Dept Clin Biol & Med, Course Biol Med, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	doi@clin.med.tokushima-u.ac.jp	Arai, Hidenori/P-9816-2017	Arai, Hidenori/0000-0002-9000-6849				Abe H, 2004, J BIOL CHEM, V279, P14201, DOI 10.1074/jbc.M310427200; Abe H, 1999, J BIOL CHEM, V274, P20874, DOI 10.1074/jbc.274.30.20874; BOJESTIG M, 1994, NEW ENGL J MED, V330, P15, DOI 10.1056/NEJM199401063300103; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; DOI T, 1990, LAB INVEST, V63, P204; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; DOI T, 1990, AM J PATHOL, V137, P541; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Hirata H, 1999, J BIOL CHEM, V274, P35703, DOI 10.1074/jbc.274.50.35703; Iehara N, 1996, KIDNEY INT, V50, P1166, DOI 10.1038/ki.1996.424; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; Makibayashi K, 2001, AM J PATHOL, V158, P1733, DOI 10.1016/S0002-9440(10)64129-6; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; NAGATA K, 1988, BIOCHEM BIOPH RES CO, V153, P428, DOI 10.1016/S0006-291X(88)81242-7; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; Razzaque MS, 1998, NEPHRON, V80, P434, DOI 10.1159/000045217; Schutze K, 1998, NAT BIOTECHNOL, V16, P737, DOI 10.1038/nbt0898-737; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; Sunamoto M, 1998, INT J EXP PATHOL, V79, P133, DOI 10.1046/j.1365-2613.1998.00061.x; Sunamoto M, 1998, LAB INVEST, V78, P967; Takamura T, 1998, J BIOL CHEM, V273, P2493, DOI 10.1074/jbc.273.5.2493; Takeuchi M, 1999, MOL MED, V5, P393, DOI 10.1007/BF03402128; Tsuji H, 1998, BIOCHEM BIOPH RES CO, V245, P583, DOI 10.1006/bbrc.1998.8489; VELASQUEZ MT, 1990, FASEB J, V4, P2850, DOI 10.1096/fasebj.4.11.2199283; VLASSARA H, 1994, LAB INVEST, V70, P138; Weigert C, 2003, BIOCHEM BIOPH RES CO, V304, P301, DOI 10.1016/S0006-291X(03)00599-0; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; Yamamura I, 1998, BIOCHEM BIOPH RES CO, V244, P68, DOI 10.1006/bbrc.1998.8216; Yasuda K, 2002, J BIOL CHEM, V277, P44613, DOI 10.1074/jbc.M208558200	30	44	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19816	19823		10.1074/jbc.M310428200	http://dx.doi.org/10.1074/jbc.M310428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004023	hybrid			2022-12-25	WOS:000221164500053
J	Zhang, ZQ; Wang, Y; Yao, RS; Li, J; Yan, Y; La Regina, M; Lemon, WL; Grubbs, CL; Lubet, RA; You, M				Zhang, ZQ; Wang, Y; Yao, RS; Li, J; Yan, Y; La Regina, M; Lemon, WL; Grubbs, CL; Lubet, RA; You, M			Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models	ONCOGENE			English	Article						antitumor B; lung cancer; chemoprevention; A/J mice; transgenic mice; p53; Ink4a/Arf	BREAST-CANCER CELLS; FEMALE A/J MICE; BETA-SITOSTEROL; ALPHA-SUBUNITS; G13 PROTEINS; GREEN TEA; TUMORIGENESIS; CARCINOGENESIS; PHYTOSTEROLS; INHIBITION	Antitumor B (ATB), also known as Zeng Sheng Ping, is a Chinese herbal mixture composed of six plants. Previously, clinical studies have shown a significant chemopreventive efficacy of ATB against human esophageal and lung cancers. In the present study, A/J mice harboring a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf and treated with benzo[a] pyrene were used to investigate the chemopreventive effects of ATB on chemically induced lung tumorigenesis. Mice with various genotypes treated with ATB displayed a significant reduction in lung tumor multiplicity and tumor load. Treatment with ATB resulted in an approximately 40% decrease in tumor multiplicity and a 70% decrease in tumor load in both wild-type mice and in mice with a loss of the Ink4a/Arf tumor suppressor genes. Interestingly, ATB decreased tumor multiplicity and volume by 50 and 90%, respectively, in mice with a dominant-negative p53 and in mice with both a p53 mutation and deletion of Ink4a/Arf. Kras2 mutation analysis of the lung tumors revealed that tumors harbored mutations in the 12th codon of Kras2. There were no differences in either the incidence or types of mutations between tumors treated with or without ATB. Oligonucleotide array analysis revealed 284 genes that were differentially expressed in mouse lung tumors as compared to the normal lung, and it was found that 114 out of these 284 genes changed their expression toward the normal levels in tumors treated with ATB. Most of the genes modulated by ATB belong to several cellular signaling pathways, including Notch (Notch homolog 2, manic fringe homolog), growth factor (FGF intracellular-binding protein, PDGFalpha), G protein-Ras-MAPK (MAPK3, MAP3K4, rab3A, Rap1, RSG5, PKCh), ubiquitin- proteasome (CDC34, Cullin1, 26S proteasome), and apoptosis (BAD promoter, caspase 3). These results suggest that ATB is an effective chemopreventive against mouse lung tumorigenesis. Furthermore, ATB exhibited an enhanced inhibitory effect in animals harboring genetic alterations (Kras2, p53, and Ink4a/Arf), which are often seen in human lung adenocarcinomas.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Comparat Med, St Louis, MO 63110 USA; Univ Alabama, Chemoprevent Ctr, Dept Surg, Birmingham, AL 35295 USA; NCI, Chemoprevent Branch, Bethesda, MD 20892 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL); University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu						Awad AB, 2001, NUTR CANCER, V40, P157, DOI 10.1207/S15327914NC402_12; Awad AB, 2000, J NUTR, V130, P2127, DOI 10.1093/jn/130.9.2127; Awad AB, 2000, ANTICANCER RES, V20, P821; Awad AB, 2000, NUTR CANCER, V36, P74, DOI 10.1207/S15327914NC3601_11; Awad AB, 2000, INT J MOL MED, V5, P541; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Castonguay A, 1998, EXP LUNG RES, V24, P605, DOI 10.3109/01902149809087389; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fan X, 1993, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V15, P71; Hansen H H, 1999, Cancer Chemother Biol Response Modif, V18, P336; LIN P, 1990, Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College, V5, P121; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MORSE MA, 1991, CANCER RES, V51, P1846; RAICHT RF, 1980, CANCER RES, V40, P403; RAO AV, 1992, NUTR CANCER, V18, P43, DOI 10.1080/01635589209514203; SHI ST, 1994, CANCER RES, V54, P4641; von Holtz RL, 1998, NUTR CANCER, V32, P8, DOI 10.1080/01635589809514709; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wang Y, 2003, CANCER RES, V63, P4389; Wattenberg LW, 1996, CANCER RES, V56, P5132; Wattenberg LW, 1997, CARCINOGENESIS, V18, P2015, DOI 10.1093/carcin/18.10.2015; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; Zhang ZQ, 2003, ONCOGENE, V22, P6257, DOI 10.1038/sj.onc.1206630; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhang ZQ, 2002, ONCOGENE, V21, P5960, DOI 10.1038/sj.onc.1205725	29	49	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3841	3850		10.1038/sj.onc.1207496	http://dx.doi.org/10.1038/sj.onc.1207496			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021904				2022-12-25	WOS:000221242500011
J	Ramirez, CJ; Fleming, MA; Potter, JD; Ostrander, GK; Ostrander, EA				Ramirez, CJ; Fleming, MA; Potter, JD; Ostrander, GK; Ostrander, EA			Marsupial BRCA1: conserved regions in mammals and the potential effect of missense changes	ONCOGENE			English	Article						breast cancer; comparative analysis; exon 11; gene evolution; missense; phylogenetics	OVARIAN-CANCER FAMILIES; SPONTANEOUS PROLIFERATIONS; AUSTRALIAN MARSUPIALS; INFORMATION CORE; MUTATIONS; BREAST; GENE; SEQUENCES; FREQUENCY; EVOLUTION	More than half of the reported missense changes in the breast cancer susceptibility protein BRCA1 occur in exon 11, but none has been clearly identified as disease associated and only 28 are designated 'probable' neutral polymorphisms. Previously, in a comparison of sequences from 57 eutherian mammal species, we found seven 'highly conserved regions' between amino acids 282 and 1103, and identified 38 missense changes as likely to disrupt gene function. These conserved regions were also present in birds and amphibians and included only six of the mutations predicted to affect function. In this new analysis, we hypothesized that using 37 ancestral sequences derived from the 57 GenBank sequences and including eight marsupial sequences would allow us to identify regions unique to mammals and re. ne our predictions of disease-associated missense changes. We identified 13 conserved regions, three of which appear to be unique to mammals, and 21 likely disease-associated missense changes, 11 of which occur in conserved regions. Seven regions identified in this analysis, including the three found only in mammalian sequences, and nine missense changes predicted to affect function are in the putative STAT1-interaction domain, suggesting that the role of STAT1 in immune response is important to mammary function. The reduction in the number of missense changes predicted to be disease associated and the identification of conserved regions specific to mammals can facilitate the further study of the role of missense changes in BRCA1-associated breast cancers.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Dept Mol & Cellular Biol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Comparat Med, Baltimore, MD 21218 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Johns Hopkins University; Johns Hopkins University	Ostrander, EA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D4-100, Seattle, WA 98109 USA.	eostrand@fhcrc.org		Potter, John/0000-0001-5439-1500; Ostrander, Elaine/0000-0001-6075-9738	NATIONAL CANCER INSTITUTE [K05CA090754, U24CA078164] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000035] Funding Source: NIH RePORTER; NCI NIH HHS [U24 CA-78164, K05 CA-90754-01] Funding Source: Medline; NHGRI NIH HHS [T32-HG00035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; Brown JR, 2001, NAT GENET, V28, P281, DOI 10.1038/90129; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; CANFIELD PJ, 1990, J COMP PATHOL, V103, P147, DOI 10.1016/S0021-9975(08)80171-5; CANFIELD PJ, 1990, J COMP PATHOL, V103, P135, DOI 10.1016/S0021-9975(08)80170-3; Casey H W, 1979, Recent Results Cancer Res, V66, P129; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chapman MA, 2003, GENOMICS, V81, P249, DOI 10.1016/S0888-7543(03)00005-3; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Findlay L., 1984, Symposia of the Zoological Society of London, P403; Fleming MA, 2003, P NATL ACAD SCI USA, V100, P1151, DOI 10.1073/pnas.0237285100; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Ganesh S, 2001, BIOCHEM BIOPH RES CO, V283, P1046, DOI 10.1006/bbrc.2001.4914; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; Hamilton J M, 1974, Adv Cancer Res, V19, P1, DOI 10.1016/S0065-230X(08)60051-2; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Huttley GA, 2000, NAT GENET, V25, P410, DOI 10.1038/78092; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; KNIGHT CH, 1984, PHYSL STRATEGIES LAC, V51, P147; KOEBERL DD, 1990, AM J HUM GENET, V47, P202; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lee WH, 2001, LANCET, pS5, DOI 10.1016/S0140-6736(01)07018-0; MADDISON DR, 2001, MACCLADE 4 ANAL PHYL; Malone KE, 2000, CANCER, V88, P1393, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P; Misdorp W, 1996, VET QUART, V18, P32, DOI 10.1080/01652176.1996.9694610; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; Nielsen R, 1998, GENETICS, V148, P929; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; Shen DJ, 1999, ONCOL RES, V11, P63; SIEGEL S., 1956, NONPARAMETRIC STAT B; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; Sokal R. R., 2012, BIOMETRY; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STRAUBE EF, 1980, J COMP PATHOL, V90, P495, DOI 10.1016/0021-9975(80)90020-1; SWOFFORD DL, 1998, PAUP ASTERISK PHYLOG; Szabo C, 2000, HUM MUTAT, V16, P123, DOI 10.1002/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y; TYNDALEBISCOE CH, 1984, PHYSL STRATEGIES LAC, V51, P389; Vail DM, 2000, CANCER INVEST, V18, P781, DOI 10.3109/07357900009012210; Vallon-Christersson J, 2001, HUM MOL GENET, V10, P353, DOI 10.1093/hmg/10.4.353; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705	47	15	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1780	1788		10.1038/sj.onc.1207292	http://dx.doi.org/10.1038/sj.onc.1207292			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001988				2022-12-25	WOS:000220029300013
J	Wang, D; Shen, Q; Chen, YQ; Wang, MH				Wang, D; Shen, Q; Chen, YQ; Wang, MH			Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta 1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase	ONCOGENE			English	Article						receptor tyrosine kinases; transforming-growth factor; epithelial-mesenchymal transitions; signal transduction	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR SNAIL; FACTOR SCATTER FACTOR; E-CADHERIN; SIGNAL-TRANSDUCTION; CELL PLASTICITY; GENE; METASTASIS; RAS; EXPRESSION	Epithelial to mesenchymal transition (EMT) is a process occurring during embryonic development and cancer progression. Using recepteur d'origine nantais (RON)expressing epithelial cells as a model, we showed that RON activation causes spindle-shaped morphology with increased cell motilities. These activities resemble those observed in EMT induced by transforming growth factor (TGF)-beta1 or by Ras-Raf signaling. By immunofluorescent and Western blot analyses, we found that constitutive RON expression results in diminished expression of E-cadherin, redistribution of beta-catenin, reorganization of actin cytoskeleton, and increased expression of vimentin, a mesenchymal. lament. RON expression is also essential for TGF-beta1-induced expression of alpha-smooth muscle actin (alpha-SMA), a specialized mesenchymal marker. In the study of signaling pathways responsible for RON-mediated EMT, it was found that PD98059, a MAP kinase inhibitor, blocks the collaborative activities of RON and TGF-beta1 in induction of alpha-SMA expression and restores epithelial cells to their original morphology. Moreover, we showed that RON expression increases Smad2 gene promoter activities and protein expression, which significantly lowers TGF-beta1 threshold for EMT induction. These results suggest that persistent RON expression and activation cause the loss of epithelial phenotypes. These changes, collaborating with TGF-beta1 signaling, could play a critical role in epithelial transdifferentiation towards invasiveness and metastasis of certain cancers.	UCHSC, Dept Med, Denver Hlth Med Ctr, Denver, CO 80204 USA; Zhejiang Univ, Lab Chang Jiang Scholar Endowment Biomed Sci, Inst Infect Dis, Sch Med, Hangzhou 310027, Zhejiang, Peoples R China; Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou 310027, Zhejiang, Peoples R China; Univ Colorado, Sch Med, Dept Med, Ctr Canc, Denver, CO USA	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; Zhejiang University; Zhejiang University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wang, MH (corresponding author), UCHSC, Dept Med, Denver Hlth Med Ctr, 777 Bannock St,Mail 4000, Denver, CO 80204 USA.	ming-hai.wang@uchsc.edu			NCI NIH HHS [R01 CA91890] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Comoglio PM, 1999, EXP CELL RES, V253, P88, DOI 10.1006/excr.1999.4684; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Ellenrieder V, 2001, CANCER RES, V61, P4222; Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010; Fujimoto K, 2001, EXP CELL RES, V266, P239, DOI 10.1006/excr.2000.5229; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gherardi E, 1997, CIBA F SYMP, V212, P24; Gilles C, 2003, CANCER RES, V63, P2658; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Grille SJ, 2003, CANCER RES, V63, P2172; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Masszi A, 2003, AM J PHYSIOL-RENAL, V284, pF911, DOI 10.1152/ajprenal.00183.2002; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nicolas FJ, 2003, J BIOL CHEM, V278, P3251, DOI 10.1074/jbc.M209019200; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Piek E, 1999, J CELL SCI, V112, P4557; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Ruiz P, 1996, WORLD J UROL, V14, P141; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Takenoshita S, 1998, GENOMICS, V48, P1, DOI 10.1006/geno.1997.5149; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Wang MH, 1996, ONCOGENE, V13, P2167; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Zhou YQ, 2002, J BIOL CHEM, V277, P38104, DOI 10.1074/jbc.M206167200; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	53	72	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1668	1680		10.1038/sj.onc.1207282	http://dx.doi.org/10.1038/sj.onc.1207282			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001985				2022-12-25	WOS:000220029300003
J	Spijker, S; Houtzager, SWJ; de Gunst, MCM; de Boer, WPH; Schoffelmeer, ANM; Smit, AB				Spijker, S; Houtzager, SWJ; de Gunst, MCM; de Boer, WPH; Schoffelmeer, ANM; Smit, AB			Morphine exposure and abstinence define specific stages of gene expression in the rat nucleus accumbens	FASEB JOURNAL			English	Article						real-time quantitative PCR; gene expression profiling; sensitization; addiction; natural withdrawal; bioinformatics	MESSENGER-RNA EXPRESSION; AMPHETAMINE-REGULATED TRANSCRIPT; RECEPTOR DOWN-REGULATION; C-FOS GENE; DOPAMINE-RECEPTOR; BEHAVIORAL SENSITIZATION; MOLECULAR-MECHANISMS; LOCOMOTOR-ACTIVITY; CHRONIC COCAINE; BRAIN	Intermittent exposure to addictive drugs causes long-lasting changes in responsiveness to these substances due to persistent molecular and cellular alterations within the meso-corticolimbic system. In this report, we studied the expression profiles of 159 genes in the rat nucleus accumbens during morphine exposure (14 days, 10 mg/kg s.c.) and drug-abstinence ( 3 weeks). We used real-time quantitative PCR to monitor gene expression after establishing its sensitivity and resolution to resolve small changes in expression for genes in various abundance classes. Morphine-exposure (5 time points) and subsequent abstinence ( 6 time points) induced phase-specific temporal gene expression of distinct functional groups of genes, for example, short-term homeostatic responses. Opiate withdrawal appeared to be a new stimulus in terms of gene expression and mediates a marked wave of gene repression. Prolonged abstinence resulted in persistently changed expression levels of genes involved in neuronal outgrowth and re-wiring. Our findings substantiate the hypothesis that this new gene program, initiated upon morphine-withdrawal, may subserve long-term neuronal plasticity involved in the persistent behavioral consequences of repeated drug-exposure.	Free Univ Amsterdam, Dept Mol & Cellular Neurobiol, Grad Sch Neurosci Amsterdam, Neurosci Res Inst, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam, Fac Sci, Dept Math, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1007 MB Amsterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Med Pharmacol, NL-1081 BT Amsterdam, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Spijker, S (corresponding author), Free Univ Amsterdam, Dept Mol & Cellular Neurobiol, Grad Sch Neurosci Amsterdam, Neurosci Res Inst, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	sspijker@bio.vu.nl	Smit, August B/E-8410-2011; Spijker, Sabine/F-2300-2011	Spijker, Sabine/0000-0002-6814-2019				Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Baca SM, 1998, BRAIN RES, V797, P55, DOI 10.1016/S0006-8993(98)00343-6; BASHEER R, 1993, J NEUROSCI RES, V36, P551, DOI 10.1002/jnr.490360507; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Berke JD, 1998, J NEUROSCI, V18, P5301, DOI 10.1523/JNEUROSCI.18-14-05301.1998; BOER D, 2001, P 2 INT C SYST BIOL, P69; Carlezon WA, 1999, SYNAPSE, V31, P256, DOI 10.1002/(SICI)1098-2396(19990315)31:4<256::AID-SYN3>3.0.CO;2-E; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Cha XY, 1997, J NEUROSCI, V17, P6864; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; Crespo JA, 2002, ANN NY ACAD SCI, V965, P78; Douglass J, 1996, GENE, V169, P241, DOI 10.1016/0378-1119(96)88651-3; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evans SJ, 2002, EUR J NEUROSCI, V16, P409, DOI 10.1046/j.1460-9568.2002.02097.x; FOSNAUGH JS, 1995, J NEUROCHEM, V64, P2377; Gao PP, 2000, J NEUROSCI RES, V60, P427, DOI 10.1002/(SICI)1097-4547(20000515)60:4<427::AID-JNR1>3.3.CO;2-4; Georges F, 2000, EUR J NEUROSCI, V12, P4475, DOI 10.1046/j.0953-816X.2000.01334.x; Georges F, 1999, EUR J NEUROSCI, V11, P481, DOI 10.1046/j.1460-9568.1999.00462.x; Gomes BA, 2002, PHARMACOL BIOCHEM BE, V72, P273, DOI 10.1016/S0091-3057(01)00757-2; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134; Guzowski JF, 2000, J NEUROSCI, V20, P3993; Harlan RE, 1998, MOL NEUROBIOL, V16, P221, DOI 10.1007/BF02741385; Hoek RM, 1997, P NATL ACAD SCI USA, V94, P14072, DOI 10.1073/pnas.94.25.14072; Horger BA, 1999, J NEUROSCI, V19, P4110; HURD YL, 1992, MOL BRAIN RES, V16, P97, DOI 10.1016/0169-328X(92)90198-K; HYMAN C, 1994, J NEUROSCI, V14, P335; Jacobs EH, 2002, FASEB J, V16, P1961, DOI 10.1096/fj.02-0272fje; Jang CG, 2000, BRAIN RES BULL, V52, P217, DOI 10.1016/S0361-9230(00)00261-6; Janis LS, 1999, J NEUROSCI, V19, P4962; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; Kalivas PW, 1999, SYNAPSE, V33, P153, DOI 10.1002/(SICI)1098-2396(199908)33:2<153::AID-SYN5>3.0.CO;2-N; Kimmel HL, 2000, J PHARMACOL EXP THER, V294, P784; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kuhar MJ, 1999, TRENDS NEUROSCI, V22, P316, DOI 10.1016/S0166-2236(98)01377-0; LIU JL, 1994, P NATL ACAD SCI USA, V91, P8537, DOI 10.1073/pnas.91.18.8537; Lu WX, 1997, SYNAPSE, V26, P269, DOI 10.1002/(SICI)1098-2396(199707)26:3<269::AID-SYN8>3.0.CO;2-5; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; Mackler SA, 2000, J NEUROSCI, V20, P6210, DOI 10.1523/JNEUROSCI.20-16-06210.2000; Martin G, 1999, J NEUROSCI, V19, P9081, DOI 10.1523/JNEUROSCI.19-20-09081.1999; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Nadon R, 2002, TRENDS GENET, V18, P265, DOI 10.1016/S0168-9525(02)02665-3; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pierce RC, 1996, J NEUROSCI, V16, P1550; Przewlocka B, 1995, EUR NEUROPSYCHOPHARM, V5, P465; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Ranaldi R, 2000, PSYCHOPHARMACOLOGY, V151, P192, DOI 10.1007/s002130000480; Robinson TE, 1999, SYNAPSE, V33, P160; SCHOFFELMEER ANM, 1995, EUR J PHARMACOL, V286, P311, DOI 10.1016/0014-2999(95)00588-7; Self DW, 1998, J NEUROSCI, V18, P1848; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; TJON GHK, 1995, EUR J PHARMACOL, V283, P169, DOI 10.1016/0014-2999(95)00319-G; Turchan J, 1997, NEUROPEPTIDES, V31, P24, DOI 10.1016/S0143-4179(97)90015-9; van Kesteren RE, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0004.2001; Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493; Vanderschuren LJMJ, 1997, PSYCHOPHARMACOLOGY, V131, P115, DOI 10.1007/s002130050273; Walters CL, 2000, NEUROPSYCHOPHARMACOL, V23, P307, DOI 10.1016/S0893-133X(00)00113-5; Wang JH, 1997, J CLIN NEUROPHYSIOL, V14, P264, DOI 10.1097/00004691-199707000-00002; WANG JQ, 1995, BRAIN RES, V673, P262, DOI 10.1016/0006-8993(94)01422-E; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; Yoburn BC, 2003, SYNAPSE, V47, P109, DOI 10.1002/syn.10149; Yue Y, 1999, J NEUROSCI, V19, P2090	66	55	56	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					848	+		10.1096/fj.03-0612fje	http://dx.doi.org/10.1096/fj.03-0612fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033927				2022-12-25	WOS:000220522800011
J	Augustus, A; Yagyu, H; Haemmerle, G; Bensadoun, A; Vikramadithyan, RK; Park, SY; Kim, JK; Zechner, R; Goldberg, IJ				Augustus, A; Yagyu, H; Haemmerle, G; Bensadoun, A; Vikramadithyan, RK; Park, SY; Kim, JK; Zechner, R; Goldberg, IJ			Cardiac-specific knock-out of lipoprotein lipase alters plasma lipoprotein triglyceride metabolism and cardiac gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; FATTY-ACID; IN-VIVO; INSULIN-RESISTANCE; DIABETES-MELLITUS; RICH LIPOPROTEINS; SKELETAL-MUSCLE; ADIPOSE-TISSUE; MICE; PROTEIN	Fatty acids are the primary energy source for the heart. The heart acquires fatty acids associated with albumin or derived from lipoprotein lipase (LpL)-mediated hydrolysis of lipoprotein triglyceride (TG). We generated heart-specific LpL knock-out mice (hLpL0) to determine whether cardiac LpL modulates the actions of peroxisome proliferator-activated receptors and affects whole body lipid metabolism. Male hLpL0 mice had significantly elevated plasma TG levels and decreased clearance of postprandial lipids despite normal postheparin plasma LpL activity. Very large density lipoprotein-TG uptake was decreased by 72% in hLpL0 hearts. However, heart uptake of albumin-bound free fatty acids was not altered. Northern blot analysis revealed a decrease in the expression of peroxisome proliferator-activated receptor alpha-response genes involved in fatty acid beta-oxidation. Surprisingly, the expression of glucose transporters 1 and 4 and insulin receptor substrate 2 was increased and that of pyruvate dehydrogenase kinase 4 and insulin receptor substrate 1 was reduced. Basal glucose uptake was increased markedly in hLpL0 hearts. Thus, the loss of LpL in the heart leads to defective plasma metabolism of TG. Moreover, fatty acids derived from lipoprotein TG and not just albumin-associated fatty acids are important for cardiac lipid metabolism and gene regulation.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Cornell Univ, Dept Nutr, Ithaca, NY 14850 USA; Graz Univ, Graz, Austria; Yale Univ, Sch Med, Dept Internal Med, Sect Endocrinol & Metab, New Haven, CT 06520 USA	Columbia University; Cornell University; University of Graz; Yale University	Goldberg, IJ (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	ijg3@columbia.edu	Park, So-Young/AAC-5528-2022	Park, So-Young/0000-0002-6018-0440; Zechner, Rudolf/0000-0001-5483-1182; Haemmerle, Guenter/0000-0001-9900-5896; Kim, Jason/0000-0002-7185-042X	NHLBI NIH HHS [HL45095, HL073029] Funding Source: Medline; NIDDK NIH HHS [U24 DK59635, R01 DK080756] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073029, R01HL045095, R37HL045095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080756, U24DK059635] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; Augustus AS, 2003, AM J PHYSIOL-ENDOC M, V284, pE331, DOI 10.1152/ajpendo.00298.2002; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Calvani M, 2000, BASIC RES CARDIOL, V95, P75, DOI 10.1007/s003950050167; Chawla A, 2003, P NATL ACAD SCI USA, V100, P1268, DOI 10.1073/pnas.0337331100; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Dumke CL, 2001, HORM METAB RES, V33, P696, DOI 10.1055/s-2001-19141; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; Finck BN, 2002, J CLIN INVEST, V109, P121, DOI 10.1172/JCI200214080; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gimeno RE, 2003, J BIOL CHEM, V278, P16039, DOI 10.1074/jbc.M211412200; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Goldberg IJ, 1996, J LIPID RES, V37, P693; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Heeren J, 2002, J MOL MED-JMM, V80, P576, DOI 10.1007/s00109-002-0351-5; Hocquette JF, 1998, COMP BIOCHEM PHYS B, V121, P201, DOI 10.1016/S0305-0491(98)10090-1; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; Levak-Frank S, 1999, P NATL ACAD SCI USA, V96, P3165, DOI 10.1073/pnas.96.6.3165; Liao RL, 2002, CIRCULATION, V106, P2125, DOI 10.1161/01.CIR.0000034049.61181.F3; LOPASCHUK GD, 1994, BBA-LIPID LIPID MET, V1213, P263, DOI 10.1016/0005-2760(94)00082-4; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sesti G, 2001, FASEB J, V15, P2099, DOI 10.1096/fj.01-0009rev; van der Vusse GJ, 2000, CARDIOVASC RES, V45, P279, DOI 10.1016/S0008-6363(99)00263-1; van Vlijmen BJM, 1999, J BIOL CHEM, V274, P35219, DOI 10.1074/jbc.274.49.35219; Velloso LA, 1998, CARDIOVASC RES, V40, P96, DOI 10.1016/S0008-6363(98)00098-4; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Yagyu H, 2003, J CLIN INVEST, V111, P419, DOI [10.1172/JCI200316751, 10.1172/JCI16751]; Yagyu H, 2002, J BIOL CHEM, V277, P10037, DOI 10.1074/jbc.M109966200; ZIONZENKOYA O, 2003, P NATL ACAD SCI USA, V100, P2730	36	92	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25050	25057		10.1074/jbc.M401028200	http://dx.doi.org/10.1074/jbc.M401028200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15028738	hybrid			2022-12-25	WOS:000221827900019
J	Matsui, T; Katsuno, Y; Inoue, T; Fujita, F; Joh, T; Niida, H; Murakami, H; Itoh, M; Nakanishi, M				Matsui, T; Katsuno, Y; Inoue, T; Fujita, F; Joh, T; Niida, H; Murakami, H; Itoh, M; Nakanishi, M			Negative regulation of Chk2 expression by p53 is dependent on the CCAAT-binding transcription factor NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; WILD-TYPE P53; CELL-CYCLE; P53-DEPENDENT APOPTOSIS; ATAXIA-TELANGIECTASIA; POTENTIAL MEDIATOR; TUMOR-SUPPRESSOR; PROTEIN-KINASE; ATM; GENE	The kinase Chk2 and tumor suppressor p53 participate in an ill defined regulatory interaction in mammalian cells. The abundance of Chk2 mRNA and protein has now been shown to be decreased by the induction of p53 in Saos2 cells. Ionizing radiation also triggered the phosphorylation and subsequent down-regulation of Chk2 in human colorectal HCT116 ( p53(+/+)) cancer cells; irradiation of its isogenic mutant HCT116 (p53(-/-)) cells, which lack functional p53, induced Chk2 phosphorylation but not its down-regulation. In addition, HCT116 (p53(+/+)) cells constitutively expressing a dominant negative p53 (V143A) failed to suppress Chk2 expression after irradiation. Reporter gene assays in HCT116 (p53(+/+)) cells revealed that wild-type p53 repressed, whereas a dominant negative p53 mutant increased, the activity of the human Chk2 gene promoter. Mutational analysis showed that a CCAAT box located between nucleotides -152 and -138 of the promoter was responsible for its negative regulation by p53. Electrophoretic mobility shift assays demonstrated that the transcription factor NF-Y binds to this CCAAT sequence. A dominant negative mutant of NF-YA abolished the effect of p53 on Chk2 promoter activity. These results suggest that p53 negatively regulates Chk2 gene transcription through modulation of NF-Y function and that this regulation may be important for reentry of cells into the cell cycle after DNA damage is repaired.	Nagoya City Univ, Grad Sch Med Sci, Dept Biochem & Cell Biol, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Internal Med & Bioregulat, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University	Nakanishi, M (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Biochem & Cell Biol, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	mkt-naka@med.nagoya-cu.ac.jp						AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Imbriano C, 2001, J BIOL CHEM, V276, P26332, DOI 10.1074/jbc.M101553200; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubicka S, 1999, J BIOL CHEM, V274, P32137, DOI 10.1074/jbc.274.45.32137; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MIYASHITA T, 1995, CELL, V80, P293; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shieh SY, 2000, GENE DEV, V14, P289; Shigeishi H, 2002, INT J CANCER, V99, P58, DOI 10.1002/ijc.10272; Sinha S, 1996, MOL CELL BIOL, V16, P328; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhao RB, 2000, GENE DEV, V14, P981	53	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25093	25100		10.1074/jbc.M403232200	http://dx.doi.org/10.1074/jbc.M403232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15044452	hybrid			2022-12-25	WOS:000221827900024
J	Suzuki, R; Tobe, K; Aoyama, M; Inoue, A; Sakamoto, K; Yamauchi, T; Kamon, J; Kubota, N; Terauchi, Y; Yoshimatsu, H; Matsuhisa, M; Nagasaka, S; Ogata, H; Tokuyama, K; Nagai, R; Kadowaki, T				Suzuki, R; Tobe, K; Aoyama, M; Inoue, A; Sakamoto, K; Yamauchi, T; Kamon, J; Kubota, N; Terauchi, Y; Yoshimatsu, H; Matsuhisa, M; Nagasaka, S; Ogata, H; Tokuyama, K; Nagai, R; Kadowaki, T			Both insulin signaling defects in the liver and obesity contribute to insulin resistance and cause diabetes in Irs2(-/-) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SUBSTRATE FAMILY; DOUBLE KNOCKOUT MICE; PHOSPHATIDYLINOSITOL 3-KINASE; HEPATIC GLUCONEOGENESIS; PHOSPHOTYROSINE PROTEIN; GLUCOSE-PRODUCTION; INDUCED ANOREXIA; IN-VIVO; LEPTIN; IRS-2	We previously reported that insulin receptor substrate-2 (IRS-2)-deficient mice develop diabetes as a result of insulin resistance in the liver and failure of beta-cell hyperplasia. In this study we introduced the IRS-2 gene specifically into the liver of Irs2(-/-) mice with adenovirus vectors. Glucose tolerance tests revealed that the IRS-2 restoration in the liver ameliorated the hyperglycemia, but the improvement in hyperinsulinemia was only partial. Endogenous glucose production (EGP) and the rate of glucose disappearance (Rd) were measured during hyperinsulinemic-euglycemic clamp studies: EGP was increased 2-fold in the Irs2(-/-) mice, while Rd decreased by 50%. Restoration of IRS-2 in the liver suppressed EGP to a level similar to that in wild-type mice, but Rd remained decreased in the Adeno-IRS-2-infected Irs2(-/-) mice. Irs2(-/-) mice also exhibit obesity and hyperleptinemia associated with impairment of hypothalamic phosphatidylinositol 3-kinase activation. Continuous intracerebroventricular leptin infusion or caloric restriction yielded Irs2(+/+) mice whose adiposity was comparable to that of Irs2(-/-) mice, and both the hyperglycemia and the hyperinsulinemia of these mice improved with increased Rd albeit partially. Finally combination treatment consisting of adenovirus-mediated gene transfer of IRS-2 and continuous intracerebroventricular leptin infusion completely reversed the hyperglycemia and hyperinsulinemia in Irs2(-/-) mice. EGP and Rd also became normal in these mice as well as in mice treated by caloric restriction plus adenoviral gene transfer. We therefore concluded that a combination of increased EGP due to insulin signaling defects in the liver and reduced Rd due to obesity accounts for the systemic insulin resistance in Irs2(-/-) mice.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan; Oita Med Univ, Sch Med, Dept Internal Med, Oita 8795593, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Jichi Med Sch, Dept Med, Div Endocrinol & Metab, Minami Kawachi, Tochigi 3290498, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Oita University; Osaka University; Jichi Medical University; University of Tsukuba	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Terauchi, Yasuo/AAO-4347-2020; Suzuki, Ryo/AAA-2736-2019; Kubota, Naoto/N-7892-2015	Suzuki, Ryo/0000-0002-2965-6906; 				Accili D, 2001, J CLIN INVEST, V108, P1575, DOI 10.1172/JCI200114454; Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Anderwald C, 2002, MOL ENDOCRINOL, V16, P1612, DOI 10.1210/me.16.7.1612; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Burcelin R, 1999, DIABETES, V48, P1264, DOI 10.2337/diabetes.48.6.1264; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Giacca A, 1997, ENDOCRINOLOGY, V138, P999, DOI 10.1210/en.138.3.999; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; Haque MS, 1999, DIABETES, V48, P1706, DOI 10.2337/diabetes.48.9.1706; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kuroda A, 2003, METABOLISM, V52, P203, DOI 10.1053/meta.2003.50026; Laustsen PG, 2002, GENE DEV, V16, P3213, DOI 10.1101/gad.1034802; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Masaki T, 2001, DIABETES, V50, P376, DOI 10.2337/diabetes.50.2.376; Mauvais-Jarvis F, 2002, CLIN ENDOCRINOL, V57, P1, DOI 10.1046/j.1365-2265.2002.01563.x; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Nagasaka S, 1999, DIABETES, V48, P1054, DOI 10.2337/diabetes.48.5.1054; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Niswender KD, 2003, DIABETES, V52, P227, DOI 10.2337/diabetes.52.2.227; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2000, J CLIN INVEST, V106, P163, DOI 10.1172/JCI10533; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; STEELE R, 1956, AM J PHYSIOL, V187, P15, DOI 10.1152/ajplegacy.1956.187.1.15; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Suzuki R, 2003, J BIOL CHEM, V278, P43691, DOI 10.1074/jbc.M307004200; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Terauchi Y, 2003, J BIOL CHEM, V278, P14284, DOI 10.1074/jbc.M211045200; Terauchi Y, 1997, J CLIN INVEST, V99, P861, DOI 10.1172/JCI119250; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; Tobe K, 2001, J BIOL CHEM, V276, P38337, DOI 10.1074/jbc.C100160200; Tsuji Y, 2001, DIABETES, V50, P1455, DOI 10.2337/diabetes.50.6.1455; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	58	56	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25039	25049		10.1074/jbc.M311956200	http://dx.doi.org/10.1074/jbc.M311956200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15028732	hybrid			2022-12-25	WOS:000221827900018
J	Colas, C; de Montellano, PRO				Colas, C; de Montellano, PRO			Horseradish peroxidase mutants that autocatalytically modify their prosthetic heme group - Insights into mammalian peroxidase heme-protein covalent bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; DISTAL SITE; CATALYTIC-PROPERTIES; HYDROGEN-PEROXIDE; PLANT PEROXIDASE; ACTIVE-SITE; ATTACHMENT; REACTIVITY; HISTIDINE; BINDING	The mammalian peroxidases, including myeloperoxidase and lactoperoxidase, bind their prosthetic heme covalently through ester bonds to two of the heme methyl groups. These bonds are autocatalytically formed. No other peroxidase is known to form such bonds. To determine whether features other than an appropriately placed carboxylic acid residue are important for covalent heme binding, we have introduced aspartate and/or glutamic acid residues into horseradish peroxidase, a plant enzyme that exhibits essentially no sequence identity with the mammalian peroxidases. Based on superposition of the horseradish peroxidase and myeloperoxidase structures, the mutated residues were Leu(37), Phe(41), Gly(69), and Ser(73). The F41E mutant was isolated with no covalently bound heme, but the heme was completely covalently bound upon incubation with H2O2. As predicted, the modified heme released from the protein was 3-hydroxymethylheme. The S73E mutant did not covalently bind its heme but oxidized it to the 8-hydroxymethyl derivative. The hydroxyl group in this modified heme derived from the medium. The other mutations gave unstable proteins. The rate of compound I formation for the F41E mutant was 100 times faster after covalent bond formation, but the reduction of compound I to compound II was similar with and without the covalent bond. The results clearly establish that an appropriately situated carboxylic acid group is sufficient for covalent heme attachment, strengthen the proposed mechanism, and suggest that covalent heme attachment in the mammalian peroxidases relates to peroxidase biology or stability rather than to intrinsic catalytic properties.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NIGMS NIH HHS [GM32488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATOR MA, 1987, J BIOL CHEM, V262, P1542; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Cheesman MJ, 2003, ARCH BIOCHEM BIOPHYS, V416, P17, DOI 10.1016/S0003-9861(03)00278-9; Colas C, 2003, CHEM REV, V103, P2305, DOI 10.1021/cr0204303; Colas C, 2002, J BIOL CHEM, V277, P7191, DOI 10.1074/jbc.M109523200; Cowley AB, 2004, BIOCHEMISTRY-US, V43, P1656, DOI 10.1021/bi035531p; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DePillis GD, 1997, J BIOL CHEM, V272, P8857; Dunford H. B., 1999, HEME PEROXIDASES, P58; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; GAZARYAN IG, 1994, FEBS LETT, V354, P248, DOI 10.1016/0014-5793(94)01125-7; HARRIS RZ, 1993, BIOCHEMISTRY-US, V32, P3658, DOI 10.1021/bi00065a019; HASINOFF BB, 1970, BIOCHEMISTRY-US, V9, P4930; Heering HA, 2002, BIOCHEM J, V363, P571, DOI 10.1042/0264-6021:3630571; Henne KR, 2001, BIOCHEMISTRY-US, V40, P12925, DOI 10.1021/bi011171z; Henriksen A, 1998, J BIOL CHEM, V273, P2241, DOI 10.1074/jbc.273.4.2241; Henriksen A, 2001, PROTEIN SCI, V10, P108, DOI 10.1110/ps.37301; Hoch U, 2001, J BIOL CHEM, V276, P11339, DOI 10.1074/jbc.M009969200; Howes BD, 2001, BIOPOLYMERS, V62, P261, DOI 10.1002/bip.1021; Jantschko W, 2002, ARCH BIOCHEM BIOPHYS, V398, P12, DOI 10.1006/abbi.2001.2674; Kooter IM, 1997, J AM CHEM SOC, V119, P11542, DOI 10.1021/ja9725460; LeBrun LA, 2002, BIOCHEMISTRY-US, V41, P5931, DOI 10.1021/bi025527y; LeBrun LA, 2002, J BIOL CHEM, V277, P12755, DOI 10.1074/jbc.M112155200; Meno K, 2002, ACTA CRYSTALLOGR D, V58, P1803, DOI 10.1107/S090744490201329X; Morawski B, 2000, PROTEIN ENG, V13, P377, DOI 10.1093/protein/13.5.377; MORITA Y, 1993, PLANT PEROXIDASES BI, P35; Nagano S, 1996, BIOCHEMISTRY-US, V35, P14251, DOI 10.1021/bi961740g; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; OZAKI S, 1995, J AM CHEM SOC, V117, P7056, DOI 10.1021/ja00132a003; Patel PK, 1997, BBA-PROTEIN STRUCT M, V1339, P79, DOI 10.1016/S0167-4838(96)00219-1; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Savenkova MI, 1998, BIOCHEMISTRY-US, V37, P10828, DOI 10.1021/bi9725780; Savenkova MI, 1996, J BIOL CHEM, V271, P24598, DOI 10.1074/jbc.271.40.24598; SAVENKOVA MI, 1996, ARCH BIOCHEM BIOPHYS, V351, P286; SMITH AT, 1992, BIOCHEM SOC T, V20, P340, DOI 10.1042/bst0200340; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; Tanaka M, 1998, BIOCHEMISTRY-US, V37, P2629, DOI 10.1021/bi9725273; Tanaka M, 1996, BIOCHEM BIOPH RES CO, V227, P393, DOI 10.1006/bbrc.1996.1518; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9889, DOI 10.1021/bi970906q; Zheng YM, 2003, BIOCHEMISTRY-US, V42, P4601, DOI 10.1021/bi020667t	43	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24131	24140		10.1074/jbc.M401687200	http://dx.doi.org/10.1074/jbc.M401687200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15039425	hybrid			2022-12-25	WOS:000221702500036
J	Nilsson, M; Wang, X; Rodziewicz-Motowidlo, S; Janowski, R; Lindstrom, V; Onnerfjord, P; Westermark, G; Grzonka, Z; Jaskolski, M; Grubb, A				Nilsson, M; Wang, X; Rodziewicz-Motowidlo, S; Janowski, R; Lindstrom, V; Onnerfjord, P; Westermark, G; Grzonka, Z; Jaskolski, M; Grubb, A			Prevention of domain swapping inhibits dimerization and amyloid fibril formation of cystatin C - Use of engineered disulfide bridges, antibodies, and carboxymethylpapain to stabilize the monomeric form of cystatin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; CYSTEINE PROTEINASES; CRYSTAL-STRUCTURE; PRION PROTEIN; BETA-PROTEIN; AGGREGATION; MECHANISM; OLIGOMER; QUANTITATION; REDUCTION	Amyloidogenic proteins like cystatin C and prion proteins have been shown to form dimers by exchange of subdomains of the monomeric proteins. This process, called "three-dimensional domain swapping," has also been suggested to play a part in the generation of amyloid fibrils. One variant of cystatin C, L68Q cystatin C, is highly amyloidogenic, and persons carrying the corresponding gene suffer from massive cerebral amyloidosis leading to brain hemorrhage and death in early adult life. The present work describes the production of two variants of wild type and L68Q cystatin C with disulfide bridges at positions selected to inhibit domain swapping without affecting the biological function of the four cystatin C variants as cysteine protease inhibitors. The capacity of the four variant proteins to form dimers was tested and compared with that of wild type and L68Q cystatin C. In contrast to the latter two proteins, all four protein variants stabilized by disulfide bridges were resistant toward the formation of dimers. The capacity of the two stabilized variants of wild type cystatin C to form amyloid fibrils was investigated and found to be reduced by 80% compared with that of wild type cystatin C. In an effort to investigate whether exogenous agents could also suppress the formation of dimers of wild type and L68Q cystatin C, a monoclonal antibody or carboxymethylpapain, an inactivated form of a cysteine protease, was added to systems inducing dimerization of wild type and L68Q cystatin C. It was observed that catalytic amounts of both the monoclonal antibody and carboxymethylpapain could suppress dimerization.	Univ Lund Hosp, Dept Clin Chem, S-22185 Lund, Sweden; Lund Univ, Dept Cell & Mol Biol, S-22184 Lund, Sweden; Univ Gdansk, Fac Chem, Dept Organ Chem, PL-80952 Gdansk, Poland; Linkoping Univ, Dept Cell Biol, S-58183 Linkoping, Sweden; Polish Acad Sci, Inst Bioorgan Chem, Ctr Biocrystallog Res, PL-60780 Poznan, Poland; Adam Mickiewicz Univ, Fac Chem, Dept Crystallog, Poznan, Poland	Lund University; Skane University Hospital; Lund University; Fahrenheit Universities; University of Gdansk; Linkoping University; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; Adam Mickiewicz University	Grubb, A (corresponding author), Univ Lund Hosp, Dept Clin Chem, S-22185 Lund, Sweden.	anders.grubb@klinkem.lu.se	Onnerfjord, Patrik/R-3131-2019	Onnerfjord, Patrik/0000-0002-2345-2937; Grubb, Anders/0000-0002-0125-3662; Janowski, Robert/0000-0002-9940-2143; Rodziewicz-Motowidlo, Sylwia/0000-0002-4471-5951; Jaskolski, Mariusz/0000-0003-1587-6489				ABRAHAMSON M, 1994, P NATL ACAD SCI USA, V91, P1416, DOI 10.1073/pnas.91.4.1416; ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; Baures PW, 1999, BIOORGAN MED CHEM, V7, P1339, DOI 10.1016/S0968-0896(99)00066-8; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bjarnadottir M, 2001, AMYLOID, V8, P1, DOI 10.3109/13506120108993809; BJORK I, 1989, BIOCHEM J, V260, P61; BLUMBERG S, 1970, EUR J BIOCHEM, V15, P97, DOI 10.1111/j.1432-1033.1970.tb00981.x; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Ekiel I, 1996, J BIOL CHEM, V271, P1314, DOI 10.1074/jbc.271.3.1314; Ellis RJ, 2002, NATURE, V416, P483, DOI 10.1038/416483a; FERNANDEZLUNA JL, 1985, J IMMUNOL METHODS, V82, P101, DOI 10.1016/0022-1759(85)90229-7; Futami J, 2000, J BIOCHEM-TOKYO, V128, P245, DOI 10.1093/oxfordjournals.jbchem.a022747; Gerhartz B, 1998, BIOCHEMISTRY-US, V37, P17309, DOI 10.1021/bi980873u; Glazer A., 1971, ENZYMES, P501; Grubb AO, 2001, ADV CLIN CHEM, V35, P63, DOI 10.1016/S0065-2423(01)35015-1; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; Jaskolski M, 2001, ACTA BIOCHIM POL, V48, P807; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLAFKI HW, 1993, BIOL CHEM H-S, V374, P1117, DOI 10.1515/bchm3.1993.374.7-12.1117; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LeVine H, 1999, METHOD ENZYMOL, V309, P467; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; LOFBERG H, 1979, SCAND J CLIN LAB INV, V39, P619, DOI 10.3109/00365517909108866; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; Newcomer ME, 2001, NAT STRUCT BIOL, V8, P282, DOI 10.1038/86134; NICKLIN MJH, 1984, BIOCHEM J, V223, P245, DOI 10.1042/bj2230245; OLAFSSON I, 1988, SCAND J CLIN LAB INV, V48, P573, DOI 10.3109/00365518809085775; Olafsson I, 2000, AMYLOID, V7, P70, DOI 10.3109/13506120009146827; Perez M, 2003, BBA-MOL BASIS DIS, V1639, P133, DOI 10.1016/j.bbadis.2003.08.003; Ray I, 2000, BRAIN RES, V853, P344, DOI 10.1016/S0006-8993(99)02315-X; RITCHIE RF, 1976, CLIN CHEM, V22, P497; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wetzel R, 2002, STRUCTURE, V10, P1031, DOI 10.1016/S0969-2126(02)00809-2; White AR, 2003, J NEUROCHEM, V87, P801, DOI 10.1046/j.1471-4159.2003.02064.x; Yamada M, 2000, NEUROPATHOLOGY, V20, P8, DOI 10.1046/j.1440-1789.2000.00268.x; Zerovnik E, 2002, BBA-PROTEIN STRUCT M, V1594, P1, DOI 10.1016/S0167-4838(01)00295-3	56	93	94	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24236	24245		10.1074/jbc.M402621200	http://dx.doi.org/10.1074/jbc.M402621200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15028721	Green Published, hybrid			2022-12-25	WOS:000221702500048
J	Zhou, XY; Murphy, FR; Gehdu, N; Zhang, JL; Iredale, JP; Benyon, RC				Zhou, XY; Murphy, FR; Gehdu, N; Zhang, JL; Iredale, JP; Benyon, RC			Engagement of alpha(v)beta(3) integrin regulates proliferation and apoptosis of hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MAMMARY-GLAND INVOLUTION; MATRIX-METALLOPROTEINASE; EXTRACELLULAR-MATRIX; RAT-LIVER; TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; CYTOCHROME-C; EXPRESSION; FIBROSIS	Hepatic stellate cells are the major source of the extracellular matrix that accumulates in fibrotic liver. During progressive liver fibrosis, hepatic stellate cells proliferate, but during resolution of fibrosis there is extensive stellate cell apoptosis that coincides with degradation of the liver scar. We have examined the possibility that the fate of stellate cells is influenced by the extracellular matrix through the intermediary of alpha(v)beta(3) integrin. alpha(v)beta(3) integrin was expressed by activated, myo-fibroblastic rat and human stellate cells in culture. Antagonism of this integrin using neutralizing antibodies, echistatin, or small inhibitory RNA to silence alpha(v) subunit expression inhibited stellate cell proliferation and their expression of proliferating cell nuclear antigen and activated forms of p44 and p42 MAPK. These alpha(v)beta(3) antagonists also increased apoptosis of cultured stellate cells, and this was associated with an increase in the BAX/BCL-2 protein ratio, induction of nuclear DNA fragmentation, and activation of intracellular caspase-3. Expression of tissue inhibitor of metalloproteinases-1 by activated stellate cells was reduced by the alpha(v)beta(3) antagonists, while matrix metalloproteinase-9 synthesis was enhanced. Stellate cells incubated with active recombinant matrix metalloproteinase-9 showed enhanced apoptosis, while cells treated with a synthetic inhibitor of this protease showed increased survival. Our studies suggest that alpha(v)beta(3) integrin regulates the fate of hepatic stellate cells. Degradation of alpha(v)beta(3) ligands surrounding activated stellate cells during resolution of liver fibrosis might decrease alpha(v)beta(3) integrin ligation, suppressing stellate cell proliferation and inducing a fibrolytic, matrix metalloproteinase-secreting phenotype that may prime stellate cells for apoptosis.	Southampton Gen Hosp, Univ Div Infect Inflammat & Repair, Liver Res Grp, Southampton SO16 6YD, Hants, England; Southampton Gen Hosp, Fetal Origins Adult Dis Div, Endocrinol & Metab Unit, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton	Benyon, RC (corresponding author), Southampton Gen Hosp, Univ Div Infect Inflammat & Repair, Liver Res Grp, South Block 811, Southampton SO16 6YD, Hants, England.	rcb@soton.ac.uk		Iredale, John/0000-0003-2174-5127				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Alexander CM, 1996, DEVELOPMENT, V122, P1723; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Benyon RC, 1998, J PEDIATR GASTR NUTR, V27, P75, DOI 10.1097/00005176-199807000-00013; Benyon RC, 2001, SEMIN LIVER DIS, V21, P373, DOI 10.1055/s-2001-17552; Benyon RC, 1999, HEPATOLOGY, V30, P977, DOI 10.1002/hep.510300431; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; BURT AD, 1993, J PATHOL, V170, P105, DOI 10.1002/path.1711700203; Cai DH, 2002, DEV DYNAM, V224, P441, DOI 10.1002/dvdy.10129; Carloni V, 1996, GASTROENTEROLOGY, V110, P1127, DOI 10.1053/gast.1996.v110.pm8613002; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; DIOSZEGI M, 1995, METHOD ENZYMOL, V248, P413; Eliceiri BP, 2000, CANCER J, V6, pS245; Faraldo MM, 2000, ADV EXP MED BIOL, V480, P169; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gaca MDA, 2003, MATRIX BIOL, V22, P229, DOI 10.1016/S0945-053X(03)00017-9; Genersch E, 2003, EUR J CELL BIOL, V82, P105, DOI 10.1078/0171-9335-00297; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Iredale JP, 2003, BMJ-BRIT MED J, V327, P143, DOI 10.1136/bmj.327.7407.143; IREDALE JP, 1995, CLIN SCI, V89, P75, DOI 10.1042/cs0890075; Isik FF, 1998, J CELL PHYSIOL, V175, P149, DOI 10.1002/(SICI)1097-4652(199805)175:2<149::AID-JCP4>3.0.CO;2-O; Issa R, 2002, FASEB J, V16, P47, DOI 10.1096/fj.02-0494fje; Issa R, 2001, GUT, V48, P548, DOI 10.1136/gut.48.4.548; Iwamoto H, 1999, J LAB CLIN MED, V134, P83, DOI 10.1016/S0022-2143(99)90057-4; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Knittel T, 2000, HISTOCHEM CELL BIOL, V113, P443; Koukoulis GK, 2001, HUM PATHOL, V32, P1356, DOI 10.1053/hupa.2001.29675; Lim MLR, 2002, J BIOMED SCI, V9, P488, DOI 10.1159/000064722; Liu XJ, 2002, WORLD J GASTROENTERO, V8, P734, DOI 10.3748/wjg.v8.i4.734; Lund LR, 1996, DEVELOPMENT, V122, P181; MAHER JJ, 1988, GASTROENTEROLOGY, V94, P1053, DOI 10.1016/0016-5085(88)90566-5; MALLYA SK, 1986, ANAL BIOCHEM, V158, P334, DOI 10.1016/0003-2697(86)90558-0; Mannello F, 2001, APOPTOSIS, V6, P479, DOI 10.1023/A:1012493808790; MARTINEZHERNANDEZ A, 1985, LAB INVEST, V53, P166; MELKKO J, 1990, CLIN CHEM, V36, P1328; MILANI S, 1989, HEPATOLOGY, V10, P84, DOI 10.1002/hep.1840100117; MILANI S, 1994, AM J PATHOL, V144, P528; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; NEUBAUER K, 1995, GASTROENTEROLOGY, V108, P1124, DOI 10.1016/0016-5085(95)90211-2; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Petitclerc E, 1999, CANCER RES, V59, P2724; Pinzani M, 2001, SEMIN LIVER DIS, V21, P397, DOI 10.1055/s-2001-17554; RAMM GA, 1995, AM J PHYSIOL-GASTR L, V269, pG532, DOI 10.1152/ajpgi.1995.269.4.G532; Reeves HL, 2002, FRONT BIOSCI-LANDMRK, V7, pD808, DOI 10.2741/reeves; REEVES HL, 1997, CELLS HEPATIC SINUSO, V6, P154; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scovassi AI, 2003, EUR J HISTOCHEM, V47, P185; STEELE JG, 1993, J BIOMED MATER RES, V27, P927, DOI 10.1002/jbm.820270712; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; TAKAHARA T, 1995, HEPATOLOGY, V21, P787; Takahara T, 1997, HEPATOLOGY, V26, P1521; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Volloch V, 2002, MATRIX BIOL, V21, P533, DOI 10.1016/S0945-053X(02)00038-0; Wiesen J, 2000, MOL REPROD DEV, V56, P534, DOI 10.1002/1098-2795(200008)56:4&lt;534::AID-MRD12&gt;3.0.CO;2-O	67	157	173	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23996	24006		10.1074/jbc.M311668200	http://dx.doi.org/10.1074/jbc.M311668200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044441	hybrid			2022-12-25	WOS:000221702500021
J	Huang, SJ; Blanchoin, L; Chaudhry, F; Franklin-Tong, VE; Staiger, CJ				Huang, SJ; Blanchoin, L; Chaudhry, F; Franklin-Tong, VE; Staiger, CJ			A gelsolin-like protein from Papaver rhoeas pollen (PrABP80) stimulates calcium-regulated severing and depolymerization of actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-INCOMPATIBILITY RESPONSE; F-ACTIN; BUNDLING PROTEIN; PLASMA GELSOLIN; BINDING PROTEINS; CAPPING PROTEIN; BARBED ENDS; MICROVILLUS CYTOSKELETON; FACTOR ADF/COFILIN; CA2+ REGULATION	The cytoskeleton is a key regulator of plant morphogenesis, sexual reproduction, and cellular responses to extracellular stimuli. During the self-incompatibility response of Papaver rhoeas L. (field poppy) pollen, the actin filament network is rapidly depolymerized by a flood of cytosolic free Ca2+ that results in cessation of tip growth and prevention of fertilization. Attempts to model this dramatic cytoskeletal response with known pollen actin-binding proteins (ABPs) revealed that the major G-actin-binding protein profilin can account for only a small percentage of the measured depolymerization. We have identified an 80-kDa, Ca2+-regulated ABP from poppy pollen (PrABP80) and characterized its biochemical properties in vitro. Sequence determination by mass spectrometry revealed that PrABP80 is related to gelsolin and villin. The molecular weight, lack of filament cross-linking activity, and a potent severing activity are all consistent with PrABP80 being a plant gelsolin. Kinetic analysis of actin assembly/disassembly reactions revealed that substoichiometric amounts of PrABP80 can nucleate actin polymerization from monomers, block the assembly of profilin-actin complex onto actin filament ends, and enhance profilin-mediated actin depolymerization. Fluorescence microscopy of individual actin filaments provided compelling, direct evidence for filament severing and confirmed the actin nucleation and barbed end capping properties. This is the first direct evidence for a plant gelsolin and the first example of efficient severing by a plant ABP. We propose that PrABP80 functions at the center of the self-incompatibility response by creating new filament pointed ends for disassembly and by blocking barbed ends from profilin-actin assembly.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Purdue Motil Grp, W Lafayette, IN 47907 USA; Univ Grenoble 1, CNRS, CEA, Physiol Cellulaire Vegetale Lab, F-38054 Grenoble, France; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); University of Birmingham	Staiger, CJ (corresponding author), Purdue Univ, Dept Biol Sci, 333 Hansen Life Sci Bldg,201 S Univ St, W Lafayette, IN 47907 USA.	cstaiger@bilbo.bio.purdue.edu	Franklin-Tong, Vernonica E/D-1287-2012; Huang, Shanjin/M-4112-2017; Staiger, Christopher/AAF-2127-2019	Huang, Shanjin/0000-0001-9517-2515; Franklin-Tong, Noni/0000-0003-1782-8413				ASHINO N, 1987, J BIOCHEM-TOKYO, V101, P609, DOI 10.1093/jb/101.3.609; BEARER EL, 1991, J CELL BIOL, V115, P1629, DOI 10.1083/jcb.115.6.1629; Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; Cardenas L, 1998, PLANT PHYSIOL, V116, P871, DOI 10.1104/pp.116.3.871; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Choe H, 2002, J MOL BIOL, V324, P691, DOI 10.1016/S0022-2836(02)01131-2; COUE M, 1985, J BIOL CHEM, V260, P5033; Franklin-Tong VE, 1999, PLANT CELL, V11, P727, DOI 10.1105/tpc.11.4.727; Franklin-Tong VE, 1997, PLANT J, V12, P1375, DOI 10.1046/j.1365-313x.1997.12061375.x; FRANKLINTONG VE, 1993, PLANT J, V4, P163, DOI 10.1046/j.1365-313X.1993.04010163.x; FRIEDERICH E, 1999, GUIDEBOOK CYTOSKELET, P175; Fu Y, 2001, J CELL BIOL, V152, P1019, DOI 10.1083/jcb.152.5.1019; Geitmann A, 2000, PLANT CELL, V12, P1239, DOI 10.1105/tpc.12.7.1239; Gibbon BC, 1999, PLANT CELL, V11, P2349, DOI 10.1105/tpc.11.12.2349; GLENNEY JR, 1980, P NATL ACAD SCI-BIOL, V77, P6458, DOI 10.1073/pnas.77.11.6458; Gungabissoon RA, 1998, PLANT J, V16, P689, DOI 10.1046/j.1365-313x.1998.00339.x; Gungabissoon RA, 2001, CELL MOTIL CYTOSKEL, V49, P104, DOI 10.1002/cm.1024; HARRIS HE, 1981, FEBS LETT, V123, P49, DOI 10.1016/0014-5793(81)80017-8; HARRIS HE, 1984, FEBS LETT, V177, P184, DOI 10.1016/0014-5793(84)81280-6; Hepler PK, 2001, ANNU REV CELL DEV BI, V17, P159, DOI 10.1146/annurev.cellbio.17.1.159; Holdaway-Clarke TL, 2003, NEW PHYTOL, V159, P539, DOI 10.1046/j.1469-8137.2003.00847.x; Honys D, 2003, PLANT PHYSIOL, V132, P640, DOI 10.1104/pp.103.020925; Huang SJ, 2003, J BIOL CHEM, V278, P44832, DOI 10.1074/jbc.M306670200; Hussey PJ, 2002, PHILOS T R SOC B, V357, P791, DOI 10.1098/rstb.2002.1086; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; Janmey PA, 1998, CHEM BIOL, V5, pR81, DOI 10.1016/S1074-5521(98)90631-7; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963; Karakesisoglou I, 1996, CELL MOTIL CYTOSKEL, V34, P36; Kinosian HJ, 1998, BIOPHYS J, V75, P3101, DOI 10.1016/S0006-3495(98)77751-3; Klahre U, 2000, PLANT PHYSIOL, V122, P35, DOI 10.1104/pp.122.1.35; KOHNO T, 1987, PROTOPLASMA, V141, P177, DOI 10.1007/BF01272900; Kovar DR, 2000, PLANT CELL, V12, P583, DOI 10.1105/tpc.12.4.583; Kovar DR, 2000, PLANT J, V24, P625, DOI 10.1046/j.1365-313x.2000.00907.x; KURTH MC, 1983, J BIOL CHEM, V258, P895; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; Lin KM, 2000, J BIOL CHEM, V275, P27746; LIU XO, 1992, PLANT PHYSIOL, V99, P1151, DOI 10.1104/pp.99.3.1151; MAEKAWA S, 1984, J BIOCHEM-TOKYO, V95, P377, DOI 10.1093/oxfordjournals.jbchem.a134618; McGough A, 1998, BIOPHYS J, V74, P764, DOI 10.1016/S0006-3495(98)74001-9; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; McGough AM, 2003, FEBS LETT, V552, P75, DOI 10.1016/S0014-5793(03)00932-3; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Messerli M, 1997, J CELL SCI, V110, P1269; MILLER DD, 1992, J CELL SCI, V101, P7; Nakayasu T, 1998, BIOCHEM BIOPH RES CO, V249, P61, DOI 10.1006/bbrc.1998.9088; Narayan K, 2003, FEBS LETT, V552, P82, DOI 10.1016/S0014-5793(03)00933-5; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PAPAYANNOPOULOS IA, 1995, MASS SPECTROM REV, V14, P49, DOI 10.1002/mas.1280140104; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; Pierson ES, 1996, DEV BIOL, V174, P160, DOI 10.1006/dbio.1996.0060; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; Pope BJ, 1997, BIOCHEMISTRY-US, V36, P15848, DOI 10.1021/bi972192p; RATHORE KS, 1991, DEV BIOL, V148, P612, DOI 10.1016/0012-1606(91)90278-B; Ren HY, 1997, PLANT CELL, V9, P1445, DOI 10.1105/tpc.9.8.1445; Ressad F, 1999, J BIOL CHEM, V274, P20970, DOI 10.1074/jbc.274.30.20970; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; Robinson RC, 1999, SCIENCE, V286, P1939, DOI 10.1126/science.286.5446.1939; Schafer DA, 1998, CELL MOTIL CYTOSKEL, V39, P166, DOI 10.1002/(SICI)1097-0169(1998)39:2<166::AID-CM7>3.0.CO;2-4; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SELVE N, 1986, EUR J BIOCHEM, V160, P379, DOI 10.1111/j.1432-1033.1986.tb09982.x; Snowman BN, 2002, PLANT CELL, V14, P2613, DOI 10.1105/tpc.002998; Staiger CJ, 2004, ANNU PLANT REV, V10, P32; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Vidali L, 2001, MOL BIOL CELL, V12, P2534, DOI 10.1091/mbc.12.8.2534; Vidali L, 2001, PROTOPLASMA, V215, P64, DOI 10.1007/BF01280304; Vidali L, 1999, PROTOPLASMA, V209, P283, DOI 10.1007/BF01453456; WAY M, 1992, J CELL BIOL, V116, P1135, DOI 10.1083/jcb.116.5.1135; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WEBER A, 1991, BIOCHEMISTRY-US, V30, P9327, DOI 10.1021/bi00102a027; Yamashiro S, 2001, J BIOCHEM-TOKYO, V130, P243, DOI 10.1093/oxfordjournals.jbchem.a002978; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1999, GUIDEBOOK CYTOSKELET, P99; Yokota E, 2000, PLANT PHYSIOL, V123, P645, DOI 10.1104/pp.123.2.645; Yokota E, 1998, PLANT PHYSIOL, V116, P1421, DOI 10.1104/pp.116.4.1421; Yokota E, 1999, PLANTA, V209, P264, DOI 10.1007/s004250050631; Yokota E, 2003, PLANT CELL PHYSIOL, V44, P1088, DOI 10.1093/pcp/pcg132; YOKOTA E, 1995, PLANT CELL PHYSL S, V36, pS132; YOKOTA E, 2000, ACTIN DYNAMIC FRAMEW, P103	85	92	106	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23364	23375		10.1074/jbc.M312973200	http://dx.doi.org/10.1074/jbc.M312973200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039433	Green Published, hybrid			2022-12-25	WOS:000221570900072
J	Xu, SW; Howat, SL; Renzoni, EA; Holmes, A; Pearson, JD; Dashwood, MR; Bou-Gharios, G; Denton, CP; du Bois, RM; Black, CM; Leask, A; Abraham, DJ				Xu, SW; Howat, SL; Renzoni, EA; Holmes, A; Pearson, JD; Dashwood, MR; Bou-Gharios, G; Denton, CP; du Bois, RM; Black, CM; Leask, A; Abraham, DJ			Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; FACTOR-BETA; SYSTEMIC-SCLEROSIS; PHOSPHATIDYLINOSITOL 3-KINASE; SCLERODERMA FIBROBLASTS; EXTRACELLULAR-MATRIX; SMOOTH-MUSCLE; MAP KINASE; INHIBITOR; FIBROSIS	The endothelins are a family of endothelium-derived peptides that possess a variety of biological activities, including potent vasoconstriction. Endothelin-1 (ET-1) is up-regulated during tissue repair and pulmonary fibrosis. Here, we use genome-wide expression array analysis to show that the addition of ET-1 ( 100 nM, 4 h) to normal lung fibroblasts directly induces expression of matrix and matrix-associated genes, including the profibrotic protein CCN2 ( connective tissue growth factor, or CTGF). ET-1 induces the MEK/ERKMAP kinase pathway in fibroblasts. Blockade of the MEK/ERK kinase pathway with U0126 abrogates the ability of ET-1 to induce expression of matrix and matrix-associated mRNAs and the CCN2 protein. The CCN2 promoter possesses an ET-1 response element, which maps to the previously identified basal control element-1 (BCE-1) site. Our results suggest that ET-1 induces a program of matrix synthesis in lung fibroblasts and that ET-1 may play a key role in connective tissue deposition during wound repair and in pulmonary fibrosis.	UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, Dept Med, London NW3 2PF, England; UCL Royal Free & Univ Coll Med Sch, Dept Mol Pathol, London NW3 2PF, England; Kings Coll London, Guys Kings & St Thomas Sch Biomed Sci, Ctr Cardiovasc Biol & Med, London SE1 1UL, England; Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Interstitial Lung Dis Unit, London SW3 6LR, England; Univ London Imperial Coll Sci Technol & Med, Dept Med, London W12 0NN, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; King's College London; Imperial College London; Royal Brompton Hospital; Imperial College London	Leask, A (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, Dept Med, London NW3 2PF, England.	a.leask@rfc.ucl.ac.uk	Leask, Andy/ABH-9433-2020; Leask, Andrew/G-5217-2015	Renzoni, Elisabetta/0000-0002-1118-797X				Abraham DJ, 1997, AM J PATHOL, V151, P831; Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; ANGGARD EE, 1990, BLOOD VESSELS, V27, P269; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Badylak SE, 2002, SEMIN CELL DEV BIOL, V13, P377, DOI 10.1016/S1084952102000940; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; BIRK DE, 1990, J CELL SCI, V95, P649; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; BULL HA, 1993, DERMATOLOGY, V187, P1, DOI 10.1159/000247187; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; GUIDRY C, 1991, J CELL BIOL, V115, P873, DOI 10.1083/jcb.115.3.873; Hakonarson H, 2001, AM J RESP CELL MOL, V25, P761, DOI 10.1165/ajrcmb.25.6.4628; Handford PA, 2000, BBA-MOL CELL RES, V1498, P84, DOI 10.1016/S0167-4889(00)00085-9; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; KAWAGUCHI Y, 1994, ANN RHEUM DIS, V53, P506, DOI 10.1136/ard.53.8.506; Kohan DE, 1997, AM J KIDNEY DIS, V29, P2, DOI 10.1016/S0272-6386(97)90004-4; Leask A, 2004, J INVEST DERMATOL, V122, P1, DOI 10.1046/j.0022-202X.2003.22133.x; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Leask A, 2003, BIOCHEM CELL BIOL, V81, P355, DOI 10.1139/O03-069; LEASK A, 2004, IN PRESS FASEB J; LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Neubauer K, 2001, CAN J GASTROENTEROL, V15, P187, DOI 10.1155/2001/870205; OHNAKA K, 1993, J BIOL CHEM, V268, P26759; OKADA T, 1994, J BIOL CHEM, V269, P3563; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; Rodriguez-Pascual F, 2003, CIRC RES, V92, P1288, DOI 10.1161/01.RES.0000078491.79697.7F; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; RYYNANEN M, 1992, J CLIN INVEST, V89, P974, DOI 10.1172/JCI115680; Saita Y, 1998, EUR J PHARMACOL, V349, P123, DOI 10.1016/S0014-2999(98)00183-6; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; Shao R, 2003, MOL BIOL CELL, V14, P2327, DOI 10.1091/mbc.02-06-0093; Simms RW, 2002, CURR OPIN RHEUMATOL, V14, P717, DOI 10.1097/00002281-200211000-00015; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; Stratton R, 2001, J CLIN INVEST, V108, P241, DOI 10.1172/JCI12020; Taddeo B, 2002, P NATL ACAD SCI USA, V99, P17031, DOI 10.1073/pnas.252588599; Teder P, 2000, AM J RESP CELL MOL, V23, P7, DOI 10.1165/ajrcmb.23.1.f192; TEERLINK JR, 1994, CIRCULATION, V90, P2510, DOI 10.1161/01.CIR.90.5.2510; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; VANCHEESWARAN R, 1994, J RHEUMATOL, V21, P1838; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Xu SW, 2001, J INVEST DERMATOL, V116, P417, DOI 10.1046/j.1523-1747.2001.01256.x; Xu SW, 1998, J CARDIOVASC PHARM, V31, pS360, DOI 10.1097/00005344-199800001-00101; Xu SW, 1997, ARTHRITIS RHEUM-US, V40, P1237; YAMANE K, 1992, J RHEUMATOL, V19, P1566; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	55	138	147	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23098	23103		10.1074/jbc.M311430200	http://dx.doi.org/10.1074/jbc.M311430200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044479	hybrid			2022-12-25	WOS:000221570900039
J	Ko, M; Ahn, J; Lee, C; Chung, HY; Jeon, SH; Chung, HY; Seong, RH				Ko, M; Ahn, J; Lee, C; Chung, HY; Jeon, SH; Chung, HY; Seong, RH			E2A/HEB and Id3 proteins control the sensitivity to glucocorticoid-induced apoptosis in thymocytes by regulating the SRG3 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; T-CELL DEVELOPMENT; DNA-BINDING; LYMPHOCYTE DEVELOPMENT; E2A PROTEINS; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL CONTROL; G(1) PROGRESSION; MAMMALIAN-CELLS; PRE-TCR	The E protein family transcription factors encoded by the E2A and HEB genes are known to play critical roles in the coordinate regulation of lymphocyte development. Previous studies have shown that T cell receptor (TCR) signals rapidly induce Id3, a dominant negative antagonist of E2A activity and allow thymocytes to survive selection events in the thymus. Here we show that SRG3 acts as a novel downstream target of E2A/HeLa E box-binding ( HEB) complex and modulates glucocorticoid ( GC) susceptibility in thymocytes in response to TCR signals. We have identified a putative E box element in the SRG3 promoter that is required for optimal promoter activity. The transcription factors E2A and HEB specifically associate with the E box element. Moreover, E2A-HEB heterodimers cooperated to activate SRG3 transcription, which was inhibited by the expression of Id proteins. TCR-mediated signals rapidly induced Id3 via MEK/ERK activation and thereby kept the E2A/HEB complex from binding to the E box element in the SRG3 promoter. Retroviral transduction of Id3 also repressed the SRG3 expression by inhibiting the E box binding activity of the E2A/HEB complex. Intriguingly, enforced Id3 expression conferred thymocyte resistance to GCs, which could be overcome by the overexpression of SRG3. Taken together, these results suggest that Id3 may enhance the viability of immature thymocytes by at least rendering them resistant to GCs through SRG3 down-regulation.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea; Hanyang Univ, Sch Med, Dept Microbiol, Seoul 133791, South Korea; Hanyang Univ, Sch Med, Dept Pathol, Seoul 133791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Hanyang University; Hanyang University	Seong, RH (corresponding author), Seoul Natl Univ, Sch Biol Sci, Kwanak Gu Shinlim Dong San 56-1,Bldg 105, Seoul 151742, South Korea.	rhseong@plaza.snu.ac.kr		Seong, Rho/0000-0001-5699-0718; Chung, Hee Yong/0000-0001-7580-0537; Ko, Myunggon/0000-0002-6007-2570				ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bain G, 1997, IMMUNITY, V6, P145, DOI 10.1016/S1074-7613(00)80421-5; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Bain G, 1998, SEMIN IMMUNOL, V10, P143, DOI 10.1006/smim.1998.0116; Barndt R, 1999, J IMMUNOL, V163, P3331; Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Choi YI, 2001, P NATL ACAD SCI USA, V98, P10267, DOI 10.1073/pnas.181076198; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Clevers H, 1998, CURR OPIN IMMUNOL, V10, P166, DOI 10.1016/S0952-7915(98)80245-8; DEED RW, 1993, ONCOGENE, V8, P599; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; Engel I, 2004, EMBO J, V23, P202, DOI 10.1038/sj.emboj.7600017; Engel I, 2001, J EXP MED, V194, P733, DOI 10.1084/jem.194.6.733; Glimcher LH, 1999, CELL, V96, P13, DOI 10.1016/S0092-8674(00)80955-1; Han SM, 2001, J IMMUNOL, V167, P805, DOI 10.4049/jimmunol.167.2.805; HARA E, 1994, J BIOL CHEM, V269, P2139; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; Iwata M, 1996, EUR J IMMUNOL, V26, P2081, DOI 10.1002/eji.1830260918; Jeon SH, 1997, J EXP MED, V185, P1827, DOI 10.1084/jem.185.10.1827; Kee BL, 2000, IMMUNOL REV, V175, P138, DOI 10.1111/j.1600-065X.2000.imr017514.x; Kim DS, 2002, IMMUNITY, V16, P9, DOI 10.1016/S1074-7613(02)00264-9; Ko M, 2004, J BIOL CHEM, V279, P21903, DOI 10.1074/jbc.M402144200; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LISTER J, 1995, J BIOL CHEM, V270, P17939, DOI 10.1074/jbc.270.30.17939; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Massari ME, 1996, MOL CELL BIOL, V16, P121; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Ohoka Y, 1996, INT IMMUNOL, V8, P297, DOI 10.1093/intimm/8.3.297; Ohoka Y, 1997, J IMMUNOL, V158, P5707; Osborne BA, 2000, CURR OPIN IMMUNOL, V12, P301, DOI 10.1016/S0952-7915(00)00091-1; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; Wilkinson B, 2002, NAT IMMUNOL, V3, P272, DOI 10.1038/ni767; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; ZHAO Y, 1995, INT IMMUNOL, V7, P1387, DOI 10.1093/intimm/7.9.1387; ZHAO Y, 1995, J IMMUNOL, V154, P6346; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	55	19	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21916	21923		10.1074/jbc.M402145200	http://dx.doi.org/10.1074/jbc.M402145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15016815	hybrid			2022-12-25	WOS:000221417100031
J	Shcheynikov, N; Kim, KH; Kim, KM; Dorwart, MR; Ko, SBH; Goto, H; Naruse, S; Thomas, PJ; Muallem, S				Shcheynikov, N; Kim, KH; Kim, KM; Dorwart, MR; Ko, SBH; Goto, H; Naruse, S; Thomas, PJ; Muallem, S			Dynamic control of cystic fibrosis transmembrane conductance regulator Cl-/HCO(3)(-)selectivity by external Cl-	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL CHLORIDE DIARRHEA; DEPENDENT HCO3-TRANSPORT; PANCREATIC-DUCT CELLS; ANION-EXCHANGER; BICARBONATE SECRETION; CL-/HCO3-EXCHANGER; EPITHELIAL-CELLS; CFTR; CHANNEL; IDENTIFICATION	HCO3- secretion is a vital activity in cystic fibrosis transmembrane conductance regulator ( CFTR)- expressing epithelia. However, the role of CFTR in this activity is not well understood. Simultaneous measurements of membrane potential and pH(i) and/ or current in CFTR-expressing Xenopus oocytes revealed dynamic control of CFTR Cl-/ HCO3- permeability ratio, which is regulated by external Cl- ( Cl-o(-)). Thus, reducing external Cl- from 110 to 0 - 10 mM resulted in the expected increase in membrane potential, but with no corresponding OH- or HCO3- influx. Approximately 3 - 4 min after reducing Cl-o(-) to 0 mM, an abrupt switch in membrane potential occurs that coincided with an increased rates of OH- and HCO3- influx. The switch in membrane permeability to OH-/ HCO(3)(-)can also be recorded as a leftward shift in the reversal potential. Furthermore, an increased rate of OH- influx in response to elevating pH(o) to 9.0 was observed only after the switch in membrane potential. The time to switch increased to 11 min at Cl-o(-) of 5 mM. Conversely, re- addition of external Cl after the switch in membrane potential did not stop HCO3- influx, which continued for about 3.9 min after Cl- addition. Importantly, addition of external Cl- to cells incubated in Cl- free medium never resulted in HCO3- efflux. Voltage and current clamp experiments showed that the delayed HCO3- transport is electrogenic. These results indicate that CFTR exists in two conformations, a Cl- only and a Cl- and OH-/HCO3- permeable state. The switch between the states is controlled by external Cl-. Accordingly, a different tryptic pattern of CFTR was found upon digestion in Cl-- containing and Cl-- free media. The physiological significance of these finding is discussed in the context of HCO3- secretion by tissues such as the pancreas and salivary glands.	Univ Texas, SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Grad Program Mol Biophys, Dallas, TX 75390 USA; Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4668550, Japan	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Nagoya University	Muallem, S (corresponding author), Univ Texas, SW Med Ctr Dallas, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	shmuel.muallem@utsouthwestern.edu	Thomas, Philip J/F-7115-2012; Ko, Shigeru/H-3450-2012	Ko, Shigeru/0000-0003-1913-6357	NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK49835] Funding Source: Medline; NIGMS NIH HHS [GM-08203] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049835, R37DK049835] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGENT BE, 1994, TXB PHYSL GASTROINTE, P1478; Chernova MN, 2003, J PHYSIOL-LONDON, V549, P3, DOI 10.1113/jphysiol.2003.039818; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; COOK DI, 1994, TXB PHYSL GASTROINTE, P1061; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; Gong XD, 2003, J PHYSIOL-LONDON, V549, P387, DOI 10.1113/jphysiol.2002.038232; GRAY MA, 1990, AM J PHYSIOL, V259, pC752, DOI 10.1152/ajpcell.1990.259.5.C752; JOHANSEN PG, 1968, LANCET, V1, P455; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; KOPELMAN H, 1988, GASTROENTEROLOGY, V95, P349, DOI 10.1016/0016-5085(88)90490-8; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; Linsdell P, 1997, J GEN PHYSIOL, V110, P365, DOI 10.1085/jgp.110.4.365; Linsdell P, 1997, J GEN PHYSIOL, V110, P355, DOI 10.1085/jgp.110.4.355; Lohi H, 2000, GENOMICS, V70, P102, DOI 10.1006/geno.2000.6355; Makela S, 2002, HUM MUTAT, V20, P425, DOI 10.1002/humu.10139; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; O'Reilly CM, 2000, GASTROENTEROLOGY, V118, P1187, DOI 10.1016/S0016-5085(00)70372-6; Paradiso AM, 2003, J PHYSIOL-LONDON, V548, P203, DOI 10.1113/jphysiol.2002.034447; Petrovic S, 2003, AM J PHYSIOL-GASTR L, V284, pG1093, DOI 10.1152/ajpgi.00454.2002; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; QUINTON PM, 1999, PHYSIOL REV, V79, P3; Reddy MM, 2003, NATURE, V423, P756, DOI 10.1038/nature01694; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; Spiegel S, 2003, AM J PHYSIOL-GASTR L, V285, pG887, DOI 10.1152/ajpgi.00083.2003; Wang XF, 2003, NAT CELL BIOL, V5, P902, DOI 10.1038/ncb1047; Wang ZH, 2002, AM J PHYSIOL-GASTR L, V282, pG573, DOI 10.1152/ajpgi.00338.2001; WRIGHT AM, 2003, J PHYSL P, V549, pC21; Xie QH, 2002, AM J PHYSIOL-RENAL, V283, pF826, DOI 10.1152/ajprenal.00079.2002	28	82	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21857	21865		10.1074/jbc.M313323200	http://dx.doi.org/10.1074/jbc.M313323200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15010471	hybrid			2022-12-25	WOS:000221417100024
J	Cheng, WH; von Kobbe, C; Opresko, PL; Arthur, LM; Komatsu, K; Seidman, MM; Carney, JP; Bohr, VA				Cheng, WH; von Kobbe, C; Opresko, PL; Arthur, LM; Komatsu, K; Seidman, MM; Carney, JP; Bohr, VA			Linkage between Werner syndrome protein and the Mre11 complex via Nbs1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; SYNDROME CELLS; REPAIR; HELICASE; KINASE; WRN; RAD50/MRE11/NBS1	The Werner syndrome and the Nijmegen breakage syndrome are recessive genetic disorders that show increased genomic instability, cancer predisposition, hypersensitivity to mitomycin C and gamma-irradiation, shortened telomeres, and cell cycle defects. The protein mutated in the premature aging disease known as the Werner syndrome is designated WRN and is a member of the RecQ helicase family. The Nbs1 protein is mutated in Nijmegen breakage syndrome individuals and is part of the mammalian Mre11 complex together with the Mre11 and Rad50 proteins. Here, we show that WRN associates with the Mre11 complex via binding to Nbs1 in vitro and in vivo. In response to gamma-irradiation or mitomycin C, WRN leaves the nucleoli and co-localizes with the Mre11 complex in the nucleoplasm. We detect an increased association between WRN and the Mre11 complex after cellular exposure to gamma-irradiation. Small interfering RNA and complementation experiments demonstrated convergence of WRN and Nbs1 in response to gamma-irradiation or mitomycin C. Nbs1 is required for the Mre11 complex promotion of WRN helicase activity. Taken together, these results demonstrate a functional link between the two genetic diseases with partially overlapping phenotypes in a pathway that responds to DNA double strand breaks and interstrand cross-links.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Maryland, Sch Med, Radiat Oncol Lab, Baltimore, MD 21201 USA; Kyoto Univ, Dept Genome Repair Dynam, Radiat Biol Res Ctr, Kyoto 6068501, Japan	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Baltimore; Kyoto University	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020	von Kobbe, Cayetano/0000-0003-3895-3790; Opresko, Patricia/0000-0002-6470-2189	NATIONAL INSTITUTE ON AGING [Z01AG000738, ZIAAG000726, Z01AG000726, ZIAAG000738] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bohr VA, 2001, ENVIRON MOL MUTAGEN, V38, P227, DOI 10.1002/em.1076; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Cheng WH, 2003, MOL CELL BIOL, V23, P6385, DOI 10.1128/MCB.23.18.6385-6395.2003; Cooper MP, 2000, GENE DEV, V14, P907; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; Goedecke W, 1999, NAT GENET, V23, P194, DOI 10.1038/13821; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Karmakar P, 2002, J BIOL CHEM, V277, P18291, DOI 10.1074/jbc.M111523200; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; McHugh PJ, 2001, LANCET ONCOL, V2, P483, DOI 10.1016/S1470-2045(01)00454-5; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Nakada D, 2003, GENE DEV, V17, P1957, DOI 10.1101/gad.1099003; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	36	95	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21169	21176		10.1074/jbc.M312770200	http://dx.doi.org/10.1074/jbc.M312770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15026416	hybrid			2022-12-25	WOS:000221273800075
J	Duensing, A; Medeiros, F; McConarty, B; Joseph, NE; Panigrahy, D; Singer, S; Fletcher, CDM; Demetri, GD; Fletcher, JA				Duensing, A; Medeiros, F; McConarty, B; Joseph, NE; Panigrahy, D; Singer, S; Fletcher, CDM; Demetri, GD; Fletcher, JA			Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)	ONCOGENE			English	Article						KIT; imatinib; GIST; kinase; signal transduction	STEM-CELL FACTOR; RECEPTOR TYROSINE KINASE; HUMAN LEUKEMIA-CELLS; SRC FAMILY KINASES; C-KIT; INTERSTITIAL-CELLS; GERMLINE MUTATION; ACTIVATING MUTATIONS; JUXTAMEMBRANE DOMAIN; HEMATOPOIETIC-CELLS	Most gastrointestinal stromal tumors (GISTs) express constitutively activated forms of the KIT receptor tyrosine kinase protein, resulting from oncogenic mutations in the extracellular, juxtamembrane, or kinase domains. KIT oncoproteins are detected early in GIST tumorigenesis, and most GIST patients respond well to treatment with the KIT kinase inhibitor imatinib mesylate (STI571, Gleevec(R)). However, GISTs can develop resistance to imatinib, and additional therapeutic strategies are needed. Little is known about oncogenic KIT signal transduction in GISTs, and whether the type of KIT mutation accounts for selective activation of downstream signaling intermediates. We therefore evaluated KIT downstream signaling profiles in 15 primary GISTs with mutations in KIT exons 9, 11, 13, and 17, and in two human GIST cell lines. All GISTs showed constitutive phosphorylation at KIT tyrosine residues Y703 and Y721. Additionally, most GISTs showed activation of MAPK p42/44, AKT, S6K, STAT1, and STAT3. STAT5 and JNK were not demonstrably activated in any GIST. Using GIST in vitro models, we showed that activation of MAPK p42/44, AKT, and S6K was KIT dependent, whereas STAT1 and STAT3 phosphorylation was only partially dependent on KIT activation. Correlation of activated signaling pathways with the type of KIT mutation revealed low levels of AKT phosphorylation in exon 9 mutant GISTs in contrast to a subset of GISTs with exon 11 mutations. However, additional factors are likely to modify the engagement of signaling pathways in GISTs as suggested by the fact that four GISTs with identical KIT exon 9 mutations had differential activation of MAPK p42/44 and STAT proteins. In summary, in this first report on KIT signal transduction in primary GISTs and GIST cell lines, we identified pathways that are constitutively activated in a KIT-dependent manner and therefore warrant further study as molecular targets in GISTs.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, Dept Surg Oncol, New York, NY 10021 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Duensing, A (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	aduensing@rics.bwh.harvard.edu; jfletcher@partners.org		Duensing, Anette/0000-0002-0168-4067; Singer, Samuel/0000-0001-9713-8230				Beghini A, 2001, CANCER, V92, P657, DOI 10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Casteran N, 2003, ONCOGENE, V22, P4710, DOI 10.1038/sj.onc.1206587; Chen H, 2003, INT J CANCER, V105, P130, DOI 10.1002/ijc.11025; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; De Miguel MP, 2002, P NATL ACAD SCI USA, V99, P10458, DOI 10.1073/pnas.122249399; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Dolci S, 2001, J BIOL CHEM, V276, P40225, DOI 10.1074/jbc.M105143200; Ernst SI, 1998, LAB INVEST, V78, P1633; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Frost MJ, 2002, MOL CANCER THER, V1, P1115; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2000, AM J SURG PATHOL, V24, P326, DOI 10.1097/00000478-200002000-00045; Hornick JL, 2002, AM J CLIN PATHOL, V117, P188; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; Isozaki K, 2000, AM J PATHOL, V157, P1581, DOI 10.1016/S0002-9440(10)64795-5; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lasota J, 1999, AM J PATHOL, V154, P53, DOI 10.1016/S0002-9440(10)65250-9; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Linnekin D, 1996, ACTA HAEMATOL-BASEL, V95, P224; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Maeyama H, 2001, GASTROENTEROLOGY, V120, P210; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Ning ZQ, 2001, LEUKEMIA LYMPHOMA, V41, P513, DOI 10.3109/10428190109060342; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Rubin BP, 2001, CANCER RES, V61, P8118; Sircar K, 1999, AM J SURG PATHOL, V23, P377, DOI 10.1097/00000478-199904000-00002; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Taniguchi M, 1999, CANCER RES, V59, P4297; Taylor ML, 2000, HEMATOL ONCOL CLIN N, V14, P517, DOI 10.1016/S0889-8588(05)70294-X; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; TSAI M, 1993, EUR J IMMUNOL, V23, P3286, DOI 10.1002/eji.1830231234; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; Voytyuk O, 2003, J BIOL CHEM, V278, P9159, DOI 10.1074/jbc.M211726200; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Wu M, 2000, GENE DEV, V14, P301; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	51	249	264	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3999	4006		10.1038/sj.onc.1207525	http://dx.doi.org/10.1038/sj.onc.1207525			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007386				2022-12-25	WOS:000221382000012
J	Qiu, JZ; Liu, R; Chapados, BR; Sherman, M; Tainer, JA; Shen, BH				Qiu, JZ; Liu, R; Chapados, BR; Sherman, M; Tainer, JA; Shen, BH			Interaction interface of human flap endonuclease-1 with its DNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCISION-REPAIR; LAGGING-STRAND; PCNA BINDING; REPLICATION; FEN-1; CLEAVAGE; MECHANISM; EXONUCLEASE; CATALYSIS; PROTEINS	Flap endonuclease-1 or FEN-1 is a structure-specific and multifunctional nuclease critical for DNA replication, repair, and recombination; however, its interaction with DNA substrates has not been fully understood. In the current study, we have defined the borders of the interaction between the FEN-1 protein and its DNA substrates and identified six clusters of conserved positively charged amino acid residues, which are in direct contact with DNA substrate. To map further the corresponding interactions between FEN-1 residues and DNA substrates, we performed biochemical assays employing a series of flap DNA substrates lacking some structural components and a series of binding-deficient point mutants of FEN-1. It was revealed that Arg(47), Arg(70), and Lys(326)-Arg(327) of FEN-1 interact with the upstream duplex of DNA substrates, whereas Lys(244)-Arg(245) interact with the downstream duplex. This result indicates the orientation of the FEN-1-DNA interaction. Moreover, Arg(70) and Arg(47) were determined to interact with the sites around the 2nd nucleotide (Arg(70)) or the 5th/6th nucleotide (Arg(47)) of the template strand in the upstream duplex portion counting from the nick point of the flap substrate. Together with previously published data and the crystallographic information from the FEN-1.DNA complex that we published recently (Chapados, B. R., Hosfield, D. J., Han, S., Qiu, J., Yelent, B., Shen, B., Tainer, J. A. (2004) Cell 116, 39-50) we are able to propose a reasonable model for how the human FEN-1 protein interacts with its DNA substrates.	City Hope Natl Med Ctr, Dept Radiat Res, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Dept Bioinformat, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Grad Program Biol Sci, Duarte, CA 91010 USA; Beckman Res Inst, Duarte, CA 91010 USA; Skaggs Inst Chem Biol, Dept Mol Biol, La Jolla, CA 92122 USA; Scripps Res Inst, La Jolla, CA 92122 USA	City of Hope; City of Hope; City of Hope; City of Hope; Beckman Research Institute of City of Hope; Scripps Research Institute; Scripps Research Institute	Shen, BH (corresponding author), City Hope Natl Med Ctr, Dept Radiat Res, 1500 E Duarte, Duarte, CA 91010 USA.	bshen@coh.org	Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Shen, Binghui/0000-0002-4408-407X	NCI NIH HHS [R01CA073764, R01CA081967] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081967, R01CA073764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allawi HT, 2003, J MOL BIOL, V328, P537, DOI 10.1016/S0022-2836(03)00351-6; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chai Q, 2001, BIOCHEM BIOPH RES CO, V286, P1073, DOI 10.1006/bbrc.2001.5523; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Chevalier BS, 2001, NAT STRUCT BIOL, V8, P312, DOI 10.1038/86181; Frank G, 2001, J BIOL CHEM, V276, P36295, DOI 10.1074/jbc.M103397200; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hohl M, 2003, J BIOL CHEM, V278, P19500, DOI 10.1074/jbc.M213155200; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hubscher U, 2001, MOL CELLS, V12, P149; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; Kim CY, 2001, BIOCHEMISTRY-US, V40, P3208, DOI 10.1021/bi002100n; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kunkel TA, 1997, CELL, V88, P155, DOI 10.1016/S0092-8674(00)81832-2; Lyamichev V, 1999, P NATL ACAD SCI USA, V96, P6143, DOI 10.1073/pnas.96.11.6143; Matsui E, 2002, J BIOL CHEM, V277, P37840, DOI 10.1074/jbc.M205235200; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Negritto MC, 2001, MOL CELL BIOL, V21, P2349, DOI 10.1128/MCB.21.7.2349-2358.2001; Parrish JZ, 2003, MOL CELL, V11, P987, DOI 10.1016/S1097-2765(03)00095-9; Qiu JZ, 2001, J BIOL CHEM, V276, P4901, DOI 10.1074/jbc.M007825200; Qiu JZ, 2002, J BIOL CHEM, V277, P24659, DOI 10.1074/jbc.M111941200; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Storici F, 2002, EMBO J, V21, P5930, DOI 10.1093/emboj/cdf587; Stucki M, 2001, J BIOL CHEM, V276, P7843, DOI 10.1074/jbc.M008829200; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Xu Y, 2001, J BIOL CHEM, V276, P30167, DOI 10.1074/jbc.M100985200; YANG JT, 1986, METHOD ENZYMOL, V130, P208	44	19	22	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24394	24402		10.1074/jbc.M401464200	http://dx.doi.org/10.1074/jbc.M401464200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15037610	hybrid			2022-12-25	WOS:000221702500065
J	Ahamed, J; Ruf, W				Ahamed, J; Ruf, W			Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; FACTOR VIIA; KINASE-C; FACTOR XA; THROMBIN; COAGULATION; EXPRESSION; ADHESION; BINDING; FIBROBLASTS	Tissue factor (TF) is the physiological activator of the coagulation cascade that plays pathophysiological roles in metastasis, angiogenesis, and inflammation. Downstream in coagulation, thrombin is the central protease that signals through G protein-coupled, protease-activated receptors (PARs). However, the TF-VIIa-Xa complex upstream in coagulation also activates PAR1 and 2. Here, we address the question of whether signaling of the TF initiation complex is a relevant pathway that leads to TF cytoplasmic domain phosphorylation. In heterologous expression systems and primary endothelial cells, we demonstrate that the ternary TF-VIIa-Xa complex induces TF phosphorylation specifically by activating PAR2 but not through PAR1 signaling. In addition, TF cytoplasmic domain phosphorylation is induced only by TF-dependent signaling but not by other coagulation factors in endothelial cells. Phosphorylation of the Pro-directed kinase target site Ser(258) is dependent on prior phosphorylation of Ser(253) by protein kinase C (PKC) alpha. TF phosphorylation is somewhat delayed and coincides with sustained PKCalpha activation downstream of PAR2 but not PAR1 signaling. Phosphatidylcholine-dependent phospholipase C is the major pathway that leads to prolonged PKCalpha recruitment downstream of PAR2. Thus, PAR2 signaling specifically phosphorylates TF in a receptor cross-talk that distinguishes upstream from downstream coagulation protease signaling.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Ruf, W (corresponding author), Scripps Res Inst, Dept Immunol, C204,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ruf@scripps.edu			NHLBI NIH HHS [HL-60742, HL-16411, HL-48752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048752, P01HL016411, R01HL060742] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bergum PW, 2001, J BIOL CHEM, V276, P10063, DOI 10.1074/jbc.M009116200; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 2002, J BIOL CHEM, V277, P16081, DOI 10.1074/jbc.M108555200; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; Colognato R, 2003, BLOOD, V102, P2645, DOI 10.1182/blood-2002-08-2497; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coughlin SR, 2003, J CLIN INVEST, V111, P25, DOI 10.1172/JCI200317564; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dorfleutner A, 2003, BLOOD, V102, P3998, DOI 10.1182/blood-2003-04-1149; DRAKE TA, 1993, AM J PATHOL, V142, P1458; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fischer EG, 1999, J CLIN INVEST, V104, P1213, DOI 10.1172/JCI7750; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Hamilton JR, 2001, J CARDIOVASC PHARM, V38, P108, DOI 10.1097/00005344-200107000-00012; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Klarenbach SW, 2003, CIRC RES, V92, P272, DOI 10.1161/01.RES.0000057386.15390.A3; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Mody RS, 1997, BIOCHEMISTRY-US, V36, P7869, DOI 10.1021/bi9701235; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Pendurthi UR, 2002, ARTERIOSCL THROM VAS, V22, P1421, DOI 10.1161/01.ATV.0000030200.59331.3F; Randolph GJ, 1998, BLOOD, V92, P4167, DOI 10.1182/blood.V92.11.4167.423k35_4167_4177; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; RUF W, 1994, BIOCHEMISTRY-US, V33, P11631, DOI 10.1021/bi00204a026; Ruf W, 2003, J THROMB HAEMOST, V1, P1495, DOI 10.1046/j.1538-7836.2003.00300.x; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Siegbahn A, 2000, BLOOD, V96, P3452, DOI 10.1182/blood.V96.10.3452.h8003452_3452_3458; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; Versteeg HH, 2002, J BIOL CHEM, V277, P27065, DOI 10.1074/jbc.M110325200; Vouret-Craviari V, 2003, J THROMB HAEMOST, V1, P1103, DOI 10.1046/j.1538-7836.2003.00238.x; Weiss EJ, 2002, BLOOD, V100, P3240, DOI 10.1182/blood-2002-05-1470; Wolberg AS, 2000, BIOCHEM BIOPH RES CO, V272, P332, DOI 10.1006/bbrc.2000.2783; Yin YJ, 2003, ARTERIOSCL THROM VAS, V23, P940, DOI 10.1161/01.ATV.0000066878.27340.22; ZIONCHECK TF, 1992, J BIOL CHEM, V267, P3561	46	112	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23038	23044		10.1074/jbc.M401376200	http://dx.doi.org/10.1074/jbc.M401376200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039423	hybrid			2022-12-25	WOS:000221570900032
J	Jin, ZH; Gao, FQ; Flagg, T; Deng, XM				Jin, ZH; Gao, FQ; Flagg, T; Deng, XM			Nicotine induces multi-site phosphorylation of bad in association with suppression of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; LUNG-CANCER; BH3 DOMAIN; CELL-DEATH; SURVIVAL; BCL-2; ADENOCARCINOMA; INHIBITOR; RECEPTORS; STAUROSPORINE	Nicotine is an important component in cigarette smoke that can activate the growth-promoting pathways to facilitate the development of lung cancer. However, the intracellular mechanism(s) by which nicotine promotes survival of lung cancer cells remains enigmatic. Bad is a proapoptotic BH3-only member of the Bcl2 family and is expressed in both small cell lung cancer and non-small cell lung cancer cells. Here we report that nicotine potently induces Bad phosphorylation at Ser(112), Ser(136), and Ser(155) in a mechanism involving activation of MAPKs ERK1/2, PI3K/AKT, and PKA in human lung cancer cells. Nicotine-induced multi-site phosphorylation of Bad results in sequestering Bad from mitochondria and subsequently interacting with 14-3-3 in the cytosol. Treatment of cells with PKC inhibitor (staurosporine), MEK-specific inhibitor (PD98059), PI3 kinase inhibitor (LY294002), or PKA inhibitor (H89) blocks the nicotine-induced Bad phosphorylation that is associated with enhanced apoptotic cell death. The fact that beta-adrenergic receptor inhibitor ( propranolol) blocks nicotine-induced activation of ERK1/2, AKT, PKA, Bad phosphorylation, and cell survival suggests that nicotine-induced Bad phosphorylation may occur through the upstream beta-adrenergic receptors. The fact that specific knockdown of Bad expression by RNA interference using short interfering RNA enhances cell survival and that nicotine has no additional survival effect on these cells suggests that Bad may act as a required target of nicotine. Thus, nicotine-induced survival may occur in a mechanism through multi-site phosphorylation of Bad, which may lead to development of human lung cancer and/or chemoresistance.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Florida, Dept Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, 1600 SW Archer Rd,Acad Res Bldg,R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu	Jin, Zhaohui/AAQ-2893-2021; Jin, Zhaohui/AAI-5562-2020	Jin, Zhaohui/0000-0001-7844-5833				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; *AM CANC SOC, 2003, CANC FACTS FIG, P13; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Bergmann A, 2002, DEV CELL, V3, P607, DOI 10.1016/S1534-5807(02)00328-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Gadek-Michalska A, 2002, J PHYSIOL PHARMACOL, V53, P275; GARNIER M, 1994, P NATL ACAD SCI USA, V91, P11743, DOI 10.1073/pnas.91.24.11743; GOUELI BS, 1995, ANAL BIOCHEM, V225, P10, DOI 10.1006/abio.1995.1100; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hayakawa J, 2000, CANCER RES, V60, P5988; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Heusch WL, 1998, CARCINOGENESIS, V19, P551, DOI 10.1093/carcin/19.4.551; Hirai I, 2001, BIOCHEM J, V359, P345, DOI 10.1042/0264-6021:3590345; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; IKEGAKI N, 1994, CANCER RES, V54, P6; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Itier V, 2001, FEBS LETT, V504, P118, DOI 10.1016/S0014-5793(01)02702-8; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Karnath B, 2002, AM J MED, V112, P399, DOI 10.1016/S0002-9343(01)01126-3; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492; PARK PG, 1995, CANCER RES, V55, P3504; Perissin L, 1996, ANTICANCER RES, V16, P3409; Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schuller HM, 1999, CANCER RES, V59, P4510; Schuller HM, 2002, NAT REV CANCER, V2, P455, DOI 10.1038/nrc824; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; Suemaru K, 1997, N-S ARCH PHARMACOL, V355, P571, DOI 10.1007/PL00004985; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Uchida S, 2002, AUTON NEUROSCI-BASIC, V96, P126, DOI 10.1016/S1566-0702(02)00004-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	50	112	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23837	23844		10.1074/jbc.M402566200	http://dx.doi.org/10.1074/jbc.M402566200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15037618	hybrid			2022-12-25	WOS:000221570900128
J	Narasimhan, J; Staschke, KA; Wek, RC				Narasimhan, J; Staschke, KA; Wek, RC			Dimerization is required for activation of eIF2 kinase Gcn2 in response to diverse environmental stress conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-BINDING; DOUBLE-STRANDED-RNA; INITIATION FACTOR-2 KINASE; PROTEIN-KINASE; TRANSLATIONAL CONTROL; MASTER REGULATOR; GENE-EXPRESSION; MECHANISM; DOMAINS; TOR	In the yeast Saccharomyces cerevisiae, starvation for amino acids induces phosphorylation of the alpha subunit of eukaryotic initiation factor 2alpha by Gcn2 protein kinase, leading to elevated translation of GCN4. Gcn4p is a transcriptional activator of hundreds of genes involved in remedying nutrient deprivation. In addition to a conserved kinase domain, Gcn2p has a regulatory region homologous to histidyl tRNA synthetase enzymes that binds uncharged tRNA that accumulates during amino acid starvation. Flanking the carboxyl terminus of the histidyl-tRNA synthetase-related domain is a region spanning 162 residues that participates in the activation of the protein kinase. Gel filtration and chemical cross-linking analysis of the recombinant carboxyl-terminal Gcn2 protein revealed that this region is a stable homodimer that is highly resistant to high concentrations of salt. Residue alterations in three hydrophobic segments and one segment with a proposed amphipathic alpha-helix in this Gcn2p carboxyl terminus blocked oligomerization, supporting the role of hydrophobic interactions in the dimerization interface of Gcn2p. Introduction of residue substitutions that impaired dimerization into the full-length protein prevented the ability of Gcn2p to phosphorylate its substrate eukaryotic initiation factor-2alpha and induce GCN4 translational expression in yeast cells subjected to a variety of stresses including amino acid limitation or exposure to rapamycin or high levels of NaCl. This latter stress can be overcome by addition of increasing amounts of K+ ions, indicating that the Na+/K+ ion balance is central to this stress induction. We conclude that dimerization involving hydrophobic segments in the carboxyl-terminal region is required for activation of Gcn2p in response to a multitude of stresses.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Wek, RC (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	rwek@iupui.edu	Staschke, Kirk/HGC-5664-2022	Staschke, Kirk/0000-0001-8722-9585	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049164] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM49164, R01GM643540] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Blumwald E, 2000, BBA-BIOMEMBRANES, V1465, P140, DOI 10.1016/S0005-2736(00)00135-8; BONNET J, 1975, FEBS LETT, V53, P154, DOI 10.1016/0014-5793(75)80008-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; DRYDALE CM, 1998, MOL CELL BIOL, V18, P17111; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; Goossens A, 2001, J BIOL CHEM, V276, P30753, DOI 10.1074/jbc.M102960200; HEITMAN J, 1993, MOL CELL BIOL, V13, P5010, DOI 10.1128/MCB.13.8.5010; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; Ho CK, 1996, VIROLOGY, V217, P272, DOI 10.1006/viro.1996.0114; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; Krishnamoorthy T, 2001, MOL CELL BIOL, V21, P5018, DOI 10.1128/MCB.21.15.5018-5030.2001; Kubota H, 2003, J BIOL CHEM, V278, P20457, DOI 10.1074/jbc.C300133200; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Norbeck J, 1998, FEMS MICROBIOL LETT, V158, P121, DOI 10.1016/S0378-1097(97)00511-9; Pascual-Ahuir M, 2001, MOL CELL BIOL, V21, P16, DOI 10.1128/MCB.21.1.16-25.2001; Qiu H, 2001, EMBO J, V20, P1425, DOI 10.1093/emboj/20.6.1425; Qiu HF, 2002, GENE DEV, V16, P1271, DOI 10.1101/gad.979402; Qiu HF, 1998, MOL CELL BIOL, V18, P2697, DOI 10.1128/MCB.18.5.2697; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Rios G, 1997, YEAST, V13, P515, DOI 10.1002/(SICI)1097-0061(199705)13:6<515::AID-YEA102>3.0.CO;2-X; Rodriguez-Hernandez CJ, 2003, J BIOL CHEM, V278, P33887, DOI 10.1074/jbc.M305220200; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Sattlegger E, 2000, EMBO J, V19, P6622, DOI 10.1093/emboj/19.23.6622; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SEIN KT, 1971, ARCH BIOCHEM BIOPHYS, V145, P164, DOI 10.1016/0003-9861(71)90023-3; SMITH DWE, 1969, J BIOL CHEM, V244, P896; Swanson MJ, 2003, MOL CELL BIOL, V23, P2800, DOI 10.1128/MCB.23.8.2800-2820.2003; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; Valenzuela L, 2001, J BACTERIOL, V183, P2331, DOI 10.1128/JB.183.7.2331-2334.2001; Vattem KM, 2001, EUR J BIOCHEM, V268, P3674, DOI 10.1046/j.1432-1327.2001.02273.x; Wang Z, 2001, MOL CELL BIOL, V21, P5742, DOI 10.1128/MCB.21.17.5742-5752.2001; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1992, MOL CELL BIOL, V12, P5700, DOI 10.1128/MCB.12.12.5700; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Williams B.R., 2001, SCI STKE, V2001, pre2; Wilson WA, 2002, CELL, V111, P155, DOI 10.1016/S0092-8674(02)01043-7; Yang RJ, 1998, J BIOL CHEM, V273, P31337, DOI 10.1074/jbc.273.47.31337; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	60	61	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22820	22832		10.1074/jbc.M402228200	http://dx.doi.org/10.1074/jbc.M402228200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15010461	hybrid			2022-12-25	WOS:000221570900007
J	Chen, RM; Fearnley, IM; Palmer, DN; Walker, JE				Chen, RM; Fearnley, IM; Palmer, DN; Walker, JE			Lysine 43 is trimethylated in subunit c from bovine mitochondrial ATP synthase and in storage bodies associated with Batten disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; ELECTROSPRAY-IONIZATION; TRANSMEMBRANE PROTEIN; HEART-MITOCHONDRIA; MUTANT MICE; MUTATIONS; PURIFICATION; METHYLATION; SEQUENCE; PEPTIDES	The hydrophobic membrane protein, subunit c, has been isolated from ATP synthase purified from bovine heart mitochondria. It has also been obtained from lysosomal storage bodies associated with ceroid lipofuscinosis from ovine liver and from human brain tissue of a victim of Batten disease. It is likely that the lysosomal protein has originated from the mitochondrion. These samples have been characterized by mass spectrometric methods. Irrespective of its source, subunit c has an intact molecular mass of 7650 Da, 42 Da greater than the value calculated from the amino acid sequence, and the protein has been modified post- translationally. In all three samples, the modification is associated with lysine 43, which lies in a polar loop region linking the two transmembrane alpha- helices of the protein. This residue is conserved throughout vertebrate sequences. The additional mass arises from trimethylation and not acetylation at the epsilon- N- position of the residue. These experiments show that the post- translational modification of subunit c is not, as has been suggested, an abnormal phenomenon associated with the etiology of Batten disease and ceroid lipofucinoses. Evidently, it occurs either before or during import of the protein into mitochondria or at a mitochondrial location after completion of the import process. The function of the trimethyllysine residue in the assembled ATP synthase complex is obscure. The residue and the modification are not conserved in all ATP synthases, and their role in the assembly and ( or) functioning of the enzyme appear to be confined to higher organisms.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Lincoln Univ, Anim & Food Sci Div, Canterbury, New Zealand	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Lincoln University - New Zealand	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust Med Res Council Bldg,Hills Rd, Cambridge CB2 2XY, England.	walker@mrc-dunn.cam.ac.uk	Palmer, David/B-7344-2008	Walker, John/0000-0001-7929-2162				Broom MF, 1998, J MED GENET, V35, P717, DOI 10.1136/jmg.35.9.717; Buchanan SK, 1996, BIOCHEM J, V318, P343, DOI 10.1042/bj3180343; Buzy A, 1996, RAPID COMMUN MASS SP, V10, P790; COLLINSON IR, 1994, BIOCHEM J, V303, P639, DOI 10.1042/bj3030639; Ezaki J, 1996, J NEUROCHEM, V67, P1677, DOI 10.1046/j.1471-4159.1996.67041677.x; FEARNLEY IM, 1987, BIOCHEMISTRY-US, V26, P8247, DOI 10.1021/bi00399a034; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; FEARNLEY IM, 1990, BIOCHEM J, V268, P751, DOI 10.1042/bj2680751; Fearnley IM, 1996, BIOCHEM SOC T, V24, P912, DOI 10.1042/bst0240912; FILLINGAME RH, 1992, BIOCHIM BIOPHYS ACTA, V1101, P240, DOI 10.1016/0005-2728(92)90235-T; FILLINGAME RH, 1976, J BIOL CHEM, V251, P6630; Gao HL, 2002, AM J HUM GENET, V70, P324, DOI 10.1086/338190; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Herva R, 2000, BRAIN PATHOL, V10, P215, DOI 10.1111/j.1750-3639.2000.tb00255.x; KATZ ML, 1990, MECH AGEING DEV, V53, P277, DOI 10.1016/0047-6374(90)90045-H; Katz ML, 1996, BBA-MOL BASIS DIS, V1317, P192, DOI 10.1016/S0925-4439(96)00054-3; KATZ ML, 1995, BIOCHEM J, V310, P887, DOI 10.1042/bj3100887; KATZ ML, 1992, BIOCHIM BIOPHYS ACTA, V1138, P97, DOI 10.1016/0925-4439(92)90048-R; Katz ML, 1997, BBA-MOL BASIS DIS, V1361, P66, DOI 10.1016/S0925-4439(97)00017-3; KATZ ML, 1994, J BIOL CHEM, V269, P9906; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; Meier T, 2003, J MOL BIOL, V325, P389, DOI 10.1016/S0022-2836(02)01204-4; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MORAND K, 1993, RAPID COMMUN MASS SP, V7, P738, DOI 10.1002/rcm.1290070811; Palmer D N, 1988, Am J Med Genet Suppl, V5, P141, DOI 10.1002/ajmg.1320310618; Palmer DN, 2002, ARCH GERONTOL GERIAT, V34, P343, DOI 10.1016/S0167-4943(02)00011-0; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; PALMER DN, 1989, J BIOL CHEM, V264, P5736; Ranta S, 1999, NAT GENET, V23, P233, DOI 10.1038/13868; Savukoski M, 1998, NAT GENET, V19, P286, DOI 10.1038/975; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; SEBALD W, 1979, FUNCTION MOL ASPECTS, P63; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Tyynela J, 1997, J NEUROPATH EXP NEUR, V56, P369, DOI 10.1097/00005072-199704000-00005; TYYNELA J, 1993, FEBS LETT, V330, P8, DOI 10.1016/0014-5793(93)80908-D; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; Vines DJ, 1999, FEBS LETT, V443, P131, DOI 10.1016/S0014-5793(98)01683-4; Wheeler RB, 2002, AM J HUM GENET, V70, P537, DOI 10.1086/338708; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; Zhang KL, 2004, PROTEOMICS, V4, P1, DOI 10.1002/pmic.200300503	45	57	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21883	21887		10.1074/jbc.M402074200	http://dx.doi.org/10.1074/jbc.M402074200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15010464	hybrid			2022-12-25	WOS:000221417100027
J	Christensen, MO; Krokowski, RM; Barthelmes, HU; Hock, R; Boege, F; Mielke, C				Christensen, MO; Krokowski, RM; Barthelmes, HU; Hock, R; Boege, F; Mielke, C			Distinct effects of topoisomerase I and RNA polymerase I inhibitors suggest a dual mechanism of nucleolar/nucleoplasmic partitioning of topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASES; SUBNUCLEAR DISTRIBUTION; SUMO-1 CONJUGATION; FIBRILLAR CENTERS; ACTINOMYCIN-D; CAMPTOTHECIN; TRANSCRIPTION; COMPLEXES; REPAIR; REPLICATION	Topoisomerase I is mostly nucleolar, because it plays a preeminent role in ribosomal DNA ( rDNA) transcription. It is cleared from nucleoli following exposure to drugs stabilizing covalent DNA intermediates of the enzyme ( e. g. camptothecin) or inhibiting RNA polymerases ( e. g. actinomycin D), an effect summarily attributed to blockade of rDNA transcription. Here we show that two distinct mechanisms are at work: ( i) Both drugs induce inactivation and segregation of the rRNA transcription machinery. With actinomycin D this leads to a co- migration of RNA- polymerase I and topoisomerase I to the nucleolar perimeter. The process has a slow onset (> 20 min), is independent of topoisomerase I activity, but requires the N- terminal domain of the enzyme to colocalize with RNA polymerase I. ( ii) Camptothecin induces, in addition, immobilization of active topoisomerase I on genomic DNA resulting in rapid nucleolar clearance and spreading of the enzyme to the entire nucleoplasm. This effect is independent of the state of rRNA transcription, involves segregation of topoisomerase I from RNA polymerase I, has a rapid onset (< 1 min), and requires catalytic activity but neither the N- terminal domain of topoisomerase I nor its major sumoylation site. Thus, nucleolar/ nucleoplasmic partitioning of topoisomerase I is regulated by interactions with RNA polymerase I and DNA but not by sumoylation.	Univ Dusseldorf, Sch Med, Inst Clin Chem & Lab Diagnost, D-40225 Dusseldorf, Germany; Univ Wurzburg, Bioctr, Dept Cell & Dev Biol, D-97074 Wurzburg, Germany	Heinrich Heine University Dusseldorf; University of Wurzburg	Mielke, C (corresponding author), Univ Dusseldorf, Sch Med, Inst Clin Chem & Lab Diagnost, Moorenstr 5, D-40225 Dusseldorf, Germany.	christian.mielke@med.uni-duesseldorf.de	Boege, Fritz/H-3261-2019					BEIDLER DR, 1995, MOL PHARMACOL, V47, P907; Buckwalter CA, 1996, CANCER RES, V56, P1674; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen HK, 1999, MOL CELL BIOL, V19, P8536; Cheutin T, 2002, J CELL SCI, V115, P3297; Christensen MO, 2002, J CELL BIOL, V157, P31, DOI 10.1083/jcb.200112023; Christensen MO, 2003, NUCLEIC ACIDS RES, V31, P7255, DOI 10.1093/nar/gkg927; Christensen MO, 2002, J BIOL CHEM, V277, P15661, DOI 10.1074/jbc.C200066200; Christensen MO, 2002, J BIOL CHEM, V277, P35932, DOI 10.1074/jbc.M204738200; CULOTTA V, 1988, CELL, V52, P585, DOI 10.1016/0092-8674(88)90471-0; Danks MK, 1996, CANCER RES, V56, P1664; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Desai SD, 2001, CANCER RES, V61, P5926; GEDIK CM, 1990, NUCLEIC ACIDS RES, V18, P1007, DOI 10.1093/nar/18.4.1007; GULDNER HH, 1986, CHROMOSOMA, V94, P132, DOI 10.1007/BF00286991; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; Jacobson MR, 1995, J CELL BIOL, V131, P1649, DOI 10.1083/jcb.131.6.1649; JORDAN EG, 1981, J CELL SCI, V52, P373; KAUFMANN SH, 1991, CANCER RES, V51, P1129; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Mao YH, 2000, CANCER RES, V60, P4538; Mao YH, 2002, P NATL ACAD SCI USA, V99, P1235, DOI 10.1073/pnas.022631899; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; Padget K, 2000, BIOCHEM PHARMACOL, V59, P629, DOI 10.1016/S0006-2952(99)00372-X; PERRY RP, 1963, EXP CELL RES, V29, P400, DOI 10.1016/S0014-4827(63)80003-8; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Pondarre C, 1997, NUCLEIC ACIDS RES, V25, P4111, DOI 10.1093/nar/25.20.4111; Rallabhandi P, 2002, J BIOL CHEM, V277, P40020, DOI 10.1074/jbc.M200388200; Rasheed ZA, 2003, ONCOGENE, V22, P7296, DOI 10.1038/sj.onc.1206935; REIMER G, 1987, J CLIN INVEST, V79, P65, DOI 10.1172/JCI112809; ROSE KM, 1988, CHROMOSOMA, V96, P411, DOI 10.1007/BF00303034; Seither P, 1998, J MOL BIOL, V275, P43, DOI 10.1006/jmbi.1997.1434; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; STEWART AF, 1987, CELL, V50, P1109, DOI 10.1016/0092-8674(87)90177-2; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Suja JA, 1997, CHROMOSOMA, V105, P459, DOI 10.1007/BF02510483; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060	45	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21873	21882		10.1074/jbc.M400498200	http://dx.doi.org/10.1074/jbc.M400498200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15014084	hybrid			2022-12-25	WOS:000221417100026
J	Yamagami, S; Morioka, D; Fukuda, R; Ohta, A				Yamagami, S; Morioka, D; Fukuda, R; Ohta, A			A basic helix-loop-helix transcription factor essential for cytochrome P450 induction in response to alkanes in yeast Yarrowia lipolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-DECANE ASSIMILATION; CANDIDA-TROPICALIS; MULTIGENE FAMILY; NUCLEAR RECEPTORS; GENE; IDENTIFICATION; PROMOTER; MALTOSA; CYP52; HYDROXYLATION	When the alkane-assimilating yeast Yarrowia lipolytica is cultivated on n-alkanes, it changes cellular metabolism for adaptation by inducing cytochrome P450 and other genes. From a comparative analysis of promoters of alkane-inducible genes, we identified a cis-acting element, ARE1 ((a) under bar lkane (r) under bar esponsive (e) under bar lement (1) under bar), which provides transcription induction in response to n-alkanes. In a genetic selection for mutants that were defective in ARE1-mediated transcription induction in the presence of n-alkanes, we found that the YAS1 ((y) under bar east (a) under bar lkane (s) under bar ignaling) gene is essential for alkane response. The YAS1 gene encodes a basic helix-loop- helix (bHLH) family protein. Loss of Yas1p causes defects in n-alkane-dependent transcription induction of the P450 gene and growth on n-alkanes. Yas1p localizes to nuclei and binds to promoters containing ARE1. Yas1p also binds to its own promoter, and the expression of YAS1 is induced by n-alkanes. These features suggest that Yas1p is a novel transcription factor mediating alkane signaling and that it provides an autoregulatory loop.	Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Ohta, A (corresponding author), Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.	aaohta@mail.ecc.u-tokyo.ac.jp						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASPERGER O, 1981, FEMS MICROBIOL LETT, V11, P309, DOI 10.1111/j.1574-6968.1981.tb06986.x; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; Barth G, 1997, FEMS MICROBIOL REV, V19, P219, DOI 10.1016/S0168-6445(97)00002-8; Barth G, 1996, NONCONVENTIONAL YEAS, P313, DOI [DOI 10.1007/978-3-642-79856-6_10, 10.1007/978-3-642-79856-6_10]; BERNINGER G, 1993, EUR J BIOCHEM, V216, P607, DOI 10.1111/j.1432-1033.1993.tb18180.x; Bon E, 2003, NUCLEIC ACIDS RES, V31, P1121, DOI 10.1093/nar/gkg213; CARDINI G, 1970, J BIOL CHEM, V245, P2789; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Iida T, 1998, YEAST, V14, P1387; Kanai T, 2000, J BACTERIOL, V182, P2492, DOI 10.1128/JB.182.9.2492-2497.2000; Khan R, 2003, MOL MICROBIOL, V49, P117, DOI 10.1046/j.1365-2958.2003.03552.x; Klug M J, 1971, Adv Microb Physiol, V5, P1; LEBEAULT JM, 1971, BIOCHEM BIOPH RES CO, V42, P413, DOI 10.1016/0006-291X(71)90386-X; Lida T, 2000, YEAST, V16, P1077, DOI 10.1002/1097-0061(20000915)16:12<1077::AID-YEA601>3.0.CO;2-K; Madzak C, 1999, MICROBIOL-UK, V145, P75, DOI 10.1099/13500872-145-1-75; Mimura J, 2003, BBA-GEN SUBJECTS, V1619, P263, DOI 10.1016/S0304-4165(02)00485-3; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OHKUMA M, 1995, DNA CELL BIOL, V14, P163, DOI 10.1089/dna.1995.14.163; OHKUMA M, 1991, DNA CELL BIOL, V10, P271, DOI 10.1089/dna.1991.10.271; OHKUMA M, 1995, BIOSCI BIOTECH BIOCH, V59, P1328, DOI 10.1271/bbb.59.1328; Robinson KA, 2000, NUCLEIC ACIDS RES, V28, P1499, DOI 10.1093/nar/28.7.1499; SANGLARD D, 1987, BIOCHEM BIOPH RES CO, V144, P251, DOI 10.1016/S0006-291X(87)80503-X; SANGLARD D, 1989, FEBS LETT, V256, P128, DOI 10.1016/0014-5793(89)81732-6; SEGHEZZI W, 1992, DNA CELL BIOL, V11, P767, DOI 10.1089/dna.1992.11.767; SEGHEZZI W, 1991, GENE, V106, P51, DOI 10.1016/0378-1119(91)90565-S; Spormann AM, 2000, BIODEGRADATION, V11, P85, DOI 10.1023/A:1011122631799; Sumita T, 2002, BIOCHEM BIOPH RES CO, V294, P1071, DOI 10.1016/S0006-291X(02)00607-1; Takagi H., 2000, MEMOIRS GEOLOGICAL S, V56, P1; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang HJJ, 1999, J BACTERIOL, V181, P5140, DOI 10.1128/JB.181.17.5140-5148.1999; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; WICKERHA.LJ, 1970, SCIENCE, V167, P1141, DOI 10.1126/science.167.3921.1141; Yamagami S, 2001, BIOCHEM BIOPH RES CO, V282, P832, DOI 10.1006/bbrc.2001.4653	38	32	34	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22183	22189		10.1074/jbc.M313313200	http://dx.doi.org/10.1074/jbc.M313313200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15044482	hybrid			2022-12-25	WOS:000221417100063
J	Zhang, HFM; Rao, JN; Guo, X; Liu, L; Zou, TT; Turner, DJ; Wang, JY				Zhang, HFM; Rao, JN; Guo, X; Liu, L; Zou, TT; Turner, DJ; Wang, JY			Akt kinase activation blocks apoptosis in intestinal epithelial cells by inhibiting caspase-3 after polyamine depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; GASTROINTESTINAL MUCOSAL GROWTH; THREONINE PROTEIN-KINASE; KAPPA-B ACTIVATION; ORNITHINE DECARBOXYLASE; IEC-6 CELLS; STEM-CELLS; PHOSPHORYLATION; SURVIVAL; EXPRESSION	Apoptosis plays a critical role in the maintenance of gut mucosal homeostasis and is regulated by numerous factors including polyamines. Although the exact roles of polyamines in apoptotic pathway are still unclear, inhibition of polyamine synthesis promotes the resistance of intestinal epithelial cells to apoptosis. Akt is a serine-threonine kinase that has been established as an important intracellular signaling in regulating cell survival. The current studies test the hypothesis that polyamines are involved in the control of Akt activity in normal intestinal epithelial cells (IEC-6 line) and that activated Akt mediates suppression of apoptosis following polyamine depletion. Depletion of cellular polyamines by alpha-difluoromethylornithine induced levels of phosphorylated Akt and increased Akt kinase activity, although it had no effect on expression of total Akt, pERK, p38, and Bcl-2 proteins. This activated Akt was associated with both decreased levels of active caspase-3 and increased resistance to tumor necrosis factor-alpha/cycloheximide-induced apoptosis. Inactivation of Akt by either treatment with LY294002 or ectopic expression of a dominant negative Akt mutant (DNMAkt) not only enhanced the caspase-3 activation in polyamine-deficient cells but also prevented the increased resistance to tumor necrosis factor-alpha/cycloheximide-induced apoptosis. Phosphorylation of glycogen synthase kinase-3, a downstream target of Akt, was also increased in alpha-difluoromethylornithine-treated cells, which was prevented by inactivation of Akt by LY294002 or DNMAkt overexpression. These results indicate that polyamine depletion induces the Akt activation mediating suppression of apoptosis via inhibition of caspase-3 in normal intestinal epithelial cells.	Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Wang, JY (corresponding author), Univ Maryland, Sch Med, Dept Surg, 10 N Greene St, Baltimore, MD 21201 USA.	jwang@smail.umaryland.edu			NIDDK NIH HHS [DK-61972, DK-57819] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057819, R01DK061972] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Bhattacharya S, 2003, AM J PHYSIOL-GASTR L, V285, pG980, DOI 10.1152/ajpgi.00206.2003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BM, 1995, NATURE, V376, P553; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDEK H, 1997, SCIENCE, V31, P275; Edwards E, 2002, CANCER RES, V62, P4671; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HALL PA, 1994, J CELL SCI, V107, P3569; HARTER JL, 1960, BIOMETRIC, P671; JOHNSON LR, 1988, PHYSIOL REV, V68, P456, DOI 10.1152/physrev.1988.68.2.456; Jones BA, 1997, AM J PHYSIOL-GASTR L, V273, pG1174, DOI 10.1152/ajpgi.1997.273.6.G1174; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeBlanc AC, 2003, PROG NEURO-PSYCHOPH, V27, P215, DOI 10.1016/S0278-5846(03)00017-4; Li L, 2002, GASTROENTEROLOGY, V123, P764, DOI 10.1053/gast.2002.35386; Li L, 2001, AM J PHYSIOL-GASTR L, V280, pG992, DOI 10.1152/ajpgi.2001.280.5.G992; Li L, 1999, AM J PHYSIOL-CELL PH, V276, pC946, DOI 10.1152/ajpcell.1999.276.4.C946; Lindsay GS, 1999, BIOCHEM J, V337, P83, DOI 10.1042/0264-6021:3370083; Liu L, 2003, AM J PHYSIOL-GASTR L, V285, pG1056, DOI 10.1152/ajpgi.00151.2003; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; LUK GD, 1980, SCIENCE, V210, P195, DOI 10.1126/science.6774420; MCCORMACK SA, 1991, AM J PHYSIOL, V260, pG795, DOI 10.1152/ajpgi.1991.260.6.G795; Montaner S, 2001, CANCER RES, V61, P2641; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; OSBORNE DL, 1990, AM J PHYSIOL, V258, pG576, DOI 10.1152/ajpgi.1990.258.4.G576; Patel AR, 1999, AM J PHYSIOL-GASTR L, V276, pG441, DOI 10.1152/ajpgi.1999.276.2.G441; Patel AR, 1998, AM J PHYSIOL-CELL PH, V275, pC590, DOI 10.1152/ajpcell.1998.275.2.C590; Pfeffer LM, 2001, J BIOL CHEM, V276, P45909, DOI 10.1074/jbc.M108097200; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; Potten CS, 1997, AM J PHYSIOL-GASTR L, V273, pG253, DOI 10.1152/ajpgi.1997.273.2.G253; POULIN R, 1995, BIOCHEM J, V311, P723, DOI 10.1042/bj3110723; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Stefanelli C, 2002, FEBS LETT, V527, P223, DOI 10.1016/S0014-5793(02)03242-8; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Suhara T, 2003, NEUROBIOL AGING, V24, P437, DOI 10.1016/S0197-4580(02)00135-5; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG JY, 1993, AM J PHYSIOL, V265, pG331, DOI 10.1152/ajpgi.1993.265.2.G331; Wang QD, 2002, J BIOL CHEM, V277, P36602, DOI 10.1074/jbc.M206306200; Weihl CC, 1999, J NEUROSCI, V19, P5360; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; ZHANG HM, 2004, GASTROENTEROLOGY, V126, P3589; ZOU TT, 2004, AM J PHYSIOL, V286, pC1109	62	84	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22539	22547		10.1074/jbc.M314337200	http://dx.doi.org/10.1074/jbc.M314337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15024023	hybrid			2022-12-25	WOS:000221417100105
J	Janse, DM; Crosas, B; Finley, D; Church, GM				Janse, DM; Crosas, B; Finley, D; Church, GM			Localization to the proteasome is sufficient for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CORE PARTICLE; 20S PROTEASOME; S PROTEASOMES; PROTEIN; UBIQUITIN; YEAST; SUBSTRATE; SYSTEM; SIGNAL	The majority of unstable proteins in eukaryotic cells are targeted for degradation through the ubiquitin-proteasome pathway. Substrates for degradation are recognized by the E1, E2, and E3 ubiquitin conjugation machinery and tagged with polyubiquitin chains, which are thought to promote the proteolytic process through their binding with the proteasome. We describe a method to bypass the ubiquitination step artificially both in vivo and in a purified in vitro system. Seven proteasome subunits were tagged with Fpr1, and fusion reporter constructs were created with the Fpr1-rapamycin binding domain of Tor1. Reporter proteins were localized to the proteasome by the addition of rapamycin, a drug that heterodimerizes Fpr1 and Tor1. Degradation of reporter proteins was observed with proteasomes that had either Rpn10 or Pre10 subunits tagged with Fpr1. Our experiments resolved a simple but central problem concerning the design of the ubiquitin-proteasome pathway. We conclude that localization to the proteasome is sufficient for degradation and, therefore, any added functions polyubiquitin chains possess beyond tethering substrates to the proteasome are not strictly necessary for proteolysis.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Church, GM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	g1m1c1@arep.med.harvard.edu		church, george/0000-0001-6232-9969	NCI NIH HHS [CM 43601] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Benaroudj N, 2000, NAT CELL BIOL, V2, P833, DOI 10.1038/35041081; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DICK LR, 1994, J IMMUNOL, V152, P3884; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Groll M, 2003, INT J BIOCHEM CELL B, V35, P606, DOI 10.1016/S1357-2725(02)00390-4; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Matouschek A, 2003, CURR OPIN STRUC BIOL, V13, P98, DOI 10.1016/S0959-440X(03)00010-1; Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671; Sakamoto KM, 2003, MOL CELL PROTEOMICS, V2, P1350, DOI 10.1074/mcp.T300009-MCP200; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; SIKORSKI RS, 1989, GENETICS, V122, P19; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; Tarcsa E, 2000, J BIOL CHEM, V275, P20295, DOI 10.1074/jbc.M001555200; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	39	82	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21415	21420		10.1074/jbc.M402954200	http://dx.doi.org/10.1074/jbc.M402954200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15039430	hybrid			2022-12-25	WOS:000221273800106
J	Milani, M; Pesce, A; Ouellet, Y; Dewilde, S; Friedman, J; Ascenzi, P; Guertin, M; Bolognesi, M				Milani, M; Pesce, A; Ouellet, Y; Dewilde, S; Friedman, J; Ascenzi, P; Guertin, M; Bolognesi, M			Heme-ligand tunneling in group I truncated hemoglobins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; DYNAMICS; CAVITIES	Truncated hemoglobins (trHbs) are small hemoproteins forming a separate cluster within the hemoglobin superfamily; their functional roles in bacteria, plants, and unicellular eukaryotes are marginally understood. Crystallographic investigations have shown that the trHb fold (a two-on-two alpha-helical sandwich related to the globin fold) hosts a protein matrix tunnel system offering a potential path for ligand diffusion to the heme distal site. The tunnel topology is conserved in group I trHbs, although with modulation of its size/structure. Here, we present a crystallographic investigation on trHbs from Mycobacterium tuberculosis, Chlamydomonas eugametos, and Paramecium caudatum, showing that treatment of trHb crystals under xenon pressure leads to binding of xenon atoms at specific (conserved) sites along the protein matrix tunnel. The crystallographic results are in keeping with data from molecular dynamics simulations, where a dioxygen molecule is left free to diffuse within the protein matrix. Modulation of xenon binding over four main sites is related to the structural properties of the tunnel system in the three trHbs and may be connected to their functional roles. In a parallel crystallographic investigation on M. tuberculosis trHbN, we show that butyl isocyanide also binds within the apolar tunnel, in excellent agreement with concepts derived from the xenon binding experiments. These results, together with recent data on atypical CO rebinding kinetics to group I trHbs, underline the potential role of the tunnel system in supporting diffusion, but also accumulation in multiple copies, of low polarity ligands/molecules within group I trHbs.	INFM, Dept Phys, I-16146 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16146 Genoa, Italy; Ist Giannina Gaslini, I-16147 Genoa, Italy; Univ Laval, Fac Sci & Genie, Dept Biochim & Microbiol, Ste Foy, PQ G1K 7P4, Canada; Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Roma Tre, Dept Biol, I-00146 Rome, Italy; Univ Roma Tre, Interdept Lab Electron Microscopy, I-00146 Rome, Italy; Ist Nazl Ric Canc, Struct Biol Unit, I-16132 Genoa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Genoa; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; Laval University; University of Antwerp; Yeshiva University; Albert Einstein College of Medicine; Roma Tre University; Roma Tre University; University of Genoa; IRCCS AOU San Martino IST	Bolognesi, M (corresponding author), INFM, Dept Phys, Via Dodecaneso 33, I-16146 Genoa, Italy.	bolognes@fisica.unige.it	Milani, Mario/B-6446-2015; Bolognesi, Martino/B-7924-2017; Pesce, Alessandra/A-3660-2015	Milani, Mario/0000-0001-6098-3991; Bolognesi, Martino/0000-0002-9253-5170; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunori M, 2001, EMBO REP, V2, P674, DOI 10.1093/embo-reports/kve159; Das TK, 1999, BIOCHEMISTRY-US, V38, P15360, DOI 10.1021/bi991237e; ESNOUSF BM, 1997, J MOL GRAPHICS, V15, P138; Falzone CJ, 2002, J MOL BIOL, V324, P1015, DOI 10.1016/S0022-2836(02)01093-8; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Hoy JA, 2004, J BIOL CHEM, V279, P16535, DOI 10.1074/jbc.M313707200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 2001, ACTA CRYSTALLOGR D, V57, P1474, DOI 10.1107/S0907444901012458; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EACBM, V26; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Milani M, 2003, BIOCHEM MOL BIOL EDU, V31, P228, DOI 10.1002/bmb.2003.494031040239; Milani M, 2003, P NATL ACAD SCI USA, V100, P5766, DOI 10.1073/pnas.1037676100; Milani M, 2001, EMBO J, V20, P3902, DOI 10.1093/emboj/20.15.3902; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; Raushel FM, 2003, ACCOUNTS CHEM RES, V36, P539, DOI 10.1021/ar020047k; Samuni U, 2003, J BIOL CHEM, V278, P27241, DOI 10.1074/jbc.M212634200; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200	32	110	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21520	21525		10.1074/jbc.M401320200	http://dx.doi.org/10.1074/jbc.M401320200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016811	hybrid			2022-12-25	WOS:000221273800117
J	Otani, K; Han, DH; Ford, EL; Garcia-Roves, PM; Ye, HG; Horikawa, Y; Bell, GI; Holloszy, JO; Polonsky, KS				Otani, K; Han, DH; Ford, EL; Garcia-Roves, PM; Ye, HG; Horikawa, Y; Bell, GI; Holloszy, JO; Polonsky, KS			Calpain system regulates muscle mass and glucose transporter GLUT4 turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SUSCEPTIBILITY LOCUS; TYPE-2 DIABETES-MELLITUS; GENOME-WIDE SEARCH; SKELETAL-MUSCLE; INSULIN-SECRETION; TRANSGENIC MICE; EXPRESSION; EXERCISE; GENE; CHROMOSOME-2	The experiments in this study were undertaken to determine whether inhibition of calpain activity in skeletal muscle is associated with alterations in muscle metabolism. Transgenic mice that overexpress human calpastatin, an endogenous calpain inhibitor, in skeletal muscle were produced. Compared with wild type controls, muscle calpastatin mice demonstrated normal glucose tolerance. Levels of the glucose transporter GLUT4 were increased more than 3-fold in the transgenic mice by Western blotting while mRNA levels for GLUT4 and myocyte enhancer factors, MEF 2A and MEF 2D, protein levels were decreased. We found that GLUT4 can be degraded by calpain-2, suggesting that diminished degradation is responsible for the increase in muscle GLUT4 in the calpastatin transgenic mice. Despite the increase in GLUT4, glucose transport into isolated muscles from transgenic mice was not increased in response to insulin. The expression of protein kinase B was decreased by similar to 60% in calpastatin transgenic muscle. This decrease could play a role in accounting for the insulin resistance relative to GLUT4 content of calpastatin transgenic muscle. The muscle weights of transgenic animals were substantially increased compared with controls. These results are consistent with the conclusion that calpain-mediated pathways play an important role in the regulation of GLUT4 degradation in muscle and in the regulation of muscle mass. Inhibition of calpain activity in muscle by overexpression of calpastatin is associated with an increase in GLUT4 protein without a proportional increase in insulin-stimulated glucose transport. These findings provide evidence for a physiological role for calpains in the regulation of muscle glucose metabolism and muscle mass.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Gunma Univ, Inst Mol & Cellular Regulat, Dept Cell Biol, Gunma 3718512, Japan	Washington University (WUSTL); University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; Gunma University	Polonsky, KS (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave,Campus Box 8066, St Louis, MO 63110 USA.	polonsky@im.wustl.edu	Roves, Pablo Garcia/A-7113-2015; Garcia-Roves, Pablo M./X-4585-2018	Garcia-Roves, Pablo M./0000-0002-8371-2067	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031842, P60DK020595, R01DK047486, R01DK031842] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47486, DK 18966, DK 31842, DK 20595] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ciccarese M, 1997, DIABETOLOGIA, V40, P1366, DOI 10.1007/s001250050835; Duggirala R, 1999, AM J HUM GENET, V64, P1127, DOI 10.1086/302316; Elbein SC, 1999, DIABETES, V48, P1175, DOI 10.2337/diabetes.48.5.1175; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; Garcia-Roves P, 2003, AM J PHYSIOL-ENDOC M, V285, pE729, DOI 10.1152/ajpendo.00216.2003; Ghosh S, 1998, J CLIN INVEST, V102, P704, DOI 10.1172/JCI2512; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Greiwe JS, 1999, J APPL PHYSIOL, V87, P222, DOI 10.1152/jappl.1999.87.1.222; GUROFF G, 1964, J BIOL CHEM, V239, P149; Hani EH, 1997, DIABETES, V46, P1225, DOI 10.2337/diab.46.7.1225; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HARSON RL, 1998, AM J HUM GENET, V63, P1130; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; MacLean PS, 2002, BIOCHEM BIOPH RES CO, V292, P409, DOI 10.1006/bbrc.2002.6654; Mahtani MM, 1996, NAT GENET, V14, P90, DOI 10.1038/ng0996-90; Mora S, 2000, J BIOL CHEM, V275, P16323, DOI 10.1074/jbc.M910259199; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Ojuka EO, 2002, AM J PHYSIOL-ENDOC M, V282, pE1008, DOI 10.1152/ajpendo.00512.2001; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; REN JM, 1993, AM J PHYSIOL, V264, pC146, DOI 10.1152/ajpcell.1993.264.1.C146; REN JM, 1993, J BIOL CHEM, V268, P16113; REN JM, 1994, J BIOL CHEM, V269, P14396; Sreenan SK, 2001, DIABETES, V50, P2013, DOI 10.2337/diabetes.50.9.2013; Thomas AW, 1997, HUM GENET, V101, P212, DOI 10.1007/s004390050617; Tidball JG, 2002, J PHYSIOL-LONDON, V545, P819, DOI 10.1113/jphysiol.2002.024935; Tidball JG, 2000, INT J BIOCHEM CELL B, V32, P1, DOI 10.1016/S1357-2725(99)00095-3; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WEINSTEIN SP, 1991, ENDOCRINOLOGY, V129, P455, DOI 10.1210/endo-129-1-455; YOUNG DA, 1986, J BIOL CHEM, V261, P6049; Zhu XL, 2001, J BIOL CHEM, V276, P21785, DOI 10.1074/jbc.M101877200	34	44	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20915	20920		10.1074/jbc.M400213200	http://dx.doi.org/10.1074/jbc.M400213200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15014085	hybrid, Green Published			2022-12-25	WOS:000221273800044
J	Xu, JK; Liu, Y; Yang, YY; Bates, S; Zhang, JT				Xu, JK; Liu, Y; Yang, YY; Bates, S; Zhang, JT			Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER RESISTANCE PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; MINIMUM FUNCTIONAL UNIT; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; DROSOPHILA-MELANOGASTER; DRUG-TRANSPORT; CELLS; MEMBRANES; DIMERIZATION	Human ATP-binding cassette G2 (ABCG2, also known as mitoxantrone resistance protein, breast cancer-resistance protein, ABC placenta) is a member of the superfamily of ATP-binding cassette ( ABC) transporters that have a wide variety of substrates. Overexpression of human ABCG2 in model cancer cell lines causes multidrug resistance by actively effluxing anticancer drugs. Unlike most of the other ABC transporters which usually have two nucleotide-binding domains and two transmembrane domains, ABCG2 consists of only one nucleotide-binding domain followed by one transmembrane domain. Thus, ABCG2 has been thought to be a half-transporter that may function as a homodimer. In this study, we characterized the oligomeric feature of human ABCG2 using non-denaturing detergent perfluorooctanoic acid and Triton X-100 in combination with gel filtration, sucrose density gradient sedimentation, and gel electrophoresis. Unexpectedly, we found that human ABCG2 exists mainly as a tetramer, with a possibility of a higher form of oligomerization. Monomeric and dimeric ABCG2 did not appear to be the major form of the protein. Further immunoprecipitation analysis showed that the oligomeric ABCG2 did not contain any other proteins. Taken together, we conclude that human ABCG2 likely exists and functions as a homotetramer.	Indiana Univ, Sch Med, Ctr Canc,Walther Canc Inst, Walther Oncol Ctr,Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; NCI, Canc Therapeut Branch, Bethesda, MD 20892 USA; NIH, Pathol Lab, Bethesda, MD 20892 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA	Zhang, JT (corresponding author), Indiana Univ, Sch Med, Ctr Canc,Walther Canc Inst, Walther Oncol Ctr,Dept Pharmacol & Toxicol, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Bates, Susan/AFP-9514-2022; Zhang, Jian-Ting/L-8334-2015		NATIONAL CANCER INSTITUTE [R29CA064539, Z01BC010622, R01CA064539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059475] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64539] Funding Source: Medline; NIGMS NIH HHS [GM 59475] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JD, 2002, MOL CANCER THER, V1, P427; Allikmets R, 1998, CANCER RES, V58, P5337; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Ewart GD, 1998, METHOD ENZYMOL, V292, P213; GEORGES E, 1993, J BIOL CHEM, V268, P1792; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; Jette L, 1997, BIOCHEMISTRY-US, V36, P13929, DOI 10.1021/bi970737+; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Litman T, 2002, BBA-BIOMEMBRANES, V1565, P6, DOI 10.1016/S0005-2736(02)00492-3; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Maliepaard M, 2001, CANCER RES, V61, P3458; Mitic LL, 2003, PROTEIN SCI, V12, P218, DOI 10.1110/ps.0233903; Miyake K, 1999, CANCER RES, V59, P8; NAITO M, 1992, BIOCHEM BIOPH RES CO, V185, P284, DOI 10.1016/S0006-291X(05)80988-X; Ozvegy C, 2001, BIOCHEM BIOPH RES CO, V285, P111, DOI 10.1006/bbrc.2001.5130; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Ramjeesingh M, 2003, BIOCHEM J, V374, P793, DOI 10.1042/BJ20030683; Ramjeesingh M, 2001, BIOCHEMISTRY-US, V40, P10700, DOI 10.1021/bi0108195; Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Soszynski M, 1998, ARCH BIOCHEM BIOPHYS, V354, P311, DOI 10.1006/abbi.1998.0687; SULLIVAN DT, 1975, BIOCHEM GENET, V13, P603, DOI 10.1007/BF00484918; Taylor JC, 2001, J BIOL CHEM, V276, P36075, DOI 10.1074/jbc.C100345200; Yang YY, 2002, J BIOL CHEM, V277, P44268, DOI 10.1074/jbc.M207003200; Yang ZG, 2002, BIOCHEMISTRY-US, V41, P13012, DOI 10.1021/bi026064z; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s	36	209	223	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19781	19789		10.1074/jbc.M310785200	http://dx.doi.org/10.1074/jbc.M310785200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15001581	hybrid			2022-12-25	WOS:000221164500049
J	Santra, MK; Beuria, TK; Banerjee, A; Panda, D				Santra, MK; Beuria, TK; Banerjee, A; Panda, D			Ruthenium red-induced bundling of bacterial cell division protein, FtsZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI FTSZ; GTP HYDROLYSIS; SMOOTH-MUSCLE; Z-RING; TUBULIN; BINDING; ZIPA; POLYMERIZATION; INHIBITION; POLYMERS	The assembly of FtsZ plays a major role in bacterial cell division, and it is thought that the assembly dynamics of FtsZ is a finely regulated process. Here, we show that ruthenium red is able to modulate FtsZ assembly in vitro. In contrast to the inhibitory effects of ruthenium red on microtubule polymerization, we found that a substoichiometric concentration of ruthenium red strongly increased the light-scattering signal of FtsZ assembly. Further, sedimentable polymer mass was increased by 1.5- and 2-fold in the presence of 2 and 10 muM ruthenium red, respectively. In addition, ruthenium red strongly reduced the GTPase activity and prevented dilution-induced disassembly of FtsZ polymers. Electron microscopic analysis showed that 4 - 10 muM of ruthenium red produced thick bundles of FtsZ polymers. The significant increase in the light-scattering signal and pelletable polymer mass in the presence of ruthenium red seemed to be due to the bundling of FtsZ protofilaments into larger polymers rather than the actual increase in the level of polymeric FtsZ. Furthermore, ruthenium red was found to copolymerize with FtsZ, and the copolymerization of substoichiometric amounts of ruthenium red with FtsZ polymers promoted cooperative assembly of FtsZ that produced large bundles. Calcium inhibited the binding of ruthenium red to FtsZ. However, a concentration of calcium 1000-fold higher than that of ruthenium red was required to produce similar effects on FtsZ assembly. Ruthenium red strongly modulated FtsZ polymerization, suggesting the presence of an important regulatory site on FtsZ and suggesting that a natural ligand, which mimics the action of ruthenium red, may regulate the assembly of FtsZ in bacteria.	Indian Inst Technol, Sch Biosci & Bioengn, Bombay 400076, Maharashtra, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Panda, D (corresponding author), Indian Inst Technol, Sch Biosci & Bioengn, Bombay 400076, Maharashtra, India.	panda@iitb.ac.in						Beuria TK, 2003, J BIOL CHEM, V278, P3735, DOI 10.1074/jbc.M205760200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1994, P NATL ACAD SCI USA, V91, P5813, DOI 10.1073/pnas.91.13.5813; CHAMBERLAIN BK, 1984, J BIOL CHEM, V259, P7547; DEINUM J, 1981, BIOCHIM BIOPHYS ACTA, V675, P209, DOI 10.1016/0304-4165(81)90228-2; DEINUM J, 1985, BIOCHIM BIOPHYS ACTA, V838, P197, DOI 10.1016/0304-4165(85)90079-0; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; ERICKSON HP, 1976, P NATL ACAD SCI USA, V73, P2813, DOI 10.1073/pnas.73.8.2813; ERICKSON HP, 1995, CELL, V80, P367, DOI 10.1016/0092-8674(95)90486-7; Errington J, 2003, MICROBIOL MOL BIOL R, V67, P52, DOI 10.1128/MMBR.67.1.52-65.2003; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200; Hale CA, 2000, J BACTERIOL, V182, P5153, DOI 10.1128/JB.182.18.5153-5166.2000; Hale CA, 1997, CELL, V88, P175, DOI 10.1016/S0092-8674(00)81838-3; Koppelman CM, 2004, MOL MICROBIOL, V51, P645, DOI 10.1046/j.1365-2958.2003.03876.x; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lu CL, 1998, CELL MOTIL CYTOSKEL, V40, P71, DOI 10.1002/(SICI)1097-0169(1998)40:1<71::AID-CM7>3.3.CO;2-Z; Lu CL, 2000, J BACTERIOL, V182, P164, DOI 10.1128/JB.182.1.164-170.2000; Lutkenhaus J, 2002, DEV CELL, V2, P519, DOI 10.1016/S1534-5807(02)00178-8; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; Ma XL, 1999, J BACTERIOL, V181, P7531, DOI 10.1128/JB.181.24.7531-7544.1999; Margolin W, 2003, CURR BIOL, V13, pR16, DOI 10.1016/S0960-9822(02)01381-7; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; NAKAMURA F, 1992, FEBS LETT, V314, P93, DOI 10.1016/0014-5793(92)81469-3; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; RayChaudhuri D, 1999, EMBO J, V18, P2372, DOI 10.1093/emboj/18.9.2372; Rivas G, 2000, J BIOL CHEM, V275, P11740, DOI 10.1074/jbc.275.16.11740; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Rothfield L, 1999, ANNU REV GENET, V33, P423, DOI 10.1146/annurev.genet.33.1.423; Rueda S, 2003, J BACTERIOL, V185, P3344, DOI 10.1128/JB.185.11.3344-3351.2003; Santra MK, 2003, J BIOL CHEM, V278, P21336, DOI 10.1074/jbc.M301303200; SASAKI T, 1992, J BIOL CHEM, V267, P21518; Small E, 2003, MICROBIOL-SGM, V149, P2235, DOI 10.1099/mic.0.26126-0; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; Wang X, 1996, MOL MICROBIOL, V21, P313, DOI 10.1046/j.1365-2958.1996.6421360.x; WARD LD, 1994, BIOCHEMISTRY-US, V33, P11900, DOI 10.1021/bi00205a028; Yamada A, 2000, BIOCHEM J, V349, P797, DOI 10.1042/bj3490797; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455	41	31	33	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25959	25965		10.1074/jbc.M312473200	http://dx.doi.org/10.1074/jbc.M312473200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15039432	hybrid			2022-12-25	WOS:000222003000006
J	Wang, ZX; Hicks, DB; Guffanti, AA; Baldwin, K; Krulwich, TA				Wang, ZX; Hicks, DB; Guffanti, AA; Baldwin, K; Krulwich, TA			Replacement of amino acid sequence features of a- and c-subunits of ATP synthases of alkaliphilic Bacillus with the Bacillus consensus sequence results in defective oxidative phosphorylation and non-fermentative growth at pH 10.5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN TA2.A1; ESCHERICHIA-COLI; FIRMUS OF4; ADENOSINE-TRIPHOSPHATE; PROTON TRANSLOCATION; GEL-ELECTROPHORESIS; UNDECAMERIC ROTOR; NA+/H+ ANTIPORTER; F1F0-ATP SYNTHASE; PSEUDOFIRMUS OF4	Mitchell's (Mitchell, P. (1961) Nature 191, 144-148) chemiosmotic model of energy coupling posits a bulk electrochemical proton gradient (Deltap) as the sole driving force for proton-coupled ATP synthesis via oxidative phosphorylation (OXPHOS) and for other bioenergetic work. Two properties of proton-coupled OXPHOS by alkaliphilic Bacillus species pose a challenge to this tenet: robust ATP synthesis at pH 10.5 that does not correlate with the magnitude of the Deltap and the failure of artificially imposed potentials to substitute for respiration-generated potentials in energizing ATP synthesis at high pH (Krulwich, T. (1995) Mol. Microbiol. 15, 403-410). Here we show that these properties, in alkaliphilic Bacillus pseudofirmus OF4, depend upon alkaliphile-specific features in the proton pathway through the a- and c-subunits of ATP synthase. Site-directed changes were made in six such features to the corresponding sequence in Bacillus megaterium, which reflects the consensus sequence for non-alkaliphilic Bacillus. Five of the six single mutants assembled an active ATPase/ATP synthase, and four of these mutants exhibited a specific defect in non-fermentative growth at high pH. Most of these mutants lost the ability to generate the high phosphorylation potentials at low bulk Deltap that are characteristic of alkaliphiles. The aLys(180) and aGly(212) residues that are predicted to be in the proton uptake pathway of the a- subunit were specifically implicated in pH-dependent restriction of proton flux through the ATP synthase to and from the bulk phase. The evidence included greatly enhanced ATP synthesis in response to an artificially imposed potential at high pH. The findings demonstrate that the ATP synthase of extreme alkaliphiles has special features that are required for nonfermentative growth and OXPHOS at high pH.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Krulwich, TA (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1603,1 G Levy Pl, New York, NY 10029 USA.	terry.krulwich@mssm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028454] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28454] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angevine CM, 2003, P NATL ACAD SCI USA, V100, P13179, DOI 10.1073/pnas.2234364100; Angevine CM, 2003, J BIOL CHEM, V278, P6066, DOI 10.1074/jbc.M210199200; AONO R, 1990, BIOCHEM J, V266, P933; Arechaga I, 2001, FEBS LETT, V494, P1, DOI 10.1016/S0014-5793(01)02300-6; Boyer PD, 1998, BBA-BIOENERGETICS, V1365, P3, DOI 10.1016/S0005-2728(98)00066-8; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; CHAPMAN AG, 1971, J BACTERIOL, V108, P1072, DOI 10.1128/JB.108.3.1072-1086.1971; CHEN KY, 1988, BIOCHEM BIOPH RES CO, V150, P185, DOI 10.1016/0006-291X(88)90503-7; Cherepanov DA, 2003, BIOPHYS J, V85, P1307, DOI 10.1016/S0006-3495(03)74565-2; CLEJAN S, 1989, J BACTERIOL, V171, P1744, DOI 10.1128/jb.171.3.1744-1746.1989; COLE HA, 1967, BIOCHIM BIOPHYS ACTA, V143, P445, DOI 10.1016/0005-2728(67)90050-3; Cook GM, 2003, J BACTERIOL, V185, P4442, DOI 10.1128/JB.185.15.4442-4449.2003; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; Gilmour R, 2000, J BACTERIOL, V182, P5969, DOI 10.1128/JB.182.21.5969-5981.2000; GUFFANTI AA, 1994, J BIOL CHEM, V269, P21576; GUFFANTI AA, 1992, J BIOL CHEM, V267, P9580; Haiens TH, 2002, FEBS LETT, V528, P35, DOI 10.1016/S0014-5793(02)03292-1; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Hicks DB, 2003, P NATL ACAD SCI USA, V100, P10213, DOI 10.1073/pnas.1832982100; HICKS DB, 1990, J BIOL CHEM, V265, P20547; HICKS DB, 1986, J BIOL CHEM, V261, P2896; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hong SJ, 2001, ARCH BIOCHEM BIOPHYS, V394, P275, DOI 10.1006/abbi.2001.2549; Ito M, 1997, J BACTERIOL, V179, P3851, DOI 10.1128/jb.179.12.3851-3857.1997; IVEY DM, 1992, RES MICROBIOL, V143, P467, DOI 10.1016/0923-2508(92)90092-3; IVEY DM, 2002, AM SOC MICR 102 GEN, P274; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Keis S, 2004, BBA-GENE STRUCT EXPR, V1676, P112, DOI 10.1016/j.bbaexp.2003.11.002; KELL DB, 1979, BIOCHIM BIOPHYS ACTA, V549, P55, DOI 10.1016/0304-4173(79)90018-1; KRULWICH TA, 1989, J BIOENERG BIOMEMBR, V21, P663, DOI 10.1007/BF00762685; KRULWICH TA, 1995, MOL MICROBIOL, V15, P403, DOI 10.1111/j.1365-2958.1995.tb02253.x; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; Lu J, 2001, FEMS MICROBIOL LETT, V205, P291, DOI 10.1111/j.1574-6968.2001.tb10963.x; Marantz Y, 1998, P NATL ACAD SCI USA, V95, P8590, DOI 10.1073/pnas.95.15.8590; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Muller DJ, 2001, FEBS LETT, V504, P219, DOI 10.1016/S0014-5793(01)02708-9; Murata T, 2003, J BIOL CHEM, V278, P21162, DOI 10.1074/jbc.M301620200; Nachliel E, 2002, BIOPHYS J, V83, P416, DOI 10.1016/S0006-3495(02)75179-5; Olsson K, 2003, J BACTERIOL, V185, P461, DOI 10.1128/JB.185.2.461-465.2003; QIU ZH, 1992, BIOCHEMISTRY-US, V31, P3297, DOI 10.1021/bi00127a036; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; ROSING J, 1972, BIOCHIM BIOPHYS ACTA, V267, P275, DOI 10.1016/0005-2728(72)90116-8; ROTTENBERG H, 1985, MODERN CELL BIOL, V4, P47; SANTANA M, 1994, J BACTERIOL, V176, P6802, DOI 10.1128/JB.176.22.6802-6811.1994; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schemidt RA, 1998, J BACTERIOL, V180, P3205, DOI 10.1128/JB.180.12.3205-3208.1998; SLATER EC, 1985, BIOCHIM BIOPHYS ACTA, V811, P217, DOI 10.1016/0304-4173(85)90012-6; Stahlberg H, 2001, EMBO REP, V2, P229, DOI 10.1093/embo-reports/kve047; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; STURR MG, 1994, J BACTERIOL, V176, P3111, DOI 10.1128/jb.176.11.3111-3116.1994; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; Takami H, 2002, NUCLEIC ACIDS RES, V30, P3927, DOI 10.1093/nar/gkf526; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Wei Y, 2003, J BACTERIOL, V185, P5133, DOI 10.1128/JB.185.17.5133-5147.2003; WILLIAMS RJP, 1978, BIOCHIM BIOPHYS ACTA, V505, P1, DOI 10.1016/0304-4173(78)90007-1; WILLIAMS RJP, 1961, J THEOR BIOL, V1, P1, DOI 10.1016/0022-5193(61)90023-6; Zhang D, 2003, BIOCHEMISTRY-US, V42, P331, DOI 10.1021/bi026649t	65	43	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26546	26554		10.1074/jbc.M401206200	http://dx.doi.org/10.1074/jbc.M401206200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15024007	hybrid			2022-12-25	WOS:000222003000079
J	Klucken, J; Shin, Y; Masliah, E; Hyman, BT; McLean, PJ				Klucken, J; Shin, Y; Masliah, E; Hyman, BT; McLean, PJ			Hsp70 reduces alpha-synuclein aggregation and toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR PROTEIN; BULBAR MUSCULAR-ATROPHY; LEWY BODY FORMATION; PARKINSONS-DISEASE; HEAT-SHOCK; MOLECULAR CHAPERONES; HUNTINGTONS-DISEASE; OXIDATIVE STRESS; IN-VITRO; NEURODEGENERATIVE SYNUCLEINOPATHIES	Aggregation and cytotoxicity of misfolded alpha-synuclein is postulated to be crucial in the disease process of neurodegenerative disorders such as Parkinson's disease and DLB (dementia with Lewy bodies). In this study, we detected misfolded and aggregated alpha-synuclein in a Triton X-100 insoluble fraction as well as a high molecular weight product by gel electrophoresis of temporal neocortex from DLB patients but not from controls. We also found similar Triton X-100 insoluble forms of alpha-synuclein in an alpha-synuclein transgenic mouse model and in an in vitro model of alpha-synuclein aggregation. Introducing the molecular chaperone Hsp70 into the in vivo model by breeding alpha-synuclein transgenic mice with Hsp70-overexpressing mice led to a significant reduction in both the high molecular weight and detergent-insoluble alpha-synuclein species. Concomitantly, we found that Hsp70 overexpression in vitro similarly reduced detergent-insoluble alpha-synuclein species and protected cells from alpha-synuclein-induced cellular toxicity. Taken together, these data demonstrate that the molecular chaperone Hsp70 can reduce the amount of misfolded, aggregated alpha-synuclein species in vivo and in vitro and protect it from alpha-synuclein-dependent toxicity.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA; Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA	Harvard University; Massachusetts General Hospital; University of California System; University of California San Diego	McLean, PJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA.	pmclean@partners.org		McLean, Pamela/0000-0003-4870-5715	NATIONAL INSTITUTE OF MENTAL HEALTH [R24MH068855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG018440, R01AG018440] Funding Source: NIH RePORTER; NIA NIH HHS [AG18440] Funding Source: Medline; NIMH NIH HHS [1R24MH68855] Funding Source: Medline; NINDS NIH HHS [NS38372A-06] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi H, 2003, J NEUROSCI, V23, P2203; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Bao YP, 2002, J BIOL CHEM, V277, P12263, DOI 10.1074/jbc.M109633200; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Campbell BCV, 2000, NEUROBIOL DIS, V7, P192, DOI 10.1006/nbdi.2000.0286; Campbell BCV, 2001, J NEUROCHEM, V76, P87, DOI 10.1046/j.1471-4159.2001.00021.x; Chai YH, 1999, J NEUROSCI, V19, P10338; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Dedeoglu A, 2002, EXP NEUROL, V176, P262, DOI 10.1006/exnr.2002.7933; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Galvin JE, 2000, AM J PATHOL, V157, P361, DOI 10.1016/S0002-9440(10)64548-8; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Gomez-Tortosa E, 2000, ACTA NEUROPATHOL, V99, P352, DOI 10.1007/s004010051135; Gomez-Tortosa E, 1998, J AM GERIATR SOC, V46, P1449, DOI 10.1111/j.1532-5415.1998.tb06016.x; Gomez-Tortosa E, 1999, NEUROLOGY, V53, P1284, DOI 10.1212/WNL.53.6.1284; Gomez-Tortosa E, 2000, ANN NY ACAD SCI, V920, P9; Hansson O, 2003, BRAIN RES, V970, P47, DOI 10.1016/S0006-8993(02)04275-0; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Junn E, 2003, P NATL ACAD SCI USA, V100, P2047, DOI 10.1073/pnas.0438021100; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2002, J NEUROCHEM, V83, P846, DOI 10.1046/j.1471-4159.2002.01190.x; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Munch G, 2000, J CHEM NEUROANAT, V20, P253, DOI 10.1016/S0891-0618(00)00096-X; Nielsen MS, 2001, J BIOL CHEM, V276, P22680, DOI 10.1074/jbc.M101181200; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Olsson T, 2004, EXP BRAIN RES, V154, P442, DOI 10.1007/s00221-003-1683-2; Pirkkala L, 2000, MOL CELL BIOL, V20, P2670, DOI 10.1128/MCB.20.8.2670-2675.2000; Plumier JCL, 1997, CELL STRESS CHAPERON, V2, P162, DOI 10.1379/1466-1268(1997)002<0162:TMETHI>2.3.CO;2; Rajdev S, 2000, ANN NEUROL, V47, P782, DOI 10.1002/1531-8249(200006)47:6<782::AID-ANA11>3.0.CO;2-3; Rockenstein E, 2002, J NEUROSCI RES, V68, P568, DOI 10.1002/jnr.10231; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Sharma N, 2001, ACTA NEUROPATHOL, V102, P329; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shtilerman MD, 2002, BIOCHEMISTRY-US, V41, P3855, DOI 10.1021/bi0120906; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Takahashi T, 2002, BRAIN RES, V938, P73, DOI 10.1016/S0006-8993(02)02498-8; Tanaka M, 2002, BIOCHEMISTRY-US, V41, P10277, DOI 10.1021/bi0258905; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Trojanowski JQ, 2001, PARKINSONISM RELAT D, V7, P247, DOI 10.1016/S1353-8020(00)00065-1; Uversky VN, 2002, J BIOL CHEM, V277, P11970, DOI 10.1074/jbc.M109541200; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898	69	392	422	3	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25497	25502		10.1074/jbc.M400255200	http://dx.doi.org/10.1074/jbc.M400255200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15044495	hybrid			2022-12-25	WOS:000221827900074
J	Zhou, ZM; Gross, S; Roussos, C; Meurer, S; Muller-Esterl, W; Papapetropoulos, A				Zhou, ZM; Gross, S; Roussos, C; Meurer, S; Muller-Esterl, W; Papapetropoulos, A			Structural and functional characterization of the dimerization region of soluble guanylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; NITRIC-OXIDE; MOLECULAR-CLONING; ACTIVITY REQUIRES; BETA(2) SUBUNIT; ENZYME SUBUNITS; CARBON-MONOXIDE; HEME-BINDING; BOVINE LUNG; 2ND SUBUNIT	Soluble guanylyl cyclase (sGC) is a ubiquitous enzyme that functions as a receptor for nitric oxide. Despite the obligate heterodimeric nature of sGC, the sequence segments mediating subunit association have remained elusive. Our initial screening for relevant interaction site(s) in the most common sGC isoenzyme, alpha(1)beta(1), identified two regions in each subunit, i.e. the regulatory domains and the central regions, contributing to heterodimer formation. To map the relevant segments in the beta(1) subunit precisely, we constructed multiple N- and C-terminal deletion variants and cotransfected them with full-length alpha(1) in COS cells. Immunoprecipitation revealed that a sequence segment spanning positions 204-408 mediates binding of beta(1) to alpha(1). The same region of beta(1)[204-408] was found to promote beta(1)/beta(1) homodimerization. Fusion of beta(1)[204-408] to enhanced green fluorescent protein conferred binding activity to the recipient protein. Coexpression of beta(1)[204-408] with alpha(1) or beta(1) targeted the sGC subunits for proteasomal degradation, suggesting that beta(1)[204-408] forms structurally deficient complexes with alpha(1) and beta(1). Analysis of deletion constructs lacking portions of the beta(1) dimerization region identified two distinct segments contributing to alpha(1) binding, i.e. an N-terminal site covering positions 204- 244 and a C-terminal site at 379-408. Both sites are crucial for sGC function because deletion of either site rendered sGC dimerization-deficient and thus functionally inactive. We conclude that the dimerization region of beta(1) extends over 205 residues of its regulatory and central domains and that two discontinuous sites of 41 and 30 residues, respectively, facilitate binding of beta(1) to the alpha(1) subunit of sGC.	Univ Athens, Sch Med, George P Livanos Marianthi Simou Labs, Dept Crit Care, Athens 10675, Greece; Univ Athens, Sch Med, Evangelismos Hosp, Pulmonol Serv, Athens 10675, Greece; Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany; Univ Patras, Dept Pharm, Mol Pharmacol Lab, Patras 26504, Greece	Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; Evangelismos Hospital; National & Kapodistrian University of Athens; Goethe University Frankfurt; University of Patras	Papapetropoulos, A (corresponding author), Univ Athens, Sch Med, George P Livanos Marianthi Simou Labs, Dept Crit Care, Ploutarchou 3,5th Floor, Athens 10675, Greece.	apapapet@upatras.gr	Andreas, Papapetropoulos/AAJ-3089-2020	Papapetropoulos, Andreas/0000-0002-4253-5930				Andreopoulos S, 2000, GEN PHARMACOL-VASC S, V34, P147, DOI 10.1016/S0306-3623(00)00062-8; Behrends S, 2000, BIOCHEM BIOPH RES CO, V271, P64, DOI 10.1006/bbrc.2000.2596; BRUNE B, 1990, EUR J BIOCHEM, V192, P683, DOI 10.1111/j.1432-1033.1990.tb19276.x; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; Figeys D, 2002, CURR OPIN MOL THER, V4, P210; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Gupta G, 1997, J CLIN INVEST, V100, P1488, DOI 10.1172/JCI119670; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; Koesling D, 1999, Rev Physiol Biochem Pharmacol, V135, P41, DOI 10.1007/BFb0033669; Koglin M, 2003, J BIOL CHEM, V278, P12590, DOI 10.1074/jbc.M212740200; Koglin M, 2001, J BIOL CHEM, V276, P30737, DOI 10.1074/jbc.M102549200; Lucas KA, 2000, PHARMACOL REV, V52, P375; Martin E, 2001, P NATL ACAD SCI USA, V98, P12938, DOI 10.1073/pnas.231486198; Mayer BJ, 1999, MOL BIOTECHNOL, V13, P201, DOI 10.1385/MB:13:3:201; Mergia E, 2003, CELL SIGNAL, V15, P189, DOI 10.1016/S0898-6568(02)00078-5; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKANE M, 1990, J BIOL CHEM, V265, P16841; Nighorn A, 1999, J BIOL CHEM, V274, P2525, DOI 10.1074/jbc.274.4.2525; OKAMOTO H, 2001, INT J BIOCHEM CELL B, V36, P472; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; Russwurm M, 2001, J BIOL CHEM, V276, P44647, DOI 10.1074/jbc.M105587200; Stasch JP, 2002, BRIT J PHARMACOL, V136, P773, DOI 10.1038/sj.bjp.0704778; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Venema RC, 2003, AM J PHYSIOL-HEART C, V285, pH669, DOI 10.1152/ajpheart.01025.2002; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; Zabel U, 2002, NAT CELL BIOL, V4, P307, DOI 10.1038/ncb775; Zabel U, 1999, J BIOL CHEM, V274, P18149, DOI 10.1074/jbc.274.26.18149; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x	35	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24935	24943		10.1074/jbc.M402105200	http://dx.doi.org/10.1074/jbc.M402105200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15037620	hybrid			2022-12-25	WOS:000221827900007
J	Reinehr, R; Becker, S; Hongen, A; Haussinger, D				Reinehr, R; Becker, S; Hongen, A; Haussinger, D			The Src family kinase yes triggers hyperosmotic activation of the epidermal growth factor receptor and CD95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; APOPTOTIC CELL-DEATH; TYROSINE KINASE; PROTEIN-KINASE; RAT HEPATOCYTES; T-CELLS; HYDROGEN-PEROXIDE; CYCLIC-AMP; C-SRC; PHOSPHORYLATION	Hyperosmotic exposure of rat hepatocytes triggers epidermal growth factor receptor ( EGFR) activation, which results in an activation of the CD95 system and sensitizes the cells toward apoptosis (Reinehr, R., Schliess, F., and Haussinger, D. (2003) FASEB J. 17, 731-733). The mechanisms underlying the hyperosmotic EGFR activation were studied. Hyperosmotic exposure (405 mosM) resulted in a rapid activation of the Src kinase family members Yes, Fyn, and Lck. Hyperosmotic Yes, but not Fyn activation, was antioxidant-sensitive and was followed by a rapid Yes/EGFR association. PP-2 abolished the hyperosmotic activation of Fyn and Lck but not activation of Yes and EGFR and their association. However, these latter processes were prevented in the presence of SU6656. SU6656 and antioxidants, but not PP-2 and AG1478, also inhibited the hyperosmotic JNK activation. Cyclic AMP had no effect on hyperosmotic Yes and JNK activation but prevented EGFR/Yes association and EGFR activation in an H89-sensitive way. When the hyperosmolarity-induced Yes-EGFR protein complex started to disappear after 30 min, an association between EGFR and CD95 became apparent, which was followed by CD95 tyrosine phosphorylation and activation. SU6656 but not PP-2 also inhibited EGFR/CD95 association, CD95 tyrosine phosphorylation, CD95 membrane trafficking, and death-inducing signaling complex (DISC) formation. EGFR knockdown had no effect on hyperosmotic Yes activation but prevented CD95 tyrosine phosphorylation, membrane targeting, and DISC formation. Hyperosmotic EGFR and CD95 activation was also largely blunted following Yes knockdown. The data suggest that hyperosmotic signaling triggers an oxidative stress-dependent Yes activation, which is followed by JNK and EGFR activation and subsequent activation of the CD95 system. However, the functional relevance of hyperosmolarity-induced Fyn and Lck activation remains to be elucidated.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Haussinger, D (corresponding author), Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	haeussin@uni-duesseldorf.de	Reinehr, Roland/G-6118-2016					Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bokemeyer D, 2000, KIDNEY INT, V58, P549, DOI 10.1046/j.1523-1755.2000.t01-1-00201.x; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Chen X, 2001, J BIOL CHEM, V276, P34617, DOI 10.1074/jbc.M103995200; Dunkelberg JC, 2001, HEPATOLOGY, V33, P1349, DOI 10.1053/jhep.2001.24750; Feranchak AP, 2003, J BIOL CHEM, V278, P44632, DOI 10.1074/jbc.M301958200; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GonzalezGarcia A, 1997, J IMMUNOL, V158, P4104; GonzalezRubio M, 1996, KIDNEY INT, V50, P164, DOI 10.1038/ki.1996.299; Graf D, 2003, ARCH BIOCHEM BIOPHYS, V415, P34, DOI 10.1016/S0003-9861(03)00224-8; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Haussinger D, 2003, GASTROENTEROLOGY, V124, P1476, DOI 10.1016/S0016-5085(03)00274-9; Haussinger D, 1996, BIOCHEM J, V313, P697; Haussinger D, 1999, BIOCHEM BIOPH RES CO, V255, P551, DOI 10.1006/bbrc.1998.9946; HERNANDEZSOTOMAYOR SMT, 1991, J BIOL CHEM, V266, P21281; JAYASURIYA H, 1992, J NAT PROD, V55, P696, DOI 10.1021/np50083a026; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Luton F, 1999, MOL CELL, V4, P627, DOI 10.1016/S1097-2765(00)80213-0; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Meves A, 2002, ARCH DERMATOL RES, V294, P243, DOI 10.1007/s00403-002-0315-1; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; NAKAMURA K, 1993, ONCOGENE, V8, P3133; Piiper A, 2003, J BIOL CHEM, V278, P7065, DOI 10.1074/jbc.M211234200; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Reinehr R, 2003, FASEB J, V17, P731, DOI 10.1096/fj.02-0915fje; Reinehr R, 2004, J BIOL CHEM, V279, P10364, DOI 10.1074/jbc.M311997200; Reinehr R, 2004, GASTROENTEROLOGY, V126, P249, DOI 10.1053/j.gastro.2003.09.044; Reinehr R, 2003, GASTROENTEROLOGY, V125, P839, DOI 10.1016/S0016-5085(03)01055-2; Reinehr R, 2002, HEPATOLOGY, V36, P602, DOI 10.1053/jhep.2002.35447; Sanguinetti AR, 2003, BIOCHEM J, V376, P159, DOI 10.1042/BJ20030336; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; Schliess F, 2002, BIOL CHEM, V383, P577, DOI 10.1515/BC.2002.059; Seki Shuichi, 1999, Medical Electron Microscopy, V32, P199; Summy JM, 2003, J CELL SCI, V116, P2585, DOI 10.1242/jcs.00466; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; vom Dahl S, 2003, J BIOL CHEM, V278, P27088, DOI 10.1074/jbc.M210699200; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	48	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23977	23987		10.1074/jbc.M401519200	http://dx.doi.org/10.1074/jbc.M401519200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15039424	hybrid			2022-12-25	WOS:000221702500019
J	Ishizawar, RC; Tice, DA; Karaoli, T; Parsons, SJ				Ishizawar, RC; Tice, DA; Karaoli, T; Parsons, SJ			The C terminus of c-Src inhibits breast tumor cell growth by a kinase-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; GTPASE-ACTIVATING PROTEIN; TYROSINE KINASE; FACTOR RECEPTOR; V-SRC; MITOGENIC RESPONSIVENESS; SH2 DOMAIN; PHOSPHORYLATION; BINDING; PP60C-SRC	Overexpression or increased activity of cellular Src (c-Src) is frequently detected in human breast cancer, implicating involvement of c-Src in the etiology of breast carcinomas. Curiously, overexpression of c- Src in tissue culture cells results in a weakly or non-transforming phenotype, indicating that it alone is not sufficient for oncogenesis. However, the protein has been demonstrated to potentiate mitogenic signals from transmembrane receptors. This report investigates the requirement for c- Src in breast cancer as a transducer and integrator of anchorage-dependent and - independent growth signals by utilizing the Src family pharmacological inhibitors, PP1 and PP2, or stable overexpression of the catalytically inactive c-Src mutant (K- c-Src). Both methods of inhibiting endogenous c- Src diminished formation of soft agar colonies and tumors in nude mice. The majority of the dominant-negative activity of K- c- Src was mapped to the Src homology 2 (SH2) domain and C-terminal half of the molecule, but not to the Unique domain, Src homology 3 (SH3) domain, or the N-terminal half of K- c- Src. Further analysis of the C terminus revealed that its ability to inhibit growth localized to the N-terminal lobe (N-lobe) of the catalytic region. These results underscore the requirement for c- Src to maintain the oncogenic phenotype of breast cancer cells and suggest that c- Src may be manipulated to inhibit cell growth by the direct disruption of its catalytic activity or the introduction of either the SH2 domain or the N-lobe of K- c-Src.	Univ Virginia Hlth Serv, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Serv, Ctr Canc, Charlottesville, VA 22908 USA; Medimmune Inc, Gaithersburg, MD 20878 USA	University of Virginia; University of Virginia; AstraZeneca; Medimmune	Parsons, SJ (corresponding author), Univ Virginia Hlth Serv, Dept Microbiol, Box 800734, Charlottesville, VA 22908 USA.	sap@virginia.edu		Ishizawar, Rumey/0000-0001-5952-7884	NATIONAL CANCER INSTITUTE [R01CA071449] Funding Source: NIH RePORTER; NCI NIH HHS [CA3948, CA71449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; Ahn BH, 2003, MOL CELL BIOL, V23, P3103, DOI 10.1128/MCB.23.9.3103-3115.2003; Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Barahmand-Pour F, 1998, J BIOL CHEM, V273, P12567, DOI 10.1074/jbc.273.20.12567; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; CALOTHY G, 1987, J VIROL, V61, P1678, DOI 10.1128/JVI.61.5.1678-1681.1987; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chin H, 1998, BLOOD, V91, P3734; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DAVIDPFEUTY T, 1993, J CELL SCI, V105, P613; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Gual P, 1998, ENDOCRINOLOGY, V139, P884, DOI 10.1210/en.139.3.884; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JOVE R, 1989, ONCOGENE RES, V5, P49; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MAA MC, 1994, MOL CELL BIOL, V14, P5466, DOI 10.1128/MCB.14.8.5466; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Magdalena J, 2003, J CELL SCI, V116, P743, DOI 10.1242/jcs.00288; Mak P, 1996, FEBS LETT, V397, P183, DOI 10.1016/S0014-5793(96)01179-9; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; MATTEN WT, 1990, J CELL BIOL, V111, P1959, DOI 10.1083/jcb.111.5.1959; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Moasser MM, 1999, CANCER RES, V59, P6145; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NAKAYAMA Y, 1994, CELL STRUCT FUNCT, V19, P397, DOI 10.1247/csf.19.397; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Potts W M, 1988, Oncogene Res, V3, P343; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Rickles RJ, 1998, CHEM BIOL, V5, P529, DOI 10.1016/S1074-5521(98)90112-0; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Senga T, 2000, ONCOGENE, V19, P273, DOI 10.1038/sj.onc.1203296; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; Sharma SV, 2001, ONCOGENE, V20, P2068, DOI 10.1038/sj.onc.1204296; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; Summy JM, 2000, ONCOGENE, V19, P155, DOI 10.1038/sj.onc.1203265; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tikhomirov O, 2003, CANCER RES, V63, P39; Tikhomirov O, 2001, J BIOL CHEM, V276, P33675, DOI 10.1074/jbc.M101394200; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Violette SM, 2001, BONE, V28, P54, DOI 10.1016/S8756-3282(00)00427-0; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109	85	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23773	23781		10.1074/jbc.M312368200	http://dx.doi.org/10.1074/jbc.M312368200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15031291	hybrid			2022-12-25	WOS:000221570900120
J	Li, XP; Gilmore, AM; Caffarri, S; Bassi, R; Golan, T; Kramer, D; Niyogi, KK				Li, XP; Gilmore, AM; Caffarri, S; Bassi, R; Golan, T; Kramer, D; Niyogi, KK			Regulation of photosynthetic light harvesting involves intrathylakoid lumen pH sensing by the PsbS protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A FLUORESCENCE; PHOTOSYSTEM-II; XANTHOPHYLL CYCLE; ENERGY-DISSIPATION; DICYCLOHEXYLCARBODIIMIDE-BINDING; MOLECULAR MECHANISM; IN-VIVO; PLANTS; LEAVES; ZEAXANTHIN	The biochemical, biophysical, and physiological properties of the PsbS protein were studied in relation to mutations of two symmetry-related, lumen-exposed glutamate residues, Glu-122 and Glu-226. These two glutamates are targets for protonation during lumen acidification in excess light. Mutation of PsbS did not affect xanthophyll cycle pigment conversion or pool size. Plants containing PsbS mutations of both glutamates did not have any rapidly inducible nonphotochemical quenching (qE) and had similar chlorophyll fluorescence lifetime components as npq4-1, a psbS deletion mutant. The double mutant also lacked a characteristic leaf absorbance change at 535 nm (DeltaA(535)), and PsbS from these plants did not bind dicyclohexylcarbodiimide (DCCD), a known inhibitor of qE. Mutation of only one of the glutamates had intermediate effects on qE, chlorophyll fluorescence lifetime component amplitudes, DCCD binding, and DeltaA(535). Little if any differences were observed comparing the two single mutants, suggesting that the glutamates are chemically and functionally equivalent. Based on these results a bifacial model for the functional interaction of PsbS with photosystem II is proposed. Furthermore, based on the extent of qE inhibition in the mutants, photochemical and nonphotochemical quenching processes of photosystem II were associated with distinct chlorophyll fluorescence lifetime distribution components.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Australian Natl Univ, Ecosyst Dynam Grp, Res Sch Biol Sci, Inst Adv Studies, Canberra, ACT 2601, Australia; Univ Aix Marseille 2, Lab Genet & Biophys Plants, Dept Biol, F-13288 Marseille, France; Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	University of California System; University of California Berkeley; Australian National University; UDICE-French Research Universities; Aix-Marseille Universite; University of Verona; Washington State University; Washington State University	Niyogi, KK (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	niyogi@nature.berkeley.edu	Caffarri, Stefano/AAX-8913-2021; Kramer, David M/B-9588-2016	Caffarri, Stefano/0000-0002-4729-7679; Kramer, David M/0000-0003-2181-6888; bassi, roberto/0000-0002-4140-8446				Aspinall-O'Dea M, 2002, P NATL ACAD SCI USA, V99, P16331, DOI 10.1073/pnas.252500999; Avenson TJ, 2004, P NATL ACAD SCI USA, V101, P5530, DOI 10.1073/pnas.0401269101; AZZI A, 1984, BIOCHIM BIOPHYS ACTA, V768, P209, DOI 10.1016/0304-4173(84)90017-X; BASSI R, 1985, CARLSBERG RES COMMUN, V50, P145, DOI 10.1007/BF02907142; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V936, P29, DOI 10.1016/0005-2728(88)90248-4; BILGER W, 1989, PLANT PHYSIOL, V91, P542, DOI 10.1104/pp.91.2.542; BILGER W, 1994, PLANTA, V193, P238, DOI 10.1007/BF00192536; CROFTS AR, 1994, FEBS LETT, V352, P265, DOI 10.1016/0014-5793(94)00976-7; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; Dominici P, 2002, J BIOL CHEM, V277, P22750, DOI 10.1074/jbc.M200604200; FRANK HA, 1994, PHOTOSYNTH RES, V41, P389, DOI 10.1007/BF02183041; GILMORE AM, 1995, P NATL ACAD SCI USA, V92, P2273, DOI 10.1073/pnas.92.6.2273; Gilmore AM, 1998, BIOCHEMISTRY-US, V37, P13582, DOI 10.1021/bi981384x; GILMORE AM, 1995, PLANTA, V197, P646, DOI 10.1007/BF00191573; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; GILMORE AM, 1993, PHOTOSYNTH RES, V35, P67, DOI 10.1007/BF02185412; Gilmore AM, 2001, PHOTOSYNTH RES, V67, P89, DOI 10.1023/A:1010657000548; Gilmore AM, 1996, PHOTOCHEM PHOTOBIOL, V64, P552, DOI 10.1111/j.1751-1097.1996.tb03105.x; GILMORE AM, 2004, CHLOROPHYLL FLUORESC; GREEN BR, 1994, PHOTOSYNTH RES, V39, P149, DOI 10.1007/BF00029382; HEBER U, 1969, BIOCHIM BIOPHYS ACTA, V180, P302, DOI 10.1016/0005-2728(69)90116-9; HOPPE J, 1980, EUR J BIOCHEM, V107, P57, DOI 10.1111/j.1432-1033.1980.tb04624.x; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; JAHNS P, 1990, EUR J BIOCHEM, V193, P731, DOI 10.1111/j.1432-1033.1990.tb19393.x; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; KIM S, 1994, BBA-BIOENERGETICS, V1188, P339, DOI 10.1016/0005-2728(94)90054-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XP, 2002, FUNCT PLANT BIOL, V29, P1131, DOI 10.1071/FP02065; Li XP, 2002, J BIOL CHEM, V277, P33590, DOI 10.1074/jbc.M204797200; Li XP, 2002, P NATL ACAD SCI USA, V99, P15222, DOI 10.1073/pnas.232447699; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Ma YZ, 2003, P NATL ACAD SCI USA, V100, P4377, DOI 10.1073/pnas.0736959100; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; Muller-Moule P, 2002, PLANT PHYSIOL, V128, P970, DOI 10.1104/pp.010924; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Pesaresi P, 1997, FEBS LETT, V402, P151, DOI 10.1016/S0014-5793(96)01518-9; Ruban AV, 2002, J BIOL CHEM, V277, P7785, DOI 10.1074/jbc.M110693200; RUBAN AV, 1992, FEBS LETT, V309, P175, DOI 10.1016/0014-5793(92)81089-5; Sacksteder CA, 2001, PHOTOSYNTH RES, V70, P231, DOI 10.1023/A:1017906626288; Sacksteder CA, 2000, P NATL ACAD SCI USA, V97, P14283, DOI 10.1073/pnas.97.26.14283; VANKOOTEN O, 1990, PHOTOSYNTH RES, V25, P147, DOI 10.1007/BF00033156; Walters RG, 1996, P NATL ACAD SCI USA, V93, P14204, DOI 10.1073/pnas.93.24.14204; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7	45	419	429	3	89	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22866	22874		10.1074/jbc.M402461200	http://dx.doi.org/10.1074/jbc.M402461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15033974	hybrid			2022-12-25	WOS:000221570900012
J	Ruggiero, BL; Topal, MD				Ruggiero, BL; Topal, MD			Triplet repeat expansion generated by DNA slippage is suppressed by human flap endonuclease 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRINUCLEOTIDE REPEATS; FRIEDREICHS-ATAXIA; IN-VITRO; SECONDARY STRUCTURE; REPETITIVE DNA; REPLICATION; REPAIR; FEN-1; YEAST; MECHANISM	Human flap endonuclease 1 (h-FEN1) mutations have dramatic effects on repeat instability. Current models for repeat expansion predict that h-FEN1 protein prevents mutations by removing 5'-flaps generated at ends of Okazaki fragments by strand displacement synthesis. The models propose that hairpin formations within flaps containing repeats enable them to escape h-FEN1 cleavage. Friedreich's ataxia is caused by expansion mutations in a d(GAA)(n) repeat tract. Single-stranded d( GAA) n repeat tracts, however, do not form stable hairpins until the repeat tracts are quite long. Therefore, to understand how d( GAA) n repeat expansions survive h-FEN1 activity, we determined the effects of h-FEN1 on d( GAA) n repeat expansion during replication of a d( TTC)(n) repeat template. Replication initiated within the repeat tract generated significant expansion that was suppressed by the addition of h-FEN1 at the start of replication. The ability of h-FEN1 to suppress expansion implies that DNA slippage generates a 5'-flap in the nascent strand independent of strand displacement synthesis by an upstream polymerase. Delaying the addition of h-FEN1 to the replication reaction abolished the ability of h- FEN1 ability to suppress d(GAA)(n) repeat expansion products of all sizes, including sizes unable to hairpin. Use of model substrates demonstrated that h- FEN1 cleaves d(GAA)(n) 5'-flaps joined to double-stranded non-repeat sequences but not those joined to double-stranded repeat tracts. The results provide evidence that, given the opportunity, short d(GAA)(n) repeat expansion products rearrange from 5'-flaps to stable internal loops inside the repeat tract. Long expansion products are predicted to form hairpinned flaps and internal loops. Once formed, these DNA conformations resist hFEN1. The biological implications of the results are discussed.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Topal, MD (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	Michael_Topal@med.unc.edu						Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FRESCO JR, 1960, P NATL ACAD SCI USA, V46, P311, DOI 10.1073/pnas.46.3.311; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Gacy AM, 1998, MOL CELL, V1, P583, DOI 10.1016/S1097-2765(00)80058-1; GACY AM, 1995, CELL, V81, P533; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Heidenfelder BL, 2003, J BIOL CHEM, V278, P2425, DOI 10.1074/jbc.M210643200; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Henricksen LA, 2002, J BIOL CHEM, V277, P22361, DOI 10.1074/jbc.M201765200; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LeProust EM, 2000, J MOL BIOL, V302, P1063, DOI 10.1006/jmbi.2000.4073; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LINDAHL T, 1969, P NATL ACAD SCI USA, V62, P597, DOI 10.1073/pnas.62.2.597; Liu Y, 2003, J BIOL CHEM, V278, P13728, DOI 10.1074/jbc.M212061200; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Lyons-Darden T, 1999, J BIOL CHEM, V274, P25975, DOI 10.1074/jbc.274.37.25975; Margolis RL, 2001, TRENDS MOL MED, V7, P479, DOI 10.1016/S1471-4914(01)02179-7; Mariappan SVS, 1999, J MOL BIOL, V285, P2035, DOI 10.1006/jmbi.1998.2435; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Otto CJ, 2001, CLIN GENET, V59, P122, DOI 10.1034/j.1399-0004.2001.590210.x; Pandolfo M, 2001, MOVEMENT DISORD, V16, P815, DOI 10.1002/mds.1162; Patterson TA, 2000, PROTEIN EXPRES PURIF, V18, P100, DOI 10.1006/prep.1999.1167; Potaman VN, 2003, J MOL BIOL, V326, P1095, DOI 10.1016/S0022-2836(03)00037-8; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Suen IS, 1999, BBA-GENE STRUCT EXPR, V1444, P14, DOI 10.1016/S0167-4781(98)00267-X; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WAGA S, 1994, J BIOL CHEM, V269, P10923; White PJ, 1999, MOL CELL BIOL, V19, P5675	47	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23088	23097		10.1074/jbc.M313170200	http://dx.doi.org/10.1074/jbc.M313170200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15037629	hybrid, Green Published			2022-12-25	WOS:000221570900038
J	Schiavoni, I; Trapp, S; Santarcangelo, AC; Piacentini, V; Pugliese, K; Baur, A; Federico, M				Schiavoni, I; Trapp, S; Santarcangelo, AC; Piacentini, V; Pugliese, K; Baur, A; Federico, M			HIV-1 Nef enhances both membrane expression and virion incorporation of Env products - A model for the Nef-dependent increase of HIV-1 infectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CD4 DOWN-REGULATION; CELL-SURFACE EXPRESSION; ENVELOPE GLYCOPROTEIN; IN-VITRO; REVERSE TRANSCRIPTION; ENDOPLASMIC-RETICULUM; CLATHRIN ADAPTER; MATRIX PROTEIN; GENE-PRODUCT	The expression of human immunodeficiency virus Nef increases the viral infectivity through mechanisms still not fully elucidated. Here we report that wild-type (wt) human immunodeficiency virus, type 1 (HIV-1), particles were neutralized by higher concentrations of either anti-Env glycoprotein (gp) 41 antibodies or recombinant soluble human CD4 compared with Deltanef HIV-1. This appeared to be the result of a Nef-induced increase of virion incorporation of both gp41 (transmembrane (TM)) and surface gp120 Env products likely originating from enhanced steady-state levels of cell membrane-associated Env products. This, in turn, seemed to be the consequence of a reduced retention of the Env precursor. Most interesting, we found that both the Nef-directed increase of Env membrane expression and the Nef-induced enhancement of HIV-1 infectivity relied on the presence of the intracytoplasmic domain of TM, supporting the hypothesis of a functional correlation between these effects. Mutagenesis studies allowed us to establish that the two leucine residues at the TM C terminus, which are part of a sorting motif involved in the control of Env membrane expression, and the 181-210-residue Nef C-terminal region were critically involved in the Nef/Env functional interaction. In conclusion, we propose that Nef increases the infectivity of HIV-1 at least in part by enhancing the amounts of Env products incorporated into virus particles.	Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Univ Erlangen Nurnberg, Dept Dermatol, D-91052 Erlangen, Germany	Istituto Superiore di Sanita (ISS); University of Erlangen Nuremberg	Federico, M (corresponding author), Ist Super Sanita, Virol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.	federico@iss.it	SCHIAVONI, ILARIA/M-4367-2015; schiavoni, ilaria/N-5524-2015; Federico, Maurizio/J-5867-2016	SCHIAVONI, ILARIA/0000-0003-1870-8907; Federico, Maurizio/0000-0003-4154-1025; Piacentini, Valentina/0000-0001-8075-8169				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Aiken C, 1997, J VIROL, V71, P5871, DOI 10.1128/JVI.71.8.5871-5877.1997; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; Aiken C, 1996, VIROLOGY, V217, P293, DOI 10.1006/viro.1996.0116; Alessandrini L, 2000, J GEN VIROL, V81, P2905, DOI 10.1099/0022-1317-81-12-2905; Arold ST, 2001, TRENDS BIOCHEM SCI, V26, P356, DOI 10.1016/S0968-0004(01)01846-1; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Boge M, 1998, J BIOL CHEM, V273, P15773, DOI 10.1074/jbc.273.25.15773; BOURINBAIAR AS, 1994, ACTA VIROL, V38, P59; Bultmann A, 2001, J VIROL, V75, P5263, DOI 10.1128/JVI.75.11.5263-5276.2001; Chazal N, 2001, J VIROL, V75, P4014, DOI 10.1128/JVI.75.8.4014-4018.2001; CHELUCCI C, 1995, BLOOD, V85, P1181, DOI 10.1182/blood.V85.5.1181.bloodjournal8551181; CHOWERS MY, 1994, J VIROL, V68, P2906, DOI 10.1128/JVI.68.5.2906-2914.1994; Courageot J, 1999, EUR J BIOCHEM, V260, P482, DOI 10.1046/j.1432-1327.1999.00193.x; Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; DORFMAN T, 1994, J VIROL, V68, P1689, DOI 10.1128/JVI.68.3.1689-1696.1994; Fackler OT, 2000, CURR BIOL, V10, P1005, DOI 10.1016/S0960-9822(00)00654-0; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; Gervaix A, 1997, P NATL ACAD SCI USA, V94, P4653, DOI 10.1073/pnas.94.9.4653; Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141; Khan M, 2001, J VIROL, V75, P12081, DOI 10.1128/JVI.75.24.12081-12087.2001; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Marechal V, 1998, J VIROL, V72, P2208; MAVILIO F, 1994, BLOOD, V83, P1988; Meylan PRA, 1998, AIDS RES HUM RETROV, V14, P1531, DOI 10.1089/aid.1998.14.1531; MILLER MD, 1995, J VIROL, V69, P579, DOI 10.1128/JVI.69.1.579-584.1995; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; ROSSI GB, 1987, ANN NY ACAD SCI, V511, P390, DOI 10.1111/j.1749-6632.1987.tb36268.x; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Schaeffer E, 2001, J VIROL, V75, P2993, DOI 10.1128/JVI.75.6.2993-3000.2001; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; Tobiume M, 2003, J VIROL, V77, P10645, DOI 10.1128/JVI.77.19.10645-10650.2003; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; Wyss S, 2001, J VIROL, V75, P2982, DOI 10.1128/JVI.75.6.2982-2992.2001; YU XF, 1992, J VIROL, V66, P4966, DOI 10.1128/JVI.66.8.4966-4971.1992; Zhou J, 2001, J VIROL, V75, P5851, DOI 10.1128/JVI.75.13.5851-5859.2001	46	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22996	23006		10.1074/jbc.M312453200	http://dx.doi.org/10.1074/jbc.M312453200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15033985	hybrid			2022-12-25	WOS:000221570900027
J	Wu, JE; Basso, F; Shamburek, RD; Amar, MJA; Vaisman, B; Szakacs, G; Joyce, C; Tansey, T; Freeman, L; Paigen, BJ; Thomas, F; Brewer, HB; Santamarina-Fojo, S				Wu, JE; Basso, F; Shamburek, RD; Amar, MJA; Vaisman, B; Szakacs, G; Joyce, C; Tansey, T; Freeman, L; Paigen, BJ; Thomas, F; Brewer, HB; Santamarina-Fojo, S			Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIARY CHOLESTEROL SECRETION; INCREASED SITOSTEROL ABSORPTION; PLASMA RATIO METHOD; DIETARY-CHOLESTEROL; BETA-SITOSTEROLEMIA; PHYTOSTEROLEMIA; ACCUMULATION; METABOLISM; TURNOVER; XANTHOMATOSIS	The individual roles of hepatic versus intestinal ABCG5 and ABCG8 in sterol transport have not yet been investigated. To determine the specific contribution of liver ABCG5/G8 to sterol transport and atherosclerosis, we generated transgenic mice that overexpress human ABCG5 and ABCG8 in the liver but not intestine (liver G5/G8-Tg) in three different genetic backgrounds: C57B1/6, apoE-KO, and low density lipoprotein receptor (LDLr)-KO. Hepatic overexpression of ABCG5/G8 enhanced hepatobiliary secretion of cholesterol and plant sterols by 1.5-2-fold, increased the amount of intestinal cholesterol available for absorption and fecal excretion by up to 27%, and decreased the accumulation of plant sterols in plasma by similar to25%. However, it did not alter fractional intestinal cholesterol absorption, fecal neutral sterol excretion, hepatic cholesterol concentrations, or hepatic cholesterol synthesis. Consequently, overexpression of ABCG5/G8 in only the liver had no effect on the plasma lipid profile, including cholesterol, HDL-C, and non-HDL-C, or on the development of proximal aortic atherosclerosis in C57B1/6, apoE-KO, or LDLr-KO mice. Thus, liver ABCG5/G8 facilitate the secretion of liver sterols into bile and serve as an alternative mechanism, independent of intestinal ABCG5/G8, to protect against the accumulation of dietary plant sterols in plasma. However, in the absence of changes in fractional intestinal cholesterol absorption, increased secretion of sterols into bile induced by hepatic overexpression of ABCG5/G8 was not sufficient to alter hepatic cholesterol balance, enhance cholesterol removal from the body or to alter atherogenic risk in liver G5/G8-Tg mice. These findings demonstrate that overexpression of ABCG5/G8 in the liver profoundly alters hepatic but not intestinal sterol transport, identifying distinct roles for liver and intestinal ABCG5/G8 in modulating sterol metabolism.	NHLBI, Mol Dis Branch, NIH, Bethesda, MD 20892 USA; NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Jackson Lab, Bar Harbor, ME 04609 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jackson Laboratory	Santamarina-Fojo, S (corresponding author), NHLBI, Mol Dis Branch, NIH, Bldg 10,Rm 7N115, Bethesda, MD 20892 USA.	silvia@mdb.nhlbi.nih.gov	Szakacs, Gergely/A-2580-2009; Vaisman, Boris L/B-3453-2008; Amar, Marcelo/AAD-5599-2019	Szakacs, Gergely/0000-0002-9311-7827; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002058, ZIAHL002058, Z01HL002064, Z01HL002063] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYOSHI T, 1986, J LIPID RES, V27, P915; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BHATTACHARYYA AK, 1974, J CLIN INVEST, V53, P1033, DOI 10.1172/JCI107640; BHATTACHARYYA AK, 1991, ARTERIOSCLER THROMB, V11, P1287, DOI 10.1161/01.ATV.11.5.1287; BJORKHEM I, 2001, METABOLIC MOL BASES, P2961; Bjornheden T, 1996, ATHEROSCLEROSIS, V123, P43, DOI 10.1016/0021-9150(95)05770-6; Bloks VW, 2004, DIABETOLOGIA, V47, P104, DOI 10.1007/s00125-003-1261-y; Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAMBLE W, 1978, J LIPID RES, V19, P1068; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; GREGG RE, 1986, J CLIN INVEST, V77, P1864, DOI 10.1172/JCI112513; Jolley CD, 1999, AM J PHYSIOL-GASTR L, V276, pG1117, DOI 10.1152/ajpgi.1999.276.5.G1117; JOLLEY CD, 1998, HEPATOLOGY, V28, P1088; Joyce CW, 2002, P NATL ACAD SCI USA, V99, P407, DOI 10.1073/pnas.012587699; Kamisako T, 2003, HEPATOL RES, V26, P348, DOI 10.1016/S1386-6346(03)00153-0; KASAMA T, 1987, J CHROMATOGR, V400, P241, DOI 10.1016/S0021-9673(01)81617-4; Kosters A, 2003, J HEPATOL, V38, P710, DOI 10.1016/S0168-8278(03)00093-X; Lambert G, 2001, J BIOL CHEM, V276, P15090, DOI 10.1074/jbc.M008466200; Lee MH, 2001, CURR OPIN LIPIDOL, V12, P141, DOI 10.1097/00041433-200104000-00007; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; LIN HJ, 1983, METABOLISM, V32, P126, DOI 10.1016/0026-0495(83)90216-0; Lu KM, 2002, J LIPID RES, V43, P565; Lu KM, 2001, AM J HUM GENET, V69, P278, DOI 10.1086/321294; LUTJOHANN D, 1995, J LIPID RES, V36, P1763; MIETTINEN TA, 1980, EUR J CLIN INVEST, V10, P27, DOI 10.1111/j.1365-2362.1980.tb00006.x; Nguyen LB, 2001, METABOLISM, V50, P1224, DOI 10.1053/meta.2001.26707; NISHINA PM, 1993, J LIPID RES, V34, P1413; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Remaley AT, 2002, BIOCHEM BIOPH RES CO, V295, P276, DOI 10.1016/S0006-291X(02)00652-6; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; SALEN G, 1989, J LIPID RES, V30, P1319; SALEN G, 1992, ARTERIOSCLER THROMB, V12, P563, DOI 10.1161/01.ATV.12.5.563; SALEN G, 1992, J LIPID RES, V33, P945; SALEN G, 1985, J LIPID RES, V26, P203; Schwarz M, 1998, J LIPID RES, V39, P1833; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; SHULMAN RS, 1976, NEW ENGL J MED, V294, P482, DOI 10.1056/NEJM197602262940907; SPADY DK, 1992, J BIOL CHEM, V267, P5584; Srivastava RAK, 2000, EUR J BIOCHEM, V267, P4272, DOI 10.1046/j.1432-1327.2000.01473.x; Tauscher A, 2003, BIOCHEM BIOPH RES CO, V307, P1021, DOI 10.1016/S0006-291X(03)01296-8; TURLEY SD, 1981, J LIPID RES, V22, P551; TURLEY SD, 1994, J LIPID RES, V35, P328; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Wang DQH, 2003, J LIPID RES, V44, P1042, DOI 10.1194/jlr.D200041-JLR200; Wang DQH, 1999, AM J PHYSIOL-GASTR L, V276, pG751, DOI 10.1152/ajpgi.1999.276.3.G751; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; ZILVERSMIT DB, 1974, J LIPID RES, V15, P465	51	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22913	22925		10.1074/jbc.M402838200	http://dx.doi.org/10.1074/jbc.M402838200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044450	hybrid			2022-12-25	WOS:000221570900018
J	Butcher, NJ; Arulpragasam, A; Minchin, RF				Butcher, NJ; Arulpragasam, A; Minchin, RF			Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine - A mechanism for the slow acetylator phenotype and substrate-dependent down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME ARYLAMINE N-ACETYLTRANSFERASE-1; RABBIT LIVER; NAT1; POLYMORPHISMS; METABOLISM; GENOTYPES; CELLS	Many drugs and chemicals found in the environment are either detoxified by N-acetyltransferase 1 (NAT1, EC 2.3.1.5) and eliminated from the body or bioactivated to metabolites that have the potential to cause toxicity and/or cancer. NAT1 activity in the body is regulated by genetic polymorphisms as well as environmental factors such as substrate-dependent down-regulation and oxidative stress. Here we report the molecular mechanism for the low protein expression from mutant NAT1 alleles that gives rise to the slow acetylator phenotype and show that a similar process accounts for enzyme down-regulation by NAT1 substrates. NAT1 allozymes NAT1 14, NAT1 15, NAT1 17, and NAT1 22 are devoid of enzyme activity and have short intracellular half-lives (similar to4 h) compared with wild-type NAT1 4 and the active allozyme NAT1 24. The inactive allozymes are unable to be acetylated by cofactor, resulting in ubiquitination and rapid degradation by the 26 S proteasome. This was confirmed by site-directed mutagenesis of the active site cysteine 68. The NAT1 substrate p-aminobenzoic acid induced ubiquitination of the usually stable NAT1 4, leading to its rapid degradation. From this study, we conclude that NAT1 exists in the cell in either a stable acetylated state or an unstable non-acetylated state and that mutations in the NAT1 gene that prevent protein acetylation produce a slow acetylator phenotype.	Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia	Royal Perth Hospital; University of Western Australia	Butcher, NJ (corresponding author), Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia.	n.butcher@uq.edu.au		Minchin, Rodney/0000-0002-3178-4835; Butcher, Neville/0000-0002-0709-5589				Anwar A, 2002, J BIOL CHEM, V277, P14060, DOI 10.1074/jbc.M111576200; Atmane N, 2003, J BIOL CHEM, V278, P35086, DOI 10.1074/jbc.M303813200; Bouchardy C, 1998, PHARMACOGENETICS, V8, P291, DOI 10.1097/00008571-199808000-00002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butcher N. J., 2002, Pharmacogenomics Journal, V2, P30, DOI 10.1038/sj.tpj.6500053; Butcher NJ, 1998, PHARMACOGENETICS, V8, P67, DOI 10.1097/00008571-199802000-00009; Butcher NJ, 2000, MOL PHARMACOL, V57, P468, DOI 10.1124/mol.57.3.468; Dairou J, 2003, BIOCHEM BIOPH RES CO, V307, P1059, DOI 10.1016/S0006-291X(03)01311-1; Dhaini HR, 2000, PHARMACOGENETICS, V10, P79, DOI 10.1097/00008571-200002000-00010; Fretland AJ, 2001, PHARMACOGENETICS, V11, P511, DOI 10.1097/00008571-200108000-00006; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; Hughes NC, 1998, PHARMACOGENETICS, V8, P55, DOI 10.1097/00008571-199802000-00008; Lin HJ, 1998, PHARMACOGENETICS, V8, P269, DOI 10.1097/00008571-199806000-00009; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; MINCHIN RF, 1995, BIOCHEM J, V307, P1; Mushtaq A, 2002, J BIOL CHEM, V277, P12175, DOI 10.1074/jbc.M104365200; RIDDLE B, 1971, J BIOL CHEM, V246, P3250; Rodrigues-Lima F, 2001, BIOCHEM J, V356, P327, DOI 10.1042/0264-6021:3560327; Sinclair J, 1997, BIOCHEM PHARMACOL, V53, P11, DOI 10.1016/S0006-2952(96)00592-8; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Stanley LA, 1996, J HISTOCHEM CYTOCHEM, V44, P1059, DOI 10.1177/44.9.8773572; STEINBERG MS, 1971, BIOCHIM BIOPHYS ACTA, V235, P89, DOI 10.1016/0005-2744(71)90036-2; WARD A, 1995, BIOCHEM PHARMACOL, V49, P1759, DOI 10.1016/0006-2952(95)00087-G; WEBER WW, 1967, MOL PHARMACOL, V3, P266; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	25	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22131	22137		10.1074/jbc.M312858200	http://dx.doi.org/10.1074/jbc.M312858200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15039438	hybrid			2022-12-25	WOS:000221417100056
J	DiBella, LM; Smith, EF; Patel-King, RS; Wakabayashi, K; King, SM				DiBella, LM; Smith, EF; Patel-King, RS; Wakabayashi, K; King, SM			A novel Tctex2-related light chain is required for stability of inner dynein arm I1 and motor function in the Chlamydomonas flagellum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER ARM; CYTOPLASMIC DYNEIN; INTERMEDIATE CHAIN; NUCLEAR TRANSFORMATION; GAMMA-SUBUNIT; HEAVY-CHAIN; PROTEIN; COMPLEX; REINHARDTII; MICROTUBULE	Tctex1 and Tctex2 were originally described in mice as putative distorters/sterility factors involved in the non-Mendelian transmission of t haplotypes. Subsequently, these proteins were found to be light chains of both cytoplasmic and axonemal dyneins. We have now identified a novel Tctex2-related protein (Tctex2b) within the Chlamydomonas flagellum. Tctex2b copurifies with inner arm I1 after both sucrose gradient centrifugation and anion exchange chromatography. Unlike the Tctex2 homologue within the outer dynein arm, analysis of a Tctex2b-null strain indicates that this protein is not essential for assembly of inner arm I1. However, a lack of Tctex2b results in an unstable dynein particle that disassembles after high salt extraction from the axoneme. Cells lacking Tctex2b swim more slowly than wild type and exhibit a reduced flagellar beat frequency. Furthermore, using a microtubule sliding assay we observed that dynein motor function is reduced in vitro. These data indicate that Tctex2b is required for the stability of inner dynein arm I1 and wild-type axonemal dynein function.	Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	University of Connecticut; University of Connecticut; Dartmouth College	King, SM (corresponding author), Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	steve@king2.uchc.edu	Wakabayashi, Ken-ichi/AAI-8617-2021; Wakabayashi, Ken-ichi/D-2440-2015	Wakabayashi, Ken-ichi/0000-0002-1025-9249	NIGMS NIH HHS [GM 51293, GM 51379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051293] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; Caggese C, 2001, MOL GENET GENOMICS, V265, P436, DOI 10.1007/s004380000431; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; DiBella LM, 2001, J BIOL CHEM, V276, P14366, DOI 10.1074/jbc.M011456200; DiBella LM, 2001, INT REV CYTOL, V210, P227; HABERMACHER G, 1995, CELL MOTIL CYTOSKEL, V32, P106, DOI 10.1002/cm.970320207; Habermacher G, 1997, J CELL BIOL, V136, P167, DOI 10.1083/jcb.136.1.167; Habermacher G, 1996, J CELL SCI, V109, P1899; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; HUANG B, 1979, J BIOL CHEM, V254, P3091; HUW LY, 1995, DEV BIOL, V170, P183, DOI 10.1006/dbio.1995.1206; Inaba K, 1999, BIOCHEM BIOPH RES CO, V256, P177, DOI 10.1006/bbrc.1999.0309; KAMIYA R, 1988, J CELL BIOL, V107, P2253, DOI 10.1083/jcb.107.6.2253; KAMIYA R, 1991, J CELL BIOL, V112, P441, DOI 10.1083/jcb.112.3.441; KAMIYA R, 1985, J CELL SCI, V74, P181; Kamiya R, 2002, INT REV CYTOL, V219, P115; Kamiya R, 2000, METHODS, V22, P383, DOI 10.1006/meth.2000.1090; KAMIYA R, 1987, EXP CELL RES, V173, P299, DOI 10.1016/0014-4827(87)90357-0; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; King SJ, 1997, J CELL BIOL, V136, P177, DOI 10.1083/jcb.136.1.177; KING SM, 1986, METHOD ENZYMOL, V134, P291; KING SM, 1990, J BIOL CHEM, V265, P19807; KING SM, 1994, J BIOL CHEM, V269, P5452; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; King SM., 2002, MOL MOTORS, P45; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; LUCK D, 1977, P NATL ACAD SCI USA, V74, P3456, DOI 10.1073/pnas.74.8.3456; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MITCHELL DR, 1986, CELL MOTIL CYTOSKEL, V6, P510, DOI 10.1002/cm.970060510; MITCHELL DR, 1985, J CELL BIOL, V100, P1228, DOI 10.1083/jcb.100.4.1228; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Myster SH, 1997, MOL BIOL CELL, V8, P607, DOI 10.1091/mbc.8.4.607; Nakamura K, 1997, CELL MOTIL CYTOSKEL, V37, P338; OKAGAKI T, 1986, J CELL BIOL, V103, P1895, DOI 10.1083/jcb.103.5.1895; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; PatelKing RS, 1997, J CELL BIOL, V137, P1081, DOI 10.1083/jcb.137.5.1081; Pazour GJ, 1998, J CELL BIOL, V141, P979, DOI 10.1083/jcb.141.4.979; Pazour GJ, 1999, MOL BIOL CELL, V10, P3507, DOI 10.1091/mbc.10.10.3507; Perrone CA, 2000, MOL BIOL CELL, V11, P2297, DOI 10.1091/mbc.11.7.2297; Perrone CA, 1998, MOL BIOL CELL, V9, P3351, DOI 10.1091/mbc.9.12.3351; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; PORTER ME, 1992, J CELL BIOL, V118, P1163, DOI 10.1083/jcb.118.5.1163; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; Silflow CD, 2001, J CELL BIOL, V153, P63, DOI 10.1083/jcb.153.1.63; Smith EF, 2002, CELL MOTIL CYTOSKEL, V52, P33, DOI 10.1002/cm.10031; SMITH EF, 1992, SCIENCE, V257, P1557, DOI 10.1126/science.1387971; Smith EF, 1997, MOL BIOL CELL, V8, P455, DOI 10.1091/mbc.8.3.455; Smith EF, 1996, J CELL BIOL, V132, P359, DOI 10.1083/jcb.132.3.359; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; TAKADA S, 1994, J CELL BIOL, V126, P737, DOI 10.1083/jcb.126.3.737; TAM LW, 1993, GENETICS, V135, P375; TANG WJY, 1982, J BIOL CHEM, V257, P508; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Wu HW, 2001, J BIOMOL NMR, V20, P89, DOI 10.1023/A:1011299813395; Yang PF, 1998, MOL BIOL CELL, V9, P3335, DOI 10.1091/mbc.9.12.3335; Yang PF, 2001, J CELL BIOL, V153, P1315, DOI 10.1083/jcb.153.6.1315	60	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21666	21676		10.1074/jbc.M313540200	http://dx.doi.org/10.1074/jbc.M313540200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15020587	hybrid			2022-12-25	WOS:000221273800134
J	Goruppi, S; Kyriakis, JM				Goruppi, S; Kyriakis, JM			The pro-hypertrophic basic helix-loop-helix protein p8 is degraded by the ubiquitin/proteasome system in a protein kinase B/Akt- and glycogen synthase kinase-3-dependent manner, whereas endothelin induction of p8 mRNA and renal mesangial cell hypertrophy require NFAT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; EXPRESSION; CLONING; STRESS; PHOSPHORYLATION; CALCINEURIN; INHIBITION; ACTIVATION	Renal disease is a common complication of diabetes. The initiating events in diabetic nephropathy are triggered by hyperglycemia and, possibly, advanced glycation end products. Subsequently, excess levels of vasoactive peptides ( especially endothelin-1 (ET-1)) accumulate in the diabetic kidney, and there is evidence that these peptides mediate many of the pathophysiological changes associated with diabetic renal disease. These changes include an excess deposition of extracellular matrix proteins into the glomerular basement membrane and renal mesangial cell hypertrophy. Our transcriptional profiling studies have revealed that the p8 gene, which encodes a putative basic helix-loop-helix protein, is strongly induced in ET-1-treated renal mesangial cells and in an animal model of diabetic nephropathy. RNA interference experiments indicated that the p8 gene is required for ET-1-induced mesangial cell hypertrophy. Here, we show that the p8 polypeptide is a phosphoprotein subject to constitutive degradation by the ubiquitin/proteasome system. This degradation is mediated by phosphatidylinositol 3-kinase and protein kinase B/Akt. By contrast, stabilization of the p8 protein requires glycogen synthase kinase-3. Finally, short interfering RNA-mediated RNA interference experiments indicated that ET-1-stimulated mesangial cell hypertrophy and p8 mRNA induction require the NFAT4 transcription factor. Thus, p8 levels in the cell are likely maintained by a balance between signal-dependent transcriptional induction and proteolysis.	Tufts Univ, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University	Kyriakis, JM (corresponding author), Tufts Univ, New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,POB 8486, Boston, MA 02111 USA.	jkyriakis@tufts-nemc.org						Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Bogoyevitch MA, 2000, CARDIOVASC RES, V45, P826, DOI 10.1016/S0008-6363(99)00386-7; Bonventre JV, 1998, CURR OPIN NEPHROL HY, V7, P425, DOI 10.1097/00041552-199807000-00013; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Encinar JA, 2001, J BIOL CHEM, V276, P2742, DOI 10.1074/jbc.M008594200; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fine L. G., 1992, KIDNEY PHYSL PATHOPH, P3113; Force T, 1999, GENE EXPRESSION, V7, P337; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 2002, EMBO J, V21, P5427, DOI 10.1093/emboj/cdf535; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hoffmeister A, 2002, J BIOL CHEM, V277, P22314, DOI 10.1074/jbc.M201657200; Igarashi T, 2001, DEV GROWTH DIFFER, V43, P693; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Mallo GV, 1997, J BIOL CHEM, V272, P32360, DOI 10.1074/jbc.272.51.32360; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 2000, CIRC RES, V87, P731, DOI 10.1161/01.RES.87.9.731; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Ree AH, 1999, CANCER RES, V59, P4675; Resjo S, 1999, BIOCHEM J, V341, P839, DOI 10.1042/0264-6021:3410839; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sorokin A, 2003, AM J PHYSIOL-RENAL, V285, pF579, DOI 10.1152/ajprenal.00019.2003; Vasseur S, 1999, EUR J BIOCHEM, V259, P670, DOI 10.1046/j.1432-1327.1999.00092.x; Vasseur S, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-25; Vasseur S, 2002, ONCOGENE, V21, P1685, DOI 10.1038/sj.onc.1205222; Vasseur S, 2002, EMBO REP, V3, P165, DOI 10.1093/embo-reports/kvf023; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Wolf G, 2002, J AM SOC NEPHROL, V13, P2611, DOI 10.1681/ASN.V13102611	42	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20950	20958		10.1074/jbc.M312401200	http://dx.doi.org/10.1074/jbc.M312401200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016802	hybrid			2022-12-25	WOS:000221273800049
J	Zhao, YM; Kwon, SW; Anselmo, A; Kaur, K; White, MA				Zhao, YM; Kwon, SW; Anselmo, A; Kaur, K; White, MA			Broad spectrum identification of cellular small ubiquitin-related modifier (SUMO) substrate proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE-3; TFII-I; FAMILY; TRANSCRIPTION; ALPHA; CLONING; DOMAIN; BETA; GENE	Reversible covalent modification of proteins with a small ubiquitin-related modifier ( SUMO) is emerging as an important system contributing to dynamic regulation of protein function. To enhance our understanding of the cell regulatory systems impacted by sumoylation, we used affinity chromatography-coupled high pressure liquid chromatography/tandem mass spectrometry for unbiased identification of candidate cellular SUMO substrate proteins. Here we describe the identification of 21 candidate sumoylated proteins from whole-cell lysates of HEK-293 cells. The nature of the proteins identified is consistent with a role for sumoylation in diverse cell regulatory systems but highlights regulation of chromatin organization and gene expression as major systems targeted by the sumoylation machinery.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zhao, YM (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Yingming.Zhao@UTSouthwestern.edu; Michael.White@UTSouthwestern.edu			NATIONAL CANCER INSTITUTE [R01CA071443, U01CA085146] Funding Source: NIH RePORTER; NCI NIH HHS [CA 71443, CA 85146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Inoue N, 1999, HUM MOL GENET, V8, P1201, DOI 10.1093/hmg/8.7.1201; Kiesslich A, 2002, J STRUCT BIOL, V140, P167, DOI 10.1016/S1047-8477(02)00571-3; Kimura Y, 2002, J BIOL CHEM, V277, P20611, DOI 10.1074/jbc.M201440200; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Lyman SK, 1999, RNA, V5, P1597, DOI 10.1017/S1355838299991288; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Qiu XB, 2002, P NATL ACAD SCI USA, V99, P14843, DOI 10.1073/pnas.232580999; Smedley D, 1999, GENOMICS, V60, P244, DOI 10.1006/geno.1999.5918; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; vanderMaarel SM, 1996, HUM MOL GENET, V5, P887, DOI 10.1093/hmg/5.7.887; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wen YD, 2003, J BIOL CHEM, V278, P1841, DOI 10.1074/jbc.M206528200; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695	20	113	120	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20999	21002		10.1074/jbc.M401541200	http://dx.doi.org/10.1074/jbc.M401541200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016812	hybrid			2022-12-25	WOS:000221273800055
J	Li, JX; Tang, MS; Liu, BC; Shi, XL; Huang, C				Li, JX; Tang, MS; Liu, BC; Shi, XL; Huang, C			A critical role of PI-3K/Akt/JNKs pathway in benzo[a]pyrene diol-epoxide (B[a]PDE)-induced AP-1 transactivation in mouse epidermal Cl41 cells	ONCOGENE			English	Article						PI-3K; Akt; MAP kinase; PAH; AP-1	POLYCYCLIC AROMATIC-HYDROCARBONS; P70 S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVATED PROTEIN-1; OPTICAL ENANTIOMERS; CATALYTIC SUBUNIT; TRANSFORMATION; GENE	Mouse skin tumorigenicity studies indicate that benzo[a]-pyrene-7,8-diol-9,10-epoxide (B[a]PDE) contributes to carcinogenesis as both a tumor initiator and promoter. However, the mechanisms that mediate B[a] PDE tumor promotion effects remain unclear. Our results demonstrated that in mouse epidermal Cl41 cells, B[a] PDE treatment resulted in marked activation of AP-1 and its upstream MAPKs, including ERKs, JNKs and p38K. B[a] PDE exposure also led to activation of phosphotidy-linositol 3-kinase (PI-3K), Akt and p70 S6 kinase (p70(S6k)). B[a]PDE-induced AP-1 transactivation was inhibited by pretreatment of cells with PI-3K inhibitors, wortmannin or Ly294002. In contrast, inhibition of p70(S6k) with rapamycin did not show any inhibitory effects. An overexpression of dominant-negative mutant of PI-3K, Deltap85, impaired B[a]PDE-induced activation of PI-3K, Akt and AP-1 transactivation. Furthermore, an overexpression of dominant-negative Akt mutant, Akt-T308A/S473A, blocked B[a]PDE-induced activation of Akt, AP-1 and JNKs, while it did not affect the activation of p70S6k, ERKs and p38 kinase. These results demonstrated that B[a] PDE was able to induce AP-1 transactivation and this AP-1 induction was specific through PI-3K/Akt/JNKs-dependent and p70(S6k)-independent pathways. This study also indicated that Akt-T308A/S473A blocks B[a]PDE-induced AP-1 activation specific through impairing JNK pathway. These findings will help us to understand the signal transduction pathways involved in the carcinogenic effects of B[a] PDE.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; Chinese Ctr Dis Control & Prevent, Natl Inst Occupat Hlth & Poisons Control, Beijing 100050, Peoples R China; Chinese Acad Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China	New York University; Chinese Center for Disease Control & Prevention; Chinese Academy of Sciences	Huang, C (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu@env.med.nyu.edu	Shi, Xianglin/B-8588-2012	Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R01CA103180, R01CA112557, R01CA094964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012451] Funding Source: NIH RePORTER; NCI NIH HHS [CA112557, CA094964, CA103180] Funding Source: Medline; NIEHS NIH HHS [ES012451] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERT RE, 1991, CARCINOGENESIS, V12, P1273, DOI 10.1093/carcin/12.7.1273; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; BERNELOTMOENS C, 1990, CARCINOGENESIS, V11, P781, DOI 10.1093/carcin/11.5.781; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Bostrom CE, 2002, ENVIRON HEALTH PERSP, V110, P451, DOI 10.1289/ehp.02110s3451; Bral CM, 1997, MOL PHARMACOL, V52, P974, DOI 10.1124/mol.52.6.974; BRESNICK E, 1977, CANCER RES, V37, P984; BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CONNEY AH, 1994, DRUG METAB REV, V26, P125, DOI 10.3109/03602539409029788; CONNEY AH, 1982, CANCER RES, V42, P4875; Cooper SJ, 2003, MOL CANCER RES, V1, P848; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DONG ZG, 1995, INT J ONCOL, V7, P359; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FUKUI Y, 1991, ONCOGENE, V6, P407; Funakoshi-Tago M, 2003, EUR J BIOCHEM, V270, P1257, DOI 10.1046/j.1432-1033.2003.03487.x; Gonzales M, 2002, ONCOGENE, V21, P2721, DOI 10.1038/sj.onc.1205366; HALL M, 1989, CARCINOGENESIS, V10, P1815, DOI 10.1093/carcin/10.10.1815; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HECHT SS, 1974, JNCI-J NATL CANCER I, V53, P1121, DOI 10.1093/jnci/53.4.1121; Heidelberger C, 1973, Adv Cancer Res, V18, P317, DOI 10.1016/S0065-230X(08)60756-3; Hoffmann D, 1997, PREV MED, V26, P427, DOI 10.1006/pmed.1997.0183; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 2002, CANCER RES, V62, P6857; Huang CS, 2002, CANCER RES, V62, P5689; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Lei W, 1998, CANCER RES, V58, P2102; LEVIN W, 1977, CANCER RES, V37, P3356; Li JJ, 1997, CANCER RES, V57, P3569; Merimsky O, 1998, CLIN DERMATOL, V16, P585, DOI 10.1016/S0738-081X(98)00043-1; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; Parrish AR, 1998, TOXICOL APPL PHARM, V152, P302, DOI 10.1006/taap.1998.8525; Parrish AR, 2002, BIOCHEM PHARMACOL, V64, P31, DOI 10.1016/S0006-2952(02)01054-7; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PHILLIPS DH, 1983, NATURE, V303, P468, DOI 10.1038/303468a0; Pitot HC, 1996, CASARETT DOULLS TOXI, P201; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; RODRIGUEZ H, 1993, CARCINOGENESIS, V14, P373, DOI 10.1093/carcin/14.3.373; SEILKIRK JK, 1982, MECH CHEM CARCINOGEN, P331; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shimada T, 1999, CHEM RES TOXICOL, V12, P623, DOI 10.1021/tx990028s; Sims P, 1974, Adv Cancer Res, V20, P165, DOI 10.1016/S0065-230X(08)60111-6; SLAGA TJ, 1979, CANCER RES, V39, P67; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; SMITH MJ, 1992, BLOOD, V79, P2107; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; Tannheimer SL, 1998, CARCINOGENESIS, V19, P1291, DOI 10.1093/carcin/19.7.1291; Thompson EJ, 2002, CANCER RES, V62, P3044; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANG JL, 1991, CARCINOGENESIS, V12, P71, DOI 10.1093/carcin/12.1.71; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	79	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3932	3944		10.1038/sj.onc.1207501	http://dx.doi.org/10.1038/sj.onc.1207501			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021902				2022-12-25	WOS:000221382000005
J	Tyagi, S; Surjit, M; Roy, AK; Jameel, S; Lal, SK				Tyagi, S; Surjit, M; Roy, AK; Jameel, S; Lal, SK			The ORF3 protein of hepatitis E virus interacts with liver-specific alpha(1)-microglobulin and its precursor alpha(1)-microglobulin/bikunin precursor (AMBP) and expedites their export from the hepatocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST 2-HYBRID SYSTEM; SELF-ASSOCIATION; STRUCTURAL PROTEINS; TRYPSIN-INHIBITOR; ALPHA-INHIBITOR; INSECT CELLS; BIKUNIN; ALPHA-1-MICROGLOBULIN; EXPRESSION; COMPLEX	Hepatitis E virus (HEV), a plus-stranded RNA virus contains three open reading frames. Of these, ORF1 encodes the viral nonstructural polyprotein; ORF2 encodes the major capsid protein and ORF3 codes for a phosphoprotein of undefined function. Using the yeast two-hybrid system to screen a human cDNA liver library we have isolated, an N-terminal deleted protein, alpha(1)-microglobulin/bikunin precursor (AMBP) that specifically interacts with the ORF3 protein of HEV. Independently cloned, full-length AMBP was obtained and tested positive for interaction with ORF3 using a variety of in vivo and in vitro techniques. AMBP, a liver-specific precursor protein codes for two different unrelated proteins alpha(1)-microglobulin (alpha(1)m) and bikunin. alpha(1)m individually interacted with ORF3. The above findings were validated by COS-1 cell immunoprecipitation, His(6) pull-down experiments, and co-localization experiments followed by fluorescence resonance energy transfer analysis. Human liver cells showing co-localization of ORF3 with endogenously expressing alpha(1)m showed a distinct disappearance of the protein from the Golgi compartment, suggesting that ORF3 enhances the secretion of alpha(1)m out of the hepatocyte. Using drugs to block the secretory pathway, we showed that alpha(1)m was not degraded in the presence of ORF3. Finally, pulse labeling of alpha(1)m showed that its secretion was expedited out of the liver cell at faster rates in the presence of the ORF3 protein. Hence, ORF3 has a directbiological role in enhancing alpha(1)m export from the hepatocyte.	Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Lal, SK (corresponding author), Int Ctr Genet Engn & Biotechnol, Virol Grp, POB 10504,Aruna Asaf Ali Rd, New Delhi 110067, India.	sunillal@icgeb.res.in			Wellcome Trust [063171] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; Ansari IH, 2000, J MED VIROL, V60, P275, DOI 10.1002/(SICI)1096-9071(200003)60:3<275::AID-JMV5>3.3.CO;2-0; AYE TT, 1992, NUCLEIC ACIDS RES, V20, P3512, DOI 10.1093/nar/20.13.3512; BEGGARD T, 1999, AM J REPROD IMMUNOL, V42, P52; BEGGARD T, 1997, EUR J BIOCHEM, V245, P676; BEGGARD T, 1998, J HISTOCHEM CYTOCHEM, V46, P887; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; BRATT T, 1993, BIOCHIM BIOPHYS ACTA, V1157, P147, DOI 10.1016/0304-4165(93)90058-G; BRATT T, 1994, FEBS LETT, V354, P57, DOI 10.1016/0014-5793(94)01087-0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DIARRAMEHRPOUR M, 1989, EUR J BIOCHEM, V179, P147, DOI 10.1111/j.1432-1033.1989.tb14532.x; Emerson SU, 2001, TRENDS MOL MED, V7, P462, DOI 10.1016/S1471-4914(01)02106-2; FALKENBERG C, 1994, BIOCHEM J, V301, P745, DOI 10.1042/bj3010745; FALKENBERG C, 1990, J BIOL CHEM, V265, P16150; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GEBHARD W, 1990, FEBS LETT, V269, P32, DOI 10.1016/0014-5793(90)81112-2; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; HE JK, 1993, J CLIN MICROBIOL, V31, P2167, DOI 10.1128/JCM.31.8.2167-2173.1993; HUANG RT, 1995, J MED VIROL, V47, P299, DOI 10.1002/jmv.1890470402; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jameel S, 1996, J VIROL, V70, P207, DOI 10.1128/JVI.70.1.207-216.1996; James P, 1996, GENETICS, V144, P1425; KALPANA GV, 1993, P NATL ACAD SCI USA, V90, P10593, DOI 10.1073/pnas.90.22.10593; KHUDYAKOV YE, 1994, VIROLOGY, V198, P390, DOI 10.1006/viro.1994.1048; KHUDYAKOV YE, 1993, VIROLOGY, V194, P89, DOI 10.1006/viro.1993.1238; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOONIN EV, 1992, P NATL ACAD SCI USA, V89, P8259, DOI 10.1073/pnas.89.17.8259; Korkaya H, 2001, J BIOL CHEM, V276, P42389, DOI 10.1074/jbc.M101546200; Lal SK, 1997, GENE, V190, P63, DOI 10.1016/S0378-1119(96)00698-1; Lindqvist A, 1996, BBA-GENE STRUCT EXPR, V1306, P98, DOI 10.1016/0167-4781(95)00235-9; Lindqvist A, 1999, GENE, V234, P329, DOI 10.1016/S0378-1119(99)00191-2; LOGDBERG L, 1981, SCAND J IMMUNOL, V13, P383, DOI 10.1111/j.1365-3083.1981.tb00148.x; LOGDBERG L, 2000, J HISTOCHEM CYTOCHEM, V48, P1; Mast EE, 1996, BAILLIERE CLIN GASTR, V10, P227, DOI 10.1016/S0950-3528(96)90004-4; MENDEZ E, 1986, P NATL ACAD SCI USA, V83, P1472, DOI 10.1073/pnas.83.5.1472; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; Odum L, 1997, HISTOCHEM J, V29, P199; Panda SK, 2000, J VIROL, V74, P2430, DOI 10.1128/JVI.74.5.2430-2437.2000; Purcell RH, 2000, LANCET, V355, P578, DOI 10.1016/S0140-6736(05)73231-1; PURCELL RH, 1988, VIRAL HEPATITIS LIVE, P131; Reyes G R, 1993, Arch Virol Suppl, V7, P15; Rouet P, 1998, BIOCHEM J, V334, P577, DOI 10.1042/bj3340577; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; Siegel R. M., 2000, SCI STKE, V2000, ppl1; Tam AW, 1997, VIROLOGY, V238, P94, DOI 10.1006/viro.1997.8817; TAM AW, 1991, VIROLOGY, V185, P120, DOI 10.1016/0042-6822(91)90760-9; Thuveson M, 1999, J BIOL CHEM, V274, P6741, DOI 10.1074/jbc.274.10.6741; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; TSAREV SA, 1992, P NATL ACAD SCI USA, V89, P559, DOI 10.1073/pnas.89.2.559; Tyagi S, 2002, J BIOL CHEM, V277, P22759, DOI 10.1074/jbc.M200185200; Tyagi S, 2002, ARCH BIOCHEM BIOPHYS, V399, P66, DOI 10.1006/abbi.2001.2745; Tyagi S, 2001, BIOCHEM BIOPH RES CO, V284, P614, DOI 10.1006/bbrc.2001.5017; Tyagi S, 2001, J VIROL, V75, P2493, DOI 10.1128/JVI.75.5.2493-2498.2001; Tyagi S, 2000, BIOCHEM BIOPH RES CO, V277, P589, DOI 10.1006/bbrc.2000.3720; Wester L, 1997, PROTEIN EXPRES PURIF, V11, P95, DOI 10.1006/prep.1997.0760; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zafrullah M, 1997, J VIROL, V71, P9045, DOI 10.1128/JVI.71.12.9045-9053.1997	62	63	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29308	29319		10.1074/jbc.M402017200	http://dx.doi.org/10.1074/jbc.M402017200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15037615	hybrid			2022-12-25	WOS:000222445300061
J	Davies, PS; Enns, CA				Davies, PS; Enns, CA			Expression of the hereditary hemochromatosis protein HFE increases ferritin levels by inhibiting iron export in HT29 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR MESSENGER-RNA; METAL-ION TRANSPORTER; TRANSFERRIN RECEPTOR; DEPENDENT REGULATION; DEFICIENT PHENOTYPE; MOLECULAR CONTROL; ANEMIA MICE; HELA-CELLS; WILD-TYPE; METABOLISM	Iron is essential for life in almost all organisms and, in mammals, is absorbed through the villus cells of the duodenum. Using a human colonic carcinoma cell line that has many duodenal characteristics, HT29, we show that genes involved in intestinal iron transport are endogenously expressed. When stably transfected to express the hereditary hemochromatosis protein HFE these cells have increased ferritin levels. We demonstrate that this is not due to an effect on the transferrin (TF)-mediated iron uptake pathway but rather due to inhibition of iron efflux from the cell. The effect of HFE was independent of its interaction with TF receptor 1 as indicated by similar results using both the wild type HFE and the W81A mutant that binds TF receptor 1 with greatly reduced affinity. HFE expression did not affect the mRNA levels of most of the genes involved in iron absorption that were tested; however, it did correspond to a decrease in hephaestin message levels. These results point to a role for HFE in inhibition of iron efflux in HT29 cells. This is a distinct role from that in HeLa and human embryonic kidney 293 cells where HFE has been shown to inhibit TF-mediated iron uptake resulting in decreased ferritin levels. Such a distinction suggests a multifunctional role for HFE that is dependent upon expression levels of proteins involved in iron transport.	Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA	Oregon Health & Science University	Enns, CA (corresponding author), Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, L215,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	ennsca@ohsu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK054488, R01DK054488] Funding Source: NIH RePORTER; NIAID NIH HHS [T32-AI07472] Funding Source: Medline; NIDDK NIH HHS [DK 54488] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Anderson GJ, 2002, CELL BIOCHEM BIOPHYS, V36, P137, DOI 10.1385/CBB:36:2-3:137; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Applied Biosystems, 2001, APPL BIOS US B, V2, P11; Ben-Arieh SV, 2001, J VIROL, V75, P10557, DOI 10.1128/JVI.75.21.10557-10562.2001; Brunt EM, 2000, AM J GASTROENTEROL, V95, P1788; Chen HJ, 2004, BLOOD, V103, P3933, DOI 10.1182/blood-2003-09-3139; CONRAD ME, 1963, BLOOD, V22, P406, DOI 10.1182/blood.V22.4.406.406; Corsi B, 1999, FEBS LETT, V460, P149, DOI 10.1016/S0014-5793(99)01330-7; Davies PS, 2003, BIOCHEM J, V373, P145, DOI 10.1042/BJ20030202; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Drakesmith H, 2002, P NATL ACAD SCI USA, V99, P15602, DOI 10.1073/pnas.242614699; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; Feeney GP, 2001, BBA-MOL CELL RES, V1538, P242, DOI 10.1016/S0167-4889(01)00075-1; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; FRACANZANI AL, 1989, GASTROENTEROLOGY, V96, P1071, DOI 10.1016/0016-5085(89)91625-9; GODEFROY O, 1990, New Biologist, V2, P875; GODEFROY O, 1988, BIOL CELL, V63, P41, DOI 10.1016/0248-4900(88)90107-4; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gunshin H, 2001, FEBS LETT, V509, P309, DOI 10.1016/S0014-5793(01)03189-1; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebron JA, 1999, J MOL BIOL, V294, P239, DOI 10.1006/jmbi.1999.3252; Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206; Montosi G, 2000, BLOOD, V96, P1125, DOI 10.1182/blood.V96.3.1125.015k19_1125_1129; Muckenthaler M, 2003, NAT GENET, V34, P102, DOI 10.1038/ng1152; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; PIETRANGELO A, 1995, GASTROENTEROLOGY, V108, P208, DOI 10.1016/0016-5085(95)90026-8; POWELL LW, 1970, GUT, V11, P727, DOI 10.1136/gut.11.9.727; Riedel HD, 1999, BLOOD, V94, P3915, DOI 10.1182/blood.V94.11.3915.423k27_3915_3921; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; Roy CN, 2000, FEBS LETT, V484, P271, DOI 10.1016/S0014-5793(00)02173-6; Roy CN, 2002, J CELL PHYSIOL, V190, P218, DOI 10.1002/JCP.10056; Salter-Cid L, 1999, P NATL ACAD SCI USA, V96, P5434, DOI 10.1073/pnas.96.10.5434; Theil EC, 1998, MET IONS BIOL SYST, V35, P403; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Waheed A, 1999, P NATL ACAD SCI USA, V96, P1579, DOI 10.1073/pnas.96.4.1579; Wang J, 2003, BIOCHEM J, V370, P891, DOI 10.1042/BJ20021607; Warren RA, 1997, J BIOL CHEM, V272, P2116; WILLIAMS AM, 1991, J BIOL CHEM, V266, P17648; Zhang AS, 2004, BLOOD, V103, P1509, DOI 10.1182/blood-2003-07-2378; Zhang AS, 2003, P NATL ACAD SCI USA, V100, P9500, DOI 10.1073/pnas.1233675100	53	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25085	25092		10.1074/jbc.M400537200	http://dx.doi.org/10.1074/jbc.M400537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15044462	hybrid			2022-12-25	WOS:000221827900023
J	Deval, J; Navarro, JM; Selmi, B; Courcambeck, J; Boretto, J; Halfon, P; Garrido-Urbani, S; Sire, J; Canard, B				Deval, J; Navarro, JM; Selmi, B; Courcambeck, J; Boretto, J; Halfon, P; Garrido-Urbani, S; Sire, J; Canard, B			A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG SUSCEPTIBILITY; IN-VITRO; M184V MUTATIONS; HIV-1 VARIANTS; TYPE-1; PROCESSIVITY; NUCLEOSIDE; INHIBITORS; MECHANISM; THERAPY	Mechanisms governing viral replicative capacity are poorly understood at the biochemical level. Human immunodeficiency virus, type 1 reverse transcriptase (HIV-1 RT) K65R or L74V substitutions confer viral resistance to 2',3'-dideoxyinosine (ddI) in vivo. The two substitutions never occur together, and L74V is frequently found in patients receiving ddI, while K65R is not. Here we show that recombinant viruses carrying K65R and K65R/L74V display the same resistance level to ddI (about 9.5-fold) relative to wild type. Consistent with this result, purified HIV-1 RT carrying K65R RT or K65R/L74V substitutions exhibits an 8-fold resistance to ddATP as judged by pre-steady state kinetics of incorporation of a single nucleotide into DNA. Resistance is due to a selective decrease of the catalytic rate constant k(pol): 22-fold (from 7.2 to 0.33 s(-1)) for K65R RT and 84-fold (from 7.2 to 0.086 s(-1)) for K65R/L74V RT. However, the K65R/L74V virus replication capacity is severely impaired relative to that of wild-type virus. This loss of viral fitness is correlated to a poor ability of K65R/L74V RT to use natural nucleotides relative to wild-type RT: 15% that of wild-type RT for dATP, 36% for dGTP, 50% for dTTP, and 25% for dCTP. The order of incorporation efficiency is wild-type RT > L74V RT > K65R RT > K65R/L74V RT. Processivity of DNA synthesis remains unaffected. These results explain why the two mutations do not combine in the clinic and might give a mechanism for a decreased viral fitness at the molecular level.	Ecole Super Ingenieurs Luminy, CNRS, F-13288 Marseille 9, France; Univ Aix Marseille 1, Ecole Super Ingenieurs Luminy, UMR 6098, F-13288 Marseille 9, France; Univ Aix Marseille 2, Ecole Super Ingenieurs Luminy, UMR 6098, F-13288 Marseille 9, France; INSERM, U372, F-13288 Marseille 9, France; Dept Sci Chim, F-13288 Marseille 9, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Canard, B (corresponding author), Ecole Super Ingenieurs Luminy, CNRS, Case 925, F-13288 Marseille 9, France.	bruno@afmb.cnrs-mrs.fr		Canard, Bruno/0000-0003-4924-1991				Arion D, 1996, J BIOL CHEM, V271, P19860, DOI 10.1074/jbc.271.33.19860; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Boretto J, 2001, ANAL BIOCHEM, V292, P139, DOI 10.1006/abio.2001.5045; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deval J, 2002, J BIOL CHEM, V277, P42097, DOI 10.1074/jbc.M206725200; Deval J, 2004, J BIOL CHEM, V279, P509, DOI 10.1074/jbc.M308806200; Devereux HL, 2001, J MED VIROL, V65, P218, DOI 10.1002/jmv.2023; Diallo K, 2003, J VIROL, V77, P8621, DOI 10.1128/JVI.77.16.8621-8632.2003; Frost SDW, 2000, J VIROL, V74, P6262, DOI 10.1128/JVI.74.14.6262-6268.2000; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; GAO WY, 1994, J BIOL CHEM, V269, P12633; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Jeffrey JL, 2003, J BIOL CHEM, V278, P18971, DOI 10.1074/jbc.M210113200; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kodama EI, 2001, ANTIMICROB AGENTS CH, V45, P1539, DOI 10.1128/AAC.45.5.1539-1546.2001; Menendez-Arias L, 2002, TRENDS PHARMACOL SCI, V23, P381, DOI 10.1016/S0165-6147(02)02054-0; Meyer PR, 2003, J VIROL, V77, P3871, DOI 10.1128/JVI.77.6.3871-3877.2003; Miller V, 2001, ANTIVIR THER, V6, P25; Miller V, 2000, AIDS, V14, P163, DOI 10.1097/00002030-200001280-00012; Naeger LK, 2001, ANTIVIR THER, V6, P115; Navarro JM, 2001, VIROLOGY, V290, P300, DOI 10.1006/viro.2001.1188; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; Pepe G, 2002, EUR J MED CHEM, V37, P865, DOI 10.1016/S0223-5234(02)01371-5; PEPE G, 1990, STUD PHYS THEO CHEM, V71, P93; Petrella Marco, 2002, AIDS Reviews, V4, P224; Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000; Quinones-Mateu ME, 2002, DRUG RESIST UPDATE, V5, P224, DOI 10.1016/S1368-7646(02)00123-1; Roy B, 1999, ANAL BIOCHEM, V269, P403, DOI 10.1006/abio.1999.4051; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; SARAFIANOS SG, 1995, BIOCHEMISTRY-US, V34, P7207, DOI 10.1021/bi00021a036; Selmi B, 2001, J BIOL CHEM, V276, P13965, DOI 10.1074/jbc.M009837200; Selmi B, 2001, J BIOL CHEM, V276, P48466, DOI 10.1074/jbc.M107003200; Sharma PL, 1997, J VIROL, V71, P8846, DOI 10.1128/JVI.71.11.8846-8851.1997; Sharma PL, 1999, J VIROL, V73, P8448, DOI 10.1128/JVI.73.10.8448-8456.1999; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; Tanaka M, 1997, ANTIMICROB AGENTS CH, V41, P1313, DOI 10.1128/AAC.41.6.1313; TERAI C, 1991, EXP CELL RES, V193, P375, DOI 10.1016/0014-4827(91)90110-G; Verhofstede C, 1999, AIDS, V13, P2541, DOI 10.1097/00002030-199912240-00007; Wainberg MA, 1999, ANTIVIR THER, V4, P87; White KL, 2002, ANTIMICROB AGENTS CH, V46, P3437, DOI 10.1128/AAC.46.11.3437-3446.2002; Winters MA, 1997, ANTIMICROB AGENTS CH, V41, P757, DOI 10.1128/AAC.41.4.757; Winters MA, 1998, J CLIN INVEST, V102, P1769, DOI 10.1172/JCI4948; ZHANG D, 1994, ANTIMICROB AGENTS CH, V38, P282, DOI 10.1128/AAC.38.2.282	47	67	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25489	25496		10.1074/jbc.M313534200	http://dx.doi.org/10.1074/jbc.M313534200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15044478	hybrid			2022-12-25	WOS:000221827900073
J	Block, ER; Matela, AR; SundarRaj, N; Iszkula, ER; Klarlund, JK				Block, ER; Matela, AR; SundarRaj, N; Iszkula, ER; Klarlund, JK			Wounding induces motility in sheets of corneal epithelial cells through loss of spatial constraints - Role of heparin-binding epidermal growth factor-like growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; EGF RECEPTOR; MOLECULAR MECHANISMS; TUMOR INVASION; DORSAL CLOSURE; ACTIVATION; EXPRESSION; DROSOPHILA; LIGANDS; INJURY	Cellular responses to wounding have often been studied at a molecular level after disrupting cell layers by mechanical means. This invariably results in damage to cells at the edges of the wounds, which has been suggested to be instrumental for initiating wound healing. To test this, we devised an alternative procedure to introduce gaps in layers of corneal epithelial cells by casting agarose strips on tissue culture plates. In contrast to mechanical wounding, removal of the strips did not lead to detectable membrane leakage or to activation of the stress-activated kinase JNK. Nonetheless, cells at the edge underwent the typical morphological transition to a highly motile phenotype, and the gaps closed at rates similar to those of mechanically induced wounds. To allow biochemical analysis of cell extracts, a procedure was devised that makes cell-free surface area acutely available to a large proportion of cells in culture. Rapid activation of the epidermal growth factor receptor ( EGFR) was detected by immunoblotting, and the addition of an EGFR-blocking antibody completely abolished wound healing. In addition, wound healing was inhibited by agents that block signaling by the heparin-binding epidermal growth factor-like growth factor (HB-EGF). Cells stimulated with cell-free tissue culture surface released a soluble factor that induced activation of the EGFR, which was distinct from HB-EGF. These studies suggest that the triggering event for the induction of motility in corneal epithelial cells is related to the sudden availability of permissive surface area rather than to mechanical damage, and they demonstrate a central role of signaling through HB-EGF.	Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Klarlund, JK (corresponding author), Univ Pittsburgh, Sch Med, Dept Ophthalmol, 203 Lothrop St, Pittsburgh, PA 15213 USA.	klarlundjk@upmc.edu			NATIONAL EYE INSTITUTE [R01EY013463, P30EY008098] Funding Source: NIH RePORTER; NEI NIH HHS [EY08098, EY013463] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahmadi Arash J., 2002, International Ophthalmology Clinics, V42, P13; Cribbs RK, 2002, J BURN CARE REHABIL, V23, P116, DOI 10.1097/00004630-200203000-00008; Danjo Y, 1998, J CELL SCI, V111, P3323; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; EBATO B, 1988, INVEST OPHTH VIS SCI, V29, P1533; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Ellis PD, 2001, BIOCHEM J, V354, P99, DOI 10.1042/0264-6021:3540099; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Harden N, 2002, DIFFERENTIATION, V70, P181, DOI 10.1046/j.1432-0436.2002.700408.x; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jacinto A, 2001, NAT CELL BIOL, V3, pE117, DOI 10.1038/35074643; Javelaud D, 2003, J BIOL CHEM, V278, P24624, DOI 10.1074/jbc.M301942200; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; KENYON KR, 2000, PRINCIPLES PRACTICES, V1, P926; Kiehart DP, 2000, J CELL BIOL, V149, P471, DOI 10.1083/jcb.149.2.471; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Lu L, 2001, EXP BIOL MED, V226, P653, DOI 10.1177/153537020222600711; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Martin P, 2002, CURR OPIN CELL BIOL, V14, P569, DOI 10.1016/S0955-0674(02)00369-1; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; Miyake K, 2003, CRIT CARE MED, V31, pS496, DOI 10.1097/01.CCM.0000081432.72812.16; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Niederkorn J Y, 1989, Reg Immunol, V2, P83; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Saika Shizuya, 2002, Cornea, V21, pS23, DOI 10.1097/00003226-200203001-00006; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Song QH, 2001, J CELL BIOCHEM, V80, P397, DOI 10.1002/1097-4644(20010301)80:3<397::AID-JCB140>3.0.CO;2-W; Stoll S, 1997, J CLIN INVEST, V100, P1271, DOI 10.1172/JCI119641; Suzuki K, 2003, PROG RETIN EYE RES, V22, P113, DOI 10.1016/S1350-9462(02)00042-3; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Vincent-Salomon A, 2003, BREAST CANCER RES, V5, P101, DOI 10.1186/bcr578; Wells A, 2000, ADV CANCER RES, V78, P31; Wells A, 2002, ACTA ONCOL, V41, P124, DOI 10.1080/028418602753669481; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wilson SE, 2003, AM J OPHTHALMOL, V136, P530, DOI 10.1016/S0002-9394(03)00085-0; Wilson SE, 2001, PROG RETIN EYE RES, V20, P625, DOI 10.1016/S1350-9462(01)00008-8; Wood W, 2002, NAT CELL BIOL, V4, P907, DOI 10.1038/ncb875; Woolley K, 2000, BIOESSAYS, V22, P911; Zieske JD, 2001, CURR OPIN OPHTHALMOL, V12, P237, DOI 10.1097/00055735-200108000-00001; Zieske JD, 2000, INVEST OPHTH VIS SCI, V41, P1346; ZIESKE JD, 1987, INVEST OPHTH VIS SCI, V28, P1668	52	109	110	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24307	24312		10.1074/jbc.M401058200	http://dx.doi.org/10.1074/jbc.M401058200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15039441	hybrid			2022-12-25	WOS:000221702500056
J	Morita, SY; Kawabe, M; Sakurai, A; Okuhira, K; Vertut-Doi, A; Nakano, M; Handa, T				Morita, SY; Kawabe, M; Sakurai, A; Okuhira, K; Vertut-Doi, A; Nakano, M; Handa, T			Ceramide in lipid particles enhances heparan sulfate proteoglycan and low density lipoprotein receptor-related protein-mediated uptake by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; ACID SPHINGOMYELINASE GENE; HUMAN APOLIPOPROTEIN-E; SMOOTH-MUSCLE-CELLS; ATHEROGENIC LIPOPROTEINS; CHOLESTERYL ESTER; LDL RECEPTOR; SPHINGOLIPID BIOSYNTHESIS; PLASMA-LIPOPROTEINS; SCAVENGER RECEPTOR	Arterial wall sphingomyelinase (SMase) has been proposed to be involved in atherogenesis. SMase modification of lipoproteins has been shown to occur in atherosclerotic lesions and to facilitate their uptake by macrophages and foam cell formation. To investigate the mechanism of macrophage uptake enhanced by SMase, we prepared lipid emulsions containing sphingomyelin (SM) or ceramide (CER) as model particles of lipoproteins. SMase remarkably increased the uptake of SM-containing emulsions by J774 macrophages without apolipoproteins. The emulsion uptake was negatively correlated with the degree of particle aggregation by pretreatment with SMase, whereas the uptake of CER-containing emulsions was significantly larger than SM-containing emulsions, indicating that enhancement of uptake is due to the generation of CER molecules in particles but not to the aggregation by SMase. Heparan sulfate proteoglycans (HSPGs) and low density lipoprotein receptor-related protein (LRP) were crucial for CER-enhanced emulsion uptake, because heparin or lactoferrin inhibited the emulsion uptake. Confocal microscopy also showed that SMase promoted both binding and internalization of emulsions by J774 macrophages, which were almost abolished by lactoferrin. Apolipoprotein E further increased the uptake of CER-containing emulsions compared with SM-containing emulsions. These findings suggest the generation of CER in lipoproteins by SMase facilitates the macrophage uptake via HSPG and LRP pathways and plays a crucial role in foam cell formation. Thus, CER may act as an important atherogenic molecule.	Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Handa, T (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan.	handatsr@pharm.kyoto-u.ac.jp	Morita, Shin-ya/U-2793-2019	Morita, Shin-ya/0000-0003-4079-707X				AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024; BARENHOLZ Y, 1982, PHOSPHOLIPIDS, P129; BISGAIER CL, 1993, J LIPID RES, V34, P1625; BU GJ, 1994, J BIOL CHEM, V269, P18521; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; de Beer F, 1999, ARTERIOSCL THROM VAS, V19, P633, DOI 10.1161/01.ATV.19.3.633; Denicola A, 2002, J BIOL CHEM, V277, P932, DOI 10.1074/jbc.M106589200; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; GEELEN MJH, 1995, J NUTR, V125, P2294, DOI 10.1093/jn/125.9.2294; Geelen MJH, 2000, BRIT J NUTR, V83, P541; Geelen MJH, 1999, J NUTR, V129, P2119, DOI 10.1093/jn/129.12.2119; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; Greenberg S, 1999, J LEUKOCYTE BIOL, V66, P712, DOI 10.1002/jlb.66.5.712; GUNTHER GR, 1973, P NATL ACAD SCI USA, V70, P1012, DOI 10.1073/pnas.70.4.1012; GUPTA AK, 1992, J LIPID RES, V33, P1741; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hevonoja T, 2000, BBA-MOL CELL BIOL L, V1488, P189, DOI 10.1016/S1388-1981(00)00123-2; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; IKEZAWA H, 1986, ARCH BIOCHEM BIOPHYS, V249, P588, DOI 10.1016/0003-9861(86)90037-8; Jeong TS, 1998, J CLIN INVEST, V101, P905, DOI 10.1172/JCI870; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; Jiang XC, 2000, ARTERIOSCL THROM VAS, V20, P2614, DOI 10.1161/01.ATV.20.12.2614; KHOO JC, 1990, J LIPID RES, V31, P645; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kraemer FB, 2000, ARTERIOSCL THROM VAS, V20, P2509, DOI 10.1161/01.ATV.20.12.2509; LABODA HM, 1986, BIOCHIM BIOPHYS ACTA, V876, P233, DOI 10.1016/0005-2760(86)90279-1; Lakkaraju A, 2002, J BIOL CHEM, V277, P15085, DOI 10.1074/jbc.M111764200; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; Li RX, 1999, J BIOL CHEM, V274, P21121, DOI 10.1074/jbc.274.30.21121; Llorente-Cortes V, 2000, ARTERIOSCL THROM VAS, V20, P1572, DOI 10.1161/01.ATV.20.6.1572; LLORENTECORTES V, 2000, ARTERIOSCLER THROMB, V22, P1905; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; Mahley RW, 1999, J LIPID RES, V40, P1; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Marathe S, 2000, ARTERIOSCL THROM VAS, V20, P2607, DOI 10.1161/01.ATV.20.12.2607; MAZZONE T, 1994, J LIPID RES, V35, P1345; Memon RA, 1998, ARTERIOSCL THROM VAS, V18, P1257, DOI 10.1161/01.ATV.18.8.1257; MERRILL AH, 1995, J BIOL CHEM, V270, P13834, DOI 10.1074/jbc.270.23.13834; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Morita S, 2003, BBA-MOL CELL BIOL L, V1631, P169, DOI 10.1016/S1388-1981(02)00365-7; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; Oorni K, 2000, J LIPID RES, V41, P1703; Oorni K, 1998, J BIOL CHEM, V273, P29127, DOI 10.1074/jbc.273.44.29127; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Perrey S, 2001, ATHEROSCLEROSIS, V154, P51, DOI 10.1016/S0021-9150(00)00457-3; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; Reaven E, 2001, P NATL ACAD SCI USA, V98, P1613, DOI 10.1073/pnas.98.4.1613; RENIER G, 1993, ARTERIOSCLER THROMB, V13, P190, DOI 10.1161/01.ATV.13.2.190; RuizArguello MB, 1996, J BIOL CHEM, V271, P26616, DOI 10.1074/jbc.271.43.26616; Saito H, 1996, J BIOL CHEM, V271, P15515, DOI 10.1074/jbc.271.26.15515; Saito H, 2000, BBA-MOL CELL BIOL L, V1486, P312, DOI 10.1016/S1388-1981(00)00071-8; Saito H, 2001, LIPIDS, V36, P27, DOI 10.1007/s11745-001-0664-1; Sakr SW, 2001, J BIOL CHEM, V276, P37649, DOI 10.1074/jbc.M105129200; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SUBBAIAH PV, 1993, J BIOL CHEM, V268, P20156; TABAS I, 1993, J BIOL CHEM, V268, P20419; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; XU XX, 1991, J BIOL CHEM, V266, P24849; YLAHERTTUALA S, 1988, J LIPID RES, V29, P563; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39; Ziere GJ, 1996, BIOCHEM J, V313, P289, DOI 10.1042/bj3130289; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	72	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24355	24361		10.1074/jbc.M402035200	http://dx.doi.org/10.1074/jbc.M402035200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15044445	hybrid			2022-12-25	WOS:000221702500061
J	Weigert, C; Brodbeck, K; Staiger, H; Kausch, C; Machicao, F; Haring, HU; Schleicher, ED				Weigert, C; Brodbeck, K; Staiger, H; Kausch, C; Machicao, F; Haring, HU; Schleicher, ED			Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; SKELETAL-MUSCLE; TRANSCRIPTION FACTORS; HEXOSAMINE PATHWAY; GENE-EXPRESSION; CYTOKINE; DIACYLGLYCEROL; ACCUMULATION	Circulating interleukin-6 (IL-6), insulin, and free fatty acid (FFA) concentrations are associated with impaired insulin action in obese and type 2 diabetic individuals. However, a causal relationship between elevated plasma FFAs and IL-6 has not been shown. Because skeletal muscle represents a major target of impaired insulin action, we studied whether FFAs may affect IL-6 expression in human myotubes. We demonstrate that specifically saturated FFAs, e. g. palmitate (0.25 mM), induce IL-6 mRNA expression and protein secretion by a proteasome-dependent mechanism that leads to a rapid and chronic activation of nuclear factor-kappaB. Insulin, high glucose concentrations, or unsaturated FFAs did not activate IL-6 expression. In fact, the unsaturated FFA linoleate inhibited palmitate-induced IL-6 production. Because inhibition of palmitate metabolism by the acyl-CoA synthetase inhibitor triacsin C did not abolish IL-6 expression, it appears that the palmitate molecule per se exerts the observed effects. Furthermore, we show that in human myotubes, IL-6 activates the phosphorylation of signal transducer and activator of transcription 3 in concentrations similar to hepatocytes. However, no inhibitory effect of IL-6 on insulin action, determined as phosphatidylinositol 3-kinase association with insulin receptor substrate-1, Akt phosphorylation, and glycogen synthesis, was detected. We conclude that IL-6 expression may be modulated by the composition of circulating FFA, e. g. by diet, and that skeletal muscle cells could be target cells for IL-6.	Univ Tubingen, Dept Internal Med, Div Endocrinol Metab & Pathobiochem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Schleicher, ED (corresponding author), Univ Tubingen, Dept Internal Med, Div Endocrinol Metab & Pathobiochem, Otfried Muller Str 10, D-72076 Tubingen, Germany.	enschlei@med.uni-tuebingen.de	Staiger, Harald/N-5871-2014	Staiger, Harald/0000-0002-9507-5333				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200; Eitel K, 2003, DIABETES, V52, P991, DOI 10.2337/diabetes.52.4.991; Eitel K, 2002, BIOCHEM BIOPH RES CO, V299, P853, DOI 10.1016/S0006-291X(02)02752-3; Febbraio MA, 2003, J PHYSIOL-LONDON, V549, P607, DOI 10.1113/jphysiol.2003.042374; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Fernandez-Real JM, 2003, DIABETES CARE, V26, P1362, DOI 10.2337/diacare.26.5.1362; Fernandez-Real JM, 2003, ENDOCR REV, V24, P278, DOI 10.1210/er.2002-0010; Grassl C, 1999, J AM SOC NEPHROL, V10, P1466; Hall AM, 2003, J BIOL CHEM, V278, P43008, DOI 10.1074/jbc.M306575200; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kanemaki T, 1998, HEPATOLOGY, V27, P1296, DOI 10.1002/hep.510270515; KARIN M, 2000, ANNU REV IMMUNOL, V16, P225; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Klover PJ, 2003, DIABETES, V52, P2784, DOI 10.2337/diabetes.52.11.2784; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Kopp HP, 2003, ARTERIOSCL THROM VAS, V23, P1042, DOI 10.1161/01.ATV.0000073313.16135.21; Krutzfeldt J, 2000, DIABETES, V49, P992, DOI 10.2337/diabetes.49.6.992; Ladner KJ, 2003, J BIOL CHEM, V278, P2294, DOI 10.1074/jbc.M207129200; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Manco M, 2000, METABOLISM, V49, P220, DOI 10.1016/S0026-0495(00)91377-5; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Montell E, 2001, AM J PHYSIOL-ENDOC M, V280, pE229, DOI 10.1152/ajpendo.2001.280.2.E229; NELSON KA, 1994, J CLIN ONCOL, V12, P213, DOI 10.1200/JCO.1994.12.1.213; Ohshima S, 1998, P NATL ACAD SCI USA, V95, P8222, DOI 10.1073/pnas.95.14.8222; Paysant J, 2000, CYTOKINE, V12, P774, DOI 10.1006/cyto.1999.0649; Penkowa M, 2003, FASEB J, V17, DOI 10.1096/fj.03-0311fje; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391; Senn JJ, 2003, J BIOL CHEM, V278, P13740, DOI 10.1074/jbc.M210689200; Staiger H, 2003, DIABETOLOGIA, V46, P956, DOI 10.1007/s00125-003-1146-0; TILG H, 1994, BLOOD, V83, P113; Tsigos C, 1997, J CLIN ENDOCR METAB, V82, P4167, DOI 10.1210/jc.82.12.4167; van Hall G, 2003, J CLIN ENDOCR METAB, V88, P3005, DOI 10.1210/jc.2002-021687; Vessby B, 2003, CURR OPIN LIPIDOL, V14, P15, DOI 10.1097/00041433-200302000-00004; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Weigert C, 2003, DIABETES, V52, P650, DOI 10.2337/diabetes.52.3.650; Weigert C, 2000, J AM SOC NEPHROL, V11, P2007, DOI 10.1681/ASN.V11112007; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zhang WJ, 2001, FASEB J, V15, P2423, DOI 10.1096/fj.01-0260com; Zhang Y, 2000, AM J PHYSIOL-ENDOC M, V279, pE196, DOI 10.1152/ajpendo.2000.279.1.E196	51	222	231	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23942	23952		10.1074/jbc.M312692200	http://dx.doi.org/10.1074/jbc.M312692200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15028733	hybrid			2022-12-25	WOS:000221702500015
J	Sudo, S; Avsian-Kretchmer, O; Wang, LS; Hsueh, AJW				Sudo, S; Avsian-Kretchmer, O; Wang, LS; Hsueh, AJW			Protein related to DAN and cerberus is a bone morphogenetic protein antagonist that participates in ovarian paracrine regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-DIFFERENTIATION FACTOR-9; TGF-BETA; GRANULOSA-CELLS; FUNCTIONAL-CHARACTERIZATION; SIGNAL-TRANSDUCTION; UBIQUITIN LIGASE; GENE FAMILY; RAT OVARY; BMP; MOUSE	Bone morphogenetic proteins (BMPs) are important for body patterning and morphogenesis, whereas several BMP antagonists regulate the functions of BMPs during embryonic development and tissue differentiation. Protein related to DAN and cerberus ( PRDC) is a secreted protein with a cystine knot structure identified by gene trapping in embryonic stem cells. Although PRDC shows sequence homology with proteins of the BMP antagonist family, its biological activity and physiological functions are unclear. We generated recombinant PRDC and its paralog, gremlin, and tested their ability to suppress actions initiated by diverse BMP proteins. Similar to the known BMP antagonist, gremlin, PRDC blocked ligand signaling induced by BMP2 and BMP4 but had minimal effects on reporter gene activation induced by GDF-9, activin, or transforming growth factor-beta. Co-precipitation assays further demonstrated the direct protein-protein interactions between PRDC and BMP2 or BMP4. Reverse transcriptase-PCR analyses indicated that PRDC transcripts are widely expressed showing higher levels in ovary, brain, and spleen. In mouse ovary, PRDC transcripts were increased following gonadotropin treatment. In situ hybridization analyses further indicated that ovarian PRDC transcripts are localized in granulosa cells of selective follicles. In addition, co-treatment with PRDC antagonized the inhibitory effects of BMP4 on the follicle-stimulating hormone stimulation of progesterone production by cultured rat granulosa cells. Thus, PRDC is a potent BMP antagonist with a wide tissue expression pattern, and ovarian PRDC expressed in granulosa cells could be involved in follicular development by antagonizing the actions of theca cell-derived BMPs.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Hsueh, AJW (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA.	aaron.hsueh@stanford.edu			NICHD NIH HHS [U54-HD-31398] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD031398] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Avsian-Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003-0227; Bell E, 2003, DEVELOPMENT, V130, P1381, DOI 10.1242/dev.00344; Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Chun SY, 2001, ENDOCRINOLOGY, V142, P2311, DOI 10.1210/en.142.6.2311; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ducy P, 2000, KIDNEY INT, V57, P2207, DOI 10.1046/j.1523-1755.2000.00081.x; Eimon PM, 2001, MECH DEVELOP, V107, P187, DOI 10.1016/S0925-4773(01)00462-2; Erickson Gregory F, 2003, Reprod Biol Endocrinol, V1, P9, DOI 10.1186/1477-7827-1-9; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Hayashi M, 1999, ENDOCRINOLOGY, V140, P1236, DOI 10.1210/en.140.3.1236; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; Leo CP, 1999, ENDOCRINOLOGY, V140, P5469, DOI 10.1210/en.140.12.5469; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Minabe-Saegusa C, 1998, DEV GROWTH DIFFER, V40, P343; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Raftery LA, 1999, DEV BIOL, V210, P251, DOI 10.1006/dbio.1999.9282; Shimasaki S, 1999, P NATL ACAD SCI USA, V96, P7282, DOI 10.1073/pnas.96.13.7282; Topol LZ, 2000, J BIOL CHEM, V275, P8785, DOI 10.1074/jbc.275.12.8785; Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Vitt UA, 2000, BIOL REPROD, V62, P370, DOI 10.1095/biolreprod62.2.370; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Wozney JM, 2002, SPINE, V27, pS2, DOI 10.1097/00007632-200208151-00002; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	42	89	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23134	23141		10.1074/jbc.M402376200	http://dx.doi.org/10.1074/jbc.M402376200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039429	hybrid			2022-12-25	WOS:000221570900043
J	Theriault, JR; Lambert, H; Chavez-Zobel, AT; Charest, G; Lavigne, P; Landry, J				Theriault, JR; Lambert, H; Chavez-Zobel, AT; Charest, G; Lavigne, P; Landry, J			Essential role of the NH2-terminal WD/EPF motif in the phosphorylation-activated protective function of mammalian Hsp27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ALPHA-CRYSTALLIN DOMAIN; CHINESE-HAMSTER CELLS; SMALL STRESS-PROTEINS; ACTIN POLYMERIZATION; QUATERNARY STRUCTURE; OLIGOMERIC STRUCTURE; SECONDARY STRUCTURE; OXIDATIVE STRESS; MAPKAP KINASE-2	Hsp27 is expressed at high levels after mild heat shock and contributes to making cells extremely resistant to subsequent treatments. The activity of the protein is regulated at the transcriptional level, but also by phosphorylation, which occurs rapidly during stress and is responsible for causing the dissociation of large 700-kDa Hsp27 oligomers into dimers. We investigated the mechanism by which phosphorylation and oligomerization modulate the protective activity of Chinese hamster Hsp27. In contrast to oligomer dissociation, which only required Ser(90) phosphorylation, activation of Hsp27 thermoprotective activity required the phosphorylation of both Ser(90) and Ser(15). Replacement of Ser(90) by Ala(90), which prevented the dissociation of the oligomer upon stress, did cause a severe defect in the protective activity. Dissociation was, however, not a sufficient condition to activate the protein because replacement of Ser15 by Ala(15), which caused little effect in the oligomeric organization of the protein, also yielded an inactive protein. Analyzes of mutants with short deletions in the NH2 terminus identified the Hsp27 WD/EPF or PF-rich domain as essential for protection, maintenance of the oligomeric structure, and in vitro chaperone activity of the protein. In light of a three-dimensional model of Hsp27 based on the crystallographic structure of wheat Hsp16.9, we propose that the conserved WD/EPF motif of mammalian Hsp27 mediates important intramolecular interactions with hydrophic surfaces of the alpha-crystallin domain of the protein. These interactions are destabilized by Ser(90) phosphorylation, making the motif free to interact with heterologous molecular targets upon the additional phosphorylation of the nearby Ser(15).	Univ Laval, Hotel Dieu Quebec, Ctr Hosp Univ Quebec, Ctr Rech cancerol, Quebec City, PQ G1R 2J6, Canada; Univ Centroccidental Lisandro Alvarado, Decanto Med, Dept Morphol, Secc Anat Microscopia, Barquisimeto, Estado Lara, Venezuela; Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	Laval University; University of Sherbrooke	Landry, J (corresponding author), Univ Laval, Hotel Dieu Quebec, Ctr Hosp Univ Quebec, Ctr Rech cancerol, 9 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	jacques.landry@med.ulaval.ca						Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; CHRETIEN P, 1988, J CELL PHYSIOL, V137, P157, DOI 10.1002/jcp.1041370119; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; Dorion S, 2002, CELL STRESS CHAPERON, V7, P200, DOI 10.1379/1466-1268(2002)007<0200:AOTMAP>2.0.CO;2; Dorion S, 2002, J BIOL CHEM, V277, P30792, DOI 10.1074/jbc.M203642200; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EHRNSPERGER M, 1998, MOL CHAPERONES LIFE, P533; Feil IK, 2001, J BIOL CHEM, V276, P12024, DOI 10.1074/jbc.M010856200; Fontaine JM, 2003, CELL STRESS CHAPERON, V8, P62, DOI 10.1379/1466-1268(2003)8<62:TSODFP>2.0.CO;2; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; Garrido C, 1997, CANCER RES, V57, P2661; Geum D, 2002, J BIOL CHEM, V277, P19913, DOI 10.1074/jbc.M104396200; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Gough J, 2001, J MOL BIOL, V313, P903, DOI 10.1006/jmbi.2001.5080; Guay J, 1997, J CELL SCI, V110, P357; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Huot J, 1996, CANCER RES, V56, P273; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Koteiche HA, 2002, FEBS LETT, V519, P16, DOI 10.1016/S0014-5793(02)02688-1; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1982, CANCER RES, V42, P2457; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schafer C, 1999, AM J PHYSIOL-CELL PH, V277, pC1032; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; SUBJECK JR, 1982, HEAT SHOCK BACTERIA, P405; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Wieske M, 2001, EUR J BIOCHEM, V268, P2083, DOI 10.1046/j.1432-1327.2001.02082.x; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137	58	96	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23463	23471		10.1074/jbc.M402325200	http://dx.doi.org/10.1074/jbc.M402325200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15033973	hybrid			2022-12-25	WOS:000221570900083
J	Collin, M; Fischetti, VA				Collin, M; Fischetti, VA			A novel secreted endoglycosidase from Enterococcus faecalis with activity on human immunoglobulin G and ribonuclease B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-HEXOSAMINIDASE; ASPARAGINE-LINKED GLYCANS; DI-N-ACETYLCHITOBIASE; FLAVOBACTERIUM-MENINGOSEPTICUM; STREPTOCOCCUS-PYOGENES; HIGH-MANNOSE; CARBOHYDRATE STRUCTURE; COCCIDIOIDES-IMMITIS; GLYCOSYL HYDROLASES; EXTENSIVE HOMOLOGY	The human pathogen Enterococcus faecalis can degrade the N-linked glycans of human RNase B to acquire nutrients, but no gene or protein has been associated with this activity. We identified an 88-kDa secreted protein, endoglycosidase (Endo) E, which is most likely responsible for this activity. EndoE, encoded by ndoE, consists of an alpha-domain with a family 18 glycosyl hydrolase motif and a beta-domain similar to family 20 glycosyl hydrolases. Phylogenetic analysis of EndoE indicates that the alpha-domain is related to human chitobiases, and the beta-domain is related to bacterial and human hexosaminidases. Recombinant expression of full-length EndoE or EndoEalpha, site-directed mutagenesis of the catalytic residues, mass spectroscopy, and homology modeling shows that EndoEalpha hydrolyzes the glycan on human RNase B, whereas EndoEalpha hydrolyzes the conserved glycan on IgG. Denaturation experiments indicate that the chitinase activity on RNase B is not dependent on the tertiary structure, although it is on IgG. The ndoE gene and secreted EndoE are present in most E. faecalis but not in Enterococcus faecium isolates. Correspondingly, E. faecalis, but not E. faecium, degrades the glycan on RNase B during growth. Thus, we have identified a secreted enzyme from E. faecalis, EndoE, which by two distinct activities hydrolyzes the glycans on RNase B and IgG. Both activities could be important for the molecular pathogenesis and persistence of E. faecalis during human infections.	Rockefeller Univ, Lab Bacterial Pathogenesis, New York, NY 10021 USA	Rockefeller University	Fischetti, VA (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis, 1230 York Ave, New York, NY 10021 USA.	vaf@rockefeller.edu	Collin, Mattias/C-6398-2009	Collin, Mattias/0000-0002-6166-7410	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011822, R37AI011822] Funding Source: NIH RePORTER; NIAID NIH HHS [AI11822] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bortone K, 2002, J MOL BIOL, V320, P293, DOI 10.1016/S0022-2836(02)00444-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Byers HL, 1999, GLYCOBIOLOGY, V9, P469, DOI 10.1093/glycob/9.5.469; CHU FK, 1986, J BIOL CHEM, V261, P172; Chui D, 2001, P NATL ACAD SCI USA, V98, P1142, DOI 10.1073/pnas.98.3.1142; CLARKE VA, 1995, J BIOL CHEM, V270, P8805, DOI 10.1074/jbc.270.15.8805; Collin M, 2003, INFECT IMMUN, V71, P2983, DOI 10.1128/IAI.71.6.2983-2992.2003; Collin M, 2002, INFECT IMMUN, V70, P6646, DOI 10.1128/IAI.70.12.6646-6651.2002; Collin M, 2001, EMBO J, V20, P3046, DOI 10.1093/emboj/20.12.3046; Collin M, 2001, INFECT IMMUN, V69, P7187, DOI 10.1128/IAI.69.11.7187-7189.2001; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DEGASPERI R, 1989, J BIOL CHEM, V264, P9329; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DUBE R, 1990, GUT, V31, P431, DOI 10.1136/gut.31.4.431; EVERS S, 1993, GENE, V124, P143, DOI 10.1016/0378-1119(93)90779-3; FISHER KJ, 1992, J BIOL CHEM, V267, P19607; Gaglani MJ, 1997, J CLIN IMMUNOL, V17, P478, DOI 10.1023/A:1027371727225; Geourjon C, 2001, PROTEIN SCI, V10, P788, DOI 10.1110/ps.30001; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hollis T, 2000, PROTEIN SCI, V9, P544, DOI 10.1110/ps.9.3.544; Homer KA, 1996, MICROBIOL-UK, V142, P1221, DOI 10.1099/13500872-142-5-1221; Hou YM, 2001, BIOCHEMISTRY-US, V40, P2201, DOI 10.1021/bi002018s; JACOB AE, 1974, J BACTERIOL, V117, P360, DOI 10.1128/JB.117.2.360-372.1974; JETT BD, 1994, CLIN MICROBIOL REV, V7, P462, DOI 10.1128/CMR.7.4.462-478.1994; Kawasaki N, 1999, ANAL BIOCHEM, V269, P297, DOI 10.1006/abio.1999.4026; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; KURANDA MJ, 1986, J BIOL CHEM, V261, P5803; Maier T, 2003, J MOL BIOL, V328, P669, DOI 10.1016/S0022-2836(03)00311-5; Mark BL, 1998, J BIOL CHEM, V273, P19618, DOI 10.1074/jbc.273.31.19618; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Mimura Y, 2001, J BIOL CHEM, V276, P45539, DOI 10.1074/jbc.M107478200; Muller A, 1999, J MOL BIOL, V293, P1257, DOI 10.1006/jmbi.1999.3233; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; Paulsen IT, 2003, SCIENCE, V299, P2071, DOI 10.1126/science.1080613; Percival RS, 1996, FEMS IMMUNOL MED MIC, V15, P35, DOI 10.1111/j.1574-695X.1996.tb00356.x; PROIA RL, 1988, P NATL ACAD SCI USA, V85, P1883, DOI 10.1073/pnas.85.6.1883; Rafay AM, 1996, J MED MICROBIOL, V44, P409, DOI 10.1099/00222615-44-6-409; Roberts G, 2001, J MED MICROBIOL, V50, P620, DOI 10.1099/0022-1317-50-7-620; Roberts G, 2000, J BACTERIOL, V182, P882, DOI 10.1128/JB.182.4.882-890.2000; SOMERVILLE CC, 1993, P NATL ACAD SCI USA, V90, P6751, DOI 10.1073/pnas.90.14.6751; SUTTON BJ, 1983, BIOCHEM SOC T, V11, P130, DOI 10.1042/bst0110130; TAO MH, 1989, J IMMUNOL, V143, P2595; TARENTINO AL, 1992, J BIOL CHEM, V267, P3868; TARENTINO AL, 1993, J BIOL CHEM, V268, P9702; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; WATANABE T, 1993, J BIOL CHEM, V268, P18567; WILSON MJ, 1995, INFECT IMMUN, V63, P206, DOI 10.1128/IAI.63.1.206-211.1995; Wright A, 1998, J IMMUNOL, V160, P3393; WRIGHT A, 1994, J EXP MED, V180, P1087, DOI 10.1084/jem.180.3.1087	57	58	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22558	22570		10.1074/jbc.M402156200	http://dx.doi.org/10.1074/jbc.M402156200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15028731	hybrid			2022-12-25	WOS:000221417100107
J	Hoffmeister, M; van der Klei, A; Rotte, C; van Grinsven, KWA; van Hellemond, JJ; Henze, K; Tielens, AGM; Martin, W				Hoffmeister, M; van der Klei, A; Rotte, C; van Grinsven, KWA; van Hellemond, JJ; Henze, K; Tielens, AGM; Martin, W			Euglena gracilis Rhodoquinone : Ubiquinone ratio and mitochondrial proteome differ under aerobic and anaerobic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TWO-DIMENSIONAL ELECTROPHORESIS; IMMOBILIZED PH GRADIENTS; ELECTRON-TRANSPORT CHAIN; PYRUVATE-DEHYDROGENASE; AMITOCHONDRIATE PROTISTS; FUNCTIONING EUKARYOTES; NADP+ OXIDOREDUCTASE; NITRATE RESPIRATION; POLYACRYLAMIDE GELS; EUBACTERIAL ORIGIN	Euglena gracilis cells grown under aerobic and anaerobic conditions were compared for their whole cell rhodoquinone and ubiquinone content and for major protein spots contained in isolated mitochondria as assayed by two-dimensional gel electrophoresis and mass spectrometry sequencing. Anaerobically grown cells had higher rhodoquinone levels than aerobically grown cells in agreement with earlier findings indicating the need for fumarate reductase activity in anaerobic wax ester fermentation in Euglena. Microsequencing revealed components of complex III and complex IV of the respiratory chain and the E1beta subunit of pyruvate dehydrogenase to be present in mitochondria of aerobically grown cells but lacking in mitochondria from anaerobically grown cells. No proteins were identified as specific to mitochondria from anaerobically grown cells. cDNAs for the E1alpha, E2, and E3 subunits of mitochondrial pyruvate dehydrogenase were cloned and shown to be differentially expressed under aerobic and anaerobic conditions. Their expression patterns differed from that of mitochondrial pyruvate: NADP(+) oxidoreductase, the N-terminal domain of which is pyruvate: ferredoxin oxidoreductase, an enzyme otherwise typical of hydrogenosomes, hydrogen-producing forms of mitochondria found among anaerobic protists. The Euglena mitochondrion is thus a long sought intermediate that unites biochemical properties of aerobic and anaerobic mitochondria and hydrogenosomes because it contains both pyruvate: ferredoxin oxidoreductase and rhodoquinone typical of hydrogenosomes and anaerobic mitochondria as well as pyruvate dehydrogenase and ubiquinone typical of aerobic mitochondria. Our data show that under aerobic conditions Euglena mitochondria are prepared for anaerobic function and furthermore suggest that the ancestor of mitochondria was a facultative anaerobe, segments of whose physiology have been preserved in the Euglena lineage.	Univ Dusseldorf, Inst Bot 3, D-40225 Dusseldorf, Germany; Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3584 CM Utrecht, Netherlands; Univ Marburg, Inst Cytobiol, D-35037 Marburg, Germany	Heinrich Heine University Dusseldorf; Utrecht University; Philipps University Marburg	Martin, W (corresponding author), Univ Dusseldorf, Inst Bot 3, D-40225 Dusseldorf, Germany.	w.martin@uni-duesseldorf.de	Martin, William/C-5680-2008; Martin, William F./O-5446-2015; van Hellemond, Jaap/T-7555-2019	Martin, William F./0000-0003-1478-6449; van Hellemond, Jaap/0000-0003-4862-7796; Tielens, Aloysius/0000-0002-5485-1105				Adachi J., 1996, COMPUTER SCI MONOGRA, V28; Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; Andersson SGE, 1999, CURR OPIN MICROBIOL, V2, P535, DOI 10.1016/S1369-5274(99)00013-2; Atteia A, 2003, PLANT MOL BIOL, V53, P175, DOI 10.1023/B:PLAN.0000009274.19340.36; ATTEIA A, 2004, IN PRESS GENE AMST; Berry S, 2003, BBA-BIOENERGETICS, V1606, P57, DOI 10.1016/S0005-2728(03)00084-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Boxma B, 2004, MOL MICROBIOL, V51, P1389, DOI 10.1046/j.1365-2958.2003.03912.x; Boyunaga H, 2001, PARASITOLOGY, V122, P169, DOI 10.1017/S0031182001007211; Bryant D, 2004, MOL BIOL EVOL, V21, P255, DOI 10.1093/molbev/msh018; Buetow DE, 1989, BIOL EUGLENA, V4, P247; CARRE I, 1988, PLANT SCI, V54, P193, DOI 10.1016/0168-9452(88)90113-6; CHAUDHARY MF, 1984, PLANTA, V162, P518, DOI 10.1007/BF00399917; CRANE F. L., 1971, Methods in Enzymology, V18C, P137, DOI 10.1016/S0076-6879(71)18022-6; de Kok A, 1998, BBA-PROTEIN STRUCT M, V1385, P353, DOI 10.1016/S0167-4838(98)00079-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V2, P387; Doeller JE, 2001, J EXP BIOL, V204, P3755; Embley TM, 2003, IUBMB LIFE, V55, P387, DOI 10.1080/15216540310001592834; FINLAY BJ, 1983, NATURE, V303, P333, DOI 10.1038/303333a0; GORG A, 1985, ELECTROPHORESIS, V6, P599, DOI 10.1002/elps.1150061206; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; Green LS, 2000, J BACTERIOL, V182, P2838, DOI 10.1128/JB.182.10.2838-2844.2000; Hannaert V, 2000, MOL BIOL EVOL, V17, P989, DOI 10.1093/oxfordjournals.molbev.a026395; HENZE K, 1995, P NATL ACAD SCI USA, V92, P9122, DOI 10.1073/pnas.92.20.9122; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; IMHOFF JF, 1992, PROKARYOTES, V3, P2141; INUI H, 1984, EUR J BIOCHEM, V142, P121, DOI 10.1111/j.1432-1033.1984.tb08258.x; INUI H, 1987, J BIOL CHEM, V262, P9130; INUI H, 1982, FEBS LETT, V150, P89, DOI 10.1016/0014-5793(82)81310-0; INUI H, 1990, ARCH BIOCHEM BIOPHYS, V280, P292, DOI 10.1016/0003-9861(90)90332-S; INUI H, 1984, J BIOCHEM-TOKYO, V96, P931, DOI 10.1093/oxfordjournals.jbchem.a134913; KITA K, 1992, PARASITOL TODAY, V8, P155, DOI 10.1016/0169-4758(92)90009-Q; Kitaoka S., 1989, BIOL EUGLENA, VIV, P2; Kobayashi M, 1996, J BIOL CHEM, V271, P16263, DOI 10.1074/jbc.271.27.16263; Komuniecki Richard, 1995, P49, DOI 10.1016/B978-012473345-9/50005-2; Margulis L, 2000, P NATL ACAD SCI USA, V97, P6954, DOI 10.1073/pnas.97.13.6954; Martin W, 2003, IUBMB LIFE, V55, P193, DOI 10.1080/1521654031000141231; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Miyadera H, 2003, EUR J BIOCHEM, V270, P1863, DOI 10.1046/j.1432-1033.2003.03553.x; Mooney BP, 2002, ANNU REV PLANT BIOL, V53, P357, DOI 10.1146/annurev.arplant.53.100301.135251; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; NAGAI J, 1971, BIOCHEM BIOPH RES CO, V42, P523, DOI 10.1016/0006-291X(71)90402-5; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Neveling U, 1998, BBA-PROTEIN STRUCT M, V1385, P367, DOI 10.1016/S0167-4838(98)00080-6; Ogbonna JC, 1998, J APPL PHYCOL, V10, P67, DOI 10.1023/A:1008011201437; PONSGENSCHMIDT E, 1988, PLANT PHYSIOL, V86, P456; POWLS R, 1966, PHYTOCHEMISTRY, V5, P1235, DOI 10.1016/S0031-9422(00)86119-1; RAMIREZPONCE MP, 1980, FEBS LETT, V119, P137, DOI 10.1016/0014-5793(80)81015-5; Rhoads DM, 1998, J BIOL CHEM, V273, P30750, DOI 10.1074/jbc.273.46.30750; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; Rotte C, 2001, MOL BIOL EVOL, V18, P710, DOI 10.1093/oxfordjournals.molbev.a003853; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHNEIDER T, 1985, PLANTA, V166, P67, DOI 10.1007/BF00397387; Shen Y, 2003, NATURE, V423, P632, DOI 10.1038/nature01651; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; SIEDOW JN, 1995, PLANT CELL, V7, P821, DOI 10.1105/tpc.7.7.821; Takaya N, 1999, ARCH BIOCHEM BIOPHYS, V372, P340, DOI 10.1006/abbi.1999.1499; Theissen U, 2003, MOL BIOL EVOL, V20, P1564, DOI 10.1093/molbev/msg174; THEISSSEUBERLING HB, 1984, PLANT CELL PHYSIOL, V25, P601; Thollesson M, 2004, BIOINFORMATICS, V20, P416, DOI 10.1093/bioinformatics/btg422; TIELENS AGM, 1994, PARASITOL TODAY, V10, P346, DOI 10.1016/0169-4758(94)90245-3; Tielens AGM, 2002, TRENDS BIOCHEM SCI, V27, P564, DOI 10.1016/S0968-0004(02)02193-X; Tielens AGM, 1998, BBA-BIOENERGETICS, V1365, P71, DOI 10.1016/S0005-2728(98)00045-0; TOKUNAGA M, 1976, BIOCHIM BIOPHYS ACTA, V429, P55, DOI 10.1016/0005-2744(76)90029-2; TOKUNAGA M, 1979, J PROTOZOOL, V26, P471, DOI 10.1111/j.1550-7408.1979.tb04655.x; Tovar J, 2003, NATURE, V426, P172, DOI 10.1038/nature01945; Tovar-Mendez A, 2003, EUR J BIOCHEM, V270, P1043, DOI 10.1046/j.1432-1033.2003.03469.x; VanHellemond JJ, 1995, J BIOL CHEM, V270, P31065, DOI 10.1074/jbc.270.52.31065; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; Yamane Y, 2001, BIOTECHNOL LETT, V23, P1223, DOI 10.1023/A:1010573218863; YOKOTA A, 1982, ARCH BIOCHEM BIOPHYS, V213, P530, DOI 10.1016/0003-9861(82)90580-X; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	73	68	70	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22422	22429		10.1074/jbc.M400913200	http://dx.doi.org/10.1074/jbc.M400913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15014069	hybrid			2022-12-25	WOS:000221417100091
J	Ivanov, VN; Hei, TK				Ivanov, VN; Hei, TK			Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACUTE PROMYELOCYTIC LEUKEMIA; GENE-EXPRESSION; C-JUN; TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAYS; SODIUM ARSENITE; DOWN-REGULATION; FAS EXPRESSION; MYELOMA CELLS	Arsenic is a well established human carcinogen and is associated with a variety of cancers including those of the skin. Paradoxically, arsenic has also been used, amid at low doses, in the treatment of leukemia for over a century. Here we demonstrate that low to moderate concentrations of arsenite ( 2 - 10 muM) that has little or no effect on normal melanocytes may induce apoptosis of human melanomas including highly metastatic ones despite their low surface Fas levels. The two prerequisites that dictate apoptotic response of melanomas upon arsenite treatment are low nuclear NF-kappaB activity and an endogenous expression of tumor necrosis factor alpha. Under these conditions, melanoma cells acquired sensitivity to tumor necrosis factor alpha- mediated killing. On the other hand, signaling pathways including those of phosphatidylinositol 3- kinase- AKT, MEK- ERK, and JNK play a protective role against arsenite- induced oxidative stress and apoptosis in melanoma cells. Suppression of these pathways dramatically accelerates arsenite- induced apoptosis. Taken together, these data could provide potential approaches to sensitize melanomas to the cytotoxic effects of arsenite through modulating the signaling pathways.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA	Columbia University; Columbia University	Ivanov, VN (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St,VC11-204, New York, NY 10032 USA.	vni3@columbia.edu	Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, R01ES011804, P42ES010349] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES009089, P42 ES10349, ES11804, P42 ES010349, P30 ES09089, R01 ES011804] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berking C, 2001, CANCER RES, V61, P8306; Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Bullani RR, 2002, MELANOMA RES, V12, P263, DOI 10.1097/00008390-200206000-00010; CALTABIANO MM, 1986, J BIOL CHEM, V261, P3381; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; CHEN CJ, 1992, BRIT J CANCER, V66, P888, DOI 10.1038/bjc.1992.380; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Dai Y, 2004, BLOOD, V103, P2761, DOI 10.1182/blood-2003-09-3037; Dai Y, 2002, BLOOD, V100, P3333, DOI 10.1182/blood-2002-03-0940; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Deramaudt BMJM, 1999, J CELL BIOCHEM, V72, P311, DOI 10.1002/(SICI)1097-4644(19990301)72:3<311::AID-JCB1>3.3.CO;2-7; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Guan BX, 2002, ONCOGENE, V21, P3121, DOI 10.1038/sj.onc.1205430; Hayashi T, 2003, BRIT J HAEMATOL, V120, P10, DOI 10.1046/j.1365-2141.2003.03929.x; Hayashi T, 2002, MOL CANCER THER, V1, P851; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; Hershko DD, 2002, J CELL BIOCHEM, V84, P687, DOI 10.1002/jcb.10083; Hill LL, 1999, J EXP MED, V189, P1285, DOI 10.1084/jem.189.8.1285; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Huang CS, 1999, CANCER RES, V59, P3053; Hussein MR, 2003, J PATHOL, V199, P275, DOI 10.1002/path.1300; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; IVANOV V, 1994, J IMMUNOL, V153, P2394; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Ivanov VN, 2001, ONCOGENE, V20, P2243, DOI 10.1038/sj.onc.1204314; Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Krasilnikov M, 2003, ONCOGENE, V22, P4092, DOI 10.1038/sj.onc.1206598; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Li G, 2001, CANCER RES, V61, P3819; Li MY, 2002, J CELL BIOCHEM, V87, P29, DOI 10.1002/jcb.10269; Liu J, 2001, TOXICOL SCI, V61, P314, DOI 10.1093/toxsci/61.2.314; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; MYKLEBUST AT, 1994, J NEURO-ONCOL, V21, P215, DOI 10.1007/BF01063770; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Yih LH, 2002, CARCINOGENESIS, V23, P867, DOI 10.1093/carcin/23.5.867; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhao WL, 2001, LEUKEMIA LYMPHOMA, V42, P1265, DOI 10.1080/10428190127514	78	51	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22747	22758		10.1074/jbc.M314131200	http://dx.doi.org/10.1074/jbc.M314131200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15028728	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000221417100126
J	Paing, MM; Temple, BRS; Trejo, J				Paing, MM; Temple, BRS; Trejo, J			A tyrosine-based sorting signal regulates intracellular trafficking of protease-activated receptor-1 - Multiple regulatory mechanisms for agonist-induced G protein-coupled receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-RECEPTOR; CLATHRIN ADAPTER; BETA-ARRESTINS; PHOSPHORYLATION; TERMINATION; ENDOCYTOSIS; CELLS	Protease-activated receptor-1 (PAR1), a G protein-coupled receptor (GPCR) for thrombin, is irreversibly proteolytically activated, internalized, and then sorted to lysosomes and degraded. Internalization and lysosomal sorting of activated PAR1 is critical for termination of receptor signaling. We previously demonstrated that activated PAR1 is rapidly phosphorylated and internalized via a clathrin- and dynamin-dependent pathway that is independent of arrestins. Toward understanding the mechanisms responsible for activated PAR1 internalization through clathrin- coated pits we examined the function of a highly conserved tyrosine-based motif, YXXL, localized in the cytoplasmic carboxyl tail of the receptor. A mutant PAR1 in which tyrosine 383 and leucine 386 were replaced with alanines (Y383A/L386A) was significantly impaired in agonist-triggered internalization and degradation compared with wild-type receptor. In contrast, constitutive internalization, and recycling of unactivated PAR1 Y383A/L386A mutant was not affected, suggesting that tonic cycling of the mutant receptor remained intact. Strikingly, a PAR1 C387Z truncation mutant in which the YXXL motif was exposed at the C terminus constitutively internalized and degraded in an agonist-independent manner, whereas C387Z truncation mutant in which the critical tyrosine and leucine were mutated to alanine (C387Z-Y383A/L386A) failed to internalize. Inhibition of PAR1 C387Z mutant constitutive internalization with dominant-negative K44A dynamin blocked agonist-independent degradation of the mutant receptor. Together these findings strongly suggest that internalization of activated PAR1 is controlled by multiple regulatory mechanisms involving phosphorylation and a highly conserved tyrosine-based motif, YXXL. This study is the first to describe a function for a tyrosine-based motif, YXXphi, in GPCR internalization and reveal novel complexities in the regulation of GPCR trafficking.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Cardiovasc Biol Ctr,RL Juliano Struct Bioinformat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Trejo, J (corresponding author), Univ N Carolina, Dept Pharmacol, 1106 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	joann_trejo@med.unc.edu		TREJO, JOANN/0000-0003-4405-6228	NHLBI NIH HHS [HL67697, HL073328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL067697, R01HL073328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Chen CH, 2004, J BIOL CHEM, V279, P10020, DOI 10.1074/jbc.M310590200; CHEN J, 1994, J BIOL CHEM, V269, P16041; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gray JA, 2002, SCIENCE, V297, P529, DOI 10.1126/science.1075453; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P2486, DOI 10.1021/bi982527i; HEIN L, 1994, J BIOL CHEM, V269, P27719; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; Kim YM, 2002, J BIOL CHEM, V277, P16340, DOI 10.1074/jbc.M200678200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Shapiro MJ, 1998, J BIOL CHEM, V273, P29009, DOI 10.1074/jbc.273.44.29009; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Trejo J, 2000, J BIOL CHEM, V275, P31255, DOI 10.1074/jbc.M003770200; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Whistler JL, 2001, J BIOL CHEM, V276, P34331, DOI 10.1074/jbc.M104627200; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868	28	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21938	21947		10.1074/jbc.M401672200	http://dx.doi.org/10.1074/jbc.M401672200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15023990	hybrid			2022-12-25	WOS:000221417100034
J	Grgic, L; Zwicker, K; Kashani-Poor, N; Kerscher, S; Brandt, U				Grgic, L; Zwicker, K; Kashani-Poor, N; Kerscher, S; Brandt, U			Functional significance of conserved histidines and arginines in the 49-kDa subunit of mitochondrial complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; IRON-SULFUR CLUSTER; YARROWIA-LIPOLYTICA; CATALYTIC CORE; N2; HYDROGENASES; SITE	We have studied the ubiquinone-reducing catalytic core of NADH: ubiquinone oxidoreductase ( complex I) from Yarrowia lipolytica by a series of point mutations replacing conserved histidines and arginines in the 49-kDa subunit. Our results show that histidine 226 and arginine 141 probably do not ligate iron-sulfur cluster N2 but that exchanging these residues specifically influences the properties of this redox center. Histidines 91 and 95 were found to be essential for ubiquinone reductase activity of complex I. Mutations at the C-terminal arginine 466 affected ubiquinone affinity and inhibitor sensitivity but also destabilized complex I. These results provide further support for a high degree of structural conservation between the 49-kDa subunit of complex I and its ancestor, the large subunit of water-soluble [NiFe] hydrogenases. In several mutations of histidine 226, arginine 141, and arginine 466 the characteristic EPR signatures of iron-sulfur cluster N2 became undetectable, but specific, inhibitor-sensitive ubiquinone reductase activity was only moderately reduced. As we could not find spectroscopic indications for a modified cluster N2, we concluded that these complex I mutants were lacking most of this redox center but were still capable of catalyzing inhibitor-resistant ubiquinone reduction at near normal rates. We discuss that this at first surprising scenario may be explained by electron transfer theory; after removal of a single redox center in a chain, electron transfer rates are predicted to be still much faster than steady-state turnover of complex I. Our results question some of the central mechanistic functions that have been put forward for iron-sulfur cluster N2.	Goethe Univ Frankfurt, Facbereich Med, Inst Biochem 1, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Brandt, U (corresponding author), Goethe Univ Frankfurt, Facbereich Med, Inst Biochem 1, Theodor Stern Kai 7,Haus 25B, D-60590 Frankfurt, Germany.	brandt@zbc.kgu.de	Brandt, Ulrich/C-4406-2008; Brandt, Ulrich/GLV-1242-2022	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811				ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; BOHM R, 1990, MOL MICROBIOL, V4, P231, DOI 10.1111/j.1365-2958.1990.tb00590.x; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Byrdin M, 2003, P NATL ACAD SCI USA, V100, P8676, DOI 10.1073/pnas.1531645100; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Duarte M, 2002, BIOCHEM J, V364, P833, DOI 10.1042/BJ20011750; Duderstadt RE, 1999, FEBS LETT, V454, P21, DOI 10.1016/S0014-5793(99)00766-8; Flemming D, 2003, J BIOL CHEM, V278, P47602, DOI 10.1074/jbc.M308967200; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Friedrich T, 2000, BBA-BIOENERGETICS, V1459, P305, DOI 10.1016/S0005-2728(00)00165-1; Garofano A, 2003, J BIOL CHEM, V278, P42435, DOI 10.1074/jbc.M305819200; Kashani-Poor N, 2001, BBA-BIOENERGETICS, V1504, P363, DOI 10.1016/S0005-2728(00)00266-8; Kashani-Poor N, 2001, J BIOL CHEM, V276, P24082, DOI 10.1074/jbc.M102296200; Kerscher S, 2002, BBA-BIOENERGETICS, V1555, P83, DOI 10.1016/S0005-2728(02)00259-1; Kerscher S, 2001, J BIOENERG BIOMEMBR, V33, P187, DOI 10.1023/A:1010726818165; Kerscher SJ, 1999, J CELL SCI, V112, P2347; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magnitsky S, 2002, J BIOENERG BIOMEMBR, V34, P193, DOI 10.1023/A:1016083419979; Montet Y, 1997, NAT STRUCT BIOL, V4, P523, DOI 10.1038/nsb0797-523; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Schagger H., 2003, MEMBRANE PROTEIN PUR, P105, DOI DOI 10.1016/B978-012361776-7/50006-1; Videira A, 1998, BBA-BIOENERGETICS, V1364, P89, DOI 10.1016/S0005-2728(98)00020-6; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Zickermann V, 2003, J BIOL CHEM, V278, P29072, DOI 10.1074/jbc.M302713200	26	65	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21193	21199		10.1074/jbc.M313180200	http://dx.doi.org/10.1074/jbc.M313180200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15004020	hybrid			2022-12-25	WOS:000221273800078
J	Pare, JF; Malenfant, D; Courtemanche, C; Jacob-Wagner, M; Roy, S; Allard, D; Belanger, L				Pare, JF; Malenfant, D; Courtemanche, C; Jacob-Wagner, M; Roy, S; Allard, D; Belanger, L			The fetoprotein transcription factor (FTF) gene is essential to embryogenesis and cholesterol homeostasis and is regulated by a DR4 element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE FEEDBACK-REGULATION; LIVER RECEPTOR HOMOLOG-1; BILE-ACID TRANSPORTER; IN-SITU HYBRIDIZATION; HEART TUBE FORMATION; NUCLEAR RECEPTOR; VISCERAL ENDODERM; ALPHA-FETOPROTEIN; HEPATOMA-CELLS; ALPHA(1)-FETOPROTEIN LOCUS	The fetoprotein transcription factor (FTF) gene was inactivated in the mouse, with a lacZ gene inserted in-frame into exon 4. LacZ staining of FTF+/- embryos shows that the mFTF gene is activated at initial stages of zygotic transcription. FTF gene activity is ubiquitous at the morula and blastocyst stages and then follows expression patterns indicative of multiple FTF functions in fetal development. FTF-/- embryos die at E6.5-7.5, with features typical of visceral endoderm dysfunction. Adult FTF+/- mice are hypocholesterolemic, and express liver FTF at about 40% of the normal level. Over-expression of liver FTF in transgenic mice indicates in vivo that FTF is an activator of CYP7A1. However, CYP7A1 expression is increased in FTF+/- liver. Gene expression profiles indicate that higher CYP7A1 expression is caused by attenuated liver cell stress signaling. Diet experiments support a model where FTF is quenched both by activated c-Jun, and by SHP as a stronger feedback mechanism to repress CYP7A1. A DR4 element is conserved in the FTF gene promoter and activated by LXR-RXR and TR-RXR, qualifying the FTF gene as a direct metabolic sensor. Liver FTF increases in rats treated with thyroid hormone or a high cholesterol diet. The FTF DR4 element tightens functional links between FTF and LXRalpha in cholesterol homeostasis and can explain transient surges of FTF gene activities during development and FTF levels lower than predicted in FTF+/- liver. The FTF-lacZ mouse establishes a central role for FTF in developmental, nutritive, and metabolic functions from early embryogenesis through adulthood.	Univ Laval, Hotel Dieu Quebec, Ctr Canc Res, Fac Med,Dept Biol Med, Quebec City, PQ G1R 2J6, Canada	Laval University	Belanger, L (corresponding author), Univ Laval, Hotel Dieu Quebec, Ctr Canc Res, Fac Med,Dept Biol Med, Quebec City, PQ G1R 2J6, Canada.	luc.belanger@crhdq.ulaval.ca						ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Annicotte JS, 2003, MOL CELL BIOL, V23, P6713, DOI 10.1128/MCB.23.19.6713-6724.2003; Aubin J, 1997, DEV BIOL, V192, P432, DOI 10.1006/dbio.1997.8746; Auwerx J, 1999, CELL, V97, P161; BELANGER L, 1994, J BIOL CHEM, V269, P5481; BELANGER L, 1975, NATURE, V256, P657, DOI 10.1038/256657a0; BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; Bohan A, 2003, J BIOL CHEM, V278, P36688, DOI 10.1074/jbc.M304011200; BOISJOYEUX B, 1995, J BIOL CHEM, V270, P10204, DOI 10.1074/jbc.270.17.10204; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Costet P, 2000, J BIOL CHEM, V275, P28240; Dawson PA, 2003, J BIOL CHEM, V278, P33920, DOI 10.1074/jbc.M306370200; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; Drover VAB, 2002, MOL ENDOCRINOL, V16, P14, DOI 10.1210/me.16.1.14; Dufort D, 1998, DEVELOPMENT, V125, P3015; Duncan SA, 1997, DEVELOPMENT, V124, P279; ELLINGERZIEGELBAUER H, 1994, MOL CELL BIOL, V14, P2786, DOI 10.1128/MCB.14.4.2786; Fayard E, 2003, J BIOL CHEM, V278, P35725, DOI 10.1074/jbc.M302370200; Galarneau L, 1998, CYTOGENET CELL GENET, V82, P269, DOI 10.1159/000015116; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; GILBERT S, 2000, THESIS LAVAL U QUEBE; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Inokuchi A, 2001, J BIOL CHEM, V276, P46822, DOI 10.1074/jbc.M104612200; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Larochelle C, 1999, DEV DYNAM, V214, P127, DOI 10.1002/(SICI)1097-0177(199902)214:2<127::AID-AJA3>3.0.CO;2-F; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Lee YK, 2002, J BIOL CHEM, V277, P2463, DOI 10.1074/jbc.M105161200; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MEEHAN RR, 1984, EMBO J, V3, P1881, DOI 10.1002/j.1460-2075.1984.tb02062.x; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; NAKAO K, 1990, MOL CELL BIOL, V10, P1461, DOI 10.1128/MCB.10.4.1461; Narita N, 1997, DEV BIOL, V189, P270, DOI 10.1006/dbio.1997.8684; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; Pare JF, 2001, J BIOL CHEM, V276, P13136, DOI 10.1074/jbc.M010737200; Rausa FM, 1998, METHODS, V16, P29, DOI 10.1006/meth.1998.0642; Rausa FM, 1999, MECH DEVELOP, V89, P185, DOI 10.1016/S0925-4773(99)00209-9; Schwartz CJE, 2001, EMBO J, V20, P510, DOI 10.1093/emboj/20.3.510; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Takase M, 2000, BBA-GENE STRUCT EXPR, V1494, P195, DOI 10.1016/S0167-4781(00)00201-3; von Hofsten J, 2003, GEN COMP ENDOCR, V132, P96, DOI 10.1016/S0016-6480(03)00034-0; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; Zhang CK, 2001, GENE, V273, P239, DOI 10.1016/S0378-1119(01)00586-8	57	119	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21206	21216		10.1074/jbc.M401523200	http://dx.doi.org/10.1074/jbc.M401523200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15014077	hybrid			2022-12-25	WOS:000221273800080
J	Ostrom, RS; Bundey, RA; Insel, PA				Ostrom, RS; Bundey, RA; Insel, PA			Nitric oxide inhibition of adenylyl cyclase type 6 activity is dependent upon lipid rafts and caveolin signaling complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; CARDIAC MYOCYTES; HEART-FAILURE; SYNTHASE; PROTEIN; ISOFORMS; RECEPTOR; CAMP; COMPARTMENTATION; PHOSPHORYLATION	Several cell types, including cardiac myocytes and vascular endothelial cells, produce nitric oxide (NO) via both constitutive and inducible isoforms of NO synthase. NO attenuates cardiac contractility and contributes to contractile dysfunction in heart failure, although the precise molecular mechanisms for these effects are poorly defined. Adenylyl cyclase (AC) isoforms type 5 and 6, which are preferentially expressed in cardiac myocytes, may be inhibited via a direct nitrosylation by NO. Because endothelial NO synthase (eNOS and NOS3), beta-adrenergic (betaAR) receptors, and AC6 all can localize in lipid raft/caveolin-rich microdomains, we sought to understand the role of lipid rafts in organizing components of betaAR-G(s)-AC signal transduction together with eNOS. Using neonatal rat cardiac myocytes, we found that disruption of lipid rafts with beta-cyclodextrin inhibited forskolin-stimulated AC activity and cAMP production, eliminated caveolin-3-eNOS interaction, and increased NO production. betaAR- and G(s)-mediated activation of AC activity were inhibited by beta-cyclodextrin treatment, but prostanoid receptor-stimulated AC activity, which appears to occur outside caveolin-rich microdomains, was unaffected unless eNOS was overexpressed and lipid rafts were disrupted. An NO donor, SNAP, inhibited basal and forskolin-stimulated cAMP production in both native cardiac myocytes and cardiac myocytes and pulmonary artery endothelial cells engineered to overexpress AC6. These effects of SNAP were independent of guanylyl cyclase activity and were mimicked by overexpression of eNOS. The juxtaposition of eNOS with betaAR and AC types 5 and 6 results in selective regulation of betaAR by eNOS activity in lipid raft domains over other G(s)-coupled receptors localized in nonraft domains. Thus co-localization of multiple signaling components in lipid rafts provides key spatial regulation of AC activity.	Univ Calif San Diego, Dept Pharmacol, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Vasc Biol Ctr Excellence, Memphis, TN 38163 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, Sch Med, 0636, La Jolla, CA 92093 USA.	pinsel@ucsd.edu		Ostrom, Rennolds/0000-0002-7204-0357	NHLBI NIH HHS [HL 53773, HL 63885, HL 71781] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071781, R01HL063885, P50HL053773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Billington CK, 1999, AM J RESP CELL MOL, V21, P597, DOI 10.1165/ajrcmb.21.5.3759; Bundey RA, 2003, ANAL BIOCHEM, V319, P318, DOI 10.1016/S0003-2697(03)00325-7; Fagan KA, 2000, J BIOL CHEM, V275, P26530, DOI 10.1074/jbc.M001369200; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gao MH, 1998, P NATL ACAD SCI USA, V95, P1038, DOI 10.1073/pnas.95.3.1038; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Gustafsson AB, 2002, AM J PHYSIOL-CELL PH, V283, pC463, DOI 10.1152/ajpcell.00299.2001; Hare JM, 2000, CIRC RES, V86, P1085, DOI 10.1161/01.RES.86.10.1085; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; HARE JM, 1995, CIRCULATION, V92, P2198, DOI 10.1161/01.CIR.92.8.2198; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; Hill J, 2000, CELL SIGNAL, V12, P233, DOI 10.1016/S0898-6568(99)00082-0; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Keaney JF, 1996, AM J PHYSIOL-HEART C, V271, pH2646, DOI 10.1152/ajpheart.1996.271.6.H2646; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; McVey M, 1999, J BIOL CHEM, V274, P18887, DOI 10.1074/jbc.274.27.18887; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Ooboshi H, 1997, AM J PHYSIOL-HEART C, V273, pH265, DOI 10.1152/ajpheart.1997.273.1.H265; Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Ostrom RS, 2003, J BIOL CHEM, V278, P24461, DOI 10.1074/jbc.M212659200; Ostrom RS, 2002, MOL PHARMACOL, V62, P983, DOI 10.1124/mol.62.5.983; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001-867; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; RAPUNDALO ST, 1989, CIRC RES, V64, P104, DOI 10.1161/01.RES.64.1.104; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Rong JX, 2003, P NATL ACAD SCI USA, V100, P13531, DOI 10.1073/pnas.1735526100; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Schwencke C, 1999, MOL ENDOCRINOL, V13, P1061, DOI 10.1210/me.13.7.1061; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; van Meer G, 2002, SCIENCE, V296, P855, DOI 10.1126/science.1071491; Ziolo MT, 2001, AM J PHYSIOL-HEART C, V281, pH2295, DOI 10.1152/ajpheart.2001.281.6.H2295	44	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19846	19853		10.1074/jbc.M313440200	http://dx.doi.org/10.1074/jbc.M313440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15007069	hybrid, Green Published			2022-12-25	WOS:000221164500057
J	Zhang, H; Wu, W; Du, Y; Santos, SJ; Conrad, SE; Watson, JT; Grammatikakis, N; Gallo, KA				Zhang, H; Wu, W; Du, Y; Santos, SJ; Conrad, SE; Watson, JT; Grammatikakis, N; Gallo, KA			Hsp90/p50(cdc37) is required for mixed-lineage kinase (MLK) 3 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DEATH-DOMAIN KINASE; MOLECULAR CHAPERONES; HSP90 FUNCTION; NEURONAL APOPTOSIS; ANSAMYCINS CAUSES; BREAST-CANCER; IN-VIVO; COMPLEX; CDC37	Mixed-lineage kinase 3 (MLK3) is a mitogen-activated protein kinase (MAPK) kinase kinase that activates MAPK pathways, including the c-Jun NH2-terminal kinase (JNK) and p38 pathways. MLK3 and its family members have been implicated in JNK-mediated apoptosis. A survey of human cell lines revealed high levels of MLK3 in breast cancer cells. To learn more about MLK3 regulation and its signaling pathways in breast cancer cells, we engineered the estrogen-responsive human breast cancer cell line, MCF-7, to stably, inducibly express FLAG epitope-tagged MLK3. FLAG.MLK3 complexes were isolated by affinity purification, and associated proteins were identified by in-gel trypsin digestion followed by liquid chromatography/tandem mass spectrometry. Among the proteins identified were heat shock protein 90alpha,beta (Hsp90) and its kinase-specific cochaperone p50(cdc37). We show that endogenous MLK3 complexes with Hsp90 and p50(cdc37). Further experiments demonstrate that MLK3 associates with Hsp90/p50(cdc37) through its catalytic domain in an activity-independent manner. Upon treatment of MCF-7 cells with geldanamycin, an ansamycin antibiotic that inhibits Hsp90 function, MLK3 levels decrease dramatically. Furthermore, tumor necrosis factor alpha-induced activation of MLK3 and JNK in MCF-7 cells is blocked by geldanamycin treatment. Our finding that geldanamycin treatment does not affect the cellular levels of the downstream signaling components, MAPK kinase 4, MAPK kinase 7, and JNK, suggests that Hsp90/p50(cdc37) regulates JNK signaling at the MAPK kinase kinase level. Previously identified Hsp90/p50(cdc37) clients include oncoprotein kinases and protein kinases that promote cellular proliferation and survival. Our findings reveal that Hsp90/p50(cdc37) also regulates protein kinases involved in apoptotic signaling.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Program, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Boston Univ, Sch Med, Boston, MA 02118 USA	Michigan State University; Michigan State University; Michigan State University; Michigan State University; Boston University	Gallo, KA (corresponding author), Michigan State Univ, Dept Physiol, 4180 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	gallok@msu.edu			NATIONAL CANCER INSTITUTE [R01CA076647, R29CA076306] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76306, CA 76647] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 2000, CELL GROWTH DIFFER, V11, P355; Bagatell R, 2001, CLIN CANCER RES, V7, P2076; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; Boudeau J, 2003, BIOCHEM J, V370, P849, DOI 10.1042/BJ20021813; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Chavany C, 1996, J BIOL CHEM, V271, P4974; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Dunn FB, 2002, J NATL CANCER I, V94, P1194; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Gross EA, 2002, J BIOL CHEM, V277, P13873, DOI 10.1074/jbc.M111994200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Miyata Y, 2001, J BIOL CHEM, V276, P21841, DOI 10.1074/jbc.M010944200; Mota M, 2001, J NEUROSCI, V21, P4949, DOI 10.1523/JNEUROSCI.21-14-04949.2001; Munster PN, 2001, CANCER RES, V61, P2945; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nollen EAA, 2002, J CELL SCI, V115, P2809; Pollock R, 2002, NAT BIOTECHNOL, V20, P729, DOI 10.1038/nbt0702-729; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Saporito MS, 2002, PROGR MED CHEM, V40, P23, DOI 10.1016/S0079-6468(08)70081-X; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schoorlemmer J, 2002, J BIOL CHEM, V277, P49111, DOI 10.1074/jbc.M205520200; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Srethapakdi M, 2000, CANCER RES, V60, P3940; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Westermarck J, 2002, EMBO J, V21, P451, DOI 10.1093/emboj/21.3.451; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200	48	25	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19457	19463		10.1074/jbc.M311377200	http://dx.doi.org/10.1074/jbc.M311377200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15001580	hybrid			2022-12-25	WOS:000221164500011
J	Guda, K; Upender, MB; Belinsky, G; Flynn, C; Nakanishi, M; Marino, JN; Ried, T; Rosenberg, DW				Guda, K; Upender, MB; Belinsky, G; Flynn, C; Nakanishi, M; Marino, JN; Ried, T; Rosenberg, DW			Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability	ONCOGENE			English	Article						azoxymethane; mice; colon tumorigenesis; chromosomal instability; spectral karyotyping; microsatellite instability	COLORECTAL-CANCER; GENOMIC INSTABILITY; BETA-CATENIN; ALTERED EXPRESSION; HIGH-FREQUENCY; AZOXYMETHANE; MUTATIONS; PATHWAYS; DNA; TUMORIGENESIS	The azoxymethane (AOM)-induced mouse colon tumor model recapitulates many of the histopathological features associated with the multistage progression of human sporadic colorectal cancers (CRCs). To better de. ne the genetic events associated with tumorigenesis in this murine model, we analysed tumors from A/J mice for chromosomal (CIN) and microsatellite (MSI) instabilities, two fundamental pathways of genomic instability that play a critical role in the pathogenesis of human CRCs. Male A/J mice, 6-week old, were injected with either AOM (n=5) (10 mg/kg b.w., i.p.) or vehicle (n=5) (0.9% NaCl solution) once a week for 6 weeks. At 32 weeks after the last dose, comparative genomic hybridization (CGH) was performed on 16 tumors harvested from five animals. Although 25% of the tumors displayed either a gain of chromosome 2 or loss of Y, the majority (75%) showed no genomic imbalances. Further analysis of chromosomal aberrations, using CGH and spectral karyotyping (SKY) was performed in our recently established A/J colon tumor-derived cell line, AJ02-NM0. Results showed a pseudotetraploid karyotype with loss of only the Y chromosome in these cultured cells, thereby providing additional evidence for the minimal role of CIN in the primary AOM-induced tumors. Interestingly, the majority (81%) of A/J tumors displayed low-level microsatellite instability (MSI-L) when analysed using mono- and dinucleotide repeat markers, and showed a significant expansion to high-level instability (MSI-H) in the AJ02-NM0 cells. This finding in cultured cells additionally provides evidence that a mild mutator pathway may contribute to the development of behaviorally benign carcinomas in situ in A/J mice. To better understand the tumorigenic process in the A/J colons, we screened for mutational alterations in key regions of the K-ras and Apc genes. Results showed a very low frequency (6%) of K-ras activating mutations, together with the absence of Apc truncation mutations in primary tumors and AJ02-NM0 cells. However, these tumors displayed intense nuclear accumulation of beta-catenin protein, indicating activation of the Wnt signaling pathway. Based on our molecular and cytogenetic findings, we propose that carcinogen-induced tumors may develop via mechanisms independent of the 'classical' CIN or MSI pathways.	NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Univ Connecticut, Ctr Hlth, Ctr Mol Med, Farmington, CT 06030 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Connecticut	Ried, T (corresponding author), NCI, Genet Branch, Ctr Canc Res, NIH, 50 South Dr,Room 1306, Bethesda, MD 20892 USA.	riedt@mail.nih.gov	guda, kishore/E-3389-2010		DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010299] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA081428] Funding Source: NIH RePORTER; NCI NIH HHS [CA81428] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; Calvert PM, 2002, ANN INTERN MED, V137, P603, DOI 10.7326/0003-4819-137-7-200210010-00012; Chan TL, 2001, ONCOGENE, V20, P4871, DOI 10.1038/sj.onc.1204653; Corpet DE, 2003, CANCER EPIDEM BIOMAR, V12, P391; De Filippo C, 1998, BRIT J CANCER, V77, P2148, DOI 10.1038/bjc.1998.359; Doug M, 2003, CARCINOGENESIS, V24, P307, DOI 10.1093/carcin/24.2.307; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Goel A, 2003, CANCER RES, V63, P1608; Guda K, 2001, MOL CARCINOGEN, V31, P204, DOI 10.1002/mc.1055; Haag JD, 1999, MOL CARCINOGEN, V24, P47, DOI 10.1002/(SICI)1098-2744(199901)24:1<47::AID-MC7>3.0.CO;2-B; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hoglund M, 2002, CANCER RES, V62, P5939; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; Jass JR, 2002, EUR J CANCER, V38, P858, DOI 10.1016/S0959-8049(02)00041-2; Jass JR, 1999, J CLIN PATHOL, V52, P455, DOI 10.1136/jcp.52.6.455; Jass JR, 2003, J PATHOL, V199, P267, DOI 10.1002/path.1266; Kambara T, 2001, CANCER RES, V61, P7743; Kislitsin D, 2002, DIGEST DIS SCI, V47, P1073, DOI 10.1023/A:1015090124153; Kohonen-Corish MRJ, 2002, CANCER RES, V62, P2092; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lindblom A, 2001, CURR OPIN ONCOL, V13, P63, DOI 10.1097/00001622-200101000-00013; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; LOTHE RA, 1993, CANCER RES, V53, P5849; Luceri C, 2000, CARCINOGENESIS, V21, P1753, DOI 10.1093/carcin/21.9.1753; Nambiar PR, 2003, INT J ONCOL, V22, P145; Nambiar PR, 2002, CANCER RES, V62, P3667; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Sheng HM, 1998, CARCINOGENESIS, V19, P543, DOI 10.1093/carcin/19.4.543; Sohn KJ, 2003, CARCINOGENESIS, V24, P217, DOI 10.1093/carcin/24.2.217; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Takahashi M, 2000, CARCINOGENESIS, V21, P1319, DOI 10.1093/carcin/21.7.1319; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tomlinson I, 2002, J PATHOL, V197, P6, DOI 10.1002/path.1071; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Walchle C, 1999, TOXICOL APPL PHARM, V157, P9, DOI 10.1006/taap.1999.8662; Wang QS, 1998, CARCINOGENESIS, V19, P2001, DOI 10.1093/carcin/19.11.2001; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Whitehall VLJ, 2001, CANCER RES, V61, P827; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Young J, 2001, AM J PATHOL, V159, P2107, DOI 10.1016/S0002-9440(10)63062-3	48	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3813	3821		10.1038/sj.onc.1207489	http://dx.doi.org/10.1038/sj.onc.1207489			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021908				2022-12-25	WOS:000221242500008
J	Jinnin, M; Ihn, H; Asano, Y; Yamane, K; Trojanowska, M; Tamaki, K				Jinnin, M; Ihn, H; Asano, Y; Yamane, K; Trojanowska, M; Tamaki, K			Tenascin-C upregulation by transforming growth factor-beta in human dermal broblasts involves Smad3, Sp1, and Ets1	ONCOGENE			English	Article						CREB-binding protein; P300; extracellular matrix	EXTRACELLULAR-MATRIX PROTEIN; HUMAN SKIN FIBROBLASTS; BREAST-CANCER CELLS; 2(I) COLLAGEN GENE; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; INCREASED EXPRESSION; FUNCTIONAL-CHARACTERIZATION; SCLERODERMA FIBROBLASTS; IN-VITRO	In cultured human dermal fibroblasts, transforming growth factor ( TGF)-beta induced the mRNA expression of tenascin-C (TN-C). The molecular mechanism(s) underlying this process is not presently understood. In this study, we performed serial 50 deletion and a transient transfection analysis to de. ne a region in the TN-C promoter mediating the inducible responsiveness to TGF-beta. This region contains an atypical nucleotide recognition element for the Smad family of transcriptional regulators. A DNA affinity precipitation assay revealed that Smad2/ Smad3 bound to this site in a transient and specific manner. Overexpression of Smad3 or Smad4 activated the TN-C promoter activity and superinduced the TN-C promoter activity stimulated by TGF-beta. Moreover, simultaneous cotransfection of Smad3 and Smad4 activated the TN-C promoter activity in a synergistic manner. Mutation of the Smad-binding sites, the Ets-binding sites, or Sp1/3-binding sites in the TN-C promoter abrogated the TGF-beta/Smad-inducible promoter activity. Immunoprecipitation analysis revealed that Smad3, Sp1, and Ets1 form a transcriptionally active complex. Furthermore, the interaction between Smads and CBP/p300 in TGF-beta signaling was confirmed. These findings demonstrate the existence of a novel, functional binding element in the proximal region of the TN-C promoter mediating responsiveness to TGF-beta involving Smad3/4, Sp1, Ets1, and CBP/p300.	Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, Tokyo 1138655, Japan; Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA	University of Tokyo; Medical University of South Carolina	Ihn, H (corresponding author), Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	IN-DER@h.u-tokyo.ac.jp		Trojanowska, Maria/0000-0001-9550-7178				Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BORSI L, 1994, CELL ADHES COMMUN, V1, P307, DOI 10.3109/15419069409097262; Boyes WK, 1997, FUND APPL TOXICOL, V40, P175, DOI 10.1006/faat.1997.2388; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chin GS, 2001, PLAST RECONSTR SURG, V108, P423, DOI 10.1097/00006534-200108000-00022; CHIQUET M, 1994, PERSPECT DEV NEUROBI, V2, P67; CHIQUETEHRISMANN R, 1995, EXPERIENTIA, V51, P853, DOI 10.1007/BF01921736; CHIQUETEHRISMANN R, 1989, CANCER RES, V49, P4322; Crossin KL, 1996, J CELL BIOCHEM, V61, P592; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Dandachi N, 2001, J PATHOL, V193, P181, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; EKBLOM P, 1989, International Journal of Developmental Biology, V33, P71; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Gore-Hyer E, 2002, AM J PHYSIOL-RENAL, V283, pF707, DOI 10.1152/ajprenal.00007.2002; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Ihn H, 2002, J IMMUNOL, V168, P1895, DOI 10.4049/jimmunol.168.4.1895; Ihn H, 2001, ARTHRITIS RHEUM, V44, P474, DOI 10.1002/1529-0131(200102)44:2<474::AID-ANR67>3.3.CO;2-R; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawakami T, 1998, J INVEST DERMATOL, V110, P47, DOI 10.1046/j.1523-1747.1998.00073.x; Kucich U, 2002, AM J RESP CELL MOL, V26, P183, DOI 10.1165/ajrcmb.26.2.4666; LACOUR JP, 1992, BRIT J DERMATOL, V127, P328, DOI 10.1111/j.1365-2133.1992.tb00450.x; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; LEROY EC, 1992, ANN RHEUM DIS, V51, P286, DOI 10.1136/ard.51.2.286; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Mackie EJ, 1997, INT J BIOCHEM CELL B, V29, P1133, DOI 10.1016/S1357-2725(97)00031-9; Makhluf HA, 1996, J INVEST DERMATOL, V107, P856, DOI 10.1111/1523-1747.ep12331160; MCCACHREN SS, 1992, ARTHRITIS RHEUM, V35, P1185, DOI 10.1002/art.1780351011; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NATALI PG, 1991, INT J CANCER, V47, P811, DOI 10.1002/ijc.2910470603; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; RETTIG WJ, 1989, J HISTOCHEM CYTOCHEM, V37, P1777, DOI 10.1177/37.12.2685108; RETTIG WJ, 1994, J CELL SCI, V107, P487; RODNAN GP, 1979, ARTHRITIS RHEUM, V22, P130, DOI 10.1002/art.1780220205; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; TUCKER RP, 1993, J CELL SCI, V104, P69; Varga J, 2002, ARTHRITIS RHEUM-US, V46, P1703, DOI 10.1002/art.10413; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; You LT, 2002, INVEST OPHTH VIS SCI, V43, P72; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200	71	99	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1656	1667		10.1038/sj.onc.1207064	http://dx.doi.org/10.1038/sj.onc.1207064			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001984				2022-12-25	WOS:000220029300002
J	Ho, L; Qin, WP; Pompl, PN; Xiang, ZM; Wang, J; Zhao, Z; Peng, YZ; Cambareri, G; Rocher, A; Mobbs, CV; Hof, PR; Pasinetti, GM				Ho, L; Qin, WP; Pompl, PN; Xiang, ZM; Wang, J; Zhao, Z; Peng, YZ; Cambareri, G; Rocher, A; Mobbs, CV; Hof, PR; Pasinetti, GM			Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						diabetes; glycogen synthase kinase; beta-amyloid; insulin-degrading enzyme	DEGRADING ENZYME; PRECURSOR PROTEIN; BETA-PROTEIN; IN-VIVO; VASCULAR FACTORS; FOLLOW-UP; MICE; BRAIN; DEMENTIA; POPULATION	Recent epidemiological evidence indicates that insulin resistance, a proximal cause of Type II diabetes [ a non-insulin dependent form of diabetes mellitus (NIDDM)], is associated with an increased relative risk for Alzheimer's disease (AD). In this study we examined the role of dietary conditions leading to NIDDM-like insulin resistance on amyloidosis in Tg2576 mice, which model AD-like neuropathology. We found that diet-induced insulin resistance promoted amyloidogenic beta-amyloid (Abeta) Abeta(1-40) and Abeta(1-42) peptide generation in the brain that corresponded with increased gamma-secretase activities and decreased insulin degrading enzyme (IDE) activities. Moreover, increased Abeta production also coincided with increased AD-type amyloid plaque burden in the brain and impaired performance in a spatial water maze task. Further exploration of the apparent interrelationship of insulin resistance to brain amyloidosis revealed a functional decrease in insulin receptor (IR)-mediated signal transduction in the brain, as suggested by decreased IR beta-subunit (IRbeta) Y-1162/1163 autophosphorylation and reduced phosphatidylinositol 3 (PI3)-kinase/pS(473)-AKT/Protein kinase (PK)-B in these same brain regions. This latter finding is of particular interest given the known inhibitory role of AKT/PKB on glycogen synthase kinase (GSK)-3alpha activity, which has previously been shown to promote Abeta peptide generation. Most interestingly, we found that decreased pS(21)-GSK-3alpha and pS(9)-GSK-3alpha phosphorylation, which is an index of GSK activation, positively correlated with the generation of brain C-terminal fragment (CTF)-gamma cleavage product of amyloid precursor protein, an index of gamma-secretase activity, in the brain of insulin-resistant relative to normoglycemic Tg2576 mice. Our study is consistent with the hypothesis that insulin resistance may be an underlying mechanism responsible for the observed increased relative risk for AD neuropathology, and presents the first evidence to suggest that IR signaling can influence Abeta production in the brain.	CUNY Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Kastor Neurobiol Aging Labs, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Adv Imaging Program, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Pasinetti, GM (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu		Pasinetti, Giulio/0000-0002-1524-5196; Mobbs, Charles/0000-0002-5815-8711				Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Bussiere T, 2002, NEUROSCIENCE, V112, P75, DOI 10.1016/S0306-4522(02)00056-8; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Cook DG, 2003, AM J PATHOL, V162, P313, DOI 10.1016/S0002-9440(10)63822-9; Di Iorio A, 1999, AGING CLIN EXP RES, V11, P345, DOI 10.1007/BF03339811; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Gibbs RB, 2003, J NEUROSCI RES, V74, P637, DOI 10.1002/jnr.10811; Grant W B, 1999, J Alzheimers Dis, V1, P197; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hof PR, 2000, J COMP NEUROL, V420, P113, DOI 10.1002/(SICI)1096-9861(20000424)420:1<113::AID-CNE8>3.0.CO;2-N; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Iivonen H, 2003, BEHAV BRAIN RES, V141, P207, DOI 10.1016/S0166-4328(02)00369-8; Johnston AM, 2003, FEBS LETT, V546, P32, DOI 10.1016/S0014-5793(03)00438-1; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kilander L, 1998, HYPERTENSION, V31, P780, DOI 10.1161/01.HYP.31.3.780; Kim JJ, 2002, GROWTH HORM IGF RES, V12, P84, DOI 10.1054/ghir.2002.0265; King DL, 2002, PHYSIOL BEHAV, V75, P627, DOI 10.1016/S0031-9384(02)00639-X; Leibson CL, 1997, AM J EPIDEMIOL, V145, P301; Levin-Allerhand J A, 2002, J Nutr Health Aging, V6, P315; Makimura Hideo, 2003, BMC Physiol, V3, P4, DOI 10.1186/1472-6793-3-4; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; Meyer JS, 2000, ANN NY ACAD SCI, V903, P411, DOI 10.1111/j.1749-6632.2000.tb06393.x; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; *NAT I DIAB DIG KI, 2002, NAT DIAB STAT FACT S; Nimchinsky EA, 2000, J COMP NEUROL, V416, P112, DOI 10.1002/(SICI)1096-9861(20000103)416:1<112::AID-CNE9>3.0.CO;2-K; Pansari K, 2002, INT J CLIN PRACT, V56, P197; Pedersen WA, 1999, J MOL NEUROSCI, V13, P159, DOI 10.1385/JMN:13:1-2:159; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; Petot GJ, 2003, METABOLISM, V52, P279, DOI 10.1053/meta.2003.50066; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Pyorala M, 2000, ARTERIOSCL THROM VAS, V20, P538, DOI 10.1161/01.ATV.20.2.538; Rajala RVS, 2002, J BIOL CHEM, V277, P43319, DOI 10.1074/jbc.M206355200; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shie FS, 2002, NEUROREPORT, V13, P455, DOI 10.1097/00001756-200203250-00019; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Stolk RP, 1997, DIABETES CARE, V20, P792, DOI 10.2337/diacare.20.5.792; Takeda K, 2003, J ENDOCRINOL, V176, P237, DOI 10.1677/joe.0.1760237; Tandrup T, 1997, J MICROSC-OXFORD, V186, P108, DOI 10.1046/j.1365-2818.1997.2070765.x; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Xiang ZM, 2002, GENE EXPRESSION, V10, P271, DOI 10.3727/000000002783992352	49	493	522	1	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					902	+		10.1096/fj.03-0978fje	http://dx.doi.org/10.1096/fj.03-0978fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033922				2022-12-25	WOS:000220522800006
J	Perrin, R; Meyer, EH; Zaepfel, M; Kim, YJ; Mache, R; Grienenberger, JM; Gualberto, JM; Gagliardi, D				Perrin, R; Meyer, EH; Zaepfel, M; Kim, YJ; Mache, R; Grienenberger, JM; Gualberto, JM; Gagliardi, D			Two exoribonucleases act sequentially to process mature 3 '-ends of atp9 mRNAs in Arabidopsis mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYNUCLEOTIDE PHOSPHORYLASE FUNCTIONS; CYTOPLASMIC MALE-STERILITY; PLANT-MITOCHONDRIA; PREFERENTIAL DEGRADATION; POLY(A) POLYMERASE; ESCHERICHIA-COLI; BINDING PROTEINS; PEA MITOCHONDRIA; POLYADENYLATION; CHLOROPLAST	In plant mitochondria, transcription proceeds well beyond the region that will become mature 3' extremities of mRNAs, and the mechanisms of 3' maturation are largely unknown. Here, we show the involvement of two exoribonucleases, AtmtPNPase and AtmtRNaseII, in the 3' processing of atp9 mRNAs in Arabidopsis thaliana mitochondria. Down-regulation of AtmtPNPase results in the accumulation of pretranscripts of several times the size of mature atp9 mRNAs, indicating that 3' processing of these transcripts is performed mainly exonucleolytically by AtmtPNPase. This enzyme is however not sufficient to completely process atp9 mRNAs, because with down-regulation of another mitochondrial exoribonuclease, AtmtRNaseII, about half of atp9 transcripts exhibit short 3' nucleotide extensions compared with mature mRNAs. These short extensions can be efficiently removed by AtmtRNaseII in vitro. Taken together, these results show that 3' processing of atp9 mRNAs in Arabidopsis mitochondria is, at least, a two-step phenomenon. First, AtmtPNPase is involved in removing 3' extensions that may reach several kilobases. Second, AtmtRNaseII degrades short nucleotidic extensions to generate the mature 3'-ends.	CNRS, Inst Biol Mol Plantes, UPR2357, F-67084 Strasbourg, France; Univ Grenoble 1, Lab Plastes & Differenciat Cellulaire, F-38041 Grenoble 9, France; CNRS, F-38041 Grenoble 9, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)	Gagliardi, D (corresponding author), CNRS, Inst Biol Mol Plantes, UPR2357, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.	dominique.gagliardi@ibmp-ulp.u-strasbg.fr	Gagliardi, Dominique/AAS-1783-2021; Gagliardi, Dominique/P-2834-2016; Meyer, Etienne H/C-1952-2008; Gualberto, José/I-5016-2015	Gagliardi, Dominique/0000-0002-5871-7544; Gagliardi, Dominique/0000-0002-5871-7544; Meyer, Etienne H/0000-0003-4712-9824; Gualberto, José/0000-0002-7296-2618				Bellaoui M, 1997, EMBO J, V16, P5057, DOI 10.1093/emboj/16.16.5057; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Dombrowski S, 1997, EMBO J, V16, P5069, DOI 10.1093/emboj/16.16.5069; Dziembowski A, 2003, J BIOL CHEM, V278, P1603, DOI 10.1074/jbc.M208287200; FINNEGAN PM, 1990, PLANT CELL, V2, P71, DOI 10.1105/tpc.2.1.71; Gagliardi D, 1999, FEBS LETT, V458, P337, DOI 10.1016/S0014-5793(99)01168-0; Gagliardi D, 1999, EMBO J, V18, P3757, DOI 10.1093/emboj/18.13.3757; Gagliardi D, 2001, J BIOL CHEM, V276, P43541, DOI 10.1074/jbc.M106601200; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; Hoffmann M, 1999, MOL GEN GENET, V261, P537, DOI 10.1007/s004380050998; KALEIKAU EK, 1992, CURR GENET, V22, P463, DOI 10.1007/BF00326411; Kuhn J, 2002, NUCLEIC ACIDS RES, V30, P439, DOI 10.1093/nar/30.2.439; Kuhn J, 2001, MOL CELL BIOL, V21, P731, DOI 10.1128/MCB.21.3.731-742.2001; Kushner SR, 2002, J BACTERIOL, V184, P4658, DOI 10.1128/JB.184.17.4658-4665.2002; Laloi C, 2001, P NATL ACAD SCI USA, V98, P14144, DOI 10.1073/pnas.241340898; Lisitsky I, 1999, EUR J BIOCHEM, V261, P468, DOI 10.1046/j.1432-1327.1999.00285.x; Lisitsky I, 1997, J BIOL CHEM, V272, P17648, DOI 10.1074/jbc.272.28.17648; LIU AW, 1992, CURR GENET, V21, P507, DOI 10.1007/BF00351661; Lupold DS, 1999, PLANT CELL, V11, P1565, DOI 10.1105/tpc.11.8.1565; Mohanty BK, 2000, P NATL ACAD SCI USA, V97, P11966, DOI 10.1073/pnas.220295997; Monde RA, 2000, BIOCHIMIE, V82, P573, DOI 10.1016/S0300-9084(00)00606-4; Nicholson AW, 1999, FEMS MICROBIOL REV, V23, P371, DOI 10.1016/S0168-6445(99)00013-3; Piwowarski J, 2003, J MOL BIOL, V329, P853, DOI 10.1016/S0022-2836(03)00528-X; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Regnier P, 2000, BIOESSAYS, V22, P235; SCHUSTER W, 1986, NUCLEIC ACIDS RES, V14, P5943, DOI 10.1093/nar/14.15.5943; Vermel M, 2002, P NATL ACAD SCI USA, V99, P5866, DOI 10.1073/pnas.092019599; Walter M, 2002, EMBO J, V21, P6905, DOI 10.1093/emboj/cdf686; Williams MA, 2000, NUCLEIC ACIDS RES, V28, P4444, DOI 10.1093/nar/28.22.4444; Yehudai-Resheff S, 2003, PLANT CELL, V15, P2003, DOI 10.1105/tpc.013326; Yehudai-Resheff S, 2001, MOL CELL BIOL, V21, P5408, DOI 10.1128/MCB.21.16.5408-5416.2001	32	70	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25440	25446		10.1074/jbc.M401182200	http://dx.doi.org/10.1074/jbc.M401182200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15037609	hybrid			2022-12-25	WOS:000221827900067
J	Soejima, H; Nakagawachi, T; Zhao, W; Higashimoto, K; Urano, T; Matsukura, S; Kitajima, Y; Takeuchi, M; Nakayama, M; Oshimura, M; Miyazaki, K; Joh, K; Mukai, T				Soejima, H; Nakagawachi, T; Zhao, W; Higashimoto, K; Urano, T; Matsukura, S; Kitajima, Y; Takeuchi, M; Nakayama, M; Oshimura, M; Miyazaki, K; Joh, K; Mukai, T			Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer	ONCOGENE			English	Article						imprinting control region; differentially methylated region; CDKN1C; CpG methylation; histone H3 lysine 9 methylation	BECKWITH-WIEDEMANN-SYNDROME; DEPENDENT KINASE INHIBITOR; SQUAMOUS-CELL CARCINOMA; DNA METHYLATION; CHROMOSOME 11P15.5; REDUCED EXPRESSION; HUMAN P57(KIP2); GASTRIC-CANCER; CONTROL REGION; WILMS-TUMORS	The putative tumor suppressor CDKN1C is an imprinted gene at 11p15.5, a well-known imprinted region often deleted in tumors. The absence of somatic mutations and the frequent diminished expression in tumors would suggest that CDKN1C expression is regulated epigenetically. It has been, however, controversial whether the diminution is caused by imprinting disruption of the CDKN1C/LIT1 domain or by promoter hypermethylation of CDKN1C itself. To clarify this, we investigated the CpG methylation index of the CDKN1C promoter and the differentially methylated region of the LIT1 CpG island (differentially methylated region (DMR)-LIT1), an imprinting control region of the domain, and CDKN1C expression in esophageal cancer cell lines. CDKN1C expression was diminished in 10 of 17 lines and statistically correlated with the loss of methylation at DMR-LIT1 in all but three. However, there was no statistical correlation between CDKN1C promoter MI and CDKN1C expression. Furthermore, loss of CpG methylation was associated with loss of histone H3 lysine 9 (H3K9) methylation at DMR-LIT1. Histone modi. cations at CDKN1C promoter were not correlated with CDKN1C expression. The data suggested that the diminished CDKN1C expression is associated with the loss of methylation of CpG and H3K9 at DMR-LIT1, not by its own promoter CpG methylation, and is involved in esophageal cancer, implying that DMR-LIT1 epigenetically regulates CDKN1C expression not through histone modifications at CDKN1C promoter, but through that of DMR-LIT1.	Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, Saga 8498501, Japan; Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4668550, Japan; Saga Med Sch, Dept Surg, Div Gen Surg, Saga 8498501, Japan; Osaka Med Ctr, Osaka 5941101, Japan; Res Inst Maternal & Child Hlth, Osaka 5941101, Japan; Tottori Univ, Grad Sch Med Sci, Dept Biomed Sci, Yonago, Tottori 6838503, Japan	Saga University; Nagoya University; Saga University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Tottori University	Soejima, H (corresponding author), Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, 5-1-1 Nabeshima, Saga 8498501, Japan.	soejimah@post.saga-med.ac.jp		Soejima, Hidenobu/0000-0001-5076-6563; Urano, Takeshi/0000-0003-3383-3554				Baffa R, 1996, CANCER RES, V56, P268; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Bliek J, 2001, HUM MOL GENET, V10, P467, DOI 10.1093/hmg/10.5.467; Diaz-Meyer N, 2003, J MED GENET, V40, P797, DOI 10.1136/jmg.40.11.797; Du MJ, 2003, HUM MOL GENET, V12, P1927, DOI 10.1093/hmg/ddg194; Feinberg AD, 2000, J CLIN INVEST, V106, P739, DOI 10.1172/JCI10911; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; Higashimoto K, 2003, AM J HUM GENET, V73, P948, DOI 10.1086/378595; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lam WWK, 1999, J MED GENET, V36, P518; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; Li YH, 2002, BLOOD, V100, P2572, DOI 10.1182/blood-2001-11-0026; Mancini-DiNardo D, 2003, HUM MOL GENET, V12, P283, DOI 10.1093/hmg/ddg024; Matsumoto M, 2000, ANTICANCER RES, V20, P1947; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; OKeefe D, 1997, AM J HUM GENET, V61, P295, DOI 10.1086/514854; Oya M, 2000, BRIT J CANCER, V83, P626, DOI 10.1054/bjoc.2000.1298; Scelfo RAM, 2002, ONCOGENE, V21, P2564, DOI 10.1038/sj.onc.1205336; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Shin JY, 2000, CANCER RES, V60, P262; Shin JY, 2000, EXP MOL MED, V32, P79, DOI 10.1038/emm.2000.14; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Thakur N, 2003, J BIOL CHEM, V278, P9514, DOI 10.1074/jbc.M212203200; Thompson JS, 1996, CANCER RES, V56, P5723; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Ueijma H, 2000, NAT GENET, V25, P375, DOI 10.1038/78040; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Weksberg R, 2001, HUM MOL GENET, V10, P2989, DOI 10.1093/hmg/10.26.2989; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yatsuki H, 2002, GENOME RES, V12, P1860, DOI 10.1101/gr.110702	47	53	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4380	4388		10.1038/sj.onc.1207576	http://dx.doi.org/10.1038/sj.onc.1207576			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15007390				2022-12-25	WOS:000221661300004
J	Wang, H; Yang, L; Jamaluddin, MS; Boyd, DD				Wang, H; Yang, L; Jamaluddin, MS; Boyd, DD			The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; GENE-EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; COLORECTAL-CANCER; UP-REGULATION; IN-VITRO; PROMOTER; IDENTIFICATION; PROTEIN; GROWTH	The urokinase-type plasminogen activator receptor (u-PAR) plays a central role in cell migration, growth, and invasion and is regulated, in part, transcriptionally. In mice, u-PAR expression is restricted to a few tissues, one of which is the colon. We therefore screened a colon expression library for regulators of u-PAR promoter activity and identified a zinc finger protein bearing consensus sequences to the Kruppel-like family of transcription factors and showing partial homology with one of the members, KLF4. Like u-PAR, KLF4 expression is predominant in the luminal surface epithelial cells of the colonic crypt, and we hypothesized that u-PAR synthesis in these cells is directed by this transcription factor. Colon cells from KLF4 null mice showed a dramatic reduction in u-PAR protein compared with wildtype mice. Conversely, KLF4 expression in HCT116 colon cancer cells increased the amount of u-PAR protein/mRNA. Transient transfection of KLF4 with a reporter driven by 5'-deleted u-PAR promoter fragments indicated the requirement of the proximal 200 base pairs for optimal expression. Mobility-shifting experiments demonstrated binding of KLF4 to multiple regions of the u-PAR promoter (-154/-128, -105/-71, and -51/-24), and chromatin immunoprecipitation assays confirmed the binding of KLF4 to the endogenous promoter. Deletion of the -144/-123 promoter region diminished but did not eliminate the ability of KLF4 to transactivate the u-PAR promoter, suggesting cooperativity of these binding sites with respect to activation of gene expression. In conclusion, we have identified KLF4 as a novel regulator of u-PAR expression that drives the synthesis of u-PAR in the luminal surface epithelial cells of the colon.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Boyd, DD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	dboyd@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA058311, R01CA089002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58311, R01 CA89002] Funding Source: Medline; NIDCR NIH HHS [R01 DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abe J, 1999, CANCER-AM CANCER SOC, V86, P2602, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2602::AID-CNCR4>3.0.CO;2-S; Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Allgayer H, 1999, J BIOL CHEM, V274, P4702, DOI 10.1074/jbc.274.8.4702; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; ALMUSJACOBS F, 1995, AM J PATHOL, V147, P688; AVERY A, 1993, BRIT J CANCER, V68, P137, DOI 10.1038/bjc.1993.301; Bianchi E, 1996, J CLIN INVEST, V98, P1133, DOI 10.1172/JCI118896; Bonavaud S, 1997, J CELL SCI, V110, P1083; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen ZY, 2002, J BIOL CHEM, V277, P46831, DOI 10.1074/jbc.M204816200; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Guda K, 2003, MOL CARCINOGEN, V37, P51, DOI 10.1002/mc.10120; Hapke S, 2001, MOL CELL BIOL, V21, P2118, DOI 10.1128/MCB.21.6.2118-2132.2001; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Katz JP, 2002, DEVELOPMENT, V129, P2619; King KE, 2003, J BIOL CHEM, V278, P11661, DOI 10.1074/jbc.M211337200; KRISTENSEN P, 1991, J CELL BIOL, V115, P1763, DOI 10.1083/jcb.115.6.1763; Lakka SS, 2003, CANCER RES, V63, P2454; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; LUND LR, 1991, EMBO J, V10, P3399, DOI 10.1002/j.1460-2075.1991.tb04904.x; Lund LR, 1996, J INVEST DERMATOL, V106, P622, DOI 10.1111/1523-1747.ep12345425; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Mahoney TS, 2001, P NATL ACAD SCI USA, V98, P10284, DOI 10.1073/pnas.181201398; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Memarzedeh S, 2002, P NATL ACAD SCI USA, V99, P10647, DOI 10.1073/pnas.152127499; Nestl A, 2001, CANCER RES, V61, P1569; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Pi HL, 2002, BIOCHEM BIOPH RES CO, V296, P206, DOI 10.1016/S0006-291X(02)00772-6; Rabbani SA, 2002, CANCER RES, V62, P2390; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.e03-05-0279; Schewe DM, 2003, CLIN CANCER RES, V9, P2267; SCHLECHTE W, 1989, CANCER RES, V49, P6064; Schmidt M, 2000, HEAD NECK-J SCI SPEC, V22, P498, DOI 10.1002/1097-0347(200008)22:5<498::AID-HED9>3.0.CO;2-W; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Shiomi H, 2000, AM J PATHOL, V156, P567, DOI 10.1016/S0002-9440(10)64761-X; Solberg H, 2001, J HISTOCHEM CYTOCHEM, V49, P237, DOI 10.1177/002215540104900211; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; Stephens RW, 1999, JNCI-J NATL CANCER I, V91, P869, DOI 10.1093/jnci/91.10.869; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; Suzuki S, 1998, GUT, V43, P798, DOI 10.1136/gut.43.6.798; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Wang AY, 2000, EUR J BIOCHEM, V267, P3248, DOI 10.1046/j.1432-1327.2000.01350.x; Wang H, 2003, AM J PATHOL, V163, P453, DOI 10.1016/S0002-9440(10)63675-9; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; Yan CH, 2003, J BIOL CHEM, V278, P2309, DOI 10.1074/jbc.M210369200; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Zannetti A, 2000, CANCER RES, V60, P1546	63	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22674	22683		10.1074/jbc.M401257200	http://dx.doi.org/10.1074/jbc.M401257200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15031282	hybrid			2022-12-25	WOS:000221417100119
J	Yadavalli, R; Guttmann, RP; Seward, T; Centers, AP; Williamson, RA; Telling, GC				Yadavalli, R; Guttmann, RP; Seward, T; Centers, AP; Williamson, RA; Telling, GC			Calpain-dependent endoproteolytic cleavage of PrPSc modulates scrapie prion propagation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; DISRUPTION; CONVERSION; INHIBITORS; DISEASE/; FEATURES; ISOFORM; CULTURE; CELLS; BRAIN	Previous studies using post-mortem human brain extracts demonstrated that PrP in Creutzfeldt-Jakob disease (CJD) brains is cleaved by a cellular protease to generate a C-terminal fragment, referred to as C2, which has the same molecular weight as PrP-(27-30), the protease-resistant core of PrPSc (1). The role of this endoproteolytic cleavage of PrP in prion pathogenesis and the identity of the cellular protease responsible for production of the C2 cleavage product has not been explored. To address these issues we have taken a combination of pharmacological and genetic approaches using persistently infected scrapie mouse brain (SMB) cells. We confirm that production of C2 is the predominant cleavage event of PrPSc in the brains of scrapie-infected mice and that SMB cells faithfully recapitulate the diverse intracellular proteolytic processing events of PrPSc and PrPC observed in vivo. While increases in intracellular calcium (Ca2+) levels in prion-infected cell cultures stimulate the production of the PrPSc cleavage product, pharmacological inhibitors of calpains and overexpression of the endogenous calpain inhibitor, calpastatin, prevent the production of C2. In contrast, inhibitors of lysosomal proteases, caspases, and the proteasome have no effect on C2 production in SMB cells. Calpain inhibition also prevents the accumulation of PrPSc in SMB and persistently infected ScN2A cells, whereas bioassay of inhibitor-treated cell cultures demonstrates that calpain inhibition results in reduced prion titers compared with control-treated cultures assessed in parallel. Our observations suggest that calpain-mediated endoproteolytic cleavage of PrPSc may be an important event in prion propagation.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; Scripps Research Institute	Telling, GC (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.	gtell2@uky.edu	guttmann, rodney/AAN-8880-2021; Telling, Glenn C/G-1217-2019	guttmann, rodney/0000-0001-5553-3099; Telling, Glenn C/0000-0002-6294-1805	NIAID NIH HHS [N01-AI-25491] Funding Source: Medline; NINDS NIH HHS [R01 NS/AI40334] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040334] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Birkett CR, 2001, EMBO J, V20, P3351, DOI 10.1093/emboj/20.13.3351; Bosque PJ, 2000, J VIROL, V74, P4377, DOI 10.1128/JVI.74.9.4377-4386.2000; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; CLARKE MC, 1970, NATURE, V225, P100, DOI 10.1038/225100a0; Doh-Ura K, 2000, J VIROL, V74, P4894, DOI 10.1128/JVI.74.10.4894-4897.2000; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Guttmann RP, 1998, J BIOL CHEM, V273, P13331, DOI 10.1074/jbc.273.21.13331; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Jimenez-Huete A, 1998, AM J PATHOL, V153, P1561, DOI 10.1016/S0002-9440(10)65744-6; Johnson GVW, 1997, BIOESSAYS, V19, P1011, DOI 10.1002/bies.950191111; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; KRISTENSSON K, 1993, NEUROLOGY, V43, P2335, DOI 10.1212/WNL.43.11.2335; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; Mishizen-Eberz AJ, 2003, J NEUROCHEM, V86, P836, DOI 10.1046/j.1471-4159.2003.01878.x; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; Morford LA, 2002, BIOCHEM BIOPH RES CO, V295, P540, DOI 10.1016/S0006-291X(02)00676-9; O'Donovan CN, 2001, J BIOL CHEM, V276, P43516, DOI 10.1074/jbc.M103894200; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pariat M, 2000, BIOCHEM J, V345, P129, DOI 10.1042/0264-6021:3450129; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Perini F, 1996, BIOCHEM BIOPH RES CO, V223, P572, DOI 10.1006/bbrc.1996.0936; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Stabach PR, 1997, BIOCHEMISTRY-US, V36, P57, DOI 10.1021/bi962034i; Supattapone S, 2002, BIOCHEM PHARMACOL, V63, P1383, DOI 10.1016/S0006-2952(02)00874-2; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Vincent B, 2001, J BIOL CHEM, V276, P37743; Weissmann C, 2002, P NATL ACAD SCI USA, V99, P16378, DOI 10.1073/pnas.172403799; Xiao YF, 2000, EUR J PHARMACOL, V399, P107, DOI 10.1016/S0014-2999(00)00366-6	40	95	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21948	21956		10.1074/jbc.M400793200	http://dx.doi.org/10.1074/jbc.M400793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15026410	hybrid			2022-12-25	WOS:000221417100035
J	Cao, HP; Tuttle, JS; Blackshear, PJ				Cao, HP; Tuttle, JS; Blackshear, PJ			Immunological characterization of tristetraprolin as a low abundance, inducible, stable cytosolic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER TRANSCRIPTION FACTOR; PROLYL ISOMERASE PIN1; ALPHA MESSENGER-RNA; AU-RICH ELEMENTS; TNF-ALPHA; BINDING; CELLS; DEFICIENCY; PATHWAY; NUCLEAR	Tristetraprolin (TTP) is a zinc finger protein that can bind to AU-rich elements within certain mRNAs, resulting in deadenylation and destabilization of those mRNAs. Its physiological targets include the mRNAs encoding the cytokines tumor necrosis factor alpha (TNF) and granulocyte-macrophage colony-stimulating factor. TTP was originally identified on the basis of its massive but transient increase in mRNA levels following mitogen stimulation of fibroblasts. It has been difficult to reconcile this transient mRNA profile with the presumed continuing "need" for TTP protein, for example, to reverse the effects of lipopolysaccharide (LPS)-stimulated TNF secretion. To investigate this and other questions concerning endogenous TTP protein in cells and tissues, we raised a high titer rabbit antiserum against full-length mouse TTP. TTP could be detected on immunoblots of mouse cytosolic tissue extracts; it was most highly expressed in spleen, but its concentration in that tissue was only about 1.5 nM. TTP could be detected readily in splenic macrophages and stromal cells from LPS-injected rats. In both LPS-treated RAW 264.7 macrophages and fetal calf serum-treated mouse embryonic fibroblasts, TTP protein was stable after induction, with minimal degradation occurring for several hours after treatment of the cells with cycloheximide. The biosynthesis of TTP was accompanied by large changes in electrophoretic mobility consistent with progressive phosphorylation. Confocal microscopy revealed that TTP accumulated in a vesicular pattern in the cytosol of the LPS-stimulated RAW 264.7 cells, and was occasionally seen in the cytosol of unstimulated dividing cells. Gel filtration of the endogenous protein suggested that its predominant structure was monomeric. TTP appears to be a low abundance, cytosolic protein in unstimulated cells and tissues, but once induced is relatively stable, in contrast to its very labile mRNA.	NIEHS, NIH, Dept Hlth & Human Serv, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA; NIEHS, NIH, Dept Hlth & Human Serv, Off Clin Res, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Blackshear, PJ (corresponding author), NIEHS, NIH, Dept Hlth & Human Serv, Lab Signal Transduct, A2-05,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	black009@niehs.nih.gov	Cao, Heping/AAC-1666-2021; Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529; Cao, Heping/0000-0002-0958-1468	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090080, Z01ES090080] Funding Source: NIH RePORTER; NIEHS NIH HHS [Z01 ES090080-08] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Blackshear PJ, 2003, J BIOL CHEM, V278, P19947, DOI 10.1074/jbc.M301290200; Brooks SA, 2002, ARTHRITIS RHEUM, V46, P1362, DOI 10.1002/art.10235; Bruno ME, 2002, ARCH BIOCHEM BIOPHYS, V406, P153, DOI 10.1016/S0003-9861(02)00452-6; Cao HP, 2003, ARCH BIOCHEM BIOPHYS, V412, P106, DOI 10.1016/S0003-9861(03)00012-2; Cao HP, 2000, ARCH BIOCHEM BIOPHYS, V373, P135, DOI 10.1006/abbi.1999.1547; CAO HP, 1995, PHYSIOL PLANTARUM, V95, P176, DOI 10.1111/j.1399-3054.1995.tb00825.x; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Carballo E, 2001, BLOOD, V98, P2389, DOI 10.1182/blood.V98.8.2389; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chrestensen CA, 2004, J BIOL CHEM, V279, P10176, DOI 10.1074/jbc.M310486200; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; Fairhurst AM, 2003, ARTHRITIS RES THER, V5, pR214, DOI 10.1186/ar778; Flores KG, 2001, HUM PATHOL, V32, P926, DOI 10.1053/hupa.2001.27106; Johnson BA, 2002, J BIOL CHEM, V277, P18029, DOI 10.1074/jbc.M110465200; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Kontoyiannis D, 2002, J EXP MED, V196, P1563, DOI 10.1084/jem.20020281; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1995, J BIOL CHEM, V270, P25266, DOI 10.1074/jbc.270.42.25266; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lidington D, 2000, J CELL PHYSIOL, V185, P117, DOI 10.1002/1097-4652(200010)185:1<117::AID-JCP11>3.0.CO;2-7; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; Murata T, 2002, BIOCHEM BIOPH RES CO, V293, P1242, DOI 10.1016/S0006-291X(02)00363-7; Phillips RS, 2002, J BIOL CHEM, V277, P11606, DOI 10.1074/jbc.M111457200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; VARNUM BC, 1989, ONCOGENE, V4, P119; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zebrowska G, 2001, ANTICANCER RES, V21, P1213; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhu W, 2001, AM J PHYSIOL-LUNG C, V281, pL499, DOI 10.1152/ajplung.2001.281.2.L499	39	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21489	21499		10.1074/jbc.M400900200	http://dx.doi.org/10.1074/jbc.M400900200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15010466	Green Accepted, hybrid			2022-12-25	WOS:000221273800114
J	Liz, MA; Faro, CJ; Saraiva, MJ; Sousa, MM				Liz, MA; Faro, CJ; Saraiva, MJ; Sousa, MM			Transthyretin, a new cryptic protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; FAMILIAL AMYLOIDOTIC POLYNEUROPATHY; ESCHERICHIA-COLI EXPRESSION; SENILE SYSTEMIC AMYLOIDOSIS; CHOLESTEROL EFFLUX; FIBRIL PROTEIN; PREALBUMIN; BINDING; ASSOCIATION; FIBRONECTIN	Transthyretin (TTR) is a plasma homotetrameric protein that acts physiologically as a transporter of thyroxine (T-4) and retinol, in the latter case through binding to retinol-binding protein (RBP). A fraction of plasma TTR is carried in high density lipoproteins by binding to apolipoprotein AI (apoA-I). We further investigated the nature of the TTR-apoA-I interaction and found that TTR from different sources (recombinant and plasmatic) is able to process proteolytically apoA-I, cleaving its C terminus after Phe-225. TTR-mediated proteolysis was inhibited by serine protease inhibitors (phenyl-methanesulfonyl fluoride, Pefabloc, diisopropyl fluorophosphate, chymostatin, and N-alpha-p-tosyl-L-phenylalanine-chloromethyl ketone), suggesting a chymotrypsin-like activity. A fluorogenic substrate corresponding to an apoA-I fragment encompassing amino acid residues 223-228 (Abz-ESFKVS-EDDnp) was used to characterize the catalytic activity of TTR, including optimum reaction conditions (37degreesC and pH 6.8) and catalytic constant (K-m=29 muM); when complexed with RBP, TTR activity was lost, whereas when complexed with T-4, only a slight decrease was observed. Cell lines expressing TTR were able to degrade Abz-ESFKVS-EDDnp 2-fold more efficiently than control cells lacking TTR expression; this effect was reversed by the presence of RBP in cell culture media, therefore proving a TTR-specific proteolytic activity. TTR can act as a novel plasma cryptic protease and might have a new, potentially important role under physiological and/or pathological conditions.	Inst Mol & Cellular Biol, Mol Neurobiol Grp, P-4150180 Oporto, Portugal; Ctr Neurociencias Coimbra, P-3004517 Coimbra, Portugal; Univ Porto, ICBAS, P-4099003 Oporto, Portugal	Universidade do Porto; Universidade de Coimbra; Universidade do Porto	Sousa, MM (corresponding author), Inst Mol & Cellular Biol, Mol Neurobiol Grp, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	msousa@ibmc.up.pt	Liz, Márcia A/K-4280-2013; Liz, Márcia/ABB-3400-2020; Sousa, Monica/K-4367-2013; Saraiva, Maria João/K-3907-2013	Liz, Márcia A/0000-0002-5126-663X; Liz, Márcia/0000-0002-5126-663X; Sousa, Monica/0000-0002-4524-2260; Saraiva, Maria João/0000-0002-3360-6899; Faro, Carlos/0000-0002-0480-8379				Almeida MR, 1997, ENDOCRINE, V6, P309, DOI 10.1007/BF02820508; Ando Y, 1999, BIOCHEM BIOPH RES CO, V261, P264, DOI 10.1006/bbrc.1999.1048; Birghan C, 2000, EMBO J, V19, P114, DOI 10.1093/emboj/19.1.114; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BOYD VL, 1992, ANAL BIOCHEM, V206, P344, DOI 10.1016/0003-2697(92)90376-I; Casarini D E, 1992, Agents Actions Suppl, V38 ( Pt 1), P422; CORNWELL GG, 1988, BIOCHEM BIOPH RES CO, V154, P648, DOI 10.1016/0006-291X(88)90188-X; de Sousa MM, 2000, AM J PATHOL, V156, P1911, DOI 10.1016/S0002-9440(10)65064-X; DICKSON PW, 1985, J BIOL CHEM, V260, P8214; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Eberini I, 2002, BIOCHEM J, V362, P627, DOI 10.1042/0264-6021:3620627; FURUYA H, 1989, BIOCHEM BIOPH RES CO, V163, P851, DOI 10.1016/0006-291X(89)92300-0; Gorshkova IN, 2000, BIOCHEMISTRY-US, V39, P15910, DOI 10.1021/bi0014406; GUSTAVSSON A, 1995, LAB INVEST, V73, P703; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; Jobin MC, 2003, FEMS MICROBIOL LETT, V220, P113, DOI 10.1016/S0378-1097(03)00088-0; Kisilevsky R, 2000, J STRUCT BIOL, V130, P99, DOI 10.1006/jsbi.2000.4222; Lee M, 2003, J LIPID RES, V44, P539, DOI 10.1194/jlr.M200420-JLR200; Monaco HL, 2000, BBA-PROTEIN STRUCT M, V1482, P65, DOI 10.1016/S0167-4838(00)00140-0; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SARAIVA MJM, 1984, J CLIN INVEST, V74, P104, DOI 10.1172/JCI111390; Schnepel J, 2000, J PROTEIN CHEM, V19, P685, DOI 10.1023/A:1007104420017; Schormann N, 1998, AMYLOID, V5, P175, DOI 10.3109/13506129809003843; Sousa MM, 2000, J BIOL CHEM, V275, P38176, DOI 10.1074/jbc.M002886200; Sousa MM, 2002, AM J PATHOL, V161, P1935, DOI 10.1016/S0002-9440(10)64469-0; Sousa MM, 2001, J BIOL CHEM, V276, P14420, DOI 10.1074/jbc.M010869200; Sousa MM, 2000, J LIPID RES, V41, P58; VIDMAR SL, 1991, EUR J BIOCHEM, V201, P71, DOI 10.1111/j.1432-1033.1991.tb16257.x; Walsh MT, 1999, AM J PATHOL, V154, P11, DOI 10.1016/S0002-9440(10)65244-3	32	73	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21431	21438		10.1074/jbc.M402212200	http://dx.doi.org/10.1074/jbc.M402212200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15033978	hybrid			2022-12-25	WOS:000221273800108
J	Nam, JH; Woo, JE; Uhm, DY; Kim, SJ				Nam, JH; Woo, JE; Uhm, DY; Kim, SJ			Membrane-delimited regulation of novel background K+ channels by MgATP in murine immature B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVITY; HUMAN T-LYMPHOCYTES; 2-AMINOETHOXYDIPHENYL BORATE; POTASSIUM CHANNELS; CALCIUM; APOPTOSIS; ATP; MODULATION; ACTIVATION; INHIBITION	In WEHI-231, a representative immature B cell line, Ca2+ entry is paradoxically augmented by treatment with 2-aminoethoxydiphenyl borate (2-APB), a blocker of inositol 1,4,5-trisphosphate receptor and of nonselective cation channels (Nam, J.H., Yun, S.S., Kim, T.J., Uhm, D.-Y., and Kim, S.J. (2003) FEBS Lett. 535, 113-118). The initial goal of the present study was to elucidate the effects of 2-APB on membrane currents, which revealed the presence of novel K+ channels in WEHI-231 cells. Under whole-cell patch clamp conditions, 2-APB induced background K+ current (I-K,I-bg) and hyperpolarization in WEHI-231 cells. Lowering of intracellular MgATP also induced the I-K,I-bg. The I-K,I-bg was blocked by micromolar concentrations of quinidine but not by tetraethylammonium. In a single channel study, two types of voltage-independent K+ channels were found with large (346 picosiemens) and medium conductance (112 picosiemens), named BKbg and MKbg, respectively. The excision of membrane patches (inside-out (i-o) patches) greatly increased the P-o of BKbg. In i-o patches, cytoplasmic MgATP (IC50=0.18 mM) decreased the BKbg activity, although non-hydrolyzable adenosine 5'-(beta,gamma-imino)-triphosphate had no effect. A pretreatment with Al3+ or wortmannin (50 muM) blocked the inhibitory effects of MgATP. A direct application of phosphoinositide 4,5-bisphosphate (10 muM) inhibited the BKbg activity. Meanwhile, the activity of MKbg was unaffected by MgATP. In cell-attached conditions, the BKbg activity was largely increased by 2-APB. In i-o patches, however, the MgATP-induced inhibition of BKbg was weakly reversed by the addition of 2-APB. In summary, WEHI-231 cells express the unique background K+ channels. The BK(bg)s are inhibited by membrane-delimited elevation of phosphoinositide 4,5-bisphosphate. The activation of BKbg would hyperpolarize the membrane, which augments the calcium influx in WEHI-231 cells.	Sungkyunkwan Univ, Sch Med, Dept Physiol, Ctr Mol Med,Samsung Biomed Res Inst, Suwon 440746, South Korea	Samsung; Sungkyunkwan University (SKKU)	Kim, SJ (corresponding author), Sungkyunkwan Univ, Sch Med, Dept Physiol, Ctr Mol Med,Samsung Biomed Res Inst, Cheoncheon Dong 300, Suwon 440746, South Korea.	sjoonkim@med.skku.ac.kr	Nam, Joohyun/AAD-4491-2021; Kim, Sung Joon/H-1825-2012	Nam, Joo Hyun/0000-0001-8300-6974; Kim, Sung-Joon/0000-0002-0289-121X				ASHCROFT FM, 2000, ION CHANNELS DIS, P97; Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; Bhattacharjee A, 2003, J NEUROSCI, V23, P11681; Bilmen JG, 2002, EUR J BIOCHEM, V269, P3678, DOI 10.1046/j.1432-1033.2002.03060.x; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Bortner CD, 2002, CELL DEATH DIFFER, V9, P1307, DOI 10.1038/sj.cdd.4401126; Braun FJ, 2003, MOL PHARMACOL, V63, P1304, DOI 10.1124/mol.63.6.1304; Chemin J, 2003, EMBO J, V22, P5403, DOI 10.1093/emboj/cdg528; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; Desai R, 2000, J BIOL CHEM, V275, P39954, DOI 10.1074/jbc.M001562200; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Han JH, 2003, J PHYSIOL-LONDON, V550, P693, DOI 10.1113/jphysiol.2003.042119; Harks EGA, 2003, FASEB J, V17, P941, DOI 10.1096/fj.02-0786fje; Hashimoto A, 2001, J IMMUNOL, V166, P1003, DOI 10.4049/jimmunol.166.2.1003; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; IGARASHI H, 1994, J IMMUNOL, V153, P2381; King LB, 2000, IMMUNOL REV, V176, P86; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; Kurosaki T, 2002, CURR OPIN IMMUNOL, V14, P341, DOI 10.1016/S0952-7915(02)00344-8; Lauritzen I, 2003, J BIOL CHEM, V278, P32068, DOI 10.1074/jbc.M302631200; LEE MY, 1994, PFLUG ARCH EUR J PHY, V429, P150, DOI 10.1007/BF02584044; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Liu QH, 2002, J EXP MED, V196, P897, DOI 10.1084/jem.20020381; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Marshall AJ, 2000, IMMUNOL REV, V176, P30; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Nam JH, 2003, FEBS LETT, V535, P113, DOI 10.1016/S0014-5793(02)03884-X; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PARTISETI M, 1992, J IMMUNOL, V148, P3361; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8; Tasker L, 2000, IMMUNOLOGY, V99, P385, DOI 10.1046/j.1365-2567.2000.00976.x; Trimarchi JR, 2002, AM J PHYSIOL-CELL PH, V282, pC588, DOI 10.1152/ajpcell.00365.2001; Verheugen JAH, 1997, CELL CALCIUM, V21, P1, DOI 10.1016/S0143-4160(97)90092-0; VERHEUGEN JAH, 1995, CELL CALCIUM, V17, P287, DOI 10.1016/0143-4160(95)90075-6; WU YJ, 1995, EUR J IMMUNOL, V25, P2279, DOI 10.1002/eji.1830250825; Wulff H, 2003, J CLIN INVEST, V111, P1703, DOI 10.1172/JCI200316921; Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3	42	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20643	20654		10.1074/jbc.M312547200	http://dx.doi.org/10.1074/jbc.M312547200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15014072	hybrid			2022-12-25	WOS:000221273800014
J	Robert, R; Thoreau, V; Norez, C; Cantereau, A; Kitzis, A; Mettey, Y; Rogier, C; Becq, F				Robert, R; Thoreau, V; Norez, C; Cantereau, A; Kitzis, A; Mettey, Y; Rogier, C; Becq, F			Regulation of the cystic fibrosis transmembrane conductance regulator channel by beta-adrenergic agonists and vasoactive intestinal peptide in rat smooth muscle cells and its role in vasorelaxation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; CL-CHANNELS; PULMONARY-HYPERTENSION; ION CHANNELS; HEART; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; MECHANISMS; CALCIUM	The signaling events that regulate vascular tone include voltage-dependent Ca2+ influx and the activities of various ionic channels; which molecular entities are involved and their role are still a matter of debate. Here we show expression of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel in rat aortic smooth muscle cells. Immunoprecipitation and in vitro protein kinase A phosphorylation show the appearance of mature band C of CFTR. An immunohistochemistry study shows CFTR proteins in smooth muscles of aortic rings but not in skeletal muscles. Using the iodide efflux method, a combination of agonists and pharmacological agents was used to dissect the function of CFTR. Agonists of the cAMP pathway, the beta-adrenergic agonist isoproterenol, and the neuropeptide vasoactive intestinal peptide activate CFTR-dependent transport from cells maintained in a high but not low extracellular potassium-rich saline, suggesting that depolarization of smooth muscle is critical to CFTR activation. Smooth muscle CFTR possesses all of the pharmacological attributes of its epithelial homologues: stimulation by the CFTR pharmacological activators MPB-07 (EC50 = 158 muM) and MPB-91 (EC50 = 20 muM) and inhibition by glibenclamide and diphenylamine-2-carboxylic acid but not by 5,11,17,23-tetrasulfonato-25,26,27,28-tetramethoxy-calix[4]arene. Contraction measurements on isolated aortic rings were performed to study the contribution of CFTR to vascular tone. With aortic rings (without endothelium) preconstricted by high K+ saline or by the beta-adrenergic agonist norepinephrine, CFTR activators produced a concentration-dependent relaxation. These results identify for the first time the expression and function of CFTR in smooth muscle where it plays an unexpected but fundamental role in the autonomic and hormonal regulation of the vascular tone.	Univ Poitiers, Lab Biomembranes & Signalisat Cellulaire, CNRS, UMR 6558, F-86022 Poitiers, France; Ctr Hosp Univ Poitiers, Lab Genet Cellulaire & Mol, Unite Propre Rech Enseignement Super, EA 2622, F-86022 Poitiers, France; Fac Med & Pharm Poitiers, Chim Organ Lab, F-86002 Poitiers, France	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; CHU Poitiers; Universite de Poitiers; Universite de Poitiers	Becq, F (corresponding author), Univ Poitiers, Lab Biomembranes & Signalisat Cellulaire, CNRS, UMR 6558, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	frederic.becq@univ-poitiers.fr	ROGIER, Christophe/C-2550-2008; Norez, Caroline/P-9567-2016; Becq, Frederic/P-9233-2016	Becq, Frederic/0000-0003-3915-0973				BECQ F, 1993, PFLUG ARCH EUR J PHY, V425, P1, DOI 10.1007/BF00374496; Becq F, 1999, J BIOL CHEM, V274, P27415, DOI 10.1074/jbc.274.39.27415; Bright-Thomas RJ, 2002, J ROY SOC MED, V95, P2; Carl A, 1996, AM J PHYSIOL-CELL PH, V271, pC9, DOI 10.1152/ajpcell.1996.271.1.C9; Chipperfield AR, 2000, PROG BIOPHYS MOL BIO, V74, P175, DOI 10.1016/S0079-6107(00)00024-9; Chruscinski A, 2001, MOL PHARMACOL, V60, P955, DOI 10.1124/mol.60.5.955; DERAND R, 2001, AM J PHYSIOL, V281, pC157; Dick GM, 1998, AM J PHYSIOL-CELL PH, V275, pC940, DOI 10.1152/ajpcell.1998.275.4.C940; Diwakar V, 2001, Paediatr Respir Rev, V2, P340, DOI 10.1053/prrv.2001.0170; Dormer RL, 2001, J CELL SCI, V114, P4073; EICHLER HG, 1989, CLIN SCI, V76, P283, DOI 10.1042/cs0760283; Fraser KL, 1999, CHEST, V115, P1321, DOI 10.1378/chest.115.5.1321; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; GADSBY DC, 1995, ANNU REV PHYSIOL, V57, P387; Henning RJ, 2001, CARDIOVASC RES, V49, P27, DOI 10.1016/S0008-6363(00)00229-7; HOROWITZ B, 1993, AM J PHYSIOL, V264, pH2214, DOI 10.1152/ajpheart.1993.264.6.H2214; Ito O, 1998, REGUL PEPTIDES, V78, P105, DOI 10.1016/S0167-0115(98)00135-9; Jackson WF, 2000, HYPERTENSION, V35, P173, DOI 10.1161/01.HYP.35.1.173; Kitamura K, 2001, JPN J PHARMACOL, V85, P351, DOI 10.1254/jjp.85.351; Kotlikoff MI, 1996, ANNU REV PHYSIOL, V58, P115, DOI 10.1146/annurev.ph.58.030196.000555; Laburthe M, 2002, REGUL PEPTIDES, V108, P165, DOI 10.1016/S0167-0115(02)00099-X; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; LEVESQUE PC, 1992, CIRC RES, V71, P1002, DOI 10.1161/01.RES.71.4.1002; Marrero MB, 1996, CLIN EXP PHARMACOL P, V23, P83; MURRAY KJ, 1990, PHARMACOL THERAPEUT, V47, P329, DOI 10.1016/0163-7258(90)90060-F; RIORDAN JR, 1989, SCIENCE, V245, P1066; Salvi SS, 1999, CHEST, V115, P1708, DOI 10.1378/chest.115.6.1708; Schultz BD, 1999, PHYSL REV S, V79, P109; SHEPPARD DN, 1993, ANN NY ACAD SCI, V707, P275, DOI 10.1111/j.1749-6632.1993.tb38058.x; SINGH AK, 1995, KIDNEY INT, V48, P985, DOI 10.1038/ki.1995.380; Sorota S, 1999, CARDIOVASC RES, V42, P361, DOI 10.1016/S0008-6363(99)00039-5; Tousson A, 1998, AM J PHYSIOL-CELL PH, V275, pC1555, DOI 10.1152/ajpcell.1998.275.6.C1555; Vizza CD, 1998, CHEST, V113, P576, DOI 10.1378/chest.113.3.576; Wei L, 2001, BMC Physiol, V1, P3, DOI 10.1186/1472-6793-1-3; Weyler RT, 1999, AM J PHYSIOL-CELL PH, V277, pC563, DOI 10.1152/ajpcell.1999.277.3.C563; WHITE CR, 1995, P SOC EXP BIOL MED, V208, P255; Woodrum DA, 2001, MOL CELL ENDOCRINOL, V177, P135, DOI 10.1016/S0303-7207(01)00407-5	37	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21160	21168		10.1074/jbc.M312199200	http://dx.doi.org/10.1074/jbc.M312199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15020588	Green Published, hybrid			2022-12-25	WOS:000221273800074
J	Wang, D; Lippard, SJ				Wang, D; Lippard, SJ			Cisplatin-induced post-translational modification of histones H3 and H4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-INDUCED PHOSPHORYLATION; P38 MAP KINASES; CELL-DEATH; CHROMOSOME CONDENSATION; EXCISION-REPAIR; STRESS; ACETYLATION; ACTIVATION; CHROMATIN; INDUCTION	The anti-cancer drug cisplatin kills cells by damaging DNA and inducing apoptosis. Understanding the detailed mechanisms by which cancer cells respond to cisplatin has the potential to improve substantially platinum-based therapy. Post-translational modification of histones alters chromatin structure, facilitating the binding of nuclear factors that mediate DNA repair, transcription, and other processes. In the present study, we have investigated the effects of cisplatin treatment on histone post-translational modification in cancer cells. We discovered that specific phosphorylation of histone H3 at Ser-10, mediated by the p38 MAPK pathway, is induced in response to cisplatin treatment. In addition, hyperacetylation of histone H4 was caused by drug treatment. These findings revealed a link between cisplatin administration and chromosomal structural alterations, providing mechanistic information about how cells respond to platinum-induced stress.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu	Wang, Dong/C-8943-2012		NATIONAL CANCER INSTITUTE [R01CA034992, R37CA034992] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Cui W, 2000, MOL CARCINOGEN, V29, P219, DOI 10.1002/1098-2744(200012)29:4<219::AID-MC1004>3.0.CO;2-D; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; He ZW, 2003, J BIOL CHEM, V278, P10588, DOI 10.1074/jbc.M208581200; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; Labrador M, 2003, GENE DEV, V17, P43, DOI 10.1101/gad.1021403; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; Miyata Y, 2001, BIOCHEM BIOPH RES CO, V283, P655, DOI 10.1006/bbrc.2001.4840; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; ROSENBERG B, 1985, CANCER, V55, P2303, DOI 10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; SORENSON CM, 1988, CANCER RES, V48, P6703; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strelkov IS, 2002, CANCER RES, V62, P75; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Wang D, 2003, BIOCHEMISTRY-US, V42, P6747, DOI 10.1021/bi034264k; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2003, ONCOGENE, V22, P5291, DOI 10.1038/sj.onc.1206507; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200	49	47	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20622	20625		10.1074/jbc.M402547200	http://dx.doi.org/10.1074/jbc.M402547200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15010460	hybrid			2022-12-25	WOS:000221273800011
J	Wang, JZ; Wei, QQ; Wang, CY; Hill, WD; Hess, DC; Dong, Z				Wang, JZ; Wei, QQ; Wang, CY; Hill, WD; Hess, DC; Dong, Z			Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CEREBELLAR GRANULE NEURONS; MICROGLIAL ACTIVATION; BAX TRANSLOCATION; FAMILY-MEMBERS; MOUSE MODEL; APOPTOSIS; DISEASE; NEUROTOXICITY; INHIBITION	Robust neuroprotective effects have been shown for minocycline. Whether it also protects nonneuronal cells or tissues is unknown. More importantly, the mechanisms of minocylcine protection appear multifaceted and remain to be clarified. Here we show that minocycline can protect kidney epithelial cells in vitro and protect the kidneys from ischemic injury in vivo. We further show that Bcl-2 is a key molecular determinant of minocycline protection. Minocycline protected kidney epithelial cells against apoptosis induced by hypoxia, azide, cisplatin, and staurosporine. The protection occurred at mitochondria, involving the suppression of Bax accumulation, outer membrane damage, and cytochrome c release. Minocycline induced Bcl-2, which accumulated in mitochondria and interacted with death-promoting molecules including Bax, Bak, and Bid. Down-regulation of Bcl-2 by specific antisense oligonucleotides abolished the cytoprotective effects of minocycline. Thus, minocycline can protect neuronal as well as nonneuronal cells and tissues. One mechanism for minocycline protection involves the induction of Bcl-2, an antiapoptotic protein.	Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Ctr Biotechnol & Genom Med, Augusta, GA 30912 USA; Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Dong, Z (corresponding author), Med Coll Georgia, Dept Cellular Biol & Anat, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	zdong@mail.mcg.edu		Wang, Cong-Yi/0000-0001-7914-168X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058831] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 58831] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Dong Z, 2000, BIOCHEM J, V347, P669, DOI 10.1042/0264-6021:3470669; Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200; Dong Z, 2003, EXP CELL RES, V288, P301, DOI 10.1016/S0014-4827(03)00214-3; Dong Z, 2003, AM J PATHOL, V163, P663, DOI 10.1016/S0002-9440(10)63693-0; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; KLEIN NC, 1995, MED CLIN N AM, V79, P789, DOI 10.1016/S0025-7125(16)30039-6; Lin SZ, 2003, LIFE SCI, V72, P1635, DOI 10.1016/S0024-3205(02)02442-6; Lin SZ, 2001, NEUROSCI LETT, V315, P61, DOI 10.1016/S0304-3940(01)02324-2; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Ryan Maria E., 1996, Current Opinion in Rheumatology, V8, P238, DOI 10.1097/00002281-199605000-00013; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sorenson CM, 1996, AM J PHYSIOL-RENAL, V271, pF184, DOI 10.1152/ajprenal.1996.271.1.F184; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tikka TM, 2002, BRAIN, V125, P722, DOI 10.1093/brain/awf068; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wang XD, 2001, GENE DEV, V15, P2922; Wei QQ, 2004, AM J PHYSIOL-RENAL, V286, pF803, DOI 10.1152/ajprenal.00093.2003; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	40	200	211	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19948	19954		10.1074/jbc.M313629200	http://dx.doi.org/10.1074/jbc.M313629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004018	hybrid			2022-12-25	WOS:000221164500069
J	Aoyama, Y; Avruch, J; Zhang, XF				Aoyama, Y; Avruch, J; Zhang, XF			Norel inhibits tumor cell growth independent of Ras or the MST1/2 kinases	ONCOGENE			English	Article						Nore1; RASSF1A; growth suppression; Ras; MST	EPIGENETIC INACTIVATION; SUPPRESSOR GENE; FAMILY PROTEIN; RASSF1A; IDENTIFICATION; BINDING; LUNG; PROLIFERATION; HIPPO	Nore1, a noncatalytic protein identified by its ability to bind selectively to active Ras, is most closely related in amino-acid sequence to the tumor suppressor RASSF1. Both are expressed predominantly as a longer (Nore1A/RASSF1A) and/or shorter (Nore1B/RASSF1C) polypeptide; all four polypeptides contain a Ras-association domain and bind, through their conserved carboxytermini, the proapoptotic protein kinases MST1 and MST2. Moreover, the expression of the longer polypeptide is downregulated in human tumor cell lines through promoter methylation (frequently for RASSF1A, less regularly for Nore1A). Forced expression of RASSF1A in several such lines (including the NSCLC line A549) has been shown to suppress tumorigenicity; herein we inquire whether Nore has growth inhibitory activity. Four tumor cell lines were tested, selected for their low expression of both Nore1A and Nore1B; the two NSCLC lines, A549 and NCI-H460, each have a mutant active Ras oncogene, whereas the two melanoma lines G361 and M14 each contain the constitutively active BRaf(V599E) oncogene and wild-type Ras. The expression of Nore1A or Nore1B suppresses colony formation by the A549 and G361 lines, as effectively in A549 as does RASSF1A; colony formation in the NCI-H460 and M14 lines is unaffected. Nore1A inhibits anchorage-independent growth by A549 cells and delays A549 progression through G1 without evidence of increased apoptosis. The growth suppressive action of Nore1A is largely unaffected by deletion of both the MST- and Ras-binding domains, as well as by mutation of the Nore1A zinc finger. Thus, Nore1 suppresses the growth of some tumor cell lines through as yet unidentified effectors, independent of Ras-like proteins or MST1/2.	Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Avruch, J (corresponding author), Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu; zhang@mmolbio.mgh.harvard.edu			NCI NIH HHS [CA073818] Funding Source: Medline; NIDDK NIH HHS [DK17776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776, R37DK017776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Belham C, 2003, J BIOL CHEM, V278, P34897, DOI 10.1074/jbc.M303663200; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cifone M A, 1982, Cancer Metastasis Rev, V1, P335, DOI 10.1007/BF00124216; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Steiner G, 1996, CANCER RES, V56, P5044; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	27	73	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3426	3433		10.1038/sj.onc.1207486	http://dx.doi.org/10.1038/sj.onc.1207486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15007383				2022-12-25	WOS:000220975000017
J	Seko, Y; Azmi, H; Fariss, R; Ragheb, JA				Seko, Y; Azmi, H; Fariss, R; Ragheb, JA			Selective cytoplasmic translocation of HuR and site-specific binding to the interleukin-2 mRNA are not sufficient for CD28-mediated stabilization of the mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-ACTIVATION; 3' UNTRANSLATED REGION; AU-RICH ELEMENTS; PROTEIN HUR; 3'-UNTRANSLATED REGION; SIGNAL INTEGRATION; CLONAL ANERGY; ELAV PROTEIN; GM-CSF; STABILITY	The interleukin-2 mRNA is a labile transcript containing AU-rich elements that is transiently stabilized by CD28 receptor signaling. For a number of protooncogenes and cytokines, the HuR protein has been shown to avidly bind the AU-rich elements that confer instability upon their mRNAs. HuR was originally thought to participate in mRNA degradation but subsequent studies indicated that it actually functions to stabilize mRNA. Binding of HuR to the mouse interleukin-2 mRNA has not been studied. We tested if HuR binds the interleukin-2 mRNA and whether such binding is related to CD28-mediated stabilization of the mRNA. First, we confirm that T cell receptor signaling, which is sufficient to induce interleukin-2 transcription, also triggers translocation of HuR from the nucleus to the cytoplasm. Interestingly, T cell receptor-triggered translocation is selective as heterogeneous nuclear ribonucleoprotein A1 does not shuttle under the same conditions. Engagement of both the T cell and CD28 receptors, which enhance interleukin-2 transcription and induce stabilization of the mRNA, did not further increase the level of cytoplasmic HuR. Using an in vitro binding assay, we demonstrate that HuR binds the interleukin-2 mRNA and localize binding to a sequence downstream of the single nonameric AU-rich element that is present in its 3'-untranslated region. However, we conclude that HuR binding to the interleukin-2 mRNA, both in vitro and in vivo, is not associated with alterations in mRNA stability.	NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA; NEI, Biol Imaging Core, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Ragheb, JA (corresponding author), Bldg 10,Rm 10N112,10 Ctr Dr,MSC-1857, Bethesda, MD 20892 USA.	jr50b@nih.gov	Fariss, Robert/ABI-1771-2020	Fariss, Robert/0000-0003-3227-7170	NATIONAL EYE INSTITUTE [Z01EY000366] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; Atasoy U, 1998, J CELL SCI, V111, P3145; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brown CY, 1996, P NATL ACAD SCI USA, V93, P13721, DOI 10.1073/pnas.93.24.13721; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen CY, 2000, GENE DEV, V14, P1236; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DOKTER WHA, 1993, J IMMUNOL, V150, P2584; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Fan XHC, 1997, GENE DEV, V11, P2557, DOI 10.1101/gad.11.19.2557; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Galban S, 2003, MOL CELL BIOL, V23, P7083, DOI 10.1128/MCB.23.20.7083-7095.2003; Gouble A, 2000, ONCOGENE, V19, P5377, DOI 10.1038/sj.onc.1203910; GROSS JA, 1992, J IMMUNOL, V149, P380; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HECHT TT, 1983, J IMMUNOL, V131, P1049; HENICS T, 1994, J BIOL CHEM, V269, P5377; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; McDyer JF, 2002, J IMMUNOL, V169, P2736, DOI 10.4049/jimmunol.169.5.2736; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Raghavan A, 2002, NUCLEIC ACIDS RES, V30, P5529, DOI 10.1093/nar/gkf682; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; Ragheb JA, 1999, J IMMUNOL, V163, P120; Ragheb JA, 1999, J IMMUNOL, V163, P3321; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; Smith JA, 1997, J EXP MED, V185, P1413, DOI 10.1084/jem.185.8.1413; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; UMLAUF SW, 1995, MOL CELL BIOL, V15, P3197; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68; Zhang J, 1999, J IMMUNOL, V162, P3819	54	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33359	33367		10.1074/jbc.M312306200	http://dx.doi.org/10.1074/jbc.M312306200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15020598	hybrid			2022-12-25	WOS:000223039700043
J	Dihazi, H; Kessler, R; Eschrich, K				Dihazi, H; Kessler, R; Eschrich, K			High osmolarity glycerol (HOG) pathway-induced phosphorylation and activation of 6-phosphofructo-2-kinase are essential for glycerol accumulation and yeast cell proliferation under hyperosmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE PATHWAYS; SACCHAROMYCES-CEREVISIAE; FRUCTOSE 2,6-BISPHOSPHATE; PROTEIN-KINASE; OSMOTIC-STRESS; GLYCOLYSIS; GLUCOSE; PHOSPHOFRUCTOKINASE-2; DEHYDROGENASE; STIMULATION	In response to changes in the environment, yeast cells coordinate intracellular activities to optimize survival and proliferation. The transductions of diverse extracellular stimuli are exerted through multiple mitogen-activated protein kinase ( MAPK) cascades. The high osmolarity glycerol ( HOG) MAPK pathway is activated by increased environmental osmolarity and results in a rise of the cellular glycerol concentration to adapt the intracellular osmotic pressure. We studied the importance of the short time regulation of glycolysis under hyperosmotic stress for the survival and proliferation of yeast cells. A stimulation of the HOG-MAPK pathway by increasing the medium osmolarity through addition of salt or glucose to cultivated yeast leads to an activation of 6-phosphofructo-2-kinase (PFK2), which is accompanied by a complex phosphorylation pattern of the enzyme. An increase in medium osmolarity with 5% NaCl activates PFK2 3-fold over the initial value. This change in the activity is the result of a 4-fold phosphorylation of the enzyme mediated by protein kinases from the HOG-MAPK pathway. In the case of hyperosmolar glucose a 5-fold PFK2 activation was achieved by a single phosphorylation with protein kinase A near the carboxyl terminus of the protein on Ser(644) and an additional 5-fold phosphorylation within the same amino-terminal fragment as in the presence of salt. The effect of hyperosmolar glucose is the result of an activation of the Ras-cAMP pathway together with the HOG-MAPK pathway. The activation of PFK2 leads to an activation of the upper part of glycolysis, which is a precondition for glycerol accumulation. Yeast cells containing PFK2 accumulate three times more glycerol than cells lacking PFK2, which are not able to grow under hypertonic stress.	Univ Hosp Gottingen, Dept Nephrol & Rheumatol, D-37075 Gottingen, Germany; Univ Leipzig, Fac Med, Inst Biochem, D-04103 Leipzig, Germany	University of Gottingen; Leipzig University	Dihazi, H (corresponding author), Univ Hosp Gottingen, Dept Nephrol & Rheumatol, Robert Koch Str 40, D-37075 Gottingen, Germany.	dihazi@med.uni-goettingen.de						ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Asara JM, 1999, J AM SOC MASS SPECTR, V10, P35, DOI 10.1016/S1044-0305(98)00129-9; Attfield PV, 1997, NAT BIOTECHNOL, V15, P1351, DOI 10.1038/nbt1297-1351; BLOMBERG A, 1992, ADV MICROB PHYSIOL, V33, P145, DOI 10.1016/S0065-2911(08)60217-9; BOLES E, 1993, YEAST, V9, P761, DOI 10.1002/yea.320090710; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; Dai YQ, 1999, ANAL CHEM, V71, P1087, DOI 10.1021/ac980684h; de Nadal E, 1999, J BACTERIOL, V181, P6456, DOI 10.1128/JB.181.20.6456-6462.1999; DEPRE C, 1993, ACTA CARDIOL, V48, P147; Dihazi H, 2003, BIOCHEMISTRY-US, V42, P6275, DOI 10.1021/bi034167r; Dihazi H, 2001, PROTEIN EXPRES PURIF, V21, P201, DOI 10.1006/prep.2000.1369; Dihazi H, 2001, BIOCHEMISTRY-US, V40, P14669, DOI 10.1021/bi0155549; FRANCOIS J, 1984, EUR J BIOCHEM, V145, P187, DOI 10.1111/j.1432-1033.1984.tb08539.x; FRANCOIS J, 1988, EUR J BIOCHEM, V171, P599, DOI 10.1111/j.1432-1033.1988.tb13830.x; Goncalves PM, 1997, MOL MICROBIOL, V25, P483, DOI 10.1046/j.1365-2958.1997.4811847.x; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Kessler R, 1996, FEBS LETT, V395, P225, DOI 10.1016/0014-5793(96)01045-9; KRETSCHMER M, 1993, BIOCHEMISTRY-US, V32, P11143, DOI 10.1021/bi00092a025; LANG G, 1974, METHOD ENZYMAT AN, P1235; LARSSON K, 1993, MOL MICROBIOL, V10, P1101, DOI 10.1111/j.1365-2958.1993.tb00980.x; LEVIN G, 1995, J BIOL CHEM, V270, P14611, DOI 10.1074/jbc.270.24.14611; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; MIESKES G, 1987, EUR J BIOCHEM, V167, P383, DOI 10.1111/j.1432-1033.1987.tb13349.x; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; RUBIN GM, 1973, J BIOL CHEM, V248, P3860; SCHWORER CM, 1985, J BIOL CHEM, V260, P3018; Siderius M, 1997, MICROBIOL-SGM, V143, P3241, DOI 10.1099/00221287-143-10-3241; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; Teige M, 2001, P NATL ACAD SCI USA, V98, P5625, DOI 10.1073/pnas.091610798; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wojda I, 2003, MICROBIOL-SGM, V149, P1193, DOI 10.1099/mic.0.26110-0	41	86	91	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23961	23968		10.1074/jbc.M312974200	http://dx.doi.org/10.1074/jbc.M312974200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15037628	hybrid			2022-12-25	WOS:000221702500017
J	Dixelius, J; Jakobsson, L; Genersch, E; Bohman, S; Ekblom, P; Claesson-Welsh, L				Dixelius, J; Jakobsson, L; Genersch, E; Bohman, S; Ekblom, P; Claesson-Welsh, L			Laminin-1 promotes angiogenesis in synergy with fibroblast growth factor by distinct regulation of the gene and protein expression profile in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA(V)BETA(3); ACTIVATED NOTCH4; TUBE FORMATION; DIFFERENTIATION; CHAIN; ALPHA-1; CANCER; ADULT; MICE; IDENTIFICATION	Laminins are widely distributed extracellular matrix proteins. Certain laminin isoforms are predominant in vascular basement membranes and may be critical in maintaining the stability of the mature vessel. On the other hand, formation of new vessels during angiogenesis requires degradation of the basement membrane, exposing the endothelial cells to other laminin isoforms in the surrounding extracellular matrix. We studied the effects of laminin-1 (LN-1) in different in vitro and in vivo models for angiogenesis. LN-1 induced angiogenesis in the chicken chorioallantoic membrane to the same extent as fibroblast growth factor-2 (FGF-2), and vascular development in embryoid bodies was stimulated in a synergistic manner by FGF-2 and LN-1. LN-1 promoted differentiation of endothelial cells in three-dimensional collagen gels, both in the absence and presence of FGF-2. Formation of tubular structures induced by LN-1 was accompanied by increased expression of Jagged-1, a marker of endothelial differentiation, and increased levels of FGF-2 and FGFR-1 transcripts. LN-1 did not regulate signal transduction pathways known to operate down stream of FGF-2. Thus, phosphorylation of ERK was detected in FGF-2- but not in LN-1-treated cells. Taken together, this suggests that laminins may play a fundamental role in angiogenesis by directly affecting gene and protein expression profiles in endothelial cells.	Univ Uppsala, Dept Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden; Lund Univ, Sect Cell & Dev Biol, Biomed Centrum B12, S-22184 Lund, Sweden	Uppsala University; Lund University	Claesson-Welsh, L (corresponding author), Univ Uppsala, Dept Genet & Pathol, Rudbeck Lab, Dag Hammarskjoldsvag 20, S-75185 Uppsala, Sweden.	Lena.Welsh@genpat.uu.se	Genersch, Elke/C-2232-2009; Jakobsson, Lars/B-4200-2011	Jakobsson, Lars/0000-0001-7956-587X; Genersch, Elke/0000-0001-7906-4530				Aumailley M, 2000, J CELL SCI, V113, P259; Bell SE, 2001, J CELL SCI, V114, P2755; Bodolay E, 2002, J CELL MOL MED, V6, P357, DOI 10.1111/j.1582-4934.2002.tb00514.x; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; De Arcangelis A, 2001, INT J CANCER, V94, P44, DOI 10.1002/ijc.1444; Doi M, 2002, J BIOL CHEM, V277, P12741, DOI 10.1074/jbc.M111228200; Ekblom P, 2003, MATRIX BIOL, V22, P35, DOI 10.1016/S0945-053X(03)00015-5; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Kadesch T, 2000, EXP CELL RES, V260, P1, DOI 10.1006/excr.2000.4921; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; Krebs LT, 2000, GENE DEV, V14, P1343; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Li XF, 2001, J CELL BIOL, V153, P811, DOI 10.1083/jcb.153.4.811; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; Ljubimova JY, 2001, CANCER RES, V61, P5601; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; Meduri G, 2000, BIOL REPROD, V62, P439, DOI 10.1095/biolreprod62.2.439; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Ponce ML, 2003, CANCER RES, V63, P5060; Ponce ML, 2003, EXP CELL RES, V285, P189, DOI 10.1016/S0014-4827(03)00056-9; Ponce ML, 2001, FASEB J, V15, P1389, DOI 10.1096/fj.00-0736com; Rahmanian M, 1997, EXP CELL RES, V237, P223, DOI 10.1006/excr.1997.3792; Sasaki T, 2002, EXP CELL RES, V275, P185, DOI 10.1006/excr.2002.5499; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; SCHNAPER HW, 1993, KIDNEY INT, V43, P20, DOI 10.1038/ki.1993.5; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Sorokin LM, 1997, DEV DYNAM, V210, P446, DOI 10.1002/(SICI)1097-0177(199712)210:4<446::AID-AJA8>3.0.CO;2-G; Thyboll J, 2002, MOL CELL BIOL, V22, P1194, DOI 10.1128/MCB.22.4.1194-1202.2002; Uyttendaele H, 2000, MICROVASC RES, V60, P91, DOI 10.1006/mvre.2000.2254; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Yoshida Y, 2001, INT J ONCOL, V18, P913	41	47	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23766	23772		10.1074/jbc.M311675200	http://dx.doi.org/10.1074/jbc.M311675200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15044497	hybrid			2022-12-25	WOS:000221570900119
J	Mamedova, AA; Holt, PJ; Carroll, J; Sazanov, LA				Mamedova, AA; Holt, PJ; Carroll, J; Sazanov, LA			Substrate-induced conformational change in bacterial complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; ESCHERICHIA-COLI; MITOCHONDRIAL NADH; MEMBRANE DOMAIN; SUBUNITS; REDOX; MECHANISM; SUBCOMPLEXES; RESOLUTION; REDUCTASE	The mechanism coupling electron transfer and proton pumping in respiratory complex I (NADH-ubiquinone oxidoreductase) has not been established, but it has been suggested that it involves conformational changes. Here, the influence of substrates on the conformation of purified complex I from Escherichia coli was studied by cross-linking and electron microscopy. When a zero-length cross-linking reagent was used, the presence of NAD(P) H, in contrast to that of NAD(+), prevented the formation of cross-links between the hydrophilic subunits of the complex, including NuoB, NuoI, and NuoCD. Comparisons using different cross-linkers suggested that NuoB, which is likely to coordinate the key ironsulfur cluster N2, is the most mobile subunit. The presence of NAD( P) H led also to enhanced proteolysis of subunit NuoG. These data indicate that upon NAD( P) H binding, the peripheral arm of the complex adopts a more open conformation, with increased distances between subunits. Single particle analysis showed the nature of this conformational change. The enzyme retains its L-shape in the presence of NADH, but exhibits a significantly more open or expanded structure both in the peripheral arm and, unexpectedly, in the membrane domain also.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Sazanov, LA (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust Med Res Council Bldg, Cambridge CB2 2XY, England.	sazanov@mrc-dunn.cam.ac.uk	Sazanov, Leonid A/ABF-2125-2021	Sazanov, Leonid A/0000-0002-0977-7989				BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; Bottcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Di Bernardo S, 2001, FEBS LETT, V508, P385, DOI 10.1016/S0014-5793(01)03111-8; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Dutton PL, 1998, BBA-BIOENERGETICS, V1364, P245, DOI 10.1016/S0005-2728(98)00031-0; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; Flemming D, 2003, J BIOL CHEM, V278, P47602, DOI 10.1074/jbc.M308967200; Friedrich T, 2004, BBA-BIOENERGETICS, V1608, P1, DOI 10.1016/j.bbabio.2003.10.002; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; Galante Y M, 1978, Methods Enzymol, V53, P15; GONDAL JA, 1985, J BIOL CHEM, V260, P2690; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hano N, 2003, J BIOENERG BIOMEMBR, V35, P257, DOI 10.1023/A:1024663715931; HATEFI Y, 1976, BIOCHEM BIOPH RES CO, V69, P1032, DOI 10.1016/0006-291X(76)90476-9; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; Holt PJ, 2003, J BIOL CHEM, V278, P43114, DOI 10.1074/jbc.M308247200; KIKUNO R, 1985, FEBS LETT, V189, P85, DOI 10.1016/0014-5793(85)80847-4; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LEONARD K, 1987, J MOL BIOL, V194, P277, DOI 10.1016/0022-2836(87)90375-5; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; Peng GH, 2003, BIOCHEMISTRY-US, V42, P3032, DOI 10.1021/bi026876v; Sazanov LA, 2003, J BIOL CHEM, V278, P19483, DOI 10.1074/jbc.M208959200; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Sazanov LA, 2000, J MOL BIOL, V302, P455, DOI 10.1006/jmbi.2000.4079; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Videira A, 1998, BBA-BIOENERGETICS, V1364, P89, DOI 10.1016/S0005-2728(98)00020-6; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; Yamaguchi M, 1998, J BIOL CHEM, V273, P8094, DOI 10.1074/jbc.273.14.8094; Yamaguchi M, 2000, EUR J BIOCHEM, V267, P329, DOI 10.1046/j.1432-1327.2000.00999.x; Zharova TV, 1997, BBA-BIOENERGETICS, V1320, P256, DOI 10.1016/S0005-2728(97)00029-7	39	73	75	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23830	23836		10.1074/jbc.M401539200	http://dx.doi.org/10.1074/jbc.M401539200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15037611	hybrid			2022-12-25	WOS:000221570900127
J	Nakao, C; Itoh, TJ; Hotani, H; Mori, N				Nakao, C; Itoh, TJ; Hotani, H; Mori, N			Modulation of the stathmin-like microtubule destabilizing activity of RB3, a neuron-specific member of the SCG10 family, by its N-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ASSOCIATED PROTEINS; ADULT-RAT BRAIN; INDIVIDUAL MICROTUBULES; DYNAMIC INSTABILITY; TERNARY COMPLEX; TUBULIN; PHOSPHORYLATION; OP18/STATHMIN; LOCALIZATION; DISSOCIATION	RB3 is a neuron-specific homologue of the SCG10/stathmin family proteins, possessing a unique N-terminal membrane-associated domain and the stathmin-like domain at the C terminus, which promotes microtubule (MT) catastrophe and/or tubulin sequestering. We examined herein the contribution of the N-terminal subdomain of RB3 to the regulation of MT dynamics. To begin with, we determined the effects of full-length (RB3-f) and short truncated (RB3-s) forms of RB3 on the polymerization of MT in vitro. RB3-s had a deletion of amino acids 1-75 from the N terminus, leaving the so-called stathmin-like domain, consisting of residues 76-217. Although both RB3-f and RB3-s exhibited MT-depolymerizing activity, RB3-f was less effective. The binding affinity for tubulin was also lower in RB3-f. Direct observation of the dynamics of individual MTs using dark field microscopy revealed that RB3-s slowed MT elongation velocity, increased catastrophes, and reduced rescues. This effect is almost identical to that by stathmin/oncoprotein 18. On the other hand, the MT elongation rate increased at lower concentrations of RB3-f. In addition, RB3-f, indicated higher rescue frequency than control as well as the catastrophe in a dose-dependent manner. The functionality of RB3-f indicated that full-length RB3 has not only stathmin-like MT destabilizing activity but also MT-associated protein-like MT stabilizing activity. Possibly, the balance of these activities is altered in a concentration-dependent manner in vitro. This interesting regulatory role of the unique N-terminal domain of RB3 in MT dynamics would contribute to the physiological regulation of neuronal morphogenesis.	Natl Inst Longev Sci, Dept Mol Genet & Aging Intervent, Aichi 4748522, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University	Mori, N (corresponding author), Nagasaki Univ, Sch Med, Dept Anat & Neurobiol, Nagasaki 8528523, Japan.	morinosm@net.nagasaki-u.ac.jp						ALLEN C, 1974, J MOL BIOL, V90, P381, DOI 10.1016/0022-2836(74)90381-7; Amayed P, 2000, BIOCHEMISTRY-US, V39, P12295, DOI 10.1021/bi000279w; Amayed P, 2002, J BIOL CHEM, V277, P22718, DOI 10.1074/jbc.M111605200; BAAS PW, 1990, J CELL BIOL, V111, P495, DOI 10.1083/jcb.111.2.495; Beilharz EJ, 1998, J NEUROSCI, V18, P9780; Bieche I, 2003, GENOMICS, V81, P400, DOI 10.1016/S0888-7543(03)00031-4; Brannstrom K, 2003, J BIOL CHEM, V278, P16651, DOI 10.1074/jbc.M300131200; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DETRICH HW, 1978, BIOCHEMISTRY-US, V17, P3900, DOI 10.1021/bi00612a002; Di Paolo G, 1997, J NEUROSCI RES, V50, P1000, DOI 10.1002/(SICI)1097-4547(19971215)50:6<1000::AID-JNR10>3.0.CO;2-8; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Grenningloh G, 2004, J NEUROBIOL, V58, P60, DOI 10.1002/neu.10279; HIMI T, 1994, NEUROSCIENCE, V60, P907, DOI 10.1016/0306-4522(94)90271-2; Honnappa S, 2003, J BIOL CHEM, V278, P38926, DOI 10.1074/jbc.M305546200; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Ichihara K, 2001, J MOL BIOL, V312, P107, DOI 10.1006/jmbi.2001.4934; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; Itoh TJ, 1997, BIOCHEMISTRY-US, V36, P12574, DOI 10.1021/bi962606z; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Lutjens R, 2000, EUR J NEUROSCI, V12, P2224, DOI 10.1046/j.1460-9568.2000.00112.x; Maekawa S, 2001, J BIOCHEM-TOKYO, V129, P691, DOI 10.1093/oxfordjournals.jbchem.a002908; Makrides V, 2003, J BIOL CHEM, V278, P33298, DOI 10.1074/jbc.M305207200; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Mori N, 2002, J NEUROSCI RES, V70, P264, DOI 10.1002/jnr.10353; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; Ozon S, 1999, J NEUROSCI RES, V56, P553, DOI 10.1002/(SICI)1097-4547(19990601)56:5<553::AID-JNR11>3.0.CO;2-J; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; Segerman B, 2000, J BIOL CHEM, V275, P35759, DOI 10.1074/jbc.M005875200; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3	40	11	13	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23014	23021		10.1074/jbc.M313693200	http://dx.doi.org/10.1074/jbc.M313693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15039434	hybrid			2022-12-25	WOS:000221570900029
J	Nakayama, T; Mikoshiba, K; Yamamori, T; Akagawa, K				Nakayama, T; Mikoshiba, K; Yamamori, T; Akagawa, K			Activation of syntaxin 1C, an alternative splice variant of HPC-1/syntaxin 1A, by phorbol 12-myristate13-acetate (PMA) suppresses glucose transport into astroglioma cells via the glucose transporter-1 (GLUT-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN-TUMORS; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; DIFFERENTIAL EXPRESSION; T-SNARE; PROTEIN; FUSION; GENE; EXOCYTOSIS; ISOFORMS	Syntaxin 1C is an alternative splice variant lacking the transmembrane domain of HPC-1/syntaxin 1A. We found previously that syntaxin 1C is expressed as a soluble protein in human astroglioma (T98G) cells, and syntaxin 1C expression is enhanced by stimulation with phorbol 12-myristate 13-acetate (PMA). However, the physiological function of syntaxin 1C is not known. In this study, we examined the relationship between syntaxin 1C and glucose transport. First, we discovered that glucose transporter-1 (GLUT-1) was the primary isoform in T98G cells. Second, we demonstrated that glucose uptake in T98G cells was suppressed following an increase in endogenous syntaxin 1C after stimulation with PMA, which did not alter the expression levels of other plasma membrane syntaxins. We further examined glucose uptake and intracellular localization of GLUT-1 in cells that overexpressed exogenous syntaxin 1C; glucose uptake via GLUT-1 was inhibited without affecting sodium-dependent glucose transport. The value of V-max for the dose- dependent uptake of glucose was reduced in syntaxin 1C-expressing cells, whereas there was no change in K-m. Immunofluorescence studies revealed a reduction in the amount of GLUT-1 in the plasma membrane in cells that expressed syntaxin 1C. Based on these results, we postulate that syntaxin 1C regulates glucose transport in astroglioma cells by changing the intracellular trafficking of GLUT-1. This is the first report to indicate that a syntaxin isoform that lacks a transmembrane domain can regulate the intracellular transport of a plasma membrane protein.	Kyorin Univ, Sch Med, Dept Physiol, Tokyo 1818611, Japan; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Dev Brain Sci Grp, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Tokyo 1088639, Japan; Natl Inst Basic Biol, Div Speciat Mech, Okazaki 4448585, Japan	Kyorin University; RIKEN; University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Nakayama, T (corresponding author), Kyorin Univ, Sch Med, Dept Physiol, 6-20-2 Shinkawa, Tokyo 1818611, Japan.	nakayama@kyorin-u.ac.jp	Mikoshiba, Katsuhiko/N-7943-2015; Yamamori, Tetsuo/N-6536-2015	Yamamori, Tetsuo/0000-0001-5016-0078; Nakayama, Takahiro/0000-0003-3064-3536				Band AM, 2002, FEBS LETT, V531, P513, DOI 10.1016/S0014-5793(02)03605-0; BELLUGI U, 1990, AM J MED GENET, P115; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOADO RJ, 1994, MOL BRAIN RES, V27, P51, DOI 10.1016/0169-328X(94)90183-X; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Craft S, 1996, NEUROBIOL AGING, V17, P123, DOI 10.1016/0197-4580(95)02002-0; CRAFT S, 1993, BEHAV NEUROSCI, V107, P926; Fladeby C, 1996, J CELL PHYSIOL, V169, P242, DOI 10.1002/(SICI)1097-4652(199611)169:2<242::AID-JCP3>3.0.CO;2-O; Foster LJ, 2000, AM J PHYSIOL-CELL PH, V279, pC877, DOI 10.1152/ajpcell.2000.279.4.C877; Fujishiro M, 2001, J BIOL CHEM, V276, P19800, DOI 10.1074/jbc.M101087200; Fujiwara T, 1997, BIOCHEM BIOPH RES CO, V231, P352, DOI 10.1006/bbrc.1997.6092; Gispen WH, 2000, TRENDS NEUROSCI, V23, P542, DOI 10.1016/S0166-2236(00)01656-8; IBARAKI K, 1995, BIOCHEM BIOPH RES CO, V211, P997, DOI 10.1006/bbrc.1995.1910; INOUE A, 1992, J BIOL CHEM, V267, P10613; Itoh TJ, 1999, CELL STRUCT FUNCT, V24, P359; Jagadish MN, 1997, BIOCHEM J, V321, P151, DOI 10.1042/bj3210151; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; McMahon RJ, 2000, BIOCHEM BIOPH RES CO, V273, P859, DOI 10.1006/bbrc.2000.2985; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUONA P, 1992, DIABETES, V41, P1587, DOI 10.2337/diabetes.41.12.1587; NAGAMATSU S, 1993, J NEUROCHEM, V61, P2048, DOI 10.1111/j.1471-4159.1993.tb07441.x; Nagamatsu S, 1996, BIOCHEM J, V319, P477, DOI 10.1042/bj3190477; Nakayama T, 1998, CYTOGENET CELL GENET, V82, P49, DOI 10.1159/000015063; Nakayama T, 2003, FEBS LETT, V536, P209, DOI 10.1016/S0014-5793(03)00015-2; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Perez-Branguli F, 2002, MOL CELL NEUROSCI, V20, P169, DOI 10.1006/mcne.2002.1122; Quinones B, 1999, J CELL SCI, V112, P4291; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe J, 1999, J CELL SCI, V112, P1865; Schreiber J, 1997, J BIOL CHEM, V272, P32286, DOI 10.1074/jbc.272.51.32286; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; Singh SP, 1998, PHARMACOL TOXICOL, V83, P83, DOI 10.1111/j.1600-0773.1998.tb01448.x; Smit MJ, 1998, P NATL ACAD SCI USA, V95, P15084, DOI 10.1073/pnas.95.25.15084; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Thurmond DC, 2000, MOL CELL BIOL, V20, P379, DOI 10.1128/MCB.20.1.379-388.2000; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Tsuru M, 2002, AM J PHYSIOL-ENDOC M, V283, pE338, DOI 10.1152/ajpendo.00457.2001; Vannucci SJ, 1997, GLIA, V21, P2, DOI 10.1002/(SICI)1098-1136(199709)21:1<2::AID-GLIA2>3.0.CO;2-C; Walmsley AR, 1998, TRENDS BIOCHEM SCI, V23, P476, DOI 10.1016/S0968-0004(98)01326-7	40	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23728	23739		10.1074/jbc.M314297200	http://dx.doi.org/10.1074/jbc.M314297200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15037634	hybrid			2022-12-25	WOS:000221570900115
J	Stegert, MR; Tamaskovic, R; Bichsel, SJ; Hergovich, A; Hemmings, BA				Stegert, MR; Tamaskovic, R; Bichsel, SJ; Hergovich, A; Hemmings, BA			Regulation of NDR2 protein kinase by multi-site phosphorylation and the S100B calcium-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY KINASE; CELL MORPHOGENESIS; GENE-EXPRESSION; DROSOPHILA; CBK1P; EXTENSIONS; ACTIVATION; MECHANISM; INTEGRITY; COMPLEX	Nuclear Dbf2-related (NDR) protein kinases are a family of AGC group kinases that are involved in the regulation of cell division and cell morphology. We describe the cloning and characterization of the human and mouse NDR2, a second mammalian isoform of NDR protein kinase. NDR1 and NDR2 share 86% amino acid identity and are highly conserved between human and mouse. However, they differ in expression pattern; mouse Ndr1 is expressed mainly in spleen, lung and thymus, whereas mouse Ndr2 shows highest expression in the gastrointestinal tract. NDR2 is potently activated in cells following treatment with the protein phosphatase 2A inhibitor okadaic acid, which also results in phosphorylation on the activation segment residue Ser-282 and the hydrophobic motif residue Thr-442. We show that Ser-282 becomes autophosphorylated in vivo, whereas Thr-442 is targeted by an upstream kinase. This phosphorylation can be mimicked by replacing the hydrophobic motif of NDR2 with a PRK2-derived sequence, resulting in a constitutively active kinase. Similar to NDR1, the autophosphorylation of NDR2 protein kinase was stimulated in vitro by S100B, an EF-hand Ca2+-binding protein of the S100 family, suggesting that the two isoforms are regulated by the same mechanisms. Further we show a predominant cytoplasmic localization of ectopically expressed NDR2.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	brian.hemmings@fmi.ch		Hergovich, Alexander/0000-0001-7018-5635				Adeyinka A, 2002, CLIN CANCER RES, V8, P3788; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bhattacharya S, 2003, BIOCHEMISTRY-US, V42, P14416, DOI 10.1021/bi035089a; Bidlingmaier S, 2001, MOL CELL BIOL, V21, P2449, DOI 10.1128/MCB.21.7.2449-2462.2001; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; Cong JL, 2001, DEVELOPMENT, V128, P2793; Du LL, 2002, MOL BIOL CELL, V13, P503, DOI 10.1091/mbc.01-07-0365; Geng W, 2000, GENETICS, V156, P1817; Hirata D, 2002, EMBO J, V21, P4863, DOI 10.1093/emboj/cdf495; Lang F, 2001, Sci STKE, V2001, pre17, DOI 10.1126/stke.2001.108.re17; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leslie NR, 2001, CHEM REV, V101, P2365, DOI 10.1021/cr000091i; Mah AS, 2001, P NATL ACAD SCI USA, V98, P7325, DOI 10.1073/pnas.141098998; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Racki WJ, 2000, EMBO J, V19, P4524, DOI 10.1093/emboj/19.17.4524; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; SAMBROOK J, 1989, MOL CLONING LABORATO, P810; Tamaskovic R, 2003, J BIOL CHEM, V278, P6710, DOI 10.1074/jbc.M210590200; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Tripodis N, 2000, GENOME RES, V10, P454, DOI 10.1101/gr.10.4.454; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915; Zallen JA, 2000, MOL BIOL CELL, V11, P3177, DOI 10.1091/mbc.11.9.3177	29	59	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23806	23812		10.1074/jbc.M402472200	http://dx.doi.org/10.1074/jbc.M402472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15037617	hybrid			2022-12-25	WOS:000221570900124
J	Han, J; Goldstein, LA; Gastman, BR; Froelich, CJ; Yin, XM; Rabinowich, H				Han, J; Goldstein, LA; Gastman, BR; Froelich, CJ; Yin, XM; Rabinowich, H			Degradation of Mcl-1 by granzyme B - Implications for Bim-mediated mitochondrial apoptotic events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; CYTOCHROME-C RELEASE; BAX-DEPENDENT APOPTOSIS; CELL-DEATH; CASPASE ACTIVATION; HEMATOPOIETIC MALIGNANCIES; FRAMESHIFT MUTATIONS; BH3-ONLY PROTEINS; BH3 DOMAIN; SURVIVAL	Recent studies have suggested that in the absence of Bid, granzyme B (GrB) can utilize an unknown alternative pathway to mediate mitochondrial apoptotic events. The current study has elucidated just such a pathway for GrB-mediated mitochondrial apoptotic alterations. Two Bcl-2 family members have been identified as interactive players in this newly discovered mitochondrial response to GrB: the pro-survival protein Mcl-1L and the pro-apoptotic protein, Bim. Expression of Mcl-1L, which localizes mainly to the outer mitochondrial membrane, decreases significantly in cells subjected to CTL-free cytotoxicity mediated by a combination of GrB and replication-deficient adenovirus. The data suggest that Mcl-1L is a substrate for GrB and for caspase-3, but the two enzymes appear to target different cleavage sites. The cleavage pattern of endogenous Mcl-1L resembles that of in vitro translated Mcl-1L subjected to similar proteolytic activity. Co-immunoprecipitation experiments performed with endogenous as well as with in vitro translated proteins suggest that Mcl-1L is a high affinity binding partner of the three isoforms of Bim (extra-long, long, and short). Bim, a BH3-only protein, is capable of mediating the release of mitochondrial cytochrome c, and this activity is inhibited by the presence of exogenous Mcl-1L. The findings presented herein imply that Mcl-1L degradation by either GrB or caspase-3 interferes with Bim sequestration by Mcl-1L.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Plast Surg, Pittsburgh, PA 15213 USA; Evanston NW Res Inst, Evanston, IL 60201 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rabinowich, H (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Res Pavil,Rm G17C,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	rabinow@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA084134] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-84134] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Bouillet P, 2002, J CELL SCI, V115, P1567; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; Froelich CJ, 2004, CELL DEATH DIFFER, V11, P369, DOI 10.1038/sj.cdd.4401381; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; Goping IS, 2003, IMMUNITY, V18, P355, DOI 10.1016/S1074-7613(03)00032-3; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Johnson DE, 2000, CANCER RES, V60, P1818; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Lomo J, 1996, CANCER RES, V56, P40; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Metkar SS, 2003, J CELL BIOL, V160, P875, DOI 10.1083/jcb.200210158; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Moulding DA, 2001, J LEUKOCYTE BIOL, V70, P783; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rinkenberger JL, 2000, GENE DEV, V14, P23; Roberts DL, 2003, BIOCHEM BIOPH RES CO, V304, P513, DOI 10.1016/S0006-291X(03)00624-7; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Thallinger C, 2003, J INVEST DERMATOL, V120, P1081, DOI 10.1046/j.1523-1747.2003.12252.x; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Thomas DA, 2001, P NATL ACAD SCI USA, V98, P14985, DOI 10.1073/pnas.261581498; Vrana JA, 2002, CANCER RES, V62, P892; Wang GQ, 2001, J EXP MED, V194, P1325, DOI 10.1084/jem.194.9.1325; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wieckowski E, 2002, CANCER RES, V62, P4884; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhang D, 2001, P NATL ACAD SCI USA, V98, P5746, DOI 10.1073/pnas.101329598; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	53	90	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22020	22029		10.1074/jbc.M313234200	http://dx.doi.org/10.1074/jbc.M313234200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15014070	hybrid			2022-12-25	WOS:000221417100043
J	Korres, H; Verma, NK				Korres, H; Verma, NK			Topological analysis of glucosyltransferase GtrV of Shigella flexneri by a dual reporter system and identification of a unique reentrant loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-ANTIGEN MODIFICATION; ESCHERICHIA-COLI K-12; MEMBRANE TOPOLOGY; ALKALINE-PHOSPHATASE; MOLECULAR CHARACTERIZATION; PROTEIN LOCALIZATION; STRUCTURE PREDICTION; GENE FUSIONS; INSERTION; GLYCOSYLTRANSFERASES	Lipopolysaccharide, particularly the O-antigen component, is one of many virulence determinants necessary for Shigella flexneri pathogenesis. O-Antigen modification is mediated by glucosyltransferase genes (gtr) encoded by temperate serotype-converting bacteriophages. The gtrV gene encodes the GtrV glucosyltransferase, an integral membrane protein that catalyzes the transfer of a glucosyl residue via an alpha1,3 linkage to rhamnose II of the O-antigen unit. This mediates conversion of S. flexneri serotype Y to serotype 5a. Analysis of the GtrV amino acid sequence using computer prediction programs indicated that GtrV had 9-11 transmembrane segments. The computer prediction models were tested by genetically fusing C-terminal deletions of GtrV to a dual reporter system composed of alkaline phosphatase and beta-galactosidase. Sandwiched GtrV-PhoA/LacZ fusions were also constructed at predetermined positions. The enzyme activities of cells with the GtrV-PhoA/LacZ fusions and the particular location of the fusions in the gtrV indicated that GtrV has nine transmembrane segments and one large N-terminal periplasmic loop with the N and C termini located on the cytoplasmic and periplasmic sides of the membrane, respectively. The existence of a unique reentrant loop was discovered after transmembrane segment IV, a feature not documented in other bacterial glycosyltransferases. Its potential role in mediating serotype conversion in S. flexneri is discussed.	Australian Natl Univ, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia	Australian National University	Verma, NK (corresponding author), Australian Natl Univ, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia.	Naresh.Verma@anu.edu.au	Verma, Naresh/C-9161-2009	Verma, Naresh/0000-0001-8109-2215				Adhikari P, 1999, J BACTERIOL, V181, P4711, DOI 10.1128/JB.181.15.4711-4718.1999; Alexeyev MF, 1999, J MOL BIOL, V285, P1503, DOI 10.1006/jmbi.1998.2412; Alexeyev MF, 2002, BIOCHEMISTRY-US, V41, P406, DOI 10.1021/bi011813i; Allison GE, 2000, TRENDS MICROBIOL, V8, P17, DOI 10.1016/S0966-842X(99)01646-7; [Anonymous], 1997, WORLD HEALTH FORUM, V18, P1; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; Baulard AR, 2003, J BIOL CHEM, V278, P2242, DOI 10.1074/jbc.M207922200; BIBI E, 1994, J BIOL CHEM, V269, P19910; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; BOYD D, 1994, MEMBRANE PROTEIN STR, P144; BRAHMBHATT HN, 1992, PATHOGENESIS SHIGELL, P45; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Caldwell AM, 2003, J BACTERIOL, V185, P374, DOI 10.1128/JB.185.1.374-376.2003; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Daniels C, 1998, MOL MICROBIOL, V28, P1211, DOI 10.1046/j.1365-2958.1998.00884.x; DeFelice LJ, 1996, BIOPHYS J, V70, P579, DOI 10.1016/S0006-3495(96)79604-2; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; Gerard P, 2002, J BACTERIOL, V184, P1925, DOI 10.1128/JB.184.7.1925-1931.2002; Ginn SL, 1997, J BACTERIOL, V179, P3786, DOI 10.1128/jb.179.11.3786-3789.1997; Girrbach V, 2000, J BIOL CHEM, V275, P19288, DOI 10.1074/jbc.M001771200; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; Guan S, 1999, MICROBIOL-UK, V145, P1263, DOI 10.1099/13500872-145-5-1263; Ha S., 2001, Current Drug Targets - Infectious Disorders, V1, P201, DOI 10.2174/1568005014606116; Haardt M, 1996, J BACTERIOL, V178, P5370, DOI 10.1128/jb.178.18.5370-5381.1996; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; Huan PT, 1997, GENE, V195, P217, DOI 10.1016/S0378-1119(97)00143-1; Jerpseth B., 1992, STRATEGIES MOL BIOL, V5, P81; KENNE L, 1978, EUR J BIOCHEM, V91, P279, DOI 10.1111/j.1432-1033.1978.tb20963.x; Kotloff KL, 1999, B WORLD HEALTH ORGAN, V77, P651; LACATENA RM, 1994, P NATL ACAD SCI USA, V91, P10521, DOI 10.1073/pnas.91.22.10521; LESTER HA, 1994, ANNU REV PHARMACOL, V34, P219; LINDBERG AA, 1988, VACCINE, V6, P146, DOI 10.1016/S0264-410X(88)80018-5; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MAKELA PH, 1984, CHEM ENDOTOXIN, V1, P419; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; Mavris M, 1997, MOL MICROBIOL, V26, P939, DOI 10.1046/j.1365-2958.1997.6301997.x; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; Miller JH., 1992, SHORT COURSE BACTERI, P72; Morera S, 1999, J MOL BIOL, V292, P717, DOI 10.1006/jmbi.1999.3094; Mulichak AM, 2001, STRUCTURE, V9, P547, DOI 10.1016/S0969-2126(01)00616-5; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; Nilsson J, 2000, FEBS LETT, V486, P267, DOI 10.1016/S0014-5793(00)02321-8; OKADA N, 1991, MOL MICROBIOL, V5, P187, DOI 10.1111/j.1365-2958.1991.tb01839.x; Oriol R, 2002, MOL BIOL EVOL, V19, P1451, DOI 10.1093/oxfordjournals.molbev.a004208; ROST B, 1995, PROTEIN SCI, V4, P521; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sambrook J, 2001, MOL CLONING LAB MANU; Sandlin RC, 1996, MOL MICROBIOL, V22, P63, DOI 10.1111/j.1365-2958.1996.tb02656.x; Sansonetti PJ, 2001, FEMS MICROBIOL REV, V25, P3, DOI 10.1111/j.1574-6976.2001.tb00569.x; Sansonetti PJ, 1998, JPN J MED SCI BIOL, V51, pS69, DOI 10.7883/yoken1952.51.Supplement1_S69; SARSERO JP, 1995, J BACTERIOL, V177, P297, DOI 10.1128/jb.177.2.297-306.1995; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Strahl-Bolsinger S, 1999, J BIOL CHEM, V274, P9068, DOI 10.1074/jbc.274.13.9068; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; van Geest M, 2000, MICROBIOL MOL BIOL R, V64, P13, DOI 10.1128/MMBR.64.1.13-33.2000; VERMA NK, 1993, GENE, V129, P99, DOI 10.1016/0378-1119(93)90702-5; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wong KKY, 2000, J BACTERIOL, V182, P2402, DOI 10.1128/JB.182.9.2402-2410.2000; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	73	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22469	22476		10.1074/jbc.M401316200	http://dx.doi.org/10.1074/jbc.M401316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15028730	hybrid			2022-12-25	WOS:000221417100096
J	Kuipers, A; de Boef, E; Rink, R; Fekken, S; Kluskens, LD; Driessen, AJM; Leenhouts, K; Kuipers, OP; Moll, GN				Kuipers, A; de Boef, E; Rink, R; Fekken, S; Kluskens, LD; Driessen, AJM; Leenhouts, K; Kuipers, OP; Moll, GN			NisT, the transporter of the lantibiotic nisin, can transport fully modified, dehydrated, and unmodified prenisin and fusions of the leader peptide with non-lantibiotic peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; LACTOCOCCUS-LACTIS; PORE-FORMATION; GENE-CLUSTER; POSTTRANSLATIONAL MODIFICATIONS; BIOLOGICAL-ACTIVITIES; NUCLEOTIDE-SEQUENCE; SYNTHETASE COMPLEX; BACILLUS-SUBTILIS; MUTACIN-II	Lantibiotics are lanthionine-containing peptide antibiotics. Nisin, encoded by nisA, is a pentacyclic lantibiotic produced by some Lactococcus lactis strains. Its thioether rings are posttranslationally introduced by a membrane-bound enzyme complex. This complex is composed of three enzymes: NisB, which dehydrates serines and threonines; NisC, which couples these dehydrated residues to cysteines, thus forming thioether rings; and the transporter NisT. We followed the activity of various combinations of the nisin enzymes by measuring export of secreted peptides using antibodies against the leader peptide and mass spectroscopy for detection. L. lactis expressing the nisABTC genes efficiently produced fully posttranslationally modified prenisin. Strikingly, L. lactis expressing the nisBT genes could produce dehydrated prenisin without thioether rings and a dehydrated form of a non-lantibiotic peptide. In the absence of the biosynthetic NisBC enzymes, the NisT transporter was capable of excreting unmodified prenisin and fusions of the leader peptide with non-lantibiotic peptides. Our data show that NisT specifies a broad spectrum (poly) peptide transporter that can function either in conjunction with or independently from the biosynthetic genes. NisT secretes both unmodified and partially or fully posttranslationally modified forms of prenisin and non-lantibiotic peptides. These results open the way for efficient production of a wide range of peptides with increased stability or novel bioactivities.	BiOMade Technol Fdn, NL-9747 AG Groningen, Netherlands; Univ Groningen, Biomol Sci & Biotechnol Inst, Dept Microbiol, NL-9751 NN Haren, Netherlands; Univ Groningen, Biomol Sci & Biotechnol Inst, Dept Mol Genet, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	Moll, GN (corresponding author), BiOMade Technol Fdn, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	Moll@biomade.nl	Driessen, Arnold J.M./D-1876-2012; Kluskens, Leon/J-3019-2013; Kuipers, Oscar/B-6752-2009	Kluskens, Leon/0000-0002-0070-7837; Kuipers, Oscar/0000-0001-5596-7735; Driessen, Arnold J.M./0000-0001-9258-9104				BIERBAUM G, 1985, ARCH MICROBIOL, V141, P249, DOI 10.1007/BF00408067; Bierbaum G, 1996, APPL ENVIRON MICROB, V62, P385, DOI 10.1128/AEM.62.2.385-392.1996; BIERBAUM G, 1999, AMINO ACIDS PEPTIDES, V4, P275; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; BUIST G, 1995, J BACTERIOL, V177, P1554, DOI 10.1128/jb.177.6.1554-1563.1995; Burrage S, 2000, CHEM-EUR J, V6, P1455, DOI 10.1002/(SICI)1521-3765(20000417)6:8<1455::AID-CHEM1455>3.3.CO;2-D; CHAKICHERLA A, 1995, J BIOL CHEM, V270, P23533, DOI 10.1074/jbc.270.40.23533; Chen P, 2001, FEMS MICROBIOL LETT, V195, P139, DOI 10.1111/j.1574-6968.2001.tb10511.x; DelvesBroughton J, 1996, ANTON LEEUW INT J G, V69, P193, DOI 10.1007/BF00399424; DRIESSEN AJM, 1995, BIOCHEMISTRY-US, V34, P1606, DOI 10.1021/bi00005a017; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; Holo H, 1995, Methods Mol Biol, V47, P195; Izaguirre G, 1997, APPL ENVIRON MICROB, V63, P3965, DOI 10.1128/AEM.63.10.3965-3971.1997; JENSEN PR, 1993, APPL ENVIRON MICROB, V59, P4363, DOI 10.1128/AEM.59.12.4363-4366.1993; KIDO Y, 1983, J ANTIBIOT, V36, P1295, DOI 10.7164/antibiotics.36.1295; Kiesau P, 1997, J BACTERIOL, V179, P1475, DOI 10.1128/jb.179.5.1475-1481.1997; Koponen O, 2002, MICROBIOL-SGM, V148, P3561, DOI 10.1099/00221287-148-11-3561; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; KUIPERS OP, 1993, FEBS LETT, V330, P23, DOI 10.1016/0014-5793(93)80911-D; Kuipers OP, 1997, TRENDS BIOTECHNOL, V15, P135, DOI 10.1016/S0167-7799(97)01029-9; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; KUIPERS OP, 1995, J BIOL CHEM, V270, P27299, DOI 10.1074/jbc.270.45.27299; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Li Peng, 2002, Current Topics in Medicinal Chemistry, V2, P325, DOI 10.2174/1568026023394209; Lombardi A, 1998, BIOORG MED CHEM LETT, V8, P1153, DOI 10.1016/S0960-894X(98)00178-4; MARKI F, 1991, BIOCHEM PHARMACOL, V42, P2027, DOI 10.1016/0006-2952(91)90604-4; MEYER C, 1995, EUR J BIOCHEM, V232, P478, DOI 10.1111/j.1432-1033.1995.tb20834.x; Moll GN, 1996, ANTON LEEUW INT J G, V69, P185, DOI 10.1007/BF00399423; Moll GN, 1998, J BACTERIOL, V180, P6565, DOI 10.1128/JB.180.24.6565-6570.1998; Moll GN, 1997, J BACTERIOL, V179, P135, DOI 10.1128/jb.179.1.135-140.1997; Murkin AS, 2002, J ORG CHEM, V67, P8389, DOI 10.1021/jo0204653; Neis S, 1997, FEMS MICROBIOL LETT, V149, P249, DOI 10.1016/S0378-1097(97)00084-0; NISSENMEYER J, 1992, J BACTERIOL, V174, P5686, DOI 10.1128/JB.174.17.5686-5692.1992; Novak J, 1996, ANAL BIOCHEM, V236, P358, DOI 10.1006/abio.1996.0181; Okeley NM, 2000, ORG LETT, V2, P3603, DOI 10.1021/ol006485d; Osapay G, 1997, J MED CHEM, V40, P2241, DOI 10.1021/jm960850i; Paul LK, 1999, FEMS MICROBIOL LETT, V176, P45, DOI 10.1016/S0378-1097(99)00217-7; Poquet I, 2000, MOL MICROBIOL, V35, P1042, DOI 10.1046/j.1365-2958.2000.01757.x; Ra R, 1999, MICROBIOL-SGM, V145, P1227, DOI 10.1099/13500872-145-5-1227; Rew Y, 2002, J MED CHEM, V45, P3746, DOI 10.1021/jm020108k; SAHL HG, 1995, EUR J BIOCHEM, V230, P827, DOI 10.1111/j.1432-1033.1995.tb20627.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SCHUSTER B, 1995, P NATL ACAD SCI USA, V92, P8433, DOI 10.1073/pnas.92.18.8433; Sen AK, 1999, EUR J BIOCHEM, V261, P524, DOI 10.1046/j.1432-1327.1999.00303.x; Siddiqui MI, 2001, INDIAN J BIOCHEM BIO, V38, P90; Siegers K, 1996, J BIOL CHEM, V271, P12294, DOI 10.1074/jbc.271.21.12294; Stein T, 2002, RAPID COMMUN MASS SP, V16, P103, DOI 10.1002/rcm.552; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; TOMKINSON B, 1994, ARCH BIOCHEM BIOPHYS, V314, P276, DOI 10.1006/abbi.1994.1442; van Kraaij C, 1999, NAT PROD REP, V16, P575, DOI 10.1039/a804531c; van Kraaij C, 2000, EUR J BIOCHEM, V267, P901, DOI 10.1046/j.1432-1327.2000.01075.x; VANDERMEER JR, 1994, J BIOL CHEM, V269, P3555; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; Vollbrecht L, 2002, J ANTIBIOT, V55, P715, DOI 10.7164/antibiotics.55.715; Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200; Xie LL, 2004, SCIENCE, V303, P679, DOI 10.1126/science.1092600	57	140	148	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22176	22182		10.1074/jbc.M312789200	http://dx.doi.org/10.1074/jbc.M312789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15044440	Green Published, hybrid			2022-12-25	WOS:000221417100062
J	Olsen, DA; Petersen, SV; Oury, TD; Valnickova, Z; Thogersen, IB; Kristensen, T; Bowler, RP; Crapo, JD; Enghild, JJ				Olsen, DA; Petersen, SV; Oury, TD; Valnickova, Z; Thogersen, IB; Kristensen, T; Bowler, RP; Crapo, JD; Enghild, JJ			The intracellular proteolytic processing of extracellular superoxide dismutase (EC-SOD) is a two-step event	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; MUTATION; SERUM; GENE; PURIFICATION; POPULATION; SEQUENCE; AFFINITY; TETRAMER; VARIANTS	Extracellular superoxide dismutase (EC-SOD) is a tetramer composed of either intact (Trp(1)-Ala(222)) or proteolytically cleaved (Trp(1)-Glu(209)) subunits. The latter form is processed intracellularly before secretion and lacks the C-terminal extracellular matrix (ECM)-binding region ((210)RKKRRRESECKAA(222)-COOH). We have previously suggested that the C-terminal processing of EC-SOD is either a one-step mechanism accomplished by a single intracellular endoproteolytic event cleaving the Glu(209)-Arg(210) peptide bond or a two-step mechanism involving two proteinases (Enghild, J.J., Thogersen, I. B., Oury, T. D., Valnickova, Z., Hojrup, P., and Crapo, J.D. (1999) J. Biol. Chem. 274, 14818-14822). In the latter case, an initial endoproteinase cleavage occurs somewhere in the region between Glu(209) and Glu(216). A carboxypeptidase specific for basic amino acid residues subsequently trims the remaining basic amino acid residues to Glu(209). A naturally occurring mutation of EC-SOD substituting Arg(213) for Gly enabled us to test these hypotheses. The mutation does not prevent proteolysis of the ECM-binding region but prevents a carboxypeptidase B-like enzyme from trimming residues beyond Gly(213). The R213G mutation is located in the ECM-binding region, and individuals carrying this mutation have an increased concentration of EC-SOD in the circulatory system. In this study, we purified the R213G EC-SOD variant from heterozygous or homozygous individuals and determined the C-terminal residue of the processed subunit to be Gly(213). This finding supports the two-step processing mechanism and indicates that the R213G mutation does not disturb the initial endoproteinase cleavage event but perturbs the subsequent trimming of the C terminus.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15261 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA	Aarhus University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Jewish Health	Enghild, JJ (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	jje@mb.au.dk	Bowler, Russell P/J-8283-2015	Bowler, Russell P/0000-0003-4651-363X; Vang Petersen, Steen/0000-0002-9338-911X; Enghild, Jan Johannes/0000-0001-9292-9172	NHLBI NIH HHS [R01 HL63700, P01 HL31992E] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063700, P01HL031992] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi T, 1996, BIOCHEM J, V313, P235, DOI 10.1042/bj3130235; ADACHI T, 1992, CLIN CHIM ACTA, V212, P89, DOI 10.1016/0009-8981(92)90176-Q; ADACHI T, 1989, J BIOL CHEM, V264, P8537; Adachi T, 1996, J BIOCHEM, V120, P184; Bowler RP, 2002, J BIOL CHEM, V277, P16505, DOI 10.1074/jbc.M105409200; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; Carlsson LM, 1996, P NATL ACAD SCI USA, V93, P5219, DOI 10.1073/pnas.93.11.5219; Crapo J D, 1978, Methods Enzymol, V53, P382; Enghild JJ, 1999, J BIOL CHEM, V274, P14818, DOI 10.1074/jbc.274.21.14818; Fattman CL, 2003, FREE RADICAL BIO MED, V35, P236, DOI 10.1016/S0891-5849(03)00275-2; FOLZ RJ, 1994, HUM MOL GENET, V3, P2251, DOI 10.1093/hmg/3.12.2251; Hames BD, 1986, GEL ELECTROPHORESIS, P1; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; Juul K, 2004, CIRCULATION, V109, P59, DOI 10.1161/01.CIR.0000105720.28086.6C; KARLSSON K, 1988, BIOCHEM J, V256, P29, DOI 10.1042/bj2560029; Marklund SL, 1997, J INTERN MED, V242, P5, DOI 10.1046/j.1365-2796.1997.00160.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OHTA H, 1993, FREE RADICAL BIO MED, V15, P151, DOI 10.1016/0891-5849(93)90054-X; Ookawara T, 2002, BIOCHEM BIOPH RES CO, V296, P54, DOI 10.1016/S0006-291X(02)00804-5; Oury TD, 1996, BIOCHEM J, V317, P51, DOI 10.1042/bj3170051; Petersen SV, 2004, J BIOL CHEM, V279, P13705, DOI 10.1074/jbc.M310217200; Petersen SV, 2003, P NATL ACAD SCI USA, V100, P13875, DOI 10.1073/pnas.2436143100; Petersen SV, 2003, BIOCHEM J, V374, P199, DOI 10.1042/BJ20030313; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; SANDSTROM J, 1994, J BIOL CHEM, V269, P19163; Stenlund P, 1997, PROTEIN SCI, V6, P2350; STROMQVIST M, 1991, J CHROMATOGR, V548, P293, DOI 10.1016/S0021-9673(01)88611-8; Wang XL, 1998, ARTERIOSCL THROM VAS, V18, P1915, DOI 10.1161/01.ATV.18.12.1915; Yamada H, 2000, NEPHRON, V84, P218, DOI 10.1159/000045580; YAMADA H, 1995, JPN J HUM GENET, V40, P177, DOI 10.1007/BF01883574; Yamada H, 1997, JPN J HUM GENET, V42, P353, DOI 10.1007/BF02766958	32	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22152	22157		10.1074/jbc.M401180200	http://dx.doi.org/10.1074/jbc.M401180200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15044467	hybrid			2022-12-25	WOS:000221417100059
J	Yang, CM; Chien, CS; Yao, CC; Hsiao, LD; Huang, YC; Wu, CB				Yang, CM; Chien, CS; Yao, CC; Hsiao, LD; Huang, YC; Wu, CB			Mechanical strain induces collagenase-3 (MMP-13) expression in MC3T3-E1 osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; GENE-EXPRESSION; SKELETAL DEVELOPMENT; SIGNAL-TRANSDUCTION; TISSUE INHIBITORS; PROTEIN-KINASE; BONE SURFACES; IN-VITRO; C-FOS	Mechanical strain plays a crucial role in bone remodeling during growth and development and healing of bone besides systemic and local factors. One of the major factors involves in remodeling process is matrix metalloproteinases (MMPs) such as MMP-13 that has been shown to degrade the native interstitial collagens in several tissues. To study how mechanical strain affects extracellular matrix degradation by MMP-13, a biaxial strain was applied to MC3T3-E1 osteoblastic cells plated onto a collagen-coated flexible elastic membrane. The MMP-13 protein and mRNA expression were determined by Western blotting and reverse transcriptase-PCR, respectively. The zymographic activities of MMP-13 increased dramatically at 30 min, reached a peak by 2-fold at 1 h, and maintained up to 4 h. Moreover, the MMP-13 and c-fos mRNA expressed at 5 min, increased to 2.8- and 3-fold at 1 h, respectively, and gradually declined thereafter. Cycloheximide and actinomycin D did not inhibit the MMP-13 and c-fos mRNA expression, suggesting that such expression does not require de novo protein synthesis and not change their stabilities. To investigate which of the mitogen-activated protein kinase (MAPK) pathways involves in the expression of MMP-13, inhibitors such as PD98059, SB203580, and SP600125 were used. However, only PD98059 (an inhibitor of MEK1/2 activation) inhibited MMP-13 and c-fos gene expression; the result was further substantiated by transfecting with the dominant negative mutants of MEK1/2 (MEK K97R) and ERK2. Taken together, our results showed that mechanical strain induces the MMP-13 expression through MEK-ERK signaling pathway to regulate mechanical adaptation.	Chang Gung Univ, Coll Med, Dept Pharmacol, Tao Yuan 333, Taiwan; Chang Gung Mem Hosp, Dept Dent, Div Orthodont, Kwei San 333, Taiwan; Natl Taiwan Univ, Coll Med, Sch Dent, Div Orthodont, Taipei 100, Taiwan	Chang Gung University; Chang Gung Memorial Hospital; National Taiwan University	Wu, CB (corresponding author), Chang Gung Mem Hosp, Dept Dent, Div Orthodont, 5 Fu Shing St, Kwei San 3332, Taiwan.	cbw@adm.cgmh.org.tw	Yao, Chung-Chen/D-1470-2018	YAO, JANE CHUNG-CHEN/0000-0002-2293-7000; Yang, Chuen-Mao/0000-0002-3208-5438				AKTIPIS S, 1981, BIOCHIM BIOPHYS ACTA, V655, P278, DOI 10.1016/0005-2787(81)90038-1; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURR DB, 1993, CALCIF TISSUE INT S1, V53, P75; CHAMBERS TJ, 1985, CELL TISSUE RES, V241, P671; CHAMBERS TJ, 1985, J CELL SCI, V76, P155; Chen NX, 2000, AM J PHYSIOL-CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989; DIMUZIO MT, 1978, J BIOL CHEM, V253, P6845; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Fitzgerald J, 1999, FASEB J, V13, P553, DOI 10.1096/fasebj.13.3.553; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FROST HM, 1994, ANGLE ORTHOD, V64, P175; Frost HM, 1998, CALCIFIED TISSUE INT, V62, P89, DOI 10.1007/s002239900399; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; HARTER LV, 1995, ENDOCRINOLOGY, V136, P528, DOI 10.1210/en.136.2.528; HASEGAWA S, 1985, CALCIFIED TISSUE INT, V37, P431, DOI 10.1007/BF02553714; Hatton JP, 2003, J BONE MINER RES, V18, P58, DOI 10.1359/jbmr.2003.18.1.58; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053; Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116; JONES DB, 1991, BIOMATERIALS, V12, P101, DOI 10.1016/0142-9612(91)90186-E; KAHN AJ, 1987, AM J OTOLARYNG, V8, P258, DOI 10.1016/S0196-0709(87)80044-3; KAMATA T, 1994, J BIOL CHEM, V269, P26006; Kletsas D, 2002, J CELL PHYSIOL, V190, P313, DOI 10.1002/jcp.10052; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Krane SM, 1996, J BIOL CHEM, V271, P28509, DOI 10.1074/jbc.271.45.28509; LAMBERT CA, 1992, LAB INVEST, V66, P444; Langholz O, 1997, EXP CELL RES, V235, P22, DOI 10.1006/excr.1997.3640; LANYON LE, 1996, BONE S1, V18, P37; Lee AA, 1999, J MOL CELL CARDIOL, V31, P1833, DOI 10.1006/jmcc.1999.1017; Lee AA, 1996, AM J PHYSIOL-CELL PH, V271, pC1400, DOI 10.1152/ajpcell.1996.271.4.C1400; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATTOT V, 1995, J CELL SCI, V108, P529; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NOSE K, 1994, EXP CELL RES, V211, P168, DOI 10.1006/excr.1994.1073; OBRIG TG, 1971, J BIOL CHEM, V246, P174; Ogata T, 2003, AM J PHYSIOL-CELL PH, V285, pC425, DOI 10.1152/ajpcell.00505.2002; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; RIFAS L, 1994, ENDOCRINOLOGY, V134, P213, DOI 10.1210/en.134.1.213; Roelofsen J, 1995, J BIOMECH, V28, P1493, DOI 10.1016/0021-9290(95)00097-6; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SOMJEN D, 1980, BIOCHIM BIOPHYS ACTA, V627, P91, DOI 10.1016/0304-4165(80)90126-9; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; Toma CD, 1997, J BONE MINER RES, V12, P1626, DOI 10.1359/jbmr.1997.12.10.1626; Uitto VJ, 1998, AM J PATHOL, V152, P1489; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; WEINSTOCK M, 1974, J CELL BIOL, V60, P92, DOI 10.1083/jcb.60.1.92; WU CB, 1995, CALCIFIED TISSUE INT, V57, P285, DOI 10.1007/BF00298884; Yang CM, 2001, BRIT J PHARMACOL, V132, P1531, DOI 10.1038/sj.bjp.0703976	56	92	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22158	22165		10.1074/jbc.M401343200	http://dx.doi.org/10.1074/jbc.M401343200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15044466	hybrid			2022-12-25	WOS:000221417100060
J	Ou, XM; Chen, K; Shih, JC				Ou, XM; Chen, K; Shih, JC			Dual functions of transcription factors, transforming growth factor-beta-inducible early gene (TIEG)2 and Sp3, are mediated by CACCC element and Sp1 sites of human monoamine oxidase (MAO) B gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; B GENES; CELL-GROWTH; TGF-BETA; PROMOTER; INHIBITOR; REPRESSOR; DOMAINS; BRAIN; MAO	Monoamine oxidases (MAO) A and B catalyze the oxidative deamination of many biogenic and dietary amines. Abnormal expression of MAO has been implicated in several psychiatric and neurodegenerative disorders. Human MAO B core promoter (-246 to -99 region) consists of CACCC element flanked by two clusters of overlapping Sp1 sites. Here, we show that cotransfection with transforming growth factor (TGF)-beta-inducible early gene ( TIEG) 2 increased MAO B gene expression at promoter, mRNA, protein, and catalytic activity levels in both SH-SY5Y and HepG2 cells. Mutation of the CACCC element increased the MAO B promoter activity, and cotransfection with TIEG2 further increased the promoter activity, suggesting that CACCC was a repressor element. This increase was reduced when the proximal Sp1 overlapping sites was mutated. Similar interactions were found with Sp3. These results showed that TIEG2 and Sp3 were repressors at the CACCC element but were activators at proximal Sp1 overlapping sites of MAO B. Gel-shift and chromatin immunoprecipitation assays showed that TIEG2 and Sp3 bound directly to CACCC element and the proximal Sp1 sites in both synthetic oligonucleotides and natural MAO B core promoter. TIEG2 had a higher affinity to Sp1 sites than CACCC element, whereas Sp3 had an equal affinity to both elements. Thus, TIEG2 was an activator, but Sp3 had no effect on MAO B gene expression. This study provides new insights into MAO B gene expression and illustrates the complexity of gene regulation.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Shih, JC (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave,PSC 528, Los Angeles, CA 90033 USA.	jcshih@usc.edu			NIMH NIH HHS [R01 MH 37020, R27 MH 39085] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037020, R37MH039085, R01MH039085] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; ARAI Y, 1988, J NEURAL TRANSM, V72, P99, DOI 10.1007/BF01250233; Asano H, 1999, MOL CELL BIOL, V19, P3571; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOND PA, 1977, CLIN CHIM ACTA, V80, P317, DOI 10.1016/0009-8981(77)90039-0; Chiarugi V, 1997, PHARMACOL RES, V35, P257, DOI 10.1006/phrs.1997.0140; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; Cook T, 1998, J BIOL CHEM, V273, P25929, DOI 10.1074/jbc.273.40.25929; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; De Luca P, 1998, J CELL BIOCHEM, V70, P281, DOI 10.1002/(SICI)1097-4644(19980801)70:2<281::AID-JCB13>3.0.CO;2-Q; DONNELLY CH, 1977, BIOCHEM PHARMACOL, V26, P853, DOI 10.1016/0006-2952(77)90398-7; FOWLER JS, 1987, SCIENCE, V235, P481, DOI 10.1126/science.3099392; Geha RM, 2001, J BIOL CHEM, V276, P9877, DOI 10.1074/jbc.M006972200; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; Jia L, 2003, MOL CANCER RES, V1, P385; JOHNSTON JP, 1968, BIOCHEM PHARMACOL, V17, P1285, DOI 10.1016/0006-2952(68)90066-X; Knoll J, 1972, Adv Biochem Psychopharmacol, V5, P393; LAN NC, 1989, GENOMICS, V4, P552, DOI 10.1016/0888-7543(89)90279-6; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Ou XM, 2001, J BIOL CHEM, V276, P14299, DOI 10.1074/jbc.M005363200; Sabol SZ, 1998, HUM GENET, V103, P273, DOI 10.1007/s004390050816; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Sun JM, 2002, J BIOL CHEM, V277, P35783, DOI 10.1074/jbc.C200378200; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Thorpe LW, 1987, J HISTOCHEM CYTOCHEM, V35, P23, DOI 10.1177/35.1.3025289; WEYLER W, 1985, J BIOL CHEM, V260, P3199; Wong WK, 2001, MOL PHARMACOL, V59, P852, DOI 10.1124/mol.59.4.852; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; ZHU QS, 1994, J NEUROSCI, V14, P7393; ZHU QS, 1992, J NEUROSCI, V12, P4437	33	57	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21021	21028		10.1074/jbc.M312638200	http://dx.doi.org/10.1074/jbc.M312638200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15024015	hybrid			2022-12-25	WOS:000221273800058
J	Strazynski, M; Eble, JA; Kresse, H; Schonherr, E				Strazynski, M; Eble, JA; Kresse, H; Schonherr, E			Interleukin (IL)-6 and IL-10 induce decorin mRNA in endothelial cells, but interaction with fibrillar collagen is essential for its translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; EXPRESSION; INTEGRIN; ANGIOGENESIS; RHODOCETIN; INHIBITOR; SULFATE; ALPHA(1)BETA(1); PROTEOGLYCANS; BIOSYNTHESIS	Decorin, a small multifunctional proteoglycan, is expressed by sprouting endothelial cells (ECs) during inflammation-induced angiogenesis in vivo and by human ECs co-cultured with fibroblasts in a collagen lattice. To investigate how decorin is induced, human EA.hy 926 ECs and/or human umbilical vein ECs were treated with interleukin (IL)-10 and IL-6. Both treatments induced decorin mRNA in human ECs. IL-6 and IL-10 led to a dose-dependent mRNA increase with a maximum at 10 and 50 ng/ml, respectively. The combination of both interleukins together had a stronger effect than one alone. Immunostaining demonstrated that both interleukins caused decorin synthesis in ECs and the formation of capillary-like structures in a collagen lattice. However, immunoprecipitations of interleukin-treated ECs cultured on plastic were negative. Only interleukin-stimulated ECs grown on a collagen type I matrix or growth factor-reduced Matrigel were able to synthesize the proteoglycan. Acid-soluble collagen type I did not support decorin protein synthesis. The addition of antibodies to alpha(1) or alpha(2) integrins or the alpha(2) integrin inhibitor rhodocetin led to an inhibition of synthesis. These data show that IL-10 and IL-6 induce decorin mRNA transcription, but additional signals from the extracellular matrix are necessary for its translation.	Cardiff Univ, Matrix Biol & Tissue Repair Res Unit, Sch Dent, Cardiff CF14 4XY, S Glam, Wales; Univ Munster, Inst Physiol Chem & Pathobiochem, D-48129 Munster, Germany; Univ Hosp Munster, D-48129 Munster, Germany	Cardiff University; University of Munster; University of Munster	Schonherr, E (corresponding author), Cardiff Univ, Matrix Biol & Tissue Repair Res Unit, Sch Dent, Heath Pk, Cardiff CF14 4XY, S Glam, Wales.	schonherreh@cardiff.ac.uk						BORDER WA, 1990, KIDNEY INT, V37, P689, DOI 10.1038/ki.1990.35; BREUER B, 1990, BIOCHEM J, V269, P551, DOI 10.1042/bj2690551; Eble JA, 2003, BIOCHEM J, V376, P77, DOI 10.1042/BJ20030373; Eble JA, 2002, MATRIX BIOL, V21, P547, DOI 10.1016/S0945-053X(02)00068-9; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; Eklund E, 2002, MATRIX BIOL, V21, P325, DOI 10.1016/S0945-053X(02)00012-4; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JARVELAINEN HT, 1992, EXP CELL RES, V203, P395, DOI 10.1016/0014-4827(92)90013-X; Jikko A, 1998, CELL BIOL INT, V22, P615, DOI 10.1006/cbir.1998.0304; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Lin ZQ, 2003, J LEUKOCYTE BIOL, V73, P713, DOI 10.1189/jlb.0802397; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Mummery RS, 2000, J IMMUNOL, V165, P5671, DOI 10.4049/jimmunol.165.10.5671; Nelimarkka L, 2001, AM J PATHOL, V158, P345, DOI 10.1016/S0002-9440(10)63975-2; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; Salek-Ardakani S, 2000, BLOOD, V96, P1879, DOI 10.1182/blood.V96.5.1879.h8001879_1879_1888; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Schonherr E, 2001, J CELL PHYSIOL, V187, P37, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1048>3.0.CO;2-W; Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Silvestre JS, 2000, CIRC RES, V87, P448; Szulgit G, 2002, J INVEST DERMATOL, V118, P409, DOI 10.1046/j.0022-202x.2001.01680.x; TRUEB B, 1987, EUR J BIOCHEM, V166, P699, DOI 10.1111/j.1432-1033.1987.tb13568.x; vandeLoo FAJ, 1997, AM J PATHOL, V151, P177; vanRoon JAG, 1996, ARTHRITIS RHEUM, V39, P829, DOI 10.1002/art.1780390516; Yamamoto T, 2001, BIOCHEM BIOPH RES CO, V281, P200, DOI 10.1006/bbrc.2001.4321	32	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21266	21270		10.1074/jbc.M309782200	http://dx.doi.org/10.1074/jbc.M309782200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15016829	hybrid			2022-12-25	WOS:000221273800087
J	Salih, E; Fluckiger, R				Salih, E; Fluckiger, R			Complete topographical distribution of both the in vivo and in vitro phosphorylation sites of bone sialoprotein and their biological implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATIONS; RAT OSTEOCLASTS; CELL ATTACHMENT; MASS-SPECTROMETRY; PROTEIN-KINASES; MATRIX PROTEINS; MESSENGER-RNA; DENTAL-PULP; RGD DOMAIN; OSTEOPONTIN	Bone sialoprotein (BSP) is a multifunctional, highly phosphorylated, and glycosylated protein with key roles in biomineralization and tissue remodeling. This work identifies the complete topographical distribution and precise location of both the in vitro and in vivo phosphorylation sites of bovine BSP by a combination of state-of-the-art techniques and approaches. In vitro phosphorylation of native and deglycosylated BSPs by casein kinase II identified seven phosphorylation sites by solid-phase N-terminal peptide sequencing that were within peptides 12 - 22 (LEDS(P) EENGVFK), 42-62 (FAVQSSSD-SS( P) EENGNGDS(P) S(P) EE), 80 - 91 (EDS(P) DENEDEES( P) E), and 135 - 145 (EDES(P) DEEEEEE). The in vivo phosphorylation regions and sites were identified by use of a novel thiol reagent, 1-S-mono[C-14] carboxy-methyldithiothreitol. This approach identified all of the phosphopeptides defined by in vitro phosphorylation, but two additional phosphopeptides were defined at residues, 250 - 264 (DNGYEIYES(P) ENGDPR), and 282 - 289 (GYDS( P) YDGQ). Furthermore, use of native BSP and matrix-assisted laser desorption ionization time-of-flight mass spectrometry identified several of the above peptides, including an additional phosphopeptide at residues 125 - 130 (AGAT(P) GK) that was not defined in either of the in vitro and in vivo studies described above. Overall, 7 in vitro and 11 in vivo phosphorylation sites were identified unequivocally, with natural variation in the quantitative extent of phosphorylation at each in vivo phosphorylation site.	Childrens Hosp, Dept Orthoped Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Orthoped Surg, Lab Study Skeletal Disorders & Rehabil, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Salih, E (corresponding author), Childrens Hosp, Dept Orthoped Res, 300 Longwood Ave, Boston, MA 02115 USA.	erdjan.salih@tch.harvard.edu		Fluckiger, Rudolf/0000-0002-4655-2244; Salih, Erdjan/0000-0003-3322-2323	NATIONAL INSTITUTE ON AGING [R01AG017969] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG 17969] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; CHAMBERS TJ, 1986, BONE MINER, V1, P127; CHEN JK, 1992, J BONE MINER RES, V7, P987; Cooper LF, 1998, J BONE MINER RES, V13, P620, DOI 10.1359/jbmr.1998.13.4.620; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; Decup F, 2000, Clin Oral Investig, V4, P110, DOI 10.1007/s007840050126; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; ENDO A, 1989, CONNECT TISSUE RES, V21, P509, DOI 10.3109/03008208909050008; FISHER LW, 1990, J BIOL CHEM, V265, P2347; GLIMCHER MJ, 1984, PHILOS T R SOC B, V304, P479, DOI 10.1098/rstb.1984.0041; Goldberg M, 2003, AM J DENT, V16, P66; Goldberg M, 2002, PATHOL BIOL, V50, P194, DOI 10.1016/S0369-8114(02)00288-2; Goldberg M, 2001, Adv Dent Res, V15, P91; GOTOH Y, 1990, EUR J BIOCHEM, V187, P49, DOI 10.1111/j.1432-1033.1990.tb15276.x; Harris NL, 2000, BONE, V27, P795, DOI 10.1016/S8756-3282(00)00392-6; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; Katayama Y, 1998, J CELL PHYSIOL, V176, P179, DOI 10.1002/(SICI)1097-4652(199807)176:1<179::AID-JCP19>3.3.CO;2-M; MIKUNITAKAGAKI Y, 1990, BIOCHEM J, V268, P585, DOI 10.1042/bj2680585; MINTZ KP, 1993, J BONE MINER RES, V8, P985; Mizuno M, 2000, CALCIFIED TISSUE INT, V66, P388, DOI 10.1007/s002230010078; NESBITT S, 1993, J BIOL CHEM, V268, P16737; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; OLDBERG A, 1989, J CELL BIOL, V109, P3183, DOI 10.1083/jcb.109.6.3183; Raynal C, 1996, ENDOCRINOLOGY, V137, P2347, DOI 10.1210/en.137.6.2347; Razzouk S, 2002, BONE, V30, P40, DOI 10.1016/S8756-3282(01)00637-8; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; ROSS FP, 1993, J BIOL CHEM, V268, P9901; Salih E, 1996, J BIOL CHEM, V271, P16897, DOI 10.1074/jbc.271.28.16897; Salih E, 2003, CONNECT TISSUE RES, V44, P223, DOI 10.1080/03008200390181708; Salih E, 2003, ANAL BIOCHEM, V319, P143, DOI 10.1016/S0003-2697(03)00254-9; Salih E, 2002, BIOCHEM J, V364, P465, DOI 10.1042/BJ20011272; Salih E, 1997, J BIOL CHEM, V272, P13966, DOI 10.1074/jbc.272.21.13966; Salih E, 1996, J BONE MINER RES, V11, P1461; Salih E, 1996, CONNECT TISSUE RES, V35, P207, DOI 10.3109/03008209609029193; Samoto H, 2003, J BIOL CHEM, V278, P28659, DOI 10.1074/jbc.M300671200; SHANKAR G, 1995, EXP CELL RES, V219, P364, DOI 10.1006/excr.1995.1240; SHANKAR G, 1993, J CELL SCI, V105, P61; Six N, 2002, J MATER SCI-MATER M, V13, P225, DOI 10.1023/A:1013846516693; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; Stubbs JT, 1997, J BONE MINER RES, V12, P1210, DOI 10.1359/jbmr.1997.12.8.1210; Stubbs JT, 1996, CONNECT TISSUE RES, V35, P393, DOI 10.3109/03008209609029217; Sung V, 1998, J CELL PHYSIOL, V176, P482, DOI 10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K; VANDIJK S, 1993, J BONE MINER RES, V8, P1499; VEIS A, 1984, CHEM BIOL MINERALIZE, P170; Wang J, 1998, BONE, V22, P621, DOI 10.1016/S8756-3282(98)00057-X; WANG J, 1999, ORTHOP T, V22, P951; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200; Zaia J, 2001, BIOCHEMISTRY-US, V40, P12983, DOI 10.1021/bi010887r; ZHOU HY, 1995, CALCIFIED TISSUE INT, V56, P403, DOI 10.1007/BF00301610	52	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19808	19815		10.1074/jbc.M310299200	http://dx.doi.org/10.1074/jbc.M310299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004024	hybrid			2022-12-25	WOS:000221164500052
J	Xiao, ZS; Hjelmeland, AB; Quarles, LD				Xiao, ZS; Hjelmeland, AB; Quarles, LD			Selective deficiency of the "bone-related" Runx2-II unexpectedly preserves osteoblast-mediated skeletogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCALCIN GENE-EXPRESSION; TRANSCRIPTION FACTOR; CHONDROCYTE DIFFERENTIATION; MORPHOGENETIC PROTEIN-2; CBFA1; PROMOTER; OVEREXPRESSION; CBFA1/RUNX2; ISOFORMS; MOUSE	Runx2 (runt-related transcription factor 2) is a master regulator of skeletogenesis. Distinct promoters in the Runx2 gene transcribe the "bone-related" Runx2-II and non-osseous Runx2-I isoforms that differ only in their respective N termini. Existing mutant mouse models with both isoforms deleted exhibit an arrest of osteoblast and chondrocyte maturation and the complete absence of mineralized bone, but they do not distinguish the separate functions of the two N-terminal isoforms. To elucidate the function of the bone-related isoform, we generated selective Runx2-II-deficient mice by the targeted deletion of the distal promoter and exon 1. Homozygous Runx2-II-deficient (Runx2-II-/-) mice unexpectedly formed axial, appendicular, and craniofacial bones derived from either intramembranous ossification or mesenchymal cells of the bone collar, but they failed to form the posterior cranium and other bones derived from endochondral ossification. Heterozygous Runx2-II-deficient mice had grossly normal skeletons, but were osteopenic. The commitment of mesenchymal cells ex vivo to the osteoblast lineage occurred in Runx2-II-/- mice, but osteoblastic gene expression was impaired. Chondrocyte maturation appeared normal, but the zone of hypertrophic chondrocytes was not transformed into metaphyseal bone, leading to widened growth plates in Runx2-II-/- mice. Compensatory increments in Runx2-I expression occurred in Runx2-II-/- mice but were not sufficient to normalize osteoblastic maturation or transcriptional activity. Our findings support distinct functions of Runx2-II and -I in the control of skeletogenesis. Runx2-I is sufficient for early osteoblastogenesis and intramembranous bone formation, whereas Runx2-II is necessary for complete osteoblastic maturation and endochondral bone formation.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Bone & Mineral Disorders, Durham, NC 27710 USA	Duke University; Duke University	Quarles, LD (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3036, Durham, NC 27710 USA.	Quarl001@mc.duke.edu		Quarles, L. Darryl/0000-0002-5082-7896; Hjelmeland, Anita/0000-0003-2200-3248	NIAMS NIH HHS [R01 AR 049712] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049712] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754; Caplan AI, 1987, BONE MINERAL RES, P117; Choi KY, 2002, EXP MOL MED, V34, P426, DOI 10.1038/emm.2002.60; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; Enomoto H, 2004, J CELL SCI, V117, P417, DOI 10.1242/jcs.00866; Enomoto H, 2003, J BIOL CHEM, V278, P23971, DOI 10.1074/jbc.M302457200; Fujita T, 2001, BIOCHEM BIOPH RES CO, V280, P348, DOI 10.1006/bbrc.2000.4108; Fujiwara M, 1999, BBA-GENE STRUCT EXPR, V1446, P265, DOI 10.1016/S0167-4781(99)00113-X; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222-6233.2002; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Inoue K, 2003, BLOOD CELL MOL DIS, V30, P157, DOI 10.1016/S1079-9796(03)00032-9; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Levanon D, 2001, GENE, V262, P23, DOI 10.1016/S0378-1119(00)00532-1; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168-9525(03)00176-8; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Park MH, 2001, J BONE MINER RES, V16, P885, DOI 10.1359/jbmr.2001.16.5.885; Rennert J, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-4; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Telfer JC, 2001, DEV BIOL, V229, P363, DOI 10.1006/dbio.2000.9991; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; Tu QS, 2003, J CLIN INVEST, V111, P1029, DOI 10.1172/JCI200317054; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Xiao ZS, 2003, J CELL BIOCHEM, V88, P493, DOI 10.1002/jcb.10375; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2	58	81	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20307	20313		10.1074/jbc.M401109200	http://dx.doi.org/10.1074/jbc.M401109200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15007057	hybrid			2022-12-25	WOS:000221164500108
J	Chen, LX; Zeng, Y; Yang, HP; Lee, TD; French, SW; Corrales, FJ; Garcia-Trevijano, ER; Avila, MA; Mato, JM; Lu, SC				Chen, LX; Zeng, Y; Yang, HP; Lee, TD; French, SW; Corrales, FJ; Garcia-Trevijano, ER; Avila, MA; Mato, JM; Lu, SC			Impaired liver regeneration in mice lacking methionine adenosyltransferase 1A	FASEB JOURNAL			English	Article						S-adenosylmethionine; partial hepatectomy; cyclin D1; hepatocyte growth factor	NITRIC-OXIDE SYNTHASE; ADENOSYL-L-METHIONINE; NF-KAPPA-B; S-ADENOSYLMETHIONINE; RAT HEPATOCYTES; KINASE CASCADE; FACTOR-ALPHA; EXPRESSION; PROLIFERATION; GROWTH	Methionine adenosyltransferase (MAT) is an essential enzyme because it catalyzes the formation of S-adenosylmethionine (SAMe), the principal biological methyl donor. Of the two genes that encode MAT, MAT1A is mainly expressed in adult liver and MAT2A is expressed in all extrahepatic tissues. Mice lacking MAT1A have reduced hepatic SAMe content and spontaneously develop hepatocellular carcinoma. The current study examined the influence of chronic hepatic SAMe deficiency on liver regeneration. Despite having higher baseline hepatic staining for proliferating cell nuclear antigen, MAT1A knockout mice had impaired liver regeneration after partial hepatectomy (PH) as determined by bromodeoxyuridine incorporation. This can be explained by an inability to up-regulate cyclin D1 after PH in the knockout mice. Upstream signaling pathways involved in cyclin D1 activation include nuclear factor kappaB (NFkappaB), the c-Jun-N-terminal kinase (JNK), extracellular signal-regulated kinases (ERKs), and signal transducer and activator of transcription-3 (STAT-3). At baseline, JNK and ERK are more activated in the knockouts whereas NFkappaB and STAT-3 are similar to wild-type mice. Following PH, early activation of these pathways occurred, but although they remained increased in wildtype mice, c-jun and ERK phosphorylation fell progressively in the knockouts. Hepatic SAMe levels fell progressively following PH in wild-type mice but remained unchanged in the knockouts. In culture, MAT1A knockout hepatocytes have higher baseline DNA synthesis but failed to respond to the mitogenic effect of hepatocyte growth factor. Taken together, our findings define a critical role for SAMe in ERK signaling and cyclin D1 regulation during regeneration and suggest chronic hepatic SAMe depletion results in loss of responsiveness to mitogenic signals.	Univ So Calif, Sch Med,Res Ctr Liver Dis,Dept Med, UCLA Res Ctr Alcohol Liver & Pancreat Dis, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA; Harbor UCLA Res & Educ Inst, Dept Pathol, Torrance, CA 90502 USA; Univ Navarra, Fdn Invest Med Aplicada, E-31080 Pamplona, Spain; CIC Biogune, Metabol Unit, Derio 48160, Bizkaia, Spain	University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Navarra; CIC bioGUNE	Lu, SC (corresponding author), Univ So Calif, Sch Med,Res Ctr Liver Dis,Dept Med, UCLA Res Ctr Alcohol Liver & Pancreat Dis, Div Gastrointestinal & Liver Dis, HMR Bldg 415,2011 Zonal Ave, Los Angeles, CA 90033 USA.	shellylu@usc.edu	Lu, Shelly/AAH-5937-2021; MATO, JOSE/A-5187-2011; Avila, Matias A/Y-6342-2019; Ruiz García-Trevijano, Elena R./ABE-1014-2021	Lu, Shelly/0000-0003-2128-5407; MATO, JOSE/0000-0003-1264-3153; Avila, Matias A/0000-0001-6570-3557; Ruiz García-Trevijano, Elena R./0000-0002-3985-1270; Corrales, Fernando/0000-0002-0231-5159				Assy N, 1997, J HEPATOL, V26, P945, DOI 10.1016/S0168-8278(97)80266-8; Avila MA, 2000, J HEPATOL, V33, P907, DOI 10.1016/S0168-8278(00)80122-1; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Factor VM, 1997, HEPATOLOGY, V26, P1434; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Garcia-Trevijano ER, 2002, GASTROENTEROLOGY, V122, P1355, DOI 10.1053/gast.2002.33020; Higgins GM, 1931, ARCH PATHOL, V12, P186; Horvath B, 2002, BRAIN RES, V955, P260, DOI 10.1016/S0006-8993(02)03364-4; Huang YF, 1998, BONE, V23, P327, DOI 10.1016/S8756-3282(98)00115-X; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; KINSELL LW, 1947, SCIENCE, V106, P589, DOI 10.1126/science.106.2763.589; KONE BC, 1995, AM J PHYSIOL-RENAL, V269, pF718, DOI 10.1152/ajprenal.1995.269.5.F718; LATASA MU, 2001, FASEB J, DOI DOI 10.1096/FJ.00-0556FJE; Li W, 2002, J BIOL CHEM, V277, P28411, DOI 10.1074/jbc.M202807200; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; Majano PL, 2001, J HEPATOL, V35, P692, DOI 10.1016/S0168-8278(01)00208-2; MARTINDUCE C, 1988, HEPATOLOGY, V8, P65; Martinez-Chantar ML, 2002, FASEB J, V16, P1292, DOI 10.1096/fj.02-0078fje; Mato JM, 2002, FASEB J, V16, P15, DOI 10.1096/fj.01-0401rev; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; Newberne P M, 1986, Adv Exp Med Biol, V206, P223; Nomura J, 2003, LIFE SCI, V72, P2117, DOI 10.1016/S0024-3205(03)00070-5; Paneda C, 2002, HEPATOLOGY, V35, P1381, DOI 10.1053/jhep.2002.32538; PASCALE RM, 1991, ANTICANCER RES, V11, P1617; Santamaria E, 2003, P NATL ACAD SCI USA, V100, P3065, DOI 10.1073/pnas.0536625100; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; SHIVAPURKAR N, 1986, CARCINOGENESIS, V8, P615; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Tombes RM, 1998, BIOCHEM J, V330, P1451; VENDEMIALE G, 1989, SCAND J GASTROENTERO, V24, P407, DOI 10.3109/00365528909093067; Yang HP, 2003, J BIOL CHEM, V278, P50887, DOI 10.1074/jbc.M307600200; Yang SQ, 2001, HEPATOLOGY, V34, P694, DOI 10.1053/jhep.2001.28054	33	61	65	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					914	+		10.1096/fj.03-1204fje	http://dx.doi.org/10.1096/fj.03-1204fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033934	Green Submitted			2022-12-25	WOS:000220522800014
J	Frigeri, A; Nicchia, GP; Balena, R; Nico, B; Svelto, M				Frigeri, A; Nicchia, GP; Balena, R; Nico, B; Svelto, M			Aquaporins in skeletal muscle: reassessment of the functional role of aquaporin-4	FASEB JOURNAL			English	Article						mdx mouse; muscular dystrophy; muscle swelling; AQP4; AQP1	WATER CHANNEL; VOLUME CHANGES; MULLER CELLS; EXPRESSION; LOCALIZATION; TRANSPORT; FIBERS; TEMPERATURE; ASTROCYTES; MOLECULES	Aquaporin-4 (AQP4) is the major water channel of the neuromuscular system, but its physiological function in both perivascular astrocytes and skeletal muscle sarcolemma is unclear. The purpose of this study was to assess the following in skeletal muscle: a) the expression of all cloned water cannels; b) the functional role of AQP4 using sarcolemma vesicles purified by means of several fractionation methods, and c) the functional effect of AQP4 reduction in mdx mice, the animal model of Duchenne muscular dystrophy (DMD). Immunofluorescence and immunoblot experiments performed with affinity purified antibodies revealed that only AQP1 and AQP4 are expressed in mouse skeletal muscle: AQP1 in endothelial cells of continuous capillaries and AQP4 on the plasma membrane of muscle fiber. Plasma membrane vesicle purification was performed with a procedure extensively used to purify and characterize dystrophin-associated proteins (DAPs) from rabbit skeletal muscle. Western blot analysis showed strong co-enrichment of the analyzed DAPs and AQP4, indicating that the membrane vesicle preparation was highly enriched in sarcolemma. Stopped-flow light-scattering measurements showed high osmotic water permeability of sarcolemma vesicles (similar to150 mum/s) compatible with the AQP-mediated pathway for water movement. Sarcolemma vesicles prepared from mdx mice revealed, in parallel with AQP4 disappearance from the plasma membrane, a strong reduction in water permeability compared with wild-type mice. Altogether, these results demonstrate high AQP4-mediated water permeability of the skeletal muscle sarcolemma. Expression of sarcolemmal AQP4 together with that of vascular AQP1 may be responsible for the fast water transfer from the blood into the muscle during intense activity. These data imply an important role for aquaporins in skeletal muscle physiology as well as an involvement of AQP4 in the molecular alterations that occur in the muscle of DMD patients.	Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Univ Bari, Ctr Excellence Comparat Gen CEGBA, I-70126 Bari, Italy; Univ Bari, Dept Human Anat, I-70124 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Frigeri, A (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.	a.frigeri@biologia.uniba.it	frigeri, Antonio/AAC-6336-2022; Svelto, Maria/P-6186-2014	Frigeri, Antonio/0000-0002-5284-2934; Svelto, Maria/0000-0002-5584-9541				Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Crosbie RH, 2002, FASEB J, V16, P943, DOI 10.1096/fj.01-0327com; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; Frigeri A, 1998, J CLIN INVEST, V102, P695, DOI 10.1172/JCI2545; Frigeri A, 2002, FASEB J, V16, P1120, DOI 10.1096/fj.01-0797fje; FRIGERI A, 1995, J CELL SCI, V108, P2993; Frigeri A, 2001, FASEB J, V15, P90, DOI 10.1096/fj.00-0260com; Frigeri A, 2001, FASEB J, V15, P1282, DOI 10.1096/fj.00-0525fje; FRIGERI A, 1997, J PHYSL P, V504, P40; GRIMDITCH GK, 1985, AM J PHYSIOL, V249, pE398, DOI 10.1152/ajpendo.1985.249.4.E398; HAMILTON MT, 1993, AM J PHYSIOL, V265, pR1318, DOI 10.1152/ajpregu.1993.265.6.R1318; Hwang SM, 2002, EXP MOL MED, V34, P69, DOI 10.1038/emm.2002.10; LANNERGREN J, 1990, J PHYSIOL-LONDON, V420, pP116; Li J, 2002, INVEST OPHTH VIS SCI, V43, P573; LIDINGER MI, 1994, AM J PHYSIOL, V266, pR1896; LUNDVALL J, 1972, ACTA PHYSIOL SCAND, V85, P258, DOI 10.1111/j.1748-1716.1972.tb05259.x; MA TH, 1993, J BIOL CHEM, V268, P22756; MA TH, 1994, AM J PHYSIOL, V266, pC189, DOI 10.1152/ajpcell.1994.266.1.C189; Marinelli RA, 2003, J BIOL CHEM, V278, P43157, DOI 10.1074/jbc.M305899200; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MENKE A, 1995, J CELL SCI, V108, P727; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; NEERING IR, 1991, BIOPHYS J, V59, P926, DOI 10.1016/S0006-3495(91)82306-2; Newman Eric A., 1995, P717; Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje; Nicchia GP, 2001, J HISTOCHEM CYTOCHEM, V49, P1547, DOI 10.1177/002215540104901208; Nicchia GP, 2000, GLIA, V31, P29, DOI 10.1002/(SICI)1098-1136(200007)31:1<29::AID-GLIA30>3.0.CO;2-3; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; NOTH J, 1974, J MEMBRANE BIOL, V17, P367, DOI 10.1007/BF01870192; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OLBRICH KC, 1997, J PHYSL P, V504, P40; Rapp G, 1998, BIOPHYS J, V75, P2984, DOI 10.1016/S0006-3495(98)77739-2; SJOGAARD G, 1985, AM J PHYSIOL, V248, pR190, DOI 10.1152/ajpregu.1985.248.2.R190; SRETER FA, 1963, AM J PHYSIOL, V205, P1290, DOI 10.1152/ajplegacy.1963.205.6.1290; TAYLOR SR, 1992, ADV EXP MED BIOL, V311, P91; TROMBITAS K, 1993, J MUSCLE RES CELL M, V14, P573, DOI 10.1007/BF00141554; Vaghy PL, 1998, FEBS LETT, V431, P125, DOI 10.1016/S0014-5793(98)00738-8; VANHEESWIJK MP, 1998, J MEMBRANE BIOL, V92, P183; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Wakayama Y, 2002, HISTOCHEM J, V34, P331, DOI 10.1023/A:1023382609541; Ward DS, 1996, AM J PHYSIOL-REG I, V271, pR1682, DOI 10.1152/ajpregu.1996.271.6.R1682; WATSON PD, 1993, AM J PHYSIOL, V265, pH1869, DOI 10.1152/ajpheart.1993.265.6.H1869; WATSON PD, 1993, AM J PHYSIOL, V264, pR790, DOI 10.1152/ajpregu.1993.264.4.R790; WOLF MB, 1985, AM J PHYSIOL, V249, pH792, DOI 10.1152/ajpheart.1985.249.4.H792; WOLF MB, 1989, AM J PHYSIOL, V256, pH282, DOI 10.1152/ajpheart.1989.256.1.H282; Yang BX, 2000, AM J PHYSIOL-CELL PH, V278, pC1108, DOI 10.1152/ajpcell.2000.278.6.C1108; Yokota T, 2000, P JPN ACAD B-PHYS, V76, P22, DOI 10.2183/pjab.76.22	51	76	77	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					905	+		10.1096/fj.03-0987fje	http://dx.doi.org/10.1096/fj.03-0987fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033928				2022-12-25	WOS:000220522800012
J	Johnson, JD; Kuang, SH; Misler, S; Polonsky, KS				Johnson, JD; Kuang, SH; Misler, S; Polonsky, KS			Ryanodine receptors in human pancreatic beta cells: localization and effects on insulin secretion	FASEB JOURNAL			English	Article						diabetes; calcium stores; exocytosis; basal hyperinsulinemia; CD38	CYCLIC ADP-RIBOSE; CA2+-INDUCED CA2+ RELEASE; GROWTH-HORMONE RELEASE; CALCIUM STORES; EXOCYTOSIS; MOBILIZATION; GONADOTROPIN; ACTIVATION; CAFFEINE; CHANNELS	It is clear that pancreatic beta-cell dysfunction, including basal hyperinsulinemia and reduced insulin release in response to glucose, is a key determinant of disease progression in type 2 diabetes, but the underlying molecular defects are not known. In diabetes, the expression and function of ryanodine receptor (RyR) Ca2+ release channels are reduced. The present studies were undertaken to define the subcellular location and role of RyR in the control of stimulated and basal insulin release from human pancreatic beta cells. Using confocal microscopy, we observed RyR immunoreactivity in a vesicular pattern. RyRs did not colocalize with insulin secretory granules but partially colocalized with endosomes. Direct activation with nanomolar concentrations of ryanodine evoked increases in cytosolic Ca2+ that were coupled to transient insulin release. Insulin release stimulated by 1 nM ryanodine was sensitive to BAPTA-AM preincubation but independent of thapsigargin-sensitive endoplasmic reticulum ( ER) Ca2+ pools. Blocking RyRs with micromolar concentrations of ryanodine led to BAPTA-resistant insulin release that was not associated with an increase in cytosolic Ca2+, which implicated alterations in luminal Ca2+. However, neither Ca2+ signals nor insulin release stimulated by glucose was blocked by 10-50 muM ryanodine, which suggests that the CD38/cyclic ADP-ribose/RyR pathway is not a primary mechanism of glucose action in nontransformed beta cells. We provide the first evidence that RyRs directly control insulin secretion in primary beta cells. Unexpectedly, stimulation of insulin secretion by ryanodine occurs independently of glucose and by two mechanisms, including a novel cytosolic Ca2+-independent mechanism likely involving changes in Ca2+ within the lumens of non-ER organelles, such as endosomes.	Washington Univ, Sch Med, Dept Internal Med, Div Metab, St Louis, MO 63110 USA	Washington University (WUSTL)	Polonsky, KS (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Metab, St Louis, MO 63110 USA.	jim@jimjohnson.ca; polonsky@im.wustl.edu	Johnson, James/B-3919-2008	Johnson, James/0000-0002-7523-9433; Kuang, Shihuan/0000-0001-9180-3180				Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; Graves TK, 2003, ENDOCRINOLOGY, V144, P3565, DOI 10.1210/en.2002-0104; Han WP, 1999, J NEUROSCI, V19, P900; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; ISLAM MS, 1995, BIOCHEM J, V306, P679, DOI 10.1042/bj3060679; Islam MS, 2002, DIABETES, V51, P1299, DOI 10.2337/diabetes.51.5.1299; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; Johnson JD, 2000, MOL CELL ENDOCRINOL, V165, P139, DOI 10.1016/S0303-7207(00)00252-5; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; Johnson JD, 2003, J NEUROENDOCRINOL, V15, P204, DOI 10.1046/j.1365-2826.2003.00977.x; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; Johnson JD, 2002, J NEUROENDOCRINOL, V14, P144, DOI 10.1046/j.0007-1331.2001.00756.x; Johnson JD, 2002, AM J PHYSIOL-CELL PH, V282, pC635, DOI 10.1152/ajpcell.00044.2001; Johnson JD, 2002, AM J PHYSIOL-ENDOC M, V282, pE810, DOI 10.1152/ajpendo.00038.2001; Johnson JD, 2000, MOL CELL ENDOCRINOL, V170, P15, DOI 10.1016/S0303-7207(00)00338-5; Johnson JD, 2000, BIOCHEM CELL BIOL, V78, P217, DOI 10.1139/bcb-78-3-217; Kahn SE, 2003, DIABETOLOGIA, V46, P3, DOI 10.1007/s00125-002-1009-0; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Masumiya H, 2001, J BIOL CHEM, V276, P39727, DOI 10.1074/jbc.M106557200; Meissner G, 2002, FRONT BIOSCI, V7, pD2072, DOI 10.2741/meissner; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MISLER S, 1992, DIABETES, V41, P662, DOI 10.2337/diabetes.41.6.662; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; Nakagaki I, 2000, PFLUG ARCH EUR J PHY, V440, P828, DOI 10.1007/s004240000372; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; Sun W, 2003, J CELL BIOL, V162, P125, DOI 10.1083/jcb.200302083; Tengholm A, 1998, DIABETES, V47, P1224, DOI 10.2337/diabetes.47.8.1224; Tengholm A, 2000, CELL CALCIUM, V27, P43, DOI 10.1054/ceca.1999.0087; Tse FT, 1999, BIOESSAYS, V21, P861, DOI 10.1002/(SICI)1521-1878(199910)21:10<861::AID-BIES8>3.0.CO;2-9; Webb DL, 1996, J BIOL CHEM, V271, P19074, DOI 10.1074/jbc.271.32.19074; Yang HT, 2002, P NATL ACAD SCI USA, V99, P9225, DOI 10.1073/pnas.142651999; Yin Y, 2002, J PHYSIOL-LONDON, V539, P409, DOI 10.1013/jphysiol.2001.012943	43	67	72	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					878	+		10.1096/fj.03-1280fje	http://dx.doi.org/10.1096/fj.03-1280fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033925				2022-12-25	WOS:000220522800009
